{"text_format":"1","workbook":"xlsx","n_sheets":5,"sheets":["Aktualni databaze","Archiv vydani 2009-2010","Original export ISI WoS 2011","1-2011","List3"],"not_rendered":{"charts":0,"images":6,"macros":1,"external_links":0,"defined_names":14,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Aktualni databaze","index":0,"n_rows":83,"n_cols":11,"rows_kept":83,"cut":false,"hidden":false,"merged":[]}
[]
[]
[]
[]
[]
[]
[]
["číslo","Autoři","Název","Periodikum","Druh","Rok/ročník/číslo/strany","IF","domácí z/ze všech autorů","Autorský podíl","UT:ISI","URL"]
[0,"Wilhelm, J; Ivica, J; Kagan, D; Svoboda, P","Early postnatal development of rat brain is accompanied by generation of lipofuscin-like pigments","MOLECULAR AND CELLULAR BIOCHEMISTRY","Article","2011/347/40575/157-162","1.896","2 ze 4",0.5,"ISI:000285421500017","http://www.ncbi.nlm.nih.gov/pubmed/20957411"]
[0,"Mohelnikova-Duchonova, B; Marsakova, L; Vrana, D; Holcatova, I; Ryska, M; Smerhovsky, Z; Slamova, A; Schejbalova, M; Soucek, P","Superoxide Dismutase and Nicotinamide Adenine Dinucleotide Phosphate Quinone Oxidoreductase Polymorphisms and Pancreatic Cancer Risk","PANCREAS","Article","2011/40/1/72-78","2.733","2 z 9",0.22222222222222221,"ISI:000285375900015","http://www.ncbi.nlm.nih.gov/pubmed/20966810"]
[0,"Marek, J; Tomek, V; Skovranek, J; Povysilova, V; Samanek, M","Prenatal ultrasound screening of congenital heart disease in an unselected national population: a 21-year experience","HEART","Article","2011/97/2/124-130","5.385","5 z 5",1,"ISI:000285380800008","http://www.ncbi.nlm.nih.gov/pubmed/21163892"]
[0,"Spacek, M; Hubacek, P; Markova, J; Zajac, M; Vernerova, Z; Kamaradova, K; Stuchly, J; Kozak, T","Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients","APMIS","Article","2011/119/1/10-16","1.745","4 z 8",0.5,"ISI:000285153600002","http://www.ncbi.nlm.nih.gov/pubmed/21143522"]
[0,"Bruha, R; Marecek, Z; Pospisilova, L; Nevsimalova, S; Vitek, L; Martasek, P; Nevoral, J; Petrtyl, J; Urbanek, P; Jiraskova, A; Ferenci, P","Long-term follow-up of Wilson Disease: natural history, treatment, mutations analysis and phenotypic correlation","LIVER INTERNATIONAL","Article","2011/31/1/83-91","2.987","1 z 11",9.0909090909090912E-2,"ISI:000285011000011","http://www.ncbi.nlm.nih.gov/pubmed/20958917"]
[0,"Patil, S; Jirak, D; Saudek, F; Hajek, M; Scheffler, K","Positive contrast visualization of SPIO-labeled pancreatic islets using echo-dephased steady-state free precession","EUROPEAN RADIOLOGY","Article","2011/21/1/214-220","3.589","1 z 5",0.2,"ISI:000284899700029","http://www.ncbi.nlm.nih.gov/pubmed/20683599"]
[0,"Honetschlagerova, Z; Huskova, Z; Vanourkova, Z; Sporkova, A; Kramer, HJ; Hwang, SH; Tsai, HJ; Hammock, BD; Imig, JD; Cervenka, L; Kopkan, L","Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension","JOURNAL OF PHYSIOLOGY-LONDON","Article","2011/589/1/207-219","4.764","5 z 11",0.45454545454545453,"ISI:000285760900020","http://jp.physoc.org/content/early/2010/11/10/jphysiol.2010.199505.abstract"]
[0,"Martin, RCG; Joshi, J; Robbins, K; Tomalty, D; Bosnjakovik, P; Derner, M; Padr, R; Rocek, M; Scupchenko, A; Tatum, C","Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study","ANNALS OF SURGICAL ONCOLOGY","Article","2011/18/1/192-198","4.130","1 z 10",0.1,"ISI:000286486700032","http://www.ncbi.nlm.nih.gov/pubmed/20740319"]
[0,"Cerny, V; Herold, I; Cvachovec, K; Sevcik, P; Adamus, M","Guidelines for Managing Neuromuscular Block: Not Only Czech Beer Deserves a Taste","ANESTHESIA AND ANALGESIA","Letter","2011/112/2/482-482","3.083","1 z 5",0.2,"ISI:000286576000034","http://www.ncbi.nlm.nih.gov/pubmed/21257703"]
[0,"Booth, C; Gilmour, KC; Veys, P; Gennery, AR; Slatter, MA; Chapel, H; Heath, PT; Steward, CG; Smith, O; O'Meara, A; Kerrigan, H; Mahlaoui, N; Cavazzana-Calvo, M; Fischer, A; Moshous, D; Blanche, S; Pachlopnick-Schmid, J; Latour, S; de Saint-Basile, G; Albert, M; Notheis, G; Rieber, N; Strahm, B; Ritterbusch, H; Lankester, A; Hartwig, NG; Meyts, I; Plebani, A; Soresina, A; Finocchi, A; Pignata, C; Cirillo, E; Bonanomi, S; Peters, C; Kalwak, K; Pasic, S; Sedlacek, P; Jazbec, J; Kanegane, H; Nichols, KE; Hanson, IC; Kapoor, N; Haddad, E; Cowan, M; Choo, S; Smart, J; Arkwright, PD; Gaspar, HB","X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease","BLOOD","Article","2011/117/1/53-62","10.555","1 z 48",2.0833333333333332E-2,"ISI:000285963900014","http://www.ncbi.nlm.nih.gov/pubmed/20926771"]
[0,"Zuna, J; Madzo, J; Krejci, O; Zemanova, Z; Kalinova, M; Muzikova, K; Zapotocky, M; Starkova, J; Hrusak, O; Horak, J; Trka, J","ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia","BLOOD","Letter","2011/117/1/368-369","10.555","9 z 11",0.81818181818181823,"ISI:000285963900052","http://www.ncbi.nlm.nih.gov/pubmed/21212293"]
[0,"Kuipers, JE; Coenen, EA; Balgobind, BV; Stary, J; Baruchel, A; de Haas, V; de Bont, ESJM; Reinhardt, D; Kaspers, GJL; Cloos, J; Danen-van Oorschot, AA; den Boer, ML; Marschalek, R; Meyer, C; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM","High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)","BLOOD","Article","2011/117/3/928-935","10.555","1 ze 17",5.8823529411764705E-2,"ISI:000286426300025","http://www.ncbi.nlm.nih.gov/pubmed/21045196"]
[0,"Schmid, JP; Canioni, D; Moshous, D; Touzot, F; Mahlaoui, N; Hauck, F; Kanegane, H; Lopez-Granados, E; Mejstrikova, E; Pellier, I; Galicier, L; Galambrun, C; Barlogis, V; Bordigoni, P; Fourmaintraux, A; Hamidou, M; Dabadie, A; Le Deist, F; Haerynck, F; Ouachee-Chardin, M; Rohrlich, P; Stephan, JL; Lenoir, C; Rigaud, S; Lambert, N; Milili, M; Schiff, C; Chapel, H; Picard, C; de Saint Basile, G; Blanche, S; Fischer, A; Latour, S","Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)","BLOOD","Article","2011/117/5/1522-1529","10.555","1 ze 33",3.0303030303030304E-2,"ISI:000286925500018","http://www.ncbi.nlm.nih.gov/pubmed/21119115"]
[0,"Dzirbikova, Z; Kiss, A; Okuliarova, M; Kopkan, L; Cervenka, L; Zeman, M","Expressions of per1 Clock Gene and Genes of Signaling Peptides Vasopressin, Vasoactive Intestinal Peptide, and Oxytocin in the Suprachiasmatic and Paraventricular Nuclei of Hypertensive TGR[mREN2]27 Rats","CELLULAR AND MOLECULAR NEUROBIOLOGY","Article","2011/31/2/225-232","2.107","1 ze 6",0.16666666666666666,"ISI:000287753500005","http://www.ncbi.nlm.nih.gov/pubmed/21061153"]
[0,"Kremlacek, J; Valis, M; Masopust, J; Urban, A; Zumrova, A; Talab, R; Kuba, M; Kubova, Z; Langrova, J","An Electrophysiological Study of Visual Processing in Spinocerebellar Ataxia Type 2 (SCA2)","CEREBELLUM","Article","2011/10/1/32-42","3.280","1 z 9",0.1111111111111111,"ISI:000287330600005","http://www.ncbi.nlm.nih.gov/pubmed/20927662"]
[0,"Ambros, IM; Brunner, B; Aigner, G; Bedwell, C; Beiske, K; Benard, J; Bown, N; Combaret, V; Couturier, J; Defferrari, R; Gross, N; Jeison, M; Lunec, J; Marques, B; Martinsson, T; Mazzocco, K; Noguera, R; Schleiermacher, G; Speleman, F; Stallings, R; Tonini, GP; Tweddle, DA; Valent, A; Vicha, A; Van Roy, N; Villamon, E; Ziegler, A; Preuner, S; Drobics, M; Ladenstein, R; Amann, G; Schuit, RJL; Potschger, U; Ambros, PF","A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma","CLINICAL CANCER RESEARCH","Article","2011/17/4/792-804","6.747","1 z 34",2.9411764705882353E-2,"ISI:000287913200018","http://www.ncbi.nlm.nih.gov/pubmed/21325297"]
[0,"Tapia, G; Cinek, O; Rasmussen, T; Witso, E; Grinde, B; Stene, LC; Ronningen, KS","Human Enterovirus RNA in Monthly Fecal Samples and Islet Autoimmunity in Norwegian Children With High Genetic Risk for Type 1 Diabetes The MIDIA study","DIABETES CARE","Article","2011/34/1/151-155","6.718","1 ze 7",0.14285714285714285,"ISI:000286497000031","http://www.ncbi.nlm.nih.gov/pubmed/20929993"]
[0,"Maruta, C; Guerreiro, M; de Mendonca, A; Hort, J; Scheltens, P","The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia","EUROPEAN JOURNAL OF NEUROLOGY","Article","2011/18/2/279-E23","2.510","1 z 5",0.2,"ISI:000286225400016","http://www.ncbi.nlm.nih.gov/pubmed/20597968"]
[0,"Carlsen, KCL; Hedlin, G; Bush, A; Wennergren, G; de Benedictis, FM; De Jongste, JC; Baraldi, E; Pedroletti, C; Barbato, A; Malmstrom, K; Pohunek, P; Pedersen, S; Piacentini, GL; Middelveld, RJM; Carlsen, KH","Assessment of problematic severe asthma in children","EUROPEAN RESPIRATORY JOURNAL","Article","2011/37/2/432-440","5.527","1 z 15",6.6666666666666666E-2,"ISI:000286730400030","http://www.ncbi.nlm.nih.gov/pubmed/21030450"]
[0,"Skoumalova, A; Ivica, J; Santorova, P; Topinkova, E; Wilhelm, J","The lipid peroxidation products as possible markers of Alzheimer's disease in blood","EXPERIMENTAL GERONTOLOGY","Article","2011/46/1/38-42","3.342","4 z 5",0.8,"ISI:000286542800006","http://www.ncbi.nlm.nih.gov/pubmed/20920571"]
[0,"Balgobind, BV; Van den Heuvel-Eibrink, MM; De Menezes, RX; Reinhardt, D; Hollink, IHIM; Arentsen-Peters, STJCM; van Wering, ER; Kaspers, GJL; Cloos, J; de Bont, ESJM; Cayuela, JM; Baruchel, A; Meyer, C; Marschalek, R; Trka, J; Stary, J; Beverloo, HB; Pieters, R; Zwaan, CM; den Boer, ML","Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL","Article","2011/96/2/221-230","6.416","2 z 20",0.1,"ISI:000287766500009","http://www.ncbi.nlm.nih.gov/pubmed/20971820"]
[0,"Anderova, M; Vorisek, I; Pivonkova, H; Benesova, J; Vargova, L; Cicanic, M; Chvatal, A; Sykova, E","Cell death/proliferation and alterations in glial morphology contribute to changes in diffusivity in the rat hippocampus after hypoxia-ischemia","JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM","Article","2011/31/3/894-907","5.457","7 z 8",0.875,"ISI:000287842700011","http://www.ncbi.nlm.nih.gov/pubmed/20877389"]
[0,"MacManus, DG; Miller, DH; Kappos, L; Gold, R; Havrdova, E; Limmroth, V; Polman, CH; Schmierer, K; Yousry, TA; Eraksoy, M; Meluzinova, E; Dufek, M; Yang, M; O'Neill, GN; Dawson, K","BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis","JOURNAL OF NEUROLOGY","Article","2011/258/3/449-456","2.903","1 z 15",6.6666666666666666E-2,"ISI:000287924200014","http://www.ncbi.nlm.nih.gov/pubmed/20963434"]
[0,"Vaneckova, I; Huskova, Z; Vanourkova, Z; Cervenka, L","Castration Has Antihypertensive and Organoprotective Effects in Male but Not in Female Heterozygous Ren-2 Rats","KIDNEY & BLOOD PRESSURE RESEARCH","Article","2011/34/1/46-52","1.714","4 ze 4",1,"ISI:000286545500006","http://www.ncbi.nlm.nih.gov/pubmed/21178362"]
[0,"Rob, L; Skapa, P; Robova, H","Fertility-sparing surgery in patients with cervical cancer","LANCET ONCOLOGY","Review","2011/12/2/192-200","14.470","3 ze 3",1,"ISI:000287286300026","http://www.ncbi.nlm.nih.gov/pubmed/20619737"]
[0,"Zaliova, M; Madzo, J; Cario, G; Trka, J","Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing","LEUKEMIA","Article","2011/25/2/313-320","8.296","3 ze 4",0.75,"ISI:000287188600016","http://www.ncbi.nlm.nih.gov/pubmed/21109770"]
[0,"Connolly, SJ; Eikelboom, J; Joyner, C; Diener, HC; Hart, R; Golitsyn, S; Flaker, G; Avezum, A; Hohnloser, SH; Diaz, R; Talajic, M; Zhu, J; Pais, P; Budaj, A; Parkhomenko, A; Jansky, P; Commerford, P; Tan, RS; Sim, KH; Lewis, BS; Van Mieghem, W; Lip, GYH; Kim, JH; Lanas-Zanetti, F; Gonzalez-Hermosillo, A; Dans, AL; Munawar, M; O'Donnell, M; Lawrence, J; Lewis, G; Afzal, R; Yusuf, S + Workgroup 993 členů","Apixaban in Patients with Atrial Fibrillation","NEW ENGLAND JOURNAL OF MEDICINE","Article","2011/364/9/806-817","47.050","1 z 1025",9.7560975609756097E-4,"ISI:000287928400006","http://www.ncbi.nlm.nih.gov/pubmed/21309657"]
[0,"Fric, P; Gabrovska, D; Nevoral, J","Celiac disease, gluten-free diet, and oats","NUTRITION REVIEWS","Review","2011/69/2/107-115","3.443","1 ze 3",0.33333333333333331,"ISI:000286885600005","http://www.ncbi.nlm.nih.gov/pubmed/21294744"]
[0,"Zaliova, M; Meyer, C; Cario, G; Vaskova, M; Marschalek, R; Stary, J; Zuna, J; Trka, J","TEL/AML1-Positive Patients Lacking TEL Exon 5 Resemble Canonical TEL/AML1 Cases","PEDIATRIC BLOOD & CANCER","Article","2011/56/2/217-225","2.134","5 z 8",0.625,"ISI:000286017500009","http://www.ncbi.nlm.nih.gov/pubmed/21157892"]
[0,"Tapia, G; Cinek, O; Rasmussen, T; Grinde, B; Stene, LC; Ronningen, KS","Longitudinal study of parechovirus infection in infancy and risk of repeated positivity for multiple islet autoantibodies: the MIDIA study","PEDIATRIC DIABETES","Article","2011/12/1/58-62","2.628","2 ze 6",0.33333333333333331,"ISI:000286617600010","http://www.ncbi.nlm.nih.gov/pubmed/21226816"]
[0,"Wadstrom, J; Biglarnia, A; Gjertsen, H; Sugitani, A; Fronek, J","Introducing Hand-Assisted Retroperitoneoscopic Live Donor Nephrectomy: Learning Curves and Development Based on 413 Consecutive Cases in Four Centers","TRANSPLANTATION","Article","2011/91/4/462-469","3.498","1 z 5",0.2,"ISI:000287127600017","http://www.ncbi.nlm.nih.gov/pubmed/21169880"]
[1,"Vlcek, M; Landor, I; Visna, P; Vavrik, P; Sindelarova, J; Sosna, A","Multidirectional Screw Fixation in the Treatment of Distal Radius Fractures Using Angle-Stable Plates","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA","Czech","2011/78/1/27-33","1.628","4 z/ze 6",0.66666666666666663,"ISI:000288143500004","http://www.achot.cz/detail.php?stat=425"]
[1,"Veigl, D; Vavrik, P; Pokorny, D; Slouf, M; Pavlova, E; Landor, I","Comparison of in Vivo Characteristics of Polyethylene Wear Particles Produced by a Metal and a Ceramic Femoral Component in Total Knee Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA","Czech","2011/78/1/49-55","1.628","4 z/ze 6",0.66666666666666663,"ISI:000288143500008","http://www.achot.cz/detail.php?stat=421"]
[1,"Veselka, J; Zemanek, D; Hajek, P; Maly, M; Adlova, R; Martinkovicova, L; Tomasov, P; Tesar, D","Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention","AMERICAN JOURNAL OF CARDIOLOGY","English","2011/107/9/1295-1299","3.575","8 z/ze 8",1,"ISI:000290605600008","http://www.ncbi.nlm.nih.gov/pubmed/21349484"]
[1,"Oschlies, I; Burkhardt, B; Chassagne-Clement, C; d'Amore, ES; Hansson, U; Hebeda, K; Mc Carthy, K; Kodet, R; Maldyk, J; Mullauer, L; Porwit, A; Schmatz, AI; Tinguely, M; Abramov, D; Wotherspoon, A; Zimmermann, M; Reiter, A; Klapper, W","Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial: Experiences and Preliminary Recommendations From the European Childhood Lymphoma Pathology Panel","AMERICAN JOURNAL OF SURGICAL PATHOLOGY","English","2011/35/6/836-844","4.062","1 z/ze 18",5.5555555555555552E-2,"ISI:000290567400007","http://www.ncbi.nlm.nih.gov/pubmed/21451365"]
[1,"van der Linden, P; Gazdzik, TS; Jahoda, D; Heylen, RJ; Skowronski, JC; Pellar, D; Kofranek, I; Gorecki, AZ; Fagrell, B; Keipert, PE; Hardiman, YJ; Levy, H","A Double-Blind, Randomized, Multicenter Study of MP4OX for Treatment of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty Under Spinal Anesthesia","ANESTHESIA AND ANALGESIA","English","2011/112/4/759-773","3.083","1 z/ze 12",8.3333333333333329E-2,"ISI:000288697000005","http://www.ncbi.nlm.nih.gov/pubmed/21317165"]
[1,"Cmejla, R; Ludikova, B; Pospisilova, D; Sukova, M; Blatny, J","Can mutations in the ribosomal protein S26 (RPS26) gene lead to Klippel-Feil syndrome in Diamond-Blackfan anemia patients? An update from the Czech Diamond-Blackfan Anemia registry","BLOOD CELLS MOLECULES AND DISEASES","English","2011/46/4/300-301","2.901","1 z/ze 5",0.2,"ISI:000289746800007","http://www.ncbi.nlm.nih.gov/pubmed/21414820"]
[1,"Vasovcak, P; Senkerikova, M; Hatlova, J; Krepelova, A","Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: Case report","BMC MEDICAL GENETICS","English","2011/12//-","1984-02-01","2 z/ze 4",0.5,"ISI:000288855300001","http://www.ncbi.nlm.nih.gov/pubmed/21406108"]
[1,"Stolz, A; Pafko, P; Harustiak, T; Smejkal, M; Simonek, J; Schutzner, J; Lischke, R","Risk factor analysis for early mortality and morbidity following pneumonectomy for non-small cell lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY","English","2011/112/4/165-169","0.317","7 z/ze 7",1,"ISI:000289503300002","http://www.ncbi.nlm.nih.gov/pubmed/21585120"]
[1,"Stolz, A; Pafko, P; Lischke, R; Harustiak, T; Simonek, J; Schutzner, J; Adamek, S","Time trend in the surgical therapy of lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY","English","2011/112/4/174-176","0.317","7 z/ze 7",1,"ISI:000289503300004","http://www.ncbi.nlm.nih.gov/pubmed/21585122"]
[1,"Hanova, M; Vodickova, L; Vaclavikova, R; Smerhovsky, Z; Stetina, R; Hlavac, P; Naccarati, A; Slyskova, J; Polakova, V; Soucek, P; Kumar, R; Hemminki, K; Vodicka, P","DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (Tp53, p21(CDKNIA), BCL2 and BAX) with respect to occupational exposure to styrene","CARCINOGENESIS","English","2011/32/1/74-79","4.795","1 z/ze 13",7.6923076923076927E-2,"ISI:000286303000012","http://www.ncbi.nlm.nih.gov/pubmed/20966084"]
[1,"Jakubova, R; Mickova, A; Buzgo, M; Rampichova, M; Prosecka, E; Tvrdik, D; Amler, E","Immobilization of thrombocytes on PCL nanofibres enhances chondrocyte proliferation in vitro","CELL PROLIFERATION","English","2011/44/2/183-191","2.917","6 z/ze 7",0.8571428571428571,"ISI:000288455000009","http://www.ncbi.nlm.nih.gov/pubmed/21401760"]
[1,"Darsova, D; Dotrelova, D","Bilateral Syphylitic Chorioretinitis in a 33-year-old Pervitin User","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Czech","2011/74/2/197-200","0.246","2 z/ze 2",1,"ISI:000289604900009","není"]
[1,"Hrdlicka, M","Autobiographies of persons with autism: unknown views on inner experience of autistic handicap","CESKOSLOVENSKA PSYCHOLOGIE","Czech","2011/55/1/82-89","0.226","1 z/ze 1",1,"ISI:000289024200008","není"]
[1,"Soucek, O; Lebl, J; Snajderova, M; Kolouskova, S; Rocek, M; Hlavka, Z; Cinek, O; Rittweger, J; Sumnik, Z","Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages","CLINICAL ENDOCRINOLOGY","English","2011/74/4/445-452","3.201","7 z/ze 9",0.77777777777777779,"ISI:000288073300006","http://www.ncbi.nlm.nih.gov/pubmed/21138463"]
[1,"Botev, R; Mallie, JP; Wetzels, JFM; Couchoud, C; Schuck, O","The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas: Current Limitations and Quo Vadis","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY","English","2011/6/4/937-950","4.844","1 z/ze 5",0.2,"ISI:000289223600034","http://www.ncbi.nlm.nih.gov/pubmed/21454722"]
[1,"Malikova, H; Liscak, R; Vojtech, Z; Prochazka, T; Vymazal, J; Vladyka, V; Druga, R","Stereotactic radiofrequency amygdalohippocampectomy: Does reduction of entorhinal and perirhinal cortices influence good clinical seizure outcome?","EPILEPSIA","English","2011/52/5/932-940","4.052","2 z/ze 7",0.2857142857142857,"ISI:000290494300013","http://www.ncbi.nlm.nih.gov/pubmed/21453360"]
[1,"Jiruska, P; Marusic, P; Jefferys, JGR; Krsek, P; Cmejla, R; Sebronova, V; Komarek, V","Sturge-Weber syndrome: a favourable surgical outcome in a case with contralateral seizure onset and myoclonic-astatic seizures","EPILEPTIC DISORDERS","English","2011/13/1/76-81","1.198","5 z/ze 7",0.7142857142857143,"ISI:000288946300011","http://www.ncbi.nlm.nih.gov/pubmed/21393095"]
[1,"Hobzova, R; Pradny, M; Zhunusbekova, NM; Sirc, J; Guryca, V; Michalek, J","Bioactive support for cell cultivation and potential grafting. Part 1: Surface modification of 2-hydroxyethyl methacrylate hydrogels for avidin immobilization","E-POLYMERS","English","2011///-","0.644","4 z/ze 6",0.66666666666666663,"ISI:000290474600001","http://www.e-polymers.org/journal/abstract.cfm?abstract_Id=3616"]
[1,"Spisek, R","Immunology in the heart of the High Tatra mountains","EUROPEAN JOURNAL OF IMMUNOLOGY","English","2011/41/3/561-565","5.179","1 z/ze 1",1,"ISI:000288097700001","http://www.ncbi.nlm.nih.gov/pubmed/21341257"]
[1,"Babjuk, M; Oosterlinck, W; Sylvester, R; Kaasinen, E; Bohle, A; Palou-Redorta, J; Roupret, M","EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update","EUROPEAN UROLOGY","English","2011/59/6/997-1008","7.667","1 z/ze 7",0.14285714285714285,"ISI:000290015300023","http://www.ncbi.nlm.nih.gov/pubmed/21458150"]
[1,"Roupret, M; Zigeuner, R; Palou, J; Boehle, A; Kaasinen, E; Sylvester, R; Babjuk, M; Oosterlinck, W","European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update","EUROPEAN UROLOGY","English","2011/59/4/584-594","7.667","1 z/ze 8",0.125,"ISI:000288013700027","http://www.ncbi.nlm.nih.gov/pubmed/21269756"]
[1,"Hollink, IHIM; van den Heuvel-Eibrink, MM; Arentsen-Peters, STCJM; Zimmermann, M; Peeters, JK; Valk, PJM; Balgobind, BV; Sonneveld, E; Kaspers, GJL; de Bont, ESJM; Trka, J; Baruchel, A; Creutzig, U; Pieters, R; Reinhardt, D; Zwaan, CM","Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL","English","2011/96/3/384-392","6.416","1 z/ze 16",6.25E-2,"ISI:000288767000008","http://www.ncbi.nlm.nih.gov/pubmed/21134981"]
[1,"Klukowska, A; Komrska, V; Jansen, M; Laguna, P","Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate (R): interim report from an ongoing prospective clinical study","HAEMOPHILIA","English","2011/17/3/399-406","2.505","1 z/ze 4",0.25,"ISI:000289894200003","http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2010.02428.x/abstract"]
[1,"Ferlito, A; Robbins, KT; Shah, JP; Medina, JE; Silver, CE; Al-Tamimi, S; Fagan, JJ; Paleri, V; Takes, RP; Bradford, CR; Devaney, KO; Stoeckli, SJ; Weber, RS; Bradley, PJ; Suarez, C; Leemans, CR; Coskun, HH; Pitman, KT; Shaha, AR; de Bree, R; Hartl, DM; Haigentz, M; Rodrigo, JP; Hamoir, M; Khafif, A; Langendijk, JA; Owen, RP; Sanabria, A; Strojan, P; Poorten, VV; Werner, JA; Bien, S; Woolgar, JA; Zbaren, P; Betka, J; Folz, BJ; Genden, EM; Talmi, YP; Strome, M; Botas, JHG; Olofsson, J; Kowalski, LP; Holmes, JD; Hisa, Y; Rinaldo, A","PROPOSAL FOR A RATIONAL CLASSIFICATION OF NECK DISSECTIONS","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK","English","2011/33/3/445-450","2.283","1 z/ze 45",2.2222222222222223E-2,"ISI:000287372900024","http://www.ncbi.nlm.nih.gov/pubmed/21086488"]
[1,"Lenicek, M; Duricova, D; Komarek, V; Gabrysova, B; Lukas, M; Smerhovsky, Z; Vitek, L","Bile Acid Malabsorption in Inflammatory Bowel Disease: Assessment by Serum Markers","INFLAMMATORY BOWEL DISEASES","English","2011/17/6/1322-1327","4.643","1 z/ze 7",0.14285714285714285,"ISI:000290442400030","http://www.ncbi.nlm.nih.gov/pubmed/21058331"]
[1,"Rockova, S; Nevoral, J; Rada, V; Marsik, P; Sklenar, J; Hinkova, A; Vlkova, E; Marounek, M","Factors affecting the growth of bifidobacteria in human milk","INTERNATIONAL DAIRY JOURNAL","English","2011/21/7/504-508","2.409","1 z/ze 8",0.125,"ISI:000290205100008","není"]
[1,"Rotnaglova, E; Tachezy, R; Salakova, M; Prochazka, B; Kosl'abova, E; Vesela, E; Ludvikova, V; Hamsikova, E; Klozar, J","HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers","INTERNATIONAL JOURNAL OF CANCER","English","2011/129/1/101-110","4.722","2 z/ze 9",0.22222222222222221,"ISI:000289987300010","http://www.ncbi.nlm.nih.gov/pubmed/21190188"]
[1,"Cardwell, CR; Stene, LC; Joner, G; Bulsara, MK; Cinek, O; Rosenbauer, J; Ludvigsson, J; Svensson, J; Goldacre, MJ; Waldhoer, T; Jarosz-Chobot, P; Gimeno, SGA; Chuang, LM; Roberts, CL; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Devoti, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Radon, K; Glatthaar, C; Patterson, CC","Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies","INTERNATIONAL JOURNAL OF EPIDEMIOLOGY","English","2011/40/2/363-374","5.262","1 z/ze 29",3.4482758620689655E-2,"ISI:000289165800015","http://www.ncbi.nlm.nih.gov/pubmed/21149280"]
[1,"Foltan, R; Hoffmannova, J; Pavlikova, G; Hanzelka, T; Klima, K; Horka, E; Adamek, S; Sedy, J","The influence of orthognathic surgery on ventilation during sleep","INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY","English","2011/40/2/146-149","1.444","1 z/ze 8",0.125,"ISI:000288471100004","http://www.ncbi.nlm.nih.gov/pubmed/21074368"]
[1,"Trc, T; Bohmova, J","Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)","INTERNATIONAL ORTHOPAEDICS","English","2011/35/3/341-348","1.825","1 z/ze 2",0.5,"ISI:000288961000005","http://www.ncbi.nlm.nih.gov/pubmed/20401752"]
[1,"Hrdlicka, M; Vodicka, J; Havlovicova, M; Urbanek, T; Blatny, M; Dudova, I","Brief Report: Significant Differences in Perceived Odor Pleasantness Found in Children with ASD","JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS","English","2011/41/4/524-527","3.063","3 z/ze 6",0.5,"ISI:000288259400015","http://www.ncbi.nlm.nih.gov/pubmed/20697793"]
[1,"Henry, DH; Costa, L; Goldwasser, F; Hirsh, V; Hungria, V; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Willenbacher, W; Woll, PJ; Wang, JM; Jiang, Q; Jun, S; Dansey, R; Yeh, H","Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","JOURNAL OF CLINICAL ONCOLOGY","English","2011/29/9/1125-1132","17.793","1 z/ze 18",5.5555555555555552E-2,"ISI:000288532500024","http://www.ncbi.nlm.nih.gov/pubmed/21343556"]
[1,"Bronsky, J; Mitrova, K; Karpisek, M; Mazoch, J; Durilova, M; Fisarkova, B; Stechova, K; Prusa, R; Nevoral, J","Adiponectin, AFABP, and Leptin in Human Breast Milk During 12 Months of Lactation","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION","English","2011/52/4/474-477","2.183","7 z/ze 9",0.77777777777777779,"ISI:000288541100021","http://www.ncbi.nlm.nih.gov/pubmed/21407103"]
[1,"Nyc, O; Pituch, H; Matejkova, J; Obuch-Woszczatynski, P; Kuijper, EJ","Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland","LANCET","English","2011/377/9775/1407-1407","30.758","2 z/ze 5",0.4,"ISI:000289963000025","http://www.ncbi.nlm.nih.gov/pubmed/21515161"]
[1,"Strahm, B; Nollke, P; Zecca, M; Korthof, ET; Bierings, M; Furlan, I; Sedlacek, P; Chybicka, A; Schmugge, M; Bordon, V; Peters, C; O'Marcaigh, A; de Heredia, CD; Bergstraesser, E; Moerloose, BD; van den Heuvel-Eibrink, MM; Stary, J; Trebo, M; Wojcik, D; Niemeyer, CM; Locatelli, F","Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","LEUKEMIA","English","2011/25/3/455-462","8.296","2 z/ze 21",9.5238095238095233E-2,"ISI:000288159500008","http://www.ncbi.nlm.nih.gov/pubmed/21212791"]
[1,"Jech, R; Bares, M; Krepelova, A; Urgosik, D; Havrankova, P; Ruzicka, E","DYT 6-A Novel THAP1 Mutation With Excellent Effect on Pallidal DBS","MOVEMENT DISORDERS","English","2011/26/5/924-925","4.014","1 z/ze 6",0.16666666666666666,"ISI:000290445400060","http://www.ncbi.nlm.nih.gov/pubmed/21425341"]
[1,"Adamovicova, M; Jech, R; Urgosik, D; Spackova, N; Krepelova, A","Pallidal Stimulation in Siblings with Pantothenate Kinase-Associated Neurodegeneration: Four-Year Follow-Up","MOVEMENT DISORDERS","English","2011/26/1/184-187","4.014","1 z/ze 5",0.2,"ISI:000288178400037","http://www.ncbi.nlm.nih.gov/pubmed/20848620"]
[1,"Laczo, J; Andel, R; Vlcek, K; Matoska, V; Vyhnalek, M; Tolar, M; Bojar, M; Hort, J","Spatial Navigation and APOE in Amnestic Mild Cognitive Impairment","NEURODEGENERATIVE DISEASES","English","2011/8/4/169-177","3.496","4 z/ze 8",0.5,"ISI:000290559000002","http://www.ncbi.nlm.nih.gov/pubmed/21124005"]
[1,"Gonsorcikova, L; Vaxillaire, M; Pruhova, S; Dechaume, A; Dusatkova, P; Cinek, O; Pedersen, O; Froguel, P; Hansen, T; Lebl, J","Familial mild hyperglycemia associated with a novel ABCC8-V84I mutation within three generations","PEDIATRIC DIABETES","English","2011/12/3/266-269","2.628","5 z/ze 10",0.5,"ISI:000289892500009","http://www.ncbi.nlm.nih.gov/pubmed/21214702"]
[1,"Kubrycht, J; Maxova, H; Nyc, O; Vajner, L; Novotna, J; Hezinova, A; Trnkova, A; Vrablova, K; Vytasek, R; Valouskova, V","Isolation of Rat Lung Mast Cells for Purposes of One-Week Cultivation Using Novel Percoll Variant Percoll PLUS","PHYSIOLOGICAL RESEARCH","English","2011/60/1/83-93","1943-01-01","10 z/ze 10",1,"ISI:000288563800009","http://www.ncbi.nlm.nih.gov/pubmed/20533857"]
[1,"Pannasch, U; Vargova, L; Reingruber, J; Ezan, P; Holcman, D; Giaume, C; Sykova, E; Rouach, N","Astroglial networks scale synaptic activity and plasticity","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA","English","2011/108/20/8467-8472","9.432","2 z/ze 8",0.25,"ISI:000290719600076","http://www.ncbi.nlm.nih.gov/pubmed/21536893"]
[1,"Pokorna, M; Necas, E; Skripsky, R; Kratochvil, J; Andrlik, M; Franek, O","How accurately can the aetiology of cardiac arrest be established in an out-of-hospital setting? Analysis by \"Concordance in Diagnosis Crosscheck Tables\"","RESUSCITATION","English","2011/82/4/391-397","2.712","2 z/ze 6",0.33333333333333331,"ISI:000289555800006","http://www.ncbi.nlm.nih.gov/pubmed/21236546"]
[1,"Sediva, A; Polouckova, A; Podrazil, M; Fronkova, E; Kalina, T","Characterization of the B-cell compartment in a patient with Schnitzler syndrome","SCANDINAVIAN JOURNAL OF RHEUMATOLOGY","English","2011/40/2/158-160","2.507","5 z/ze 5",1,"ISI:000288127800016","http://www.ncbi.nlm.nih.gov/pubmed/20874520"]
[1,"Levova, K; Moserova, M; Kotrbova, V; Sulc, M; Henderson, CJ; Wolf, CR; Phillips, DH; Frei, E; Schmeiser, HH; Mares, J; Arlt, VM; Stiborova, M","Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model","TOXICOLOGICAL SCIENCES","English","2011/121/1/43-56","4.814","1 z/ze 12",8.3333333333333329E-2,"ISI:000289807200005","http://toxsci.oxfordjournals.org/content/121/1/43.abstract"]

{"sheet":"Archiv vydani 2009-2010","index":1,"n_rows":494,"n_cols":52,"rows_kept":494,"cut":false,"hidden":false,"merged":[]}
[null,null,"INFO: Tento sešit obsahuje archiv a přehled všech záznamů nalezených a uveřejněných v roce 2009 ve formátu PDF."]
[]
[null,null,"Tip: textové pole lze využít k rychlému dohledání autora (sloupec \"B\" zde) či názvu (textové pole ve sloupci \"I\" napravo)."]
[]
["číslo bulletinu","PT","AU","BA","ED","GP","AF","CA","TI","SO","SE","LA","DT","CT","CY","CL","SP","HO","DE","ID","AB","C1","RP","EM","FU","FX","CR","NR","TC","PU","PI","PA","SN","BN","DI","J9","JI","PD","PY","VL","IS","PN","SU","SI","BP","EP","AR","DI","PG","SC","GA","UT"]
[1,"J","Qasim, W; Cavazzana-Calvo, M; Davies, EG; Davis, J; Duval, M; Eames, G; Farinha, N; Filopovich, A; Fischer, A; Friedrich, W; Gennery, A; Heilmann, C; Landais, P; Horwitz, M; Porta, F; Sedlacek, P; Seger, R; Slatten, M; Teague, L; Eapen, M; Veys, P",null,null,null,"Qasim, Waseem; Cavazzana-Calvo, Marina; Davies, E. Graham; Davis, Jeffery; Duval, Michel; Eames, Gretchen; Farinha, Nuno; Filopovich, Alexandra; Fischer, Alain; Friedrich, Wilhelm; Gennery, Andrew; Heilmann, Carsten; Landais, Paul; Horwitz, Mitchell; Porta, Fulvio; Sedlacek, Petr; Seger, Reinhard; Slatten, Mary; Teague, Lochie; Eapen, Mary; Veys, Paul",null,"Allogeneic Hematopoietic Stem-Cell Transplantation for Leukocyte Adhesion Deficiency","Pediatrics",null,"English","Article",null,null,null,null,null,"leukocyte adhesion deficiency; stem-cell transplantation; reduced-intensity conditioning","BONE-MARROW-TRANSPLANTATION; INTENSITY-CONDITIONING REGIMEN; DISEASE PHENOTYPE; UNRELATED DONOR; 6-YEAR-OLD BOY; REVERSION; IMMUNODEFICIENCY; SURVIVAL; TYPE-1","OBJECTIVES. Leukocyte adhesion deficiency is a rare primary immune disorder caused by defects of the CD18 beta-integrin molecule on immune cells. The condition usually presents in early infancy and is characterized by deep tissue infections, leukocytosis with impaired formation of pus, and delayed wound healing. Allogeneic hematopoietic stem-cell transplantation offers the possibility of curative therapy, and with patient numbers at any individual center being limited, we surveyed the transplant experience at 14 centers worldwide. METHODS. The course of 36 children with a confirmed diagnosis of leukocyte adhesion deficiency who underwent hematopoietic stem-cell transplantation between 1993 and 2007 was retrospectively analyzed. Data were collected by the registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research. RESULTS. At a median follow-up of 62 months (extending to 14 years), the overall survival rate was 75%. Myeloablative conditioning regimens were used in 28 patients, and reduced-intensity conditioning in 8 patients, with no deaths in this subgroup. Survival rates after matched family donor and unrelated donor transplants were similar, with 11 of 14 matched family donor and 12 of 14 unrelated donor recipients alive; mortality was greatest after haploidentical transplants, after which 4 of 8 children did not survive. Twenty-seven transplant recipients were alive, with full donor engraftment in 17 cases, mixed multilineage chimerism in 7 patients, and mononuclear cell-restricted chimerism in an additional 3 cases. CONCLUSIONS. Hematopoietic stem-cell transplantation offers long-term benefit in leukocyte adhesion deficiency and should be considered as an early therapeutic option if a suitable HLA-matched stem-cell donation is available. Reduced-intensity conditioning was particularly safe, and mixed-donor chimerism seems sufficient to prevent significant symptoms, although careful long-term monitoring will be required for these patients. Pediatrics 2009; 123: 836-840","[Qasim, Waseem; Davies, E. Graham; Veys, Paul] Great Ormond St Hosp Sick Children, Dept Immunol, London WC1N 1EH, England; [Cavazzana-Calvo, Marina; Fischer, Alain; Landais, Paul] Hop Necker Enfants Malad, Dept Immunol, Paris, France; [Davis, Jeffery] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada; [Duval, Michel] Hop St Justine, Serv Hematooncol, Montreal, PQ H3T 1C5, Canada; [Eames, Gretchen] Cook Childrens Med Ctr, Dept Blood & Marrow Transplantat, Ft Worth, TX USA; [Farinha, Nuno] Hosp Sao Joao, Hematol & Oncol Unit, Oporto, Portugal; [Filopovich, Alexandra] Cincinnati Childrens Hosp Med Ctr, Dept Immunol, Cincinnati, OH USA; [Friedrich, Wilhelm] Univ Ulm, Dept Blood & Marrow Transplantat, Ulm, Germany; [Gennery, Andrew; Slatten, Mary] Newcastle Gen Hosp, Dept Immunol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Heilmann, Carsten] Rigshosp, Dept Blood & Marrow Transplantat, DK-2100 Copenhagen, Denmark; [Horwitz, Mitchell] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA; [Porta, Fulvio] Univ Brescia, Pediat Clin, Brescia, Italy; [Sedlacek, Petr] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Seger, Reinhard] Univ Hosp Childrens, Div Immunol Hematol & Oncol, Zurich, Switzerland; [Teague, Lochie] Starship Childrens Hosp, Auckland, New Zealand; [Eapen, Mary] Med Coll Wisconsin, Ctr Int Blood, Milwaukee, WI 53226 USA; [Eapen, Mary] Med Coll Wisconsin, Marrow Transplant Res Stat Ctr, Milwaukee, WI 53226 USA","Qasim, W, Great Ormond St Hosp Sick Children, Dept Immunol, 30 Guilford St, London WC1N 1EH, England","w.qasim@ich.ucl.ac.uk","Registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation ; Public Health Service [U24-CA76518-10]; National Cancer Institute ; National Institute of Allergy and Infectious Diseases ; National Heart, Lung, and Blood Institute ","We are grateful for assistance from the Registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research. Dr Qasim was supported by the Leukemia Research Fund. Support from Public Health Service grant U24-CA76518-10 from the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute is also acknowledged.",null,23,0,"AMER ACAD PEDIATRICS","ELK GROVE VILLAGE","141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA","0031-4005",null,"10.1542/peds.2008-1191","PEDIATRICS","Pediatrics","MAR",2009,123,3,null,null,null,836,840,null,null,5,"Pediatrics","413XH","ISI:000263825500016"]
[1,"J","Dequeker, E; Stuhrmann, M; Morris, MA; Casals, T; Castellani, C; Claustres, M; Cuppens, H; Des Georges, M; Ferec, C; Macek, M; Pignatti, PF; Scheffer, H; Schwartz, M; Witt, M; Schwarz, M; Girodon, E",null,null,null,"Dequeker, Els; Stuhrmann, Manfred; Morris, Michael A.; Casals, Teresa; Castellani, Carlo; Claustres, Mireille; Cuppens, Harry; des Georges, Marie; Ferec, Claude; Macek, Milan; Pignatti, Pier-Franco; Scheffer, Hans; Schwartz, Marianne; Witt, Michal; Schwarz, Martin; Girodon, Emmanuelle",null,"Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders - updated European recommendations","European Journal of Human Genetics",null,"English","Article",null,null,null,null,null,"guidelines; recommendations; genetic testing; cystic fibrosis; CFTR; CFTR-related disorders","TRANSMEMBRANE CONDUCTANCE REGULATOR; FETAL ECHOGENIC BOWEL; CONGENITAL ABSENCE; VAS-DEFERENS; UNIPARENTAL DISOMY; DISSEMINATED BRONCHIECTASIS; OBSTRUCTIVE AZOOSPERMIA; GENOMIC REARRANGEMENTS; BAYESIAN-ANALYSIS; RISK-ASSESSMENT","The increasing number of laboratories offering molecular genetic analysis of the CFTR gene and the growing use of commercial kits strengthen the need for an update of previous best practice guidelines (published in 2000). The importance of organizing regional or national laboratory networks, to provide both primary and comprehensive CFTR mutation screening, is stressed. Current guidelines focus on strategies for dealing with increasingly complex situations of CFTR testing. Diagnostic flow charts now include testing in CFTR-related disorders and in fetal bowel anomalies. Emphasis is also placed on the need to consider ethnic or geographic origins of patients and individuals, on basic principles of risk calculation and on the importance of providing accurate laboratory reports. Finally, classification of CFTR mutations is reviewed, with regard to their relevance to pathogenicity and to genetic counselling.","[Girodon, Emmanuelle] Grp Hosp Henri Mondor Albert Chenevier, APHP, Serv Biochim & Genet, F-94010 Creteil, France; [Dequeker, Els; Cuppens, Harry] Ctr Human Genet, Kuleuven, Belgium; [Stuhrmann, Manfred] Hannover Med Sch, Inst Humangenet, D-30623 Hannover, Germany; [Morris, Michael A.] Univ Hosp, Serv Med Genet, Lab Diagnost Mol, Geneva, Switzerland; [Casals, Teresa] IDIBELL, Ctr Genet Medica & Mol, Barcelona, Spain; [Castellani, Carlo] Osped Civile, Cyst Fibrosis Ctr, I-37126 Verona, Italy; [Claustres, Mireille; des Georges, Marie] CHU Montpellier, Serv Genet Mol, Montpellier, France; [Claustres, Mireille; des Georges, Marie] INSERM, U827, Montpellier, France; [Ferec, Claude] Genet Mol Lab, Brest, France; [Macek, Milan] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Pignatti, Pier-Franco] Univ Verona, Sect Biol & Genet, I-37100 Verona, Italy; [Scheffer, Hans] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Schwartz, Marianne] Mol Genet Lab, Copenhagen, Denmark; [Witt, Michal] Polish Acad Sci, Inst Human Genet, Dept Mol & Clin Genet, PL-60479 Poznan, Poland; [Schwarz, Martin] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England","Girodon, E, Grp Hosp Henri Mondor Albert Chenevier, APHP, Serv Biochim & Genet, 51 Av Marechal de Lattre de Tassigny, F-94010 Creteil, France","emmanuelle.girodon@inserm.fr","EU project EuroGentest [FP6-512148]; European Cystic Fibrosis Network ","This study was supported and performed within the framework of the EU project EuroGentest (FP6-512148) and the European Cystic Fibrosis Network.",null,81,3,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,"10.1038/ejhg.2008.136","EUR J HUMAN GENET","Eur. J. Hum. Genet.","JAN",2009,17,1,null,null,null,51,65,null,null,15,"Biochemistry & Molecular Biology; Genetics & Heredity","382EU","ISI:000261588800008"]
[1,"J","Vasakova, M; Sterclova, M; Kolesar, L; Slavcev, A; Pohunek, P; Sulc, J; Skibova, J; Striz, I",null,null,null,"Vasakova, M.; Sterclova, M.; Kolesar, L.; Slavcev, A.; Pohunek, P.; Sulc, J.; Skibova, J.; Striz, I.",null,"Bronchoalveolar Lavage Fluid Cellular Characteristics, Functional Parameters and Cytokine and Chemokine Levels in Interstitial Lung Diseases","Scandinavian Journal of Immunology",null,"English","Article",null,null,null,null,null,null,"IDIOPATHIC PULMONARY-FIBROSIS; EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS; ENDOTHELIAL GROWTH-FACTOR; ALVEOLAR MACROPHAGES; ANGIOGENIC ACTIVITY; CC-CHEMOKINE; SARCOIDOSIS; EXPRESSION; CCL18; IL-8","Idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and sarcoidosis belong to interstitial lung diseases (ILD) where an imbalance of regulatory, profibrotic and antifibrotic cytokines is hypothesized. The relationship of bronchoalveolar lavage (BAL) fluid (BALF) cytokines, BALF cell profile and ILD course is supposed. The aim of our study was to correlate BALF cytokine and chemokine levels with BALF cellular characteristics and lung function parameters in different ILD. Twenty-two sarcoidosis, seven IPF and 11 HP patients underwent lung function tests and BAL. The BALF differential cell counts and superficial cell markers were characterized, and MCP-1, MIP-1 alpha, MIP-1 beta, RANTES, epithelial neutrophil-activating protein (ENA)-78, FGF, G-CSF, GM-CSF, IFN-gamma, interleukin (IL)-1 alpha, IL-1RA, IL-1 beta, -2 beta, -4 beta, -5 beta, -6 beta, -8 beta, -10 beta, -17 beta, tumour necrosis factor (TNF)-alpha, thromobopoietin (Tpo) and vascular endothelial growth factor (VEGF) values measured. The BALF VEGF values were highest in sarcoidosis (P = 0.0526). IL-1RA values were higher in IPF and HP compared with sarcoidosis (P = 0.0334). IL-8/ENA-78 ratio positively correlated with BALF neutrophil counts in IPF (r = 0.89, P = 0.04). Vital capacity and TLCO values positively correlated with VEGF and negatively with IL-8 BALF levels in all ILDs but the correlations were most significant in sarcoidosis group. We suppose that VEGF plays a role in ILDs' early phases and has rather angiogenic than profibrotic effect. On the contrary, IL-8 is probably upregulated in advanced ILDs with prominent fibrosis and marked lung functions decline. We state that BALF VEGF, IL-8 and ENA-78 levels and IL-8/ENA-78 ratio could become useful markers of ILDs' phase, activity and prognosis. They might also be helpful in treatment modality choice.","[Vasakova, M.; Sterclova, M.] Charles Univ Prague, Dept Resp Dis, Sch Med 1, Univ Thomayer Hosp Prague, Prague 14059 4, Czech Republic; [Kolesar, L.; Slavcev, A.; Striz, I.] Inst Clin & Expt Med, Dept Immunol, Prague, Czech Republic; [Pohunek, P.; Sulc, J.] Charles Univ Prague, Dept Pediat, Sch Med 2, Univ Hosp Motol, Prague 14059 4, Czech Republic; [Skibova, J.] Inst Clin & Expt Med, Med Stat Unit, Prague, Czech Republic","Vasakova, M, Charles Univ Prague, Dept Resp Dis, Sch Med 1, Univ Thomayer Hosp Prague, Videnska 800, Prague 14059 4, Czech Republic","martina.vasakova@ftn.cz","MHCR [9131-3/2007]","The study was supported with grant MHCR 9131-3/2007.",null,28,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,"10.1111/j.1365-3083.2008.02222.x","SCAND J IMMUNOL","Scand. J. Immunol.","MAR",2009,69,3,null,null,null,268,274,null,null,7,"Immunology","405XR","ISI:000263258000011"]
[1,"J","Rubio-Cabezas, O; Minton, JAL; Caswell, R; Shield, JP; Deiss, D; Sumnik, Z; Cayssials, A; Herr, M; Loew, A; Lewis, V; Ellard, S; Hattersley, AT",null,null,null,"Rubio-Cabezas, Oscar; Minton, Jayne A. L.; Caswell, Richard; Shield, Julian P.; Deiss, Dorothee; Sumnik, Zdenek; Cayssials, Amely; Herr, Mathias; Loew, Anja; Lewis, Vaughan; Ellard, Sian; Hattersley, Andrew T.",null,"Clinical Heterogeneity in Patients With FOXP3 Mutations Presenting With Permanent Neonatal Diabetes","Diabetes Care",null,"English","Article",null,null,null,null,null,null,"X-LINKED SYNDROME; REGULATORY T-CELLS; IMMUNE DYSREGULATION; SYNDROME IPEX; SWISS-MODEL; POLYENDOCRINOPATHY; ENTEROPATHY; MELLITUS; PROTEIN; IMMUNODYSREGULATION","OBJECTIVE - Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is caused by FOXP3 mutations. We aimed to determine the prevalence, genetics, and clinical phenotype of FOXP3 mutations in a large cohort with permanent neonatal diabetes (PNDM). RESEARCH DESIGN AND METHODS - The 11 coding exons and the polyadenylation region of FOXP3 Were sequenced in 26 male subjects with diabetes diagnosed before 6 months of age in whom common genetic causes of PNDM had been excluded. Ten subjects had at least one additional immune-related disorder, and the remaining 16 had isolated diabetes. RESULTS - We identified four hemizygous FOXP3 Mutations in 6 of 10 patients with associated immune-related disorders and in 0 of 16 patients with isolated diabetes (P = 0.002). Three patients with two novel mutations (R337Q and P339A) and the previously reported L76QfsX53 developed classic IPEX syndrome and died within the First, 13 months. The novel mutation V408M was found in three patients from two unrelated families and had a mild phenotype with hypothyroidism and autoimmune enteropathy (it = 2) or nephrotic syndrome (n = 1) and survival to 12-15 years. CONCLUSIONS - FOXP3 mutations result in similar to 4% of cases of male patients with permanent diabetes diagnosed before 6 months. Patients not only have classic IPEX syndrome but, unexpectedly. may have a more benign phenotype. FOXP3 sequencing should be performed in any male patient with the diagnosis of diabetes in the first 6 months who develops other possible autoimmune-associated conditions, even in the absence of full IPEX syndrome.","[Rubio-Cabezas, Oscar; Minton, Jayne A. L.; Ellard, Sian; Hattersley, Andrew T.] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England; [Rubio-Cabezas, Oscar] Hosp Infantil Univ Nino Jesus, Dept Endocrinol, Madrid, Spain; [Caswell, Richard] Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales; [Deiss, Dorothee; Herr, Mathias] Virchow Childrens Hosp, Dept Pediat Diabetol & Endocrinol, Berlin, Germany; [Sumnik, Zdenek] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Cayssials, Amely] Hosp Italiano Buenos Aires, Dept Pediat, Buenos Aires, DF, Argentina; [Herr, Mathias] DRK Kliniken Berlin Westend, Klin Kinder & Jugendmed, Berlin, Germany; [Loew, Anja] Kinderklin Dritter Orden, Munich, Germany; [Lewis, Vaughan] Royal Devon & Exeter Fdn Trust, Dept Pediat, Exeter, Devon, England","Hattersley, AT, Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England","andrew.hattersley@pms.ac.uk","Wellcome Trust [067463/Z/2/Z]; \"Instituto de Salud Carlos III\" [FIS CM06/00013]; Czech Ministry of Education [021620819]; Czech Ministry of Health [64203]","This work was funded by the Wellcome Trust (grant 067463/Z/2/Z). O.R.C. is supported by an \"Ayuda para contratos post-Formacion Sanitaria Especializada\" from the \"Instituto de Salud Carlos III\" (FIS CM06/00013). Z.S. is supported by the Czech Ministry of Education (grant 021620819) and by the Czech Ministry of Health (grant 64203). A.T.H. is a Wellcome Trust Research Leave Fellow. No potential conflicts of interest relevant to this article were reported. We thank Andrew Parrish for his technical assistance. We also thank Olga Kordonouri for tier clinical input and help with the writing of the manuscript.",null,26,0,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,"10.2337/dc08-1188","DIABETES CARE","Diabetes Care","JAN",2009,32,1,null,null,null,111,116,null,null,6,"Endocrinology & Metabolism","390UA","ISI:000262188000023"]
[1,"J","Zuna, J; Burjanivova, T; Mejstrikova, E; Zemanova, Z; Muzikova, K; Meyer, C; Horsley, SW; Kearney, L; Colman, S; Ptoszkova, H; Marschalek, R; Hrusak, O; Stary, J; Greaves, M; Trka, J",null,null,null,"Zuna, Jan; Burjanivova, Tatiana; Mejstrikova, Ester; Zemanova, Zuzana; Muzikova, Katerina; Meyer, Claus; Horsley, Sharon W.; Kearney, Lyndal; Colman, Susan; Ptoszkova, Hana; Marschalek, Rolf; Hrusak, Ondrej; Stary, Jan; Greaves, Mel; Trka, Jan",null,"Covert Preleukemia Driven by MLL Gene Fusion","Genes Chromosomes & Cancer",null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; CLONAL EXPANSION; INFANT LEUKEMIA; REARRANGEMENT; INV(11)(Q21Q23); IDENTIFICATION; CHILDHOOD","Acute leukemia is considered to be a two- or multiple-step process. Although there is a considerable knowledge regarding the character of the \"first hit,\" the nature of the \"second hit\" remains unanswered in most of the cases including leukemias with MLL gene rearrangement. We demonstrate here a striking sequence of events, which include a covert, protracted preleukemic phase characterized by a dominant MLL/FOXO3A clone with intact myeloid differentiation and the subsequent acquisition of a secondary genetic abnormality, leading to overt lymphoblastic leukemia. Backtracking of the secondary acute lymphoblastic leukemia (sALL) with the MLL rearrangement showed no blasts in the bone marrow (BM) during the protracted preleukemic phase. However, at the same time (more than 1 year before the sALL diagnosis) the MLL/FOXO3A was present in up to 90% of BM cells including myeloid lineage, suggesting that the fusion arose in a multipotent progenitor. To identify potential \"second hit\" precipitating sALL we compared DNA in preleukemic versus fully leukemic samples. The analysis revealed a 10 Mb gain on 19q13.32 in the sALL, absent in the preleukemic specimen. These data provide insight into the dynamics of leukemogenesis in secondary leukemia with MILL rearrangement. (C) 2008 Wiley-Liss, Inc.","[Zuna, Jan; Burjanivova, Tatiana; Mejstrikova, Ester; Muzikova, Katerina; Hrusak, Ondrej; Trka, Jan] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, CLIP, Prague 15006 5, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Sch Med 1, Inst Clin Biochem, Ctr Oncocytogenet, Prague 15006 5, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Sch Med 1, Diagnost Lab, Prague 15006 5, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Univ Frankfurt, DCLA, Inst Pharmaceut Biol, Frankfurt, Main, Germany; [Horsley, Sharon W.; Kearney, Lyndal; Colman, Susan; Greaves, Mel] Inst Canc Res, Sect Haematooncol, London SW3 6JB, England; [Ptoszkova, Hana] Univ Hosp Ostrava, Dept Paediat, Ostrava, Czech Republic","Zuna, J, Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, CLIP, V Uvalu 84, Prague 15006 5, Czech Republic","jan.zuna@lfmotol.cuni.cz","MSMT CR [21620813]; IGA-MZ [NR/8269-3]","Supported by: MSMT CR, Grant number 21620813; IGA-MZ, Grant number: NR/8269-3; Leukaemia Research (UK).",null,35,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1045-2257",null,"10.1002/gcc.20622","GENE CHROMOSOME CANCER","Gene Chromosomes Cancer","JAN",2009,48,1,null,null,null,98,107,null,null,10,"Oncology; Genetics & Heredity","380IU","ISI:000261460200008"]
[1,"J","Ercan, O; Alikasifoglu, M; Erginoz, E; Janda, J; Kabicek, P; Rubino, A; Constantopoulos, A; Ilter, O; Vural, M",null,null,null,"Ercan, Oya; Alikasifoglu, Mujgan; Erginoz, Ethem; Janda, Jan; Kabicek, Pavel; Rubino, Armido; Constantopoulos, Andreas; Ilter, Ozdemir; Vural, Mehmet",null,"Demography of adolescent health care delivery and training in Europe","European Journal of Pediatrics",null,"English","Article",null,null,null,null,null,"Adolescent health; Europe; Training","GENERAL-PRACTITIONERS; UNMET EDUCATION; YOUNG TEENAGERS; NATIONAL-SURVEY; MEDICINE; NEEDS; ATTITUDES; SERVICES; PROFESSIONALS; CONSULTATION","We aimed to determine the status of and factors associated with adolescent health care delivery and training in Europe on behalf of the European Paediatric Association-UNEPSA. A questionnaire was mailed to the presidents of 48 national paediatric societies in Europe. For statistical analyses, non-parametric tests were used as appropriate. Six of the countries had a paediatric (PSPCA), 14 had a combined and nine had a general practitioner/family doctor system for the primary care of adolescents (GP/FDSA). Paediatricians served children 17 years of age or older in 15 and 17, up to 16 years of age in three and six, and up to 14 years of age in six and six countries in outpatient and inpatient settings, respectively. Fifteen and 18 of the countries had some kind of special inpatient wards and outpatient clinics for adolescents, respectively. Twenty-eight of the countries had some kind of national/governmental screening or/and preventive health programmes for adolescents. In countries with a PSPCA, the gross national income (GNI) per capita was significantly lower than in those with a GP/FDSA, and the mean upper age limit of adolescents was significantly higher than in those with the other systems. In the eastern part of Europe, the mortality rate of 10-14 year olds was significantly higher than that in the western part (p=0.008). Training in adolescent medicine was offered in pre-graduate education in 14 countries in the paediatric curriculum and in the context of paediatric residency and GP/family physician residency programmes in 18 and nine countries, respectively. Adolescent medicine was reported as a recognised subspecialty in 15 countries and as a certified subspecialty of paediatrics in one country. In countries with a PSPCA, paediatric residents were more likely to be educated in adolescent medicine than paediatric residents in countries with a GP/FDSA. The results of the present study show that there is a need for the reconstruction and standardisation of adolescent health care delivery and training in European countries. The European Paediatric Association-UNEPSA could play a key role in the implementation of the proposals suggested in this paper.","[Ercan, Oya; Alikasifoglu, Mujgan] Istanbul Univ, Cerrahpasa Med Fac, Div Adolescent Med, Dept Paediat, Istanbul, Turkey; [Ercan, Oya] Istanbul Univ, Cerrahpasa Med Fac, Div Endocrinol, Dept Paediat, Istanbul, Turkey; [Erginoz, Ethem] Istanbul Univ, Cerrahpasa Med Fac, Dept Publ Hlth, Istanbul, Turkey; [Janda, Jan] Univ Hosp Motol, Dept Pediat 1, Prague, Czech Republic; [Kabicek, Pavel] Charles Univ Prague, Dept Paediat & Adolescent Med, Fac Med 1, Prague, Czech Republic; [Rubino, Armido] Univ Naples Federico 2, Fac Med & Chirurg, Naples, Italy; [Constantopoulos, Andreas] Univ Athens, Dept Paediat, Athens, Greece; [Vural, Mehmet] Nisantasi Ihlamur Yolu, TR-80200 Istanbul, Turkey","Vural, M, Nisantasi Ihlamur Yolu, 2 Cehreli Apt 67-9, TR-80200 Istanbul, Turkey","vuralm@istanbul.edu.tr",null,null,null,34,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,"10.1007/s00431-008-0759-1","EUR J PEDIAT","Eur. J. Pediatr.","APR",2009,168,4,null,null,null,417,426,null,null,10,"Pediatrics","407KR","ISI:000263362500004"]
[1,"J","Krsek, P; Pieper, T; Karlmeier, A; Hildebrandt, M; Kolodziejczyk, D; Winkler, P; Pauli, E; Blumcke, I; Holthausen, H",null,null,null,"Krsek, Pavel; Pieper, Tom; Karlmeier, Anja; Hildebrandt, Michelle; Kolodziejczyk, Dieter; Winkler, Peter; Pauli, Elisabeth; Bluemcke, Ingmar; Holthausen, Hans",null,"Different presurgical characteristics and seizure outcomes in children with focal cortical dysplasia type I or II","Epilepsia",null,"English","Article",null,null,null,null,null,"Epilepsy surgery; Cortical malformation; MRI; EEG; Neuropsychology; Seizure outcome","NEURONAL MIGRATION DISORDERS; PEDIATRIC EPILEPSY SURGERY; DUAL PATHOLOGY; INTRACTABLE EPILEPSY; CLINICAL CORRELATIONS; MALFORMATIONS; CLASSIFICATION; FEATURES; SUBTYPES; ABNORMALITIES","Cortical dysplasia (FCD) is a frequent cause of epilepsy in childhood. Two major pathological variants are distinguished, FCD type I and II. The aim of the study was to characterize differences between FCD type I and II with respect to imaging and EEG findings, clinical and neuropsychological presentations, and surgical outcome. Forty children with refractory epilepsy and histopathologically confirmed FCD were retrospectively analyzed. FCD type I was identified in 24 and FCD type II in 16 patients. Characteristic MRI abnormalities in FCD type I included subtle white matter signal changes and regional reduction of the white matter volume. Typical MRI findings in FCD type II were increased cortical thickness, transmantle sign, gray-white matter junction blurring, fluid-attenuated inversion recovery (FLAIR) and proton density (PD) gray matter signal changes as well as T1w, and PD white matter signal changes. Continuous EEG slowing was significantly more common in patients with FCD type I. Children with FCD type I presented with lower levels of intelligence and were suffering more often from maladaptive behavior and behavioral disorders. Surgical outcome was significantly worse in the FCD type I group (seizure freedom was achieved in 21% FCD type I patients and in 75% FCD type II subjects, p < 0.001). Clinically important differences were found in children with distinct histopathological subtypes of FCD. Due to prominent neuropsychological deficits and worse seizure outcome, treatment strategies in FCD type I are more challenging than previously reported and these children should be recognized and specifically addressed within the incoherent group of patients with malformative brain disorders.","[Krsek, Pavel] Charles Univ Prague, Sch Med 2, Dept Pediat Neurol, Motol Hosp, Prague 15006 5, Czech Republic; [Pieper, Tom; Karlmeier, Anja; Holthausen, Hans] Behandlungszentrum Vogtareuth, Neuropediat Clin, Epilepsy Ctr Children, Vogtareuth, Germany; [Pieper, Tom; Karlmeier, Anja; Holthausen, Hans] Behandlungszentrum Vogtareuth, Clin Neurorehabil, Vogtareuth, Germany; [Hildebrandt, Michelle; Bluemcke, Ingmar] Univ Hosp Erlangen, Ctr Epilepsy Surg, Dept Neuropathol & Neuropathol Reference, Erlangen, Germany; [Kolodziejczyk, Dieter] Behandlungszentrum Vogtareuth, Clin Neurosurg & Neuroradiol, Vogtareuth, Germany; [Winkler, Peter] Olga Hosp, Dept Radiol, Stuttgart, Germany; [Pauli, Elisabeth] Univ Hosp Erlangen, Dept Neurol, Epilepsy Ctr, Erlangen, Germany","Krsek, P, Charles Univ Prague, Sch Med 2, Dept Pediat Neurol, Motol Univ Hosp, V Uvalu 84, Prague 15006 5, Czech Republic","pavel.krsek@post.cz","IGA [NR/8843-4]; FNM [00000064203]; German Research Council [DFG Bl 421/1-2]; European Community [LSHM-CT-2006-037315]; ELAN ; FAU Erlangen-Nurernberg ","The study has been supported by grants IGA NR/8843-4, FNM 00000064203, German Research Council (DFG Bl 421/1-2), European Community (FP6, Epicure; contract-no. LSHM-CT-2006-037315), and ELAN fund of the university hospital, medical faculty, FAU Erlangen-Nurernberg. Conflict of interest: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. All authors report no conflict of interest.",null,58,0,"BLACKWELL PUBLISHING","OXFORD","9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND","0013-9580",null,"10.1111/j.1528-1167.2008.01682.x","EPILEPSIA","Epilepsia","JAN",2009,50,1,null,null,null,125,137,null,null,13,"Clinical Neurology","391HN","ISI:000262224500012"]
[1,"J","Morfin, F; Dupuis-Girod, S; Frobert, E; Mundweiler, S; Carrington, D; Sedlacek, P; Bierings, M; Cetkovsky, P; Kroes, ACM; van Tol, MJD; Thouvenot, D",null,null,null,"Morfin, Florence; Dupuis-Girod, Sophie; Frobert, Emilie; Mundweiler, Stephanie; Carrington, David; Sedlacek, Petr; Bierings, Marc; Cetkovsky, Petr; Kroes, Aloys C. M.; van Tol, Maarten J. D.; Thouvenot, Danielle",null,"Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone","Antiviral Therapy",null,"English","Article",null,null,null,null,null,null,"BONE-MARROW-TRANSPLANTATION; SPECTRUM ANTIVIRAL ACTIVITY; HEMORRHAGIC CYSTITIS; INFECTIONS; RECIPIENTS; THERAPY; REPLICATION; DRUGS; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE; NUCLEOSIDE","Background: We have previously reported that human adenovirus (HAdV) reference strains clearly show species-dependent resistance to ribavirin, whereas different species of HAdV are equally sensitive to cidofovir. All the serotypes tested were susceptible to cidofovir, whereas only serotypes from species C were sensitive to ribavirin. Here, we aimed to extend these investigations to clinical isolates. Methods: In vitro, we tested 126 isolates obtained from 65 patients included in a European survey of HAdV infection. Results: Among the 126 isolates tested, all presented cidofovir 50% inhibitory concentration (IC50) in the same range as the HAdV 5 reference strain. Regarding ribavirin, all isolates from species C (79 tested) showed an IC50 comparable with previously reported results for reference strains; however, 24/32, 2/6 and 3/3 tested isolates from species A, B and D, respectively, were shown to have a ribavirin IC50 comparable with the HAdV 5 reference strain (species Q, contrary to previous observations for reference strains of the same species. Among patients who were treated with cidofovir for disseminated HAdV infection, >= 4 sequential isolates could be obtained from 9 patients; no variation in cidofovir susceptibility could be detected. Conclusions: Cidofovir is active in vitro in all HAdV clinical isolates. Ribavirin was revealed to be active on most HAdV isolates from species A, B and D, and in all isolates from species C. Finally, no resistance to cidofovir became apparent in sequential isolates obtained from treated patients.","[Morfin, Florence; Frobert, Emilie; Mundweiler, Stephanie; Thouvenot, Danielle] Univ Lyon 1, Lab Virol & Pathogenese Humaine, CNRS, FRE 3011, F-69365 Lyon, France; [Morfin, Florence; Mundweiler, Stephanie; Thouvenot, Danielle] Hosp Civils Lyon, Ctr Biol & Pathol Est, Virol Lab, Lyon, France; [Dupuis-Girod, Sophie] Hosp Civils Lyon, Hop Debrousse, Hematol & Bone Marrow Transplantat Unit, Lyon, France; [Dupuis-Girod, Sophie] Hosp Civils Lyon, Genet Unit, Hop Hotel Dieu, Lyon, France; [Carrington, David] Reg Virus Lab, Bristol, Avon, England; [Sedlacek, Petr] Motol Univ Hosp, Dept Pediat, Prague, Czech Republic; [Bierings, Marc] Wilhelmina Kinderziekenhuis Hematol, Utrecht, Netherlands; [Cetkovsky, Petr] UHKT, Inst Hematol & Blood Transfus, Prague, Czech Republic; [Kroes, Aloys C. M.] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands; [van Tol, Maarten J. D.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands","Morfin, F, Univ Lyon 1, Lab Virol & Pathogenese Humaine, CNRS, FRE 3011, F-69365 Lyon, France","florence.morfin-sherpa@chu-lyon.fr","European funding EC [QLK2-CT-2002-01432]","This work has received European funding (EC project QLK2-CT-2002-01432).",null,33,0,"INT MEDICAL PRESS LTD","LONDON","2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND","1359-6535",null,null,"ANTIVIR THER","Antivir. Ther.",null,2009,14,1,null,null,null,55,61,null,null,7,"Infectious Diseases; Pharmacology & Pharmacy; Virology","413RC","ISI:000263809200006"]
[1,"J","Phillip, M; Lebenthal, Y; Lebl, J; Zuckerman-Levin, N; Korpal-Szczyrska, M; Marques, JS; Steensberg, A; Jons, K; Kappelgaard, AM; Ibanez, L",null,null,null,"Phillip, Moshe; Lebenthal, Yael; Lebl, Jan; Zuckerman-Levin, Nehama; Korpal-Szczyrska, Maria; Marques, Jorge Sales; Steensberg, Adam; Jons, Kirsten; Kappelgaard, Anne-Marie; Ibanez, Lourdes","European Norditropin SGA Study Grp","European Multicentre Study in Children Born Small for Gestational Age with Persistent Short Stature: Comparison of Continuous and Discontinuous Growth Hormone Treatment Regimens","Hormone Research",null,"English","Article",null,null,null,null,null,"Small for gestational age; Growth hormone; Short stature","CATCH-UP GROWTH; DOSE-RESPONSE TRIAL; GH TREATMENT; TURNER-SYNDROME; DOUBLE-BLIND; INSULIN SENSITIVITY; ADULT HEIGHT; FINAL HEIGHT; LONG-TERM; RETARDATION","The most effective growth hormone (GH)treatment regimen for increasing height in short children born small for gestational age (SGA) has not been well defined. Methods: Short SGA children (n=151, age 3-8 years, height less than -2.5 standard deviation scores) were randomised to receive low-dose GH for 2 years (0.033/0.033 mg/kg/day, n=51), high-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n=51) or were untreated for 1 year then received mid-dose GH for 1 year (0/0.067 mg/kg/day, n=47). Height, bone age and adverse events were determined at check-ups every 3 months. Results: The mean +/- SD additional height gain with GH after 1 year, relative to untreated controls, was higher with discontinuous high-dose than with continuous low-dose GH (6.5 +/- 0.2 vs. 3.3 +/- 0.2 cm). After 2 years, the additional height gain was similar between high- and low-dose GH groups (between-group treatment difference=0.2, 95% CI=-0.8 to 1.2 cm, p=0.702). Patients treated exclusively in the last year had a similar height gain to those in the other treatment groups (p=0.604). Conclusions: In short SGA children, continuous low-dose and discontinuous high- dose GH regimens were associated with similar height gain. Treatment with mid-dose GH for 1 year also led to a similar improvement in growth. Copyright (C) 2008 S. Karger AG, Basel","[Phillip, Moshe] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Natl Ctr Childhood Diabet, Inst Endocrinol & Diabet, IL-69978 Tel Aviv, Israel; [Phillip, Moshe; Lebenthal, Yael] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Zuckerman-Levin, Nehama] Meyer Childrens Hosp, Rambam Med Ctr, Haifa, Israel; [Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Korpal-Szczyrska, Maria] Med Univ Gdansk, Dept Pediat Endocrinol, Gdansk, Poland; [Marques, Jorge Sales] Ctr Hosp Vila Nova Gaia, Dept Pediat, Gaia, Portugal; [Steensberg, Adam; Jons, Kirsten; Kappelgaard, Anne-Marie] Novo Nordisk AS, Global Dev, Copenhagen, Denmark; [Ibanez, Lourdes] Univ Barcelona, Hosp St Joan de Deu, Endocrine Unit, Barcelona, Spain","Phillip, M, Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Natl Ctr Childhood Diabet, Inst Endocrinol & Diabet, 14 Kaplan St,Petah Tikva 492-2, IL-69978 Tel Aviv, Israel","mosheph@post.tau.ac.il","Novo Nordisk A/S ","This study was sponsored by Novo Nordisk A/S. The authors are grateful to the following investigators and study sites who participated in the study. Leo Dunkel, Marita Lipsanen-Nyman, Ilkka Sipila, Timo Otonkoski and Risto Lapatto, Helsinki, Raimo Voutilainen, Sirpa Tenhola, Ulla Sankilampi, Kuopio, and Paivi Tapanainen and Riitta Veijola, Oulu, Finland; Jirina Zapletalova, Olomouc, Dana Novotna, Brno, Jaroslav Skvor, Usti nad Labem, and Jan Lebl, Stanislava Kolouskova and Bozena Kalvachova, Prague, Czech Republic; Ester Liberman, Eli Hershkovitz and Neta Loewenthal, Be'er Sheva, Moshe Phillip and Yael Lebenthal, Petach-Tikva, Zvi Zadik and Amnon Zang, Rehovot, and Ze'ev Hochberg, Nehama Zukerman-Levin and Dov Tiosano, Haifa, Israel; Tomasz Romer and Alicja Korpysz, Warsaw, Jerzy Starzyk, Agata Zygmunt Gorska, Malgorzata Kumorowicz-Kopiec, Dominika Janus, Dorota Roztoczynska, Anna Kalicka-Kasperczyk, Aleksandra Gorska, Katarzyna Dolezal-Oltarzewska, Dorota Bilecka and Edyta Piatkowska, Krakow, and Maria Korpal-Szczyrska, Bohdana Dorant, Halina Kaminska and Dorota Birkholz, Gdansk, Poland; Eberhard Keller, Johannes Weigel, Alexandra Keller and Sabine Liebermann, Leipzig, Klaus-Peter Ullrich, Gotha, and Stefan Wirth and Philip Wintermeyer, Wuppertal, Germany; Manuel Jorge Fontoura Pinheiro de Magalhaes and Cintia Goncalves Castro-Correia, Porto, Mario Aires Marcelo da Fonseca, Matosinhos, Luis Francisco Simoes de Moura and Maria Alice Santos Cordeiro Mirante, Coimbra, and Jorge Manuel Sales Marques, Jacinto Americo Silva Torres, Rosa Armenia Martins Campos and Marta Vila Real Magalhaes Coelho, Vila Nova de Gaia, Portugal; Jesus Argente Oliver, Jesus Pozo, Ricardo Gracia Bouthelier, Antonio Oliver Iguacel, Amparo Rodriguez Sanchez and Dolores Rodriguez Arnao, Madrid, Concepcion Carles Genotes and Vicente Albiach, Valencia, Antonio Carrascosa Lezcano and Diego Yeste, Francisco Rodriguez-Hierro and Lourdes Ibanez, Barcelona, Juan Manuel Fernandez Garcia and Carlos ;Ruiz, Granada, Juan Pedro Lopez-Siguero, Maria Jose Martinez Aedo and Almudena del Pino, Malaga, and Manuel Pombo Arias and Jesus Barreiro Conde, Santiago de Compostela, Spain; Olle Soder and Eva Horemizova, Stockholm, Jan Aman, Orebro, and Mirek Vejvoda and Christian Penno, Helsingborg, Sweden.",null,37,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0301-0163",null,"10.1159/000173742","HORMONE RES","Horm. Res.",null,2009,71,1,null,null,null,52,59,null,null,8,"Endocrinology & Metabolism","394DB","ISI:000262424700008"]
[1,"J","Cada, Z; Chovanec, M; Smetana, K; Betka, J; Lacina, L; Plzak, J; Kodet, R; Stork, J; Lensch, M; Kaltner, H; Andre, S; Gabius, HJ",null,null,null,"Cada, Z.; Chovanec, M.; Smetana, K., Jr.; Betka, J.; Lacina, L.; Plzak, J.; Kodet, R.; Stork, J.; Lensch, M.; Kaltner, H.; Andre, S.; Gabius, H-J.",null,"Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas?","Histology And Histopathology",null,"English","Article",null,null,null,null,null,"Carcinoma; Collagen IV; Galectin; Keratinization; Lectin","MAMMALIAN LECTINS; P53-INDUCED GENE-1; ENDOGENOUS LECTINS; NUCLEAR PRESENCE; ANIMAL LECTINS; TUMOR-CELLS; EXPRESSION; CANCER; DIFFERENTIATION; PROGRESSION","The human lectin galectin-7 (Gal-7; p53-induced gene-1) has anti- and pro-malignant features in different in vitro models. We tried to clarify relation of its expression to cellular and clinical parameters in head and neck squamous and basal cell carcinomas. Using a non-cross-reactive antibody, immunohistochemical staining in squamous cell epithelia (epidermis, epithelium of oropharynx and larynx) (n = 57), squamous cell carcinomas (n = 47) and lymph node metastases (n = 25), as well as basal cell carcinomas (n = 10) were studied. This monitoring was flanked by processing to assess the level of differentiation (cytokeratins 10 and 14), proliferation (Ki67) and basal lamina formation (collagen IV). The results were correlated with clinical and pathological findings (grading, TNM-staging, extracapsular spread, angio- and lymphangioinvasion, perineural invasion, recurrence and survival). Gal-7 resides in all layers of epithelia with cytoplasmic and nuclear localization in normal specimens. Basal cell carcinomas were devoid of the Gal-7 respective signal. Squamous cell carcinomas were positive, presenting different staining profiles. Intense staining was predominantly found in squamous cell cancers with high degrees of differentiation and keratinization. Fittingly, poor level of differentiation (P = 0.0009), absence of keratinization (P = 0.0105) and significant discontinuity or absence of collagen IV expression in the peritumoral basal lamina (P = 0.0024) was found in Gal-7-negative tumors. Gal-7 presence was not related to gender, primary tumor site, T-stage, Nstage, clinical stage, extracapsular spread, angio- and lymphangioinvasion, perineural spread or treatment outcome at a statistically significant level. Immunohistochemical analysis revealed a positive correlation for differentiation and keratinization to Gal-7 presence in squamous cell carcinomas. Absence of Gal-7 expression was detected in basal cell carcinomas. These clinical data delineate Gal-7 influence on differentiation in vivo, without evidence for a role in dissemination reported for lymphoma.","[Chovanec, M.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Inst Anat, Prague 15006 5, Czech Republic; [Cada, Z.; Chovanec, M.; Betka, J.; Plzak, J.] Fac Hosp Motol, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Chovanec, M.; Smetana, K., Jr.; Plzak, J.] Fac Hosp Motol, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Lacina, L.; Stork, J.] Gen Teaching Hosp, Dept Dermatovenerol, Prague, Czech Republic; [Kodet, R.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Kodet, R.] Fac Hosp Motol, Inst Pathol & Mol Med, Prague, Czech Republic; [Lensch, M.; Kaltner, H.; Andre, S.; Gabius, H-J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Chovanec, M, Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Inst Anat, Uvalu 84, Prague 15006 5, Czech Republic","martin.chovanec@lf1.cuni.cz","IGA MZ CR [NR 9049-3]; Ministry of Education, Youth and Sport of the Czech Republic [MSM 002160806]; GA CR [304/08/P175]; LMUexcellent and by an EC Marie Curie Research Training Network [MRTN-CT-2005-019561]","The study was supported by the IGA MZ CR, project No. NR 9049-3, by the Ministry of Education, Youth and Sport of the Czech Republic, project No. MSM 002160806, by the GA CR, project No 304/08/P175, by the research initiative LMUexcellent and by an EC Marie Curie Research Training Network grant (contract No. MRTN-CT-2005-019561). Authors are grateful to Dr. B. Friday and Prof. Dr. S. Namirha for valuable discussion, to Prof. Dr. D. Sedmera for critical reading as well as to Eva Vancovu and Vit Hajduch for excellent technical assistance.",null,40,0,"F HERNANDEZ","MURCIA","PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN","0213-3911",null,null,"HISTOL HISTOPATHOL","Histol. Histopath.","JAN",2009,24,1,null,null,null,41,48,null,null,8,"Cell Biology; Pathology","383TP","ISI:000261696700005"]
[1,"J","Seidel, MG; Minkov, M; Witt, V; Matthes-Martin, S; Potschger, U; Worel, N; Leitner, G; Stary, J; Gadner, H; Peters, C",null,null,null,"Seidel, Markus G.; Minkov, Milen; Witt, Volker; Matthes-Martin, Susanne; Poetschger, Ulrike; Worel, Nina; Leitner, Gerda; Stary, Jan; Gadner, Helmut; Peters, Christina",null,"Granulocyte Transfusions in Children and Young Adults Does the Dose Matter?","Journal of Pediatric Hematology Oncology",null,"English","Article",null,null,null,null,null,"febrile neutropenia; invasive aspergillosis; granulocyte transfusions; infectious complications; stem cell transplantation; high-dose chemotherapy","STEM-CELL TRANSPLANTATION; G-CSF; STIMULATING FACTOR; INDIUM-111-LABELED GRANULOCYTES; NEUTROPENIC PATIENTS; PEDIATRIC-PATIENTS; SEVERE INFECTIONS; DONORS; RECIPIENTS; EFFICACY","Background: Granulocyte transfusions (GTs) may increase the absolute neutrophil count (ANC) before hematopoietic regeneration in neutropenic patients after chemotherapy or hematopoietic stem cell transplantation and Support anti-infective immunity. Procedure: We assessed efficacy and tolerability of 778 GTs in 70 treatment episodes of 49 children and 10 Young adults [median age 6.28 y (range: 0.13 to 17.7 y) and 21 y (18.0 to 28.0), respectively] suffering from bacterial (n = 55) and/or fungal (n = 31) infections during neutropenia owing to conventional chemotherapy (n = 14), hematopoietic stein cell transplantation conditioning (it 44), or the underlying disease (n = 1). We analyzed the impact of body weight. organ dysfunction, neutrophil close on ANC increment. infection elimination, and survival. Results: The median day-5 ANC increment was 1460/mu L, correlating to the administered close. However, 28-day survival did not correlate to the neutrophil dose nor to the ANC increment., potentially owing to the high number of neutrophils transfused to all patients (median > 6 x 10(9)/kg within 5d). The 28-day survival probability of the total patient cohort was 0.72 +/- 0.06 and the 100-day survival was 0.52 +/- 0.07. Adverse reactions were rare including fever (<= World Health Organization grade 111. 14%), chills (3%), and mild pulmonary complications (1%). Conclusions: These data corroborate the empirical evidence that GT with sufficient cell doses and rapid availability are a feasible, well-tolerated supplemental means to fight severe infections in neutropenic patients.","[Seidel, Markus G.; Minkov, Milen; Witt, Volker; Matthes-Martin, Susanne; Poetschger, Ulrike; Gadner, Helmut; Peters, Christina] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Worel, Nina; Leitner, Gerda] Med Univ Vienna, Clin Blood Grp Serol & Transfus Med, Vienna, Austria; [Stary, Jan] Univ Hosp Praha Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic","Peters, C, St Anna Childrens Hosp, Kinderspitalgasse 6, A-1090 Vienna, Austria","christina.peters@Stanna.at",null,null,null,22,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1077-4114",null,null,"J PEDIAT HEMATOL ONCOL","J. Pediatr. Hematol. Oncol.","MAR",2009,31,3,null,null,null,166,172,null,null,7,"Oncology; Hematology; Pediatrics","415HL","ISI:000263924800004"]
[1,"J","Hajek, M; Krsek, P; Dezortova, M; Marusic, P; Zamecnik, J; Kyncl, M; Tomasek, M; Krijtova, H; Komarek, V",null,null,null,"Hajek, Milan; Krsek, Pavel; Dezortova, Monika; Marusic, Petr; Zamecnik, Josef; Kyncl, Martin; Tomasek, Martin; Krijtova, Hana; Komarek, Vladimir",null,"H-1 MR spectroscopy in histopathological subgroups of mesial temporal lobe epilepsy","European Radiology",null,"English","Article",null,null,null,null,null,"MR spectroscopy; Temporal lobe epilepsy; Hippocampus; Malformations of cortical development; Treatment outcome","MAGNETIC-RESONANCE-SPECTROSCOPY; HIPPOCAMPAL SCLEROSIS; DUAL PATHOLOGY; LATERALIZATION; LOBECTOMY; SPECTRA; SURGERY; P-31; ABNORMALITIES; DYSFUNCTION","The aim of the study was to analyze the lateralizing value of proton magnetic resonance spectroscopy (H-1 MRS) in histopathologically different subgroups of mesial temporal lobe epilepsies (MTLE) and to correlate results with clinical, MRI and seizure outcome data. A group of 35 patients who underwent resective epilepsy surgery was retrospectively studied. Hippocampal H-1 MR spectra were evaluated. Metabolite concentrations were obtained using LCModel and NAA/Cr, NAA/Cho, NAA/(Cr+Cho), Cho/Cr ratios and coefficients of asymmetry were calculated. MRI correctly lateralized 89% of subjects and H-1 MRS 83%. MRI together with H-1 MRS correctly lateralized 100% of patients. Nineteen subjects had \"classical\" hippocampal sclerosis (HS), whereas the remaining 16 patients had \"mild\" HS. Nineteen patients had histopathologically proven malformation of cortical development (MCD) in the temporal pole; 16 subjects had only HS. No difference in H-1 MRS findings was found between patients in different histopathological subgroups of MTLE. Our results support the hypothesis that H-1 MRS abnormalities do not directly reflect histopathological changes in MTLE patients. Subjects with non-lateralized H-1 MRS abnormalities did not have a worse postoperative seizure outcome. We found no significant impact of contralateral H-1 MRS abnormality on post-surgical seizure outcome.","[Krsek, Pavel; Komarek, Vladimir] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Pediat Neurol, Prague 15006 5, Czech Republic; [Hajek, Milan; Dezortova, Monika] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Prague, Czech Republic; [Marusic, Petr; Tomasek, Martin; Krijtova, Hana] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Neurol, Prague 15006 5, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Kyncl, Martin] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Radiol, Prague 15006 5, Czech Republic","Krsek, P, Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Pediat Neurol, V Uvalu 84, Prague 15006 5, Czech Republic","pavel.krsek@post.cz","GACR [309/02/D076]; IGA [NR/8843-4, 00000064203, MZ0IKEM2005]","Supported by grants GACR no. 309/02/D076 and IGA no. NR/8843-4 and Research Projects nos. 00000064203 and MZ0IKEM2005.",null,41,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0938-7994",null,"10.1007/s00330-008-1156-x","EUROPEAN RADIOL","Eur. Radiol.","FEB",2009,19,2,null,null,null,400,408,null,null,9,"Radiology, Nuclear Medicine & Medical Imaging","396GA","ISI:000262579000017"]
[1,"J","Ondrouskova, E; Slovackova, J; Pelkova, V; Prochazkova, J; Soucek, K; Benes, P; Smarda, J",null,null,null,"Ondrouskova, Eva; Slovackova, Jana; Pelkova, Vendula; Prochazkova, Jirina; Soucek, Karel; Benes, Petr; Smarda, Jan",null,"Heavy metals induce phosphorylation of the Bcl-2 protein by Jun N-terminal kinase","Biological Chemistry",null,"English","Article",null,null,null,null,null,"Bcl-2; heavy metals; Jun N-terminal kinase; phosphorylation; posttranslational modification","ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; SIGNALING PATHWAY; FAMILY PROTEINS; BREAST-CANCER; CELL-DEATH; INHIBITION; ARREST; ZINC; MICROTUBULES","The Bcl-2 protein is one of the key components of biochemical pathways controlling programmed cell death. The function of this protein can be regulated by post-translational modifications. Phosphorylation of Bcl-2 has been considered to be significantly associated with cell cycle arrest in the G2/M phase of the cell cycle, and with cell death caused by defects of microtubule dynamics. This study shows that phosphorylation of Bcl-2 can be induced by heavy metals due to activation of the Jun N-terminal kinase pathway that is not linked to the G2/M cell cycle arrest. Furthermore, we demonstrate that hyperphosphorylated Bcl-2 protein is a more potent inhibitor of zinc-induced cell death than its hypophosphorylated mutant form. These data suggest that regulation of Bcl-2 protein function by phosphorylation is an important part of cell responses to stress.","[Ondrouskova, Eva; Slovackova, Jana; Pelkova, Vendula; Prochazkova, Jirina; Benes, Petr; Smarda, Jan] Masaryk Univ, Inst Expt Biol, Fac Sci, CZ-61137 Brno, Czech Republic; [Slovackova, Jana] Univ Hosp, Dept Pathol, CZ-62500 Brno, Czech Republic; [Pelkova, Vendula] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CZ-15006 Prague, Czech Republic; [Prochazkova, Jirina; Soucek, Karel] Acad Sci Czech Republic, Inst Biophys, CZ-61265 Brno, Czech Republic","Smarda, J, Masaryk Univ, Inst Expt Biol, Fac Sci, Kotlarska 2, CZ-61137 Brno, Czech Republic","smarda@sci.muni.cz","Ministry of Education, Youth and Sports of the Czech Republic [MSM0021622415]; Grant Agency of the Czech Republic [301/06/0036]; Grant Agency of Academy of Sciences of the Czech Republic [IAA501630801]; Czech Science Foundation [204/07/0834]; Research Plans [AVOZ50040507]; Academy of Sciences of the Czech Republic [AVOZ50040702]","We are grateful to M. Cleary, D. Huang, and S. Lin for providing the expression vectors and to Sevcikova for stable transfection of BM2 cells and for the correction of English in the manuscript. We also thank A. Kozubik and J. Hofmanova for the kind provision of FACSCalibur and J. Maresova for technical assistance. This work was funded by grant MSM0021622415 of the Ministry of Education, Youth and Sports of the Czech Republic, grant 301/06/0036 of the Grant Agency of the Czech Republic, grant IAA501630801 of the Grant Agency of Academy of Sciences of the Czech Republic, grant 204/07/0834 of the Czech Science Foundation and by the Research Plans AVOZ50040507, and AVOZ50040702 of Academy of Sciences of the Czech Republic.",null,53,0,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1431-6730",null,"10.1515/BC.2009.007","BIOL CHEM","Biol. Chem.","JAN",2009,390,1,null,null,null,49,58,null,null,10,"Biochemistry & Molecular Biology","405TT","ISI:000263247800008"]
[1,"J","Mazanec, R; Horacek, O; Kobesova, A; Smetana, R",null,null,null,"Mazanec, R.; Horacek, O.; Kobesova, A.; Smetana, R.",null,"Hereditary Neuropathy","Ceska a Slovenska Neurologie a Neurochirurgie",null,"Czech","Article",null,null,null,null,null,"hereditary neuropathy; Charcot-Marie-Tooth; pes cavus; electromyography; molecular genetics","MARIE-TOOTH-DISEASE; MUSCULAR-ATROPHY SYNDROME; SENSORY NEUROPATHY; CENTRAL CONDUCTION; ASCORBIC-ACID; NERVE BIOPSY; MOUSE MODEL; MUTATIONS; GENE; MOTOR","Hereditary neuropathy is a clinically and genetically heterogeneous group of diseases which most often represent a hereditary neuromuscular disorder. The prevalence is approximately 17-40 per 100,000. The most frequent form is called Charcot-Marie-Tooth disease (CMT) or hereditary motor and sensitive neuropathy (HMSN). In most cases, the clinical symptoms appear in the 1(st) and 2(nd) decade and include atrophy and weakness of lower limb muscles (peroneal atrophy), the pes cavus deformity of the foot with a shortened Achilles tendon, areflexia in the lower limbs and the stocking type sensory disorder. The basic classification of hereditary neuropathies is based on electrophysiological studies which classify CMT disease into two basic types. Type no. 1 - demyelinisation - with the n. medianus motor fibre conduction velocity at forearm below 38 m/s, and type no. 2 - axonal - with a velocity above 38 m/s. Molecular geneticists have so far identified causal mutations in 40 genes and have made a major contribution to molecular genetic classification of CMT disease and to the understanding of pathogenesis of the most frequent forms of hereditary neuropathies. Heredity involves all types of monogenic Mendelian inheritance: autosomal dominant, autosomal recessive and gonosomal dominant. Because causal therapy does not exist, current therapeutic approach is based on rehabilitation, prosthetic and orthopedic treatment. In a vast majority of cases, the prognosis of patients is good as this condition does not impair their standard life expectancy, even though it has a major impact on the patients' quality of life.","[Mazanec, R.] LF UK FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic; [Horacek, O.; Kobesova, A.] LF UK FN Motole, Rehabilitacni Klin 2, Prague 15006 5, Czech Republic; [Smetana, R.] LF UK FN Motole, Il Ortoped Klin 2, Prague 15006 5, Czech Republic","Mazanec, R, LF UK FN Motole, Neurol Klin 2, V Uvalu 84, Prague 15006 5, Czech Republic","radim.mazanec@email.cz",null,null,null,54,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,1,null,null,null,5,16,null,null,12,"Neurosciences; Surgery","413EB","ISI:000263774600001"]
[1,"J","de Vries, ACH; Bredius, RGM; Lankester, AC; Bierings, M; Trebo, M; Sedlacek, P; Niemeyer, CM; Zecca, M; Locatelli, F; van den Heuvel-Eibrink, MM",null,null,null,"de Vries, Andrica C. H.; Bredius, Robbert G. M.; Lankester, Arjan C.; Bierings, Marc; Trebo, Monika; Sedlacek, Petr; Niemeyer, Charlotte M.; Zecca, Marco; Locatelli, Franco; van den Heuvel-Eibrink, Marry M.",null,"HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia","Haematologica-The Hematology Journal",null,"English","Letter",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; WORKING-GROUP; CHILDREN; JMML",null,"[van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus Med Ctr, NL-3015 GJ Rotterdam, Netherlands; [Bredius, Robbert G. M.; Lankester, Arjan C.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands; [Bierings, Marc] UMCU Wilhelmina Childrens Hosp, Dept Pediat Hematol Oncol, Utrecht, Netherlands; [Trebo, Monika] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Niemeyer, Charlotte M.] Univ Freiburg, Dept Pediat, D-7800 Freiburg, Germany; [Zecca, Marco; Locatelli, Franco] Univ Pavia, Fondaz IRCCS Policlin San Matteo, I-27100 Pavia, Italy","van den Heuvel-Eibrink, MM, Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus Med Ctr, Room Sp 2568,Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","m.vandenheuvel@erasmusmc.nl",null,null,null,11,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2008.000216","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","FEB",2009,94,2,null,null,null,302,304,null,null,3,"Hematology","404PE","ISI:000263164700027"]
[1,"J","Eckschlager, T; Radvanska, J; Slaby, K; Prusa, R; Hochova, I; Radvansky, J",null,null,null,"Eckschlager, T.; Radvanska, J.; Slaby, K.; Prusa, R.; Hochova, I.; Radvansky, J.",null,"Changes of blood count, lymphocyte subpopulations and immunoglobulin levels in nephroblastoma long term survivors","Neoplasma",null,"English","Article",null,null,null,null,null,"nephroblastoma long-term survivors; blood count; lymphocyte subpopulations; immunoglobulin G, A, M serum levels","WILMS-TUMOR; HODGKINS-DISEASE; CANCER; CHILDHOOD","The aim of this study was to investigate the frequency of blood count, lymphocyte subpopulations, and immunoglobulin levels alterations in a group of healthy nephroblastoma long-term survivors. The group included 122 nephroblastoma long-term survivors who were at least five years post anticancer therapy and free of any sign of recurrence. The proportion of lumphocyte subpopulations was analyzed by flow cytometry using antibodies anti CD45 FITC/CD14 PE, anti CD3 FITC/CD16+CD56 PE. anti CD4 FITC/CD8 PE and anti CD20 FITC. Immunoglobulin G, A, and M levels were evaluated by immunoturbidimetry. Total blood Count was, also examined. The Occurrence of decreased immunoglobulin levels, leukocytes, lymphocytes, and granulocytes count, proportion of T lymphocytes and their CD4+ subpopulation are not frequent. The most frequently decreased lymphocyte subpopulation was CD8 (15.5%). The most frequent abnormal findings were increased proportion of NK cells (38.5%), B lymphocytes (38,52%), decreased number of erythrocytes (25.2%), hemoglobin levels (41.7%) and hematocrit (13.9%). The only significant differences between results of immunological examination and course of the disease were more frequently decreased proportion of CD4+ lymphocytes ill recurrent disease Survivors and lower IgA levels in survivors after radiotherapy. We found decreased at least one immunological parameter in one fifth of the Survivors. The most frequently altered parameter was hemoglobin, which was decreased in 41.7% of survivors. Decraesed hemoglobin may worsen quality of survivors' life.","[Eckschlager, T.; Radvanska, J.] 2nd Med Sch & Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Slaby, K.; Radvansky, J.] 2nd Med Sch & Univ Hosp Motol, Dept Sport Med, Prague, Czech Republic; [Prusa, R.] 2nd Med Sch & Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Prague, Czech Republic; [Hochova, I.] 2nd Med Sch & Univ Hosp Motol, Dept Clin Hematol, Prague, Czech Republic","Eckschlager, T, 2nd Med Sch & Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic","eckschlagertomas@yahoo.com","IGA [NR/87/96-3]; MSMT [0021620813]","This work Was Supported by the grants IGA NR/87/96-3 and MSMT No 0021620813.",null,13,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2009,56,1,null,null,null,9,12,null,null,4,"Oncology","396TN","ISI:000262614200002"]
[1,"J","Krsek, P; Maton, B; Jayakar, P; Dean, P; Korman, B; Rey, G; Dunoyer, C; Pacheco-Jacome, E; Morrison, G; Ragheb, J; Vinters, HV; Resnick, T; Duchowny, M",null,null,null,"Krsek, P.; Maton, B.; Jayakar, P.; Dean, P.; Korman, B.; Rey, G.; Dunoyer, C.; Pacheco-Jacome, E.; Morrison, G.; Ragheb, J.; Vinters, H. V.; Resnick, T.; Duchowny, M.",null,"Incomplete resection of focal cortical dysplasia is the main predictor of poor postsurgical outcome","Neurology",null,"English","Article",null,null,null,null,null,null,"PEDIATRIC EPILEPSY SURGERY; SURGICAL-TREATMENT; INTRACTABLE EPILEPSY; INTRINSIC EPILEPTOGENICITY; CHILDREN; MALFORMATIONS; LESIONS; EEG; CLASSIFICATION; SUBTYPES","Background: Focal cortical dysplasia (FCD) is recognized as the major cause of focal intractable epilepsy in childhood. Various factors influencing postsurgical seizure outcome in pediatric patients with FCD have been reported. Objective: To analyze different variables in relation to seizure outcome in order to identify prognostic factors for selection of pediatric patients with FCD for epilepsy surgery. Methods: A cohort of 149 patients with histologically confirmed mild malformations of cortical development or FCD with at least 2 years of postoperative follow-up was retrospectively studied; 113 subjects had at least 5 years of postoperative follow-up. Twenty-eight clinical, EEG, MRI, neuropsychological, surgical, and histopathologic parameters were evaluated. Results: The only significant predictor of surgical success was completeness of surgical resection, defined as complete removal of the structural MRI lesion (if present) and the cortical region exhibiting prominent ictal and interictal abnormalities on intracranial EEG. Unfavorable surgical outcomes are mostly caused by overlap of dysplastic and eloquent cortical regions. There were nonsignificant trends toward better outcomes in patients with normal intelligence, after hemispherectomy and with FCD type II. Other factors such as age at seizure onset, duration of epilepsy, seizure frequency, associated pathologies including hippocampal sclerosis, extent of EEG and MRI abnormalities, as well as extent and localization of resections did not influence outcome. Twenty-five percent of patients changed Engel's class of seizure outcome after the second postoperative year. Conclusions: The ability to define and fully excise the entire region of dysplastic cortex is the most powerful variable influencing outcome in pediatric patients with focal cortical dysplasia. Neurology (R) 2009;72:217-223","[Krsek, P.] Charles Univ Prague, Sch Med 2, Motol Univ Hosp, Dept Pediat Neurol, CZ-15006 Prague 5, Czech Republic; [Maton, B.; Jayakar, P.; Dean, P.; Dunoyer, C.; Resnick, T.; Duchowny, M.] Miami Childrens Hosp, Inst Brain, Dept Neurol, Miami, FL USA; [Maton, B.; Jayakar, P.; Dean, P.; Dunoyer, C.; Resnick, T.; Duchowny, M.] Miami Childrens Hosp, Inst Brain, Comprehens Epilepsy Program, Miami, FL USA; [Korman, B.; Rey, G.] Miami Childrens Hosp, Inst Brain, Neuropsychol Sect, Miami, FL USA; [Pacheco-Jacome, E.] Miami Childrens Hosp, Inst Brain, Dept Radiol, Miami, FL USA; [Morrison, G.; Ragheb, J.] Miami Childrens Hosp, Inst Brain, Dept Neurol Surg, Miami, FL USA; [Resnick, T.; Duchowny, M.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA","Krsek, P, Charles Univ Prague, Sch Med 2, Motol Univ Hosp, Dept Pediat Neurol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","pavel.krsek@post.cz","[IGA NR/8843-4]; [VZ MZO 00064203]","Supported by grant IGA NR/8843-4 and VZ MZO 00064203.",null,30,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0028-3878",null,null,"NEUROLOGY","Neurology","JAN 20",2009,72,3,null,null,null,217,223,null,null,7,"Clinical Neurology","396XE","ISI:000262624300005"]
[1,"J","Duricova, D; Pedersen, N; Lenicek, M; Hradsky, O; Bronsky, J; Adamcova, M; Elkjaer, M; Andersen, PS; Vitek, L; Larsen, K; Lukas, M; Nevoral, J; Wewer, V; Munkholm, P",null,null,null,"Duricova, D.; Pedersen, N.; Lenicek, M.; Hradsky, O.; Bronsky, J.; Adamcova, M.; Elkjaer, M.; Andersen, P. S.; Vitek, L.; Larsen, K.; Lukas, M.; Nevoral, J.; Wewer, V.; Munkholm, P.",null,"Infliximab dependency in children with Crohn's disease","Alimentary Pharmacology & Therapeutics",null,"English","Article",null,null,null,null,null,null,"INFLAMMATORY-BOWEL-DISEASE; EVIDENCE BASED CONSENSUS; MAINTENANCE INFLIXIMAB; PEDIATRIC-PATIENTS; NATURAL-HISTORY; FOLLOW-UP; THERAPY; COHORT; GENE; NOD2/CARD15",null,"[Pedersen, N.; Elkjaer, M.; Munkholm, P.] Univ Copenhagen, Herlev Hosp, Med Sect, Gastrointestinal Unit, DK-2730 Herlev, Denmark; [Lenicek, M.; Vitek, L.] Charles Univ Prague, Inst Clin Biochem, Prague, Czech Republic; [Lenicek, M.; Vitek, L.] Charles Univ Prague, Diagnost Lab, Fac Med 1, Prague, Czech Republic; [Hradsky, O.; Bronsky, J.; Nevoral, J.] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Hradsky, O.; Bronsky, J.; Nevoral, J.] Univ Hosp Motol Prague, Prague, Czech Republic; [Larsen, K.] Univ Copenhagen, Hvidovre Hosp, Dept Stat Unit, DK-2650 Hvidovre, Denmark; [Lukas, M.] Charles Univ Prague, IBD Ctr, ISCARE IVF As, Prague, Czech Republic; [Wewer, V.] Univ Copenhagen, Hvidovre Hosp, Dept Paediat, DK-2650 Hvidovre, Denmark; [Duricova, D.; Vitek, L.] Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Prague, Czech Republic; [Adamcova, M.] Charles Univ Prague, Dept Paediat, Hosp Fac Med 1, Prague, Czech Republic; [Andersen, P. S.] State Serum Inst, Dept Clin Biochem, Copenhagen, Denmark","Munkholm, P, Herlev Univ Hosp, Dept Med Gastroenterol, Herlev Ringvej 75, DK-2730 Herlev, Denmark","pia_munkholm@mail.dk",null,null,null,37,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0269-2813",null,"10.1111/j.1365-2036.2009.03926.x","ALIMENT PHARMACOL THERAPEUT","Aliment. Pharmacol. Ther.","APR 1",2009,29,7,null,null,null,null,null,null,"10.1111/j.1365-2036.2009.03926.x",8,"Gastroenterology & Hepatology; Pharmacology & Pharmacy","415BI","ISI:000263908900011"]
[1,"J","Webb, NJA; Prokurat, S; Vondrak, K; Watson, AR; Hughes, DA; Marks, SD; Moghal, NE; Fitzpatrick, MM; Milford, DV; Saleem, MA; Jones, CA; Friman, S; Van Damme-Lombaerts, R; Janssen, F; Hamer, C; Rhodes, S",null,null,null,"Webb, Nicholas J. A.; Prokurat, Sylwester; Vondrak, Karel; Watson, Alan R.; Hughes, David A.; Marks, Stephen D.; Moghal, Nadeem E.; Fitzpatrick, Maggie M.; Milford, David V.; Saleem, Moin A.; Jones, Caroline A.; Friman, Styrbjorn; Van Damme-Lombaerts, Rita; Janssen, Francoise; Hamer, Clare; Rhodes, Sarah",null,"Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data","Pediatric Nephrology",null,"English","Article",null,null,null,null,null,"Renal transplantation; Basiliximab; Interleukin-2 receptor (IL2R) antibodies; Graft survival; Acute rejection; Long-term survival","PEDIATRIC RENAL-TRANSPLANTATION; CYCLOSPORINE MICROEMULSION; RECIPIENTS; TOLERABILITY; EFFICACY; CHILDREN","A total of 192 children and adolescents undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS, n=93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B, n=99). Six-month outcome data have previously been reported; this manuscript reports the 2-year data. Complete 2-year data were available on 164 (85.4%) of the original 192 patients. There was a single death in the TAS arm. Kaplan-Meier estimates of survival free of graft loss at 2 years were 94.9% in the TAS + B arm and 89.6% in the TAS arm [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.17 to 1.54, P=0.23]. Estimates of survival free from rejection at 2 years were 75.2% in the TAS + B arm and 68.7% in the TAS arm (HR 0.81; 95% CI 0.46 to 1.40, P=0.44). The mean estimated glomerular filtration rate (GFR) at 2 years, was 65.8 ml/min per 1.73 m(2) body surface area in the TAS arm and 66.7 ml/min per 1.73 m(2) in the TAS + B arm (P=0.78). Blood pressure and cholesterol levels were similar in the two arms, and there was no evidence of a difference in the incidence of infection or malignancy. These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk.","[Webb, Nicholas J. A.] Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester M27 4HA, Lancs, England; [Prokurat, Sylwester] Childrens Mem Hlth Inst, Dept Paediat Nephrol, Warsaw, Poland; [Vondrak, Karel] Univ Hosp Motol, Pediat Clin, Prague, Czech Republic; [Watson, Alan R.] Children & Young Peoples Kidney Unit, Nottingham, England; [Hughes, David A.] Royal Hosp Sick Children, Dept Paediat Nephrol, Glasgow G3 8SJ, Lanark, Scotland; [Marks, Stephen D.] Great Ormond St Hosp Sick Children, Dept Paediat Nephrol, London, England; [Moghal, Nadeem E.] Royal Victoria Infirm, Dept Paediat Nephrol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Fitzpatrick, Maggie M.] St James Univ Hosp, Dept Paediat Nephrol, Leeds, W Yorkshire, England; [Milford, David V.] Birmingham Childrens Hosp, Dept Paediat Nephrol, Birmingham, W Midlands, England; [Saleem, Moin A.] Bristol Childrens Hosp, Dept Paediat Nephrol, Bristol, Avon, England; [Jones, Caroline A.] Royal Liverpool Childrens Hosp, Dept Paediat Nephrol, Liverpool L7 7DG, Merseyside, England; [Friman, Styrbjorn] SU Sahlgrenska Univ Hosp, Gothenburg, Sweden; [Van Damme-Lombaerts, Rita] U2 Gasthuisberg, Louvain, Belgium; [Janssen, Francoise] Hop Univ Enfants Reine Fabiola, Brussels, Belgium; [Hamer, Clare] Manchester Royal Infirm, Dept Transplantat, Manchester M13 9WL, Lancs, England; [Rhodes, Sarah] Pennine Acute Hosp NHS Trust, Dept Res & Dev, Manchester, Lancs, England","Webb, NJA, Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester M27 4HA, Lancs, England","nicholas.webb@cmmc.nhs.uk","Astellas (formerly Fujisawa) ","This study was supported by an unrestricted educational grant from Astellas (formerly Fujisawa). The authors would like to thank all members of their transplant teams who contributed to data collection.",null,13,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-008-0931-x","PEDIAT NEPHROL","Pediatr. Nephrol.","JAN",2009,24,1,null,null,null,177,182,null,null,6,"Pediatrics; Urology & Nephrology","403DY","ISI:000263064300025"]
[1,"J","Szabo, P; Dam, TK; Smetana, K; Dvorankova, B; Kurbler, D; Brewer, CF; Gabius, HJ",null,null,null,"Szabo, P.; Dam, T. K.; Smetana, K., Jr.; Dvorankova, B.; Kuerbler, D.; Brewer, C. F.; Gabius, H. -J.",null,"Phosphorylated Human Lectin Galectin-3: Analysis of Ligand Binding by Histochemical Monitoring of Normal/Malignant Squamous Epithelia and by Isothermal Titration Calorimetry","Anatomia Histologia Embryologia",null,"English","Article",null,null,null,null,null,null,"TUMOR-CELL LINES; ENDOGENOUS LECTINS; GANGLIOSIDE GM(1); MAMMALIAN LECTINS; CARCINOMA CELLS; N-GLYCAN; IN-VIVO; EXPRESSION; SITES; DIFFERENTIATION","The human lectin galectin-3 is a multifunctional effector with special functions in regulation of adhesion and apoptosis. Its unique trimodular organization includes the 12-residue N-terminal sequence, a substrate for protein kinase CK1-dependent phosphorylation. As a step towards elucidating its significance, we prepared phosphorylated galectin-3, labelled it and used it as a tool in histochemistry. We monitored normal and malignant squamous epithelia. Binding was suprabasal with obvious positive correlation to the degree of differentiation and negative correlation to proliferation. The staining pattern resembled that obtained with the unmodified lectin. Basal cell carcinomas were invariably negative. The epidermal positivity profile was akin to distribution of the desmosomal protein desmoglein, as also seen with keratinocytes in vitro. In all cases, binding was inhibitable by the presence of lactose, prompting further investigation of the activity of the lectin site by a sensitive biochemical method, i.e. isothermal titration calorimetry. The overall affinity and the individual enthalpic and entropic contributions were determined. No effect of phosphorylation was revealed. This strategic combination of histo- and biochemical techniques applied to an endogenous effector after its processing by a protein kinase thus enabled a detailed monitoring of the binding properties of the post-translationally modified lectin. It underscores the value of using endogenous lectins as a histochemical tool. The documented approach has merit for applications beyond lectinology.","[Kuerbler, D.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Szabo, P.; Smetana, K., Jr.; Dvorankova, B.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Dam, T. K.; Brewer, C. F.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Dam, T. K.; Brewer, C. F.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; [Smetana, K., Jr.; Dvorankova, B.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic; [Gabius, H. -J.] Univ Munich, Fac Vet Med, Inst Physiol Chem, D-80539 Munich, Germany","Kurbler, D, German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany","d.kuebler@dkfz.de","Ministry of Education, Youth and Sport of the Czech Republic [MSM 002160806, 1M0021620803]; Agency of the Ministry of Health of the Czech Republic [NR-9049-3]; EC Marie Curie Research Training Network [MRTN-CT-2005-019561]","This study was supported by the Ministry of Education, Youth and Sport of the Czech Republic, project no. MSM 002160806 and no. 1M0021620803, by the Grant Agency of the Ministry of Health of the Czech Republic, project no. NR-9049-3, an EC Marie Curie Research Training Network grant (contract no. MRTN-CT-2005-019561) and by the research initiative LMU excellent. Authors are grateful to Drs Jan Plzak, Martin Chovanec and Lukas Lacina for providing tumour samples and to Eva Vancova, Iva Burdova and Vit Hajduch for excellent technical assistance.",null,62,0,"BLACKWELL PUBLISHING","OXFORD","9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND","0340-2096",null,"10.1111/j.1439-0264.2008.00899.x","ANAT HISTOL EMBRYOL","Anat. Histol. Embryol.","FEB",2009,38,1,null,null,null,68,75,null,null,8,"Anatomy & Morphology; Veterinary Sciences","394MP","ISI:000262451100011"]
[1,"J","Babic, M; Horak, D; Jendelova, P; Glogarova, K; Herynek, V; Trchova, M; Likavcanova, K; Lesny, P; Pollert, E; Hajek, M; Sykova, E",null,null,null,"Babic, Michal; Horak, Daniel; Jendelova, Pavla; Glogarova, Katerina; Herynek, Vit; Trchova, Miroslava; Likavcanova, Katarina; Lesny, Petr; Pollert, Emil; Hajek, Milan; Sykova, Eva",null,"Poly(N,N-dimethylacrylamide)-Coated Maghemite Nanoparticles for Stem Cell Labeling","Bioconjugate Chemistry",null,"English","Article",null,null,null,null,null,null,"IRON-OXIDE NANOPARTICLES; IN-VIVO; SUPERPARAMAGNETIC NANOPARTICLES; MIGRATION; TRANSFECTION; PROGENITOR; PARTICLES; TRACKING; AGENT; VITRO","Maghemite (gamma-Fe2O3) nanoparticles were obtained by the coprecipitation of Fe(II) and Fe (III) salts with ammonium hydroxide followed by oxidation with sodium hypochlorite. Solution radical polymerization of N,N-dimethylacrylamide (DMAAm) in the presence of maghemite nanoparticles yielded poly(N,N-dimethylacrylamide) (PDMAAm)-coated maghemite nanoparticles. The presence of PDMAAm on the maghemite particle surface was confirmed by elemental analysis and ATR FTIR spectroscopy. Other methods of nanoparticle characterization involved scanning and transmission electron microscopy, atomic adsorption spectroscopy (AAS), and dynamic light scattering (DLS). The conversion of DMAAm during polymerization and the molecular weight of PDMAAm bound to maghemite were determined by using gas and size-exclusion chromatography, respectively. The effect of ionic 4,4'-azobis(4-cyanovaleric acid) (ACVA) initiator on nanoparticle morphology was elucidated. The nanoparticles exhibited long-term colloidal stability in water or physiological buffer. Rat and human bone marrow mesenchymal stem cells (MSCs) were labeled with uncoated and PDMAAm-coated maghemite nanoparticles and with Endorem as a control. Uptake of the nanoparticles was evaluated by Prussian Blue staining, transmission electron microscopy, T-2-MR relaxometry, and iron content analysis. Significant differences in labeling efficiency were found for human and rat cells. PDMAAm-modified nanoparticles demonstrated a higher efficiency of intracellular uptake into human cells in comparison with that of dextran-modified (Endorem) and unmodified nanoparticles. In gelatin, even a small number of labeled cells changed the contrast in MR images. PDMAAm-coated nanoparticles provided the highest T-2 relaxivity of all the investigated particles. In vivo MR imaging of PDMAAm-modified iron oxide-labeled rMSCs implanted in a rat brain confirmed their better resolution compared with Endorem-labeled cells.","[Babic, Michal; Horak, Daniel; Trchova, Miroslava] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Babic, Michal; Horak, Daniel; Jendelova, Pavla; Herynek, Vit; Lesny, Petr; Hajek, Milan; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Jendelova, Pavla; Glogarova, Katerina; Likavcanova, Katarina; Lesny, Petr; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Herynek, Vit; Hajek, Milan] Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Pollert, Emil] Acad Sci Czech Republic, Inst Phys, Prague 16253 6, Czech Republic","Horak, D, Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic","horak@imc.cas.cz","Center for Cell Therapy and Tissue Repair [1M0538]; Grant Agency of AS CR [KAN201110651, KAN200200651]; Grant Agency of the Czech Republic [203/09/1242]; EC-FP6 project DiMI [LSHB-CT-2005-512146]","The financial support of the Center for Cell Therapy and Tissue Repair No. 1M0538, the Grant Agency of AS CR (grants KAN201110651 and KAN200200651), the Grant Agency of the Czech Republic (203/09/1242) and the EC-FP6 project DiMI (LSHB-CT-2005-512146) is gratefully acknowledged.",null,28,0,"AMER CHEMICAL SOC","WASHINGTON","1155 16TH ST, NW, WASHINGTON, DC 20036 USA","1043-1802",null,"10.1021/bc800373x","BIOCONJUGATE CHEMISTRY","Bioconjugate Chem.","FEB",2009,20,2,null,null,null,283,294,null,null,12,"Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic","409TP","ISI:000263529000015"]
[1,"J","Hubacek, P; Muzikova, K; Hrdlickova, A; Cinek, O; Hyncicova, K; Hrstkova, H; Sedlacek, P; Stary, J",null,null,null,"Hubacek, Petr; Muzikova, Katerina; Hrdlickova, Alena; Cinek, Ondrej; Hyncicova, Katerina; Hrstkova, Hana; Sedlacek, Petr; Stary, Jan",null,"Prevalence of HHV-6 Integrated Chromosomally Among Children Treated for Acute Lymphoblastic or Myeloid Leukemia in the Czech Republic","Journal of Medical Virology",null,"English","Article",null,null,null,null,null,"human herpesvirus 6; leukemia; chromosomal integration","HUMAN-HERPESVIRUS 6; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; PERIPHERAL-BLOOD LEUKOCYTES; HUMAN-HERPESVIRUS-6 INFECTION; LABORATORY DIAGNOSIS; DNA; ENCEPHALITIS; ENCEPHALOPATHY; DISEASE","Chromosomal integration of human herpesvirus 6 (HHV-6) is a novel situation found in a small percentage of individuals. While active HHV-6 infection is treatable using antivirals, the abnormally high level of HHV-6 DNA found in chromosomal integration of HHV-6 (Cl-HHV-6) is not affected by such drugs. Stored DNA samples taken originally for detection of fusion genes and minimal residual disease from 339 pediatric patients treated for leukemia in the Czech Republic between the years 1995-2007 were tested retrospectively. Using real-time quantitative PCR technology, the quantity of HHV-6 DNA detected was normalized to 100,000 human genome equivalents as assessed by quantitation of the albumin gene. HHV-6 DNA was detected in 107 samples from 91 patients (26.8%). In the majority of samples (99) only a minute level of normalized viral copies (NVCs) (median 1.84 NVCs) was detected. A high viral load of approximately 100,000 NVCs was detected in 5 patients (1.5%; median 140,150 NVCs), in all of whom were confirmed subsequently Cl-HHV-6 by a detection of HHV-6 DNA in hair follicles or in the nails. In all but one patient with HHV-6 variant B, variant A of the virus was detected. None of the patients with Cl-HHV-6 had complications attributable to HHV-6 infection. The prevalence of CI-HHV-6 in childhood leukemia does not differ from that published for other patients or healthy populations. Where high levels of HHV-6 DNA are present, Cl-HHV-6 should be confirmed as soon as possible so that potentially toxic but ineffective antiviral treatment can be stopped. J. Med. Virol. 81:258263, 2009. (c) 2008 Wiley-Liss, Inc.","[Hubacek, Petr; Muzikova, Katerina; Sedlacek, Petr; Stary, Jan] Motol Univ Hosp, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hrdlickova, Alena; Cinek, Ondrej; Hyncicova, Katerina] Motol Univ Hosp, Dept Paediat, CZ-15006 Prague, Czech Republic; [Hrstkova, Hana] Brno Univ Hosp, Dept Paediat 1, Brno, Czech Republic","Hubacek, P, Motol Univ Hosp, Dept Paediat Haematol & Oncol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","petr.hubacek@lfmotol.cuni.cz","Czech Ministry of Health [FNM00064203]; Czech Ministry of Education [MSMT0021620813]","Czech Ministry of Health; Grant number: FNM00064203; Grant sponsor: Czech Ministry of Education; Grant number: MSMT0021620813.",null,34,1,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0146-6615",null,"10.1002/jmv.21371","J MED VIROL","J. Med. Virol.","FEB",2009,81,2,null,null,null,258,263,null,null,6,"Virology","389LX","ISI:000262095300008"]
[1,"J","Benesova, J; Hock, M; Butenko, O; Prajerova, I; Anderova, M; Chvatal, A",null,null,null,"Benesova, Jana; Hock, Miroslav; Butenko, Olena; Prajerova, Iva; Anderova, Miroslava; Chvatal, Alexander",null,"Quantification of Astrocyte Volume Changes During Ischemia In Situ Reveals Two Populations of Astrocytes in the Cortex of GFAP/EGFP Mice","Journal of Neuroscience Research",null,"English","Article",null,null,null,null,null,"Indexing terms: ischemia; volume regulation; astrocyte processes; acidification; patch-clamp","CENTRAL-NERVOUS-SYSTEM; K+-CL-COTRANSPORTER; 3-DIMENSIONAL CONFOCAL MORPHOMETRY; MIDDLE-CEREBRAL-ARTERY; CELL-VOLUME; AMINO-ACIDS; GLUTAMATE TRANSPORTERS; CULTURED ASTROCYTES; REACTIVE ASTROCYTES; BRAIN-CELLS","Energy depletion during ischemia leads to disturbed ionic homeostasis and accumulation of neuroactive substances in the extracellular space, subsequently leading to volume changes in astrocytes. Confocal microscopy combined with 3D reconstruction was used to quantify ischemia-induced astrocyte volume changes in cortical slices of GFAP/EGFP transgenic mice. Twenty-minutes of oxygen-glucose deprivation (OGD) or oxygen-glucose deprivation combined with acidification (OGD(pH) (6.8)) revealed the presence of two distinct astrocytic populations, the first showing a large volume increase (HR astrocytes) and the second displaying a small volume increase (LR astrocytes). In addition, changes in resting membrane potential (V-m), measured by the patch-clamp technique, supported the existence of two astrocytic populations responding differently to ischemia. Although one group markedly depolarized during OGD or OGD(pH) (6.8), only small changes in V-m toward more negative values were observed in the second group. Conversely, acidification (ACF(pH) (6.8)) led to a uniform volume decrease in all astrocytes, accompanied by only a small depolarization. Interestingly, two differently responding populations were not detected during acidification. Differences in the expression of inwardly rectifying potassium channels (Kir4.1), glial fibrillary acidic protein (GFAP), and taurine levels in cortical astrocytes were detected using immunohistochemical methods. We conclude that two distinct populations of astrocytes are present in the cortex of GFAP/EGFP mice, based on volume and V-m changes during exposure to OGD or OGD(pH) (6.8). Immunohistochemical analysis suggests that-the diverse expression of Kir4.1 channels and GFAP as well as differences in the accumulation of taurine might contribute to the distinct ability of astrocytes to regulate their volume. (C) 2008 Wiley-Liss, Inc.","[Benesova, Jana; Butenko, Olena; Prajerova, Iva; Anderova, Miroslava; Chvatal, Alexander] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab, Prague 14220 4, Czech Republic; [Benesova, Jana; Butenko, Olena; Prajerova, Iva; Chvatal, Alexander] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Hock, Miroslav] Acad Sci Czech Republic, Inst Physiol, Dept Epithelial Physiol, Prague, Czech Republic; [Anderova, Miroslava; Chvatal, Alexander] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Chvatal, A, Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab, Videnska 1083, Prague 14220 4, Czech Republic","anderova@biomed.cas.cz","Grant Agency of the Czech Republic [305/06/1316, 305/06/1464]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554]","Grant Agency of the Czech Republic: Contract grant number: 305/06/1316; Contract grant number: 305/06/1464; Contract grant sponsor: Academy of Sciences of the Czech Republic; Contract grant number: AVOZ50390512; Contract grant sponsor: Ministry of Education, Youth and Sports of the Czech Republic: Contract grant number: LC554.",null,75,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0360-4012",null,"10.1002/jnr.21828","J NEUROSCI RES","J. Neurosci. Res.","JAN",2009,87,1,null,null,null,96,111,null,null,16,"Neurosciences","397QX","ISI:000262678300011"]
[1,"J","Prochazkova, K; Pavlikova, K; Minarik, M; Sumerauer, D; Kodet, R; Sedlacek, Z",null,null,null,"Prochazkova, Kamila; Pavlikova, Kristyna; Minarik, Marek; Sumerauer, David; Kodet, Roman; Sedlacek, Zdenek",null,"Somatic TP53 Mutation Mosaicism in a Patient With Li-Fraumeni Syndrome","American Journal of Medical Genetics Part A",null,"English","Article",null,null,null,null,null,"cancer predisposition; TP53 mutation; Li-Fraumeni syndrome; somatic mosaicism; allelic imbalance; de novo mutation","GERMLINE P53 MUTATIONS; NEUROFIBROMATOSIS TYPE-1; FAMILIAL SYNDROME; BREAST-CANCER; GENE; ELECTROPHORESIS; NEOPLASMS; SARCOMAS; TUMORS","We present a girl who developed adrenocortical adenoma at the age of I year and osteosarcoma at the age of 5 years. There was no history of cancer in her parents and their relatives. However, both tumors were typical for the Li-Fraumeni syndrome (LFS), and the patient met criteria for germline TP53 mutation testing. A mutation in codon 282 (Arg282Trp) was identified in her blood lymphocyte genomic DNA. The substitution was found in neither of her parents, which indicated a possibility of a de novo mutation. Unexpectedly, sequencing of the DNA of the patient repeatedly showed allelic imbalance in favor of the normal allele. This observation prompted us to investigate the putative somatic mosaicism in the patient consisting of normal cells and cells heterozygous for the mutation. The imbalance was also examined in two other non-invasively sampled tissues, buccal cells, and cells from the urine sediment, and sequencing was confirmed with two other independent methods. While the findings in blood and the urine sediment were similar, in buccal cells both alleles were present in equal amounts. The allele ratio in lymphocytes was consistent with a mosaic where about 2/3 of cells carried two normal alleles and only 1/3 was heterozygous for the mutation. Despite the mosaicism the girl developed two early childhood tumors of mesodermal origin, and her phenotype was thus not milder than that of other germline TP53 mutation carriers. To our knowledge this is the first description of somatic mosaicism for a de novo TP53 mutation in LFS. (c) 2008 Wiley-Liss, Inc.","[Prochazkova, Kamila; Pavlikova, Kristyna; Sedlacek, Zdenek] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Prochazkova, Kamila; Pavlikova, Kristyna; Sumerauer, David; Kodet, Roman; Sedlacek, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Minarik, Marek] Genomac Int, Lab Mol Genet & Oncol, Prague, Czech Republic; [Sumerauer, David] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Kodet, Roman] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic","Sedlacek, Z, Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, V Uvalu 84, Prague 15006 5, Czech Republic","zdenek.sedlacek@lfmotol.cuni.cz","Ministry of Education of the Czech Republic [MSM0021620813]; Ministry of Health of the Czech Republic [MZ000064203]","We thank Dr. Drahuse Novotna for karyotyping of the patient. The work was supported by grants MSM0021620813 (Ministry of Education of the Czech Republic) and MZ000064203 (Ministry of Health of the Czech Republic).",null,25,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4825",null,"10.1002/ajmg.a.32574","AM J MED GENET PART A","Am. J. Med. Genet. A","FEB",2009,"149A",2,null,null,null,206,211,null,null,6,"Genetics & Heredity","408KH","ISI:000263433400011"]
[1,"J","Gebousky, P; Karny, M; Krizova, H; Wald, M",null,null,null,"Gebousky, Petr; Karny, Miroslav; Krizova, Hana; Wald, Martin",null,"Staging of upper limb lymphedema from routine lymphoscintigraphic examinations","Computers in Biology and Medicine",null,"English","Article",null,null,null,null,null,"Quantitative lymphoscintigraphy; Secondary lymphedema of upper limbs; Staging; Bayesian evaluation; Probabilistic mixtures","CANCER-RELATED LYMPHEDEMA; BREAST-CANCER; RADIONUCLIDE LYMPHOSCINTIGRAPHY; DIAGNOSIS","Secondary lymphedema of upper limbs, a frequent complication after a breast cancer therapy, can be successfully treated only when diagnosed at an early, ideally latent, stage. Lymphoscintigraphy is a promising candidate to this purpose. A slow lymphatic dynamics of upper limbs allows. however, a routine collection at most three images reflecting it. This makes an exploitation of lymphoscintigraphy to early-stage diagnosis a complex task. Recently, a Bayesian methodology extracting diagnostic information from the available sparse data has been developed. It properly detects lymphedema occurrence but not a desirable disease staging. The present paper proposes Bayesian diagnostic processing of lymphoscintigraphic and routine clinical data. Its staging ability was tested on diagnostic data of 88 women at the age of 39-84 years (60.2 +/- 10.4) with a suspicion of unilateral secondary lymphedema of upper limbs caused by a breast cancer treatment. Less than 20 of them had simply detectable disease stages. Information about accumulation dynamics of the lymphatic system contained in lymphoscintigraphic images was quantified via estimation of a simplified accumulation model [P. Gebousky, M. Karny, A. Quinn, Lymphoscintigraphy of upper limbs: a Bayesian framework. in: J.M. Bernardo, M.J. Bayarri, J.O. Berger (Eds.), Bayesian Statistics, vol. 7, University Press, Oxford, 2003, pp. 543-552]. The sole use of this approach, referred as \"Bayesian quantitative lymphoscintigraphy\", was found insufficient for a finer staging of the disease to typical categories (healthy, latent, reversible, spontaneously irreversible, elephantiasis). For this reason, the results of Bayesian quantitative lymphoscintigraphy were attached to routinely available qualitative lymphoscintigraphic inspection and clinical data. These combined data were modelled by normal probabilistic mixtures. Their Bayesian estimates were used for a computerized disease staging. The resulting model predicts expert's conclusions on the presence of a lymphedema in 95% cases. A finer staging is successful in 85% cases of suspicious limbs. Model cross-validation and a closer look on patients' data indicate that the combined data are still insufficiently informative. it calls for the further improvements of the inspection methods. Even under the current inspection conditions, the proposed processing provides clinicians a reliable quantitative \"second\" opinion on the disease staging. (c) 2008 Elsevier Ltd. All rights reserved.","[Gebousky, Petr; Karny, Miroslav] Acad Sci Czech Republic, Inst Informat Theory & Automat, Dept Adapt Syst, CR-18208 Prague 8, Czech Republic; [Krizova, Hana] Charles Univ Prague, Inst Nucl Med, Fac Med 1, Prague 12000 2, Czech Republic; [Wald, Martin] Univ Hosp Motol, Surg Clin, Prague 15006 5, Czech Republic","Karny, M, Acad Sci Czech Republic, Inst Informat Theory & Automat, Dept Adapt Syst, POB 18, CR-18208 Prague 8, Czech Republic","school@utia.cas.cz","MSMT CR [2C06001, 1M0572]","This research was supported by MSMT CR by Grants 2C06001 and 1M0572.",null,26,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0010-4825",null,"10.1016/j.compbiomed.2008.10.003","COMPUT BIOL MED","Comput. Biol. Med.","JAN",2009,39,1,null,null,null,1,7,null,null,7,"Biology; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology","407YD","ISI:000263399300001"]
[1,"J","Brynda, E; Houska, M; Kysilka, J; Praadny, M; Lesny, P; Jendelovaa, P; Michaalek, J; Sykovaa, E",null,null,null,"Brynda, Eduard; Houska, Milan; Kysilka, Jiri; Pradny, Martin; Lesny, Petr; Jendelova, Pavla; Michalek, Jiri; Sykova, Eva",null,"Surface modification of hydrogels based on poly(2-hydroxyethyl methacrylate) with extracellular matrix proteins","Journal of Materials Science-Materials in Medicine",null,"English","Article",null,null,null,null,null,null,"2-HYDROXYETHYL METHACRYLATE; COPOLYMERS; ADHESION; CHARGE","Infrared attenuated total reflection spectroscopy was used for in situ observation of the deposition of collagen I on poly(2-hydroxyethyl methacrylate-co-methacrylic acid, 2.9%) hydrogels and subsequent attachment of laminin or fibronectin on the collagen surface. While there was no adsorption of collagen dissolved in an acid solution on the hydrogel surface, it deposited on the surface at pH 6.5. The collagen layers with attached laminin or fibronectin were stable on hydrogel surface in physiological solution. The modification with collagen and particularly with collagen and laminin or fibronectin allowed the adhesion and growth of mesenchymal stromal cells and astrocytes on the hydrogel surface.","[Brynda, Eduard; Houska, Milan; Kysilka, Jiri; Pradny, Martin; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Brynda, Eduard; Pradny, Martin; Lesny, Petr; Jendelova, Pavla; Michalek, Jiri; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Lesny, Petr; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic","Brynda, E, Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic","brynda@imc.cas.cz","Academy of Sciences of the Czech Republic [AA400500507, KAN20670701, 1QS400500558, 309/06/1246, 1A8697-5, AVOZ503905703]","The study was supported by the Grant Agency of the Academy of Sciences of the Czech Republic (contract AA400500507), by the Academy of Sciences of the Czech Republic (contracts KAN20670701 and 1QS400500558), the Grant Agency of the Czech Republic (contract 309/06/1246), and grants 1A8697-5 and AVOZ503905703.",null,15,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-4530",null,"10.1007/s10856-008-3625-9","J MATER SCI-MATER MED","J. Mater. Sci.-Mater. Med.","APR",2009,20,4,null,null,null,909,915,null,null,7,"Engineering, Biomedical; Materials Science, Biomaterials","411WK","ISI:000263683900009"]
[1,"J","Dudova, I; Hrdlicka, M",null,null,null,"Dudova, Iva; Hrdlicka, Michal",null,"The importance of olfactory functions in psychiatry","Ceskoslovenska Psychologie",null,"Czech","Article",null,null,null,null,null,"olfaction; neuropsychiatry; neurodegenerative disorders; schizophrenia; autism","ALZHEIMERS-DISEASE; PARKINSON-DISEASE; IDENTIFICATION; DIAGNOSIS; DISORDER; AUTISM","Authors deal with experimental and clinical utilization of olfaction examination in neuropsychiatric disorders. They mention briefly the importance of olfaction and the anatomy of olfactory track and olfactory brain centers. They explain methods of olfaction examination, especially the most frequent used tests - UPSIT and Sniffin 'Sticks. The olfaction disorders are one of the early symptoms of some serious neurodegenerative disorders. In the case of Parkinson and Alzheimer diseases, the olfaction examination is included in recommended procedures of differential diagnostics judgment. The most explored psychiatric disorder associated with olfaction disorders is schizophrenia. The changes in olfactory threshold measurement, olfactory identification and discrimination, and olfactory memory were described. The results of several studies in autistic patients proved the deficit in olfactory functions and suggested the possibility to utilize the screening examination of olfactory functions as a bio-behavioral marker of autistic spectrum disorders.","[Dudova, Iva; Hrdlicka, Michal] FN Motol, Detska Psychiat Klinika UK 2LF, Prague, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Lekarska Fak 1, Prague, Czech Republic","Dudova, I, Detska Psychiat Klinika FN Motole, Uvalu 84, Prague 15006, Czech Republic","iva.dudova@lfmotol.cuni.cz",null,null,null,25,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2009,53,1,null,null,null,34,39,null,null,6,"Psychology, Multidisciplinary","414UN","ISI:000263890800003"]
[2,"J","Bartunkova, J; Kayserova, J; Shoenfeld, Y",null,null,null,"Bartunkova, Jirina; Kayserova, Jana; Shoenfeld, Yehuda",null,"Allergy and autoimmunity: Parallels and dissimilarity The Yin and Yang of Immunopathology","Autoimmunity Reviews",null,"English","Article",null,null,null,null,null,"Autoimmune disease; Allergy; HLA; Cytokines; Autoantigens","SYSTEMIC-LUPUS-ERYTHEMATOSUS; ATOPIC-DERMATITIS; IMMUNOGLOBULIN-E; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; SJOGRENS-SYNDROME; DISEASES; ASTHMA; IGE; CHILDREN","The etiopathogenesis of allergy and autoimmune diseases is caused by genetic and acquired (environmental) factors, which might be common to both immmunopathologies. Genetic factors play an important role in the development and process of immunopathological diseases. Several studies suggest a close relation between gene polymorphism of HLA and cytokines and development of autoimmunity and allergy. Certain gene polymorphisms act as risk or as protective factors. The infection also plays an important role in the induction of allergy and autoimmunity - as a trigger or as a protective factor. Moreover, similar clinical manifestations of both immunopathologies could result in diagnostic problems. This review summarizes the linkage of mechanisms of etiopathogenesis, clinical manifestations and therapeutic strategy between allergic and autoimmune diseases. (C) 2008 Elsevier B.V. All rights reserved.","[Bartunkova, Jirina; Kayserova, Jana] Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Shoenfeld, Yehuda] Tel Aviv Univ, Ctr Autoimmune Dis, Dept Med B, Sheba Med Ctr, IL-52621 Tel Hashomer, Israel","Bartunkova, J, Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic","jirina.bartunkova@lfmotol.cuni.cz",null,null,null,40,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1568-9972",null,"10.1016/j.autrev.2008.09.004","AUTOIMMUN REV","Autoimmun. Rev.","FEB",2009,8,4,null,null,null,302,308,null,null,7,"Immunology","419JL","ISI:000264215500005"]
[2,"C","Krizkova, S; Fabrik, I; Adam, V; Kukacka, J; Prusa, R; Trnkova, L; Strnadel, J; Horak, V; Kizek, R",null,null,null,"Krizkova, Sona; Fabrik, Ivo; Adam, Vojtech; Kukacka, Jiri; Prusa, Richard; Trnkova, Libuse; Strnadel, Jan; Horak, Vratislav; Kizek, Rene",null,"Effects of Reduced Glutathione, Surface Active Agents, and Ionic Strength on the Detection of Metallothioneins by Using of Brdicka Reaction","Electroanalysis",null,"English","Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Differential pulse voltammetry; Adsorptive transfer stripping technique; Proteins; Metallothionein; Brdicka reaction","CURRENT STRIPPING CHRONOPOTENTIOMETRY; HEAVY-METAL IONS; ELECTROCHEMICAL-BEHAVIOR; MERCURY-ELECTRODE; EXPRESSION; BIOSENSOR; MELANOMA; LEVEL; CELLS","We investigated the effects of two surface active agents (sodium dodecyl sulfate, SDS, and polyoxyethylene sorbitol, Tween-20), ionic strength and reduced glutathione (GSH) on MT signals measured by adsorptive transfer stripping differential pulse voltammetry Brdicka reaction. If we compared the GSH and MT signals at the accumulation time of 120 s, the MT signal was more than two hundred times higher than the GSH one. The influence of Tween-20 was investigated in a broad concentration range (from 10(-8) to 10(-11) %, v/v). We found that the catalytic Cat2 signal decreased for more than 60% with increasing Tween-20 content. In the case of using SDS (10(-3) - 10(-6) M), the increase of Cat2 peak in the presence of the highest SDS concentration was determined. The height of Cat2 peak enhanced with increasing ionic strength mimicking by NaCl concentration. Based on the enhancement of the Cat2 peak we determined the ionic strength of fibroblasts sample and recalculated the concentration of MT determined there.","[Krizkova, Sona; Fabrik, Ivo; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Dept Anim Nutr & Forage Prod, Fac Agron, CZ-61300 Brno, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, CZ-15006 Prague, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Strnadel, Jan; Horak, Vratislav] Acad Sci Czech Republic, Lab Tumour Biol, Dept Anim Embryol Cell & Tissue Differentitat, Inst Anim Physiol & Genet, CZ-27721 Libechov, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,34,1,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,"10.1002/elan.200804406","ELECTROANAL","Electroanalysis","FEB",2009,21,"2009-05-03",null,null,null,640,644,null,null,5,"Chemistry, Analytical; Electrochemistry","417GC","ISI:000264063500057"]
[2,"C","Fabrik, I; Kukacka, J; Baloun, J; Sotornik, I; Adam, V; Prusa, R; Vajtr, D; Babula, P; Kizek, R",null,null,null,"Fabrik, Ivo; Kukacka, Jiri; Baloun, Jiri; Sotornik, Ivo; Adam, Vojtech; Prusa, Richard; Vajtr, David; Babula, Petr; Kizek, Rene",null,"Electrochemical Investigation of Strontium-Metallothionein Interactions-Analysis of Serum and Urine of Patients with Osteoporosis","Electroanalysis",null,"English","Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Strontium; Metallothionein; Differential pulse voltammetry; Brdicka reaction; Heavy metal-protein interaction; Osteoporosis; Human blood serum and urine","TRANSGENIC TOBACCO PLANTS; LIQUID-CHROMATOGRAPHY; BRDICKA REACTION; GENE-EXPRESSION; BONE-RESORPTION; QUANTIFICATION; BIOSENSOR; RATS; VOLTAMMETRY; GLUTATHIONE","The main aim of this paper is to study interaction between strontium and metallothionein (MT), and to determine changes in strontium and thiols (MT, reduced glutathione, cysteine, and homocysteine) level in plasma, serum, and urine samples of patients treated with strontium ranelate (SrR). To investigate the interactions between MT and strontium(II) ions, adsorptive transfer stripping technique coupled with differential pulse voltammetry (DPV) the Brdicka reaction was employed. Besides standard Brdicka signals (Co, RS2Co, Cat1, Cat2, Cat3), we observed new signal related to Sr-MT interaction. Further we investigated the effect of various time of interaction, concentration of strontium(II) ions and temperature of supporting electrolyte on Brdicka signals. Optimal time of interaction was 240 s. Under temperature of supporting electrolyte 20 degrees C, we measured linear dependence of Cat3 signal height on strontium(II) ions concentration. After that we have investigated the possibility of strontium-MT interactions, we were interested in strontium, MT and low molecular mass thiols levels in serum and urine of patients treated with strontium(II) ions to cure osteoporosis. Strontium concentration determined by atomic absorption spectrometry was 55 +/- 5 mu g/L before and 10,500 +/- 1,400 mu g/L at the 30(th) day of SrR administration. Levels of metallothionein in serum ranged from 0.1 to 6.4 mu M. Correlation between serum strontium concentration and MT level was determined and correlation coefficient was R = 0.93.","[Fabrik, Ivo; Baloun, Jiri; Adam, Vojtech; Kizek, Rene] Mendal Univ Agr & Forestry, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Kukacka, Jiri; Prusa, Richard; Vajtr, David] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Sotornik, Ivo] Inst Clin & Expt Med, Dept Nephrol, CZ-14021 Prague, Czech Republic; [Adam, Vojtech] Mendal Univ Agr & Forestry, Dept Anim Nutr & Forage Prod, Fac Agron, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Dept Nat Drugs, Fac Pharm, CZ-61242 Brno, Czech Republic","Kizek, R, Mendal Univ Agr & Forestry, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,44,0,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,"10.1002/elan.200804431","ELECTROANAL","Electroanalysis","FEB",2009,21,"2009-05-03",null,null,null,650,656,null,null,7,"Chemistry, Analytical; Electrochemistry","417GC","ISI:000264063500059"]
[2,"C","Huska, D; Adam, V; Zitka, O; Kukacka, J; Prusa, R; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Zitka, Ondrej; Kukacka, Jiri; Prusa, Richard; Kizek, Rene",null,"Chronopotentiometric Stripping Analysis of Gelatinase B, Collagen and Their Interaction","Electroanalysis",null,"English","Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Matrix metalloproteinases; Chronopotentiometric stripping analysis; Collagen; Protein-protein interaction; Cancer","SENSITIVE ELECTROCHEMICAL DETECTION; MATRIX METALLOPROTEINASES; METALLOTHIONEIN DETERMINATION; CONTAINING PEPTIDES; HEAVY-METALS; FISH-TISSUES; PROTEIN P53; VOLTAMMETRY; LACTOFERRIN; ELECTRODES","Matrix metalloproteinases (MMP) belong to a group of zinc-dependent proteins that play a central role in the breakdown of extracellular matrices. Collagen, elastin, gelatin and casein are the main components of extracellular matrix cleaved by MMP This paper aims to analyze the interaction between gelatinase B (MMP-9) and collagen using chronopotentiometric stripping analysis with adsorptive transfer stripping technique (AdTS CPSA). Under optimized experimental conditions (time accumulation of 90 s, supporting electrolyte 0.2 M acetate buffer pH 5, stripping current.1 mu A), the detection limit (3 signal/noise) for MMP-9 was estimated as being 100 pM. The interaction between MMP-9 and collagen was studied according to the following scheme: i) HMDE surface was renewed. ii) Renewed surface of HMDE collagen (1 mu g/mL) was accumulated for 90 s under open circuit. iii) The electrode was rinsed in ACS grade water and immersed in 5 mu L drop of MMP-9. iv) The interaction between MMP-9 with collagen took place at open circuit. v) The electrode was then rinsed in ACS grade water. vi) The rinsed electrode was transferred into an electrochemical cell and measured in acetate buffer (pH 5). The CPSA signal of collagen after its interaction with MMP-9 increased more than 30% compared to that of only collagen. This increase in signal is likely due to the cleavage of collagen by MMP-9, hence its easy access to the electrode's surface.","[Huska, Dalibor; Adam, Vojtech; Zitka, Ondrej; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Zitka, Ondrej] Masaryk Univ, Fac Sci, Dept Biochem, CZ-61137 Brno, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,40,0,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,"10.1002/elan.200804440","ELECTROANAL","Electroanalysis","FEB",2009,21,"2009-05-03",null,null,null,536,541,null,null,6,"Chemistry, Analytical; Electrochemistry","417GC","ISI:000264063500042"]
[2,"J","Cmejla, R; Cmejlova, J; Handrkova, H; Petrak, J; Petrtylova, K; Mihal, V; Stary, J; Cerna, Z; Jabali, Y; Pospisilova, D",null,null,null,"Cmejla, Radek; Cmejlova, Jana; Handrkova, Helena; Petrak, Jiri; Petrtylova, Kvetoslava; Mihal, Vladimir; Stary, Jan; Cerna, Zdena; Jabali, Yahia; Pospisilova, Dagmar",null,"Identification of Mutations in the Ribosomal Protein L5 (RPL5) and Ribosomal Protein L11 (RPL11) Genes in Czech Patients With Diamond-Blackfan Anemia","Human Mutation",null,"English","Article",null,null,null,null,null,"ribosomal protein L5; RPL5; ribosomal protein L11; RPL11; ribosomal protein L23; RPL23; Diamond-Blackfan anemia; DBA","ADENOSINE-DEAMINASE ACTIVITY; INHIBITION; P53; RNA; UBIQUITINATION; ACTIVATION; SUBUNITS; PATHWAY; MDM2; S19","Diamond-Blackfan anemia (DBA) is a congenital red blood cell aplasia that is usually diagnosed during early infancy. Apart from defects in red blood cell maturation, the disorder is also associated with various physical anomalies in 40% of patients. Mutations in the ribosomal protein (RP) S19 are found in 25% of patients, while mutations in other proteins of the small ribosomal subunit-RPS17 and RPS24-have been found in a fraction of patients. Recently, mutations in RPL5, RPL11, and RPL35a of the large ribosomal subunit have also been reported in several DBA patients. Here, we present the identification of mutations in the RPL5 and RPL11 genes in patients from the Czech DBA Registry. Mutations in RPL5 were identified in eight patients from 6 out of 28 families (21.4%), and mutations in RPL11 in two patients from 2 out of 28 families (7.1%). Interestingly, all 10 patients with either an RPL5 or RPL11 mutation exhibited one or more physical anomalies; specifically, thumb anomalies (flat thenar) were always present, while no such anomaly was observed in seven patients with an RPS19 mutation. Moreover, 9 out of 10 patients with either an RPL5 or RPL11 mutation were born small for gestational age (SGA) compared to 3 out of 7 patients froth the RPS19-mutated group. These observations may suggest that mutations, at least in RPL5, seem to generally have more profound impact on fetal development than mutations in RPS19. Since RPL5 and RPL11, together with RPL23, are also involved in the MDM2-mediated p53 pathway regulation, we also screened the RPL23 gene for mutations; however, no mutations were identified. Hum Mutat 30, 321-327, 2009. (C) 2009 Wiley-Liss, Inc.","[Cmejla, Radek; Cmejlova, Jana; Handrkova, Helena; Petrak, Jiri] Inst Hematol & Blood Transfus, Dept Cell Physiol, CR-12820 Prague, Czech Republic; [Petrtylova, Kvetoslava] Univ Hosp Motol, Dept Hematol, Prague, Czech Republic; [Mihal, Vladimir] Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Cerna, Zdena] Charles Univ Hosp, Dept Pediat, Plzen, Czech Republic; [Jabali, Yahia] Reg Hosp Ceske Budejovice, Dept Pediat, Ceske Budejovice, Czech Republic; [Petrak, Jiri] Charles Univ Prague, Dept Pathol Physiol, Fac Med 1, Prague, Czech Republic","Cmejla, R, Inst Hematol & Blood Transfus, Dept Cell Physiol, U Nemocnice 1, CR-12820 Prague, Czech Republic","racm@centrum.cz; pospisid@fnol.cz","Ministry of Health [00023736]; Grant Agency of Charles University [25792892807]; Ministry of Education, Czech Republic [MSMT LC06044, MSM 6198959205]","We thank Dr. David Hardekopf for reading the manuscript. This work was supported by the Ministry of Health (00023736 to R.C.); the Grant Agency of Charles University (25792892807 to H.H.); and the Ministry of Education, Czech Republic (MSMT LC06044 to R.C. and J.P.; MSM 6198959205 D.P.).",null,25,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,"10.1002/humu.20874","HUM MUTAT","Hum. Mutat.","MAR",2009,30,3,null,null,null,321,327,null,null,7,"Genetics & Heredity","416NB","ISI:000264011700007"]
[2,"J","Rygl, M; Novotna, J; Herget, J; Skaba, R; Snajdauf, J",null,null,null,"Rygl, M.; Novotna, J.; Herget, J.; Skaba, R.; Snajdauf, J.",null,"Parameters of Healing in Approximative Intestinal Anastomosis","European Journal of Pediatric Surgery",null,"English","Article",null,null,null,null,null,"approximative anastomosis; matrix metalloproteinase; anastomotic strength; extremely low birth weight neonates","NECROTIZING ENTEROCOLITIS; MATRIX METALLOPROTEINASES; PERITONEAL DRAINAGE; GASTROINTESTINAL-TRACT; COLONIC ANASTOMOSES; BREAKING STRENGTH; SUTURE TECHNIQUE; SMALL-BOWEL; LAPAROTOMY; RAT","Introduction: The restoration of bowel continuity using multiple classic anastomoses is mostly impossible in unstable critically ill extremely low birth weight neonates. The parameters of healing of approximative anastomoses in which integrity and continuity of bowel is achieved with limited number of stitches were evaluated in an experimental study. Material and Methods: Small bowel anastomoses were performed in twenty-two adult male rats. An approximative ileo-ileal anastomosis was performed with five seromuscular-interrupted sutures only; in the control group the anastomosis was performed with the conventional technique of interrupted sutures. The mechanical and biochemical parameters were compared. Results: All anastomoses in both groups healed well without obstruction. The mean operating time needed for an approximative anastomosis was shorter (16 +/- 7.1 min versus 23.6 +/- 6.2 min, p = 0.016). The strength of the approximative anastomoses on the 1st day after surgery was 55 +/- 15 torr; the strength of the conventional anastomoses was 55 +/- 42 torr. The strength of the approximative anastomoses after 7 days was 249 +/- 39 torr; the strength of the conventional anastomoses was 218 23 torr(p = 0.118). The activity of the collagenolytic enzymes matrix metalloproteinase-2 and matrix metalloproteinase-9 in the anastomotic area was significantly increased compared with the activity in samples of non-operated bowel. There was no significant difference in collagenolytic activity between both types of anastomoses. Conclusion: The approximative anastomosis is a time-saving alternative to conventional anastomoses with a comparable Course of anastomotic healing, anastomotic strength, and changes in collagen metabolism.","[Rygl, M.; Skaba, R.; Snajdauf, J.] Charles Univ Prague, Sch Med 2, Dept Pediat Surg, Prague 15006, Czech Republic; [Novotna, J.] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, Prague 15006, Czech Republic; [Herget, J.] Charles Univ Prague, Sch Med 2, Dept Physiol, Prague 15006, Czech Republic","Rygl, M, Charles Univ Prague, Sch Med 2, Dept Pediat Surg, V Uvalu 84, Prague 15006, Czech Republic","mrygl@yahoo.com","FNM MZO [00064203/6309]","Supported by Research Project FNM MZO 00064203/6309.",null,27,0,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0939-7248",null,"10.1055/s-2008-1039010","EUR J PEDIATR SURG","Eur. J. Pediatr. Surg.","FEB",2009,19,1,null,null,null,25,29,null,null,5,"Pediatrics; Surgery","417FN","ISI:000264062000006"]
[2,"J","Lonnerholm, G; Valsecchi, MG; De Lorenzo, P; Schrappe, M; Hovi, L; Campbell, M; Mann, G; Janka-Schaub, G; Li, CK; Stary, J; Hann, I; Pieters, R",null,null,null,"Lonnerholm, Gudmar; Valsecchi, Maria Grazia; De Lorenzo, Paola; Schrappe, Martin; Hovi, Liisa; Campbell, Myriam; Mann, Georg; Janka-Schaub, Gritta; Li, Chi-Kong; Stary, Jan; Hann, Ian; Pieters, Rob","Interfant-99 Study Grp","Pharmacokinetics of High-Dose Methotrexate in Infants Treated for Acute Lymphoblastic Leukemia","Pediatric Blood & Cancer",null,"English","Article",null,null,null,null,null,"ALL; infants; methotrexate; phamacokinetics","CHILDREN; DRUG; CHEMOTHERAPY; RESISTANCE","Background. Interfant-99 was an international collaborative treatment protocol for infants with acute lymphoblastic leukemia (ALL). Procedure. We collected data on 103 infants at the time of their first treatment with high-close methotrexate (HD MTX), 5 g/m(2). Children <6 months of age received two-third of the calculated close based on body surface area (BSA), children 6-12 months three-fourth of the calculated dose, and children >12 months full dose. Results. The median steady-state MTX concentration at the end of the 24-hr infusion was 57.8 mu M (range 9.5-313). The median systemic clearance was 6.22 L/hr/m(2) BSA, and tended to increase with age (P = 0.099). Boys had higher clearance than girls, 6.77 and 5.28 L/hr/m(2) (P = 0.030), and tended to have lower median MTX concentration at 24 hr. Eight infants had MTX levels below 20 mu M, a level judged to be sufficient in B-lineage ALL in children >1 year of age. All infants tolerated the close well enough to receive a second dose of HD MTX without dose reduction. We found no significant effect on disease-free survival for MTX steady-state concentration, MTX clearance, or time to MTX below 0.2 mu M. Conclusions. Our data provide no Support for a change in the dosing rules for MTX used in Interfant-99. However, in view of the poor treatment results for infants, one might consider increase in the dose for patients who reach plasma levels below median after the first MTX dose. Pediatr Blood Cancer 2009;52:596-601. (C) 2009 Wiley-Liss, Inc.","[Lonnerholm, Gudmar] Univ Hosp, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden; [Valsecchi, Maria Grazia; De Lorenzo, Paola] Univ Milano Bicocca, Dept Clin Med & Prevent, Bicocca, Italy; [Schrappe, Martin] Univ Med Ctr Schleswig Holstein, Kiel, Germany; [Hovi, Liisa] Univ Helsinki, Helsinki, Finland; [Campbell, Myriam] Univ Chile, Chilean Natl Pediat Oncol Grp, PINDA, Dept Hematol & Oncol,Hosp Roberto Rio, Santiago, Chile; [Mann, Georg] St Anna Childrens Hosp, Vienna, Austria; [Janka-Schaub, Gritta] Univ Hosp Hamburg Eppendorf, Hamburg, Germany; [Li, Chi-Kong] Prince Wales Hosp, HKPHOSG, Shatin, Hong Kong, Peoples R China; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Hann, Ian] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands","Lonnerholm, G, Univ Hosp, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden","gudmar.lonnerholm@kbh.uu.se",null,null,null,16,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,"10.1002/pbc.21925","PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","MAY",2009,52,5,null,null,null,596,601,null,null,6,"Oncology; Hematology; Pediatrics","418SK","ISI:000264168800010"]
[2,"C","Huska, D; Adam, V; Babula, P; Hrabeta, J; Stiborova, M; Eckschlager, T; Trnkova, L; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Babula, Petr; Hrabeta, Jan; Stiborova, Marie; Eckschlager, Tomas; Trnkova, Libuse; Kizek, Rene",null,"Square-Wave Voltammetry as a Tool for Investigation of Doxorubicin Interactions with DNA Isolated from Neuroblastoma Cells","Electroanalysis",null,"English","Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Intercalating drug; Doxorubicin; Nucleic acids; Voltammetry; Adsorptive transfer stripping technique","GLASSY-CARBON ELECTRODE; FLOW-INJECTION ANALYSIS; ELECTROCHEMICAL BIOSENSOR; GOLD NANOPARTICLES; ETHIDIUM-BROMIDE; ANTICANCER DRUG; PASTE ELECTRODE; NUCLEIC-ACIDS; TUMOR-CELLS; BEHAVIOR","We investigated ethidium bromide intercalation into DNA molecule as a model system to test square-wave voltammetry (SWV) as a suitable method for this purpose We found that 0.13 mu g EtBr intercalates into 1 mu g dsDNA in average. Further, SWV was utilized for investigation of doxorubicin-DNA interactions. Intercalated doxorubicin reduced observed dsDNA cytosine and adenine (CA) signal, but also provided new signal called DOXO at -0.35 V. This phenomenon was observed at both single and double stranded DNA standards. We also employed adsorptive transfer stripping technique coupled with SWV for study of doxorubicin-DNA interactions. Doxorubicin intercalation into dsDNA molecule adsorbed onto working electrode was fast, because we observed considerable changes in CA and DOXO signals after 360 s. Finally, we detected doxorubicin-DNA adducts formed in doxorubicin treated neuroblastoma cells.","[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Nat Drugs, CZ-61242 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,55,0,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,"10.1002/elan.200804429","ELECTROANAL","Electroanalysis","FEB",2009,21,"2009-05-03",null,null,null,487,494,null,null,8,"Chemistry, Analytical; Electrochemistry","417GC","ISI:000264063500035"]
[3,"J","Lastovicka, J; Budinsky, V; Spisek, R; Barunkova, J",null,null,null,"Lastovicka, J.; Budinsky, V.; Spisek, R.; Barunkova, J.",null,"Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers","Cellular Immunology",null,"English","Article",null,null,null,null,null,"H-3-thymidine incorporation; CSFE staining; Expression of activation markers; Immunodeficiencies","DIACETATE SUCCINIMIDYL ESTER; FLOW CYTOMETRIC ANALYSIS; FLUORESCENT DYES; T-CELLS; IN-VIVO; CD69 EXPRESSION; MIGRATION; KINETICS; DIVISION","The measurement of cell proliferation after mitogenic stimulation is an important parameter used in diagnosis of immunodeficiencies in clinical laboratory as well as in various fields of lymphocyte research. Recent methods try to overcome the radioactive assay using tritiated thymidine (H-3) by flow-cytometric methods using different fluorochromes such as CFSE or even to substitute these direct methods by tracing the expression of cell-membrane activation markers associated with various steps of proliferation cycle. In our study we compared the H-3 assay with CFSE-staining method and expression of activation markers (CD69, HLA-DR, CD25, CD27, CD71, CD152, CD134 and CD195) on a sample of 128 consecutive patients and healthy controls evaluated in clinical laboratory. We also tested various concentrations of USE and its impact on proliferation activity and expression of activation markers. We found that CFSE in concentration from 37 nM to 10 mu M decreases the proliferative capacity (expressed in cpm 3 H assay) due to the decreased viability of proliferating cells (measured as 7-AAD+) in concentration-dependent manner. Moreover, CFSE substantially modulates the expression of activation molecules (decreasing CD69, HLA-DR, CD25 the majority of examinated molecules). We found a good correlation between CFSE-staining method with H-3 assay, if CFSE low population is gated on CD3+ population (correlation coefficient 0.801), but only in samples with stimulation index (SI) higher then 25. In poorly proliferating samples (SI <= 25) no correlation was found due to several false positive results in USE test. Statistically significant correlation between proliferation assessed as 3 H-thymidine incorporation and expression of activation markers was found in the case of CD25, CD27, CD38, CD152, CD71, still only in samples with higher proliferation activity (SI > 25). No correlation was found with CD134, CD195, HLA-DR and CD69. We conclude that standard assay with H-3-thymidine incorporation is unreplaceable assay in diagnosis of severe cellular immunodeficiencies as CFSE assay have high proportion of false positive results. Researchers tracing cell-membrane bound molecules on dividing cells stained by CFSE must take into account that USE may substantially modulate the expression of these markers and decrease the viability of stained cells. (C) 2009 Elsevier Inc. All rights reserved.","[Lastovicka, J.] Charles Univ Prague, Sch Med 2, Inst Immunol, Prague 15006 5, Czech Republic; Charles Univ Prague, Univ Hosp Motol, Prague 15006 5, Czech Republic","Lastovicka, J, Charles Univ Prague, Sch Med 2, Inst Immunol, V Uvalu 84, Prague 15006 5, Czech Republic","jan.lastovicka@lfmotol.cuni.cz","VZ MSM [002162 0812]","This work was supported by the research project VZ MSM 002162 0812.",null,22,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0008-8749",null,"10.1016/j.cellimm.2009.01.007","CELL IMMUNOL","Cell. Immunol.",null,2009,256,"2009-02-01",null,null,null,79,85,null,null,7,"Cell Biology; Immunology","426IH","ISI:000264700700011"]
[3,"J","Jelinkova, H; Sulc, J; Dostalova, T; Koranda, P; Nemec, M; Hofmanova, P",null,null,null,"Jelinkova, H.; Sulc, J.; Dostalova, T.; Koranda, P.; Nemec, M.; Hofmanova, P.",null,"Bracket debonding by mid-infrared laser radiation","Laser Physics Letters",null,"English","Article",null,null,null,null,null,"bracket debonding; infrared lasers; Tm:YAG 1.997 mu m laser; Nd:YAG 1.444 mu m laser; GaAs laser diode","ER-YAG LASER; CARBON-DIOXIDE LASER; CERAMIC BRACKETS; BOND STRENGTH; ORTHODONTIC BRACKETS; REMOVAL; SHEAR; DENTIN; ABLATION; INVITRO","The purpose of the study was to determine the proper laser radiation for ceramic bracket debonding and the investigation of the tooth root temperature injury. The debonding was investigated by diode-pumped continuously running Tm:YAP and Nd:YAG lasers, and by GaAs laser diode generating radiation with the wavelengths 1.997 mu m, 1.444 mu m, and 0.808 mu m, respectively. The possibility of brackets removal by laser radiation was investigated together with the tooth and, it specifically, root temperature rise. From the results it follows that continuously running diode pumped Tm:YAG or Nd:YAG laser generating wavelengths 1.997 mu m or 1.444 mu m, respectively, having the output power 1 W can be good candidates for ceramic brackets debonding.","[Jelinkova, H.; Sulc, J.; Koranda, P.; Nemec, M.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague 1, Czech Republic; [Dostalova, T.; Hofmanova, P.] Charles Univ Prague, Sch Med 2, Dept Pediat Stomatol, Prague 15006 5, Czech Republic","Jelinkova, H, Czech Tech Univ, Fac Nucl Sci & Phys Engn, Brehova 7, CR-11519 Prague 1, Czech Republic","helena.jelinkova@fjfi.cvut.cz","Czech Ministry of Education [MSM6840770022]","This research has been supported by the Grant of the Czech Ministry of Education No. MSM6840770022 \"Laser systems, radiation and modern optical applications\". The authors wish to thank their colleagues Jan Adamek and Jan Siegl from The Department of Materials, FNSPE CVUT Prague, for the provided Scanning Electron Microscopy measurements as well as to Jaroslav Racek from 1st Medical Faculty, Department of Stomatology, Charles University Prague for bracketing of tooth samples.",null,33,0,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1612-2011",null,"10.1002/lapl.200810117","LASER PHYS LETT","Laser Phys. Lett.","MAR",2009,6,3,null,null,null,222,228,null,null,7,"Instruments & Instrumentation","421OZ","ISI:000264369500008"]
[3,"J","Tsenov, G; Redkozubova, O; Kubova, H; Mares, P",null,null,null,"Tsenov, Grygoryi; Redkozubova, Olga; Kubova, Hana; Mares, Pavel",null,"Effects of lamotrigine on cortically-elicited phenomena in adult rats: Differences between acute application and late consequences of early postnatal administration","Brain Research",null,"English","Article",null,null,null,null,null,"Lamotrigine; Early-life administration-cerebral cortex; Evoked potential; Epileptic afterdischarge-rat","ANTIEPILEPTIC DRUG LAMOTRIGINE; EPILEPTIC AFTERDISCHARGES; SEIZURE DEVELOPMENT; KINDLED SEIZURES; STIMULATION; GABAPENTIN; TIAGABINE; AMYGDALA; BRAIN; MODEL","Lamotrigine (LTG) is increasingly used in pediatric epileptology but there are no experimental data on delayed consequences of early life administration of LTG on epileptic phenomena. Therefore we used cortically induced epileptic phenomena to study these possible effects and compared the results with data on acute administration of LTG in adult rats. Naive adult rats as well as animals with a history of LTG administration in early postnatal period (daily from postnatal day 7 to 11 in a dose of 10 and/or 20 mg/kg i.p.) were implanted with cortical stimulation and recording electrodes. Cortical interhemispheric responses and epileptic afterdischarges (ADs) were elicited by stimulation of sensorimotor area in both groups. Acute administration of LTG (10 and/or 20 mg/kg i.p.) did not affect cortical interhemispheric evoked responses but increased thresholds for elicitation of movements elicited by stimulation, spike-and-wave ADs and accompanying clonic seizures. On the contrary, duration of ADs was increased. Animals injected with LTG postnatally exhibited increased thresholds for transition of ADs into a limbic type (mixed ADs), decreased incidence of the limbic type and suppression of recurrent ADs. Evoked responses exhibited a steeper input-output curve in a group receiving the 20 mg/kg dose of LTG during early development. Our results demonstrated a specific anticonvulsant effect as a delayed consequence of early-life administration of LTG; it differed from effects of acute administration of LTG to adult rats. (C) 2008 Elsevier B.V. All rights reserved.","[Tsenov, Grygoryi; Redkozubova, Olga; Kubova, Hana; Mares, Pavel] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CZ-14220 Prague 4, Czech Republic; [Mares, Pavel] Charles Univ Prague, Fac Med 2, CZ-14220 Prague, Czech Republic; [Redkozubova, Olga] Moscow MV Lomonosov State Univ, Fac Biol, Moscow, Russia","Mares, P, Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Videnska 1083, CZ-14220 Prague 4, Czech Republic","maresp@biomed.cas.cz","GlaxoSmithKline [Q1S501210509]; Academy of the Czech Republic [LC554, AV0Z5011009]","This study was supported by a grant from GlaxoSmithKline, a grant No.Q1S501210509 of the Grant Agency of the Academy of the Czech Republic and by research projects LC554 and AV0Z5011009.",null,35,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993",null,"10.1016/j.brainres.2008.12.054","BRAIN RES","Brain Res.","MAR 3",2009,1258,null,null,null,null,65,70,null,null,6,"Neurosciences","423ZU","ISI:000264536100008"]
[3,"J","Vanourkova, Z; Kramer, HJ; Erbanova, M; Backer, A; Cervenka, L; Huskova, Z; Chabova, VC; Tesar, V; Dvorak, P; Maly, J; Vaneckova, I",null,null,null,"Vanourkova, Zdenka; Kramer, Herbert J.; Erbanova, Michaela; Baecker, Angela; Cervenka, Ludek; Huskova, Zuzana; Chabova, Vera Certikova; Tesar, Vladimir; Dvorak, Pavel; Maly, Jan; Vaneckova, Ivana",null,"Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension","Vascular Pharmacology",null,"English","Article",null,null,null,null,null,"Hypertension; Inducible; Endothelin receptors; Cyp1A1-Ren-2 rats","DEPENDENT MALIGNANT HYPERTENSION; END-ORGAN DAMAGE; SALT-SENSITIVE HYPERTENSION; ETA-RECEPTOR; REN-2 RATS; SYSTEM; RENIN; KIDNEY; INFLAMMATION; BOSENTAN","We found previously that selective blockade of endothelin ETA receptors is superior to nonselective ETA/ETB in attenuating hypertension and survival rate in Ren-2 transgenic rats (TGR). In the present pilot study, we were interested in whether similar effects will be found in TGR with inducible malignant hypertension (iTGR; official strain name Cyp1A1-Ren-2rats), which were derived from the original Ren-2 transgenic rat strain. Studies were performed in three-month old male iTGR. Treatment with either bosentan, a non-selective ETA/ETB, or with atrasentan. a selective ETA receptor blocker, was started on day 2 of the experiment. Feeding with indole-3-carbinole (13C; 0.3% in rat chow), a natural xenobiotic which activates the Cyp1a1 promoter of the mouse Ren-2 gene, began on day 3 and lasted for 4 days until day 6. Systolic BP, body weight, plasma ANG II and tissue ANG II and ET-1 concentrations were determined daily. Severe hypertension developed as early as 1 day after beginning of 13C feeding which was accompanied by a significant reduction in body weight and by increases in plasma and tissue ANG II and left ventricle EN concentrations. Atrasentan or bosentan had no effects on the rise in BP or plasma and tissue ANG II concentrations but prevented the rise in heart ventricle ET-1 concentration. Our data show that blockade of the ET system does not prevent or attenuate the rapid development of severe hypertension in iTGR; a long-term protective effect of ET blockade on cardiac (and renal) damage, however. cannot be excluded and awaits further investigations. (C) 2009 Elsevier Inc. All rights reserved.","[Vanourkova, Zdenka; Erbanova, Michaela; Cervenka, Ludek; Huskova, Zuzana; Chabova, Vera Certikova; Maly, Jan; Vaneckova, Ivana] Inst Clin & Expt Med, Ctr Med Expt, CZ-14021 Prague 4, Czech Republic; [Vanourkova, Zdenka; Erbanova, Michaela; Cervenka, Ludek; Huskova, Zuzana; Chabova, Vera Certikova; Vaneckova, Ivana] Inst Clin & Expt Med, Cardiovasc Res Ctr, CZ-14021 Prague, Czech Republic; [Kramer, Herbert J.; Baecker, Angela] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Chabova, Vera Certikova; Tesar, Vladimir] Charles Univ Prague, Fac Med 1, Dept Nephrol, Prague, Czech Republic; [Dvorak, Pavel] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic","Vaneckova, I, Inst Clin & Expt Med, Ctr Med Expt, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic","ivvn@medicon.cz",null,null,null,34,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1537-1891",null,"10.1016/j.vph.2009.01.002","VASC PHARMACOL","Vasc. Pharmacol.","MAY-JUN",2009,50,"2009-06-05",null,null,null,194,199,null,null,6,"Pharmacology & Pharmacy","421AG","ISI:000264329700008"]
[3,"J","Fencl, F; Janda, J; Blahova, K; Hribal, Z; Stekrova, J; Puchmajerova, A; Seeman, T",null,null,null,"Fencl, Filip; Janda, Jan; Blahova, Kveta; Hribal, Zdenek; Stekrova, Jitka; Puchmajerova, Alena; Seeman, Tomas",null,"Genotype-phenotype correlation in children with autosomal dominant polycystic kidney disease","Pediatric Nephrology",null,"English","Article",null,null,null,null,null,"Autosomal dominant polycystic kidney disease; PKD1 gene; PKD2 gene; Renal function; Ultrasound; Blood pressure; Hypertension; Children","RENAL-DISEASE; CLINICAL-FEATURES; BLOOD-PRESSURE; IN-UTERO; PKD2; PROGNOSIS; GENE; ADOLESCENTS; PROGRESSION; CHILDHOOD","Adults with autosomal dominant polycystic kidney disease (ADPKD) and PKD1 mutations have a more severe disease than do patients with PKD2 mutations. The aim of this study was to compare phenotypes between children with mutations in the PKD1/PKD2 genes. Fifty PKD1 children and ten PKD2 children were investigated. Their mean age was similar (8.6 +/- 5.4 years and 8.9 +/- 5.6 years). Renal ultrasound was performed, and office blood pressure (BP), ambulatory BP, creatinine clearance and proteinuria were measured. The PKD1 children had, in comparison with those with PKD2, significantly greater total of renal cysts (13.3 +/- 12.5 vs 3.0 +/- 2.1, P = 0.004), larger kidneys [right/left kidney length 0.89 +/- 1.22 standard deviation score (SDS) vs 0.17 +/- 1.03 SDS, P = 0.045, and 1.19 +/- 1.42 SDS vs 0.12 +/- 1.09 SDS, P = 0.014, successively] and higher ambulatory day-time and night-time systolic BP (day-time/night-time BP index 0.93 +/- 0.10 vs 0.86 +/- 0.05, P = 0.021 and 0.94 +/- 0.07 vs 0.89 +/- 0.04, P = 0.037, successively). There were no significant differences in office BP, creatinine clearance or proteinuria. Prenatal renal cysts (14%), hypertension defined by ambulatory BP (27%) and enlarged kidneys (32%) were observed only in the PKD1 children. This is the first study on genotype-phenotype correlation in children with ADPKD. PKD1 children have more and larger renal cysts, larger kidneys and higher ambulatory BP than do PKD2 children. Renal cysts and enlarged kidneys detected prenatally are highly specific for children with PKD1.","[Fencl, Filip; Janda, Jan; Blahova, Kveta; Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat, Prague 15006, Czech Republic; [Hribal, Zdenek] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Imaging Methods, Prague 15006, Czech Republic; [Stekrova, Jitka; Puchmajerova, Alena] Charles Univ Prague, Inst Biol, Prague 15006, Czech Republic; [Stekrova, Jitka] Charles Univ Prague, Dept Med Genet, Fac Med 1, Prague 15006, Czech Republic; [Puchmajerova, Alena] Charles Univ Prague, Dept Med Genet, Fac Med 2, Prague 15006, Czech Republic","Fencl, F, Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat, Uvalu 84, Prague 15006, Czech Republic","filipfencl@seznam.cz","VZ MZ [CR 00064203]; MSMT [CR 0021620819]; IGA [MZ CR NR/9427-3]","This study was supported by grants VZ MZ CR 00064203, MSMT CR 0021620819 and IGA MZ CR NR/9427-3. We thank all paediatric nephrologists for referring children with polycystic kidney diseases to our centre, and we wish to thank Dr. J. Zidovska, Dr. J. Reiterova, Dr. M. Koudova, Dr. I. Grochova and Dr. F. Losan for information about the families. We are grateful to the families for their cooperation.",null,33,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-008-1090-9","PEDIAT NEPHROL","Pediatr. Nephrol.","MAY",2009,24,5,null,null,null,983,989,null,null,7,"Pediatrics; Urology & Nephrology","423ZQ","ISI:000264535700007"]
[3,"J","Seeman, T",null,null,null,"Seeman, Tomas",null,"Hypertension after renal transplantation","Pediatric Nephrology",null,"English","Article",null,null,null,null,null,"Hypertension; Children; Renal transplantation; Graft function; Graft survival; Blood pressure control; Angiotensin-converting enzyme inhibitors","AMBULATORY BLOOD-PRESSURE; LEFT-VENTRICULAR MASS; ARTERIAL-HYPERTENSION; ALLOGRAFT SURVIVAL; KIDNEY-TRANSPLANTATION; GRAFT-SURVIVAL; CYCLOSPORINE MICROEMULSION; CARDIOVASCULAR-DISEASE; PEDIATRIC-PATIENTS; NATIVE KIDNEYS","Hypertension is a common and serious complication after renal transplantation. It is an important risk factor for graft loss and morbidity and mortality of transplanted children. The etiology of posttransplant hypertension is multifactorial: native kidneys, immunosuppressive therapy, renal-graft artery stenosis, and chronic allograft nephropathy are the most common causes. Blood pressure (BP) in transplanted children should be measured not only by casual BP (CBP) measurement but also regularly by ambulatory BP monitoring (ABPM). The prevalence of posttransplant hypertension ranges between 60% and 90% depending on the method of BP measurement and definition. Left ventricular hypertrophy is a frequent type of end-organ damage in hypertensive children after transplantation (50-80%). All classes of antihypertensive drugs can be used in the treatment of posttransplant hypertension. Hypertension control in transplanted children is poor; only 20-50% of treated children reach normal BP. The reason for this poor control seems to be inadequate antihypertensive therapy, which can be improved by increasing the number of antihypertensive drugs. Improved hypertension control leads to improved long-term graft and patient survival in adults. In children, there is a great potential for antihypertensive treatment that could also result in improved graft and patient survival.","[Seeman, Tomas] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15006, Czech Republic; [Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Transplantat Ctr Univ, Prague 15006, Czech Republic","Seeman, T, Charles Univ Prague, Dept Pediat, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic","tomas.seeman@lfmotol.cuni.cz",null,null,null,90,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-007-0627-7","PEDIAT NEPHROL","Pediatr. Nephrol.","MAY",2009,24,5,null,null,null,959,972,null,null,14,"Pediatrics; Urology & Nephrology","423ZQ","ISI:000264535700005"]
[3,"J","Hilgert, N; Huentelman, MJ; Thorburn, AQ; Fransen, E; Dieltjens, N; Mueller-Malesinska, M; Pollak, A; Skorka, A; Waligora, J; Ploski, R; Castorina, P; Primignani, P; Ambrosetti, U; Murgia, A; Orzan, E; Pandya, A; Arnos, K; Norris, V; Seeman, P; Janousek, P; Feldmann, D; Marlin, S; Denoyelle, F; Nishimura, CJ; Janecke, A; Nekahm-Heis, D; Martini, A; Mennucci, E; Toth, T; Sziklai, I; del Castillo, I; Moreno, F; Petersen, MB; Iliadou, V; Tekin, M; Incesulu, A; Nowakowska, E; Bal, J; de Heyning, PV; Roux, AF; Blanchet, C; Goizet, C; Lancelot, G; Fialho, G; Caria, H; Liu, XZ; Xiaomei, OY; Govaerts, P; Gronskov, K; Hostmark, K; Frei, K; Dhooge, I; Vlaeminck, S; Kunstmann, E; Van Laer, L; Smith, RJH; Van Camp, G",null,null,null,"Hilgert, Nele; Huentelman, Matthew J.; Thorburn, Ashley Q.; Fransen, Erik; Dieltjens, Nele; Mueller-Malesinska, Malgorzata; Pollak, Agnieszka; Skorka, Agata; Waligora, Jaroslaw; Ploski, Rafal; Castorina, Pierangela; Primignani, Paola; Ambrosetti, Umberto; Murgia, Alessandra; Orzan, Eva; Pandya, Arti; Arnos, Kathleen; Norris, Virginia; Seeman, Pavel; Janousek, Petr; Feldmann, Delphine; Marlin, Sandrine; Denoyelle, Francoise; Nishimura, Carla J.; Janecke, Andreas; Nekahm-Heis, Doris; Martini, Alessandro; Mennucci, Elena; Toth, Timea; Sziklai, Istvan; del Castillo, Ignacio; Moreno, Felipe; Petersen, Michael B.; Iliadou, Vasiliki; Tekin, Mustafa; Incesulu, Armagan; Nowakowska, Ewa; Bal, Jerzy; de Heyning, Paul Van; Roux, Anne-Francoise; Blanchet, Catherine; Goizet, Cyril; Lancelot, Guenaelle; Fialho, Graca; Caria, Helena; Liu, Xue Zhong; Xiaomei, Ouyang; Govaerts, Paul; Gronskov, Karen; Hostmark, Karianne; Frei, Klemens; Dhooge, Ingeborg; Vlaeminck, Stephen; Kunstmann, Erdmute; Van Laer, Lut; Smith, Richard J. H.; Van Camp, Guy",null,"Phenotypic variability of patients homozygous for the GJB2 mutation 35delG cannot be explained by the influence of one major modifier gene","European Journal of Human Genetics",null,"English","Article",null,null,null,null,null,"hereditary hearing loss; connexin 26; 35delG; association study; modifier gene","GENOME-WIDE ASSOCIATION; HEARING-LOSS; DISEASE; DNA; IDENTIFICATION","Hereditary hearing loss (HL) is a very heterogeneous trait, with 46 gene identifications for non-syndromic HL. Mutations in GJB2 cause up to half of all cases of severe-to-profound congenital autosomal recessive non-syndromic HL, with 35delG being the most frequent mutation in Caucasians. Although a genotype-phenotype correlation has been established for most GJB2 genotypes, the HL of 35delG homozygous patients is mild to profound. We hypothesise that this phenotypic variability is at least partly caused by the influence of modifier genes. By performing a whole-genome association (WGA) study on 35delG homozygotes, we sought to identify modifier genes. The association study was performed by comparing the genotypes of mild/moderate cases and profound cases. The first analysis included a pooling-based WGA study of a first set of 255 samples by using both the Illumina 550K and Affymetrix 500K chips. This analysis resulted in a ranking of all analysed single-nucleotide polymorphisms (SNPs) according to their P-values. The top 250 most significantly associated SNPs were genotyped individually in the same sample set. All 192 SNPs that still had significant P-values were genotyped in a second independent set of 297 samples for replication. The significant P-values were replicated in nine SNPs, with combined P-values between 3 x 10(-3) and 1 x 10(-4). This study suggests that the phenotypic variability in 35delG homozygous patients cannot be explained by the effect of one major modifier gene. Significantly associated SNPs may reflect a small modifying effect on the phenotype. Increasing the power of the study will be of greatest importance to confirm these results.","[Hilgert, Nele; Fransen, Erik; Dieltjens, Nele; Van Laer, Lut; Van Camp, Guy] Univ Antwerp, Dept Med Genet, B-2610 Antwerp, Belgium; [Huentelman, Matthew J.; Thorburn, Ashley Q.] Translat Genom Res Inst, Phoenix, AZ USA; [Mueller-Malesinska, Malgorzata; Pollak, Agnieszka; Skorka, Agata] Inst Physiol & Pathol Hearing, Warsaw, Poland; [Waligora, Jaroslaw] Med Univ Warsaw, Dept Diabetol Newborn Pathol & Birth Defects, Warsaw, Poland; [Ploski, Rafal] Med Univ Warsaw, Dept Med Genet, Warsaw, Poland; [Castorina, Pierangela] Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, UO Audiol, Milan, Italy; [Primignani, Paola] Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Med Genet Lab, Milan, Italy; [Ambrosetti, Umberto] Univ Milan, Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, ENT & Ophthalmol Dept,UO Audiol, Milan, Italy; [Murgia, Alessandra] Univ Padua, Dept Pediat, Rare Dis Ctr, Padua, Italy; [Orzan, Eva] Univ Hosp Padova, Pediat Audiol Unit, Dept Otolaryngol & Otosurgery, Padua, Italy; [Pandya, Arti] Virginia USA Commonwealth Univ, Sch Med, Dept Human Genet, Richmond, VA USA; [Arnos, Kathleen; Norris, Virginia] Gallaudet Univ, Dept Biol, Washington, DC 20002 USA; [Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague, Czech Republic; [Janousek, Petr] Charles Univ Prague, Dept Child ENT, Sch Med 2, Prague, Czech Republic; [Janousek, Petr] Univ Hosp Motol, Prague, Czech Republic; [Feldmann, Delphine] Hop Enfants Armand Trousseau, AP HP, Serv Biochim & Biol Mol, Paris, France; [Marlin, Sandrine] Hop Enfants Armand Trousseau, AP HP, Unite Genet Med, Paris, France; [Denoyelle, Francoise] Hop Enfants Armand Trousseau, AP HP, Serv ORL & Chirurg Cervico Faciale, Paris, France; [Denoyelle, Francoise] UPMC Paris 06, Paris, France; [Nishimura, Carla J.; Smith, Richard J. H.] Univ Iowa, Dept Otolaryngol & Interdept PhD Program Genet, Iowa City, IA USA; [Janecke, Andreas] Innsbruck Med Univ, Div Clin Genet, Innsbruck, Austria; [Nekahm-Heis, Doris] Innsbruck Med Univ, Clin Dept Hearing Voice & Speech Disorders, Innsbruck, Austria; [Martini, Alessandro; Mennucci, Elena] Univ Hosp, Audiol & ENT Dept, Ferrara, Italy; [Toth, Timea; Sziklai, Istvan] Debrecen Univ Med, Dept Otolaryngol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; [del Castillo, Ignacio; Moreno, Felipe] Hosp Ramon & Cajal, Unidad Genet Mol, E-28034 Madrid, Spain; [del Castillo, Ignacio; Moreno, Felipe] CIBERER, Madrid, Spain; [Petersen, Michael B.] Aghia Sophia Childrens Hosp, Dept Genet, Inst Child Hlth, Athens, Greece; [Iliadou, Vasiliki] Aristotle Univ Thessaloniki, Dept Psychoacoust Neurootol, AHEPA Hosp, Psychiat Clin 3, GR-54006 Thessaloniki, Greece; [Tekin, Mustafa] Ankara Univ, Sch Med, Div Pediat Mol Genet, TR-06100 Ankara, Turkey; [Incesulu, Armagan] Eskisehir Osmangazi Univ, Dept Otolaryngol Head & Neck Surg, Eskisehir, Turkey; [Nowakowska, Ewa] Inst Mother & Child Hlth, Dept Audiol & Laryngol, Warsaw, Poland; [Bal, Jerzy] Inst Mother & Child Hlth, Dept Med Genet, Warsaw, Poland; [de Heyning, Paul Van] Univ Antwerp, Dept Otorhinolaryngol, Univ Antwerp Hosp, B-2020 Antwerp, Belgium; [Roux, Anne-Francoise] CHU Montpellier, Genet Mol Lab, Montpellier, France; [Blanchet, Catherine] Hop Montpellier, ENT Dept, Sensory Genet Dis Natl Reference Ctr, Montpellier, France; [Goizet, Cyril] Univ Victor Segalen Bordeaux 2, Lab Genet Humaine Dev & Canc, Bordeaux, France; [Lancelot, Guenaelle] CHU Pellegrin, Genet Mol Lab, Bordeaux, France; [Fialho, Graca; Caria, Helena] Univ Lisbon, Fac Sci, Ctr Biodivers Funct & Integrat Genom, P-1699 Lisbon, Portugal; [Liu, Xue Zhong; Xiaomei, Ouyang] Univ Miami, Dept Otolaryngol, Miami, FL USA; [Govaerts, Paul] Eargroup, Antwerp, Belgium; [Gronskov, Karen] Kennedy Ctr, Med Genet Lab, Glostrup, Denmark; [Hostmark, Karianne] Bispebjerg Hosp, Dept Audiol, DK-2400 Copenhagen, Denmark; [Frei, Klemens] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Dhooge, Ingeborg; Vlaeminck, Stephen] Univ Ziekenhuis Gent, Klin Audiol, Ghent, Belgium; [Kunstmann, Erdmute] Univ Wurzburg, Dept Human Genet, Wurzburg, Germany","Van Camp, G, Univ Antwerp, Dept Med Genet, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium","guy.vancamp@ua.ac.be","EUROHEAR [LSHG-CT2004-512063]; Fund for Scientific Research Flanders (FWO-F) [G. 0138.07]; MNiSW [0711/ P01/ 2006/ 31]; Oticon Foundation ; National Institutes of Health [DC02842]","We are very grateful to all patients who cooperated in this study. This study was supported in part by grants from EUROHEAR (LSHG-CT2004-512063), the Fund for Scientific Research Flanders (FWO-F, Grant G. 0138.07), the MNiSW Grant 0711/ P01/ 2006/ 31, the Oticon Foundation (Denmark, MBP) and the National Institutes of Health (NIDCD DC02842 to RJHS). Nele Hilgert is a fellow of the Fund for Scientific Research Flanders (FWO-F).",null,21,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,"10.1038/ejhg.2008.201","EUR J HUMAN GENET","Eur. J. Hum. Genet.","APR",2009,17,4,null,null,null,517,524,null,null,8,"Biochemistry & Molecular Biology; Genetics & Heredity","421JJ","ISI:000264354900015"]
[3,"J","Obermannova, B; Banghova, K; Sumnik, Z; Dvorakova, HM; Betka, J; Fencl, F; Kolouskova, S; Cinek, O; Lebl, J",null,null,null,"Obermannova, Barbora; Banghova, Karolina; Sumnik, Zdenek; Dvorakova, Hana M.; Betka, Jan; Fencl, Filip; Kolouskova, Stanislava; Cinek, Ondrej; Lebl, Jan",null,"Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene","European Journal of Pediatrics",null,"English","Article",null,null,null,null,null,"Primary hyperparathyroidism; Hypercalcaemia; Newborn; Parathyroidectomy; Bisphosphonates","CALCIUM-SENSING RECEPTOR; BENIGN HYPOCALCIURIC HYPERCALCEMIA; AUTOSOMAL-DOMINANT HYPOCALCEMIA; FUNCTIONAL-CHARACTERIZATION; POLYMORPHISMS","We present a male patient with neonatal severe primary hyperparathyroidism, whose manifestation was exceptionally serious for the heterozygous inactivating mutation he carried in the CASR gene. The patient presented soon after birth with respiratory distress requiring long-term mechanical ventilation, bone and chest deformities, feeding problems, and hypotonia. He had hypercalcaemia, hypophosphataemia, and hyperparathyroidism. There was no known history of calcium metabolism disorders in the family. As the impact on calcaemia of a rescue therapy with bisphosphonates was only transient, a subtotal and subsequently total parathyroidectomy were performed in the fourth month of life. Afterwards his clinical status improved and the fractures healed, but his neuropsychological development is delayed due to cerebral atrophy. Genetic analysis revealed a heterozygous missense CASR mutation R185Q, and an approximately equal expression of the mutated and wild-type RNA in the parathyroid tissue. The mother of the child was homozygous for the wild-type allele; the father is unknown. In conclusion, this patient demonstrates how serious neonatal hyperparathyroidism can be when caused by a heterozygous mutation. This may be attributable to a combination of dominant-negative action of the mutant allele with an intrauterine foetal hyperparathyroidism developed in the mother's normocalcaemic environment, further aggravated by a putative maternal vitamin D deficiency during pregnancy.","[Obermannova, Barbora] Univ Hosp Motol, Dept Paediat, Prague 15006, Czech Republic; [Dvorakova, Hana M.] Charles Univ Prague, Fac Med 2, Dept Neonatol, Prague, Czech Republic; [Betka, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol, Prague, Czech Republic; [Obermannova, Barbora; Banghova, Karolina; Sumnik, Zdenek; Fencl, Filip; Kolouskova, Stanislava; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic","Obermannova, B, Univ Hosp Motol, Dept Paediat, Uvalu 84, Prague 15006, Czech Republic","obermannova@seznam.cz","Czech Ministry of Education [MSM0021620814, MSM0021620819]; Czech Ministry of Health [MZ000064203]","The study was supported by an institutional grant from the Czech Ministry of Education ( grants MSM0021620814 and MSM0021620819), and by the Czech Ministry of Health ( grants MZ000064203). Drs. M. Mrhalova and L. Krskova, Institute of Pathology, Motol University Hospital, Prague, are acknowledged for assistance with the RNA analysis.",null,18,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,"10.1007/s00431-008-0794-y","EUR J PEDIAT","Eur. J. Pediatr.","MAY",2009,168,5,null,null,null,569,573,null,null,5,"Pediatrics","420WY","ISI:000264321100009"]
[3,"J","Camajova, J; Berwouts, S; Matthijs, G; Macek, M; Dequeker, E",null,null,null,"Camajova, Jana; Berwouts, Sarah; Matthijs, Gert; Macek, Milan, Jr.; Dequeker, Elisabeth",null,"Variability in the use of CE-marked assays for in vitro diagnostics of CFTR gene mutations in European genetic testing laboratories","European Journal of Human Genetics",null,"English","Article",null,null,null,null,null,"cystic fibrosis; CE-marked IVD assays; validation; verification; mutation detection; variability","QUALITY-CONTROL","DNA diagnostics of genetic diseases increasingly shifts towards utilization of commercial assays. Cystic fibrosis (CF)-related DNA diagnostics were used as a model for a pilot survey of the variability in the utilization of qualitative CE-marked in vitro diagnostic (IVD) assays and the scale of their modification by end users. A structured questionnaire, developed in the context of the EuroGentest project, was distributed within the frame of the 2005 annual CF external quality assessment (EQA) scheme. Its aim was to evaluate the variability in the use of different CE-marked IVD assays in routine CF DNA diagnostics. Survey results were analysed and sequentially discussed with respective users and/or manufacturers. In total, 125 responses from EQA scheme participants were received. Almost half of the respondents modified manufacturer-recommended protocols. They also reported sporadic and/or recurrent problems with assay performance and genotyping of particular alleles. Nonetheless, only half of the respondents performed in-house verification before the implementation of the assay in clinical diagnostics and/or after modification of the recommended protocol. Results of this survey substantiate the importance of guidelines for proper verification of CE-marked IVD assays in DNA diagnostics, using CF as a model.","[Berwouts, Sarah; Matthijs, Gert; Dequeker, Elisabeth] Katholieke Univ Leuven, Ctr Human Genet, B-3000 Leuven, Belgium; [Camajova, Jana; Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague, Czech Republic; [Camajova, Jana; Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic","Dequeker, E, Katholieke Univ Leuven, Ctr Human Genet, Campus Gasthuisberg Herestr 49, B-3000 Leuven, Belgium","els.dequeker@med.kuleuven.be","EuroGentest [FP6-512148]; VZFNM [00064203/6112/]; EU ","This work was supported by EuroGentest (FP6-512148), VZFNM 00064203/6112/ and EU CF Network. We are grateful to all laboratories that took part in the survey, including Drs A Corveleyn and F Le Calvez, who contributed to the development of the questionnaire. We appreciate the encouraging role of Professor J-J Cassiman. Input from Abbott Molecular, Innogenetics and Tepnel Diagnostics was helpful.",null,8,1,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,"10.1038/ejhg.2008.209","EUR J HUMAN GENET","Eur. J. Hum. Genet.","APR",2009,17,4,null,null,null,537,540,null,null,4,"Biochemistry & Molecular Biology; Genetics & Heredity","421JJ","ISI:000264354900018"]
[4,"J","Rozkova, D; Tiserova, H; Fucikova, J; Last'ovicka, J; Podrazil, M; Uclova, H; Budinsky, V; Prausova, J; Linke, Z; Minarik, I; Sediva, A; Spisek, R; Bartunkova, J",null,null,null,"Rozkova, Daniela; Tiserova, Hana; Fucikova, Jitka; Last'ovicka, Jan; Podrazil, Michal; Uclova, Hana; Budinsky, Vit; Prausova, Jana; Linke, Zdenek; Minarik, Ivo; Sediva, Anna; Spisek, Radek; Bartunkova, Jirina",null,"FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer","Clinical Immunology",null,"English","Review",null,null,null,null,null,"Dendritic cells; Cancer immunotherapy; Prostate cancer; Chemo-immunotherapy; PSA","REGULATORY T-CELLS; DYING TUMOR-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSES; OVARIAN-CANCER; CHEMOTHERAPY; EXPOSURE; IMMUNOTHERAPY; CALRETICULIN; VACCINE","Immunotherapy has emerged as another treatment modality in cancer. The goat of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them. In half of these patients, DC immunotherapy resulted in transient clinical responses. Tregs, among other factors, potently inhibit tumor-specific T cells. Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of combined immunotherapy, we continued palliative chemotherapy with docetaxel to reduce the tumor cell burden. DC-based vaccination induced prostate cancer cell-specific immune response. Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%. (C) 2009 Elsevier Inc. All rights reserved.","[Rozkova, Daniela; Tiserova, Hana; Fucikova, Jitka; Last'ovicka, Jan; Podrazil, Michal; Uclova, Hana; Budinsky, Vit; Minarik, Ivo; Sediva, Anna; Spisek, Radek; Bartunkova, Jirina] Charles Univ Prague, Inst Immunol, Fac Med 2, Univ Hosp Motol, Prague 5, Czech Republic; [Prausova, Jana; Linke, Zdenek] Charles Univ Prague, Fac Med 2, Dept Radiotherapy & Oncol, Univ Hosp Motol, Prague 5, Czech Republic; [Minarik, Ivo] Charles Univ Prague, Fac Med 2, Dept Urol, Univ Hosp Motol, Prague 5, Czech Republic","Bartunkova, J, Charles Univ Prague, Inst Immunol, Fac Med 2, V Uvalu 84, Prague 5, Czech Republic","jirina.bartunkova@lfmotol.cuni.cz","Czech Ministry of Education [MSM 0021620812]; GACR [310/08/0838]","This study was supported by project MSM 0021620812 from the Czech Ministry of Education and grant GACR 310/08/0838. We would like to thank Prof. Vaclav Pelouch for his continuous support.",null,38,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616",null,"10.1016/j.clim.2009.01.001","CLIN IMMUNOL","Clin. Immunol.","APR",2009,131,1,null,null,null,1,10,null,null,10,"Immunology","428GC","ISI:000264835000001"]
[4,"J","Joshi, S; Sedivy, V; Hodyc, D; Herget, J; Gurney, AM",null,null,null,"Joshi, Shreena; Sedivy, Vojtech; Hodyc, Daniel; Herget, Jan; Gurney, Alison M.",null,"KCNQ Modulators Reveal a Key Role for KCNQ Potassium Channels in Regulating the Tone of Rat Pulmonary Artery Smooth Muscle","Journal of Pharmacology and Experimental Therapeutics",null,"English","Article",null,null,null,null,null,null,"LINOPIRDINE DUP 996; INNER HAIR-CELLS; K+ CHANNELS; SENSORY NEURONS; K(V)7 CHANNELS; VASCULAR-TONE; CURRENTS; MYOCYTES; VASOCONSTRICTION; HYPERTENSION","Potassium channels are central to the regulation of pulmonary vascular tone. The smooth muscle cells of pulmonary artery display a background K+ conductance with biophysical properties resembling those of KCNQ (K(V)7) potassium channels. Therefore, we investigated the expression and functional role of KCNQ channels in pulmonary artery. The effects of selective KCNQ channel modulators were investigated on K+ current and membrane potential in isolated pulmonary artery smooth muscle cells (PASMCs), on the tension developed by intact pulmonary arteries, and on pulmonary arterial pressure in isolated perfused lungs and in vivo. The KCNQ channel blockers, linopirdine and XE991 [10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone], inhibited the noninactivating background K+ conductance in PASMCs and caused depolarization, vasoconstriction, and raised pulmonary arterial pressure without constricting several systemic arteries or raising systemic pressure. The KCNQ channel openers, retigabine and flupirtine, had the opposite effects. PASMCs were found to express KCNQ4 mRNA, at higher levels than mesenteric artery, along with smaller amounts of KCNQ1 and 5. It is concluded that KCNQ channels, most probably KCNQ4, make an important contribution to the regulation of pulmonary vascular tone, with a greater contribution in pulmonary compared with systemic vessels. The pulmonary vasoconstrictor effect of KCNQ blockers is a potentially serious side effect, but the pulmonary vasodilator effect of the openers may be useful in the treatment of pulmonary hypertension.","[Gurney, Alison M.] Univ Manchester, Fac Life Sci, Core Technol Facil, Manchester M13 9NT, Lancs, England; [Sedivy, Vojtech; Hodyc, Daniel; Herget, Jan] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague, Czech Republic; [Sedivy, Vojtech; Hodyc, Daniel; Herget, Jan] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Gurney, AM, Univ Manchester, Fac Life Sci, Core Technol Facil, Floor 2,46 Grafton St, Manchester M13 9NT, Lancs, England","alison.gurney@manchester.ac.uk","Biotechnology and Biological Sciences Research Council [BBS/B/11761/2]; Tenovus Scotland ; Leonardo da Vinci Programme ; Grant Agency of Charles University [2419/2007]; Centre for Cardiovascular Research [MSMT 1M 0510]; Czech Science Foundation [305/08/0108]","This work was supported by the Biotechnology and Biological Sciences Research Council [Grant BBS/B/11761/2]; Tenovus Scotland; Leonardo da Vinci Programme; the Grant Agency of Charles University [Grant 2419/2007]; the Centre for Cardiovascular Research [Grant MSMT 1M 0510]; and the Czech Science Foundation [Grant 305/08/0108].",null,42,0,"AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA","0022-3565",null,"10.1124/jpet.108.147785","J PHARMACOL EXP THER","J. Pharmacol. Exp. Ther.","APR",2009,329,1,null,null,null,368,376,null,null,9,"Pharmacology & Pharmacy","426KW","ISI:000264708200041"]
[4,"J","Horvath, R; Budinsky, V; Kayserova, J; Kalina, T; Formankova, R; Stary, J; Bartunkova, J; Sedlacek, P; Spisek, R",null,null,null,"Horvath, Rudolf; Budinsky, Vit; Kayserova, Jana; Kalina, Tomas; Formankova, Renata; Stary, Jan; Bartunkova, Jirina; Sedlacek, Petr; Spisek, Radek",null,"Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: Implications for the development of acute graft-versus host disease","Clinical Immunology",null,"English","Article",null,null,null,null,null,"Dendritic cell; Acute GVHD; Corticosteroids; BMT; HSCT","ANTIGEN-PRESENTING CELLS; PERIPHERAL-BLOOD; LANGERHANS CELLS; STEADY-STATE; T-CELLS; IN-VIVO; DIFFERENTIATION; GVHD; GENERATION; MATURATION","Allogeneic hematopoetic stem cell transplantation (HSCT) represents a unique opportunity to monitor the kinetics of reconstitution of dendritic cells (DCs) and their dynamics in distinct pathologies. We analyzed DCs reconstitution after myeloablative HSCT We separately analyzed patients with acute GVHD. DCs were monitored from the earliest phase of hematopoetic reconstitution until day + 365. Both myeloid DCs and plasmacytoid DCs appeared at earliest stages after engraftment and relative numbers within white blood cells compartment peaked between days 19-25 after HSCT Their proportion then gradually declined and absolute numbers of both DC subsets remained lower than in controls during the whole follow-up. Patients with acute GVHD had significantly tower numbers of circulating DCs. Decrease in DC counts preceded onset of clinical symptoms by at least 24 h and was independent of corticosteroids administration. This study reveals quantification of plasmacytoid and myeloid DCs as a potential biomarker for the prediction of acute GVHD development. (C) 2008 Published by Elsevier Inc.","[Horvath, Rudolf; Budinsky, Vit; Kayserova, Jana; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, Prague 5, Czech Republic; [Kalina, Tomas; Formankova, Renata; Stary, Jan; Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 5, Czech Republic","Spisek, R, Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, V Uvalu 84, Prague 5, Czech Republic","radek.spisek@lfmotol.cuni.cz","Czech Ministry of Education [MSM 0021620812]; GACR [310/08/0838]; MZ [CR 00064203]","This study was supported by project MSM 0021620812 from The Czech Ministry of Education, grant GACR 310/08/0838 and by MZ CR 00064203.",null,43,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616",null,"10.1016/j.clim.2008.10.009","CLIN IMMUNOL","Clin. Immunol.","APR",2009,131,1,null,null,null,60,69,null,null,10,"Immunology","428GC","ISI:000264835000007"]
[5,"J","Tachezy, R; Klozar, J; Rubenstein, L; Smith, E; Salakova, M; Smahelova, J; Ludvikova, V; Rotnaglova, E; Kodet, R; Hamsikova, E",null,null,null,"Tachezy, Ruth; Klozar, Jan; Rubenstein, Linda; Smith, Elaine; Salakova, Martina; Smahelova, Jana; Ludvikova, Viera; Rotnaglova, Elika; Kodet, Roman; Hamsikova, Eva",null,"Demographic and Risk Factors in Patients With Head and Neck Tumors","Journal of Medical Virology",null,"English","Article",null,null,null,null,null,"HPV; PCR; oral cancer; oropharyngeal cancer; antibodies; ELISA","HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER PATIENTS; ORAL-CANCER; FOLLOW-UP; OROPHARYNGEAL CANCER; CARCINOMA PATIENTS; PROGNOSTIC-FACTOR; IMMUNE-RESPONSE; SEXUAL-BEHAVIOR; ANTIBODIES","The association between human papillomavirus (HPV) infection and the development of head and neck cancer has been documented recently. In this study on 86 head and neck cancer patients and 124 controls, data regarding demographics, behavioral risk factors, and risks related to HPV exposure were collected. HPV detection was carried out using polymerase chain reaction in the tumors and in oral exfoliated cells, and HPV typing by a reverse line blot assay specific for 37 HPV types. Sera were tested by an enzyme-linked immunosorbent assay specific for HPV proteins. Head and neck cancer cases report significantly more oral-anal contact (P=0.02) and tobacco and alcohol use than controls (P=0.001; P=0.02, respectively). High-risk HPV DNA was detected in 43% of oral washings of cases and 4% of controls (P<0.0001). The association between the presence of high-risk HPV DNA in oral exfoliated cells and in tumor tissues was statistically significant (adjusted P<0.0001). The prevalence of HPV-specific antibodies was significantly higher in cases than in controls (adjusted P<0.0001). These results provide epidemiological and immunological evidence for HR HPV as a strong risk factor (OR = 44.3, P<0.0001) for head and neck cancer, even after controlling for age, tobacco and alcohol use. The detection of high-risk HPV DNA in oral exfoliated cells and HPV-specific antibodies in serum can be considered as clinically relevant surrogate markers for the presence of a HPV-associated head and neck cancer, with a high sensitivity (83%) and specificity (88%). J. Med. Virol. 81:878-887,2009. (C) 2009 Wiley-Liss, Inc.","[Tachezy, Ruth; Salakova, Martina; Smahelova, Jana; Ludvikova, Viera; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, Prague, Czech Republic; [Klozar, Jan; Rotnaglova, Elika] Charles Univ Prague, Fac Med 1, Dept Otolaryngol Head & Neck Surg, Prague, Czech Republic; [Rubenstein, Linda; Smith, Elaine] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Inst Pathol & Mol Biol, Prague, Czech Republic","Tachezy, R, Inst Haematol & Blood Transfus U Nemocnice 1, Dept Expt Virol, Prague 12820 2, Czech Republic","rutach@uhkt.cz","Ministry of Health, Czech Republic [NR/8852-3, NR/9466-3]; NIH FIRCA [1R03TW001500-01]","Ministry of Health, Czech Republic; Grant numbers: NR/8852-3, NR/9466-3; Grant sponsor: NIH FIRCA; Grant number: 1R03TW001500-01.",null,47,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0146-6615",null,"10.1002/jmv.21470","J MED VIROL","J. Med. Virol.","MAY",2009,81,5,null,null,null,878,887,null,null,10,"Virology","429FR","ISI:000264906800016"]
[5,"J","Hubacek, P; Virgili, A; Ward, KN; Pohlreich, D; Keslova, P; Goldova, B; Markova, M; Zajac, M; Cinek, O; Nacheva, EP; Sedlacek, P; Cetkovsky, P",null,null,null,"Hubacek, Petr; Virgili, Anna; Ward, Katherine N.; Pohlreich, David; Keslova, Petra; Goldova, Barbora; Markova, Marketa; Zajac, Miroslav; Cinek, Ondrej; Nacheva, Elisabeth P.; Sedlacek, Petr; Cetkovsky, Petr",null,"HHV-6 DNA throughout the tissues of two stem cell transplant patients with chromosomally integrated HHV-6 and fatal CMV pneumonitis","British Journal af Haematology",null,"English","Article",null,null,null,null,null,"human herpesvirus 6; cytomegalovirus; tissue; infection","HUMAN HERPESVIRUS-6; QUANTITATIVE-ANALYSIS; HUMAN-HERPESVIRUS-6; BLOOD; INFECTION; DISEASE; ASSAY; LOAD","Two patients with the characteristic high human herpesvirus 6 (HHV-6) DNA loads in peripheral blood caused by chromosomally integrated (CI) virus received a haematopoietic stem cell transplant (HSCT) from a donor without CI HHV-6. Both patients died in consequence of cytomegalovirus (CMV) pneumonitis. At autopsy, high amounts of CMV DNA were detected in lungs but at much lower levels in other organs. In contrast HHV-6 DNA was detected at high levels throughout the organs with the exception of donor-derived haematopoietic tissue. In individuals with chromosomal integration, HHV-6 DNA is found in every tissue of recipient origin indicating inheritance through the germ line.","[Hubacek, Petr; Keslova, Petra; Sedlacek, Petr] Charles Univ Prague, Motol Univ Hosp, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hubacek, Petr; Keslova, Petra; Sedlacek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague, Czech Republic; [Goldova, Barbora] Charles Univ Prague, Fac Med 1, Inst Pathol, CZ-15006 Prague 5, Czech Republic; [Pohlreich, David; Markova, Marketa; Cetkovsky, Petr] Inst Hematol & Blood Transfus, Prague, Czech Republic; [Ward, Katherine N.] Royal Free & Univ Coll Med Sch, Dept Infect, London, England; [Virgili, Anna; Nacheva, Elisabeth P.] Royal Free & Univ Coll Med Sch, Dept Acad Haematol, London, England; [Cinek, Ondrej] Fac Med 2, Dept Paediat, Prague, Czech Republic; [Zajac, Miroslav] Fac Med 2, Dept Med Microbiol, Prague, Czech Republic","Hubacek, P, Charles Univ Prague, Motol Univ Hosp, Dept Paediat Haematol & Oncol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","petr.hubacek@lfmotol.cuni.cz","NIH Research through the University College London/University College London Hospitals Comprehensive Biomedical Research Centre ; Leukaemia Research [05079, 05098]; [MZ 000064203]; [MSM 0021620813]","This work was supported by grants MZ 000064203 and MSM 0021620813. K. N. Ward acknowledges funding from the NIH Research through the University College London/University College London Hospitals Comprehensive Biomedical Research Centre and E. P. Nacheva acknowledges Leukaemia Research Fund grants 05079 and 05098.",null,14,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,"10.1111/j.1365-2141.2009.07622.x","BRIT J HAEMATOL","Br. J. Haematol.","MAY",2009,145,3,null,null,null,394,398,null,null,5,"Hematology","430SP","ISI:000265009100014"]
[5,"J","Sedlacek, P; Vavra, V; Masova, I; Codl, D; Laznickova, T; Malaskova, L; Nyc, O; Stary, J",null,null,null,"Sedlacek, Petr; Vavra, Vladimir; Masova, Ivana; Codl, Daniel; Laznickova, Tana; Malaskova, Ludmila; Nyc, Otakar; Stary, Jan",null,"Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia","Mycoses",null,"English","Letter",null,null,null,null,null,null,null,"Invasive fungal infection negatively influences the morbidity and mortality in heavily immuno-incompetent patients. Diagnosis of non-Aspergillus mould infections remains challenging despite application of a wide spectrum of non-culture-based microbiological techniques. Invasive diagnostic procedures are often essential. In this article, we present the case of a 15-month-old boy diagnosed with Rhizopus microsporus var. rhizopodiformis liver mycetoma during induction chemotherapy for acute promyelocytic leukaemia. Following surgery, he was effectively treated with a combination of ABLC and posaconazole during ongoing intensive chemotherapy. Posaconazole was also used as long-term secondary prophylaxis.","[Sedlacek, Petr; Vavra, Vladimir; Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Sch Med 2, Prague 15006 5, Czech Republic; [Masova, Ivana] Inst Hlth, Lab Mycol, Prague, Czech Republic; [Codl, Daniel; Laznickova, Tana; Nyc, Otakar] Charles Univ Prague, Dept Clin Microbiol, Teaching Hosp Motol, Sch Med 2, Prague 15006 5, Czech Republic; [Malaskova, Ludmila] Masaryk Univ, Dept Clin Biochem, Fac Med, Brno, Czech Republic","Sedlacek, P, Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","petr.sedlacek@lfmotol.cuni.cz",null,null,null,0,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0933-7407",null,"10.1111/j.1439-0507.2008.01595.x","MYCOSES","Mycoses","MAY",2009,52,3,null,null,null,276,279,null,null,4,"Dermatology; Mycology","428AM","ISI:000264820200013"]
[5,"J","Hajek, P; Alan, D; Vejvoda, J; Linhartova, K; Skapa, P; Hajsmannova, Z; Veselka, J",null,null,null,"Hajek, Petr; Alan, David; Vejvoda, Jiri; Linhartova, Katerina; Skapa, Petr; Hajsmannova, Zdenka; Veselka, Josef",null,"Treatment of a large left main coronary artery thrombus by aspiration thrombectomy","Journal of Thrombosis and Thrombolysis",null,"English","Article",null,null,null,null,null,"Left main coronary artery; Thrombus; Aspiration thrombectomy","ACUTE MYOCARDIAL-INFARCTION","A left main coronary artery thrombosis is a life-threatening condition demanding immediate therapeutic management. Traditional treatment options include thrombolysis, percutaneous coronary intervention (PCI) with stenting or cardiac bypass surgery. The number of reported cases in which aspiration thrombectomy has been used is limited. Indications for this therapeutic approach are determined by coronary anatomy, clinical stability, and hemodynamic condition of the patient. We present the case of an acute left main coronary artery thrombosis leading to progressive deterioration of left ventricle function that was successfully treated with aspiration thrombectomy.","[Hajek, Petr; Alan, David; Vejvoda, Jiri; Linhartova, Katerina; Veselka, Josef] Charles Univ Prague, Sch Med 1, Ctr Cardiovasc, Dept Cardiol, Prague 15006 5, Czech Republic; [Hajek, Petr; Alan, David; Vejvoda, Jiri; Linhartova, Katerina; Veselka, Josef] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Hajsmannova, Zdenka] Charles Univ Prague, Dept Hematol, Inst Clin Biochem & Hematol, Fac Hosp, Plzen, Czech Republic; [Hajsmannova, Zdenka] Charles Univ Prague, Fac Med, Plzen, Czech Republic","Hajek, P, Charles Univ Prague, Sch Med 1, Ctr Cardiovasc, Dept Cardiol, V Uvalu 84, Prague 15006 5, Czech Republic","petr.hajek@fnmotol.cz","Ministry of Health of Czech Republic [00064203]","Supported by grant from the Ministry of Health of Czech Republic 00064203.",null,4,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0929-5305",null,"10.1007/s11239-008-0209-y","J THROMB THROMBOLYSIS","J. Thromb. Thrombolysis","APR",2009,27,3,null,null,null,352,354,null,null,3,"Hematology; Peripheral Vascular Disease","428XV","ISI:000264886300015"]
[6,"J","Svojgr, K; Burjanivova, T; Vaskova, M; Kalina, T; Stary, J; Trka, J; Zuna, J",null,null,null,"Svojgr, Karel; Burjanivova, Tatiana; Vaskova, Martina; Kalina, Tomas; Stary, Jan; Trka, Jan; Zuna, Jan",null,"Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia","Immunology Letters",null,"English","Article",null,null,null,null,null,"Acute lymphoblastic leukemia; Prognosis; Childhood; PAG; LAT; NTAL; LIME","T-CELL-ACTIVATION; B-LYMPHOCYTES; MEMBRANE MICRODOMAINS; ENRICHED MICRODOMAINS; PROTEIN; LAT; DIFFERENTIATION; LIME; PAG; SINGLE","Transmembrane adaptor proteins are key mediators of antigen receptor signaling in lymphocytes. By influencing proliferation and differentiation, these molecules might play a role in ethiopathogenesis of acute lymphoblastic leukemia (ALL). The aim of this study was to characterize expression of PAG, LAT, NTAL and LIME adaptors at the mRNA and protein levels in normal B- and T-precursors. Moreover, diagnostic samples of childhood ALL cases were analyzed. During normal lymphocyte development, some adaptors show significant dynamics (gradual decrease of NTAL and increase of LAT and LIME during the T-cell maturation, decrease of PAG in B-precursors, high levels of LIME in peripheral B-lymphocytes). Analysis of childhood ALL samples revealed that in B-cell precursor ALL, the TEL/AML1 subgroup have unique adaptor profile compared to other leukemias. Moreover, NTAL expression separates T lineage leukemias into two subgroups with good and poor response to initial prednisone therapy showing prognostic impact of this molecule in T-ALL (C) 2009 Elsevier B.V. All rights reserved.","[Svojgr, Karel] Charles Univ Prague, CLIP, Sch Med 2, Dept Pediat Hematol & Oncol,Fac Med 2, Prague 15006 5, Czech Republic","Svojgr, K, Charles Univ Prague, CLIP, Sch Med 2, Dept Pediat Hematol & Oncol,Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic","karel.svojgr@lfmotol.cuni.cz","GAUK [7356/2007]; MSMT [21620813, 2B06064]; IGA [NR9108-3]","We appreciate collaboration of all the Czech Pediatric Hematology Working Group (CPH) centers for providing diagnostic material and data. We would like to thank to Karel Drbal for valuable discussion and to Pavel Semerak for technical assistance. This study was supported by grants GAUK 7356/2007, MSMT 21620813, MSMT 2B06064 and IGA NR9108-3.","AHN E, 2006, BLOOD, V107, P1521, DOI 10.1182/blood-2005-05-1859; BAUMGARTNER M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; BEILLARD E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; BENE MC, 1995, LEUKEMIA, V9, P1783; BOUBLIKOVA L, 2006, LEUKEMIA, V20, P254, DOI 10.1038/sj.leu.2404047; BRDICKA T, 2000, J EXP MED, V191, P1591; BRDICKA T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; BRDICKOVA N, 2003, J EXP MED, V198, P1453, DOI 10.1084/jem.20031484; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; FINCO TS, 1998, IMMUNITY, V9, P617; HANCOCK JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; HERZOG S, 2007, J IMMUNOL, V178, P2336; HOREJSI V, 2004, IMMUNOL LETT, V92, P43, DOI 10.1016/j.imlet.2003.10.013; HOREJSI V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; HUR EM, 2003, J EXP MED, V198, P1463, DOI 10.1084/jem.20030232; KLEIN U, 2003, ANN NY ACAD SCI, V987, P166; MUTCH CM, 2007, INT IMMUNOL, V19, P19, DOI 10.1093/intimm/dxl118; POSEVITZFEJFAR A, 2008, EUR J IMMUNOL, V38, P250, DOI 10.1002/eji.2006366641; ROEDERER M, 2001, CYTOMETRY, V45, P194; SMIDA M, 2007, BLOOD, V110, P596, DOI 10.1182/blood-2006-07-038752; STAAL FJT, 2001, STEM CELLS, V19, P165; STORK B, 2004, IMMUNITY, V21, P681; SU YW, 2003, IMMUNITY, V19, P295; SU YW, 2004, EUR J IMMUNOL, V34, P3614, DOI 10.1002/eji.200425445; SVEC A, 2005, IMMUNOL LETT, V100, P94, DOI 10.1016/j.imlet.2005.05.002; TEDOLDI S, 2006, BLOOD, V107, P213, DOI 10.1182/blood-2005-06-2273; TKACZYK C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2000-08-2769; VASKOVA M, 2006, EXP HEMATOL, V34, P573, DOI 10.1016/j.exphem.2006.01.018; VASKOVA M, 2008, TISSUE ANTIGENS, V71, P57, DOI 10.1111/j.1399-0039.2007.00968.x; WANG Y, 2005, MOL CELL BIOL, V25, P4455, DOI 10.1128/MCB.25.11.4455-4465.2005; ZHANG WG, 1999, IMMUNITY, V10, P323; ZHU MH, 2006, IMMUNITY, V25, P757, DOI 10.1016/j.immuni.2006.08.025; ZUNA J, 2005, LEUKEMIA RES, V29, P633, DOI 10.1016/j.leukres.2004.11.007",33,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0165-2478",null,"10.1016/j.imlet.2008.12.008","IMMUNOL LETT","Immunol. Lett.","FEB 21",2009,122,2,null,null,null,185,192,null,null,8,"Immunology","432JM","ISI:000265129300019"]
[6,"C","Horak, D; Babic, M; Jendelova, P; Herynek, V; Trchova, M; Likavcanova, K; Kapcalova, M; Hajek, M; Sykova, E",null,null,null,"Horak, Daniel; Babic, Michal; Jendelova, Pavla; Herynek, Vit; Trchova, Miroslava; Likavcanova, Katarina; Kapcalova, Miroslava; Hajek, Milan; Sykova, Eva",null,"Effect of different magnetic nanoparticle coatings on the efficiency of stem cell labeling","Journal of Magnetism and Magnetic Materials",null,"English","Proceedings Paper","7th International Conference on Scientific and Clinical Applications of Magnetic Carriers","MAY 20-24, 2008","Vancouver, CANADA",null,null,"Magnetic nanoparticles; Maghemite; MRI; Stem cells; Biocompatibility; Contrast agent","IRON-OXIDE NANOPARTICLES; IN-VIVO TRACKING; SPINAL-CORD-INJURY; SUPERPARAMAGNETIC NANOPARTICLES; TRANSFECTION AGENTS; ARTERIAL-DISEASE; PROGENITOR CELLS; CONTRAST AGENTS; TRANSPLANTATION; POLYMERIZATION","Maghemite nanoparticles with various coatings were prepared by the coprecipitation method and characterized by transmission electron microscopy, dynamic light scattering and IR in terms of morphology, size, polydispersity and surface coating. The labeling efficiency and the viability of both rat and human mesenchymal stem cells labeled with Endorem (R), poly(L-lysine) (PLL)-modified Endorem (R), uncoated gamma-Fe2O3, D-mannose-, PLL- or poly(N,N-dimethylacrylamide) (PDMAAm)-coated gamma-Fe2O3 nanoparticles were compared. Coated gamma-Fe2O3 nanoparticles labeled cells better than did Endorem (R). High relaxation rates and in vitro magnetic resonance imaging of cells labeled with coated nanoparticles showed clearly visible contrast compared with unlabeled cells or cells labeled with Endorem (R). (c) 2009 Elsevier B.V. All rights reserved.","[Horak, Daniel; Babic, Michal; Trchova, Miroslava] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Horak, Daniel; Babic, Michal; Jendelova, Pavla; Hajek, Milan; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Jendelova, Pavla; Likavcanova, Katarina; Kapcalova, Miroslava; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Herynek, Vit; Hajek, Milan] Inst Clin & Expt Med, Prague 14021 4, Czech Republic","Horak, D, Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic","horak@imc.cas.cz",null,null,"ARBAB AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655; BABIC M, 2008, BIOCONJUGATE CHEM, V19, P740, DOI 10.1021/bc700410z; BABIC M, 2009, BIOCONJUGATE CHEM, V20, P283; BARTSCH T, 2006, J CARDIOVASC NURS, V21, P430; BULTE JW, 2006, METHODS MOL MED, V124, P419; BULTE JWM, 2001, NAT BIOTECHNOL, V19, P1141; BULTE JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; ESATO K, 2002, CELL TRANSPLANT, V11, P747; FAN QL, 2007, BIOMATERIALS, V28, P5426, DOI 10.1016/j.biomaterials.2007.08.039; FRANK JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; GROMAN EV, 2007, BIOCONJUGATE CHEM, V18, P1763, DOI 10.1021/bc070024w; GUPTA AK, 2004, BIOMATERIALS, V25, P3029, DOI 10.1016/j.biomaterials.2003.09.095; GUPTA AK, 2004, J MATER SCI-MATER M, V15, P493; GUPTA AK, 2005, BIOMATERIALS, V26, P1565, DOI 10.1016/j.biomaterials.2004.05.022; HENDRIKX M, 2006, CIRCULATION S, V114, P1101; HORAK D, 2007, BIOCONJUGATE CHEM, V18, P635, DOI 10.1021/bc060186c; HORAK D, 2007, J SEP SCI, V30, P1751, DOI 10.1002/jssc.200700088; ISHIYAMA M, 1993, CHEM PHARM BULL, V41, P1118; ITO A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1; JENDELOVA P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; JENDELOVA P, 2007, REGEN MED, V2, P635; KALISH H, 2003, MAGNET RESON MED, V50, P275, DOI 10.1002/mrm.10556; KIRCHER MF, 2002, RADIOLOGY S, V225, P453; KOSHIKAWA MK, 2000, PHYS CHEM CHEM PHYS, V2, P1497; LEWIN M, 2000, NAT BIOTECHNOL, V18, P410; MASSART R, 1981, IEEE T MAGN, V17, P1247; MORISSON SA, 2005, J NANOSCI NANOTECHNO, V5, P1323; MOVIGLIA GA, 2006, CYTOTHERAPY, V8, P202, DOI 10.1080/14653240600736048; OMIDKHODA A, 2007, TOXICOL IN VITRO, V21, P1191, DOI 10.1016/j.tiv.2007.03.010; POLLERT E, 2006, J MAGN MAGN MATER, V306, P241, DOI 10.1016/j.jmmm.2006.03.069; SCHACHINGER V, 2006, EUR HEART J, V27, P2775, DOI 10.1093/eurheartj/ehl388; SCHELLENBERGER EA, 2004, BIOCONJUGATE CHEM, V15, P1062, DOI 10.1021/bc049905i; SONVICO F, 2005, BIOCONJUGATE CHEM, V16, P1181, DOI 10.1021/bc050050z; SUN SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852; SYKOVA E, 2006, CELL TRANSPLANT, V15, P675; VYMAZAL J, 1992, MAGN RESON MED, V27, P368",36,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0304-8853",null,"10.1016/j.jmmm.2009.02.082","J MAGN MAGN MATER","J. Magn. Magn. Mater.","MAY",2009,321,10,null,null,null,1539,1547,null,null,9,"Materials Science, Multidisciplinary; Physics, Condensed Matter","434ME","ISI:000265278000048"]
[6,"J","Ryska, M; Laszikova, E; Pantoflicek, T; Ryska, O; Prazak, J; Koblihova, E",null,null,null,"Ryska, M.; Laszikova, E.; Pantoflicek, T.; Ryska, O.; Prazak, J.; Koblihova, E.",null,"Fractionated Plasma Separation and Adsorption Significantly Decreases Intracranial Pressure in Acute Liver Failure: Experimental Study","European Surgical Research",null,"English","Article",null,null,null,null,null,"Acute liver failure; Experimental treatment; Fractionated plasma separation and absorption","FULMINANT HEPATIC-FAILURE; ALBUMIN DIALYSIS; EXTRACORPOREAL SYSTEM; SUPPORT; PROMETHEUS(R); BRAIN; TRANSPLANTATION; MANAGEMENT; DEVICES; MODEL","Background: The aim of the study was to determine the influence of fractionated plasma separation and absorption (FPSA) on intracranial pressure (ICP) in acute liver failure (ALF). Methods: A surgical model of ALF in pigs (35-40 kg) was used. We compared laboratory data and haemodynamic parameters from the ALF control group to the ALF group treated by Prometheus using ANOVA with repeated measures and grouping factors, by calculating the area under the curve, and by the Mann-Whitney rank test. Results: Bilirubin levels differed significantly in favour of the FPSA treatment group: after 6 h 12.81 +/- 6.54 versus 29.84 +/- 9.99, after 9 h 11.94 +/- 4.14 versus 29.95 +/- 12.36 (p < 0.01) and after 12 h 13.88 +/- 6.31 versus 26.10 +/- 12.23 mmol/l (p < 0.05). ICP values differed significantly in favour of the FPSA treatment group: after 9 h 19.1 +/- 4.09 versus 24.1 +/- 2.85 (p < 0.01), after 10 h 21.9 +/- 3.63 versus 25.1 +/- 2.19, after 11 h 22.5 +/- 3.98 versus 26.3 +/- 3.50, and after 12 h 24.0 +/- 4.66 versus 29.8 +/- 5.88 mm Hg (p < 0.05). Conclusion: The authors demonstrated that a significant decrease in ICP was found in pigs with ALF following treatment by FPSA. Copyright (c) 2009 S. Karger AG, Basel","[Ryska, M.; Pantoflicek, T.; Koblihova, E.] Charles Univ Prague, Sch Med 2, Dept Surg, CZ-16000 Prague 6, Czech Republic; [Prazak, J.] Charles Univ Prague, Sch Med 2, Dept Anaesthesiol Resuscitat & Intens Care, CZ-16000 Prague, Czech Republic; [Ryska, M.; Laszikova, E.; Pantoflicek, T.; Koblihova, E.] Charles Univ Prague, Sch Med 2, Ctr Cell Therapy & Tissue Repair, CZ-16000 Prague 6, Czech Republic; [Laszikova, E.] Cent Mil Hosp, Dept Anaesthesiol & Resuscitat, Prague, Czech Republic; [Ryska, O.] Charles Univ Prague, Sch Med 1, Dept Surg, CZ-16000 Prague 6, Czech Republic","Ryska, M, Charles Univ Prague, Sch Med 2, Dept Surg, U Vojenske Nem 1200, CZ-16000 Prague 6, Czech Republic","miroslav.ryska@uvn.cz","Czech Ministry of Health [CEZ: L17/98: 00023001, S9140]","This study was supported by the Research Centre (LN00A065), funded by grants from the Czech Ministry of Health CEZ: L17/98: 00023001 and S9140.","BISMUTH H, 1995, ANN SURG, V222, P109; CARRARO P, 1998, INT J CLIN LAB RES, V28, P196; DETRY O, 2006, WORLD J GASTROENTERO, V12, P7405; EVENEPOEL P, 2005, BLOOD PURIFICAT, V23, P349, DOI 10.1159/000086885; FALKENHAGEN D, 1999, ARTIF ORGANS, V23, P81; HASSANEIN TI, 2007, HEPATOLOGY, V46, P1853, DOI 10.1002/hep.21930; KIESLICHOVA E, 2005, PHYSIOL RES, V54, P485; KRAMER DJ, 2008, LIVER TRANSPLANT S2, V14, S85, DOI 10.1002/lt.21649; KRISPER P, 2005, J HEPATOL, V43, P451, DOI 10.1016/j.jhep.2005.02.038; LALEMAN W, 2006, CRIT CARE, V10, ARTN R108; NYCKOWSKI P, 2006, TRANSPLANT P, V38, P219, DOI 10.1016/j.transproceed.2005.12.010; OGRADY J, 2007, CLIN LIVER DIS, V11, P291; PHUA J, 2008, CURR OPIN CRIT CARE, V14, P208; RIFAI K, 2003, J HEPATOL, V39, P984, DOI 10.1016/S0168-8278(03)00468-9; RIFAI K, 2005, BLOOD PURIFICAT, V23, P298, DOI 10.1159/000086552; ROSE C, 2007, HEPATOLOGY, V46, P1883, DOI 10.1002/hep.21877; RYSKA M, 2004, EUR SURG RES, V36, P179, DOI 10.1159/000077261; SANTORO A, 2006, TRANSPLANT P, V38, P1078, DOI 10.1016/j.transproceed.2006.02.017; SEN S, 2006, CRIT CARE MED, V34, P158, DOI 10.1097/01.CCM.0000196203.39832.3C; STADLBAUER V, 2006, CRIT CARE, V10, ARTN R169; STANGE J, 1993, ARTIF ORGANS, V17, P809; STEINER LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; TOFRENG F, 2002, HEPATOLOGY, V36, P1333; WILLIAMS R, 2006, CLIN MED, V6, P482",24,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0014-312X",null,"10.1159/000208790","EUR SURG RES","Eur. Surg. Res.",null,2009,42,4,null,null,null,230,235,null,null,6,"Surgery","432KH","ISI:000265131400005"]
[6,"J","Erbanova, M; Thumova, M; Huskova, Z; Vaneckova, I; Vanourkova, Z; Mullins, JJ; Kramer, HJ; Burgelova, M; Rakusan, D; Cervenka, L",null,null,null,"Erbanova, Michaela; Thumova, Monika; Huskova, Zuzana; Vaneckova, Ivana; Vanourkova, Zdenka; Mullins, John J.; Kramer, Herbert J.; Buergelova, Marcela; Rakusan, Dan; Cervenka, Ludek",null,"Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats","Journal of Hypertension",null,"English","Article",null,null,null,null,null,"angiotensin II levels; autoregulation; glomerular filtration rate; hypertension; inducible transgenic renin gene rats; renal blood flow; renin-angiotensin system; sodium excretion","RENIN-ANGIOTENSIN SYSTEM; AT(1) RECEPTOR BLOCKADE; ONE-CLIP HYPERTENSION; SALT-SENSITIVE RATS; II-INFUSED RATS; AT(2) RECEPTOR; ARTERIAL-PRESSURE; BLOOD-FLOW; KIDNEY; MICE","Objective The present study was performed to characterize the autoregulatory efficiency of renal blood flow and glomerular filtration rate and the pressure-natriuresis relationship in transgenic rats with inducible angiotensin II (ANG II)-dependent hypertension (Cyp1a1-Ren-2 rats). Methods The renin gene was induced in Cyp1a1-Ren-2 rats through dietary administration of the natural xenobiotic indole-3-carbinol (13C, 0.3%) for 12 and 24 h, respectively. Noninduced rats served as controls. Anesthetized rats were prepared for renal function studies and an aortic clamp was placed above the junction of the left renal artery to regulate the level of renal arterial pressure. Plasma renin activity, ANG II and aldosterone levels were measured at the end of the experiment by radioimmunoassay. Results Administration of 13C resulted in progressive increases in plasma renin activity and plasma and kidney ANG II levels; however, it did not significantly alter aldosterone levels as compared with those in noninduced rats. 13C induction for 12h did not cause significant changes in blood pressure as compared with those in noninduced rats. 13C induction for 24 h elicited a significant rise in blood pressure. Twelve-hour 13C induction caused an impairment of the autoregulatory efficiency of renal blood flow and glomerular filtration rate and of the pressure-natriuresis relationship as compared with that in noninduced rats. In addition, 24 h 13C induction of the renin gene resulted in a marked reduction in renal blood flow and glomerular filtration rate and a further impairment of the pressure-natriuresis mechanism as compared with that in noninduced rats. Conclusion Our findings indicate that an impairment of the pressure-natriuresis mechanism precedes the development of ANG II-dependent hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 27:575-586 (C) 2009 Wolters Kluwer Health/Lippincott Williams & Wilkins.","[Erbanova, Michaela; Thumova, Monika; Huskova, Zuzana; Vaneckova, Ivana; Vanourkova, Zdenka; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Erbanova, Michaela; Thumova, Monika; Huskova, Zuzana; Vaneckova, Ivana; Vanourkova, Zdenka; Rakusan, Dan; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Mullins, John J.] Univ Edinburgh, Sch Med, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Kramer, Herbert J.] Univ Bonn, Nephrol Sect, Dept Med, D-5300 Bonn, Germany; [Buergelova, Marcela] Thomayer Teaching Hosp, Dept Nephrol, Transplant Ctr, Inst Clin & Expt Med, Prague, Czech Republic; [Rakusan, Dan] Thomayer Teaching Hosp, Dept Internal Med, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Czech Republic (GACR) [305/07/0167]; Center for Cardiovascular Research [IM6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Agency of Academy of Science of Czech Republic [. IAA-11-700-701]; German Research Foundation (Deutsche forschungsgemeinschaft) [Kra 433/14-2, 436 TSE 113/50/0-1]","The present study was Supported by grant No. 305/07/0167 awarded to I.V. by the Grant Agency of Czech Republic (GACR). M.E. and Z.H. are partly supported from the Center for Cardiovascular Research (IM6798582302). L.C. is Supported by the institutional financial Support of the Institute for Clinical and Experimental Medicine (MZO 00023001). M.B. is supported by grant No. IAA-11-700-701 awarded to M.B. by the Grant Agency of Academy of Science of Czech Republic (GAAV). H.J. Kramer is Supported by grants from the German Research Foundation (Deutsche forschungsgemeinschaft), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1).","BARRETT GL, 1988, CLIN EXP HYPERTENS A, V10, P1279; CAREY RM, 2005, CURR OPIN NEPHROL HY, V14, P67; CERVENKA L, 1998, AM J PHYSIOL-RENAL, V274, F940; CERVENKA L, 2002, HYPERTENSION, V40, P735, DOI 10.1161/01.HYP.0000036452.28493.74; CERVENKA L, 2003, J HYPERTENS, V21, P1531, DOI 10.1097/01.hjh.0000084716.53355.c4; CERVENKA L, 2008, J HYPERTENS, V26, P1379; CHOLEWA BC, 2001, AM J PHYSIOL-REG I, V281, R987; COFFMAN TM, 2008, HYPERTENSION, V51, P811, DOI 10.1161/HYPERTENSIONAHA.105.063636; FOX J, 1992, AM J PHYSIOL 2, V262, F902; GUYTON AC, 1990, HYPERTENSION PATHOPH, P1029; HALL JE, 1992, AM J PHYSIOL, V262, R61; HALL JE, 1999, J AM SOC NEPHROL S12, V10, S258; HALL JE, 2000, KIDNEY PHYSL PATHOPH, P1009; HUSKOVA Z, 2006, KIDNEY BLOOD PRESS R, V29, P74, DOI 10.1159/000092981; INSCHO EW, 1999, J AM SOC NEPHROL S11, V10, S178; KANTACHUVESIRI S, 2001, J BIOL CHEM, V276, P36727; KOBORI H, 2007, PHARMACOL REV, V59, P251, DOI 10.1124/pr.59.3.3; LI JS, 1998, HYPERTENSION S 2, V31, P487; LI XC, 2004, BRIT J PHARMACOL, V142, P821, DOI 10.1038/sj.bjp.0705838; MATTSON DL, 1991, AM J PHYSIOL, V260, R1200; MIAO CY, 2005, J HYPERTENS, V23, P1225; MITCHELL KD, 1990, HYPERTENSION PATHOPH, P1437; MITCHELL KD, 2006, J RENIN-ANGIO-ALDO S, V7, P74; MITCHELL KD, 2007, ACTA PHYSIOL HUNG, V94, P31, DOI 10.1556/APhysiol.94.2007.1-2.5; PADIA SH, 2008, HYPERTENSION, V51, P460, DOI 10.1161/HYPERTENSIONAHA.107.103242; PLOTH DW, 1981, HYPERTENSION, V3, P67; ROMAN RJ, 1985, AM J PHYSIOL, V248, F199; ROMAN RJ, 1986, AM J PHYSIOL, V251, F57; ROMAN RJ, 1991, AM J PHYSIOL, V261, R595; ROSTAND SG, 1982, KIDNEY INT, V21, P330; SCHUNKERT H, 1992, AM J PHYSIOL, V263, E863; SIRAGY HM, 2005, HYPERTENSION, V45, P133, DOI 10.1161/01.HYP.0000149105.75125.2a; SPRINGATE J, 1997, KIDNEY BLOOD PRESS R, V20, P1; TAKENAKA T, 1990, CLIN EXP HYPERTENS A, V12, P1377; VANDERMARK J, 1994, AM J PHYSIOL-RENAL, V266, F739; VANECKOVA I, 1997, PFLUG ARCH EUR J PHY, V434, P587; VANECKOVA I, 2002, KIDNEY BLOOD PRESS R, V25, P315, DOI 10.1159/000066791; VANOURKOVA Z, 2006, J HYPERTENS, V24, P2465; VERREY F, 2000, KIDNEY PHYSL PATHOPH, P1441; WANG CT, 2000, AM J PHYSIOL-RENAL, V279, F319",40,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/HJH.0b013e32831cbd5a","J HYPERTENSION","J. Hypertens.","MAR",2009,27,3,null,null,null,575,586,null,null,12,"Peripheral Vascular Disease","432QM","ISI:000265149200019"]
[6,"J","Poljakova, J; Eckschlager, T; Hrabeta, J; Hrebackova, J; Smutny, S; Frei, E; Martinek, V; Kizek, R; Stiborova, M",null,null,null,"Poljakova, Jitka; Eckschlager, Tomas; Hrabeta, Jan; Hrebackova, Jana; Smutny, Svatopluk; Frei, Eva; Martinek, Vaclav; Kizek, Rene; Stiborova, Marie",null,"The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells","Biochemical Pharmacology",null,"English","Article",null,null,null,null,null,"Ellipticine; Anticancer drug; Neuroblastoma; Cytotoxicity; DNA adduct","ENVIRONMENTAL-POLLUTANT 3-NITROBENZANTHRONE; HUMAN CYTOCHROME-P450 ENZYMES; CARCINOGEN ARISTOLOCHIC ACID; PROSTAGLANDIN-H SYNTHASE; HUMAN METABOLITE; CYCLE ARREST; CANCER-CELLS; DEOXYGUANOSINE ADDUCTS; LIVER-MICROSOMES; IN-VIVO","Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase 11 and formation of covalent DNA adducts mediated by cytochromes P450 and peroxidases. Here, the molecular mechanism of DNA-mediated ellipticine action in human neuroblastoma IMR-32, UKF-NB-3 and UKF-NB-4 cancer cell lines was investigated. Treatment of neuroblastoma cells with ellipticine resulted in apoptosis induction, which was verified by the appearance of DNA fragmentation, and in inhibition of cell growth. These effects were associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by the cytochrome P450- and peroxidase-mediated ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine. The expression of these enzymes at mRNA and protein levels and their ability to generate ellipticine-DNA adducts in neuroblastoma cells were proven, using the real-time polymerase chain reaction, Western blotting analyses and by analyzing ellipticine-DNA adducts in incubations of this drug with neuroblastoma S9 fractions, enzyme cofactors and DNA. The levels of DNA adducts correlated with toxicity of ellipticine to IMR-32 and UKF-NB-4 cells, but not with that to UKF-NB-3 cells. In addition, hypoxic cell culture conditions resulted in a decrease in ellipticine toxicity to IMR-32 and UKF-NB-4 cells and this correlated with lower levels of DNA adducts. Both these cell lines accumulated in S phase, suggesting that ellipticine-DNA adducts interfere with DNA replication. The results demonstrate that among the multiple modes of ellipticine antitumor action, formation of covalent DNA adducts by ellipticine is the predominant mechanism of cytotoxicity to IMR-32 and UKF-NB-4 neuroblastoma cells. (C) 2009 Elsevier Inc. All rights reserved.","[Poljakova, Jitka; Martinek, Vaclav; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Eckschlager, Tomas; Hrabeta, Jan; Hrebackova, Jana] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Eckschlager, Tomas; Hrabeta, Jan; Hrebackova, Jana; Smutny, Svatopluk] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Smutny, Svatopluk] Charles Univ Prague, Sch Med 2, Dept Surg 1, Prague 15006 5, Czech Republic; [Frei, Eva] German Canc Res Ctr, Div Mol Toxicol, D-69120 Heidelberg, Germany; [Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Brno 61300, Czech Republic","Stiborova, M, Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic","stiborov@natur.cuni.cz","Grant Agency of the Czech Republic [203/06/0329]; Internal Grant Agency of Ministry of Health of the Czech Republic [NR9522-3/2007]; Ministry of Education of the Czech Republic [MSM0021620813, 1M0505]","The work was supported by the Grant Agency of the Czech Republic (grant 203/06/0329), Internal Grant Agency of Ministry of Health of the Czech Republic (grant NR9522-3/2007) and Ministry of Education of the Czech Republic (grants MSM0021620813 and 1M0505). Fruitful help of Dr. A. Vicha, M.D. (Department of Pediatric Hematology and Oncology, 2nd Medical School, Charles University and University Hospital Motol, Prague, Czech Republic) is gratefully acknowledged. We thank Prof.J. Cinatljr. U. W. Goethe University, Frankfurt, Germany) for providing cell lines.","AIMOVA D, 2005, BIOMED PAP, V149, P437; ARLT VM, 2004, CHEM RES TOXICOL, V17, P1092, DOI 10.1021/tx049912v; ARLT VM, 2006, CANCER LETT, V234, P220, DOI 10.1016/j.canlet.2005.03.035; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1; BEDRNICEK J, 2005, NEOPLASMA, V52, P415; BOREKDOHALSKA L, 2004, COLLECT CZECH CHEM C, V69, P603, DOI 10.1135/cccc20040603; BRODEUR GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; BROSCHARD TH, 1994, CARCINOGENESIS, V15, P2331; CHANG CY, 1998, MOL CELL BIOL, V18, P525; CHU Y, 1992, NUCLEIC ACIDS RES, V20, P4033; CINATL J, 1997, ANTI-CANCER DRUG, V8, P958; DIPPLE A, 1999, INT J ONCOL, V14, P103; DRACINSKY M, 2007, TETRAHEDRON LETT, V48, P6893, DOI 10.1016/j.tetlet.2007.07.160; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1; FOSSE P, 1992, MOL PHARMACOL, V42, P590; FREI E, 2002, BIOCHEM PHARMACOL, V64, P289; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998; GARBETT NC, 2004, CURR MED CHEM ANTICA, V4, P149; HAKURA A, 2003, REGUL TOXICOL PHARM, V37, P20, DOI 10.1016/S0273-2300(02)00024-7; HARDESTY CT, 1972, CANCER RES, V32, P1884; KHAN QA, 1999, ONCOLOGY-BASEL, V57, P258; KOTCHETKOV R, 2003, INT J CANCER, V104, P36, DOI 10.1002/ijc.10917; KOVACIC P, 1986, ANTI-CANCER DRUG DES, V1, P197; KUO PL, 2005, ANTI-CANCER DRUG, V16, P789; KUO PL, 2005, CANCER LETT, V223, P293, DOI 10.1016/j.canlet.2004.09.046; KUO YC, 2006, LIFE SCI, V78, P2550, DOI 10.1016/j.lfs.2005.10.041; LANZA F, 1997, CYTOMETRY, V30, P134; MARIS JM, 1999, J CLIN ONCOL, V17, P2264; MONNOT M, 1991, J BIOL CHEM, V25, P1820; MOSEROVA M, 2008, NEUROENDOCRINOL LETT, V29, P728; OHASHI M, 1995, JPN J CANCER RES, V86, P819; POLJAKOVA J, 2006, COLLECT CZECH CHEM C, V71, P1169, DOI 10.1135/cccc20061169; POLJAKOVA J, 2007, CANCER LETT, V252, P270, DOI 10.1016/j.canlet.2006.12.037; REKHA GK, 1997, CANCER CHEMOTH PHARM, V40, P215; RENDIC S, 1997, DRUG METAB REV, V29, P413; ROSS WP, 2006, TRENDS MOL MED, V12, P440; SCHWAB M, 1999, NATURWISSENSCHAFTEN, V86, P71; SCHWALLER MA, 1995, J BIOL CHEM, V270, P22709; SIMOES ML, 2008, TOXICOL APPL PHARM, V232, P86, DOI 10.1016/j.taap.2008.06.006; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271; STIBOROVA M, 2001, BIOCHEM PHARMACOL, V62, P675; STIBOROVA M, 2002, CANCER RES, V62, P5678; STIBOROVA M, 2003, CHEM RES TOXICOL, V16, P38, DOI 10.1021/tx0200818; STIBOROVA M, 2003, INT J CANCER, V107, P885, DOI 10.1002/ijc.11511; STIBOROVA M, 2004, CANCER RES, V64, P8374; STIBOROVA M, 2005, CANCER LETT, V220, P145, DOI 10.1016/j.canlet.2004.07.036; STIBOROVA M, 2005, INT J CANCER, V113, P189, DOI 10.1002/ijc.20564; STIBOROVA M, 2006, BIOMED PAP, V150, P13; STIBOROVA M, 2006, DRUG METAB DISPOS, V34, P1398, DOI 10.1124/dmd.106.009373; STIBOROVA M, 2006, GEN PHYSIOL BIOPHYS, V25, P245; STIBOROVA M, 2007, INT J CANCER, V120, P243, DOI 10.1002/ijc.22247; STIBOROVA M, 2007, TOXICOLOGY, V236, P50, DOI 10.1016/j.tox.2007.03.026; STIBOROVA M, 2008, TOXICOL APPL PHARM, V226, P318, DOI 10.1016/j.taap.2007.09.017; SUGIKAWA E, 1999, ANTICANCER RES, V19, P3099; UENG YF, 1997, BIOCHEMISTRY-US, V36, P370",55,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0006-2952",null,"10.1016/j.bcp.2009.01.021","BIOCHEM PHARMACOL","Biochem. Pharmacol.","MAY 1",2009,77,9,null,null,null,1466,1479,null,null,14,"Pharmacology & Pharmacy","433IH","ISI:000265197000003"]
[7,"J","Ibrahim, I; Horacek, J; Bartos, A; Hajek, M; Ripova, D; Brunovsky, M; Tintera, J",null,null,null,"Ibrahim, Ibrahim; Horacek, Jiri; Bartos, Ales; Hajek, Milan; Ripova, Daniela; Brunovsky, Martin; Tintera, Jaroslav",null,"Combination of voxel based morphometry and diffusion tensor imaging in patients with Alzheimer's disease","Neuroendocrinology Letters",null,"English","Article",null,null,null,null,null,"Alzheimer's disease; voxel-based morphometry; diffusion tensor imaging; MRI; white matter; grey matter; fractional anisotropy; age","MILD COGNITIVE IMPAIRMENT; WHITE-MATTER DAMAGE; CORPUS-CALLOSUM; AGE; PROGRESSION; NETWORK; DYSFUNCTION; ANISOTROPY; BRAINS; VOLUME","OBJECTIVE: The aim of the study was to assess structural changes in gray matter (GM) volume and fractional anisotropy (FA) in patients with Alzheimer's disease (AD) compared to control subjects using Voxel-Based Morphometry (VBM). Fractional anisotropy in the corpus callosum of both groups was also calculated using ROI analysis. METHODS: Twenty-one patients and twenty-three control subjects underwent MRI examination using T1-weighted 3D MPRAGE sequence and diffusion spin-echo echo-planar imaging sequence in six directions. Structural MRI analyses for GM volume and FA were performed using an optimized VBM protocol implemented in SPM5. The influence of age and Mini-Mental State Examination (MMSE) was dealt with multiple regression analysis either for the whole group or for AD patients and controls separately. RESULTS: Patients showed significant reduction of GM volume mainly in the temporal lobes. In AD patients, no correlation was observed between GM volume and age or MMSE. FA was reduced in AD patients mainly in frontal and temporal lobes. In both groups no correlation was found between FA and age or MMSE. Patients with AD showed a significant decrease in FA and an increase in mean diffusivity (p < 0.0001) in the corpus callosum. CONCLUSIONS: In patients with AD we observed a significant reduction in FA values and GM volume; however, no correlation with age and MMSE was proven for both FA and GM for AD patients. This finding supports the hypothesis that morphological changes in patients with AD are not a continuous aging related process but represent qualitative changes.","[Ibrahim, Ibrahim; Hajek, Milan; Tintera, Jaroslav] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Prague 14021, Czech Republic; [Ibrahim, Ibrahim; Tintera, Jaroslav] Ctr Neuropsychiat Studies, Prague, Czech Republic; [Ibrahim, Ibrahim] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Horacek, Jiri; Bartos, Ales; Ripova, Daniela; Brunovsky, Martin] Prague Psychiat Ctr, Prague, Czech Republic; [Bartos, Ales] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Neurol, Fac Med 3, Prague, Czech Republic","Ibrahim, I, Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Videnska 1958-9, Prague 14021, Czech Republic","ibib@medicon.cz","Ministry of Health, Czech Republic [IGA IA8600, NR-8792-3]; Ministry of Education, Youth and Sports, Czech Republic [MZ0PCP2005, MZ0IKEM2005, 1M0517]","This work was supported by grants IGA IA8600 and NR-8792-3 from the Internal Grant Agency of the Ministry of Health, Czech Republic and projects MZ0PCP2005, MZ0IKEM2005 and 1M0517 from the Ministry of Education, Youth and Sports, Czech Republic.",null,38,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,39,45,null,null,7,"Endocrinology & Metabolism; Neurosciences","436PR","ISI:000265426800011"]
[7,"J","Vasakova, M; Sterclova, M; Kolesar, L; Slavcev, A; Pohunek, P; Sulc, J; Striz, I",null,null,null,"Vasakova, Martina; Sterclova, Martina; Kolesar, Libor; Slavcev, Antonij; Pohunek, Petr; Sulc, Jan; Striz, Ilja",null,"Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases","Respiratory Medicine",null,"English","Article",null,null,null,null,null,"Lung fibrosis; Bronchoalveolar lavage fluid; Cytokines; Chemokines; Genetic polymorphism","IDIOPATHIC PULMONARY-FIBROSIS; EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS; BRONCHOALVEOLAR LAVAGE FLUID; ALVEOLAR MACROPHAGES; CC-CHEMOKINE; ANGIOGENIC ACTIVITY; SARCOIDOSIS; EXPRESSION; PATHOGENESIS; CCL18","Background: The aim of our study is to investigate correlations of T(H)1/T(H)2 cytokine gene polymorphisms and bronchoalveolar Lavage fluid (BALF) cytokine values in interstitial. Lung diseases (ILD). Methods: In 16 sarcoidosis, 7 idiopathic pulmonary fibrosis (IPF) and 8 hypersensitivity pneumonitis (HP) patients we evaluated IL-1 alpha, -1R, -1RA, -2, -4, -4R alpha, -6, -10, -12, IFN-gamma, TGF-beta 1 and TNF-alpha gene polymorphisms in peripheral blood, and MCP-1,MIP-1 alpha, MIP-1 beta, RANTES, ENA-78, FGF, G-CSIF, GM-CSF, IFN-gamma, IL-1 alpha, IL-1RA, IL-1 beta, -2, -4, -5, -6, -8, -10, -17, TNF-alpha, Tpo and VEGF values in BALF. Results: We found higher TNF-alpha values in IL-1R pst 1970 TT homozygotes regardless of diagnosis (p = 0.0126). In the sarcoidosis group IL-4R alpha(+1902)AA and IL-10(-1082)G allele correlated with higher BALF ENA-78 levels (p = 0.0258, p = 0.0230). In the HP group the IL-6 (-174)CG and IL-6(nt565)AG correlated with higher ENA-78 BALF levels (p = 0.0253). In the IPF group the IL-1 beta +3962 CC homozygotes had lower IL-1 PA BALF values (p = 0.046). BALF chemokine values did not differ between ILD subgroups, except for IL-8, which was higher in stage III sarcoidosis patients compared to stage I. Conclusion: Our results show a probable influence of gene polymorphisms, namely IL-4R alpha and IL-10 on ENA-78 BALF levels in sarcoidosis, IL-6 on ENA-78 BALF levels in HP and IL-1-beta on IL-1RA BALF values in the IPF group. The TNF-alpha BALF values correlated with IL-1R pst 1970 gene polymorphisms. (C) 2008 Elsevier Ltd. All rights reserved.","[Vasakova, Martina; Sterclova, Martina] Charles Univ Prague, Univ Thomayer Hosp, Sch Med 1, Dept Resp Dis, Prague 14059 4, Czech Republic; [Kolesar, Libor; Slavcev, Antonij; Striz, Ilja] Inst Clin & Expt Med, Dept Immunol, Prague 14021 4, Czech Republic; [Pohunek, Petr; Sulc, Jan] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Pediat, Prague 15006 5, Czech Republic","Vasakova, M, Charles Univ Prague, Univ Thomayer Hosp, Sch Med 1, Dept Resp Dis, Videnska 800, Prague 14059 4, Czech Republic","martina.vasakova@ftn.cz","MHCR [9131-3/2007]","The authors thank Mgr. Jetena Skibova for statistical evaluation of the results. The study is supported by grant MHCR 9131-3/2007.",null,32,0,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","0954-6111",null,"10.1016/j.rmed.2008.11.006","RESP MED","Respir. Med.","MAY",2009,103,5,null,null,null,773,779,null,null,7,"Cardiac & Cardiovascular Systems; Respiratory System","437CC","ISI:000265462600016"]
[7,"J","Cejka, C; Platenik, J; Buchal, R; Guryca, V; Sirc, J; Vejrazka, M; Crkovska, J; Ardan, T; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, Cestmir; Platenik, Jan; Buchal, Richard; Guryca, Vilem; Sirc, Jakub; Vejrazka, Martin; Crkovska, Jirina; Ardan, Taras; Michalek, Jiri; Brunova, Blanka; Cejkova, Jitka",null,"Effect of Two Different UVA Doses on the Rabbit Cornea and Lens","Photochemistry and Photobiology",null,"English","Article",null,null,null,null,null,null,"INDUCED LIPID-PEROXIDATION; MAS H-1-NMR SPECTROSCOPY; HUMAN SKIN FIBROBLASTS; SUPEROXIDE-DISMUTASE; GLUTATHIONE-PEROXIDASE; ALDEHYDE DEHYDROGENASE; PHOTOREFRACTIVE KERATECTOMY; ULTRAVIOLET-RADIATION; METABOLIC PROFILE; ACTION SPECTRUM","The aim of the present paper was to examine the irradiation effect of two doses of UVA rays (365 nm) on the rabbit cornea and lens. Corneas of anesthetized adult albino rabbits were irradiated with UVA rays for 5 days (daily dose 1.01 J cm(-2) in one group of rabbits and daily dose 2.02 J cm(-2) in the second group of animals). The third day after the last irradiation, the rabbits were killed, and their eyes were employed for spectrophotometrical, biochemical and immunohistochemical investigations. Normal eyes served as controls. Absorption spectra of the whole corneal centers were recorded over the UV-VIS (visible) spectral range. Levels of antioxidant and prooxidant enzymes, nitric oxide synthases and nitric oxide (indirectly measured as nitrate concentration) were investigated in the cornea. Malondialdehyde, a byproduct of lipid peroxidation, was examined in the cornea and lens. The results show that the staining for endothelial nitric oxide synthase was more pronounced in corneas irradiated with the higher UVA dose. Otherwise, UVA rays at either dose did not significantly change corneal light absorption properties and did not cause statistically significant metabolic changes in the cornea or lens. In conclusion, UVA rays at the employed doses did not evoke harmful effects in the cornea or lens.","[Cejka, Cestmir; Ardan, Taras; Cejkova, Jitka] Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, Prague, Czech Republic; [Platenik, Jan; Buchal, Richard; Vejrazka, Martin; Crkovska, Jirina] Charles Univ Prague, Fac Med 1, Inst Med Biochem, CR-11636 Prague 1, Czech Republic; [Guryca, Vilem; Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Cejka, Cestmir; Brunova, Blanka] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, CR-11636 Prague, Czech Republic","Cejkova, J, Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, Prague, Czech Republic","cejkova@biomed.cas.cz","Czech Republic [47/2006/C/2.LF, 304/06/1379, AVOZ50390512]; Ministry of Education, Youth & Sports of the Czech Republic [MSM0021620807]","Supported by a grant from the Grant Agency of Charles University of the Czech Republic No. 47/2006/C/2.LF, by a grant from the Grant Agency of the Czech Republic No. 304/06/1379, by a grant from the Academy of Sciences of the Czech Republic AVOZ50390512 and in part by Research Plan No. MSM0021620807 from the Ministry of Education, Youth & Sports of the Czech Republic. The assistance of Mrs. Dana Domanyiova in the nitrate assay is acknowledged.",null,46,0,"AMER SOC PHOTOBIOLOGY","AUGUSTA","BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 USA","0031-8655",null,"10.1111/j.1751-1097.2008.00478.x","PHOTOCHEM PHOTOBIOL","Photochem. Photobiol.","MAY-JUN",2009,85,3,null,null,null,794,800,null,null,7,"Biochemistry & Molecular Biology; Biophysics","436RB","ISI:000265431300020"]
[7,"J","Pitzen, TR; Chrobok, J; Stulik, J; Ruffing, S; Drumm, J; Sova, L; Kucera, R; Vyskocil, T; Steudel, WI",null,null,null,"Pitzen, Tobias R.; Chrobok, Jiri; Stulik, Jan; Ruffing, Sabine; Drumm, Joerg; Sova, Laurentius; Kucera, Roman; Vyskocil, Tomas; Steudel, Wolf Ingo",null,"Implant Complications, Fusion, Loss of Lordosis, and Outcome After Anterior Cervical Plating With Dynamic or Rigid Plates Two-Year Results of a Multi-Centric, Randomized, Controlled Study","Spine",null,"English","Article",null,null,null,null,null,"cervical spine; surgery; randomized controlled study; implants; complications","INTERBODY FUSION; FOLLOW-UP; SPINE; STABILIZATION; FIXATION; REMOVAL; BONE","Study Design. Prospective, controlled, randomized, multicenter study. Objective. To analyze implant complications and speed. Summary of Background Data. Rigid plate designs, in which the screws are locked to the plate, are in common use and thought to provide more fixation than dynamic designs, in which the screws may glide when the graft is settling. The aim of the study is to analyze (1) implant complications, (2) speed of fusion, (3) loss of lordosis, and (4) clinical outcome in both types of plates. Methods. One hundred thirty-two patients were included and assigned by randomization to one of the groups in which they received a routine anterior cervical discectomy and autograft fusion with either a dynamic plate (ABC, study group) or a rigid plate (CSLP, control group). At discharge, after 3 and 6 months and finally after 2 years, implant complications, segmental mobility, absence of radiolucencies, absence of bone sclerosis, evidence of bridging trabecular bone, loss of lordosis, Visual Analog Scale (VAS) and Neck Disability Score were recorded. All radiographic measurements were performed by an independent radiologist. Results. There have been 4 patients with implant complications within the control group and no implant complications within the study group, P = 0.045. Mean segmental mobility before discharge for the study group was 1.7 mm, 1.4 mm after 3 months, 0.8 mm after 6 months, and 0.4 mm after 2 years. For the control group, these values were 1.0, 1.8, 1.6, and 0.5 mm. The difference at 6 months between both groups was significant (P = 0.024). Neither absence of radiolucencies, nor absence of sclerosis, nor evidence of bridging bone showed significant differences between the 2 groups through the postoperative follow-up (P > 0.05). The loss of segmental lordosis for the study group with respect to intraoperative radiograph was 1.3 at discharge and 4.3 after 2 years. For the controlgroup, these values were 0.9, 0.7. The difference at 2 years was significant (P = 0.003). Clinical postoperative outcome (VAS and ODI) was not different between the 2 groups through the postoperative follow-up (P > 0.05). Conclusion. Dynamic cervical plate designs provide less implant complications (no patient) compared with rigid plate designs (4 patients). Speed of fusion was faster in the presence of a dynamic plate. However, loss of segmental lordosis is significantly higher if dynamic plates are used, which did not result in differences regarding clinical outcome between dynamic and constrained plates after 2 years. Thus, dynamic plates should be considered to be the preferred treatment option because of the lower risk for implant failure-related revision surgery.","[Pitzen, Tobias R.] SRH Waldklinikum Gera gGmbH, D-07548 Gera, Germany; [Chrobok, Jiri; Kucera, Roman] Homolka Hosp, Prague, Czech Republic; [Stulik, Jan; Vyskocil, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Ruffing, Sabine] Bundesknappschaftsklin Puttlingen, Puttlingen, Germany; [Drumm, Joerg; Steudel, Wolf Ingo] Univ Saarland, Dept Neurosurg, D-6650 Homburg, Germany; [Sova, Laurentius] Bundeswehrkrankenhaus Ulm, Dept Neurosurg, Ulm, Germany","Pitzen, TR, SRH Waldklinikum Gera gGmbH, Str Friedens 122, D-07548 Gera, Germany","pitzen@t-online.de",null,null,null,23,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0362-2436",null,"10.1097/BRS.0b013e318198ce10","SPINE","SPINE","APR 1",2009,34,7,null,null,null,641,646,null,null,6,"Clinical Neurology; Orthopedics","440CX","ISI:000265677500001"]
[7,"J","Pluta, M; Rob, L; Charvat, M; Chmel, R; Halaska, M; Skapa, P; Robova, H",null,null,null,"Pluta, Marek; Rob, Lukas; Charvat, Martin; Chmel, Roman; Halaska, Michael, Jr.; Skapa, Petr; Robova, Helena",null,"Less radical surgery than radical hysterectomy in early stage cervical cancer - A pilot study","Gynecologic Oncology",null,"English","Article",null,null,null,null,null,"Sentinel lymph node; Early cervical cancer IB1; Laparoscopical lymphadenectomy; Conservative surgery; Parametrectomy; Morbidity","SENTINEL NODE IDENTIFICATION; PARAMETRIAL INVOLVEMENT; PELVIC LYMPHADENECTOMY; SURGICAL-TREATMENT; LYMPH-NODES; IB-IIA; PARAMETRECTOMY; TRACHELECTOMY; DYSFUNCTION; MANAGEMENT","Objective. The purpose of this pilot study was to evaluate the feasibility and safety of a less radical Surgery: laparoscopic lymphadenectomy followed by a simple vaginal hysterectomy in sentinel lymph node (SLN) negative early cervical cancer patients. Treatment-associated morbidity and oncological outcome were evaluated. Patients and methods. From December 2000 to September 2007, 60 patients (50 squamous and 10 adenocarcinoma patients) in stages 3-IA1, 11-IA2 and 46-IB1 with median age of 44.6 years (range 3364 years) were enrolled. Patients were selected based on favorable cervical tumors (IA1 with lymph-vascular space invasion [LVSI], IA2 and IB1 with tumor size less than 20 mm and less than half of stromal invasion). All patients underwent laparoscopic SLN identification using frozen section (FS). Negative SLN patients underwent complete pelvic laparoscopic lymphadenectomy and vaginal hysterectomy. FS positive patients underwent radical hysterectomy with low paraaortic lymphadenectomy. Results. The average number of sentinel nodes per side was 1.4 with detection rate per side of 95%. The average number of removed nodes was 23.2. Five patients (8.3%) were SLN positive. There were two false negative FS results (both were micrometastases in SLN). Median follow-up was 47 months (range 12-92). There were no recurrences in 55 SLN negative patients and in 5 SLN positive patients. Conclusion. Lymphatic mapping and SLN identification improved safety in less radical surgery in early stage cervical cancer. This preliminary study showed that it is both feasible and safe to reduce the radicality of parametrial resection for small tumor volume in SLN negative patients. Results also indicated that treatment-associated morbidity is low. (C) 2009 Elsevier Inc. All rights reserved.","[Pluta, Marek; Rob, Lukas; Charvat, Martin; Chmel, Roman; Halaska, Michael, Jr.; Robova, Helena] Charles Univ Prague, Dept Gynecol & Obstet, Div Oncogynecol, Fac Med 2, Prague 15006 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic","Rob, L, Fac Hosp Motol, Dept Gynecol & Obstet, Fac Med 2, Uvalu 84, Prague 15000 5, Czech Republic","lukas.rob@lfmotol.cuni.cz","IGA [MZCR NS99144]","This work is supported by grant IGA MZCR NS99144.",null,30,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0090-8258",null,"10.1016/j.ygyno.2009.02.005","GYNECOL ONCOL","Gynecol. Oncol.","MAY",2009,113,2,null,null,null,181,184,null,null,4,"Oncology; Obstetrics & Gynecology","436GJ","ISI:000265400400007"]
[7,"J","Zamecnik, J; Pitha, J; Schutzner, J; Vesely, D; Jakubicka, B",null,null,null,"Zamecnik, J.; Pitha, J.; Schutzner, J.; Vesely, D.; Jakubicka, B.",null,"Myasthenia Gravis - a Critical Assessment of the Contribution of Muscle Biopsy Performed During Thymectomy","Ceska a Slovenska Neurologie a Neurochirurgie",null,"Czech","Article",null,null,null,null,null,"myasthenia gravis; muscle biopsy; thymectomy; prognosis","MITOCHONDRIA; MUSK","Objective: Surprisingly, structural changes outside the neuromuscular junctions were reported in limited series of myasthenia gravis (MG) muscles previously - mainly small collection of interstitial lymphocytes and atrophy of type II muscle fibers. However, the pathophysiological mechanisms remained unclear. We performed a systematic study on MG muscle biopsies to contribute to understanding of the association to MG and to demonstrate possible prognostic value. Methods: Sternothyroid muscle biopsies from 207 MG patients taken during thymectomy were analyzed histopathologically and by histochemistry and morphometry and correlated to the clinical features and the outcome of MG patients. Results: In 143 MG patients, no obvious pathological changes were observed in muscle biopsies. In 20 patients we observed an interstitial infiltration by mature naive CD45RA+Iymphocytes. The lymphocytic infiltration associated with the thymus pathology, mainly with thymoma. The morphometry disclosed selective atrophy of type II muscle fibers in 35 cases. The atrophy of type II muscle fibers was related to long-term corticosteroid treatment and the potential prognostic value could be demonstrated for its detection: the MG patients with type II fibers atrophy presented slower tendency to reach remission. Further, in 12 cases we demonstrated mild changes in mitochondrial metabolism, in 34 cases we disclosed angular atrophic fibers; no prognostic value was demonstrated for these changes. Conclusions: The previously reported histopathological changes in MG muscle are rare and mostly do not represent a feature of the MG, rather a consequence of the thymic disorder or of the long-term steroid therapy. The value of muscle biopsy performed during thymectomy for the particular MG patient remains controversial.","[Zamecnik, J.; Jakubicka, B.] UK 2 LF & FN Motole, Ustav Patol & Mol Mediciny, Prague 15006 5, Czech Republic; [Pitha, J.] UK 1 LF & VFN, Neurol Klin, Prague, Czech Republic; [Schutzner, J.] UK 1 LF & FN Motole, Chirurg Klin 3, Prague, Czech Republic; [Vesely, D.] UK 2 LF & FN Bulovka, Infekcni Klin 1, Prague, Czech Republic","Zamecnik, J, UK 2 LF & FN Motole, Ustav Patol & Mol Mediciny, Uvalu 84, Prague 15006 5, Czech Republic","josef.zamecnik@lfmotol.cuni.cz",null,null,null,23,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,2,null,null,null,147,154,null,null,8,"Neurosciences; Surgery","436WJ","ISI:000265446500007"]
[7,"J","Szabo, M; Peliskova, P; Kvapil, M; Matous, M",null,null,null,"Szabo, Marcela; Peliskova, Pavlina; Kvapil, Milan; Matous, Milos",null,"Positive effect of long-term tailored physical activity therapy on diabetes mellitus management in an obese type 2 diabetic patient","Neuroendocrinology Letters",null,"English","Article",null,null,null,null,null,"obese type 2 diabetic; individualized physical activity; withdrawal insulin therapy; insulin sensitisers; control of diabetes; weight loss","CARDIORESPIRATORY FITNESS; MEN; EXERCISE; MORTALITY; DIAMETER","The case history of a 44-year-old, severely obese Caucasian man with serious decompensation of diabetes and subsequent withdrawal of high-dose insulin is reported. Insulin was withdrawn after 5 years of continuous therapy and the patient was treated for 6 months with diet, individualized physical therapy and oral antidiabetic drugs from the group of insulin sensitizers. Six months later, oral antidiabetics were discontinued for low blood glucose levels, and the treatment was limited to therapeutic life style changes. After insulin withdrawal, the patient's condition markedly improved: he showed better diabetes control, decrease in insulin resistance, weight loss, reduced BMI, reduced waist circumference, sagittal abdominal diameter and body fat, increased fitness level, normalized blood pressure and decreased heart rate at rest.","[Szabo, Marcela; Peliskova, Pavlina; Kvapil, Milan] Charles Univ Prague, Univ Hosp Motol, Dept Med, Sch Med 2, Prague 15006 6, Czech Republic; [Matous, Milos] Charles Univ Prague, Univ Hosp Motol, Dept Rehabil & Sport Med, Sch Med 2, Prague 15006 6, Czech Republic","Szabo, M, Charles Univ Prague, Univ Hosp Motol, Dept Med, Sch Med 2, Uvalu 84, Prague 15006 6, Czech Republic","mszabo@seznam.cz","IGA of Czech Republic [NR/8975-3/2006]","Grant of IGA of Czech Republic N. NR/8975-3/2006 supports this study",null,8,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,22,24,null,null,3,"Endocrinology & Metabolism; Neurosciences","436PR","ISI:000265426800008"]
[7,"J","Koutek, J; Kocourkova, J; Hladikova, M; Hrdlicka, M",null,null,null,"Koutek, Jiri; Kocourkova, Jana; Hladikova, Marie; Hrdlicka, Michal",null,"Suicidal behavior in children and adolescents: Does a history of trauma predict less severe suicidal attempts?","Neuroendocrinology Letters",null,"English","Article",null,null,null,null,null,"suicidal attempt; child; adolescent; risk factor; intensity of suicidal intent; somatic severity","CHILDHOOD TRAUMA; RISK-FACTORS; ADULTS; DEPRESSION; ABUSE","OBJECTIVES: The aim of this study was to identify risk factors and possible predictors of severity of suicidal behavior of children and adolescents. METHODS: Seventy-seven patients (15 boys and 62 girls) aged 15.5 +/- 1.6 years on average, hospitalized due to a suicidal attempt in the department of pediatric psychiatry, were examined. Structured interviews with patients and their parents were used to clinically assess circumstances of suicidal behavior, relevant risk factors and severity of suicidal behavior. RESULTS: The results indicated that patients with any previous traumatic experience tended to have somatically less severe suicidal attempts (p = 0.050). Intensity of suicidal intent was associated with a history of depression (p = 0.014) and anxiety disorders (p = 0.004), and the current stress from a mental disorder (p = 0.014). Somatic severity of suicidal behavior was significantly associated with intensity of suicidal intent (p = 0.014). A history of any trauma (previous traumatic experience predicted less severe suicidal behavior, p = 0.053) and the current stress from sexual problems (p = 0.067) were identified as predictors of somatic severity of suicidality. These two predictors showed only a trend level of significance. The only significant predictor of intensity of suicidal intent was the current stress from a mental illness (p = 0.017). CONCLUSIONS: Several risk factors of somatic severity of suicidal behavior and intensity of suicidal intent were described. The most important finding of the study was the association between a history of psychological trauma and a tendency to have less somatically severe suicidal behavior.","[Koutek, Jiri; Kocourkova, Jana; Hrdlicka, Michal] Charles Univ Prague, Fac Med 2, Dept Pediat Psychiat, Prague 15006, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Fac Med 2, Dept Med Informat, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic","Koutek, J, Charles Univ Prague, Fac Med 2, Dept Pediat Psychiat, Uvalu 84, Prague 15006, Czech Republic","jiri.koutek@lfmotol.cuni.cz","[MSM 0021620849]","The study was supported by grant MSM 0021620849.",null,28,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,99,106,null,null,8,"Endocrinology & Metabolism; Neurosciences","436PR","ISI:000265426800021"]
[7,"J","Hackel, M; Masopust, V; Bojar, M; Ghaly, Y; Horinek, D",null,null,null,"Haeckel, Martin; Masopust, Vaclav; Bojar, Martin; Ghaly, Youssef; Horinek, Daniel",null,"The Epidural Steroids in the prevention of epidural fibrosis: MRI and clinical findings","Neuroendocrinology Letters",null,"English","Article",null,null,null,null,null,"epidural steroids; epidural fibrosis; prevention; discectomy; pain","BACK SURGERY SYNDROME; LUMBAR DISC SURGERY; NUCLEUS PULPOSUS; INTERVERTEBRAL DISC; METHYLPREDNISOLONE; CORTICOSTEROIDS; HERNIATION; NERVE; PAIN; ARACHNOIDITIS","BACKGROUND: Epidural fibrosis (EF) represents a frequent and poorly manageable complication of lumbar disk surgery. OBJECTIVES: To investigate the influence of perioperative Epidural Steroid (ES) application on the development of EF. METHODS: One hundred and seventy eight patients underwent L4/5 or L5/S1 discectomy. The study group receiving ES comprised of eighty five patients, and a further control group comprising eighty two patients received a placebo. At a 12 month follow-up, all subjects underwent contrast magnet resonance imaging of the lumbosacral spine. One hundred and sixty seven patients filled in a predetermined questionnaire containing the Visual Analogue Scale (VAS; pain scale) during the first postoperative days and 12 months after. Intergroup differences were analysed and a correlation between the extent of EF and VAS was examined. RESULTS: The groups did not differ regarding the extent of EF. There was a statistically significant correlation between the degree of fibrosis and VAS (p<0.05). However, there was no significant difference in subjective pain assessment between both groups 12 months postoperatively. The application of ES did not influence their return to work. Patients receiving ES experienced less pain on the first and third days after surgery. The average hospital stay after surgery was shorter in the steroid treated group (4.5 days) compared to 5.2 days in the control group (p<0.05). CONCLUSIONS: The application of ES did not prove to be useful in the prevention of Failed Back Surgery Syndrome and epidural scar formation. Postoperative pain was decreased in the steroid treated group during the first postoperative week, but not 12 months postoperatively.","[Haeckel, Martin; Masopust, Vaclav; Horinek, Daniel] Charles Univ Prague, Cent Mil Hosp, Fac Med 1, Dept Neurosurg, Prague 16000 6, Czech Republic; [Bojar, Martin] Univ Hosp Motol, Sch Med 2, Dept Neurol, Prague, Czech Republic; [Horinek, Daniel] Univ Marburg, Fac Med, Dept Neurosurg, D-35033 Marburg, Germany; [Ghaly, Youssef] Charles Univ Prague, Fac Med 2, Lab Neuroirnaging Res, Inst Pathol Physiol, Prague 15800 5, Czech Republic","Horinek, D, Charles Univ Prague, Cent Mil Hosp, Fac Med 1, Dept Neurosurg, Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic","daniel.horinek@uvn.cz","IGA - MZ [NR-8848]","The paper is supported by a grant from IGA - MZ (NR-8848).",null,24,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,51,55,null,null,5,"Endocrinology & Metabolism; Neurosciences","436PR","ISI:000265426800013"]
[7,"J","Kuba, R; Brazdil, M; Kalina, M; Prochazka, T; Hovorka, J; Nezadal, T; Hadac, J; Brozova, K; Sebronova, V; Komarek, V; Marusic, P; Oslejskova, H; Zarubova, J; Rektor, I",null,null,null,"Kuba, Robert; Brazdil, Milan; Kalina, Miroslav; Prochazka, Tomas; Hovorka, Jiri; Nezadal, Tomas; Hadac, Jan; Brozova, Klara; Sebronova, Vera; Komarek, Vladimir; Marusic, Petr; Oslejskova, Hana; Zarubova, Jana; Rektor, Ivan",null,"Vagus nerve stimulation: Longitudinal follow-up of patients treated for 5 years","Seizure-European Journal of Epilepsy",null,"English","Article",null,null,null,null,null,"Vagus nerve stimulation; Efficacy; Long-term outcome; Complications","REFRACTORY EPILEPSY; PARTIAL SEIZURES; LONG-TERM; CLINICAL-EXPERIENCE; CHILDREN; THERAPY; TRIAL","We performed a retrospective, multicenter, open-label study to evaluate the efficacy Of vagus nerve stimulation (VNS) in all patients in the Czech Republic who have received this treatment for at least 5 years (n = 90). The mean last follow-up was 6.6 +/- 1.1 years (79 +/- 13 months). The median number of seizures among all patients decreased from 41.2 seizures/month in the prestimulation period to 14.9 seizures/month at 5 years follow-up visit. The mean percentage of seizure reduction was 55.9%. The responder rate in these patients is in concordance with the decrease of overall seizure frequency. At 1 year after beginning the stimulation, 44.4% of patients were responders; this percentage increased to 58.7% after 2 years. At the 5 years last follow-up 64.4% of patients were responders, 15.5% experienced >= 90% seizure reduction, and 5.5% were seizure-free. A separate analysis of patients younger than 16 years of age showed lower efficacy rates of VNS in comparison to the whole group. Complications and chronic adverse effects occurred in 13.3% of patients. VNS is an effective and safe method to refractory epilepsy in common clinical practice. (C) 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","[Kuba, Robert; Brazdil, Milan; Oslejskova, Hana; Rektor, Ivan] St Annes Univ Hosp, Dept Neurol 1, Brno Epilepsy Ctr, Brno 53, Pekarska, Czech Republic; [Kalina, Miroslav; Prochazka, Tomas] Homolce Hosp, Epilepsy Ctr, Prague, Czech Republic; [Hovorka, Jiri; Nezadal, Tomas] Charles Univ Prague, Frantisku Hosp, Neurol Epileptol & Neuropsychiat Dept, Sch Med 1, Prague 1, Czech Republic; [Hadac, Jan; Brozova, Klara; Zarubova, Jana] Thomayers Teaching Hosp, Ctr Epileptol & Epileptosurg, Prague, Czech Republic; [Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Motol Hosp, Fac Med 2, Dept Pediat Neurol, CR-11636 Prague, Czech Republic; [Marusic, Petr] Charles Univ Prague, Motol Hosp, Fac Med 2, Dept Neurol, CR-11636 Prague 1, Czech Republic","Kuba, R, St Annes Univ Hosp, Dept Neurol 1, Brno Epilepsy Ctr, Brno 53, Pekarska, Czech Republic","robert.kuba@fnusa.cz; mbrazd@med.muni.cz; miroslav.kalina@homolka.cz; tomas.prochazka@homolka.cz; Hovorka@nnfp.cz; tumas@post.cz; hadac@cesnet.cz; klara.brozova@ftn.cz; vera.sebronova@lf2.cuni.cz; vladimir.komarek@lf2.cuni.cz; petr.marusic@lf2.cuni.cz; hoslej@fnbrno.cz; jana.zarubova@ftn.cz; irektor@med.muni.cz",null,null,null,25,0,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","1059-1311",null,"10.1016/j.seizure.2008.10.012","SEIZURE-EUR J EPILEP","Seizure","MAY",2009,18,4,null,null,null,269,274,null,null,6,"Clinical Neurology; Neurosciences","437CY","ISI:000265465000007"]
[8,"J","Kalitova, P; Plzak, J; Kodet, R; Astl, J",null,null,null,"Kalitova, Petra; Plzak, Jan; Kodet, Roman; Astl, Jaromir",null,"Angiosarcoma of the thyroid","European Archives of Oto-Rhino-Laryngology",null,"English","Article",null,null,null,null,null,"Angiosarcoma; Thyroid gland; Total thyroidectomy; Immunohistochemistry; Fasciin; CD 31","EPITHELIOID ANGIOSARCOMA; GLAND; HEMANGIOSARCOMA","Hemangiosarcoma of the thyroid gland is a very rare entity. The therapy of this tumor is difficult because of its locally aggressive and destructive behavior with a high recurrence rate. We report a case of 60-year-old man with history of 1 month rapidly enlarging neck mass in the thyroid region. Ultrasound examination and CT scan showed resistance arising from the left thyroid lobe. FNAC revealed necrotic tumor mass without any cytological specification. Because of the clinical findings, a total thyroidectomy was indicated. The surgery was complicated by invasion of the tumor mass into the surrounding tissues. Therefore, only left side hemithyroidectomy was performed. Histopathology including histochemistry proved positive staining for Factor VIII, Fasciin, and CD31 in tumor cells. In this case, adjuvant oncological treatment was planned, but the patient died because of massive bleeding from the tumor mass. The histological diagnosis of thyroid hemangiosarcoma is mostly difficult. The treatment of the first choice is radical surgery. If the tumor cannot be treated by surgery, then radiotherapy, eventually chemotherapy is indicated. The prognosis is not favorable.","[Kalitova, Petra; Plzak, Jan; Astl, Jaromir] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 15006 5, Czech Republic; [Kalitova, Petra] Charles Univ Prague, Inst Physiol, Fac Med 1, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Fac Hosp Motol, Prague 15006 5, Czech Republic","Kalitova, P, Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Uvalu 84, Prague 15006 5, Czech Republic","petra.kalitova@lf1.cuni.cz","IGA MZ CR [NR9049-3]","This study was supported by the IGA MZ CR No. NR9049-3. Many thanks to Daniel Drtik, M. D., from the ENT Department, Hospital Most, Czech Republic and Ivan Cech, M. D., from the Department of Radiology, Hospital Most, Czech Republic for providing CT imaging.",null,13,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,"10.1007/s00405-008-0820-8","EUR ARCH OTO-RHINO-LARYNGOL","Eur. Arch. Oto-Rhino-Laryn.","JUN",2009,266,6,null,null,null,903,905,null,null,3,"Otorhinolaryngology","440FH","ISI:000265685700021"]
[8,"J","Vajtr, D; Benada, O; Kukacka, J; Prusa, R; Houstava, L; Toupalik, P; Kizek, R",null,null,null,"Vajtr, D.; Benada, O.; Kukacka, J.; Prusa, R.; Houstava, L.; Toupalik, P.; Kizek, R.",null,"Correlation of Ultrastructural Changes of Endothelial Cells and Astrocytes Occurring during Blood Brain Barrier Damage after Traumatic Brain Injury with Biochemical Markers of Blood Brain Barrier Leakage and Inflammatory Response","Physiological Research",null,"English","Article",null,null,null,null,null,"Blood brain barrier; Expansive contusion; Metalloproteinases; S-100B protein; Interleukin-6","NEURON-SPECIFIC-ENOLASE; SEVERE HEAD-INJURY; S-100B PROTEIN; CONTUSION; TOMOGRAPHY; RELEASE; RAT","Focal cerebral contusion can be dynamic and expansive. It has been proved that subsequent expansive contusion is caused by brain parenchyma damage, especially BBB damage. We investigated a group of patients with traumatic brain injury. The patients (n=18) were divided into group I (n=7) of patients submitted to neurosurgery due to expansive contusion, and group II (n=11) of patients without surgery. Serum concentrations of NSE and S-100B protein were measured by electrochemiluminescence immunoassay, interleukin-6 (IL-6) was measured by chemiluminescent sequential immunometric assay and matrix metalloproteinases (MMP-9, MMP-2) were measured by immunoassays. Cortical biopsy specimens of brain were investigated by electron microscopy in patients with trauma brain injury submitted to neurosurgery. Biochemical investigation from first day up to third day after traumatic brain injury proved increased values of IL-6 (302.2 +/- 119.9 vs. 59.6 +/- 11.9 ng/l, p<0.02) and S-100B protein (3.064 +/- 1.064 vs. 0.649 +/- 0.182 mu g/l, p<0.05) in patients with expansive lesion compared to patients without expansive contusion. Significantly higher levels of MMP-9 (150.4 +/- 28.46 vs. 74.11 +/- 13.16 ng/l, p<0.05) and of MMP- 2 (814.5 +/- 126.3 vs. 523.1 +/- 25.28 ng/l, p<0.05) were found during first 3 days after admission in group I compared to group II. MMP- 9 has also elevated in group II from lower values after admission (74.11 +/- 13.16 ng/l) up to high levels on the 10th day of hospitalization (225.1 +/- 49.35 ng/l). Ultrastructural investigation of endothelial cells and surrounded tissue revealed perivascular hemorrhage, increased pinocytic activity of endothelial cells, and cytotoxic edema of astroglial cells. Multivesical bodies were disclosed inside the endothelial cells. Higher levels of serum protein S-100B and IL-6 correlated with ultrastructural changes of endothelial cells, and with inflammatory response following TBI, respectively.","[Vajtr, D.; Kukacka, J.; Prusa, R.] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Vajtr, D.; Kukacka, J.; Prusa, R.] Univ Hosp Motol, Prague, Czech Republic; [Benada, O.] Acad Sci Czech Republic, Inst Microbiol, Prague, Czech Republic; [Vajtr, D.] Charles Univ Prague, Fac Med 1, Dept Forens Med & Toxicol, Prague 15006 5, Czech Republic; [Houstava, L.] Charles Univ Prague, Fac Med 3, Dept Neurosurg, Prague 15006 5, Czech Republic; [Toupalik, P.] Charles Univ Prague, Fac Med 2, Dept Forens Med, Prague 15006 5, Czech Republic; [Kizek, R.] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Brno, Czech Republic","Vajtr, D, Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, V Uvalu 84, Prague 15006 5, Czech Republic","vajtr.david.1LFUK@seznam.cz","IGA CR [NR/8793-3/2006]; Institutional Scientific Project [AV0Z50200510]","We thank M. Elleder for expert assistance. Our work was supported by IGA CR, reg. no. NR/8793-3/2006 and Institutional Scientific Project AV0Z50200510.",null,21,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,2,null,null,null,263,268,null,null,6,"Physiology","442PM","ISI:000265853100013"]
[8,"J","Mahelkova, G; Bacakova, L; Korynta, J; Vajner, L; Vytasek, R",null,null,null,"Mahelkova, G.; Bacakova, L.; Korynta, J.; Vajner, L.; Vytasek, R.",null,"Effect of Culture Substrate and Culture Conditions on Lens Epithelial Cell Proliferation and alpha-smooth Muscle Actin Expression","Folia Biologica",null,"English","Article",null,null,null,null,null,"alpha-smooth muscle actin; cell proliferation; culture substrates; lens epithelial cells","POSTERIOR CAPSULE OPACIFICATION; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; CATARACT; TRANSDIFFERENTIATION; ADHESION; DIFFERENTIATION; INDUCTION; MIGRATION; CYTOKINES","The most common complication following cataract surgery is posterior capsule opacification. This results from migration, proliferation and transdifferentiation of residual lens epithelial cells (LECs). We studied the effect of several culture substrates and culture conditions on LEC proliferation and alpha-smooth muscle actin (alpha-SMA) expression. We used primary and secondary cultures of porcine LECs cultivated on collagen I, collagen IV, microscopic glass slides, and uncoated plastic dishes. We studied the cell proliferation and expression of alpha-SMA and alpha-, beta-, and gamma-crystallins. The effect of the medium exchange protocol was studied using the TOTL-86 rabbit epithelial lens cell line. There was no difference in growth characteristics of primary cultures on different substrates. In secondary cultures, LECs adhered better to collagen-coated surfaces. The culture substrate influenced LEC proliferation and alpha-SMA expression. The proliferation was greater when the medium was changed than when extra medium was added on the 4(th) day. The cells did not synthesize alpha-, beta- or gamma-crystallin. The culture substrate influences the adhesion ability, proliferation and alpha-SMA expression in lens epithelial cells. In addition, it is necessary to consider the effects of the medium exchange protocol, serum supplementation, cell density and other cell culture conditions in lens epithelial cell experiments.","[Mahelkova, G.] Charles Univ Prague, Fac Med 2, Inst Physiol, Prague 15000 5, Czech Republic; [Mahelkova, G.] Charles Univ Prague, Fac Med 2, Clin Ophthalmol, Prague 15000 5, Czech Republic; [Vajner, L.] Charles Univ Prague, Fac Med 2, Inst Histol & Embryol, Prague 15000 5, Czech Republic; [Vytasek, R.] Charles Univ Prague, Fac Med 2, Inst Med Chem & Biochem, Prague 15000 5, Czech Republic; [Bacakova, L.] Acad Sci Czech Republic, Inst Physiol, Dept Growth & Differentiat Cell Populat, Prague, Czech Republic; [Korynta, J.] Univ Edinburgh, Edinburgh, Midlothian, Scotland","Mahelkova, G, Charles Univ Prague, Fac Med 2, Inst Physiol, Plzenska 221, Prague 15000 5, Czech Republic","gabriela.czakoova@post.cz","Charles University in Prague, Czech Republic [51/2001/C/2.LF]; Agency of the Czech Republic [305/08/0108]; Academy of Sciences of the Czech Republic [1QS500110564]","This work was supported by grant No. 51/2001/C/2.LF of Charles University in Prague, Czech Republic, grant No. 305/08/0108 of the Grant Agency of the Czech Republic and grant No. 1QS500110564 of the Academy of Sciences of the Czech Republic.",null,41,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2009,55,2,null,null,null,66,76,null,null,11,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","441JM","ISI:000265765100006"]
[8,"J","Sedy, J; Zicha, J; Kunes, J; Jendelova, P; Sykova, E",null,null,null,"Sedy, J.; Zicha, J.; Kunes, J.; Jendelova, P.; Sykova, E.",null,"Rapid but not Slow Spinal Cord Compression Elicits Neurogenic Pulmonary Edema in the Rat","Physiological Research",null,"English","Article",null,null,null,null,null,"Neurogenic pulmonary edema; Rat; Spinal cord injury; Blood pressure; Heart rate","STEM-CELLS; INJURY; MODEL; PERMEABILITY; ISOFLURANE; PROMOTES; REPAIR","The development of neurogenic pulmonary edema (NPE) can be elicited by an immediate epidural balloon compression of the thoracic spinal cord. To evaluate whether a slower balloon inflation could prevent NPE development, we examined the extent of NPE in animals lesioned with a rapid (5 mu l - 5 mu l - 5 mu l) or slow rate (3 mu l - 2 mu l - 2 mu l - 2 mu l - 2 mu l - 2 mu l - 2 mu l) of balloon inflation. These groups were compared with the NPE model ( immediate inflation to 15 mu l) and with healthy controls. Slow balloon inflation prevented NPE development, whereas the pulmonary index and histology revealed a massive pulmonary edema in the group with a rapid rate of balloon inflation. Pulmonary edema was preceded by a considerable decrease in heart rate during the inflation procedure. Moreover, rapid inflation of balloon in spinal channel to either 5 mu l or 10 mu l did not cause NPE. Thus, a slow rate of balloon inflation in the thoracic epidural space prevents the development of neurogenic pulmonary edema, most likely due to the better adaptation of the organism to acute circulatory changes (rapid elevation of systemic blood pressure accompanied by profound heart rate reduction) during the longer balloon inflation period. It should be noted that spinal cord transection at the same level did not cause neurogenic pulmonary edema.","[Sedy, J.; Jendelova, P.; Sykova, E.] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Sedy, J.; Jendelova, P.; Sykova, E.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sedy, J.; Jendelova, P.; Sykova, E.] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sedy, J.; Zicha, J.; Kunes, J.] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Kunes, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Sedy, J, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","jirisedy@hotmail.com","EC [LSHB-CT-2005-518233]; [AV0Z50390512]; [AV0Z50110509]; [1M0538]; [LC554]; [GACR309/06/1246]; [IGA MZ 1A8697-5]; [IGA MZ NR/8339-3]; [1M0510]","We thank Dominika Duskov~ and Iva Nahodilov~ for their excellent technical assistance. We thank James Dutt for critical reading of the manuscript. We acknowledge the support provided by the grants AV0Z50390512, AV0Z50110509, 1M0538, LC554, GACR309/06/1246, IGA MZ 1A8697-5, IGA MZ NR/8339-3, 1M0510 and the EC FP6 project RESCUE (LSHB-CT-2005-518233).",null,24,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,2,null,null,null,269,277,null,null,9,"Physiology","442PM","ISI:000265853100014"]
[9,"J","Peichl, P; Kautzner, J; Gebauer, R",null,null,null,"Peichl, Petr; Kautzner, Josef; Gebauer, Roman",null,"Ablation of atrial tachycardias after correction of complex congenital heart diseases: utility of intracardiac echocardiography","Europace",null,"English","Article",null,null,null,null,null,null,"INTRAATRIAL REENTRANT TACHYCARDIA; CATHETER ABLATION; GREAT-ARTERIES; MUSTARD OPERATION; MAPPING SYSTEM; TRANSPOSITION; FLUTTER; ARRHYTHMIA; FONTAN","Our goal was to analyse the utility of intracardiac echocardiography (ICE) for navigation and ablation of atrial tachycardias (ATs) after surgical correction of congenital heart disease (CHD). Catheter ablation of ATs was performed in seven patients (one woman, mean age 21 +/- 6 years) after correction of complex CHD: d-transposition of the great arteries (Mustard procedure in two patients, Senning procedure in two patients) and univentricular circulation (total cavopulmonary connection in two patients, atriopulmonary connection in one patient). The ablation was guided by a combination of electroanatomical mapping (CARTO, Biosense-Webster) and ICE (Acuson, Siemens). Intracardiac echocardiography was used during mapping to identify relevant anatomical structures and monitor tissue contact and for guidance of atrial baffle puncture. Biatrial mapping was necessary in six of seven patients and atrial baffle puncture in three. The clinical AT was abolished in all patients. No complications were noted. During follow-up of 23 +/- 13 months, two patients (28%) had arrhythmia recurrence. One patient developed atrial fibrillation, and recurrent AT in the other patient was controlled by re-ablation. Despite complicated cardiac anatomy, catheter ablation of AT after complex CHD can be performed safely and with a high success rate. Intracardiac echocardiography facilitates mapping, identification of relevant cardiac structures, and could be used for safe guidance of transbaffle puncture.","[Peichl, Petr; Kautzner, Josef] Inst Clin & Expt Med, Dept Cardiol, Prague 14021 4, Czech Republic; [Gebauer, Roman] Pediat Heart Ctr Motol, Prague, Czech Republic","Peichl, P, Inst Clin & Expt Med, Dept Cardiol, Videnska 1958-9, Prague 14021 4, Czech Republic","pepi@medicon.cz","Ministry of Health of the Czech Republic [MZO 00023001]","This study was supported by research grant no.: MZO 00023001 of the Ministry of Health of the Czech Republic (Research in Cardiovascular Diseases, Diabetes Mellitus and Transplantations of LifePreserving Organs).",null,15,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129",null,"10.1093/europace/eun316","EUROPACE","Europace","JAN",2009,11,1,null,null,null,48,53,null,null,6,"Cardiac & Cardiovascular Systems","386PD","ISI:000261894200011"]
[9,"J","Veselka, J; Zemanek, D; Tomasov, P; Duchonova, R; Linhartova, K",null,null,null,"Veselka, Josef; Zemanek, David; Tomasov, Pavol; Duchonova, Radka; Linhartova, Katerina",null,"Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective","Heart and Vessels",null,"English","Article",null,null,null,null,null,"Hypertrophic cardiomyopathy; Ablation; Therapy; Obstruction","MYECTOMY; IMPROVEMENT; EXPERIENCE; SURGERY","Echo-guided alcohol septal ablation (ASA) is an alternative treatment for highly symptomatic patients with obstructive hypertrophic cardiomyopathy (HOCM). Previous reports suggest that a low dose of alcohol (1.5-2 ml) is as effective as the classic dose (2-4 ml) used in the past. Because a larger infarct might be associated with a potential long-term risk, in this pilot study we wanted to determine whether an ultra-low dose of alcohol (1 ml) would be effective in the mid-term follow-up. Seventy patients (55 +/- 13 years, range 24-81 years, septum thickness < 31 mm) with a highly symptomatic HOCM receiving maximum medical therapy were enrolled. Thirty-five consecutive patients (group I) have been treated with an ultra-low alcohol dose (1.0 +/- 0.1 ml) and compared with a control group II of 35 patients treated by the same medical team using the classic alcohol dose (2.5 +/- 0.8 ml) in the past. At 6-month follow-up, both groups of patients improved in dyspnea (2.9 +/- 0.6 vs 1.5 +/- 0.5 New York Heart Association [NYHA] class for group I; P < 0.01, and 2.5 +/- 0.7 vs 1.4 +/- 0.4 NYHA class for group II; P < 0.01) and angina (2.1 +/- 1 vs 0.6 +/- 0.8 Canadian Cardiovascular Society [CCS] class for group I; P < 0.01, and 2.1 +/- 0.9 vs 0.7 +/- 0.7 CCS class for group II; P < 0.01). There was a significant decrease in left ventricular (LV) ejection fraction (P < 0.05), septum thickness (P < 0.01), and LV outflow gradient (P < 0.01) in both groups of patients. However, there was no significant difference with regard to the extent of symptomatic or echocardiographic changes and complications between both groups. These results suggest that the ultra-low dose of alcohol (1 ml) is still effective in the treatment of the majority of HOCM patients without extreme septum hypertrophy (< 31 mm).","[Veselka, Josef; Zemanek, David; Tomasov, Pavol; Duchonova, Radka; Linhartova, Katerina] Univ Hosp Motol, Ctr Cardiovasc, Dept Cardiol, Prague 15000 5, Czech Republic","Veselka, J, Univ Hosp Motol, Ctr Cardiovasc, Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic","veselka.josef@seznam.cz","Ministry of Health of the Czech Republic [00064203]","The study was supported by grant 00064203 from the Ministry of Health of the Czech Republic.",null,23,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0910-8327",null,"10.1007/s00380-008-1083-4","HEART VESSELS","Heart Vessels","JAN",2009,24,1,null,null,null,27,31,null,null,5,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","397XZ","ISI:000262697000005"]
[9,"J","Sedlackova, L; Nguyen, TTH; Zlacka, D; Sosna, A; Hromadnikova, I",null,null,null,"Sedlackova, Lucie; Nguyen, Thi Thu Hien; Zlacka, Denisa; Sosna, Antonin; Hromadnikova, Ilona",null,"Cell surface and relative mRNA expression of heat shock protein 70 in human synovial cells","Autoimmunity",null,"English","Article",null,null,null,null,null,"mRNA expression; Hsp70; synovial cells; real-time PCR; cell surface expression; flow cytometry","HEAT-SHOCK PROTEINS; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; ANTIINFLAMMATORY DRUGS; MOLECULAR CHAPERONES; ENHANCED EXPRESSION; MEMBRANE EXPRESSION; TISSUE; ACTIVATION; MORPHOLOGY","Heat shock proteins (Hsps) have been repeatedly implicated to participate in the pathogenesis of rheumatoid arthritis (RA). Methods: Herein, Hsp70 cell surface and mRNA expression were studied in human fibroblast-like synovial cells, dermal fibroblasts and peripheral blood leukocytes derived from 24 RA patients, who underwent synovectomy by using flow-cytometric analysis and real-time quantitative reverse-transcriptase polymerase chain reaction. For comparison, peripheral blood leukocytes of 17 healthy controls were tested. Results: Significantly higher Hsp70 membrane positivity was found on fibroblast-like synovial cells in RA patients (average 18.3%, median 16.5%) than on autologous and healthy control peripheral blood lymphocytes (RA patients: average 4.7%, median 2.9%, p=0.002; healthy controls: average 6.0%, median 4.5%, p=0.002) and/or autologous dermal fibroblasts (average 5.1%, median 4.3%, p0.001). Strong Hsp70 cell surface expression was also found on peripheral blood monocytes of RA patients (average 53.0%, median 58.1%) and healthy controls (average 49.4%, median 47.5%, p=0.52). Peripheral blood granulocytes of healthy controls (average 41.8%, median 41.4%) showed significantly increased Hsp70 expression comparing with RA patients (average 10.7%, median 6.4%, p=0.005). Significantly higher Hsp70 gene expression was observed in synovial cells of RA patients (average 2.04, median 1.7) when compared with autologous peripheral blood leukocytes (average 0.75, median 0.68; p0.001). However, the difference in Hsp70 gene expression between RA-derived synovial cells and healthy control peripheral blood leukocytes (average 1.69, median 1.64) was not observed (p=0.83). We also found significantly lower relative gene expression in peripheral blood leukocytes of RA patients in comparison with healthy controls (p0.001). Interestingly, we found that Hsp70 gene expression in RA non-affected skin dermis gained from the operation wound was 3.7-fold higher in average (average 7.6, median 8.3) when compared to autologous RA-affected synovial tissue (p0.001); 10.1-fold higher in average when compared to autologous peripheral blood leukocytes (p0.001) and 4.5-fold higher in average comparing to control peripheral blood leukocytes (p0.001). Conclusion: Hsp70 gene expression in RA-affected synovial tissue is followed by Hsp70 cell surface expression on fibroblast-like synovial cells growing from RA synovial tissue. Hsp70 may be translocated to the cell surface from the cytosol and/or Hsp70 released from inflamed synovial tissue may be captured onto the membrane of synovial cells from the extracellular space via Hsp receptors. As a physiological response to potentially harmful enviromental stress factors, skin dermis produces higher levels of Hsp70 comparing to the cells of internal organs and tissues.","[Sedlackova, Lucie; Nguyen, Thi Thu Hien; Zlacka, Denisa; Hromadnikova, Ilona] Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Prague 10000 10, Czech Republic; [Sosna, Antonin] Charles Univ Prague, Univ Hosp Motol, Clin Orthoped 1, Fac Med 1, Prague 10000 10, Czech Republic","Sedlackova, L, Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Ruska 87, Prague 10000 10, Czech Republic","lucie.sedlackova@lf3.cuni.cz","University Hospital Motol in Prague ; University Hospital Motol in Prague) ; TRANSNET [MRTN-CT-2004-512253]; STEMDIAGNOSTICS [LSHB-CT-2007-037703]","We would like to thank colleagues Assoc. Prof. Stanislav Popelka, M. D., David Veigl, M. D. and Assoc. Prof. Jan Pech, M. D. from 1st Clinic of Orthopedics, University Hospital Motol in Prague, for providing the patient samples and Pavla Vavrincova, M. D. (Rheumatology Outpatient Department, University Hospital Motol in Prague) for collaboration. This project was supported by TRANSNET (No. MRTN-CT-2004-512253) and STEMDIAGNOSTICS (No. LSHB-CT-2007-037703).",null,24,0,"TAYLOR & FRANCIS LTD","ABINGDON","4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND","0891-6934",null,"10.1080/08916930802227466","AUTOIMMUNITY","Autoimmunity",null,2009,42,1,null,null,null,17,24,null,null,8,"Immunology","391QE","ISI:000262247000002"]
[9,"J","Alan, S; Jan, S; Tomas, H; Robert, L; Jan, S; Pavel, P",null,null,null,"Alan, Stolz; Jan, Simonek; Tomas, Harustiak; Robert, Lischke; Jan, Schutzner; Pavel, Pafko",null,"Does Chemotherapy Increase Morbidity and Mortality After Pneumonectomy?","Journal of Surgical Oncology",null,"English","Article",null,null,null,null,null,"chemotherapy; mortality; pneumonectomy","CELL LUNG-CANCER; BRONCHOPLEURAL FISTULA; INDUCTION CHEMOTHERAPY; COMPLICATIONS; RISK; RESECTION; SURGERY; THERAPY; IMPACT; STUMP","Background: The impact of chemotherapy on postoperative complications after pneumonectomy remains unclear, and the procedure is often considered as potentially dangerous. Methods: This retrospective review of prospectively collected data included 269 patients operated from January 1, 1998 through December 31, 2007. Group 1 included patients those who received preoperative chemotherapy (PCT) and pneumonectomy (54 patients, 20%), and group 2 included patients who underwent pneumonectomy alone (215 patients, 80%). Results: Overall 30- and 90-day mortality rates were 5.9% and 8.9%, respectively. Postoperative mortality at 30 days was 5.6% in group 1 and 6% in group 2 (P = 0.16), and 11.1% for group 1 and 8.3% in group 2 at 90 days (P = 0.8). Incidence of postoperative respiratory failure was 3.7% in group 1 and 3.2% in group 2 (P = 0.62) incidence of empyema was 5.5% in group 1 and 2.8% in group 2 (P = 0.1). Incidence of bronchopleural fistula (BPF) was 3.7% in group 1 and 2.8% in group 2 (P = 0.55); risk of BPF was higher following right pneumonectomy (6.1%) versus left pneumonectomy (0%, P = 0.003). Conclusions: PCT does not significantly increase postoperative morbidity and early mortality after pneumonectomy in our experience.","[Alan, Stolz; Jan, Simonek; Tomas, Harustiak; Robert, Lischke; Jan, Schutzner; Pavel, Pafko] Charles Univ Prague, Dept Thorac Surg, Univ Hosp Motol, Prague, Czech Republic","Alan, S, Charles Univ Prague, Dept Thorac Surg, Univ Hosp Motol, V Uvalu 84, Prague, Czech Republic","stolz@seznam.cz",null,null,null,19,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0022-4790",null,"10.1002/jso.21181","J SURG ONCOL","J. Surg. Oncol.","JAN 1",2009,99,1,null,null,null,38,41,null,null,4,"Oncology; Surgery","391KN","ISI:000262232300010"]
[9,"J","Sedy, J",null,null,null,"Sedy, Jiri",null,"Elevation of Parathyroid Hormone Levels in Children Who Underwent Parathyroidectomy for Hyperparathyroidism","Archives of Surgery",null,"English","Letter",null,null,null,null,null,null,null,null,"[Sedy, Jiri] First Fac Med, Dept Surg 3, Prague 15006 5, Czech Republic; [Sedy, Jiri] Teaching Hosp Motol, Prague 15006 5, Czech Republic","Sedy, J, First Fac Med, Dept Surg 3, 5 Uvalu 84, Prague 15006 5, Czech Republic","jirisedy@hotmail.com",null,null,null,2,0,"AMER MEDICAL ASSOC","CHICAGO","515 N STATE ST, CHICAGO, IL 60610-0946 USA","0004-0010",null,null,"ARCH SURG","Arch. Surg.","JAN",2009,144,1,null,null,null,92,93,null,null,5,"Surgery","395VK","ISI:000262551400027"]
[9,"J","Veselka, J; Cerna, D; Zimolova, P; Martinkovicova, L; Fiedler, J; Hajek, P; Maly, M; Zemanek, D; Duchonova, R",null,null,null,"Veselka, Josef; Cerna, Daniela; Zimolova, Petra; Martinkovicova, Lucie; Fiedler, Jiri; Hajek, Petr; Maly, Martin; Zemanek, David; Duchonova, Radka",null,"Feasibility, Safety, and Early Outcomes of Direct Carotid Artery Stent Implantation With Use of the FilterWire EZ (TM) Embolic Protection System","Catheterization and Cardiovascular Interventions",null,"English","Article",null,null,null,null,null,"peripheral vascular disease; restenosis; complications adult cath/intervention","HIGH-RISK PATIENTS; DISTAL PROTECTION; CONSENSUS DOCUMENT; ENDARTERECTOMY; STENOSIS; ANGIOPLASTY; PERFORMANCE; EXPERIENCE; COMMITTEE; TRIAL","Objectives: To report on early outcomes of prospective single-center registry, which evaluated feasibility, safety, and effectiveness of direct carotid stenting using FilterWire EZ (TM) Embolic Protection System in high-risk patients. Background: Little is known about the use of direct carotid stenting with FilterWire EZ (TM) Embolic Protection System and different carotid stents. Methods: Between September 2005 and August 2008, 176 consecutive patients (70 +/- 9 years, 36% symptomatic, 89% at high risk) underwent 214 direct carotid artery stenting procedures with FilterWire EZ (TM) Embolic Protection System and different carotid stents. This study included both symptomatic (>= 50% carotid artery stenosis) as well as asymptomatic (>= 70% carotid artery stenosis) patients. The primary endpoint was the rate of 30-day adverse events, defined as neurological death, stroke, or myocardial infarction. Results: We implanted 218 stents (55% with closed cell design) in 214 procedures. The technical success rate of direct stenting was 96%. Carotid artery stenosis before and after direct carotid artery stenting were 82% +/- 10% and 10% +/- 13%, respectively. The median of fluoroscopic time was 6 min (range 2.5-31.5 min). There were two (0.9%) minor strokes and one (0.5%) myocardial infarction within 30 post-procedural days; the primary endpoint occurred in three patients (1.4%). Two patients expired from nonneurological causes unrelated to carotid stenting. Conclusion: Direct carotid stenting with FilterWire EZ (TM) Embolic Protection System is feasible and safe. Short-term results with respect to neurological events are acceptable. (C) 2009 Wiley-Liss, Inc.","[Veselka, Josef; Cerna, Daniela; Zimolova, Petra; Martinkovicova, Lucie; Fiedler, Jiri; Hajek, Petr; Maly, Martin; Zemanek, David; Duchonova, Radka] Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Prague, Czech Republic","Veselka, J, Ctr Cardiovasc, Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic","veselka.josef@seznam.cz",null,null,null,24,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,"10.1002/ccd.21936","CATHETER CARDIOVASC INTERV","Catheter. Cardiovasc. Interv.","MAY 1",2009,73,6,null,null,null,733,738,null,null,6,"Cardiac & Cardiovascular Systems","439YJ","ISI:000265663500004"]
[9,"J","Nevoral, J; Rada, V; Vlkova, E; Blahova, K; Bronsky, J; Bubakova, D; Killer, J",null,null,null,"Nevoral, J.; Rada, V.; Vlkova, E.; Blahova, K.; Bronsky, J.; Bubakova, D.; Killer, J.",null,"Intestinal microbiota in exclusively breast-fed infants with blood-streaked stools","Folia Microbiologica",null,"English","Article",null,null,null,null,null,null,"BOVINE BETA-LACTOGLOBULIN; GERM-FREE; IMMUNODEFICIENT MICE; ALLERGIC COLITIS; MUCOSAL IMMUNITY; HUMAN-MILK; MICROFLORA; CHILDREN; IMMUNOCOMPETENT; INFLAMMATION","Intestinal microbiota in exclusively breast-fed infants with blood-streaked stools and in healthy exclusively breast-fed babies was compared. Total anaerobes, bifidobacteria, lactobacilli, coliform bacteria, enterococci and clostridia were quantified by cultivation methods in feces of 17 full-term exclusively breastfed patients (aged 16.3 +/- 7.4 weeks) with blood-streaked stools and in the control group of 22 healthy fullterm exclusively breast-fed infants (13.7 +/- 6.4 weeks). Specific fluorescence in situ hybridization kits for Bifidobacterium spp. were used for the quantitative detection of bifidobacteria in samples. Control samples had significantly (p < 0.05) higher counts of total anaerobes. Bifidobacteria were not detected in patients' samples in 65 % and in controls in 36 % (p < 0.01). Bifidobacteria counts were also significantly higher in the control group (p < 0.01). Furthermore, clostridia strains were detected only in feces from bifidobacteria-negative infants reaching counts > 8 log CFU/g. Lactobacilli were not detected in 65 % patients and in 45 % control samples. However, this difference was not significant as well as the difference in lactobacilli counts. Eosinophilia was observed in 35 % of patients, low IgA concentration in 71 % and also low IgG concentration in 71 %. pANCA positivity was found in 53 % of patients. In conclusion a significant low proportion of bifidobacterial microbiota in patients with blood-streaked stools was shown in comparison with controls.","[Nevoral, J.; Blahova, K.; Bronsky, J.] Charles Univ Prague, Sch Med 2, Dept Pediat, Prague 15006, Czech Republic; [Nevoral, J.; Blahova, K.; Bronsky, J.] Univ Hosp Motol, Prague 15006, Czech Republic; [Rada, V.; Vlkova, E.; Killer, J.] Czech Univ Life Sci Prague, Dept Microbiol Nutr & Dietet, Prague, Czech Republic; [Bubakova, D.] Ctr Hlth, Prague 10, Czech Republic","Nevoral, J, Charles Univ Prague, Sch Med 2, Dept Pediat, Prague 15006, Czech Republic","jiri.nevoral@seznam.cz","Ministry of Health of Czech Republic [IGA MZ NR/8310-5]; Agency of Ministry of Education, Youth and Sports of Czech Republic, [MSM 604 607 0901]; [VZ 64203/6903]","The work was supported by grant IGA MZ NR/8310-5 from the Ministry of Health of Czech Republic and grant no. MSM 604 607 0901 of the Grant Agency of Ministry of Education, Youth and Sports of Czech Republic, VZ 64203/6903.",null,26,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,"10.1007/s12223-009-0026-5","FOLIA MICROBIOL PRAGUE","Folia Microbiol.","MAR",2009,54,2,null,null,null,167,171,null,null,5,"Biotechnology & Applied Microbiology; Microbiology","442HS","ISI:000265832900014"]
[9,"J","Boelens, JJ; Bierings, M; Tilanus, M; Lie, J; Sedlacek, P",null,null,null,"Boelens, J. J.; Bierings, M.; Tilanus, M.; Lie, J.; Sedlacek, P.",null,"Outcomes of transplantation of unrelated cord blood in children with malignant and non-malignant diseases: an Utrecht-Prague collaborative study","Bone Marrow Transplantation",null,"English","Letter",null,null,null,null,null,null,"GRAFT",null,"[Boelens, J. J.; Bierings, M.] Univ Med Ctr Utrecht, Dept Immunol Hematol, Utrecht, Netherlands; [Boelens, J. J.; Bierings, M.] Univ Med Ctr Utrecht, BMT, Utrecht, Netherlands; [Tilanus, M.] Univ Hosp Maastricht, Tissue Typing Lab, Maastricht, Netherlands; [Lie, J.] Europdonor, Leiden, Netherlands; [Sedlacek, P.] Univ Hosp Motol, Dept Paediat Hematol & Oncol, Prague, Czech Republic","Boelens, JJ, Univ Med Ctr Utrecht, Dept Immunol Hematol, Utrecht, Netherlands","j.j.boelens@umcutrecht.nl",null,null,null,5,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369",null,"10.1038/bmt.2008.367","BONE MARROW TRANSPLANT","Bone Marrow Transplant.","APR",2009,43,8,null,null,null,655,657,null,null,3,"Biophysics; Oncology; Hematology; Immunology; Transplantation","443BJ","ISI:000265884900008"]
[9,"J","Maly, M; Hrachovinova, I; Tomasov, P; Salaj, P; Hajek, P; Veselka, J",null,null,null,"Maly, Martin; Hrachovinova, Ingrid; Tomasov, Pavol; Salaj, Peter; Hajek, Petr; Veselka, Josef",null,"Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma - a pilot study","European Journal of Haematology",null,"English","Article",null,null,null,null,null,"tissue factor; microparticles; platelets; acute coronary syndrome","FACTOR PATHWAY INHIBITOR; HUMAN ATHEROSCLEROTIC PLAQUES; SHED MEMBRANE MICROPARTICLES; MYOCARDIAL-INFARCTION; P-SELECTIN; BLOOD; COAGULATION; HEMOSTASIS","Tissue factor (TF) is a main initiator of coagulation cascade. Its determination in conditions of acute coronary syndrome is logistically difficult. Hence, in our study, the activity and the concentration of TF and the count of microparticles in the platelet free plasma (PFP) were determined. Blood was drawn from both coronary sinus and femoral vein circulation in a cohort of 40 patients. TF activity was measured by activation of factor X in the presence of factor VIIa, whereas microparticles were detected using flow cytometry. TF antigen concentrations were determined using the ELISA test. TF activity in the stable angina subgroup was not significantly different from the control group (18.12 +/- 3.35 mOD/min vs. 17.72 +/- 4.05 mOD/min, respectively), but it was significantly lower in the unstable angina (7.62 +/- 4.19 mOD/min) and myocardial infarction (MI) (3.56 +/- 3.85 mOD/min) subgroups (P < 0.05). Results from the coronary sinus and femoral vein circulations were not significantly different. The count of microparticles decreased according to the severity of the acute coronary syndrome: control group, 520 +/- 172; stable angina subgroup, 532 +/- 167; unstable angina subgroup, 392 +/- 142; and MI subgroup, 165 +/- 30 (P < 0.05). There were no significant differences in concentrations of TF antigen in four subgroups. These results suggest that the procoagulant TF-bearing microparticles could be recruited from PFP by interaction with platelets and blood cells in the conditions of acute coronary syndrome.","[Maly, Martin; Tomasov, Pavol; Hajek, Petr; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Fac Med 1, Prague 15006 5, Czech Republic; [Hrachovinova, Ingrid; Salaj, Peter] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Maly, M, Univ Hosp Motol, Dept Cardiol, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic","martin.maly@fnmotol.cz","Ministry of Health of Czech Republic [00064203]","Supported by the grant from the Ministry of Health of Czech Republic No. 00064203.",null,18,0,"BLACKWELL PUBLISHING","OXFORD","9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND","0902-4441",null,"10.1111/j.1600-0609.2008.01175.x","EUR J HAEMATOL","Eur. J. Haematol.","FEB",2009,82,2,null,null,null,148,153,null,null,6,"Hematology","393CA","ISI:000262347300009"]
[9,"J","Gebauer, RA; Tomek, V; Salameh, A; Marek, J; Chaloupecky, V; Gebauer, R; Matejka, T; Vojtovic, P; Janousek, J",null,null,null,"Gebauer, Roman A.; Tomek, Viktor; Salameh, Aida; Marek, Jan; Chaloupecky, Vaclav; Gebauer, Roman; Matejka, Tomas; Vojtovic, Pavel; Janousek, Jan",null,"Predictors of left ventricular remodelling and failure in right ventricular pacing in the young","European Heart Journal",null,"English","Article",null,null,null,null,null,"Permanent cardiac pacing; Heart failure; Cardiac resynchronization therapy; Congenital heart disease; Children","COMPLETE ATRIOVENTRICULAR-BLOCK; CONGENITAL HEART-DISEASE; DILATED CARDIOMYOPATHY; RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION; CHILDREN; DYSFUNCTION; EXPERIENCE; PACEMAKER; ATRIAL","To identify risk factors for left ventricular (LV) dysfunction in right ventricular (RV) pacing in the young. Left ventricular function was evaluated in 82 paediatric patients with either non-surgical (n = 41) or surgical (n= 41) complete atrioventricular block who have been 100% RV paced for a mean period of 7.4 years. Left ventricular shortening fraction (SF) decreased from a median (range) of 39 (24-62)% prior to implantation to 32 (8-49)% at last follow-up (P < 0.05). Prevalence of a combination of LV dilatation (LV end-diastolic diameter >+2z-values) and dysfunction (SF < 0.26) was found to increase from 1.3% prior to pacemaker implantation to 13.4% (11/82 patients) at last follow-up (P = 0.01). Ten of these 11 patients had progressive LV remodelling and 8 of 11 were symptomatic. The only significant risk factor for the development of LV dilatation and dysfunction was the presence of epicardial RV free wall pacing (OR = 14.3, P < 0.001). Other pre-implantation demographic, diagnostic, and haemodynamic factors including block aetiology, pacing variables, and pacing duration did not show independent significance. Right ventricular pacing leads to pathologic LV remodelling in a significant proportion of paediatric patients. The major independent risk factor is the presence of epicardial RV free wall pacing, which should be avoided whenever possible.","[Salameh, Aida; Janousek, Jan] Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany; [Gebauer, Roman A.; Tomek, Viktor; Chaloupecky, Vaclav; Gebauer, Roman; Matejka, Tomas; Vojtovic, Pavel] Univ Hosp Motol, Kardioctr & Cardiovasc Res Ctr, Prague, Czech Republic; [Marek, Jan] Great Ormond St Hosp Sick Children, Dept Pediat Cardiol, London, England","Janousek, J, Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany","jan.janousek@medizin.uni-leipzig.de","Ministry of Health, Czech Republic [NR/9472-3]","Funding for this work was provided by the Ministry of Health, Czech Republic (Grant NR/9472-3 to R. A. G.). Funding to pay the Open Access publication charges for this article was provided by the institutional research budget of the Heart Center of the University of Leipzig, Germany.",null,22,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0195-668X",null,"10.1093/eurheartj/ehp060","EUR HEART J","Eur. Heart J.","MAY",2009,30,9,null,null,null,1097,1104,null,null,8,"Cardiac & Cardiovascular Systems","441AD","ISI:000265740200015"]
[9,"J","Stolz, AJ; Lischke, R; Schutzner, J; Petrik, F; Harustiak, T; Pafko, P",null,null,null,"Stolz, A. J.; Lischke, R.; Schutzner, J.; Petrik, F.; Harustiak, T.; Pafko, P.",null,"Predisposing factors of atelectasis following pulmonary lobectomy","Acta Chirurgica Belgica",null,"English","Article",null,null,null,null,null,"Atelectasis; chronic obstructive pulmonary disease; lobectomy","COLLEGE-OF-PHYSICIANS; NONCARDIOTHORACIC SURGERY; LUNG RESECTION; COMPLICATIONS; RISK; BRONCHOSCOPY; THORACOTOMY; STRATEGIES; CESSATION; SMOKING","Background : The aims of our study were to investigate postoperative atelectasis complicating pulmonary lobectomy, identify risk factors and evaluate its relationship to other postoperative complications. Material and methods : From January 2004 to April 2007, 412 patients underwent pulmonary lobectomy. We performed a retrospective analysis of our prospective database. Post-lobectomy atelectasis (PLA) was defined as an ipsilateral opacification of the remaining lobe with an ipsilateral shift of the mediastinum on the chest radiography, requiring bronchoscopy. Results : The incidence of PLA was 6.6%, comprising 29% of all postoperative pulmonary complications seen. There was no statistically significant difference in patient age, gender, ASA score, cardiovascular co-morbidity or operation time for the PLA group versus the group without this complication.. Current smokers were at a higher risk for PLA, but this incidence did not reach statistical significance. Chronic obstructive pulmonary disease (COPD) was the only pre-operative variable increasing the risk of PLA (p < 0.05). Patients undergoing a right upper lobectomy, either on its own or in combination with a right middle lobe resection, had a significantly higher incidence of PLA when compared with all other types of resection (p < 0.05). Conclusions : Patients with COPD and those undergoing right upper lobe resection have an increased risk of PLA. In this group of patients we should use pre-operative (cessation of cigarette smoking, treatment of airflow obstruction in patients with COPD), intra-operative (duration of operation) and postoperative (intensive physiotherapy and effective postoperative pain control) measures to decrease the risk of PLA. Although often solitary, PLA is associated with a longer hospital stay.","[Stolz, A. J.; Lischke, R.; Schutzner, J.; Harustiak, T.; Pafko, P.] Charles Univ Prague, Univ Hosp Motol, Dept Surg, Prague, Czech Republic; [Petrik, F.] Charles Univ Prague, Univ Hosp Motol, Dept Pneumol, Prague, Czech Republic","Stolz, AJ, Univ Hosp Motol, Dept Surg, V Uvalu 84, Prague 5, Czech Republic","stolz@seznam.cz",null,null,null,17,0,"ACTA MEDICAL BELGICA","BRUSSELS","AVENUE CIRCULAIRE 138 A, B-1180 BRUSSELS, BELGIUM","0001-5458",null,null,"ACTA CHIR BELG","Acta Chir. Belg.","JAN-FEB",2009,109,1,null,null,null,81,85,null,null,5,"Surgery","419ER","ISI:000264202400016"]
[9,"J","Tomek, V; Skovranek, J; Gebauer, RA",null,null,null,"Tomek, Viktor; Skovranek, Jan; Gebauer, Roman A.",null,"Prenatal Diagnosis and Management of Fetal Long QT Syndrome","Pediatric Cardiology",null,"English","Article",null,null,null,null,null,"Long QT syndrome; Tachyarrhythmias; Echocardiography; Pregnancy",null,"This report describes a fetus presenting with second-degree atrioventricular block, sinus bradycardia, and transient ventricular tachycardia with ventriculoatrial dissociation. Long QT syndrome (LQTS) was suspected due to the association of heart rhythm disturbances and very short transmitral early deceleration time. This impaired relaxation of the left ventricle was explained by the extreme prolongation of the refractory period caused by the prolonged relaxation time. The infant was treated successfully with beta-blockers and implantation of a pacemaker. The prognosis is poor when LQTS presents utero or during the first week of life. To date, only a few case reports of a fetus with LQTS have been published.","[Tomek, Viktor; Skovranek, Jan; Gebauer, Roman A.] Univ Hosp Motol, Kardioctr, Prague 15008 5, Czech Republic; [Tomek, Viktor; Skovranek, Jan; Gebauer, Roman A.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15008 5, Czech Republic","Tomek, V, Univ Hosp Motol, Kardioctr, V Uvalu 84, Prague 15008 5, Czech Republic","viktor.tomek@seznam.cz","Internal Grant Agency, Ministry of Health, Czech Republic [NR9451-3/2007]","This publication was supported by grant NR9451-3/2007 from the Internal Grant Agency, Ministry of Health, Czech Republic.",null,7,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,"10.1007/s00246-008-9294-0","PEDIAT CARDIOL","Pediatr. Cardiol.","FEB",2009,30,2,null,null,null,194,196,null,null,3,"Cardiac & Cardiovascular Systems; Pediatrics","403QQ","ISI:000263097500019"]
[10,"J","Zaliova, M; Fronkova, E; Krejcikova, K; Muzikova, K; Mejstrikova, E; Stary, J; Trka, J; Zuna, J",null,null,null,"Zaliova, M.; Fronkova, E.; Krejcikova, K.; Muzikova, K.; Mejstrikova, E.; Stary, J.; Trka, J.; Zuna, J.",null,"Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring","Leukemia",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukaemia; BCR/ABL; Ig/TCR; minimal residual disease; relapse","ACUTE LYMPHOBLASTIC-LEUKEMIA; TIME QUANTITATIVE PCR; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; EXTREMELY POOR-PROGNOSIS; PHILADELPHIA-CHROMOSOME; GENE REARRANGEMENTS; MOLECULAR RESPONSE; CONCERTED ACTION; MESSENGER-RNA","Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL). Although quantitative detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is currently considered to be the standard method, leukaemia fusion genes provide other possible targets for MRD follow-up, as already demonstrated in TEL/AML1-positive ALLs. We analysed and compared MRD levels quantified by BCR/ABL transcript detection and by the standard Ig/TCR-based method in 218 bone marrow specimens from 17 children with BCR/ABL-positive ALL. We found only a limited overall correlation of MRD levels as assessed by the two methods (correlation coefficient R-2 = 0.64). The correlation varied among patients from excellent (R-2 = 0.99) to very poor (R-2 = 0.17). Despite identical sensitivity of the approaches, 20% of the samples were negative by the Ig/TCR approach whereas positive by the BCR/ABL method. We show that multilineage involvement is at least partly responsible for the discrepancy. Moreover, our data demonstrate that BCR/ABL monitoring enables better and earlier prediction of relapse compared to the standard Ig/TCR methodology. We conclude that BCR/ABL-based MRD monitoring of childhood ALL is a clinically relevant tool and should be performed in parallel with the standard Ig/TCR follow-up. Leukemia (2009) 23, 944-951; doi:10.1038/leu.2008.386; published online 22 January 2009","[Zuna, J.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CLIP, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Zuna, J, Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CLIP, V Uvalu 84, Prague 15006 5, Czech Republic","jan.zuna@lfmotol.cuni.cz","[MSM0021620813]; [MZO00064203]; [NS10004]","This work was supported by grants MSM0021620813, MZO00064203 and NS10004. We acknowledge all participating centres within the Czech Paediatric Haematology Working Group (CPH) for clinical management and sample collection.",null,47,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2008.386","LEUKEMIA","Leukemia","MAY",2009,23,5,null,null,null,944,951,null,null,8,"Oncology; Hematology","444UO","ISI:000266006100017"]
[10,"J","Lapcikova, M; Slouf, M; Dybal, J; Zolotarevova, E; Entlicher, G; Pokorny, D; Gallo, J; Sosna, A",null,null,null,"Lapcikova, Monika; Slouf, Miroslav; Dybal, Jiri; Zolotarevova, Eva; Entlicher, Gustav; Pokorny, David; Gallo, Jiri; Sosna, Antonin",null,"Nanometer size wear debris generated from ultra high molecular weight polyethylene in vivo","Wear",null,"English","Article",null,null,null,null,null,"Ultra high molecular weight polyethylene; Nanometer size wear debris; Morphology of wear particles; Total hip replacement","UHMWPE WEAR; PERIPROSTHETIC TISSUES; PARTICLES; HIP; ARTHROPLASTIES; QUANTIFICATION; PROSTHESES; NUMBER; VITRO","Ultra high molecular weight polyethylene (UHMWPE) wear debris is a major cause of long-term failure of total hip replacements. UHMWPE wear particle sizes range from submicron to several millimeters, but the particles below 10 mu m exhibit the highest biological activity. Some in vitro wear particles, produced in joint simulators. were shown to be smaller than 0.2 mu m and recently even in vitro particles as small as several tens of nanometers have been detected. This study brings the first evidence that nano-sized wear particles with sizes below 0.05 mu m are produced in vivo. UHMWPE wear nanoparticles were revealed by high-resolution, field emission gun scanning electron microscopy (FEGSEM) in the periprosthetic tissues of two different patients. Purity of the isolated wear nanoparticles was confirmed by energy-dispersive analysis of X-rays (EDS) and infrared spectroscopy (IR). Morphology of wear nanoparticles was determined by image analysis of FEGSEM micrographs. The average equivalent diameters of wear particles in the first and the second patient were 18.5 and 21.2 nm, respectively. Nanoscale wear debris could only be reliably detected if the isolation protocol included intensive sonication and if higher-than-usual magnifications were employed during FEGSEM analysis. (C) 2008 Elsevier B.V. All rights reserved.","[Lapcikova, Monika; Slouf, Miroslav; Dybal, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague 16206 6, Czech Republic; [Zolotarevova, Eva; Entlicher, Gustav] Charles Univ Prague, Fac Sci, Prague 12840 2, Czech Republic; [Pokorny, David; Sosna, Antonin] Fac Hosp Motol, Orthopaed Clin, Prague 15606 5, Czech Republic; [Gallo, Jiri] Palacky Univ, Fac Med & Dent, Dept Orthopaed, Olomouc 77520 6, Czech Republic","Slouf, M, Acad Sci Czech Republic, Inst Macromol Chem, Heyrovskeho Namesti 2, Prague 16206 6, Czech Republic","slouf@imc.cas.cz","Ministry of Education, Youth and Sports of the Czech Republic [2B06096]","Financial support through grant 2B06096 (Ministry of Education, Youth and Sports of the Czech Republic) is gratefully acknowledged.",null,20,0,"ELSEVIER SCIENCE SA","LAUSANNE","PO BOX 564, 1001 LAUSANNE, SWITZERLAND","0043-1648",null,"10.1016/j.wear.2008.06.005","WEAR","Wear","JAN 5",2009,266,"2009-02-01",null,null,null,349,355,null,null,7,"Engineering, Mechanical; Materials Science, Multidisciplinary","381LY","ISI:000261538800041"]
[10,"J","Gal, P; Toporcer, T; Grendel, T; Vidova, Z; Smetana, K; Dvorankova, B; Gal, T; Mozes, S; Lenhardt, L; Longauer, F; Sabol, M; Sabo, J; Backor, M",null,null,null,"Gal, Peter; Toporcer, Tomas; Grendel, Tomas; Vidova, Zuzana; Smetana, Karel, Jr.; Dvorankova, Barbora; Gal, Tomas; Mozes, Stefan; Lenhardt, L'udovit; Longauer, Frantisek; Sabol, Marian; Sabo, Jan; Backor, Martin",null,"Effect of Atropa belladonna L. on skin wound healing: Biomechanical and histological study in rats and in vitro study in keratinocytes, 3T3 fibroblasts, and human umbilical vein endothelial cells","Wound Repair and Regeneration",null,"English","Article",null,null,null,null,null,null,"MUSCARINIC RECEPTORS; CHOLINERGIC SYSTEM; EXPRESSION; DIFFERENTIATION; GROWTH; PROLIFERATION; ANGIOGENESIS; STIMULATION; MECHANISMS; EXTRACT","The effect of Atropa belladonna L. (AB) aqueous extract on skin wound healing was studied in male Sprague-Dawley rats subjected to two parallel full-thickness skin incisions on the back. Specimens for histological evaluation were collected on days 2 and 5 whereas for biomechanical testing, they were collected on day 5. In the in vitro study, a different concentration of AB extract was used to test the differentiation of keratinocytes using a panel of selected antibodies, proliferation, and cell survival of 3T3 fibroblasts and human umbilical vein endothelial cells using the MTT-assay. Results of the in vivo experiments showed in AB-treated wounds a shortened process of inflammation and accelerated collagen formation, as well as significantly increased wound stiffness as compared with control tissues. The in vitro examination showed that control keratinocytes were cytokeratin 19 free, while samples exposed to the highest AB extract concentration expressed CK19. Moreover, all concentrations were stimulatory to human umbilical vein endothelial cell proliferation. In addition, only the AB extract at the lowest tested concentration increased fibroblast growth, but higher concentrations decreased cell survival. In conclusion, our results indicate that the AB water extract positively affects early phases of skin wound healing in rats. However, the in vitro results on the inverse relation between the concentration of the AB extract and its effects on cell proliferation may be important for future research.","[Gal, Peter] E Slovak Inst Cardiovasc Dis, Kosice 04011, Slovakia; [Gal, Peter; Toporcer, Tomas; Grendel, Tomas; Sabo, Jan] Safarik Univ, Dept Med Biophys, Kosice, Slovakia; [Gal, Peter; Backor, Martin] Safarik Univ, Inst Biol & Ecol, Kosice, Slovakia; [Gal, Peter; Vidova, Zuzana] Safarik Univ, Dept Pharmacol, Kosice, Slovakia; [Smetana, Karel, Jr.; Dvorankova, Barbora; Gal, Tomas] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Mozes, Stefan] Slovak Acad Sci, Inst Anim Physiol, Kosice, Slovakia; [Gal, Peter; Lenhardt, L'udovit] Univ Vet Med, Dept Pathol Anat, Kosice, Slovakia; [Longauer, Frantisek] Safarik Univ, Dept Forens Med, Kosice, Slovakia; [Sabol, Marian] Safarik Univ, Dept Med & Clin Microbiol, Kosice, Slovakia","Gal, P, E Slovak Inst Cardiovasc Dis, Irieda SNP 1, Kosice 04011, Slovakia","galovci@yahoo.com","Slovak Research and Development Agency [APVV-0325-07]; Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806]","We thank Danielle Miller for her editorial help in preparing this manuscript. We also thank M. Harakal'ova, A. Sucha, I. Tomkova, and E. Vancova for their useful technical assistance. This study was supported in part by the Slovak Research and Development Agency (No. APVV-0325-07) and by the Ministry of Education, Youth and Sport of the Czech Republic (No. MSM0021620806). We thank U.S. Steel Kosice and Tatra banka (both from Slovak Republic) for buying us the Olympus BX51 fluorescence microscope.",null,32,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1067-1927",null,"10.1111/j.1524-475X.2009.00475.x","WOUND REPAIR REGEN","Wound Repair Regen.","MAY-JUN",2009,17,3,null,null,null,378,386,null,null,9,"Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery","448DZ","ISI:000266244600013"]
[11,"J","Jarolim, L; Sedy, J; Schmidt, M; Nanka, O; Foltan, R; Kawaciuk, I",null,null,null,"Jarolim, Ladislav; Sedy, Jiri; Schmidt, Marek; Nanka, Ondrej; Foltan, Rene; Kawaciuk, Ivan",null,"Gender Reassignment Surgery in Male-to-Female Transsexualism: A Retrospective 3-Month Follow-up Study with Anatomical Remarks","Journal of Sexual Medicine",null,"English","Article",null,null,null,null,null,"Male-To-Female Transsexualism; Sex Reassignment Surgery; Anatomy","SEX-REASSIGNMENT; DORSALIS PENIS/CLITORIDIS; VAGINOPLASTY; PROSTATE; CLITOROPLASTY; COMPLICATIONS; NEOCLITORIS; CONVERSION; DISORDERS; CARCINOMA","Greater acceptance of sexual minorities has enabled people with transsexualism access to adequate treatment and social integration. Gender reassignment surgery is a complex phase in the care of transsexual patients. In response to a greater volume of patients, surgical techniques have evolved and the outcome in patients with male-to-female transsexualism is now a very accurate imitation of female genitalia, enabling sexual intercourse with orgasm. To evaluate the results of surgical reassignment of genitalia in male-to-female transsexuals. A retrospective 3-month follow-up study of patients' opinions following gender reassignment surgery in 129 patients having a primary procedure (eight of whom had later sigmoideocolpoplasty) and five patients undergoing reoperation following an initial unsuccessful procedure at other units. All patients were male transsexuals. The surgical techniques are described in detail. Sexual functions and complications 3 months after surgery. All patients were satisfied with the first phase operation. Thirteen patients (9.7%) underwent successful sigmoideocolpoplasty. Main complications were as follows: rectal lesions developing during preparation of the vaginal canal (1.5%); bleeding from the stump of the shortened urethra in the first 48 hours postoperatively requiring secondary suturing (4.5%); temporary urinary retention requiring repeated insertion of urinary catheters for up to 6 days (5.2%); and healing of the suture between the perineum and the posterior aspect of the vaginal introitus healing by secondary intention (5.2%). The neoclitoris had erogenous sensitivity in 93.9% of patients and 65.3% reached orgasm in the first 3 months. Surgical conversion of the genitalia is a safe and important phase of the treatment of male-to-female transsexuals. Jarolim L, Sedy J, Schmidt M, Nanka O, Foltan R, and Kawaciuk I. Gender reassignment surgery in male-to-female transsexualism: A retrospective 3-month follow-up study with anatomical remarks. J Sex Med 2009;6:1635-1644.","[Jarolim, Ladislav; Schmidt, Marek; Kawaciuk, Ivan] Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Nanka, Ondrej] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Jarolim, Ladislav; Schmidt, Marek; Kawaciuk, Ivan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic","Jarolim, L, Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic","ladislav.jarolim@lfmotol.cuni.cz","Ministry of Education, Youth and Sport of The Czech Republic [VZ 0021620806]","This study was supported by a grant from the Ministry of Education, Youth and Sport of The Czech Republic VZ 0021620806.",null,41,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1743-6095",null,"10.1111/j.1743-6109.2009.01245.x","J SEX MED","J. Sex. Med.","JUN",2009,6,6,null,null,null,1635,1644,null,null,10,"Urology & Nephrology","451JA","ISI:000266465300015"]
[11,"J","Ryden, A; Stechova, K; Durilova, M; Faresjo, M",null,null,null,"Ryden, Anna; Stechova, Katerina; Durilova, Marianna; Faresjo, Maria",null,"Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes","Diabetes-Metabolism Research and Reviews",null,"English","Article",null,null,null,null,null,"Type 1 diabetes; high-risk children; T-helper cells; T-regulatory cells; cytokines; chemokines","MONOCYTE CHEMOATTRACTANT PROTEIN-1; GLUTAMIC-ACID DECARBOXYLASE; CHRONIC AUTOIMMUNE-DISEASE; BLOOD MONONUCLEAR-CELLS; IFN-GAMMA; HIGH-RISK; NOD MICE; T-CELLS; CYTOKINE PRODUCTION; REGULATORY-CELLS/","Background Type 1 diabetes (T1D) is all autoimmune disease dominated by loss of self-tolerance resulting in depletion of the beta-cells. This Study aims to confirm previous observations of a dominant T-helper (Th)1-like profile during the period close to onset of disease. Further, to follow the immune response from onset to 2 years duration, the Study focused on spontaneous as well as autoantigen-induced immune profile. Methods Peripheral blood mononuclear cells were collected 4 days and 1 and 2 years after diagnosis of T1D children, from healthy children carrying the human leukocyte antigen-risk genes and from high-risk children (ICA >= 20 IJDF units). Peripheral blood mononuclear cells were stimulated with glutamic acid decarboxylase (GAD(65)) and phytohaemagglutinin (PHA). Cytokines and chemokines were detected in cell-culture supernatants by protein microarray (naive T-cells; interleukin (IL)-7, Th1; interferon-gamma, turnout necrosis factor-beta, Th2; IL-5, Th3; transforming growth factor-beta, T-regulatory cell type 1; IL-10 and inflammatory cytokines; tumour necrosis factor-alpha, IL-6 and chemokines; monocyte chemoattractant protein-1, monokine upregulated by IFN-gamma) in relation to clinical outcome (C-peptide). Results High-risk children showed a dominant Th1-associated profile with high spontaneous and GAD(65)-induced secretion. The mitogen PHA instead induced a Th2-associated response exclusively in high-risk children. In contrast, newly diagnosed T1D children showed a pronounced Th3-associated cytokine profile as well as a burst of inflammatory cytokines and chemokines secreted both spontaneously and by GAD(65) and PHA stimulation. The immune response to GAD(65) and PHA, however, diminished with duration of disease. Conclusion A dominant Thl-associated immune profile was observed during the pre-diabetic phase. This Th1 dominance, however, diminished in favour of a temporary increase in a Th3-associated and inflammatory immune profile at the onset of disease. Copyright (C) 2009 John Wiley & Sons, Ltd.","[Ryden, Anna; Faresjo, Maria] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Res Ctr,Div Paediat & Diabet, S-58185 Linkoping, Sweden; [Stechova, Katerina; Durilova, Marianna] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Stechova, Katerina; Durilova, Marianna] Univ Hosp Motol, Prague, Czech Republic; [Faresjo, Maria] Jonkoping Univ, Sch Hlth Sci, Dept Nat Sci & Biomed, Jonkoping, Sweden","Faresjo, M, Linkoping Univ, Fac Hlth Sci, Div Paediat, S-58185 Linkoping, Sweden","maria.faresjo@liu.se","Swedish Child Diabetes Foundation (Barndiabetesfonden) ; Schelin Foundation ; Child Medicine Research Foundation ; Research Project of the University Hospital Motol [00064203]","This project was generously supported by the Swedish Child Diabetes Foundation (Barndiabetesfonden), the Schelin Foundation, the Child Medicine Research Foundation and the Research Project of the University Hospital Motol (No. 00064203).",null,45,0,"JOHN WILEY & SONS LTD","CHICHESTER","THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND","1520-7552",null,"10.1002/dmrr.958","DIABETES-METAB RES REV","Diabetes-Metab. Res. Rev.","MAY",2009,25,4,null,null,null,335,343,null,null,9,"Endocrinology & Metabolism","449RH","ISI:000266347200008"]
[11,"J","Pacova, H; Astl, J; Martinek, J",null,null,null,"Pacova, H.; Astl, J.; Martinek, J.",null,"The pathogenesis of chronic inflammation and malignant transformation in the human upper airways: the role of beta-defensins, eNOS, cell proliferation and apoptosis","Histology and Histopathology",null,"English","Article",null,null,null,null,null,"Tonsillitis chronica; Tonsillar carcinoma; Nasal polyposis; Defensins; Apoptosis; Proliferation","NITRIC-OXIDE SYNTHASE; EXPRESSION PATTERNS; PALATINE TONSIL; ORAL-TISSUES; CARCINOMA; BETA-DEFENSIN-2; PEPTIDES; MUCOSA; NO","The surrounding environment contains plenty of pathogens, which represent a danger of infection. The simplest way for the pathological microorganism to enter the organism is the upper airways. Inflammation of the upper airways is among the most common and frequent diseases. This category includes nasal polyposis and chronic tonsillitis. In many cases it is associated with disorders in relation to the immune response. An inflammatory infiltration of mononuclears, eosinophils, plasma and mast cells can be found in the histological structure of the polypous as well as tonsillar mucosa. One aim of this study was to determine the expression of beta-defensins and various proteins, with a possible potential role in relation to the rise and development of those changes. Another aim was to determine the relationship between the inflammatory and malignant processes in the tonsils. The samples of nasal polyps were obtained during clinically indicated endonasal surgery from patients diagnosed with nasal polyposis (n=50). The samples of tonsils were collected during surgery from patients suffering from chronic tonsillitis (n=11) or tonsillar carcinoma (n=17). Immunohistochemical procedures for the detection of human beta-defensin 1, 2, 3 (HBD-1,2, 3), Ki-67, endothelial nitric oxide synthase (eNOS) and cleaved caspase 3 were performed on cryostate and paraffin sections. It was proven that HBD are secreted in fairly large amounts in cases of chronic inflammation. Their secretion during the malignant transformation is limited. This is a very probable fact that plays a role in malignant transformation in tonsillar tissue. The crucial role in the development of chronic inflammation, and maybe that of malignant transformation, is played by eNOS and its product NO molecule. eNOS and the NO molecule are involved in cell cycle regulation, in the apoptotic processes and cell proliferation, as well as in the angiogenesis and vasculogenesis. Our result confirmed that eNOS is presented in the tissues of the upper airways in both chronic inflammation and carcinomatous processes. Ki-67 and cleaved caspase 3 were used as markers of cell proliferation and apoptosis.","[Pacova, H.; Martinek, J.] Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Prague 12801 2, Czech Republic; [Pacova, H.; Astl, J.] Fac Med 1, Dpt Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Pacova, H.; Astl, J.] Teaching Hosp Motol, Prague, Czech Republic","Pacova, H, Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Albertov 4, Prague 12801 2, Czech Republic","Hpac@seznam.cz","IGA Ministry of Health, CR [9077 NR]","The authors would like to express their thanks to Mrs. Blazkeova, Mrs. Kratinova, Mrs. Kolarova and Miss Kosova from the Instute of Histology and Embryology for their substantial help in processing the material and realization of immunohistochemical procedures during this experimental study. This project was supported by Grant project No. 9077 NR, IGA Ministry of Health, CR.",null,24,0,"F HERNANDEZ","MURCIA","PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN","0213-3911",null,null,"HISTOL HISTOPATHOL","Histol. Histopath.","JUL",2009,24,7,null,null,null,815,820,null,null,6,"Cell Biology; Pathology","450NG","ISI:000266407500002"]
[12,"J","Sedy, J; Zicha, J; Kunes, J; Sykova, E",null,null,null,"Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav; Sykova, Eva",null,"Atropine may prevent the development of neurogenic pulmonary edema","Medical Hypotheses",null,"English","Article",null,null,null,null,null,null,"SPINAL-CORD-INJURY; MODEL; COMPLICATIONS; RAT","Neurogenic pulmonary edema is an acute life-threatening complication of central nervous system injury. We introduce a hypothesis that early i.v. administration of high-dose atropine can prevent neurogenic pulmonary edema development on the basis of the prevention of baroreflex-induced bradycardia, which was recognized as a major factor in neurogenic pulmonary edema formation. To validate this hypothesis, a clinical trial in patients suffering from subarachnoid haemorrhage should be performed, with atropine administered i.v. immediately after the maintenance of the living functions, intubation and ability to monitor patient. (C) 2009 Elsevier Ltd. All rights reserved.","[Sedy, Jiri; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Sedy, Jiri; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sedy, Jiri; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sedy, Jiri] Charles Univ Prague, Fac Med 1, Inst Dent Res, Prague, Czech Republic; [Sedy, Jiri] Gen Univ Hosp, Prague, Czech Republic; [Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague, Czech Republic; [Zicha, Josef; Kunes, Jaroslav] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague, Czech Republic","Sedy, J, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","jirisedy@hotmail.com","EC [LSHB-CT-2005-518233]; [AVOZ50390512]; [1M0021620803]; [GACR309/06/1246]; [1A8697-5]; [AVOZ50110509]; [IM0510]; [IM0538 AVOZ50390703]; [LC554]; [GACR309/09/1430]; [IGA MZ 1A8697-5]","We thank to James Dutt for critical reading of the manuscript. We acknowledge the support provided by the Grants AVOZ50390512, 1M0021620803, GACR309/06/1246, 1A8697-5, EC FP6 project RESCUE (LSHB-CT-2005-518233), AVOZ50110509, IM0510, IM0538 AVOZ50390703, LC554, GACR309/09/1430, and IGA MZ 1A8697-5.",null,17,0,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0306-9877",null,"10.1016/j.mehy.2008.12.051","MED HYPOTHESES","Med. Hypotheses","JUL",2009,73,1,null,null,null,42,44,null,null,3,"Medicine, Research & Experimental","452ZG","ISI:000266579100013"]
[12,"J","Hollink, IHIM; van den Heuvel-Eibrink, MM; Zimmermann, M; Balgobind, BV; Arentsen-Peters, STCJM; Alders, M; Willasch, A; Kaspers, GJL; Trka, J; Baruchel, A; de Graaf, SSN; Creutzig, U; Pieters, R; Reinhardt, D; Zwaan, CM",null,null,null,"Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Zimmermann, Martin; Balgobind, Brian V.; Arentsen-Peters, Susan T. C. J. M.; Alders, Marielle; Willasch, Andre; Kaspers, Gertjan J. L.; Trka, Jan; Baruchel, Andre; de Graaf, Siebold S. N.; Creutzig, Ursula; Pieters, Rob; Reinhardt, Dirk; Zwaan, C. Michel",null,"Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia","Blood",null,"English","Article",null,null,null,null,null,null,"WT1 GENE; NORMAL KARYOTYPE; NUCLEOPHOSMIN MUTATIONS; TANDEM DUPLICATION; TREATMENT STRATEGY; TUMOR-SUPPRESSOR; DRUG-RESISTANCE; PEDIATRIC AML; TRIALS; FLT3","Wilms tumor 1 (WT1) mutations have recently been identified in approximately 10% of adult acute myeloid leukemia (AML) with normal cytogenetics (CN-AML) and are associated with poor outcome. Using array-based comparative genome hybridization in pediatric CN-AML samples, we detected a WT1 deletion in one sample. The other WT1 allele was mutated. This prompted us to further investigate the role of WT1 aberrations in childhood AML. Mutations were found in 35 of 298 (12%) diagnostic pediatric AML samples. In 19 of 35 (54%) samples, more than one WT1 aberration was found: 15 samples had 2 different mutations, 2 had a homozygous mutation, and 2 had a mutation plus a WT1 deletion. WT1 mutations clustered significantly in the CN-AML subgroup (22%; P < .001) and were associated with FLT3/ITD (43 vs 17%; P < .001). WT1 mutations conferred an independent poor prognostic significance (WT1 mutated vs wildtype patients: 5-year probability of overall survival [pOS] 35% vs 66%, P = .002; probability of event-free survival 22% vs 46%, P < .001; and cumulative incidence of relapse or regression 70% vs 44%, P < .001). Patients with both a WT1 mutation and a FLT3/ITD had a dismal prognosis (5-year pOS 21%). WT1 mutations occur at a significant rate in childhood AML and are a novel independent poor prognostic marker. (Blood. 2009; 113: 5951-5960)","[Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Balgobind, Brian V.; Arentsen-Peters, Susan T. C. J. M.; Pieters, Rob; Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Zimmermann, Martin; Reinhardt, Dirk] Med High Sch, Dept Pediat Oncol Hematol, AML BFM Study Grp, Hannover, Germany; [Alders, Marielle] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Willasch, Andre] Univ Childrens Hosp Frankfurt, Dept Hematol & Oncol, Frankfurt, Germany; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] St Louis Hosp, Paris, France; [de Graaf, Siebold S. N.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Oncol Hematol, NL-6525 ED Nijmegen, Netherlands; [Creutzig, Ursula] Univ Childrens Hosp, AML BFM Study Grp, Munster, Germany","Zwaan, CM, Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","c.m.zwaan@erasmusmc.nl","Pediatric Oncology Foundation Rotterdam (KOCR) ; The Netherlands Organization for Scientific Research (NWO ; Deutsche Krebshilfe ","I. H. I. M. H. was funded by the Pediatric Oncology Foundation Rotterdam (KOCR), B. V. B. was funded by The Netherlands Organization for Scientific Research (NWO), and D. R. was funded by the Deutsche Krebshilfe.",null,33,1,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2008-09-177949","BLOOD","Blood","JUN 4",2009,113,23,null,null,null,5951,5960,null,null,10,"Hematology","454BH","ISI:000266656100038"]
[12,"J","Funa, NS; Kriz, V; Zang, G; Calounova, G; Akerblom, B; Mares, J; Larsson, E; Sun, Y; Betsholtz, C; Welsh, M",null,null,null,"Funa, Nina S.; Kriz, Vitezslav; Zang, Guangxiang; Calounova, Gabriela; Akerblom, Bjoern; Mares, Jaroslav; Larsson, Erik; Sun, Ying; Betsholtz, Christer; Welsh, Michael",null,"Dysfunctional Microvasculature as a Consequence of Shb Gene Inactivation Causes Impaired Tumor Growth","Cancer Research",null,"English","Article",null,null,null,null,null,null,"ENDOTHELIAL-CELL APOPTOSIS; BLOOD-VESSEL FORMATION; FOCAL ADHESION KINASE; NEURAL STEM-CELLS; ADAPTER PROTEIN; VASCULAR-PERMEABILITY; VE-CADHERIN; RHO-KINASE; ANGIOGENESIS; DIFFERENTIATION","Shb (Src homology 2 protein B) is an adapter protein downstream of the vascular endothelial growth factor receptor receptor-2 (VEGFR-2). Previous experiments have suggested a role for Shb in endothelial cell function. Recently, the Shb gene was inactivated and Shb null mice were obtained on a mixed genetic background, but not on C57B16 mice. The present study was performed to address endothelial function in the Shb knockout mouse and its relevance for tumor angiogenesis. Tumor growth was retarded in Shb mutant mice, and this correlated with decreased angiogenesis both in tumors and in Matrigel plugs. Shb null mice display an abnormal endothelial ultrastructure in liver sinusoids and heart capillaries with cytoplasmic extensions projecting toward the lumen. Shb null heart VE-cadherin staining was less distinct than that of control heart, exhibiting in the former case a wavy and punctuate pattern. Experiments on isolated endothelial cells suggest that these changes could partly reflect cytoskeletal abnormalities. Vascular permeability was increased in Shb null mice in heart, kidney, and skin, whereas VEGF-stimulated vascular permeability was reduced in Shb null mice. It is concluded that Shb plays an important role in maintaining a functional vasculature in adult mice, and that interference with Shb signaling may provide novel means to regulate tumor angiogenesis. [Cancer Res 2009;69(5):2141-8]","[Funa, Nina S.; Zang, Guangxiang; Calounova, Gabriela; Akerblom, Bjoern; Welsh, Michael] Uppsala Univ, Dept Med Cell Biol, S-75123 Uppsala, Sweden; [Larsson, Erik] Uppsala Univ, Dept Genet & Pathol, S-75123 Uppsala, Sweden; [Kriz, Vitezslav] Masaryk Univ, Dept Biol, Brno, Czech Republic; [Zang, Guangxiang] Jilin Univ, Sch Stomatol, Dept Pathol, Changchun, Peoples R China; [Calounova, Gabriela; Mares, Jaroslav] Charles Univ Prague, Dept Med Genet, Prague, Czech Republic; [Sun, Ying; Betsholtz, Christer] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden","Welsh, M, Uppsala Univ, Dept Med Cell Biol, Box 571,Husargatan 3, S-75123 Uppsala, Sweden","Michael.welsh@mcb.uu.se","Juvenile Diabetes Research Foundation International ; Swedish Cancer Foundation ; Swedish Research Council ; Swedish Diabetes Association ; Wallenberg Foundation ; Family Ernfors Fund ","Received 10/2/2008; revised 12/3/2008; accepted 12/15/2008; published OnlineFirst 02/17/2009. Grant support: Juvenile Diabetes Research Foundation International, Swedish Cancer Foundation, Swedish Research Council, Swedish Diabetes Association, Wallenberg Foundation, and Family Ernfors Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. We thank Drs. Laura Benjamin, Sara Weis David Millstone, Orian Kallskog, and Lena Claesson-Welsh for helpful advice. The technical assistance by Anders Ahlander, Barbro Einarsson, Irja Johansson, Britta Isaksson, Ing-Marie Morsare, and Eva Tornelius is gratefully acknowledged.",null,49,0,"AMER ASSOC CANCER RESEARCH","PHILADELPHIA","615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA","0008-5472",null,"10.1158/0008-5472.CAN-08-3797","CANCER RES","Cancer Res.","MAR 1",2009,69,5,null,null,null,2141,2148,null,null,8,"Oncology","415ML","ISI:000263937800058"]
[12,"J","Seeman, T; Malikova, M; Blahova, K; Seemanova, E",null,null,null,"Seeman, Tomas; Malikova, Marcela; Blahova, Kveta; Seemanova, Eva",null,"Polycystic kidney and hepatic disease with mental retardation and hand anomalies in three siblings","Pediatric Nephrology",null,"English","Article",null,null,null,null,null,"Autosomal recessive inheritance; Facial dysmorphy; Hand anomalies; Hepatic fibrosis; Mental retardation; Polycystic kidneys; Proximal implanted thumbs","FIBROSIS; ARPKD","A family with three children affected with congenital polycystic kidneys, hepatic fibrosis, mental retardation, minor anomalies of the hands, and dysmorphic facial features is reported. All children progressed to chronic renal failure. Linkage to the locus for autosomal recessive polycystic kidney disease was excluded by haplotype analysis. The family is endogamic, and the affected siblings are of both sexes, which is in agreement with an autosomal recessive determination of this syndrome. A similar syndrome was reported in 1990 by Labrune et al. [J Pediatr Gastroenterol Nutr (1990) 10:540-543]. Our report provides further evidence for the etiological heterogeneity of polycystic kidney with hepatic fibrosis. The syndrome reported here should be considered in the differential diagnosis of the early manifestation of polycystic kidneys. Mental retardation and hand anomalies are the hallmarks for the differential diagnosis of this syndrome.","[Seeman, Tomas; Blahova, Kveta] Charles Univ Prague, Dept Pediat, Sch Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Malikova, Marcela; Seemanova, Eva] Charles Univ Prague, Dept Clin Genet, Sch Med 2, Univ Hosp Motol,Inst Biol & Med Genet, Prague 15006, Czech Republic","Seeman, T, Charles Univ Prague, Dept Pediat, Sch Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic","tomas.seeman@lfmotol.cuni.cz","VZ MZ CR [0006420301]; VZ MSMT CR [0021620819]; IGA [NR9457-3]","We thank Prof. Klaus Zerres and Dr. Carsten Bergmann from the Aachen University of Technology for haplotype analysis of the ARPKD, Dr. Karel Vondrak for providing clinical data and Dr. Pavel Dvorak for technical support. Supported by grant VZ MZ CR 0006420301, VZ MSMT CR 0021620819 and IGA NR9457-3.",null,10,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-008-1049-x","PEDIAT NEPHROL","Pediatr. Nephrol.","JUL",2009,24,7,null,null,null,1409,1412,null,null,4,"Pediatrics; Urology & Nephrology","451XN","ISI:000266504300020"]
[12,"J","Horinek, D; Brezova, V; Nimsky, C; Belsan, T; Martinkovic, L; Masopust, V; Vrana, J; Kozler, P; Plas, J; Krysl, D; Varjassyova, A; Ghaly, Y; Benes, V",null,null,null,"Horinek, D.; Brezova, V.; Nimsky, C.; Belsan, T.; Martinkovic, L.; Masopust, V.; Vrana, J.; Kozler, P.; Plas, J.; Krysl, D.; Varjassyova, A.; Ghaly, Y.; Benes, V.",null,"The MRI volumetry of the posterior fossa and its substructures in trigeminal neuralgia: a validated study","Acta Neurochirurgica",null,"English","Article",null,null,null,null,null,"Trigeminal neuralgia; Neurovascular conflict; Posterior fossa; MRI volumetry; Validation","PREDICTING NEUROVASCULAR COMPRESSION; MICROVASCULAR DECOMPRESSION; PATHOGENESIS; PATHOLOGY; SECONDARY; CONFLICT; ACCURATE; DISEASE","Our aim was to determine whether the anatomical configuration of the posterior fossa and its substructures might represent a predisposition factor for the occurrence of clinical neurovascular conflict in trigeminal neuralgia (TN). We used MRI volumetry in 18 patients with TN and 15 controls. The volume of the pontomesencephalic cistern, Meckel's cave and the trigeminal nerve on the clinical and non-affected sides was compared. The reliability has been assessed in all measurements. The posterior fossa volume was not different in the clinical and control groups; there was no difference between the affected and non-affected sides when measuring the pontomesencephalic cistern and Meckel's cave volume either. The volume of the clinically affected trigeminal nerve was significantly reduced, but with a higher error of measurement. We did not find any association between the clinical neurovascular conflict (NVC) and the size of the posterior fossa and its substructures. MRI volumetry may show the atrophy of the affected trigeminal nerve in clinical NVC.","[Horinek, D.; Masopust, V.; Kozler, P.; Plas, J.; Benes, V.] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Cent Mil Hosp Prague, Prague 16000 6, Czech Republic; [Horinek, D.; Nimsky, C.] Univ Marburg, Fac Med, Dept Neurosurg, D-35033 Marburg, Germany; [Horinek, D.; Brezova, V.; Martinkovic, L.; Vrana, J.; Ghaly, Y.] Charles Univ Prague, Inst Pathol Physiol, Lab Neuroimaging Res, Fac Med 2, Prague 15800 5, Czech Republic; [Krysl, D.; Varjassyova, A.] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15800 5, Czech Republic; [Belsan, T.; Vrana, J.] Cent Mil Hosp Prague, Dept Radiol, Prague 16000 6, Czech Republic; [Varjassyova, A.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 11000 1, Czech Republic","Horinek, D, Charles Univ Prague, Dept Neurosurg, Fac Med 1, Cent Mil Hosp Prague, Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic","daniel.horinek@uvn.cz","Grantova agentura Ceske republiky [309/08/P223]; European Federation of Neurological Societies fellowship ","The project is supported by Grantova agentura Ceske republiky 309/08/P223. Dr. Horinek holds a scientific European Federation of Neurological Societies fellowship.",null,23,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0001-6268",null,"10.1007/s00701-009-0283-8","ACTA NEUROCHIR","Acta Neurochir.","JUN",2009,151,6,null,null,null,669,675,null,null,7,"Clinical Neurology; Surgery","456AZ","ISI:000266811700017"]
[13,"J","Baran, R; Tosti, A; Hartmane, I; Altmeyer, P; Hercogova, J; Koudelkova, V; Ruzicka, T; Combemale, P; Mikazans, I",null,null,null,"Baran, R.; Tosti, A.; Hartmane, I.; Altmeyer, P.; Hercogova, J.; Koudelkova, V.; Ruzicka, T.; Combemale, P.; Mikazans, I.",null,"An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis","Journal of the European Academy of Dermatology and Venereology",null,"English","Article",null,null,null,null,null,"ciclopirox; hydroxypropyl chitosan; onychomycosis; water-soluble nail lacquer","ITRACONAZOLE; TERBINAFINE","Background A new 8% ciclopirox-medicated nail lacquer (P-3051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use. Objective This study aims to assess the efficacy and safety of P-3051 vs. the market 8% ciclopirox nail lacquer. Methods This is a multicentre, randomized, three-arm, placebo-controlled, parallel groups, evaluator-blinded study. Overall, 467 patients with onychomycosis of at least one big toenail were randomized to receive P-3051, the reference drug or placebo in a 2 : 2 : 1 ratio for a 48-week treatment by daily application, followed by a 12-week follow-up. Results The study satisfied its objective by demonstrating that P-3051 was both superior to placebo and non-inferior to reference in the complete cure rate after a 48-week active treatment period. Switching the non-inferiority to superiority hypothesis, the superiority of P-3051 vs. reference was nearly significant at week 48 (confirmed at week 52), and it was significant at week 60 (cure rate for P-3051 is 119% higher than reference; P < 0.05). Altogether, the results on primary endpoint exceed expectations; superiority test was performed also on secondary endpoints to confirm the superiority trend of the study. At the end of follow-up, percentages of patients who achieved the endpoint 'responder' in the P-3051 group were 66% higher than reference (P < 0.05), and those who achieved the endpoint 'decrease of diseased nail' were 40% higher (P < 0.05). Conclusion Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.","[Baran, R.] Nail Dis Ctr, Cannes, France; [Tosti, A.] Univ Bologna, Dept Dermatol, I-40138 Bologna, Italy; [Hartmane, I.; Mikazans, I.] Clin Ctr Skin & STD, Riga, Latvia; [Altmeyer, P.] Ruhr Univ Bochum, Klin Dermatol & Allergol, Bochum, Germany; [Hercogova, J.] Charles Univ Prague, Fac Med 2, Bulovka Univ Hosp, Dermatovenereol Dept, Prague, Czech Republic; [Koudelkova, V.] Fac Hosp, Dermatovenereol Clin, Hradec Kralove, Czech Republic; [Ruzicka, T.] Univ Munich, Munich, Germany; [Combemale, P.] Hop Desgenettes, Serv Dermatol, Lyon, France","Baran, R, Nail Dis Ctr, Cannes, France","baran.r@wanadoo.fr",null,null,null,17,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0926-9959",null,"10.1111/j.1468-3083.2009.03164.x","J EUR ACAD DERMATOL VENEREOL","J. Eur. Acad. Dermatol. Venereol.","JUL",2009,23,7,null,null,null,773,781,null,null,9,"Dermatology","453UG","ISI:000266637800004"]
[13,"J","Grycova, L; Sklenovsk, P; Lansky, Z; Janovska, M; Otyepka, M; Amler, E; Teisinger, J; Kubala, M",null,null,null,"Grycova, Lenka; Sklenovsk, Petr; Lansky, Zdenek; Janovska, Marika; Otyepka, Michal; Amler, Evzen; Teisinger, Jan; Kubala, Martin",null,"ATP and magnesium drive conformational changes of the Na+/K+-ATPase cytoplasmic headpiece","Biochimica et Biophysica Acta-Biomembranes",null,"English","Article",null,null,null,null,null,"Na+/K+-ATPase; P-type ATPase; ATP; Magnesium; Tryptophan fluorescence; Conformational change","SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; CALCIUM-PUMP; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NUCLEOTIDE-BINDING; ENERGY TRANSDUCTION; ISOLATED DOMAIN; ALPHA-SUBUNIT; ION-TRANSPORT","Conformational changes of the Na+/K+-ATPase isolated large cytoplasmic segment connecting transmembrane helices M4 and M5 (C45) induced by the interaction with enzyme ligands (i.e. Mg2+ and/or ATP) were investigated by means of the intrinsic tryptophan fluorescence measurement and molecular dynamic simulations. Our data revealed that this model system consisting of only two domains retained the ability to adopt open or closed conformation, i.e. behavior, which is expected from the crystal structures of relative Ca2+-ATPase from sarco(endo)plasmic reticulum for the corresponding part of the entire enzyme. Our data revealed that the C45 is found in the closed conformation in the absence of any ligand, in the presence of Mg2+ only, or in the simultaneous presence of Mg2+ and ATP. Binding of the ATP alone (i.e. in the absence of Mg2+) induced open conformation of the C45. The fact that the transmembrane part of the enzyme was absent in our experiments suggested that the observed conformational changes are consequences only of the interaction with ATP or Mg2+ and may not be related to the transported cations binding/ release, as generally believed. Our data are consistent with the model, where ATP binding to the low-affinity site induces conformational change of the cytoplasmic part of the enzyme, traditionally attributed to E2 -> E1 transition, and subsequent Mg2+ binding to the enzyme-ATP complex induces in turn conformational change traditionally attributed to E1 -> E2 transition. (C) 2009 Elsevier B.V. All rights reserved.","[Janovska, Marika; Kubala, Martin] Palacky Univ, Biophys Lab, Fac Sci, Olomouc 77146, Czech Republic; [Grycova, Lenka; Lansky, Zdenek; Teisinger, Jan] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Sklenovsk, Petr; Otyepka, Michal] Palacky Univ, Dept Phys Chem, Fac Sci, Olomouc 77146, Czech Republic; [Amler, Evzen] Charles Univ Prague, Inst Biophys, Fac Med 2, Prague, Czech Republic","Kubala, M, Palacky Univ, Biophys Lab, Fac Sci, Tr Svobody 26, Olomouc 77146, Czech Republic","mkubala@prfnw.upol.cz","Czech Science Foundation [GACR 203/07/0564, GACR 522-08-H003, GACR 303/07/0915]; Czech Ministry of Schools, Youth and Sports [LC512, MSM 6198959215, MSM 6198959216]","This work was supported by the grants of the Czech Science Foundation GACR 203/07/0564, GACR 522-08-H003 and GACR 303/07/0915, and the research projects of Czech Ministry of Schools, Youth and Sports LC512, MSM 6198959215 and MSM 6198959216.",null,48,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0005-2736",null,"10.1016/j.bbamem.2009.02.004","BBA-BIOMEMBRANES","Biochim. Biophys. Acta-Biomembr.","MAY",2009,1788,5,null,null,null,1081,1091,null,null,11,"Biochemistry & Molecular Biology; Biophysics","447KS","ISI:000266190600019"]
[13,"J","Amant, F; Van Calsteren, K; Halaska, MJ; Beijnen, J; Lagae, L; Hanssens, M; Heyns, L; Lannoo, L; Ottevanger, NP; Bogaert, WV; Ungar, L; Vergote, I; du Bois, A",null,null,null,"Amant, Frederic; Van Calsteren, Kristel; Halaska, Michael J.; Beijnen, Jos; Lagae, Lieven; Hanssens, Myriam; Heyns, Liesbeth; Lannoo, Lore; Ottevanger, Nelleke P.; Bogaert, Walter Vanden; Ungar, Laszlo; Vergote, Ignace; du Bois, Andreas",null,"Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting","International Journal of Gynecological Cancer",null,"English","Review",null,null,null,null,null,"Cancer; Pregnancy; Gynecologic; Cervical; Ovarian; Chemotherapy; Vulvar; Neonatal; Offspring; Cognitive","OF-THE-LITERATURE; ENDODERMAL SINUS TUMOR; PELVIC LYMPH-NODES; CERVICAL INTRAEPITHELIAL NEOPLASIA; METASTATIC BREAST-CANCER; SQUAMOUS-CELL CARCINOMA; EPITHELIAL OVARIAN-CARCINOMA; CLINICAL-PRACTICE GUIDELINES; TERM-FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY","Background: Gynecologic cancer during pregnancy is a special challenge because cancer or its treatment may affect not only the pregnant women in general but directly involve the reproductive tract and fetus. Currently, there are no guidelines on how to deal with this special coincidence. Methods: An international consensus meeting on staging and treatment of gynecological malignancies during pregnancy was organised including a systematic literature search, and interpretation followed by a physical meeting of all participants with intensive discussion. In the absence of large trials and randomized studies, recommendations were based on available literature data and personal experience thus representing a low but best achievable level of evidence. Findings: Randomized trials and prospective Studies on cancer treatment during pregnancy are lacking. Gynecological cancer during pregnancy is a demanding problem, and multidisciplinary expertise should be available. Counseling both parents on the maternal prognosis and fetal risk is needed. When there is a firm desire to continue the pregnancy, gynecological cancer can be treated in selected cases. The staging and treatment should follow the standard approach as much as possible. Guidelines for safe pelvic surgery during pregnancy are presented. Mainly in cervical and ovarian cancer, chemotherapy and an alternative surgical approach need to be considered. Administration of chemotherapy during the second or third trimester may probably not increase the incidence of congenital malformations. Until now, the long-term Outcome of children in utero exposed to oncological treatment modalities is poorly documented, but preterm birth oil its own is associated with cognitive impairment. Delivery should be postponed preferably until after a gestational age of 35 weeks. Interpretation: Further research including international registries for gynecologic cancer in pregnancy is urgently needed. The gathering of both available literature and personal experience allowed only suggesting models for treatment of gynecologic cancer in pregnancy.","[Amant, Frederic] Katholieke Univ Leuven, Div Gynaecol Oncol, Dept Obstet & Gynaecol, UZ Gasthuisberg,Leuven Canc Inst LKI, B-3000 Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Div Oncogynaecol, Dept Obstet & Gynaecol, Fac Med 2, Prague, Czech Republic; [Beijnen, Jos] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands; [Ottevanger, Nelleke P.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands; [Ungar, Laszlo] Natl Canc Inst, Budapest, Hungary; [du Bois, Andreas] Dr Horst Schmidt Klin, Dept Gynaecol & Gynaecol Oncol, Wiesbaden, Germany","Amant, F, Katholieke Univ Leuven, Div Gynaecol Oncol, Dept Obstet & Gynaecol, UZ Gasthuisberg,Leuven Canc Inst LKI, Herestr 49, B-3000 Louvain, Belgium","Frederic.amant@uz.kuleuven.ac.be","UCB chair ","Frederic Amant is clinical researcher for Research Foundation-Flanders (F.WO.); Kristel Van Calsteren is aspirant for Research Foundation-flanders (F.W.O.). Lieven Lagae is holderofthe UCB chair in Cognitive dysfunctions in Childhood.",null,158,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,"10.1111/IGC.0b013e3181a1d0ec","INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","MAY",2009,19,null,null,"Suppl. 1",null,"S1","S12",null,null,12,"Oncology; Obstetrics & Gynecology","457ZG","ISI:000266976900001"]
[13,"J","Balascakova, M; Holubova, A; Skalicka, V; Zemkova, D; Kracmar, P; Gonsorcikova, L; Camajova, J; Piskackova, T; Lebl, J; Drevinek, P; Gregor, V; Vavrova, V; Votava, F; Macek, M",null,null,null,"Balascakova, Miroslava; Holubova, Andrea; Skalicka, Veronika; Zemkova, Dana; Kracmar, Petr; Gonsorcikova, Lucie; Camajova, Jana; Piskackova, Tereza; Lebl, Jan; Drevinek, Pavel; Gregor, Vladimir; Vavrova, Vera; Votava, Felix; Macek, Milan, Jr.",null,"Pilot newborn screening project for cystic fibrosis in the Czech Republic: Defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease","Journal of Cystic Fibrosis",null,"English","Article",null,null,null,null,null,"CF carriers; CFTR gene; Cystic fibrosis (OMIM 219700); Decentralisation of health care; DNA testing; Incidence; Immunoreactive trypsinogen; Newborn screening; Prenatal diagnosis",null,"The objective need for cystic fibrosis (CF) newborn screening (NBS) in the Czech Republic has recently been substantiated by a significant delay of its symptomatic diagnosis. This trend most likely resulted from the process of decentralisation of health care which led to the deterioration of care for patients who need specialised approaches. Applied newborn screening model (IRT/DNA/IRT) was efficacious enough to detect CF cases with median age at diagnosis of 37 days. The incidence of CF (I in 6946 live births) ascertained in this project was lower than that established previously by epidemiological studies (1 in 2700-1 in 3300). However, adjustment far broadly applied ultrasound-based prenatal diagnosis (PND) in the 2nd trimester of pregnancy, that was performed within the period of the project (1/2/2005-2/11/2006), rendered an incidence estimate of I in 4023. This value is closer to that observed in other CF NBS programmes and reflects influence of PND on the incidence of CF. (C) 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Balascakova, Miroslava; Holubova, Andrea; Camajova, Jana; Piskackova, Tereza; Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Cyst Fibrosis Ctr, Sch Med 2, CZ-15606 Prague 5, Czech Republic; [Balascakova, Miroslava; Holubova, Andrea; Skalicka, Veronika; Zemkova, Dana; Gonsorcikova, Lucie; Camajova, Jana; Piskackova, Tereza; Lebl, Jan; Drevinek, Pavel; Vavrova, Vera; Macek, Milan, Jr.] Charles Univ Prague, Fac Hosp Motol, CZ-15606 Prague, Czech Republic; [Skalicka, Veronika; Zemkova, Dana; Gonsorcikova, Lucie; Lebl, Jan; Drevinek, Pavel; Vavrova, Vera] Charles Univ Prague, Dept Paediat, Cyst Fibrosis Ctr, Sch Med 2, CZ-15606 Prague 5, Czech Republic; [Gregor, Vladimir] Charles Univ Prague, Dept Med Genet, Fac Thomayer Hosp, CZ-15606 Prague 5, Czech Republic; [Kracmar, Petr; Votava, Felix] Charles Univ Prague, Dept Paediat, Med Sch 3, CZ-15606 Prague 5, Czech Republic; [Kracmar, Petr; Votava, Felix] Charles Univ Prague, Fac Hosp Kralovske Vinohrady, CZ-15606 Prague 5, Czech Republic","Macek, M, Charles Univ Prague, Dept Biol & Med Genet, Cyst Fibrosis Ctr, Sch Med 2, V Uvalu 84, CZ-15606 Prague 5, Czech Republic","Milan.Macek.Jr@LFmotol.cuni.cz","IGA Czech Ministry of Health [MSM0021620814, VZFNMOO064203]","Supported by IGA Czech Ministry of Health 9986-3, MSM0021620814 and VZFNMOO064203.",null,20,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,"10.1016/j.jcf.2009.01.002","J CYST FIBROS","J. Cyst. Fibros","MAY",2009,8,3,null,null,null,224,227,null,null,4,"Respiratory System","451HQ","ISI:000266461700010"]
[13,"J","Laczo, J; Vlcek, K; Vyhnalek, M; Vajnerova, O; Ort, M; Holmerova, I; Tolar, M; Andel, R; Bojar, M; Hort, J",null,null,null,"Laczo, Jan; Vlcek, Kamil; Vyhnalek, Martin; Vajnerova, Olga; Ort, Michael; Holmerova, Iva; Tolar, Martin; Andel, Ross; Bojar, Martin; Hort, Jakub",null,"Spatial navigation testing discriminates two types of amnestic mild cognitive impairment","Behavioural Brain Research",null,"English","Article",null,null,null,null,null,"Morris Water Maze; Spatial navigation; Humans; Hippocampus; Memory; Frontal lobe; Mild cognitive impairment; Alzheimer's disease","ALZHEIMERS-DISEASE; TOPOGRAPHICAL DISORIENTATION; HIPPOCAMPAL-LESIONS; PREFRONTAL CORTEX; EXPLICIT MEMORY; HUMANS; DEMENTIA; DEFICITS; TASK; RATS","The hippocampus is essential for consolidation of declarative information and spatial navigation. Alzheimer's disease (AD) diagnosis tends to be preceded by a long prodromal period and mild cognitive impairment (MCI). Our goal was to test whether amnestic MCI comprises two different subgroups, with hippocampal and non-hippocampal memory impairment, that vary with respect to spatial navigation ability. A total of 52 patients were classified into two subgroups: non-amnestic MCI (naMCI) (n = 10) and amnestic MCI (aMCI) (n = 42). The aMCI subgroup was further stratified into memory impairment of hippocampal type-hippocampal aMCI (HaMCI) (n = 10) (potential preclinical AD) and isolated retrieval impairment-non-hippocampal (NHaMCI) (n = 32). Results were compared to control (n = 28) and AD (n = 21) groups. We used the Hidden Goal Task, a human analogue of the Morris Water Maze, to examine spatial navigation either dependent (egocentric) or independent of individual's position (allocentric). Overall, the HaMCI group performed poorer on spatial navigation than the NHaMCI group, especially in the latter trials when the HaMCI group exhibited limited capacity to learn and the NHaMCI group exhibited a learning effect. Finally, the HaMCI group performed almost identically as the AD group. Spatial navigation deficit is particularly pronounced in individuals with hippocampus-related memory impairment and may signal preclinical AD. (C) 2009 Elsevier B.V. All rights reserved.","[Laczo, Jan; Vyhnalek, Martin; Ort, Michael; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, Prague 15006 5, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory & Computat Neurosci, Prague, Czech Republic; [Vajnerova, Olga] Charles Univ Prague, Inst Physiol, Sch Med 2, Prague 15006 5, Czech Republic; [Ort, Michael] Charles Univ Prague, Dept Psychiat, Sch Med 1, Prague 15006 5, Czech Republic; [Holmerova, Iva] Ctr Gerontol, Prague, Czech Republic; [Tolar, Martin] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Andel, Ross] Univ S Florida, Florida Alzheimers Dis Res Ctr, Tampa, FL USA","Laczo, J, Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","JanLaczo@seznam.cz","Czech Republic [309/09/1053, 309/09/0286]; Ministry of Education Youth and Sports of the Czech Republic [IM0517, LC554, AVOZ50110509]","Supported by the Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286, Ministry of Education Youth and Sports of the Czech Republic Grants IM0517 and LC554, and research project AVOZ50110509.",null,57,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0166-4328",null,"10.1016/j.bbr.2009.03.041","BEHAV BRAIN RES","Behav. Brain Res.","SEP 14",2009,202,2,null,null,null,252,259,null,null,8,"Behavioral Sciences; Neurosciences","458HK","ISI:000267006300015"]
[13,"J","Pytlik, R; Stehlik, D; Soukup, T; Kalbacova, M; Rypacek, F; Trc, T; Mulinkova, K; Michnova, P; Kideryova, L; Zivny, J; Klener, P; Vesela, R; Trneny, M; Klener, P",null,null,null,"Pytlik, Robert; Stehlik, David; Soukup, Tomas; Kalbacova, Marie; Rypacek, Frantisek; Trc, Tomas; Mulinkova, Katarina; Michnova, Petra; Kideryova, Linda; Zivny, Jan; Klener, Pavel, Jr.; Vesela, Romana; Trneny, Marek; Klener, Pavel",null,"The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering","Biomaterials",null,"English","Article",null,null,null,null,null,"Tissue engineering; Multipotent mesenchymal stromal cells; Human serum; Expansion; Differentiation; Orthopedic surgery","MARROW-DERIVED STEM; FETAL CALF SERUM; IN-VITRO; PROGENITOR CELLS; SCALE EXPANSION; DIFFERENTIATION; CULTURE; GROWTH; TRANSPLANTATION; PROLIFERATION","Clinical application of human multipotent mesenchymal stromal cells (hMSCs) requires their expansion to be safe and rapid. We aimed to develop an expansion protocol which would avoid xenogeneic proteins, including fetal calf serum (FCS), and which would shorten the cultivation time and avoid multiple passaging. First, we have compared research-grade alpha-MEM medium with clinical grade CellGro (TM) for Hematopoietic Cells' Medium. When FCS was used for supplementation and non-adherent cells were discarded, both media were comparable. Both media were comparable also when pooled human serum (hS) was used instead of FCS, but the numbers of hMSCs were lower when non-adherent cells were discarded. However, significantly more hMSCs were obtained both in alpha-MEM and in CellGro (TM) supplemented with hS when the non-adherent cells were left in the culture. Furthermore, addition of recombinant cytokines and other supplements (EGF, PDGF-BB, M-CSF, FGF-2, dexamethasone, insulin and ascorbic acid) to the CellGro (TM) Co-culture system with hS led to 40-fold increase of hMSCs' yield after two weeks of cultivation compared to alpha-MEM with FCS. The hMSCs expanded in the described co-culture system retain their osteogenic, adipogenic and chondrogenic differentiation potential in vitro and produce bone-like mineralized tissue when propagated on 3D polylactide scaffolds in immunodeficient mice. Our protocol thus allows for very effective one-step, xenogeneic protein-free expansion of hMSCs, which can be easily transferred into good manufacturing practice (GMP) conditions for large-scale, clinical-grade production of hMSCs for purposes of tissue engineering. (c) 2009 Elsevier Ltd. All rights reserved.","[Pytlik, Robert; Michnova, Petra; Kideryova, Linda; Klener, Pavel, Jr.; Vesela, Romana; Trneny, Marek; Klener, Pavel] Charles Univ Prague, Fac Med 1, Dept Med 1, Prague 12808 2, Czech Republic; [Stehlik, David; Trc, Tomas] Charles Univ Prague, Fac Med 2, Dept Children & Adult Orthoped Surg, Prague 12808 2, Czech Republic; [Soukup, Tomas] Charles Univ Prague, Fac Med, Inst Histol & Embryol, Hradec Kralove, Czech Republic; [Kalbacova, Marie] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 12808 2, Czech Republic; [Rypacek, Frantisek; Mulinkova, Katarina] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Zivny, Jan; Klener, Pavel, Jr.] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague 12808 2, Czech Republic","Pytlik, R, Charles Univ Prague, Fac Med 1, Dept Med 1, U Nemocnice 2, Prague 12808 2, Czech Republic","pytlikr@seznam.cz",null,null,null,54,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0142-9612",null,"10.1016/j.biomaterials.2009.03.001","BIOMATERIALS","Biomaterials","JUL",2009,30,20,null,null,null,3415,3427,null,null,13,"Engineering, Biomedical; Materials Science, Biomaterials","455FR","ISI:000266744100007"]
[13,"J","Kotalova, R; Jirsa, M; Vavrova, V; Vrabelova-Pouchla, S; Macek, M",null,null,null,"Kotalova, Radana; Jirsa, Milan; Vavrova, Vera; Vrabelova-Pouchla, Slavka; Macek, Milan, Jr.",null,"Wilson disease as a cause of liver injury in cystic fibrosis","Journal of Cystic Fibrosis",null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Wilson disease; Liver disease; Cholestasis; Jaundice","DIAGNOSIS; ATP7B; GENE","Cystic fibrosis-related liver disease affects approximately one third of all patients with cystic fibrosis. Initial signs of other liver diseases including the genetically determined disorders of the liver co-inherited with cystic fibrosis may be obscured by or ascribed to cystic fibrosis-related liver disease. We report a patient shown to suffer simultaneously from cystic fibrosis and hepatic Wilson disease. Our case documents that in patients with cystic fibrosis presenting with liver disease, when unusual clinical and/or laboratory abnormalities appear and fail to respond to standard therapy, a second disease, including rare inherited metabolic disorders such as the hepatic form of Wilson disease or alpha(1)-antitrypsin deficiency, should be suspected. (c) 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Kotalova, Radana] Charles Univ Prague, Sch Med 2, Dept Pediat, Prague 15006 5, Czech Republic; [Kotalova, Radana; Macek, Milan, Jr.] Fac Hosp Motol, Prague 15006 5, Czech Republic; [Macek, Milan, Jr.] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Jirsa, Milan] Inst Clin & Expt Med, Prague, Czech Republic; [Vavrova, Vera; Vrabelova-Pouchla, Slavka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic","Kotalova, R, Charles Univ Prague, Sch Med 2, Dept Pediat, V Uvalu 84, Prague 15006 5, Czech Republic","radana.kotalova@scznam.cz","Institute of Clinical and Experimental Medicine [MZO:00023001]; Ministry of Health of the Czech Republic [VZ FNM 00064203(6112), IGA 9488-3]","We thank A. S. Knisely, M.D., King's College Hospital, London, UK, for comments. MJ was supported by the Institute of Clinical and Experimental Medicine, MZO:00023001, MM was supported by VZ FNM 00064203(6112) and IGA 9488-3 from the Ministry of Health of the Czech Republic.",null,8,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,"10.1016/j.jcf.2008.09.003","J CYST FIBROS","J. Cyst. Fibros","JAN",2009,8,1,null,null,null,63,65,null,null,3,"Respiratory System","395WI","ISI:000262553800012"]
[14,"J","Salek, C; Minarikova, P; Benesova, L; Nosek, V; Strnad, R; Zavoral, M; Minarik, M",null,null,null,"Salek, Cyril; Minarikova, Petra; Benesova, Lucie; Nosek, Vladimir; Strnad, Robin; Zavoral, Miroslav; Minarik, Marek",null,"Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer","Anticancer Research",null,"English","Article",null,null,null,null,null,"Pancreatic cancer; K-ras; p53; p16; DPC4; prognostic markers","DUCTAL ADENOCARCINOMA; CLINICOPATHOLOGICAL PARAMETERS; EPIGENETIC ALTERATIONS; CLINICAL-RELEVANCE; TUMOR-MARKER; EXPRESSION; CARCINOMA; DIAGNOSIS; SURVIVAL; CHEMOTHERAPY","Background: K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned. Patients and Methods: Fifty three consecutive patients with advanced pancreatic cancer (stage III and IV) who underwent EUS-guided fine needle aspiration (FNA) were enrolled into the study (28 males, 25 females, 63+/-10.5 years). Samples were evaluated on-site for presence of malignant cells. DNA was extracted from Giemsa stained smears using laser microdissection, and mutation status of K-ras and p53 was tested by cycling-gradient capillary electrophoresis (CGCE). In addition, allelic losses of tumor suppressor genes p16 (INK4, CDKN2A) and DPC4 (MADH4, SMAD4) were detected by monitoring the loss of heterozygosity (LOH) at 9p and 18q loci. Molecular data were compared with survival statistics using Kaplan-Meier method. Results: The median survival in K-ras positive group was 7.0 +/- 2.4 months (95% CI 2.3-11.7) and in K-ras negative group was 10.0 +/- 0.6 months (95% CI 8.7-11.3). The median survival in p53 positive group was 10.0+/-2.2 months (95% CI 5.6-14.4) and in p53 negative group was 6.0+/-2.5 months (95% CI 1.1-10.9). The median survival in LOH 9p positive group was 9.0+/-5.1 months (95% CI 0-18.9), in LOH 9p negatives was 10.0+/-5.0 months (95% CI 0.2-19.8). The median survival in LOH 18q positive group was 10.0+/-4.2 months (95% CI 1.8-18.2) and in LOH 18q negative group was 3.0+/-1.3 months (95% CI 0.5-5.5). After the adjustment for age using Cox proportional hazards model, none of the evaluated molecular markers was shown to be an independent prognostic marker for survival of patients with pancreatic cancer. Conclusion: None of the studied molecular markers was identified as an independent factor determining survival prognosis.","[Salek, Cyril; Benesova, Lucie; Minarik, Marek] Genomac Int Ltd, Lab Mol Genet & Oncol, Prague 15541 5, Czech Republic; [Salek, Cyril; Minarikova, Petra; Nosek, Vladimir; Zavoral, Miroslav] Cent Mil Hosp, Clin Internal Med, Dept Gastroenterol, Prague, Czech Republic; [Salek, Cyril; Minarikova, Petra; Nosek, Vladimir; Zavoral, Miroslav] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Strnad, Robin] Cent Mil Hosp, Dept Surg, Prague, Czech Republic; [Strnad, Robin] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Minarik, M, Genomac Int Ltd, Lab Mol Genet & Oncol, Bavorska 856, Prague 15541 5, Czech Republic","mminarik@email.com","Czech Ministry of Industry and Trade research [FI-IM3/215]","The authors thank Jelena Skibova and Dr. Katerina Benesova for their substantial help with statistical analysis. This project was supported by the Czech Ministry of Industry and Trade research grant no. FI-IM3/215.",null,43,0,"INT INST ANTICANCER RESEARCH","ATHENS","EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE","0250-7005",null,null,"ANTICANCER RES","Anticancer Res.","MAY",2009,29,5,null,null,null,1803,1810,null,null,8,"Oncology","462WR","ISI:000267389300078"]
[14,"J","Blaha, M; Schwab, J; Vajnerova, O; Bednar, M; Padr, R; Bittner, P; Tichy, M",null,null,null,"Blaha, M.; Schwab, J.; Vajnerova, O.; Bednar, M.; Padr, R.; Bittner, P.; Tichy, M.",null,"Model of Closed Head Injury in Rats - Experimental Study","Česká a slovenská neurologie a neurochirurgie",null,"Czech","Article",null,null,null,null,null,"brain injury; intracranial pressure; animal models","INTRACRANIAL-PRESSURE","Objective: The objective of this study is to create a reproducible model of closed head injury in rats using the acceleration-deceleration mechanism, The model should result in increased intracranial pressure (ICP) and neurological deterioration animals, and generate graded brain injury. Material and method: In order to provoke cranial traumas we constructed an impactor with selectable weights and a mobile impact surface, Within the first pilot group of 40 rats, we tested only its basic setup. Afterwards, within the second group of 21 rats, we provoked an experimental cranial trauma using a weight of 400 grams dropped from a height ranging from 30 to 100 centimetres at a constant surface elasticity. Within the third control group of 15 rats, we measured physiological parameters including ICP. Results: According to the height of fall, four types of brain injuries were established - lethal, severe, moderate, and mild. With the lethal injury (45-100 cm), an immediate convulsions with subsequent death occurred in all the rats. A severe injury (40 cm) showed 50% mortality. Neurological deterioration and an average ICP of 9.3 +/- 3.76 mmHg was recorded in the surviving animals. A moderate brain injury (35 cm) resulted in lower mortality, the neurological deficit occurred in half of the survivors and ICP achieved 7.6 +/- 3.54 mmHg. Within the group of mild brain injury (30 cm), all animals survived without any neurological and behavioral deterioration with an ICP of 5.5 +/- 0.74 mmHg. The control group without any injury had an ICP of 2.9 +/- 0.81 mmHg. Conclusion: The described model of closed head injury in rats using a modified impactor with adjustable weights is suitable for both single-stage and two-stage experiments examining craniocerebral injuries. By simply changing the fall height of the impactor, reproducible severe, moderate, or mild brain injury can be created. The intracranial pressure elevation and the neurological deterioration correlate with these grades of brain injury.","[Blaha, M.; Schwab, J.; Tichy, M.] FN Motol, Neurochirurg Oddeleni, Prague 15006 5, Czech Republic; [Blaha, M.; Schwab, J.; Vajnerova, O.; Bittner, P.; Tichy, M.] LF UK, Ustav Fyziol, Prague, Czech Republic; [Bednar, M.] CLINICUM, Anesteziol Resuscitacni Oddeleni, Prague, Czech Republic; [Padr, R.] FN Motol, Klin Zobrazovacich Metod, Prague 15006 5, Czech Republic; [Padr, R.] 2 LF UK, Prague, Czech Republic","Blaha, M, FN Motol, Neurochirurg Oddeleni, V Uvalu 84, Prague 15006 5, Czech Republic","drmartinblaha@yahoo.com",null,null,null,18,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,3,null,null,null,235,241,null,null,7,"Neurosciences; Surgery","459JD","ISI:000267097100005"]
[14,"J","Hromadnikova, I; Benesova, M; Zejskova, L; Stehnova, J; Doucha, J; Sedlacek, P; Dlouha, K; Krofta, L",null,null,null,"Hromadnikova, Ilona; Benesova, Martina; Zejskova, Lenka; Stehnova, Jana; Doucha, Jindrich; Sedlacek, Petr; Dlouha, Klara; Krofta, Ladislav",null,"The Effect of DYS-14 Copy Number Variations on Extracellular Fetal DNA Quantification in Maternal Circulation","Dna and Cell Biology",null,"English","Article",null,null,null,null,null,null,"CONGENITAL ADRENAL-HYPERPLASIA; QUANTITATIVE PCR MEASUREMENT; TESTIS-SPECIFIC PROTEIN; REAL-TIME PCR; SEX DETERMINATION; GENDER DETERMINATION; PRENATAL-DIAGNOSIS; GROWTH RESTRICTION; PLASMA; SERUM","The aims of our research involved to investigate DYS-14 copy number variations in healthy males, to quantify extracellular DNA in maternal circulation in normal versus complicated pregnancies, and to study variations in the DYS-14 copy number in extracellular male fetal DNA. Fifty-five healthy males, 43 uncomplicated male singleton pregnancies (23 sampled at the 16th week and 20 sampled at the 36th week), and 15 pregnancies with placental insufficiency (PI)-related complications (mean 34.1 weeks) were analyzed using real-time PCR with DYS-14 sequence, sex determining region Y (SRY), and beta-globin (GLO) genes used as markers. Increased levels of extracellular DNA were detected in PI-related complications relative to gestational age-matched controls (SRY, p<0.001; DYS-14, p=0.007; GLO, p<0.001). When the mean +2SD (standard deviation) of controls was used as a cutoff, SRY, DYS-14, and GLO achieved 91.7%, 68.8%, and 94.4% accuracy, respectively, for differentiation between normal and complicated pregnancies. Considerable variations in the DYS-14 copy number in healthy males (mean 52.6) and extracellular DNA were found. A lower DYS-14 copy number was observed in PI-related complications (mean 83.5) compared to uncomplicated pregnancies (16th week: mean 114.2, p=0.02; 36th week: mean 142.8, p=0.04). The DYS-14 copy number was higher in extracellular DNA throughout gestation relative to healthy males. We concluded that, regarding interindividual copy number variations, the DYS-14 sequence is not an optimal marker for extracellular fetal DNA quantification for differentiation between normal and complicated pregnancies.","[Hromadnikova, Ilona; Benesova, Martina; Zejskova, Lenka; Stehnova, Jana] Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Prague 10000 10, Czech Republic; [Doucha, Jindrich] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Clin Obstet & Gynecol, Prague 10000 10, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 10000 10, Czech Republic; [Dlouha, Klara; Krofta, Ladislav] Inst Care Mother & Child, Prague, Czech Republic","Hromadnikova, I, Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Ruska 87, Prague 10000 10, Czech Republic","ilona.hromadnikova@lf3.cuni.cz","MSM [0021620806]; SAFE [LSHB-CT-2004-503243]","We thank the staff of the Clinic of Obstetrics and Gynaecology and the Department of Paediatric Haematology and Oncology, University Hospital Motol, and the Institute for the Care of the Mother and Child for their participation in the collection of data used for this analysis. This work was supported by grant projects MSM 0021620806 and SAFE LSHB-CT-2004-503243.",null,31,0,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1044-5498",null,"10.1089/dna.2009.0855","DNA CELL BIOL","DNA Cell Biol.","JUL",2009,28,7,null,null,null,351,358,null,null,8,"Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity","461RA","ISI:000267285500007"]
[14,"J","Lu, TT; Lao, O; Nothnagel, M; Junge, O; Freitag-Wolf, S; Caliebe, A; Balascakova, M; Bertranpetit, J; Bindoff, LA; Comas, D; Holmlund, G; Kouvatsi, A; Macek, M; Mollet, I; Nielsen, F; Parson, W; Palo, J; Ploski, R; Sajantila, A; Tagliabracci, A; Gether, U; Werge, T; Rivadeneira, F; Hofman, A; Uitterlinden, AG; Gieger, C; Wichmann, HE; Ruether, A; Schreiber, S; Becker, C; Nurnberg, P; Nelson, MR; Kayser, M; Krawczak, M",null,null,null,"Lu, Timothy Tehua; Lao, Oscar; Nothnagel, Michael; Junge, Olaf; Freitag-Wolf, Sandra; Caliebe, Amke; Balascakova, Miroslava; Bertranpetit, Jaume; Bindoff, Laurence Albert; Comas, David; Holmlund, Gunilla; Kouvatsi, Anastasia; Macek, Milan; Mollet, Isabelle; Nielsen, Finn; Parson, Walther; Palo, Jukka; Ploski, Rafal; Sajantila, Antti; Tagliabracci, Adriano; Gether, Ulrik; Werge, Thomas; Rivadeneira, Fernando; Hofman, Albert; Uitterlinden, Andre Gerardus; Gieger, Christian; Wichmann, Heinz-Erich; Ruether, Andreas; Schreiber, Stefan; Becker, Christian; Nuernberg, Peter; Nelson, Matthew Roberts; Kayser, Manfred; Krawczak, Michael",null,"An evaluation of the genetic-matched pair study design using genome-wide SNP data from the European population","European Journal of Human Genetics",null,"English","Article",null,null,null,null,null,"population structure; matching; association; ancestry; microarray","DISEASE ASSOCIATION; GENOTYPE DATA","Genetic matching potentially provides a means to alleviate the effects of incomplete Mendelian randomization in population-based gene-disease association studies. We therefore evaluated the genetic-matched pair study design on the basis of genome-wide SNP data (309 790 markers; Affymetrix GeneChip Human Mapping 500K Array) from 2457 individuals, sampled at 23 different recruitment sites across Europe. Using pair-wise identity-by-state (IBS) as a matching criterion, we tried to derive a subset of markers that would allow identification of the best overall matching (BOM) partner for a given individual, based on the IBS status for the subset alone. However, our results suggest that, by following this approach, the prediction accuracy is only notably improved by the first 20 markers selected, and increases proportionally to the marker number thereafter. Furthermore, in a considerable proportion of cases (76.0%), the BOM of a given individual, based on the complete marker set, came from a different recruitment site than the individual itself. A second marker set, specifically selected for ancestry sensitivity using singular value decomposition, performed even more poorly and was no more capable of predicting the BOM than randomly chosen subsets. This leads us to conclude that, at least in Europe, the utility of the genetic-matched pair study design depends critically on the availability of comprehensive genotype information for both cases and controls. European Journal of Human Genetics (2009) 17, 967-975; doi:10.1038/ejhg.2008.266; published online 21 January 2009","[Lu, Timothy Tehua; Nothnagel, Michael; Junge, Olaf; Freitag-Wolf, Sandra; Caliebe, Amke; Krawczak, Michael] Univ Kiel, Inst Med Informat & Stat, D-24105 Kiel, Germany; [Lao, Oscar; Kayser, Manfred] Erasmus Univ, Med Ctr Rotterdam, Dept Forens Mol Biol, Rotterdam, Netherlands; [Balascakova, Miroslava; Macek, Milan] Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Balascakova, Miroslava; Macek, Milan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Bertranpetit, Jaume; Comas, David] Univ Pompeu Fabra, CEXS UPF PRBB, CSIC, Inst Evolutionary Biol, Barcelona, Spain; [Bindoff, Laurence Albert] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway; [Bindoff, Laurence Albert] Univ Bergen, Dept Clin Med, Bergen, Norway; [Holmlund, Gunilla] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Linkoping, Sweden; [Kouvatsi, Anastasia] Aristotle Univ Thessaloniki, Dept Genet Dev & Mol Biol, GR-54006 Thessaloniki, Greece; [Mollet, Isabelle] EFS RA Site Lyon, Lab Empreintes Genet, Lyon, France; [Nielsen, Finn] Univ Copenhagen, Dept Clin Biochem, Copenhagen, Denmark; [Nielsen, Finn] Univ Copenhagen, Ctr Pharmacogenom, Copenhagen, Denmark; [Parson, Walther] Med Univ Innsbruck, Inst Legal Med, Innsbruck, Austria; [Palo, Jukka; Sajantila, Antti] Univ Helsinki, Dept Forens Med, SF-00300 Helsinki, Finland; [Ploski, Rafal] Warsaw Med Univ, Dept Med Genet, Warsaw, Poland; [Tagliabracci, Adriano] Univ Ancona, Ist Med Legale, Ancona, Italy; [Gether, Ulrik] Univ Copenhagen, Dept Neurosci & Pharmacol, Mol Neuropharmacol Grp, Copenhagen, Denmark; [Gether, Ulrik] Univ Copenhagen, Dept Neurosci & Pharmacol, Ctr Pharmacogenom, Copenhagen, Denmark; [Werge, Thomas] Copenhagen Univ Hosp, Mental Hlth Ctr Sct Hans, Res Inst Biol Psychiat, Copenhagen, Denmark; [Werge, Thomas] Univ Copenhagen, Ctr Pharmacogenom, Copenhagen, Denmark; [Rivadeneira, Fernando; Uitterlinden, Andre Gerardus] Erasmus Univ, Med Ctr Rotterdam, Dept Internal Med, Genet Lab, Rotterdam, Netherlands; [Hofman, Albert; Uitterlinden, Andre Gerardus] Erasmus Univ, Med Ctr Rotterdam, Dept Epidemiol & Biostat, Rotterdam, Netherlands; [Gieger, Christian; Wichmann, Heinz-Erich] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Wichmann, Heinz-Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Ruether, Andreas; Schreiber, Stefan] Univ Kiel, Inst Med Mol Biol, Kiel, Germany; [Becker, Christian; Nuernberg, Peter] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Becker, Christian; Nuernberg, Peter] Univ Cologne, Inst Genet, Cologne, Germany; [Nelson, Matthew Roberts] GlaxoSmithKline Inc, Genet, Res Triangle Pk, NC USA","Krawczak, M, Univ Kiel, Inst Med Informat & Stat, Haus 31,Arnold Heller Str 3, D-24105 Kiel, Germany","krawczak@medinfo.uni-kiel.de","Netherlands Forensic Institute ; Affymetrix ; German National Genome Research Network ; German Federal Ministry of Education and Research ; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg ; Munich Center of Health Sciences ; Netherlands Organization for Scientific Research [NWO 175.010.2005.011]; European Commission [201865, QLG2-CT-2001-00916]; Czech Ministry of Health [00064203, NS/9488-3]; Helse-Vest, Regional Health Authority Norway ; Swedish National Board of Forensic Medicine [99:22, 02:20]; Academy of Finland [80578, 109265, 111713]","All sample donors are gratefully acknowledged for their participation. We thank the following colleagues for their help and support: J Kooner and J Chambers of the LOLIPOP study and D Waterworth, V Mooser, G Waeber and P Vollenweider of the CoLaus study for providing access to their collections through the GlaxoSmithKline-sponsored Population Reference Sample (POPRES) project; K King for preparing the POPRES data; M Simoons, E Sijbrands, A van Belkum, J Laven, J Lindemans, E Knipers and B Stricker for their financial contribution to the Rotterdam study; P Arp, M Jhamai, W van IJken and R van Schaik for generating the Rotterdam study dataset; T Meitinger, P Lichtner, G Eckstein and all genotyping staff at the Helmholtz Zentrum Munchen for generating the KORA study dataset; H von Eller-Eberstein for providing access to the PopGen data; R Borup, C Schjerling, H Ullum, E Haastrup and numerous colleagues at the Copenhagen University Hospital Blood Bank for making the Danish data available; and S Brauer for DNA sample management. We also wish to thank Affymetrix for making the GeneChip Human Mapping 500K Array genotypes of the CEPH-CEU trios publicly available, and the Centre d'Etude du Polymorphisme Humain (CEPH) for the original sample collection. This work was supported by the Netherlands Forensic Institute (M Ka), Affymetrix (M Ka and M Kr), the German National Genome Research Network and the German Federal Ministry of Education and Research (H-EW, SS, M Kr and PN); the Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg and the Munich Center of Health Sciences as part of LMUinnovativ (H-EW), the Netherlands Organization for Scientific Research (AGU: NWO 175.010.2005.011), the European Commission (AGU: GEFOS; 201865, AS: LD Europe; QLG2-CT-2001-00916); the Czech Ministry of Health (MM: VZFNM 00064203 and IGA NS/9488-3), Helse-Vest, Regional Health Authority Norway (LAB), the Swedish National Board of Forensic Medicine (GH: RMVFoU 99:22, 02:20) and the Academy of Finland (AS: 80578, OMLL, JP: 109265 and 111713). None of the funding organization had any influence on the design, conduct or conclusions of the study.",null,29,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,"10.1038/ejhg.2008.266","EUR J HUMAN GENET","Eur. J. Hum. Genet.","JUL",2009,17,7,null,null,null,967,975,null,null,9,"Biochemistry & Molecular Biology; Genetics & Heredity","459VZ","ISI:000267141600017"]
[14,"J","Janousek, J; Gebauer, RA; Abdul-Khaliq, H; Turner, M; Kornyei, L; Grollmuss, O; Rosenthal, E; Villain, E; Fruh, A; Paul, T; Blom, NA; Happonen, JM; Bauersfeld, U; Jacobsen, JR; van den Heuvel, F; Delhaas, T; Papagiannis, J; Trigo, C",null,null,null,"Janousek, J.; Gebauer, R. A.; Abdul-Khaliq, H.; Turner, M.; Kornyei, L.; Grollmuss, O.; Rosenthal, E.; Villain, E.; Frueh, A.; Paul, T.; Blom, N. A.; Happonen, J-M; Bauersfeld, U.; Jacobsen, J. R.; van den Heuvel, F.; Delhaas, T.; Papagiannis, J.; Trigo, C.","Assoc European Paediat Cardiology","Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates","Heart",null,"English","Article",null,null,null,null,null,null,"RESYNCHRONIZATION THERAPY; DILATED CARDIOMYOPATHY; VENTRICULAR DYSFUNCTION; ATRIOVENTRICULAR-BLOCK; YOUNG-PATIENTS; FAILURE; ATRIAL; TRANSPOSITION; REGURGITATION; PACEMAKER","Background: Cardiac resynchronisation therapy (CRT) is increasingly used in children in a variety of anatomical and pathophysiological conditions, but published data are scarce. Objective: To record current practice and results of CRT in paediatric and congenital heart disease. Design: Retrospective multicentre European survey. Setting: Paediatric cardiology and cardiac surgery centres. Patients: One hundred and nine patients aged 0.24-73.8 (median 16.9) years with structural congenital heart disease (n=87), congenital atrioventricular block (n=12) and dilated cardiomyopathy (n=10) with systemic left (n=69), right (n=36) or single (n=4) ventricular dysfunction and ventricular dyssynchrony during sinus rhythm (n=25) or associated with pacing (n=84). Interventions: CRT for a median period of 7.5 months (concurrent cardiac surgery in 16/109). Main outcome measures: Functional improvement and echocardiographic change in systemic ventricular function. Results: The z score of the systemic ventricular end-diastolic dimension decreased by median 1.1 (p < 0.001). Ejection fraction (EF) or fractional area of change increased by a mean (SD) of 11.5 (14.3)% (p < 0.001) and New York Heart Association (NYHA) class improved by median 1.0 grade (p < 0.001). Non-response to CRT (18.5%) was multivariably predicted by the presence of primary dilated cardiomyopathy (p=0.002) and poor NYHA class (p=0.003). Presence of a systemic left ventricle was the strongest multivariable predictor of improvement in EF/fractional area of change (p < 0.001). Results were independent of the number of patients treated in each contributing centre. Conclusion: Heart failure associated with ventricular pacing is the largest indication for CRT in paediatric and congenital heart disease. CRT efficacy varies widely with the underlying anatomical and pathophysiological substrate.","[Janousek, J.; Grollmuss, O.] Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany; [Gebauer, R. A.] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Gebauer, R. A.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Abdul-Khaliq, H.] German Heart Ctr Berlin, Berlin, Germany; [Turner, M.] Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England; [Turner, M.] Univ Bristol, Bristol, Avon, England; [Kornyei, L.] Hungarian Paediat Heart Ctr, Budapest, Hungary; [Rosenthal, E.] Guys & St Thomas Trust, Evelina Childrens Hosp, London, England; [Villain, E.] Hop Necker Enfants Malad, Dept Pediat Cardiol, Paris, France; [Frueh, A.] Univ Oslo, Rikshosp, Univ Hosp, Paediat Care Unit, N-0027 Oslo, Norway; [Paul, T.] Univ Hosp, Dept Paediat Cardiol & Intens Care, Gottingen, Germany; [Blom, N. A.] Leiden Univ, Dept Paediat Cardiol, Med Ctr, Leiden, Netherlands; [Happonen, J-M] Univ Helsinki, Cent Hosp, Dept Paediat, Div Paediat Cardiol, Helsinki, Finland; [Bauersfeld, U.] Univ Childrens Hosp Zurich, Div Paediat Cardiol, Zurich, Switzerland; [Jacobsen, J. R.] Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark; [van den Heuvel, F.] Univ Med Ctr Groningen, Div Paediat Cardiol, Beatrix Childrens Hosp, Groningen, Netherlands; [Delhaas, T.] AZ Maastricht, Div Paediat Cardiol, Maastricht, Netherlands; [Papagiannis, J.] Onassis Cardiac Surg Ctr, Dept Paediat Cardiol, Athens, Greece; [Trigo, C.] Hosp Santa Maria, Serv Cardiol Pediat, Lisbon, Portugal","Janousek, J, Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany","jan.janousek@medizin.uni-leipzig.de","Ministry of Health, Czech Republic [NR/9472- 3]; University Hospital Motol, Prague, Czech Republic [64203]","Ministry of Health, Czech Republic (grant NR/9472- 3 to RAG) and University Hospital Motol, Prague, Czech Republic (research project No 64203 to RAG).",null,23,0,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,"10.1136/hrt.2008.160465","HEART","Heart","JUL 15",2009,95,14,null,null,null,1165,1171,null,null,7,"Cardiac & Cardiovascular Systems","463OQ","ISI:000267441900008"]
[14,"J","Robova, H; Charvat, M; Strnad, P; Hrehorcak, M; Taborska, K; Skapa, P; Rob, L",null,null,null,"Robova, Helena; Charvat, Martin; Strnad, Pavel; Hrehorcak, Martin; Taborska, Katerina; Skapa, Petr; Rob, Lukas",null,"Lymphatic Mapping in Endometrial Cancer Comparison of Hysteroscopic and Subserosal Injection and the Distribution of Sentinel Lymph Nodes","International Journal of Gynecological Cancer",null,"English","Article",null,null,null,null,null,"Endometrial cancer; Sentinel lymph node; Hysteroscopy; Subserosal injection","SENTINEL NODE BIOPSY; WOMEN; LYMPHADENECTOMY; BLUE","Introduction: Endometrial cancer incidence increases over the age of 65 and lymphadenectomy in these women is a morbid procedure. Sentinel lymph node (SLN) should avoid extensive lymphadenectomy in node negative patients. The aim of this prospective study is to determine the feasibility and usefulness of lymphatic mapping and SLN identification in the management of endometrial cancer. Methods: From January 2004 to December 2007 101 women with endometrial cancer participated in the study. We injected Tc-99 hysteroscopically, peritumorally 2 hours before laparotomy in 24 women. We applied Tc-99 and blue dye subserously after laparotomy and before adhesiolysis in 67 women. Ten patients with metastatic disease in ovary, omentum, peritoneum, and bulky nodes were excluded from analysis. Results: We detected SLN in 12 women (50%) in hysteroscopic group and ill 49 women (73.1%) in subserous group. We identified 133 SLNs in 61 women. We found 20 SLNs (15.0%) in supraobturator region, 78 (58.6%) in external iliac area, 11 (8.3%) in paraaortal area, 13 (9.8%) on common iliac artery, 8 (6.0%) in medial part of lateral parametrium, and 3 (2.3%) in presacral area. Conclusions: Sentinel lymph node identification is a new strategy that can be used to examine nodal status with a high successful rate in breast, cervical, and vulvar cancer. Results in endometrial cancer are not as successful, however. In the future, it will be necessary to find optimal timing, the best route of application, and the \"right\" size of the Tc-99m particles. Subserous application seems to be superior to hysteroscopic application.","[Robova, Helena; Charvat, Martin; Strnad, Pavel; Hrehorcak, Martin; Rob, Lukas] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Div Gynaecol Oncol, Prague, Czech Republic; [Taborska, Katerina] Charles Univ Prague, Fac Med 2, Dept Endocrinol, Prague, Czech Republic; [Taborska, Katerina] Charles Univ Prague, Fac Med 2, Dept Nucl Med, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol Anat, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Mol Med, Prague, Czech Republic","Rob, L, Fac Hosp Motol, Dept Obstet & Gynaecol, Vuvalu 84, Prague 15000 5, Czech Republic","lukas.rob@ifmotol.cuni.cz","IGA MZ [CR NR-8873-3]","This work is supported by grant IGA MZ CR NR-8873-3.",null,19,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,"10.1111/IGC.0b013e3181a1c0b1","INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","APR",2009,19,3,null,null,null,391,394,null,null,4,"Oncology; Obstetrics & Gynecology","457ZE","ISI:000266976600016"]
[14,"J","Pinskerova, V; Samuelson, KM; Stammers, J; Maruthainar, K; Sosna, A; Freeman, MAR",null,null,null,"Pinskerova, V.; Samuelson, K. M.; Stammers, J.; Maruthainar, K.; Sosna, A.; Freeman, M. A. R.",null,"The knee in full flexion AN ANATOMICAL STUDY","Journal of Bone and Joint Surgery-British Volume",null,"English","Article",null,null,null,null,null,null,"LIVING KNEE; MOVEMENT; KINEMATICS; JOINT; MRI","There has been only one limited report dating from 1941 using dissection which has described the tibiofemoral joint between 120 degrees and 160 degrees of flexion despite the relevance of this arc to total knee replacement. We now provide a full description having examined one living and eight cadaver knees using MRI, dissection and previously published cryosections in one knee. In the range of flexion from 120 degrees to 160 degrees the flexion facet centre of the medial femoral condyle moves back 5 mm and rises up on to the posterior horn of the medial meniscus. At 160 degrees the posterior horn is compressed in a synovial recess between the femoral cortex and the tibia. This limits flexion. The lateral femoral condyle also rolls back with the posterior horn of the lateral meniscus moving with the condyle. Both move down over the posterior tibia at 160 degrees of flexion. Neither the events between 120 degrees and 160 degrees nor the anatomy at 160 degrees could result from a continuation of the kinematics up to 120 degrees. Therefore hyperflexion is a separate arc. The anatomical and functional features of this arc suggest that it would be difficult to design an implant for total knee replacement giving physiological movement from 0 degrees to 160 degrees.","[Pinskerova, V.; Sosna, A.; Freeman, M. A. R.] Charles Univ Prague, Orthopaed Clin 1, Fac Hosp Motol, Prague 5, Czech Republic","Maruthainar, K, Royal Natl Orthopaed & Royal Free Hosp Rotat, Dept Trauma & Orthopaed, Ctr Biomed Engn, Brockley Hill, Stanmore HA7 4LP, Middx, England","kunalan@gmail.com",null,null,null,14,0,"BRITISH EDITORIAL SOC BONE JOINT SURGERY","LONDON","22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND","0301-620X",null,"10.1302/0301-620X.91B6.22319","J BONE JOINT SURG-BRIT VOL","J. Bone Joint Surg.-Br. Vol.","JUN",2009,"91B",6,null,null,null,830,834,null,null,5,"Orthopedics; Surgery","458PF","ISI:000267035300023"]
[14,"J","Kideryova, L; Lacina, L; Dvorankova, B; Stork, J; Cada, Z; Szabo, P; Andre, S; Kaltner, H; Gabius, HJ; Smetana, K",null,null,null,"Kideryova, L.; Lacina, L.; Dvorankova, B.; Stork, J.; Cada, Z.; Szabo, P.; Andre, S.; Kaltner, H.; Gabius, H. -J.; Smetana, K., Jr.",null,"Phenotypic characterization of human keratinocytes in coculture reveals differential effects of fibroblasts from benign fibrous histiocytoma (dermatofibroma) as compared to cells from its malignant form and to normal fibroblasts","Journal of Dermatological Science",null,"English","Article",null,null,null,null,null,"Benign fibrous histiocytoma; Fibroblasts; Galectin; Keratin; Nucleostemin","STEM-CELLS; IN-VITRO; OVERLYING DERMATOFIBROMA; STROMAL FIBROBLASTS; MAMMALIAN LECTINS; EPIDERMAL-CELLS; HAIR FOLLICLE; EXPRESSION; CARCINOMA; GALECTIN-1","Background: Benign and malignant fibrous histiocytoma present with a considerable difference concerning cellular organization in their vicinity. Objective: Normally appearing epithelium covers the malignant form in contrast to hyperplastic epidermis for benign tumors. It is an open question as to whether the tumor-associated fibroblasts are capable to affect phenotypic features of normal keratinocytes, prompting this comparative analysis. Methods: Fibroblasts were isolated from benign and malignant fibrous histiocytomas, respectively, and also from normal dermis. The resulting cell populations were thoroughly characterized immunocytochemically using a large panel of antibodies. The three fibroblast preparations were cocultured with normal interfollicular keratinocytes. Their phenotype was characterized for distinct properties including differentiation and proliferation. Results: Fibroblasts prepared from both tumor types were phenotypically practically identical with normal dermal fibroblasts. Their activities on keratinocytes were different. Cells prepared from benign fibrous histiocytoma were capable to effect strong expression of keratin 19 and production of a galectin-1-rich extracellular matrix. Fibroblasts isolated from malignant fibrous histiocytoma led to a phenotype very similar to that when keratinocytes were cocultured with normal dermal fibroblasts. Conclusion: Fibroblasts prepared from benign fibrous histiocytoma were biologically active on keratinocytes in a particular manner. Our results on fibroblast activity are suggested to be relevant for morphologic differences observed in vivo between normal epidermis and epidermis adjacent to the Studied tumor types. (C) 2009 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.","[Lacina, L.; Dvorankova, B.; Cada, Z.; Szabo, P.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Kideryova, L.] Charles Univ Prague, Fac Med 1, Dept Internal Med 1, Prague 12800 2, Czech Republic; [Lacina, L.; Dvorankova, B.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Lacina, L.; Stork, J.] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol, Prague 12800 2, Czech Republic; [Cada, Z.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 12800 2, Czech Republic; [Andre, S.; Kaltner, H.; Gabius, H. -J.] Univ Munich, Fac Vet Med, Inst Physiol Chem, Munich, Germany","Smetana, K, Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic","Karel.Smetana@lf1.cuni.cz","Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806, 1M0538]; EC Marie Curie Research Training Network [2005-019561]","Authors are grateful to Mrs. Iva BurdovA for excellent technical assistance. This study was supported by the Ministry of Education, Youth and Sports of the Czech Republic, Project Nos. MSM 0021620806 and 1M0538 as well as an EC Marie Curie Research Training Network (Contract No. 2005-019561).",null,49,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0923-1811",null,"10.1016/j.jdermsci.2009.03.009","J DERMATOLOGICAL SCI","J. Dermatol. Sci.","JUL",2009,55,1,null,null,null,18,26,null,null,9,"Dermatology","459FJ","ISI:000267086100003"]
[15,"J","Topinkova, E; Maresova, V",null,null,null,"Topinkova, Eva; Maresova, Vilma",null,"Tetanus and Pertussis vaccines: their usefulness in the aging population","Aging Clinical and Experimental Research",null,"English","Review",null,null,null,null,null,"Aging; pertussis vaccination; tetanus vaccination","UNITED-STATES; BOOSTER VACCINATION; DIPHTHERIA; ADULTS; IMMUNITY; IMMUNIZATION; ADOLESCENTS; NETHERLANDS; TOXOIDS; PREVENTION","Immunization is a safe, effective and simple way of preventing life-threatening tetanus infection in children and adults, and is therefore recommended for all age groups in all European countries. In older persons, despite waning immunity with increasing age, the majority of vaccinees attain protective tetanus immunity under a proper vaccination schedule. Based on the scientific evidence, decennial boosters are recommended for elderly persons who have received primary tetanus vaccination in the past. Until recently, pertussis vaccination was understood as an early childhood intervention. Due to decreasing immunity, re-vaccination of youngsters and adults is recommended and is also considered for seniors 60 years and over. Routine immunization of seniors against pertussis every ten years yields a high level of protection of older individuals, and at the same time contributes to epidemiological control of pertussis in the population. (Aging Clin Exp Res 2009; 21: 229-235) (C) 2009. Editrice Kurtis","[Topinkova, Eva] Charles Univ Prague, Fac Med 1, Dept Geriatr, Prague 12000 2, Czech Republic; [Topinkova, Eva] Charles Univ Prague, Fac Med 1, Gen Teaching Hosp, Prague 12000 2, Czech Republic; [Maresova, Vilma] Charles Univ Prague, Fac Med 2, Dept Infect Dis, Prague 12000 2, Czech Republic","Topinkova, E, Charles Univ Prague, Fac Med 1, Dept Geriatr, Londynska 15, Prague 12000 2, Czech Republic","Topinkova.eva@vfn.cz","IGA Ministry of Health, Czech Republic [10029-4]","The work of Prof. Topinkova was supported by a grant of IGA Ministry of Health, Czech Republic No. 10029-4.",null,46,1,"EDITRICE KURTIS S R L","MILAN","VIA LUIGI ZOJA 30, 20153 MILAN, ITALY","1594-0667",null,null,"AGING CLIN EXP RES","Aging Clin. Exp. Res.","JUN",2009,21,3,null,null,"Sp. Iss. SI",229,235,null,null,7,"Geriatrics & Gerontology","466HP","ISI:000267652500006"]
[15,"J","Wilhelm, J; Vytasek, R; Ostadalova, I; Vajner, L",null,null,null,"Wilhelm, Jiri; Vytasek, Richard; Ostadalova, Ivana; Vajner, Ludek",null,"Evaluation of different methods detecting intracellular generation of free radicals","Molecular and Cellular Biochemistry",null,"English","Article",null,null,null,null,null,"Reactive oxygen species; Fluorescent probes; Autofluorescence; Cellular ageing; Tissue thin sections","NADPH OXIDASE ACTIVITY; OXIDATIVE STRESS; SUPEROXIDE-PRODUCTION; DIHYDRORHODAMINE 123; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; CARDIAC MYOCYTES; IN-VITRO; HYDROETHIDINE","Reactive oxygen species (ROS) play several biological roles. We investigated the applicability of fluorescent probes for their detection (i) in rabbit lens epithelial cells during ageing in culture, and (ii) in thin sections of rat heart. We used dihydroethidium (DHE), dichlorofluorescin (DCFH), and dihydrorhodamine 123 (DHR) together with detection of autofluorescence both in cells and in chloroform extracts. Superoxide production was confirmed by a specific histochemical method using Mn2+. All methods demonstrated higher production of ROS in older cells. All probes revealed different sites of ROS production in young and old cells and could be used for investigation of ROS generation during cell ageing. In the thin sections of rat heart DCFH was not suitable for intracellular ROS detection. The results indicate that the potential of fluorescent dyes in ROS detection is not usually fully exploited, and that blue autofluorescence is associated with oxidative damage.","[Wilhelm, Jiri; Vytasek, Richard] Charles Univ Prague, Dept Med Chem & Biochem, Cardiovasc Res Ctr, Sch Med 2, Prague 15000 5, Czech Republic; [Ostadalova, Ivana] Acad Sci Czech Republic, Inst Physiol, Cardiovasc Res Ctr, CR-14220 Prague 4, Czech Republic; [Vajner, Ludek] Charles Univ Prague, Dept Histol & Embryol, Sch Med 2, Prague 15000 5, Czech Republic","Wilhelm, J, Charles Univ Prague, Dept Med Chem & Biochem, Cardiovasc Res Ctr, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","jiri.wilhelm@lfmotol.cuni.cz","Grant Agency of the Czech Republic [305/08/0108]; Czech Ministry of Education, Youth and Physical Education [1MO510]; AV OZ [50110509]","This study was supported by grant No. 305/08/0108 from the Grant Agency of the Czech Republic, a grant of Czech Ministry of Education, Youth and Physical Education No. 1MO510 and grant AV OZ No. 50110509.",null,26,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,"10.1007/s11010-009-0086-5","MOL CELL BIOCHEM","Mol. Cell. Biochem.","AUG",2009,328,"2009-02-01",null,null,null,167,176,null,null,10,"Cell Biology","465MX","ISI:000267592600020"]
[15,"J","Pardini, B; Naccarati, A; Polakova, V; Smerhovsky, Z; Hlavata, I; Soucek, P; Novotny, J; Vodickova, L; Tomanova, V; Landi, S; Vodicka, P",null,null,null,"Pardini, Barbara; Naccarati, Alessio; Polakova, Veronika; Smerhovsky, Zdenek; Hlavata, Ivona; Soucek, Pavel; Novotny, Jan; Vodickova, Ludmila; Tomanova, Vera; Landi, Stefano; Vodicka, Pavel",null,"NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic","Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis",null,"English","Article",null,null,null,null,null,"NBN 657del5; Colorectal cancer; NBS","NIJMEGEN-BREAKAGE-SYNDROME; REPAIR GENETIC POLYMORPHISMS; NBS1 GENE; ATAXIA-TELANGIECTASIA; BREAST-CANCER; CHROMOSOMAL INSTABILITY; LYMPHOMA; CARRIERS; PROTEIN; NIBRIN","The most frequent Nijmegen breakage syndrome (NBS)-causing mutation is a 5-base pair deletion in gene coding for nibrin (NBN 657del5), which results in a non-fully functional protein product and is particularly frequent in Central and Eastern Europe. Recent studies have investigated whether NBN 657del5 carriage may predispose to an increased risk of different types of cancer. The Czech Republic has one of the highest incidences of colorectal cancer in the world as well as high incidence of NBS. To assess whether NBN 657del5 associates with an increased risk of sporadic colorectal cancer, we have screened 771 colorectal cancer patients, 614 controls with negative colonoscopy and 818 healthy blood donors from the Czech Republic. There were no significant differences between the frequencies of heterozygous carriers among the three groups. The present results do not provide any evidence that the exceeding risk of CRC in this population is attributable to the high frequency of heterozygous carriage of the NBN 657del5. (c) 2009 Elsevier B.V. All rights reserved.","[Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14200 4, Czech Republic; [Polakova, Veronika; Hlavata, Ivona; Vodicka, Pavel] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Hlavata, Ivona; Soucek, Pavel; Vodickova, Ludmila] Natl Inst Publ Hlth, Prague, Czech Republic; [Novotny, Jan] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Tomanova, Vera] Jihlava Hosp, Dept Gastroenterol, Jihlava, Czech Republic; [Landi, Stefano] Univ Pisa, Dept Biol, I-56100 Pisa, Italy","Vodicka, P, Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200 4, Czech Republic","pvodicka@biomed.cas.cz","Czech Science Foundation [GACR 310/07/1430, GACR 305/09/P194]","This study was supported by the grants: Czech Science Foundation, no.: GACR 310/07/1430 and GACR 305/09/P194, Internal Grant Agency of the Czech Ministry of Health, no.: IGA 8563-5/2005, and MSM0021620808.",null,29,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,"10.1016/j.mrfmmm.2009.04.004","MUTAT RES-FUNDAM MOL MECH MUT","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","JUN 18",2009,666,"2009-02-01",null,null,null,64,67,null,null,4,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","463VX","ISI:000267462100010"]
[15,"J","Hubackova, M; Vaclavikova, R; Mrhalova, M; Kubackova, K; Kodet, R; Gut, I; Soucek, P",null,null,null,"Hubackova, Miluse; Vaclavikova, Radka; Mrhalova, Marcela; Kubackova, Katerina; Kodet, Roman; Gut, Ivan; Soucek, Pavel",null,"NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristcs of human mammary tumors","Pharmacogenetics and Genomics",null,"English","Article",null,null,null,null,null,"breast cancer; immunohistochemistry; NQO1; polymorphism; transcript","BREAST-CANCER; NAD(P)H-QUINONE OXIDOREDUCTASE-1; C609T POLYMORPHISM; DT-DIAPHORASE; PROTEASOMAL DEGRADATION; PANCREATIC-CANCER; NQOI POLYMORPHISM; CLINICAL-RESPONSE; MITOMYCIN-C; P53","Objective The aim of this study was to further clarify the recently reported role of NAD(P)H:quinone oxidoreductase 1 (NQO1) as a strong prognostic and predictive factor in breast cancer. Methods NQO1 transcript levels were monitored in mammary tumors by real-time polymerase chain reaction. NQO1 protein levels were immunohistochemically determined in formalin-fixed paraffin-embedded tissues. NQO1 polymorphism (Pro187Ser, rs1800566) was also assessed. Evaluation (N=52) and validation (N=53) sets were analyzed subsequently. Results Carriers of variant NQO1-Ser allele had significantly more frequently NQO1-negative protein expression (P=0.001) in both sets. NQO1 transcript levels in samples with negative protein expression were significantly lower than in those with positive NQO1 protein expression (P=0.007) in both sets. Patients with stages 0/I/II had more often positive NQO1 protein expression than patients with stages III/IV (P=0.022) in the evaluation set. Significant association between NQO1 protein expression and TP53 protein status was also found (P=0.037). However, both associations were not replicated by analysis of the validation set. Analysis of both sets combined did not show significant association of NQO1 protein expression either with stage (P=0.231) or with TP53 protein status (P>0.999). Thus, the results observed in the evaluation set were effects of small sample size. Conclusion The role of NQO1 in human mammary gland carcinogenesis does not seem to be directly associated with classical clinico-pathological factors. Pharmacogenetics and Genomics 19:505-512 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Hubackova, Miluse; Vaclavikova, Radka; Gut, Ivan; Soucek, Pavel] Natl Inst Publ Hlth, Lab Toxicogenom, Prague 10042 10, Czech Republic; [Hubackova, Miluse] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Kubackova, Katerina] Charles Univ Prague, Sch Med 2, Dept Radiotherapy Oncol, Prague, Czech Republic; Hosp Motol, Prague, Czech Republic","Soucek, P, Natl Inst Publ Hlth, Lab Toxicogenom, Srobarova 48, Prague 10042 10, Czech Republic","psoucek@szu.cz","Czech Ministry of Health [8563-5, 9426-3]; Agency of Charles University [94507]; Ministry of Health and Faculty Hospital [MZO 00064203/6704]","This work Was Supported by grants front Internal Grant Agency of the Czech Ministry of Health, no: 8563-5, 9426-3, a grant from the Grant Agency of Charles University, no: 94507 and Research Project of the Ministry of Health and Faculty Hospital no: MZO 00064203/6704.",null,24,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1744-6872",null,"10.1097/FPC.0b013e32832cf9cf","PHARMACOGENET GENOMICS","Pharmacogenet. Genomics","JUL",2009,19,7,null,null,null,505,512,null,null,8,"Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy","465WD","ISI:000267619000003"]
[16,"J","Musova, Z; Mazanec, R; Krepelova, A; Ehler, E; Vales, J; Jaklova, R; Prochazka, T; Koukal, P; Marikova, T; Kraus, J; Havlovicova, M; Sedlacek, Z",null,null,null,"Musova, Zuzana; Mazanec, Radim; Krepelova, Anna; Ehler, Edvard; Vales, Jiri; Jaklova, Radka; Prochazka, Tomas; Koukal, Petr; Marikova, Tatana; Kraus, Josef; Havlovicova, Marketa; Sedlacek, Zdenek",null,"Highly Unstable Sequence Interruptions of the CTG Repeat in the Myotonic Dystrophy Gene","American Journal of Medical Genetics Part A",null,"English","Article",null,null,null,null,null,"myotonic dystrophy; CTG repeat; interruptions; DMPK gene","SPINOCEREBELLAR ATAXIA; TRINUCLEOTIDE REPEATS; FRIEDREICH ATAXIA; CAA INTERRUPTIONS; TRIPLET REPEAT; CGG REPEATS; INSTABILITY; EXPANSION; ALLELES; TYPE-1","Myotonic dystrophy type I is caused by the expansion of a CTG repeat in the 3' UTR of the DMPK gene. A length exceeding 50 CTG triplets is pathogenic. Intermediate alleles with 35-49 triplets are not disease-causing but show instability in intergenerational transmissions. We report on the identification of multiple patients with different patterns of CCG and CTC interruptions in the DMPKCTG repeat tract that display unique intergenerational instability. In patients bearing interrupted expanded alleles, the location of the interruptions changed dramatically between generations and the repeats tended to contract. The phenotype for these patients corresponded to the classical form of the disease, but in some cases without muscular dystrophy and possibly with a later onset than expected. Symptomatic patients bearing interrupted intermediate length repeat tracts were also identified, although the role of the interruptions in their phenotype remains unclear. The identification of interruptions in the DMPK repeat has important consequences for molecular genetic testing where they can lead to false negative conclusions. (C) 2009 Wiley-Liss, Inc.","[Musova, Zuzana; Krepelova, Anna; Marikova, Tatana; Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic; [Musova, Zuzana; Mazanec, Radim; Krepelova, Anna; Marikova, Tatana; Kraus, Josef; Havlovicova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Ehler, Edvard] Reg Hosp Pardubice, Dept Neurol, Pardubice, Czech Republic; [Vales, Jiri] Univ Hosp Plzen, Dept Neurol, Plzen, Czech Republic; [Jaklova, Radka] Univ Hosp Plzen, Dept Med Genet, Plzen, Czech Republic; [Prochazka, Tomas] Na Homolce Hosp, Dept Neurol, Prague, Czech Republic; [Koukal, Petr] EMG Lab, Ceska Lipa, Czech Republic; [Kraus, Josef] Charles Univ Prague, Dept Child Neurol, Sch Med 2, Prague 15006 5, Czech Republic","Musova, Z, Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","zuzana.musova@lfmotol.cuni.cz","Ministry of Health of the Czech Republic [MZ000064203]","We thank an anonymous reviewer for helpful comments. The work was supported by grant MZ000064203 from the Ministry of Health of the Czech Republic.",null,40,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4825",null,"10.1002/ajmg.a.32987","AM J MED GENET PART A","Am. J. Med. Genet. A","JUL",2009,"149A",7,null,null,null,1365,1374,null,null,10,"Genetics & Heredity","467VA","ISI:000267770000001"]
[16,"J","Azad, AK; Rauh, R; Vermeulen, F; Jaspers, M; Korbmacher, J; Boissier, B; Bassinet, L; Fichou, Y; des Georges, M; Stanke, F; De Boeck, K; Dupont, L; Balascakova, M; Hjelte, L; Lebecque, P; Radojkovic, D; Castellani, C; Schwartz, M; Stuhrmann, M; Schwarz, M; Skalicka, V; de Monestrol, I; Girodon, E; Ferec, C; Claustres, M; Tummler, B; Cassiman, JJ; Korbmacher, C; Cuppens, H",null,null,null,"Azad, Abul Kalam; Rauh, Robert; Vermeulen, Francois; Jaspers, Martine; Korbmacher, Judit; Boissier, Brigitte; Bassinet, Laurence; Fichou, Yann; des Georges, Marie; Stanke, Frauke; De Boeck, Kris; Dupont, Lieven; Balascakova, Miroslava; Hjelte, Lena; Lebecque, Patrick; Radojkovic, Dragica; Castellani, Carlo; Schwartz, Marianne; Stuhrmann, Manfred; Schwarz, Martin; Skalicka, Veronika; de Monestrol, Isabelle; Girodon, Emmanuelle; Ferec, Claude; Claustres, Mireille; Tuemmler, Burkhard; Cassiman, Jean-Jacques; Korbmacher, Christoph; Cuppens, Harry",null,"Mutations in the Amiloride-Sensitive Epithelial Sodium Channel in Patients With Cystic Fibrosis-Like Disease","Human Mutation",null,"English","Article",null,null,null,null,null,"CF; CFTR; ENaC; SCNN1A","TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA-SUBUNIT; PSEUDOHYPOALDOSTERONISM TYPE-1; CONGENITAL ABSENCE; LIDDLES SYNDROME; CFTR MUTATIONS; ALPHA-SUBUNIT; LUNG-DISEASE; VAS-DEFERENS; NA+ CHANNEL","We investigated whether mutations in the genes that code for the different subunits of the amiloride-sensitive epithelial sodium channel (ENaC) might result in cystic fibrosis (CF)-like disease. In a small fraction of the patients, the disease could be potentially explained by an ENaC mutation by a Mendelian mechanism, such as p.V114I and p.F61L in SCNN1A. More importantly, a more than three-fold significant increase in incidence of several rare ENaC polymorphisms was found in the patient group (30% vs. 9% in controls), indicating an involvement of ENaC in some patients by a polygenetic mechanism. Specifically, a significantly higher number of patients carried c.-55+5G > C or p.W493R in SCNN1A in the heterozygous state, with odds ratios (ORs) of 13.5 and 2.7, respectively. The p.W493R-SCNN1A polymorphism was even found to result in a four-fold more active ENaC channel when heterologously expressed in Xenopus laevis oocytes. About I in 975 individuals in the general population will be heterozygous for the hyperactive p.W493R-SCNN1A mutation and a cystic fibrosis transmembrane conductance regulator (CFTR) gene that results in very low amounts (0-10%) functional CFTR. These ENaC/CFTR genotypes may play a hitherto unrecognized role in lung diseases. Hum Mutat 30:1093-1103, 2009. (C) 2009 Wiley-Liss, Inc.","[Azad, Abul Kalam; Jaspers, Martine; Radojkovic, Dragica; Cassiman, Jean-Jacques; Cuppens, Harry] Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; [Rauh, Robert; Korbmacher, Judit; Korbmacher, Christoph] Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, Erlangen, Germany; [Vermeulen, Francois; De Boeck, Kris] Univ Hosp Gasthuisberg, Dept Pediat, Louvain, Belgium; [Boissier, Brigitte; Bassinet, Laurence; Girodon, Emmanuelle] Hop Henri Mondor, Serv Biochim & Genet, F-94010 Creteil, France; [Fichou, Yann; Ferec, Claude] CHU Brest, Lab Genet Mol & Histocompatibil, F-29285 Brest, France; [des Georges, Marie; Claustres, Mireille] IURC, CHU Montpellier, Genet Mol Lab, Montpellier, France; [Stanke, Frauke; Tuemmler, Burkhard] Hannover Med Sch, Klin Forschergrp, D-30623 Hannover, Germany; [Dupont, Lieven] Univ Hosp Gasthuisberg, Dept Pulmonol, Louvain, Belgium; [Balascakova, Miroslava; Skalicka, Veronika] Charles Univ Prague, Sch Med, Inst Biol & Med Genet, Pneumol Clin, Prague, Czech Republic; [Balascakova, Miroslava; Skalicka, Veronika] Charles Univ Prague, Sch Med, Pediat Clin, Prague, Czech Republic; [Balascakova, Miroslava; Skalicka, Veronika] Univ Hosp Motol, Prague, Czech Republic; [Hjelte, Lena; de Monestrol, Isabelle] Karolinska Univ Hosp, Stockholm Cyst Fibrosis CF Ctr, Huddinge, Sweden; [Lebecque, Patrick] Univ Catholique Louvain, Clin St Luc, Pediat Pulmonol & Cyst Fibrosis Unit, B-1200 Brussels, Belgium; [Castellani, Carlo] Azienda Osped Verona, Cyst Fibrosis Ctr, Verona, Italy; [Schwarz, Martin] Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark; [Stuhrmann, Manfred] Hannover Med Sch, Inst Humangenet, D-30623 Hannover, Germany; [Schwarz, Martin] Royal Manchester Childrens Hosp, Mol Genet Lab, Manchester M27 1HA, Lancs, England","Cuppens, H, Katholieke Univ Leuven, Ctr Human Genet, Gasthuisberg O&N1 602,Herestr 49, B-3000 Louvain, Belgium","harry.cuppens@med.kuleuven.be","Alphonse and Jean Forton Fund-Koning Boudewijn Stichting [2005 04 R7 115 130]; Het Fonds voor Wetenschappelijk Onderzoek Vlaanderen [G.0521.06, 1.5.111.07]; Interuniversity Attraction Poles [IAP P6/05]; EU [QLG1-CT-2001-01005-CFPRONET]; Vaincre La Mucoviscidose [RC0532]; Deutsche Forschungsgemeinschaft [SFB 423, TP A12]; Katholieke Universiteit Leuven, Belgium [1110]; [VZFNM 00064203]; [NR/9488-3]","These investigations were realized by grants from the Alphonse and Jean Forton Fund-Koning Boudewijn Stichting (2005 04 R7 115 130); Het Fonds voor Wetenschappelijk Onderzoek Vlaanderen (G.0521.06 and 1.5.111.07), the Interuniversity Attraction Poles (IAP P6/05); the EU grant (QLG1-CT-2001-01005-CFPRONET), the Vaincre La Mucoviscidose (RC0532), and the Deutsche Forschungsgemeinschaft (SFB 423, TP A12). A.K.A. is a recipient of a doctoral fellowship award from the Interfaculty Council for Development Cooperation (1110) of the Katholieke Universiteit Leuven, Belgium. J.J.C. holds the Arthur Bax and Anna Vanluffelen Chair of Human Genetics, KU Leuven, Belgium. We thank Steffen Fieuws for his advice in statistical analysis and Dieter Gruenert for providing the 16HBE14o- cell line. We also acknowledge Milan Macek, Jr., Vera Vavrova, Libor Fila, and Daniela Zemkova for their assistance in clinical data collection and support. They were supported by grants VZFNM 00064203 and NR/9488-3.",null,37,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,"10.1002/humu.21011","HUM MUTAT","Hum. Mutat.","JUL",2009,30,7,null,null,null,1093,1103,null,null,11,"Genetics & Heredity","468CQ","ISI:000267791700009"]
[17,"J","Hejcl, A; Lesny, P; Pradny, M; Sedy, J; Zamecnik, J; Jendelova, P; Michalek, J; Sykova, E",null,null,null,"Hejcl, A.; Lesny, P.; Pradny, M.; Sedy, J.; Zamecnik, J.; Jendelova, P.; Michalek, J.; Sykova, E.",null,"Macroporous hydrogels based on 2-hydroxyethyl methacrylate. Part 6: 3D hydrogels with positive and negative surface charges and polyelectrolyte complexes in spinal cord injury repair","Journal of Materials Science-Materials in Medicine",null,"English","Article",null,null,null,null,null,null,"MULTILAYER FILMS; AXONAL GROWTH; CELL-ADHESION; RAT-BRAIN; PROTEIN; TRANSPLANTATION; BIOMATERIALS; COPOLYMERS; POLYMER","Macroporous hydrogels are artificial biomaterials commonly used in tissue engineering, including central nervous system (CNS) repair. Their physical properties may be modified to improve their adhesion properties and promote tissue regeneration. We implanted four types of hydrogels based on 2-hydroxyethyl methacrylate ( HEMA) with different surface charges inside a spinal cord hemisection cavity at the Th8 level in rats. The spinal cords were processed 1 and 6 months after implantation and histologically evaluated. Connective tissue deposition was most abundant in the hydrogels with positively-charged functional groups. Axonal regeneration was promoted in hydrogels carrying charged functional groups; hydrogels with positively charged functional groups showed increased axonal ingrowth into the central parts of the implant. Few astrocytes grew into the hydrogels. Our study shows that HEMA-based hydrogels carrying charged functional groups improve axonal ingrowth inside the implants compared to implants without any charge. Further, positively charged functional groups promote connective tissue infiltration and extended axonal regeneration inside a hydrogel bridge.","[Hejcl, A.; Lesny, P.; Sedy, J.; Jendelova, P.; Sykova, E.] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Hejcl, A.; Lesny, P.; Pradny, M.; Sedy, J.; Jendelova, P.; Michalek, J.; Sykova, E.] Charles Univ Prague, Dept Neurosci, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Hejcl, A.; Lesny, P.; Pradny, M.; Sedy, J.; Jendelova, P.; Michalek, J.; Sykova, E.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Pradny, M.; Michalek, J.] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Zamecnik, J.] Charles Univ Prague, Dept Pathol & Mol Med, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Hejcl, A.] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic","Hejcl, A, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","ales.hejcl@mnul.cz","Academy of Sciences of the Czech Republic [AVOZ50390703]; Ministry of Education of the Czech Republic [1M0538]; Grant agency of the Czech Academy of Science [GAAV IAA500390902]; Ministry of Health of the Czech Republic [1A8697-5]; EC FP6 project RESCUE [LSHB-CT-2005-518233]","We thank James Dutt for reading of the manuscript. This work was supported by the following grants: AVOZ50390703 from the Academy of Sciences of the Czech Republic, 1M0538 from the Ministry of Education of the Czech Republic, GAAV IAA500390902 from the Grant agency of the Czech Academy of Science, 1A8697-5 from the Ministry of Health of the Czech Republic, and the EC FP6 project RESCUE (LSHB-CT-2005-518233).",null,31,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-4530",null,"10.1007/s10856-009-3714-4","J MATER SCI-MATER MED","J. Mater. Sci.-Mater. Med.","JUL",2009,20,7,null,null,null,1571,1577,null,null,7,"Engineering, Biomedical; Materials Science, Biomaterials","472BD","ISI:000268103200020"]
[17,"J","Jirickova, A; Sulc, J; Pohunek, P; Kittnar, O; Dohnalova, A; Kofranek, J",null,null,null,"Jirickova, A.; Sulc, J.; Pohunek, P.; Kittnar, O.; Dohnalova, A.; Kofranek, J.",null,"Prevalence of Tidal Expiratory Flow Limitation in Preschool Children with and without Respiratory Symptoms: Application of the Negative Expiratory Pressure (NEP) Method","Physiological Research",null,"English","Article",null,null,null,null,null,"Preschool children; Respiratory disorders; Expiratory flow limitation; Negative expiratory pressure technique","OBSTRUCTIVE PULMONARY-DISEASE; DYNAMIC HYPERINFLATION; CYSTIC-FIBROSIS; CHRONIC DYSPNEA; SLEEP-APNEA; ORTHOPNEA; VOLUME; COPD; BRONCHODILATOR; GENIOGLOSSUS","Negative expiratory pressure (NEP) applied at the mouth during tidal expiration provides a non-invasive method for detecting expiratory flow limitation. Forty-two children were studied, i.e. 25 children with different respiratory symptoms (R) and 17 without any respiratory symptoms (NR). Children were examined without any sedation. A preset NEP of -5 cm H2O was applied; its duration did not exceed duration of tidal expiration. A significance of FL was judged by determining of a flow-limited range (in % of tidal volume). FL was found in 48 % children of R group. No patient of the NR group elicited FL (P<0.001 R vs. NR). The frequency of upper airway collapses was higher in R group (12 children) than in NR group (5 children). In conclusion, a high frequency of tidal FL in the R group was found, while it was not present in NR group. A relatively high frequency of expiratory upper airway collapses was found in both groups, but it did not differ significantly. NEP method represents a reasonable approach for tidal flow limitation testing in non-sedated preschool children.","[Jirickova, A.] Charles Univ Prague, Fac Med 1, Inst Physiol, Dept Physiol, Prague 12800 2, Czech Republic; [Sulc, J.; Pohunek, P.] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 12800 2, Czech Republic; [Sulc, J.; Pohunek, P.] Charles Univ Prague, Univ Hosp Motol, Prague 12800 2, Czech Republic; [Kofranek, J.] Charles Univ Prague, Fac Med 1, Dept Pathophysiol, Prague 12800 2, Czech Republic","Jirickova, A, Charles Univ Prague, Fac Med 1, Inst Physiol, Dept Physiol, Albertov 5, Prague 12800 2, Czech Republic","adriana.jirickova@lf1.cuni.cz","Czech Ministry of Health, the Research Initiative [NR 9131-3]; Czech Ministry of Health [AV CR 1ET201210527, MZO 00064203 / 6404]","The authors wish to thank Marie Spirova and Sona Hornickova for their technical assistance. The study was supported by the Grant NR 9131-3 of the Int. Grant Agency of the Czech Ministry of Health, the Research Initiative MSM - 111100008, by the Grant AV CR 1ET201210527 and by the Research Project No. MZO 00064203 / 6404 of the Czech Ministry of Health.",null,40,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,3,null,null,null,373,382,null,null,10,"Physiology","472JC","ISI:000268125600008"]
[17,"J","Kolar, P; Neuwirth, J; Sanda, J; Suchanek, V; Svata, Z; Volejnik, J; Pivec, M",null,null,null,"Kolar, P.; Neuwirth, J.; Sanda, J.; Suchanek, V.; Svata, Z.; Volejnik, J.; Pivec, M.",null,"Analysis of Diaphragm Movement during Tidal Breathing and during its Activation while Breath Holding Using MRI Synchronized with Spirometry","Physiological Research",null,"English","Article",null,null,null,null,null,"Diaphragm fiction; Magnetic resonance Paging; Thorax; Posture","OBSTRUCTIVE PULMONARY-DISEASE; CHEST-WALL; MOTION; FLUOROSCOPY; EMPHYSEMA","Using magnetic resonance imaging (MRI) in conjunction with synchronized spirometry we analyzed and compared diaphragm movement during tidal breathing and voluntary movement of the diaphragm while breath holding. Breathing cycles of 16 healthy subjects were examined using a dynamic sequence (77 slices in sagittal plane during 20 s, 1NSA, 240x256, TR4.48, TE2.24, FA90, TSE1, FOV 328). The amplitude of movement of the apex and dorsal costophrenic angle of the diaphragm were measured for two test conditions: tidal breathing and voluntary breath holding. The maximal inferior and superior positions of the diaphragm were subtracted from the corresponding positions during voluntary movements while breath holding. The average amplitude of inferio-superior movement of the diaphragm apex during tidal breathing was 27.3 +/- 10.2 mm (mean +/- SD), and during voluntary movement while breath holding was 32.5 +/- 16.2 mm. Movement of the costophrenic angle was 39 +/- 17.6 mm during tidal breathing and 45.5 +/- 21.2 mm during voluntary movement while breath holding. The inferior position of the diaphragm was lower in 11 of 16 subjects (68.75 %) and identical in 2 of 16 (12.5 %) subjects during voluntary movement compared to the breath holding. Pearson's correlation coefficient was used to demonstrate that movement of the costophrenic angle and apex of the diaphragm had a linear relationship in both examined situations (r=0.876). A correlation was found between the amplitude of diaphragm movement during tidal breathing and lung volume (r=0.876). The amplitude of movement of the diaphragm with or without breathing showed no correlation to each other (r=0.074). The movement during tidal breathing shows a correlation with the changes in lung volumes. Dynamic MRI demonstrated that individuals are capable of moving their diaphragm voluntarily, but the amplitude of movement differs from person to person. In this study, the movements of the diaphragm apex and the costophrenic angle were synchronous during voluntary movement of the diaphragm while breath holding. Although the sample is small, this study confirms that the function of the diaphragm is not only respiratory but also postural and can be voluntarily controlled.","[Kolar, P.; Pivec, M.] Charles Univ Prague, Fac Med 2, Dept Rehabil, Prague 5, Motol, Czech Republic; [Kolar, P.; Neuwirth, J.; Sanda, J.; Suchanek, V.; Svata, Z.; Pivec, M.] Univ Hosp Motol, Prague, Czech Republic; [Neuwirth, J.; Sanda, J.; Suchanek, V.; Svata, Z.] Charles Univ Prague, Fac Med 2, Dept Imaging Methods, Prague 5, Motol, Czech Republic; [Volejnik, J.] Kurka Med SRO, Prague, Czech Republic","Kolar, P, Charles Univ Prague, Fac Med 2, Dept Rehabil, Prague 5, Motol, Czech Republic","pavel.kolar@fnmotol.cz",null,null,null,21,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,3,null,null,null,383,392,null,null,10,"Physiology","472JC","ISI:000268125600009"]
[17,"J","Stechova, K; Spalova, I; Durilova, M; Bartaskova, D; Cerny, M; Cerna, M; Pithova, P; Chudoba, D; Stavikova, V; Ulmannova, T; Faresjo, M",null,null,null,"Stechova, K.; Spalova, I.; Durilova, M.; Bartaskova, D.; Cerny, M.; Cerna, M.; Pithova, P.; Chudoba, D.; Stavikova, V.; Ulmannova, T.; Faresjo, M.",null,"Influence of Maternal Hyperglycaemia on Cord Blood Mononuclear Cells in Response to Diabetes-associated Autoantigens","Scandinavian Journal of Immunology",null,"English","Article",null,null,null,null,null,null,"T-CELLS; MOTHERS; PREGNANCY; CHILDREN; NEWBORNS; MELLITUS; FATHERS; RISK","Perfect maternal diabetes compensation is crucial for the outcome of the baby. However, little is known how hyperglycaemia influences the specific immune response. Furthermore, babies of type 1 diabetes (T1D) mothers have less risk of development T1D than babies with a T1D father. This study aimed to analyze the effect of maternal hyperglycaemia on newborns with focus on the response to diabetes-associated autoantigens. Populations: (1) Newborns of T1D mothers split into groups according to maternal diabetes compensation during the 3rd trimester: perfect (n = 15) or acceptable (n = 25) compensation. (2) newborns with T1D father (n = 12) (3) newborns with a mother treated for either gestational or type 2 diabetes (n = 10) (4) control newborns (n = 25). Spontaneous as well as diabetes-associated autoantigen-stimulated production of 23 cytokines and chemokines were tested using protein microarray. In addition, the influence of glucose on cytokine and chemokine responsiveness was analyzed in vitro. The study groups differed in their spontaneous as well as stimulated cytokine and chemokine spectra. A prominent Th1 response (high IFN-gamma) from autoantigen stimulation was observed especially in babies of T1D fathers (P = 0.001) and also in mothers with perfect diabetes compensation during the 3rd trimester (P = 0.016) in comparison with control newborns. By contrast, cord blood mononuclear cells cultivated in vitro in high glucose concentration decreased the diabetogenic stimulated Th1 cytokine response. Maternal 'sweet' as well as 'autoimmune environment' may both lead to lower occurrence of T1D within their offspring. Further studies will reveal the exact immunological mechanism of this observation.","[Stechova, K.] Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, Prague 15006 5, Czech Republic; [Stechova, K.; Durilova, M.; Stavikova, V.; Ulmannova, T.] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Spalova, I.] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Prague, Czech Republic; [Bartaskova, D.; Pithova, P.] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague, Czech Republic; [Cerny, M.] Charles Univ Prague, Fac Med 2, Neonatal Intens Care Unit, Prague, Czech Republic; [Chudoba, D.] Charles Univ Prague, Fac Med 2, Dept Biol & Genet, Prague, Czech Republic; [Cerna, M.] Inst Care Mother & Child, Prague, Czech Republic; [Faresjo, M.] Linkoping Univ, Fac Hlth Sci, Div Paediat, Linkoping, Sweden; [Faresjo, M.] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Diabet Res Ctr, Linkoping, Sweden; [Faresjo, M.] Jonkoping Univ, Sch Hlth Sci, Dept Nat Sci & Biomed, Jonkoping, Sweden","Stechova, K, Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, V Uvalu 84, Prague 15006 5, Czech Republic","info@labao.cz","Research Project of University Hospital Motol [00064203-6207]","This project was supported by Research Project of University Hospital Motol No. 00064203-6207.",null,19,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,"10.1111/j.1365-3083.2009.02282.x","SCAND J IMMUNOL","Scand. J. Immunol.","AUG",2009,70,2,null,null,null,149,158,null,null,10,"Immunology","471MJ","ISI:000268061600010"]
[17,"J","Huska, D; Hubalek, J; Adam, V; Vajtr, D; Horna, A; Trnkova, L; Havel, L; Kizek, R",null,null,null,"Huska, Dalibor; Hubalek, Jaromir; Adam, Vojtech; Vajtr, David; Horna, Ales; Trnkova, Libuse; Havel, Ladislav; Kizek, Rene",null,"Automated nucleic acids isolation using paramagnetic microparticles coupled with electrochemical detection","Talanta",null,"English","Article",null,null,null,null,null,"mRNA; Isolation; Magnetic particle and bead; Cyclic voltammetry; Square wave voltammetry; Brain tissue; Maize plants; Cadmium","TRAUMATIC BRAIN-INJURY; ELIMINATION VOLTAMMETRY; MAGNETIC PARTICLES; DNA HYBRIDIZATION; OSZILLOGRAPHISCHE POLAROGRAPHIE; CARBON ELECTRODES; GENOMIC DNA; NANOPARTICLES; EXTRACTION; OLIGONUCLEOTIDES","Easy, efficient and low demanding separation of mRNA from biological material is needed to study gene expression and to use in chip technologies. It is common knowledge that each mRNA molecule contains sequence of 25 adenines. This feature can be used for binding mRNA on the surface of the particles coated by thymine chains. The present work reports on suggesting and optimizing of mRNA separation and detection from biological material via paramagnetic microparticles coupled with electrochemical detection. Primarily we optimized cyclic and square wave voltammetric conditions to detect poly(A),which was used as standard to mimic behaviour of mRNA. Under the optimized square wave voltammetric conditions (frequency 280 Hz, accumulation time 200 s, supporting electrolyte and its temperature: acetate buffer 4.6 and 35 degrees C) we estimated detection limit down to 1 ng of poly(A) per ml. To enhance effectiveness and repeatability of isolation of nucleic acid automated approach for rinsing and hybridizing was proposed. We optimized the whole procedure and experimental conditions. Using automated way of isolation and under optimized conditions the yield of poly(A) (isolated concentration of poly(A)/given concentration of poly(A)*100) was approximately 75%. The suggested and optimized method for poly(A) isolation and detection was utilized for the analysis of brain tissues of patients with traumatic brain injury. The total amount of isolated mRNA varied from 40 to 760 g of mRNA per g of brain tissue. The isolation of mRNA from six samples per run was not longer than 2.5 h. Moreover, we applied the optimized procedure on fully automated pipetting instrument to isolate mRNA. The instrument was successfully tested on the analysis of extracts from roots of maize plants treated with cadmium(II) ions. (C) 2009 Elsevier B.V. All rights reserved.","[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Huska, Dalibor; Havel, Ladislav] Mendel Univ Agr & Forestry Brno, Dept Plant Biol, CZ-61300 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-60200 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Vajtr, David] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Horna, Ales] Tomas Bata Univ, Fac Technol, CZ-76272 Zlin, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz","GACR [102/08/1546, KAN208130801]","Financial support from the grant GACR 102/08/1546 and KAN208130801 is highly acknowledged.",null,51,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0039-9140",null,"10.1016/j.talanta.2009.04.007","TALANTA","Talanta","JUL 15",2009,79,2,null,null,null,402,411,null,null,10,"Chemistry, Analytical","473OK","ISI:000268216900046"]
[18,"J","Lassuthova, P; Barankova, L; Haberlova, J; Mazanec, R; Wallace, A; Huehne, K; Rautenstrauss, B; Seeman, P",null,null,null,"Lassuthova, Petra; Barankova, Lucia; Haberlova, Jana; Mazanec, Radim; Wallace, Andrew; Huehne, Kathrin; Rautenstrauss, Bernd; Seeman, Pavel",null,"Mutations in the LMNA gene do not cause axonal CMT in Czech patients","Journal of Human Genetics",null,"English","Article",null,null,null,null,null,"autosomal recessive Charcot-Marie-Tooth disease; HMSN II; Lamin A/C; MLPA; mutation","CHARCOT-MARIE-TOOTH; LAMIN A/C GENE; MUSCULAR-DYSTROPHY; HEREDITARY MOTOR; DISEASE MAPS; NEUROPATHY; FAMILIES; TYPE-2; LOCUS; FORM","The LMNA gene was sequenced in 98 Czech patients from 94 unrelated families with early-onset axonal Charcot-Marie-Tooth (CMT) disease consistent with both autosomal recessive inheritance and sporadic cases. Biallelic pathogenic mutations were not found in any patient in this group. One patient carried the c.1870C>T mutation that is predicted to result in the amino-acid substitution, p. Arg624Cys, on one allele, but the second causative mutation was not detected. LMNA mutation is not likely to be associated with the disease in this family. To exclude larger deletions/duplications in the LMNA gene not detectable by sequencing, 48 patients from this group were also analyzed with multiplex ligation-dependent probe amplification. No rearrangements in the LMNA gene were detected. We conclude that mutations in the LMNA gene are absent from a large group of Czech patients with axonal autosomal recessive CMT disease. Consequently, LMNA mutation screening does not seem to be relevant for axonal CMT DNA diagnostics. A similar situation may apply to other European populations. Journal of Human Genetics (2009) 54, 365-368; doi:10.1038/jhg.2009.43; published online 8 May 2009","[Lassuthova, Petra; Haberlova, Jana; Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague 15006 5, Czech Republic; [Barankova, Lucia; Mazanec, Radim] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Wallace, Andrew] St Marys Hosp, Dept Med Genet, NGRL Manchester, Manchester M13 0JH, Lancs, England; [Huehne, Kathrin; Rautenstrauss, Bernd] Univ Erlangen Nurnberg, Inst Human Genet, D-8520 Erlangen, Germany; [Rautenstrauss, Bernd] MGZ Med Genet Zentrum, Munich, Germany","Lassuthova, P, Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Uvalu 84, Prague 15006 5, Czech Republic","petra.lassuthova@gmail.com","Czech Ministry of Health [NR 8330-3]","This study was supported by the Czech Ministry of Health (Grant IGA NR 8330-3). We thank our patients and their families for their participation.",null,22,0,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1434-5161",null,"10.1038/jhg.2009.43","J HUM GENET","J. Hum. Genet.","JUN",2009,54,6,null,null,null,365,368,null,null,4,"Genetics & Heredity","474VP","ISI:000268312700010"]
[18,"J","Haberlova, J; Claeys, KG; De Jonghe, P; Seeman, P",null,null,null,"Haberlova, J.; Claeys, K. G.; De Jonghe, P.; Seeman, P.",null,"Cranial nerves palsy as an initial feature of an early onset distal hereditary motor neuropathy - A new distal hereditary motor neuropathy phenotype","Neuromuscular Disorders",null,"English","Article",null,null,null,null,null,"Distal hereditary motor neuropathy; Cranial nerve palsy; Slow progression; Autosomal dominant inheritance","MUSCULAR-ATROPHY; PARALYSIS","Distal hereditary motor neuropathy is a heterogeneous group of disorders characterised by a pure motor axonal neuropathy. It is occasionally associated with additional signs such as facial weakness, vocal cord paralysis, weakness of the diaphragm, and pyramidal signs. Although predominantly the inheritance is autosomal dominant, all types of inheritance have been described. Here we report a Czech family with cranial nerves palsy as an initial feature of a non progressive infantile onset dominant distal hereditary motor neuropathy. This family may represent a new subtype of distal hereditary motor neuropathy. (C) 2009 Elsevier B.V. All rights reserved.","[Haberlova, J.; Seeman, P.] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15200 5, Czech Republic; [Claeys, K. G.] Grp Hosp Pitie Salpetriere, Inst Myol, F-75634 Paris, France; [De Jonghe, P.] Univ Antwerp VIB, Dept Mol Genet, Neurogenet Grp, B-2610 Antwerp, Belgium; [De Jonghe, P.] Univ Antwerp Hosp, Dept Neurol, Antwerp, Belgium","Haberlova, J, Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15200 5, Czech Republic","jana.haberlova@gmail.com",null,null,null,6,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966",null,"10.1016/j.nmd.2009.03.005","NEUROMUSCULAR DISORD","Neuromusc. Disord.","JUN",2009,19,6,null,null,null,427,428,null,null,2,"Clinical Neurology; Neurosciences","474SV","ISI:000268305200009"]
[18,"J","Lassuthova, P; Barankova, L; Kraus, J; Marikova, T; Seeman, P",null,null,null,"Lassuthova, Petra; Barankova, Lucia; Kraus, Josef; Marikova, Tat'ana; Seeman, Pavel",null,"Emery-Dreifuss Muscular Dystrophy: A Novel Mutation in the LMNA Gene","Pediatric Neurology",null,"English","Article",null,null,null,null,null,null,"LAMIN A/C GENE; SUDDEN-DEATH","Described here is the phenotypical expression of a novel LMNA mutation c.1157 G>T in a Czech patient with an early-onset form of Emery-Dreifuss muscular dystrophy. The mutation predicts aberrant splicing. Now 21 years old, the patient has had slowly progressing muscle dystrophy since the age of one and early contractures of elbows. He is the only family member affected. Even though the dystrophy typically affects the heart as well, in the present case these signs are not yet expressed. (C) 2009 by Elsevier Inc. All rights reserved.","[Lassuthova, Petra; Kraus, Josef; Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Barankova, Lucia] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague 15006 5, Czech Republic; [Marikova, Tat'ana] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Prague 15006 5, Czech Republic","Lassuthova, P, Charles Univ Prague, Dept Child Neurol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","petra.lassuthova@gmail.com","Czech Republic Ministry of Health [8330-3]","Thanks go to the patient and his family for participating in this project. Thanks also go to Kathrin Huehne, PhD, and Professor Bernd Rautenstrauss, MD, PhD, for their help, and to Professor Zdenek Lukas. MD, DrSc, for muscle biopsy evaluation. This study was supported by a grant from the Czech Republic Ministry of Health (Internal Grant Agency of Ministry of Health of Czech Republic NR 8330-3).",null,14,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0887-8994",null,"10.1016/j.pediatrneurol.2009.03.009","PEDIAT NEUROL","Pediatr. Neurol.","AUG",2009,41,2,null,null,null,127,130,null,null,4,"Clinical Neurology; Pediatrics","473ME","ISI:000268210200010"]
[18,"C","Goubau, C; Wilschanski, M; Skalicka, V; Lebecque, P; Southern, KW; Sermet, I; Munck, A; Derichs, N; Middleton, PG; Hjelte, L; Padoan, R; Vasar, M; De Boeck, K",null,null,null,"Goubau, C.; Wilschanski, M.; Skalicka, V.; Lebecque, P.; Southern, K. W.; Sermet, I.; Munck, A.; Derichs, N.; Middleton, P. G.; Hjelte, L.; Padoan, R.; Vasar, M.; De Boeck, K.",null,"Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis","Thorax",null,"English","Proceedings Paper","8th International Congress on Pediatric Pulmonolgy","MAR 29-31, 2008","Nice, FRANCE",null,null,null,"NASAL POTENTIAL DIFFERENCE; TRANSMEMBRANE REGULATOR GENE; PULMONARY-FUNCTION; CLINICAL-TRIALS; MUTATIONS; DISEASE; CONSENSUS; EXACERBATIONS; GUIDELINES; MANAGEMENT","Background: In patients with symptoms suggestive of cystic fibrosis (CF) and intermediate sweat chloride values (30-60 mmol/l), extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal were compared with subjects in whom this was not the case and patients with classic CF. Methods: The phenotypic features of four groups were compared: 59 patients with CFTR dysfunction, 46 with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 patients with CF and pancreatic sufficiency (CF-PS) and 62 with CF and pancreatic insufficiency (CF-PI). Results: The CFTR dysfunction group had more lower respiratory tract infections (p = 0.01), more isolation of CF pathogens (p<0.001) and clubbing (p = 0.001) than the CF unlikely group, but less frequent respiratory tract infections with CF pathogens than the CF-PS group (p = 0.05). Patients in the CF-PS group had a milder phenotype than those with PI. Many features showed stepwise changes through the patient groups. Conclusion: Patients with intermediate sweat chloride values and two CFTR mutations or an abnormal NPD measurement have a CF-like phenotype compatible with CFTR dysfunction and, as a group, differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PI patients.","[Goubau, C.; De Boeck, K.] Univ Louvain, Dept Paediat, Louvain, Belgium; [Wilschanski, M.] Hadassah Med Org, Dept Paediat Gastroenterol, Jerusalem, Israel; [Skalicka, V.] Fac Hosp Motol, Dept Paediat, Prague, Czech Republic; [Lebecque, P.] Univ Catholique Louvain, Clin St Luc, B-1200 Brussels, Belgium; [Southern, K. W.] Royal Liverpool Childrens Hosp, Liverpool L7 7DG, Merseyside, England; [Sermet, I.] Hop Necker Enfants Malad, Paris, France; [Munck, A.] Hop Robert Debre, F-75019 Paris, France; [Derichs, N.] Hannover Med Sch, Dept Paediat, D-30623 Hannover, Germany; [Middleton, P. G.] Westmead Hosp, Ludwig Engel Ctr Resp Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia; [Middleton, P. G.] Univ Sydney, Westmead, NSW 2145, Australia; [Hjelte, L.] Karolinska Univ, Huddinge Hosp, Stockholm CF Ctr, Karolinska Inst, Stockholm, Sweden; [Padoan, R.] Osped Bambini Brescia, CF Ctr, Brescia, Italy; [Vasar, M.] Tartu Univ Clin, Childrens Clin, Tartu, Estonia","De Boeck, K, Katholieke Univ Leuven Hosp, Dept Paediat, Herestr 49, B-3000 Louvain, Belgium","christiane.deboeck@uzleuven.be",null,null,null,41,0,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","0040-6376",null,"10.1136/thx.2008.104752","THORAX","Thorax","AUG",2009,64,8,null,null,null,683,691,null,null,9,"Respiratory System","476AB","ISI:000268408000011"]
[18,"J","Weerkamp, F; Dekking, E; Ng, YY; van der Velden, VHJ; Wai, H; Bottcher, S; Bruggemann, M; van der Sluijs, AJ; Koning, A; Boeckx, N; Van Poecke, N; Lucio, P; Mendonca, A; Sedek, L; Szczepanski, T; Kalina, T; Kovac, M; Hoogeveen, PG; Flores-Montero, J; Orfao, A; Macintyre, E; Lhermitte, L; Chen, R; Brouwer-De Cock, KAJ; van der Linden, A; Noordijk, AL; Comans-Bitter, WM; Staal, FJT; van Dongen, JJM",null,null,null,"Weerkamp, F.; Dekking, E.; Ng, Y. Y.; van der Velden, V. H. J.; Wai, H.; Boettcher, S.; Brueggemann, M.; van der Sluijs, A. J.; Koning, A.; Boeckx, N.; Van Poecke, N.; Lucio, P.; Mendonca, A.; Sedek, L.; Szczepanski, T.; Kalina, T.; Kovac, M.; Hoogeveen, P. G.; Flores-Montero, J.; Orfao, A.; Macintyre, E.; Lhermitte, L.; Chen, R.; Brouwer-De Cock, K. A. J.; van der Linden, A.; Noordijk, A. L.; Comans-Bitter, W. M.; Staal, F. J. T.; van Dongen, J. J. M.","EuroFlow Consortium EU-FP6 LSHB-","Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients","Leukemia",null,"English","Article",null,null,null,null,null,"BCR-ABL protein; t(9;22); CML; precursor-B-ALL; immunobead; flow cytometry","CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; RESIDUAL DISEASE DETECTION; PHILADELPHIA-CHROMOSOME; C-ABL; TYROSINE KINASE; ANTIBODY RECOGNITION; GENE TRANSCRIPTS","BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR-ABL aberrations of utmost importance for diagnosis, classification and treatment of leukemia patients. BCR-ABL aberrations are currently detected by karyotyping, fluorescence in situ hybridization (FISH) or PCR techniques, which are time consuming and require specialized facilities. We developed a simple flow cytometric immunobead assay for detection of BCR-ABL fusion proteins in cell lysates, using a bead-bound anti-BCR catching antibody and a fluorochrome-conjugated anti-ABL detection antibody. We noticed protein stability problems in lysates caused by proteases from mature myeloid cells. This problem could largely be solved by adding protease inhibitors in several steps of the immunobead assay. Testing of 145 patient samples showed fully concordant results between the BCR-ABL immunobead assay and reverse transcriptase PCR of fusion gene transcripts. Dilution experiments with BCR-ABL positive cell lines revealed sensitivities of at least 1%. We conclude that the BCR-ABL immunobead assay detects all types of BCR-ABL proteins in leukemic cells with high specificity and sensitivity. The assay does not need specialized laboratory facilities other than a flow cytometer, provides results within similar to 4 h, and can be run in parallel to routine immunophenotyping. Leukemia (2009) 23, 1106-1117; doi: 10.1038/leu.2009.93; published online 23 April 2009","[van Dongen, J. J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; [Weerkamp, F.; Dekking, E.; Ng, Y. Y.; Brouwer-De Cock, K. A. J.; van der Linden, A.; Noordijk, A. L.] Dynomics, Rotterdam, Netherlands; [Wai, H.; Chen, R.] BD Biosci, San Jose, CA USA; [Boettcher, S.; Brueggemann, M.] Univ Klin Schleswig Holstein, Dept Med 2, Kiel, Germany; [van der Sluijs, A. J.; Koning, A.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Boeckx, N.; Van Poecke, N.] Univ Hosp Leuven, Dept Lab Med, Louvain, Belgium; [Lucio, P.; Mendonca, A.] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Lisbon, Portugal; [Sedek, L.; Szczepanski, T.] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Kalina, T.; Kovac, M.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Flores-Montero, J.; Orfao, A.] Univ Salamanca, Dept Med, Canc Res Ctr, IBMCC CSIC USAL, E-37008 Salamanca, Spain; [Flores-Montero, J.; Orfao, A.] Univ Salamanca, Cytometry Serv, E-37008 Salamanca, Spain; [Macintyre, E.; Lhermitte, L.] Hop Necker Enfants Malad, Dept Hematol, Paris, France","van Dongen, JJM, Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands","j.j.m.vandongen@erasmusmc.nl","European Commission through the STREP [LSHB-CT-2006-018708]; Fondo de Investigaciones Sanitarias (FIS) [EST-08-90881]; Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Madrid, Spain) ","This study was supported by the European Commission through the STREP grant EU-FP6, LSHB-CT-2006-018708, entitled Euro-Flow, 'Flow cytometry for fast and sensitive diagnosis and follow-up of haematological malignancies'. Work carried out at Salamanca was supported in part by a grant (EST-08-90881) from the Fondo de Investigaciones Sanitarias (FIS) of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Madrid, Spain).",null,45,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.93","LEUKEMIA","Leukemia","JUN",2009,23,6,null,null,null,1106,1117,null,null,12,"Oncology; Hematology","456DQ","ISI:000266820700011"]
[19,"J","Norambuena, PA; Copeland, JA; Krenkova, P; Stambergova, A; Macek, M",null,null,null,"Norambuena, Patricia A.; Copeland, Joshua A.; Krenkova, Petra; Stambergova, Alexandra; Macek, Milan, Jr.",null,"Diagnostic method validation: High resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene","Clinical Biochemistry",null,"English","Article",null,null,null,null,null,"DNA diagnostics; Genotyping; High resolution melting (HRM); Diagnostic validation; Methylenetetrahydrofolate reductase gene (MTHFR); Organization for Economic Cooperation and Development (OECD) guidelines; Small amplicons","SINGLE-NUCLEOTIDE POLYMORPHISMS; METHYLENETETRAHYDROFOLATE REDUCTASE; VASCULAR-DISEASE; RISK-FACTOR; CFTR GENE; MUTATION; DNA; CANCER; IDENTIFICATION; SYSTEM","Objectives: According to OECD guidelines methods implemented in a diagnostic laboratory should be properly validated prior their implementation. For this purpose we selected genotyping by High Resolution Melting (HRM) of small amplicons using common variants in MTHFR as a model. Design and methods: We selected previously typed samples on which selected analytical validation-related parameters relevant to DNA diagnostics - specificity, sensitivity, precision, robustness and ability to perform reliable calls were evaluated. Results: Correct genotype was assigned in 375/381 (98.4%) for c.677 C>T (rs1801133: C>T; p.A222 V) and in 102/104 (98.1%) for c.1298 A>C (rs1801131: A>C; p.E429A) of all cases. Low analytical failure rate and very high specificity/sensitivity were achieved. Similarly, precision and robustness were consistent. Conclusions: We have successfully validated HRM of small amplicons using common MTHFR variants as a model. We proved that this technique is highly reliable for routine diagnostics and our diagnostic validation strategy can serve as a model for other applications. (C) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","[Macek, Milan, Jr.] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic","Macek, M, Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Uvalu 84, Prague 15006 5, Czech Republic","patynorambuena@gmail.com; milan.macek.jr@lfmotol.cuni.cz","VZFNM [00064203(6112)]; IGA [NR9448-3]; Czech Ministry of Health and EuroGentest [FP6-512148]","We thank I. Anguelovd, M. Fialova A. Nestorovic and E. Raugova for sample preparation and technical assistance. We acknowledge helpful consultations with Dr. N. van der Stoep (Leiden University Medical Centre) and Dr. M. Morris (Geneva University Hospital). Supported by VZFNM 00064203(6112) and IGA NR9448-3 from the Czech Ministry of Health and EuroGentest (FP6-512148).",null,39,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0009-9120",null,"10.1016/j.clinbiochem.2009.04.015","CLIN BIOCHEM","Clin. Biochem.","AUG",2009,42,12,null,null,null,1308,1316,null,null,9,"Medical Laboratory Technology","478YS","ISI:000268625300015"]
[19,"J","Merkerova, M; Vasikova, A; Bruchova, H; Libalova, H; Topinka, J; Balascak, I; Sram, RJ; Brdicka, R",null,null,null,"Merkerova, Michaela; Vasikova, Alzbeta; Bruchova, Hana; Libalova, Helena; Topinka, Jan; Balascak, Ivan; Sram, Radim J.; Brdicka, Radim",null,"Differential gene expression in umbilical cord blood and maternal peripheral blood","European Journal of Haematology",null,"English","Article",null,null,null,null,null,"gene expression; umbilical cord blood; peripheral blood; hematopoiesis; immune system","VERSUS-HOST-DISEASE; IMMUNE-RESPONSES; UNRELATED DONORS; DENDRITIC CELLS; BONE-MARROW; TRANSPLANTATION; ADULTS; LYMPHOCYTES; ENGRAFTMENT; RECOVERY","Objectives: Umbilical cord blood (UCB) has become a useful alternative source of hematopoietic stem cells for clinical and research applications. UCB represents neonatal blood and differs from adult blood in many aspects, displaying different cell composition and various features of cellular immaturity. To understand molecular basis of phenotypic differences between neonatal and adult blood, we studied variations in transcriptome of UCB and maternal peripheral blood (PB). Methods: Using Illumina microarrays, we determined gene expression profiles of UCB and PB samples obtained from 30 mothers giving birth to living baby. Results: Out of 20 589 tested genes, 424 genes were down-regulated and 417 genes were up-regulated in UCB compared with PB. Reduced expression of many immunity-related pathways (e.g. TLR pathway, Jak-STAT pathway, cytokine-cytokine receptor interaction) in neonatal blood cells may contribute to the poor response to antigens, increasing susceptibility to infections at the time of disappearance of protective maternal antibodies. On the other hand, overexpression of erythropoiesis-related genes (glycophorins, fetal hemoglobins, enzymes catalysing heme synthesis and erythrocyte differentiation) in UCB probably enforces red cell production in newborns. Conclusions: Our study demonstrates that neonatal and maternal bloods show specific gene expression profiles, likely reflecting differences in phenotypes of immunologically immature and fully evolved hematopoietic cells.","[Merkerova, Michaela; Vasikova, Alzbeta; Bruchova, Hana; Brdicka, Radim] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Libalova, Helena; Topinka, Jan; Sram, Radim J.] Acad Sci Czech Republic, Inst Expt Med, Prague 4, Czech Republic; [Balascak, Ivan] Fac Hosp Motol, Prague 5, Czech Republic","Brdicka, R, Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic","Radim.Brdicka@uhkt.cz","Czech Ministry of Education Youth and Sports [2B06088]","The authors wish to thank Mgr. Viktor Stranecky (Institute of Inherited Metabolic Disorders, 1st Faculty of Medicine of Charles University, Prague) for the array data analyses. The study was supported by the Czech Ministry of Education Youth and Sports (Grant No. 2B06088).",null,23,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0902-4441",null,"10.1111/j.1600-0609.2009.01281.x","EUR J HAEMATOL","Eur. J. Haematol.","SEP",2009,83,3,null,null,null,183,190,null,null,8,"Hematology","479TP","ISI:000268684100003"]
[19,"J","Gehre, F; Spisek, R; Kharat, AS; Matthews, P; Kukreja, A; Anthony, RM; Dhodapkar, MV; Vollmer, W; Tomasz, A",null,null,null,"Gehre, Florian; Spisek, Radek; Kharat, Arun S.; Matthews, Phillip; Kukreja, Anjli; Anthony, Robert M.; Dhodapkar, Madhav V.; Vollmer, Waldemar; Tomasz, Alexander",null,"Role of Teichoic Acid Choline Moieties in the Virulence of Streptococcus pneumoniae","Infection and Immunity",null,"English","Article",null,null,null,null,null,null,"LIPOTEICHOIC ACID; CELL-WALL; IN-VIVO; POLYSACCHARIDE; PNEUMOCOCCUS","In recent reports it was shown that genetically modified choline-free strains of Streptococcus pneumoniae (D39Cho(-) licA64 and D39ChiplicB31) expressing the type II capsular polysaccharide were virtually avirulent in the murine sepsis model, in sharp contrast to the isogenic and highly virulent strains D39Cho(-) and D39Chip, which have retained the choline residues at their surface. We now demonstrate that this choline-associated virulence is independent of Toll-like receptor 2 recognition. Also, despite the lack of virulence, choline-free strains of S. pneumoniae were able to activate splenic dendritic cells, induce secretion of proinflammatory cytokines, and produce specific protective immunity against subsequent challenge. However, after this transient engagement of the immune system the choline-free bacteria were rapidly cleared from the blood, while the isogenic virulent strain D39Cho(-) continued to grow, accompanied by prolonged expression of cytokines, eventually killing the experimental animals. The critical contribution of choline residues to the virulence potential of pneumococci appears to be the role that these amino alcohol residues play in a pneumococcal immune evasion strategy, the mechanism of which is unknown at the present time.","[Gehre, Florian; Kharat, Arun S.; Tomasz, Alexander] Rockefeller Univ, Microbiol Lab, New York, NY 10065 USA; [Spisek, Radek] Univ Hosp Moto, Dept Immunol, Prague, Czech Republic; [Spisek, Radek] Second Med Fac, Prague, Czech Republic; [Spisek, Radek; Matthews, Phillip; Kukreja, Anjli; Dhodapkar, Madhav V.] Rockefeller Univ, Lab Tumor Immunol & Immunotherapy, New York, NY 10065 USA; [Anthony, Robert M.] Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10065 USA; [Kharat, Arun S.] Marathwada Univ, Dept Biotechnol, Aurungabad, India; [Dhodapkar, Madhav V.] Yale Univ, Sect Hematol, New Haven, CT USA; [Vollmer, Waldemar] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England","Tomasz, A, Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10065 USA","tomasz@rockefeller.edu","American Austrian Foundation ; Irene Diamond Foundation ","Partial support for these studies was provided by grants from the American Austrian Foundation and the Irene Diamond Foundation to the laboratory of Alexander Tomasz.",null,20,0,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0019-9567",null,"10.1128/IAI.00986-08","INFEC IMMUNITY","Infect. Immun.","JUL",2009,77,7,null,null,null,2824,2831,null,null,8,"Immunology; Infectious Diseases","460XV","ISI:000267227000024"]
[20,"J","Krskova, L; Kalinova, M; Brizova, H; Mrhalova, M; Sumerauer, D; Kodet, R",null,null,null,"Krskova, Lenka; Kalinova, Marketa; Brizova, Helena; Mrhalova, Marcela; Sumerauer, David; Kodet, Roman",null,"Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma","Cancer Genetics and Cytogenetics",null,"English","Article",null,null,null,null,null,null,"SYT-SSX; PROLIFERATIVE ACTIVITY; TUMOR-TYPE; APOPTOSIS; PROTEIN; FUSION; OVEREXPRESSION; PROGNOSIS; CELLS; TRANSLOCATION","Synovial sarcoma (SS) is a highly aggressive soft tissue sarcoma that causes death in more than half of the affected patients. An immunohistochemical and molecular study of the BCL2, MKI67, and CCND1 genes (expressing the BCL2, KI-67, and cyclin D1 proteins, respectively) was performed to determine the expression profiles in correlation with mRNA levels, and to assess the possible utility of these genes as a potential target for the treatment. Cyclin D1 staining was identified in 18 of 30 cases (60%), and CCND1 mRNA was overexpressed in 15 of 32 cases (47%). KI-67 nuclear immunoreactivity was found in 14 of 29 cases (48%), and MKI67 mRNA was overexpressed in 12 of 32 cases (37.5%). The high level of MKI67 mRNA was observed predominantly in monophasic SS. BCL2, a negative regulator of apoptosis, was expressed in all 32 cases. The intensity of the BCL2 protein expression correlated well with the mRNA level (P < 0.0001). The high level of BCL2 mRNA correlated with a high level of CCND1 mRNA, but not with MKI67 mRNA level. Despite advances in therapy of sarcomas, the prognosis of patients with SS remains unfavorable, and a search for an improved therapy approach remains necessary. The strong immunopositivity of BCL2 in SS correlates well with a high level of BCL2 mRNA. Treatment with antisense BCL2 (G3139) may therefore represent an appropriate alternative therapy for patients with BCL2-positive synovial sarcomas. (C) 2009 Elsevier Inc. All rights reserved.","[Krskova, Lenka; Kalinova, Marketa; Brizova, Helena; Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague 15006, Czech Republic; [Krskova, Lenka; Kalinova, Marketa; Brizova, Helena; Mrhalova, Marcela; Sumerauer, David; Kodet, Roman] Fac Hosp Motol, Prague 15006, Czech Republic; [Sumerauer, David] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague 15006, Czech Republic","Krskova, L, Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Uvalu 84, Prague 15006, Czech Republic","lenka.krskova@lfmotol.cuni.cz","Grant Agency of Charles University GAUK [200 052 (63/2005/C)]; Internal Grant of Faculty Hospital Moto [IGFNM 9756]; Research Project of the Ministry of Education [MSM 0021620813]; Research Project of the Ministry of Health of Czech Republic [FNM MZO 00064203]","This study was supported by the Grant Agency of Charles University GAUK 200 052 (63/2005/C), Internal Grant of Faculty Hospital Moto IGFNM 9756, the Research Project of the Ministry of Education MSM 0021620813, and the Research Project of the Ministry of Health of Czech Republic FNM MZO 00064203.",null,34,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,"10.1016/j.cancergencyto.2009.03.008","CANCER GENET CYTOGENET","Cancer Genet. Cytogenet.","AUG",2009,193,1,null,null,null,1,8,null,null,8,"Oncology; Genetics & Heredity","482XC","ISI:000268922900001"]
[20,"J","Finkova, A; Vazna, A; Hrachovina, O; Bendova, S; Prochazkova, K; Sedlacek, Z",null,null,null,"Finkova, Alena; Vazna, Alzbeta; Hrachovina, Ondrej; Bendova, Sarka; Prochazkova, Kamila; Sedlacek, Zdenek",null,"The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations","Cancer Genetics and Cytogenetics",null,"English","Article",null,null,null,null,null,null,"P53 GENE; BREAST-CANCER; CPG METHYLATION; TELOMERE LENGTH; HCHK2 MUTATIONS; BLOOD-CELLS; INDIVIDUALS; EPIMUTATION; CARCINOGENESIS; EXPRESSION","Germline TP53 mutations are found in only 70% of families with the Li-Fraumeni syndrome (LFS), and with an even lower frequency in families suggestive of LFS but not meeting clinical criteria of the syndrome. Despite intense efforts, to date, no other genes have been associated with the disorder in a significant number of TP53 mutation-negative families. A search for defects in TP53 other than heterozygous missense mutations showed that neither intron variants nor sequence variants in the TP53 promoter are frequent in LFS, and multiexon deletions have been found to be responsible for US only in several cases. Another cancer predisposition syndrome, hereditary non-polyposis colon cancer, has been associated with epigenetic silencing of one allele of the MLH1 or MSH2 genes. This prompted us to test the methylation of the TP53 gene promoter in a set of 14 families suggestive of LFS using bisulphite sequencing of three DNA fragments from the 5' region of the gene. We found no detectable methylation at any of the CG dinucleotides tested. Thus, epigenetic silencing of the TP53 promoter is not a frequent cause of the disorder in families suggestive of LFS but with no germline mutations in the coding part of the gene. (C) 2009 Elsevier Inc. All rights reserved.","[Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic","Sedlacek, Z, Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Vuvalu 84, Prague 15006 5, Czech Republic","zdenek.sedlacek@lfmotol.cuni.cz","[MSM0021620813]; [MZO00064203]","This work was supported by grants MSM0021620813 and MZO00064203.",null,37,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,"10.1016/j.cancergencyto.2009.04.014","CANCER GENET CYTOGENET","Cancer Genet. Cytogenet.","AUG",2009,193,1,null,null,null,63,66,null,null,4,"Oncology; Genetics & Heredity","482XC","ISI:000268922900008"]
[20,"J","Eckschlager, T; Adam, V; Hrabeta, J; Figova, K; Kizek, R",null,null,null,"Eckschlager, Tomas; Adam, Vojtech; Hrabeta, Jan; Figova, Katarina; Kizek, Rene",null,"Metallothioneins and Cancer","Current Protein & Peptide Science",null,"English","Review",null,null,null,null,null,"Metallothioneins; cancer marker; cancer cell chemoresistance; detection","CAPILLARY-ZONE-ELECTROPHORESIS; PERFORMANCE LIQUID-CHROMATOGRAPHY; CURRENT STRIPPING CHRONOPOTENTIOMETRY; DIFFERENTIAL-PULSE POLAROGRAPHY; MASS-SPECTROMETRIC DETECTION; BIOINORGANIC SPECIATION ANALYSIS; CURVE RESOLUTION ANALYSIS; MESSENGER-RNA EXPRESSION; MERCURY SATURATION ASSAY; KI-67 ANTIGEN-EXPRESSION","Metallothioneins (MTs) are low molecular, cysteine-rich proteins that have naturally-occurring Zn2+ in both clusters. They may serve as a reservoir of metals for synthesis of apoenzymes and zinc-finger transcription regulators. MTs are also involved with several important proteins e. g. p53, NF-kappa B, PKCl, and GTPase Rab3A. New biological roles for these proteins have been identified including those needed in the carcinogenic process. However, their use as a predictive marker remains controversial. Several reports have disclosed MTs expression as a prognostic factor for tumor progression and drug resistance in a variety of malignancies particularly breast, prostatic, ovarial, head and neck, non-small cell lung cancer, melanoma, and soft tissue sarcoma. The role of MTs as a tumor disease marker or as a cause of resistance in cancer treatment is reviewed and discussed. Moreover, we describe some analytical methods that were developed to detect MTs.","[Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas; Hrabeta, Jan; Figova, Katarina] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz","Grant Agency of the Czech Academy of Sciences [GA AV IAAA401990701]; Ministry of Education, Youth and Sports [MSM 0021620813]","The financial support from the Grant Agency of the Czech Academy of Sciences (grant no. GA AV IAAA401990701) and from the Ministry of Education, Youth and Sports (grant no. MSM 0021620813) is greatly acknowledged.",null,235,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-2037",null,null,"CURR PROTEIN PEPT SCI","Curr. Protein Pept. Sci.","AUG",2009,10,4,null,null,null,360,375,null,null,16,"Biochemistry & Molecular Biology","482VS","ISI:000268918200004"]
[20,"J","Cejkova, J; Ardan, T; Cejka, C; Malec, J; Jirsova, K; Filipec, M; Ickova, ER; Dotielova, D; Brunova, B",null,null,null,"Cejkova, J.; Ardan, T.; Cejka, C.; Malec, J.; Jirsova, K.; Filipec, M.; Ickova, E. Ruz; Dotielova, D.; Brunova, B.",null,"Ocular surface injuries in autoimmune dry eye. The severity of microscopical disturbances goes parallel with the severity of symptoms of dryness","Histology and Histopathology",null,"English","Review",null,null,null,null,null,"Autoimmune dry eye; Oxidative injuries; Pro-inflammatory cytokines; Reactive oxygen and nitrogen species; Antioxidant enzymes","NITRIC-OXIDE SYNTHASE; SJOGRENS-SYNDROME; XANTHINE OXIDOREDUCTASE; TEAR FLUID; CONJUNCTIVAL EPITHELIUM; INFLAMMATORY CYTOKINES; OXIDATIVE REACTIONS; CELLS; INTERLEUKIN-1-BETA; EXPRESSION","Autoimmune dry eye (Sjogren's syndrome, SS) is a chronic systemic disease characterized by salivary and lacrimal gland inflammation and tissue damage leading to keratoconjunctivitis sicca and xerostomia. In this review attention has been devoted to the cause of the development of oxidative injuries of the ocular surface of patients suffering from SS. It was shown that lacrimal glands and diseased conjunctival epithelium reveal increased expression of pro-inflammatory cytokines which are released into the tear fluid. A high amount of pro-inflammatory cytokines highly induce the elevated expression and activity of enzymatic systems that generate reactive oxygen and nitrogen species. An abundant amount of these toxic products leads to a decrease in antioxidants and to the formation of cytotoxic related oxidants, such as peroxynitrite. All these factors, together with reactive oxygen species from polymorphonuclear leukocytes, contribute to the development of oxidative injuries at the ocular surface. From the clinical point of view it is important that the level of severity of the above described microscopical disturbances found in conjunctival epithelial cells goes parallel with the level of severity of dry eye symptoms.","[Cejkova, J.; Ardan, T.; Cejka, C.] Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, CR-14220 Prague 4, Czech Republic; [Cejka, C.; Dotielova, D.; Brunova, B.] Charles Univ Prague, Motol Hosp, Dept Ophthalmol Children & Adults, Sch Med 2, Prague, Czech Republic; [Jirsova, K.; Filipec, M.; Ickova, E. Ruz] Gen Teaching Hosp, Eye Clin, Prague, Czech Republic; [Jirsova, K.; Filipec, M.; Ickova, E. Ruz] Gen Teaching Hosp, Lab Biol & Pathol Eye, Inst Inherited Metab Disorders, Prague, Czech Republic","Cejkova, J, Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, Videnska 1083, CR-14220 Prague 4, Czech Republic","cejkova@biomed.cas.cz","Ministry of Health of the Czech Republic [NR/8828-3]","This work was supported by a grant from the Ministry of Health of the Czech Republic No. NR/8828-3.",null,30,0,"F HERNANDEZ","MURCIA","PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN","0213-3911",null,null,"HISTOL HISTOPATHOL","Histol. Histopath.","OCT",2009,24,10,null,null,null,1357,1365,null,null,9,"Cell Biology; Pathology","484WO","ISI:000269079900012"]
[20,"J","Dhir, V; Reisch, N; Bleicken, CM; Lebl, J; Kamrath, C; Schwarz, HP; Grotzinger, J; Sippell, WG; Riepe, FG; Arlt, W; Krone, N",null,null,null,"Dhir, Vivek; Reisch, Nicole; Bleicken, Caroline M.; Lebl, Jan; Kamrath, Clemens; Schwarz, Hans-Peter; Groetzinger, Joachim; Sippell, Wolfgang G.; Riepe, Felix G.; Arlt, Wiebke; Krone, Nils",null,"Steroid 17 alpha-Hydroxylase Deficiency: Functional Characterization of Four Mutations (A174E, V178D, R440C, L465P) in the CYP17A1 Gene","Journal of Clinical Endocrinology & Metabolism",null,"English","Article",null,null,null,null,null,null,"GENOTYPE-PHENOTYPE CORRELATIONS; ISOLATED 17,20-LYASE DEFICIENCY; CONGENITAL ADRENAL-HYPERPLASIA; DIFFERENTIAL INHIBITION; P450 OXIDOREDUCTASE; CYTOCHROME P450C17; POINT MUTATION; IDENTIFICATION; ALDOSTERONE; FEMALE","Context: Steroid 17 alpha-hydroxylase (CYP17A1, alias P450c17) deficiency (17OHD) is a rare form of congenital adrenal hyperplasia. The CYP17A1 enzyme catalyzes two distinct reactions, 17 alpha-hydroxylase and 17,20-lyase activities. Objective: The aim of the study was to analyze the structural and functional consequences of three novel (A174E, V178D, and L465P) and one previously reported (R440C) CYP17A1 mutation found in three patients clinically and biochemically presenting with 17OHD. Patients and Methods: Two patients suffering from 46, XY disordered sex development presented at ages 5.5 and 8.8 yr, respectively, with tall stature and hypertension. Mutation analysis revealed compound heterozygous CYP17A1 mutations (A174E/K388X; V178D/R440C). The third patient (46, XX) presented with primary amenorrhea and hypertension at age 15 yr. She was homozygous for the novel L465P mutation. Functional studies employing a yeast microsomal expression system compared wild-type and mutant CYP17A1 both with regard to 17 alpha-hydroxylase and 17,20-lyase activity. Mutants were examined in a computational three-dimensional model of the CYP17A1 protein. Results: The activity assays showed that all three mutants retain only 0-7% of both 17 alpha-hydroxylase and 17,20-lyase activity relative to CYP17A1 wild-type activity, corresponding to the in vivo situation. Enzyme kinetic studies proved the impairment of both reactions, respectively. Computer-based three-dimensional model analysis of CYP17A1 using CYP2B4 as template showed that three of the mutations had no direct effect on the active center, whereas one affects the heme coordination. Conclusion: The functional studies revealed that the described missense mutations result in severe 17OHD. Our data are important to predict the phenotypic expressions and provide important information for patient management and genetic counseling. (J Clin Endocrinol Metab 94: 3058-3064, 2009)","[Krone, Nils] Univ Birmingham, Ctr Endocrinol Diabet & Metab, Sch Clin & Expt Med, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 11000, Czech Republic; [Kamrath, Clemens] Zentrum Kinderheilkunde I, Zentrum Kinder & Jugendmed, D-60596 Frankfurt, Germany; [Schwarz, Hans-Peter] Univ Hosp Munich, von Haunersches Kinderspital, Dept Endocrinol, D-80337 Munich, Germany; [Groetzinger, Joachim] Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; [Sippell, Wolfgang G.; Riepe, Felix G.] Univ Hosp Schleswig Holstein, Dept Pediat, Div Pediat Endocrinol & Diabet, D-24105 Kiel, Germany","Krone, N, Univ Birmingham, Ctr Endocrinol Diabet & Metab, Sch Clin & Expt Med, Inst Biomed Res, Wolfson Dr, Birmingham B15 2TT, W Midlands, England","n.p.krone@bham.ac.uk","Deutsche Forschungsgemeinschaft [AL203-9, KR 3363/1-1]; European Community's Seventh Framework Program [PIEFGA2008- 221058]; Medical Research Council UK [G116/172]; Wellcome Trust [GR079865MA]","This work was supported by the Deutsche Forschungsgemeinschaft (Grant AL203-9 to W. A.; Grant KR 3363/1-1 to N. K.), the European Community's Seventh Framework Program (Marie Curie Intra-European Fellowship for Career Development under grant agreement PIEFGA2008- 221058 to N. R.), the Medical Research Council UK (Senior Clinical Fellowship G116/172 to W. A.), and the Wellcome Trust (Clinician Scientist Fellowship GR079865MA to N. K.).",null,33,0,"ENDOCRINE SOC","CHEVY CHASE","8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA","0021-972X",null,"10.1210/jc.2009-0172","J CLIN ENDOCRINOL METAB","J. Clin. Endocrinol. Metab.","AUG",2009,94,8,null,null,null,3058,3064,null,null,7,"Endocrinology & Metabolism","479UW","ISI:000268687700058"]
[20,"J","Gimpel, C; Wuhl, E; Arbeiter, K; Drozdz, D; Trivelli, A; Charbit, M; Gellermann, J; Dusek, J; Jankauskiene, A; Emre, S; Schaefer, F",null,null,null,"Gimpel, Charlotte; Wuehl, Elke; Arbeiter, Klaus; Drozdz, Dorota; Trivelli, Antonella; Charbit, Marina; Gellermann, Jutta; Dusek, Jiri; Jankauskiene, Augustina; Emre, Sevinc; Schaefer, Franz","ESCAPE Trial Grp","Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials","Journal of Hypertension",null,"English","Article",null,null,null,null,null,"adolescents; ambulatory blood pressure measurement; antihypertensive drugs; children; clinical trial; hypertension","CHRONIC-RENAL-FAILURE; MASKED HYPERTENSION; MASS INDEX; ADOLESCENTS; HOME; EFFICACY; OFFICE; REPRODUCIBILITY; INFANTS; HEALTHY","Background Casual office blood pressure (CBP) measurements are still standard in antihypertensive drug trials. In pediatric hypertensive trials, ethical considerations, very low disease prevalence and the marked impact of white-coat hypertension create the need for very sensitive and reproducible techniques of BP assessment. We hypothesized that ambulatory BP monitoring (ABPM) may identify treatment effects more sensitively than CBP and thereby reduce sample sizes required in pediatric antihypertensive trials. Methods Standard deviations (SDs) were used to assess population variability of CBP and ABPM at baseline and after 6 months standardized antihypertensive treatment from a trial investigating the BP-lowering effect of ramipril in children with chronic kidney disease. Results In 157 hypertensive children, ramipril had a similar mean BP-lowering effect on clinic and ambulatory 24-h BP for systolic (-10 vs. -11 mm Hg, P = NS) and diastolic values (-9 vs. -11 mm Hg, P = NS). However, the SDs of the CBP responses were up to 39% larger than those of ABPM (SBP 15.5 vs. 9.4; DBP 13.8 vs. 8.8; both P< 0.0001). Using power analysis, we demonstrate that, depending on the magnitude of the expected antihypertensive effect and trial design, the utilization of ABPM in antihypertensive drug efficacy studies allows reduction of sample sizes by 57-75%. This reduction of cohort size with ABPM is substantially greater than previously observed for adults. Conclusion The primary use of ABPM can substantially reduce the number of children put at potential risk in blinded antihypertensive drug trials by up to three quarters. J Hypertens 27:1568-1574 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Gimpel, Charlotte; Wuehl, Elke; Schaefer, Franz] Univ Heidelberg Hosp, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, D-69120 Heidelberg, Germany; [Arbeiter, Klaus] Univ Childrens Hosp, Vienna, Austria; [Drozdz, Dorota] Jagiellonian Univ, Dialysis Unit, Polish Amer Childrens Hosp, Coll Med, Krakow, Poland; [Trivelli, Antonella] G Gaslini Inst Children, Genoa, Italy; [Charbit, Marina] Hop Necker Enfants Malad, Paris, France; [Gellermann, Jutta] Univ Childrens Hosp, Charite, Berlin, Germany; [Dusek, Jiri] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Jankauskiene, Augustina] Vilnius State Univ, Childrens Hosp, Vilnius, Lithuania; [Emre, Sevinc] Univ Istanbul, Istanbul Fac Med, Istanbul, Turkey","Schaefer, F, Univ Heidelberg Hosp, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, Neuenheimer Feld 430, D-69120 Heidelberg, Germany","franz.schaefer@med.uni-heidelberg.de","European Commission [QLG1-CT- 2002-00908]; Boehringer Ingelheim Stiftung ; Baxter Extramural ; Aventis Pharma ","Support for this study was obtained from the (5th Framework Programme (QLG1-CT- 2002-00908), the Boehringer Ingelheim Stiftung, the Baxter Extramural Grant Program and Aventis Pharma.",null,33,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/HJH.0b013e32832cb2a8","J HYPERTENSION","J. Hypertens.","AUG",2009,27,8,null,null,null,1568,1574,null,null,7,"Peripheral Vascular Disease","481JD","ISI:000268803900011"]
[20,"J","Bindu, S; Sanosh, KP; Smetana, K; Balakrishnan, A; Kim, TN",null,null,null,"Bindu, S.; Sanosh, K. P.; Smetana, K.; Balakrishnan, A.; Kim, T. N.",null,"An in vivo Evaluation of Ultra-fine Grained Titanium Implants","Journal of Materials Science & Technology",null,"English","Article",null,null,null,null,null,"Surfaces; Grain size; Titanium; In vivo; Biocompatibility","SEVERE PLASTIC-DEFORMATION; CELL RESPONSE; BIOMEDICAL APPLICATIONS; CORROSION-RESISTANCE; SURFACE-ROUGHNESS; FIBROBLASTS; BIOCOMPATIBILITY; ALLOYS; VITRO; BONE","The present work focuses mainly on an in vivo evaluation of ultra fine grained titanium (UFG-Ti) obtained by severe plastic deformation (SPD). The SPD on, commercially produced Grade 2 titanium (Cp-Ti) resulted in the refinement of the grain size by several orders of magnitude. Polished surfaces having similar roughness from both UFG-Ti and Cp-Ti were prepared. In vitro test revealed the presence of fibronectin, which was involved in the attachment of the cells to the substrate. Phase contrast micrographs showed the highest signal of fibronectin in UFG-Ti, indicating that it is more cytocompatible than Cp-Ti. In vivo tests, by subcutaneous implantation of the metals in the rats showed the better biocompatibility of UFG-Ti over Cp-Ti. The improved biocompatibility of UFG-Ti was attributed to the presence of surface discontinuities (in the form of nano-defects), surface energy, higher wettability, surface stress and stable TiO2 films, which increased the protein adsorption on the surface.","[Sanosh, K. P.; Balakrishnan, A.; Kim, T. N.] Paichai Univ, Dept Informat & Elect Mat Engn, Taejon 302735, South Korea; [Bindu, S.] Paichai Univ, Dept Life Sci & Genet Engn, Taejon 302735, South Korea; [Smetana, K.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Smetana, K.] Charles Univ Prague, Inst Anat, Fac Med 2, Prague, Czech Republic; [Smetana, K.] Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Kim, TN, Paichai Univ, Dept Informat & Elect Mat Engn, Taejon 302735, South Korea","the_krecian@yahoo.com","Paichai Bio-Medicinal Resources Research Center (RRC) ","Paichai Bio-Medicinal Resources Research Center (RRC) was acknowledged for their support.",null,38,0,"JOURNAL MATER SCI TECHNOL","SHENYANG","72 WENHUA RD, SHENYANG 110015, PEOPLES R CHINA","1005-0302",null,null,"J MATER SCI TECHNOL","J. Mater. Sci. Technol.","JUL",2009,25,4,null,null,null,556,560,null,null,5,"Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering","480ZE","ISI:000268775200027"]
[20,"J","Meyer, C; Kowarz, E; Hofmann, J; Renneville, A; Zuna, J; Trka, J; Ben Abdelali, R; Macintyre, E; De Braekeleer, E; De Braekeleer, M; Delabesse, E; de Oliveira, MP; Cave, H; Clappier, E; van Dongen, JJM; Balgobind, BV; van den Heuvel-Eibrink, MM; Beverloo, HB; Panzer-Grumayer, R; Teigler-Schlegel, A; Harbott, J; Kjeldsen, E; Schnittger, S; Koehl, U; Gruhn, B; Heidenreich, O; Chan, LC; Yip, SF; Krzywinski, M; Eckert, C; Moricke, A; Schrappe, M; Alonso, CN; Schafer, BW; Krauter, J; Lee, DA; zur Stadt, U; Kronnie, GT; Sutton, R; Izraeli, S; Trakhtenbrot, L; Lo Nigro, L; Tsaur, G; Fechina, L; Szczepanski, T; Strehl, S; Ilencikova, D; Molkentin, M; Burmeister, T; Dingermann, T; Klingebiel, T; Marschalek, R",null,null,null,"Meyer, C.; Kowarz, E.; Hofmann, J.; Renneville, A.; Zuna, J.; Trka, J.; Ben Abdelali, R.; Macintyre, E.; De Braekeleer, E.; De Braekeleer, M.; Delabesse, E.; de Oliveira, M. P.; Cave, H.; Clappier, E.; van Dongen, J. J. M.; Balgobind, B. V.; van den Heuvel-Eibrink, M. M.; Beverloo, H. B.; Panzer-Gruemayer, R.; Teigler-Schlegel, A.; Harbott, J.; Kjeldsen, E.; Schnittger, S.; Koehl, U.; Gruhn, B.; Heidenreich, O.; Chan, L. C.; Yip, S. F.; Krzywinski, M.; Eckert, C.; Moericke, A.; Schrappe, M.; Alonso, C. N.; Schaefer, B. W.; Krauter, J.; Lee, D. A.; zur Stadt, U.; Kronnie, G. Te; Sutton, R.; Izraeli, S.; Trakhtenbrot, L.; Lo Nigro, L.; Tsaur, G.; Fechina, L.; Szczepanski, T.; Strehl, S.; Ilencikova, D.; Molkentin, M.; Burmeister, T.; Dingermann, T.; Klingebiel, T.; Marschalek, R.",null,"New insights to the MLL recombinome of acute leukemias","Leukemia",null,"English","Article",null,null,null,null,null,"MLL; translocations partner genes; acute leukemia; ALL; AML","ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL BREAKPOINT SEQUENCES; PARTIAL TANDEM DUPLICATION; MINIMAL-RESIDUAL-DISEASE; HISTONE METHYLATION; PARTNER GENES; PROTEIN; TRANSLOCATIONS; IDENTIFICATION","Chromosomal rearrangements of the human MLL gene are associated with high-risk pediatric, adult and therapy-associated acute leukemias. These patients need to be identified, treated appropriately and minimal residual disease was monitored by quantitative PCR techniques. Genomic DNA was isolated from individual acute leukemia patients to identify and characterize chromosomal rearrangements involving the human MLL gene. A total of 760 MLL-rearranged biopsy samples obtained from 384 pediatric and 376 adult leukemia patients were characterized at the molecular level. The distribution of MLL breakpoints for clinical subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, pediatric and adult) and fused translocation partner genes (TPGs) will be presented, including novel MLL fusion genes. Combined data of our study and recently published data revealed 104 different MLL rearrangements of which 64 TPGs are now characterized on the molecular level. Nine TPGs seem to be predominantly involved in genetic recombinations of MLL: AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, MLLT4/AF6, ELL, EPS15/AF1P, MLLT6/AF17 and SEPT6, respectively. Moreover, we describe for the first time the genetic network of reciprocal MLL gene fusions deriving from complex rearrangements. Leukemia (2009) 23, 1490-1499; doi:10.1038/leu.2009.33; published online 5 March 2009","[Meyer, C.; Kowarz, E.; Hofmann, J.; Dingermann, T.; Marschalek, R.] Univ Frankfurt, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol, ZAFES, D-60438 Frankfurt, Germany; [Renneville, A.] CHU Lille, Dept Hematol, Biol & Pathol Ctr, F-59037 Lille, France; [Renneville, A.] INSERM, Team 3, U837, F-59045 Lille, France; [Zuna, J.; Trka, J.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol Oncol, CLIP, Prague, Czech Republic; [Ben Abdelali, R.; Macintyre, E.] Univ Paris 05, AP HP Necker, Paris, France; [De Braekeleer, E.; De Braekeleer, M.] Univ Bretagne Occidentale, Fac Med & Sci Sante, Lab Histol Embryol & Cytogenet, Brest, France; [De Braekeleer, E.; De Braekeleer, M.] INSERM, U613, Brest, France; [Delabesse, E.] CHU Purpan, Hematol Lab, Toulouse, France; [de Oliveira, M. P.] Inst Nacl Canc Rio de Janeiro, Res Ctr, Pediat Hematol Oncol Program, Rio De Janeiro, Brazil; [Cave, H.; Clappier, E.] Hop Robert Debre, Dept Genet, F-75019 Paris, France; [van Dongen, J. J. M.] Sophia Childrens Univ Hosp, Dept Immunol, Erasmus MC, Rotterdam, Netherlands; [Balgobind, B. V.; van den Heuvel-Eibrink, M. M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Beverloo, H. B.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Panzer-Gruemayer, R.; Strehl, S.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Teigler-Schlegel, A.; Harbott, J.] Childrens Univ Hosp, Dept Pediat Hematol & Oncol, Giessen, Germany; [Kjeldsen, E.] Aarhus Univ, Cancercytogenet Lab, Aarhus, Denmark; [Schnittger, S.] MLL Munich Leukemia Lab, Munich, Germany; [Koehl, U.; Klingebiel, T.] Univ Frankfurt, Dept Pediat Hematol & Oncol, Frankfurt, Germany; [Gruhn, B.] Univ Jena, Dept Pediat, Jena, Germany; [Heidenreich, O.] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Chan, L. C.; Yip, S. F.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Krzywinski, M.] Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Eckert, C.] Charite, Dept Pediat Oncol & Hematol, CVK, D-13353 Berlin, Germany; [Moericke, A.; Schrappe, M.] Univ Schleswig Holstein, Dept Paediat, Kiel, Germany; [Alonso, C. N.] Hosp Nacl Pediatria Prof Dr JP Garrahan, Serv Hematooncol, Buenos Aires, DF, Argentina; [Schaefer, B. W.] Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland; [Krauter, J.] Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany; [Lee, D. A.] Univ Texas MD Anderson Canc Ctr, Cell Therapy Sect, Div Pediat, Houston, TX 77030 USA; [zur Stadt, U.] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany; [Kronnie, G. Te] Univ Padua, Dept Paediat & Oncohematol, Padua, Italy; [Sutton, R.] Sydney Childrens Hosp, Childrens Canc Inst, Sydney, NSW, Australia; [Izraeli, S.; Trakhtenbrot, L.] Chaim Sheba Med Ctr, Dept Pediat Hematooncol, Tel Aviv, Israel; [Izraeli, S.; Trakhtenbrot, L.] Canc Res Ctr, Tel Aviv, Israel; [Izraeli, S.; Trakhtenbrot, L.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Lo Nigro, L.] Univ Catania, Ctr Pediat Hematol Oncol, Catania, Italy; [Tsaur, G.; Fechina, L.] Reg Children Hosp 1, Pediat Oncol & Hematol Ctr, Res Inst Med Cell Technol, Ekaterinburg, Russia; [Szczepanski, T.] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Ilencikova, D.] Natl Canc Hosp, Dept Clin Genet, Bratislava, Slovakia; [Molkentin, M.; Burmeister, T.] Charite, CBF, Fac Med 3, D-13353 Berlin, Germany","Marschalek, R, Univ Frankfurt, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol, ZAFES, Max von Laue Str 9, D-60438 Frankfurt, Germany","Rolf.Marschalek@em.uni-frankfurt.de","Deutsche Krebshilfe [107819]; German Jose Carreras Leukemia foundation [R06/22]; Polish Ministry of Science and Higher Education [2 P054 095 30]","This work was made possible by and conducted within the framework of the International BFM Study Group. This study was supported by grant 107819 from the Deutsche Krebshilfe to RM, TD and TK; supported by grant R06/22 from the German Jose Carreras Leukemia foundation to TB and supported by grant 2 P054 095 30 from the Polish Ministry of Science and Higher Education to TS.",null,42,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.33","LEUKEMIA","Leukemia","AUG",2009,23,8,null,null,null,1490,1499,null,null,10,"Oncology; Hematology","482CR","ISI:000268862000017"]
[20,"J","Herynek, V; Ruzickova, K; Jendelova, P; Sykova, E; Hajek, M",null,null,null,"Herynek, Vit; Ruzickova, Katerina; Jendelova, Pavla; Sykova, Eva; Hajek, Milan",null,"Metabolic changes in the rat brain after a photochemical lesion treated by stem cell transplantation assessed by 1H MRS","Magnetic Resonance Materials in Physics Biology and Medicine",null,"English","Article",null,null,null,null,null,"Mesenchymal stem cell transplantation; Magnetic resonance spectroscopy; Rats; Wistar","MARROW STROMAL CELLS; CENTRAL-NERVOUS-SYSTEM; OLIGODENDROCYTE PRECURSOR CELLS; MAGNETIC-RESONANCE TRACKING; IRON-OXIDE NANOPARTICLES; SPINAL-CORD-INJURY; BONE-MARROW; N-ACETYLASPARTATE; CONTRAST AGENT; GROWTH-FACTOR","Metabolite changes in an experimental lesion in the rat cortex and in the contralateral hemisphere after the intravenous administration of mesenchymal stem cells (MSCs) were assessed by proton MR spectroscopy to verify the impact of the cell treatment on the brain tissue. Wistar rats with a photochemical cortical lesion and transplanted MSCs or sham transplanted rats were examined. Proton spectra were obtained from the lesion and from the contralateral cortex. Magnetic resonance spectroscopy revealed a gradual recovery of the damaged tissue; however, we found no significant differences in metabolite concentrations in the lesioned hemisphere between treated and untreated animals. Higher concentrations of glutamate and N-acetyl aspartate were found in the contralateral hemisphere in cell-treated animals compared to untreated ones. Lesioned animals showed neurogenesis in the contralateral hemisphere; the number of newly generated cells in stem cell-treated animals was 50% higher than those observed in untreated animals. No direct impact of cell transplantation was observed in the lesion. However, changes in the contralateral hemisphere suggest that the transplanted MSCs might stimulate repair processes and plasticity resulting in the generation of newborn cells, which might enable the faster adoption of the damaged tissue's function by healthy tissue.","[Herynek, Vit; Hajek, Milan] Inst Clin & Expt Med, MR Unit, Dept Radiodiagnost & Intervent Radiol, Prague 14021, Czech Republic; [Herynek, Vit; Ruzickova, Katerina; Jendelova, Pavla; Sykova, Eva; Hajek, Milan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006, Czech Republic; [Ruzickova, Katerina; Jendelova, Pavla; Sykova, Eva] Inst Expt Med ASCR, Prague 14220, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006, Czech Republic","Herynek, V, Inst Clin & Expt Med, MR Unit, Dept Radiodiagnost & Intervent Radiol, Videnska 1958-9, Prague 14021, Czech Republic","vit.herynek@medicon.cz","Academy of Sciences of the Czech Republic [AV0Z50390703, KAN201110651]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538, LC554]; Ministry of Health of the Czech Republic [MZ01IKEM2005]; National Grant Agency of the Czech Republic [GACR 309/06/1594]; EC-FP6 [LSHB-CT-2005-512146]","This work was supported by grants from the Academy of Sciences of the Czech Republic AV0Z50390703, KAN201110651, the Ministry of Education, Youth and Sports of the Czech Republic 1M0538, LC554, the Ministry of Health of the Czech Republic MZ01IKEM2005, the National Grant Agency of the Czech Republic GACR 309/06/1594 and the EC-FP6 project DiMI: LSHB-CT-2005-512146.",null,43,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0968-5243",null,"10.1007/s10334-009-0166-2","MAGN RESON MATER PHYS BIOL M","Magn. Reson. Mat. Phys. Biol. Med.","AUG",2009,22,4,null,null,null,211,220,null,null,10,"Radiology, Nuclear Medicine & Medical Imaging","482QM","ISI:000268903800002"]
[20,"J","Havrdova, E; Zivadinov, R; Krasensky, J; Dwyer, MG; Novakova, I; Dolezal, O; Ticha, V; Dusek, L; Houzvickova, E; Cox, JL; Bergsland, N; Hussein, S; Svobodnik, A; Seidl, Z; Vaneckova, M; Horakova, D",null,null,null,"Havrdova, E.; Zivadinov, R.; Krasensky, J.; Dwyer, M. G.; Novakova, I.; Dolezal, O.; Ticha, V.; Dusek, L.; Houzvickova, E.; Cox, J. L.; Bergsland, N.; Hussein, S.; Svobodnik, A.; Seidl, Z.; Vaneckova, M.; Horakova, D.",null,"Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis","Multiple Sclerosis",null,"English","Article",null,null,null,null,null,"azathioprine; beta-interferon; corticosteroids; disease modifying therapies; placebo-controlled","RELAPSING-REMITTING MS; PLACEBO-CONTROLLED TRIAL; BRAIN ATROPHY; DOUBLE-BLIND; THERAPY; DISEASE; MRI; GUIDELINES; EFFICACY; METHYLPREDNISOLONE","Background Studies evaluating interferon beta (IFN beta) for multiple sclerosis (MS) showed only partial efficacy. In many patients, IFN beta does not halt relapses or disability progression. One strategy to potentially enhance efficacy is to combine IFN beta with classical immunosuppressive agents, such as azathioprine (AZA) or corticosteroids, commonly used for other autoimmune disorders. Objective The Avonex-Steroids-Azathioprine study was placebo-controlled trial and evaluated efficacy of IFN beta-1a alone and combined with low-dose AZA alone or low-dose AZA and low-dose corticosteroids as initial therapy. Methods A total of 181 patients with relapsing-remitting MS (RRMS) were randomized to receive IFN beta-1a 30 mu g intramuscularly (IM) once weekly, IFN beta-1a 30 mu g IM once weekly plus AZA 50 mg orally once daily, or IFN beta-1a 30 mu g IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day. The primary end point was annualized relapse rate (ARR) at 2 years. Patients were eligible for enrollment in a 3-year extension. Results At 2 years, adjusted ARR was 1.05 for IFN beta-1a, 0.91 for IFN beta-1a plus AZA, and 0.73 for combination. The cumulative probability of sustained disability progression was 16.8% for IFN beta-1a, 20.7% for IFN beta-1a plus AZA, and 17.5% for combination. There were no statistically significant differences among groups for either measure at 2 and 5 years. Percent T2 lesion volume change at 2 years was significantly lower for combination (+14.5%) versus IFN beta-1a alone (+30.3%, P < 0.05). Groups had similar safety profiles. Conclusion In IFN beta-naive patients with early active RRMS, combination treatment did not show superiority over IFN beta-1a monotherapy. Multiple Sclerosis 2009; 15: 965-976. http://msj.sagepub.com","[Havrdova, E.] Charles Univ Prague, Dept Neurol, Sch Med 1, Fac Med 1, Prague 12808 2, Czech Republic; [Zivadinov, R.; Dwyer, M. G.; Cox, J. L.; Bergsland, N.; Hussein, S.] SUNY Buffalo, Dept Neurol, Buffalo Neuroimaging Anal Ctr, Buffalo, NY 14260 USA; [Krasensky, J.; Seidl, Z.; Vaneckova, M.] Charles Univ Prague, Dept Radiol, Fac Med 1, Prague 12808 2, Czech Republic; [Dusek, L.; Svobodnik, A.] Masaryk Univ, Fac Med, Ctr Biostat & Anal, Brno, Czech Republic; [Dusek, L.; Svobodnik, A.] Masaryk Univ, Fac Sci, Brno, Czech Republic; [Houzvickova, E.] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 12808 2, Czech Republic","Havrdova, E, Charles Univ Prague, Dept Neurol, Sch Med 1, Fac Med 1, Katerinska 30, Prague 12808 2, Czech Republic","eva.havrdova@gmail.com","Czech Ministry of Education [MSM 0021620849]","The authors thank the subjects who participated in this study. MRI acquisition and analysis was supported by Biogen Idec. EH, DH, OD, ZS, JK, and MV acknowledge financial support from the Czech Ministry of Education (research program MSM 0021620849). Sabrina Maurer and Matthew Hasson, Scientific Connexions, Newtown, Pennsylvania, USA assisted in the first draft of this paper and provided technical and editorial support during the preparation for submission; funding for these activities was provided by Biogen Idec.",null,42,0,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","1352-4585",null,"10.1177/1352458509105229","MULT SCLER","Mult. Scler.","AUG",2009,15,8,null,null,null,965,976,null,null,12,"Clinical Neurology","481IC","ISI:000268800000012"]
[21,"J","Veselka, J; Zemanek, D; Hajek, P; Maly, M; Adlova, R; Martinkovicova, L; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tesar, David",null,"Effect of Two-Day Atorvastatin Pretreatment on the Incidence of Periprocedural Myocardial Infarction Following Elective Percutaneous Coronary Intervention: A Single-Center, Prospective, and Randomized Study","American Journal of Cardiology",null,"English","Article",null,null,null,null,null,null,"PREPROCEDURAL STATIN THERAPY; INJURY; EXTENT; TRIAL","Both randomized and observational studies have suggested that pretreatment with statins may reduce the incidence of periprocedural myocardial infarction (PMI) in patients with stable angina during elective percutaneous coronary intervention (PCI). The purpose of this randomized study (Clinical Trial Registration No. NCT00469326) was to investigate the effect of 2-day atorvastatin therapy on the incidence of PMI in patients with stable angina pectoris undergoing elective PCI. A total of 200 patients with stable angina pectoris who were not taking statins and who had been referred for PCI were enrolled and randomized (ratio 1:1) to a 2-day pretreatment regimen with atorvastatin 80 mg/day and subsequent PCI or immediate PCI. The serum concentration of creatine kinase-MB mass and troponin I were measured before and 16 to 24 hours after PCI. The incidence of PMI was assessed using established criteria. Of the patients, 10% in the atorvastatin group and 12% in the control group had a postprocedural creatine kinase-MB mass elevation >= 3 times the upper limit of normal (p = 0.65). The incidence of PMI as determined by the postinterventional release of troponin I >= 3 times the upper limit of normal was 17% in the atorvastatin group and 16% in the control group (p = 0.85). The median creatine kinase-MB mass peak after PCI was 1.46 ng/ml (interquartile range 0.83 to 2.52) in the atorvastatin group and 1.40 ng/ml (inter-quartile range 0.90 to 2.54) in the control group (p = 0.70). The median peak troponin I level after PCI was 0.100 ng/ml (0.096 to 0.385) in the atorvastatin group and 0.100 ng/ml (0.60 to 0.262) in the control group (p = 0.54). On multivariate analysis, the only independent predictor of PMI was patient age (odds ratio 1.09, 95% confidence interval 1.025 to 1.159, p = 0.006). In conclusion, in the present study 2-day pre-PCI therapy with atorvastatin did not reduce the occurrence of PMI in patients with stable angina pectoris undergoing elective PCI. (c) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;104:630-633)","[Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tesar, David] Charles Univ Prague, Dept Cardiol, Ctr Cardiovasc, Univ Hosp,Motol Med Sch 1, Prague, Czech Republic","Veselka, J, Charles Univ Prague, Dept Cardiol, Ctr Cardiovasc, Univ Hosp,Motol Med Sch 1, Prague, Czech Republic","veselka.josef@seznam.cz","Ministry of Health of the Czech Republic, Prague, Czech Republic [00064203]","This work was supported by Grant 00064203 from the Ministry of Health of the Czech Republic, Prague, Czech Republic.",null,13,0,"EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","BRIDGEWATER","685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA","0002-9149",null,"10.1016/j.amjcard.2009.04.048","AMER J CARDIOL","Am. J. Cardiol.","SEP 1",2009,104,5,null,null,null,630,633,null,null,4,"Cardiac & Cardiovascular Systems","493RW","ISI:000269756600003"]
[21,"J","Kubinova, S; Horak, D; Sykova, E",null,null,null,"Kubinova, Sarka; Horak, Daniel; Sykova, Eva",null,"Cholesterol-modified superporous poly(2-hydroxyethyl methacrylate) scaffolds for tissue engineering","Biomaterials",null,"English","Article",null,null,null,null,null,"Cell adhesion; Cell viability; Hydrogel; PolyHEMA; Porosity","MESENCHYMAL STEM-CELLS; POROUS HYDROGELS; PORE-SIZE; ADHESION; BONE; SURFACE; ADSORPTION; BEHAVIOR; ENERGY; FILMS","Modifications of poly(2-hydroxyethyl methacrylate) (PHEMA) with cholesterol and laminin have been developed to design scaffolds that promote cell-surface interaction. Cholesterol-modified superporous PHEMA scaffolds have been prepared by the bulk radical copolymerization of 2-hydroxyethyl methacrylate (HEMA), cholesterol methacrylate (CHLMA) and the cross-linking agent ethylene dimethacrylate (EDMA) in the presence of ammonium oxalate crystals to introduce interconnected superpores in the matrix. With the aim of immobilizing laminin (LN), carboxyl groups were also introduced to the scaffold by the copolymerization of the above monomers with 2-[(methoxycarbonyl)methoxy]ethyl methacrylate (MCMEMA). Subsequently, the MCMEMA moiety in the resulting hydrogel was hydrolyzed to 12(methacryloyloxy)ethoxy]acetic acid (MOEAA), and laminin was immobilized via carbodiimide and N-hydroxysulfosuccinimide chemistry. The attachment, viability and morphology of mesenchymal stem cells (MSCs) were evaluated on both nonporous and superporous laminin-modified as well as laminin-unmodified PHEMA and poly(2-hydroxyethyl methacrylate-co-cholesterol methacrylate) P(HEMA-CHLMA) hydrogels. Neat PHEMA and laminin-modified PHEMA (LN-PHEMA) scaffolds facilitated MSC attachment, but did not support cell spreading and proliferation: the viability of the attached cells decreased with time of cultivation. In contrast, MSCs spread and proliferated on P(HEMA-CHLMA) and LN-P(HEMA-CHLMA) hydrogels. (C) 2009 Elsevier Ltd. All rights reserved.","[Horak, Daniel] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Horak, Daniel; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic","Horak, D, Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic","horak@imc.cas.cz","EU [LSHM-CT-2007-037862]; Academy of Sciences of the Czech Republic [KAN200520804]","Financial support of the EU grant Artemis (LSHM-CT-2007-037862) and the Academy of Sciences of the Czech Republic (KAN200520804) is gratefully acknowledged.",null,35,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0142-9612",null,"10.1016/j.biomaterials.2009.05.007","BIOMATERIALS","Biomaterials","SEP",2009,30,27,null,null,null,4601,4609,null,null,9,"Engineering, Biomedical; Materials Science, Biomaterials","488DX","ISI:000269330400019"]
[21,"J","Loh, ML; Sakai, DS; Flotho, C; Kang, M; Fliegauf, M; Archambeault, S; Mullighan, CG; Chen, L; Bergstraesser, E; Bueso-Ramos, CE; Emanuel, PD; Hasle, H; Issa, JP; van den Heuvel-Eibrink, MM; Locatelli, F; Stary, J; Trebo, M; Wlodarski, M; Zecca, M; Shannon, KM; Niemeyer, CM",null,null,null,"Loh, Mignon L.; Sakai, Debbie S.; Flotho, Christian; Kang, Michelle; Fliegauf, Manfred; Archambeault, Sophie; Mullighan, Charles G.; Chen, Leslie; Bergstraesser, Eva; Bueso-Ramos, Carlos E.; Emanuel, Peter D.; Hasle, Henrik; Issa, Jean-Pierre; van den Heuvel-Eibrink, Marry M.; Locatelli, Franco; Stary, Jan; Trebo, Monica; Wlodarski, Marcin; Zecca, Marco; Shannon, Kevin M.; Niemeyer, Charlotte M.",null,"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","Blood",null,"English","Article",null,null,null,null,null,null,"ACQUIRED UNIPARENTAL DISOMY; C-CBL; LYMPHOBLASTIC-LEUKEMIA; MYELOID MALIGNANCIES; LIGASE ACTIVITY; ACTIVATION; PTPN11; GROWTH; RAS; NEUROFIBROMATOSIS","Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11 genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism arrays, we identified a region of 11q isodisomy that contains the CBL gene in several JMML samples, and subsequently identified CBL mutations in 27 of 159 JMML samples. Thirteen of these mutations alter codon Y371. In this report, we also demonstrate that CBL and RAS/PTPN11 mutations were mutually exclusive in these patients. Moreover, the exclusivity of CBL mutations with respect to other Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML. (Blood. 2009; 114: 1859-1863)","[Loh, Mignon L.; Sakai, Debbie S.; Kang, Michelle; Archambeault, Sophie; Chen, Leslie; Shannon, Kevin M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Loh, Mignon L.; Sakai, Debbie S.; Kang, Michelle; Archambeault, Sophie; Chen, Leslie; Shannon, Kevin M.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Flotho, Christian; Fliegauf, Manfred; Wlodarski, Marcin; Niemeyer, Charlotte M.] Univ Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; [Mullighan, Charles G.] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA; [Bergstraesser, Eva; Issa, Jean-Pierre] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [Bueso-Ramos, Carlos E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Emanuel, Peter D.] Univ Arkansas, Ctr Comprehens Canc, Little Rock, AR 72204 USA; [Hasle, Henrik] Aarhus Univ Hosp, Dept Pediat, Skejby, Denmark; [van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Erasmus MC, Dutch Childrens Oncol Grp, Rotterdam, Netherlands; [Locatelli, Franco; Zecca, Marco] Univ Pavia, Fdn IRCCS, Policlin San Matteo, I-27100 Pavia, Italy; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Trebo, Monica] St Anna Childrens Hosp, Vienna, Austria","Loh, ML, 513 ParnassusAve,HSE-302,Box 0519, San Francisco, CA 94143 USA","lohm@peds.ucsf.edu","National Institutes of Health [CA113557, CA108631, CA104282, CA72614, CA95621]; California Institute of Regenerative Medicine [T1-00002]; V Foundation for Cancer Research ; Frank A. Campini Foundation [LLS 6059-09]; Deutsche Kinderkrebsstiftung ; Deutsche Forschungsgemeinschaft ","The authors thank the referring physicians and patients/families who contributed samples to this work, the National Children's Cancer Foundation for facilitating the submission of some of the JMML samples, and all the investigators in the EWOG-MDS. This work was supported in part by the National Institutes of Health (grants CA113557, M. L. L.; CA108631, M. L. L., K. M. S., L. C.; CA104282, M. L. L., K. M. S.; CA72614, K. M. S.; CA95621, M. L. L., M. K., P. D. E., K. M. S.), California Institute of Regenerative Medicine (T1-00002; D. S. S.), V Foundation for Cancer Research (M. L. L., K. M. S.), the Frank A. Campini Foundation (M. L. L., K. M. S.), LLS 6059-09 (M. L. L.), the American Lebanese Syrian Associated Charities (C. G. M.), the Deutsche Kinderkrebsstiftung (C. M. N., C. F.), the Deutsche Forschungsgemeinschaft",null,32,1,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2009-01-198416","BLOOD","Blood","AUG 27",2009,114,9,null,null,null,1859,1863,null,null,5,"Hematology","488WI","ISI:000269380600022"]
[21,"J","Vasovcak, P; Puchmajerova, A; Roubalik, J; Krepelova, A",null,null,null,"Vasovcak, Peter; Puchmajerova, Alena; Roubalik, Jan; Krepelova, Anna",null,"Mutations in STK11 gene in Czech Peutz-Jeghers patients","BMC Medical Genetics",null,"English","Article",null,null,null,null,null,null,"SEX-CORD TUMOR; MUCOCUTANEOUS PIGMENTATION; GASTRIC ADENOCARCINOMA; GERMLINE MUTATION; CANCER; LINKAGE; LOCUS; RISK; LKB1; CARCINOMA","Background: Peutz-Jeghers syndrome (PJS) is an autosomal dominant hereditary disease characterized by mucocutaneous pigmentation and gastrointestinal hamartomatous polyposis. The germline mutations in the serine/threonine kinase 11 (STK11) gene have been shown to be associated with the disease. Individuals with PJS are at increased risk for development of various neoplasms. The aim of the present study was to characterize the genotype and phenotype of Czech patients with PJS. Methods: We examined genomic DNA of 8 individuals from five Czech families by sequencing analysis of STK11 gene, covering its promotor region, the entire coding region and the splice-site boundaries, and by multiplex ligation-dependent probe amplification (MLPA) assay designed for the identification of large exonic deletions or duplications of STK11 gene. Results: We found pathogenic mutations in STK11 gene in two families fulfilling the diagnostic criteria of PJS and in one of three sporadic cases not complying with the criteria. The patient with the frameshift mutation in STK11 gene developed aggressive gastric cancer. No other studied proband has developed a carcinoma so far. Conclusion: Our results showed that a germline mutation of STK11 gene can be found not only in probands fulfilling the PJS diagnostic criteria, but also in some sporadic cases not complying with the criteria. Moreover, we observed a new case of aggressive gastric cancer in a young patient with a frameshift mutation of STK11 gene.","[Vasovcak, Peter; Puchmajerova, Alena; Krepelova, Anna] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Roubalik, Jan] Bata Hosp, Digest Endoscopy Ctr, Zlin, Czech Republic","Vasovcak, P, Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague, Czech Republic","pevas78@hotmail.com; alena.puchmajerova@lfmotol.cuni.cz; roubalik@bnzlin.cz; anna.krepelova@fnmotol.cz",null,null,null,44,0,"BIOMED CENTRAL LTD","LONDON","CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND","1471-2350",null,"10.1186/1471-2350-10-69","BMC MED GENET","BMC Med. Genet.","JUL 19",2009,10,null,null,null,null,null,null,69,null,8,"Genetics & Heredity","491FK","ISI:000269563000001"]
[21,"J","Halaska, MJ; Pentheroudakis, G; Strnad, P; Stankusova, H; Chod, J; Robova, H; Petruzelka, L; Rob, L; Pavlidis, N",null,null,null,"Halaska, Michael J.; Pentheroudakis, George; Strnad, Pavel; Stankusova, Hana; Chod, Jiri; Robova, Helena; Petruzelka, Lubos; Rob, Lukas; Pavlidis, Nicholas",null,"Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study","Breast Journal",null,"English","Article",null,null,null,null,null,"breast cancer; chemotherapy; outcome; pregnancy; pregnancy-associated breast cancer; prognosis","IN-UTERO; CHEMOTHERAPY; CARCINOMA; PROGNOSIS; WOMEN","Pregnancy-associated breast cancer (PABC) is a rare and challenging problem. We sought to describe epidemiology, management and outcome of women in whom breast cancer was diagnosed during pregnancy or within one year after delivery. Thirty-two women with PABC were referred to two European Union oncology centers between 1995 and 2007, 16 during pregnancy and 16 within 1 year after delivery. Data concerning diagnosis, management, delivery and fetal and maternal outcome were recorded. A group of 32 patients (matched controls) presenting with nonpregnancy-associated breast cancer (non-PABC) was matched for age at diagnosis, tumor size and stage to each PABC patient. Differences in outcome between the PABC and non-PABC groups were then assessed. Histological features were similar in both groups, except that estrogen receptor-negative tumors were more common in the PABC group. Three patients received chemotherapy and two others underwent surgery during pregnancy, with no excess toxicity or severe maternal/fetal adverse effects. All children in the PABC group were healthy, except for one exposed to epirubicin in utero and born with rectal atresia. Overall survival was similar in PABC and non-PABC patients (p = 0.449). The subgroup of patients with breast cancer diagnosed within one year after delivery showed a shorter time to relapse than controls or patients with gestational cancer (p = 0.0178). PABC is a special situation, necessitating individualized, multi-disciplinary management. Prognosis is similar for women with nongestational cancer matched for age and stage though poorer outcome postpartum should be further investigated.","[Halaska, Michael J.; Strnad, Pavel; Chod, Jiri; Robova, Helena; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 1, Prague 15000 5, Czech Republic; [Pentheroudakis, George; Pavlidis, Nicholas] Ioannina Univ Hosp, Dept Med Oncol, Ioannina, Greece; [Stankusova, Hana] FN Motol, Dept Radiat & Oncol, Prague, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Dept Oncol, Fac Med 1, Prague 15000 5, Czech Republic","Halaska, MJ, Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 1, Prague Uvalu 84, Prague 15000 5, Czech Republic","mhalaska@centrum.cz","Ministry of Health of the Czech Republic [9455-3]","The work was supported by a grant from the Ministry of Health of the Czech Republic, IGA MZ NR 9455-3. Thanks for the co-operation of DTC, Prague.",null,31,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1075-122X",null,"10.1111/j.1524-4741.2009.00760.x","BREAST J","Breast J.","SEP-OCT",2009,15,5,null,null,null,461,467,null,null,7,"Oncology; Obstetrics & Gynecology","487IP","ISI:000269265800003"]
[21,"J","Veselka, J",null,null,null,"Veselka, Josef",null,"Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Is it Safe?","Catheterization and Cardiovascular Interventions",null,"English","Letter",null,null,null,null,null,null,null,null,"Univ Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic","Veselka, J, Univ Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic",null,null,null,null,8,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,"10.1002/ccd.22046","CATHETER CARDIOVASC INTERV","Catheter. Cardiovasc. Interv.","SEP 1",2009,74,3,null,null,null,520,521,null,null,2,"Cardiac & Cardiovascular Systems","488ZO","ISI:000269389200029"]
[21,"J","Latta, J; Ehler, E; Zamecnik, J",null,null,null,"Latta, J.; Ehler, E.; Zamecnik, J.",null,"Acquired Neuromyotonia with Minor Central Symptoms and Antibodies against Voltage-Gated Potassium Channels - a Case Report","Česká a slovenská neurologie a neurochirurgie",null,"Czech","Article",null,null,null,null,null,"neuromyotonia; Morvan's disease; voltage-gated potassium channels; arrhythmia; myokymia; fasciculation","CENTRAL-NERVOUS-SYSTEM; MORVANS-SYNDROME; DISCHARGES; EMG","A 52-year-old still healthy man developed, over several weeks, a myalgic syndrome with fatigue and muscle weakness, tingling and fasciculation, predominantly in the lower limbs. Such disorders caused inability to walk independently. Upon admission, the clinical findings included muscle weakness and muscle stiffness with tenderness, autonomic symptoms with sweating, intermittent tachycardia, constipation, and also personality and behavioral changes with insomnia and late-night confusion. The electromyography showed a persisting activity with discharges, which were provoked by voluntary activity, and in particular by the stimulation of motor fibres. The patient was treated with carbamazepine and methylprednisolone. Hypertonia, myalgia and central symptoms subsided. At that stage, the results came back with highly elevated antibodies against voltage-gated potassium channels in serum. However, the patient suddenly died of malignant arrhythmia.","[Latta, J.; Ehler, E.] Pardub Krajska Nemocnice AS, Neurol Klin, Pardubice 53203, Czech Republic; [Zamecnik, J.] UK 2 LF & FN Motol, Ustav Patol & Mol Med, Prague, Czech Republic","Latta, J, Pardub Krajska Nemocnice AS, Neurol Klin, Kyjevska 44, Pardubice 53203, Czech Republic","janci82@gmail.com",null,null,null,16,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,373,377,null,null,5,"Neurosciences; Surgery","486HZ","ISI:000269188200013"]
[21,"J","Hoza, D; Lastovka, M; Bojar, M; Cerny, R; Sturm, D; Kraus, J; Liby, P; Tichy, M",null,null,null,"Hoza, D.; Lastovka, M.; Bojar, M.; Cerny, R.; Sturm, D.; Kraus, J.; Liby, P.; Tichy, M.",null,"An Improvement in Smooth Pursuit Eye Movements and Phonation Following Selective Dorsal Rhizotomy","Česká a slovenská neurologie a neurochirurgie",null,"Czech","Article",null,null,null,null,null,"rhizotomy; spasticity; ocular pursuit","SPASTIC CEREBRAL-PALSY; POSTERIOR RHIZOTOMY; CHILDREN; PERFORMANCE","Backgrounds: Selective dorsal rhizotomy (SDR) represents a standard therapeutic technique for the treatment of spasticity. Besides reducing spasticity of the lower limbs, an improvement in motor skills of the upper limbs and an improvement in speech and eye movements have also been repeatedly documented in literature. Aim: The objective of this study was to objectify the improvement in phonation and eye tracking. Methods: Eight patients underwent videooculographic testing and 1 1 underwent acoustic speech analysis. The measured parameters were a deviation from basic frequency, shimmer, jitter and phonation index in the acoustic speech analysis and a correlation coefficient of the horizontal stimulus upon videooculography. Results: Seven of the eleven patients demonstrated an improvement in acoustic parameters; four subjects reported an improvement in eye tracking. Conclusion: Improvement in phonation and eye tracking following selective dorsal rhizotomy was objectified by testing techniques. The described suprasegmental effects of SDR can be explained by a possibly reduced response of the pathologic polysynaptic due to deafferentation, which developed following selective dorsal rhizotomy.","[Hoza, D.; Liby, P.; Tichy, M.] Neurochirurg Oddeleni FN Motole, Prague 15006, Czech Republic; [Lastovka, M.] LF UK & VFN Praze, Foniatr Klin 1, Prague, Czech Republic; [Bojar, M.; Cerny, R.; Sturm, D.] LF UK & FN Motole, Neurol Klin 2, Prague, Czech Republic; [Kraus, J.] LF UK & FN Motole, Klin Detske Neurol 2, Prague, Czech Republic","Hoza, D, Neurochirurg Oddeleni FN Motole, Uvalu 84,5 Motol, Prague 15006, Czech Republic","david.hoza@yahoo.de",null,null,null,18,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,378,382,null,null,5,"Neurosciences; Surgery","486HZ","ISI:000269188200014"]
[21,"J","Neuschlova, L; Sterbova, K; Zackova, J; Komarek, V",null,null,null,"Neuschlova, L.; Sterbova, K.; Zackova, J.; Komarek, V.",null,"Analysis of Psychological Profile and Video-EEG Monitoring in Sleep in Children with Developmental Dysphasia","Česká a slovenská neurologie a neurochirurgie",null,"Czech","Article",null,null,null,null,null,"dysphasia; electroencephalography","LANGUAGE IMPAIRMENT; SLI; COMORBIDITY; DISORDERS; EPILEPSY","Aim: We analyzed data from 37 children diagnosed with developmental dysphasia, who were referred for all-night video-EEG monitoring in order to detect epileptiform activity in sleep. Methods: We compared the results of a psychological evaluation in different groups of children, we focused on performance and verbal IQ and a vocabulary exam. Epileptiform discharges in sleep EEG were present in 12 children. Six of these children were included in an open prospective study of administering oral Diazepam for 6 to 8 months; these children were compared to six control subjects without discharges in the EEG and without medication. The aim was to verify the effect of a reduction in epileptiform activity on language development. Results: Comparison of the initial psychological evaluations showed a tendency towards worse scores in both verbal and nonverbal skills in patients with epileptiform EEG activity. This trend was not evident in the youngest category. In the six children with epileptiform activity who participated in our prospective study with oral Diazepam, we found a marked improvement in verbal skills, demonstrated as an increase in verbal IQ, only in one case. Conclusion: Our results do not support the hypothesis that children with developmental dysphasia and epileptiform EEG may benefit from antiepileptic treatment. However, our sample is not large enough for statistical evaluation. Our study may serve as a valuable source of information for further prospective studies in patients with developmental dysphasia.","[Neuschlova, L.; Sterbova, K.; Zackova, J.; Komarek, V.] UK 2 LF & FN Motol, Klin Detske Neurol, Prague 15000, Czech Republic","Komarek, V, UK 2 LF & FN Motol, Klin Detske Neurol, Uvalu 84,5 Motol, Prague 15000, Czech Republic","vladimir.komarek@lfmotol.cuni.cz",null,null,null,32,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,343,349,null,null,7,"Neurosciences; Surgery","486HZ","ISI:000269188200008"]
[21,"J","Cakrt, O; Kolar, P; Cerny, R; Funda, T; Jerabek, J",null,null,null,"Cakrt, O.; Kolar, P.; Cerny, R.; Funda, T.; Jerabek, J.",null,"Electrotactile Stimulation of the Tongue: a New Option in the Rehabilitation of Postural Stability - a Case Report","Česká a slovenská neurologie a neurochirurgie",null,"Czech","Article",null,null,null,null,null,"biofeedback; postural balance; rehabilitation; cerebellar syndrome","SUBSTITUTION; BALANCE","A completely new technique in the rehabilitation of patients suffering from balance disorders is the use of biological feedback by way of electrotactile stimulation - the BrainPort (R) system. Thanks to electrotactile stimulation of the tongue, the patient is informed of the actual position of his head. The principle part of the equipment is an accelerometer, which transmits information concerning changes in head positions to electrical impulses, which the patient feels on their tongue. The technique is predominantly used in peripheral disorders of the labyrinth where satisfactory compensation has not been achieved with standard processes. The technique is also promising in patients with central stability disorders. This paper demonstrates the promising effect of this rehabilitative approach in patients with palleocerebellar disorders.","[Cakrt, O.; Kolar, P.] LF UK & FN Motole, Klin Rehabil & Telovychovneho Lekarstvi 2, Prague 15006, Czech Republic; [Cerny, R.; Jerabek, J.] LF UK & FN Motole, Neurol Klin Dospelych 2, Prague 15006, Czech Republic; [Funda, T.; Jerabek, J.] LF UK Praze, CVUT FBMI, Spolecne Pracoviste Biomed Inzenyrstvi FBMI, Prague, Czech Republic","Cakrt, O, LF UK & FN Motole, Klin Rehabil & Telovychovneho Lekarstvi 2, Uvalu 84,5 Motol, Prague 15006, Czech Republic","ondrej.cakrt@lfmotol.cuni.cz",null,null,null,10,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,364,367,null,null,4,"Neurosciences; Surgery","486HZ","ISI:000269188200011"]
[21,"J","Krijtova, H; Marusic, P",null,null,null,"Krijtova, H.; Marusic, P.",null,"Paroxysmal Kinesigenic Dyskinesia - a Case Report of a Young Woman with Alternating Hemidystonia","Česká a slovenská Neurologie a neurochirurgie",null,"Czech","Article",null,null,null,null,null,"paroxysmal dyskinesia; alternating hemidystonia","FAMILIAL INFANTILE CONVULSIONS; CHOREOATHETOSIS; MUTATIONS; EPILEPSY; LINKAGE; PERFUSION; SEIZURES; THERAPY; GENES","Paroxysmal kinesigenic dyskinesia is a neurological disorder characterized by brief episodes of dystonia and choreathetosis triggered by sudden voluntary movement. The attacks typically last less than one minute and may occur even several times a day. Besides familiar idiopathic forms with autosomal dominant inheritance, sporadic cases may occur, or symptomatic forms may be associated with some CNS diseases and may manifest with the same type of paroxysms. At the beginning we review current knowledge on this disorder, including the historical development of the concept of paroxysmal dyskinesia. Then we present the case of a young woman who has suffered from sporadic idiopathic paroxysmal kinesigenic dyskinesia since she was 13 years old. Diagnosis was proved during video-EEG monitoring and her paroxysms can be characterised as alternating hemidystonia. She has been successfully treated with 300mg of lamotrigine per day.","[Krijtova, H.; Marusic, P.] LF & FN Motol, Neurol Klin UK 2, Prague 15006, Czech Republic","Krijtova, H, LF & FN Motol, Neurol Klin UK 2, Uvalu 84,5 Motol, Prague 15006, Czech Republic","hana.krijtova@fnmotol.cz",null,null,null,32,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,368,372,null,null,5,"Neurosciences; Surgery","486HZ","ISI:000269188200012"]
[21,"J","Hummelova-Fanfrdlova, Z; Rektorova, I; Sheardova, K; Bartos, A; Linek, V; Ressner, P; Zapletalova, J; Vyhnalek, M; Hort, J",null,null,null,"Hummelova-Fanfrdlova, Zuzana; Rektorova, Irena; Sheardova, Katerina; Bartos, Ales; Linek, Vladimir; Ressner, Pavel; Zapletalova, Jana; Vyhnalek, Martin; Hort, Jakub",null,"Czech adaptation of Addenbrooke's Cognitive Examination","Československá psychologie",null,"Czech","Article",null,null,null,null,null,"Addenbrooke's Cognitive Examination; dementia; Alzheimer disease; frontotemporal dementia","ALZHEIMERS-DISEASE; SPEAKING POPULATION; DEMENTIA; VALIDATION; BATTERY; SCALE","The goal of the study was to validate the quality of Czech adaptation of Addenbrooke's Cognitive Examination (ACE). ACE is a neuropsychological screening test battery serving for dementia detection and differentiation between dementia in Alzheimer disease and the frontotemporal dementia. The research sample consisted of 60 patients with diagnosis of probably dementia of Alzheimer type according DSM IV and NINCDS-ADRDA criteria. All patients passed neurological, basic biochemical, and morphological examinations. Psychological tests and scales including ACE were also administrated. The most expressive cognitive deficits in ACE were found in memory and verbal fluency subtests. The statistic procedures assessed good sensitivity of Czech adaptation of ACE: cut-off score 88 showed 100% sensitivity and that of 83 showed 96.6% sensitivity for dementia detection. The item test reliability assessed by Cronbach's alpha was 0.8. It can be stated that the Czech adaptation of Addenbrooke's Cognitive Examination represents not only a new useful test for cognitive deficits assessment but is also a sufficiently quality and sensitive test for dementia detection.","[Hummelova-Fanfrdlova, Zuzana] LF MU, Ustav Psychol & Somat, Brno 66243, Czech Republic; [Hummelova-Fanfrdlova, Zuzana; Rektorova, Irena; Sheardova, Katerina] FN & Sv Anny, Neurol Klin 1, Brno 65691, Czech Republic; [Bartos, Ales] UK 3 LF & FN Kralovske Vinohrady, Neurol Klin, Prague 10034, Czech Republic; [Linek, Vladimir] VFN, Prague 12000, Czech Republic; [Ressner, Pavel] FN Olomouc, Neurol Klin, Olomouc 77520, Czech Republic; [Zapletalova, Jana] Lekarska Fak UP, Ustav Lekarske Biofyz, Olomouc 77515, Czech Republic; [Vyhnalek, Martin; Hort, Jakub] Neurol Klin UK, LF & FN Motol 2, Prague 15018, Czech Republic; [Bartos, Ales] Psychiat Ctr Praha, AD Ctr, Prague 18103, Czech Republic","Hummelova-Fanfrdlova, Z, LF MU, Ustav Psychol & Somat, Komenskeho Nam 2, Brno 66243, Czech Republic","zuzana.fanfrdlova@fnusa.cz",null,null,null,19,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2009,53,4,null,null,null,376,388,null,null,13,"Psychology, Multidisciplinary","488YL","ISI:000269386200005"]
[21,"J","Kucera, A; Pycha, K; Pajer, P; Spisek, R; Skaba, R",null,null,null,"Kucera, A.; Pycha, K.; Pajer, P.; Spisek, R.; Skaba, R.",null,"Dendritic Cell-Based Immunotherapy Induces Transient Clinical Response in Advanced Rat Fibrosarcoma - Comparison with Preventive Anti-tumour Vaccination","Folia Biologica",null,"English","Article",null,null,null,null,null,"dendritic cells; immunotherapy; cancer immunotherapy; chemotherapy","DYING TUMOR-CELLS; CANCER-IMMUNOTHERAPY; T-CELLS; CHEMOTHERAPY; EXPOSURE; IMMUNITY; IMMUNOSURVEILLANCE; IMMUNOPREVENTION; INDUCTION; VACCINES","In this study we present the models of preventive and therapeutic vaccination of sarcoma-bearing rats with dendritic cells that present tumour antigens from killed tumour cells. We present the characteristics of dendritic cell-based vaccine and its capacity to induce anti-tumour immune response both in vitro and in vivo. We show that preventive vaccination efficiently prevents tumour growth. On the other hand, vaccination of rats with established tumours did not lead to eradication of the tumours. Despite the induction of a vigorous immune response after administration of dendritic cell-based vaccine and transient decrease in tumour progression, tumours eventually resumed their growth and animals vaccinated with dendritic cells succumbed to cancer. In both settings, preventive and therapeutic, dendritic cell-based vaccination induced a vigorous tumour-specific T-cell response. These results argue for the timing of cancer immunotherapy to the stages of low tumour load. Immunotherapy initiated at the stage of minimal residual disease, after reduction of tumour load by other modalities, will have much better chance to offer a clinical benefit to cancer patients than the immunotherapy at the stage of metastatic disease.","[Spisek, R.] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006, Czech Republic; [Kucera, A.; Pycha, K.; Skaba, R.] Charles Univ Prague, Fac Med 2, Dept Paediat Surg, Prague 15006, Czech Republic; [Kucera, A.; Pycha, K.; Skaba, R.] Univ Hosp Motol, Dept Paediat Surg, Prague, Czech Republic; [Spisek, R.] Univ Hosp Motol, Dept Immunol, Prague, Czech Republic; [Pajer, P.] Acad Sci Czech Republic, Inst Mol Genet, Dept Mol Virol, Prague, Czech Republic","Spisek, R, Charles Univ Prague, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 15006, Czech Republic","radek.spisek@lfmotol.cuni.cz","The Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620812]","This study was supported by research grant MSM0021620812 from The Ministry of Education, Youth and Sports of the Czech Republic.",null,26,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2009,55,4,null,null,null,119,125,null,null,7,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","488SD","ISI:000269369200001"]
[21,"J","Cada, Z; Smetana, K; Lacina, L; Plzakova, Z; Stork, J; Kaltner, H; Russwurm, R; Lensch, M; Andre, S; Gabius, HJ",null,null,null,"Cada, Z.; Smetana, K., Jr.; Lacina, L.; Plzakova, Z.; Stork, J.; Kaltner, H.; Russwurm, R.; Lensch, M.; Andre, S.; Gabius, H. -J.",null,"Immunohistochemical Fingerprinting of the Network of Seven Adhesion/Growth-Regulatory Lectins in Human Skin and Detection of Distinct Tumour-Associated Alterations","Folia Biologica",null,"English","Article",null,null,null,null,null,"apoptosis; galectin; glycohistochemistry; glycoprotein; Integrin; stroma; sugar code","NECK SQUAMOUS-CELL; GALECTIN-7 P53-INDUCED GENE-1; HUMAN NEUROBLASTOMA-CELLS; ENTEROCYTE-LIKE CELLS; ENDOGENOUS LECTINS; IN-VITRO; RT-PCR/IMMUNOHISTOCHEMISTRY; HYPOPHARYNGEAL CANCER; EXTRACELLULAR-MATRIX; PROGNOSTIC RELEVANCE","Glycans of natural glycoconjugates are considered as a source of biological information relevant to cell adhesion or growth. Sugar-based messages are decoded and translated into responses by endogenous lectins. This mechanism assigns a functional dimension to tumour-associated changes of glycosylation. Consequently, it calls for mapping the lectin presence in tumours. Such an analysis has so far commonly been performed with the scope to determine expression of a few distinct proteins, e.g. from the effector family of galectins with focus on galectins-1 and -3. Due to the emerging evidence for functional divergence among galectins it is timely to address the challenge to evaluate their presence beyond these few family members. Having raised a panel of non-cross-reactive antibodies against seven human galectins covering all three subfamilies, we describe their expression profiles in human skin. Comparison of normal and malignant tissues enabled us to define galectin-type-dependent alterations, arguing in favour of distinct functionalities. It is concluded that comprehensive monitoring performed to define the different aspects of the galectin network, as documented in this pilot study, is advisable for future histopathologic studies aimed at delineating clinical correlations.","[Cada, Z.; Smetana, K., Jr.; Lacina, L.; Plzakova, Z.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Cada, Z.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 12800 2, Czech Republic; [Lacina, L.; Stork, J.] Charles Univ Prague, Fac Med 1, Dept Dermatovenerol, Prague 12800 2, Czech Republic; [Smetana, K., Jr.; Lacina, L.; Plzakova, Z.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Kaltner, H.; Russwurm, R.; Lensch, M.; Andre, S.; Gabius, H. -J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Smetana, K, Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic","karel.smetana@lfl.cuni.cz","Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806]; Mizutani Foundation for Glycoscience (Tokyo, Japan) ; EC Marie Curie Research Training Network [HRTN-CT-2005-019561]","This study was supported by the Ministry of Education, Youth and Sports of the Czech Republic (project No. MSM 0021620806), the Mizutani Foundation for Glycoscience (Tokyo, Japan) and an EC Marie Curie Research Training Network grant (contract No. HRTN-CT-2005-019561).",null,67,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2009,55,4,null,null,null,145,152,null,null,8,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","488SD","ISI:000269369200005"]
[21,"J","Bartlett, JR; Friedman, KJ; Ling, SC; Pace, RG; Bell, SC; Bourke, B; Castaldo, G; Castellani, C; Cipolli, M; Colombo, C; Colombo, JL; Debray, D; Fernandez, A; Lacaille, F; Macek, M; Rowland, M; Salvatore, F; Taylor, CJ; Wainwright, C; Wilschanski, M; Zemkova, D; Hannah, WB; Phillips, MJ; Corey, M; Zielenski, J; Dorfman, R; Wang, YF; Zou, F; Silverman, LM; Drumm, ML; Wright, FA; Lange, EM; Durie, PR; Knowles, MR",null,null,null,"Bartlett, Jaclyn R.; Friedman, Kenneth J.; Ling, Simon C.; Pace, Rhonda G.; Bell, Scott C.; Bourke, Billy; Castaldo, Giuseppe; Castellani, Carlo; Cipolli, Marco; Colombo, Carla; Colombo, John L.; Debray, Dominique; Fernandez, Adriana; Lacaille, Florence; Macek, Milan, Jr.; Rowland, Marion; Salvatore, Francesco; Taylor, Christopher J.; Wainwright, Claire; Wilschanski, Michael; Zemkova, Dana; Hannah, William B.; Phillips, M. James; Corey, Mary; Zielenski, Julian; Dorfman, Ruslan; Wang, Yunfei; Zou, Fei; Silverman, Lawrence M.; Drumm, Mitchell L.; Wright, Fred A.; Lange, Ethan M.; Durie, Peter R.; Knowles, Michael R; Clancy JP; Sindel LJ; Roberts DM; Roberts V; Radford PJ; Argel N; Morgan WJ; Douthit JL; Schellhase DE; Anderson P; Taggart A; Morrissey B; Platzker AC; Woo MS; Fukushima L; Hsu E; Shay GF; Hardy KA; Moss RB; Dunn CE; Pian MS; Wojtczak HA; Burns L; Henig NR; Nielson DW; Landon C; Thompson A; Accurso FJ; Nick JA; Jones M; Lapin C; Drapeau VM; Egan ME; Padman R; Winnie GB; George C; Olson EL; Light MJ; Geller DE; Gondor M; Flanary J; Stecenko AA; Guill MF; McColley SA; McColley SA; Potter EM; Chung Y; Garvey M; Howenstine MS; Sannuti A; Yeley J; Sloven DG; Ahrens RC; Teresi M; Riva CM; Davis S; Quiniones-Ellis B; Gabor C; Lever TF; Welch R; Cairns A; Corrigan M; Zeitlin PL; Brass L; Dorkin H; Levy H; Huntington I; O'Sullivan BP; Simon RH; Nasr SZ; Lumeng N; Ball ME; Toder DS; Honicky RE; Fitch S; Contreras L; Regelmann WE; Phillips JR; McNamara J; Johnson M; Ruiz FE; Adcock KG; Konig P; Black P; Weigel JD; Noyes BE; Kociela VL; Ferkol T Jr; Boyle M; Colombo JL; Brascia T; Parker HW; Zanni RL; Fiel SB; Lomas P; Taylor-Cousar J; Borowitz D; DeCelie-Germana JK; Cohen R; Gannon M; DiMango EA; Mencin AA; Lobritto SJ; Benitez M; Walker PA; Berdella MN; Langfelder-Schwind E; Ren CL; Rovitelli AK; Anbar RD; Lindner DM; Perciaccante RG; Dozor AJ; Knowles MR; Leigh MW; Taylor-Cousar J; Voynow JA; Auten KJ; Schechter MS; Omlor GJ; Ouellette DA; Karp CL; Joseph PM; Konstan MW; McCoy KS; Royce F; Bartosik S; Vauthy PA; Vauthy ML; Kramer JC; Hensel S; Perez CR; Thomas NJ; Hess JC; Holsclaw DS; Scanlin TF; Rubenstein R; Murray C; Skotleski M; Fiel SB; Sexauer WP; Ko A; Hillman J; Orenstein DM; Schechter MS; Flume PA; Brown D; Schoumacher R; Culbreath B; Moore PE; Slovis B; Dambro N; Garbarz J; Hiatt PW; Olivier KN; Amaro R; Macleod L; Liou TG; Froh DK; Epstein CE; Schmidt J; Elliot G; Williams R; Anderson M; Gadd J; Gibson RL; McNamara S; Worrell K; Moskowitz SM; McCarthy M; Llewellyn C; Wicks S; Moffett KS; Baer LS; do Pico GA; Makholm LM; Rock MJ; Osmond SR; Biller J; Miller T; Fernandez A; Renteria F; Bell SC; Wainwright C; Lewindon P; Selvadurai H; Gaskin K; Van Biervliet S; Montgomery M; Rabin HR; Leong J; Zuberbuhler P; Brown NE; Tabak J; Davidson AG; Nakielna EM; Habbick B; Waters I; Wiltse S; Kepron W; Pasterkamp H; Garey DN; Bishop G; Noseworthy M; Michael RT; Dale AM; Gosse FA; Robinson W; Durie PR; Corey M; Freitag A; Pedder L; Van Wylick R; Lougheed MD; Kodiattu L; Jackson M; Malhotra K; Lyttle B; Paterson NA; Aaron S; Boland M; Kovesi T; Smith A; Kumar VJ; Zinger S; Tullis E; Simard F; Rivard L; Cantin A; Cote G; Lands LC; Marcotte JE; Matouk E; Berthiaume Y; Jeanneret A; Van Spall M; Rivard G; Boucher J; Petit N; Holmes B; Cotton D; Ramlall K; Repetto G; Macek M Jr; Vavrova V; Bartosova J; Fila L; Debray D; Lacaille F; Munck A; Tümmler B; Rowland M; Bourke B; Canny G; Gallagher C; Rivlin J; Picard E; Blau H; Wilschanski M; Springer C; Kerem E; Yahav Y; Bujanover Y; Casciaro R; Colombo C; Castaldo G; Salvatore F; Raia V; Cipolli M; Castellani C; Sinaasappel M; Dooijes D; Ling SC; Kayserova H; Ozcelik U; Kiper N; Dogru D; Taylor CJ; McGaw J.","Gene Modifier Study Grp","Genetic Modifiers of Liver Disease in Cystic Fibrosis","Jama-Journal of The American Medical Association",null,"English","Article",null,null,null,null,null,null,"TRANSMEMBRANE CONDUCTANCE REGULATOR; ALPHA-1-ANTITRYPSIN DEFICIENCY; LUNG-DISEASE; RISK-FACTORS; ALPHA(1)-ANTITRYPSIN DEFICIENCY; SEVERITY; EPIDEMIOLOGY; ASSOCIATION; EXPRESSION; CIRRHOSIS","Context A subset (approximate to 3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective To assess whether any of 9 polymorphisms in 5 candidate genes (alpha(1)-antitrypsin or alpha(1)-antiprotease [SERPINA1], angiotensin-converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor beta 1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P = 3.3 x 10(-6)) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P = 2.8 x 10(-3)). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P = 1.4 x 10(-3)) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P = 1.5 x 10(-8)). Conclusions The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, approximate to 5) of developing severe liver disease with portal hypertension. JAMA. 2009;302(10):1076-1083","[Bartlett, Jaclyn R.; Pace, Rhonda G.; Hannah, William B.; Knowles, Michael R.] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; [Wang, Yunfei; Lange, Ethan M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Wang, Yunfei; Zou, Fei; Wright, Fred A.; Lange, Ethan M.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Wang, Yunfei; Zou, Fei; Wright, Fred A.; Lange, Ethan M.] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; [Friedman, Kenneth J.] Lab Corp Amer, Ctr Mol Biol & Pathol, Res Triangle Pk, NC USA; [Ling, Simon C.; Durie, Peter R.] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada; [Ling, Simon C.; Corey, Mary; Durie, Peter R.] Univ Toronto, Toronto, ON, Canada; [Bell, Scott C.] Prince Charles Hosp, Adult Cyst Fibrosis Ctr, Chermside, Qld, Australia; [Bourke, Billy; Rowland, Marion] Our Ladys Childrens Hosp, Childrens Res Ctr, Crumlin, Ireland; [Rowland, Marion] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Castaldo, Giuseppe; Salvatore, Francesco] Univ Naples Federico 2, CEINGE Adv Biotechnol, Naples, Italy; [Castaldo, Giuseppe; Salvatore, Francesco] Univ Naples Federico 2, Dept Biochem & Med Biotechnol, Naples, Italy; [Castellani, Carlo; Cipolli, Marco] Azienda Osped Verona, Cyst Fibrosis Ctr, Verona, Italy; [Colombo, Carla] Univ Milan, CF Ctr, Fdn IRCCS Osped Maggiore Policlin, Milan, Italy; [Colombo, John L.] Univ Nebraska Med Ctr, Dept Pediat, Pulm Sect, Omaha, NE USA; [Debray, Dominique] Ctr Hosp Univ Bicetre, Serv Hepatol Pediat, Le Kremlin Bicetre, France; [Fernandez, Adriana] La Plata Childrens Hosp, Cyst Fibrosis Ctr, Buenos Aires, DF, Argentina; [Lacaille, Florence] Hop Necker Enfants Malad, Pediat Hepatogastroenterol Nutr Unit, Paris, France; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol, Prague, Czech Republic; [Macek, Milan, Jr.] Charles Univ Prague, Dept Med Genet, Prague, Czech Republic; [Zemkova, Dana] Charles Univ Prague, Dept Pediat, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; [Taylor, Christopher J.] Univ Sheffield, Acad Unit Child Hlth, Dept Paediat Gastroenterol, Sheffield, S Yorkshire, England; [Wainwright, Claire] Royal Childrens Hosp, Queensland Childrens Resp Ctr, Brisbane, Qld, Australia; [Wilschanski, Michael] Hadassah Med Org, Dept Pediat Gastroenterol, Jerusalem, Israel; [Silverman, Lawrence M.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Drumm, Mitchell L.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Drumm, Mitchell L.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA","Knowles, MR, Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, 7019 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA","knowles@med.unc.edu","Cystic Fibrosis Foundation [SILVER0Z00, KNOWLE00A0, DRUMM04P0, DRUMM0A00]; National Institutes of Health [NIH R01GM074175, NIH/NIDDK DK066368, CTRC RR00046, CTSA UL1RR025747]; Prince Charles Hospital Foundation ; OWHC/CIHR Fellowship ; Czech Ministry of Health [VZFNM00064203, NS9488/3]; MIUR, Rome, Italy ; Regione Campania, Italy ; Health Research Board Grant [RFRD-05-07]; Genome Canada through the Ontario Genomics Institute [2004-OGI-3-05]; Lloyd Carr-Harris Foundation ; Canadian Cystic Fibrosis Foundation ","This study was supported by grants from the Cystic Fibrosis Foundation (SILVER0Z00, KNOWLE00A0, DRUMM04P0, DRUMM0A00); the National Institutes of Health (NIH R01GM074175, NIH/NIDDK DK066368, CTRC RR00046, CTSA UL1RR025747); the Prince Charles Hospital Foundation; the OWHC/CIHR Fellowship; the Czech Ministry of Health (VZFNM00064203, NS9488/3); MIUR, Rome, Italy, and Regione Campania, Italy; a Fellowship in Rare Diseases from The Health Research Board Grant (RFRD-05-07); Genome Canada through the Ontario Genomics Institute (2004-OGI-3-05); the Lloyd Carr-Harris Foundation; and the Canadian Cystic Fibrosis Foundation.",null,41,0,"AMER MEDICAL ASSOC","CHICAGO","515 N STATE ST, CHICAGO, IL 60610-0946 USA","0098-7484",null,null,"JAMA-J AM MED ASSN","JAMA-J. Am. Med. Assoc.","SEP 9",2009,302,10,null,null,null,1076,1083,null,null,8,"Medicine, General & Internal","491XH","ISI:000269616200025"]
[21,"J","Simko, F; Pechanova, O; Pelouch, V; Krajcirovicova, K; Mullerova, M; Bednarova, K; Adamcova, M; Paulis, L",null,null,null,"Simko, Fedor; Pechanova, Olga; Pelouch, Vaclav; Krajcirovicova, Kristina; Mullerova, Martina; Bednarova, Kristina; Adamcova, Michaela; Paulis, Ludovit",null,"Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats","Journal of Hypertension",null,"English","Article",null,null,null,null,null,"captopril; fibrosis; melatonin; myocardial hypertrophy; simvastatin; spironolactone","NAME-INDUCED HYPERTENSION; VASCULAR REACTIVITY; NITRIC-OXIDE; HYPERTROPHY; REGRESSION; HEART; ANGIOTENSIN; PREVENTION; FIBROSIS; STATINS","Objective Melatonin was shown to reduce blood pressure, oxidative load and to increase nitric oxide bioavailability predisposing melatonin to have antiremodelling potential. Design The aim of this study was to show whether melatonin can reverse left ventricular remodelling in spontaneously hypertensive rats (SHR) and to compare this potential protective effect with captopril, spironolactone, or simvastatin. Methods Six groups of 3-month old rats (eight per group) were treated for 5 weeks: control untreated Wistar rats, control SHR, SHR plus melatonin (10 mg/kg per 24 h), SHR plus captopril (100 mg/kg per 24 h), SHR plus spironolactone (200 mg/kg per 24 h) and SHR plus simvastatin (10 mg/kg per 24 h). Their systolic blood pressure (SBP) was measured by the tail-cuff method. The relative weights of the left ventricle, nitric oxide synthase (NOS) activity, endothelial NOS and nuclear factor kappa B (NF-kappa B) protein expression, conjugated dienes concentration, level of collagenous proteins and hydroxyproline were measured. Results SBP was reduced by all drugs investigated but most prominently by captopril in SHR. The activity of NOS and endothelial NOS expression increased in the left ventricles of SHR compared with controls. Melatonin and spironolactone further increased NOS expression. Left ventricular oxidative load, estimated by NF-kappa B expression and conjugated dienes concentration, increased in SHR. Only melatonin reduced NF-kappa B expression and decreased conjugated diens concentration. Only captopril reduced left ventricular hypertrophy in SHR, whereas melatonin reduced collagenous protein concentration and hydroxyproline content in the left ventricle. Conclusion It is concluded that although melatonin, in comparison with captopril, did not reverse left ventricle hypertrophy, it reversed left ventricular fibrosis. This protection by melatonin may be caused by its prominent antioxidative effect. J Hypertens 27 (suppl 6): S5-S10 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Simko, Fedor; Krajcirovicova, Kristina; Mullerova, Martina; Bednarova, Kristina; Paulis, Ludovit] Comenius Univ, Dept Pathophysiol, Sch Med, Bratislava 81108, Slovakia; [Simko, Fedor] Comenius Univ, Clin Med 3, Sch Med, Bratislava 81108, Slovakia; [Pechanova, Olga; Paulis, Ludovit] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Pechanova, Olga] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Pechanova, Olga] Acad Sci Czech Republic, Cardiovasc Res Ctr, Prague, Czech Republic; [Pelouch, Vaclav] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Hradec Kralove, Czech Republic; [Adamcova, Michaela] Charles Univ Prague, Sch Med, Dept Physiol, Hradec Kralove, Czech Republic","Simko, F, Comenius Univ, Dept Pathophysiol, Sch Med, Sasinkova 4, Bratislava 81108, Slovakia","fedor.simko@fmed.uniba.sk","VEGA [1/0187/09, 2/0178/09, APVV-0538-07, MSM0021620820]","This study is supported by research grants of VEGA no. 1/0187/09 and no. 2/0178/09, APVV-0538-07 and MSM0021620820.",null,30,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/01.hjh.0000358830.95439.e8","J HYPERTENSION","J. Hypertens.","AUG",2009,27,null,null,"Suppl. 6",null,"S5","S10",null,null,6,"Peripheral Vascular Disease","491AO","ISI:000269549400002"]
[21,"J","Lurbe, E; Cifkova, R; Cruickshank, JK; Dillon, MJ; Ferreira, I; Invitti, C; Kuznetsovah, T; Laurent, S; Mancia, G; Morales-Olivas, F; Rascher, W; Redon, J; Schaefer, F; Seeman, T; Stergiou, G; Wuhl, E; Zanchetti, A",null,null,null,"Lurbe, Empar; Cifkova, Renata; Cruickshank, J. Kennedy; Dillon, Michael J.; Ferreira, Isabel; Invitti, Cecilia; Kuznetsovah, Tatiana; Laurent, Stephane; Mancia, Giuseppe; Morales-Olivas, Francisco; Rascher, Wolfgang; Redon, Josep; Schaefer, Franz; Seeman, Tomas; Stergiou, George; Wuehl, Elke; Zanchetti, Alberto",null,"Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension","Journal of Hypertension",null,"English","Review",null,null,null,null,null,"adolescents; children; European; management of high blood pressure; recommendations; society of hypertension","LEFT-VENTRICULAR HYPERTROPHY; INTIMA-MEDIA THICKNESS; TARGET-ORGAN DAMAGE; ANGIOTENSIN RECEPTOR BLOCKER; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; WHITE COAT HYPERTENSION; CHRONIC KIDNEY-DISEASES; CORONARY-HEART-DISEASE; CHRONIC-RENAL-FAILURE","Hypertension in children and adolescents has gained ground in cardiovascular medicine, thanks to the progress made in several areas of pathophysiological and clinical research. These guidelines represent a consensus among specialists involved in the detection and control of high blood pressure in children and adolescents. The guidelines synthesize a considerable amount of scientific data and clinical experience and represent best clinical wisdom upon which physicians, nurses and families should base their decisions. They call attention to the burden of hypertension in children and adolescents, and its contribution to the current epidemic of cardiovascular disease, these guidelines should encourage public policy makers, to develop a global effort to improve identification and treatment of high blood pressure among children and adolescents. J Hypertens 27: 1719-1742 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Lurbe, Empar] Univ Valencia, Consorcio Hosp Gen, Dept Pediat, Valencia 46014, Spain; [Lurbe, Empar; Redon, Josep] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid, Spain; [Cifkova, Renata] Inst Clin & Expt Med, Dept Prevent Cardiol, Prague, Czech Republic; [Cruickshank, J. Kennedy] Univ Manchester, Div Cardiovasc & Endocrine Sci, Manchester Royal Infirm, Cardiovasc Res Grp, Manchester, Lancs, England; [Dillon, Michael J.] UCL Inst Child Hlth, Nephrourol Unit, London, England; [Ferreira, Isabel] Maastricht Univ, Med Ctr, CAPHRI, CARIM,Dept Internal Med Clin Epidemiol & Med Tech, Maastricht, Netherlands; [Invitti, Cecilia] IRCCS, Ist Auxolog Italiano, Unit Metab Dis & Diabet, Milan, Italy; [Kuznetsovah, Tatiana] Univ Leuven, Lab Hypertens, Louvain, Belgium; [Laurent, Stephane] Hop Europeen, Dept Pharmacol, Paris, France; [Mancia, Giuseppe] Univ Milano Bicocca, Osped San Gerardo, Milan, Italy; [Morales-Olivas, Francisco] Univ Valencia, Dept Pharmacol, Valencia, Spain; [Rascher, Wolfgang] Univ Klinikum, Kinder & Judendklin, Erlangen, Germany; [Redon, Josep] Univ Valencia, Hosp Clin, Dept Internal Med, Valencia, Spain; [Schaefer, Franz; Wuehl, Elke] Univ Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Heidelberg, Germany; [Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Stergiou, George] Third Univ, Sotiria Hosp, Dept Med, Hypertens Ctr, Athens, Greece; [Zanchetti, Alberto] Univ Milan, Ctr Interuniv Fisiol Clin & Ipertens, Milan, Italy; [Zanchetti, Alberto] Ist Auxol Italiano, Milan, Italy","Lurbe, E, Univ Valencia, Consorcio Hosp Gen, Dept Pediat, Avda Tres Cruces S-N, Valencia 46014, Spain","empar.lurbe@uv.es",null,null,null,173,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/HJH.0b013e32832f4f6b","J HYPERTENSION","J. Hypertens.","SEP",2009,27,9,null,null,null,1719,1742,null,null,24,"Peripheral Vascular Disease","491AP","ISI:000269549500001"]
[21,"J","Paulis, L; Pechanova, O; Zicha, J; Krajcirovicova, K; Barta, A; Pelouch, V; Adamcova, M; Simko, F",null,null,null,"Paulis, Ludovit; Pechanova, Olga; Zicha, Josef; Krajcirovicova, Kristina; Barta, Andrej; Pelouch, Vaclav; Adamcova, Michaela; Simko, Fedor",null,"Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of N-G-nitro-L-arginine-methyl ester hypertensive rats","Journal of Hypertension",null,"English","Article",null,null,null,null,null,"collagen; fibrosis; hydroxyproline; hypertension; hypertrophy; melatonin; N-G-nitro-L-arginine-methyl ester; nitric oxide","NAME-INDUCED HYPERTENSION; BLOOD-PRESSURE; HEART; CARDIOMYOPATHY; EXPRESSION; REGRESSION; AORTA; CAPTOPRIL; BRAIN; OXIDE","Objective Melatonin was shown to reduce blood pressure, enhance nitric oxide availability and scavenge free radicals. There is, however, a shortage of data with respect to the effect of melatonin on pathological left ventricular remodelling associated with haemodynamic overload. Design We investigated whether melatonin was able to prevent left ventricular hypertrophy (LVH) and fibrosis associated with N-G-nitro-L-arginine-methyl ester (L-NAME)induced hypertension. Methods Four groups of male Wistar rats were investigated: control, L-NAME (50 mg/kg per day), melatonin (10 mg/kg per day) and L-NAME plus melatonin. Blood pressure was measured non-invasively each week. After 5 weeks of treatment the animals were killed and nitric oxide synthase (NOS) activity, endothelial and inducible NOS expression, the level of collagenous proteins, hydroxyproline and conjugated dienes in the left ventricle were determined. Results The administration of L-NAME inhibited NOS activity, increased conjugated dienes concentration, elevated blood pressure and induced LVH and fibrosis (indicated by increased collagenous proteins and hydroxyproline levels). The addition of melatonin to L-NAME treatment failed to prevent the attenuation of NOS activity and the development of LVH and prevented hypertension only partly. The administration of melatonin, however, completely prevented the increase in conjugated dienes concentration and the development of left ventricular fibrosis. NOS expression was not different among experimental groups. Conclusion Melatonin prevented the development of left ventricular fibrosis and the increase in oxidative load in rats with L-NAME-induced hypertension. The antifibrotic effect of melatonin seems to be independent of its effects on NOS activity and might be linked to its antioxidant properties. J Hypertens 27 (suppl 6):S11-S16 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Paulis, Ludovit] Charite, Cardiovasc Res Ctr, D-10115 Berlin, Germany; [Paulis, Ludovit; Krajcirovicova, Kristina; Simko, Fedor] Comenius Univ, Sch Med, Dept Pathophysiol, Bratislava, Slovakia; [Paulis, Ludovit; Pechanova, Olga; Barta, Andrej] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Paulis, Ludovit; Pechanova, Olga; Barta, Andrej] Slovak Acad Sci, Ctr Excellence Cardiovasc Res, Bratislava, Slovakia; [Pechanova, Olga; Zicha, Josef] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Pechanova, Olga; Zicha, Josef] Acad Sci Czech Republic, Cardiovasc Res Ctr, Prague, Czech Republic; [Pelouch, Vaclav] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague, Czech Republic; [Adamcova, Michaela] Charles Univ Prague, Sch Med, Dept Physiol, Hradec Kralove, Czech Republic; [Simko, Fedor] Comenius Univ, Sch Med, Clin Med 3, Bratislava, Slovakia","Paulis, L, Charite, Cardiovasc Res Ctr, Hess Str 3-4, D-10115 Berlin, Germany","ludo@lfuk.sk","VEGA [1/0187/09, 2/0178/09]; APVV [0538-07]; Marie Curie Intra European Fellowship COME-in-CARE [PIEF-GA-2009-237834]; [MSM0021620820]","This work was partly supported by VEGA grants no. 1/0187/09 and no. 2/0178/09, APVV grant 0538-07, the research project MSM0021620820 and by a Marie Curie Intra European Fellowship COME-in-CARE, PIEF-GA-2009-237834 within the 7th European Community Framework Programme.",null,31,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/01.hjh.0000358831.33558.97","J HYPERTENSION","J. Hypertens.","AUG",2009,27,null,null,"Suppl. 6",null,"S11","S16",null,null,6,"Peripheral Vascular Disease","491AO","ISI:000269549400003"]
[21,"J","Brabec, P; Sufliarsky, J; Linke, Z; Plank, L; Mrhalova, M; Pavlik, T; Klimes, D; Gregor, J",null,null,null,"Brabec, P.; Sufliarsky, J.; Linke, Z.; Plank, L.; Mrhalova, M.; Pavlik, T.; Klimes, D.; Gregor, J.","GIST Registry Investigators","A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia","Neoplasma",null,"English","Article",null,null,null,null,null,"Gastrointestinal stromal tumor; registry; epidemiology; incidence; survival; risk category","GIST; DIAGNOSIS; KIT","Due to problems with identification and an incomplete understanding on the gastrointestinal stromal tumors (GIST) before 2001, there has been a lack of comprehensive long-term population-based studies on GIST epidemiology at present date. We used data from the online registry of Czech and Slovak GIST patients (http://gist.registry.cz/), which has been compiled and maintained since 2006 and involves patients diagnosed from the year 2000. 278 patients were included in this study. Most of the tumors fell into the high-risk category (58.7%), followed by the intermediate (21.4%), low (16.6%) and very low (3.3%) categories. Locations other than the small intestine and stomach had significantly higher contribution of high-risk tumors. The median time of overall Survival was 93.2 months, 5-year relative survival was 78.3% overall, 71.9% for patients with high-risk tumors, 91.1% for intermediate patients, and 91.9% for patients from the low- and very low-risk category. The annual crude incidence between the years 2001-2005 was 0.52 cases per 100,000 inhabitants. The annual European ASR and World ASR were 0.44 and 0.31 per 100,000 inhabitants, respectively. Presented data generally correspond to the whole-population studies recently published, including actual data on epidemiology, clinical characteristics, and survival of patients. The registry helps in improving GIST diagnostics, knowledge about the properties and behaviour of tumors, communication among physicians, and, last but not least, therapeutical options and results.","[Brabec, P.; Pavlik, T.; Klimes, D.; Gregor, J.] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Sufliarsky, J.] Natl Oncol Inst, Clin Internal Med, Bratislava, Slovakia; [Linke, Z.; Mrhalova, M.] Fac Hosp Motol, Radiotherapeut Oncol Dpt, Prague, Czech Republic; [Plank, L.] Martin Fac Hosp, Dpt Pathol Anat, Martin, Slovakia","Gregor, J, Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic","gregor@iba.muni.cz","Novartis ","This work was supported by the Novartis education grant. Authors thank all centers involved in the GIST project for their cooperation and data colection.",null,12,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,"10.4149/neo_2009_05_459","NEOPLASMA","Neoplasma",null,2009,56,5,null,null,null,459,464,null,null,6,"Oncology","488EY","ISI:000269333200014"]
[21,"J","Hrdlicka, M; Zedkova, I; Blatny, M; Urbanek, T",null,null,null,"Hrdlicka, Michal; Zedkova, Iveta; Blatny, Marek; Urbanek, Tomas",null,"Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study","Neuroendocrinology Letters",null,"English","Article",null,null,null,null,null,"schizophrenia; antipsychotics; weight gain; adolescence","2ND-GENERATION ANTIPSYCHOTICS; ONSET SCHIZOPHRENIA; DRUG-TREATMENT; DOUBLE-BLIND; CHILDREN; RISPERIDONE; OLANZAPINE; TOLERABILITY; OBESITY; MEDICATIONS","OBJECTIVES: The aim of the study was to assess weight changes associated with certain atypical (AAP) and typical (TAP) antipsychotic drugs in patients with early-onset schizophrenia and other related psychotic disorders. METHODS: Our retrospective study included 109 patients (52 boys, 57 girls) with a mean age of 15.8 +/- 1.6 years. The patients were evaluated based to their medical records prior to starting therapy, and then after 1, 3, and 6 weeks of treatment. RESULTS: During the first week of treatment, the AAP group (n = 85; risperidone, olanzapine, ziprasidone, and clozapine) gained 1.5% of baseline weight whereas the TAP group (n = 24; haloperidol perphenazine, and sulpiride) gained only 0.2% (p = 0.049). Differences in relative changes between the two groups were not significant at weeks 3 and 6. Expressed as absolute values, patients in our sample gained an average of 3.4 kg (SD 3.2) on AAP and 2.0 kg (SD 3.9) on TAP during 6 weeks of treatment (p = 0.335). Only the risperidone, olanzapine, and clozapine groups had sufficient numbers of patients to allow a comparison at the endpoint of the study (week 6). The patients gained, on average, 3.6 kg (SD 2.6) on risperidone, 4.4 kg (SD 2.5) on olanzapine, and 2.1 kg (SD 4.0) on clozapine during the six weeks of treatment (p = 0.286). CONCLUSIONS: In our study, we did not find a difference in weight gain between the AAP and TAP groups, as large as has been described in the literature. It also seems plausible that the unique and variable weight changes associated with individual AAPs in the pediatric population are different from those observed in the adult population.","[Hrdlicka, Michal; Zedkova, Iveta] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic; [Blatny, Marek; Urbanek, Tomas] Acad Sci Czech Republic, Inst Psychol, Brno 60200, Czech Republic","Hrdlicka, M, Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic","michal.hrdlicka@lfmotol.cuni.cz","Ministry of Education, Youth and Sports, Czech Republic [MSM 0021620849]; Academy of Sciences, Czech Republic [AV0Z70250504]","Supported by Ministry of Education, Youth and Sports, Czech Republic (research grant MSM 0021620849) and by Academy of Sciences, Czech Republic (research plan AV0Z70250504).",null,32,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","FEB",2009,30,2,null,null,null,256,261,null,null,6,"Endocrinology & Metabolism; Neurosciences","492MZ","ISI:000269663900013"]
[21,"J","Malina, M; Cinek, O; Janda, J; Seeman, T",null,null,null,"Malina, Michal; Cinek, Ondrej; Janda, Jan; Seeman, Tomas",null,"Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation","Pediatric Nephrology",null,"English","Article",null,null,null,null,null,"Actin cytoskeleton; Cyclosporine; NPHS2 gene; Proteinuria; Steroid-resistant nephrotic syndrome","ALPORT-SYNDROME; WT1","Autosomal recessive steroid-resistant nephrotic syndrome (NS) is a rare, genetically determined nephropathy caused mainly by a mutation in the NPHS2 gene. This type of NS is usually resistant to other immunosuppressive therapy as well, but a few cases of cyclosporine A-induced partial remission of inherited NS have been reported. We present a boy that developed NS at the age of 18 months. There was no decrease of proteinuria on standard prednisolone therapy, and a diagnosis of steroid-resistant NS was established. However, the proteinuria decreased significantly following the initiation of cyclosporine A therapy (from 1280 to 380 mg/m(2) per day) without any negative effects on renal function (stable glomerular filtration rate 130-150 ml/min per 1.73 m(2)). The molecular genetic test revealed a homozygous R138Q mutation in the NPHS2 gene. Our case demonstrates that cyclosporine A can induce partial remission in patients with genetic forms of NS without influencing the glomerular filtration rate. However, its long-term effect and safety in children with hereditary forms of nephrotic syndrome have yet to be investigated.","[Malina, Michal; Cinek, Ondrej; Janda, Jan; Seeman, Tomas] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15006 5, Czech Republic","Malina, M, Charles Univ Prague, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","michal.malina@lfmotol.cuni.cz","Ministry of Health and Education of the Czech Republic [VZ MZ CR Nr. 0006420301, MSMT CR Nr. 0021620819]","We would like to thank to Dr. M. Konecna from the Pediatric Department of Trinec hospital for the initial diagnosis and long- term follow- up of the patient and Dr. T. Sulakova from Faculty of Health studies, Teaching Hospital Ostrava for performing renal biopsy. This study was supported by grants of the Ministry of Health and Education of the Czech Republic VZ MZ CR Nr. 0006420301 and MSMT CR Nr. 0021620819.",null,11,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-009-1211-0","PEDIAT NEPHROL","Pediatr. Nephrol.","OCT",2009,24,10,null,null,null,2051,2053,null,null,3,"Pediatrics; Urology & Nephrology","487XX","ISI:000269312900021"]
[21,"J","Acharya, S; Banerjee, D; Fronek, J; Fossati, N; Chemla, ES",null,null,null,"Acharya, Sanjukta; Banerjee, Debasish; Fronek, Jiri; Fossati, Nicoletta; Chemla, Eric S.",null,"High-Output Cardiac Failure Following Insertion of Right Femoral Artery to Left Femoral Vein PTFE Graft for Haemodialysis: A Case Report","Seminars in Dialysis",null,"English","Article",null,null,null,null,null,null,"FISTULA; ACCESS; FLOW","Arteriovenous grafts used for hemodialysis can produce high-output cardiac failure as a result of shunting of blood through the dialysis access. The following case demonstrates that the problem can occur shortly after graft formation and improved with graft ligation. It caused haemodynamic compromise because of previously undiagnosed, underlying valvular heart disease. It also caused a diagnostic difficulty in the immediate postoperative period as it was mistaken for postsurgical hemorrhage.","[Acharya, Sanjukta; Banerjee, Debasish; Fronek, Jiri; Chemla, Eric S.] St Georges Hosp NHS Trust, Renal & Transplantat Unit, London SW17 0QT, England; [Fossati, Nicoletta] St Georges Hosp NHS Trust, Dept Anaesthesia, London SW17 0QT, England; [Fronek, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Banerjee, D, St Georges Hosp NHS Trust, Renal & Transplantat Unit, London SW17 0QT, England","Debasish.Banerjee@stgeorges.nhs.uk",null,null,null,4,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0894-0959",null,"10.1111/j.1525-139X.2009.00612.x","SEMIN DIALYSIS","Semin. Dial.","JUL-AUG",2009,22,4,null,null,null,462,464,null,null,3,"Urology & Nephrology","487HW","ISI:000269263600030"]
[21,"J","Kopkan, L; Huskova, Z; Vanourkova, Z; Thumova, M; Skaroupkova, P; Maly, J; Kramer, HJ; Dvorak, P; Cervenka, L",null,null,null,"Kopkan, Libor; Huskova, Zuzana; Vanourkova, Zdenka; Thumova, Monika; Skaroupkova, Petra; Maly, Jan; Kramer, Herbert J.; Dvorak, Pavel; Cervenka, Ludek",null,"Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats","Vascular Pharmacology",null,"English","Article",null,null,null,null,null,"Renin transgenic rats; Hypertension; Angiotensin II; Oxidative stress; Tempol; Apocynin","END-ORGAN DAMAGE; ENDOTHELIN RECEPTOR BLOCKADE; SALT-SENSITIVE HYPERTENSION; BLOOD-PRESSURE; NADPH OXIDASE; CARDIAC-HYPERTROPHY; NITRIC-OXIDE; ANG-II; RENAL-FUNCTION; PIVOTAL ROLE","Results of our previous studies have suggested that enhanced generation of superoxide (O-2(-)) may contribute to the pathophysiology of hypertension in Ren-2 transgenic rats (TGR). The present study was performed to evaluate in TGR the effects of chronic treatment with the O-2(-) scavenger tempol and the antioxidant apocynin on the development of hypertension. Systolic blood pressure (SBP) was monitored from 30 to 99 days of age in TGR and in normotensive Hannover Sprague-Dawley (HanSD) rats. At the end of the experiment, urinary protein and 8-isoprostane excretion were determined and angiotensin II (ANG II) and malondialdehyde (MDA) levels were measured in kidney and cardiac tissues. Cardiac hypertrophy was assessed as the ratio of left heart ventricle weight to tibia length (LVW/TL). Although tempol and apocynin treatment in TGR significantly decreased 8-isoprostane excretion and MAD tissue concentrations as compared with untreated TGR, it did not alter the course of SBP, LVW/TL ratio, proteinuria or ANG II levels that were enhanced as compared with HanSD rats. Our data suggest that the development of hypertension in TGR is clearly ANG II-dependent but the contribution of oxidative stress to the development of hypertension in this model appears to be negligible. (C) 2009 Elsevier Inc. All rights reserved.","[Kopkan, Libor; Huskova, Zuzana; Vanourkova, Zdenka; Thumova, Monika; Skaroupkova, Petra; Maly, Jan; Dvorak, Pavel; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14021 Prague 4, Czech Republic; [Kopkan, Libor; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Cervenka, L, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14021 Prague 4, Czech Republic","luce@medicon.cz","Institute for Clinical and Experimental Medicine [MZO 00023001]; Academy of Science of Czech Republic [KJB 502 030 801]; Czech Science Foundation [305/08/P053]; GACR [305/07/J006]; Center for Cardiovascular Research [1M6798582302]; German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn [Kra 433/14-2, 436 TSE 113/50/0-1]","This study was supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). L.K. is supported by grant no. KJB 502 030 801 awarded by the Grant Agency of the Academy of Science of Czech Republic. Z.H. is supported by grant no. 305/08/P053 awarded by the Czech Science Foundation (GAU). U. is supported by grant no. 305/07/J006 awarded by GACR. Z.V. is supported from the Center for Cardiovascular Research (1M6798582302). H.J. Kramer is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1).",null,62,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1537-1891",null,"10.1016/j.vph.2009.06.001","VASC PHARMACOL","Vasc. Pharmacol.","AUG-SEP",2009,51,"2009-03-02",null,null,null,175,181,null,null,7,"Pharmacology & Pharmacy","486EH","ISI:000269178100017"]
[22,"J","Kotlin, R; Reicheltova, Z; Maly, M; Suttnar, J; Sobotkova, A; Salaj, P; Hirmerova, J; Riedel, T; Dyr, JE",null,null,null,"Kotlin, Roman; Reicheltova, Zuzana; Maly, Martin; Suttnar, Jiri; Sobotkova, Alzbeta; Salaj, Peter; Hirmerova, Jana; Riedel, Tomas; Dyr, Jan E.",null,"Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen","Thrombosis and Haemostasis",null,"English","Article",null,null,null,null,null,"Dysfibrinogenemia; fibrinogen; missense mutation; pulmonary embolism; thrombosis","ENDOPLASMIC-RETICULUM STORAGE; GAMMA-CHAIN; POLYMERIZATION SITE; COILED-COIL; ABNORMAL FIBRINOGEN; CRYSTAL-STRUCTURE; BINDING-SITE; ARG-PRO; A-ALPHA; MUTATION","Congenital dysfibrinogenemia is a rare disease characterised by inherited abnormality in the fibrinogen molecule, resulting in functional defects. Two patients, a 26-year-old woman and a 61-year-old man, both with history of thrombotic events, had abnormal coagulation test results. DNA sequencing showed the heterozygous gamma Y363N mutation (Fibrinogen Praha 111) and the heterozygous A alpha N106D mutation (Fibrinogen Plzen), respectively. Fibrin polymerisation, after addition of either thrombin or reptilase, showed remarkably delayed polymerisation in both cases. Fibrinolysis experiments showed slower tPA initiated lysis of clots. SDS-PAGE did not show any difference between normal and Praha III and Plzen fibrinogens. Both mutations had a significant effect on platelet aggregation. In the presence of either ADP or TRAP, both mutations caused the decrease of platelet aggregation. SEM revealed abnormal clot morphology, with a large number of free ends and narrower fibres of both fibrin Praha III and PIzen. Praha III mutation was situated in the polymerisation pocket \"a\". The replacement of the bulky aromatic side chain of tyrosine by the polar uncharged small side chain of asparagine may lead to a conformational change, possibly altering the conformation of the polymerisation pocket. The Plzen mutation is situated in the coiled-coil connector and this replacement of polar uncharged asparagine residue by polar acidic aspartate changes the alpha-helical conformation of the coiled-coil connector; and may destabilise hydrogen bonds in its neighborhood. Although both mutations are situated in different regions of the molecule, both mutations have a very similar effect on fibrinogen functions and both are connected with thromboses.","[Kotlin, Roman; Reicheltova, Zuzana; Suttnar, Jiri; Sobotkova, Alzbeta; Salaj, Peter; Riedel, Tomas; Dyr, Jan E.] Inst Hematol & Blood Transfus, Prague 12820 2, Czech Republic; [Maly, Martin] Motol Univ Hosp, Dept Cardiol, Prague, Czech Republic; [Hirmerova, Jana] Univ Hosp Plzen, Dept Internal Med 2, Plzen, Czech Republic; [Riedel, Tomas] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic","Kotlin, R, Inst Hematol & Blood Transfus, Nemocnice 1, Prague 12820 2, Czech Republic","kotlinr@uhkt.cz","Ministry of Health of the Czech Republic [NS 9636-3/2008, 2373601]; Czech Republic [KAN200670701]","This work was supported by a grant of the Internal Grant Agency of The Ministry of Health of the Czech Republic, number NS 9636-3/2008; by a grant of The Academy of Sciences of the Czech Republic, number KAN200670701; and by a grant of The Ministry of Health of the Czech Republic, number 2373601",null,44,1,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","0340-6245",null,"10.1160/TH08-11-0771","THROMB HAEMOST","Thromb. Haemost.","SEP",2009,102,3,null,null,null,479,486,null,null,8,"Hematology; Peripheral Vascular Disease","495KN","ISI:000269890200009"]
[23,"J","Eiselleova, L; Matulka, K; Kriz, V; Kunova, M; Schmidtova, Z; Neradil, J; Tichy, B; Dvorakova, D; Pospisilova, S; Hampl, A; Dvorak, P",null,null,null,"Eiselleova, Livia; Matulka, Kamil; Kriz, Vitezslav; Kunova, Michaela; Schmidtova, Zuzana; Neradil, Jakub; Tichy, Boris; Dvorakova, Dana; Pospisilova, Sarka; Hampl, Ales; Dvorak, Petr",null,"A Complex Role for FGF-2 in Self-Renewal, Survival, and Adhesion of Human Embryonic Stem Cells","Stem Cells",null,"English","Article",null,null,null,null,null,"Fibroblast growth factor-2; Human ESCs; Self-renewal; Cell survival; Adhesion","FIBROBLAST-GROWTH-FACTOR; CULTURE-CONDITIONS; GENE-EXPRESSION; HUMAN ESCS; MOUSE; DIFFERENTIATION; PROLIFERATION; IMPLANTATION; RECEPTOR; FORMS","The transcription program that is responsible for the pluripotency of human ESCs (hESCs) is believed to be comaintained by exogenous fibroblast growth factor-2 (FGF-2), which activates FGF receptors (FGFRs) and stimulates the mitogen-activated protein kinase (MAPK) pathway. However, the same pathway is stimulated by insulin receptors, insulin-like growth factor 1 receptors, and epidermal growth factor receptors. This mechanism is further complicated by intracrine FGF signals. Thus, the molecular mechanisms by which FGF-2 promotes the undifferentiated growth of hESCs are unclear. Here we show that, in undifferentiated hESCs, exogenous FGF-2 stimulated the expression of stem cell genes while suppressing cell death and apoptosis genes. Inhibition of autocrine FGF signaling caused upregulation of differentiation-related genes and downregulation of stem cell genes. Thus, exogenous FGF-2 reinforced the pluripotency maintenance program of intracrine FGF-2 signaling. Consistent with this hypothesis, expression of endogenous FGF-2 decreased during hESC differentiation and FGF-2 knockdown-induced hESC differentiation. In addition, FGF-2 signaling via FGFR2 activated MAPK kinase/extracellular signal-regulated kinase and AKT kinases, protected hESC from stress-induced cell death, and increased hESC adhesion and cloning efficiency. This stimulation of self-renewal, cell survival, and adhesion by exogenous and endogenous FGF-2 may synergize to maintain the undifferentiated growth of hESCs. STEM CELLS 2009;27:1847-1857","[Eiselleova, Livia; Matulka, Kamil; Kriz, Vitezslav; Kunova, Michaela; Schmidtova, Zuzana; Neradil, Jakub; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Dept Biol, Brno 62500, Czech Republic; [Eiselleova, Livia; Matulka, Kamil; Kunova, Michaela; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Ctr Chem Genet, Brno 62500, Czech Republic; [Tichy, Boris; Dvorakova, Dana; Pospisilova, Sarka] Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematooncol, Brno 62500, Czech Republic; [Hampl, Ales; Dvorak, Petr] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Embryol, Prague, Czech Republic; [Hampl, Ales; Dvorak, Petr] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Dvorak, P, Masaryk Univ, Fac Med, Dept Biol, Kamenice 5,Bldg A6, Brno 62500, Czech Republic","pdvorak@med.muni.cz","Ministry of Education, Youth, and Sport of the Czech Republic [MSM0021622430, LC06077, 1M0538]; Academy of Sciences of the Czech Republic [AV0Z50390512, AV0Z50390703]; European Commission Framework Programme 6 [LSHG-CT-2006-018739]","We thank Peter W. Andrews of the University of Sheffield, Sheffield, U. K., for sorted SSEA3-positive hESCs and Outi Hovatta of the Karolinska Institutet, Huddinge, Sweden, for the HS237 hESC line. This study was supported by the Ministry of Education, Youth, and Sport of the Czech Republic (MSM0021622430, LC06077, 1M0538), the Academy of Sciences of the Czech Republic (AV0Z50390512, AV0Z50390703), and European Commission Framework Programme 6 (contract LSHG-CT-2006-018739) funding.",null,46,0,"ALPHAMED PRESS","DURHAM","318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA","1066-5099",null,"10.1002/stem.128","STEM CELLS","Stem Cells","AUG",2009,27,8,null,null,null,1847,1857,null,null,11,"Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology","497HZ","ISI:000270050900016"]
[23,"C","Giaccone, G; Zatloukal, P; Roubec, J; Floor, K; Musil, J; Kuta, M; van Klaveren, RJ; Chaudhary, S; Gunther, A; Shamsili, S",null,null,null,"Giaccone, Giuseppe; Zatloukal, Petr; Roubec, Jaromir; Floor, Karijn; Musil, Jaromir; Kuta, Milan; van Klaveren, Rob J.; Chaudhary, Subhash; Gunther, Adrie; Shamsili, Setareh",null,"Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer","Journal of Clinical Oncology",null,"English","Proceedings Paper","International Conference of the American-Association-for-Cancer-Research/National-Cancer-Institute/European-Organisation-for-Research-and-Treatment-of-Cancer","OCT 22-26, 2007","San Francisco, CA","Amer Assoc Canc Res, NCI, European Org Res & Treatment Canc",null,null,"ANTI-APOPTOSIS GENE; ANTIAPOPTOSIS GENE; PROGNOSTIC-FACTORS; EXPRESSION; CHEMOTHERAPY; DOCETAXEL; CARCINOMA; NEUROBLASTOMA; THERAPY; MARKER","Purpose To evaluate the antitumor activity and safety of YM155, a novel, small-molecule suppressor of survivin, as single-agent therapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIb/IV NSCLC who had experienced treatment failure during one or two prior chemotherapy regimens (at least one of which was platinum based) received YM155 as a continuous intravenous infusion (4.8 mg/m(2)/d) over 168 hours followed by observation for 14 days in 21-day treatment cycles. The primary end point was objective tumor response rate (ORR). Secondary end points included duration of stable disease (SD), progression-free survival (PFS), overall survival (OS), safety and pharmacokinetic profiles, and pharmacodynamic evaluations. Results Thirty-seven patients received YM155. Two patients achieved a confirmed partial response, with an ORR of 5.4% (95% CI, 0.7% to 18.2%). An additional 14 patients (37.8%) achieved SD resulting in a disease control rate of 43.2% (95% CI, 27.1% to 60.5%). Median duration of PFS was 1.7 months (95% CI, 1.3 to 2.8 months). Median duration of OS was 6.6 months (95% CI, 4 to 12.2 months), with a 1-year survival rate of 35.1%. Treatment with YM155 was well tolerated with the majority of treatment discontinuations not treatment related. Conclusion YM155 exhibited modest single-agent activity in patients with refractory, advanced NSCLC. A favorable safety/tolerability profile was reported. Further evaluation of YM155 in combination with chemotherapy and other targeted agents may be warranted. J Clin Oncol 27:4481-4486. (C) 2009 by American Society of Clinical Oncology","Vrije Univ Med Ctr, Amsterdam, Netherlands; Erasmus MC, Rotterdam, Netherlands; Astellas Pharma Europe BV, Leiderdorp, Netherlands; Charles Univ Prague, Fac Med 3, Prague, Czech Republic; Teaching Hosp Bulovka, Prague, Czech Republic; Charles Univ Prague, Fac Med 2, Prague, Czech Republic; Teaching Hosp Motol, Prague, Czech Republic; Teaching Hosp Ostrava Poruba, Ostrava, Czech Republic; Nemocnice Chomutov, Chomutov, Czech Republic; Onkol Ctr JG Mendla, Novy Jicin, Czech Republic","Giaccone, G, NCI, Med Oncol Branch, 10 Ctr Dr, Bethesda, MD 20892 USA","giacconeg@mail.nih.gov",null,null,null,35,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2008.21.1862","J CLIN ONCOL","J. Clin. Oncol.","SEP 20",2009,27,27,null,null,null,4481,4486,null,null,6,"Oncology","496ZO","ISI:000270019900009"]
[23,"J","Balgobind, BV; Raimondi, SC; Harbott, J; Zimmermann, M; Alonzo, TA; Auvrignon, A; Beverloo, HB; Chang, M; Creutzig, U; Dworzak, MN; Forestier, E; Gibson, B; Hasle, H; Harrison, CJ; Heerema, NA; Kaspers, GJL; Leszl, A; Litvinko, N; Lo Nigro, L; Morimoto, A; Perot, C; Pieters, R; Reinhardt, D; Rubnitz, JE; Smith, FO; Stary, J; Stasevich, I; Strehl, S; Taga, T; Tomizawa, D; Webb, D; Zemanova, Z; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, Brian V.; Raimondi, Susana C.; Harbott, Jochen; Zimmermann, Martin; Alonzo, Todd A.; Auvrignon, Anne; Beverloo, H. Berna; Chang, Myron; Creutzig, Ursula; Dworzak, Michael N.; Forestier, Erik; Gibson, Brenda; Hasle, Henrik; Harrison, Christine J.; Heerema, Nyla A.; Kaspers, Gertjan J. L.; Leszl, Anna; Litvinko, Nathalia; Lo Nigro, Luca; Morimoto, Akira; Perot, Christine; Pieters, Rob; Reinhardt, Dirk; Rubnitz, Jeffrey E.; Smith, Franklin O.; Stary, Jan; Stasevich, Irina; Strehl, Sabine; Taga, Takashi; Tomizawa, Daisuke; Webb, David; Zemanova, Zuzana; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,"Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","Blood",null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; CHILDRENS-ONCOLOGY-GROUP; AML TRIALS; CHROMOSOMAL-ABNORMALITIES; GROUP-B; CANCER; MLL; MULTICENTER; ADOLESCENTS","Translocations involving chromosome 11q23 frequently occur in pediatric acute myeloid leukemia (AML) and are associated with poor prognosis. In most cases, the MLL gene is involved, and more than 50 translocation partners have been described. Clinical outcome data of the 11q23-rearranged subgroups are scarce because most 11q23 series are too small for meaningful analysis of subgroups, although some studies suggest that patients with t(9;11)(p22;q23) have a more favorable prognosis. We retrospectively collected outcome data of 756 children with 11q23- or MLL-rearranged AML from 11 collaborative groups to identify differences in outcome based on translocation partners. All karyotypes were centrally reviewed before assigning patients to subgroups. The event-free survival of 11q23/MLL-rearranged pediatric AML at 5 years from diagnosis was 44%(+/- 5%), with large differences across subgroups (11% +/- 5% to 92% +/- 5%). Multivariate analysis identified the following subgroups as independent prognostic predictors: t(1;11)(q21;q23) (hazard ratio [HR] = 0.1, P = .004); t(6;11)(q27;q23) (HR = 2.2, P < .001); t(10;11)(p12;q23) (HR = 1.5, P = .005); and t(10;11)(p11.2;q23) (HR = 2.5, P = .005). We could not confirm the favorable prognosis of the t( 9; 11)( p22; q23) subgroup. We identified large differences in outcome within 11q23/MLL-rearranged pediatric AML and novel subgroups based on translocation partners that independently predict clinical outcome. Screening for these translocation partners is needed for accurate treatment stratification at diagnosis. (Blood. 2009; 114: 2489-2496)","[Balgobind, Brian V.; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [Raimondi, Susana C.; Rubnitz, Jeffrey E.] St Jude Childrens Hosp, Memphis, TN 38105 USA; [Raimondi, Susana C.; Alonzo, Todd A.; Heerema, Nyla A.; Smith, Franklin O.] Childrens Oncol Grp, Arcadia, CA USA; [Harbott, Jochen] Univ Giessen, Acute Myeloid Leukemia Berlin Frankfurt Munster S, Dept Pediat Hematol & Oncol, Giessen, Germany; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster S, D-3000 Hannover, Germany; [Auvrignon, Anne; Perot, Christine] Hop Trousseau, F-75571 Paris, France; [Beverloo, H. Berna] Dutch Working Grp Hematooncol Genome Diagnost, Dutch Childhood Oncol Grp, The Hague, Netherlands; [Beverloo, H. Berna] Erasmus MC, Dept Clin Genet, NL-3000 CB Rotterdam, Netherlands; [Chang, Myron] Ctr Data, Childrens Oncol Grp, Gainesville, FL USA; [Creutzig, Ursula] Univ Hosp, Acute Myeloid Leukemia Berlin Frankfurt Munster S, Munster, Germany; [Dworzak, Michael N.; Strehl, Sabine] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Forestier, Erik] Umea Univ Hosp, Nord Soc Pediat Hematol & Oncol, Dept Clin Sci, S-90185 Umea, Sweden; [Gibson, Brenda] Royal Hosp Sick Children, Dept Pediat Oncol Hematol, Glasgow G3 8SJ, Lanark, Scotland; [Hasle, Henrik] Aarhus Univ, Nord Soc Pediat Hematol & Oncol, Dept Pediat, Hosp Skejby, Aarhus, Denmark; [Harrison, Christine J.] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Kaspers, Gertjan J. L.; Webb, David] Berlin Frankfurt Munster Study Grp, Acute Myeloid Leukemia Comm 1, Frankfurt, Germany; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Leszl, Anna] Univ Padua, Pediat Clin, Italian Assoc Pediat Hematol Oncol, Padua, Italy; [Litvinko, Nathalia; Stasevich, Irina] Res Ctr Pediat Oncol & Hematol, Minsk, Byelarus; [Lo Nigro, Luca] Univ Catania, Pediat Clin, Italian Assoc Pediat Hematol Oncol, Catania, Italy; [Morimoto, Akira; Taga, Takashi; Tomizawa, Daisuke] Japanese Pediat Leukemia Lymphoma Study Grp, Tokyo, Japan; [Morimoto, Akira] Jichi Med Univ, Dept Pediat, Jichi, Tochigi, Japan; [Smith, Franklin O.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Smith, Franklin O.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Stary, Jan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Taga, Takashi] Shiga Univ Med Sci, Dept Pediat, Shiga, Japan; [Tomizawa, Daisuke] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Webb, David] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Gen Univ Hosp, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague, Czech Republic","van den Heuvel-Eibrink, MM, Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rm Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands","m.vandenheuvel@erasmusmc.nl","International Pediatric AML Group of the I-Berlin-Frankfurt-Munster Study Group-SG ; American Lebanese Syrian Associated Charities ; Czech Ministry of Education [MSM0021620813]; Children's Oncology Group Chair's [U10 CA98543]; COG Statistics Data Center [U10 CA98413]; Swedish Children's Cancer Foundation ; NWO Netherlands Organization for Scientific Research ; Foundation Childhood Oncology Center Rotterdam ","The authors thank Dr Angela McArthur for editorial assistance and Dr Riccardo Masetti and Francesca Predieri for collecting data. This work was supported by the International Pediatric AML Group of the I-Berlin-Frankfurt-Munster Study Group-SG, which is chaired by Prof. Gertjan J. L. Kaspers (1999-2007) and Dr David Webb (2007-present). This work was further supported in part by the American Lebanese Syrian Associated Charities, the Czech Ministry of Education (MSM0021620813), Children's Oncology Group Chair's Grant U10 CA98543, COG Statistics & Data Center Grant U10 CA98413, and the Swedish Children's Cancer Foundation. The project of B. V. B. is funded by the NWO Netherlands Organization for Scientific Research and the Foundation Childhood Oncology Center Rotterdam.",null,33,1,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2009-04-215152","BLOOD","Blood","SEP 17",2009,114,12,null,null,null,2489,2496,null,null,8,"Hematology","495WD","ISI:000269925000017"]
[23,"J","Sedy, J; Zicha, J; Kunes, J; Hejcl, A; Sykova, E",null,null,null,"Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav; Hejcl, Ales; Sykova, Eva",null,"The role of nitric oxide in the development of neurogenic pulmonary edema in spinal cord-injured rats: the effect of preventive interventions","American Journal of Physiology-Regulatory Integrative and Comparative Physiology",null,"English","Article",null,null,null,null,null,"blood pressure; heart rate; atropine","HEART-RATE; ISOFLURANE; MODEL; BAROREFLEX; RABBITS; REFLEX; SEVOFLURANE; INHIBITION; MECHANISMS","Sedy J, Zicha J, Kunes. J, Hejc. l A, Sykova E. The role of nitric oxide in the development of neurogenic pulmonary edema in spinal cord-injured rats: the effect of preventive interventions. Am J Physiol Regul Integr Comp Physiol 297: R1111-R1117, 2009. First published August 12, 2009; doi: 10.1152/ajpregu.00251.2009.-Neurogenic pulmonary edema (NPE) is an acute life-threatening complication following an injury of the spinal cord or brain, which is associated with sympathetic hyperactivity. The role of nitric oxide (NO) in NPE development in rats subjected to balloon compression of the spinal cord has not yet been examined. We, therefore, pretreated Wistar rats with the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) either acutely (just before the injury) or chronically (for 4 wk prior to the injury). Acute (but not chronic) L-NAME administration enhanced NPE severity in rats anesthetized with 1.5% isoflurane, leading to the death of 83% of the animals within 10 min after injury. Pretreatment with either the ganglionic blocker pentolinium (to reduce blood pressure rise) or the muscarinic receptor blocker atropine (to lessen heart rate decrease) prevented or attenuated NPE development in these rats. We did not observe any therapeutic effects of atropine administered 2 min after spinal cord compression. Our data indicate that NPE development is dependent upon a marked decrease of heart rate under the conditions of high blood pressure elicited by the activation of the sympathetic nervous system. These hemodynamic alterations are especially pronounced in rats subjected to acute NO synthase inhibition. In conclusion, nitric oxide has a partial protective effect on NPE development because it attenuates sympathetic vasoconstriction and consequent baroreflex-induced bradycardia following spinal cord injury.","[Sedy, Jiri; Hejcl, Ales; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Sedy, Jiri] Charles Univ Prague, Inst Dent Res, Fac Med 1, Prague, Czech Republic; [Sedy, Jiri] Gen Univ Hosp, Prague, Czech Republic; [Zicha, Josef; Kunes, Jaroslav] Cardiovasc Res Ctr, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic","Sedy, J, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","jirisedy@hotmail.com","Ministry of Education of the Czech Republic [AV0Z50390512, AV0Z50110509, 1M0538, LC554, 1M0510]; Grant Agency of the Czech Republic [GACR309/06/1246, GACR 305/08/0139]; Czech Ministry of Health [IGA MZ 1A8697-5, IGA MZ NR/8339-3]; Internal Agency of the Academy of the Czech Republic [IAA 500390902]; European Comission [LSHB-CT-2005-518233]","We acknowledge the support provided by the Grants AV0Z50390512, AV0Z50110509, 1M0538, LC554, and 1M0510 by the Ministry of Education of the Czech Republic, Grants GACR309/06/1246 and GACR 305/08/0139 by Grant Agency of the Czech Republic, Grants IGA MZ 1A8697-5 and IGA MZ NR/8339-3 by Czech Ministry of Health, Grant IAA 500390902 by Internal Agency of the Academy of the Czech Republic and the European Comission FP6 project RESCUE (LSHB-CT-2005-518233).",null,27,0,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","0363-6119",null,"10.1152/ajpregu.00251.2009","AMER J PHYSIOL-REGUL INTEGR C","Am. J. Physiol.-Regul. Integr. Comp. Physiol.","OCT",2009,297,4,null,null,null,"R1111","R1117",null,null,7,"Physiology","498YY","ISI:000270184100023"]
[24,"J","Plevova, P; Walczyskova, S; Jeziskova, I; Jurckova, N; Krepelova, A; Puchmajerova, A; Pavlikova, K; Foretova, L; Zapletalova, J; Silhanova, E",null,null,null,"Plevova, P.; Walczyskova, S.; Jeziskova, I.; Jurckova, N.; Krepelova, A.; Puchmajerova, A.; Pavlikova, K.; Foretova, L.; Zapletalova, J.; Silhanova, E.",null,"Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer","Neoplasma",null,"English","Article",null,null,null,null,null,"breast cancer; cancer risk; colon cancer; colon polyposis; germline mutation; PML gene","LYNCH-SYNDROME; NUCLEAR-BODY; PML; MUTATIONS; PROTEINS; ROLES; CELLS","The promyelocytic leukemia (PML) gene is an important tumor suppressor gene. We tested the hypothesis that germline disruption of the PML gene may be associated with a cancer predisposition syndrome. Mutation analysis of the PML gene was performed in 111 patients with familial adult cancer or young age-onset adult cancer. These were mostly breast and colon cancer, or colon polyposis patients in whom mutation analyses of the BRCA1, BRCA2, MLH1, MSH2, APC or TP53 genes did not detect a pathogenic germline mutation. Heteroduplex analysis and direct sequencing were used for mutation screening. Mutation-specific methods were designed for frequency determination of novel variants in the general population. No deleterious nonsense or frameshift germline mutations were detected. Several missense single-nucleotide substitutions were found, including two novel missense variants, c.83C>T (p.Thr28Ile) in exon 1 in a 42-year-old breast cancer patient and c.1558C>T (p.Pro520Ser) in exon 6 in a 32-year-old colon cancer patient, that were not detected in 100 and 214 non-cancer persons, respectively. Frequency of the c.2260G>C (p.Ala754Pro) variant in isoform IV of the PML gene was higher in patients with colon polyposis and cancer than in the control group (P = 0.029). In conclusion, germline disruption of the PML gene is probably not associated with a highly penetrant susceptibility to adult-onset breast and colon cancer. Pathogenicity of c.83C>T and c.1558C>T variants in the PML gene is uncertain. Carriers of the c.2260G>C variant in PMLIV isoform may be at an increased risk of colon polyposis and cancer.","[Plevova, P.; Walczyskova, S.; Jeziskova, I.; Jurckova, N.; Silhanova, E.] Fac Hosp Ostrava, Dept Med Genet, Ostrava, Czech Republic; [Krepelova, A.; Puchmajerova, A.; Pavlikova, K.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Krepelova, A.; Puchmajerova, A.; Pavlikova, K.] Charles Univ Prague, Dept Biol & Med Genet, Fac Hosp Prague Motol, Prague, Czech Republic; [Foretova, L.] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; [Zapletalova, J.] Palacky Univ, Dept Biophys, Fac Med, CR-77147 Olomouc, Czech Republic","Plevova, P, Fac Hosp Ostrava, Dept Med Genet, Ostrava, Czech Republic","pavlina.plevova@volny.cz","Ministry of Health Care of the Czech Republic [NR/9092-3]","This work was supported by the Internal Grant Agency of the Ministry of Health Care of the Czech Republic (grant number NR/9092-3).",null,18,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,"10.4149/neo_2009_06_500","NEOPLASMA","Neoplasma",null,2009,56,6,null,null,null,500,507,null,null,8,"Oncology","501GM","ISI:000270369200007"]
[24,"J","Dusatkova, P; Hradsky, O; Lenicek, M; Bronsky, J; Nevoral, J; Kotalova, R; Bajerova, K; Vitek, L; Lukas, M; Cinek, O",null,null,null,"Dusatkova, Petra; Hradsky, Ondrej; Lenicek, Martin; Bronsky, Jiri; Nevoral, Jiri; Kotalova, Radana; Bajerova, Katerina; Vitek, Libor; Lukas, Milan; Cinek, Ondrej",null,"Association of IL23R p.381Gln and ATG16L1 p.197Ala With Crohn Disease in the Czech Population","Journal of Pediatric Gastroenterology and Nutrition",null,"English","Article",null,null,null,null,null,"Age at onset; ATG16L1; Crohn disease; Genetic association; IL23R","INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; ITALIAN POPULATION; SUSCEPTIBILITY; GENE; VARIANT; EXPRESSION; PHENOTYPE; AUTOPHAGY; CELLS","Objectives: An association of variants in the genes encoding the interleukin 23 receptor (IL23R, p.Arg381Gln, rs11209026), and the autophagy-related gene 16-like 1 (ATG16L1, p.Ala197Thr, rs2241880) with Crohn disease (CD) was identified by whole genome association studies, and subsequently confirmed by other works. The aim of this study was to assess this association in the Czech population. Subjects and Methods: In a case-control study 333 patients with CD (137 paediatric and 196 adult-onset) and 499 unrelated healthy controls were genotyped using TaqMan SNP assays. Results: The IL23R p.381Gln allele was protective against CD in the Czech population (allelic frequency 3.2% in patients vs 5.5% in control subjects; OR 0.56, 95% CI 0.33-0.93, P=0.02). ATG16L1 p.197Ala allele conferred increased risk of CD (allelic frequency 60% in patients vs 51% in controls; OR 1.25, 95% CI 1.02-1.52, P=0.03). There was no appreciable difference in the effect of the associated alleles across the strata of CARD15-conferred risk. The IL23R and ATG16L1 variants did not influence the age at diagnosis, and in the genotype-phenotype analysis, the only detected association was a weak one between IL23R p.381Gln and involvement of the upper gastrointestinal tract (uncorrected P=0.031). Conclusions: We confirmed the role of IL23R and ATG16L1 in the CD susceptibility in the Czech population, and found a weak protective effect of IL23R p.381Gln against upper gastrointestinal tract involvement. JPGN 49:405-410, 2009.","[Dusatkova, Petra; Hradsky, Ondrej; Bronsky, Jiri; Nevoral, Jiri; Kotalova, Radana; Cinek, Ondrej] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Dusatkova, Petra; Hradsky, Ondrej; Bronsky, Jiri; Nevoral, Jiri; Kotalova, Radana; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, CZ-15006 Prague, Czech Republic; [Lenicek, Martin; Vitek, Libor] Charles Univ Prague, Inst Clin Biochem, CZ-15006 Prague, Czech Republic; [Lenicek, Martin; Vitek, Libor] Charles Univ Prague, Diagnost Lab, Fac Med 1, CZ-15006 Prague, Czech Republic; [Bajerova, Katerina] Fac Hosp, Pediat Internal Med Clin 1, Brno, Czech Republic; [Lukas, Milan] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, CZ-15006 Prague, Czech Republic","Cinek, O, Charles Univ Prague, Dept Pediat, Univ Hosp Motol, V Uvalu 84, CZ-15006 Prague, Czech Republic","Ondrej.Cinek@Lfmotol.cuni.cz","Czech Ministry of Health [MZ00064203]; University Hospital Motol ; Charles University in Prague [GAUK 7660/2007]","This study was supported by grants from the Czech Ministry of Health (MZ00064203), the University Hospital Motol, and the grant agency of the Charles University in Prague (GAUK 7660/2007).",null,28,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIAT GASTROENTEROL NUTR","J. Pediatr. Gastroenterol. Nutr.","OCT",2009,49,4,null,null,null,405,410,null,null,6,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","502PU","ISI:000270473200006"]
[24,"J","Lins, S; Kim, R; Kruger, L; Chrzanowska, KH; Seemanova, E; Digweed, M",null,null,null,"Lins, Stephan; Kim, Ryong; Krueger, Lars; Chrzanowska, Krystyna H.; Seemanova, Eva; Digweed, Martin",null,"Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome","Gene",null,"English","Article",null,null,null,null,null,"DNA repair; Nonsense-mediated mRNA decay; Hypomorphic mutation; Proteasome inhibition","MESSENGER-RNA DECAY; NBS1 CONTRIBUTES; GENE-MUTATIONS; DISEASE; PROTEIN; CANCER; OVEREXPRESSION; IDENTIFICATION; TRANSFORMATION; MALIGNANCIES","Patients affected by the autosomal recessive Nijmegen Breakage Syndrome (NBS [MIM 251260]) have possibly the highest risk for developing a malignancy of all the chromosomal instability syndromes. This reflects the profound disturbance to genomic integrity and cellular homeostasis that is caused by the mutation of the essential mammalian gene, NBN. Whilst null-mutation of Nbn is lethal in the mouse, NBS patients survive due to the fact that the common human founder mutation, found in over 90% of patients, is in fact hypomorphic and leads, by alternative translation, to varying amounts of a partially functional carboxy-terminal protein fragment, p70-nibrin. The expression level of p70-nibrin correlates with cancer incidence amongst patients. Using real-time PCR we have now found that the variation in p70-nibrin expression cannot be attributed to differences in mRNA quantity and that nonsense-mediated mRNA decay is not responsible for the observed variation. We discuss an alternative explanation for p70-nibrin expression variation. (C) 2009 Elsevier B.V. All rights reserved.","[Lins, Stephan; Kim, Ryong; Krueger, Lars; Digweed, Martin] Charite, Inst Human Genet, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Kim, Ryong] Red Cross Gen Hosp, Inst Clin Chem, Pyongyang, South Korea; [Chrzanowska, Krystyna H.] Childrens Mem Hlth Inst, Dept Med Genet, PL-04730 Warsaw, Poland; [Seemanova, Eva] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Dept Clin Genet, Prague 15006 5, Motol, Czech Republic","Digweed, M, Charite, Inst Human Genet, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany","martin.digweed@charite.de","Deutsche Forschungsgemeinschaft [SFB577]","Mrs Susanne Rothe, Ms Janina Radszewski, Mrs Veronique Dutrannoy-Tonsing and Mr. Bastian Salewsky are gratefully acknowl- edged for their excellent technical assistance. We are grateful to Dr. Kenshi Komatsu for providing the NBS GM7166VA7 fibroblasts. This work was supported by the Deutsche Forschungsgemeinschaft (SFB577).",null,26,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-1119",null,"10.1016/j.gene.2009.07.013","GENE","Gene","NOV 1",2009,447,1,null,null,null,12,17,null,null,6,"Genetics & Heredity","503IL","ISI:000270527200002"]
[24,"J","Sochorova, K; Budinsky, V; Rozkova, D; Tobiasova, Z; Dusilova-Sulkova, S; Spisek, R; Bartunkova, J",null,null,null,"Sochorova, Klara; Budinsky, Vit; Rozkova, Daniela; Tobiasova, Zuzana; Dusilova-Sulkova, Sylvie; Spisek, Radek; Bartunkova, Jirina",null,"Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells","Clinical Immunology",null,"English","Article",null,null,null,null,null,"Immunomodulatory effect; Vitamin D; VDR activators; Paricalcitol; Calcitriol; Dendritic cell; Chronic kidney disease","VITAMIN-D-RECEPTOR; CHRONIC KIDNEY-DISEASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; SECONDARY HYPERPARATHYROIDISM; UREMIC RATS; EXPRESSION; IMMUNITY; ATHEROSCLEROSIS; DIFFERENTIATION; CALCIFICATION","Paricalcitol (19-nor-1,25/OH2/D-2), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. In contrast to calcitriol, paricalcitol has a reduced effect on intestinal calcium resorption thus avoiding undesirable hypercalcemia. Information about immunomodulatory activity of paricalcitol is scarce. In this study we show that, in all investigated aspects, paricalcitol retains significant immunomodulatory activity, comparable to calcitriol. Both VDR agonists impaired differentiation of immature dendritic cells (DCs) from monocytes. The presence of VDR agonists during DC differentiation abolished their capacity to be activated and, despite potent Toll-like receptor mediated stimulation, VDR agonist-treated DCs remained in the immature state. In accordance with these findings, VDR-treated DCs produced no bioactive IL-12 and had a significantly decreased capacity to induce antigen-specific Tcells while the capacity to induce functional Tregs remained unchanged when compared to control DCs. As DCs and Tcells play an important role in the pathogenesis of atherosclerosis, in end-stage renal disease patients, paricalcitol should be a VDR agonist of choice for the reduction of the risk of atherosclerosis due to its immunomodulatory effect proven in this study and known limited hypercalcemic effect. The immunomodulatory potency of paricalcitol makes it a drug of interest in the therapy of chronic immune-mediated inflammatory diseases. (C) 2009 Elsevier Inc. All rights reserved.","[Sochorova, Klara; Budinsky, Vit; Rozkova, Daniela; Tobiasova, Zuzana; Spisek, Radek; Bartunkova, Jirina] Charles Univ Prague, Inst Immunol, Fac Med 2, Prague 15006, Czech Republic; [Sochorova, Klara; Budinsky, Vit; Rozkova, Daniela; Tobiasova, Zuzana; Spisek, Radek; Bartunkova, Jirina] Univ Hosp Motol, Prague 15006, Czech Republic; [Dusilova-Sulkova, Sylvie] Charles Univ Prague, Dept Gerontol & Metab, Fac Med, Prague 15006, Czech Republic; [Dusilova-Sulkova, Sylvie] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic","Bartunkova, J, Charles Univ Prague, Inst Immunol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","jirina.bartunkova@lfmotol.cuni.cz","The Czech Ministry of Education [MSM 0021620812, MSM 0021620819]; Charles University [GAUK 7588/2007]","Supported by research grants MSM 0021620812 and MSM 0021620819 from The Czech Ministry of Education and GAUK 7588/2007 from Charles University.",null,32,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616",null,"10.1016/j.clim.2009.06.011","CLIN IMMUNOL","Clin. Immunol.","OCT",2009,133,1,null,null,null,69,77,null,null,9,"Immunology","500IN","ISI:000270292400008"]
[24,"J","Verdecchia, P; Sleight, P; Mancia, G; Fagard, R; Trimarco, B; Schmieder, RE; Kim, JH; Jennings, G; Jansky, P; Chen, JH; Liu, LS; Gao, P; Probstfield, J; Teo, K; Yusuf, S",null,null,null,"Verdecchia, Paolo; Sleight, Peter; Mancia, Giuseppe; Fagard, Robert; Trimarco, Bruno; Schmieder, Roland E.; Kim, Jae-Hyung; Jennings, Garry; Jansky, Petr; Chen, Jyh-Hong; Liu, Lisheng; Gao, Peggy; Probstfield, Jeffrey; Teo, Koon; Yusuf, Salim","ONTARGET TRANSCEND Investigators","Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","Circulation",null,"English","Article",null,null,null,null,null,"angiotensin; electrocardiography; epidemiology; hypertrophy; prognosis","ESSENTIAL-HYPERTENSION; ARTERIAL-HYPERTENSION; CARDIAC-HYPERTROPHY; AT(2) RECEPTORS; BLOOD-PRESSURE; SERIAL CHANGES; MASS; REGRESSION; REDUCTION; EVENTS","Background-Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. Methods and Results-In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07). Conclusions-In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone. (Circulation. 2009;120:1380-1389.)","[Verdecchia, Paolo; Sleight, Peter; Teo, Koon; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L2X2, Canada; [Verdecchia, Paolo] Hosp S Maria Misericordia, Clin Res Unit Prevent Cardiol, Perugia, Italy; [Sleight, Peter] John Radcliffe Hosp, Oxford OX3 9DU, England; [Mancia, Giuseppe] Univ Milano Bicocca, Milan, Italy; [Fagard, Robert] Catholic Univ Leuven, Hypertens Unit, Louvain, Belgium; [Trimarco, Bruno] Univ Naples Federico 2, Dept Clin Med & Cardiovasc & Immunol Sci, Naples, Italy; [Schmieder, Roland E.] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Kim, Jae-Hyung] Catholic Univ Korea, St Pauls Hosp, Dept Cardiol, Div Cardiol, Seoul, South Korea; [Jennings, Garry] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Jansky, Petr] Univ Hosp Motol, Dept Cardiovasc Surg, Prague, Czech Republic; [Chen, Jyh-Hong] Natl Cheng Kung Univ, Coll Med, Div Cardiol, Dept Med, Tainan 70101, Taiwan; [Liu, Lisheng] Chinese Acad Med Sci, Fu Wai Hosp, Dept Hypertens, Beijing 100037, Peoples R China; [Probstfield, Jeffrey] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA","Verdecchia, P, McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L2X2, Canada","verdec@tin.it","Boehringer-Ingelheim ","This study was supported by Boehringer-Ingelheim.",null,37,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,"10.1161/CIRCULATIONAHA.109.865774","CIRCULATION","Circulation","OCT 6",2009,120,14,null,null,null,1380,1389,null,null,10,"Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease","502VQ","ISI:000270488800007"]
[25,"J","Feber, J; Spatenka, J; Seeman, T; Matousovic, K; Zeman, L; Dusek, J; Moravek, J; Janda, J; Barrowman, NJ; Guerra, L; Leonard, M",null,null,null,"Feber, Janusz; Spatenka, Jaroslav; Seeman, Tomas; Matousovic, Karel; Zeman, Lubos; Dusek, Jiri; Moravek, Jiri; Janda, Jan; Barrowman, Nicholas J.; Guerra, Luis; Leonard, Michael",null,"Urinary tract infections in pediatric renal transplant recipients - a two center risk factors study","Pediatric Transplantation",null,"English","Article",null,null,null,null,null,"pediatric renal transplantation; risk factors; pyelonephritis","KIDNEY-TRANSPLANTATION; VESICOURETERAL REFLUX; BLADDER DYSFUNCTION; CHILDREN; PYELONEPHRITIS; AUGMENTATION","UTI are common in renal Tx recipients and may significantly impact on the graft function. The aim of our study was to evaluate the prevalence, risk factors, and significance of UTI in Tx children. We performed a retrospective cross-sectional study of 76 Tx patients, median age at Tx was 13.4 yr. Twenty-one of 76 (28%) patients developed at least one UTI during the mean follow-up time of 3.3 +/- 2.0 yr post-Tx. The first UTI occurred at a median of 160 days post-Tx. The RR of having UTI was significantly higher in patients with the primary diagnosis of obstructive uropathy (RR = 2.6, 95th CI = 1.1-6.0, p = 0.032), history of PN pre Tx (RR = 2.7, 95th CI = 1.3-5.4, p = 0.009) and pre Tx VUR (RR = 2.2, 95th CI = 1.1-4.5, p = 0.045). These three factors also significantly decreased the infection-free survival time to the first UTI. Most UTI caused reversible acute allograft dysfunction, but the long-term graft function could not be reliably assessed with SCr. In conclusion, UTI occurred in 28% of pediatric Tx recipients, mostly during the first year post-Tx despite antibiotic prophylaxis. The diagnosis of obstructive uropathy, history of UTI and VUR prior to Tx were significant risk factors.","[Feber, Janusz] Childrens Hosp Eastern Ontario, Div Pediat Nephrol, Ottawa, ON K1H 8L1, Canada; [Spatenka, Jaroslav] Univ Hosp Motol, Transplant Ctr, Prague, Czech Republic; [Seeman, Tomas; Dusek, Jiri; Janda, Jan] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Matousovic, Karel] Univ Hosp Motol, Dept Internal Med, Prague, Czech Republic; [Zeman, Lubos; Moravek, Jiri] Univ Hosp Motol, Dept Pediat Surg, Prague, Czech Republic; [Barrowman, Nicholas J.] Childrens Hosp Eastern Ontario, Res Inst, Clin Res Unit, Ottawa, ON K1H 8L1, Canada; [Barrowman, Nicholas J.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Guerra, Luis; Leonard, Michael] Childrens Hosp Eastern Ontario, Div Pediat Urol, Ottawa, ON K1H 8L1, Canada","Feber, J, Childrens Hosp Eastern Ontario, Div Nephrol, Dept Pediat, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada","jfeber@cheo.on.ca","[MSM 0021620810]; [MSM 0021620819]","We thank Stephanie Barnes for the revision of the manuscript. Grant support: research projects MSM 0021620810 and MSM 0021620819 (Czech Republic).",null,26,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1397-3142",null,"10.1111/j.1399-3046.2008.01079.x","PEDIATR TRANSPLANT","Pediatr. Transplant.","NOV",2009,13,7,null,null,null,881,886,null,null,6,"Pediatrics; Transplantation","505CS","ISI:000270666600016"]
[25,"J","Hubacek, P; Keslova, P; Formankova, R; Pochop, P; Cinek, O; Zajac, M; Lochmanova, J; Stary, J; Sedlacek, P",null,null,null,"Hubacek, Petr; Keslova, Petra; Formankova, Renata; Pochop, Pavel; Cinek, Ondrej; Zajac, Miroslav; Lochmanova, Jana; Stary, Jan; Sedlacek, Petr",null,"Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet","Pediatric Transplantation",null,"English","Article",null,null,null,null,null,"cytomegalovirus; transplantation; ganciclovir resistance; cidofovir; foscarnet","PHARMACOKINETIC PROPERTIES; IMMUNOCOMPROMISED PATIENTS; ANTIVIRAL ACTIVITY; THERAPEUTIC USE; GANCICLOVIR; INFECTION","We report an 18-yr-old female patient with repeated CMV reactivations after HSCT treated by several pre-emptive courses of virostatic therapy. Seven months after HSCT, she developed CMV encephalitis/retinitis. Initial therapy with GCV and hyperimmune globulin failed, and later on GCV-resistant strain was detected. Continual increase of CMV DNA in peripheral blood led us to combined therapy with CDV and FCV, which was successful and free of severe renal toxicity. To our best knowlegde, this is the first reported case of successful CMV treatment with a combination of CDV and FCV.","[Hubacek, Petr; Keslova, Petra; Formankova, Renata; Stary, Jan; Sedlacek, Petr] Charles Univ Prague, Dept Paediat Haematol & Oncol, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Pochop, Pavel] Charles Univ Prague, Dept Ophthalmol Children & Adults, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague, Czech Republic; [Cinek, Ondrej] Charles Univ Prague, Dept Paediat, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Zajac, Miroslav] Charles Univ Prague, Dept Microbiol, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Lochmanova, Jana] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Dept Internal Med, Brno, Czech Republic; [Lochmanova, Jana] Masaryk Univ, Brno, Czech Republic","Sedlacek, P, Charles Univ Prague, Dept Paediat Haematol & Oncol, Sch Med 2, Motol Univ Hosp, Uvalu 84, CZ-15006 Prague 5, Czech Republic","petr.hubacek@lfmotol.cuni.cz",null,null,null,7,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1397-3142",null,"10.1111/j.1399-3046.2008.01070.x","PEDIATR TRANSPLANT","Pediatr. Transplant.","NOV",2009,13,7,null,null,null,919,922,null,null,4,"Pediatrics; Transplantation","505CS","ISI:000270666600022"]
[25,"J","Markova, J; Trnkova, Z; Michkova, P; Maaloufova, J; Stary, J; Cetkovsky, P; Schwarz, J",null,null,null,"Markova, Jana; Trnkova, Zuzana; Michkova, Petra; Maaloufova, Jacqueline; Stary, Jan; Cetkovsky, Petr; Schwarz, Jiri",null,"Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome","Leukemia & Lymphoma",null,"English","Article",null,null,null,null,null,"Core-binding factor-acute myeloid leukemia; AML1/ETO; CBF beta/MYH11; minimal residual disease; C-KIT mutation; FLT3/ITD; FLT3 Asp835 mutation","INTERNAL TANDEM DUPLICATION; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TIME QUANTITATIVE PCR; JAK2-V617F ACTIVATING MUTATION; AML1/MTG8 FUSION TRANSCRIPTS; MRC AML TRIALS; RT-PCR; PROGNOSTIC IMPACT; MYELODYSPLASTIC SYNDROME","Mutational analysis of C-KIT, fms-like tyrosine kinase 3 (FLT3), and JAK2 genes was performed in 60 patients with core binding factor acute myeloid leukemia (CBF-AML). Patients reaching molecular remission had lower incidence of relapse and better overall survival (OS) than those not achieving molecular remission (p = 0.008 and 0.044, respectively). The overall incidence of C-KIT mutations was 33.3%, FLT3/internal tandem duplication (ITD) 6.6%, FLT3(D835) 10.0% and JAK2(V617F) mutations 3.3%. C-KIT mutations did not predict for clinical/molecular relapse (p = 0.33). OS of patients with C-KIT mutations was identical to patients without them when all patients with CBF-AML were analyzed together (p = 0.58). When AML1/ETO-positive patients were evaluated separately, OS in C-KIT-mutated patients was slightly inferior to unmutated ones (p = 0.14). Patients with CBF-AML with a mutated C-KIT gene were also more prone to extramedullary disease (p = 0.08). Of six patients harboring various FLT3(D835) mutations, four (66.7%) relapsed, whereas among 43 cases without these mutations, 16 relapses (37%) were observed (p = 0.08). Our results on minimal residual disease, C-KIT, and FLT3/ITDs are in line with previous studies. Surprisingly, a possible role for FLT3(D835) mutations was noted in addition. These results need validation in even larger patient cohorts than ours. For routine clinical practice, it may be meaningful to screen for C-KIT mutations in AML1/ETO-positive patients, as well as for FLT3(D835) mutations in CBF-AML.","[Markova, Jana; Trnkova, Zuzana; Michkova, Petra; Maaloufova, Jacqueline; Cetkovsky, Petr; Schwarz, Jiri] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Stary, Jan] Fac Hosp Motol, Dept Pediat Hematol & Oncol, Prague 5, Czech Republic","Schwarz, J, Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic","jiri.schwarz@uhkt.cz","Czech Ministry of Health [00237360001]","All the authors disclose no potential conflicts of interest. Supported by the Research project of the Czech Ministry of Health 00237360001.",null,60,1,"TAYLOR & FRANCIS LTD","ABINGDON","4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND","1042-8194",null,"10.1080/10428190903085951","LEUK LYMPHOMA","Leuk. Lymphoma",null,2009,50,9,null,null,null,1448,1460,null,null,13,"Oncology; Hematology","503QC","ISI:000270552100011"]
[25,"J","Burgelova, M; Vanourkova, Z; Thumova, M; Dvorak, P; Opocensky, M; Kramer, HJ; Zelizko, M; Maly, J; Baderf, M; Cervenka, L",null,null,null,"Buergelova, Marcela; Vanourkova, Zdenka; Thumova, Monika; Dvorak, Pavel; Opocensky, Martin; Kramer, Herbert J.; Zelizko, Michal; Maly, Jan; Baderf, Michael; Cervenka, Ludek",null,"Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension","Journal of Hypertension",null,"English","Article",null,null,null,null,null,"angiotensin II; angiotensin-(1-7); angiotensin-converting enzyme 2; renal function; renin-angiotensin system; two-kidney one-clip Goldblatt hypertension","ANGIOTENSIN-(1-7)-PRODUCING FUSION PROTEIN; RENAL FUNCTIONAL-RESPONSES; REN-2 TRANSGENIC RATS; BLOOD-PRESSURE; II LEVELS; INTRARENAL INFUSION; KIDNEY-DISEASE; NITRIC-OXIDE; EXPRESSION; BLOCKADE","Objective Recent studies have shown that the heptapeptide angiotensin-(1-7) [Ang-(1-7)] exerts important vasoactive actions and can act as an endogenous physiological antagonist of angiotensin II (Ang II) within the renin-angiotensin system (RAS). The present study was performed to evaluate the effects, first, of chronic increases of Ang-(1-7) levels, second, of [7-D-Ala], an Ang-(1-7) receptor antagonist, and, third, of an angiotensin-converting enzyme 2 (ACE2) inhibitor on the course of hypertension and of renal function of the nonclipped kidney in two-kidney, one-clip (2K1C) Goldblatt hypertensive rats. Methods Blood pressure (BP) was monitored by radiotelemetry. Elevation of the effect of circulating Ang-(1-7) levels was achieved either by chronic subcutaneous infusion of Ang-(1-7) through osmotic minipumps or by employing transgenic rats that express an Ang-(1-7)-producing fusion protein [Ang-(1-7) TGR+/+] (and its control Ang-(1-7) TGR-/-). [7-D-Ala] was also infused subcutaneously and the ACE2 inhibitor was administrated in drinking water. On day 25 after clipping, rats were anesthetized and renal function was evaluated. Results Chronic infusion of Ang-(1-7) did not modify the course of 2K1C hypertension and did not alter renal function as compared with saline vehicle-infused 2K1C rats. Chronic infusion of [7-D-Ala] or treatment with the ACE2 inhibitor worsened the course of hypertension and elicited decreases in renal hemodynamics. [Ang-(1-7) TGR+/+] and [Ang-(1-7) TGR-/-] rats exhibited a similar course of hypertension. Conclusion The present data support the notion that Ang(1-7) serves as an important endogenous vasodilator and natriuretic agent and its deficiency might contribute to the acceleration of 2K1C Goldblatt hypertension. J Hypertens 27: 1988-2000 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Vanourkova, Zdenka; Thumova, Monika; Dvorak, Pavel; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Buergelova, Marcela; Opocensky, Martin; Maly, Jan] Transplant Ctr, Dept Nephrol, Prague, Czech Republic; [Vanourkova, Zdenka; Thumova, Monika; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Med Policlin, Dept Med, Nephrol Sect, D-5300 Bonn, Germany; [Zelizko, Michal] Inst Clin & Expt Med, Dept Cardiol, CZ-14000 Prague 4, Czech Republic; [Baderf, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Grant Agency of Academy of Science of Czech Republic [IAA 511-700-701]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Czech Science Foundation [305/08/J006]; German Research Foundation (Deutsche Forschungsgemeinschaft) [Kra 433/14-2, 436 TSE 113/50/0-1]","This study was supported by grant No. IAA 511-700-701 awarded to M. B. by the Grant Agency of Academy of Science of Czech Republic (GAAV). Z. V. is partly supported from the Center for Cardiovascular Research (1M6798582302). L. C. is supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001) and by a grant awarded by the Czech Science Foundation (GAC. R) No. 305/08/J006. H. J. Kramer is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1).",null,43,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/HJH.0b013e32832f0d06","J HYPERTENSION","J. Hypertens.","OCT",2009,27,10,null,null,null,1988,2000,null,null,13,"Peripheral Vascular Disease","503NM","ISI:000270543300012"]
[25,"J","Stechova, K; Pomahacova, R; Hrabak, J; Durilova, M; Sykora, J; Chudoba, D; Stavikova, V; Flajsmanova, K; Varvarovska, J",null,null,null,"Stechova, K.; Pomahacova, R.; Hrabak, J.; Durilova, M.; Sykora, J.; Chudoba, D.; Stavikova, V.; Flajsmanova, K.; Varvarovska, J.",null,"Reactivity to Helicobacter pylori Antigens in Patients Suffering from Thyroid Gland Autoimmunity","Experimental and Clinical Endocrinology & Diabetes",null,"English","Article",null,null,null,null,null,"Helicobacter pylori; autoimmune thyroiditis; cytokine; chemokine","DC-SIGN; DIABETES-MELLITUS; LEWIS-X; INFECTION; DISEASE; CHILDREN; CELLS; LIPOPOLYSACCHARIDE; POPULATION; ANTIBODIES","The role of infection in autoimmunity is widely discussed. In this Study we concentrated on relationship between Helicobacter pylori as a very important gastroduodenal pathogen and autoimmune thyroiditis (AT). Forty seven AT patients and 34 healthy controls were enrolled. They were split into: THP (H. pylori positive patients, n = 17), THN (H. pylori negative patients, n = 30), CP (H. pylori positive controls, n = 17) and CN groups (H.pylori negative controls, n=17). By protein microarray we analysed production of 23 cytokines and chemokines prior and post stimulation with H.pylori lysate and its lipopolysacharide (LPS). Reactivity to lysate as well as to bacterial LPS differed within groups. The lowest basal cytokine and chemokine production was observed in CN group but these subjects reacted significantly to specific stimulation by increasing IFN-gamma (in comparison with THP p=0.01 for LPS and p=0.004 for H. pylori lysate) and TGFbeta production (p=0.015 for LIPS). In contrast, IL-10 and IL-5 were decreased in this group. In CP, THN and THP groups, we observed in general higher chemokine response. THP group increased proinflammatory IL-6 after specific stimulation as well (in comparison with CP p < 0.0001 for LPS stimulation). We observed different \"reactivity pattern\" to H. pylori within groups with low basal cytokine and chemokine production in healthy H.pylori negative controls but with clear specific response in IFN-gamma and TGF-beta production in this group. Adequate immune reaction which is joined to appropriate immunoregulation leads to prevention of the chronic infection and on the other hand may prevent the development of \"connected\" diseases such as autoimmune.","[Stechova, K.] Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, Prague 15006 5, Motol, Czech Republic; [Stechova, K.; Durilova, M.; Stavikova, V.; Flajsmanova, K.] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Pomahacova, R.; Sykora, J.; Varvarovska, J.] Charles Univ Prague, Fac Med Plzen, Dept Paediat, Prague, Czech Republic; [Hrabak, J.] Charles Univ Prague, Fac Med Plzen, Dept Microbiol, Prague, Czech Republic; [Chudoba, D.] Charles Univ Prague, Fac Med 2, Dept Biol & Genet, Prague, Czech Republic","Stechova, K, Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, V Uvalu 84, Prague 15006 5, Motol, Czech Republic","info@labao.cz","Grant Agency of Ministry of Health IGA MZCR [NR 8887-3]","This project was supported by the project of internal Grant Agency of Ministry of Health IGA MZCR No NR 8887-3.",null,35,0,"JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH","STUTTGART","RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY","0947-7349",null,"10.1055/s-0029-1214385","EXP CLIN ENDOCRINOL DIABETES","Exp. Clin. Endocrinol. Diabet.","SEP",2009,117,8,null,null,null,423,431,null,null,9,"Endocrinology & Metabolism","505GM","ISI:000270680100011"]
[25,"J","Stejskalova, E; Malis, J; Snajdauf, J; Pycha, K; Urbankova, H; Bajciova, V; Stary, J; Kodet, R; Jarosova, M",null,null,null,"Stejskalova, Eva; Malis, Josef; Snajdauf, Jiri; Pycha, Karel; Urbankova, Helena; Bajciova, Viera; Stary, Jan; Kodet, Roman; Jarosova, Marie",null,"Cytogenetic and array comparative genomic hybridization analysis of a series of hepatoblastomas","Cancer Genetics and Cytogenetics",null,"English","Article",null,null,null,null,null,null,"IN-SITU HYBRIDIZATION; GENETIC ALTERATIONS; ABNORMALITIES; ABERRATIONS; 1Q; RHABDOMYOSARCOMA; REARRANGEMENTS; TRANSLOCATION; MICROARRAYS; REGION","Hepatoblastoma is the most common primary hepatic tumor in children, and only a limited number of detailed karyotypic analyses have been reported to date. In the present study, cytogenetic abnormalities were identified in nine cases of hepatoblastoma from a single institution. Among characteristic chromosomal changes detected were simple numerical aberrations, structural alterations of chromosomes 1, 2, and 8, and the recurrent unbalanced rearrangements der(4)t(1;4)(q25.2;q35.1) and der(6)t(1;6)(q21;q26). Array comparative genomic hybridization was applied in four of the cases. The combined cytogenetic, molecular cytogenetic, and histopathologic analyses are presented here, together with clinical data. The results substantially confirm previous findings of aberrations involving chromosomal loci on 1q, 2 or 2q, 4q, 6q, 8 or 8q, and 20 as significant in the development and clinical course of this disease. (C) 2009 Elsevier Inc. All rights reserved.","[Stejskalova, Eva; Malis, Josef; Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Snajdauf, Jiri; Pycha, Karel] Univ Hosp Motol, Dept Pediat Surg, Prague 15006 5, Czech Republic; [Urbankova, Helena; Jarosova, Marie] Palacky Univ Hosp, Dept Hematooncol, Olomouc, Czech Republic; [Bajciova, Viera] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic; [Kodet, Roman] Univ Hosp Motol, Inst Pathol & Mol Med, Prague 15006 5, Czech Republic","Stejskalova, E, Univ Hosp Motol, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic","eva.stejskalova@lfmotol.cuni.cz","Ministry of Health [IGA MZ NR/9050-3]","The authors thank Mrs. H. Mendlova, D. Honsova, J. Sulcova, and J. Balcarkova for their invaluable technical assistance. This work was supported by a grant from the internal grant agency of the Ministry of Health (IGA MZ NR/9050-3).",null,26,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,"10.1016/j.cancergencyto.2009.06.001","CANCER GENET CYTOGENET","Cancer Genet. Cytogenet.","OCT 15",2009,194,2,null,null,null,82,87,null,null,6,"Oncology; Genetics & Heredity","504AO","ISI:000270585200003"]
[26,"J","Tejral, G; Kolacna, L; Schoner, W; Amler, E",null,null,null,"Tejral, G.; Kolacna, L.; Schoner, W.; Amler, E.",null,"The pi-Helix Formation between Asp(369) and Thr(375) as a Key Factor in E-1-E-2 Conformational Change of Na+/K+-ATPase","Physiological Research",null,"English","Article",null,null,null,null,null,"Computer modeling; Molecular dynamics simulations; Molecular structure; Na+/K+-ATPase; E-1/E-2 conformation","PROTEIN SECONDARY STRUCTURE; NA,K-ATPASE ALPHA-SUBUNIT; CALCIUM-PUMP; BINDING-SITE; 3-DIMENSIONAL STRUCTURE; SARCOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FOLD RECOGNITION; H-4-H-5 LOOP","Molecular modeling of the H-4-H-5-loop of the alpha(2) isoform of Na+/K+-ATPase in the E-1 and E-2 conformations revealed that twisting of the nucleotide (N) domain toward the phosphorylation (P) domain is connected with the formation of a short pi-helix between Asp(369) and Thr(375). This conformational change close to the hinge region between the N-domain and the P-domain could be an important event leading to a bending of the N-domain by 64.7 degrees and to a shortening of the distance between the ATP binding site and the phosphorylation site (Asp(369)) by 1.22 nm from 3.22 nm to 2.00 nm. It is hypothesized that this shortening mechanism is involved in the Na+-dependent formation of the Asp(369) phospho-intermediate as part of the overall Na+/K+-ATPase activity.","[Tejral, G.; Kolacna, L.; Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Czech Republic; [Tejral, G.; Kolacna, L.; Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague, Czech Republic; [Tejral, G.; Amler, E.] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic; [Schoner, W.] Univ Giessen, Inst Biochem & Endocrinol, Giessen, Germany","Amler, E, Charles Univ Prague, Fac Med 2, Inst Biophys, Uvalu 84, Prague 15006 5, Czech Republic","evzen.amler@lfmotol.cuni.cz","AS CR [1ET400110403, IAA500390702]; Ministry of Education, Youth and Sport of the Czech Republic [1M0510, 1M6798582302]; NPV II [2B06130]; AV0 - ASCR Institutional research [AV0Z50390512, AV0Z50390703]; Czech Science Foundation [GA202/09/1151]; EU [214539]","This work was supported by the Grant Agency of AS CR grants No. 1ET400110403 and IAA500390702, the Ministry of Education, Youth and Sport of the Czech Republic grants No. 1M0510 (1M6798582302) and NPV II 2B06130, AV0 - ASCR Institutional research plans AV0Z50390512 and AV0Z50390703 and by Czech Science Foundation grant No. GA202/09/1151, EU project BIOSCENT ID number 214539.",null,45,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,4,null,null,null,583,589,null,null,7,"Physiology","507ME","ISI:000270857000014"]
[26,"J","Wuhl, E; Trivelli, A; Picca, S; Litwin, M; Peco-Antic, A; Zurowska, A; Testa, S; Jankauskiene, A; Emre, S; Caldas-Afonso, A; Anarat, A; Niaudet, P; Mir, S; Bakkaloglu, A; Enke, B; Montini, G; Wingen, AM; Sallay, P; Jeck, N; Berg, U; Caliskan, S; Wygoda, S; Hohbach-Hohenfellner, K; Dusek, J; Urasinski, T; Arbeiter, K; Neuhaus, T; Gellermann, J; Drozdz, D; Fischbach, M; Moller, K; Wigger, M; Peruzzi, L; Mehls, O; Schaefer, F",null,null,null,"Wuehl, Elke; Trivelli, Antonella; Picca, Stefano; Litwin, Mieczyslaw; Peco-Antic, Amira; Zurowska, Aleksandra; Testa, Sara; Jankauskiene, Augustina; Emre, Sevinc; Caldas-Afonso, Alberto; Anarat, Ali; Niaudet, Patrick; Mir, Sevgi; Bakkaloglu, Aysin; Enke, Barbara; Montini, Giovanni; Wingen, Ann-Margret; Sallay, Peter; Jeck, Nikola; Berg, Ulla; Caliskan, Salim; Wygoda, Simone; Hohbach-Hohenfellner, Katharina; Dusek, Jiri; Urasinski, Tomasz; Arbeiter, Klaus; Neuhaus, Thomas; Gellermann, Jutta; Drozdz, Dorota; Fischbach, Michel; Moeller, Kristina; Wigger, Marianne; Peruzzi, Licia; Mehls, Otto; Schaefer, Franz; Schaefer F; Mehls O; Wühl E; Gimpel C; Schaefer F; Wühl E; Gimpel C; Ozaltin F; Querfeld U; Bonzel KE; Balasz I; Perfumo F; Müller-Wiefel DE; Offner G; Gimpel C; Klaus G; Ardissino G; Charbit M; Fernandes-Teixeira A; Matteucci MC; Mastrostefano A; Celsi G; Terzic J; Fydryk J; Coppo R; Grenda R; Janas R",null,"Strict Blood-Pressure Control and Progression of Renal Failure in Children","New England Journal of Medicine",null,"English","Article",null,null,null,null,null,null,"CONVERTING-ENZYME INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; GLOMERULAR-FILTRATION-RATE; KIDNEY-DISEASE; FOLLOW-UP; RAMIPRIL; INSUFFICIENCY; PROTEINURIA; HYPERTENSION; NEPHROPATHY","Background Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor. Methods After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion. Results A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P = 0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease. Conclusions Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.)","[Wuehl, Elke; Mehls, Otto; Schaefer, Franz] Univ Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, D-69120 Heidelberg, Germany; [Enke, Barbara] Childrens Hosp, Hannover Med Sch, Hannover, Germany; [Wingen, Ann-Margret] Univ Childrens Hosp Essen, Essen, Germany; [Jeck, Nikola] Univ Marburg, Dept Pediat, Marburg, Germany; [Wygoda, Simone] Urban Hosp St Georg, Leipzig, Germany; [Hohbach-Hohenfellner, Katharina] Univ Childrens Hosp, Mainz, Germany; [Gellermann, Jutta] Charite Childrens Hosp, Berlin, Germany; [Moeller, Kristina] Univ Childrens Hosp Hamburg Eppendorf, Hamburg, Germany; [Wigger, Marianne] Univ Childrens Hosp, Rostock, Germany; [Trivelli, Antonella] G Gaslini, Genoa, Italy; [Picca, Stefano] Osped Pediat Bambino Gesu, Rome, Italy; [Testa, Sara] Policlin Mangiagalli, Ist Ricovero & Cura, Carattere Sci Osp Maggiore, Milan, Italy; [Montini, Giovanni] Univ Padua, Azienda Osped, Padua, Italy; [Peruzzi, Licia] Osped Infantile Regina Margherita, Turin, Italy; [Litwin, Mieczyslaw] Childrens Mem Hlth Hosp, Warsaw, Poland; [Zurowska, Aleksandra] Med Univ Gdansk, Dept Pediat & Adolescent Nephrol & Hypertens, Gdansk, Poland; [Urasinski, Tomasz] Pomeranian Acad Med, Szczecin, Poland; [Drozdz, Dorota] Jagiellonian Univ, Coll Med, Polish Amer Childrens Hosp, Krakow, Poland; [Peco-Antic, Amira] Univ Childrens Hosp, Belgrade, Serbia; [Jankauskiene, Augustina] Vilnius State Univ, Childrens Hosp, Vilnius, Lithuania; [Emre, Sevinc] Univ Istanbul, Istanbul Fac Med, Istanbul, Turkey; [Anarat, Ali] Cukurova Univ, Sch Med, Adana, Turkey; [Mir, Sevgi] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey; [Bakkaloglu, Aysin] Hacettepe Univ, Fac Med, TR-06100 Ankara, Turkey; [Caliskan, Salim] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey; [Niaudet, Patrick] Hop Necker Enfants Malad, Paris, France; [Caldas-Afonso, Alberto] Hosp Sao Joao, Oporto, Portugal; [Fischbach, Michel] Hop Univ Strasbourg, Strasbourg, France; [Sallay, Peter] Semmelweis Univ Budapest, Dept Pediat 1, Budapest, Hungary; [Berg, Ulla] Huddinge Univ Hosp, Karolinska Inst, Stockholm, Sweden; [Dusek, Jiri] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Arbeiter, Klaus] Univ Childrens Hosp, Vienna, Austria; [Neuhaus, Thomas] Univ Childrens Hosp, Zurich, Switzerland","Schaefer, F, Univ Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany","franz.schaefer@med.uni-heidelberg.de","Boehringer Ingelheim Stiftung ; European Commission [QLRT-2001-00908]; Kuratorium fur Dialyse und Nierentransplantation, Neu-Isenburg ; Baxter Extramural Grant Program ","Supported by grants from the Boehringer Ingelheim Stiftung; the European Commission (Fifth Framework Programme, QLRT-2001-00908); Kuratorium fur Dialyse und Nierentransplantation, Neu-Isenburg; and the Baxter Extramural Grant Program.",null,33,0,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"N ENGL J MED","N. Engl. J. Med.","OCT 22",2009,361,17,null,null,null,1639,1650,null,null,12,"Medicine, General & Internal","508YW","ISI:000270977400006"]
[26,"J","Frisova, V; Kavalcova, L; Kyncl, M; Vlk, R; Kucera, A; Rocek, M",null,null,null,"Frisova, Veronika; Kavalcova, Lucie; Kyncl, Martin; Vlk, Radovan; Kucera, Alexandr; Rocek, Miloslav",null,"Congenital Gastric Outlet Obstruction by Pyloric Membrane: Prenatal and Postnatal Diagnosis and Management","Fetal Diagnosis and Therapy",null,"English","Article",null,null,null,null,null,"Gastric outlet obstruction; Pyloric atresia; Polyhydramnios; Prenatal diagnosis; Ultrasonography; Fetal magnetic resonance imaging; Pyloroplasty","ATRESIA","Congenital gastric outlet obstruction is a rare condition representing only 1% of all gastrointestinal atresias. Prenatal diagnosis is uncommon and mostly confined to the third trimester of cases presenting a combination of polyhydramnios with dilated stomach. We report a case of congenital gastric outlet obstruction by pyloric membrane which was diagnosed prenatally in the third trimester by sonography and magnetic resonance imaging. The anomaly appeared to be isolated, thus a favorable outcome was expected. A baby girl weighing 3,430 g was delivered spontaneously at 36 weeks. Postnatal imaging methods confirmed the presence of a congenital gastric obstruction. 21 h after delivery, the baby underwent laparotomy, at which time a malrotation and pyloric membrane were found and resolved. The postoperative course was uneventful and the baby was discharged at the age of 18 days and remains well at controls. Copyright (C) 2009 S. Karger AG, Basel","[Frisova, Veronika; Kyncl, Martin; Rocek, Miloslav] Charles Univ Prague, Dept Imaging Methods, Fac Med 2, CZ-15006 Prague, Czech Republic; [Kavalcova, Lucie; Kucera, Alexandr] Charles Univ Prague, Dept Paediat Surg, Fac Med 2, CZ-15006 Prague, Czech Republic; [Vlk, Radovan] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, CZ-15006 Prague, Czech Republic; Fac Hosp Motol, Prague, Czech Republic","Frisova, V, Charles Univ Prague, Dept Imaging Methods, Fac Med 2, Uvalu 84, CZ-15006 Prague, Czech Republic","veronika.frisova@gmail.com","MZO [0064203/6312, 0064203/6309, 0064203/6202]","Supported by grants of MZO 0064203/6312, 0064203/6309 and 0064203/6202.",null,6,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1015-3837",null,"10.1159/000242455","FETAL DIAGN THER","Fetal Diagn. Ther.",null,2009,26,2,null,null,null,98,101,null,null,4,"Obstetrics & Gynecology","506KY","ISI:000270774900008"]
[26,"J","Rasmussen, T; Stene, LC; Samuelsen, SO; Cinek, O; Wetlesen, T; Torjesen, PA; Ronningen, KS",null,null,null,"Rasmussen, Trond; Stene, Lars C.; Samuelsen, Sven O.; Cinek, Ondrej; Wetlesen, Turid; Torjesen, Peter A.; Ronningen, Kjersti S.",null,"Maternal BMI Before Pregnancy, Maternal Weight Gain During Pregnancy, and Risk of Persistent Positivity for Multiple Diabetes-Associated Autoantibodies in Children With the High-Risk HLA Genotype The MIDIA study","Diabetes Care",null,"English","Article",null,null,null,null,null,null,"BODY-MASS INDEX; TYPE-1; COHORT; TRENDS; AGE","OBJECTIVE - To assess whether maternal BMI before pregnancy and weight gain during pregnancy predicted the risk of islet autoimmunity in genetically susceptible children. RESEARCH DESIGH AHD METHODS - Of 46,939 newborns screened for the high-risk HLA genotype DR4-DQ8/DR3-DQ2, 1,003 were positive and 885 were followed with serial blood samples tested for autoantibodies to insulin, GAD, and insulinoma-associated protein 2 (IA2). The end point was defined as repeated positivity for two or three autoantibodies or the onset of type I diabetes (islet autoimmunity). RESULTS - Thirty-six children developed islet autoimmunity, of whom 10 developed type I diabetes. Both maternal BMI >= 30 kg/m(2) before pregnancy and maternal weight gain >= 15 kg predicted the increased risk of islet autoimmunity (hazard ratio [HR] 2.5, P = 0.023, and HR 2.5, P = 0.015, respectively), independent of maternal diabetes. CONCLUSIONS - Maternal weight may predict risk of islet autoimmunity in offspring with a high genetic susceptibility for type I diabetes.","[Rasmussen, Trond; Stene, Lars C.; Samuelsen, Sven O.; Wetlesen, Turid; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Samuelsen, Sven O.] Univ Oslo, Dept Math, Oslo, Norway; [Cinek, Ondrej] Motol Univ Hosp, Dept Pediat, Prague, Czech Republic; [Torjesen, Peter A.] Univ Oslo, Aker Univ Hosp, Hormone Lab, Oslo, Norway","Rasmussen, T, Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway","trond.rasmussen@fhi.no","Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association, the Children With Diabetes Foundation [Food-CT-2005-016320]","This study was funded by the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, and 166515/V50), the Norwegian Diabetes Association, the Children With Diabetes Foundation (Denver, CO), and NewGeneris (grant Food-CT-2005-016320).",null,12,0,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,"10.2337/dc09-0663","DIABETES CARE","Diabetes Care","OCT",2009,32,10,null,null,null,1904,1906,null,null,3,"Endocrinology & Metabolism","509HE","ISI:000271004900027"]
[27,"J","Klaboch, J; Opatrna, S; Matousovic, K; Sefrna, F; Havlin, J; Schuck, O",null,null,null,"Klaboch, Jan; Opatrna, Sylvie; Matousovic, Karel; Sefrna, Frantisek; Havlin, Jan; Schueck, Otto",null,"Acid-Base Balance in Peritoneal Dialysis Patients: A Stewart-Fencl Analysis","Renal Failure",null,"English","Article",null,null,null,null,null,"acid-base balance; bicarbonate; icodextrin; lactate; peritoneal dialysis; Stewart principle","CAPD PATIENTS; METABOLIC-ACIDOSIS; HEMODIALYSIS-PATIENTS; BICARBONATE LEVELS; NUTRITIONAL-STATUS; PRACTICE PATTERNS; IMPACT; FLUID; BIOCOMPATIBILITY; ICODEXTRIN","Background. Evaluation of acid-base disorders using the Stewart-Fencl principle is based on assessment of independent factors: strong ion difference (SID) and the total concentration of non-volatile weak acids (Atot). This approach allows for a more detailed evaluation of the cause of acid-base imbalance than the conventional bicarbonate-centered approach based on the Henderson-Hasselbalch principle, which is a necessary yet insufficient condition to describe the state of the system. The aim of our study was to assess acid-base disorders in peritoneal dialysis (PD) patients using both of these principles. Methods. A total of 17 patients with chronic renal failure (10 men), aged 60.7 (22-84) years, treated by PD for 25.7 (1-147) months were examined. A control group included 17 healthy volunteers (HV) (8 males), with a mean age of 42.7 (22-77) years and normal renal function. Patients were treated with a solution containing bicarbonate (25 mmol/L) and lactate (15 mmol/L) as buffers; eleven of them used, during the nighttime dwell, a solution with icodextrin buffered by lactate at a concentration of 40 mmol/L. The following equations were employed for calculations of acid-base parameters according to the Stewart-Fencl principle. The first is SID = [Na+] + [K+] + 2[Ca2+] + 2[Mg2+] - [Cl-] - [UA(-)], where SID is the strong ion difference and [UA(-)] is the concentration of undetermined anions. For practical calculation of SID, the second equation, SID = [HCO3-] + [Alb(-)] + [Pi(-)], was used, where [Alb(-)] and [Pi(-)] are the charges carried by albumin and phosphates. The third is Atot, the total concentration of weak non-volatile acids, albumin [Alb] and phosphates [Pi]. Results. The capillary blood pH in PD group was 7.41 (7.27-7.48), [HCO3-] levels 23.7 (17.6-29.5) mmol/L, SID 36.3 (29.5-41.3) mmol/L, sodium-chloride difference 39.0 (31.0-44.0) mmol/L, [Pi] 1.60 (0.83-2.54) mmol/L, and [Alb] 39.7 (28.8-43.4) g/L (median, min-max). Bicarbonate in blood correlated positively with SID (Rho = 0.823; p < 0.001), with the sodium-chloride difference (Rho = 0.649; p < 0.01) and pH (Rho = 0.754; p < 0.001), and negatively with residual renal function (Rho = -0.517; p < 0.05). Moreover, the sodium-chloride difference was also found to correlate with SID (Rho = 0.653; p < 0.01). While the groups of PD and HV patients did not differ in median bicarbonate levels, significantly lower median value of SID were observed in PD patients, 36.3 vs. 39.3 mmol/L (p < 0.01); additionally, PD patients were shown to have significantly lower mean value of serum sodium levels, 138 vs. 141 mmol/L (p < 0.01), and serum chlorides levels, 100 vs. 104 mmol/L (p < 0.001). Despite the higher [UA(-)] levels in PD patients, 9.1 vs. 5.4 mmol/L (p < 0.001), this parameter was not found to correlate with bicarbonate levels. Conclusions. The results suggest that the decreased bicarbonate in PD patients results from a combination of decreased sodium-chloride difference and mildly increased unmeasured anions.","[Klaboch, Jan; Opatrna, Sylvie; Sefrna, Frantisek] Charles Univ Prague, Dept Med 1, Sch Med, Plzen 30460, Czech Republic; [Klaboch, Jan; Opatrna, Sylvie; Sefrna, Frantisek] Teaching Hosp, Plzen, Czech Republic; [Matousovic, Karel; Havlin, Jan; Schueck, Otto] Charles Univ Prague, Sch Med 2, Dept Med, Prague, Czech Republic; [Matousovic, Karel; Havlin, Jan; Schueck, Otto] Motol Univ Hosp, Prague, Czech Republic","Opatrna, S, Charles Univ Prague, Sch Med, Dept Med, Alej Svobody 80, Plzen 30460, Czech Republic","opatrna@fnplzen.cz","Main Research Project [0021620819]","The study was supported by the Main Research Project No. MSM 0021620819.",null,47,0,"TAYLOR & FRANCIS INC","PHILADELPHIA","325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA","0886-022X",null,"10.3109/08860220903134076","RENAL FAIL","Ren. Fail.",null,2009,31,8,null,null,null,625,632,null,null,8,"Urology & Nephrology","509KK","ISI:000271015200001"]
[27,"J","Topinka, J; Milcova, A; Libalova, H; Novakova, Z; Rossner, P; Balascak, I; Sram, RJ",null,null,null,"Topinka, J.; Milcova, A.; Libalova, H.; Novakova, Z.; Rossner, P., Jr.; Balascak, I.; Sram, R. J.",null,"Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. Part I: Bulky DNA adducts","Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis",null,"English","Article",null,null,null,null,null,"Air pollution; DNA adducts; PAHs; Complex mixtures; Placenta; Tobacco smoke","POLYCYCLIC AROMATIC-HYDROCARBONS; HUMAN-PLACENTA; AIR-POLLUTION; CHILDRENS HEALTH; FETAL-GROWTH; TISSUES; WOMEN; RADIOIMMUNOASSAY; SUSCEPTIBILITY; POPULATION","P-32-postlabelling and PAH-ELISA using the antiserum #29 were employed to analyze DNA adducts in venous and umbilical cord blood and the placenta of 79 mothers giving birth to 80 living babies in Prague (Czech Republic) Ambient air exposure was measured by stationary measurements of basic air Pollutants (PM2.5. c-PAHs) during the entire pregnancy Tobacco smoke exposure was assessed by questionnaire data and by plasma cotinine levels The total DNA adduct levels in the lymphocytes of mothers and newborns were elevated by 30-40%(p < 0.001)compared with the placenta B[a]P-like DNA adduct(adduct with the identical chromatographic mobility on TLC as major BPDE derived DNA adduct) levels were elevated in the blood of mothers compared with the placenta and the blood of newborns(p < 0.05 and p < 0.01) In tobacco smoke-exposed mothers, higher DNA adduct levels in the blood of mothers and newborns compared with the placenta were found (p < 0.001), whereas the total and B[a]P-like adduct levels were comparable in the blood of mothers and newborns B[a]P-like adducts were elevated in the blood of mothers unexposed to tobacco smoke compared with that of corresponding newborns and the placenta (p < 0.01) Total and B[a]P-like DNA adducts were increased in the placenta of tobacco smoke-exposed compared with unexposed mothers (p < 0.001 and p < 0.01). In lymphocytes of tobacco smoke-exposed mothers, the comparison of total adduct levels (1.18 +/- 0.67 vs. 0.92 +/- 0.28)and B[a]P-like DNA adducts (0.22 +/- 0.12 adducts/10(8) nucleotides vs 0.15 +/- 0.06 adducts/10(8) nucleotides) with newborns indicated a 30-40% increase of adducts in mothers. Almost equal PAH-DNA adduct levels were detected by anti-BPDE-DNA ELISA in the placenta of tobacco smoke-exposed and unexposed mothers Our results suggest a protective effect of the placental barrier against the genotoxic effect of some tobacco smoke components between the circulation of mother and child We found a correlation between adduct levels in the blood of mothers and newborns (C) 2009 Elsevier B.V. All rights reserved","[Topinka, J.; Milcova, A.; Libalova, H.; Novakova, Z.; Rossner, P., Jr.; Sram, R. J.] AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Prague 14220 4, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Topinka, J, AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic",null,"Czech Ministry of the Education [2B06088]; Academy of Sciences of the Czech Republic [AVOZ50390512]","We thank the gynecological staff of the University Hospital in Prague-Motol. The study was supported by the Czech Ministry of the Education (grant number 2B06088) and by the Academy of Sciences of the Czech Republic (grant number AVOZ50390512).",null,35,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,"10.1016/j.mrfmmm.2009.04.011","MUTAT RES-FUNDAM MOL MECH MUT","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","OCT 2",2009,669,"2009-02-01",null,null,null,13,19,null,null,7,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","510CO","ISI:000271065800003"]
[27,"J","Rossner, P; Milcova, A; Libalova, H; Novakova, Z; Topinka, J; Balascak, I; Sram, RJ",null,null,null,"Rossner, P., Jr.; Milcova, A.; Libalova, H.; Novakova, Z.; Topinka, J.; Balascak, I.; Sram, R. J.",null,"Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. Part II. Oxidative damage","Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis",null,"English","Article",null,null,null,null,null,"Air pollution; Oxidative stress; Newborns; Mothers","AMBIENT AIR-POLLUTION; OF-THE-LITERATURE; DNA-DAMAGE; GESTATIONAL-AGE; CORD BLOOD; IN-VIVO; STRESS; PLASMA; PREGNANCY; HEALTHY","Oxidative damage to macromolecules may have numerous negative health consequences. We measured oxidative damage to DNA, proteins and lipids in 80 newborns and 79 mothers, analyzed the effect of mother's tobacco smoke exposure on oxidative stress, and assessed correlations between oxidative stress markers and bulky and PAH (polycyclic aromatic hydrocarbons)-specific DNA adducts. Mean levels (+/-S.D.) of 8-oxodeoxyguanosine (8-oxodG) per 10(5) dG in the placenta were 2.85 +/- 0.78; we did not see a difference between 8-oxodG levels in newborns born to mothers exposed and unexposed to tobacco smoke. Protein carbonyl levels. a marker of protein oxidation, were comparable in the umbilical cord and in maternal venous blood plasma (17.4 +/- 3.2 and 17.6 +/- 4.2 nmol/ml plasma in newborns and mothers, respectively, p = 0.66). Lipid peroxidation measured as levels of 15-F-2t-isoprostane (15-F-2t-IsoP) in plasma was significantly higher in newborns than in mothers (362 +/- 129 and 252 +/- 130 pg/ml in newborns and mothers, respectively, p < 0.001) We did not find any effect of tobacco smoke exposure on either biomarker in any group. Levels of both protein carbonyls and 15-F-2t-IsoP in cord blood significantly correlated with those in maternal plasma (p < 0.001). 8-oxodG levels positively correlated with plasma carbonyls in cord plasma, as well as with cotinine levels (marker of tobacco smoke exposure) in maternal plasma. 8-oxodG levels also correlated with bulky DNA adducts in lymphocyte DNA of newborns and mothers and with PAH-DNA adducts in the placenta. Our results showed higher lipid peroxidation in newborns than in mothers, close correlation of analyzed oxidative stress markers between newborns and mothers, and a relationship between oxidative stress and induction of DNA adducts. (C) 2009 Elsevier B.V. All rights reserved","[Rossner, P., Jr.; Milcova, A.; Libalova, H.; Novakova, Z.; Topinka, J.; Sram, R. J.] AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Prague 14220 4, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Rossner, P, AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","prossner@biomedcas.cz","Czech Ministry of the Education [21306088]; Academy of Sciences of the Czech Republic [AVOZ50390512]","We thank the gynecological staff of the University Hospital in Prague-Motol. The study was supported by Czech Ministry of the Education (grant number 21306088) and by Academy of Sciences of the Czech Republic (grant number AVOZ50390512).",null,45,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,"10.1016/j.mrfmmm.2009.04.010","MUTAT RES-FUNDAM MOL MECH MUT","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","OCT 2",2009,669,"2009-02-01",null,null,null,20,26,null,null,7,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","510CO","ISI:000271065800004"]
[28,"J","Seeman, T; Dusek, J; Vondrak, K; Spatenka, J; Feber, J",null,null,null,"Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Spatenka, Jaroslav; Feber, Janusz",null,"Profiling proteinuria in children after renal transplantation","Pediatric Nephrology",null,"English","Article",null,null,null,null,null,"Tubular proteinuria; Glomerular proteinuria; Renal transplantation; Children; Albuminuria; Alpha-1-microglobulin","KIDNEY-TRANSPLANTATION; RECIPIENTS; SURVIVAL; HISTOPATHOLOGY; ADOLESCENTS; EXCRETION; SIROLIMUS; BLOCKADE; DISEASES; ALBUMIN","Proteinuria is a common complication after renal transplantation (RTx). In adults, tubular proteinuria prevails and is associated with impaired graft survival. In the absence of studies on proteinuria profiling in transplanted children, we aimed at analyzing the types of proteinuria in transplanted children. Fifty-three children (11.8 years) were analyzed in a cross-sectional study. Morning urine was tested for total protein (PROT), albumin (ALB) and alpha-1-microglobulin (AMG). The type of proteinuria was assessed by the alpha-1-microglobulin/albumin algorithm (AAA): [AAA = AMG x 100/(AMG+ALB]. Median PROT, ALB, and AMG (in mg/mmol creatinine) were 20.0, 3.8, and 4.9, respectively. Pathological total proteinuria (> 22 mg protein/mmol creatinine) was found in 47% of children (25/53). Only 20% of patients with pathological total proteinuria (5/25) had glomerular proteinuria, whereas 80% (20/25) had tubular proteinuria. Three of five children with glomerular proteinuria had chronic allograft nephropathy. Both AMG and albuminuria negatively correlated with the estimated glomerular filtration rate (eGFR) (p = 0.021 and 0.003, respectively). In conclusion, tubular proteinuria was present in 80% of children post-RTx and may be associated with impaired graft function; glomerular proteinuria is associated mainly with chronic allograft nephropathy.","[Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Spatenka, Jaroslav] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, Prague 15006, Czech Republic; [Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Spatenka, Jaroslav] Charles Univ Prague, Transplantat Ctr, Univ Hosp Motol, Fac Med 2, Prague 15006, Czech Republic; [Feber, Janusz] Childrens Hosp Eastern Ontario, Div Pediat Nephrol, Ottawa, ON K1H 8L1, Canada","Seeman, T, Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","tomas.seeman@lfmotol.cuni.cz","Ministry of Health of the Czech Republic [NR/9524-3]; VZ MSMT [0021620819]","This study was supported by grant IGA of the Ministry of Health of the Czech Republic, reg. No NR/9524-3, and grant VZ MSMT reg. No. 0021620819.",null,25,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-009-1275-x","PEDIAT NEPHROL","Pediatr. Nephrol.","DEC",2009,24,12,null,null,null,2439,2444,null,null,6,"Pediatrics; Urology & Nephrology","512WV","ISI:000271283400021"]
[28,"J","Sulakova, T; Janda, J; Cerna, J; Janstova, V; Sulakova, A; Slany, J; Feber, J",null,null,null,"Sulakova, Terezie; Janda, Jan; Cerna, Jana; Janstova, Vlasta; Sulakova, Astrid; Slany, Jaroslav; Feber, Janusz",null,"Arterial HTN in children with T1DM-frequent and not easy to diagnose","Pediatric Diabetes",null,"English","Article",null,null,null,null,null,"children; T1DM; HTN; ABP monitoring; OBP","AMBULATORY BLOOD-PRESSURE; GLOMERULAR-FILTRATION RATE; TYPE-1 DIABETIC-PATIENTS; PLASMA CREATININE; FOLLOW-UP; ADOLESCENTS; HYPERTENSION; MICROALBUMINURIA; BIOPSIES; VALUES","Introduction To evaluate the diagnostic efficacy of the office blood pressure (OBP) and ambulatory blood pressure monitoring (ABPM) in the assessment of hypertension (HTN) in children with diabetes mellitus type 1 (T1DM). Methods We analyzed OBP and ABPM measurements in 84 diabetic children (43 boys) obtained at a median age of 14.9 yr and 6.3 +/- 3.5 yr after diagnosis of T1DM. OBP and ABPM results were converted into standard deviation scores (SDS). In addition, we analyzed blood pressure loads and nighttime dipping. The comparison between OBP and ABPM was performed using kappa coefficient and receiver operator curve (ROC). Results HTN was diagnosed in 43/84 (51%) patients using OBP (> 95th percentile), and in 24/84 (29%) patients using ABPM ( >= 95th percentile during 24 h, day or night). Both methods were in agreement in 33 ABPM normotensive and 16 ABPM hypertensive patients (most had nighttime HTN); 32% patients had white-coat HTN and 9.5% patients had masked HTN. The kappa coefficient was 0.175 (95% CI from -0.034 to 0.384) suggesting poor agreement between OBP and ABPM. Diastolic OBP was a better predictor of ABPM HTN (ROC area under the curve (AUC) = 0.71 +/- 0.06) than systolic OBP (AUC = 0.58 +/- 0.07). The percentage of non-dippers ranged from 7 to 23% in ABPM normotensive patients, and 21-42% in ABPM hypertensive patients who also had significantly higher BP loads (p < 0.0001). Conclusion Children with T1DM often suffer from nocturnal, white coat- and masked HTN, which can not be assessed and predicted by the OBP.","[Sulakova, Terezie; Cerna, Jana; Janstova, Vlasta; Sulakova, Astrid; Slany, Jaroslav] Tech Univ Ostrava, Dept Pediat, Univ Hosp Ostrava, Ostrava 70852, Czech Republic; [Sulakova, Terezie; Cerna, Jana; Janstova, Vlasta; Sulakova, Astrid; Slany, Jaroslav] Tech Univ Ostrava, Fac Hlth Studies, Ostrava 70852, Czech Republic; [Janda, Jan] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15400, Czech Republic; [Feber, Janusz] Univ Ottawa, Dept Pediat, Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada","Sulakova, T, Tech Univ Ostrava, Dept Pediat, Univ Hosp Ostrava, Tr 17 I Istopadu 1790, Ostrava 70852, Czech Republic","terezie.sulakova@fnspo.cz",null,null,null,34,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,"10.1111/j.1399-5448.2009.00514.x","PEDIATR DIABETES","Pediatr. Diabetes","NOV",2009,10,7,null,null,null,441,448,null,null,8,"Endocrinology & Metabolism; Pediatrics","512LP","ISI:000271251100005"]
[28,"J","Vymazal, T; Horacek, M; Durpekt, R; Hladikova, M; Cvachovec, K",null,null,null,"Vymazal, Tomas; Horacek, Michal; Durpekt, Radim; Hladikova, Marie; Cvachovec, Karel",null,"Is Allogeneic Blood Transfusion a Risk Factor for Sternal Dehiscence Following Cardiac Surgery? A Prospective Observational Study","International Heart Journal",null,"English","Article",null,null,null,null,null,"Sternal dehiscence; Immune modulation; Blood transfusion; Cardiac surgery","BYPASS GRAFT-SURGERY; RED-CELLS; ANEMIA; LENGTH; MORBIDITY; MORTALITY; STORAGE","Sternal dehiscence following cardiac Surgery has a multifactorial etiology. Significant risk factors contributing to sternal dehiscence include chronic obstructive pulmonary disease (COPD), obesity, or re-exploration due to bleeding or pericardial tamponade. We have focused on the role of allogeneic blood transfusion as a factor leading to the poor healing of surgical wounds. A prospective Observational study of 1553 elective and emergency cardiac surgery patients was performed between January 2003 and June 2007. All of the patients enrolled in this Study underwent median sternotomy. We studied the relationship between sternal dehiscence following cardiac Surgery and the total number of packed red blood cells transfused. The incidence of sternal dehiscence in the study group was 3.4%. Diabetic patients did not have a higher incidence Of Wound dehiscence. Although COPD,(2)) obesity,(2)) and re-exploration(4)) contributed to sternal dehiscence, the number of allogeneic blood transfusions during the perioperative period was an important independent risk factor for sternal dehiscence. Patients with sternal dehiscence received an average of 7.6 transfusion units (TU) of allogeneic blood versus 1.6 TU of allogeneic blood in the group without sternal dehiscence (P < 0.00005). The dehiscence affected patients without any other significant risk factor who received 6 or more TU, or patients with at least one significant risk factor who received 4 of more TU of allogeneic blood. According to our results, the total amount of allogeneic blood transfused is an important risk factor contributing to sternal dehiscence. Regardless of other risk preconditions, the transfusion of 6 or more TU Could result in sternal dehiscence following cardiac surgery. (Int Heart J 2009; 50: 601-608)","[Vymazal, Tomas; Horacek, Michal; Cvachovec, Karel] Univ Hosp Motol, Dept Anesthesiol & Intens Care Med, Prague 15006 5, Czech Republic; [Durpekt, Radim] Univ Hosp Motol, Dept Cardiovasc Surg, Prague 15006 5, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Fac Med 2, Dept Med Informat, Prague, Czech Republic","Vymazal, T, Univ Hosp Motol, Dept Anesthesiol & Intens Care Med, Prague 15006 5, Czech Republic",null,null,null,null,20,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1349-2365",null,null,"INT HEART J","Int. Heart J.","SEP",2009,50,5,null,null,null,601,607,null,null,7,"Cardiac & Cardiovascular Systems","513EB","ISI:000271304100006"]
[28,"J","van der Linden, MH; Valsecchi, MG; De Lorenzo, P; Moricke, A; Janka, G; Leblanc, TM; Felice, M; Biondi, A; Campbell, M; Hann, I; Rubnitz, JE; Stary, J; Szczepanski, T; Vora, A; Ferster, A; Hovi, L; Silverman, LB; Pieters, R",null,null,null,"van der Linden, Marieke H.; Valsecchi, Maria Grazia; De Lorenzo, Paola; Moericke, Anja; Janka, Gritta; Leblanc, Thierry M.; Felice, Maria; Biondi, Andrea; Campbell, Myriam; Hann, Ian; Rubnitz, Jeffrey E.; Stary, Jan; Szczepanski, Tomasz; Vora, Ajay; Ferster, Alina; Hovi, Liisa; Silverman, Lewis B.; Pieters, Rob",null,"Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol","Blood",null,"English","Article",null,null,null,null,null,null,"ONCOLOGY-GROUP; PROGNOSTIC-FACTORS; INFANTS; EXPERIENCE; THERAPY; TRIAL","Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487. (Blood. 2009; 114: 3764-3768)","[Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol & Haematol, NL-3015 GJ Rotterdam, Netherlands; [Valsecchi, Maria Grazia; De Lorenzo, Paola] Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy; [Moericke, Anja] Univ Med Ctr Schleswig Holstein, Kiel, Germany; [Janka, Gritta] Univ Hosp Hamburg Eppendorf, Cooperat Study Grp Treatment ALL, Hamburg, Germany; [Leblanc, Thierry M.] Hop St Louis, French ALL Grp, Paris, France; [Felice, Maria] Argentina Hosp Pediat, Buenos Aires, DF, Argentina; [Biondi, Andrea] Univ Milano Bicocca, Assoc Italiana Ematol Oncol Pediat, Monza, Italy; [Campbell, Myriam] Hosp Roberto Del Rio, Programa Infantil Nacl Drogas Antineplasicas, Santiago, Chile; [Hann, Ian] Great Ormond St Hosp Sick Children, UK Childrens Canc Study Grp, London WC1N 3JH, England; [Rubnitz, Jeffrey E.] St Jude Childrens Hosp, Memphis, TN 38105 USA; [Stary, Jan] Charles Univ Prague, Czech Paediat Haematol, Univ Hosp Motol, Prague, Czech Republic; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Szczepanski, Tomasz] Med Univ Silesia, Polish Paediat Leukemia & Lymphoma Study Grp, Zabrze, Poland; [Vora, Ajay] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; [Ferster, Alina] Hop Univ Enfants Reine Fabiola, Childrens Leukemia Grp, Brussels, Belgium; [Hovi, Liisa] Univ Helsinki, Nord Soc Paediat Haematol & Oncol, Helsinki, Finland; [Silverman, Lewis B.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Pieters, Rob] Dutch Childhood Oncol Grp, The Hague, Netherlands","Pieters, R, Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol & Haematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","rob.pieters@erasmusmc.nl","KiKa ; Associazione Italiana Ricerca sul Cancro Regional [Cod 1105]; Fondazione Tettamanti and Comitato MM Verga ; Polish Ministry of Science and Higher Education [2 P054 095 30]; Czech Ministry of Education [MSM0021620813]; Deutsche Krebshilfe ","M. H. v. d. L. is supported by KiKa. The many participating institutes of all study groups are acknowledged for their support. This study in Associazione Italiana Ematologia Oncologia Pediatrica is partially supported by Associazione Italiana Ricerca sul Cancro Regional Grant Cod 1105 (to A. B. and M. G. V.). The international study operating center was partially supported by Fondazione Tettamanti and Comitato MM Verga (to M. G. V. and P. D. L.). T. S. was supported by the Polish Ministry of Science and Higher Education (grant 2 P054 095 30). Czech Paediatric Haematology was supported by the Czech Ministry of Education (grant MSM0021620813). Berlin-Frankfurt-Munster Germany was supported by Deutsche Krebshilfe.",null,20,0,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2009-02-204214","BLOOD","Blood","OCT 29",2009,114,18,null,null,null,3764,3768,null,null,5,"Hematology","512RO","ISI:000271268100010"]
[29,"J","Vaclavikova, E; Dvorakova, S; Sykorova, V; Bilek, R; Dvorakova, K; Vlcek, P; Skaba, R; Zelinka, T; Bendlova, B",null,null,null,"Vaclavikova, Eliska; Dvorakova, Sarka; Sykorova, Vlasta; Bilek, Radovan; Dvorakova, Katerina; Vlcek, Petr; Skaba, Richard; Zelinka, Tomas; Bendlova, Bela",null,"RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest","Endocrine",null,"English","Article",null,null,null,null,null,"RET proto-oncogene; RET mutation; Medullary thyroid carcinoma; Hirschsprung's disease; Pheochromocytoma; Genetics","MEDULLARY-THYROID CARCINOMA; MULTIPLE ENDOCRINE NEOPLASIA; GERMLINE MUTATIONS; PRIMARY HYPERPARATHYROIDISM; PROPHYLACTIC THYROIDECTOMY; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNGS-DISEASE; CLINICAL-PRACTICE; TYPE-2; PHEOCHROMOCYTOMA","Activating germline RET mutations are presented in patients with familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia (MEN) types 2A and 2B, whereas inactivating germline mutations in patients with Hirschsprung's disease (HSCR). The aim of this study was to evaluate genotype-phenotype correlations of the frequently discussed Tyr791Phe mutation in exon 13 of the RET proto-oncogene. Screening of three groups of patients was performed (276 families with medullary thyroid carcinoma (MTC), 122 families with HSCR, and 29 patients with pheochromocytoma). We found this mutation in 3 families with apparently sporadic MTC, 3 families with FMTC/MEN2, 1 patient with pheochromocytoma, and 3 families with HSCR. All gene mutation carriers have a silent polymorphism Leu769Leu in exon 13. In three families second germline mutations were detected: Cys620Phe (exon 10) in MEN2A family, Met918Thr (exon 16) in MEN2B family, and Ser649Leu (exon 11) in HSCR patient. Detection of the Tyr791Phe mutation in MEN2/MTC and also in HSCR families leads to the question whether this mutation has a dual character (gain-of-function as well as loss-of-function). A rare case of malignant pheochromocytoma in a patient with the Tyr791Phe mutation is presented. This study shows various clinical characteristics of the frequently discussed Tyr791Phe mutation.","[Vaclavikova, Eliska; Dvorakova, Sarka; Sykorova, Vlasta; Bendlova, Bela] Res Inst Endocrinol, Dept Mol Endocrinol, CR-11694 Prague 1, Czech Republic; [Bilek, Radovan] Res Inst Endocrinol, Dept Proteohormones & Biofactors, CR-11694 Prague, Czech Republic; [Dvorakova, Katerina] Res Inst Endocrinol, Dept Clin Endocrinol, CR-11694 Prague 1, Czech Republic; [Vlcek, Petr] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Vlcek, Petr; Skaba, Richard] Teaching Hosp Motol, Prague, Czech Republic; [Skaba, Richard] Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Prague, Czech Republic; [Zelinka, Tomas] First Fac Med, Clin Dept Endocrinol & Metab, Dept Med 3, Prague, Czech Republic; [Zelinka, Tomas] Gen Teaching Hosp, Prague, Czech Republic","Vaclavikova, E, Res Inst Endocrinol, Dept Mol Endocrinol, Narodni 8, CR-11694 Prague 1, Czech Republic","evaclavikova@endo.cz","GACR 301/06/P425 ; IGA MH CR NR/9165-3 ","The study was supported by GACR 301/06/P425 and IGA MH CR NR/9165-3.",null,39,0,"HUMANA PRESS INC","TOTOWA","999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA","0969-711X",null,"10.1007/s12020-009-9242-7","ENDOCRINE","Endocrine","DEC",2009,36,3,null,null,null,419,424,null,null,6,"Endocrinology & Metabolism","515VT","ISI:000271501700011"]
[29,"J","Kalina, T; Stuchly, J; Janda, A; Hrusak, O; Ruzickova, S; Sediva, A; Litzman, J; Vlkova, M",null,null,null,"Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej; Ruzickova, Sarka; Sediva, Anna; Litzman, Jiri; Vlkova, Marcela",null,"Profiling of Polychromatic Flow Cytometry Data on B-Cells Reveals Patients' Clusters in Common Variable Immunodeficiency","Cytometry Part A",null,"English","Article",null,null,null,null,null,"B-lymphocyte subsets; common variable immunodeficiency; flow cytometry; probability binning; B-lymphocyte profiling","CLASSIFICATION; SUBGROUPS; PACKAGE; DISEASE; CD27","The aim of this study was to find an objective computational approach for phenotype analysis of common variable immunodeficiency (CVID) patients that describes all differences in the six-color space and to form groups of patients using computational methods. CVID is a heterogeneous primary immunodeficiency disorder where molecular defect is recognized in <10% of the cases and is unknown in the majority of patients. The current CVID classification, EUROClass, is based on quantification of selected B-cell subsets. Using six-color polychromatic flow cytometry, we analyzed B-cell phenotypes in a cohort of 48 CVID patients and 49 healthy donors. We used a \"probability binning\" algorithm to create 1,024 bins (each bin is a six-color gate) that covered the cells' distribution within the entire B-cell compartment. A matrix file recording cellular content in all the bins was made. The hierarchical clustering of the individual samples was analyzed using a Pearson correlation of the bins' values. The Cut tree algorithm found 12 clusters. In six clusters, healthy individuals predominated; in one cluster, smB+CD21low (CVID patients by EUROClass) cells prevailed; in one cluster, smB-CD21norm cells prevailed; in one cluster, smB+CD21low cells prevailed; the remaining cluster was mixed. The overall reproducibility of probability binning clustering was confirmed by matching of replicates to the original cohort using the similarity matrix of the Pearson correlation, 15 replicates matched the same individual, three replicates matched a different individual within the same cluster, and three replicates matched to a different cluster. We were able to define B-cell subsets over- or under-represented in a particular cluster and display them back in the flow cytometry software. We describe a new analytical approach that enables a search in an objective computational environment for patient cohorts that are defined by similar B-cell profiles and thus contribute to the description of differences between CVID patient groups. (C) 2009 International Society for Advancement of Cytometry","[Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej; Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic; [Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej] CLIP, Prague, Czech Republic; [Stuchly, Jan] Charles Univ Prague, Fac Math & Phys, Dept Numer Math, Prague, Czech Republic; [Ruzickova, Sarka] Acad Sci Czech Republic, Inst Biotechnol, Lab Diagnost Autoimmune Dis, PRI, Prague, Czech Republic; [Sediva, Anna] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Litzman, Jiri; Vlkova, Marcela] St Annes Fac Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Litzman, Jiri; Vlkova, Marcela] Masaryk Univ, Fac Med, Brno, Czech Republic","Kalina, T, Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic","tomas.kalina@lfmotol.cuni.cz","Czech Ministry of Health [NR/9198-3]","Grant sponsor: Czech Ministry of Health; Grant number: NR/9198-3.",null,19,1,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4922",null,"10.1002/cyto.a.20801","CYTOMETRY PART A","Cytom. Part A","NOV",2009,"75A",11,null,null,null,902,909,null,null,8,"Biochemical Research Methods; Cell Biology","515UN","ISI:000271498500003"]
["nemá","J","Chlumsky, J; Havlin, J",null,null,null,"Chlumsky, Jaromir; Havlin, Jan",null,"Spontaneous jugular vein thrombosis","ACTA CARDIOLOGICA",null,"English","Article",null,null,null,null,null,"Spontaneous jugular vein thrombosis; anticoagulation treatment","CATHETER","Jugular vein thrombosis (JVT) is usually secondary to central venous catheterisation, distant malignancy, hypercoagulable state or ovarian hyperstimulation syndrome. Spontaneous internal JVT is an extremely rare entity. A 61-year-old man presented with swelling of the right side of his face. An ultrasonographic scan showed thrombosis of the right jugular vein. Clinical tests, including oncomarkers, X-ray, CT scan and abdominal ultrasonography, searching for malignancy, were negative. The patient was heparinized immediately using LMWH and then underwent warfarin anticoagulation therapy for 6 months. One year later the patient was in good clinical condition with no malignancy diagnosed. Aetiology and the treatment of spontaneous JVT are discussed.","[Chlumsky, Jaromir] Charles Univ Prague, Univ Hosp Motol, Dept Med, Prague 15000 5, Czech Republic","Chlumsky, J, Charles Univ Prague, Univ Hosp Motol, Dept Med, Uvalu 84, Prague 15000 5, Czech Republic","jaromirchlumsky@seznam.cz",null,null,null,16,0,"ACTA CARDIOLOGICA","BRUSSELS","AVENUE CIRCULAIRE 138A, 1180 BRUSSELS, BELGIUM","0001-5385",null,"10.2143/AC.64.5.2042704","ACTA CARDIOL","Acta Cardiol.","OCT",2009,64,5,null,null,null,689,691,null,null,3,"Cardiac & Cardiovascular Systems","524ZU","ISI:000272183700020"]
["nemá","J","Svehlik, M; Zwick, EB; Steinwender, G; Linhart, WE; Schwingenschuh, P; Katschnig, P; Ott, E; Enzinger, C",null,null,null,"Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Linhart, Wolfgang E.; Schwingenschuh, Petra; Katschnig, Petra; Ott, Erwin; Enzinger, Christian",null,"Gait Analysis in Patients With Parkinson's Disease Off Dopaminergic Therapy","ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION",null,"English","Article",null,null,null,null,null,"Biomechanics; Levodopa; Neurologic gait disorders; Parkinson Disease; Rehabilitation","BASAL GANGLIA; WALKING; BIOMECHANICS; PARAMETERS","Objective: To compare time-distance, kinematic, and kinetic gait parameters in patients with idiopathic Parkinson's disease (PD) off dopaminergic therapy with a group of healthy control subjects. Design: A group-comparison study. Setting: Gait analysis laboratory. Participants: Patients with PD (n=20) and healthy age-matched controls (n=20). Interventions: Not applicable. Main Outcome Measures: Time-distance, kinematic, and kinetic gait variables. Results: PD patients walked slower with shorter stride-length, comparable cadence, and longer double support times. Kinematics showed a reduction of the range of motion in the hip, knee, and ankle joints. Maximum hip extension and the ankle plantar flexion were significantly reduced. Kinetic gait parameters showed reduced push-off ankle power and lift-off hip power generation. Strong correlations between these important body advancement mechanisms and the walking velocity were observed. Conclusions: In addition to previously described dysfunctional kinematics, abnormal kinetic parameters play an important role in the characterization of gait in PD patients off therapy. Hence, these parameters could be used to document treatment effects of parkinsonian gait disorders.","[Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, A-8036 Graz, Austria; [Schwingenschuh, Petra; Katschnig, Petra; Ott, Erwin] Med Univ Graz, Dept Neurol, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Sch Med 2, Dept Children & Adult Orthopaed & Traumatol, Prague, Czech Republic","Svehlik, M, Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, Auenbruggerpl 34, A-8036 Graz, Austria","martin.spejlik@seznam.cz",null,null,null,28,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0003-9993",null,"10.1016/j.apmr.2009.06.017","ARCH PHYS MED REHABIL","Arch. Phys. Med. Rehabil.","NOV",2009,90,11,null,null,null,1880,1886,null,null,7,"Rehabilitation; Sport Sciences","520XC","ISI:000271881900010"]
["nemá","J","Mahenthiralingam, E; Marchbank, A; Drevinek, P; Garaiova, I; Plummer, S",null,null,null,"Mahenthiralingam, Eshwar; Marchbank, Angela; Drevinek, Pavel; Garaiova, Iveta; Plummer, Sue",null,"Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption","BMC MICROBIOLOGY",null,"English","Article",null,null,null,null,null,null,"CYSTIC-FIBROSIS; PROBIOTICS; DIFFERENTIATION; IDENTITY; LACTIS; PCR","Background: The Lactic Acid Bacteria (LAB) are important components of the healthy gut flora and have been used extensively as probiotics. Understanding the cultivable diversity of LAB before and after probiotic administration, and being able to track the fate of administered probiotic isolates during feeding are important parameters to consider in the design of clinical trials to assess probiotic efficacy. Several methods may be used to identify bacteria at the strain level, however, PCR-based methods such as Random Amplified Polymorphic DNA (RAPD) are particularly suited to rapid analysis. We examined the cultivable diversity of LAB in the human gut before and after feeding with two Lactobacillus strains, and also tracked the fate of these two administered strains using a RAPD technique. Results: A RAPD typing scheme was developed to genetically type LAB isolates from a wide range of species, and optimised for direct application to bacterial colony growth. A high-throughput strategy for fingerprinting the cultivable diversity of human faeces was developed and used to determine: (i) the initial cultivable LAB strain diversity in the human gut, and (ii) the fate of two Lactobacillus strains (Lactobacillus salivarius NCIMB 30211 and Lactobacillus acidophilus NCIMB 30156) contained within a capsule that was administered in a small-scale human feeding study. The L. salivarius strain was not cultivated from the faeces of any of the 12 volunteers prior to capsule administration, but appeared post-feeding in four. Strains matching the L. acidophilus NCIMB 30156 feeding strain were found in the faeces of three volunteers prior to consumption; after taking the Lactobacillus capsule, 10 of the 12 volunteers were culture positive for this strain. The appearance of both Lactobacillus strains during capsule consumption was statistically significant (p < 0.05). Conclusion: We have shown that genetic strain typing of the cultivable human gut microbiota can be evaluated using a high throughput RAPD technique based on single bacterial colonies. Validation of this strategy paves the way for future systematic studies on the fate and efficacy of bacterial probiotics during human clinical trials.","[Mahenthiralingam, Eshwar; Marchbank, Angela; Drevinek, Pavel] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; [Drevinek, Pavel] 2nd Med Sch, Dept Paediat, Prague 15006, Czech Republic; [Garaiova, Iveta; Plummer, Sue] Obsidian Res Ltd, Port Talbot SA12 7BZ, Wales","Mahenthiralingam, E, Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales","MahenthiralingamE@cardiff.ac.uk; MarchbankAM@cardiff.ac.uk; Pavel.drevinek@lfmotol.cuni.cz; ivetag@obsidianresearch.co.uk; suep@obsidianresearch.co.uk","Wellcome Trust [075586]","This work was supported by a grant from the HELP Wales Programme and Cultech Ltd. P. D. acknowledges salary funding from the Wellcome Trust (grant 075586). We thank: Catrin Thomas and Mark Weaver for technical assistance; Martin Day, Peter Vandamme, Julian Marchesi and Nigel Plummer for helpful discussions concerning the manuscript; and Peter Randerson for advice on the statistical analysis.",null,21,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2180",null,"10.1186/1471-2180-9-251","BMC MICROBIOL","BMC Microbiol.","DEC 7",2009,9,null,null,null,null,null,null,251,null,15,"Microbiology","535YM","ISI:000273007900001"]
["nemá","J","Zwick, EB; Svehlik, M; Steinwender, G; Linhart, WE",null,null,null,"Zwick, E. B.; Svehlik, M.; Steinwender, G.; Linhart, W. E.",null,"Short-term Effects of Botulinum Toxin A and Serial Casting on Triceps Surae Muscle Length and Equinus Gait in Children with Cerebral Palsy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"English","Article",null,null,null,null,null,"cerebral palsy; botulinum toxin A; pes equinus; gait analysis","LOWER-LIMB SPASTICITY; DOUBLE-BLIND; GASTROCNEMIUS; MANAGEMENT; MULTICENTER; INJECTIONS; DISORDERS; EFFICACY; THERAPY; TRIAL","Aims: The aim of the study was to perform a comprehensive analysis of the short-term effects of a standardized high dose of BTX-A and serial casting on spastic equinus in children with cerebral palsy. A second goal was to evaluate this short-term effect on muscle lengths of the triceps surae. Materials and methodology: Prospective study on 10 children (17 limbs) with spastic cerebral palsy and equinus gait pattern. Three-dimensional kinematic and kinetic gait analysis with musculo-skeletal modelling was used to evaluate pre- and 10 weeks post-treatment results. The paired Student's T-test was used for data analysis. Results: Walking velocity and stride length did not change after BTX-A application. The maximal ankle angle at the end of single support increased (p = 0.045) which led to a change of the ankle angle slope quotient towards normal positive values (p = 0.001). Abnormal ankle power generation in the first part of single stance changed towards normal (p = 0.012). Notably, the ankle plantar-flexor power was not reduced 10 weeks after BTX-A injection (p = 0.486). No lengthening of the triceps surae muscles compared to the baseline assessment was found. Conclusions: Beneficial functional changes in ankle kinematics and kinetics after the application of BTX-A when combined with serial casting were demonstrated. The results of our study underline the possible differences in effect of BTX-A on intrafusal and extrafusal muscle fibres.","[Zwick, E. B.; Svehlik, M.; Steinwender, G.; Linhart, W. E.] Med Univ Graz, Dept Paediat Orthopaed, Dept Paediat Surg, A-8036 Graz, Austria; [Svehlik, M.] Charles Univ Prague, Dept Child & Adult Orthopaed & Traumatol, Sch Med 2, Prague, Czech Republic","Svehlik, M, Med Univ Graz, Dept Paediat Orthopaed, Dept Paediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria","martin.spejlik@seznam.cz",null,null,null,34,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,6,null,null,null,553,558,null,null,6,"Neurosciences; Surgery","529LW","ISI:000272519700008"]
["nemá","J","Sobotkova, V; Blatny, M; Jelinek, M; Hrdlicka, M; Urbanek, T",null,null,null,"Sobotkova, Veronika; Blatny, Marek; Jelinek, Martin; Hrdlicka, Michal; Urbanek, Tomas",null,"Typology of antisocial behavior in early adolescence and its relation to further forms of risk behavior","CESKOSLOVENSKA PSYCHOLOGIE",null,"Czech","Article",null,null,null,null,null,"antisocial behavior; typology; substances; early adolescence","NO SAFE HAVEN; VIOLENCE EXPOSURE; URBAN YOUTH; PERSONALITY; CHILDREN","The study deals with antisocial behavior of adolescents in urban areas, its typology and its relation to substances. The sample was formed by pupils of the seventh and ninth classes of primary schools or their equivalents on the other types of schools in regional capitals of the Czech Republic. The sample was gained due to the international SAHA project and consisted of 2973 persons. The twelve years old cohort consisted of 1447 persons (54% of girls) and the fourteen years old cohort consisted of 1526 persons (53% of girls). By the means of non-hierarchic cluster analysis (k-means) of items of antisocial behavior scale, four types of persons were identified. The typology was validated by help of relation to substances (cigarettes, alcohol, marihuana, and hard drugs). The higher was the measure of antisocial behavior showed by the persons, the more the persons reported the use of substances.","[Sobotkova, Veronika; Blatny, Marek; Jelinek, Martin; Urbanek, Tomas] Psychol Ustav AV CR, Brno 60200, Czech Republic; [Hrdlicka, Michal] FN Motol, Detska Psychiat Klin UK, Prague, Czech Republic","Sobotkova, V, Psychol Ustav AV CR, Veveri 97, Brno 60200, Czech Republic","vero-nika@psu.cas.cz",null,null,null,44,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2009,53,5,null,null,null,428,440,null,null,13,"Psychology, Multidisciplinary","523FG","ISI:000272056900002"]
["nemá","J","Turnovcova, K; Ruzickova, K; Vanecek, V; Sykova, E; Jendelova, P",null,null,null,"Turnovcova, Karolina; Ruzickova, Katerina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla",null,"Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media","CYTOTHERAPY",null,"English","Article",null,null,null,null,null,"cell cycle; cell differentiation; cell-surface antigens; clinical trials; colony-forming units; population doubling time","FETAL CALF SERUM; IN-VITRO EXPANSION; STEM-CELLS; ANIMAL SERUM; THERAPY; ANTIBODIES; PROLIFERATION; DETERMINANT; SUBSTITUTE; EXPRESSION","Background aims Human mesenchymal stromal cells (hMSC) are a promising tool for future clinical application, but their use requires rapid cell expansion in media suitable for clinical use. Therefore, we tested the influence of several culture media on colony formation, population doubling (PD) time, cell cycle and surface marker expression. Methods hMSC isolated from human bone marrow (BM) obtained from healthy donors were seeded and expanded in different culture media: alpha-minimum essential medium (MEM) supplemented with 2.5%, 5%, 10% or 20% fetal bovine serum (FBS), 5% or 10% human cord blood serum (hCBS), 5% or 10% human blood serum from AB adult donors (hABS), or mesenchymal stem cell growth medium (MSCGM (TM)). The number, diameter and total area of the colonies formed and PD time were determined, and the cell cycle and 16 surface markers were analyzed. Results Colony-forming efficiency was best in alpha-MEM/hCBS and alpha-MEM/hABS, good in MSCGM and worst in alpha-MEM/FBS. The shortest PD time was achieved in media enriched with human sera or MSCGM, while the time was increased in alpha-MEM/FBS. The largest proliferating fraction was seen in MSCGM followed by media enriched with human sera; the fraction was smallest in alpha-MEM/FBS. Staining for CD34, CD45, CD235a and CD271 was negative, while that for CD29, CD44, CD73, CD90, CD105 and human leukocyte antigen (HLA)-A, -B, -C was positive in all media tested. Media with human serum did not adversely affect the differentiation potential of hMSC, and differentiation into osteoblasts was enhanced. Conclusions The choice of serum influences hMSC expansion and cell properties; alpha-MEM supplemented with hABS seems to be a promising candidate for clinical use.","[Turnovcova, Karolina; Ruzickova, Katerina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Turnovcova, Karolina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Turnovcova, Karolina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic","Jendelova, P, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","jendel@biomed.cas.cz","EC FP6 projects RESCUE [LSHB-CT2005- 518233]; ENINET [LSHM-CT-2005-019063]; [AV0Z50390703]; [1M0538]; [LC554]; [309/08/H079]","We thank Jarmila Kasparova for technical assistance, James Dutt for critical reading of the manuscript and Marie Hladikova for statistical analysis. This study was supported by the grants AV0Z50390703, 1M0538, LC554, 309/08/H079 and the EC FP6 projects RESCUE (LSHB-CT2005- 518233) and ENINET (LSHM-CT-2005-019063).",null,39,0,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","1465-3249",null,"10.3109/14653240903188947","CYTOTHERAPY","Cytotherapy",null,2009,11,7,null,null,null,874,885,null,null,12,"Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental","523AS","ISI:000272043100008"]
["nemá","J","Krizkova, S; Blahova, P; Nakielna, J; Fabrik, I; Adam, V; Eckschlager, T; Beklova, M; Svobodova, Z; Horak, V; Kizek, R",null,null,null,"Krizkova, Sona; Blahova, Pavlina; Nakielna, Johana; Fabrik, Ivo; Adam, Vojtech; Eckschlager, Tomas; Beklova, Miroslava; Svobodova, Zdenka; Horak, Vratislav; Kizek, Rene",null,"Comparison of Metallothionein Detection by Using Brdicka Reaction and Enzyme-Linked Immunosorbent Assay Employing Chicken Yolk Antibodies","ELECTROANALYSIS",null,"English","Article",null,null,null,null,null,"Metallothionein; Differential pulse voltammetry; ELISA; Chicken yolk antibodies; Human blood serum; Immunoassays; Antibodies","PERFORMANCE LIQUID-CHROMATOGRAPHY; CADMIUM-INDUCED METALLOTHIONEIN; MESSENGER-RNA EXPRESSION; MERCURY SATURATION ASSAY; CAPILLARY-ELECTROPHORESIS; ELECTROCHEMICAL TECHNIQUES; ZINC SUPPLEMENTATION; SPECIATION ANALYSIS; MASS-SPECTROMETRY; FISH-TISSUES","In this Study, two methods for metallothioneins (MT) determination in a biological sample were compared. Particularly, twenty five human and nine pig blood serum samples and liver and kidney samples from thirty five carps (Cyprinus carpio) were analyzed by enzyme-linked immunosorbent assay and differential pulse voltammetry Brdicka's reaction. The results obtained by these two methods were in good agreement. For commercially available NIT standard the correlation coefficient between the single concentrations signal height was 0.99. In biological samples the correlation coefficients were 0.90 for fish liver and kidney samples, 0.91 for pig blood serum and 0.93 for human blood serum.","[Krizkova, Sona; Blahova, Pavlina; Nakielna, Johana; Fabrik, Ivo; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague, Czech Republic; [Beklova, Miroslava] Univ Vet & Pharmaceut Sci, Dept Vet Ecol & Environm Protect, CZ-61242 Brno, Czech Republic; [Svobodova, Zdenka] Univ Vet & Pharmaceut Sci, Fac Vet Hyg & Ecol, Dept Vet Publ Hlth & Toxicol, CZ-61242 Brno, Czech Republic; [Svobodova, Zdenka] Univ S Bohemia Ceske Budejovice, Res Inst Fish Culture & Hydrobiol, CZ-38925 Vodnany, Czech Republic; [Horak, Vratislav] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Dept Anim Embryol Cell & Tissue Differentitat, Lab Tumour Biol,Vvi, CZ-27721 Libechov, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz","INCHEMBIOL [MSM 0021622412, MSM 6215712402, MSM 0021620813, GAAV IAA401990701]","Financial support from INCHEMBIOL MSM 0021622412, MSM 6215712402, MSM 0021620813, GAAV IAA401990701 and Ligra. proti rakovine Prague is highly acknowledged. Moreover, the authors express their thanks to Veronika Kohoutkova for English correction.",null,92,0,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,"10.1002/elan.200900243","ELECTROANAL","Electroanalysis","DEC",2009,21,23,null,null,null,2575,2583,null,null,9,"Chemistry, Analytical; Electrochemistry","532HW","ISI:000272738800010"]
["nemá","J","Krizkova, S; Adam, V; Eckschlager, T; Kizek, R",null,null,null,"Krizkova, Sona; Adam, Vojtech; Eckschlager, Tomas; Kizek, Rene",null,"Using of chicken antibodies for metallothionein detection in human blood serum and cadmium-treated tumour cell lines after dot- and electroblotting","ELECTROPHORESIS",null,"English","Article",null,null,null,null,null,"Cancer cell lines; Differential pulse voltammetry-Brdicka reaction; Dot immunobinding assay; Metallothionein; Western blot","PERFORMANCE LIQUID-CHROMATOGRAPHY; TRANSFER STRIPPING TECHNIQUE; IMMUNOSORBENT-ASSAY ELISA; MESSENGER-RNA EXPRESSION; MERCURY SATURATION ASSAY; CAPILLARY-ELECTROPHORESIS; BRDICKA REACTION; ELECTROCHEMICAL DETECTION; MASS-SPECTROMETRY; EISENIA-FOETIDA","Metallothionein (MT) is a low-molecular mass protein playing an essential role in homeostasis of heavy metal ions. Its relation with formation and progression of a tumour disease is discussed in this article. Here, we propose a new methodological approach for visualization of MT on PVDF membranes after dot- and electroblotting by using a commercial mouse monoclonal antibody E9 and polyclonal chicken antibodies. The optimized procedure was as follows. We dotted 1 mu m sample volume on PVDF membrane and let it to dry. Then, we blocked the membrane surface with 2% BSA in PBS for 30 min After that, the membrane was incubated in chicken primary antibody (diluted 1:500), washed, and incubated in rabbit-anti-chicken secondary antibody conjugated with horseradish peroxidase. To visualize the interaction, we used 3-aminoethyl-9-carbazole. Under these conditions, we estimated detection limit as 3 pa of NIT per 1 mu L. The optimal approach was further utilized for detection of MT level in two human fibroblast cell lines and in blood serum obtained from children with medulloblastoma. The results were in good agreement with differential pulse voltammetry-Brdicka reaction.","[Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Dept Anim Nutr & Forage Prod, Fac Agron, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CR-11636 Prague, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,89,0,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","0173-0835",null,"10.1002/elps.200900201","ELECTROPHORESIS","Electrophoresis","NOV",2009,30,21,null,null,null,3726,3735,null,null,10,"Biochemical Research Methods; Chemistry, Analytical","524EG","ISI:000272126000011"]
["nemá","J","Gebauer, RA; Tomek, V; Kubus, P; Razek, V; Matejka, T; Salameh, A; Kostelka, M; Janousek, J",null,null,null,"Gebauer, Roman A.; Tomek, Viktor; Kubus, Petr; Razek, Vit; Matejka, Tomas; Salameh, Aida; Kostelka, Martin; Janousek, Jan",null,"Differential effects of the site of permanent epicardial pacing on left ventricular synchrony and function in the young: implications for lead placement","EUROPACE",null,"English","Article",null,null,null,null,null,"Permanent pacing; Heart block; Ventricular dysfunction; Left ventricular pacing; Right ventricular pacing; Children","CARDIAC RESYNCHRONIZATION THERAPY; DUAL-CHAMBER; ATRIOVENTRICULAR-BLOCK; CHILDREN; HEART; DYSSYNCHRONY; PACEMAKER; FAILURE; ATRIAL; TRIAL","To analyse left ventricular (LV) synchrony and function with respect to the epicardial pacing site in the young. Left ventricular function and synchrony (M-mode, speckle tracking) were evaluated during mid-term follow-up in 32 children with complete non-surgical (n = 15) or surgical (n = 17) atrioventricular block (structural heart disease in 21/32) paced from LV apex (n = 19), right ventricular (RV) apex (n = 7), and RV free wall (n = 6), respectively. Data are in the following order: LV apical, RV apical, and RV free wall pacing. Septal to posterior wall motion delay (SPWMD) = median 0, 69, and 136 ms (P < 0.001), septal to lateral mechanical delay = 54 +/- 29, 73 +/- 24, and 129 +/- 70 ms (P = 0.001), apical to basal mechanical delay = 96 +/- 37, 106 +/- 50, and 79 +/- 18 ms (P NS), and LV ejection fraction (LVEF) = 57 +/- 9, 49 +/- 12, and 33 +/- 10% (P < 0.001), respectively. Left ventricular ejection fraction correlated negatively with SPWMD (R-2 = 0.454, P < 0.001) and septal to lateral mechanical delay (R-2 = 0.320, P < 0.001) but not with apical to basal mechanical delay. Right ventricular free wall pacing (P = 0.014) and SPWMD (P = 0.044) were negative multivariable predictors of LVEF. Compared with other sites, LV apical pacing preserves septal to lateral LV synchrony and systolic function and may be the preferred epicardial pacing site in the young.","[Gebauer, Roman A.; Razek, Vit; Salameh, Aida; Janousek, Jan] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04289 Leipzig, Germany; [Tomek, Viktor; Kubus, Petr; Matejka, Tomas] Univ Hosp Motol, Kardiocentrum, Prague, Czech Republic; [Tomek, Viktor; Kubus, Petr; Matejka, Tomas] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Kostelka, Martin] Univ Leipzig, Ctr Heart, Dept Cardiac Surg, Leipzig, Germany","Gebauer, RA, Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany","roman.gebauer@med.uni-leipzig.de","Ministry of Health, Czech Republic [NR/9472-3]","This work was supported by the grant of the Ministry of Health, Czech Republic (NR/9472-3 to V.T. and P.K.).",null,22,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129",null,"10.1093/europace/eup342","EUROPACE","Europace","DEC",2009,11,12,null,null,null,1654,1659,null,null,6,"Cardiac & Cardiovascular Systems","524YE","ISI:000272179500015"]
["nemá","J","Snajdauf, J; Rygl, M; Petru, O; Kalousova, J; Kuklova, P; Mixa, V; Keil, R; Hribal, Z",null,null,null,"Snajdauf, J.; Rygl, M.; Petru, O.; Kalousova, J.; Kuklova, P.; Mixa, V.; Keil, R.; Hribal, Z.",null,"Duodenum-Sparing Technique of Head Resection in Solid Pseudopapillary Tumor of the Pancreas in Children","EUROPEAN JOURNAL OF PEDIATRIC SURGERY",null,"English","Article",null,null,null,null,null,"solid pseudopapillary tumor of the pancreas; duodenum-sparing technique; pancreatic surgery in children","PRESERVING RESECTION; PAPILLARY; NEOPLASM; PANCREATICODUODENECTOMY; LESIONS","Aim of study: Aim of the Study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors Of the head of the pancreas. Methods: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results. Results: There were 13 patients (12 girls and one boy) with an average age of 14 years (9-17.5 years) at operation. In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved. Patients with body and tail involvement underwent distal pancreatic resection. In 6 patients with head involvement a duodenum-sparing resection of the head and end-to-end anastomosis of the excluded jejunal loop either to the corpus or tail of the pancreas were performed. One girl underwent a modified Whipple operation. She developed a biliary fistula which closed after three weeks with endoscopic stenting. One patient with head resection developed a biliary fistula which closed after two weeks of stenting. One patient who underwent resection of the pancreatic head complained of recurrent abdominal pain one year postoperatively. All patients are alive without tumor recurrence at 6 months to 16 years after operation. Conclusion: SPTP is a rare pancreatic tumor with a low degree of malignancy. No perioperative chemotherapy is necessary. Therefore duodenal resection in cases of SPTP in the head of the gland seems too invasive and mutilating. The authors consider the duodenum-sparing technique to be more appropriate for the developing organism of a child. Favorable short and long-term results support this opinion.","[Snajdauf, J.] Charles Univ Prague, Inst Postraguate Med, Sch Med 2, Dept Pediat Surg, Prague 15000, Czech Republic; [Rygl, M.; Petru, O.; Kalousova, J.; Kuklova, P.; Mixa, V.; Keil, R.; Hribal, Z.] Charles Univ Prague, Fac Med 2, Prague 15000, Czech Republic; [Rygl, M.; Petru, O.; Kalousova, J.; Kuklova, P.; Mixa, V.; Keil, R.; Hribal, Z.] Charles Univ Prague, Teaching Hosp Motol, Prague 15000, Czech Republic","Snajdauf, J, Charles Univ Prague, Inst Postraguate Med, Sch Med 2, Dept Pediat Surg, Uvalu 84, Prague 15000, Czech Republic","jiri.snajdauf@fnmotol.cz",null,null,null,20,0,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0939-7248",null,"10.1055/s-0029-1237729","EUR J PEDIATR SURG","Eur. J. Pediatr. Surg.","DEC",2009,19,6,null,null,null,354,357,null,null,4,"Pediatrics; Surgery","538UD","ISI:000273208600003"]
["nemá","J","Szczurowska, E; Mares, P",null,null,null,"Szczurowska, Ewa; Mares, Pavel",null,"Controversial action of positive modulator of subtype 7 of metabotropic glutamate receptors AMN082 on cortical epileptic afterdischarges in immature rats","EUROPEAN JOURNAL OF PHARMACOLOGY",null,"English","Article",null,null,null,null,null,"Cortical seizure; Ontogeny; Metabotropic glutamate receptor; Electrocorticogram; Convulsion; (Rat)","METHYL-D-ASPARTATE; AGONIST; ACTIVATION; SEIZURES; NUCLEUS; BRAIN; ACID; GABA","Some age-dependent epilepsies of infancy and childhood Cannot be Sufficiently treated with contemporaneous antiepileptics, therefore search for new mechanisms and new drugs active in pediatric patients is necessary. Possible anticonvulsant action of AMN082 (N,N'-dibenzhydryl-ethane-1,2-dihydrochloride). a positive allosteric modulator of metabotropic glutamate receptor subtype 7, was examined in a model of epileptic afterdischarges elicited in three age groups of immature rats ( 12, 18 and 25 days old) by electrical stimulation of sensorimotor cortex. AMN082 did not exhibit ail anticonvulsant action against spike-and-wave type of afterdischarges generated in thalamocortical system; on the contrary, moderate proconvulsant action Was found in 12- and 18-day-old rats (more marked prolongation of afterdischarges with repeated stimulations). On the other hand, AMN082 significantly shortened the second type of afterdischarges reflecting spread of epileptic activity into limbic system frequently recorded in 25-day-old rats. These contradictory results mean that AMN082 will not be a broad-spectrum anticonvulsant but it might be useful as a seizure-specific antiepileptic drug. (C) 2009 Elsevier B.V. All rights reserved","[Mares, Pavel] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CZ-14220 Prague 4, Czech Republic; Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Mares, P, Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Videnska 1083, CZ-14220 Prague 4, Czech Republic","maresp@biomed.cas.cz","Grant Agency of the Czech Republic [305/06/1188]; Academy of Sciences of the Czech Republic [AVOZ 50110905]","This Study Was Supported by a grant No. 305/06/1188 of the Grant Agency of the Czech Republic and by research project AVOZ 50110905 of the Academy of Sciences of the Czech Republic.",null,25,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0014-2999",null,"10.1016/j.ejphar.2009.09.009","EUR J PHARMACOL","Eur. J. Pharmacol.","NOV 25",2009,623,"2010-03-01",null,null,null,37,40,null,null,4,"Pharmacology & Pharmacy","520NZ","ISI:000271853500006"]
["nemá","J","Barbato, A; Frischer, T; Kuehni, CE; Snijders, D; Azevedo, I; Baktai, G; Bartoloni, L; Eber, E; Escribano, A; Haarman, E; Hesselmar, B; Hogg, C; Jorissen, M; Lucas, J; Nielsen, KG; O'Callaghan, C; Omran, H; Pohunek, P; Strippoli, MPF; Bush, A",null,null,null,"Barbato, A.; Frischer, T.; Kuehni, C. E.; Snijders, D.; Azevedo, I.; Baktai, G.; Bartoloni, L.; Eber, E.; Escribano, A.; Haarman, E.; Hesselmar, B.; Hogg, C.; Jorissen, M.; Lucas, J.; Nielsen, K. G.; O'Callaghan, C.; Omran, H.; Pohunek, P.; Strippoli, M-P. F.; Bush, A.",null,"Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children","EUROPEAN RESPIRATORY JOURNAL",null,"English","Review",null,null,null,null,null,"Consensus statement; diagnosis; primary ciliary dyskinesia; treatment","LINKED RETINITIS-PIGMENTOSA; CONGENITAL HEART-DISEASE; RECOMBINANT HUMAN DNASE; SITUS-INVERSUS TOTALIS; OUTER DYNEIN ARM; KARTAGENERS-SYNDROME; CYSTIC-FIBROSIS; MUCOCILIARY CLEARANCE; IMMOTILE-CILIA; LUNG TRANSPLANTATION","Primary ciliary dyskinesia (PCD) is associated with abnormal ciliary structure and function, which results in retention of mucus and bacteria in the respiratory tract, leading to chronic oto-sino-pulmonary disease, situs abnormalities and abnormal sperm motility. The diagnosis of PCD requires the presence of the characteristic clinical phenotype and either specific ultrastructural ciliary defects identified by transmission electron microscopy or evidence of abnormal ciliary function. Although the management of children affected with PCD remains uncertain and evidence is limited, it remains important to follow-up these patients with an adequate and shared care system in order to prevent future lung damage. This European Respiratory Society consensus statement on the management of children with PCD formulates recommendations regarding diagnostic and therapeutic approaches in order to permit a more accurate approach in these patients. Large well-designed randomised controlled trials, with clear description of patients, are required in order to improve these recommendations on diagnostic and treatment approaches in this disease.","[Barbato, A.] Univ Padua, Dept Paediat, Paediat Pulmonol Unit, I-35128 Padua, Italy; [Frischer, T.] Univ Vienna, Dept Paediat, Vienna, Austria; [Eber, E.] Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria; [Kuehni, C. E.; Strippoli, M-P. F.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Bartoloni, L.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; [Azevedo, I.] Hosp Sao Joao, Dept Paediat, Oporto, Portugal; [Baktai, G.] Paediat Inst Svabhegy, Budapest, Hungary; [Escribano, A.] Univ Valencia, Dept Paediat, Paediat Pulmonol Unit, Clin Univ Hosp, Valencia, Spain; [Haarman, E.] Emma Childrens Hosp, Acad Med Ctr, Dept Paediat & Neonatol, Amsterdam, Netherlands; [Hesselmar, B.] Gothenburg Univ, Dept Paediat, Inst Clin Sci, Sahlgrenska Acad, Gothenburg, Sweden; [Hogg, C.; Bush, A.] Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England; [Lucas, J.] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [O'Callaghan, C.] Univ Leicester, Div Paediat, Dept Infect Immun & Inflammat, Leicester, Leics, England; [O'Callaghan, C.] Leicester Childrens Hosp, Leicester, Leics, England; [Jorissen, M.] Univ Hosp Leuven, Dept Ear Nose & Throat, Louvain, Belgium; [Nielsen, K. G.] Rigshosp, Copenhagen Univ Hosp, Paediat Pulm Serv, DK-2100 Copenhagen, Denmark; [Nielsen, K. G.] Rigshosp, Copenhagen Univ Hosp, Cyst Fibrosis Ctr, Dept Paediat,Clin 1,Juliane Marie Ctr, DK-2100 Copenhagen, Denmark; [Omran, H.] Univ Hosp Freiburg, Dept Paediat & Adolescent Med, Freiburg, Germany; [Pohunek, P.] Univ Hosp Motol, Dept Paediat, Prague, Czech Republic; [Pohunek, P.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic","Barbato, A, Univ Padua, Dept Paediat, Paediat Pulmonol Unit, Via Giustiniani 3, I-35128 Padua, Italy","barbato@pediatria.unipd.it",null,null,null,115,0,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,"10.1183/09031936.00176608","EUR RESP J","Eur. Resp. J.","DEC",2009,34,6,null,null,null,1264,1276,null,null,13,"Respiratory System","530XD","ISI:000272625000005"]
["nemá","J","Sobotkova, A; Masova-Chrastinova, L; Suttnar, J; Stikarova, J; Majek, P; Reicheltova, Z; Kotlin, R; Weisel, JW; Maly, M; Dyr, JE",null,null,null,"Sobotkova, Alzbeta; Masova-Chrastinova, Leona; Suttnar, Jiri; Stikarova, Jana; Majek, Pavel; Reicheltova, Zuzana; Kotlin, Roman; Weisel, John W.; Maly, Martin; Dyr, Jan E.",null,"Antioxidants change platelet responses to various stimulating events","FREE RADICAL BIOLOGY AND MEDICINE",null,"English","Article",null,null,null,null,null,"Platelet; Adhesion; Aggregation; Resveratrol; Trolox; Free radicals","PERFORMANCE LIQUID-CHROMATOGRAPHY; BLOOD-PLATELETS; VITAMIN-E; HYDROGEN-PEROXIDE; WHOLE-BLOOD; DIABETIC-PATIENTS; FLOW CONDITIONS; AGGREGATION; RESVERATROL; ACTIVATION","The role of platelets in hemostasis may be influenced by alteration of the platelet redox state-the presence of antioxidants and the formation of reactive oxygen and nitrogen species. We investigated the effects of two antioxidants, resveratrol and trolox, on platelet activation. Trolox and resveratrol inhibited aggregation of washed platelets and platelet-rich plasma activated by ADP, collagen, and thrombin receptor-activating peptide. Resveratrol was a more effective agent in reducing platelet static and dynamic adhesion in comparison with trolox. The antioxidant capacity of resveratrol was, however, the same as that of trolox. After incubation of platelets with antioxidants, the resveratrol intraplatelet concentration was about five times lower than the intracellular concentration of trolox. Although both antioxidants comparably lowered hydroxyl radical and malondialdehyde production in platelets stimulated with collagen, TxB(2) levels were decreased by resveratrol much more effectively than by trolox. Cyclooxygenase I was inhibited by resveratrol and not by trolox. Our data indicate that antioxidants, apart from nonspecific redox or radical-quenching mechanisms, inhibit platelet activation also by specific interaction with target proteins. The results also show the importance Of Studying platelet activation under conditions of real blood flow in contact with reactive surfaces, e.g., using dynamic adhesion experiments. (C) 2009 Elsevier Inc. All rights reserved.","[Sobotkova, Alzbeta; Masova-Chrastinova, Leona; Suttnar, Jiri; Stikarova, Jana; Majek, Pavel; Reicheltova, Zuzana; Kotlin, Roman; Dyr, Jan E.] Inst Hematol & Blood Transfus, Prague 12800 2, Czech Republic; [Weisel, John W.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Maly, Martin] Motol Univ Hosp, Dept Cardiol, Prague 15006 5, Czech Republic","Masova-Chrastinova, L, Inst Hematol & Blood Transfus, U Nemocnice 1, Prague 12800 2, Czech Republic","leona.chrastinova@uhkt.cz","Ministry of Health, Czech Republic [NS10633-3/2009, MZ 02373601]; Academy of Sciences, Czech Republic [KAN200670701]","This study was supported by Grants NS10633-3/2009 and MZ 02373601 from the Ministry of Health, Czech Republic, and by Grant KAN200670701 from the Academy of Sciences, Czech Republic.",null,43,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0891-5849",null,"10.1016/j.freeradbiomed.2009.09.015","FREE RADICAL BIOL MED","Free Radic. Biol. Med.","DEC 15",2009,47,12,null,null,null,1707,1714,null,null,8,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","528II","ISI:000272436900002"]
["nemá","J","Dorfman, R; Li, WL; Sun, L; Lin, F; Wang, YQ; Sandford, A; Pare, PD; McKay, K; Kayserova, H; Piskackova, T; Macek, M; Czerska, K; Sands, D; Tiddens, H; Margarit, S; Repetto, G; Sontag, MK; Accurso, FJ; Blackman, S; Cutting, GR; Tsui, LC; Corey, M; Durie, P; Zielenski, J; Strug, LJ",null,null,null,"Dorfman, Ruslan; Li, Weili; Sun, Lei; Lin, Fan; Wang, Yongqian; Sandford, Andrew; Pare, Peter D.; McKay, Karen; Kayserova, Hana; Piskackova, Tereza; Macek, Milan; Czerska, Kamila; Sands, Dorota; Tiddens, Harm; Margarit, Sonia; Repetto, Gabriela; Sontag, Marci K.; Accurso, Frank J.; Blackman, Scott; Cutting, Garry R.; Tsui, Lap-Chee; Corey, Mary; Durie, Peter; Zielenski, Julian; Strug, Lisa J.",null,"Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results","HUMAN GENETICS",null,"English","Article",null,null,null,null,null,null,"SINGLE-LOCUS APPROXIMATIONS; PANCREATIC-DUCT CELLS; LOD-SCORE ANALYSIS; LINKAGE ANALYSIS; HAPLOTYPE RECONSTRUCTION; OLIGOGENIC TRAITS; DISEASE SEVERITY; GENOTYPE DATA; I ERROR; ASSOCIATION","Cystic fibrosis (CF) is a monogenic disease due to mutations in the CFTR gene. Yet, variability in CF disease presentation is presumed to be affected by modifier genes, such as those recently demonstrated for the pulmonary aspect. Here, we conduct a modifier gene study for meconium ileus (MI), an intestinal obstruction that occurs in 16-20% of CF newborns, providing linkage and association results from large family and case-control samples. Linkage analysis of modifier traits is different than linkage analysis of primary traits on which a sample was ascertained. Here, we articulate a source of confounding unique to modifier gene studies and provide an example of how one might overcome the confounding in the context of linkage studies. Our linkage analysis provided evidence of a MI locus on chromosome 12p13.3, which was segregating in up to 80% of MI families with at least one affected offspring (HLOD = 2.9). Fine mapping of the 12p13.3 region in a large case-control sample of pancreatic insufficient Canadian CF patients with and without MI pointed to the involvement of ADIPOR2 in MI (p = 0.002). This marker was substantially out of Hardy-Weinberg equilibrium in the cases only, and provided evidence of a cohort effect. The association with rs9300298 in the ADIPOR2 gene at the 12p13.3 locus was replicated in an independent sample of CF families. A protective locus, using the phenotype of no-MI, mapped to 4q13.3 (HLOD = 3.19), with substantial heterogeneity. A candidate gene in the region, SLC4A4, provided preliminary evidence of association (p = 0.002), warranting further follow-up studies. Our linkage approach was used to direct our fine-mapping studies, which uncovered two potential modifier genes worthy of follow-up.","[Li, Weili; Corey, Mary; Strug, Lisa J.] Hosp Sick Children, Child Hlth Evaluat Sci Program, Toronto, ON M5G 1X8, Canada; [Dorfman, Ruslan; Sun, Lei; Lin, Fan; Wang, Yongqian; Tsui, Lap-Chee; Zielenski, Julian] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; [Sun, Lei; Corey, Mary; Strug, Lisa J.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Sandford, Andrew; Pare, Peter D.] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada; [McKay, Karen] Childrens Hosp Westmead, Dept Resp Med, Westmead, NSW, Australia; [Kayserova, Hana] Slovak Acad Sci, Inst Mol Physiol & Genet, Bratislava 83334, Slovakia; [Piskackova, Tereza; Macek, Milan] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Czerska, Kamila; Sands, Dorota] Inst Mother & Child Hlth, Warsaw, Poland; [Tiddens, Harm] Sophia Childrens Univ Hosp, Erasmus Med Ctr Rotterdam, Rotterdam, Netherlands; [Margarit, Sonia; Repetto, Gabriela] Univ Desarrollo Santiago, Clin Alemana, Ctr Human Genet, Santiago, Chile; [Sontag, Marci K.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Accurso, Frank J.] Univ Colorado Denver, Childrens Hosp, Mike McMorris Cyst Fibrosis Care & Res Ctr, Dept Pediat, Aurora, CO 80045 USA; [Blackman, Scott; Cutting, Garry R.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA; [Tsui, Lap-Chee] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; [Durie, Peter] Hosp Sick Children, Program Physiol & Expt Med, Toronto, ON M5G 1X8, Canada","Strug, LJ, Hosp Sick Children, Child Hlth Evaluat Sci Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada","ruslan.dorfman@gmail.com; lisa.strug@utoronto.ca","Genome Canada through the Ontario Genomics Institute [2004-OGI-3-05]; Canadian Cystic Fibrosis Foundation ; Ontario Research Fund ; NIH [HG-0004314]; Natural Sciences and Engineering Research Council ; Canadian Institutes of Health Research ; Ontario Women's Health Council ; [VZFNM00064203]","This project was supported by Genome Canada through the Ontario Genomics Institute per research agreement 2004-OGI-3-05, by the Canadian Cystic Fibrosis Foundation, by the Ontario Research Fund-Research Excellence Program. L.J. Strug is supported by the NIH (HG-0004314) and the Natural Sciences and Engineering Research Council. R. Dorfman was supported by the joint Fellowship of Canadian Institutes of Health Research and Ontario Women's Health Council. Support by VZFNM00064203 to Milan Macek. The authors express gratitude to all CF patients and their families for participating in this study. The authors thank Nicole Anderson, Jennifer Breaton, Mary Cristofi, Roxanne Rousseau, and Michael Van Spall for their exceptional effort in recruiting and ascertaining Canadian CF families for the study, as well Drs. Miroslava Balascakova, Vera Vavrova and Dana Zemkova for provision of patients with MI. The authors are indebted to the following individuals from member institutions of the Canadian Consortium for CF Genetic Studies for ascertaining patient data and blood samples from CF patients and their families: S. Aaron, P. Barrett, B. Beaurivage, Y. Berthiaume, P. Bigonesse, M. Boland, L. Boucher, J. Boucher, S. Bourgh, F. Brosseau, N.E. Brown, C. Brunoro, N. Bureau, A. Cantin, L. Charette, G. Cote, A. Dale, G. Davidson, K. Devesceri, R. Dicaire, V. Fauvel, A. Freitag, D. N. Garey, M. Gaul, W. Gervais, J. Gjevre, F. Gosse, A. Gravelle, B. Habbick, R. Hennessey, S. B. Holmes, J. Hopkins, D. Hughes, M. Jackson, J. Jacob, A. Jeanneret, P. Kean, W. Kepron, T. Kovesi, V. J. Kumar, L. Lands, M. LaPerriere, J. Leong, R. Levesque, D. Lougheed, M. Lowe, B. Lyttle, K. Malhotra, J. E. Marcotte, S. Marsolais, C. Martineau, E. Matouk, D. McCulloch, R. T. Michael, M. Montgomery, R. Morris, E. M. Nakielna, F. Paquet, H. Pasterkamp, N. Patterson, L. Pedder, L. Peterson, N. Petit, C. Piche, M. Plante, H. R. Rabin, K. Ramlall, F. Raymong, L. Rivard, G. Rivard, M. Roussin, M. Ruel, J. Salgado, L. Semple, E. Sheppard, F. Simard, A. Smith, M. Solomon, R. Stackhouse, J. Tabak, L. Taylor, A. Tsang, E. Tullis, C. Turtle, K. Vandamheen, M. van Spall, R. van Wylick, I. Waters, T. Wells, S. Wiltse, and P. Zuberbuhler.",null,58,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6717",null,"10.1007/s00439-009-0724-8","HUM GENET","Hum. Genet.","DEC",2009,126,6,null,null,null,763,778,null,null,16,"Genetics & Heredity","521MG","ISI:000271924900004"]
["nemá","J","Krepela, E; Dankova, P; Moravcikova, E; Krepelova, A; Prochazka, J; Cermak, J; Schutzner, J; Zatloukal, P; Benkova, K",null,null,null,"Krepela, Evzen; Dankova, Petra; Moravcikova, Erika; Krepelova, Anna; Prochazka, Jan; Cermak, Jan; Schutzner, Jan; Zatloukal, Petr; Benkova, Kamila",null,"Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma","INTERNATIONAL JOURNAL OF ONCOLOGY",null,"English","Article",null,null,null,null,null,"non-small cell lung carcinoma; survivin; hepatitis B X-interacting protein; X-chromosome-linked inhibitor of apoptosis protein; expression; apoptosis","X-LINKED INHIBITOR; NF-KAPPA-B; HUMAN CANCER-CELLS; GENE-EXPRESSION; RADIATION SENSITIZATION; PRECLINICAL MODELS; ENDOTHELIAL-CELLS; CASPASE ACTIVITY; SMAC MIMETICS; IAP","Members of the inhibitor of apoptosis protein (IAP) family, survivin and X-chromosome-linked IAP (XIAP), contribute to apoptosis resistance of cancer cells, and in increase in their expression may elevate the apoptotic threshold of malignant tumours during their growth and progression. In the present study, we investigated the expression status of survivin and its interactants hepatitis B X-interacting protein (HBXIP) and XIAP in non-small cell lung carcinoma (NSCLC) cell lines and NSCLC tumours and matched lungs from surgically treated patients in relation to their clinicopathological data. The expression of survivin, HBXIP and XIAP mRNAs was quantitated by real-time RT-PCR. The expression of survivin and XIAP proteins was analysed by Western blotting and ELISA. Survivin mRNA and protein levels were highly upregulated in NSCLC cells and tissues as compared to the lungs. In fact, the levels of survivin mRNA and protein in the tumours were more than 10-fold higher in 96 (64%) and 72 (82%) of the 150 and 88 examined NSCLC patients, respectively. The expression of survivin mRNA was higher in squamous cell lung carcinomas than in tune, adenocarcinomas (LACs; P=0.003) and in less-differentiated tumours than in well-differentiated ones (P=0.007). The level of survivin protein was higher in stage IB and stage II+III tumours (P=0.049 and P=0.044), than in stage IA tumours. The BIRC5 promoter polymorphism at nucleotide -31 did not influence the expression of survivin mRNA and protein in NSCLC cells and tumours. HBXIP mRNA was abundantly expressed in NSCLC cell lines and NSCLC tumours and lungs, while its level was comparable in the tumours and lungs. The expression of XIAP mRNA in NSCLC cell lines and NSCLC tumours and lungs was not significantly different. However, the expression of XIAP protein was higher in NSCLC tumours, particularly in LACs, as compared to the lungs (P=0.017 and P=0.004). In conclusion, the overexpression of survivin in the majority of NSCLCs together with the abundant or upregulated expression of HBXIP and XIAP suggest that tumours are endowed with resistance against a variety of apoptosis-inducing conditions.","[Krepela, Evzen; Zatloukal, Petr] Univ Hosp Bulovka, Dept Pneumol & Thorac Surg, Div Pneumol, Prague 18081 8, Czech Republic; [Cermak, Jan] Univ Hosp Bulovka, Div Surg, Prague 18081 8, Czech Republic; [Krepela, Evzen; Dankova, Petra; Moravcikova, Erika; Prochazka, Jan] Univ Hosp Bulovka, Labs Mol & Cell Biol, Prague 18081 8, Czech Republic; [Benkova, Kamila] Univ Hosp Bulovka, Dept Pathol, Prague 18081 8, Czech Republic; [Krepelova, Anna] Univ Hosp Motol, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic; [Schutzner, Jan] Univ Hosp Motol, Fac Med 1, Dept Surg 3, Prague, Czech Republic","Krepela, E, Univ Hosp Bulovka, Dept Pneumol & Thorac Surg, Div Pneumol, Budinova 2, Prague 18081 8, Czech Republic","krepelae@fnb.cz","Ministry of Health, Czech Republic [NR/7860-5, MZO 00064211]","This work was supported by a grant (no. NR/7860-5) and an institutional research project (no. MZO 00064211) from the Ministry of Health, Czech Republic.",null,89,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1019-6439",null,"10.3892/ijo_00000464","INT J ONCOL","Int. J. Oncol.","DEC",2009,35,6,null,null,null,1449,1462,null,null,14,"Oncology","518QQ","ISI:000271708600026"]
["nemá","J","Schejbalova, A; Havlas, V; Trc, T",null,null,null,"Schejbalova, Alena; Havlas, Vojtech; Trc, Tomas",null,"Irreducible dislocation of the hip in cerebral palsy patients treated by Schanz proximal femoral valgus osteotomy","INTERNATIONAL ORTHOPAEDICS",null,"English","Article",null,null,null,null,null,null,"HEAD RESECTION; UNSTABLE HIPS; PAINFUL HIP; CHILDREN; ARTHRODESIS; REPLACEMENT; SUBLUXATION","Palliative Schanz proximal femoral valgus osteotomy is considered a common option for treatment of irreducible hip dislocation in cerebral palsy. From 1992 to 2005, Schanz osteotomy was indicated on 55 occasions in 35 nonambulatory patients with the quadriplegic form of cerebral palsy aged 9-18. Postoperatively, the main emphasis focussed on clinical presentation, improvement of hip range of motion, and pain relief. X-rays were carried out at three, six, and 12 months postoperatively with subsequent average follow up 98 +/- 4.5 months. In all patients, the range of hip abduction and flexion increased. In 54 (98.2%) cases painful symptoms significantly improved. One patient (1.8%) had a subsequent femoral head excision because of persistent hip pain. Transient hip pain persisted in four patients (7.3%). Schanz valgus osteotomy improves the hip range of motion, relieves pain, and facilitates care of the patient. Schanz femoral osteotomy is a less invasive method compared to proximal femoral excision and should preferably be used in older children with neurogenic hip dislocation in whom reconstructive surgery is not indicated.","[Schejbalova, Alena; Havlas, Vojtech; Trc, Tomas] Charles Univ Prague, Dept Orthopaed Surg, Sch Med 2, Prague 15006 5, Czech Republic; [Havlas, Vojtech] Dumfries & Galloway Royal Infirm, Dept Orthopaed Surg, Dumfries, Scotland","Havlas, V, Charles Univ Prague, Dept Orthopaed Surg, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","vojtech.havlas@seznam.cz","IGA MZ NR [8333-3]","The work was supported by grant IGA MZ NR 8333-3.",null,25,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,"10.1007/s00264-008-0676-y","INT ORTHOP","Int. Orthop.","DEC",2009,33,6,null,null,null,1713,1717,null,null,5,"Orthopedics","524WE","ISI:000272174300040"]
["nemá","J","Zamecnik, J; Vesely, D; Jakubicka, B; Cibula, A; Pitha, J; Schutzner, J; Mazanec, R",null,null,null,"Zamecnik, Josef; Vesely, Dan; Jakubicka, Branislav; Cibula, Adrian; Pitha, Jiri; Schutzner, Jan; Mazanec, Radim",null,"Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: steroid-induced change with prognostic impact","JOURNAL OF CELLULAR AND MOLECULAR MEDICINE",null,"English","Article",null,null,null,null,null,"Myasthenia gravis; muscle atrophy; corticosteroids; prognosis; morphometry","HISTOGRAPHIC ANALYSIS; MYOPATHY; EXPRESSION; BIOPSIES; THYMOMA","Selective atrophy of type II muscle fibres has been long recognized as an enigmatic but consistent feature of myasthenia gravis (MG) muscle; however, the pathophysiology and the mechanism of that change have remained obscure. In the present study, the results of histomorphometric analysis performed on muscle biopsies from 207 thymectomized seropositive MG patients were correlated with clinical features of MG to demonstrate possible pathophysiological associations and potential prognostic impact. The atrophy of type II fibres was verified in 35 cases (16.9%), being more pronounced in fibres of IIB subtype. It was neither significantly associated with the duration and severity of MG nor with the age of the patients. On the other hand, we demonstrated that the atrophy associated with long-term treatment with corticosteroids, and correlated with increasing doses. Thus, we suppose that the atrophy of type II muscle fibres in seropositive MG is steroid induced rather than MG-associated event. Although the MG patients with atrophy of type II fibres did not differ from the remaining MG cases in terms of improvement in the disease during the follow-up period, our analysis provides clear evidence that they presented a significantly slower tendency to reach an asymptomatic state after thymectomy. Therefore, the steroid-induced atrophy of type II fibres in MG muscle might be considered to be an unfavourable prognostic factor.","[Zamecnik, Josef; Vesely, Dan; Jakubicka, Branislav; Cibula, Adrian] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006, Czech Republic; [Zamecnik, Josef; Vesely, Dan; Jakubicka, Branislav; Cibula, Adrian; Schutzner, Jan; Mazanec, Radim] Univ Hosp Motol, Prague, Czech Republic; [Vesely, Dan] Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Vesely, Dan] Univ Hosp Bulovka, Bulovka, Czech Republic; [Pitha, Jiri] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 15006, Czech Republic; [Pitha, Jiri] Charles Univ Prague, Dept Neurol, Fac Med 3, Prague 15006, Czech Republic; [Schutzner, Jan] Charles Univ Prague, Dept Surg 3, Fac Med 1, CR-11636 Prague 1, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 15006, Czech Republic","Zamecnik, J, Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","josef.zamecnik@lfmotol.cuni.cz","Ministry of Health of the Czech Republic [IGA MZCR NR/8924-3, VZ FNM 00064203]","The study was supported by the Grant of Ministry of Health of the Czech Republic No. IGA MZCR NR/8924-3 and by the Research Project No. VZ FNM 00064203.",null,35,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1582-1838",null,"10.1111/j.1582-4934.2008.00431.x","J CELL MOL MED","J. Cell. Mol. Med.","AUG",2009,13,"8B",null,null,null,2008,2018,null,null,11,"Cell Biology; Medicine, Research & Experimental","525CN","ISI:000272190800036"]
["nemá","J","Eckerle, S; Brune, V; Doring, C; Tiacci, E; Bohle, V; Sundstrom, C; Kodet, R; Paulli, M; Falini, B; Klapper, W; Chaubert, AB; Willenbrock, K; Metzler, D; Brauninger, A; Kuppers, R; Hansmann, ML",null,null,null,"Eckerle, S.; Brune, V.; Doering, C.; Tiacci, E.; Bohle, V.; Sundstrom, C.; Kodet, R.; Paulli, M.; Falini, B.; Klapper, W.; Chaubert, A. B.; Willenbrock, K.; Metzler, D.; Braeuninger, A.; Kueppers, R.; Hansmann, M. -L",null,"Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma","LEUKEMIA",null,"English","Article",null,null,null,null,null,"anaplastic large cell lymphoma; Hodgkin lymphoma; gene expression profiling; lymphoma pathogenesis","NF-KAPPA-B; REED-STERNBERG CELLS; T-CELL; CLASSICAL HODGKIN; MOLECULAR-BIOLOGY; CDNA ARRAYS; DISEASE; TRANSCRIPTION; PROMOTER; FEATURES","Anaplastic large cell lymphoma (ALCL) is a main type of T-cell lymphomas and comprises three distinct entities: systemic anaplastic lymphoma kinase (ALK) positive, systemic ALK(-) and cutaneous ALK(-) ALCL (cALCL). Little is known about their pathogenesis and their cellular origin, and morphological and immunophenotypical overlap exists between ALK(-) ALCL and classical Hodgkin lymphoma (cHL). We conducted gene expression profiling of microdissected lymphoma cells of five ALK(+) and four ALK(-) systemic ALCL, seven cALCL and sixteen cHL, and of eight subsets of normal T and NK cells. The analysis supports a derivation of ALCL from activated T cells, but the lymphoma cells acquired a gene expression pattern hampering an assignment to a CD4(+), CD8(+) or CD30(+) T-cell origin. Indeed, ALCL display a down-modulation of many T-cell characteristic molecules. All ALCL types show significant expression of NF kappa B target genes and upregulation of genes involved in oncogenesis (e. g. EZH2). Surprisingly, few genes are differentially expressed between systemic and cALCL despite their different clinical behaviour, and between ALK(-) ALCL and cHL despite their different cellular origin. ALK(+) ALCL are characterized by expression of genes regulated by pathways constitutively activated by ALK. This study provides multiple novel insights into the molecular biology and pathogenesis of ALCL. Leukemia (2009) 23, 2129-2138; doi: 10.1038/leu.2009.161; published online 6 August 2009","[Eckerle, S.; Brune, V.; Tiacci, E.; Bohle, V.; Kueppers, R.] Univ Duisburg Essen, Inst Cell Biol Canc Res, Sch Med, D-45122 Essen, Germany; [Eckerle, S.; Brune, V.; Doering, C.; Willenbrock, K.; Braeuninger, A.; Hansmann, M. -L] Goethe Univ Frankfurt, Senckenberg Inst Pathol, Sch Med, Frankfurt, Germany; [Doering, C.; Metzler, D.] Goethe Univ Frankfurt, Inst Informat, Frankfurt, Germany; [Sundstrom, C.] Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden; [Kodet, R.] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Paulli, M.] Univ Pavia, Policlin San Matteo, Inst Pathol Anat, I-27100 Pavia, Italy; [Falini, B.] Univ Perugia, Inst Hematol, I-06100 Perugia, Italy; [Klapper, W.] Univ Hosp Schleswig Holstein, Haematopathol Sect, Inst Pathol, Kiel, Germany; [Chaubert, A. B.] CHU Vaudois, Inst Pathol, CH-1011 Lausanne, Switzerland; [Braeuninger, A.] Univ Munster, Inst Pathol, Munster, Germany; [Klapper, W.] Univ Hosp Schleswig Holstein, Lymph Node Registry, Kiel, Germany","Kuppers, R, Univ Duisburg Essen, Inst Cell Biol Canc Res, Sch Med, Virchowstr 173, D-45122 Essen, Germany","ralf.kueppers@uk-essen.de","Deutsche Forschungsgemeinschaft [KU1315/5-2, BR1238/6-2 and 6-3, WI2015/1-1]; Deutsche Krebshilfe and the Associazione Italiana per la Ricerca sul Cancro (AIRC) ; German Jose Carreras Leukemia Foundation [F 05/01]","We highly appreciate the excellent technical assistance of Ralf Lieberz, Nicole Dieckert, Yvonne Michel, Ingrid Kremser and Klaus Lennartz. We thank Dr Detlef Gussow and Melanie Kuhnl from Merck KGaA, Darmstadt, Germany for the opportunity to scan the Affymetrix arrays in their laboratory. This work was supported by grants from the Deutsche Forschungsgemeinschaft (KU1315/5-2, BR1238/6-2 and 6-3 and WI2015/1-1), the Deutsche Krebshilfe and the Associazione Italiana per la Ricerca sul Cancro (AIRC). Enrico Tiacci was recipient of a fellowship (F 05/01) granted by the German Jose Carreras Leukemia Foundation.",null,43,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.161","LEUKEMIA","Leukemia","NOV",2009,23,11,null,null,null,2129,2138,null,null,10,"Oncology; Hematology","518BV","ISI:000271666000021"]
["nemá","J","Vrana, D; Pikhart, H; Mohelnikova-Duchonova, B; Holcatova, I; Strnad, R; Slamova, A; Schejbalova, M; Ryska, M; Susova, S; Soucek, P",null,null,null,"Vrana, D.; Pikhart, H.; Mohelnikova-Duchonova, B.; Holcatova, I.; Strnad, R.; Slamova, A.; Schejbalova, M.; Ryska, M.; Susova, S.; Soucek, P.",null,"The association between glutathione S-transferase gene polymorphisms and pancreatic cancer in a central European Slavonic population","MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS",null,"English","Article",null,null,null,null,null,"Glutathione S-transferases; Pancreas; Cancer; Risk","RISK; ADENOCARCINOMA; GSTM1; METAANALYSIS; GSTT1","In the first case-control study on pancreatic cancer conducted on 253 cases and 403 controls in the Czech Republic we observed that the GSTP1-codon 105 Val variant allele and the GSTT1-null genotype were associated with an elevated risk for pancreatic cancer (OR = 1.38; 95%CI = 0.96-1.97 and OR = 1.56; 95%CI = 0.93-2.61, respectively). Combination of GSTT1-null and GSTP1-codon 105 Val variants further increased the risk for pancreatic cancer (OR = 2.50; 95%CI = 1.20-5.20). In conclusion, this study suggests population-specific associations of polymorphisms in key biotransformation genes with elevated risk for pancreatic cancer. (C) 2009 Elsevier B.V. All rights reserved.","[Vrana, D.; Mohelnikova-Duchonova, B.; Susova, S.; Soucek, P.] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Pikhart, H.] UCL, Int Inst Soc & Hlth, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Holcatova, I.; Slamova, A.; Schejbalova, M.] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, CR-11636 Prague, Czech Republic; [Strnad, R.; Ryska, M.] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic","Soucek, P, Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic","psoucek@szu.cz","Ministry of Health Czech Republic [8563-5, 9422-3]","This work was supported by the Grant Agency of the Ministry of Health Czech Republic, grants No. 8563-5 and 9422-3.",null,17,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1383-5718",null,"10.1016/j.mrgentox.2009.09.005","MUTAT RES-GENET TOXICOL E M","Mutat. Res. Genet. Toxicol. Environ. Mutagen.","NOV-DEC",2009,680,"2010-02-01",null,null,"Sp. Iss. SI",78,81,null,null,4,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","534DK","ISI:000272875500012"]
["nemá","J","Hyrsl, L; Zavada, J; Zavadova, Z; Kawaciuk, I; Vesely, S; Skapa, P",null,null,null,"Hyrsl, L.; Zavada, J.; Zavadova, Z.; Kawaciuk, I.; Vesely, S.; Skapa, P.",null,"Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract","NEOPLASMA",null,"English","Article",null,null,null,null,null,"Carbonic anhydrase IX; diagnostic antigen; transitional cell carcinoma","HYPOXIA; IDENTIFICATION; CANCER; SERUM","We investigated the expression of cell-associated CAIX protein in histological sections of the transitional cell carcinoma (TCC) of the urinary tract and of the soluble form of CAIX (s-CAIX) shed by the tumor into the serum and urine of TCC patients. A total of 23 patients with histologically confirmed TCC or squamous cell carcinoma (SCC) were enrolled in the pilot study. Sixteen healthy individuals served as controls. Membrane-bound CAIX was present in the tumor cells near the endoluminal surface. Necrosis was observed in only 4 samples. Using Western blots, s-CAIX concentrated from urine was visualized as a double band at 50 and 54 kDa. In most cases, the presence of s-CAIX in the urine correlated with CAIX expression in the tumor. On the other hand, s-CAIX did not exceed the normal level in the serum of TCC patients. Urine from patients with TCC of the urinary bladder and renal pelvis contained s-CAIX, allowing the detection of tumors in approximately 70% of the patients. Moreover, two additional patients with suspected, but unconfirmed bladder tumor, with s-CAIX detected in urine, developed tumors identified as TCC within six months. We suggest that after a simple, rapid and sensitive test, monitoring s-CAIX levels in urine will be developed, it may be useful for early detection of relapse in patients following transurethral tumor resection.","[Hyrsl, L.; Kawaciuk, I.; Vesely, S.] Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic; [Zavada, J.; Zavadova, Z.] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Prague, Czech Republic; [Skapa, P.] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Hyrsl, L.; Kawaciuk, I.; Vesely, S.; Skapa, P.] Hosp Motol, Prague, Czech Republic","Hyrsl, L, Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic","lhyrsl@volny.cz","Bayer Diagnostics, USA ","This research was supported by Bayer Diagnostics, USA. The authors thank Hillary Hoffman for language correction.",null,13,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,"10.4149/neo_2009_04_298","NEOPLASMA","Neoplasma",null,2009,56,4,null,null,null,298,302,null,null,5,"Oncology","522IM","ISI:000271991100004"]
["nemá","J","Sliva, J; Dolezal, T; Sykora, D; Vosmanska, M; Krsiak, M",null,null,null,"Sliva, Jiri; Dolezal, Tomas; Sykora, David; Vosmanska, Magda; Krsiak, Miloslav",null,"Guaifenesin enhances the analgesic potency of ibuprofen, nimesulide and celecoxib in mice","NEUROENDOCRINOLOGY LETTERS",null,"English","Article",null,null,null,null,null,"ibuprofen; nimesulide; celecoxib; guaifenesin; pain; combination analgesics","PARACETAMOL; DONKEYS; ETHER; MOUSE","OBJECTIVES: Previously, we found that guaifenesin enhances analgesia induced by paracetamol. The aim of the present study was to determine whether guaifenesin is able to also increase analgesic activity in the non-steroid anti-inflammatory drugs ibuprofen, nimesulide and celecoxib. In addition we investigated the influence of guaifenesin on plasma levels of nimesulide. METHODS: A model of visceral pain consisting of intraperitoneal injection of acetic acid (writhing test) was used. Levels of nimesulide in plasma were measured by HPLC. All drugs were given orally and tested in mice. RESULTS: Guaifenesin alone did not produce any antinociceptive effect. Simultaneous administration of guaifenesin (200 mg/kg) and subanalgesic doses of ibuprofen (10 and 30 mg/kg), nimesulide (10 and 20 mg/kg) or celecoxib (I and 5 mg/kg) resulted in a significant antinociceptive effects. The plasma levels of nimesulide were significantly higher in combination with guaifenesin at 30, 60 and 90 min after oral administration in comparison to nimesulide monotherapy. CONCLUSION: The present results suggest that guaifenesin might enhance the analgesic activity of various non-steroidal anti-inflammatory drugs.","[Sliva, Jiri; Dolezal, Tomas; Krsiak, Miloslav] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Prague 10000 10, Czech Republic; [Sliva, Jiri] Charles Univ Prague, Fac Med 2, Dept Pharmacol, Prague 10000 10, Czech Republic; [Sykora, David; Vosmanska, Magda] Fac Chem Engn, Dept Analyt Chem, Prague, Czech Republic","Sliva, J, Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10000 10, Czech Republic","slivaj@seznam.cz","[VZ: MSM0021620816]","This study was supported by research grants VZ: MSM0021620816. The authors would like to thank to Zentiva, a. s. for the ibuprofen and nimesulide, and Pfizer Ltd. for the celecoxib used in this study.",null,18,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2009,30,3,null,null,null,352,356,null,null,5,"Endocrinology & Metabolism; Neurosciences","525FH","ISI:000272199300010"]
["nemá","J","Sedlackova, J; Vondracek, P; Hermanova, M; Zamecnik, J; Hruba, Z; Haberlova, J; Kraus, J; Marikova, T; Hedvicakova, P; Vohanka, S; Fajkusova, L",null,null,null,"Sedlackova, Jana; Vondracek, Petr; Hermanova, Marketa; Zamecnik, Josef; Hruba, Zuzana; Haberlova, Jana; Kraus, Josef; Marikova, Tat'ana; Hedvicakova, Petra; Vohanka, Stanislav; Fajkusova, Lenka",null,"Point mutations in Czech DMD/BMD patients and their phenotypic outcome","NEUROMUSCULAR DISORDERS",null,"English","Article",null,null,null,null,null,"Duchenne muscular dystrophy; DMD; BMD; Point mutation; Nonsense mediated mRNA decay","MESSENGER-RNA DECAY; DUCHENNE MUSCULAR-DYSTROPHY; LGMD2A PATIENTS; GENE; EXPRESSION; TRANSCRIPTS; SEQUENCES; DELETIONS; DISEASE; MUSCLE","Duchenne and Becker muscular dystrophies (DMD/BMD) are associated with mutations in the DMD gene. We determined the mutation status of 47 patients with dystrophinopathy without deletion or duplication in the DMD gene by screening performed by reverse transcription-PCR, protein truncation test, and DNA sequencing. We describe three patients with a mutation creating a premature termination codon (p.E55X, p.E1110X, and p.S3497PfsX2) but with a mild phenotype, which present three different ways of rescuing the DMD phenotype. In one patient we detected the insertion of a repetitive sequence AluYa5 in intron 56, which led to skipping of exon 57. Further, using quantitative analysis of DMD mRNA carrying various mutated alleles, we examine levels of mRNA degradation due to nonsense mediated mRNA decay. The quantity of dystrophin mRNA is different depending on the presence of a mutation leading to a premature termination codon, and position of the analysed mRNA region with respect to its 5' end or 3' end. Average relative amounts of DMD mRNAs carrying a premature termination codon is 48% and 17%, when using primers amplifying the 5' and 3' cDNA regions, respectively. (C) 2009 Elsevier B.V. All rights reserved.","[Sedlackova, Jana; Hruba, Zuzana; Fajkusova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, CZ-62500 Brno, Czech Republic; [Sedlackova, Jana; Fajkusova, Lenka] Masaryk Univ, Fac Sci, Dept Funct Genom & Prote, Inst Expt Biol, CS-61137 Brno, Czech Republic; [Vondracek, Petr] Univ Hosp Brno, Dept Child Neurol, Brno, Czech Republic; [Hermanova, Marketa] Univ Hosp Brno, Inst Pathol, Brno, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Zamecnik, Josef; Haberlova, Jana; Kraus, Josef; Marikova, Tat'ana; Hedvicakova, Petra] Univ Hosp Motol, Prague, Czech Republic; [Haberlova, Jana; Kraus, Josef] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague, Czech Republic; [Marikova, Tat'ana; Hedvicakova, Petra] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Vohanka, Stanislav] Univ Hosp Brno, Neurol Clin, Brno, Czech Republic","Fajkusova, L, Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Cernopolni 9, CZ-62500 Brno, Czech Republic","lfajkusova@fnbrno.cz","MSMT [LC06023]; [MSM0021622415]; [VZ FNM 00064203]","This work was supported by the project MSMT LC06023, and institutional support MSM0021622415 and VZ FNM 00064203.",null,24,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966",null,"10.1016/j.nmd.2009.08.011","NEUROMUSCULAR DISORD","Neuromusc. Disord.","NOV",2009,19,11,null,null,null,749,753,null,null,5,"Clinical Neurology; Neurosciences","522SZ","ISI:000272020400002"]
["nemá","J","Filova, E; Bullett, NA; Bacakova, L; Grausova, L; Haycock, JW; Hlucilova, J; Klima, J; Shard, A",null,null,null,"Filova, E.; Bullett, N. A.; Bacakova, L.; Grausova, L'.; Haycock, J. W.; Hlucilova, J.; Klima, J.; Shard, A.",null,"Regionally-Selective Cell Colonization of Micropatterned Surfaces Prepared by Plasma Polymerization of Acrylic Acid and 1,7-Octadiene","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Micropatterning; Plasma polymerization; Mesenchymal stem cells; Endothelial cells; Smooth muscle cells","SMOOTH-MUSCLE-CELLS; ENDOTHELIAL-CELLS; HUMAN KERATINOCYTES; IN-VITRO; GROWTH-FACTOR; ADHESION; ADSORPTION; BINDING; ACID/1,7-OCTADIENE; PROLIFERATION","Micropatterned surfaces have been used as a tool for controlling the extent and strength of cell adhesion, the direction of cell growth and the spatial distribution of cells. In this study, chemically micropatterned surfaces were prepared by successive plasma polymerization of acrylic acid (AA) and 1,7-octadiene (OD) through a mask. Rat vascular smooth muscle cells (VSMC), bovine endothelial cells (EC), porcine mesenchymal stem cells (MSC) or human skeletal muscle cells (HSKMC) were seeded on these surfaces in densities from 9,320 cells/cm(2) to 31,060 cells/cm(2). All cell types adhered and grew preferentially on the strip-like AA domains. Between day 1 and 7 after seeding, the percentage of cells on AA domains ranged from 84.5 to 63.3 % for VSMC, 85.3 to 73.5 % for EC, 98.0 to 90.0 % for MSC, and 93.6 to 55.0.% for HSKMC. The enzyme-linked immunosorbent assay (ELISA) revealed that the concentration of alpha-actin per mg of protein was significantly higher in VSMC on AA, Similarly, immunofluorescence staining of von Willebrand factor showed more apparent Weibel-Palade bodies in EC on AA domains. MSC growing on AA had better developed beta-actin cytoskeleton, although they were less stained for hyaluronan receptor (CD44). In accordance with this, MSC on AA contained a higher concentration of beta-actin, although the concentration of CD44 was lower. HSKMC growing on AA had a better developed alpha-actin cytoskeleton. These results based on four cell types suggest that plasma polymerization is a suitable method for producing spatially defined patterned surfaces for controlled cell adhesion, proliferation and maturation.","[Filova, E.] Acad Sci Czech Republic, Dept Growth & Differentiat Cell Populat, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Filova, E.; Bacakova, L.] Acad Sci Czech Republic, Cardiovasc Res Ctr, Inst Physiol Vvi, Prague 4, Czech Republic; [Bullett, N. A.; Haycock, J. W.; Shard, A.] Univ Sheffield, Dept Mat Engn, Sheffield, S Yorkshire, England; [Bullett, N. A.] CellTran Ltd, Innovat Ctr, Sheffield, S Yorkshire, England; [Hlucilova, J.; Klima, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Vvi, Libechov, Czech Republic; [Klima, J.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Filova, E, Acad Sci Czech Republic, Dept Growth & Differentiat Cell Populat, Inst Physiol, Videnska 1083, CR-14220 Prague 4, Czech Republic","filova@biomed.cas.cz","Academy of Sciences of the Czech Republic [A 5011301, KAN 101120701]","The study was supported by the Academy of Sciences of the Czech Republic (grants No. A 5011301 and KAN 101120701). We also thank Mrs. Ivana ZajanovA (Inst. Physiol., Acad. Sci. CR) for her excellent technical assistance and Mr. Robin Healey (Czech Technical University, Prague) for the language revision of the manuscript.",null,29,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,5,null,null,null,669,684,null,null,16,"Physiology","523NF","ISI:000272080200008"]
["nemá","J","Klima, J; Lacina, L; Dvorankova, B; Herrmann, D; Carnwath, JW; Niemann, H; Kaltner, H; Andre, S; Motlik, J; Gabius, HJ; Smetana, K",null,null,null,"Klima, J.; Lacina, L.; Dvorankova, B.; Herrmann, D.; Carnwath, J. W.; Niemann, H.; Kaltner, H.; Andre, S.; Motlik, J.; Gabius, H. -J.; Smetana, K., Jr.",null,"Differential Regulation of Galectin Expression/Reactivity during Wound Healing in Porcine Skin and in Cultures of Epidermal Cells with Functional Impact on Migration","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Epidermis; Keratinocytes; Lectin; Skin; Wound healing","HUMAN NEUROBLASTOMA-CELLS; ENDOGENOUS LECTINS; GANGLIOSIDE GM(1); EXPRESSION PROFILES; HUMAN KERATINOCYTES; MAMMALIAN LECTINS; TUMOR PROGRESSION; NUCLEAR PRESENCE; STEM-CELLS; N-GLYCAN","The glycophenotyping of mammalian cells with plant lectins maps aspects of the glycomic profile and disease-associated alterations. A salient step toward delineating their functional dimension is the detection of endogenous lectins. They can translate sugar-encoded changes into cellular responses. Among them, the members of the lectin family of galectins are emerging regulators of cell adhesion, migration and proliferation. Focusing on galectins-1, -3 and -7, we addressed the issue whether their expression is regulated during wound healing in porcine skin as model. A conspicuous upregulation is detected for galectin-1 in the dermis and a neoexpression in the epidermis, where an increased level of galectin-7 was also found. Applying biotinylated tissue lectins as probes, the signal intensities for accessible binding sites decreased, intimating an interaction of the cell lectin with reactive sites. In contrast, galectin-3 parameters remained rather constant. Of note, epidermal cells in culture also showed an increase in expression/presence of galectin-1, measured on the levels of mRNA and protein, in this case by Western blotting and quantitative immunocytochemistry. Used as matrix, galectin-1 conferred resistance to trypsin treatment to attached human keratinocytes and reduced migration into scratch-wound areas in vitro. This report thus presents new information on endogenous lectins in wound healing and differential regulation among the three tested cases.","[Klima, J.; Motlik, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic; [Klima, J.; Lacina, L.; Dvorankova, B.; Motlik, J.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Lacina, L.; Dvorankova, B.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Lacina, L.] Charles Univ Prague, Fac Med 1, Dept Dermatovenerol, Prague 12800 2, Czech Republic; [Herrmann, D.; Carnwath, J. W.; Niemann, H.] Inst Farm Anim Genet FAL, Dept Biotechnol, Neustadt, Germany; [Kaltner, H.; Andre, S.; Gabius, H. -J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Smetana, K, Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic","karel.smetana@lf1.cuni.cz","Ministry of Education, Youth, and Sport of the Czech Republic [MSM0021620806, 1M0538]; EC [MRTN-CT-2005-019561]; LMUexcellent ; German-Czech Collaboration in the Field of Agricultural Research [3/04]","This study was supported by the grants MSM0021620806 and 1M0538 from the Ministry of Education, Youth, and Sport of the Czech Republic, an EC grant (MRTN-CT-2005-019561) for a Marie Curie Research Training Network, the research initiative LMUexcellent and the German-Czech Collaboration in the Field of Agricultural Research (project no. 3/04). The authors are grateful to Eva Vancova, Iva Burdova and Vit Hajduch for their excellent technical assistance.",null,51,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,6,null,null,null,873,884,null,null,12,"Physiology","539YP","ISI:000273296600012"]
["nemá","J","Zaloudikova, M; Vizek, M; Herget, J",null,null,null,"Zaloudikova, M.; Vizek, M.; Herget, J.",null,"Hyperoxia Blunts Acute Hypoxia- and PGF(2a)-Induced Pulmonary Vasoconstriction in Chronically Hypoxic Rats","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Hypoxia; Hyperoxia; Isolated pulmonary arteries; Hypoxic pulmonary vasoconstriction","CA2+ SENSITIZATION; SMOOTH-MUSCLE; MECHANISM; ARTERIES; CALCIUM; LUNGS; HYPERTENSION; INJURY","We investigated the influence of oxygenation of in vitro lung preparation on the pulmonary vascular reactivity. Small pulmonary vessels isolated from adult male Wistar rats exposed for 4 days to hypoxia (F-iO2 = 0.1, group CH) were compared with those of normoxic controls (group N). The bath in the chamber of small vessel myograph was saturated with gas mixture containing either 21 % or 95 % of O-2 with 5 % CO2 and we measured the reactions of vessels to acute hypoxic challenge with 0 % O-2 or to PGF(2 alpha). We did not observe any difference of the contractile responses between both groups when the normoxic conditions were set in the bath. When the bath oxygenation was increased to 95 % O-2, the contractions induced by hypoxic challenge and PGF(2 alpha) decreased in chronically hypoxic rats and did not change in normoxic controls. We hypothesize that reduced reactivity of vessels from hypoxic rats in hyperoxia results from the effect of chronic hypoxia on Ca2+ signaling in the vascular smooth muscle, which is modulated by increased free radical production during the exposure to chronic hypoxia and further hyperoxia.","[Zaloudikova, M.; Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Prague 15006 5, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15006, Czech Republic; [Zaloudikova, M.; Vizek, M.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Zaloudikova, M, Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Plzenska 130-221, Prague 15006 5, Czech Republic","marie.zaloudikova@lfmotol.cuni.cz","GACR [305/06/P385, 305/05/08/108, 1M510]","This study was partially supported by grants GACR 305/06/P385, GACR 305/05/08/108, Center 1M510.",null,20,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,6,null,null,null,917,920,null,null,4,"Physiology","539YP","ISI:000273296600018"]
["nemá","J","Kuncova, K; Janda, A; Kasal, P; Zamecnik, J",null,null,null,"Kuncova, Klara; Janda, Ales; Kasal, Pavel; Zamecnik, Josef",null,"Immunohistochemical Prognostic Markers in Intracranial Ependymomas: Systematic Review and Meta-Analysis","PATHOLOGY & ONCOLOGY RESEARCH",null,"English","Review",null,null,null,null,null,"Ependymoma; Immunohistochemistry; Ki-67; Meta-analysis; MIB-1; prognosis","KI-67 IMMUNOLABELING INDEX; CENTRAL-NERVOUS-SYSTEM; EPITHELIAL DIFFERENTIATION; CELL-PROLIFERATION; LABELING INDEX; EXPRESSION; SURVIVAL; CHILDHOOD; TUMORS; CHILDREN","Distinction between grade II ependymomas and anaplastic ependymomas based on histopathological examination solely is problematic and, therefore, the management of intracranial ependymomas remains controversial. The aim of this study was to conduct a systematic review (SR) and meta-analysis (MA) of data published on immunohistochemical prognostic markers (IPM) in intracranial ependymomas (IE), and to establish an evidence-based perspective on their clinical value. Following the extensive search based on a strictly defined group of key words, 30 studies reporting results on IPM in IE were identified. Due to a pronounced inter-study heterogeneity, only 14 publications fulfilled the criteria for inclusion into SR. From the total of 67 immunohistochemical markers, 18 were found to correlate with prognosis. However, owing to inadequate data publishing, MA could be performed only with data on proliferation marker MIB-1 (Ki-67) from 5 publications, including 337 patients: The pooled hazard ratio for overall survival was 3.16 (95% confidence interval = 1.96-5.09; p < 0.001) implicating that patients suffering from tumors with higher immunohistochemical expression of MIB-1 had a significantly worse outcome. Marked inter-study heterogeneity and incomplete data publishing in primary studies significantly limited extent of the SR, and the possibility of performing MA. Although the prognostic impact of MIB-1 immunoexpression in IE could be confirmed, there remains lack of further reliable IPM that could be used in routine diagnosis. We encourage to search for new, useful markers, as well as to standardize lab-techniques and data interpretation algorithms across laboratories in order to increase data compatibility.","[Kuncova, Klara; Janda, Ales; Kasal, Pavel; Zamecnik, Josef] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic; [Janda, Ales; Kasal, Pavel] Charles Univ Prague, Univ Hosp Motol, Dept Med Informat, Prague, Czech Republic; [Janda, Ales] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic","Zamecnik, J, Charles Univ Prague, Sch Med 2, Prague, Czech Republic","josef.zamecnik@lfmotol.cuni.cz","Ministry of Health of the Czech Republic [VZ FNM 00064203]; Ministry of Education [VZ MSM CR 0021620812]","The publication was supported in part by the grant VZ FNM 00064203 of the Ministry of Health of the Czech Republic and grant VZ MSM CR 0021620812 of the Ministry of Education. The authors state no financial conflicts of interest. We wish to thank Marie Hladikova for critical remarks on the manuscript.",null,50,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1219-4956",null,"10.1007/s12253-009-9160-2","PATHOL ONCOL RES","Pathol. Oncol. Res.","DEC",2009,15,4,null,null,null,605,614,null,null,10,"Oncology; Pathology","539UE","ISI:000273283100009"]
["nemá","J","Jahnova, H; Chrastina, P; Havlova, M; Zamecnik, J",null,null,null,"Jahnova, H.; Chrastina, P.; Havlova, M.; Zamecnik, J.",null,"Adult Form of Glutaric Aciduria Type II - Underdiagnosed Cause of Proximal Myopathy - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"glutaric aciduria type II; multiple acyl coenzyme A dehydrogenase deficiency; proximal myopathy; riboflavin","COA DEHYDROGENATION DEFICIENCY; MUTATIONS","Glutaric aciduria type II or multiple acyl-CoA dehydrogenase deficiency (MIM 231680) is an autosomal recessively inherited disorder with heterogeneous clinical manifestation and genetic background, biochemically characterized by the accumulation of specific metabolites sourcing from the deficient capacity of flavin oxidative enzymes transferring electrons into the system of electron-transfer flavoprotein (ETF) and electron-transfer flavoprotein:ubiquinone oxidoreductase (ETF:QO). Clinical phenotypes include not only the lethal neonatal forms, but also the late-onset disorder, which usually manifests with proximal myopathic syndrome and sometimes with attacks of hypoketotic hypoglycemia. The incidence of the myopathic form of glutaric aciduria type II has not been determined; nevertheless, owing to easier access to novel diagnostic methods, including tandem mass spectrometry, and the ever increasing awareness of clinicians, the number of diagnosed patients has been growing constantly. The case report of our patient, for the first time diagnosed on the DNA level in the Czech Republic, illustrates not only the clinical course of the disease, but also the possibilities of diagnostics and therapy. It might serve as an inspiration for neurological practice.","[Jahnova, H.; Chrastina, P.] VFN, Ustav Dedicnych Metab Poruch, Prague 12808 2, Czech Republic; [Jahnova, H.; Chrastina, P.; Havlova, M.] 1 LF UK, Prague, Czech Republic; [Jahnova, H.] FNKV, Klin Deti & Dorostu, Prague, Czech Republic; [Havlova, M.] VFN, Neurol Klin, Prague 12808 2, Czech Republic; [Zamecnik, J.] 2 LF UK, Prague, Czech Republic","Jahnova, H, VFN, Ustav Dedicnych Metab Poruch, Ke Karlovu 2, Prague 12808 2, Czech Republic","helena.jahnova@vfn.cz",null,null,null,9,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,3,null,null,null,260,264,null,null,5,"Neurosciences; Surgery","459JD","ISI:000267097100010"]
["nemá","J","Picha, D; Moravcova, L; Rusina, R",null,null,null,"Picha, D.; Moravcova, L.; Rusina, R.",null,"S-100 Protein and Neuron Specific Enolasis in the Clinical Diagnostics of Brain Impairment","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"neuron-specific enolase; S-100 protein","MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; SERUM-LEVELS; ACIDIC PROTEIN; S100B; INJURY; NEUROFILAMENT; SCLEROSIS; DYNAMICS; DISEASE","Within a group of 28 patients with clinically manifested CNS affection, the concentration of S-100 protein and neuron specific enolasis in the serum and in the cerebrospinal fluid was monitored using commercial sets, The concentrations of neuron specific enolasis in the serum corresponded to normal serum values, in the cerebrospinal fluid a pathologically increased value was identified only once. With the S-100 protein, abnormally increased values were recorded three times in the serum while in the cerebrospinal fluid all the measured values except for two were pathologically increased. The correlation of levels of the examined neuropeptides with the clinical condition of patients with nerve lesion has not been proved.","[Picha, D.; Moravcova, L.] 2 LF UK, Infekcini Klin 1, Prague 18081 8, Czech Republic; [Picha, D.; Moravcova, L.] FN Na Bulovce, Prague, Czech Republic; [Rusina, R.] Neurol Klin IPVZ, Prague, Czech Republic; [Rusina, R.] FTNsP, Prague, Czech Republic","Picha, D, 2 LF UK, Infekcini Klin 1, Budinova 2, Prague 18081 8, Czech Republic","dusan.picha@fnb.cz",null,null,null,18,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2009,72,3,null,null,null,274,278,null,null,5,"Neurosciences; Surgery","459JD","ISI:000267097100013"]
["nemá","J","Reiter, J; Michalek, J; Pradny, M; Chmelikova, D; Sirc, J",null,null,null,"Reiter, Jakub; Michalek, Jiri; Pradny, Martin; Chmelikova, Dana; Sirc, Jakub",null,"Li+ and H+ Conducting Polyelectrolytes with Covalently Bonded Anions","CHEMICKE LISTY",null,"Czech","Article",null,null,null,null,null,null,"POLYMER ELECTROLYTES; GEL ELECTROLYTES; POLY(ETHYLENE OXIDE); LITHIUM-SALTS; BATTERIES; COMPLEXES","New single-ion conducting methacrylate-based polyelectrolytes were prepared by radical copolymerization of methacrylic acid (MA) or lithium methacrylate (LiMA), 2-ethoxyethyl methacrylate (EOEMA) and 2-methoxyethyl methacrylate (EGMEMA) as purely cation-conducting (Li+ or H+) polyelectrolytes with covalently bonded carboxylic groups. For conductivity improvement, a series of polyelectrolytes with an embedded aprotic solvent, propylene carbonate (PC) or dimethylformamide (DMF) were prepared. After optimisation of the polyelectrolyte composition, the highest conductivity values were found for poly(MA-EOEMA)-PC (2.2-10-(6) S cm(-1)) and poly(LiMA-EGMEMA)-DMF (1.9-10(-4) S cm(-1)). The polyelectrolytes were also characterized by voltammetry and thermogravimetry. The accessible potential window on gold electrode is ca. 1.75-2 V for H+ polyelectrolytes and over 3.5 V for Li+ polyelectrolytes. The polyelectrolytes without aprotic solvents are stable up to 185 degrees C and those containing the solvents up to 105-115 degrees C.","[Reiter, Jakub] Acad Sci Czech Republic, Inst Inorgan Chem, VVI, CZ-25068 Rez, Czech Republic; [Michalek, Jiri; Pradny, Martin; Chmelikova, Dana; Sirc, Jakub] Acad Sci Czech Republic, Inst Macromol Chem, VVI, CR-16206 Prague, Czech Republic; [Michalek, Jiri; Pradny, Martin; Sirc, Jakub] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15018, Czech Republic","Reiter, J, Acad Sci Czech Republic, Inst Inorgan Chem, VVI, CZ-25068 Rez, Czech Republic","reiter@iic.cas.cz",null,null,null,22,0,"CHEMICKE LISTY","PRAGUE 6","NOVOTNEHO LAVKA 5, PRAGUE 6 116 68, CZECH REPUBLIC","0009-2770",null,null,"CHEM LISTY","Chem. Listy",null,2009,103,10,null,null,null,832,838,null,null,7,"Chemistry, Multidisciplinary","514BS","ISI:000271369100008"]
["nemá","J","Seeman, T; Pohl, M; Misselwitz, J; John, U",null,null,null,"Seeman, Tomas; Pohl, Michael; Misselwitz, Joachim; John, Ulrike",null,"Angiotensin Receptor Blocker Reduces Proteinuria Independently of Blood Pressure in Children Already Treated with Angiotensin-Converting Enzyme Inhibitors","KIDNEY & BLOOD PRESSURE RESEARCH",null,"English","Article",null,null,null,null,null,"Angiotensin receptor blocker; Proteinuria; Chronic kidney disease; Angiotensin-converting enzyme inhibitors","NONDIABETIC RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; NEPHROPATHIES; COMBINATION; PROGRESSION; ADOLESCENTS; THERAPY","Background/Aims: Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) has higher antiproteinuric effects than single blockade in adults. In children, little is known on dual blockade of the renin-angiotensin system. The study investigates whether adding an ARB to proteinuric children already on ACEI reduces proteinuria. Methods: A total of 10 children (median age 13.3 years) with chronic kidney disease and persistent proteinuria despite maximal dose of ACEI were included. Losartan was given at an initial dose 0.8 mg/kg/day. Proteinuria, blood pressure (BP) and renal function (glomerular filtration rate) were measured. Results: Mean proteinuria decreased from 484 +/- 290 mg/mmol creatinine to 223 +/- 197 after 1-3 months of losartan treatment and remained stable at 234 +/- 153, 224 +/- 177 and 195 +/- 133 after 3-6, 6-12 months and at the last follow-up check (median 1.9 years, p < 0.05 for all visits vs. before treatment). The median percentage decrease in proteinuria was 66, 56, 44 and 66% during the study periods. No significant change in BP, glomerular filtration rate or serum potassium was observed. One child complained of rash, which led to discontinuation of losartan. Conclusion: Adding an ARB to current ACEI treatment can further reduce proteinuria in children with chronic kidney disease without affecting BP. Copyright (C) 2009 S. Karger AG, Basel","[Seeman, Tomas] Charles Univ Prague, Sch Med 2, Dept Pediat, Prague, Czech Republic; [Pohl, Michael; Misselwitz, Joachim; John, Ulrike] Univ Jena, Dept Pediat, Jena, Germany","Seeman, T, Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","tomas.seeman@lfmotol.cuni.cz","Ministry of Health and the Ministry of Education of the Czech Republic [VZ MZ 0006420301, MZOFNM2005, VZ MSMT 0021620819]","This study was supported by grants from the Ministry of Health and the Ministry of Education of the Czech Republic (VZ MZ 0006420301, MZOFNM2005 and VZ MSMT 0021620819).",null,21,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,"10.1159/000266478","KIDNEY BLOOD PRESSURE RES","Kidney Blood Pressure Res.",null,2009,32,6,null,null,null,440,444,null,null,5,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","543CZ","ISI:000273548900008"]
["nemá","J","Willasch, AM; Gruhn, B; Coliva, T; Kalinova, M; Schneider, G; Kreyenberg, H; Steinbach, D; Weber, G; Hollink, I; Zwaan, CM; Biondi, A; van der Velden, VHJ; Reinhardt, D; Cazzaniga, G; Bader, P; Trka, J",null,null,null,"Willasch, A. M.; Gruhn, B.; Coliva, T.; Kalinova, M.; Schneider, G.; Kreyenberg, H.; Steinbach, D.; Weber, G.; Hollink, Ihim; Zwaan, C. M.; Biondi, A.; van der Velden, V. H. J.; Reinhardt, D.; Cazzaniga, G.; Bader, P.; Trka, J.","European Study Grp WT1 Expression","Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study","LEUKEMIA",null,"English","Article",null,null,null,null,null,"WT1 expression; minimal residual disease; real-time PCR; childhood AML; WT1 gene mutations; standardized approach","ACUTE MYELOID-LEUKEMIA; RT-PCR ANALYSIS; POLYMERASE-CHAIN-REACTION; QUALITY-CONTROL PROGRAM; MYELODYSPLASTIC SYNDROMES; PROGNOSTIC IMPLICATIONS; CANCER PROGRAM; BONE-MARROW; EXPRESSION; TRANSCRIPTS","A standardized, sensitive and universal method for minimal residual disease (MRD) detection in acute myeloid leukemia (AML) is still pending. Although hyperexpression of Wilms' tumor (WT1) gene transcript has been frequently proposed as an MRD marker in AML, wide comparability of the various methods used for evaluating WT1 expression has not been given. We established and standardized a multicenter approach for quantifying WT1 expression by quantitative reverse transcriptase PCR (qRT-PCR), on the basis of a primer/probe set combination at exons 6 and 7. In a series of quality-control rounds, we analyzed 69 childhood AML samples and 47 normal bone marrow (BM) samples from 4 participating centers. Differences in the individual WT1 expressions levels ranged within < 0.5 log of the mean in 82% of the cases. In AML samples, the median WT1/1E + 04 Abelson (ABL) expression was 3.5E + 03 compared with that of 2.3E + 01 in healthy BM samples. As 11.5% of childhood AML samples in this cohort harbored WT1 mutations in exon 7, the effect of mutations on WT1 expression has been investigated, showing that mutated cases expressed significantly higher WT1 levels than wild-type cases. Hence, our approach showed high reproducibility and applicability, even in patients with WT1 mutations; therefore, it can be widely used for the quantitation of WT1 expression in future clinical trials. Leukemia (2009) 23, 1472-1479; doi:10.1038/leu.2009.51; published online 26 March 2009","[Willasch, A. M.; Kreyenberg, H.; Weber, G.; Bader, P.] Univ Frankfurt, Dept Pediat Hematol Oncol & Hemostaseol, Hosp Children & Adolescents 3, D-60590 Frankfurt, Germany; [Gruhn, B.] Schiller Univ Jena, Dept Pediat Hematol & Oncol, Univ Childrens Hosp, Jena, Germany; [Coliva, T.; Biondi, A.; Cazzaniga, G.] Univ Milan, Dept Pediat Hematol & Oncol, Bicocca Clin Pediat, Osped San Gerardo, Monza, Italy; [Kalinova, M.; Trka, J.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Kalinova, M.; Trka, J.] Univ Childrens Hosp, Prague, Czech Republic; [Schneider, G.] Univ Frankfurt, Dept Comp Sci & Math, Frankfurt, Germany; [Steinbach, D.] Univ Ulm, Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Ulm, Germany; [Hollink, Ihim; Zwaan, C. M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Hematol & Oncol, Rotterdam, Netherlands; [van der Velden, V. H. J.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Reinhardt, D.] Med High Sch, Dept Pediat Oncol & Hematol, AML BFM Study Grp, Hannover, Germany","Willasch, AM, Univ Frankfurt, Dept Pediat Hematol Oncol & Hemostaseol, Hosp Children & Adolescents 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany","andre.willasch@kgu.de","Deutsche Jose Carreras Leukamie Stiftung [DJCLS R04/09]; Munich, Germany ; Czech Ministry of Education [0021620813]; Prague, Czech Republic ; 'Fondazione Tettamanti, Fondazione Cariplo and AIRC', Italy ; KOCR Foundation ","This work was supported by the 'Deutsche Jose Carreras Leukamie Stiftung e. V. (DJCLS R04/09)', Munich, Germany (PB, HK, AMW), by the 'Research Project of the Czech Ministry of Education (No. 0021620813)', Prague, Czech Republic (JT, MK), by the 'Fondazione Tettamanti, Fondazione Cariplo and AIRC', Italy (AB, GC) and by the 'KOCR Foundation', Rotterdam, The Netherlands (IHIMH, CMZ). We thank Vida Meyer (Frankfurt), Nadine Pfaffendorf (Jena), Vincenzo Rossi (Monza) and Patricia Hoogeveen (Rotterdam) for their excellent technical assistance.",null,35,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.51","LEUKEMIA","Leukemia","AUG",2009,23,8,null,null,null,1472,1479,null,null,8,"Oncology; Hematology","482CR","ISI:000268862000015"]
["nemá","J","Novak, F; Kolar, F; Hamplova, B; Mrnka, L; Pelouch, V; Ostadal, B; Novakova, O",null,null,null,"Novak, F.; Kolar, F.; Hamplova, B.; Mrnka, L.; Pelouch, V.; Ostadal, B.; Novakova, O.",null,"Myocardial Phospholipid Remodeling under Different Types of Load Imposed during Early Postnatal Development","PHYSIOLOGICAL RESEARCH",null,"English","Review",null,null,null,null,null,"Phospholipids; Cardiolipin; Myocardium; Postnatal development; Pressure overload; Chronic hypoxia; Thyroid status","FATTY-ACID-COMPOSITION; PROTEIN-KINASE-C; DEVELOPING RAT-HEART; CHRONIC HYPOXIA; VENTRICULAR MYOCARDIUM; ACYL COMPOSITION; NEONATAL-RAT; BETA-ADRENOCEPTORS; PRESSURE-OVERLOAD; SKELETAL-MUSCLE","Normal increase in hemodynamic load during early postnatal life is associated with heart growth and maturation of membrane structures that is accompanied by remodeling of membrane protein and lipid components. This review describes remodeling of phospholipids (PL) in rat myocardium during normal postnatal development and during accelerated cardiac growth induced by additional workload (aorta constriction, chronic hypoxia and hyperthyroidism) imposed on the heart early after birth. Normal physiological load after birth stimulates the development of membrane structures and synthesis of PL. While hyperthyroidism accelerates these processes, pressure overload has an inhibitory effect. These changes primarily influence the maturation of mitochondrial membranes as cardiolipin is one of the most affected PL species. The most sensitive part of PL structure in their remodeling process are PL acyl chains, particularly polyunsaturated fatty acids that are the key components determining the basic physicochemical properties of the membrane bilayer and thus the function of membrane-bound proteins and membrane-derived signaling lipid molecules. It is evident that PL remodeling may significantly influence both normal and pathological postnatal development of myocardium.","[Novak, F.; Hamplova, B.; Mrnka, L.; Novakova, O.] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague 12800 2, Czech Republic; [Novak, F.] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12800 2, Czech Republic; [Pelouch, V.] Charles Univ Prague, Fac Med 2, Prague 12800 2, Czech Republic; [Kolar, F.; Ostadal, B.] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Novak, F.; Kolar, F.; Pelouch, V.; Ostadal, B.] Cardiovasc Res Ctr, Prague, Czech Republic","Novakova, O, Charles Univ Prague, Fac Sci, Dept Cell Biol, Vinicna 7, Prague 12800 2, Czech Republic","olnov@natur.cuni.cz","Ministry of Education, Youth and Sports of the Czech Republic [0021620858, 1M0510, AV0Z 20110509]","Supported by the Ministry of Education, Youth and Sports of the Czech Republic grants No. 0021620858, 1M0510 and grant AV0Z 20110509.",null,137,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,"Suppl. 2",null,"S13","S32",null,null,20,"Physiology","542ZC","ISI:000273537200003"]
["nemá","J","Vernerova, Z; Kujal, P; Kramer, HJ; Backer, A; Cervenka, L; Vaneckova, I",null,null,null,"Vernerova, Z.; Kujal, P.; Kramer, H. J.; Baecker, A.; Cervenka, L.; Vaneckova, I.",null,"End-Organ Damage in Hypertensive Transgenic Ren-2 Rats: Influence of Early and Late Endothelin Receptor Blockade","PHYSIOLOGICAL RESEARCH",null,"English","Review",null,null,null,null,null,"Endothelin receptors; Hypertension; Morphology; Podocytes; Ren-2 rats","BLOOD-PRESSURE; GLOMERULAR PODOCYTE; SALT; KIDNEY; CELLS; GLOMERULOSCLEROSIS; FIBROGENESIS; INJURY","The rat strain transgenic for the murine Ren-2 renin gene (TGR) is defined as a monogenic model of angiotensin II-dependent hypertension with endogenous activation of the renin-angiotensin system. Homozygous males TGR develop malignant hypertension with a strong salt-sensitive component. These animals show severe hypertension, proteinuria and high mortality. Morphological changes of renal parenchyma correspond to chronic ischemic glomerular changes. Heterozygous TGR develop only mild hypertension and thus provide a more suitable model of hypertension regarding to clinical studies. Within the renal parenchyma, secondary focal segmental glomerulosclerosis (FSGS) predominates. High-salt diet in heterozygous animals induces transition from benign to malignant phase of hypertension. In this case, ischemic glomerular changes are superimposed on preexisting secondary FSGS. In the regression model of hypertension (late-onset treatment) the effect of salt intake is attenuated. In homozygous TGR, early selective ETA receptor blockade decreased blood pressure and ameliorated end-organ damage. Late selective ETA receptor blockade reduced podocyte injury despite final severe hypertension. Survival rate was markedly improved in both regimens with ETA selective blockade, while there was only partial improvement with early non-selective blockade. Both bosentan and atrasentan decreased ET-1 levels in both regimens. In heterozygous TGR, early and late ETA treatment substantially while ETA/AT(B) treatment partially improved survival rate. Significant effect on BP was found with early and late ETA blockade, while ETA/ETB blockade had no effect. Bosentan and atrasentan similarly decreased ET-1 levels on both regimens. In conclusion, selective ETA receptor blockade is superior to nonselective ETA/ETB receptor blockade in attenuating hypertension and end-organ damage. Its effect is more pronounced when applied early in the life.","[Vernerova, Z.; Kujal, P.; Cervenka, L.; Vaneckova, I.] Ctr Med Expt, Inst Clin & Expt Med, CZ-14021 Prague 4, Czech Republic; [Vernerova, Z.; Kujal, P.] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Kramer, H. J.; Baecker, A.] Univ Bonn, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany; [Cervenka, L.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic; [Cervenka, L.; Vaneckova, I.] Cardiovasc Res Ctr, Prague, Czech Republic","Vaneckova, I, Ctr Med Expt, Inst Clin & Expt Med, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic","ivvn@medicon.cz","Czech Science Foundation [305/07/J004]","This study was supported by grant no. 305/07/J004 awarded to I.V. by the Czech Science Foundation.",null,35,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,"Suppl. 2",null,"S69","S78",null,null,10,"Physiology","542ZC","ISI:000273537200007"]
["nemá","J","Chovanec, M; Novotna, J; Wilhelm, J; Hampl, V; Vizek, M; Herget, J",null,null,null,"Chovanec, M.; Novotna, J.; Wilhelm, J.; Hampl, V.; Vizek, M.; Herget, J.",null,"Hypercapnia Attenuates Hypoxic Pulmonary Hypertension by Inhibiting Lung Radical Injury","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Chronic hypoxia; Chronic hypercapnia; Pulmonary hypertension; Hypoxic lung injury","CARBON-DIOXIDE; NEWBORN RAT; DAMAGE; PEROXYNITRITE; ERYTHROCYTES; REPERFUSION","Chronic lung hypoxia results in hypoxic pulmonary hypertension. Concomitant chronic hypercapnia partly inhibits the effect of hypoxia on pulmonary vasculature. Adult male rats exposed to 3 weeks hypoxia (Fi(02)=0.1) combined with hypercapnia (Fi(C02)=0.04-0.05) had lower pulmonary arterial blood pressure, increased weight of the right heart ventricle, and less pronounced structural remodeling of the peripheral pulmonary arteries compared with rats exposed only to chronic hypoxia (Fi(02)=0.1). According to our hypothesis, hypoxic pulmonary hypertension is triggered by hypoxic injury to the walls of the peripheral pulmonary arteries. Hypercapnia inhibits release of both oxygen radicals and nitric oxide at the beginning of exposure to the hypoxic environment. The plasma concentration of nitrotyrosine, the marker of peroxynitrite activity, is lower in hypoxic rats exposed to hypercapnia than in those exposed to hypoxia alone. Hypercapnia blunts hypoxia-induced collagenolysis in the walls of prealveolar pulmonary arteries. We conclude that hypercapnia inhibits the development of hypoxic pulmonary hypertension by the inhibition of radical injury to the walls of peripheral pulmonary arteries.","[Chovanec, M.; Hampl, V.; Herget, J.] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Sch Med 2, Prague 15000 5, Czech Republic; [Novotna, J.; Wilhelm, J.] Charles Univ Prague, Dept Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Chovanec, M.; Novotna, J.; Wilhelm, J.; Hampl, V.; Vizek, M.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic; [Chovanec, M.] Na Homolce Hosp, Dept Cardiol, Prague, Czech Republic","Chovanec, M, Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","milan.chovanec@lfmotol.cuni.cz","GACR [305/05/08/108]; GAUK [78007]; Cardiovascular Research Center [1M510]","Supported by grants GACR 305/05/08/108 and GAUK 78007 as well as by Cardiovascular Research Center 1M510. Preliminary report of the part of results was presented at the Experimental Biology Meeting 2009, New Orleans, USA and Meeting of the Czech Physiological Society, 2001 and 2002, Prague, Czech Republic. We would like to thank to our lab assistants: Ms Olga Hnilickova and Pavlina Smolkova for assisting experiments and Ms Elizabeth \"Liz\" Coling help with the manuscript preparation.",null,38,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,"Suppl. 2",null,"S79","S85",null,null,7,"Physiology","542ZC","ISI:000273537200008"]
["nemá","J","Hampl, V; Jakoubek, V",null,null,null,"Hampl, V.; Jakoubek, V.",null,"Regulation of Fetoplacental Vascular Bed by Hypoxia","PHYSIOLOGICAL RESEARCH",null,"English","Review",null,null,null,null,null,"Placenta; Hypoxia; Intrauterine growth restriction; Vasoconstriction; Ion channels","PULMONARY ARTERIAL-HYPERTENSION; PLACENTAL BLOOD-FLOW; POTASSIUM CHANNELS; HIGH-ALTITUDE; NITRIC-OXIDE; VASOCONSTRICTION; RESISTANCE; OXYGEN; PREGNANCY; RAT","Important fetal and perinatal pathologies, especially intrauterine growth restriction (IUGR), are thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels, leading to placental hypoperfusion and thus fetal undernutrition. However, the effects of hypoxia on the fetoplacental vessels have been surprisingly little studied. We review here available experimental data on acute hypoxic fetoplacental vasoconstriction (HFPV) and on chronic hypoxic elevation of fetoplacental vascular resistance. The mechanism of HFPV includes hypoxic inhibition of potassium channels in the plasma membrane of fetoplacental vascular smooth muscle and consequent membrane depolarization that activates voltage gated calcium channels. This in turn causes calcium influx and contractile apparatus activation. The mechanism of chronic hypoxic elevation of fetoplacental vascular resistance is virtually unknown except of signs of the involvement of morphological remodeling.","[Hampl, V.; Jakoubek, V.] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Motol, Czech Republic; [Hampl, V.; Jakoubek, V.] Charles Univ Prague, Cardiovasc Res Ctr, Prague 15000 5, Motol, Czech Republic","Hampl, V, Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 130-221, Prague 15000 5, Motol, Czech Republic",null,"Charles University [82/2004/C, 55/2001/c/2.LF]; Czech Ministry of Education [1M6798582302]","The experimental work of our group reviewed here was funded by the Grant Agency of the Charles University (# 82/2004/C and 55/2001/c/2.LF) and Czech Ministry of Education (# 1M6798582302). We acknowledge an inspiration by the dissertation of V. Jakoubek, although there are no direct quotations.",null,49,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,"Suppl. 2",null,"S87","S93",null,null,7,"Physiology","542ZC","ISI:000273537200009"]
["nemá","J","Tomek, V; Marek, J; Jicinska, H; Skovranek, J",null,null,null,"Tomek, V.; Marek, J.; Jicinska, H.; Skovranek, J.",null,"Fetal Cardiology in the Czech Republic: Current Management of Prenatally Diagnosed Congenital Heart Diseases and Arrhythmias","PHYSIOLOGICAL RESEARCH",null,"English","Review",null,null,null,null,null,"Prenatal; Echocardiography; Congenital heart defect; Arrhythmias; Heart failure","COMPLETE ATRIOVENTRICULAR-BLOCK; ECHOCARDIOGRAPHY; EXPERIENCE; BORN; MALFORMATIONS; TACHYCARDIA; PREVENTION; ANTIBODIES; MORBIDITY; MORTALITY","Reliable diagnosis of congenital heart defects and arrhythmias in utero has been possible since the introduction of fetal echocardiography. The nation-wide prenatal ultrasound screening program in the Czech Republic enabled detection of cardiac abnormities in 1/3 of patients born with any congenital heart disease and up to 83 % of those with critical forms. Prenatal frequency of individual heart anomalies significantly differed from the postnatal frequency. Fetal isolated complete atrioventricular block and supraventricular tachycardia may lead to heart failure and are important causes of fetal mortality. The regression of heart failure was achieved by a conversion to the sinus rhythm in the supraventricular tachycardia and by increase of ventricular rate in the complete atrioventricular block.","[Tomek, V.; Marek, J.; Skovranek, J.] Univ Hosp Motol, Kardioctr, Prague 15008 5, Czech Republic; [Tomek, V.; Marek, J.; Skovranek, J.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15008 5, Czech Republic; [Jicinska, H.] Univ Hosp Brno, Dept Pediat Cardiol, Brno, Czech Republic","Tomek, V, Univ Hosp Motol, Kardioctr, Uvalu 84, Prague 15008 5, Czech Republic","viktor.tomek@fnmotol.cz","Ministry of Health, Czech Republic ; Ministry of Education of the Czech Republic ; [NR9451-3/2007]; [1MO510]","The publication was supported by the grant NR9451-3/2007, Internal Grant Agency, Ministry of Health, Czech Republic and 1MO510, Ministry of Education of the Czech Republic.",null,35,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,"Suppl. 2",null,"S159","S166",null,null,8,"Physiology","542ZC","ISI:000273537200015"]
["nemá","J","Druga, R",null,null,null,"Druga, R.",null,"Neocortical Inhibitory System","FOLIA BIOLOGICA",null,"English","Review",null,null,null,null,null,"cortical interneurons; GABAergic neurons; calcium-binding proteins; neuropeptides","CALCIUM-BINDING PROTEINS; LOCAL-CIRCUIT NEURONS; MEDIAL PREFRONTAL CORTEX; RAT VISUAL-CORTEX; DIAPHORASE-POSITIVE NEURONS; HUMAN TEMPORAL NEOCORTEX; PARVALBUMIN-IMMUNOREACTIVE NEURONS; PRIMARY SOMATOSENSORY CORTEX; GLUTAMIC-ACID DECARBOXYLASE; CENTRAL AUDITORY-SYSTEM","The neocortex contains two neuron types, excitatory (glutamatergic) pyramidal cells and inhibitory nonpyramidal (GABAergic) cells. GABAergic, inhibitory interneurons are morphologically distinct from excitatory pyramidal cells and account for 20-25 % of all neocortical neurons. Recent studies discovered that besides morphological features, inhibitory interneurons are molecularly and physiologically heterogenous and differ significantly in arrangement and terminations of their axonal endings. In neocortical interneurons, GABA is also co-localized with calcium-binding proteins (parvalbumin, calbindin, calretinin), with neuropeptides and nitric oxide synthase. Axons of GABAergic neurons target distinct domains of pyramidal neurons. Double-bouquet, Martinotti and neurogliaform cells (CB-IR, CR-IR) target distal dendrites of pyramidal neurons and probably regulate the vertical integration of synaptic input along the dendritic tree of pyramids. Basket cells (PV-IR) innervate soma and proximal dendrites, and Chandelier cells (PV-IR) exhibit synaptic contacts on the axon initial segment of pyramidal neurons. GABAergic neocortical interneurons are interconnected by gap junctions. Most often coupling is bidirectional and occurs between interneurons of the same type. Cortical pyramidal neurons derive from the dorsal telencephalon while the majority of interneurons derive from the ganglionic eminences of the ventral telencephalon, and tangentially migrate into cortex. Adult mammalian neurogenesis is not restricted to the hippocampus, but a small number of the new neurons is also generated in the neocortex. New cortical neurons are GABAergic and co-express calbindin and calretinin. Quantitative analysis of selected areas of the neocortex (neuropsychiatric diseases, models of epilepsy, aging) demonstrate a decrease in density of PV-IR and CB-IR neurons but not CR-IR neurons.","[Druga, R.] Charles Univ Prague, Inst Anat, Fac Med 2, Prague 12800 2, Czech Republic; [Druga, R.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic","Druga, R, Charles Univ Prague, Inst Anat, Fac Med 2, Unemocnice 3, Prague 12800 2, Czech Republic","rastislav.druga@lfl.cuni.cz","Grant Agency of the Czech Republic [309/07/1336, 304/07/1137]; Czech Ministry of Education, Youth and Sports [LC 554]","This work was supported by the Grant Agency of the Czech Republic, grants Nos. 309/07/1336 and 304/07/1137, and by project of the Czech Ministry of Education, Youth and Sports LC 554.",null,133,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2009,55,6,null,null,null,201,217,null,null,17,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","549HX","ISI:000274039700002"]
["nemá","J","Krenkova, P; Norambuena, P; Stambergova, A; Macek, M",null,null,null,"Krenkova, P.; Norambuena, P.; Stambergova, A.; Macek, M., Jr.",null,"Evaluation of High-Resolution Melting (HRM) for Mutation Scanning of Selected Exons of the CFTR Gene","FOLIA BIOLOGICA",null,"English","Article",null,null,null,null,null,"CFTR; high-resolution melting; HRM; mutation detection","PERFORMANCE LIQUID-CHROMATOGRAPHY; GRADIENT GEL-ELECTROPHORESIS; DNA; POLYMORPHISMS; SENSITIVITY; SEQUENCE","Hereby we present evaluation of high-resolution melting for mutation scanning applied to the cystic fibrosis transmembrane conductance regulator gene. High resolution melting was used for mutation scanning of selected samples derived from cystic fibrosis patients with a known cystic fibrosis transmembrane conductance regulator genotype. We tested 19 different disease-causing cystic fibrosis transmembrane conductance regulator mutant genotypes located within six exons of the cystic fibrosis transmembrane conductance regulator gene (4, 7, 10, 11, 14b and 22). Normalized melting curves of tested samples were compared to sequenced-verified wildtype samples. Determined mutations are as follows: p.F508del, p.1507del, p.G551D, p.R347P, c.17171-1G>A, c.621+1G>T, p.V122X, p.I336K, p.R553X, c.2789+5G>A, c.574delA, c.1811+1G>C, p.L1335F, p.L1335P, p.L1324P and p.M470V and represent minimally 76.5 % of all cystic fibrosis alleles detected in the Czech cystic fibrosis population. All analysed samples with mutant genotypes were unambiguously distinguished from wild-type samples. High-resolution melting analysis enabled reliable detection of all single-nucleotide polymorphism classes and 1- or 3- base pair deletions. We examined the specificity, sensitivity and precision of this methodology. High-resolution melting analysis is an economical, sensitive and specific close-tube method and has a high utility for the detection of unknown mutations in cystic fibrosis DNA diagnostics.","[Krenkova, P.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Dept Biol & Med Genet, Cyst Fibrosis Ctr, Prague 15006 5, Czech Republic","Krenkova, P, Charles Univ Prague, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","petra.krenkova@email.cz","EuroGentest [FP6-512145]; [VZFNM00064203]; [NR-9448-3/2007]","This study was supported by VZFNM00064203, EuroGentest (FP6-512145) and NR-9448-3/2007.",null,23,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2009,55,6,null,null,null,238,242,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","549HX","ISI:000274039700006"]
["nemá","J","Paclt, I; Koudelova, J; Pacltova, D; Kopeckova, M",null,null,null,"Paclt, Ivo; Koudelova, Jitka; Pacltova, Dagmar; Kopeckova, Marta",null,"Dopamine beta hydroxylase (DBH) plasma activity in childhood mental disorders","NEUROENDOCRINOLOGY LETTERS",null,"English","Article",null,null,null,null,null,"dopamine beta hydroxylase; ADHD; child depression; child schizophrenia; noradrenergic system","PLATELET MONOAMINE-OXIDASE; ATTENTION DEFICIT DISORDER; METABOLIZING ENZYMES DBH; PSYCHIATRIC-PATIENTS; CONDUCT DISORDER; SCHIZOPHRENIC-PATIENTS; ENDOGENOUS-DEPRESSION; CEREBROSPINAL-FLUID; GENE POLYMORPHISMS; AFFECTIVE-ILLNESS","BACKGROUND: Developmental study of dopaminergic and noradrenergic systems in child psychiatric disorders are rare. DBH activity is one of noradrenergic biochemical marker that is correlate in Psychiatry to clinical and genetic data. OBJECTIVES: The main aim of the present study was to measure DBH activity at the onset of acute schizophrenia and depressive disorder in children and adolescents without pharmacological treatment and to compare these values with DBH activity in healthy controls. The authors also investigated untreated ADHD children. METHODS: We examined 42 control healthy children, 15 children non-treated with acute schizophrenia, 15 non-treated children with acute depressive disorders and 30 non-treated ADHD children, all in age 7-14. Plasma DBH level was provided by Nagatsu (1972; 1974). Depressed children were reexamined after clinical remission. RESULTS: DBH activity is statistically significantly decreased in non-treated depressive disorder and ADHD in children and adolescents. DBH activity is normalised during antidepressant therapy in child depression. Child schizophrenia patients present with normal DBH activity. CONCLUSION: These results are similar to the results that have been observed in adult patients with schizophrenia and depression and in previous studies of DBH activity in children with ADHD. These results also indicate hypoactivity of the noradrenergic system in children with ADHD and depression.","[Paclt, Ivo; Koudelova, Jitka] Charles Univ Prague, Dept Psychiat, Fac Med 1, Prague 12800 2, Czech Republic; [Pacltova, Dagmar] Dept Gen Practitioner Children & Adolescent, Prague, Czech Republic; [Kopeckova, Marta] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Univ Hosp Motol, Prague 12800 2, Czech Republic","Paclt, I, Charles Univ Prague, Dept Psychiat, Fac Med 1, Ke Karlovu 11, Prague 12800 2, Czech Republic","ivopaclt@seznam.cz","[NR/95 34/3 MZ]","Supported by grant NR/95 34/3 MZ, CR, 2007-2009.",null,54,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2009,30,5,null,null,null,604,609,null,null,6,"Endocrinology & Metabolism; Neurosciences","565CJ","ISI:000275266300009"]
["nemá","J","Kocourkova, J; Koutek, J; Hrdlicka, M",null,null,null,"Kocourkova, Jana; Koutek, Jiri; Hrdlicka, Michal",null,"Self-harm in adolescence: a girl who swallowed needles","NEUROENDOCRINOLOGY LETTERS",null,"English","Article",null,null,null,null,null,"self-harm; adolescence; therapy","PERSONALITY; BEHAVIORS; STRESS; INJURY","Self-harm represents a serious and pathological behavior that occurs most notably during adolescent years and currently seems to be a problem that is on the increase. Self-harm is a self destructive behavior which most frequently takes the form of cutting and burning. Relative to suicidal behavior, self-harm, in and of itself, is not intended to be lethal and tends to be repeated and addictive. However, in cases of self-harm the risk of suicidal behavior cannot be ignored. This presentation is a case study of a girl who engaged in an unusual form of self-harm, by swallowing needles.","[Kocourkova, Jana; Koutek, Jiri; Hrdlicka, Michal] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 15006, Czech Republic","Kocourkova, J, Charles Univ Prague, Dept Child Psychiat, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","jana.kocourkova@lfmotol.cuni.cz","MSM [0021620849]","Supported by grant MSM 0021620849.",null,16,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2009,30,6,null,null,null,705,708,null,null,4,"Endocrinology & Metabolism; Neurosciences","565CK","ISI:000275266400005"]
["nemá","J","Hort, J; Bartos, A; Pirttila, T; Scheltens, P",null,null,null,"Hort, J.; Bartos, A.; Pirttila, T.; Scheltens, P.",null,"Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe","EUROPEAN JOURNAL OF NEUROLOGY",null,"English","Article",null,null,null,null,null,"Alzheimer's disease; beta-amyloid; biomarker; cerebrospinal fluid; phosphorylated tau; total tau","MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; PHOSPHORYLATED TAU; CSF BIOMARKERS; PREDICTION; A-BETA-42; CRITERIA; ADULTS","Background and purpose: Cerebrospinal fluid (CSF) biomarkers have been reported to be useful in dementia diagnosis. Not much is known about their use in clinical practice in Europe. Methods: We analyzed data from a survey on the use of CSF biomarkers in the diagnosis of dementia across Europe using a questionnaire which was filled out by representatives of the 25 member countries of the European Federation of Neurological Societies (EFNS). Results: Cerebrospinal fluid beta-amyloid, total tau, and phosphorylated tau proteins are frequently evaluated in the majority of the countries (in 18 out of 23 countries). No major technical or ethical issues were found that would hamper the procedure's ability to become routine in early and differential diagnostics of Alzheimer's disease. Cut-off values for beta-amyloid (median 500, range 300-849 pg/ml), total tau (367; 195-450 pg/ml) and phosphorylated tau (60; 40-85 pg/ml) varied considerably amongst countries and even within every country. Conclusions: Cerebrospinal fluid analysis of beta-amyloid, tau, and phosphorylated tau is frequently used in Europe. However, the use of various cut off values seriously hampers comparability and yields a potential threat to an interpretation and balanced use in clinical practice. We recommend that each laboratory establishes normative data and that multi-centered studies should be organized to explore the reasons for any differences.","[Hort, J.] Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2,Univ Hosp Motol, Prague, Czech Republic; [Bartos, A.] Charles Univ Prague, Fac Med 3, Dept Neurol, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Bartos, A.] Prague Psychiat Ctr, Alzheimer Dis Ctr, Prague, Czech Republic; [Pirttila, T.] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Scheltens, P.] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Alzheimer Ctr, Amsterdam, Netherlands","Hort, J, Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2,Univ Hosp Motol, Prague, Czech Republic","jakub.hort@seznam.cz","[KAN200520701]; [GACR 309/09/1053]","Many thanks to all participants in this survey: Reinhold Schmidt (Austria), Jean-Pierre Brion (Belgium), Gunhild Waldemar (Denmark), Bruno Dubois (France), Alexander Tsiskaridze (Georgia), Hayrettin Tumani, Katharina Buerger (Germany), Elisabeth Kapaki (Greece), Peter Klivenyi (Hungary), Judith Aharon-Peretz (Israel), Giovanni Frisoni, Antonio Federico, Lucilla Parnetti, Daniella Galimberti, Alessandra Bizarro, (Italy), Gintaras Kaubrys (Lithuania), Frank-Erik de Leeuw (the Netherland), Olaf Aaserud, Tormod Fladby (Norway), Konrad Rejdak (Poland), Alexandre Mendonca (Portugal), Bogdan Popescu (Romania), Elka Stefanova (Serbia) Pablo Martinez-Lage (Spain), Zuzana Gdovinova (Slovakia), Miro Denislic (Slovenia), Carsten Wikkelso (Sweden), Hakan Gurvit (Turkey), Martin Rossor, Geoffrey Keir, Axel Petzold (UK). Data analysis and writing of the paper was partly supported by the project KAN200520701 and GACR 309/09/1053.",null,17,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-5101",null,"10.1111/j.1468-1331.2009.02753.x","EUR J NEUROLOGY","Eur. J. Neurol.","JAN",2010,17,1,null,null,null,90,96,null,null,7,"Clinical Neurology; Neurosciences","534JY","ISI:000272893600016"]
["nemá","J","Mejstrikova, E; Fronkova, E; Kalina, T; Omelka, M; Batinic, D; Dubravcic, K; Pospisilova, K; Vaskova, M; Luria, D; Cheng, SH; Ng, M; Leung, Y; Kappelmayer, J; Kiss, F; Izraeli, S; Stark, B; Schrappe, M; Trka, J; Stary, J; Hrusak, O",null,null,null,"Mejstrikova, Ester; Fronkova, Eva; Kalina, Tomas; Omelka, Marek; Batinic, Drago; Dubravcic, Klara; Pospisilova, Klara; Vaskova, Martina; Luria, Drorit; Cheng, Suk Hang; Ng, Margaret; Leung, Yonna; Kappelmayer, Janos; Kiss, Flora; Izraeli, Shai; Stark, Batia; Schrappe, Martin; Trka, Jan; Stary, Jan; Hrusak, Ondrej",null,"Detection of Residual B Precursor Lymphoblastic Leukemia by Uniform Gating Flow Cytometry","PEDIATRIC BLOOD & CANCER",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; flow cytometry; minimal residual disease; non-malignant background","BIOMED-1 CONCERTED ACTION; TIME QUANTITATIVE PCR; RECEPTOR GENE REARRANGEMENTS; ACUTE MYELOID-LEUKEMIA; BONE-MARROW; TREATMENT RESPONSE; DISEASE DETECTION; FOLLOW-UP; T-ALL; CHILDHOOD","Background. Residual disease (RD) is an important prognostic factor in acute lymphoblastic leukemia (ALL). Flow cytometry (FC)-based RD detection is easy to perform, but interpretation requires expert analysis due to individual differences among patients. Procedure. We focused at the design of standardized and reproducible RD monitoring in ALL. RD was investigated by a uniform gating strategy, which was designed internationally and tested in one center by Ig/TCR rearrangements. Results. For each gate, positivity cutoff value was assigned using quantification of non-leukemic background. Comparing to Ig/TCR at 0.1% level, 80 of 103 specimens were correctly diagnosed by FC. The predictive value of FC RD at day 15 was then analyzed. In B lineage ALL, day 15 FC significantly correlated with Ig/TCR results at day 33 and/or week 12 (P<0.01). No significant correlation was found in T lineage ALL. Conclusions. Thus, FC with preset uniform gating at day 15 predicts PCR-detectable MRD in B precursor ALL. Presented data may be used to define new polychromatic cytometric diagnostics of MRD including semiautomatic assessment. Pediatr Blood Cancer 2010;54:62-70. (C) 2009 Wiley-Liss, Inc.","[Hrusak, Ondrej] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Sch Med 2, Fac Med 2, Prague, Czech Republic; [Mejstrikova, Ester; Fronkova, Eva; Kalina, Tomas; Pospisilova, Klara; Vaskova, Martina; Trka, Jan; Hrusak, Ondrej] CLIP, Prague, Czech Republic; [Omelka, Marek] Charles Univ Prague, Fac Math & Phys, Jaroslav Hajek Ctr Theoret & Appl Stat, Prague, Czech Republic; [Batinic, Drago; Dubravcic, Klara] Univ Clin Hosp Ctr, Inst Clin, Lab Diag, Zagreb, Croatia; [Luria, Drorit; Stark, Batia] Rabin Med Ctr, Felsenstein Med Res Ctr, Schneider Childrens Med Ctr Israel, Dept Pediat Hematol Oncol, Petah Tiqwa, Israel; [Cheng, Suk Hang; Ng, Margaret; Leung, Yonna] Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Kappelmayer, Janos; Kiss, Flora] Debrecen Univ Med, Dept Clin Biochem & Mol Pathol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; [Izraeli, Shai] Scheba Med Ctr, Tel Hashomer, Israel; [Schrappe, Martin] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany","Hrusak, O, Univ Hosp Motol, Dept Pediat Hematol & Oncol, Sch Med 2, Fac Med 2, Uvalu 84, Prague, Czech Republic","ondrej.hrusak@lfmotol.cuni.cz",null,null,null,41,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,"10.1002/pbc.22261","PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","JAN",2010,54,1,null,null,null,62,70,null,null,9,"Oncology; Hematology; Pediatrics","525ON","ISI:000272225800013"]
["nemá","J","Tuttelmann, F; Krenkova, P; Romer, S; Nestorovic, AR; Ljujic, M; Stambergova, A; Macek, M; Macek, M; Nieschlag, E; Gromoll, J; Simoni, M",null,null,null,"Tuettelmann, F.; Krenkova, P.; Roemer, S.; Nestorovic, A. R.; Ljujic, M.; Stambergova, A.; Macek, M., Jr.; Macek, M., Sr.; Nieschlag, E.; Gromoll, J.; Simoni, M.",null,"A common haplotype of protamine 1 and 2 genes is associated with higher sperm counts","INTERNATIONAL JOURNAL OF ANDROLOGY",null,"English","Article",null,null,null,null,null,"male infertility; PRM1; PRM2; protamine; semen parameters; SNP","SINGLE-NUCLEOTIDE POLYMORPHISMS; HUMAN MALE POPULATIONS; MALE-INFERTILITY; MESSENGER-RNA; FERTILE; SPERMATOGENESIS; IDENTIFICATION; EXPRESSION; QUALITY; PROTEIN","P>Sperm chromatin compaction in the sperm head is achieved when histones are replaced by protamines during spermatogenesis. Haploinsufficiency of the protamine 1 (PRM1) or PRM2 gene causes infertility in mice. However, the published data remain inconclusive about a role of PRM1/2 variants in male infertility and their association with semen parameters. By full sequence analysis, we assessed the frequency of sequence variations in PRM1 and PRM2 in three groups of Caucasian patients with idiopathic teratozoospermia and normal (n = 88) or reduced sperm concentration (n = 83) and in men with a high percentage of normal sperm morphology and normal concentrations (n = 77). Two rare (c.54G > A and c.102G > T) and one common SNP (c.230A > C) were identified in PRM1. In PRM2, some rare heterozygous mutations and the two common intronic SNPs 298G > C and 373C > A were detected. None of the PRM1/2 variants was associated with teratozoospermia or individually with other semen parameters. However, significant linkage disequilibrium was detected between the common SNPs of PRM1 and PRM2 which formed haplotypes. Analysis of the pooled group (n = 248) revealed that homozygous carriers of the common haplotype ACC had a twofold higher sperm concentration and count than men lacking this haplotype, with sperm counts of heterozygotes for ACC being midway between the homozygotes. This markedly decreased sperm output might either be caused by spermatozoa lacking the ACC haplotype not being viable, or subject to negative selection. In addition, a significant deviation from Hardy-Weinberg-Equilibrium of these SNPs might indicate natural selection in favour of the ACC allele which leads to higher sperm output and therefore better fertility. In conclusion, for the first time we describe an association of a common haplotype formed by PRM1 and PRM2 with sperm output in a large group of men.","[Tuettelmann, F.; Nieschlag, E.; Gromoll, J.] Univ Munster, Inst Human Genet, D-48149 Munster, Germany; [Tuettelmann, F.; Roemer, S.; Simoni, M.] Univ Munster, Ctr Reprod Med & Androl, D-48149 Munster, Germany; [Krenkova, P.; Stambergova, A.; Macek, M., Jr.; Macek, M., Sr.] Fac Med 2, Ctr Reprod Genet, Inst Biol & Med Genet, Prague, Czech Republic; [Krenkova, P.; Stambergova, A.; Macek, M., Jr.; Macek, M., Sr.] Univ Hosp Motol, Prague, Czech Republic; [Nestorovic, A. R.] Inst Mol Genet & Genet Engn, Belgrade 11001, Serbia; [Simoni, M.] Univ Modena & Reggio Emilia, Dept Med Endocrinol Metab & Geriatr, Modena, Italy","Tuttelmann, F, Univ Munster, Inst Human Genet, Vesaliusweg 12-14, D-48149 Munster, Germany","frank.tuettelmann@ukmuenster.de","Czech Ministry of Health [IGA NR9448-3/2007]","The authors would like to thank the patients and physicians who took care of them at the Centre of Reproductive Medicine and Andrology and Susan Nieschlag, MA, for language editing of the manuscript. This study was supported by the Czech Ministry of Health IGA NR9448-3/2007",null,24,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0105-6263",null,"10.1111/j.1365-2605.2009.01003.x","INT J ANDROL","Int. J. Androl.","FEB",2010,33,1,null,null,null,"E240","E248",null,null,9,"Andrology","541YH","ISI:000273457000030"]
["nemá","J","Strnad, H; Lacina, L; Kolar, M; Cada, Z; Vlcek, C; Dvorankova, B; Betka, J; Plzak, J; Chovanec, M; Sachova, J; Valach, J; Urbanova, M; Smetana, K",null,null,null,"Strnad, Hynek; Lacina, Lukas; Kolar, Michal; Cada, Zdenek; Vlcek, Cestmir; Dvorankova, Barbora; Betka, Jan; Plzak, Jan; Chovanec, Martin; Sachova, Jana; Valach, Jaroslav; Urbanova, Marketa; Smetana, Karel, Jr.",null,"Head and neck squamous cancer stromal fibroblasts produce growth factors influencing phenotype of normal human keratinocytes","HISTOCHEMISTRY AND CELL BIOLOGY",null,"English","Article",null,null,null,null,null,"Cancer microenvironment; BMP-4; IGF-2; Epithelial-mesenchymal interaction; Cancer-associated fibroblasts","EPITHELIAL-MESENCHYMAL TRANSITION; EMBRYONIC STEM-CELLS; IN-VITRO; IGF-II; PROSTATE-CANCER; GENE-EXPRESSION; OVARIAN-CANCER; CARCINOMA; TUMORS; MICROENVIRONMENT","Epithelial-mesenchymal interaction between stromal fibroblasts and cancer cells influences the functional properties of tumor epithelium, including the tumor progression and spread. We compared fibroblasts prepared from stroma of squamous cell carcinoma and normal dermal fibroblasts concerning their biological activity toward normal keratinocytes assessed by immunocytochemistry and profiling of gene activation for growth factors/cytokines by microarray chip technology. IGF-2 and BMP-4 were determined as candidate factors responsible for tumor-associated fibroblast activity that influences normal epithelia. This effect was confirmed by addition of recombinant IGF-2 and BMP4, respectively, to the culture medium. This hypothesis was also verified by inhibition experiments where blocking antibodies were employed in the medium conditioned by cancer-associated fibroblast. Presence of these growth factors was also detected in tumor samples.","[Dvorankova, Barbora; Smetana, Karel, Jr.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic; [Strnad, Hynek; Kolar, Michal; Vlcek, Cestmir; Sachova, Jana; Urbanova, Marketa] Acad Sci Czech Republic, Inst Mol Genet, CR-14220 Prague 4, Czech Republic; [Lacina, Lukas] Charles Univ Prague, Inst Anat, Dept Dermatovenereol, Prague 12800 2, Czech Republic; [Betka, Jan; Urbanova, Marketa] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague 15006 5, Czech Republic; [Cada, Zdenek; Plzak, Jan; Chovanec, Martin] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Inst Anat, Prague 15006 5, Czech Republic","Smetana, K, Charles Univ Prague, Inst Anat, Fac Med 1, Nemocnice 3, Prague 12800 2, Czech Republic","karel.smetana@lf1.cuni.cz","Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806, NPVII 2B06106, AV0Z50520514]; Grant Agency of the Czech Republic [304/08/P175]","This study was supported by Ministry of Education, Youth and Sport of the Czech Republic, projects No. MSM0021620806, NPVII 2B06106, AV0Z50520514 and project of Grant Agency of the Czech Republic No. 304/08/P175. Authors are grateful to Iva Burdova and Vit Hajduch for excellent technical assistance.",null,52,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0948-6143",null,"10.1007/s00418-009-0661-6","HISTOCHEMISTRY CELL BIOL","Histochem. Cell Biol.","FEB",2010,133,2,null,null,null,201,211,null,null,11,"Cell Biology; Microscopy","545PC","ISI:000273745800006"]
["nemá","J","Gefen, N; Binder, V; Zaliova, M; Linka, Y; Morrow, M; Novosel, A; Edry, L; Hertzberg, L; Shomron, N; Williams, O; Trka, J; Borkhardt, A; Izraeli, S",null,null,null,"Gefen, N.; Binder, V.; Zaliova, M.; Linka, Y.; Morrow, M.; Novosel, A.; Edry, L.; Hertzberg, L.; Shomron, N.; Williams, O.; Trka, J.; Borkhardt, A.; Izraeli, S.",null,"Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53","LEUKEMIA",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia (ALL); ETV6/RUNX1; TEL/AML1; microRNA","ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMAS; GENE-EXPRESSION; DOWN-SYNDROME; BA/F3 CELLS; STEM-CELLS; PROLIFERATION; RNA; MUTATIONS; MICRORNAS","MicroRNAs (miRNAs) regulate the expression of multiple proteins in a dose-dependent manner. We hypothesized that increased expression of miRNAs encoded on chromosome 21 (chr 21) contribute to the leukemogenic function of trisomy 21. The levels of chr 21 miRNAs were quantified by qRT-PCR in four types of childhood acute lymphoblastic leukemia (ALL) characterized by either numerical (trisomy or tetrasomy) or structural abnormalities of chr 21. Suprisingly, high expression of the hsa-mir-125b-2 cluster, consisting of three miRNAs, was identified in leukemias with the structural ETV6/RUNX1 abnormality and not in ALLs with trisomy 21. Manipulation of ETV6/RUNX1 expression and chromatin immunoprecipitation studies showed that the high expression of the miRNA cluster is an event independent of the ETV6/RUNX1 fusion protein. Overexpression of hsa-mir-125b-2 conferred a survival advantage to Ba/F3 cells after IL-3 withdrawal or a broad spectrum of apoptotic stimuli through inhibition of caspase 3 activation. Conversely, knockdown of the endogenous miR-125b in the ETV6/RUNX1 leukemia cell line REH increased apoptosis after Doxorubicin and Staurosporine treatments. P53 protein levels were not altered by miR-125b. Together, these results suggest that the expression of hsa-mir-125b-2 in ETV6/RUNX1 ALL provides survival advantage to growth inhibitory signals in a p53-independent manner. Leukemia (2010) 24, 89-96; doi:10.1038/leu.2009.208; published online 5 November 2009","[Gefen, N.; Binder, V.; Hertzberg, L.; Izraeli, S.] Chaim Sheba Med Ctr, Sect Funct Genom & Leukemia Res, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Gefen, N.; Hertzberg, L.; Izraeli, S.] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Binder, V.; Linka, Y.; Novosel, A.; Borkhardt, A.] Univ Dusseldorf, Dept Pediat Hematol Oncol & Immunol, Dusseldorf, Germany; [Zaliova, M.; Trka, J.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Zaliova, M.; Trka, J.] Univ Hosp Motol, Prague, Czech Republic; [Edry, L.; Shomron, N.] Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel; [Morrow, M.; Williams, O.] UCL, Inst Child Hlth, London, England; [Hertzberg, L.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel","Izraeli, S, Chaim Sheba Med Ctr, Sect Funct Genom & Leukemia Res, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Ramat Gan, Israel","sizraeli@sheba.health.gov.il","National Institute of Health [R01 CA120772-01A2]; German Israeli Foundation ; The Wolfson Foundation ; Israel Science Foundation Morasha ; Children with Leukaemia UK ; Leukemia Research Fund UK ; Curtis Katz [MSM0021620813, MZO00064203]; Jewish National Fund, UK ; Claudine Galli Foundation ; Converging Technologies program ; Elterninitiative Kinderkrebsklinik Duesseldorf ","We thank J Crispino, G Lavi and Y Sidi for providing reagents; M Oren for fruitful discussions and provision of reagents; the Department of Pediatric Hematology and Oncology, Dr von Haunersches Kinderspital, Munich, Germany, for providing clinical samples; members of SI and AB laboratories for helpful discussions and, in particular, P Landgraf for his excellent criticism and advice. SI, NG, VB and AB designed experiments. NG, VB, YL, MM, OW, MZ, JT, LE, NS, AN designed and performed experiments. LH analyzed data. NG, VB, AB, SI wrote the paper. This work was supported by National Institute of Health R01 CA120772-01A2 (SI), German Israeli Foundation (SI & AB), The Wolfson Foundation (SI, NS), Israel Science Foundation Morasha (SI), Children with Leukaemia UK (SI), Leukemia Research Fund UK (OW and MM), Curtis Katz (SI), MSM0021620813 and MZO00064203 (JT and MZ), Jewish National Fund, UK (SI), Claudine Galli Foundation (NG), Converging Technologies program (LH), Elterninitiative Kinderkrebsklinik Duesseldorf (AB). The study has been performed as partial fulfillment of the requirements for PhD degree of Nir Gefen and Libi Hertzberg, Sackler School of Medicine, Tel Aviv University.",null,42,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.208","LEUKEMIA","Leukemia","JAN",2010,24,1,null,null,null,89,96,null,null,8,"Oncology; Hematology","543KW","ISI:000273577100012"]
["nemá","J","Kubinova, S; Sykova, E",null,null,null,"Kubinova, Sarka; Sykova, Eva",null,"Nanotechnology for treatment of stroke and spinal cord injury","NANOMEDICINE",null,"English","Review",null,null,null,null,null,"cell therapy; contrast agents; magnetic resonance; nanofibers; scaffold; spinal cord lesion","MESENCHYMAL STEM-CELLS; SUPERPARAMAGNETIC IRON-OXIDE; MAGNETIC-RESONANCE TRACKING; PEPTIDE NANOFIBER SCAFFOLD; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; BONE-MARROW; RAT-BRAIN; ELECTROSPUN NANOFIBERS","The use of nanotechnology in cell therapy and tissue engineering offers promising future perspectives for brain and spinal cord injury treatment. Stem cells have been shown to selectively target injured brain and spinal cord tissue and improve functional recovery. To allow cell detection, superparamagnetic iron-oxide nanoparticles can be used to label transplanted cells. MRI is then a suitable method for the in vivo tracking of grafted cells in the host organism. CNS, and particularly spinal cord, injury is accompanied by tissue damage and the formation of physical and biochemical barriers that prevent axons from regenerating. One aspect of nanomedicine is the development of biologically compatible nanofiber scaffolds that mimic the structure of the extracellular matrix and can serve as a permissive bridge for axonal regeneration or as a drug-delivery system. The incorporation of biologically active epitopes and/or the utilization of these scaffolds as stem cell carriers may further enhance their therapeutic efficacy.","[Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic","Sykova, E, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic","sykova@biomed.cas.cz","EC [LSHM-CT-2005-019063]; GACR [203/09/1242, KAN201110651, KAN200520804]; [A VOZ503 90 703]; [1M0538]; [LC 554]; [IGA MZ 1A8697-5]; [GAAV IAA 500 390 902]","This work was supported through grants: A VOZ503 90 703, 1M0538, LC 554, IGA MZ 1A8697-5, GAAV IAA 500 390 902, the EC FP6 project ENINET (LSHM-CT-2005-019063), GACR 203/09/1242 KAN201110651 and KAN200520804. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,88,0,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1743-5889",null,"10.2217/NNM.09.93","NANOMEDICINE","Nanomedicine","JAN",2010,5,1,null,null,null,99,108,null,null,10,"Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology","544QV","ISI:000273674900015"]
["nemá","J","Hromadka, R; Kubena, AA; Pokorny, D; Popelka, S; Jahoda, D; Sosna, A",null,null,null,"Hromadka, Rastislav; Kubena, Alen Antonin; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin",null,"Lesser tuberosity is more reliable than bicipital groove when determining orientation of humeral head in primary shoulder arthroplasty","SURGICAL AND RADIOLOGIC ANATOMY",null,"English","Article",null,null,null,null,null,"Shoulder arthroplasty; Humeral head retroversion; Bicipital groove; Greater tuberosity; Lesser tuberosity; Crest of greater tuberosity","PECTORALIS MAJOR TENDON; PROXIMAL HUMERUS; COMPUTED-TOMOGRAPHY; RETROVERSION; HEMIARTHROPLASTY; PROSTHESIS; FRACTURES; LANDMARK; REPLACEMENT; REASONS","The objective of the study was to provide statistical evaluation of position of bone landmarks of proximal humerus in relation to transepicondylar line and find out which one is the most suitable for setup of the head retroversion in case of humeral head destruction. We measured 185 dry humeral preparations (92 left, 93 right). Structures of interest on the proximal humerus were marked with pointers of custom made steel frame. Angular relationships between the humeral head axis and medial margin of the greater tuberosity, lateral margin of the lesser tuberosity, bicipital groove, and crest of the greater tuberosity were evaluated with respect to intramedullary axis of the proximal humeral shaft. The angle between the humeral head axis and medial margin of greater tuberosity was 11.5 +/- A 9.0A degrees, the angle between the lateral margin of the lesser tuberosity and the axis was 47.5 +/- A 7.4A degrees, the angle between the bicipital groove and the axis was 31.6 +/- A 8.8A degrees at the level of the humeral head. The angle between the crest of the greater tuberosity and the axis was 26.6 +/- A 9.6A degrees in plane of the surgical neck. We statistically proved that the lateral margin of lesser tuberosity is more reliable than the bicipital groove; medial margin of the greater and transepicondylar line for reconstruction of humeral head retroversion. We suggest that the lesser tuberosity should be used to determine the retroversion, especially in cases when the margin of humeral head was destructed.","[Hromadka, Rastislav; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague 15006, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006, Czech Republic; [Kubena, Alen Antonin] Charles Univ Prague, Fac Sci, Dept Evolut Biol, Prague 15006, Czech Republic","Hromadka, R, Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, V Uvalu 84, Prague 15006, Czech Republic","rastho@gmail.com; voodoolinek@gmail.com; david.pokorny@lf1.cuni.cz; mudr.popelka@volny.cz; david.jahoda@post.cz; sosna.orto@email.cz",null,null,null,19,0,"SPRINGER FRANCE","PARIS","22 RUE DE PALESTRO, PARIS, 75002, FRANCE","1279-8517",null,"10.1007/s00276-009-0543-6","SURG RADIOL ANATOMY","Surg. Radiol. Anat.","JAN",2010,32,1,null,null,null,31,37,null,null,7,"Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery","544UX","ISI:000273685900006"]
["nemá","J","Rozkova, D; Novotna, L; Pytlik, R; Hochova, I; Kozak, T; Bartunkova, J; Spisek, R",null,null,null,"Rozkova, Daniela; Novotna, Linda; Pytlik, Robert; Hochova, Ivana; Kozak, Tomas; Bartunkova, Jirina; Spisek, Radek",null,"Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation","INTERNATIONAL JOURNAL OF CANCER",null,"English","Article",null,null,null,null,null,"B-Cell chronic lymphocytic leukemia; toll-like receptors; tumor immunology; B-cells; cancer immunotherapy","CHRONIC LYMPHOCYTIC-LEUKEMIA; CD38 EXPRESSION; PROGNOSTIC INDICATORS; MARKER EXPRESSION; UP-REGULATION; CPG MOTIFS; ACTIVATION; INTERLEUKIN-6; APOPTOSIS; MEMORY","Toll-like receptor (TLR) stimulation plays a crucial role in the homeostasis of human B cells. We investigated the expression of TLRs 1-9 on the cells of B-cell chronic lymphocytic leukemia (B-CLL) and analyzed the functional consequences of TLR stimulation on leukemic cells. We showed that B-CLL cells express similar set of TLRs as memory B cells of healthy donors, i.e. TLR-1, TLR-2, TLR-6, TLR-7 and TLR-9. However, in contrast to memory B cells, B-CLL cells lack TLR-4 expression. Expression of TLRs correlates with their capacity to respond to specific TLR agonists. At the level of phenotype, ODN2006 (TLR-9 agonist) is the most potent stimulus. B-CLL cells also respond to the stimulation with loxoribine, Pam3CSK4 and MALP-2 (TLR-7, TLR1/TLR2 and TLR2/TLR6 agonists, respectively). TLR-7 and TLR-9 stimulation induces production of IL-6 and TNF alpha. In 47% of tested patients, treatment with ODN2006, MALP-2 and Pam3CSK4 reduced leukemic cells survival. Stimulation of B-CLL cells with TLR-9 agonists, loxoribine, MALP-2 and Pam3CSK4 induces significant proliferation. We report that TLR stimulation induces expression of CD38, a negative prognostic marker, on B-CLL cells. Expression of CD38 is induced by direct stimulation of B-CLL cells through TLR-7 and TLR-9 or CD38 can be induced on B-CLL cells indirectly by a soluble factor induced in non-B-CLL cells after stimulation with TLR-2, TLR-3 or TLR-5 agonists; the nature of this factor remains unknown. Our results argue for cautious evaluation of immunointervention strategies based on the administration of TLR agonists in the treatment of B-CLL as their effects on B-CLL cells may be tumor promoting as well as tumor suppressing.","[Rozkova, Daniela; Novotna, Linda; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, Prague 15006 5, Motol, Czech Republic; [Pytlik, Robert] Charles Univ Prague, Gen Univ Hosp, Fac Med 1, Dept Med 1, Prague 15006 5, Motol, Czech Republic; [Hochova, Ivana] Charles Univ Prague, Univ Hosp Motel, Fac Med 2, Dept Hematol, Prague 15006 5, Motol, Czech Republic; [Kozak, Tomas] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Clin Hematol, Prague 15006 5, Motol, Czech Republic","Rozkova, D, Charles Univ Prague, Dept Immunol, Sch Med 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic","daniela.rozkova@lfmotol.cuni.cz","Grant Agency of Czech Republic [310/08/P353]; Ministry of Education [MSM 0021620812]","Grant sponsor: Grant Agency of Czech Republic; Grant number: 310/08/P353; Grant sponsor: Ministry of Education; Grant number: MSM 0021620812",null,45,0,"JOHN WILEY & SONS INC","HOBOKEN","111 RIVER ST, HOBOKEN, NJ 07030 USA","0020-7136",null,"10.1002/ijc.24832","INT J CANCER","Int. J. Cancer","MAR 1",2010,126,5,null,null,null,1132,1143,null,null,12,"Oncology","547PU","ISI:000273902300010"]
["nemá","J","Barinka, F; Druga, R; Marusic, P; Krsek, P; Zamecnik, J",null,null,null,"Barinka, Filip; Druga, Rastislav; Marusic, Petr; Krsek, Pavel; Zamecnik, Josef",null,"Calretinin immunoreactivity in focal cortical dysplasias and in non-malformed epileptic cortex","EPILEPSY RESEARCH",null,"English","Article",null,null,null,null,null,"Epilepsy; Cortical dysplasia; Calretinin; Inhibitory interneurons","CALCIUM-BINDING PROTEINS; LOCAL-CIRCUIT NEURONS; HUMAN TEMPORAL CORTEX; CAJAL-RETZIUS CELLS; PREFRONTAL CORTEX; ALZHEIMERS-DISEASE; CALBINDIN D-28K; SYNAPTIC CONNECTIONS; HUMAN NEOCORTEX; PARVALBUMIN","Focal cortical dysplasias (FCDs) represent a prominent cause of pharmacologically intractable epilepsy. In FCD, the decrease of parvalbumin immunoreactive (PV+) inhibitory interneurons has been repeatedly documented. Here, we wanted to show whether another interneuronal population, the calretinin immunoreactive (CR+) neurons, exhibits any change in human FCD. We also investigated samples of morphologically normal temporal neocortex resected together with sclerotic hippocampus (nHSTN), where decrease of PV+ interneurons was previously documented as well Brain tissue from 24 patients surgically treated for pharmacoresistant epilepsy was examined. Calretinin immunoreactivity was qualitatively evaluated and the density of CR+ neuronal profiles was quantified. As a control, post-mortem acquired neocortical samples of nine patients without any brain affecting disease were used. CR+ neurons were located predominantly in superficial cortical layers both in controls and pathological samples. Similarly, the morphology of CR+ neurons was unaffected in pathological samples. The overall density of CR+ neurons was significantly decreased in FCD type I (to approximately 70% of control values) and even more in FCD type II (to approximately 50% of controls). In nHSTN, no change compared to controls was found in CR+ neuronal density. Our results may contribute to the better understanding of the role of individual interneuronal populations in epileptogenesis. (C) 2009 Elsevier B.V. All rights reserved.","[Barinka, Filip; Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 2, Prague 12800, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 1, Prague 12800, Czech Republic; [Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 12800, Czech Republic; [Marusic, Petr] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Prague 12800, Czech Republic; [Krsek, Pavel] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague 12800, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 12800, Czech Republic","Barinka, F, Charles Univ Prague, Dept Anat, Fac Med 2, U Nemocnice 3, Prague 12800, Czech Republic","filipbarinka@yahoo.co.uk","Agency of Charles University [35407]; Ministry of Health of the Czech Republic: IGA MZCR [NS/9915-4, NR/8843-4, VZ FNM 00064203]","This work was supported by Grant Agency of Charles University, Grant No. 35407 and by Grants of the Ministry of Health of the Czech Republic: IGA MZCR NS/9915-4, NR/8843-4 and VZ FNM 00064203.",null,48,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0920-1211",null,"10.1016/j.eplepsyres.2009.09.021","EPILEPSY RES","Epilepsy Res.","JAN",2010,88,1,null,null,null,76,86,null,null,11,"Clinical Neurology","549NQ","ISI:000274058700007"]
["nemá","J","Seeman, T; Dusek, J; Vondrak, K; Janda, J",null,null,null,"Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Janda, Jan",null,"Ramipril in the treatment of proteinuria in children after renal transplantation","PEDIATRIC TRANSPLANTATION",null,"English","Article",null,null,null,null,null,"ramipril; proteinuria; hypertension; renal transplantation; graft function","ANTIPROTEINURIC EFFICACY; BLOOD-PRESSURE; HYPERTENSION; RECIPIENTS; SURVIVAL; ADOLESCENTS; INHIBITION; MANAGEMENT; DISEASES; FAILURE","The efficacy and safety of ACEI in adult patients with hypertension and proteinuria after renal transplantation is proven however data on the effectiveness of ACEI in transplanted children are rare. The aim of the present study was to investigate the effect of ramipril on proteinuria and BP in children after R-Tx. Twelve transplanted children (median age 15.3 yr, median time after R-Tx 4.5 yr) with proteinuria with or without hypertension were prospectively treated with ramipril for six months. Proteinuria was assessed as protein/creatinine ratio. Office BP was evaluated and hypertension defined as BP >= 95th centile. Graft function was assessed (Schwartz formula). The starting dose of ramipril was 1.5 mg/m2/24-h. Proteinuria declined in 92% of children from a median 39 to 22 mg/mmol creatinine (p < 0.01). The median decline of proteinuria was 9 mg/mmol creatinine, it reached 23% of the initial values. The prevalence of hypertension did not change significantly (50% initially vs. 33% after six months). Graft function and serum potassium level did not change significantly, two children developed mild hyperkalemia. Ramipril can reduce proteinuria in most transplanted children; its antiproteinuric effect is exhibited even without BP lowering effect.","[Seeman, Tomas] Charles Univ Prague, Dept Pediat, Prague 15006, Czech Republic; Charles Univ Prague, Transplantat Ctr, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic","Seeman, T, Charles Univ Prague, Dept Pediat, V Ulavu 84, Prague 15006, Czech Republic","tomas.seeman@lfmotol.cuni.cz","IGA of the Ministry of Health or the Czech Republic [NR/9524-3, 0021620819]","This study was supported by grants IGA of the Ministry of Health or the Czech Republic reg. Nr. NR/9524-3 and VZ MSMT reg. Nr. 0021620819.",null,25,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1397-3142",null,"10.1111/j.1399-3046.2009.01216.x","PEDIATR TRANSPLANT","Pediatr. Transplant.","MAR",2010,14,2,null,null,null,283,287,null,null,5,"Pediatrics; Transplantation","553TL","ISI:000274389600022"]
["nemá","J","Maton, B; Krsek, P; Jayakar, P; Resnick, T; Koehn, M; Morrison, G; Ragheb, J; Castellano-Sanchez, A; Duchowny, M",null,null,null,"Maton, Bruno; Krsek, Pavel; Jayakar, Prasanna; Resnick, Trevor; Koehn, Monica; Morrison, Glenn; Ragheb, John; Castellano-Sanchez, Amilcar; Duchowny, Michael",null,"Medically intractable epilepsy in Sturge-Weber syndrome is associated with cortical malformation: Implications for surgical therapy","EPILEPSIA",null,"English","Article",null,null,null,null,null,"Sturge-Weber syndrome; Epilepsy; Young children; Polymicrogyria; Cortical dysplasia","PEDIATRIC EPILEPSY; FDG-PET; CHILDREN; DISEASE; ABNORMALITIES; DYSPLASIA; MIGRATION; PERFUSION; SURGERY; MRI","Purpose: Anecdotal reports have described cortical malformations in epileptic patients with Sturge-Weber syndrome (SWS). No data are available regarding the prevalence and significance of this association. Methods: We reviewed retrospectively the clinical profile, preoperative magnetic resonance imaging (MRI) studies, and pathology reports of all patients with SWS and medically intractable epilepsy evaluated in our epilepsy surgery program between 1979 and 2006. Results: Twelve patients (male/female = 7/5) were identified. Mean age at seizure onset was 11.1 +/- 16.7 months. Seizures occurred daily in seven patients and weekly in five patients. A facial port-wine stain was noted in 10 cases. Eleven patients evidenced developmental delay and eight were hemiparetic. Eight patients underwent excisional surgery for epilepsy (mean age 10.3 +/- 6.5 year), including hemispherectomy (n = 4) and focal cortical resection (n = 4). Tissue was available for neuropathology in six operated cases and revealed polymicrogyria. (n = 3) and cortical dysplasia (n = 4). Polymicrogyria. was associated with cortical dysplasia in one child. Brain MRIs were reviewed in 10 of 12 patients and were consistent with cortical malformations in all cases. Conclusions: We conclude that cortical malformations are frequent in patients with medically intractable epilepsy and Sturge-Weber-syndrome and may be the primary cause of epilepsy.","[Duchowny, Michael] Miami Childrens Hosp, Dept Neurol, Inst Brain, Miami, FL 33155 USA; [Krsek, Pavel] Charles Univ Prague, Sch Med 2, Motol Univ Hosp, Dept Pediat Neurol, Prague, Czech Republic; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Koehn, Monica] Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield, WI USA; [Morrison, Glenn; Ragheb, John] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Castellano-Sanchez, Amilcar] Miami Childrens Hosp, Dept Pathol, Miami, FL USA","Duchowny, M, Miami Childrens Hosp, Dept Neurol, Inst Brain, 3200 SW 60th Court,Suite 302, Miami, FL 33155 USA","michael.duchowny@mch.com","[VZ MZO 00064204]","This work was partially support by grant VZ MZO 00064204. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",null,51,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,"10.1111/j.1528-1167.2009.02304.x","EPILEPSIA","Epilepsia","FEB",2010,51,2,null,null,null,257,267,null,null,11,"Clinical Neurology","550RB","ISI:000274144900010"]
["nemá","J","Keil, R; Snajdauf, J; Rygl, M; Pycha, K; Kotalova, R; Drabek, J; Stovicek, J; Procke, M",null,null,null,"Keil, R.; Snajdauf, J.; Rygl, M.; Pycha, K.; Kotalova, R.; Drabek, J.; Stovicek, J.; Procke, M.",null,"Diagnostic efficacy of ERCP in cholestatic infants and neonates - a retrospective study on a large series","ENDOSCOPY",null,"English","Article",null,null,null,null,null,null,"ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; EXTRAHEPATIC BILIARY ATRESIA; MR CHOLANGIOGRAPHY; TRIANGULAR CORD; LIVER-BIOPSY; CHILDREN; DISEASES; SURGERY; AGE","Background and study aims: Cholestatic jaundice in infants is a serious condition, requiring timely and accurate diagnostic evaluation. Our aim was to determine the safety and diagnostic efficacy of endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of cholestatic liver disease in neonates and infants. Patients and methods: ERCP procedures in cholestatic infants performed in our endoscopy unit between December 1998 and March 2008 were reviewed retrospectively (n = 104 children, 48 boys, 56 girls; mean age 7 weeks, range 3-25 weeks; mean weight 4.05 kg, range 1.5-4.8 kg). Endoscopic findings were compared with final diagnoses. Statistical analysis was performed and sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of ERCP were calculated both separately for each diagnosis and on aggregate. Results: Cannulation of the papilla was successful in 95 of 104 patients (success rate 91.3%). Biliary atresia of any type was found in 51 children (53.7%), with a sensitivity of 86%, a specificity of 94%, a PPV of 96%, and a NPV of 100%. Choledochal cysts were found in seven children (7.4%), with a sensitivity of 100%, a specificity of 90%, PPV of 86%, and NPV of 100%. Biliary stones were found in seven patients (7.4%). Other structural pathology was found in six patients, and no abnormality was seen in 24 patients. No severe complications occurred during or after ERCP. Conclusions: ERCP in cholestatic infants, when performed in an expert center, is a safe and reliable procedure that can detect biliary tract abnormalities (e. g. biliary atresia, bile duct stones or choledochal cysts) with high sensitivity and specificity. Laparotomies can be prevented in infants by demonstrating normal patency of the biliary tract by ERCP or by magnetic resonance cholangiography if improvements in this technique are made.","[Keil, R.; Drabek, J.; Stovicek, J.; Procke, M.] Charles Univ Prague, Motol Univ Hosp, Dept Internal Med Gastroenterol & Endoscopy, Sch Med 2, Prague, Czech Republic; [Snajdauf, J.; Rygl, M.; Pycha, K.] Charles Univ Prague, Motol Univ Hosp, Dept Pediat Surg, Sch Med 2, Prague, Czech Republic; [Kotalova, R.] Charles Univ Prague, Motol Univ Hosp, Dept Pediat, Sch Med 2, Prague, Czech Republic","Procke, M, FN Motol, Interni Klin UK 2 LF, V Uvalu 84, Prague 15006 5, Czech Republic","michal.procke@fnmotol.cz",null,null,null,33,0,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0013-726X",null,"10.1055/s-0029-1215372","ENDOSCOPY","Endoscopy","FEB",2010,42,2,null,null,null,121,126,null,null,6,"Gastroenterology & Hepatology; Surgery","552XZ","ISI:000274329800006"]
["nemá","J","Hrebackova, J; Hrabeta, J; Eckschlager, T",null,null,null,"Hrebackova, J.; Hrabeta, J.; Eckschlager, T.",null,"Valproic Acid in the Complex Therapy of Malignant Tumors","CURRENT DRUG TARGETS",null,"English","Review",null,null,null,null,null,"Valproic acid; histone deacetylase inhibitors; antiangiogenic effect; anticancer effect; clinical studies","HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; NITRIC-OXIDE SYNTHASE; HUMAN NEUROBLASTOMA-CELLS; HEMATOPOIETIC STEM-CELLS; PROSTATE-CANCER CELLS; GROWTH IN-VITRO; NF-KAPPA-B; GENE-EXPRESSION","Valproic acid (VPA) has been used for epilepsy treatment since the 1970s. Recently, it was demonstrated that it inhibits histone deacetylases (HDAC), modulates cell cycle, induces tumor cell death and inhibits angiogenesis in various tumor models. The exact anticancer mechanisms of VPA remains unclear, but HDAC inhibition, extracellular-regulated kinase activation, protein kinase C inhibition, Wnt-signaling activation, proteasomal degradation of HDAC, possible downregulation of telomerase activity and DNA demethylation participate in its anticancer effect. Hyperacetylation of histones, as a result of HDAC inhibition, seems to be the most important mechanism of VPA's antitumor action. Preclinical data suggest that the anticancer effect of chemotherapy is augmented when VPA is used in combination with cytostatics. Besides the effects of pretreatment with HDAC inhibitors, which increases the efficiency of 5-aza-2'-deoxycytidine, VP-16, ellipticine, doxorubicin and cisplatin, pre-exposure to VPA increases the cytotoxicity of topoisomerase II inhibitors. There are two suggested cell death mechanisms caused by potentiation of anticancer drugs by HDAC inhibitors that are neither exclusive nor synergistic. The first involves apoptosis and can be both p53 dependent or independent; the second involves mechanisms other than apoptosis. In resistant chronic myeloid leukemia (CML), VPA restores sensitivity to imatinib. We have demonstrated the synergistic effects of VPA and cisplatin in neuroblastoma cells. VPA can be taken orally, crosses the blood brain barrier and can be used for extended periods. Clinical trials in patients with malignancies are being conducted. The use of VPA prior to or together with anticancer drugs may thus prove a beneficial treatment.","[Eckschlager, T.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Eckschlager, T, Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","eckschlagertomas@yahoo.com","Ministry of Health of the Czech Republic [NR9522-3/2007]; Ministry of Education of the Czech Republic [MSM0021620813]","Research on VPA at the Department of Pediatric Hematology and Oncology, 2<SUP>nd</SUP> Faculty of Medicine, Charles University, Prague is supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic (grant NR9522-3/2007) and the Ministry of Education of the Czech Republic (grants MSM0021620813).",null,165,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-4501",null,null,"CURR DRUG TARGETS","Curr. Drug Targets","MAR",2010,11,3,null,null,null,361,379,null,null,19,"Pharmacology & Pharmacy","554FB","ISI:000274419800010"]
["nemá","J","Prusa, R; Doupovcova, J; Warunek, D; Stankovic, AK",null,null,null,"Prusa, Richard; Doupovcova, Jana; Warunek, David; Stankovic, Ana K.",null,"Improving laboratory efficiencies through significant time reduction in the preanalytical phase","CLINICAL CHEMISTRY AND LABORATORY MEDICINE",null,"English","Letter",null,null,null,null,null,"analysis of variance (ANOVA); blood collection tube; centrifugation time; clinical acceptance limits; clotting time; collection time; confidence interval; emergency department; preanalytical turnaround time; total turnaround time","EMERGENCY-DEPARTMENT; TURNAROUND TIME; QUALITY",null,"[Prusa, Richard; Doupovcova, Jana] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006, Czech Republic; [Prusa, Richard; Doupovcova, Jana] Fac Hosp Motol, Prague 15006, Czech Republic; [Warunek, David; Stankovic, Ana K.] BD Diagnost Preanalyt Syst, Franklin Lakes, NJ USA","Prusa, R, Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, V Uvalu 84,Praha 5, Prague 15006, Czech Republic","richard.prusa@fnmotol.cz",null,null,null,7,0,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1434-6621",null,"10.1515/CCLM.2010.036","CLIN CHEM LAB MED","Clin. Chem. Lab. Med.","FEB",2010,48,2,null,null,null,293,296,null,null,4,"Medical Laboratory Technology","552JM","ISI:000274286000023"]
["nemá","J","Mohelnikova-Duchonova, B; Vrana, D; Holcatova, I; Ryska, M; Smerhovsky, Z; Soucek, P",null,null,null,"Mohelnikova-Duchonova, Beatrice; Vrana, David; Holcatova, Ivana; Ryska, Miroslav; Smerhovsky, Zdenek; Soucek, Pavel",null,"CYP2A13, ADH1B, and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk","PANCREAS",null,"English","Article",null,null,null,null,null,"pancreas; cancer; polymorphism; CYP2A13; ADH1","TOBACCO-SPECIFIC CARCINOGEN; SQUAMOUS-CELL CARCINOMA; ALDEHYDE DEHYDROGENASE; METABOLIC-ACTIVATION; ACINAR-CELLS; LUNG-CANCER; ALCOHOL; CONSUMPTION; ETHANOL; CYTOCHROME-P450","Objectives: Pancreatic carcinoma etiology and molecular pathogenesis are weakly understood. Based on the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, we studied the association of polymorphisms in the tobacco carcinogen-metabolizing gene CYP2A13 (Arg101Stop) and the alcohol-metabolizing genes ADH1B (Arg48His) and ADH1C (Ile350Val) with pancreatic cancer risk. Methods: Polymorphisms were studied by allelic discrimination. Results: In a hospital-based case-control study, CYP2A13 variant alleles coding an inactive enzyme were found in 7 of 265 cancer-free controls and in none of 235 pancreatic carcinoma patients. Neither ADH1B or ADH1C polymorphisms alone nor their combinations showed a significant effect on pancreatic cancer risk. Conclusions: The first study of the roles of CYP2A13, ADH1B, and ADH1C in pancreatic cancer etiology suggested that the controls may have a lower ability to bioactivate tobacco-derived procarcinogens than the cases.","[Mohelnikova-Duchonova, Beatrice; Vrana, David; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Vrana, David] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic; [Vrana, David] Gen Teaching Hosp, Prague, Czech Republic; [Holcatova, Ivana] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic; [Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Ryska, Miroslav] Cent Mil Hosp, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol, Prague, Czech Republic","Soucek, P, Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic","psoucek@szu.cz","Ministry of Health, Czech Republic [8563-5, 9422-3]","This work was supported by the Internal grant agency of the Ministry of Health, Czech Republic (grants Nos. 8563-5 and 9422-3).",null,33,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0885-3177",null,"10.1097/MPA.0b013e3181bab6c2","PANCREAS","Pancreas","MAR",2010,39,2,null,null,null,144,148,null,null,5,"Gastroenterology & Hepatology","561WE","ISI:000275010000004"]
["nemá","J","Huskova, Z; Vanourkova, Z; Erbanova, M; Thumova, M; Opocensky, M; Mullins, JJ; Kramer, HJ; Burgelova, M; Cervenka, L",null,null,null,"Huskova, Zuzana; Vanourkova, Zdenka; Erbanova, Michaela; Thumova, Monika; Opocensky, Martin; Mullins, John J.; Kramer, Herbert J.; Buergelova, Marcela; Cervenka, Ludek",null,"Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats","JOURNAL OF HYPERTENSION",null,"English","Article",null,null,null,null,null,"aldosterone; angiotensin II; high and low-salt diet; hypertension; inducible renin gene transgenic rats; renin-angiotensin system","BLOOD-PRESSURE RESEARCH; END-ORGAN DAMAGE; ANG-II; CONVERTING ENZYME; DEPENDENT HYPERTENSION; SENSITIVE HYPERTENSION; FUNCTIONAL-RESPONSES; ARTERIAL-PRESSURE; RECEPTOR BLOCKADE; SODIUM INTAKE","Objective We evaluated the effects of salt restriction and of increasing dietary salt loading on blood pressure and the renin-angiotensin system in transgenic rats with inducible hypertension. Methods Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration of the natural xenobiotic indole-3-carbinol (0.3%), which activates the renin gene. Rats were fed either a normal-salt diet (0.6% NaCl), three different high-salt diets (2, 4 and 8% NaCl) or a low-salt diet (< 0.04% NaCl). Blood pressure was monitored by radiotelemetry. Angiotensin II (ANG II) levels were determined by radioimmunoassay. Results Induction of the renin gene by administration of indole-3-carbinol resulted in normal-salt diet fed animals in the development of severe hypertension that was accompanied by marked increases in plasma and kidney ANG II levels. Feeding the low-salt diet substantially attenuated the development of hypertension. Treatment with the 2 and 4% high-salt diet did not worsen the course of hypertension and did not alter ANG II levels when compared with rats on the normal salt diet. Feeding the 8% high-salt diet exacerbated the course of hypertension and was associated with further strong increases in plasma and kidney ANG II levels. Conclusion Our results demonstrate that after induction of the renin gene in Cyp1a1-Ren-2 transgenic rats inappropriate increases in plasma and kidney ANG II levels in response to very high dietary salt intake are responsible for the development of severe hypertension in this model of inducible renin transgenic rats. J Hypertens 28:495-509 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Huskova, Zuzana; Vanourkova, Zdenka; Erbanova, Michaela; Thumova, Monika; Opocensky, Martin; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Huskova, Zuzana; Vanourkova, Zdenka; Erbanova, Michaela; Thumova, Monika; Opocensky, Martin; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Mullins, John J.] Univ Edinburgh, Sch Med, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Kramer, Herbert J.] Univ Bonn, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany; [Buergelova, Marcela] Charles Univ Prague, Dept Nephrol, Inst Clin & Expt Med, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Czech Science Foundation [GAC. R 305/08/P053, GAC. R 305/08/J006]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Grant Agency of Academy of Science of Czech Republic [GAAV - IAA 511-700-701]; German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn [Kra 433/142, 436 TSE 113/50/0-1]","This study was supported by grant no. GAC. R 305/08/P053 awarded to Z. H. by the Czech Science Foundation. Z. V. is supported from the Center for Cardiovascular Research (1M6798582302). M. O. and M. T are supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). L. C. is supported by grant from Czech Science Foundation (GAC. R 305/08/J006). M. B. is supported by grant from the Grant Agency of Academy of Science of Czech Republic (GAAV - IAA 511-700-701). H.J.K. is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 433/142 and 436 TSE 113/50/0-1).",null,56,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/HJH.0b013e3283345d69","J HYPERTENSION","J. Hypertens.","MAR",2010,28,3,null,null,null,495,509,null,null,15,"Peripheral Vascular Disease","562QN","ISI:000275068200013"]
["nemá","J","Walkowska, A; Skaroupkova, P; Huskova, Z; Vanourkova, Z; Chabova, VC; Tesar, V; Kramer, HJ; Falck, JR; Imig, JD; Kompanowska-Jezierska, E; Sadowski, J; Cervenka, L",null,null,null,"Walkowska, Agnieszka; Skaroupkova, Petra; Huskova, Zuzana; Vanourkova, Zdenka; Chabova, Vera Certikova; Tesar, Vladimir; Kramer, Herbert J.; Falck, John R.; Imig, John D.; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Cervenka, Ludek",null,"Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats","JOURNAL OF HYPERTENSION",null,"English","Article",null,null,null,null,null,"20-hydroxyeicosatetraenoic acid; cytochrome P-450 metabolites; epoxyeicosatrienoic acids; renal function; renin-angiotensin system; two-kidney one-clip Goldblatt hypertension","SOLUBLE EPOXIDE HYDROLASE; REN-2 TRANSGENIC RATS; ANGIOTENSIN-II LEVELS; EPOXYEICOSATRIENOIC ACIDS; BLOOD-PRESSURE; NITRIC-OXIDE; 20-HYDROXYEICOSATETRAENOIC ACID; TUBULOGLOMERULAR FEEDBACK; HYPERPOLARIZING FACTORS; RENAL-FUNCTION","Objective The contribution of epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) as cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip (2K1C) Goldblatt hypertensive rats was investigated during the phases of initial and stable hypertension, that is, 7 or 27 days after clipping, respectively. Methods Male Hannover Sprague-Dawley rats had the right renal artery clipped or underwent sham operation. Urinary excretion of EETs, their inactive metabolites dihydroxyeicosatrienoic acids and of 20-HETE was measured. Intrarenal cytochrome P-450 protein expression and the activities of epoxygenase, omega-hydroxylase and soluble epoxide hydrolase were also determined. The responses of renal hemodynamics and electrolyte excretion of the nonclipped kidney to left renal artery infusions of inhibitors of EETs or 20-HETE formation (MS-PPOH and DDMS, respectively) were measured. Results In 2K1C rats, urinary excretion of EETs was significantly lower and that of 20- HETE was higher than that in sham-operated animals only on day 27 after clipping. Intrarenal inhibition of EETs significantly decreased renal hemodynamics and sodium excretion in sham-operated but not in 2K1C rats. Intrarenal inhibition of 20-HETE decreased sodium excretion in sham-operated rats but elicited increases in renal hemodynamics and sodium excretion in 2K1C rats. Conclusion Our results indicate that the nonclipped kidney of Goldblatt 2K1C rats in the phase of sustained hypertension exhibits decreased intrarenal EETs and elevated 20-HETE levels as compared with the kidney of sham-operated animals. This suggests that altered production and action of cytochrome P-450-derived metabolites during this stable phase contributes to the mechanism of Goldblatt 2K1C hypertension. J Hypertens 28:582-593 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Walkowska, Agnieszka; Skaroupkova, Petra; Huskova, Zuzana; Vanourkova, Zdenka; Chabova, Vera Certikova; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Polish Acad Sci, Lab Renal & Body Fluid Physiol, M Mossakowski Med Res Ctr, Warsaw, Poland; [Skaroupkova, Petra; Huskova, Zuzana; Vanourkova, Zdenka] Charles Univ Prague, Cardiovasc Res Ctr, Prague, Czech Republic; [Chabova, Vera Certikova; Tesar, Vladimir] Charles Univ Prague, Dept Nephrol, Fac Med 1, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Nephrol Sect, Med Policlin, Dept Med, D-5300 Bonn, Germany; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Czech Science Foundation [305/08/J006, 305/08/P053]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Ministry of Health of the Czech Republic [NS/10499-3]; National Institutes of Health [HL59699, DK38226]; Advancing a Healthier Wisconsin ; German Research Foundation (DFG), Bonn [Kra 433/14-2, 436 TSE 113/50/0-1]; Robert A. Welch Foundation ; NIH [GM31278]","The present study was supported by grant No. 305/08/J006 awarded to L. C.. by Czech Science Foundation (GACR). Z.H. is supported by the grant awarded by Czech Science Foundation (GACR) No. 305/08/P053. A. W. was partly supported by the Center for Cardiovascular Research (1M6798582302) and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). Z.V. was partly supported by grant No. NS/10499-3 awarded to L. C.. by the Internal Grant Agency of the Ministry of Health of the Czech Republic. J.D.I. is supported by grants from the National Institutes of Health (HL59699 and DK38226) and Advancing a Healthier Wisconsin. H.J.K. is supported by grants from the German Research Foundation (DFG), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1). J.R.F. was supported by the Robert A. Welch Foundation and NIH GM31278.",null,51,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/HJH.0b013e328334dfd4","J HYPERTENSION","J. Hypertens.","MAR",2010,28,3,null,null,null,582,593,null,null,12,"Peripheral Vascular Disease","562QN","ISI:000275068200023"]
["nemá","J","Cardwell, CR; Stene, LC; Joner, G; Davis, EA; Cinek, O; Rosenbauer, J; Ludvigsson, J; Castell, C; Svensson, J; Goldacre, MJ; Waldhoer, T; Polanska, J; Gimeno, SGA; Chuang, LM; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Pozzilli, P; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Patterson, CC",null,null,null,"Cardwell, C. R.; Stene, L. C.; Joner, G.; Davis, E. A.; Cinek, O.; Rosenbauer, J.; Ludvigsson, J.; Castell, C.; Svensson, J.; Goldacre, M. J.; Waldhoer, T.; Polanska, J.; Gimeno, S. G. A.; Chuang, L. -M.; Parslow, R. C.; Wadsworth, E. J. K.; Chetwynd, A.; Pozzilli, P.; Brigis, G.; Urbonaite, B.; Sipetic, S.; Schober, E.; Ionescu-Tirgoviste, C.; de Beaufort, C. E.; Stoyanov, D.; Buschard, K.; Patterson, C. C.",null,"Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data","DIABETOLOGIA",null,"English","Article",null,null,null,null,null,"Birthweight; Epidemiology; Meta-analysis; Risk factors; Type 1 diabetes mellitus","SUBSEQUENT RISK; EARLY-LIFE; IN-UTERO; POPULATION; MELLITUS; CHILDREN; DETERMINANTS; IDDM; GROWTH; UK","We investigated whether children who are heavier at birth have an increased risk of type 1 diabetes. Relevant studies published before February 2009 were identified from literature searches using MEDLINE, Web of Science and EMBASE. Authors of all studies containing relevant data were contacted and asked to provide individual patient data or conduct pre-specified analyses. Risk estimates of type 1 diabetes by category of birthweight were calculated for each study, before and after adjustment for potential confounders. Meta-analysis techniques were then used to derive combined ORs and investigate heterogeneity between studies. Data were available for 29 predominantly European studies (five cohort, 24 case-control studies), including 12,807 cases of type 1 diabetes. Overall, studies consistently demonstrated that children with birthweight from 3.5 to 4 kg had an increased risk of diabetes of 6% (OR 1.06 [95% CI 1.01-1.11]; p = 0.02) and children with birthweight over 4 kg had an increased risk of 10% (OR 1.10 [95% CI 1.04-1.19]; p = 0.003), compared with children weighing 3.0 to 3.5 kg at birth. This corresponded to a linear increase in diabetes risk of 3% per 500 g increase in birthweight (OR 1.03 [95% CI 1.00-1.06]; p = 0.03). Adjustments for potential confounders such as gestational age, maternal age, birth order, Caesarean section, breastfeeding and maternal diabetes had little effect on these findings. Children who are heavier at birth have a significant and consistent, but relatively small increase in risk of type 1 diabetes.","[Cardwell, C. R.; Patterson, C. C.] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; [Stene, L. C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, L. C.; Joner, G.] Oslo Univ Hosp, Oslo Diabet Res Ctr, Oslo, Norway; [Joner, G.] Univ Oslo, Fac Med, Oslo, Norway; [Davis, E. A.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Cinek, O.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, J.] Univ Dusseldorf, Inst Biometr & Epidemiol, German Diabet Ctr, Leibniz Inst, Dusseldorf, Germany; [Ludvigsson, J.] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, J.] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Castell, C.] Advisory Comm Diabet Catalonia, Dept Hlth, Barcelona, Spain; [Svensson, J.] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, M. J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, T.] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Polanska, J.] Silesian Tech Univ, Fac Automat Control Elect & Comp Sci, Gliwice, Poland; [Gimeno, S. G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, L. -M.] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Parslow, R. C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, E. J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, A.] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Pozzilli, P.] Univ Campus Biomed, Rome, Italy; [Brigis, G.] Riga Stradins Univ, Dept Publ Hlth & Epidemiol, Riga, Latvia; [Urbonaite, B.] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, S.] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, E.] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Ionescu-Tirgoviste, C.] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, C. E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, D.] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, K.] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark","Cardwell, CR, Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland","c.cardwell@qub.ac.uk","Czech Republic Ministry of Education [0021620814]; Department of Health in Taiwan [DOH 92- TD1052]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Centro Internazionale Studi Diabete (Italy, Rome) ; Swedish Child Diabetes Foundation ; NHS National Coordinating Centre for Research Capacity Development UK ; Research Council of Norway ; German Research Foundation [HE 234/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes UK ; Northern Ireland Department of Health and Social Services ","The authors acknowledge support for the conduct of the original studies from the following the Czech Republic Ministry of Education (grant MSM 0021620814), the Department of Health in Taiwan (grant DOH 92- TD1052), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 94/0943-0), the Centro Internazionale Studi Diabete (Italy, Rome), The Swedish Child Diabetes Foundation, the NHS National Coordinating Centre for Research Capacity Development UK, the Research Council of Norway, the German Research Foundation (grant HE 234/1-1), the Ministry for Science and Technological Development of Serbia (number 145084, 2006-2010), EUBIROD (funded by the European Commission Health Information Strand, DG-SANCO 2005, contract number 2007115), Diabetes UK and the Northern Ireland Department of Health and Social Services. Thanks also to G. Soltesz (University of Pecs, Pecs, Hungary) and G. Dahlquist (Umea University, Umea, Sweden), the co-ordinators of the EURODIAB Substudy 2. We also thank M. Jane (Department of Health, Barcelona, Spain).",null,59,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X",null,"10.1007/s00125-009-1648-5","DIABETOLOGIA","Diabetologia","APR",2010,53,4,null,null,null,641,651,null,null,11,"Endocrinology & Metabolism","562WU","ISI:000275087100008"]
["nemá","J","Amemori, T; Jendelova, P; Ruzickova, K; Arboleda, D; Sykova, E",null,null,null,"Amemori, Takashi; Jendelova, Pavla; Ruzickova, Katerina; Arboleda, David; Sykova, Eva",null,"Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells does not have synergistic effects after spinal cord injury in the rat","CYTOTHERAPY",null,"English","Article",null,null,null,null,null,null,"STEM-CELLS; SCHWANN-CELLS; IN-VIVO; CAVITY FORMATION; LAMINA-PROPRIA; WHITE-MATTER; MIGRATION; RECOVERY; RHO; REGENERATION","Background aims. Olfactory ensheathing glia (OEG) and mesenchymal stromal cells (MSC) are suitable candidates for transplantation therapy of spinal cord injury (SCI). Both facilitate functional improvement after SCI by producing trophic factors and cytokines. In this study, the co-transplantation of both types of cells was studied to clarify their additive and/ or synergistic effects on SCI. Methods. A balloon-induced compression lesion was used to produce SCI in rats. OEG, MSC or both OEG and MSC (3 x 10<SU5</SU cells of each cell type) were implanted by intraspinal injection 1 week after SCI. The effect of transplantation was assessed using behavioral, electrophysiologic and histologic methods. Results. Hindlimb function was examined with Basso, Beattie and Bresnahan (BBB) and Plantar tests. Improvement was found in all three groups of transplanted rats with different time-courses, but there was no significant difference among the groups at the end of the experiment. Motor-evoked potentials after SCI decreased in amplitude from 7 mV to 10 mu V. Linear regression analysis showed a modest recovery in amplitude following transplantation, but no change in the control rats. Histologic findings showed that the white and gray matter were significantly spared by transplantation after SCI. Conclusions. Functional improvement was achieved with transplantation of OEG and/or MSC, but the co-transplantation of OEG and MSC did not show synergistic effects. The poor migration of OEG and MSC might prevent their concerted action. Pre-treatment with a Rho antagonist and a combination of intraspinal and intravenous injection of the cells might be beneficial for SCI therapy.","[Amemori, Takashi] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220 4, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Amemori, T, Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Videnska 1083, Prague 14220 4, Czech Republic","tamemori@hotmail.com","EU [LSHM-CT-2005-019063]; [AVOZ50390703]; [IAA500390902]; [GACR309/06/1246]; [LC554]; [1M0538]; [1A8697-5]","We thank James Dutt for critical reading of the manuscript. This work was supported by the following grants: AVOZ50390703, IAA500390902, GACR309/06/1246, LC554, 1M0538 and 1A8697-5. The EU FP6 project ENINET (LSHM-CT-2005-019063.",null,67,0,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","1465-3249",null,"10.3109/14653240903440103","CYTOTHERAPY","Cytotherapy","APR",2010,12,2,null,null,null,212,225,null,null,14,"Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental","563EL","ISI:000275110600010"]
["nemá","J","Lahtinen, L; Ndode-Ekane, XE; Barinka, F; Akamine, Y; Esmaeili, MH; Rantala, J; Pitkanen, A",null,null,null,"Lahtinen, Laura; Ndode-Ekane, Xavier Ekolle; Barinka, Filip; Akamine, Yumiko; Esmaeili, Mohammed Hossein; Rantala, Jukka; Pitkanen, Asla",null,"Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus","NEUROBIOLOGY OF DISEASE",null,"English","Article",null,null,null,null,null,"Angiogenesis; Epilepsy; Epileptogenesis; Granule cell dispersion; Hippocampus; Neurodegeneration; Neurogenesis; Plasminogen; Proteinase","TEMPORAL-LOBE EPILEPSY; ENDOTHELIAL GROWTH-FACTOR; GRANULE CELL DISPERSION; FOCAL CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; DENTATE GYRUS; MICE LACKING; FACTOR VEGF; BRAIN; EXPRESSION","Expression of urokinase-type plasminogen activator (uPA) is increased after brain injury, suggesting that, like in cancer tissue, uPA plays roles in brain remodeling. Here we injured brain with intrahippocampal kainic acid (KA) injection in adult Wt and uPA-/- mice. At 20 days post-injury, uPA-/- mice had more severe loss of contralateral pyramidal (p<0.05) and hilar neurons (p<0.05) than Wt mice. The number of doublecortin (DCX)-positive newly born neurons was also reduced in uPA-/- mice as compared to Wt (p<0.01). No difference was observed in granule cell dispersion or distribution of DCX-positive neurons in the dentate gyrus. uPA deficiency did not affect the total length of hippocampal blood vessels or vessel density. No differences were observed in the severity of status epilepticus or consequent epilepsy between the genotypes. These data indicate that uPA deficiency can unfavorably modulate both delayed neurodegeneration and neurogenesis but has little effect on post-injury neuronal migration and vascular density. Our results favor the idea that elevated uPA during the post-injury phase is neuroprotective. (C) 2009 Elsevier Inc. All rights reserved.","[Lahtinen, Laura; Ndode-Ekane, Xavier Ekolle; Akamine, Yumiko; Rantala, Jukka; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland; [Barinka, Filip] Charles Univ Prague, Fac Med 2, Dept Anat, Prague 12800, Czech Republic; [Esmaeili, Mohammed Hossein] Qazvine Med Sci Univ, Dept Physiol, Qazvine, Iran","Pitkanen, A, Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland","asla.pitkanen@uku.fi","Grant Agency of Charles University in Prague [35407]; Mobility Fund of Charles University in Prague ; NENS-Network of European Neuroscience Schools ; North-Savo Regional Fund of the Finnish Cultural Foundation ; EC [FP6, MEST-CF-2005-019217]; The Sigrid Juselius Foundation ; Academy of Finland ","Supported by Grant Agency of Charles University in Prague (Grant No. 35407), Mobility Fund of Charles University in Prague, and by NENS-Network of European Neuroscience Schools (F.B.), North-Savo Regional Fund of the Finnish Cultural Foundation (L.L.), EC FP6, MEST-CF-2005-019217 (X.E.), The Sigrid Juselius Foundation (A.P.), and the Academy of Finland (A.P.). We thank Nick Hayward, MSc, for reviewing and editing the language of the manuscript.",null,60,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0969-9961",null,"10.1016/j.nbd.2009.12.008","NEUROBIOL DISEASE","Neurobiol. Dis.","MAR",2010,37,3,null,null,"Sp. Iss. SI",692,703,null,null,12,"Neurosciences","560PH","ISI:000274914100022"]
["nemá","J","Bekku, Y; Vargova, L; Goto, Y; Vorisek, I; Dmytrenko, L; Narasaki, M; Ohtsuka, A; Fassler, R; Ninomiya, Y; Sykova, E; Oohashi, T",null,null,null,"Bekku, Yoko; Vargova, Lydia; Goto, Yoshinobu; Vorisek, Ivan; Dmytrenko, Lesia; Narasaki, Masahiro; Ohtsuka, Aiji; Faessler, Reinhard; Ninomiya, Yoshifumi; Sykova, Eva; Oohashi, Toshitaka",null,"Bral1: Its Role in Diffusion Barrier Formation and Conduction Velocity in the CNS","JOURNAL OF NEUROSCIENCE",null,"English","Article",null,null,null,null,null,null,"TYROSINE-PHOSPHATASE BETA; CENTRAL-NERVOUS-SYSTEM; EXTRACELLULAR-SPACE; LINK PROTEIN; TENASCIN-R; PERINEURONAL NETS; RAT CEREBELLUM; ANISOTROPIC DIFFUSION; VOLUME TRANSMISSION; BRAIN-DEVELOPMENT","At the nodes of Ranvier, excitable axon membranes are exposed directly to the extracellular fluid. Cations are accumulated and depleted in the local extracellular nodal region during action potential propagation, but the impact of the extranodal micromilieu on signal propagation still remains unclear. Brain-specific hyaluronan-binding link protein, Bral1, colocalizes and forms complexes with negatively charged extracellular matrix (ECM) proteins, such as versican V2 and brevican, at the nodes of Ranvier in the myelinated white matter. The link protein family, including Bral1, appears to be the linchpin of these hyaluronan-bound ECM complexes. Here we report that the hyaluronan-associated ECM no longer shows a nodal pattern and that CNS nerve conduction is markedly decreased in Bral1-deficient mice even though there were no differences between wild-type and mutant mice in the clustering or transition of ion channels at the nodes or in the tissue morphology around the nodes of Ranvier. However, changes in the extracellular space diffusion parameters, measured by the real-time iontophoretic method and diffusion-weighted magnetic resonance imaging (MRI), suggest a reduction in the diffusion hindrances in the white matter of mutant mice. These findings provide a better understanding of the mechanisms underlying the accumulation of cations due to diffusion barriers around the nodes during saltatory conduction, which further implies the importance of the Bral1-based extramilieu for neuronal conductivity.","[Bekku, Yoko; Ninomiya, Yoshifumi; Oohashi, Toshitaka] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008558, Japan; [Narasaki, Masahiro; Ohtsuka, Aiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Human Morphol, Okayama 7008558, Japan; [Vargova, Lydia; Vorisek, Ivan; Dmytrenko, Lesia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 14220, Czech Republic; [Vargova, Lydia; Vorisek, Ivan; Dmytrenko, Lesia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 14220, Czech Republic; [Vargova, Lydia; Vorisek, Ivan; Dmytrenko, Lesia; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220, Czech Republic; [Goto, Yoshinobu] Int Univ Hlth & Welf, Fac Rehabil, Dept Occupat Therapy, Fukuoka 8318501, Japan; [Faessler, Reinhard] Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany","Oohashi, T, Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008558, Japan","oohashi@cc.okayama-u.ac.jp","Japanese Society for the Promotion of Science (JSPS) [18791206, 20791195, 15591857, 17046012]; JSPS ; Academy of Sciences of the Czech Republic ; Ryobi Teien Memory Foundation ; Ministry of Education, Youth and Sports [1M0538, 50390512]; Grant Agency of the Czech Republic [309/09/1597]; Ministry of Health of the Czech Republic Internal [NS 9915-4]","This work was supported by a Grant-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science (JSPS) (Grants 18791206 and 20791195 to Y. B., and Grants 15591857 and 17046012 to T. O.), the Researcher Exchange Program between the JSPS and the Academy of Sciences of the Czech Republic (ASCR) (to Y. B.), the Ryobi Teien Memory Foundation (to Y. B.), The Ministry of Education, Youth and Sports Grant 1M0538 (to E. S.), ASCR Grant 50390512 (to E. S.), Grant Agency of the Czech Republic Grant 309/09/1597 (to L. V. and E. S.), and Ministry of Health of the Czech Republic Internal Grant Agency Grant NS 9915-4 (to L. V.). We thank Mai Saito for technical assistance; Drs. Wei-Dong Su, Satoshi Hirakawa, and Xiao-Hong Zhou for their help with gene targeting; Dr. Hiroko Baba for kind suggestions; Dr. Yasunori Murakami for helpful comments on this manuscript; Dr. Elior Peles for the gift of anti-Caspr antibody; and James Dutt for editing this manuscript.",null,47,0,"SOC NEUROSCIENCE","WASHINGTON","11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA","0270-6474",null,"10.1523/JNEUROSCI.5598-09.2010","J NEUROSCI","J. Neurosci.","FEB 24",2010,30,8,null,null,null,3113,3123,null,null,11,"Neurosciences","560VB","ISI:000274930500032"]
["nemá","J","Garin, I; Edghill, EL; Akerman, I; Rubio-Cabezas, O; Rica, I; Locke, JM; Maestro, MA; Alshaikh, A; Bundak, R; del Castillo, G; Deeb, A; Deiss, D; Fernandez, JM; Godbole, K; Hussain, K; O'Connell, M; Klupa, T; Kolouskova, S; Mohsin, F; Perlman, K; Sumnik, Z; Rial, JM; Ugarte, E; Vasanthi, T; Johnstone, K; Flanagan, SE; Martinez, R; Castano, C; Patch, AM; Fernandez-Rebollo, E; Raile, K; Morgan, N; Harries, LW; Castano, L; Ellard, S; Ferrer, J; de Nanclares, G; Hattersley, AT",null,null,null,"Garin, Intza; Edghill, Emma L.; Akerman, Ildem; Rubio-Cabezas, Oscar; Rica, Itxaso; Locke, Jonathan M.; Angel Maestro, Miguel; Alshaikh, Adnan; Bundak, Ruveyde; del Castillo, Gabriel; Deeb, Asma; Deiss, Dorothee; Fernandez, Juan M.; Godbole, Koumudi; Hussain, Khalid; O'Connell, Michele; Klupa, Thomasz; Kolouskova, Stanislava; Mohsin, Fauzia; Perlman, Kusiel; Sumnik, Zdenek; Rial, Jose M.; Ugarte, Estibaliz; Vasanthi, Thiruvengadam; Johnstone, Karen; Flanagan, Sarah E.; Martinez, Rosa; Castano, Carlos; Patch, Ann-Marie; Fernandez-Rebollo, Eduardo; Raile, Klemens; Morgan, Noel; Harries, Lorna W.; Castano, Luis; Ellard, Sian; Ferrer, Jorge; Perez de Nanclares, Guiomar; Hattersley, Andrew T.","Neonatal Diabet Int Grp","Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA",null,"English","Article",null,null,null,null,null,"gene regulation; genetic testing; gene expression regulation; RNA instability; promoter regions","PANCREATIC BETA-CELL; ACTIVATING MUTATIONS; PROMOTER ACTIVITY; TRANSCRIPTION FACTOR; MUTANT MICE; MELLITUS; REGION; TRANSLATION; EXPRESSION; CHILDHOOD","Heterozygous coding mutations in the INS gene that encodes preproinsulin were recently shown to be an important cause of permanent neonatal diabetes. These dominantly acting mutations prevent normal folding of proinsulin, which leads to beta-cell death through endoplasmic reticulum stress and apoptosis. We now report 10 different recessive INS mutations in 15 probands with neonatal diabetes. Functional studies showed that recessive mutations resulted in diabetes because of decreased insulin biosynthesis through distinct mechanisms, including gene deletion, lack of the translation initiation signal, and altered mRNA stability because of the disruption of a polyadenylation signal. A subset of recessive mutations caused abnormal INS transcription, including the deletion of the C1 and E1 cis regulatory elements, or three different single base-pair substitutions in a CC dinucleotide sequence located between E1 and A1 elements. In keeping with an earlier and more severe beta-cell defect, patients with recessive INS mutations had a lower birth weight (-3.2 SD score vs.-2.0 SD score) and were diagnosed earlier (median 1 week vs. 10 weeks) compared to those with dominant INS mutations. Mutations in the insulin gene can therefore result in neonatal diabetes as a result of two contrasting pathogenic mechanisms. Moreover, the recessively inherited mutations provide a genetic demonstration of the essential role of multiple sequence elements that regulate the biosynthesis of insulin in man.","[Garin, Intza; Rica, Itxaso; Martinez, Rosa; Fernandez-Rebollo, Eduardo; Castano, Luis] Hosp Cruces, Endocrinol & Diabet Res Grp, Baracaldo 48903, Spain; [Garin, Intza; Akerman, Ildem; Angel Maestro, Miguel; Martinez, Rosa; Castano, Carlos; Fernandez-Rebollo, Eduardo; Castano, Luis; Ferrer, Jorge] Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Metab, Madrid 48903, Spain; [Garin, Intza; Martinez, Rosa; Fernandez-Rebollo, Eduardo; Castano, Luis] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Madrid 48903, Spain; [Edghill, Emma L.; Rubio-Cabezas, Oscar; Locke, Jonathan M.; Johnstone, Karen; Flanagan, Sarah E.; Patch, Ann-Marie; Morgan, Noel; Harries, Lorna W.; Ellard, Sian; Hattersley, Andrew T.] Univ Exeter, Inst Biomed & Clin Sci, Peninsula Med Sch, Exeter, Devon, England; [Akerman, Ildem; Angel Maestro, Miguel; Castano, Carlos; Ferrer, Jorge] Hosp Clin Barcelona, Barcelona, Spain; [Akerman, Ildem; Angel Maestro, Miguel; Castano, Carlos; Ferrer, Jorge] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Rubio-Cabezas, Oscar] Univ Nino Jesus, Hosp Infantil, Dept Endocrinol, Madrid, Spain; [Alshaikh, Adnan] Natl Guard Hlth Affairs, King Abdulaziz Med City, Jeddah, Saudi Arabia; [Bundak, Ruveyde] Istanbul Univ Hosp, Dept Pediat Endocrinol, Istanbul, Turkey; [Deeb, Asma] Imperial Coll London Diabet Ctr, Abu Dhabi, U Arab Emirates; [Deiss, Dorothee; Raile, Klemens] Virchow Childrens Hosp, Dept Pediat Diabetol & Endocrinol, Berlin, Germany; [Fernandez, Juan M.] Hosp Univ San Cecilio, Dept Pediat Endocrinol, Granada 18012, Spain; [Godbole, Koumudi] Deenanath Mangehskar Hosp & Res Ctr, Pune, Maharashtra, India; [Hussain, Khalid] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [O'Connell, Michele] Royal Childrens Hosp, Melbourne, Australia; [Klupa, Thomasz] Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland; [Kolouskova, Stanislava; Sumnik, Zdenek] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Mohsin, Fauzia] Bangladesh Inst Res & Rehabil Diabet Endocrine &, Pediat Diabet Team, Dhaka, Bangladesh; [Perlman, Kusiel] Hosp Sick Children, Div Endocrinol, Toronto, ON M5G 1X8, Canada; [Rial, Jose M.] Hosp Nuestra Senora Candelaria, Dept Pediat Endocrinol, Tenerife 38010, Spain; [Ugarte, Estibaliz] Hosp Basurto, Dept Endocrinol, Bilbao 48013, Spain; [Vasanthi, Thiruvengadam] Kanchi Kamakoti Childs Trust Hosp, Chennai, Tamil Nadu, India","de Nanclares, G, Hosp Cruces, Endocrinol & Diabet Res Grp, Baracaldo 48903, Spain","gnanclares@osakidetza.net; andrew.hattersley@pms.ac.uk","European Union [LSHM-CT-2006-518153, REG/F.2(2009)D/518731]; Wellcome Trust [067463/Z/2/Z, 081278/Z/06/Z]; Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas ; Instituto de Salud Carlos III of the Spanish Ministry of Health [PI06/0690, CM06/00013, CP03/0064]; Basque Department of Education [BFI06.266]; Czech Ministry of Education [021620819, 64203]; Polish Diabetes Association ; Research Councils United Kingdom ; Peninsula Medical School ","We thank Chris Boustred, Piers Fulton, Amna Khamis, Andrew Parrish, Gustavo Perez-Nanclares, Xavi Garcia, and Eleftheria Eiakogiannaki for technical assistance; Ann Kelly, Anthony Dixon, Srikanth Bellary, and Abigail Britten for supplying the Pakistani control DNAs; Dr Roland Stein (Vanderbilt University) for providing a human insulin promoter plasmid; and Dr Jun-ichi Miyazaki for the MIN6 cells. This work was funded by the European Union ( Integrated Project EURODIA LSHM-CT-2006-518153 in the Framework Programme 6 and CEED3 RTD REG/F.2(2009)D/518731 in the Framework Programme) To A. T. H. and J.F, Wellcome Trust Grants 067463/Z/2/Z ( to A. T. H.) and 081278/Z/06/Z ( to L. W. H.); the Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas and PI06/0690 from the Instituto de Salud Carlos III of the Spanish Ministry of Health ( to G.P.d.N.); Grant BFI06.266 from the Basque Department of Education ( to I. G.); an \"Ayuda para contratos post-Formacion Sanitaria Especializada\" from the \"Instituto de Salud Carlos III\" (FIS CM06/00013) ( to O.R.-C.); FIS researcher Grant CP03/0064 from the Instituto de Salud Carlos III of the Spanish Ministry of Health ( to G.P.d.N.); and Grants 021620819 from the Czech Ministry of Education and 64203 from the Czech Ministry of Health ( to Z.S.). Work in Poland is supported by the Polish Diabetes Association. A. T. H. is a Wellcome Trust Research Leave Fellow, L. W. H. is a Research Councils United Kingdom Academic Fellow, and J.M.L. is funded by a Peninsula Medical School PhD studentship.",null,44,0,"NATL ACAD SCIENCES","WASHINGTON","2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA","0027-8424",null,"10.1073/pnas.0910533107","PROC NAT ACAD SCI USA","Proc. Natl. Acad. Sci. U. S. A.","FEB 16",2010,107,7,null,null,null,3105,3110,null,null,6,"Multidisciplinary Sciences","556OC","ISI:000274599500072"]
["nemá","J","Mares, P; Stehlikova, M",null,null,null,"Mares, Pavel; Stehlikova, Mariana",null,"Anticonvulsant doses of ganaxolone do not compromise motor performance in immature rats","NEUROSCIENCE LETTERS",null,"English","Article",null,null,null,null,null,"Cortical seizures; Behavior; Ganaxolone; Ontogeny; Rat","CORTICAL EPILEPTIC AFTERDISCHARGES; ELECTRICAL-STIMULATION; RECEPTOR; SEIZURES; NEUROSTEROIDS; MICE; ALLOPREGNANOLONE","Neuroactive steroids that function as positive modulators of GABA-A receptors are potential anticonvulsant drugs. We previously demonstrated that ganaxolone is effective against pentetrazol-induced motor seizures in immature rats. In the present study, we examined the effects of ganaxolone in another model, cortical epileptic afterdischarges (ADs). The possible side effects of ganaxolone were studied in rats 12,18, and 25 days of age following the implantation of epidural electrodes. Low-frequency stimulation of the sensorimotor cortical area elicited ADs characterized by a spike-and-wave rhythm and clonic seizures. Ganaxolone (5, 10, 20, or 40 mg/kg) was administered intraperitoneally after the first AD and stimulation was repeated five More times. The highest dose of ganaxolone (40 mg/kg) suppressed progressive prolongation of ADs in 25-day-old rats and postponed it in 12-day-old rats. No significant effect was observed in 18-day-old animals. Movements during stimulation and clonic seizures accompanying ADs were not affected by ganaxolone. Ganaxolone at doses of 20 and 40 mg/kg had no significant effect on motor function, such as surface righting, negative geotaxis, wire mesh ascending, and bar holding. After administration of 40 mg/kg ganaxolone to 18- and 25-day-old rats, spontaneous locomotion in the open field tended to decrease. Doses of ganaxolone with a moderate anticonvulsant effect in the present model did not seriously compromise motor performance. (C) 2009 Elsevier Ireland Ltd. All rights reserved.","[Mares, Pavel; Stehlikova, Mariana] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague 14220 4, Czech Republic; [Mares, Pavel; Stehlikova, Mariana] Charles Univ Prague, Fac Med 2, Clin Rehabil & Sport Med, Prague, Czech Republic","Mares, P, Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Videnska 1083, Prague 14220 4, Czech Republic","maresp@biomed.cas.cz","Grant Agency of the Czech Republic [203/06/1605]; Ministry of Education of the Czech Republic [LC554]; Academy of Sciences of the Czech Republic [AV0Z 50110905]","This study was supported by grant no. 203/06/1605 of the Grant Agency of the Czech Republic and by Research projects no. LC554 of the Ministry of Education of the Czech Republic and AV0Z 50110905 of the Academy of Sciences of the Czech Republic.",null,21,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0304-3940",null,"10.1016/j.neulet.2009.12.037","NEUROSCI LETT","Neurosci. Lett.","JAN 29",2010,469,3,null,null,null,396,399,null,null,4,"Neurosciences","558DX","ISI:000274722100024"]
["nemá","J","Steinemann, D; Arning, L; Praulich, I; Stuhrmann, M; Hasle, H; Stary, J; Schlegelberger, B; Niemeyer, CM; Flotho, C",null,null,null,"Steinemann, Doris; Arning, Larissa; Praulich, Inka; Stuhrmann, Manfred; Hasle, Henrik; Stary, Jan; Schlegelberger, Brigitte; Niemeyer, Charlotte M.; Flotho, Christian",null,"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,"English","Article",null,null,null,null,null,"mitotic recombination; NF1-inactivating mechnisms; juvenile myelomonocytic leukemia","NF1 GENE; RAS; MICRODELETION; INACTIVATION; GERMLINE; SPECTRUM","Children with neurofibromatosis type 1 (NF-1), being constitutionally deficient for one allele of the NF1 gene, are at greatly increased risk of juvenile myelomonocytic leukemia (JMML). NF1 is a negative regulator of RAS pathway activity, which has a central role in JMML. To further clarify the role of biallelic NF1 gene inactivation in the pathogenesis of JMML, we investigated the somatic NF1 lesion in 10 samples from children with JMML/NF-1. We report that two-thirds of somatic events involved loss of heterozygosity (LOH) at the AT,1 locus, predominantly caused by segmental uniparental disomy of large parts of chromosome arm 17q. One-third of leukemias showed compound-heterozygous NF1-inactivating mutations. A minority of cases exhibited somatic interstitial deletions. The Findings reinforce the emerging role of somatic mitotic recombination as a leukemogenic mechanism. In addition, they support the concept that biallelic NF-1 inactivation in hematopoietic progenitor cells is required for transformation to JMML in children with NF-1.","[Flotho, Christian] Univ Freiburg, Zentrum Kinder & Jugendmed, D-79106 Freiburg, Germany; [Steinemann, Doris; Praulich, Inka; Stuhrmann, Manfred; Schlegelberger, Brigitte] Hannover Med Sch, D-3000 Hannover, Germany; [Arning, Larissa] Ruhr Univ Bochum, Bochum, Germany; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Aarhus, Denmark; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic","Flotho, C, Univ Freiburg, Zentrum Kinder & Jugendmed, Mathildenstr 1, D-79106 Freiburg, Germany","christian.flotho@uniklinik-freiburg.de","Deutsche Forschungsgemeinschaft [KR3473/1-1]","this work was supported by grant KR3473/1-1 from Deutsche Forschungsgemeinschaft (to C.F)",null,17,1,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2009.010355","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","FEB",2010,95,2,null,null,null,320,323,null,null,4,"Hematology","559EC","ISI:000274803700021"]
["nemá","J","Hempel, G; Relling, MV; de Rossi, G; Stary, J; De Lorenzo, P; Valsecchi, MG; Barisone, E; Boos, J; Pieters, R",null,null,null,"Hempel, Georg; Relling, Mary V.; de Rossi, Giulio; Stary, Jan; De Lorenzo, Paola; Valsecchi, Maria Grazia; Barisone, Elena; Boos, Joachim; Pieters, Rob",null,"Pharmacokinetics of Daunorubicin and Daunorubicinol in Infants With Leukemia Treated in the Interfant 99 Protocol","PEDIATRIC BLOOD & CANCER",null,"English","Article",null,null,null,null,null,"daunorubicin; infants; leukemia; pharmacokinetics","ACUTE LYMPHOBLASTIC-LEUKEMIA; RISK-FACTORS; MODEL; THERAPY; CARDIOTOXICITY; QUANTIFICATION; DOXORUBICIN; LY335979","Background. There is all extreme paucity of pharmacokinetic data for anticancer agents in infants. Therefore, we aimed at characterizing the pharmacokinetics for daunorubicin in infants and examined their relationship to age, body weight, and body Surface area. Procedure. Leukemia patients treated according to the Interfant 99 protocol received 30 mg/m(2) daunorubicin, with dose reduction to 3/4 for patients 6-12 months old and 2/3 for patients < 6 months, respectively. Plasma samples from 21 patients (aged 0.05-1.88 years) were collected and analyzed for daunorubicin and daunorubicinol. Samples from 12 children (age 1.6-18.8 years), who received daunorubicin in all earlier investigation, were used for pharmacokinetic model building using the software NONMEM. Results. Plasma concentration time profiles could be described using a two compartment model. Daunorubicin clearance was 43.9 L hr(-1) m(-2) +/- 65% and central Volume of distribution 16.4 L m(-2) +/- 46%, whereas apparent clearance of daunorubicinol was 19.1 L hr(-1) m(-2) +/- 32% and apparent Volume of distribution 228 L m(-2) +/- 80% (mean +/- interindividual variability). No age-dependency in any of the BSA-normalized pharmacokinetic parameters was observed. Consequently, due to the empirical close reduction in infants the overall exposure to daunorubicinol in infants was smaller than would be expected from older children. Patients aged < 6 months experienced more infections in the induction phase than the group aged 6-12 months at diagnosis. Other toxicities were similar in both groups. Conclusion. We observed no indication of ail age-dependency in the pharmacokinetics of daunorubicin. Pediatr Blood Cancer 2010;54:355-360. (C) 2009 Wiley-Liss, Inc.","[Hempel, Georg] Inst Pharmazeut & Med Chem, Klin Pharm, D-48149 Munster, Germany; [Hempel, Georg; Boos, Joachim] Univ Klinikum Munster, Klin & Poliklin Kinder & Jugendmed, Munster, Germany; [Relling, Mary V.] St Jude Childrens Hosp, Dept Pharmaceut, Memphis, TN 38105 USA; [de Rossi, Giulio] Osped Pediat Bambino Gesu, Res Inst, Rome, Italy; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [De Lorenzo, Paola; Valsecchi, Maria Grazia] Univ Milano Bicocca, Osped San Gerardo Nuovo, Pediat Clin, Monza, Italy; [Barisone, Elena] Univ Turin, Dept Pediat Oncohematol, Turin, Italy; [Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands; [Pieters, Rob] DCOG, The Hague, Netherlands","Hempel, G, Inst Pharmazeut & Med Chem, Klin Pharm, Hittorfstr 58-62, D-48149 Munster, Germany","georg.hempel@uni-muenster.de","German Bundesministerium fur Bildung und Forschung [1EC0401]","This work was supported by the German Bundesministerium fur Bildung und Forschung (Grant Number #1EC0401). We thank all the participating clinical centers for collecting the blood samples, Dr. William Evans and Ms. Emily Melton for St. Jude daunorubicin data, and Sandra Schulz and Petra Schulze-Westhoff for technical support.",null,19,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,"10.1002/pbc.22266","PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","MAR",2010,54,3,null,null,null,355,360,null,null,6,"Oncology; Hematology; Pediatrics","554FR","ISI:000274421400006"]
["nemá","J","Cardwell, CR; Stene, LC; Joner, G; Bulsara, MK; Cinek, O; Rosenbauer, J; Ludvigsson, J; Jane, M; Svensson, J; Goldacre, MJ; Waldhoer, T; Jarosz-Chobot, P; Gimeno, SGA; Chuang, LM; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Pozzilli, P; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Devoti, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Patterson, CC",null,null,null,"Cardwell, Chris R.; Stene, Lars C.; Joner, Geir; Bulsara, Max K.; Cinek, Ondrej; Rosenbauer, Joachim; Ludvigsson, Johnny; Jane, Mireia; Svensson, Jannet; Goldacre, Michael J.; Waldhoer, Thomas; Jarosz-Chobot, Przemyslawa; Gimeno, Suely G. A.; Chuang, Lee-Ming; Parslow, Roger C.; Wadsworth, Emma J. K.; Chetwynd, Amanda; Pozzilli, Paolo; Brigis, Girts; Urbonaite, Brone; Sipetic, Sandra; Schober, Edith; Devoti, Gabriele; Ionescu-Tirgoviste, Constantin; de Beaufort, Carine E.; Stoyanov, Denka; Buschard, Karsten; Patterson, Chris C.",null,"Maternal Age at Birth and Childhood Type 1 Diabetes: A Pooled Analysis of 30 Observational Studies","DIABETES",null,"English","Article",null,null,null,null,null,null,"PERINATAL RISK-FACTORS; PARENTAL AGE; ENVIRONMENTAL-FACTORS; MELLITUS; DELIVERY; IDDM; DETERMINANTS; CHILDREN; ORDER; WEIGHT","OBJECTIVE-The aim if the study was to investigate whether children born to older mothers have an increased risk of type 1 diabetes by performing a pooled analysis of previous studies using individual patient data to adjust for recognized confounders. RESEARCH DESIGN AND METHODS-Relevant studies published before June 2009 were identified from MEDLINE, Web of Science, and EMBASE. Authors of studies were contacted and asked to provide individual patient data or conduct prespecified analyses. Risk estimates of type 1 diabetes by maternal age were calculated for each study, before and after adjustment for potential confounders. Meta-analysis techniques were used to derive combined odds ratios and to investigate heterogeneity among studies. RESULTS-Data were available for 5 cohort and 25 case-control studies, including 14,724 cases of type 1 diabetes. Overall, there was, on average, a 5% (95% CI 2-9) increase in childhood type 1 diabetes odds per 5-year increase in maternal age (P = 0.006), but there was heterogeneity among studies (heterogeneity I-2 = 70%). In studies with a low risk of bias, there was a more marked increase in diabetes odds of 10% per 5-year increase in maternal age. Adjustments for potential confounders little altered these estimates. CONCLUSIONS-There was evidence of a weak but significant linear increase in the risk of childhood type 1 diabetes across the range of maternal ages, but the magnitude of association varied between studies. A very small percentage of the increase in the incidence of childhood type 1 diabetes in recent years could be explained by increases in maternal age. Diabetes 59:486-494, 2010","[Cardwell, Chris R.; Patterson, Chris C.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland; [Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, Lars C.] Oslo Univ Hosp, Oslo Res Ctr, Oslo, Norway; [Joner, Geir] Univ Oslo, Inst Hlth Management & Hlth Econ, Oslo, Norway; [Bulsara, Max K.] Univ Notre Dame, Inst Hlth & Rehabil Res, Fremantle, Australia; [Cinek, Ondrej] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, Joachim] Univ Dusseldorf, Leibniz Inst, German Diabet Ctr, Inst Biometr & Epidemiol, Dusseldorf, Germany; [Ludvigsson, Johnny] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, Johnny] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Jane, Mireia] Dept Hlth, Publ Hlth Div, Barcelona, Spain; [Svensson, Jannet] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, Thomas] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Jarosz-Chobot, Przemyslawa] Med Univ Silesia, Dept Pediat Endocrinol & Diabet, Katowice, Poland; [Gimeno, Suely G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Parslow, Roger C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, Emma J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, Amanda] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Pozzilli, Paolo] Univ Campus Biomed, Rome, Italy; [Brigis, Girts] Riga Stradins Univ, Dept Epidemiol & Publ Hlth, Riga, Latvia; [Urbonaite, Brone] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, Sandra] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, Edith] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Devoti, Gabriele] Univ Lecce, Dept Social Sci & Commun, I-73100 Lecce, Italy; [Ionescu-Tirgoviste, Constantin] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, Carine E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, Denka] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, Karsten] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark","Cardwell, CR, Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland","c.cardwell@qub.ac.uk","Czech Republic Ministry of Education [MSM 0021620814]; Department of Health of Catalonia ; Department of Health of Taiwan [DOH 90-TD1028]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Centro Internazionale Studi Diabete (Italy, Rome) ; The Swedish Child Diabetes Foundation ; National Health Service (NHS) National Coordinating Centre for Research Capacity Development U.K. ; Research Council of Norway ; German Research Foundation [HE 24/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes U.K ; Northern Ireland Department of Health and Social Services ","We acknowledge support from the following: the Czech Republic Ministry of Education (Grant MSM 0021620814), Department of Health of Catalonia (C. Castell MD, PhD, Barcelona, Spain), Department of Health of Taiwan (DOH 90-TD1028), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant 94/0943-0), the Centro Internazionale Studi Diabete (Italy, Rome), The Swedish Child Diabetes Foundation, the National Health Service (NHS) National Coordinating Centre for Research Capacity Development U.K., the Research Council of Norway, the German Research Foundation (Grant HE 24/1-1), the Ministry for Science and Technological Development of Serbia (no. 145084, 2006-2010), EUBIROD funded by the European Commission Health Information Strand (DG-SANCO 2005, contract no. 2007115), Diabetes U.K., and the Northern Ireland Department of Health and Social Services.",null,50,0,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0012-1797",null,"10.2337/db09-1166","DIABETES","Diabetes","FEB",2010,59,2,null,null,null,486,494,null,null,9,"Endocrinology & Metabolism","554LG","ISI:000274435900020"]
["nemá","J","Weber, C; Kocher, S; Neeser, K; Bartaskova, D",null,null,null,"Weber, Christian; Kocher, Serge; Neeser, Kurt; Bartaskova, Dagmar",null,"Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective","CURRENT MEDICAL RESEARCH AND OPINION",null,"English","Article",null,null,null,null,null,"Diabetes complications; Diabetes mellitus; Healthcare costs; Matched-pair analysis; Self-measurement of blood glucose","GLYCEMIC CONTROL; METAANALYSIS; MORTALITY; THERAPY; RISK","Objective: A growing body of evidence indicates that self-measurement of blood glucose (SMBG) also has beneficial effects in people with type 2 diabetes, irrespective of the type of therapy. The objective of this analysis was to determine the economic impact of SMBG by comparing the cost share of self-monitoring and the direct costs of diabetes-related complications in users and non-users. Research design and methods: A matched-pair analysis based on the cohorts of a large retrospective study of patients with type 2 diabetes (ROSSO) was conducted. The average annual direct costs of diabetes monitoring, treatment-related services, complications and follow-up costs of the disease for SMBG users versus non-users were calculated from the perspective of the Czech statutory health insurance system. Univariate sensitivity analysis was performed to determine the main cost drivers. Limitations of this study are: (1) differences in medical facilities/practice between Germany and the Czech Republic, (2) causal relationship between SMBG and health outcomes is missing, (3) ROSSO underestimated the number of test strips used, (4) Czech cost data are scarce. Results: In patients treated with oral antidiabetic drugs (OAD) only, total annual costs in Czech koruna (CZK) were CZK 16 476 for SMBG users and CZK 19 440 for non-users. In patients treated with OAD + insulin, total annual costs were CZK 32 590 and CZK 48 600, respectively. The main cost drivers were stroke and myocardial infarction in patients treated with OAD only, and stroke, dialysis and myocardial infarction in patients treated with OAD + insulin. Conclusion: Cost analysis indicated that SMBG provides a rapid return on initial investment. By increasing the number of patients using SMBG, the statutory health insurance system in the Czech Republic may save several million CZK annually.","[Weber, Christian; Kocher, Serge; Neeser, Kurt] Inst Med Informat & Biostat, CH-4058 Basel, Switzerland; [Bartaskova, Dagmar] Motol Univ Hosp, Prague, Czech Republic","Neeser, K, Inst Med Informat & Biostat, Clarastr 12, CH-4058 Basel, Switzerland","neeser@imib.ch","Roche Diagnostics GmbH, Mannheim, Germany ","This manuscript was sponsored by an unrestricted grant from Roche Diagnostics GmbH, Mannheim, Germany. The sponsor had no form of contribution or input to the contents of the article or its drafting.",null,31,0,"LIBRAPHARM/INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND","0300-7995",null,"10.1185/03007990903479224","CURR MED RES OPIN","Curr. Med. Res. Opin.","FEB",2010,26,2,null,null,null,289,296,null,null,8,"Medicine, General & Internal; Medicine, Research & Experimental","554PL","ISI:000274446800005"]
["nemá","J","Zwaan, CM; Reinhardt, D; Zimmerman, M; Hasle, H; Stary, J; Stark, B; Dworzak, M; Creutzig, U; Kaspers, GJL",null,null,null,"Zwaan, Christian M.; Reinhardt, Dirk; Zimmerman, Martin; Hasle, Henrik; Stary, Jan; Stark, Batia; Dworzak, Michael; Creutzig, Ursula; Kaspers, Gertjan J. L.","Int BFM Study Grp Paediat AML","Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","BRITISH JOURNAL OF HAEMATOLOGY",null,"English","Article",null,null,null,null,null,"acute myeloid leukaemia; relapse; children; gemtuzumab ozogamicin; phase II study","STEM-CELL TRANSPLANTATION; PEDIATRIC-PATIENTS; VENOOCCLUSIVE DISEASE; INITIAL TREATMENT; DOSE CYTARABINE; EFFICACY; SAFETY; CHEMOTHERAPY; THERAPY; INDUCTION","The prognosis of children with relapsed/refractory acute myeloid leukaemia (AML) is poor, and new therapies are needed. Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody linked to the antitumor antibiotic calicheamicin. We conducted an investigator-initiated phase II study with GO to assess its efficacy and safety, administering two dosages of 7 5 mg/m(2) with a 14 d-interval. Thirty children who were refractory to re-induction at first relapse or suffered from second relapse of AML received a total of 64 infusions of GO. The response rate [complete remission (CR) and CR with insufficient platelet recovery] was 37%. Nine patients were subsequently transplanted (median time to transplant, 4 weeks, range 3-21 weeks), and three of these patients are currently in continuous CR with a median follow-up of >3 years, and can considered to be cured. This resulted in a statistically significant survival advantage for children who responded to GO versus those who did not [27% (standard error 13%) vs. 0%, respectively, P = 0.001]. All other children died, mainly from progressive disease. The treatment was generally well tolerated by most patients. The frequency of transient transaminatis was low. All but one patient received defibrotide prophylaxis during the transplant procedure, and no cases of veno-occlusive disease were noted. This study showed a favourable safety/efficacy profile of single-agent GO in children with refractory first or second relapse of AML.","[Zwaan, Christian M.] Erasmus MC, Sophia Childrens Hosp, Dept Paediat Oncol Haematol, NL-3015 GJ Rotterdam, Netherlands; [Zwaan, Christian M.; Kaspers, Gertjan J. L.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Reinhardt, Dirk; Zimmerman, Martin; Creutzig, Ursula] Hannover Med Sch, AML BFM Study Grp, D-30623 Hannover, Germany; [Hasle, Henrik] Aarhus Univ Hosp Skejby, Dept Paediat, Aarhus, Denmark; [Stary, Jan] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Stark, Batia] Schneider Childrens Med Ctr Israel, Ctr Paediat Haematol Oncol, Petah Tiqwa, Israel; [Dworzak, Michael] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Dept Paediat Haematol Oncol, Amsterdam, Netherlands","Zwaan, CM, Erasmus MC, Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","c.m.zwaan@erasmusmc.nl","Wyeth ","CMZ and GJK received an unrestricted grant from Wyeth to support running this study.",null,36,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,"10.1111/j.1365-2141.2009.08011.x","BRIT J HAEMATOL","Br. J. Haematol.","MAR",2010,148,5,null,null,null,768,776,null,null,9,"Hematology","554AF","ISI:000274407200009"]
["nemá","J","Durila, M; Kalincik, T; Pacakova, Z; Cvachovec, K",null,null,null,"Durila, Miroslav; Kalincik, Tomas; Pacakova, Zuzana; Cvachovec, Karel",null,"Discard volume necessary for elimination of heparin flush effect on thromboelastography","BLOOD COAGULATION & FIBRINOLYSIS",null,"English","Article",null,null,null,null,null,"arterial blood sampling; coagulation; discard volume; heparin flush; kaolin-activated; thromboelastography","MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; LIVER-TRANSPLANTATION; COAGULATION; HYPERCOAGULABILITY; THROMBELASTOGRAPHY; SURGERY; ASSAY","Heparin is commonly used to prevent obstruction of indwelling arterial catheters with blood clots. It is known to affect the outcomes of analysis of coagulation parameters with thromboelastography (TEG); therefore, it has been recommended to neutralize its effect with heparinase. However, heparinase may also neutralize the effect of low molecular weight heparin and endogenous heparinoids present in critically ill patients and thus yields unreliable results. The aim of this study was to evaluate the minimal discard blood volume needed to eliminate the effect of heparin flush on TEG parameters without the use of heparinase. Ten patients with indwelling arterial catheter were included in the study. Coagulation parameters were evaluated with kaolin-activated TEG. Blood samples were obtained after discarding 1, 2, 3, 4, 5 or 10 ml of blood to eliminate the effect of heparin. We investigated the influence of the discard volume on time until the first detectable clot (R), speed of clot development (alpha angle), maximal amplitude of the measured clot and time to maximal amplitude of the measured clot. We found an increase in coagulation (reflecting the heparin elimination) with the increasing discard volume between 1 and 4 ml. This was obvious from an increase in alpha angle and maximal amplitude of the measured clot and a decrease in R and time to maximal amplitude of the measured clot (P<0.001). However, values obtained after discarding 4, 5 and 10 ml of blood did not differ markedly. To obtain valid information about TEG parameters, it is necessary to discard volume of at least 4 ml of blood (i.e., five times the volume of catheter dead space). Blood Coagul Fibrinolysis 21:192-195 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Durila, Miroslav; Cvachovec, Karel] Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Prague 15006 5, Czech Republic; [Durila, Miroslav; Cvachovec, Karel] Charles Univ Prague, Inst Postgrad Med Educ, Prague 15006 5, Czech Republic; [Kalincik, Tomas] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Pacakova, Zuzana] Czech Univ Agr, Fac Econ & Management, Prague, Czech Republic","Durila, M, Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic","durila4@yahoo.com","Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education ; Charles University in Prague, Prague ; Czech Republic and BioVendor Company - Lekarska technika, s.r.o., Brno, Czech Republic ","This study is supported by the Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education, Charles University in Prague, Prague, Czech Republic and BioVendor Company - Lekarska technika, s.r.o., Brno, Czech Republic.",null,14,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0957-5235",null,"10.1097/MBC.0b013e3283338c0d","BLOOD COAGULAT FIBRINOL","Blood Coagul. Fibrinolysis","MAR",2010,21,2,null,null,null,192,195,null,null,4,"Hematology","555LZ","ISI:000274513600017"]
["nemá","J","Grenda, R; Watson, A; Trompeter, R; Tonshoff, B; Jaray, J; Fitzpatrick, M; Murer, L; Vondrak, K; Maxwell, H; van Damme-Lombaerts, R; Loirat, C; Mor, E; Cochat, P; Milford, DV; Brown, M; Webb, NJA",null,null,null,"Grenda, R.; Watson, A.; Trompeter, R.; Toenshoff, B.; Jaray, J.; Fitzpatrick, M.; Murer, L.; Vondrak, K.; Maxwell, H.; van Damme-Lombaerts, R.; Loirat, C.; Mor, E.; Cochat, P.; Milford, D. V.; Brown, M.; Webb, N. J. A.",null,"A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric Renal Transplantation: The TWIST Study","AMERICAN JOURNAL OF TRANSPLANTATION",null,"English","Article",null,null,null,null,null,"Early steroid withdrawal; linear growth; pediatric kidney transplant","TACROLIMUS-BASED IMMUNOSUPPRESSION; MYCOPHENOLATE-MOFETIL; RECEIVING CYCLOSPORINE; BASILIXIMAB INDUCTION; DACLIZUMAB INDUCTION; FOLLOW-UP; CHILDREN; RECIPIENTS; THERAPY; MULTICENTER","Minimizing steroid exposure in pediatric renal transplant recipients can improve linear growth and reduce metabolic disorders. This randomized multicenter study investigated the impact of early steroid withdrawal on mean change in height standard deviation score (SDS) and the safety and efficacy of two immunosuppressive regimens during the first 6 months after transplantation. Children received tacrolimus, MMF, two doses of daclizumab and steroids until day 4 (TAC/MMF/DAC, n = 98) or tacrolimus, MMF and standard-dose steroids (TAC/MMF/STR, n = 98). Mean change in height SDS was 0.16 +/- 0.32 with TAC/MMF/DAC and 0.03 +/- 0.32 with TAC/MMF/STR. The mean treatment group difference was 0.13 (p < 0.005 [95% CI 0.04-0.22]), 0.21 in prepubertal (p = 0.009 [95% CI 0.05-0.36]) and 0.05 in pubertal children (p = ns). Frequency of biopsy-proven acute rejection was 10.2%, TAC/MMF/DAC, and 7.1%, TAC/MMF/STR. Patient and graft survival and renal function were similar. Significantly greater reductions in total cholesterol and triglycerides but significantly higher incidences of infection and anemia were found with TAC/MMF/DAC (p < 0.05 all comparisons). Early steroid withdrawal significantly aided growth at 6 months more so in prepubertal than pubertal children. This was accompanied by significantly better lipid and glucose metabolism profiles without increases in graft rejection or loss.","[Grenda, R.] Childrens Mem Hlth Inst, Warsaw, Poland; [Watson, A.] Univ Nottingham Hosp, Nottingham NG7 2UH, England; [Trompeter, R.] Great Ormond St Hosp Sick Children, London, England; [Toenshoff, B.] Univ Childrens Hosp, Heidelberg, Germany; [Jaray, J.] Semmelweis Univ Med, H-1085 Budapest, Hungary; [Fitzpatrick, M.] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; [Murer, L.] Azienda Osped Padova, Dipartimento Pediat, Padua, Italy; [Vondrak, K.] Univ Hosp Motol, Prague, Czech Republic; [Maxwell, H.] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland; [van Damme-Lombaerts, R.] Univ Ziekenhuis KU Leuven, Louvain, Belgium; [Loirat, C.] Hop Robert Debre, F-75019 Paris, France; [Mor, E.] Rabin Med Ctr, Petah Tiqwa, Israel; [Cochat, P.] Hop Femme Mere Enfant, Lyon, France; [Milford, D. V.] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Webb, N. J. A.] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England","Grenda, R, Childrens Mem Hlth Inst, Warsaw, Poland","r.grenda@czd.pl","Astellas Pharma Europe Ltd ","The following investigators also participated in the TWIST study: Claude Guyot, Mihai Lucan, Bernd Hoppe, Nadeem Moghal, Moin Saleem, Caroline Jones, Luca Dello Strologo, Styrbjorn Friman, Mignon McCulloch, Nathalie Godefroid, Lars Pape, Po-Huang Lee, Alberto Edefonti, Francesco Perfumo, Dierdra Hahn. We acknowledge writing and editorial assistance provided by C. Krcmar who received payment from Astellas Pharma Europe Ltd for this work. The study sponsor, Astellas Pharma Europe Ltd, supplied funding and monitored the progress and conduct of the study.",null,36,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1600-6135",null,"10.1111/j.1600-6143.2010.03047.x","AM J TRANSPLANT","Am. J. Transplant.","APR",2010,10,4,null,null,null,828,836,null,null,9,"Surgery; Transplantation","571QA","ISI:000275768300019"]
["nemá","J","Plzak, J; Lacina, L; Chovanec, M; Dvorankova, B; Szabo, P; Cada, Z; Smetana, K",null,null,null,"Plzak, Jan; Lacina, Lukas; Chovanec, Martin; Dvorankova, Barbora; Szabo, Pavol; Cada, Zdenek; Smetana, Karel, Jr.",null,"Epithelial-Stromal Interaction in Squamous Cell Epithelium-derived Tumors: An Important New Player in the Control of Tumor Biological Properties","ANTICANCER RESEARCH",null,"English","Review",null,null,null,null,null,"Cancer-associated fibroblasts; cancer microenvironment; tumor stroma; squamous cell carcinoma; basal cell carcinoma; review","EPIDERMAL STEM-CELLS; BREAST-CANCER; IN-VITRO; MESENCHYMAL TRANSITIONS; NORMAL KERATINOCYTES; HAIR FOLLICLE; ORAL-CAVITY; CARCINOMA; MICROENVIRONMENT; EXPRESSION","Mesenchymal-epithelial interaction is important in the morphogenesis of squamous epithelia and their appendages, and in the control of the hair cycle postnatally. This review summarizes data regarding the interaction between stromal fibroblasts and tumor cells, with an emphasis on tumors originating from squamous epithelium. Tumor stromal fibroblasts as important element of the cancer stem cell niche are able to participate in the control of the biological properties of tumors. We propose these stromal cells and their products as novel targets for anticancer therapy.","[Plzak, Jan; Lacina, Lukas; Chovanec, Martin; Dvorankova, Barbora; Szabo, Pavol; Cada, Zdenek; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Plzak, Jan; Chovanec, Martin; Cada, Zdenek] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 12800 2, Czech Republic; [Lacina, Lukas] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol, Prague 12800 2, Czech Republic; [Plzak, Jan; Lacina, Lukas; Chovanec, Martin; Dvorankova, Barbora; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic","Smetana, K, Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic","jan.pizak@lfl.cuni.cz; karel.smetana@lfl.cuni.cz","Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806, 1M0538, NPVII 2B06106, 304/08/P175]; European Comission [MRTN-CT-2005-019561]","Some of the results presented in this review were obtained in research projects supported by the Ministry of Education, Youth and Sport of the Czech Republic (project no. MSM0021620806, 1M0538 and NPVII 2B06106), Grant Agency of the Czech Republic (project no. 304/08/P175) and European Comission (contract no. MRTN-CT-2005-019561).",null,63,0,"INT INST ANTICANCER RESEARCH","ATHENS","EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE","0250-7005",null,null,"ANTICANCER RES","Anticancer Res.","FEB",2010,30,2,null,null,null,455,462,null,null,8,"Oncology","572IC","ISI:000275821200026"]
["nemá","J","Boesgaard, TW; Pruhova, S; Andersson, EA; Cinek, O; Obermannova, B; Lauenborg, J; Damm, P; Bergholdt, R; Pociot, F; Pisinger, C; Barbetti, F; Lebl, J; Pedersen, O; Hansen, T",null,null,null,"Boesgaard, Trine W.; Pruhova, Stepanka; Andersson, Ehm A.; Cinek, Ondrej; Obermannova, Barbora; Lauenborg, Jeannet; Damm, Peter; Bergholdt, Regine; Pociot, Flemming; Pisinger, Charlotta; Barbetti, Fabrizio; Lebl, Jan; Pedersen, Oluf; Hansen, Torben",null,"Further evidence that mutations in INS can be a rare cause of Maturity-Onset Diabetes of the Young (MODY)","BMC MEDICAL GENETICS",null,"English","Article",null,null,null,null,null,null,"INSULIN GENE-MUTATIONS; CHILDREN","Background: Insulin gene (INS) mutations have recently been described as a common cause of permanent neonatal diabetes (PNDM) and a rare cause of diabetes diagnosed in childhood or adulthood. Methods: INS was sequenced in 116 maturity-onset diabetes of the young (MODYX) patients (n = 48 Danish and n = 68 Czech), 83 patients with gestational diabetes mellitus (GDM), 34 type 1 diabetic patients screened negative for glutamic acid decarboxylase (GAD), and 96 glucose tolerant individuals. The control group was randomly selected from the population-based sampled Inter99 study. Results: One novel heterozygous mutation c. 17G>A, R6H, was identified in the pre-proinsulin gene (INS) in a Danish MODYX family. The proband was diagnosed at 20 years of age with mild diabetes and treated with diet and oral hypoglycaemic agent. Two other family members who carried the INS R6H were diagnosed with diabetes when 51 years old and with GDM when 27 years old, respectively. A fourth mutation carrier had normal glucose tolerance when 20 years old. Two carriers of INS R6H were also examined twice with an oral glucose tolerance test (OGTT) with 5 years interval. They both had a similar to 30% reduction in beta-cell function measured as insulinogenic index. In a Czech MODYX family a previously described R46Q mutation was found. The proband was diagnosed at 13 years of age and had been treated with insulin since onset of diabetes. Her mother and grandmother were diagnosed at 14 and 35 years of age, respectively, and were treated with oral hypoglycaemic agents and/or insulin. Conclusion: Mutations in INS can be a rare cause of MODY and we conclude that screening for mutations in INS should be recommended in MODYX patients.","[Boesgaard, Trine W.; Andersson, Ehm A.; Bergholdt, Regine; Pociot, Flemming; Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Boesgaard, Trine W.; Andersson, Ehm A.; Bergholdt, Regine; Pociot, Flemming; Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pruhova, Stepanka; Cinek, Ondrej; Obermannova, Barbora; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Lauenborg, Jeannet; Damm, Peter] Rigshosp, Copenhagen Univ Hosp, Dept Obstet, Ctr Pregnant Women Diabet, Copenhagen, Denmark; [Pisinger, Charlotta] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Barbetti, Fabrizio] Bambino Gesu Childrens Hosp IRCCS, Dept Paediat Med, Endocrinol & Diabet Unit, Rome, Italy; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Inst Biomed Sci, Copenhagen, Denmark; [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark","Boesgaard, TW, Steno Diabet Ctr, DK-2820 Gentofte, Denmark","tweb@hagedorn.dk","Norwegian Financial Mechanism, Norway [CZ0100]","The study was supported by the Danish Medical Research Council and the Danish Diabetes Association. The authors wish to thank A. Forman, I.-L. Wantzin and M. Stendal for technical assistance, G. Lademann for secretarial support, A. L. Nielsen for database management, M. M. H. Kristensen for grant management, and the members of the Inter99 team. The authors from the Czech Republic were supported by a grant \"Monogenic diabetes in childhood: from genetic to therapy\" from Norway though the Norwegian Financial Mechanism (No CZ0100).",null,9,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,"10.1186/1471-2350-11-42","BMC MED GENET","BMC Med. Genet.","MAR 12",2010,11,null,null,null,null,null,null,42,null,4,"Genetics & Heredity","579SQ","ISI:000276394100001"]
["nemá","J","Creutzig, U; Zimmermann, M; Dworzak, M; Urban, C; Henze, G; Kremens, B; Lakomek, M; Bourquin, JP; Stary, J; Reinhardt, D",null,null,null,"Creutzig, Ursula; Zimmermann, Martin; Dworzak, Michael; Urban, Christian; Henze, Guenter; Kremens, Bernhard; Lakomek, Max; Bourquin, Jean-Pierre; Stary, Jan; Reinhardt, Dirk","AML-BFM Study Grp","Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses","BRITISH JOURNAL OF HAEMATOLOGY",null,"English","Article",null,null,null,null,null,"acute promyelocytic leukaemia; children; therapy; anthracyclines; cardiotoxicity","ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; ARSENIC TRIOXIDE; TRANSRETINOIC ACID; INDUCTION THERAPY; RANDOMIZED-TRIAL; AIDA PROTOCOL; PETHEMA GROUP; EARLY DEATHS; CHILDREN","P>Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity. Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA). Outcomes achieved by treatment with a reduced cumulative anthracycline dose (350 mg/m2) were comparable to those reported for studies with higher doses. Five-year overall survival of the total cohort was 89 +/- 4% and event-free survival (pEFS) was 73 +/- 6%. Overall survival was similar when comparing AML-BFM trial periods (trial 93: 88 +/- 8%, 98: 85 +/- 7% and 2004: 94 +/- 8%, P-(logrank) = 0 center dot 63). Seventy-five (93%) patients achieved complete remission. Most fatal events occurred during the first 6 weeks of treatment. Long-term cardiotoxicity was observed in one patient. Two patients suffered from secondary haematological malignancies. Salvage treatment was effective in 7/9 patients (78%) with relapsed APL, who now are long-term survivors after second line combination treatment with arsenic trioxide (4/7 patients) and stem cell transplantation (5/7 patients). Our results demonstrate that - combined with ATRA - a lower cumulative anthracycline dose can be used safely to maintain high cure rates and promote the reduction of long-term sequelae, such as cardiotoxicity in APL patients.","[Creutzig, Ursula] Univ Childrens Hosp, Dept Paediat Haematol Oncol, Munster, Germany; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Dept Paediat Haematol Oncol, D-3000 Hannover, Germany; [Dworzak, Michael] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Urban, Christian] Med Univ Graz, Dept Paediat & Adolescent Med, Div Paediat Haematol & Oncol, Graz, Austria; [Henze, Guenter] Charite, Univ Berlin, Dept Paediat Oncol Haematol, D-13353 Berlin, Germany; [Kremens, Bernhard] Univ Essen Gesamthsch, Dept Paediat Haematol Oncol & Endocrinol, Essen, Germany; [Lakomek, Max] Univ Childrens Hosp, Dept Paediat Haematol Oncol, Gottingen, Germany; [Bourquin, Jean-Pierre] Univ Childrens Hosp, Dept Paediat Oncol, Zurich, Switzerland; [Stary, Jan] Charles Univ Prague, Dept Paediat Haematol Oncol, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic","Creutzig, U, Klin & Poliklin Kinderheilkunde, Albert Schweitzer Str 33, D-48129 Munster, Germany","ursula@creutzig.de","Deutsche Krebshilfe e.V ; Czech Ministry of Education [MSM0021620813]","Supported by the Deutsche Krebshilfe e.V. and partly by grant from the Czech Ministry of Education (MSM0021620813). The current principal investigators of the Cooperative AML-BFM Trials are listed in Appendix 1.",null,46,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,"10.1111/j.1365-2141.2010.08107.x","BRIT J HAEMATOL","Br. J. Haematol.","MAY",2010,149,3,null,null,null,399,409,null,null,11,"Hematology","582MO","ISI:000276601900009"]
["nemá","J","Naccarati, A; Pardini, B; Polakova, V; Smerhovsky, Z; Vodickova, L; Soucek, P; Vrana, D; Holcatova, I; Ryska, M; Vodicka, P",null,null,null,"Naccarati, A.; Pardini, B.; Polakova, V.; Smerhovsky, Z.; Vodickova, L.; Soucek, P.; Vrana, D.; Holcatova, I.; Ryska, M.; Vodicka, P.",null,"Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic","CARCINOGENESIS",null,"English","Article",null,null,null,null,null,null,"P53 CODON-72 POLYMORPHISM; COLORECTAL-CANCER; BLADDER-CANCER; LUNG-CANCER; POPULATION; CARCINOMA; ADENOCARCINOMA; RECONSTRUCTION; SUSCEPTIBILITY; PROGRESSION","Pancreatic carcinoma is the fourth leading cause of cancer-related deaths in the Czech Republic, with only a minimum of patients surviving 5 years. The aetiology and molecular pathogenesis are still weakly understood. TP53 has a fundamental role in cell cycle and apoptosis and is frequently mutated in solid tumours, including pancreatic cancer. Based on the assumption that genetic variation may affect susceptibility to cancer development, the role of TP53 polymorphisms in modulating the risk of pancreatic cancer may be of major importance. We investigated four selected polymorphisms in TP53 (rs17878362:A(1)> A(2), rs1042522:G > C, rs12947788:C > T and rs17884306:G > A) in association with pancreatic cancer risk in a case-control study, including 240 cases and controls (for a total of 1827 individuals) from the Czech Republic. Carriers of the variant C allele of rs1042522 polymorphism were at an increased risk of pancreatic cancer [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.26-2.39; P = 0.001]. Haplotype analysis showed that in comparison with the most common haplotype (A(1)GCG), the A(2)CCG haplotype was associated with an increased risk (OR 1.39; 95% CI 1.02-1.88; P = 0.034) and the A(1)CCG with a reduced risk (OR 0.30; 95% CI 0.12-0.76; P = 0.011) for this cancer. These results reflect previous findings of a recent association study, where haplotypes constructed on the same TP53 variants were associated with colorectal cancer risk [Polakova et al. (2009) Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum. Mutat., 30, 661-668.]. Genetic variation in TP53 may contribute, alone or in concert with other risk factors, to modify the inherited susceptibility to pancreatic cancer, as well as to other gastrointestinal cancers.","[Naccarati, A.; Pardini, B.; Polakova, V.; Vodickova, L.; Vodicka, P.] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14200, Czech Republic; [Smerhovsky, Z.; Vodickova, L.; Soucek, P.; Vrana, D.] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042, Czech Republic; [Ryska, M.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague 15006, Czech Republic; [Vrana, D.] Charles Univ Prague, Dept Oncol, Gen Teaching Hosp, Prague 12808 2, Czech Republic; [Vrana, D.] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Holcatova, I.] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague 12800, Czech Republic; [Ryska, M.] Cent Mil Hosp, Prague 15006, Czech Republic","Vodicka, P, Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200, Czech Republic","pvodicka@biomed.cas.cz","Grant Agency of the Czech Republic [GACR 305/09/P194]; Internal Grant Agency of the Czech Ministry of Health [IGA 8563-5/2005, IGA 9422-3/2007]","Grant Agency of the Czech Republic (GACR 305/09/P194); Internal Grant Agency of the Czech Ministry of Health (IGA 8563-5/2005, IGA 9422-3/2007).",null,42,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,"10.1093/carcin/bgq032","CARCINOGENESIS","Carcinogenesis","APR",2010,31,4,null,null,null,666,670,null,null,5,"Oncology","578HV","ISI:000276285200018"]
["nemá","J","Veselka, J; Zemanek, D; Tomasov, P; Homolova, S; Adlova, R; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Tomasov, Pavol; Homolova, Stanislava; Adlova, Radka; Tesar, David",null,"Complications of Low-Dose, Echo-Guided Alcohol Septal Ablation","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,"English","Article",null,null,null,null,null,"hypertrophic cardiomyopathy; hemodynamics; cardiomyopathy","HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; TRANSCORONARY ABLATION; SINGLE-CENTER; EXPERIENCE; PREDICTORS","Background: Alcohol septal ablation (ASA) is a catheter-based intervention that has been used as an alternative to surgical myectomy in highly symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Methods: This retrospective study was designed to evaluate the incidence of major complications in the mid-term follow-up of low-dose (1-2.5 ml of ethanol), echo-guided alcohol septal ablation. Results: A total of 101 consecutive patients (56 +/- 15 years) with highly symptomatic HOCM were enrolled. At 6 months, there was a significant decrease in resting outflow gradient accompanied by reduction in basal septal diameter and improvement in symptoms (P < 0.01). Two patients (2%) experienced procedural ventricular tachycardias terminated by electrical cardioversion. A total of 87 patients (86%) underwent an uneventful postprocedural hospital stay. The postprocedural complete heart block occurred in 10 patients (10%), and subsequent permanent pacemaker was implanted in four cases (4%). Sustained ventricular arrhythmias requiring electrical cardioversion occurred in four patients (4%) within postprocedural hospital stay. Subsequently, ICD was not implanted in any of these cases. The patients were repeatedly examined by Holter ECG monitoring, and in the mid-term follow-up (6-50 months), they stayed asymptomatic and without any ventricular arrhythmias. Conclusion: This study demonstrates the same early incidence of complete heart block requiring permanent pacemaker implantation (4%) and sustained ventricular arrhythmias following low-dose, echo-guided ASA. (C) 2009 Wiley-Liss, Inc.","[Veselka, Josef] Charles Univ Prague, Ctr Cardiovasc, Dept Cardiol, Sch Med 1,Univ Hosp Motol, Prague 15000 5, Czech Republic","Veselka, J, Charles Univ Prague, Ctr Cardiovasc, Dept Cardiol, Sch Med 1,Univ Hosp Motol, 5 Uvalu 84, Prague 15000 5, Czech Republic","veselka.josef@seznam.cz","Ministry of Health of the Czech Republic [00064203]","Grant sponsor: Ministry of Health of the Czech Republic; grant number: 00064203",null,17,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,"10.1002/ccd.22326","CATHETER CARDIOVASC INTERV","Catheter. Cardiovasc. Interv.","MAR 1",2010,75,4,null,null,null,546,550,null,null,5,"Cardiac & Cardiovascular Systems","582HW","ISI:000276588600015"]
["nemá","J","Jakabcin, J; Spacek, R; Bystron, M; Kvasnak, M; Jager, J; Veselka, J; Kala, P; Cervinka, P",null,null,null,"Jakabcin, Jozef; Spacek, Radim; Bystron, Marian; Kvasnak, Martin; Jager, Jiri; Veselka, Josef; Kala, Petr; Cervinka, Pavel",null,"Long-Term Health Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting Stents with or without the IVUS Guidance. Randomized Control Trial. HOME DES IVUS","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,"English","Article",null,null,null,null,null,null,"BARE-METAL STENTS; INTRAVASCULAR ULTRASOUND ANALYSIS; ARTERY-DISEASE; DOUBLE-BLIND; FOLLOW-UP; IMPLANTATION; THROMBOSIS; RISK; 6-MONTH; LESIONS","Objective: To assess the role of the intravascular ultrasound (IVUS) during implantation of Drug-eluting stents (DES) on long-term outcome in patients with complex coronary artery disease and high clinical risk profile with special attention to the development of late stent thrombosis (LST). Methods: Two hunderd and ten patients were randomly assigned to receive DES either with (N = 105) or without (N = 105) the IVUS guidance. Dual antiplatelet treatment was administered for 6 months in all patients. At 18-month follow-up, the rates of Major adverse cardiac events (MACEs) (death, myocardial infarction, and reintervention) were assessed in both groups with special attention to possible LST. Stent thrombosis was classified according to Academic Research Consortium (ARC). Results: At the 18-month follow-up, there was no significant difference between both groups regarding MACE (11% vs. 12%; P = NS). Stent thrombosis has occurred in four patients (3.8%) in the group with and in 6 patients (5.7%; P = NS) in the group without the IVUS guidance. Conclusions: In our randomized trial we failed to demonstrate the superiority of the IVUS guidance during DES implantation over standard high-pressure postdilatation. However we confirmed worrisome results concerning DES thrombosis after discontinuation of dual antiplatelet-treatment with documented stent thrombosis related events in almost 5% of patients with 50% of mortality in this high-risk clinical scenario. (C) 2009 Wiley-Liss, Inc.","[Jakabcin, Jozef; Spacek, Radim; Bystron, Marian; Kvasnak, Martin; Jager, Jiri; Cervinka, Pavel] Masaryk Hosp, Dept Cardiol, Usti Nad Labem, Czech Republic; [Veselka, Josef] Fac Hosp Motol, Dept Cardiol, Prague, Czech Republic; [Kala, Petr] Fac Hosp, Cardiovasc Dept, Brno, Czech Republic","Cervinka, P, Socialni Pece 3316-12A, Usti Nad Labem 40113, Czech Republic","Pavel.Cervinka@mnul.cz",null,null,null,25,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,"10.1002/ccd.22244","CATHETER CARDIOVASC INTERV","Catheter. Cardiovasc. Interv.","MAR 1",2010,75,4,null,null,null,578,583,null,null,6,"Cardiac & Cardiovascular Systems","582HW","ISI:000276588600021"]
["nemá","J","Urbanova, M; Plzak, J; Strnad, H; Betka, J",null,null,null,"Urbanova, Marketa; Plzak, Jan; Strnad, Hynek; Betka, Jan",null,"Circulating nucleic acids as a new diagnostic tool","CELLULAR & MOLECULAR BIOLOGY LETTERS",null,"English","Review",null,null,null,null,null,"Circulating nucleic acids; RNA; DNA; Diagnostics; Cancer","POLYMERASE-CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER PATIENTS; BARR-VIRUS DNA; REAL-TIME PCR; MATERNAL PLASMA; MESSENGER-RNA; FETAL DNA; NASOPHARYNGEAL CARCINOMA; COLORECTAL-CANCER","The discovery of circulating nucleic acids in the 1940s opened up new possibilities for the non-invasive detection, monitoring and screening of various human disorders. Several tumour markers that enable early cancer detection or tumour behaviour prediction have been detected in the plasma of cancer patients. Maternal plasma analysis can be used to detect certain fetal abnormalities, with the quantification of cell-free nucleic acids used to screen for several pregnancy-associated disorders. Some other applications are in transplant monitoring and graft rejection assessment, and in certain medical emergencies such as trauma and burn severity stratification. Many studies have yielded promising results in this field, but the techniques have yet to be applied in routine clinical practice. Large-scale studies using similar technologies and a broad spectrum of patients are still needed to verify the results of the various studies.","[Urbanova, Marketa; Plzak, Jan; Betka, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Fac Hosp Motol,Inst Postgrad Med, Prague 15006 5, Czech Republic; [Urbanova, Marketa; Strnad, Hynek] Acad Sci Czech Republic, Inst Mol Genet, Dept Genom & Bioinformat, CR-14220 Prague 4, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic","Plzak, J, Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Fac Hosp Motol,Inst Postgrad Med, Uvalu 84, Prague 15006 5, Czech Republic","jan.plzak@lf1.cuni.cz","GAUK [60608]; MSMT NPV II [2B06106]","This study was supported by grant GAUK No. 60608 and project MSMT NPV II. No. 2B06106.",null,94,0,"VERSITA","WARSAW 41","9 DRUGA POPRZECNA ST, 04-604 WARSAW 41, POLAND","1425-8153",null,"10.2478/s11658-010-0004-6","CELL MOL BIOL LETT","Cell. Mol. Biol. Lett.","JUN",2010,15,2,null,null,null,242,259,null,null,18,"Biochemistry & Molecular Biology; Cell Biology","574CS","ISI:000275966600005"]
["nemá","J","Prajerova, I; Honsa, P; Chvatal, A; Anderova, M",null,null,null,"Prajerova, Iva; Honsa, Pavel; Chvatal, Alexandr; Anderova, Miroslava",null,"Neural Stem/Progenitor Cells Derived from the Embryonic Dorsal Telencephalon of D6/GFP Mice Differentiate Primarily into Neurons After Transplantation into a Cortical Lesion","CELLULAR AND MOLECULAR NEUROBIOLOGY",null,"English","Article",null,null,null,null,null,"Ischemia; Ion channels; Patch-clamp; Injury and repair","CENTRAL-NERVOUS-SYSTEM; RADIAL GLIAL-CELLS; RAT SPINAL-CORD; NEOCORTICAL PYRAMIDAL NEURONS; GATED K+ CHANNELS; STEM-CELLS; PROGENITOR CELLS; PRECURSOR CELLS; IN-VITRO; NEUROSPHERE CULTURES","D6 is a promoter/enhancer of the mDach1 gene that is involved in the development of the neocortex and hippocampus. It is expressed by proliferating neural stem/progenitor cells (NSPCs) of the cortex at early stages of neurogenesis. The differentiation potential of NSPCs isolated from embryonic day 12 mouse embryos, in which the expression of green fluorescent protein (GFP) is driven by the D6 promoter/enhancer, has been studied in vitro and after transplantation into the intact adult rat brain as well as into the site of a photochemical lesion. The electrophysiological properties of D6/GFP-derived cells were studied using the whole-cell patch-clamp technique, and immunohistochemical analyses were carried out. D6/GFP-derived neurospheres expressed markers of radial glia and gave rise predominantly to immature neurons and GFAP-positive cells during in vitro differentiation. One week after transplantation into the intact brain or into the site of a photochemical lesion, transplanted cells expressed only neuronal markers. D6/GFP-derived neurons were characterised by the expression of tetrodotoxin-sensitive Na+-currents and K (A)- and K (DR) currents sensitive to 4-aminopyridine. They were able to fire repetitive action potentials and responded to the application of GABA. Our results indicate that after transplantation into the site of a photochemical lesion, D6/GFP-derived NSPCs survive and differentiate into neurons, and their membrane properties are comparable to those transplanted into the non-injured cortex. Therefore, region-specific D6/GFP-derived NSPCs represent a promising tool for studying neurogenesis and cell replacement in a damaged cellular environment.","[Prajerova, Iva; Honsa, Pavel; Chvatal, Alexandr; Anderova, Miroslava] ASCR VVI, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Prague 14220 4, Czech Republic; [Prajerova, Iva; Honsa, Pavel; Chvatal, Alexandr] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic; [Chvatal, Alexandr; Anderova, Miroslava] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic","Anderova, M, ASCR VVI, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220 4, Czech Republic","anderova@biomed.cas.cz","Grant Agency of the Czech Republic [305/09/0717, 309/08/H079]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]; Charles University [GAUK62/2006/C/2]","The authors would like to thank to Dr. Z. Kozmik and Dr. O. Machon for their generous gift of D6/GFP mice. This study was supported by the following grants: 305/09/0717 and 309/08/H079 from the Grant Agency of the Czech Republic, AVOZ50390512 from the Academy of Sciences of the Czech Republic, LC554 and 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic and GAUK62/2006/C/2. LF from the Grant Agency of Charles University.",null,91,1,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0272-4340",null,"10.1007/s10571-009-9443-x","CELL MOL NEUROBIOL","Cell. Mol. Neurobiol.","MAR",2010,30,2,null,null,null,199,218,null,null,20,"Cell Biology; Neurosciences","570UW","ISI:000275704800005"]
["nemá","J","Jesina, P; Vinsova, K; Brantova, O; Tesarova, M; Hajkova, Z; Hansikova, H; Wenchich, L; Honzik, T; Magner, M; Zamecnik, J; Ryska, P; Zeman, J",null,null,null,"Jesina, P.; Vinsova, K.; Brantova, O.; Tesarova, M.; Hajkova, Z.; Hansikova, H.; Wenchich, L.; Honzik, T.; Magner, M.; Zamecnik, J.; Ryska, P.; Zeman, J.",null,"Myoclonic Epilepsy and Deafness in Siblings with the 7512T > C Mutation in the Mitochondrial Encoded tRNA(Ser(UCN)) Gene - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"mitochondrial disease; myoclonic epilepsy; deafness; calcification in basal ganglia; cytochrom c oxidase deficiency; transfer RNA",null,"Mitochondrial diseases are a very heterogeneous group of disorders affecting the nervous system, heart and skeletal muscle. The mutations are situated in nuclear DNA with Mendelian heredity and in mitochondrial DNA with maternal-type heredity. We describe a natural clinical course, the results of biochemical and molecular genetic measurements from two siblings with mitochondrial disorders due to mutation 7512T>C in the gene for mitochondrial tRNA for serine. The mutation is associated with myoclonic epilepsy, deafness, ataxia, calcification in the basal ganglia and decreased cytochrome c oxidase activity. The data should prove helpful in the exact diagnosis of patients with this phenotype.","[Jesina, P.; Vinsova, K.; Brantova, O.; Tesarova, M.; Hajkova, Z.; Hansikova, H.; Wenchich, L.; Honzik, T.; Magner, M.; Zeman, J.] UK 1 LF, Klin Detskeho & Dorostoveho Lekarstvi, Prague 12808 2, Czech Republic; [Jesina, P.; Vinsova, K.; Brantova, O.; Tesarova, M.; Hajkova, Z.; Hansikova, H.; Wenchich, L.; Honzik, T.; Magner, M.; Zeman, J.] VFN Praze, Prague 12808 2, Czech Republic; [Zamecnik, J.] UK 2 LF, Ustav Patol & Mol Med, Prague, Czech Republic; [Zamecnik, J.] FN Motole, Prague, Czech Republic; [Ryska, P.] FN Hradec Kralove, Hradec Kralove, Czech Republic","Jesina, P, UK 1 LF, Klin Detskeho & Dorostoveho Lekarstvi, Ke Karlovu 2, Prague 12808 2, Czech Republic","paveljesina@seznam.cz",null,null,null,10,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,1,null,null,null,68,72,null,null,5,"Neurosciences; Surgery","569KA","ISI:000275593800010"]
["nemá","J","Magner, M; Vesela, K; Honzik, T; Jesina, P; Vobruba, V; Petrak, B; Zeman, J; Klement, P",null,null,null,"Magner, M.; Vesela, K.; Honzik, T.; Jesina, P.; Vobruba, V.; Petrak, B.; Zeman, J.; Klement, P.",null,"Sco2 Protein Deficiency-Based Mitochondrial Encephalomyopathy with the SMA-like Picture of Neurogenic Muscle Atrophy - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"mitochondrial encephalopathy; neurogenic muscle atrophy; spinal muscular atrophy; SMA; cytochrome c oxidase; SCO2 gene","GENE; MUTATIONS; DISEASE; OXIDASE","Various mitochondrial diseases with clinical, electromyographical and histological signs imitating spinal muscular atrophy (\"SMA-like diseases\") with no detected mutation in SMN1 gene have been described in recent years. Respiratory chain disorder was considered due to broad impairment of the central and peripheral nervous systems (encephalopathy, neuropathy) and other tissue and organ involvement (cardiomyopathy, myopathy, hepatopathy). The number of previously-reported mitochondrial syndromes with \"SMA-like\" sign development is limited, Revealing the phenotype in a detailed clinical context may lead to targeted molecular-genetic analysis and specific diagnostics without calling upon other investigations. A typical representative of this syndrome group is mitochondrial encephalopathy with cardiomyopathy and lactic acidosis arising out of a mutation in gene coding protein Sco2 protein, which is involved in the assembly of mitochondrial cytochrome c oxidase. Two case histories are presented, of patients in whom SMA-like phenotype development led to SCO2 gene investigation and correct diagnosis.","[Petrak, B.; Klement, P.] UK 2 LF, Klin Detske Neurol, Prague 12808 2, Czech Republic; [Petrak, B.] FN Motole, Prague 12808 2, Czech Republic","Klement, P, UK 2 LF, Klin Detske Neurol, Ke Karlovu 2, Prague 12808 2, Czech Republic","petrklement@seznam.cz",null,null,null,9,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,1,null,null,null,73,75,null,null,3,"Neurosciences; Surgery","569KA","ISI:000275593800011"]
["nemá","J","Bohm, M; Baumhakel, M; Teo, K; Sleight, P; Probstfield, J; Gao, P; Mann, JF; Diaz, R; Dagenais, GR; Jennings, GLR; Liu, LS; Jansky, P; Yusuf, S",null,null,null,"Boehm, Michael; Baumhaekel, Magnus; Teo, Koon; Sleight, Peter; Probstfield, Jeffrey; Gao, Peggy; Mann, Johannes F.; Diaz, Rafael; Dagenais, Gilles R.; Jennings, Garry L. R.; Liu, Lisheng; Jansky, Petr; Yusuf, Salim","ONTARGET TRANSCEND Erectile Dysfun","Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials","CIRCULATION",null,"English","Article",null,null,null,null,null,"trials; erectile dysfunction; cardiovascular diseases; drugs","ENDOTHELIAL PROGENITOR CELLS; CONVERTING-ENZYME-INHIBITORS; CORONARY-HEART-DISEASE; SEXUAL FUNCTION; ANGIOTENSIN-II; VASCULAR-DISEASE; MEN; HYPERTENSION","Background-Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND). Methods and Results-In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81, P=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94, P=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29, P=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58, P=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26, P=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9, P=0.742). The study medications did not influence the course or development of ED. Conclusions-ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101. (Circulation. 2010; 121: 1439-1446.)","[Boehm, Michael; Baumhaekel, Magnus] Univ Saarland, Dept Cardiol, D-6600 Saarbrucken, Germany; [Teo, Koon; Gao, Peggy; Yusuf, Salim] McMaster Univ Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Sleight, Peter] Univ Oxford, Oxford, England; [Probstfield, Jeffrey] Univ Washington, Sch Med, Seattle, WA USA; [Mann, Johannes F.] Schwabing Gen Hosp, Dept Nephrol Hypertens & Rheumatol, Munich, Germany; [Diaz, Rafael] Inst Cardiovasc Rosario, Dept Cardiol, Rosario, Santa Fe, Argentina; [Dagenais, Gilles R.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Jennings, Garry L. R.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Liu, Lisheng] Chinese Hypertens League Inst, Beijing, Peoples R China; [Jansky, Petr] Motol Univ Hosp, Dept Internal Med, Prague, Czech Republic","Bohm, M, Univ Klinkum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, Kirrberger Str 1, D-66424 Homburg, Germany","boehm@uks.eu","Boehringer-Ingelheim, Germany ","The ONTARGET/TRANSCEND Erectile Dysfunction Substudy was supported by Boehringer-Ingelheim, Germany.",null,28,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,"10.1161/CIRCULATIONAHA.109.864199","CIRCULATION","Circulation","MAR 30",2010,121,12,null,null,null,1439,"U114",null,null,10,"Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease","575RD","ISI:000276084400009"]
["nemá","J","Declerck, PJ; Darendeliler, F; Goth, M; Kolouskova, S; Micle, I; Noordam, C; Peterkova, V; Volevodz, NN; Zapletalova, J; Ranke, MB",null,null,null,"Declerck, Paul J.; Darendeliler, Feyza; Goth, Miklos; Kolouskova, Stanislava; Micle, Ioana; Noordam, Cees; Peterkova, Valentina; Volevodz, Natalia N.; Zapletalova, Jirina; Ranke, Michael B.",null,"Biosimilars: controversies as illustrated by rhGH","CURRENT MEDICAL RESEARCH AND OPINION",null,"English","Article",null,null,null,null,null,"Biopharmaceutical; Biosimilar; Follow-on biologic; Healthcare economics; Human growth hormone; Similar biological medicinal product","HUMAN GROWTH-HORMONE; NATIONAL COOPERATIVE GROWTH; CAPITAL FEMORAL EPIPHYSIS; SHORT STATURE; CHILDREN; SAFETY; EFFICACY; PRODUCTS; DATABASE; THERAPY","Background and scope: Similar biological medicinal products, also called 'biosimilars', are copies of biopharmaceutical products whose patent has expired. Whether biosimilars are truly comparable and interchangeable with their reference biopharmaceutical products in terms of quality, efficacy and tolerability, is still a matter of debate. This review discusses the controversies related to the criteria for regulatory approval of biosimilars. These concerns are illustrated using recombinant human growth hormone (rhGH) biosimilars as an example. Methods: Publications on the regulatory approval of biosimilars in general and rhGH biosimilars in particular were searched in MEDLINE by exploding and combining the medical subject heading terms 'human growth hormone', 'efficacy' or 'safety' and the free-text words 'biosimilar', 'biopharmaceutical', 'similar biological medicinal product', 'follow-up biologic' or 'biogeneric'. Searches were limited to full-text English-language articles. The websites from the European Medicines Agency (EMA) and from the American Food and Drug Administration were also consulted. Regulatory status: To obtain regulatory approval of a biosimilar product by EMA, demonstration of comparability with an approved reference biopharmaceutical product in terms of quality, efficacy and tolerability is needed. Thus, comparative quality studies, non-clinical and clinical efficacy and tolerability studies are required. However, in contrast to the reference product, comparative non-clinical pharmacokinetics, safety pharmacology, reproduction toxicology, mutagenicity and carcinogenicity studies are not mandatory to obtain approval of a biosimilar. In addition, comparable efficacy and tolerability only needs to be established by one study in a single population during a limited time interval (12 months) and often allows extrapolation to all other approved indications of the reference product. Consequently, for the currently approved rhGH biosimilars, long-term efficacy and tolerability in all indications has not been proven to the same degree as for the reference products. Conclusions: The validity of the current criteria for comparability and interchangeability of biosimilars and their reference products remains controversial. The authors conclude that long-term clinical investigations and systematic monitoring of the efficacy and tolerability of rhGH biosimilars in all indications are needed. In addition, the medico-economical environment should allow physicians to take a free and informed decision about the type of rhGH to be prescribed.","[Declerck, Paul J.] Katholieke Univ Leuven, Lab Pharmaceut Biol, Fac Pharmaceut Sci, B-3000 Louvain, Belgium; [Darendeliler, Feyza] Istanbul Fac Med, Istanbul, Turkey; [Goth, Miklos] State Hlth Ctr, Dept Internal Med 2, Budapest, Hungary; [Micle, Ioana] Univ Med & Farm Timisoara, Timisoara, Romania; [Micle, Ioana] Clin Emergency Hosp Children Louis Turcanu, Timisoara, Romania; [Kolouskova, Stanislava] Univ Hosp Motol, Prague, Czech Republic; [Noordam, Cees] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Peterkova, Valentina; Volevodz, Natalia N.] Russian Acad Sci, Endocrinol Sci Ctr, Moscow, Russia; [Zapletalova, Jirina] Palacky Univ, Univ Hosp, CR-77147 Olomouc, Czech Republic; [Zapletalova, Jirina] Palacky Univ, Fac Med, CR-77147 Olomouc, Czech Republic; [Ranke, Michael B.] Univ Childrens Hosp, Tubingen, Germany","Declerck, PJ, Katholieke Univ Leuven, Lab Pharmaceut Biol, Fac Pharmaceut Sci, Campus Gasthuisberg O&N2,PB 824,Herestr 49, B-3000 Louvain, Belgium","Paul.Declerck@pharm.kuleuven.be","Pfizer Emerging Markets Europe ; OTKA [68660]; Eli Lilly ; Novo Nordisk ; Pfizer ","This study was funded by an unrestricted grant from Pfizer Emerging Markets Europe. M. G. has disclosed that he has received speaker fees from Merck Serono and Novartis and is supported by an OTKA grant No. 68660. C. N. has disclosed that he has received honoraria for consultancy/advisory board attendance from Ipsen Pharma and Pfizer. M. B. R. has disclosed that he has received honoraria for advisory board attendance from Pfizer, Germany. J.Z. has disclosed that she has received grants/research funding from Eli Lilly, Novo Nordisk and Pfizer; honoraria for consultancy/advisory board attendance from Eli Lilly, Novo Nordisk and Pfizer; and speaker fees from Eli Lilly and Pfizer. F. D., P.J.D., S. K., I. M., V. P. and N. V. have not declared any conflicts of interest regarding rhGH products.",null,52,0,"LIBRAPHARM/INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND","0300-7995",null,"10.1185/03007991003719642","CURR MED RES OPIN","Curr. Med. Res. Opin.","MAY",2010,26,5,null,null,null,1219,1229,null,null,11,"Medicine, General & Internal; Medicine, Research & Experimental","583MO","ISI:000276680900025"]
["nemá","J","Lotti, T; Hercogova, J; Prignano, F",null,null,null,"Lotti, Torello; Hercogova, Jana; Prignano, Francesca",null,"The concept of psoriatic disease: Can cutaneous psoriasis any longer be separated by the systemic comorbidities?","DERMATOLOGIC THERAPY",null,"English","Article",null,null,null,null,null,"Psoriasis; comorbidities; psoriatic arthritis; cardiovascular disease; metabolic syndrome; inflammatory bowel disease; depression","RISK; ASSOCIATION; LYMPHOMA; WEIGHT","Psoriasis is a general inflammatory status in which the skin is usually visibly involved. Recent papers show that several comorbidities, including psoriatic arthritis, metabolic syndrome, cancer, osteoporosis, cardiovascular disease, chronic inflammatory bowel disease etc., are significantly associated with psoriasis. Detecting association between psoriasis and comorbidities, properly evaluate confounders and make a correct distinction among absolute risk, relative risk and clinical relevance is mandatory, before embracing the fact the psoriasis is, in fact, a complex and common international disease.","[Lotti, Torello] Univ Florence, Sch Med, Dept Dermatol Sci, I-50129 Florence, Italy; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Lotti, T, Univ Florence, Sch Med, Dept Dermatol Sci, Via Lorenzo 2 Magnif 104, I-50129 Florence, Italy","tlotti@unifi.it",null,null,null,16,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","MAR-APR",2010,23,2,null,null,null,119,122,null,null,4,"Dermatology","574RT","ISI:000276011200004"]
["nemá","J","Hercogova, J; Ricceri, F; Tripo, L; Lotti, T; Prignano, F",null,null,null,"Hercogova, Jana; Ricceri, Frederica; Tripo, Lara; Lotti, Torello; Prignano, Francesca",null,"Psoriasis and body mass index","DERMATOLOGIC THERAPY",null,"English","Article",null,null,null,null,null,"body mass index; metabolic syndrome; obesity; psoriasis","METABOLIC SYNDROME; PLAQUE PSORIASIS; OBESITY; WEIGHT; INFLAMMATION; ASSOCIATION; THERAPY; DISEASE; RISK","Recently, it has emerged a strong association between increased adiposity, obesity, and psoriasis. Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used to classify underweight, overweight and obesity in adults. Psoriasis has also been associated with systemic obesity-related disorders including type 2 diabetes, hypertension, ischemic heart disease, and combined hyperlipidemia, as a part of metabolic syndrome. Not only the obesity may be associated with higher psoriasis incidence and activity, and prevalence of obesity-related syndromes, but it may also influence the therapeutic approach to disease and the clinical response to systemic treatment. Consequently, the approach of the experienced dermatologist will take into account all the aspects of the patient clinical conditions including the analysis of BMI for the choice of the best suitable therapy.","[Prignano, Francesca] Univ Florence, Sch Med, Dept Dermatol Sci, I-50129 Florence, Italy; [Lotti, Torello; Prignano, Francesca] Chares Univ, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Prignano, F, Univ Florence, Sch Med, Dept Dermatol Sci, Via Lorenzo 2 Magnif 104, I-50129 Florence, Italy","francesca.prignano@unifi.it",null,null,null,16,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","MAR-APR",2010,23,2,null,null,null,152,154,null,null,3,"Dermatology","574RT","ISI:000276011200008"]
["nemá","J","Pradny, M; Slouf, M; Martinova, L; Michalek, J",null,null,null,"Pradny, Martin; Slouf, Miroslav; Martinova, Lenka; Michalek, Jiri",null,"macroporous hydrogels based on 2-hydroxyethyl methacrylate. Part 7: Methods of preparation and comparison of resulting physical properties","E-POLYMERS",null,"English","Article",null,null,null,null,null,"porous hydrogels; 2-hydroxyethyl methacrylate; porosity; morphology; nanofibers","SUPERPOROUS HYDROGELS; POLYELECTROLYTE COMPLEXES; COPOLYMERS; CHARGES","Five methods of preparation of macroporous hydrogels are described and compared: precipitation polymerization, polymerization in presence of salt, polymerization in presence of gas-releasing compound, lyophilization and electrospinning. Crosslinked copolymers based on 2-hydroxyethyl methacrylate were selected as model hydrogels. Hydrogels were characterized by SEM microscopy, porosity, communicating/non-communicating pore ratio, pore sizes and their distributions. The advantages and drawbacks of the methods of preparation, modification of hydrogel properties, reproducibility and issues related to their preparation are discussed. The most convenient method was preparation in presence of salts. One type of porous hydrogel was based on a hydrogel matrix composed of nanofibers prepared by electrospinning method. The nanofibers have shown unique properties due to their large specific surface. The least suitable method seems to be the preparation of porous hydrogels by polymerization using gas (nitrogen) releasing initiator, 2,2'-azobisisobutyronitrile. The use of prepared porous hydrogels is intended especially for scaffolds in tissue engineering.","[Pradny, Martin; Slouf, Miroslav; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Pradny, Martin; Michalek, Jiri] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15000 5, Czech Republic; [Martinova, Lenka] Tech Univ Liberec, Fac Text Engn, Liberec 46117, Czech Republic","Pradny, M, Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic","pradny@imc.cas.cz; lenka.martinova@tul.cz","Grant Agency of the Czech Republic [106/09/1000, 304/07/1129]","This study was supported by the Grant Agency of the Czech Republic, projects No. 106/09/1000 and 304/07/1129.",null,21,0,"EUROPEAN POLYMER FEDERATION","STRASBOURG","1, QUAI LEZAY-MARNESIA, F067000 STRASBOURG, FRANCE","1618-7229",null,null,"E-POLYMERS","e-Polymers","APR 13",2010,null,null,null,null,null,null,null,43,null,12,"Polymer Science","584HS","ISI:000276742700001"]
["nemá","J","Betka, J; Chovanec, M; Klozar, J; Taudy, M; Plzak, J; Kodetova, D; Lisy, J",null,null,null,"Betka, Jan; Chovanec, Martin; Klozar, Jan; Taudy, Milos; Plzak, Jan; Kodetova, Dana; Lisy, Jiri",null,"Transoral and combined transoral-transcervical approach in the surgery of parapharyngeal tumors","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,"English","Article",null,null,null,null,null,"Parapharyngeal space; Transoral approach; External approach; Surgery; Salivary gland; Tumor; Nerve sheath tumor","SPACE TUMORS; MANAGEMENT; DIAGNOSIS; SKULL; BASE","The goal of parapharyngeal space (PPS) tumor surgery is to obtain adequate visualization to ensure complete removal with preservation of the surrounding nerves and vessels. Different surgical approaches have been described. Transoral approach is the most controversial one due to cited limited exposure, risk of tumor spillage, and possibility of neurovascular injury. We performed retrospective analysis of 26 consecutive patients who had undergone transoral or combined transoral-transcervical resection of PPS tumors from January 1997 to December 2007. Both approaches were safely employed to remove selected PPS tumors. Majority of treated tumors were pleomorphic adenomas (14 minor salivary gland and 7 deep lobe parotid gland tumors). Two cases of malignant salivary gland tumors, 4 nerve sheath tumors and 1 lymphangioma were also excised. Mean tumor size was 6.1 cm (range 2-11 cm). Visualization was felt to be adequate and dissection safe. Radical resection was achieved in 24 cases. Near-total resection was achieved in two cases where otherwise other approach would be suitable but cannot be undertaken because of patient refusal and comorbidities. Patients with malignant tumors had postoperative radiotherapy. Radically treated cases are disease free. One of the near-totally resected tumors needed revision surgery. Neither major complications nor disordered healing were observed. Transoral approach provides access to selected cases of PPS tumors based on preoperative imaging methods and fine-needle aspiration cytology. Risk of non-radical resection is acceptable. It can be combined with external approach to achieve safe resection of some benign tumors which would need transmandibular approach.","[Betka, Jan; Chovanec, Martin; Klozar, Jan; Taudy, Milos; Plzak, Jan] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Prague 15006 5, Czech Republic; [Chovanec, Martin; Plzak, Jan] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Chovanec, Martin; Plzak, Jan] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic; [Kodetova, Dana] Charles Univ Prague, Inst Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Dept Radiodiagnost, Fac Med 2, Prague 15006 5, Czech Republic","Chovanec, M, Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic","martin.chovanec@lf1.cuni.cz",null,null,null,16,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,"10.1007/s00405-009-1071-z","EUR ARCH OTO-RHINO-LARYNGOL","Eur. Arch. Oto-Rhino-Laryn.","MAY",2010,267,5,null,null,null,765,772,null,null,8,"Otorhinolaryngology","573YL","ISI:000275954000017"]
["nemá","J","Witjes, JA; Redorta, JP; Jacqmin, D; Sofras, F; Malmstrom, PU; Riedl, C; Jocham, D; Conti, G; Montorsi, F; Arentsen, HC; Zaak, D; Mostafid, AH; Babjuk, M",null,null,null,"Witjes, J. Alfred; Palou Redorta, Juan; Jacqmin, Didier; Sofras, Frank; Malmstrom, Per-Uno; Riedl, Claus; Jocham, Dieter; Conti, Giario; Montorsi, Francesco; Arentsen, Harm C.; Zaak, Dirk; Mostafid, A. Hugh; Babjuk, Marko",null,"Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations","EUROPEAN UROLOGY",null,"English","Review",null,null,null,null,null,"Carcinoma in situ; CIS detection; Hexaminolevulinate; Non-muscle-invasive bladder cancer; PDD; Photodynamic diagnosis; Recurrence","WHITE-LIGHT CYSTOSCOPY; CARCINOMA IN-SITU; TRANSURETHRAL RESECTION; PHOTODYNAMIC DIAGNOSIS; PHASE-III; HEXYL AMINOLEVULINATE; RECURRENCE RATE; 7 EORTC; MULTICENTER; RISK","Context: Compared with standard white-light cystoscopy, photodynamic diagnosis with blue light and the photosensitiser hexaminolevulinate has been shown to improve the visualisation of bladder tumours, reduce residual tumour rates by at least 20%, and improve recurrence-free survival. There is currently no overall European consensus outlining specifically where hexaminolevulinate is or is not indicated. Objective: Our aim was to define specific indications for hexaminolevulinate guided fluorescence cystoscopy in the diagnosis and management of non-muscle invasive bladder cancer (NMIBC). Evidence acquisition: A European expert panel was convened to review the evidence for hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and management of NMIBC (identified through a PubMed MESH search) and available guidelines from across Europe. On the basis of this information and drawing on the extensive clinical experience of the panel, specific indications for the technique were then identified through discussion. Evidence synthesis: The panel recommends that hexaminolevulinate-guided fluorescence cystoscopy be used to aid diagnosis at initial transurethral resection following suspicion of bladder cancer and in patients with positive urine cytology but negative white-light cystoscopy for the assessment of tumour recurrences in patients not previously assessed with hexaminolevulinate, in the initial follow-up of patients with carcinoma in situ (CIS) or multifocal tumours, and as a teaching tool. The panel does not currently recommend the use of hexaminolevulinate-guided fluorescence cystoscopy in patients for whom cystectomy is indicated or for use in the outpatient setting with flexible cystoscopy. Conclusions: Evidence is available to support the use of hexaminolevulinate-guided fluorescence cystoscopy in a range of indications, as endorsed by an expert panel. (c) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Witjes, J. Alfred] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Palou Redorta, Juan] Univ Autonoma Barcelona, Fundacio Puigvert, E-08193 Barcelona, Spain; [Jacqmin, Didier] Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France; [Sofras, Frank] Univ Crete, Dept Urol, Iraklion, Greece; [Malmstrom, Per-Uno] Univ Uppsala Hosp, Dept Surg Sci, Uppsala, Sweden; [Riedl, Claus] Landesklinikum Thermenreg Baden, Dept Urol, Baden, Austria; [Jocham, Dieter] Med Univ Lubeck, Dept Urol, D-23538 Lubeck, Germany; [Conti, Giario] St Anna Hosp, Dept Urol & Androl, Como, Italy; [Montorsi, Francesco] Univ Vita Salute San Raffaele, Milan, Italy; [Arentsen, Harm C.] Radboud Univ Nijmegen, Dept Urol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Zaak, Dirk] Univ Munich, Munich, Germany; [Mostafid, A. Hugh] N Hampshire Hosp, Basingstoke, Hants, England; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Dept Urol, Fac Hosp Motol, Prague, Czech Republic","Witjes, JA, Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands","F.Witjes@uro.umcn.nl","GE Healthcare ","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: This article was sponsored by an educational grant from GE Healthcare. The company had no role in the preparation or approval of the manuscript but checked the factual and medical content. Editorial control resides with the authors and editor.",null,49,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,"10.1016/j.eururo.2010.01.025","EUR UROL","Eur. Urol.","APR",2010,57,4,null,null,null,607,614,null,null,8,"Urology & Nephrology","571GH","ISI:000275739300015"]
["nemá","J","Babjuk, M",null,null,null,"Babjuk, Marko",null,"Current Value of Neoadjuvant Chemotherapy Prior to Cystectomy","EUROPEAN UROLOGY SUPPLEMENTS",null,"English","Proceedings Paper","7th Meeting of the EAU Section of Oncological Urology (ESOU)","JAN 15-17, 2010","Vienna, AUSTRIA","European Assoc Urol",null,"Bladder cancer; Cisplatin-based combination; Distant metastases; Invasive; M-VAC; Neoadjuvant chemotherapy; Radical cystectomy","TRANSITIONAL-CELL-CARCINOMA; INVASIVE BLADDER-CANCER; GEMCITABINE PLUS CISPLATIN; RADICAL CYSTECTOMY; RANDOMIZED-TRIAL; THERAPY; SERIES; METHOTREXATE; METAANALYSIS; VINBLASTINE","Context: Radical cystectomy with a pelvic lymph node dissection is considered the most effective treatment option today for patients with muscle-invasive bladder cancer. Unfortunately, in spite of some progress, disease-specific survival rates after cystectomy have not dramatically changed in the last few decades. The significant risk of distant failure indicates that additional systemic treatment is mandatory. Objective: The primary objective of the review was to summarize the data about the benefit of neoadjuvant systemic chemotherapy before cystectomy for muscle-invasive bladder cancer. Evidence acquisition: The papers evaluating cystectomy cohorts were analyzed including a thorough analysis of treatment failures. The papers presenting prospective randomized trials and meta-analyses on neoadjuvant chemotherapy in bladder cancer were critically reviewed. Evidence synthesis: The rationale for chemotherapy before cystectomy is to treat micrometastases beyond the margins of local therapy already present at the time of diagnosis of invasive bladder cancer. Results of prospective randomized trials indicate survival benefit after neoadjuvant platinum-based combination chemotherapy. To improve the interpretation of data from prospective randomized trials, several meta-analyses were conducted. The most recent meta-analysis, published in 2005, evaluated the individual data from 3005 patients enrolled in 11 prospective controlled trials that compared neoadjuvant chemotherapy plus local treatment with local treatment alone. The data comprised 98% of all patients from known eligible randomized controlled trials. The analysis found significant survival benefit associated with platinum-based combination chemotherapy. It was equivalent to a 5% absolute improvement in overall survival (p = 0.003) and a 9% improvement in disease-free survival (p < 0.0001) at 5 yr. Conclusions: Radical cystectomy with pelvic lymph node dissection remains the standard treatment for muscle-invasive bladder cancer. The quality of surgery is essential for optimal treatment results. The data from prospective randomized trials and meta-analyses provide support for preoperative application of platinum-based combination chemotherapy in all patients. (C) 2010 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 1, Prague, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic","Babjuk, M, FN Motol, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic","marek.babjuk@lfmotol.cuni.cz",null,null,null,25,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-9056",null,"10.1016/j.eursup.2010.02.001","EUR UROL SUPPL","Eur. Urol. Suppl.","APR",2010,9,3,null,null,null,424,427,null,null,4,"Urology & Nephrology","581MJ","ISI:000276527200009"]
["nemá","J","Rob, L; Pluta, M; Robova, H",null,null,null,"Rob, Lukas; Pluta, Marek; Robova, Helena",null,"Less radical surgery than radical hysterectomy in early stage cervical cancer - A pilot study","GYNECOLOGIC ONCOLOGY",null,"English","Letter",null,null,null,null,null,null,"INVOLVEMENT",null,"[Rob, Lukas; Pluta, Marek; Robova, Helena] Fac Hosp Motol, Dept Obstet & Gynecol, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L, Fac Hosp Motol, Dept Obstet & Gynecol, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic","lukas.rob@lfmotol.cuni.cz",null,null,null,7,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0090-8258",null,"10.1016/j.ygyno.2009.12.007","GYNECOL ONCOL","Gynecol. Oncol.","APR",2010,117,1,null,null,null,148,148,null,null,1,"Oncology; Obstetrics & Gynecology","582JV","ISI:000276594200028"]
["nemá","J","Zitka, O; Krizkova, S; Adam, V; Horna, A; Kukacka, J; Prusa, R; Zizkova, V; Kizek, R",null,null,null,"Zitka, Ondrej; Krizkova, Sona; Adam, Vojtech; Horna, Ales; Kukacka, Jiri; Prusa, Richard; Zizkova, Vera; Kizek, Rene",null,"Utilizing Automated Chip Electrophoresis for Study of Lactoferrin and Matrix Metalloproteinases","CHEMICKE LISTY",null,"Czech","Article",null,null,null,null,null,null,"CAPILLARY-ELECTROPHORESIS; PROTEINS; IDENTIFICATION; MICROCHIP; QUALITY; SYSTEM; VARIETY","Automated chip capillary electrophoresis was used in detection and isolation of lactoferrin and a human matrix metalloproteinase (MMP-9) as well as in investigation of interactions and cleavage of collagen with MMP-9. The method is a sensitive and simple technique superior to SDS-PAGE. It is useful in proteomic research.","[Zitka, Ondrej] Masaryk Univ, Ustav Biochem, Prirodovedecka Fak, CS-61137 Brno, Czech Republic; [Adam, Vojtech] Mendelova Univ Brne, Ustav Vyzivy Zvirat & Picninarstvi, Agron Fak, Brno 61300, Czech Republic; [Zitka, Ondrej; Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendelova Univ Brne, Ustav Chem & Biochem, Agron Fak, Brno 61300, Czech Republic; [Horna, Ales] Univ Tomase Bati Zline, Univ Inst, Zlin 76272, Czech Republic; [Horna, Ales] Radanal SRO, Pardubice 53003, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Ustav Klin Biochem & Patobiochem, Lekarska Fak 2, Prague 15006 5, Czech Republic; [Zizkova, Vera] Vyzkumny Ustav Pletarsky, Brno 60200, Czech Republic","Zitka, O, Masaryk Univ, Ustav Biochem, Prirodovedecka Fak, Kotlarska 2, CS-61137 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,24,0,"CHEMICKE LISTY","PRAGUE 6","NOVOTNEHO LAVKA 5, PRAGUE 6 116 68, CZECH REPUBLIC","0009-2770",null,null,"CHEM LISTY","Chem. Listy",null,2010,104,3,null,null,null,197,201,null,null,5,"Chemistry, Multidisciplinary","581SZ","ISI:000276546100010"]
["nemá","J","Machovcova, A",null,null,null,"Machovcova, Alena",null,"Caustic Ulcers Caused by Cement Aqua: Report of a Case","INDUSTRIAL HEALTH",null,"English","Article",null,null,null,null,null,"Caustic ulcers; Cement aqua; Occupational injury","SKIN BURNS; WET CEMENT","Chromium is widely used in various industries including construction sector. Skin contact with cement has been associated with allergic or irritant contact dermatitis. Contact dermatitis is one of the most frequently reported health problems among construction workers. Irritant contact dermatitis from cement ranges from cement burns to cumulative irritant contact dermatitis. Cement burns are rarely reported and are considered a severe form of acute irritant contact dermatitis. They are associated with amateur user working in a short ready-mix time-frame with poor protective measures. They usually result in significant morbidity and initially are associated with minimal discomfort. We report a typical case.","Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic","Machovcova, A, Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic","alena.machovcova@fnmotol.cz","VZ FNM MZO [00064203/6904]","This study is supported by grant VZ FNM MZO 00064203/6904.",null,11,0,"NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN","KAWASAKI KANAGAWA","21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN","0019-8366",null,null,"IND HEALTH","Ind. Health","MAR",2010,48,2,null,null,null,215,216,null,null,2,"Environmental Sciences; Public, Environmental & Occupational Health; Toxicology","577WZ","ISI:000276256000012"]
["nemá","J","Witso, E; Cinek, O; Aldrin, M; Grinde, B; Rasmussen, T; Wetlesen, T; Ronningen, KS",null,null,null,"Witso, Elisabet; Cinek, Ondrej; Aldrin, Magne; Grinde, Bjorn; Rasmussen, Trond; Wetlesen, Turid; Ronningen, Kjersti S.",null,"Predictors of sub-clinical enterovirus infections in infants: a prospective cohort study","INTERNATIONAL JOURNAL OF EPIDEMIOLOGY",null,"English","Article",null,null,null,null,null,"Enterovirus; breastfeeding; infant; multivariable logistic regression; prospective cohort study; predictors","DOSE-RESPONSE RELATIONSHIP; UNITED STATES CITIES; CONTINUING SURVEILLANCE; INTRAFAMILIAL SPREAD; DIABETES-MELLITUS; HEALTHY CHILDREN; ENTERIC VIRUSES; GROUNDWATER; ILLNESS; RISK","Background Enterovirus infections are common, although most often subclinical. The present purpose was to assess the impact of breastfeeding and other factors on enterovirus infections in infancy. Methods A prospective observational study was carried out on a population-based cohort of 639 Norwegian infants aged 3-12 months. The outcome was enterovirus RNA measured in monthly stool samples. Data on underlying determinants, such as dietary feeding and household factors, were reported in parental questionnaires. Multivariable logistic regression was performed to allow for common confounders. Statistical analyses were performed by GLLAMM using Stata 9.2, which corrects for subject-specific random effects. Results The prevalence of enterovirus in stools was 11.1% (475/4279). Risk of enterovirus infection decreased with increasing number of daily breastfeeds; the effect was most pronounced at the age of 3 months [odds ratio (OR), 0.85; 95% confidence interval (CI) 0.8-0.9, P < 0.001], gradually declining thereafter, reaching no effect at 11 months. Increased risk was associated with having one or more sibling(s) (OR 1.89; 95% CI 1.2-3.0), particularly if they attended daycare (OR 2.46; 95% CI 1.4-4.2), and with increasing exposure to other children (OR 1.04; 95% CI 1.0-1.1). There was a tendency towards higher prevalence of infection when a household's drinking water came from a well, and a protective effect of owning a dog or cat. Conclusions Several factors may modify the risk for enterovirus infections in the first year of life. This study supports the protective effect of breastfeeding. The protection decreased with age and increased with dose of ingested milk.","[Witso, Elisabet; Wetlesen, Turid; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Dept Genes & Environm, Div Epidemiol, Oslo, Norway; [Cinek, Ondrej] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic; [Aldrin, Magne] Norwegian Comp Ctr, Stat Anal Pattern Recognit & Image Anal SAMBA, Oslo, Norway; [Grinde, Bjorn] Norwegian Inst Publ Hlth, Dept Virol, Div Infect Dis Control, Oslo, Norway; [Rasmussen, Trond] Norwegian Inst Publ Hlth, Dept Informat Syst, Div Adm & Support, Oslo, Norway","Witso, E, Hagedorn Res Inst, Niels Steensensvej 1,NLE2-10, DK-2820 Gentofte, Denmark","elwi@novonordisk.com",null,null,null,46,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0300-5771",null,"10.1093/ije/dyp333","INT J EPIDEMIOL","Int. J. Epidemiol.","APR",2010,39,2,null,null,null,459,468,null,null,10,"Public, Environmental & Occupational Health","578OT","ISI:000276303800025"]
["nemá","J","Boucek, J; Mrkvan, T; Chovanec, M; Kuchar, M; Betka, J; Boucek, V; Hladikova, M; Betka, J; Eckschlager, T; Rihova, B",null,null,null,"Boucek, Jan; Mrkvan, Tomas; Chovanec, Martin; Kuchar, Martin; Betka, Jaroslav; Boucek, Vladimir; Hladikova, Marie; Betka, Jan; Eckschlager, Tomas; Rihova, Blanka",null,"Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck","JOURNAL OF CELLULAR AND MOLECULAR MEDICINE",null,"English","Article",null,null,null,null,null,"regulatory T cells; head and neck squamous cell carcinoma; tumour markers; early recurrence; lymphocyte subpopulations","PERIPHERAL-BLOOD; IMMUNE-RESPONSES; LYMPHOCYTE SUBSETS; OVARIAN-CARCINOMA; ABSOLUTE COUNTS; CANCER-PATIENTS; TUMOR; EXPRESSION; DISEASE; CIRCULATION","Regulatory T cells (Treg) are important regulators of anti-cancer immune responses, and an increase in Treg frequency was observed in the blood of cancer patients. Blood samples from 112 patients with head and neck squamous cell carcinoma antigen (HNSCC) were obtained at the time of tumour diagnosis, and lymphocyte subpopulations (CD3+; CD3-CD16+CD56+; CD4+; CD8+; CD19+; CD4+CD45RA+) with emphasis on Treg counts (CD3+CD4+CD25+), complete blood count and tumour markers (squamous cell carcinoma [SCC]; CEA; alpha-1-antitrypsin [AAT]; Cyfra 21-1; C-reactive protein [CRP]) were analysed. The data were grouped according to TNM classification, and their significance for the course of the disease at an interval of 1 year after the end of the therapy was determined. The percentage of CD8+ cells increased and the CD/D8 ratio decreased with tumour grade. The ratio of B lymphocytes decreased in patients with locoregional metastases (11.25% versus 9.22%). Treg (15.2%) and CD4+ cells (45.3%) increased, while NK cells (11.8%) decreased in HNSCC patients compared to controls (9.0%, 38.1% and 15.8%, respectively). The data obtained at time of diagnosis were used to assess the significance of tumour markers (SCC, Cyfra 21-1 and AAT) for evaluation of prognosis. The erythrocyte counts (4.64 x 1012/l versus 4.45 x 1012/l) and haemoglobin levels (14.58 g/dl versus 14.05 g/dl) decreased, while Treg counts (8.91% versus 15.70%) increased in patients with early recurrence. Our results show that examination of these parameters could be helpful for prognostication in HNSCC patients and aid improvement of treatment strategy.","[Boucek, Jan; Chovanec, Martin; Kuchar, Martin; Betka, Jaroslav; Betka, Jan] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Boucek, Jan; Mrkvan, Tomas; Betka, Jaroslav; Rihova, Blanka] ASCR, Inst Microbiol, Vvi, Prague, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Dept Med Informat, Fac Med 2, Prague 15006 5, Czech Republic; [Boucek, Vladimir] Hosp Rudolf & Stephania Benesov, Dept Haematol & Blood transfus, Machova, Benesov, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic","Boucek, J, Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic","jboucek99@seznam.cz","Czech Ministry of Health [grant NR 8883-3]; Ministry of Education, Youth and Sports of The Czech Republic [MSM 0021620813, 1M0505]; Institutional Research Concept [AV0Z50200510]","The research was supported by the Internal Grant Agency of the Czech Ministry of Health (grant NR 8883-3), by the Ministry of Education, Youth and Sports of The Czech Republic (Grant MSM 0021620813 and No. 1M0505) and by Institutional Research Concept AV0Z50200510.",null,39,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1582-1838",null,"10.1111/j.1582-4934.2008.00650.x","J CELL MOL MED","J. Cell. Mol. Med.","JAN-FEB",2010,14,"2010-02-01",null,null,null,426,433,null,null,8,"Cell Biology; Medicine, Research & Experimental","569YV","ISI:000275639700037"]
["nemá","J","Drevinek, P; Baldwin, A; Lindenburg, L; Joshi, LT; Marchbank, A; Vosahlikova, S; Dowson, CG; Mahenthiralingam, E",null,null,null,"Drevinek, Pavel; Baldwin, Adam; Lindenburg, Laurens; Joshi, Lovleen Tina; Marchbank, Angela; Vosahlikova, Sarka; Dowson, Christopher G.; Mahenthiralingam, Eshwar",null,"Oxidative Stress of Burkholderia cenocepacia Induces Insertion Sequence-Mediated Genomic Rearrangements That Interfere with Macrorestriction-Based Genotyping","JOURNAL OF CLINICAL MICROBIOLOGY",null,"English","Article",null,null,null,null,null,null,"CYSTIC-FIBROSIS PATIENTS; CEPACIA COMPLEX; INDUCED TRANSPOSITION; SUPEROXIDE-DISMUTASE; SP-NOV; EPIDEMIOLOGY; RESISTANCE","Burkholderia cenocepacia can cause serious infections and epidemics in patients with cystic fibrosis (CF). A CF population in the Czech Republic experienced an epidemic outbreak caused by a B. cenocepacia ST-32 strain. The clonality of the isolates was evident by multilocus sequence typing; however, fingerprinting profiles obtained by pulsed-field gel electrophoresis (PFGE) showed substantial band variability. We investigated whether the PFGE pattern diversity resulted from genomic rearrangements mediated by insertion sequences (IS); in addition, we determined whether stressful growth conditions altered the transposition activity of these IS. DNA probes for IS commonly found in B. cenocepacia were designed using the B. cenocepacia J2315 genome. Southern hybridization analysis of ST-32 isolates demonstrated diversity in both the copy number and the insertion site for a homologue of ISBcen20. Movement of the ISBcen20 homologue was detected when the ST-32 isolate CZ1238 was exposed to oxidative stress (growth in the presence of H2O2). PFGE analysis of CZ1238 derivatives exposed to oxidative stress demonstrated genomic rearrangements. Interestingly, when the closely related B. cenocepacia strain J2315 was exposed to oxidative stress, no movement of ISBcen20 was detected. Since frameshift mutations are present within the transposases of all copies of this IS in J2315, our data suggest that the transposase is inactive. In summary, we have demonstrated for the first time that IS movement can be mediated by oxidative stress and can lead to genomic rearrangements in the CF pathogen B. cenocepacia. These IS movements may alter the PFGE fingerprints of isolates that are clonal by other typing methods.","[Drevinek, Pavel; Lindenburg, Laurens; Joshi, Lovleen Tina; Marchbank, Angela; Mahenthiralingam, Eshwar] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales; [Baldwin, Adam; Dowson, Christopher G.] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; [Drevinek, Pavel; Vosahlikova, Sarka] Charles Univ Prague, Sch Med 2, Dept Paediat, Prague, Czech Republic","Drevinek, P, Charles Univ Prague, Sch Med 2, Dept Paediat, Prague, Czech Republic","pavel.drevinek@Lfmotol.cuni.cz","Wellcome Trust [075586]; Ministry of Education of the Czech Republic [MSM0021620812]","This work was funded by grants from the Wellcome Trust (075586) and the Ministry of Education of the Czech Republic (MSM0021620812).",null,22,0,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0095-1137",null,"10.1128/JCM.01433-09","J CLIN MICROBIOL","J. Clin. Microbiol.","JAN",2010,48,1,null,null,null,34,40,null,null,7,"Microbiology","576NL","ISI:000276151500003"]
["nemá","J","Charvat, J; Chlumsky, J; Svab, P; Zamrazil, V",null,null,null,"Charvat, J.; Chlumsky, J.; Svab, P.; Zamrazil, V.",null,"The Impact of Early Diastolic Myocardial Relaxation on the Other Parameters of Diastolic Function and Association of Tissue Doppler Parameters of Diastolic Function with Diabetes Compensation and Duration in Type 2 Diabetic Patients","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,"English","Article",null,null,null,null,null,"DIABETES MELLITUS; DIASTOLIC FUNCTION; TISSUE DOPPLER ECHOCARDIOGRAPHY","LEFT-VENTRICULAR RELAXATION; OVERT HEART-DISEASE; ARTERIAL-HYPERTENSION; DYSFUNCTION; MELLITUS; ECHOCARDIOGRAPHY; PREVALENCE","This study assessed the impact of tissue Doppler derived myocardial early diastolic relaxation velocity (E-m) on the other parameters of diastolic function (preload dependent transmitral early diastolic velocity [E], tissue Doppler derived myocardial late diastolic velocity [A(m)], preload dependent transmitral late diastolic velocity [A]) and evaluated the correlation of these parameters with selected clinical variables in type 2 diabetic patients. Using tissue Doppler echocardiography, 82 type 2 diabetic patients were evaluated, divided into two equal groups of E-m < 7.5 cm/s or 7.5 cm/s. Patients with E-m < 7.5 cm/s had significantly lower E/A and E-m/A(m), and higher E/E-m values. Multi linear regression showed a negative correlation between E-m and glycated haemoglobin (Hb(A1c)) and duration of diabetes, a negative correlation of E-m/Am with age, duration of diabetes and Hb(A1c), and a positive correlation of E/E-m with age, duration of diabetes and use of diuretics. The E/A ratio only correlated negatively with age. It is concluded that Ern is a reliable parameter of diastolic function, and that the tissue Doppler parameters of diastolic function are associated with diabetes compensation and diabetes duration.","[Charvat, J.; Chlumsky, J.; Svab, P.; Zamrazil, V.] Charles Univ Prague, Fac Med 2, Dept Med, Prague 15006 5, Czech Republic","Charvat, J, Charles Univ Prague, Fac Med 2, Dept Med, V Uvalu 84, Prague 15006 5, Czech Republic","jiri.charvat@lfmotol.cuni.cz","Internal Grant Agency, Ministry of Health, Czech Republic [NR/9520-3]","This study was supported by the Internal Grant Agency, Ministry of Health, Czech Republic (NR/9520-3).",null,23,0,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","JAN-FEB",2010,38,1,null,null,null,127,133,null,null,7,"Medicine, Research & Experimental; Pharmacology & Pharmacy","584YG","ISI:000276789900014"]
["nemá","J","McCormick, J; Mehta, G; Olesen, HV; Viviani, L; Macek, M; Mehta, A",null,null,null,"McCormick, Jonathan; Mehta, Gita; Olesen, Hanne V.; Viviani, Laura; Macek, Milan, Jr.; Mehta, Anil","European Registry Working Grp","Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis","LANCET",null,"English","Article",null,null,null,null,null,null,"MORTALITY; AGE; OUTCOMES; UK","Background Country-specific patients' registries are rarely used to make international comparisons because of protocol discrepancies in data collation. We present data from a European cystic fibrosis registry that is dedicated to collection of demographic data, and assess whether the resources available in countries with and without European Union (EU) membership affects care and survival of patients. Methods Data for demographic indicators age, age at diagnosis, sex, and genotype for patients with cystic fibrosis from 35 European countries were combined, and used to establish the differences in demographic indicators between EU and non-EU countries. EU membership status in 2003 was used to divide countries. We modelled demographic indicators of EU countries on non-EU countries to estimate the size of the cystic fibrosis population if non-EU countries had had the same resources available for patients as did EU countries. Findings Data were gathered for 29 025 patients, who had a median age of 16.3 years (IQR 8.9-24.8), with a difference of 4.9 years (95% CI 4.4-5.1; p<0.0001) between EU (median 17.0 years, IQR 9.5-25.6) and non-EU countries (12.1 years, 6.0-19.2). The proportion of patients older than 40 years was higher in EU countries (1205 [5%]) than in non-EU countries (76 [2%]), with an odds ratio of 2.4 (95% CI 1.9-3.0, p<0.0001). We estimated that the cystic fibrosis population in non-EU countries would increase by 84% if patients had a demographic profile comparable to that of patients in EU countries. Interpretation Future studies need to establish the reasons for the lower proportion of patients with cystic fibrosis in non-EU countries than in EU countries, such as underdiagnosis and premature childhood mortality.","[McCormick, Jonathan] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Acad Clin Practice, Div Clin Populat Sci & Educ, Dundee DD1 9SY, Scotland; [Mehta, Gita; Mehta, Anil] Univ Dundee, Ninewells Hosp & Med Sch, Div Med Sci, Coll Med Dent & Nursing, Dundee DD1 9SY, Scotland; [Olesen, Hanne V.] Aarhus Univ Hosp, Cyst Fibrosis Ctr Aarhus, DK-8000 Aarhus, Denmark; [Viviani, Laura] Univ Milan, Dipartimento Med Lavoro, Clin Lavoro Luigi Devoto, Sez Stat Med & Biometria GA Maccacaro, Milan, Italy; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic","McCormick, J, Univ Dundee, Ninewells Hosp & Med Sch, Ctr Acad Clin Practice, Div Clin Populat Sci & Educ, MACHS Bldg, Dundee DD1 9SY, Scotland","jonathan.mccormick@nhs.net","European Community [LSHM-CT-2005-018932]; Czech Ministry of Health [MZOFNM2005, 9448/3]","EuroCareCF was supported by the European Community's Sixth Framework Programme for Research, priority one Life Sciences, Genomics and Biotechnology for Health (contract number LSHM-CT-2005-018932) which supported GM and Margaret Fraser; we thank Margaret Fraser for expert data validation. MM was supported by grants from the Czech Ministry of Health (local grant number MZOFNM2005, and Internal Grant Agency [IGA] number 9448/3). We thank David Sheppard, Scientific Coordinator of EuroCareCF; and all the cystic fibrosis patient groups, the legal and ethics experts of EuroCareCF, and the US Cystic Fibrosis Foundation for their support.",null,23,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","MAR 20",2010,375,9719,null,null,null,1007,1013,null,null,7,"Medicine, General & Internal","575YU","ISI:000276110700033"]
["nemá","J","Rob, L; Halaska, M; Robova, H",null,null,null,"Rob, Lukas; Halaska, Michael; Robova, Helena",null,"Nerve-sparing and individually tailored surgery for cervical cancer","LANCET ONCOLOGY",null,"English","Review",null,null,null,null,null,null,"LAPAROSCOPIC RADICAL HYSTERECTOMY; POSTSURGICAL BLADDER FUNCTION; PELVIC AUTONOMIC NERVES; SURGICAL-TREATMENT; SEXUAL FUNCTION; LYMPH-NODES; NEOADJUVANT CHEMOTHERAPY; PARAMETRIAL INVOLVEMENT; CARDINAL LIGAMENT; PLEXUS TRAUMA","Cancer of the cervix is the second most common cancer in women worldwide, with about 500000 new cases and 273 000 deaths reported annually. Ideal surgical management of cervical cancer should reduce early and late morbidity without compromising oncological disease control. Type of surgical radicality in early cervical cancer should be a consequence of exact preoperative and intraoperative assessments of risk factors. During the past 15 years, substantial progress has been made in understanding the neuroanatomy of the autonomic pelvic plexus. This progress has resulted in individually tailored surgery for cervical cancer. The concept of preservation of autonomic nerves during radical hysterectomy has become standard in many oncogynaecological centres. Nerve-sparing radical hysterectomy and individually tailored surgery, in comparison with standard radical hysterectomy, have led to a much improved quality of life. Since 2008, there has been a new classification of radical hysterectomy, which includes nerve-sparing techniques. 5-year survival in early stage cervical cancer is 88-97% and more than 50% of women are younger than 50 years of age. Thus, we must take into consideration the quality of life of these patients. In this Review, we focus on the neuroanatomy of the pelvis and the possible damage of autonomic nerves, and suggest options for the sparing of these nerves during surgery for cervical cancer.","[Rob, Lukas; Halaska, Michael; Robova, Helena] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L, Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Uvalu 84, Prague 15000 5, Czech Republic","lukas.rob@lfmotol.cuni.cz","Czech Ministry of Health [MZ CR NS 9905-4]","The authors are supported by grant MZ CR NS 9905-4 from the Czech Ministry of Health.",null,72,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","MAR",2010,11,3,null,null,null,292,301,null,null,10,"Oncology","568MA","ISI:000275525300029"]
["nemá","J","Bruggemann, M; Schrauder, A; Raff, T; Pfeifer, H; Dworzak, M; Ottmann, OG; Asnafi, V; Baruchel, A; Bassan, R; Benoit, Y; Biondi, A; Cave, H; Dombret, H; Fielding, AK; Foa, R; Gokbuget, N; Goldstone, AH; Goulden, N; Henze, G; Hoelzer, D; Janka-Schaub, GE; Macintyre, EA; Pieters, R; Rambaldi, A; Ribera, JM; Schmiegelow, K; Spinelli, O; Stary, J; von Stackelberg, A; Kneba, M; Schrappe, M; van Dongen, JJM",null,null,null,"Brueggemann, M.; Schrauder, A.; Raff, T.; Pfeifer, H.; Dworzak, M.; Ottmann, O. G.; Asnafi, V.; Baruchel, A.; Bassan, R.; Benoit, Y.; Biondi, A.; Cave, H.; Dombret, H.; Fielding, A. K.; Foa, R.; Goekbuget, N.; Goldstone, A. H.; Goulden, N.; Henze, G.; Hoelzer, D.; Janka-Schaub, G. E.; Macintyre, E. A.; Pieters, R.; Rambaldi, A.; Ribera, J-M; Schmiegelow, K.; Spinelli, O.; Stary, J.; von Stackelberg, A.; Kneba, M.; Schrappe, M.; van Dongen, J. J. M.","European Working Grp Adult Acute L; Int Berlin-Frankfurt-Munster Study","Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","LEUKEMIA",null,"English","Review",null,null,null,null,null,"acute lymphoblastic leukemia; ALL; minimal residual disease; MRD; flow cytometry; PCR","ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; POLYMERASE-CHAIN-REACTION; TIME QUANTITATIVE PCR; PRECURSOR-B-ALL; ACUTE PROMYELOCYTIC LEUKEMIA; BONE-MARROW-TRANSPLANTATION; IG/TCR GENE REARRANGEMENTS; STEM-CELL TRANSPLANTATION; FLOW-CYTOMETRY","Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols. Leukemia (2010) 24, 521-535; doi:10.1038/leu.2009.268; published online 24 December 2009","[Brueggemann, M.; Raff, T.; Kneba, M.] Univ Hosp Schleswig Holstein, Dept Hematol, D-24116 Kiel, Germany; [Schrauder, A.; Schrappe, M.] Univ Hosp Schleswig Holstein, Dept Pediat, D-24116 Kiel, Germany; [Pfeifer, H.; Ottmann, O. G.; Goekbuget, N.] Goethe Univ Frankfurt, Med Klin 2, Dept Hematol & Oncol, Frankfurt, Germany; [Dworzak, M.] St Anna Childrens Hosp, Dept Hematooncol, A-1090 Vienna, Austria; [Asnafi, V.; Macintyre, E. A.] AP HP GH Necker Enfants Malad & Paris Descartes U, Dept Hematol, Paris, France; [Baruchel, A.] St Louis Univ Hosp, Dept Pediat Hematol, Paris, France; [Bassan, R.; Rambaldi, A.; Spinelli, O.] Osped Riuniti Bergamo, Unita Strutturale Complessa Ematol, I-24100 Bergamo, Italy; [Benoit, Y.] Ghent Univ Hosp, Dept Pediat Hematol Oncol, B-9000 Ghent, Belgium; [Biondi, A.] Univ Milano Bicocca, Pediat Clin, Osped Nuovo San Gerardo, Monza, Italy; [Biondi, A.] Childhood Leukemia Res Ctr M Tettamanti, Monza, Italy; [Cave, H.] CHU Robert Debre, Dept Genet, Paris, France; [Dombret, H.] CHU St Louis, Dept Hematol, Paris, France; [Fielding, A. K.] UCL, Dept Hematol, London, England; [Foa, R.] Univ Roma La Sapienza, Div Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy; [Goldstone, A. H.; von Stackelberg, A.] Univ Coll London Hosp, Dept Hematol, London, England; [Goulden, N.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Henze, G.] Charite, Univ Berlin, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany; [Janka-Schaub, G. E.] Univ Hamburg Hosp, Clin Pediat Hematol & Oncol, Dept Pediat Hematol & Oncol, D-2000 Hamburg, Germany; [Pieters, R.] Sophia Childrens Univ Hosp, Erasmus MC, Univ Med Ctr, Dept Paediat Oncol & Haematol, Rotterdam, Netherlands; [Ribera, J-M] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Dept Haematol, Badalona, Spain; [Schmiegelow, K.] Univ Copenhagen, Inst Gynaecol Obstet & Paediat, Copenhagen, Denmark; [Schmiegelow, K.] Rigshosp, Univ Hosp, Paediat Clin, DK-2100 Copenhagen, Denmark; [Stary, J.] Charles Univ Prague, Dept Paediat Haematol & Oncol, CLIP, Fac Med 2, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [van Dongen, J. J. M.] Erasmus MC, Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands","Bruggemann, M, Univ Hosp Schleswig Holstein, Dept Hematol, Campus Kiel,Chemnitzstr 33, D-24116 Kiel, Germany","m.brueggemann@med2.uni-kiel.de","European LeukemiaNet ","This study was supported in part by the European LeukemiaNet.",null,91,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.268","LEUKEMIA","Leukemia","MAR",2010,24,3,null,null,null,521,535,null,null,15,"Oncology; Hematology","566UV","ISI:000275399600004"]
["nemá","J","Hlinakova, P; Dostalova, T; Danek, J; Nedoma, J; Hlavacek, I",null,null,null,"Hlinakova, P.; Dostalova, T.; Danek, J.; Nedoma, J.; Hlavacek, I.",null,"Temporomandibular joint and its two-dimensional and three-dimensional modelling","MATHEMATICS AND COMPUTERS IN SIMULATION",null,"English","Proceedings Paper","1st IMACS International Conference on Computational Biomechanics and Biology (ICCBB 2007)","SEP 10-14, 2007","Pilsen, CZECH REPUBLIC","IMACS","Univ W Bohemia","Dentistry; Temporomandibular joint; Mathematical modelling; Contact problem; Finite element method","JAW","Detailed knowledge about the function and morphology of temporomandibular joint are necessary for clinical applications and for analyses of the function of temporomandibular joint prosthesis. Movements of temporomandibular Joint are biomechanically sophisticated and are up-to-date not clear Therefore, the aim of the paper is to give the suitable mathematical approach for analyses of temporomandibular joint In the paper the analysis of the temporomandibular joint, loaded by traction and compression forces. is presented and shortly discussed The obtained results, based on two- and three-dimensional mathematical models, represent an introductory work for further studies of biomechanical aspects of temporomandibular joint and of its artificial replacements The models are based on the theory of contact problems in linear elasticity. For the numerical solutions of the investigated problems the FEM approaches are used and the used algorithm is based on an active-set method for quadratic programming (C) 2009 IMACS. Published by Elsevier B V All rights reserved","[Danek, J.] Univ W Bohemia, Dept Math, Plzen, Czech Republic; [Hlinakova, P.; Dostalova, T.] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague, Czech Republic; [Danek, J.; Nedoma, J.; Hlavacek, I.] Acad Sci Czech Republic, Inst Comp Sci, Prague, Czech Republic; [Hlavacek, I.] Acad Sci Czech Republic, Inst Math, CR-11567 Prague, Czech Republic","Danek, J, Univ W Bohemia, Dept Math, Plzen, Czech Republic",null,null,null,null,9,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-4754",null,"10.1016/j.matcom.2009.08.007","MATH COMPUT SIMULAT","Math. Comput. Simul.","FEB",2010,80,6,null,null,"Sp. Iss. SI",1256,1268,null,null,13,"Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Mathematics, Applied","579OE","ISI:000276380400022"]
["nemá","J","Laczo, J; Andel, R; Vyhnalek, M; Vlcek, K; Magerova, H; Varjassyova, A; Tolar, M; Hort, J",null,null,null,"Laczo, J.; Andel, R.; Vyhnalek, M.; Vlcek, K.; Magerova, H.; Varjassyova, A.; Tolar, M.; Hort, J.",null,"Human Analogue of the Morris Water Maze for Testing Subjects at Risk of Alzheimer's Disease","NEURODEGENERATIVE DISEASES",null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Mild cognitive impairment; Spatial memory; Water maze task; Apolipoprotein E","MILD COGNITIVE IMPAIRMENT","Background: Patients with Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) have difficulties with spatial orientation. Objective: To test hypothesis that spatial navigation is impaired early in MCI patients representing the presymptomatic stage of AD. Methods: We tested patients with probable AD (n = 21), MCI, further classified according to Petersen's criteria as amnestic MCI (aMCI) single domain (n = 11), aMCI multiple domain (n = 31), or nonamnestic MCI (n = 7). The aMCI group was also stratified using cued recall according to Dubois' criteria into memory impairment of the hippocampal type (n = 10) and isolated memory retrieval impairment-nonhippocampal (n = 32) and also according to ApoE4 status into E4+ (n = 12) and E4-(n = 30). These patients and controls (n = 28) were tested in the human variant of the Morris water maze. Depending on the subtest, the subjects could use the egocentric or allocentric (hippocampus-dependent) navigation. Results: The AD and aMCI multiple domain groups were impaired in all subtests. The aMCI single domain group was impaired in allocentric subtests. The hippocampal MCI group performed poorer than the nonhippocampal MCI group and similarly to the AD group. The ApoE4+ group was as bad as the AD group when compared with the E4- group. Conclusion: aMCI subjects represent a very heterogeneous population, and spatial memory or cued recall examination can add more value to aMCI classification. ApoE4+ patients are more impaired than ApoE4- patients. Copyright (C) 2010 S. Karger AG, Basel","[Hort, J.] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, CZ-15006 Prague, Czech Republic; [Vlcek, K.] Acad Sci Czech Republic, Dept Neurophysiol Memory, Prague, Czech Republic; [Andel, R.] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Tolar, M.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA","Hort, J, Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, V Uvalu 84, CZ-15006 Prague, Czech Republic","jakub.hort@seznam.cz","Czech Republic [309/09/1053, 309/09/0286]","Supported by the Grant Agency of the Czech Republic grants 309/09/1053 and 309/09/0286.",null,8,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854",null,"10.1159/000289226","NEURODEGENER DIS","Neurodegener. Dis.",null,2010,7,"2010-03-01",null,null,"Sp. Iss. SI",148,152,null,null,5,"Clinical Neurology; Neurosciences","584GM","ISI:000276739200033"]
["nemá","J","Bruchova, H; Vasikova, A; Merkerova, M; Milcova, A; Topinka, J; Balascak, I; Pastorkova, A; Sram, RJ; Brdicka, R",null,null,null,"Bruchova, H.; Vasikova, A.; Merkerova, M.; Milcova, A.; Topinka, J.; Balascak, I.; Pastorkova, A.; Sram, R. J.; Brdicka, R.",null,"Effect of Maternal Tobacco Smoke Exposure on the Placental Transcriptome","PLACENTA",null,"English","Article",null,null,null,null,null,"Placenta; Gene expression; Tobacco smoke exposure","INTRAUTERINE GROWTH RESTRICTION; DIFFERENTIAL GENE-EXPRESSION; C RECEPTOR GENES; LOW-BIRTH-WEIGHT; CIGARETTE-SMOKING; ENVIRONMENTAL-POLLUTANTS; TRANSPLACENTAL TRANSFER; FETAL-GROWTH; RISK-FACTOR; PREGNANCY","Smoking in pregnancy increases a woman's risk of preterm delivery resulting in serious neonatal health problems and chronic lifelong disabilities for the children (e.g, mental retardation, learning problems) To study the effects of tobacco smoke on the placental transcriptome, we performed gene expression profiling on placentas from women exposed to tobacco smoke in pregnancy (N = 12) and from those without significant exposure (N = 64). Gene expression profiles were determined by Illumina HumanRef-8 v2 Expression BeadChips with 18,216 gene probes. Microarray data were normalized by quantile method and filtered for a detection P-value <0.01. Differential gene expression was determined by moderated t-statistic A linear model was fitted for each gene given a series of arrays using ImFit function Multiple testing correction was performed using the Benjamini and Hochberg method. Abundant levels of transcripts were found for genes encoding placental hormones (CSH1, CSHL1), pregnancy-specific proteins (PSG3. PSG4, PAPPA), and hemoglobins (HBB, HHG, HBA) Comparative analysis of smokers vs nonsmokers revealed the differential expression of 241 genes (P < 0.05) In smoker cohort, we detected high up-regulation of xenobiotic genes (CYP1A1, CYP1B1, CYB5A, COX412), collagen genes (e.g, COL6A3, COL1A1, COL1A2), coagulation genes (175, F13A1) as well as thrombosis-related genes (CD36. ADAMTS9, GAS6). In smokers, we identified deregulated genes that show tissue non-specific induction and may be considered as general biomarkers of tobacco smoke exposure Further, we also found genes specifically deregulated in the exposed placentas. Functional annotation analysis suggested processes and pathways affected by tobacco smoke exposure that may represent molecular mechanisms of smoke-induced placental abnormalities (C) 2009 Elsevier Ltd. All rights reserved.","[Bruchova, H.] Inst Hematol & Blood Transfus, Dept Mol Genet, CR-12820 Prague, Czech Republic; [Milcova, A.; Topinka, J.; Pastorkova, A.; Sram, R. J.] AS CR, Inst Expt Med, VVI, Prague, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Bruchova, H, Inst Hematol & Blood Transfus, Dept Mol Genet, Nemocnice 1, CR-12820 Prague, Czech Republic",null,"Czech Ministry of Education Youth and Sports [2B06088]","The authors wish to thank the gynecological staff of the University Hospital in Prague-Motol We thank Mgr. Viktor Stranecky (Institute of Inherited Metabolic Disorders, 1st Medical Faculty of Charles University, Prague) for microarray data analyses The work was supported by the Czech Ministry of Education Youth and Sports (Grant no. 2B06088).",null,45,0,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","0143-4004",null,"10.1016/j.placenta.2009.12.016","PLACENTA","Placenta","MAR",2010,31,3,null,null,null,186,191,null,null,6,"Developmental Biology; Obstetrics & Gynecology; Reproductive Biology","570TA","ISI:000275699700004"]
["nemá","J","Kayserova, J; Capkova, S; Skalicka, A; Vernerova, E; Polouckova, A; Malinova, V; Bartunkova, J; Sediva, A",null,null,null,"Kayserova, J.; Capkova, S.; Skalicka, A.; Vernerova, E.; Polouckova, A.; Malinova, V.; Bartunkova, J.; Sediva, A.",null,"Serum Immunoglobulin Free Light Chains in Severe Forms of Atopic Dermatitis","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,"English","Article",null,null,null,null,null,null,"INFLAMMATORY DISEASES; IG; IMMEDIATE; RESPONSES; ALLERGY; MARKER; TARGET; URINE; CELLS","An increase in immunoglobulin free light chains (FLC) was recently described in several pathological conditions, including asthma. FLC pathology is classically associated with monoclonal gammopathies. Its association with allergic disorders is surprising and unexplained. We therefore tested a cohort of children with severe atopic dermatitis (SCORAD 50-80) to determine the serum levels of free kappa and lambda chains, and correlated the results with clinical status and relevant laboratory markers. Seventy-three patients with severe forms of AD, all children from 3 months to 3 years of age and ninety healthy age-matched controls were included in the study. Light chains in sera were tested using the Freelite assay (Binding Site, Birmingham, UK). There were highly significant differences in both kappa (mean: 7.05 and 3.22 mg/l) and lambda (mean: 10.99 and 9.8 mg/l) serum levels between patients and controls, respectively (P < 0.0001). The kappa/lambda ratio in patients with allergy (mean: 0.64) was significantly higher than in controls (0.33) (P < 0.0001). We further observed significantly increased levels of FLC and their ratio in the group of patients with severe forms of AD in comparison to the group of patients with a resting stage of the disease or healthy controls (P < 0.05 and P < 0.0001, respectively). On the other hand, we could not confirm any association of FLC levels with age or total IgE levels. In conclusion, an increase in FLC reflects disease activity in children with severe atopic dermatitis. FLC might thus represent an additional diagnostic marker independent of total IgE levels.","[Kayserova, J.; Skalicka, A.; Vernerova, E.; Polouckova, A.; Bartunkova, J.; Sediva, A.] Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Capkova, S.] Univ Hosp Motol, Dept Dermatol, Pediat Outpatient Dept, Prague, Czech Republic; [Malinova, V.] Gen Univ Hosp, Fac Med 1, Dept Pediat & Adolescent Med, Prague, Czech Republic","Sediva, A, Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Uvalu 84, Prague 15006, Czech Republic","anna.sediva@fnmotol.cz","Ministry of Health, Czech Republic [VZ MZ CR 00064203]; Ministry of Education, Youth and Sports, Czech Republic [VZ MSM 0021620812, GAUK 7840/2007]","The study was supported by the Ministry of Health, Czech Republic VZ MZ CR 00064203, the Ministry of Education, Youth and Sports, Czech Republic VZ MSM 0021620812 and GAUK 7840/2007.",null,21,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,"10.1111/j.1365-3083.2010.02376.x","SCAND J IMMUNOL","Scand. J. Immunol.","APR",2010,71,4,null,null,null,312,316,null,null,5,"Immunology","573MQ","ISI:000275918400012"]
["nemá","J","Lukas, D; Pan, N; Sarkar, A; Weng, M; Chaloupek, J; Kostakova, E; Ocheretna, L; Mikes, P; Pociute, M; Amler, E",null,null,null,"Lukas, D.; Pan, N.; Sarkar, A.; Weng, M.; Chaloupek, J.; Kostakova, E.; Ocheretna, L.; Mikes, P.; Pociute, M.; Amler, E.",null,"Auto-model based computer simulation of Plateau-Rayleigh instability of mixtures of immiscible liquids","PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS",null,"English","Article",null,null,null,null,null,"Rayleigh instability; Liquid mixture; Auto-model; Markov Random Field","SYSTEMS","The classic theory to derive the characteristic Rayleigh wavelength, i.e., the distance between neighbouring droplets into which an originally cylindrical liquid body disintegrates, as a consequence of Rayleigh instability, is analysed in terms of the phenomenon of self-organization due to the mechanism of 'fastest forming instability'. The paper aims at simulating this self-organization with Monte Carlo dynamics while accounting spatial interactions in lattices of Markov Random Fields that enable also modelling of Plateau-Rayleigh instability of instable mixtures of dispersed immiscible liquids. The Hammersley and Clifford theorem, concerning the general form of energy function, belonging to Markov Random Fields, is introduced for detailed classification of a simple model used for computer simulation. The relevant Auto-model, with Kawasaki dynamics, is chosen to investigate the liquid jet and the instability of the liquid's cylindrical film. The computer-simulated outputs show encouraging agreement with the classic analytical predictions on main features of the Rayleigh instability. The model is also used as a foundation stone for developing a simple analytical approach for the estimation of Rayleigh wavelength of jets and cylindrical films, composed of instable mixtures of immiscible liquids. Qualitatively, the theory agrees with both computer simulation and experiment. (C) 2010 Elsevier B.V. All rights reserved.","[Lukas, D.; Sarkar, A.; Chaloupek, J.; Kostakova, E.; Ocheretna, L.; Mikes, P.] Tech Univ Liberec, Fac Text Engn, Dept Nonwovens, Nanosci Ctr, Liberec 46117 1, Czech Republic; [Lukas, D.; Mikes, P.] Clemson Univ, Sch Mat Sci & Engn, Clemson, SC 29634 USA; [Pan, N.] Univ Calif Davis, Div Text & Clothing, Dept Biol & Agr Engn, Davis, CA 95616 USA; [Weng, M.] Zhejiang Sci Tech Univ, Minist Educ, Key Lab Adv Text Mat & Mfg Technol, Hangzhou 310018, Peoples R China; [Pociute, M.] Kaunas Univ Technol, Fac Design & Technol, LT-51424 Kaunas, Lithuania; [Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague, Czech Republic; [Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic","Lukas, D, Tech Univ Liberec, Fac Text Engn, Dept Nonwovens, Nanosci Ctr, Studentska 2, Liberec 46117 1, Czech Republic","david.lukas@tul.cz","Agency of AS [IAA500390702]; Ministry of Education of the Czech Republic [CEP1-1M0554]; NTC [M02-CD03]; GACR [102/08/H081]; \"Research Center - TEXTILE, TUL\" [LN00B090]","The authors are very thankful to Konstantin Kornev from Clemson University, SC, and to Ales Linka from the Technical University of Liberec (TUL), for consultations and inspiration on the theory of Markov Random Fields respectively. The authors are also obliged to Miroslav Brezina from TUL for the introduction to the theory of H-surfaces of revolution. This work was supported by the Grant Agency of AS CR grant no. IAA500390702. D.L. and J.C. are also thankful to The Ministry of Education of the Czech Republic for their support in the frame of \"The Research Centre for Advanced Conservation Technologies\" (the project CEP1-1M0554). N.P. and D.L. acknowledge the support from NTC Grant M02-CD03 which supported their joint work at UC Davis. A.S. has been supported by GACR Grant no. 102/08/H081 \"Advanced Application of Physical Fields\". The next co-author (M.P.) is thankful for the support granted by a \"Research Center - TEXTILE, TUL\", Grant No. LN00B090. L.O. and P.M. thank Cummins Filtration for their support and interest in this work.",null,27,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-4371",null,"10.1016/j.physa.2010.01.046","PHYSICA A","Physica A","JUN 1",2010,389,11,null,null,null,2164,2176,null,null,13,"Physics, Multidisciplinary","586ET","ISI:000276886300002"]
["nemá","J","Mehta, P; Locatelli, F; Stary, J; Smith, FO",null,null,null,"Mehta, Parinda; Locatelli, Franco; Stary, Jan; Smith, Franklin O.",null,"Bone Marrow Transplantation for Inherited Bone Marrow Failure Syndromes","PEDIATRIC CLINICS OF NORTH AMERICA",null,"English","Article",null,null,null,null,null,"Inherited bone marrow failure syndromes; Bone marrow transplantation; Gene mutation; Diagnostic tests","SHWACHMAN-DIAMOND-SYNDROME; STEM-CELL TRANSPLANTATION; UMBILICAL-CORD BLOOD; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; FANCONI-ANEMIA PATIENTS; LOW-DOSE CYCLOPHOSPHAMIDE; RIBOSOMAL-PROTEIN S19; COLONY-STIMULATING FACTOR; OF-THE-LITERATURE; INTENSITY CONDITIONING REGIMEN","The inherited bone marrow failure (BMF) syndromes are characterized by impaired hematopoiesis and cancer predisposition. Most inherited BMF syndromes are also associated with a range of congenital anomalies. Progress in improving the outcomes for children with inherited BMF syndromes has been limited by the rarity of these disorders, as well as disease-specific genetic, molecular, cellular, and clinical characteristics that increase the risks of complications associated with hematopoietic stem cell transplantation (HSCT). As a result, the ability to develop innovative transplant approaches to circumvent these problems has been limited. Recent progress has been made, as best evidenced in studies adding fludarabine to the preparative regimen for children undergoing unrelated donor HSCT for Fanconi anemia. The rarity of these diseases coupled with the far more likely incremental improvements that will result from ongoing research will require prospective international clinical trials to improve the outcome for these children.","[Mehta, Parinda; Smith, Franklin O.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Mehta, Parinda; Smith, Franklin O.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Locatelli, Franco] Univ Pavia, Osped Pediat Bambino Gesu, Rome, Italy; [Locatelli, Franco] IRCCS Policlin San Matteo, Pediat Haematol Oncol Fdn, I-27100 Pavia, Italy; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic","Smith, FO, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA","frank.smith@cchmc.org",null,null,null,166,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0031-3955",null,"10.1016/j.pcl.2010.01.002","PEDIAT CLIN N AMER","Pediatr. Clin. N. Am.","FEB",2010,57,1,null,null,null,147,"+",null,null,25,"Pediatrics","588AW","ISI:000277039300009"]
["nemá","J","Hippmann, R; Dostalova, T; Zvarova, J; Nagy, M; Seydlova, M; Hanzlicek, P; Kriz, P; Smidl, L; Trmal, J",null,null,null,"Hippmann, R.; Dostalova, T.; Zvarova, J.; Nagy, M.; Seydlova, M.; Hanzlicek, P.; Kriz, P.; Smidl, L.; Trmal, J.",null,"Voice-supported Electronic Health Record for Temporomandibular Joint Disorders","METHODS OF INFORMATION IN MEDICINE",null,"English","Article",null,null,null,null,null,"Electronic health record; structured data entry; dentistry; temporomandibular joint disorder","OPENSDE","Objectives: To identify support of structured data entry for an electronic health record application in temporomandibular joint disorders. Methods: The methods of structuring information in dentistry are described and the interactive DentCross component is introduced. A system of structured voice-supported data entry in electronic health record on several real cases in the field of dentistry is performed. The connection of this component to the MUDRLite electronic health record is described. Results: The use of DentVoice, an application which consists of the electronic health record MUDRLite and the voice-controlled interactive component DentCross, to collect dental information required by temporomandibular joint disorders is shown. Conclusions: The DentVoice application with the DentCross component showed the practical ability of the temporomandibular joint disorder treatment support.","[Hippmann, R.; Dostalova, T.; Seydlova, M.; Kriz, P.] Charles Univ Prague, Sch Med 2, Dept Paediat Stomatol, Prague 15006, Czech Republic; [Hippmann, R.; Dostalova, T.; Zvarova, J.; Nagy, M.; Seydlova, M.; Hanzlicek, P.] Ctr Biomed Informat, Prague, Czech Republic; [Zvarova, J.; Nagy, M.; Hanzlicek, P.] Acad Sci Czech Republic, Inst Comp Sci, VVI, EuroMISE Ctr,Dept Med Informat, Prague, Czech Republic; [Smidl, L.; Trmal, J.] Univ W Bohemia, Dept Cybernet, Plzen 30614, Czech Republic","Hippmann, R, Charles Univ Prague, Sch Med 2, Dept Paediat Stomatol, V Uvalu 84, Prague 15006, Czech Republic","r.hip@seznam.cz","Ministry of Education of the Czech Republic [1M06014]; Institute of Computer Science ASCR, v.v.i. [AV0Z10300504]","The work was supported by the project 1M06014 of the Ministry of Education of the Czech Republic and by the project AV0Z10300504 of the Institute of Computer Science ASCR, v.v.i.",null,24,1,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","0026-1270",null,"10.3414/ME9301","METHODS INFORM MED","Methods Inf. Med.",null,2010,49,2,null,null,null,168,172,null,null,5,"Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics","586TO","ISI:000276936300010"]
["nemá","J","Bronsky, J; Jirsa, M; Nevoral, J; Hrebicek, M",null,null,null,"Bronsky, J.; Jirsa, M.; Nevoral, J.; Hrebicek, M.",null,"Role of Common Canalicular Transporter Gene Variations in Aetiology of Idiopathic Gallstones in Childhood","FOLIA BIOLOGICA",null,"English","Article",null,null,null,null,null,"cholelithiasis; polymorphism; ABCB11; ABCG8","SALT EXPORT PUMP; DISEASE; MDR3; CHOLELITHIASIS; CHOLESTASIS; ASSOCIATION; DEFICIENCY; CIRRHOSIS; LIVER","Variations in genes encoding canalicular transportes, for biliary lipids may affect concentrations of biliary lipids in bile and promote cholesterol crystallization and gallstone formation. In our study we investigated the contribution of heterozygosity for common variations considered either potentially pathogenic or susceptibility alleles for cholesterol cholelithiasis in adults (c.523A>G (p.Thr175Ala) and c.1954A>G (p.Arg652Gly) in ABCB4, c.1331T>C (p.Val444Ala) in ABCB11 and c.55 G>C (p.Asp19His) in ABCG8) to the aetiology of paediatric idiopathic gallstone disease. Genotyping was performed in 35 paediatric subjects with idiopathic gallstones with positive family history for gallstones and 150 population controls. The ABCB4 variant p.Thr175Ala was found only in the controls, not in the patients. The frequency of the remaining three variant alleles and the corresponding genotypes did not differ between patients and controls. We conclude that the studied common variations in genes encoding canalicular transporters known to contribute to genetic predisposition to cholesterol gallstones in adulthood do not contribute specifically to the aetiology of paediatric idiopathic gallstones.","[Jirsa, M.] Charles Univ Prague, Inst Clin & Expt Med, Fac Med 1, Prague 14021 4, Czech Republic; [Bronsky, J.; Nevoral, J.] Charles Univ Prague, Fac Med 2, Prague 14021 4, Czech Republic; [Bronsky, J.; Nevoral, J.] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Prague 14021 4, Czech Republic; [Hrebicek, M.] Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Prague 14021 4, Czech Republic","Jirsa, M, Charles Univ Prague, Inst Clin & Expt Med, Fac Med 1, Lab Expt Hepatol Bldg ZI,Videnska 1958-9, Prague 14021 4, Czech Republic","milan.jirsa@ikem.cz","Ministry of Health of the Czech Republic [NR/9079-3]","This study was supported by grant NR/9079-3 from the Ministry of Health of the Czech Republic.",null,16,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2010,56,1,null,null,null,9,13,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","588LO","ISI:000277071800002"]
["nemá","J","Vazna, A; Musova, Z; Vlckova, M; Novotna, D; Dvorakova, L; Hrdlicka, M; Havlovicova, M; Sedlacek, Z",null,null,null,"Vazna, Alzbeta; Musova, Zuzana; Vlckova, Marketa; Novotna, Drahuse; Dvorakova, Lenka; Hrdlicka, Michal; Havlovicova, Marketa; Sedlacek, Zdenek",null,"FMR1 Gene Expansion, Large Deletion of Xp, and Skewed X-Inactivation in a Girl With Mental Retardation and Autism","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,"English","Article",null,null,null,null,null,"fragile X syndrome; Xp deletion; array CGH; skewed X-inactivation; mental retardation; autism","FULL MUTATION; FEMALES; CHROMOSOME; PHENOTYPE; MICROPHTHALMIA","We describe a girl with mild facial anomalies, mild mental retardation, and atypical autism with a remarkable behavioral phenotype of persistent anger, aggression, and dysphoria. The occurrence of late-onset tremor and premature ovarian failure in the maternal branch of the family pointed to a possible defect in the FMR1 gene. Indeed, the patient carried a full FMR1 mutation. Unexpectedly, both alleles of the gene were almost completely methylated. Cytogenetic examination of the patient revealed in addition a large de novo deletion in band Xp22 on one of her X chromosomes. The deletion was fine mapped using oligonucleotide array CGH, and its breakpoints were localized using sequencing. The size of the deletion was about 17.4 Mb, and it contained more than 90 protein-coding genes. Microsatellite analysis indicated paternal origin of the aberrant chromosome. The large rearrangement was the most probable cause of the X-inactivation skewing, thus explaining the methylation of not only the expanded (maternal) but also the normal (paternal) FMR1 alleles. This pattern of skewed X-inactivation was confirmed using the analysis of methylation at the AR locus. The relatively mild phenotype of the patient resulted most likely from unmasking of the FMR1 defect. Although the deleted region contained many important genes, the phenotypic contribution of the rearranged X chromosome was probably limited by its almost complete inactivation. However, reduced dose of several genes escaping X-inactivation might also play a role in the phenotype of the patient. (C) 2010 Wiley-Liss, Inc.","[Vazna, Alzbeta; Musova, Zuzana; Vlckova, Marketa; Novotna, Drahuse; Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague 15006 5, Czech Republic; [Vazna, Alzbeta; Musova, Zuzana; Vlckova, Marketa; Novotna, Drahuse; Hrdlicka, Michal; Havlovicova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Dvorakova, Lenka] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 15006 5, Czech Republic; [Dvorakova, Lenka] Gen Univ Hosp, Prague, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006 5, Czech Republic","Sedlacek, Z, Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","zdenek.sedlacek@lfmotol.cuni.cz","Ministries of Education and Health of the Czech Republic [NR/9457-3, MZO00064203, MSM0021620806]; European Commission [043318, 223692]","This work was supported by grants NR/9457-3, MZO00064203, and MSM0021620806 from the Ministries of Education and Health of the Czech Republic, and INCORE (043318) and CHERISH (223692) from the European Commission.",null,23,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4825",null,"10.1002/ajmg.a.33352","AM J MED GENET PART A","Am. J. Med. Genet. A","MAY",2010,"152A",5,null,null,null,1273,1277,null,null,5,"Genetics & Heredity","597ES","ISI:000277739800025"]
["nemá","J","Prochazka, P; Hrabeta, J; Vicha, A; Eckschlager, T",null,null,null,"Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Eckschlager, Tomas",null,"Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine","CANCER GENETICS AND CYTOGENETICS",null,"English","Article",null,null,null,null,null,null,"TUMOR-CELLS; DOUBLE MINUTES; HL-60 CELLS; C-MYC; AMPLIFICATION; GENES; ELIMINATION; RESISTANCE; TUMORIGENICITY; HYBRIDIZATION","Amplified MYCN, common in neuroblastomas, can be detected as double minutes (dmin) or homogenously staining chromosomal regions (hsr). Expulsion of amplified MYCN has only been described in dmin. We used hydroxyurea (HU), which accelerates the expulsion of amplified genes and cytostatics (used in neuroblastoma therapy), to describe MYCN amplification changes after chemotherapy. We used IMR-32, SK-N-AS, UKF-NB-2, UKF-NB-3, UKF-NB-4, and derived sublines resistant to doxorubicin, cisplatin, and vincristine. The loss of amplified MYCN copies was investigated using comparative genomic hybridization and by fluorescent in situ hybridization. We found expulsion of amplified MYCN from hsr in UKF-NB-4 and IMR-32 cell lines, and determined the exact number of amplified MYCN copies. After the first cultivation with HU, some amplified MYCN was lost. UKF-NB-4 lost 20 copies on average, and IMR-32 lost 15 copies (P < 0.001). After the second cultivation, cells without MYCN amplification were found. In comparison to sensitive cell lines, drug-resistant cell lines lost 17 copies on average. Our data show that expulsion of amplified MYCN genes is also possible from hsr and may be induced, not only by HU, but by other cytostatics as well. (C) 2010 Elsevier Inc. All rights reserved.","[Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Eckschlager, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague 15006, Czech Republic","Prochazka, P, Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic","proch.pavel@gmail.com","Grant Agency of Charles University [7926/2007]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620813]","We thank J. Cinatl Jr. (Institute for Medical Virology, Johann Wolfgang Goethe University Hospital, Frankfurt am Mein, Germany), who kindly provided cell lines. This research was supported by the Grant Agency of Charles University (grant 7926/2007) and by the Ministry of Education, Youth and Sports of the Czech Republic (grant MSM0021620813).",null,26,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,"10.1016/j.cancergencyto.2009.08.005","CANCER GENET CYTOGENET","Cancer Genet. Cytogenet.","JAN 1",2010,196,1,null,null,null,96,104,null,null,9,"Oncology; Genetics & Heredity","592QX","ISI:000277395600015"]
["nemá","J","Maxova, H; Bacakova, L; Eckhardt, A; Miksik, I; Lisa, V; Novotna, J; Herget, J",null,null,null,"Maxova, Hana; Bacakova, Lucie; Eckhardt, Adam; Miksik, Ivan; Lisa, Vera; Novotna, Jana; Herget, Jan",null,"Growth of Vascular Smooth Muscle Cells on Collagen I Exposed to RBL-2H3 Mastocytoma Cells","CELLULAR PHYSIOLOGY AND BIOCHEMISTRY",null,"English","Article",null,null,null,null,null,"Pulmonary hypertension; Vascular remodeling; Mast cells; Proteases; Collagen degradation; Smooth muscle cell proliferation; High performance liquid chromatography; Mass spectrometry","MAST-CELLS; PULMONARY-HYPERTENSION; MATRIX METALLOPROTEINASES; MYOCARDIAL-INFARCTION; PROLIFERATION; HYPOXIA; ATHEROSCLEROSIS; INHIBITION; ARTERIES; CULTURE","Remodeling of the peripheral pulmonary vasculature during chronic hypoxia is characterized by accelerated collagenolysis and thickening of the vascular wall. Low molecular weight peptides, products of cleavage by interstitial collagenase and muscular layer in the peripheral pulmonary vessels, are typically present. The aim of this \"in vitro\" study was to verify that mast cells (RBL-2H3) as a potent source of a variety of biomolecules which can affect vessel wall remodeling are capable of splitting collagen and then facilitating the growth of vascular smooth muscle cells (VSMC). Collagen I was exposed to RBL-2H3 cells cultured 48 hours under normoxic or hypoxic (3% O-2) conditions and then seeded with VSMC. The VSMC proliferated with the shortest doubling time and reached the highest cell population density on the collagen pre-modified with hypoxic RBL-2H3 cells. This increased growth activity of VSMC was probably due to the fragmentation of collagen by proteases released from RBL-2H3 cells. Absolute amount of collagen fragments was similar in samples exposed to normoxic and hypoxic RBL-2H3 cells, but the concentration of at least one collagen fragment was significantly higher under hypoxic conditions. Mast cells exposed to hypoxia are more capable to split collagen and facilitate the growth of VSMC. Copyright (C) 2010 S. Karger AG, Basel","[Maxova, Hana] Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Novotna, Jana] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Herget, Jan] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Maxova, Hana; Bacakova, Lucie; Eckhardt, Adam; Miksik, Ivan; Novotna, Jana; Herget, Jan] Cardiovasc Res Ctr, Prague, Czech Republic; [Bacakova, Lucie; Eckhardt, Adam; Miksik, Ivan; Lisa, Vera] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic","Maxova, H, Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","hana.maxova@lfmotol.cuni.cz","Grant Agency of the CR [305/08/0108]; Ministry of Education, Youth and Sports of the CR [1M0510]","This study was supported by the Grant Agency of the CR (grant No. 305/08/0108) and by the Centre for Cardiovascular Research (project No. 1M0510 of the Ministry of Education, Youth and Sports of the CR). We also thank Mrs. Ivana Zajanova for her excellent technical assistance. Mr. Robin Healey (Czech Technical University, Prague) is gratefully acknowledged for his language revision of the manuscript.",null,30,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1015-8987",null,"10.1159/000315080","CELL PHYSIOL BIOCHEM","Cell. Physiol. Biochem.",null,2010,25,6,null,null,null,615,622,null,null,8,"Cell Biology; Physiology","599DI","ISI:000277890000006"]
["nemá","J","Kriz, J; Kafunkova, P; Schreier, B; Kolar, P",null,null,null,"Kriz, J.; Kafunkova, P.; Schreier, B.; Kolar, P.",null,"Body Weight Support Locomotion Training in Spinal Cord Injured Patients","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Review",null,null,null,null,null,"spinal cord injury; plasticity; locomotion; rehabilitation; robotic device; treadmill","GAIT REHABILITATION; PARAPLEGIC PATIENTS; PLASTICITY; WALKING; FEASIBILITY; INDIVIDUALS; PATTERN; HUMANS","Body weight support locomotion training is a classical rehabilitation method in patients who have suffered injury to the spinal cord. It is based on the discovery that repetitive cyclic passive movements can stimulate locomotor centres in the spinal cord. Numerous studies have documented motor recovery in vertebrate animals and in incomplete spinal-cord-injured humans. Manual-assisted, body-weight support treadmill training requires a large number of physiotherapists working in an ergonomically inconvenient position. New approaches to robotic locomotion training are therefore being developed. The aim is to design a device that provides minimal necessary locomotion assistance depending on the severity of the motor impairment.","[Kriz, J.; Kafunkova, P.; Schreier, B.; Kolar, P.] UK 2 LF & FN Motole, Klin Rehabilitace & Telovychovneho Lekarstvi, Spinalni Jednotka, Prague 15006 5, Czech Republic","Kriz, J, UK 2 LF & FN Motole, Klin Rehabilitace & Telovychovneho Lekarstvi, Spinalni Jednotka, Praha Ovalu 84, Prague 15006 5, Czech Republic","jiri.kriz@fnmotol.cz",null,null,null,37,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,2,null,null,null,124,130,null,null,7,"Neurosciences; Surgery","593AC","ISI:000277422500002"]
["nemá","J","Chabova, VC; Walkowska, A; Kompanowska-Jezierska, E; Sadowski, J; Kujal, P; Vernerova, Z; Vanourkova, Z; Kopkan, L; Kramer, HJ; Falck, JR; Imig, JD; Hammock, BD; Vaneckova, I; Cervenka, L",null,null,null,"Chabova, Vera Certikova; Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Kujal, Petr; Vernerova, Zdenka; Vanourkova, Zdena; Kopkan, Libor; Kramer, Herbert J.; Falck, John R.; Imig, John D.; Hammock, Bruce D.; Vaneckova, Ivana; Cervenka, Ludek",null,"Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats","CLINICAL SCIENCE",null,"English","Article",null,null,null,null,null,"cytochrome P450 (CYP450); end-organ damage; hypertension; renin-angiotensin system (RAS); soluble epoxide hydrolase","SOLUBLE EPOXIDE HYDROLASE; SMOOTH-MUSCLE-CELLS; SALT-SENSITIVE HYPERTENSION; ACTIVATED PROTEIN-KINASE; II-INDUCED HYPERTENSION; ANGIOTENSIN-II; ARACHIDONIC-ACID; NITRIC-OXIDE; EPOXYGENASE METABOLITES; RECEPTOR BLOCKADE","Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine) Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.","[Chabova, Vera Certikova; Kujal, Petr; Vernerova, Zdenka; Vanourkova, Zdena; Kopkan, Libor; Vaneckova, Ivana; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14021 Prague 4, Czech Republic; [Chabova, Vera Certikova] Charles Univ Prague, Dept Nephrol, Fac Med 1, Prague, Czech Republic; [Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Polish Acad Sci, Mossakowski Med Res Ctr, Lab Renal & Body Fluid Physiol, Warsaw, Poland; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Vanourkova, Zdena; Kopkan, Libor; Vaneckova, Ivana] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Med Policlin, Nephrol Sect, Dept Med, D-5300 Bonn, Germany; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Ctr Canc, Davis, CA 95616 USA; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14021 Prague 4, Czech Republic",null,"Czech Science Foundation (GACR) [305/08/J006, 305/07/0167, 305/07/J004]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Ministry of Health of the Czech Republic [NS/10500-3, NS/10499-3, NS/9699-4]; Academy of Science of Czech Republic [GAAV-IAA 511-700-701]; German Research Foundation (DEG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; National Institutes of Health (NIH) [IIL59699, DK38226, GM31278]; Robert A Welch Foundation ; National Institute of Enviromental Health Sciences (NIEHS) [R01 ES002710, P42 ES004699]","L.C was supported by the Czech Science Foundation (GACR) [grant number 305/08/J006]. A W was partly supported by the Center for Cardiovascular Research [grant number 1M6798582302] and the Institute for Clinical and Experimental Medicine [grant number MZO 00023001]. V C.C. was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/10500-3]. Z.V was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/10499-3] L.K. was supported by the Grant Agency of Academy of Science of Czech Republic [grant number GAAV-IAA 511-700-701] and the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/9699-4] I V. was supported by the GACR [grants numbers 305/07/0167, 305/07/J004] H.J.K was supported by the German Research Foundation (DEG), Bonn [grant numbers Kra 436/14-2, 436 TSE 113/57/0-1]. J D.I. was supported the National Institutes of Health (NIH) [grant numbers IIL59699, DK38226] and Advancing a Healthier Wisconsin J.R.F was supported by the Robert A Welch Foundation and the NIH [grant number GM31278] B.D.H was supported by the National Institute of Enviromental Health Sciences (NIEHS) [grant number R01 ES002710] and the NIEHS Superfund Program [grant number P42 ES004699].",null,60,0,"PORTLAND PRESS LTD","LONDON","THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND","0143-5221",null,"10.1042/CS20090459","CLIN SCI","Clin. Sci.","MAY",2010,118,"2010-10-09",null,null,null,617,632,null,null,16,"Medicine, Research & Experimental","599HA","ISI:000277900600007"]
["nemá","J","Tapia, G; Cinek, O; Rasmussen, T; Grinde, B; Ronningen, KS",null,null,null,"Tapia, German; Cinek, Ondrej; Rasmussen, Trond; Grinde, Bjorn; Ronningen, Kjersti S.",null,"No Ljungan Virus RNA in Stool Samples From the Norwegian Environmental Triggers of Type 1 Diabetes (MIDIA) Cohort Study","DIABETES CARE",null,"English","Article",null,null,null,null,null,null,"LONGITUDINAL OBSERVATION; ENTEROVIRUS; INFANTS; VOLES","OBJECTIVE - Ljungan virus (LjV) has been proposed as a potential environmental factor for type 1 diabetes. The objective was to test for any association of LjV with type 1 diabetes. RESEARCH DESIGN AND METHODS - A nested case-control design was used to test for any association between the development of pre-diabetic autoimmunity and presence of LjV in stool samples (n = 3,803) in the Norwegian Environmental Triggers of Type 1 Diabetes (MIDIA) study. The children followed were 27 infants who developed pre-diabetic autoimmunity during or shortly after the sampling period, 54 matched control subjects, and 94 other children. RESULTS - No LjV RNA was detected. CONCLUSIONS - The results indicate that LjV is rare in young children. LjV does not seem to be involved in the development of human type 1 diabetes.","[Tapia, German; Rasmussen, Trond; Grinde, Bjorn; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Oslo, Norway; [Tapia, German; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Tapia, G, Norwegian Inst Publ Hlth, Oslo, Norway","german.tapia@fhi.no","Norwegian Organization for Health and Rehabilitation [2005/2/0128]; European Economic Area and Norway Grants [A/CZ0046/1/0014]; Ministry of Education of the Czech Republic [MSM0021620814]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association ; Children With Diabetes Foundation ; New-Generis [Food-CT-2005-016320]","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (Grant 2005/2/0128), European Economic Area and Norway Grants (Grant A/CZ0046/1/0014 through the Research Support Fund, Prague, the Czech Republic), the Ministry of Education of the Czech Republic (Grant MSM0021620814), the Research Council of Norway (Grants 135893/330, 155300/320, 156477/730, and 166515/V50), the Norwegian Diabetes Association, the Children With Diabetes Foundation (Denver, CO), and New-Generis (Grant Food-CT-2005-016320). No potential conflicts of interest relevant to this article were reported.",null,13,0,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,"10.2337/dc09-1951","DIABETES CARE","Diabetes Care","MAY",2010,33,5,null,null,null,1069,1071,null,null,3,"Endocrinology & Metabolism","595RV","ISI:000277631200024"]
["nemá","J","Kabelka, Z; Groh, D; Katra, R; Jurovcik, M",null,null,null,"Kabelka, Zdenek; Groh, Daniel; Katra, Rami; Jurovcik, Michal",null,"Bacterial infection complications in children with cochlear implants in the Czech Republic","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY",null,"English","Article",null,null,null,null,null,"Cochlear implants; Infection; Complications; Pseudomonas aeruginosa; Staphylococcus aureus; Reimplantation","PSEUDOMONAS-AERUGINOSA; BIOFILM FORMATION; SURGERY; EPIDEMIOLOGY; MANAGEMENT",null,"[Kabelka, Zdenek] Charles Univ Prague, Dept Otolaryngol, Sch Med 2, Prague 15006, Czech Republic; Fac Hosp Motol, Prague 15006, Czech Republic","Kabelka, Z, Charles Univ Prague, Dept Otolaryngol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic","Zdenek.Kabelka@fnmotol.cz","VZ FN Motol, Czech Republic [00000064203/ 650]","This work was supported by the VZ FN Motol 00000064203/ 650, Czech Republic.",null,24,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-5876",null,"10.1016/j.ijpor1.2010.02.007","INT J PED OTORHINOLARYNGOL","Int. J. Pediatr. Otorhinolaryngol.","MAY",2010,74,5,null,null,null,499,502,null,null,4,"Otorhinolaryngology; Pediatrics","597GP","ISI:000277745000012"]
["nemá","J","Drevinek, P; Vosahlikova, S; Dedeckova, K; Cinek, O; Mahenthiralingam, E",null,null,null,"Drevinek, Pavel; Vosahlikova, Sarka; Dedeckova, Klara; Cinek, Ondrej; Mahenthiralingam, Eshwar",null,"Direct Culture-Independent Strain Typing of Burkholderia cepacia Complex in Sputum Samples from Patients with Cystic Fibrosis","JOURNAL OF CLINICAL MICROBIOLOGY",null,"English","Article",null,null,null,null,null,null,"SP-NOV; MULTIVORANS; IDENTIFICATION; CENOCEPACIA","We examined if multilocus sequence typing (MLST), a method for genotyping and species identification of Burkholderia cepacia complex bacteria, could be applied directly to cystic fibrosis sputum. The redesigned nested-PCR MLST format was successfully used to accurately identify strains in 23 sputum samples, of which 8 were culture negative.","[Drevinek, Pavel; Vosahlikova, Sarka; Dedeckova, Klara; Cinek, Ondrej] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15006, Czech Republic; [Mahenthiralingam, Eshwar] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales","Drevinek, P, Charles Univ Prague, Dept Pediat, Sch Med 2, Uvalu 84, Prague 15006, Czech Republic","pavel.drevinek@Lfmotol.cuni.cz","Czech Ministry of Health [NS 10543-3]; Czech Ministry of Education [MSM0021620812]","This work was supported by grants from the Czech Ministry of Health (NS 10543-3) and the Czech Ministry of Education (MSM0021620812).",null,15,0,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0095-1137",null,"10.1128/JCM.02359-09","J CLIN MICROBIOL","J. Clin. Microbiol.","MAY",2010,48,5,null,null,null,1888,1891,null,null,4,"Microbiology","592DV","ISI:000277356600059"]
["nemá","J","Ehlers, S; Herbst, C; Zimmermann, M; Scharn, N; Germeshausen, M; von Neuhoff, N; Zwaan, CM; Reinhardt, K; Hollink, IH; Klusmann, JH; Lehrnbecher, T; Roettgers, S; Stary, J; Dworzak, M; Welte, K; Creutzig, U; Reinhardt, D",null,null,null,"Ehlers, Stephanie; Herbst, Christin; Zimmermann, Martin; Scharn, Nicole; Germeshausen, Manuela; von Neuhoff, Nils; Zwaan, Christian Michel; Reinhardt, Katarina; Hollink, Iris H.; Klusmann, Jan-Henning; Lehrnbecher, Thomas; Roettgers, Silja; Stary, Jan; Dworzak, Michael; Welte, Karl; Creutzig, Ursula; Reinhardt, Dirk",null,"Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse","JOURNAL OF CLINICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"SEVERE CONGENITAL NEUTROPENIA; ACUTE MYELOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HYPERPROLIFERATIVE RESPONSES; CELLS; EXPRESSION; MUTATIONS; INDUCTION; CHILDREN; GROWTH","Purpose This prospective, multicenter Acute Myeloid Leukemia Berlin-Frankfurt-Muenster (AML-BFM) 98 study randomly tested the ability of granulocyte colony-stimulating factor (G-CSF) to reduce infectious complications and to improve outcomes in children and adolescents with acute myeloid leukemia (AML). However, a trend toward an increased incidence of relapses in the standard-risk (SR) group after G-CSF treatment was observed. Patients and Methods Of 154 SR patients in the AML-BFM 98 cohort, 50 patients were tested for G-CSF receptor (G-CSFR) RNA isoform I and IV expression, G-CSFR cell surface expression, and acquired mutations in the G-CSFR gene. Results In patients randomly assigned to receive G-CSF after induction, 16 patients overexpressing the G-CSFR isoform IV showed an increased 5-year cumulative incidence of relapse (50% +/- 13%) compared with 14 patients with low-level isoform IV expression (14% +/- 10%; log-rank P = .04). The level of G-CSFR isoform IV had no significant effect in patients not receiving G-CSF (P = .19). Multivariate analyses of the G-CSF-treated subgroup, including the parameters G-CSFR isoform IV overexpression, sex, and favorable cytogenetics as covariables, revealed the prognostic relevance of G-CSFR isoform IV overexpression for 5-year event-free survival (P = .031) and the 5-year cumulative incidence of relapse (P = .049). Conclusion Our results demonstrate that children and adolescents with AMLs that overexpress the differentiation-defective G-CSFR isoform IV respond to G-CSF administration after induction, but with a significantly higher incidence of relapse.","[Ehlers, Stephanie] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; Goethe Univ Frankfurt, Frankfurt, Germany; Univ Giessen, Dept Pediat Hematol & Oncol, Giessen, Germany; Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany; Erasmus MC Sophia Childrens Hosp, Dept Pediat Hematol & Oncol, Rotterdam, Netherlands; Charles Univ Prague, Sch Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; St Anna Childrens Hosp, Vienna, Austria","Ehlers, S, Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany","ehlers.stephanie@mh-hannover.de","Jose Carreras International Leukemia Foundation ","Supported by grants from the Jose Carreras International Leukemia Foundation.",null,38,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2009.25.9010","J CLIN ONCOL","J. Clin. Oncol.","MAY 20",2010,28,15,null,null,null,2591,2597,null,null,7,"Oncology","598JO","ISI:000277832400016"]
["nemá","J","Hess, L; Votava, M; Schreiberova, J; Malek, J; Horacek, M",null,null,null,"Hess, L.; Votava, M.; Schreiberova, J.; Malek, J.; Horacek, M.",null,"Experience with a naphthylmedetomidine - ketamine - hyaluronidase combination in inducing immobilization in anthropoid apes","JOURNAL OF MEDICAL PRIMATOLOGY",null,"English","Article",null,null,null,null,null,"chimpanzee; immobilization; medetomidine; naphthylmedetomidine; orangutan","ALPHA-2-ADRENOCEPTOR AGONIST NAPHTHYLMEDETOMIDINE; MEDETOMIDINE ANALOGS; ALPHA(2)-ADRENOCEPTORS; DEXMEDETOMIDINE; BEHAVIOR; MICE","Background The aim of the study was to compare the effect of naphthylmedetomidine to medetomidine on the behavior of orangutans and chimpanzees. Methods The immobilization was performed as part of a medical examination in five chimpanzees and three orangutans. Following pre-medication with midazolam (0.70-1.20 mg/kg p.o.), naphthylmedetomidine (50-70 mu g/kg), or medetomidine (20-30 mu g/kg) was given with ketamine (3 mg/kg) and hyaluronidase (150 M.U.) into musculus deltoideus. Results We observed the distinct anti-aggressive effect of naphthylmedetomidine. The immobilization with naphthylmedetomidine was shallower and the influence on cardiac frequency less substantial compared to medetomidine. The overall sedative effect of naphthylmedetomidine lasted for less time, and its effect was incompletely antagonized with atipamezole in comparison to medetomidine. Conclusions Naphthylmedetomidine could replace medetomidine for inducing immobilization and sedation. A combination of naphthylmedetomidine-ketamine is suitable for relocating animals to other cages or for painless medical examinations.","[Votava, M.] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Prague 10034 10, Czech Republic; [Hess, L.] Inst Clin & Expt Med, Lab Expt Anaesthesiol, Prague, Czech Republic; [Schreiberova, J.] Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Schreiberova, J.] Univ Prague, Fac Med, Dept Anaesthesiol & Intens Care Med Charles, Hradec Kralove, Czech Republic; [Malek, J.] Charles Univ Prague, Fac Med 3, Dept Anaesthesiol & Crit Care Med, Prague, Czech Republic; [Horacek, M.] Charles Univ Prague, Fac Med 2, Dept Anaesthesiol & Intens Care Med, Prague, Czech Republic","Votava, M, Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10034 10, Czech Republic","martin.votava@lf3.cuni.cz","Czech Ministry of Health [IGA NR/9168]","This work was supported by a grant (IGA NR/9168) from the Czech Ministry of Health. Next, we thank the Faculty of Pharmacy University of Helsinki for the provision of naphthylmedetomidine for experimental purposes.",null,13,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0047-2565",null,"10.1111/j.1600-0684.2010.00404.x","J MED PRIMATOL","J. Med. Primatol.","JUN",2010,39,3,null,null,null,151,159,null,null,9,"Veterinary Sciences; Zoology","592XS","ISI:000277415800003"]
["nemá","J","Hromadka, R; Kubena, AA; Pokorny, D; Popelka, S; Jahoda, D; Sosna, A",null,null,null,"Hromadka, Rastislav; Kubena, Ales Antonin; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin",null,"Attachments of muscles as landmarks for implantation of shoulder hemiarthoplasty in fractures","JOURNAL OF SHOULDER AND ELBOW SURGERY",null,"English","Article",null,null,null,null,null,"Shoulder arthroplasty; humeral head retroversion; transepicondylar line; greater tubercle; lesser tubercle; crest of greater tubercle","PROXIMAL HUMERUS; BICIPITAL GROOVE; COMPUTED-TOMOGRAPHY; 4-PART FRACTURES; HEMIARTHROPLASTY; ARTHROPLASTY; RETROVERSION; REPLACEMENT; MALPOSITION; ORIENTATION","Background: The attachments of muscles and the position of the humeral head are important for a good functional outcome of shoulder hemiarthroplasties after displaced fractures of the proximal humerus. Deviations in the attachments and changes in their spatial position with respect to the humeral head during surgical reconstruction change the biomechanics and reduce the range of motion of the should joint post-operatively. Methods and Results: We used 198 humerus preparations and using 3-dimensional analysis measured the angular relationships between the humeral head axis and medial margin of the greater tuberosity (11.9 degrees +/- 9.1 degrees), lateral margin of the lesser tuberosity (48.0 degrees +/- 7.8 degrees), and the crest of the greater tuberosity (27.1 degrees +/- 9.6 degrees). Conclusion: This study provides average values of the positions of the greater and lesser tuberosities with respect to the humeral head axis. We show that the greater and lesser tuberosities are more reliable than the transepicondylar line for reconstruction of humeral head retroversion.","[Hromadka, Rastislav; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Kubena, Ales Antonin] Charles Univ Prague, Fac Sci, Dept Evolut Biol, Prague, Czech Republic","Hromadka, R, 1 LF UK & FN Motol, Ortoped Klin 1, Uvalu 84, Prague 15006 5, Czech Republic","rastislav.hromadka@lf1.cuni.cz",null,null,null,22,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","1058-2746",null,"10.1016/j.jse.2009.03.023","J SHOULDER ELBOW SURG","J. Shoulder Elbow Surg.","JAN",2010,19,1,null,null,null,130,136,null,null,7,"Orthopedics; Sport Sciences; Surgery","592HA","ISI:000277367800023"]
["nemá","J","Balgobind, BV; Lugthart, S; Hollink, IH; Arentsen-Peters, STJCM; van Wering, ER; de Graaf, SSN; Reinhardt, D; Creutzig, U; Kaspers, GJL; de Bont, ESJM; Stary, J; Trka, J; Zimmermann, M; Beverloo, HB; Pieters, R; Delwel, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, B. V.; Lugthart, S.; Hollink, I. H.; Arentsen-Peters, S. T. J. C. M.; van Wering, E. R.; de Graaf, S. S. N.; Reinhardt, D.; Creutzig, U.; Kaspers, G. J. L.; de Bont, E. S. J. M.; Stary, J.; Trka, J.; Zimmermann, M.; Beverloo, H. B.; Pieters, R.; Delwel, R.; Zwaan, C. M.; van den Heuvel-Eibrink, M. M.",null,"EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia","LEUKEMIA",null,"English","Article",null,null,null,null,null,"EVI1 expression; pediatric AML; MDS1/EVI1 expression","ZINC-FINGER PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-CELLS; GENE-EXPRESSION; ONCOLOGY-GROUP; TREATMENT STRATEGY; TRANSFORMING GENE; PR DOMAIN; AML; ACTIVATION","Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the role of EVI1 is unknown. We studied 228 pediatric AML samples for EVI1+ using gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML. It was predominantly found in MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually exclusive with core-binding factor AML, t(15;17), and NPM1 mutations. Fluorescent in situ hybridization (FISH) was performed to detect cryptic 3q26 abnormalities. However, none of the EVI1+ patients harbored structural 3q26 alterations. Although significant differences in 4 years pEFS for EVI1+ and EVI1 pediatric AML were observed (28%+/- 11 vs 44%+/- 4, P=0.04), multivariate analysis did not identify EVI1+ as an independent prognostic factor. We conclude that EVI1+ can be found in similar to 10% of pediatric AML. Although EVI1+ was not an independent prognostic factor, it was predominantly found in subtypes of pediatric AML that are related with an intermediate to unfavorable prognosis. Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML. Leukemia (2010) 24, 942-949; doi:10.1038/leu.2010.47; published online 1 April 2010","[Balgobind, B. V.; Hollink, I. H.; Arentsen-Peters, S. T. J. C. M.; Pieters, R.; Zwaan, C. M.; van den Heuvel-Eibrink, M. M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [van Wering, E. R.; de Graaf, S. S. N.] DCOG, The Hague, Netherlands; [Lugthart, S.; Delwel, R.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands; [de Graaf, S. S. N.] Radboud Univ Nijmegen Med Ctr, Dept Pediat Oncol Hematol, Nijmegen, Netherlands; [Reinhardt, D.; Zimmermann, M.] Hannover Med Sch, Dept Pediat Hematol Oncol, AML BFM Study Grp, D-3000 Hannover, Germany; [Creutzig, U.] Univ Hosp, Dept Pediat Hematol Oncol, AML BFM Study Grp, Munster, Germany; [Kaspers, G. J. L.] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [de Bont, E. S. J. M.] Beatrix Childrens Hosp, Univ Med Ctr Groningen, Dept Pediat Oncol Hematol, Groningen, Netherlands; [Stary, J.; Trka, J.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Beverloo, H. B.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands","van den Heuvel-Eibrink, MM, Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","m.vandenheuvel@erasmusmc.nl","NWO 'Netherlands Organization for Scientific Research' ; KOCR 'Kinder-Oncologisch Centrum Rotterdam' ; EHA ","This work was funded by the NWO 'Netherlands Organization for Scientific Research' (BVB), KOCR 'Kinder-Oncologisch Centrum Rotterdam' (BVB and IHH) and EHA (SL).",null,50,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2010.47","LEUKEMIA","Leukemia","MAY",2010,24,5,null,null,null,942,949,null,null,8,"Oncology; Hematology","595DS","ISI:000277591500005"]
["nemá","J","Figova, K; Sobotkova, E; Duskova, M; Ludvikova, V; Vonka, V; Eckschlager, T",null,null,null,"Figova, K.; Sobotkova, E.; Duskova, M.; Ludvikova, V.; Vonka, V.; Eckschlager, T.",null,"In vitro and in vivo effects of reovirus on HPV16-transformed mice cells","NEOPLASMA",null,"English","Article",null,null,null,null,null,"reovirus type 3; HPV16-transformed mouse cell lines; apoptosis; cell cycle; immunization/challenge experiments","HUMAN-PAPILLOMAVIRUS TYPE-16; HERPES-SIMPLEX-VIRUS; ANTITUMOR IMMUNITY; ONCOLYTIC REOVIRUS; DENDRITIC CELLS; HPV16-ASSOCIATED TUMORS; THERAPY; CANCER; APOPTOSIS; MELANOMA","Oncolytic viruses are examined to serve as anticancer therapeutics. It is expected that in addition to direct oncolytic effect their action will also help eliciting a solid antitumor immunity. In presented series of experiments we have employed two HPV16-transformed mouse (strain C57/B6) cell lines, TC-1 and MK16/III/ABC (MK16), and reovirus type 3, strain Dearing (RV). Both cell lines are highly susceptible to RV and produce large amounts of infectious virus in vitro while normal human are not susceptible to RV. Still, some differences were encountered. TC-1 cells produced moderately lesser amounts of infectious virus, but, paradoxically, were more efficient producers of M antigen of RV and as a consequence of virus infection died more rapidly than simultaneously infected MK16 cells. Minor differences between the cell lines were observed in the percentage of cells arrested in theG2/M phase of the cell cycle and in some markers of apoptosis. When inoculating high doses (5x10(6)) of infected cells (MOI 10 PFU/cell) into syngeneic animals their oncogenic activity was strongly suppressed, nearly completely in the case of MK16 cells and somewhat less efficiently in the case of more oncogenic TC-1 cells. Immunizing experiments in which non-oncogenic doses (10(6)) of RV infected TC-1 cells were tested in parallel with the same doses of irradiated cells brought surprising results. When immunized animals were challenged with TC-1 cells, the irradiated cells proved to be a much better immunogen that the infected cells. However, when challenged with MK16 cells the opposite was true. It is believed that this difference was associated with the different biological properties of the cell lines tested.","[Figova, K.; Eckschlager, T.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic; [Figova, K.; Eckschlager, T.] Univ Hosp Motol, Prague 15006, Czech Republic; [Sobotkova, E.; Duskova, M.; Ludvikova, V.; Vonka, V.] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic","Figova, K, Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006, Czech Republic","eckschlagertomas@yahoo.com","GACR [301/05/2240, MSMT0021620813]","We thank J. Cinatl Jr. (Institute for Medical Virology, Johann Wolfgang Goethe University Hospital, Frankfurt am Mein, Germany) who kindly provided reovirus, normal human fibroblasts and Vero cells. This research was supported by the grants GACR No. 301/05/2240 and MSMT0021620813.",null,33,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,"10.4149/neo_2010_03_207","NEOPLASMA","Neoplasma",null,2010,57,3,null,null,null,207,214,null,null,8,"Oncology","592WQ","ISI:000277412800003"]
["nemá","J","Anders, M; Dvorakova, J; Rathova, L; Havrankova, P; Pelcova, P; Vaneckova, M; Jech, R; Holcat, M; Seidl, Z; Raboch, J",null,null,null,"Anders, Martin; Dvorakova, Jana; Rathova, Lucie; Havrankova, Petra; Pelcova, Petra; Vaneckova, Manuela; Jech, Robert; Holcat, Martin; Seidl, Zdenek; Raboch, Jiri",null,"Efficacy of repetitive transcranial magnetic stimulation for the treatment of refractory chronic tinnitus: A randomized, placebo controlled study","NEUROENDOCRINOLOGY LETTERS",null,"English","Article",null,null,null,null,null,"rTMS; transcranial magnetic stimulation; neuronavigation; chronic refractory tinnitus","MOTOR CORTEX EXCITABILITY; DOUBLE-BLIND; RTMS; SUPPRESSION; DEPRESSION; PLASTICITY","OBJECTIVE: The pathophysiologic mechanisms of idiopathic tinnitus remain unclear. Low frequency rTMS applied over the auditory cortex has been proposed as a new and causally oriented treatment approach for pathological conditions with abnormal, increased cortical activity including tinnitus with increased activity in the auditory cortex. However available studies are characterized by a positive reports on the therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) for treatment of tinnitus, there are few details about the duration of specific treatment effects. DESIGN: The design of the study was randomized, prospective, placebo-controlled. Right-handed patients were treated with either real or sham 1 Hz frequency rTMS over a period of two weeks. Fifty-two patients with chronic, treatment resistant tinnitus and stable medication were enrolled in the study after giving written informed consent and forty-two patients completed the study and were included in data analysis. RESULTS: The ability to reduce the symptoms of tinnitus appeared in both randomized groups immediately after the 1 Hz rTMS and sham stimulation phase. There was a significant reduction in both groups of the tinnitus total score on the Tinnitus Handicap Inventory (THI) (real rTMS p=0.005; sham rTMS p=0.049) and Tinnitus Questionnaire (TQ) total score (real rTMS p=0.003; sham rTMS p=0.049). On the THI evaluation scale, in the real rTMS a mild worsening was noted during week 6 in comparison with the state attained in week 2. During the subsequent course of the study a significant reduction of the total score persisted in the case of THI (real rTMS week 14 p=0.033 and borderline week 26 p=0.058).The reduction of symptoms as evaluated using the TQ was significant compared to baseline in the real rTMS group at week 2, 6 and 14 (p=0.003; p=0.024; p=0.022). The group treated with sham stimulation reached significant reduction of symptoms only at week 2 (p=0.049). A comparison of the difference in the recorded values of the total score during follow-up in relation to baseline expressed as a percentage demonstrates the difference in the effect of rTMS and sham stimulation as evaluated by both the basic scales. Graphical analysis of mean patterns of treatment response according to stimulation type shows a similarity between treatment response patterns evaluated by reduction of the total scores using THI and TQ. CONCLUSIONS: The principal finding of this study is that real 1 Hz rTMS treatment was capable of significantly reducing the total baseline score of basic scales that measure tinnitus severity. This result is important as it proves that significant reduction of symptoms can be achieved even in a group of patients with long-term symptoms resistant to pharmacological treatment.","[Anders, Martin; Dvorakova, Jana; Pelcova, Petra; Raboch, Jiri] Charles Univ Prague, Dept Psychiat, Fac Med 1, Prague 12000 2, Czech Republic; [Anders, Martin; Dvorakova, Jana; Havrankova, Petra; Pelcova, Petra; Vaneckova, Manuela; Seidl, Zdenek; Raboch, Jiri] Gen Teaching Hosp, Prague 12000 2, Czech Republic; [Rathova, Lucie; Jech, Robert; Holcat, Martin] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague 12000 2, Czech Republic; [Rathova, Lucie; Jech, Robert; Holcat, Martin] Motol Teaching Hosp, Prague, Czech Republic; [Havrankova, Petra] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 12000 2, Czech Republic; [Vaneckova, Manuela; Seidl, Zdenek] Charles Univ Prague, Dept Radiol, Fac Med 1, Prague 12000 2, Czech Republic","Anders, M, Charles Univ Prague, Dept Psychiat, Fac Med 1, Ke Karlovu 11, Prague 12000 2, Czech Republic","martin.anders@vfn.cz","[IGA MZCR NR/8805-4]; [MSM 0021620849]","This study was supported by research grants IGA MZCR NR/8805-4 and MSM 0021620849.",null,40,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2010,31,2,null,null,null,238,249,null,null,12,"Endocrinology & Metabolism; Neurosciences","596RF","ISI:000277702100013"]
["nemá","J","Calda, P; Brestak, M; Tomek, V; Ostadal, B; Sonek, J",null,null,null,"Calda, Pavel; Brestak, Miroslav; Tomek, Viktor; Ostadal, Bohuslav; Sonek, Jiri",null,"Left ventricle shortening fraction: a comparison between euploid and trisomy 21 fetuses in the first trimester","PRENATAL DIAGNOSIS",null,"English","Article",null,null,null,null,null,"trisomy 21; first trimester; marker; shortening fraction of the left ventricle","CARDIAC DEVELOPMENT; DOWN-SYNDROME; FETAL; PREGNANCY","Objectives Measurement of the shortening fraction of the left ventricle (SFLV) is an objective way to assess systolic performance. The aim of the study was to compare first trimester SFLV values in euploid fetuses to those in fetuses with trisomy 21. Methods We measured SFLV in 56 fetuses from 11 weeks to 13 weeks 6 days. The left ventricular diastolic diameter (LVDD) and left ventricular systolic diameter (LVSD) were measured offline, and SFLV was calculated. The data were analyzed using Mann Whitney U test. Results We found a significant difference in the SFLV measurements between the group of 49 euploid fetuses and the 7 fetuses with trisomy 21 [38.00(95% CI: 33.72-42.27) vs 49.93 (95% CI: 43.72-56.13)] (p < 0.05). There was also a significant difference in the nuchal translucency measurements between the two groups: 1.78 mm (95% CI: 1.08-2.48 mm) in the euploid population versus 5.06 mm (95% CI: 3.61-6.71 mm) in the fetuses with trisomy 21 (p < 0.05). There were no significant differences between the group of euploid fetuses and the group of trisomy 21 fetuses in the following parameters: CRL (chorionic villus sampling), LVDD and LVSD. Conclusions SFLV is a well-defined, simple measurement of systolic function of the fetal myocardium. SFLV values in fetuses with trisomy 21 appear to be significantly higher than in euploid fetuses. Copyright (C) 2010 John Wiley & Sons, Ltd.","[Calda, Pavel; Brestak, Miroslav] Charles Univ Prague, Dept Gynecol & Obstet, Fac Med 1, Fetal Med Ctr, Prague 12852 2, Czech Republic; [Calda, Pavel; Brestak, Miroslav] Charles Univ Prague, Gen Teaching Hosp, Fetal Med Ctr, Prague 12852 2, Czech Republic; [Tomek, Viktor] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Tomek, Viktor] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Ostadal, Bohuslav] Acad Sci Czech Republic, Inst Physiol, Cardiovasc Res Ctr, Prague, Czech Republic; [Sonek, Jiri] Wright State Univ, Dayton, OH 45435 USA; [Sonek, Jiri] Fetal Med Fdn USA, Dayton, OH USA","Calda, P, Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 1, Fetal Med Ctr, Apolinarska 18, Prague 12852 2, Czech Republic","calda@gynstart.cz",null,null,null,14,0,"JOHN WILEY & SONS LTD","CHICHESTER","THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND","0197-3851",null,"10.1002/pd.2500","PRENATAL DIAG","Prenat. Diagn.","APR",2010,30,4,null,null,null,368,371,null,null,4,"Genetics & Heredity; Obstetrics & Gynecology","595RH","ISI:000277629600013"]
["nemá","J","Brabec, J; Rulseh, A; Hoyt, B; Vizek, M; Horinek, D; Hort, J; Petrovicky, P",null,null,null,"Brabec, Jiri; Rulseh, Aaron; Hoyt, Brian; Vizek, Martin; Horinek, Daniel; Hort, Jakub; Petrovicky, Pavel",null,"Volumetry of the human amygdala - An anatomical study","PSYCHIATRY RESEARCH-NEUROIMAGING",null,"English","Article",null,null,null,null,null,"Anatomy; Cytoarchitecture; Aging; MRI","ALZHEIMERS-DISEASE; HIPPOCAMPAL-FORMATION; FACIAL EXPRESSION; LATERAL VENTRICLE; ENTORHINAL CORTEX; BIPOLAR DISORDER; MR-IMAGES; SCHIZOPHRENIA; BRAIN; COMPLEX","A striking feature of the studies that have addressed the measurement of the amygdala is the wide range of volumes encountered, with reports of volumes ranging from 1 to almost 4 cm(3). Another striking feature is the number of discrepancies in the landmarks adopted for manual tracing in magnetic resonance imaging (MRI). The goal of our study was to assess the anatomical volume of the amygdala on the basis of its cytoarchitecture while comparing the differences in age and sex. This study was performed on 21 normal male brains (mean age of 56.8 years) and 9 normal female brains (mean age of 61.2 years). The volume of the amygdala was measured by planimetry of Nissl-stained serial sections using ImageJ software. To address the complexity of the amygdala, we elected to use two types of amygdalar measurement that differ mainly in the definition of anterior pole boundaries. The average size of the classic amygdala was 1.24 cm(3) (S.D. = 0.14), while the average size of the amygdala with wider borders was 1.63 cm(3) (S.D. = 0.2). No interhemispheric or intersexual differences were observed for either type of amygdalar measurement. Neither sex revealed any statistically important relationship between volume of the amygdala and age. Our study was concerned exclusively with the anatomical volume of the amygdala rather than the MM volume. Nevertheless, our results may have important implications for MM studies because as of yet there is no gold standard for manual volumetry of the amygdala. (C) 2009 Elsevier Ireland Ltd. All rights reserved.","[Brabec, Jiri; Rulseh, Aaron; Hoyt, Brian; Petrovicky, Pavel] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic; [Brabec, Jiri] Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK USA; [Vizek, Martin; Horinek, Daniel] Charles Univ Prague, Inst Pathol Physiol, Sch Med 2, Prague 12800 2, Czech Republic; [Vizek, Martin; Horinek, Daniel] Charles Univ Prague, Lab Neuroimaging Res, Sch Med 2, Prague 12800 2, Czech Republic; [Hort, Jakub] Charles Univ Prague, Dept Neurol, Univ Hosp Motol, Sch Med 2, Prague 12800 2, Czech Republic","Brabec, J, Charles Univ Prague, Inst Anat, Fac Med 1, U Nemocnice 3, Prague 12800 2, Czech Republic","jiri.brabec@lf1.cuni.cz","Ministry of Health of the Czech Republic ; Internal Grant Agency (IGA) [MZ 2006, NR8931-4]","This work was supported by the Ministry of Health of the Czech Republic, Internal Grant Agency grant IGA MZ 2006, NR8931-4. We thank Kveta Patkova and Bohuslava Fulinova for the excellent technical assistance, and Associate Professor David Sedmera, M.D., PhD., Institute of Anatomy, for the helpful advice and comments. We are deeply indebted to the donors and their families who have made this study possible.",null,53,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0925-4927",null,"10.1016/j.pscychresns.2009.11.005","PSYCHIAT RES-NEUROIMAG","Psychiatry Res. Neuroimaging","APR 30",2010,182,1,null,null,null,67,72,null,null,6,"Clinical Neurology; Neuroimaging; Psychiatry","594KJ","ISI:000277536200010"]
["nemá","J","Adam, V; Fabrik, I; Eckschlager, T; Stiborova, M; Trnkova, L; Kizek, R",null,null,null,"Adam, Vojtech; Fabrik, Ivo; Eckschlager, Tomas; Stiborova, Marie; Trnkova, Libuse; Kizek, Rene",null,"Vertebrate metallothioneins as target molecules for analytical techniques","TRAC-TRENDS IN ANALYTICAL CHEMISTRY",null,"English","Article",null,null,null,null,null,"Capillary electrophoresis; Electrochemistry; ELISA; Gel electrophoresis; High-performance liquid chromatography; Immunochemistry; Metallothionein; Saturation assay; Spectrometry; Voltammetry","LINKED-IMMUNOSORBENT-ASSAY; PLASMA-MASS SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; CAPILLARY-ZONE-ELECTROPHORESIS; BIOINORGANIC SPECIATION ANALYSIS; TRANSFER STRIPPING TECHNIQUE; RABBIT LIVER APOTHIONEINS; MERCURY SATURATION ASSAY; TUMOR-CELL LINES; HPLC-ICP-MS","Metallothioneins (MTs) are a family of ubiquitous, biologically interesting proteins that have been isolated and studied in a wide variety of organisms, including prokaryotes, plants, invertebrates and vertebrates. Due to the property of MTs being metal-inducible and their high affinity to metal ions, homeostasis of heavy-metal levels is probably their most important biological function. MTs are also involved in other important biochemical pathways, including scavenging of reactive oxygen species, activation of transcription factors and participation in carcinogenesis. Detection and quantification of MTs are not simple due to the unique primary structure and their relatively low molecular mass. Analytical methods are based on: a) detection of bound metal ion; b) detection of free -SH groups; c) protein mobility in electrical field; and, d) interaction with different types of sorbent. This review highlights techniques used for detection and determination of MTs with discussion of the advantages and the disadvantages of particular approaches. (C) 2010 Elsevier Ltd. All rights reserved.","[Adam, Vojtech; Fabrik, Ivo; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz","GA AV [IAA401990701]; INCHEMBIOL [MSM0021622412]","Financial support from GA AV IAA401990701 and INCHEMBIOL MSM0021622412 is highly acknowledged. The authors wish to express their great thanks to Dr. Harry Martin and Dr. Jitka Petrlova for language correction.",null,106,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0165-9936",null,"10.1016/j.trac.2010.02.004","TRAC-TREND ANAL CHEM","Trac-Trends Anal. Chem.","MAY",2010,29,5,null,null,null,409,418,null,null,10,"Chemistry, Analytical","596PW","ISI:000277698300014"]
["nemá","J","Krskova, L; Mrhalova, M; Hilska, I; Sumerauer, D; Drahokoupilova, E; Mudry, P; Kodet, R",null,null,null,"Krskova, Lenka; Mrhalova, Marcela; Hilska, Irena; Sumerauer, David; Drahokoupilova, Eva; Mudry, Peter; Kodet, Roman",null,"Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma","VIRCHOWS ARCHIV",null,"English","Article",null,null,null,null,null,"Bone marrow; Minimal disseminated disease; Real-time PCR; Alveolar rhabdomyosarcoma","POLYMERASE-CHAIN-REACTION; INTERGROUP RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; MOLECULAR DIAGNOSIS; PERIPHERAL-BLOOD; MINIMAL DISEASE; TUMOR-CELLS; PCR ASSAY; EXPRESSION; CHILDREN","Childhood rhabdomyosarcoma (RMS) has two major histological subtypes: alveolar (aRMS) and embryonal. The aim of the study was to monitor minimal disseminated disease (MDD) using real-time quantitative reverse-transcription PCR (RQ-RT-PCR) of the PAX3-FKHR, PAX7-FKHR fusion genes and myoD1 gene. We prepared an assay using RQ-RT-PCR for a quantitative assessment of MDD in aRMS by using hydrolysis probe for quantification of PAX3-FKHR, PAX7-FKHR and myoD1 genes and beta-2-microglobulin housekeeping gene. Primary tumor samples (44), samples of local recurrences (26) from 48 patients with aRMS were examined by nested RT-PCR and RQ-RT-PCR techniques. Additionally, bone marrow samples (115), peripheral blood progenitor cell samples (27), and peripheral blood samples (25) from 33 aRMS patients were tested. PAX3/7-FKHR and myoD1 transcripts proved to be a sensitive tool for detection of MDD in RMS. We were able to identify 15/25 patients with bone marrow (BM) involvement at the time of presentation using RQ-RT-PCR. We analyzed PAX3-FKHR or PAX7-FKHR expression during the course of the disease. The RQ-RT-PCR results correlated well with nested RT-PCR results (p < 0.0001). The presence of metastases is the most adverse prognostic factor in RMS, and bone marrow is a frequent site of the tumor dissemination in RMS, especially in aRMS. Our results detecting the fusion transcripts or myoD1 transcript in the BM or peripheral blood suggest that patients with positive findings are at high risk of the tumor progression.","[Krskova, Lenka; Mrhalova, Marcela; Hilska, Irena; Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Krskova, Lenka; Mrhalova, Marcela; Hilska, Irena; Sumerauer, David; Drahokoupilova, Eva; Kodet, Roman] Fac Hosp Motol, Prague, Czech Republic; [Sumerauer, David; Drahokoupilova, Eva] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Mudry, Peter] Fac Hosp Brno, Clin Pediat Oncol, Brno, Czech Republic","Krskova, L, Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic","lkrskova@email.cz","Ministry of Education, Youth and Sports of the Czech Republic [0021620813]; Ministry of Health [MZOFNM2005]; [GACR 304/07/0532]","The study was supported by the Grant GACR 304/07/0532, the Research Project of the Ministry of Education, Youth and Sports of the Czech Republic No. 0021620813 and by the Research Project of the Ministry of Health MZOFNM2005. All experiments comply with the current laws of Czech Republic.",null,19,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0945-6317",null,"10.1007/s00428-010-0913-9","VIRCHOWS ARCHIV","Virchows Arch.","MAY",2010,456,5,null,null,null,463,472,null,null,10,"Pathology","592BM","ISI:000277349900001"]
["nemá","J","Palova, S; Szabo, K; Charvat, J; Slavicek, J; Medova, E; Mlcek, M; Kittnar, O",null,null,null,"Palova, S.; Szabo, K.; Charvat, J.; Slavicek, J.; Medova, E.; Mlcek, M.; Kittnar, O.",null,"ECG Body Surface Mapping Changes in Type 1 Diabetic Patients with and without Autonomic Neuropathy","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Diabetes mellitus type 1; Autonomic neuropathy; ECG Body Surface Mapping","CORONARY-ARTERY DISEASE; POTENTIAL MAPS; MELLITUS; SYSTEM","ECG body surface mapping (BSM) parameters in patients with diabetes mellitus Type 1 (DM1) are significantly different comparing to healthy non-diabetic subjects. Hypothesis that these changes are more pronounced in DM1 patients with autonomic neuropathy (AN) was tested. The parameters of BSM were registered by diagnostic system Cardiag 112.2 in 54 DM1 patients including 25 with AN and 30 control subjects. AN was diagnosed according to Ewing criteria when two or more Ewing tests were abnormal. In classic 12-lead ECG the heart rate was increased, QRS and QT shortened (p<0.01) and QT(c) prolonged in DM1 patients. The VCG measurement of QRS-STT angles and spatial QRS-STT angle showed non-significant differences. The absolute values of maximum and minimum in depolarization and repolarization isopotential, isointegral, isoarea maps were significantly different in DM1 patients in comparison with controls (p<0.01). The changes were more pronounced in DM1 patients with AN than in DM patients without AN (p<0.05). The QT duration measured in 82 leads of thorax was significantly shortened in 68 leads of both groups of DM1 patients (p<0.01) when compared with controls. In 34 of them this shortening was more pronounced in DM1 patients with AN than in DM1 patients without AN (p<0.05). The results showed that the method of ECG BSM is capable to confirm the presence of autonomic neuropathy in diabetic patients.","[Slavicek, J.; Medova, E.; Mlcek, M.; Kittnar, O.] Charles Univ Prague, Fac Med 1, Inst Physiol, Prague 12800 2, Czech Republic; [Palova, S.; Szabo, K.; Charvat, J.] Charles Univ Prague, Fac Med 2, Dept Med, Prague 12800 2, Czech Republic","Kittnar, O, Charles Univ Prague, Fac Med 1, Inst Physiol, Albertov 5, Prague 12800 2, Czech Republic","otomar.kittnar@lf1.cuni.cz","[GAUK 53/2004]; [GAAV 1ET201210527]","This work was partially supported by Grants GAUK 53/2004, GAAV 1ET201210527. The authors wish to thank to Assoc. Prof Ljuba Bacharova for her kind remarks, to Dr. Eva Medova and to Mrs. Tereza Vavrikova for registration and evaluation of parameters of heart electric field, for preparation and correction of manuscript, and to Mrs. Alena Dohnalova for the statistical measurements.",null,20,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,2,null,null,null,203,209,null,null,7,"Physiology","600VE","ISI:000278016200007"]
["nemá","J","Polanska, M; Hulejova, H; Petrtyl, M; Bastl, Z; Spirovova, I; Krulis, Z; Horak, Z; Veigl, D; Senolt, L",null,null,null,"Polanska, M.; Hulejova, H.; Petrtyl, M.; Bastl, Z.; Spirovova, I.; Krulis, Z.; Horak, Z.; Veigl, D.; Senolt, L.",null,"Surface Modification of Cyclic Olefin Copolymers for Osteochondral Defect Repair Can Increase Pro-Destructive Potential of Human Chondrocytes In Vitro","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Osteochondral defects; Cycloolefin copolymer; Chondrocytes; Biocompatibility","MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; CYTOTOXICITY; PATHOGENESIS; ARTHRITIS; COLLAGEN","Materials on the basis of cycloolefin copolymers (COC) are suitable for subchondral defect repairs. The objective of this study was to evaluate the influence of surface modification of COC and COC/LLDPE blends on the viability and gene expression of chondrocytes. Human chondrocytes were incubated on the surface of the studied materials. Half of the materials were plasmatically modified with a subsequent type II collagen application. The gene expression of matrix metalloproteinases (MMP-1,-3,-13), pro-inflammatory cytokines (IL-1, TNF-alpha) and apoptotic molecules (BAX, Bcl-2) was evaluated using quantitative Taq-Man PCR after 48 h incubation. Chondrocyte viability was evaluated by the MTT test after 2, 4 and 8 days of incubation. The synthesis of MMPs was measured by ELISA assay in cell culture medium after 48 h of incubation. Chondrocytes incubated on plasmatically modified in contrast to unmodified materials demonstrated significantly increased gene expression of IL-1 (p<0.05), MMP-1 and MMP-3 (p<0.05 for both comparisons) as well as MMP-13 (p<0.001). Increased gene expression was confirmed by significantly increased production of active forms of particular MMPs into the cell culture medium. Unlike surface unmodified polymers, the modified materials showed time-dependent reduction of chondrocyte viability. The gene expression of TNF-a and apoptotic molecules by chondrocytes was not significantly changed by different materials. Cycloolefin copolymers and their blends may represent suitable materials for tissue engineering, however, their surface modification followed by collagen type II application may, at least under in vitro conditions, reduce the viability of chondrocytes and induce their pro-destructive behavior. The potential benefit or disadvantage of surface modifications of materials for osteochondral defect repairs needs to be further elucidated.","[Polanska, M.; Hulejova, H.; Senolt, L.] Charles Univ Prague, Fac Med 1, Inst Rheumatol, Prague 12850 2, Czech Republic; [Petrtyl, M.] Czech Tech Univ, Fac Civil Engn, CR-16635 Prague, Czech Republic; [Bastl, Z.; Spirovova, I.] Acad Sci Czech Republic, Inst Phys Chem, Prague, Czech Republic; [Krulis, Z.; Horak, Z.] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Veigl, D.] Fac Med 1, Orthoped Clin 1, Prague, Czech Republic; [Veigl, D.] Fac Hosp Motol, Prague, Czech Republic","Polanska, M, Charles Univ Prague, Fac Med 1, Inst Rheumatol, Slupi 4, Prague 12850 2, Czech Republic","polanska@revma.cz","Grant Agency of the Czech Republic [106/06/0761]","The presented work was carried out with the support of a implants. grant provided by Grant Agency of the Czech Republic, reg. no. 106/06/0761.",null,21,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,2,null,null,null,247,253,null,null,7,"Physiology","600VE","ISI:000278016200012"]
["nemá","J","von Neuhoff, C; Reinhardt, D; Sander, A; Zimmermann, M; Bradtke, J; Betts, DR; Zemanova, Z; Stary, J; Bourquin, JP; Haas, OA; Dworzak, MN; Creutzig, U",null,null,null,"von Neuhoff, Christine; Reinhardt, Dirk; Sander, Annette; Zimmermann, Martin; Bradtke, Jutta; Betts, David R.; Zemanova, Zuzana; Stary, Jan; Bourquin, Jean-Pierre; Haas, Oskar A.; Dworzak, Michael N.; Creutzig, Ursula",null,"Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98","JOURNAL OF CLINICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOGENOUS LEUKEMIA; CHILDRENS-CANCER-GROUP; TUMOR-SUPPRESSOR GENE; POOR-PROGNOSIS; CYTOGENETIC ABNORMALITIES; ONCOLOGY-GROUP; DE-NOVO; FLT3 MUTATIONS; GROUP-B; TRANSLOCATION","Purpose Because cytogenetic data are essential for risk stratification of childhood acute myeloid leukemia (AML), the impact of chromosomal aberrations is crucial. Patients and Methods Data of a large group of patients younger than 18 years treated according to study AML-Berlin-Frankfurt- Munster (BFM) 98 (n = 454), including their cytogenetics, were analyzed. Results The favorable outcome in the subgroups of patients with t(8;21), inv(16), and t( 15; 17), with an overall survival of 91% (SE,4%), 92% (SE,6%), and 87% (SE,5%), respectively, was confirmed. Within this group, the 5-year probability of event-free survival (pEFS) of all 17 children with t( 8; 21) and additional aberrations apart from del(9q) or -X/-Y was 100%. As expected, the cytogenetic finding of a complex karyotype (n = 35; pEFS, 33%; SE, 8%) or a monosomy 7 (n = 12; pEFS, 17%; SE, 11%) was associated with a poor outcome. Compared with remaining patients with cytogenetic data ( pEFS, 48%; SE, 2%), prognosis in patients with an MLL rearrangement (n = 91) was inferior ( pEFS, 34%; SE, 5%; P = .0005). Particularly, children with t( 9; 11) and additional aberrations (n = 13; pEFS, 31%; SE, 14%) and MLL rearrangements other than t( 9; 11) and t( 11; 19) (n = 41; pEFS, 24%; SE, 7%) had an unfavorable outcome. Nine patients with aberrations in 12p showed an adverse prognosis ( pEFS, 11%; SE, 10%). The outcome of patients with aberrations of chromosome 5 (n = 13) was better than expected ( pEFS, 50%; SE, 13%). Conclusion Because the prognostic value of rare recurrent chromosomal aberrations still has to be elucidated, these data will contribute to future risk stratification for the treatment of pediatric AML. J Clin Oncol 28:2682-2689. (C) 2010 by American Society of Clinical Oncology","[von Neuhoff, Christine] Hannover Med Sch, D-30625 Hannover, Germany; Univ Giessen, Oncogenet Lab, Giessen, Germany; Univ Munster, Childrens Hosp, Munster, Germany; Our Ladys Childrens Hosp, Natl Ctr Med Genet, Dublin, Ireland; Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague, Czech Republic; Charles Univ Prague, Fac Med 1, Prague, Czech Republic; Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; Univ Zurich, Zurich, Switzerland; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria","von Neuhoff, C, Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany","neuhoff.christine.von@mh-hannover.de","Deutsche Krebshilfe e.V. [70-320/70-2315-Ri 4]; Center of Oncocytogenetics, Charles University in Prague [MSM0021620813]","Supported by Deutsche Krebshilfe e.V. Grant No. 70-320/70-2315-Ri 4, research grant (Center of Oncocytogenetics, Charles University in Prague) MSM0021620813.",null,62,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2009.25.6321","J CLIN ONCOL","J. Clin. Oncol.","JUN 1",2010,28,16,null,null,null,2682,2689,null,null,8,"Oncology","601ZV","ISI:000278108800006"]
["nemá","J","Jelinek, M; Smetana, K; Kocourek, T; Dvorankova, B; Zemek, J; Remsa, J; Luxbacher, T",null,null,null,"Jelinek, M.; Smetana, K.; Kocourek, T.; Dvorankova, B.; Zemek, J.; Remsa, J.; Luxbacher, T.",null,"Biocompatibility and sp(3)/sp(2) ratio of laser created DLC films","MATERIALS SCIENCE AND ENGINEERING B-ADVANCED FUNCTIONAL SOLID-STATE MATERIALS",null,"English","Proceedings Paper","1st European and International Conference on Bioinspired and Biointegrated Materials as New Frontiers Nanomaterials held at the 2009 EMRS Spring Meeting","JUN 08-12, 2009","Strasbourg, FRANCE","European Mat Res Sci",null,"Biocompatibility; Thin films; DLC; Laser ablation; In vitro; Zeta potential","ION IMPLANTATION-DEPOSITION; AMORPHOUS-CARBON FILMS; THIN-FILMS; DIAMOND; PHOTOELECTRON; SPECTROSCOPY","Thin diamond-like carbon (DLC) films of various diamond/graphitic content were created using pulsed laser deposition method. \"Diamond\" sp(3) concentration in region from 32% to 62% was determined using X-ray photoelectron and Auger spectroscopy (XPS/XAES). Zeta potential test was conducted to measure electric surface properties. In vitro test of DLC layers was arranged using normal human fibroblasts. The study was stressed on cytotoxicity, adhesion and cell proliferation. Correlations between sp(3), sp(2) bonds and surface and biological properties of DLC layers are discussed. (c) 2010 Elsevier B.V. All rights reserved.","[Jelinek, M.; Kocourek, T.; Zemek, J.; Remsa, J.] Inst Phys ASCR, Prague 18221 8, Czech Republic; [Jelinek, M.; Kocourek, T.] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Smetana, K.; Dvorankova, B.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Smetana, K.; Dvorankova, B.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Luxbacher, T.] Anton Paar GmbH, A-8054 Graz, Austria","Jelinek, M, Inst Phys ASCR, Na Slovance 2, Prague 18221 8, Czech Republic","jelinek@fzu.cz",null,null,null,26,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0921-5107",null,"10.1016/j.mseb.2010.01.010","MATER SCI ENG B-ADV FUNCT SOL","Mater. Sci. Eng. B-Adv. Funct. Solid-State Mater.","MAY 25",2010,169,"2010-03-01",null,null,"Sp. Iss. SI",89,93,null,null,5,"Materials Science, Multidisciplinary; Physics, Condensed Matter","608MP","ISI:000278588700017"]
["nemá","J","Pokorna, M; Necas, E; Kratochvil, J; Skripsky, R; Andrlik, M; Franek, O",null,null,null,"Pokorna, Milana; Necas, Emanuel; Kratochvil, Jaroslav; Skripsky, Roman; Andrlik, Michal; Franek, Ondrej",null,"A SUDDEN INCREASE IN PARTIAL PRESSURE END-TIDAL CARBON DIOXIDE (PETCO2) AT THE MOMENT OF RETURN OF SPONTANEOUS CIRCULATION","JOURNAL OF EMERGENCY MEDICINE",null,"English","Article",null,null,null,null,null,"cardiac arrest; advanced life support; capnography; end-tidal carbon dioxide; return of spontaneous circulation; asynchronous compression-ventilation; cardiopulmonary resuscitation","HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; NONINVASIVE MONITOR; CO2; OUTPUT","Background: Previous studies established that a level of partial pressure end-tidal carbon dioxide (PETCO2) of 10 mm Hg divided patients undergoing advanced life support (ALS) into those likely to be resuscitated (values > 10 mm Hg) and those likely to die during ALS (values < 10 mm Hg). Objective: The study tested the significance of a sudden increase in the PETCO2 in signaling the return of spontaneous circulation (ROSC) during ALS. Material and Methods: PETCO2 values were continuously recorded during ALS in out-of-hospital patients with cardiac arrest. Constant ventilation was maintained by an automatic device. There were 108 patients, representing two extreme outcomes of ALS, who were subdivided into two groups. The first group included 59 patients with a single ROSC followed by a stable spontaneous circulation. The second group included 49 patients with no signs of ROSC. Results: ROSC was associated with a sudden increase in PETCO2 that remained significantly higher than before ROSC. PETCO2 did not rise during the entire ALS in the second group of patients without ROSC and was lower than in the first group of patients. Conclusions: In constantly ventilated patients, PETCO2 is significantly higher (about 10 mm Hg) after ROSC than before ROSC. A sudden increase in PETCO2 exceeding 10 mm Hg may indicate ROSC. Consequently, the rule of 10 mm Hg may be extended to include a sudden increase in continuously recorded PETCO2 by more than 10 mm Hg as an indicator of the possibility of ROSC. (C) 2010 Elsevier Inc.","[Pokorna, Milana; Kratochvil, Jaroslav; Skripsky, Roman; Franek, Ondrej] Emergency Med Serv Prague, Prague 10100, Czech Republic; [Pokorna, Milana] Univ Hosp Motol, Dept Emergency Med, Prague, Czech Republic; [Necas, Emanuel; Andrlik, Michal] Charles Univ Prague, Fac Med 1, Dept Pathophysiol, Prague, Czech Republic; [Kratochvil, Jaroslav] Univ Hosp Na Bulovce, Dept Internal Med 2, Prague, Czech Republic; [Skripsky, Roman] Thomayer Univ Hosp, Dept Anaesthesiol & Resuscitat, Prague, Czech Republic","Pokorna, M, Emergency Med Serv Prague, Korunni 98, Prague 10100, Czech Republic",null,"Ministry of Health of the Czech Republic [IGA NR/7970-3]; Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806]","This work is a part of the study \"Sudden cardiac arrest in out-of-hospital care. Analysis of causes and comparison of different methods recommended for circulatory restoration.\" The study was financially supported from the grant IGA NR/7970-3 provided by the Ministry of Health of the Czech Republic and by the project MSM 0021620806 of the Ministry of Education, Youth and Sports of the Czech Republic. The authors would like to acknowledge all contributors, Drs.: T. Garnol, M. Sykorova, A. Skoupy, R. Zub, K. Kucera, D. Kobr, J. Knor, J. Vosatka, T. Charvat, M. Uher, J. Valasek, who collaborated in collection of P<INF>ET</INF>CO<INF>2</INF> data; Dr. Z. Schwarz who provided general support for the study and all cooperative physicians of Prague's hospitals and departments of pathology.",null,26,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0736-4679",null,"10.1016/j.jemermed.2009.04.064","J EMERG MED","J. Emerg. Med.","JUN",2010,38,5,null,null,null,614,621,null,null,8,"Emergency Medicine","610NH","ISI:000278739200012"]
["nemá","J","Drevinek, P; Mahenthiralingam, E",null,null,null,"Drevinek, P.; Mahenthiralingam, E.",null,"Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence","CLINICAL MICROBIOLOGY AND INFECTION",null,"English","Review",null,null,null,null,null,"Burkholderia cepacia; epidemiology; genomics; multilocus; review; sequence typing; virulence factors","SURVIVAL IN-VIVO; CONTROLS BIOFILM FORMATION; QUORUM-SENSING SYSTEM; CEPACIA-COMPLEX; PSEUDOMONAS-CEPACIA; GENOMOVAR-III; SP-NOV; ORNIBACTIN BIOSYNTHESIS; GLOBAL EPIDEMIOLOGY; OXIDATIVE STRESS","P>Burkholderia cepacia complex (Bcc) bacteria have gained notoriety as pathogens in cystic fibrosis (CF) because they are difficult to identify and treat, and also have the ability to spread between CF individuals. Of the 17 formally named species within the complex, Burkholderia multivorans and Burkholderia cenocepacia dominate in CF. Multilocus sequence typing has proven to be a very useful tool for tracing the global epidemiology of Bcc bacteria and has shown that B. cenocepacia strains with high transmissibility, such as the ET-12 strain (ST-28) and the Czech strain (ST-32), have spread epidemically within CF populations in Canada and Europe. The majority of research on the molecular pathogenesis of Bcc bacteria has focused on the B. cenocepacia ET-12 epidemic lineage, with gene mutation, genome sequence analysis and, most recently, global gene expression studies shedding considerable light on the virulence and antimicrobial resistance of this pathogen. These studies demonstrate that the ability of B. cenocepacia to acquire foreign DNA (genomic islands, insertion sequences and other mobile elements), regulate gene expression via quorum sensing, compete for iron during infection, and mediate antimicrobial resistance and inflammation via its membrane and surface polysaccharides are key features that underpin the virulence of different strains. With the wealth of molecular knowledge acquired in the last decade on B. cenocepacia strains, we are now in a much better position to develop strategies for the treatment of pathogenic colonization with Bcc and to answer key questions on pathogenesis concerning, for example, the factors that trigger the rapid clinical decline in CF patients.","[Drevinek, P.] Charles Univ Prague, Dept Paediat, Sch Med 2, Prague 15006, Czech Republic; [Mahenthiralingam, E.] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales","Drevinek, P, Charles Univ Prague, Dept Paediat, Sch Med 2, Uvalu 84, Prague 15006, Czech Republic","pavel.drevinek@Lfmotol.cuni.cz","Czech Ministry of Education [MSM0021620812]; Czech Ministry of Health [NS 10543-3]; Cystic Fibrosis Foundation [MAHENT06V0]","P. Drevinek acknowledges support from the Czech Ministry of Education (grant MSM0021620812) and the Czech Ministry of Health (grant NS 10543-3). E. Mahenthiralingam acknowledges the support for the B. cenocepacia microarray program provided by the Cystic Fibrosis Foundation (grant MAHENT06V0).",null,83,1,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1198-743X",null,"10.1111/j.1469-0691.2010.03237.x","CLIN MICROBIOL INFECT","Clin. Microbiol. Infect.","JUL",2010,16,7,null,null,null,821,830,null,null,10,"Infectious Diseases; Microbiology","609HC","ISI:000278645700004"]
["nemá","J","Lane, JC; Warady, BA; Feneberg, R; Majkowski, NL; Watson, AR; Fischbach, M; Kang, HG; Bonzel, KE; Simkova, E; Stefanidis, CJ; Klaus, G; Alexander, SR; Ekim, M; Bilge, I; Schaefer, F",null,null,null,"Lane, Jerome C.; Warady, Bradley A.; Feneberg, Reinhard; Majkowski, Nancy L.; Watson, Alan R.; Fischbach, Michel; Kang, Hee Gyung; Bonzel, Klaus E.; Simkova, Eva; Stefanidis, Constantinos J.; Klaus, Guenter; Alexander, Steven R.; Ekim, Mesiha; Bilge, Ilmay; Schaefer, Franz","IPPR","Relapsing Peritonitis in Children Who Undergo Chronic Peritoneal Dialysis: A Prospective Study of the International Pediatric Peritonitis Registry","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,"English","Article",null,null,null,null,null,null,"GUIDELINES","Background and objectives: The International Pediatric Peritonitis Registry (IPPR) was established to collect prospective data regarding peritoneal dialysis (PD)-associated peritonitis in children. In this report, we present the IPPR results that pertain to relapsing peritonitis (RP). Design, setting, participants, & measurements: This was an online, prospective entry into the IPPR of data that pertain to peritonitis cases by participating centers. Results: Of 490 episodes of nonfungal peritonitis, 52 (11%) were followed by a relapse. There was no significant difference between RP and non-RP in distribution of causative organisms and antibiotic sensitivities. Initial empiric therapy ceftazidime with either first-generation cephalosporin or glycopeptide (vancomycin or teicoplanin) was not associated with relapse. Switching to monotherapy with a first-generation cephalosporin on the basis of culture results was associated with higher relapse rate (23%) than other final antibiotic therapies (0 to 9%). Culture-negative RP was less likely to have a satisfactory early treatment response than non-RP (82 versus 98%). Young age, single-cuff catheter, downward-pointing exit site, and chronic systemic antibiotic prophylaxis were additional independent risk factors for RP in the multivariate analysis. Compared with non-RP, RP was associated with a lower rate of full functional recovery (73 versus 91%), higher ultrafiltration problems (14 versus 2%), and higher rate of permanent PD discontinuation (17 versus 7%). Conclusions: This is the largest multicenter, prospective study to date to examine RP in children. In addition, this is the first report in the literature to examine specifically the relationship of postempiric antibiotic treatment regimens to the subsequent risk for relapse. Clin J Am Soc Nephrol 5: 1041-1046, 2010. doi: 10.2215/CJN.05150709","[Lane, Jerome C.] Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Dept Pediat,Div Kidney Dis, Chicago, IL 60614 USA; [Warady, Bradley A.] Childrens Mercy Hosp, Pediat Nephrol Sect, Kansas City, MO 64108 USA; [Feneberg, Reinhard; Schaefer, Franz] Univ Heidelberg, Ctr Pediat & Adolescent Med, Pediat Nephrol Div, Heidelberg, Germany; [Lane, Jerome C.; Majkowski, Nancy L.] DaVita Childrens Dialysis Ctr, Chicago, IL USA; [Watson, Alan R.] Univ Nottingham Hosp, Childrens Renal & Urol Unit, Nottingham NG7 2UH, England; [Fischbach, Michel] Univ Strasbourg, Hop Hautepierre, Dept Pediat, Strasbourg, France; [Kang, Hee Gyung] Seoul Natl Univ, Childrens Hosp, Dept Pediat, Seoul, South Korea; [Bonzel, Klaus E.] Univ Essen Gesamthsch, Dept Pediat Nephrol, Essen, Germany; [Simkova, Eva] Motol Childrens Hosp, Pediat Nephrol Div, Prague, Czech Republic; [Stefanidis, Constantinos J.] Univ Athens, Dept Pediat, Athens, Greece; [Klaus, Guenter] KfH Kidney Ctr Children & Adolescents, Marburg, Germany; [Alexander, Steven R.] Stanford Univ, Lucille Salter Packard Childrens Hosp, Palo Alto, CA 94304 USA; [Ekim, Mesiha] Ankara Univ, Sch Med, Dept Pediat Nephrol, TR-06100 Ankara, Turkey; [Bilge, Ilmay] Istanbul Univ, Fac Med, Dept Pediat Nephrol, Istanbul, Turkey","Lane, JC, Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Dept Pediat,Div Kidney Dis, 2300 Childrens Plaza,Box 37, Chicago, IL 60614 USA","j-lane@northwestern.edu","International Society for Peritoneal Dialysis ; Baxter Health Care ","The TPPR was funded by grants provided by the International Society for Peritoneal Dialysis and Baxter Health Care.",null,15,0,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,"10.2215/CJN.05150709","CLIN J AM SOC NEPHROL","Clin. J. Am. Soc. Nephrol.","JUN",2010,5,6,null,null,null,1041,1046,null,null,6,"Urology & Nephrology","608OY","ISI:000278596200014"]
["nemá","J","Brizova, H; Kalinova, M; Krskova, L; Mrhalova, M; Kodet, R",null,null,null,"Brizova, Helena; Kalinova, Marketa; Krskova, Lenka; Mrhalova, Marcela; Kodet, Roman",null,"A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase II alpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma","VIRCHOWS ARCHIV",null,"English","Article",null,null,null,null,null,"Real-time PCR; Proliferation markers; Ki-67; Topoisomerase II alpha; TPX2; Mantle cell lymphoma; Mol Pathol; Quantitative Path; Lymphoma","CYCLIN D1 OVEREXPRESSION; EUROPEAN-MCL-NETWORK; PROGNOSTIC-FACTORS; MESSENGER-RNA; EXPRESSION; SURVIVAL; FEATURES; PROTEIN; GENE; IDENTIFICATION","A clinical course of patients with mantle cell lymphoma (MCL) is aggressive, and the disease is rarely curable. Proliferation rate is the most important prognostic factor. We developed a novel, reliable, rapid, and routinely applicable approach allowing a precise quantitative assessment of three proliferation markers, Ki-67, topoisomerase II alpha, and TPX2. A total of 95 lymphoma specimens were measured in the study by real-time reverse transcription PCR (RQ-RT-PCR). We tested the reproducibility and accuracy of the assay and correlated the results with the immunohistochemical staining of the corresponding proteins. The results obtained indicated individual variability of the mRNA expression levels, reflecting heterogeneity of the proliferation rate in individual patients. In general, we observed the highest mRNA expression in the group of Burkitt lymphomas and the lowest in patients with reactive lymphadenopathies. We found increased proliferation rate in MCLs with high cyclin D1 mRNA, indicating a quantitative control of the cell cycle. We observed a correlation between mRNA expression level and the immunohistochemical staining of corresponding proteins, which significantly argues for the prognostic significance of the mRNA expression measuring. We confirmed the accuracy of the current assay for a precise quantitative examination of the proliferation activity. Real-time RT-PCR provides a novel approach applicable for clinical trials, and it represents a potent approach allowing to stratify MCL patients for entry into clinical trials according to the expression of the proliferation signature genes in their tumors. This approach may contribute to improved and individualized therapeutic options respecting the individual progression risk of patients with MCL.","[Brizova, Helena; Kalinova, Marketa; Krskova, Lenka; Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Brizova, Helena; Kalinova, Marketa; Krskova, Lenka; Mrhalova, Marcela; Kodet, Roman] Fac Hosp Motol, Prague 15006 5, Czech Republic","Brizova, H, Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, V Uvalu 84, Prague 15006 5, Czech Republic","helena.brizova@fnmotol.cz","Internal grant of faculty hospital in Motol [9756, GAUK 46/2006/C/2.LF]; Ministry of Health [00064203/6704]","This work was supported by the Internal grant of faculty hospital in Motol no. 9756, Grant GAUK 46/2006/C/2.LF, and the Research project of the Ministry of Health no. 00064203/6704. We thank Dr. W. Klapper and the late Prof. Dr. R. Parwaresh (Department of Hematopathology and Lymph Node Registry, University Hospitals of Schleswig-Holstein, Kiel, Germany) who kindly provided us a sample of the antibody Ki-S2 against TPX2.",null,36,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0945-6317",null,"10.1007/s00428-010-0922-8","VIRCHOWS ARCHIV","Virchows Arch.","JUN",2010,456,6,null,null,null,671,679,null,null,9,"Pathology","605RD","ISI:000278363800010"]
["nemá","J","Sochman, J; Peregrin, JH; Burgelova, M; Kopkan, L; Kramer, HJ; Cervenka, L",null,null,null,"Sochman, Jan; Peregrin, Jan H.; Buergelova, Marcela; Kopkan, Libor; Kramer, Herbert J.; Cervenka, Ludek",null,"N-Acetylcysteine Attenuates Iodine Contrast Agent-Induced Nephropathy in 5/6-Nephrectomized Rats","KIDNEY & BLOOD PRESSURE RESEARCH",null,"English","Article",null,null,null,null,null,"Iodine contrast agent-induced nephropathy; Iohexol; Meglumine-ioxithalamate; N-acetylcysteine; 5/6-Nephrectomized Wistar rats","RADIOCONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; SODIUM-BICARBONATE; CARDIAC-SURGERY; OXYGEN-TENSION; NITRIC-OXIDE; PREVENTION; MEDIA; METAANALYSIS","Aims: In the present study we tested the efficacy of N-acetylcysteine (NAC) to minimize nephrotoxic effects of iodine contrast agents in intact rats as well as in 5/6-nephrectomized (5/6-Nx) rats. Methods: Rats were allocated to a group of intact rats (n = 42) and a group of 5/6-Nx rats (n = 42). After 1 month of recovery from surgery, 5/6-Nx rats and intact (sham-operated) animals received either 6 ml/kg body weight (b.w.) meglumine ioxithalamate (Telebrix 350) or 6 ml/kg b.w. iohexol (Omnipaque 350) intravenously with or without pretreatment with 100 mg/kg b.w. NAC. Plasma and urinary concentrations of creatinine, sodium and protein in 24-hour urine collections were determined prior to and on days 1, 3 and 7 after drug administration. Results: In intact animals, contrast agents caused no significant changes in kidney function throughout the duration of the experiment. In contrast, significant increases in plasma creatinine levels and decreases in creatinine clearance were induced by both contrast agents in 5/6-Nx rats. These changes were significantly attenuated by NAC pretreatment. Conclusion: The results of the present study demonstrate that iodine contrast agent-induced nephropathy in 5/6-Nx rats is significantly attenuated by intravenous pretreatment with NAC. Copyright (C) 2010 S. Karger AG, Basel","[Kopkan, Libor; Cervenka, Ludek] Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Sochman, Jan] Charles Univ Prague, Dept Cardiol, CZ-14000 Prague, Czech Republic; [Peregrin, Jan H.] Charles Univ Prague, Dept Diagnost & Intervent Radiol, CZ-14000 Prague 4, Czech Republic; [Buergelova, Marcela] Charles Univ Prague, Nephrol & Transplant Ctr, CZ-14000 Prague 4, Czech Republic; [Kopkan, Libor] Charles Univ Prague, Cardiovasc Res Ctr, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, CZ-14000 Prague 4, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany","Cervenka, L, Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Institute for Clinical and Experimental Medicine [MZO 00023001]; EU [CZ.2.16/3.1.00/22126]; Grant Agency of Academy of Science of Czech Republic [GAAV - IAA 511-700-701]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9699-4]; Czech Science Foundation [NS/10499-3 (IGA), 305/08/J006]; Center for Cardiovascular Research [1M6798582302]; German Research Foundation (DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]","This study was supported by institutional finance support from the Institute for Clinical and Experimental Medicine (#MZO 00023001). It was also supported by financial support from the EU by the Operational Program Prague - Competitiveness; Project 'CEVKOON' (#CZ.2.16/3.1.00/22126). L. K. is supported by a grant from the Grant Agency of Academy of Science of Czech Republic (GAAV - IAA 511-700-701) and by grant No. NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. L. C. is currently supported by grant No. NS/10499-3 (IGA) and by grant No. 305/08/J006 awarded by the Czech Science Foundation and also by financial support from the Center for Cardiovascular Research (#1M6798582302). H.J.K. is supported by grants from the German Research Foundation (DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1).",null,55,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,"10.1159/000315435","KIDNEY BLOOD PRESSURE RES","Kidney Blood Pressure Res.",null,2010,33,2,null,null,null,149,156,null,null,8,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","606CK","ISI:000278398500008"]
["nemá","J","Nyc, O; Matejkova, J",null,null,null,"Nyc, O.; Matejkova, J.",null,"Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review","FOLIA MICROBIOLOGICA",null,"English","Review",null,null,null,null,null,null,"GRAM-NEGATIVE BACILLI; CYSTIC-FIBROSIS; ANTIMICROBIAL SUSCEPTIBILITY; XANTHOMONAS-MALTOPHILIA; ACINETOBACTER-BAUMANNII; CLINICAL STRAINS; RISK-FACTORS; INFECTIONS; RESISTANCE; EMERGENCE","Stenotrophomonas maltophilia (Sm) plays an important role as an opportunistic pathogen in immunocompromised individuals. The growing detection rates of this bacterium in hospitalized patients are associated with the invasiveness of therapeutic and diagnostic procedures and the selection pressure of antibiotic therapy. A broad range of infections that can be caused by Sm is frequently bound to biofilm. The high level of intrinsic resistance to many unrelated antibiotics and increasing acquired resistance to the drug of choice, trimethoprim-sulfamethoxazole pose a threat for the near future when our treatment options may become depleted. Prevention of colonization and infection consists in consequent implementation of the rules governing nosocomial infection control, rational use of antibiotics including the optimization of selection and testing of antimicrobial agents suitable for the treatment of stenotrophomonad infections.","[Nyc, O.; Matejkova, J.] Charles Univ Prague, Dept Clin Microbiol, Fac Med 2, Prague 15006, Czech Republic","Nyc, O, Charles Univ Prague, Dept Clin Microbiol, Fac Med 2, Prague 15006, Czech Republic",null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [9138-3/2007]","This work was partially supported by grant of the Internal Grant Agency of the Ministry of Health of the Czech Republic (no. 9138-3/2007).",null,55,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,"10.1007/s12223-010-0043-4","FOLIA MICROBIOL PRAGUE","Folia Microbiol.","MAY",2010,55,3,null,null,null,286,294,null,null,9,"Biotechnology & Applied Microbiology; Microbiology","607AA","ISI:000278469400015"]
["nemá","J","Brozkova, D; Mazanec, R; Haberlova, J; Sakmaryova, I; Seeman, P",null,null,null,"Brozkova, D.; Mazanec, R.; Haberlova, J.; Sakmaryova, I.; Seeman, P.",null,"Clinical and in silico evidence for and against pathogenicity of 11 new mutations in the MPZ gene","CLINICAL GENETICS",null,"English","Article",null,null,null,null,null,"CMT; CMT1B; hereditary neuropathy; HMSN III; MPZ; P0","MARIE-TOOTH-DISEASE; HEREDITARY NEUROPATHY; PRESSURE PALSIES; LATE-ONSET; PHENOTYPES; LIABILITY; 1B","Mutations in the myelin protein zero (MPZ) gene are one of the frequent causes of Charcot-Marie-Tooth (CMT) hereditary neuropathies. Because the mutation rate of MPZ gene is rather high and some mutations are reported as polymorphisms, the proper clinical, electrophysiological examination and the segregation of the new mutation in larger families are crucial for the correct interpretation of the pathogenic or non-pathogenic character of each novel mutation. We examined 11 families with novel MPZ mutations. Eight of the mutations (L48Q, T65N, E97fs, G103W, P132T, T143R, V146G, c. 645+ 1G>T) seem to be pathogenic on the basis of perfect segregation with the CMT phenotype and two (G213R and D246N), on the contrary, seem to be non-pathogenic/rare polymorphisms because they are present in healthy relatives. The character of the V46M mutation is difficult to interpret definitely; it may cause a sensory neuropathy or may also be a rare polymorphism. Phenotypes associated with each of the new mutations include severe hereditary motor and sensory neuropathy type III (HMSN III), and mild phenotype CMT1B presented mostly with only decreased or absent reflexes, foot deformities and mild or even absent atrophies in the lower limbs. Our report and careful family investigations with genotype-phenotype correlations should help to improve genetic counselling and correct interpretation of DNA testing results in further isolated patients or smaller families worldwide where these novel mutations might be found.","[Brozkova, D.; Haberlova, J.; Sakmaryova, I.; Seeman, P.] Charles Univ Prague, Sch Med 2, DNA Lab, Dept Child Neurol, Prague 15006, Czech Republic; [Mazanec, R.] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague 15006, Czech Republic; Univ Hosp Motol, Prague 15006, Czech Republic","Brozkova, D, Charles Univ Prague, Sch Med 2, DNA Lab, Dept Child Neurol, V Uvalu 84, Prague 15006, Czech Republic","dana.brozkova@seznam.cz","IGA MH CR NS [10552-3]","The project was supported by grant IGA MH CR NS 10552-3.",null,18,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0009-9163",null,"10.1111/j.1399-0004.2010.01423.x","CLIN GENET","Clin. Genet.","JUL",2010,78,1,null,null,null,81,87,null,null,7,"Genetics & Heredity","606CB","ISI:000278397300013"]
["nemá","J","Vytasek, R; Sedova, L; Vilim, V",null,null,null,"Vytasek, Richard; Sedova, Liliana; Vilim, Vladimir",null,"Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis","BMC MUSCULOSKELETAL DISORDERS",null,"English","Article",null,null,null,null,null,null,"STRESS MARKER LEVELS; DISEASE-ACTIVITY; INFLAMMATORY MARKERS; PLASMA PENTOSIDINE; MAILLARD REACTION; IGG ANTIBODIES; SYNOVIAL-FLUID; PROTEINS; N-EPSILON-(CARBOXYETHYL)LYSINE; GLYCOSYLATION","Background: Levels of pentosidine ( representative of advanced glycation end-products) in sera of patients with rheumatoid arthritis are increased when compared with sera of other diagnoses or healthy controls. These levels have been reported to correlate with clinical indices of rheumatoid arthritis activity and with laboratory markers of inflammation. The purpose of this study was to find out if these findings pertain to other advanced glycation end-products. Methods: We have developed two immunoassays based on new monoclonal antibodies to advanced glycation end-products. Antibody 103-E3 reacts with an unidentified antigen, formed in the reaction of proteins with ribose, while antibody 8-C1 responds to N-epsilon-(carboxyethyl)lysine. We have used these monoclonal antibodies to measure levels of advanced glycation end-products in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and healthy controls. We calculated the correlations between advanced glycation end-product levels in rheumatoid arthritis sera and the Disease Activity Score 28 (DAS28), age, disease duration, CRP, anti-CCP, rheumatoid factor and treatment with corticosteroids, respectively. Results: Levels of both glycation products were significantly higher in sera of patients with rheumatoid arthritis when compared with sera of patients with systemic lupus erythematosus, osteoarthritis, or the healthy controls. Neither the level of N-epsilon-(carboxyethyl) lysine nor the level of the 103-E3 antigen in rheumatoid arthritis sera correlated with the DAS28-scored rheumatoid arthritis activity. The levels of both antigens in rheumatoid arthritis sera did not correlate with age, gender, corticosteroid treatment, or levels of CRP, anti-CCP antibodies, and rheumatoid factor in sera. Conclusions: We report highly specific increases in the levels of two advanced glycation end-products in sera of patients with rheumatoid arthritis. This increase could be explained neither by rheumatoid arthritis activity nor by inflammation. We propose a working hypothesis that presumes the existence of a link between advanced glycation end-product formation and induction of autoimmunity.","[Sedova, Liliana; Vilim, Vladimir] Inst Rheumatol, CZ-12850 Prague, Czech Republic; [Vytasek, Richard] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, CZ-15006 Prague, Czech Republic","Vilim, V, Inst Rheumatol, Na Slupi 4, CZ-12850 Prague, Czech Republic","vili@revma.cz","IGA [NR/9122-4]","This study was supported by grant NR/9122-4 from IGA, MZ(sic)R. We are greatly indebted to Prof. C. Dostal for providing sera of patients with SLE, to Dr L. Senolt for providing sera of patients with OA, and to Dr M. Braun for sharing serum samples with known concentration of pentosidine. We thank all members of our \"healthy controls\" cohort for donation of sera, and M. Horackova a H. (sic)erna for technical assistance.",null,45,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2474",null,"10.1186/1471-2474-11-83","BMC MUSCULOSKELET DISORD","BMC Musculoskelet. Disord.","MAY 3",2010,11,null,null,null,null,null,null,83,null,11,"Orthopedics; Rheumatology","605ZY","ISI:000278390900001"]
["nemá","J","Ostadal, P; Alan, D; Vejvoda, J; Kukacka, J; Macek, M; Hajek, P; Mates, M; Kvapil, M; Kettner, J; Wiendl, M; Aschermann, O; Slaby, J; Holm, F; Telekes, P; Horak, D; Blasko, P; Zemanek, D; Veselka, J; Cepova, J",null,null,null,"Ostadal, Petr; Alan, David; Vejvoda, Jiri; Kukacka, Jiri; Macek, Milan; Hajek, Petr; Mates, Martin; Kvapil, Milan; Kettner, Jiri; Wiendl, Martin; Aschermann, Ondrej; Slaby, Josef; Holm, Frantisek; Telekes, Peter; Horak, David; Blasko, Peter; Zemanek, David; Veselka, Josef; Cepova, Jana",null,"Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)","TRIALS",null,"English","Article",null,null,null,null,null,null,"ACUTE MYOCARDIAL-INFARCTION; PLASMA PROTEIN-A; UNSTABLE ANGINA; STATIN THERAPY; ATORVASTATIN TREATMENT; REPERFUSION; SIMVASTATIN; ELEVATION; PATHWAY; EVENTS","Background: Statins have been proved to be effective in reduction of mortality and morbidity when started in the early secondary prevention in stabilized patients after acute coronary syndrome (ACS). The safety and efficacy of statin administration directly in the first-line therapy in unstable ACS patients is not clear. The aim of our study was, therefore, to assess the effect of statin treatment initiated immediately at hospital admission of patients with ACS. Methods: The trial was stopped prematurely after enrollment of one hundred and fifty-six patients with ACS that were randomized at admission to fluvastatin 80 mg (N = 78) or placebo (N = 78). Study medication was administered immediately after randomization and then once daily for 30 days; all patients were then encouraged to continue in open-label statin therapy and at the end of one-year follow-up 75% in the fluvastatin group and 78% in the placebo group were on statin therapy. Results: We did not demonstrate any difference between groups in the level of C-reactive protein, interleukin 6, and pregnancy-associated plasma protein A on Day 2 and Day 30 (primary endpoint). Fluvastatin-therapy, however, significantly reduced one-year occurrence of major adverse cardiovascular events (11.5% vs. 24.4%, odds ratio (OR) 0.40, 95% CI 0.17-0.95, P = 0.038). This difference was caused mainly by reduction of recurrent symptomatic ischemia (7.7% vs. 20.5%, OR 0.32, 95% CI 0.12-0.88, P = 0.037). Conclusions: This study failed to prove the effect of fluvastatin given as first-line therapy of ACS on serum markers of inflammation and plaque instability. Fluvastatin therapy was, however, safe and it may reduce cardiovascular event rate that supports immediate use of a statin in patients admitted for ACS.","[Ostadal, Petr; Mates, Martin; Aschermann, Ondrej] Na Homolce Hosp, Ctr Heart, Dept Cardiol, Prague, Czech Republic; [Alan, David; Vejvoda, Jiri; Hajek, Petr; Zemanek, David; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Prague, Czech Republic; [Kukacka, Jiri; Cepova, Jana] Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Prague, Czech Republic; [Kukacka, Jiri; Macek, Milan; Kvapil, Milan; Cepova, Jana] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Macek, Milan] Univ Hosp Motol, Inst Biol & Med Genet, Prague, Czech Republic; [Kvapil, Milan] Univ Hosp Motol, Dept Internal Med, Prague, Czech Republic; [Kettner, Jiri; Wiendl, Martin] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Slaby, Josef] Hosp Kolin, Dept Med, Kolin, Czech Republic; [Holm, Frantisek; Telekes, Peter; Horak, David] Reg Hosp Liberec, Dept Cardiol, Liberec, Czech Republic; [Blasko, Peter] Fac Hosp Nitra, Dept Internal Med, Nitra, Slovakia","Ostadal, P, Na Homolce Hosp, Ctr Heart, Dept Cardiol, Prague, Czech Republic","ostadal@yahoo.com","Czech Ministry of Health [00000064203]; Novartis Pharma Czech republic ","The FACS trial was supported by the Czech Ministry of Health and by Novartis Pharma Czech republic. Moreover, authors received research funds, consultancy honoraria, and speakers honoraria from AstraZeneca, Hoffman La Roche, Novartis, Pfizer, and Servier. The FACS trial was supported by the grant of the Czech Ministry of Health, No. 00000064203. Study medication, insurance, and clinical monitoring were kindly sponsored by Novartis Pharma Czech Republic.",null,24,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1745-6215",null,"10.1186/1745-6215-11-61","TRIALS","Trials","MAY 25",2010,11,null,null,null,null,null,null,61,null,8,"Medicine, Research & Experimental","621BP","ISI:000279548900001"]
["nemá","J","Adam, V; Petrlova, J; Wang, J; Eckschlager, T; Trnkova, L; Kizek, R",null,null,null,"Adam, Vojtech; Petrlova, Jitka; Wang, Joseph; Eckschlager, Tomas; Trnkova, Libuse; Kizek, Rene",null,"Zeptomole Electrochemical Detection of Metallothioneins","PLOS ONE",null,"English","Article",null,null,null,null,null,null,"PLASMA-MASS SPECTROMETRY; CANCER; CHRONOPOTENTIOMETRY; SPECIATION; PROTEOMICS; PROTEINS; LEVEL","Background: Thiol-rich peptides and proteins possess a large number of biological activities and may serve as markers for numerous health problems including cancer. Metallothionein (MT), a small molecular mass protein rich in cysteine, may be considered as one of the promising tumour markers. The aim of this paper was to employ chronopotentiometric stripping analysis (CPSA) for highly sensitive detection of MT. Methodology/Principal Findings: In this study, we used adsorptive transfer stripping technique coupled with CPSA for detection of cysteine, glutathione oxidized and reduced, phytochelatin, bovine serum albumin, and metallothionein. Under the optimal conditions, we were able to estimate detection limits down to tens of fg per ml. Further, this method was applied to detect metallothioneins in blood serum obtained from patients with breast cancer and in neuroblastoma cells resistant and sensitive to cisplatin in order to show the possible role of metallothioneins in carcinogenesis. It was found that MT level in blood serum was almost twice higher as compared to the level determined in healthy individuals. Conclusions/Significance: This paper brings unique results on the application of ultra-sensitive electroanalytical method for metallothionein detection. The detection limit and other analytical parameters are the best among the parameters of other techniques. In spite of the fact that the paper is mainly focused on metallothionein, it is worth mentioning that successful detection of other biologically important molecules is possible by this method. Coupling of this method with simple isolation methods such as antibody-modified paramagnetic particles may be implemented to lab-on-chip instrument.","[Adam, Vojtech; Petrlova, Jitka; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic; [Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CS-61137 Brno, Czech Republic","Adam, V, Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic","kizek@sci.muni.cz","GAAV [IAA40199071]","Financial support from GAAV IAA40199071 is highly acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,24,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,"10.1371/journal.pone.0011441","PLOS ONE","PLoS One","JUL 6",2010,5,7,null,null,null,null,null,"e11441",null,8,"Biology; Multidisciplinary Sciences","620TI","ISI:000279522500009"]
["nemá","J","Rossnerova, A; Balascak, I; Rossner, P; Sram, RJ",null,null,null,"Rossnerova, A.; Balascak, I.; Rossner, P., Jr.; Sram, R. J.",null,"Frequency of chromosomal aberrations in Prague mothers and their newborns","MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS",null,"English","Article",null,null,null,null,null,"Carcinogenic polycyclic aromatic hydrocarbons; Chromosomal aberrations; Fluorescence in situ hybridization; Mothers; Newborns","POLYCYCLIC AROMATIC-HYDROCARBONS; IN-SITU HYBRIDIZATION; CYTOGENETIC ANALYSIS; ENVIRONMENTAL EXPOSURE; PERIPHERAL LYMPHOCYTES; AIR-POLLUTION; CANCER-RISK; AMBIENT AIR; LIFE-STYLE; FISH","The capital city of Prague is one of the most polluted areas of the Czech Republic. The impact of air pollution on the level of chromosomal aberrations was systematically studied: analyses were performed using fluorescence in situ hybridization (FISH) with whole-chromosome painting for chromosomes #1 and #4. In the present study, we analyzed the levels of stable (one-way and two-way translocations) and unstable (acentric fragments) chromosomal aberrations in 42 mothers living in Prague and in their newborns. The average age of the mothers was 29 years (range, 20-40 years). Blood samples were collected from October 2007 to February 2008. The average levels of carcinogenic polycyclic aromatic hydrocarbons (c-PAHs) and benzo[a]pyrene (B[a]P) in respirable particles (PM2.5), as determined by stationary monitoring, were 21.0 +/- 112.3 ng/m(3) and 2.9 +/- 1.8 ng/m(3), respectively. We did not observe any effect of either c-PAH or B[a]P exposure on the genomic frequency of translocations (per 100 cells, F-G/100) in either group due to their similar exposure during the winter months. The mean values of F-G/100 representing stable aberrations were 0.09 +/- 0.13 vs 0.80 +/- 0.79 (p < 0.001) for newborns vs mothers, indicating a significant increase of F-G/100 with age. On the other hand, the frequency of unstable aberrations did not differ between the two groups. Our results demonstrate how the patterns of different types of aberration differed between newborns and mothers: we observed 64.3% unstable aberrations and 35.7% stable aberrations in newborns vs 19.7% and 80.3% in mothers, respectively. Our results indicate that after birth the frequencies of aberrations are very low and that the aberrations are represented mainly by acentric fragments. The changes observed in mothers show a shift to stable aberrations represented mainly by two-way translocations. The mother's age affected the level of aberrations in newborns: the group of children born to older mothers (31-40 years) had significantly increased F-G/100 levels. (C) 2010 Elsevier B.V. All rights reserved.","[Rossnerova, A.; Rossner, P., Jr.; Sram, R. J.] AS CR, Lab Genet Ecotoxicol, Inst Expt Med, VVI, Prague 14220 4, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague 5, Czech Republic","Sram, RJ, AS CR, Lab Genet Ecotoxicol, Inst Expt Med, VVI, Videnska 1083, Prague 14220 4, Czech Republic","sram@biomed.cas.cz","Ministry of Education of the Czech Republic [2B06088]; Academy of Sciences of the Czech Republic [AVOZ50390512]","We would like to thank the gynecological staff of the University Hospital in Prague-Motol for the collection of samples, Ms. Irena Chvatalova for technical assistance during the collection and processing of samples and Mr. James Dutt for language editing. The Ministry of Education of the Czech Republic (2B06088) and the Academy of Sciences of the Czech Republic (AVOZ50390512) are gratefully acknowledged for their financial support.",null,30,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1383-5718",null,"10.1016/j.mrgentox.2010.04.015","MUTAT RES-GENET TOXICOL E M","Mutat. Res. Genet. Toxicol. Environ. Mutagen.","JUN 17",2010,699,"2010-02-01",null,null,null,29,34,null,null,6,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","620VL","ISI:000279528700006"]
["nemá","J","Kubinova, S; Horak, D; Kozubenko, N; Vanecek, V; Proks, V; Price, J; Cocks, G; Sykova, E",null,null,null,"Kubinova, Sarka; Horak, Daniel; Kozubenko, Nataliya; Vanecek, Vaclav; Proks, Vladimir; Price, Jack; Cocks, Graham; Sykova, Eva",null,"The use of superporous Ac-CGGASIKVAVS-OH-modified PHEMA scaffolds to promote cell adhesion and the differentiation of human fetal neural precursors","BIOMATERIALS",null,"English","Article",null,null,null,null,null,"Cell adhesion; Laminin; Mesenchymal stem cell; Neural cell; PolyHEMA","HYDROGELS; PEPTIDE; DEGRADATION; ATTACHMENT; OUTGROWTH; IKVAV","Modifications of poly(2-hydroxyethyl methacrylate) (PHEMA) with laminin-derived Ac-CGGASIKVAVS-OH peptide sequences have been developed to construct scaffolds that promote cell adhesion and neural differentiation. Radical copolymerization of 2-hydroxyethyl methacrylate with 2-aminoethyl methacrylate (AEMA) and ethylene dimethacrylate in the presence of ammonium oxalate crystals resulted in the formation of superporous P(HEMA-AEMA) hydrogels. They were reacted with gamma-thiobutyrolactone to yield 2-(4-sulfanylbutanamido)ethyl methacrylate (P(HEMA-AEMA)-SH) unit. The Ac-CGGASIKVAVS-OH peptide was immobilized to the sulfhydryl groups of P(HEMA-AEMA)-SH by 2,2'-dithiodipyridine linking reagent via 2-[4-(2-pyridyldisulfanyl)butanamido]ethyl methacrylate (P(HEMA-AEMA)-TPy). The adhesion and morphology of rat mesenchymal stem cells were investigated on the Ac-CGGASIKVAVS-OH-modified P(HEMA-AEMA) as well as on PHEMA, P(HEMA-AEMA)-SH and P(HEMA-AEMA)-TPy hydrogels. Superporous Ac-CGGASIKVAVS-OH-modified PHEMA scaffolds significantly increased the number of attached cells and their growth area on the hydrogel surface in the absence and in the presence of serum in the culture medium. Additionally, the Ac-CGGASIKVAVS-OH peptide supported the attachment, proliferation, differentiation and process spreading of human fetal neural stem cells during the first two weeks of expansion and contributed to the formation of a high percentage of more mature neural cells after four weeks of expansion. The Ac-CGGASIKVAVS-OH modification of superporous P(HEMA-AEMA) hydrogels improves cell adhesive properties and promotes neural stem cell differentiation. (C) 2010 Elsevier Ltd. All rights reserved.","[Horak, Daniel; Proks, Vladimir] Acad Sci Czech Republic, Inst Macromol Chem, VVI, CR-16206 Prague 6, Czech Republic; [Kubinova, Sarka; Kozubenko, Nataliya; Vanecek, Vaclav; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, VVI, Prague 14220 4, Czech Republic; [Horak, Daniel; Kozubenko, Nataliya; Vanecek, Vaclav; Proks, Vladimir; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15018 5, Czech Republic; [Price, Jack; Cocks, Graham] Kings Coll London, Ctr Cellular Basis Behav, Inst Psychiat, London SE5 9NU, England; [Vanecek, Vaclav; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic","Horak, D, Acad Sci Czech Republic, Inst Macromol Chem, VVI, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic","horak@imc.cas.cz","EC [LSHM-CT-2007-037862, AVOZ 503 90 703, 1M0538, LC 554, GAAV IAA 500 390 902, KAN200200651, P108/10/1560, GA CR 309/08/H079]","We thank James Dutt for critical reading of the manuscript. This work was supported through grants: the EC FP6 project Artemis (LSHM-CT-2007-037862), AVOZ 503 90 703, 1M0538, LC 554, GAAV IAA 500 390 902, KAN200200651, P108/10/1560, GA CR 309/08/H079.",null,30,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0142-9612",null,"10.1016/j.biomaterials.2010.04.040","BIOMATERIALS","Biomaterials","AUG",2010,31,23,null,null,null,5966,5975,null,null,10,"Engineering, Biomedical; Materials Science, Biomaterials","623DZ","ISI:000279719600007"]
["nemá","J","Liscak, R; Malikova, H; Kalina, M; Vojtech, Z; Prochazka, T; Marusic, P; Vladyka, V",null,null,null,"Liscak, Roman; Malikova, Hana; Kalina, Miroslav; Vojtech, Zdenek; Prochazka, Tomas; Marusic, Petr; Vladyka, Vilibald",null,"Stereotactic radiofrequency amygdalohippocampectomy in the treatment of mesial temporal lobe epilepsy","ACTA NEUROCHIRURGICA",null,"English","Article",null,null,null,null,null,"Temporal lobe epilepsy; Stereotactic neurosurgery; Amygdalohippocampectomy; Surgical outcome","RESECTION; SURGERY; EXTENT; RADIOSURGERY; LOBECTOMY","Minimally invasive percutaneous single trajectory stereotactic radiofrequency amygdalohippocampectomy was used to treat mesial temporal lobe epilepsy (MTLE). The aim of the study was to evaluate complications and effectiveness of this procedure. A group of 51 patients with MTLE was treated using stereotactic thermo-lesion of amygdalohippocampal complex under local anaesthesia. The target was reached through the occipital approach with a single trajectory using MRI stereotactic localisation. Thermocoagulation of the amygdalohippocampal complex was planned according to the individual anatomy of each patient. Amygdalohippocampectomy was performed using a string electrode with a 10-mm active tip, and 16-38 lesions (median = 25) were performed in all patients along the 30- to 45-mm trajectory (median = 35) in the amygdalohippocampal complex. The procedure was well tolerated by all patients with no severe permanent morbidity; meningitis was recorded in two patients (4%), hematoma was detected in four patients, clinically insignificant in three of them, and one patient required temporary ventricular drainage (2%). Thirty-two patients were followed up over at least 2 years, and the clinical outcomes were evaluated by Engel's classification; 25 of them (78%) were Engel I, five (16%) were Engel II, and two (6%) were Engel IV. Stereotactic amygdalohippocampectomy is a minimally invasive procedure with low morbidity and good results that can be the method of choice in selected patients with MTLE.","[Liscak, Roman; Vladyka, Vilibald] Hosp Homolce, Dept Stereotact & Radiat Neurosurg, Prague 15030, Czech Republic; [Malikova, Hana] Hosp Homolce, Dept Radiol, Prague 15030, Czech Republic; [Kalina, Miroslav; Vojtech, Zdenek; Prochazka, Tomas] Hosp Homolce, Dept Neurol, Prague 15030, Czech Republic; [Marusic, Petr] Charles Univ Prague, Motol Hosp, Dept Neurol, Fac Med 2, Prague, Czech Republic","Liscak, R, Hosp Homolce, Dept Stereotact & Radiat Neurosurg, Roentgenova 2, Prague 15030, Czech Republic","roman.liscak@homolka.cz",null,null,null,32,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0001-6268",null,"10.1007/s00701-010-0637-2","ACTA NEUROCHIR","Acta Neurochir.","AUG",2010,152,8,null,null,null,1291,1298,null,null,8,"Clinical Neurology; Surgery","622YV","ISI:000279704300004"]
["nemá","J","Bartak, V; Popelka, S; Hromadka, R; Pech, J; Jahoda, D; Sosna, A",null,null,null,"Bartak, V.; Popelka, S.; Hromadka, R.; Pech, J.; Jahoda, D.; Sosna, A.",null,"TOEFIT-PLUS System for Replacement of the First Metatarsophalangeal Joint","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"hallux rigidus; ToeFit; first metatarsophalangeal joint; replacement","HALLUX-RIGIDUS; GREAT TOE; ARTHROPLASTY; IMPLANT","PURPOSE OF THE STUDY Hallux rigidus is a frequent disease of the first metatarsophalangeal (MTP) joint. It is a painful condition markedly reducing joint motion. For grade-3 and grade-4 disease, as classified by Coughlin, first MTP joint replacement is another option of surgical treatment, in addition to resection arthroplasty or arthrodesis. MATERIAL AND METHODS In a group of 27 patients with symptomatic hallux rigidus, 28 MTP joint replacements using a TOEFIT-PLUS implant were carried out in the 2005-2009 period. There were 24 women and three men, with an average age of 56.3 years. The average follow-up was 24 months (range, 4 to 48). Indication for surgery included hallux rigidus in 20, conditions following Keller's arthroplasty in five, necrosis of the first metatarsus head in two cases and a condition after the Austin procedure in one patient. Pain, assessed by the Kitaoka score, and the range of joint motion;were evaluated before the surgery and at the final follow-up visit this also included the radiographic assessment of implant position and its integration. RESULTS Of the 28 implants used, nine were hemiprosthetic and 19 total joint replacements. The average time between surgery and full weight-bearing was 6.6 weeks (range, 5 to 8) in both groups. The post-operative Kitaoka score was 87.1 (68-100) as compared with the preoperative value of 36.3 (24-52), and this difference was statistically significant. The range of motion at the first MTP improved from 14.7 degrees pre-operatively to 38.5 post-operatively. There was no statistically significant difference in joint function, as assessed by the Kitaoka score and range of motion, between the two groups (hemiprosthetic vs. total joint replacements). The complications included prolonged skin healing with minor dehiscence in four cases. Revision surgery was required in three cases because of restricted joint motion associated with pain. In three cases of the total joint replacement group, there was radiographic evidence of asymptomatic osteolysis around both the phalangeal and the metatarsal component. In the hemiarthroplasty group, no osteolysis was recorded. DISCUSSION Up to now several types of implants have been developed to alleviate pain and restore and maintain the first MTP motion in patients with hallux rigidus. The TOEFIT-PLUS implant belongs to the most recent ones. Our results are in agreement with those of other currently used replacements in terms of clinical and functional evaluation. The complications recorded in our study are also similar to those reported in the literature, which include aseptic loosening, dislocation and mechanical failure of the implant. There is no consistent approach to their treatment. Arthrodesis with tricortical graft seems to be an option, but it carries a considerable risk of failure. Since in our patients aseptic loosening was recorded only in the total joint replacement group, hemiarthroplasty has recently been preferred, because it has clinical and functional outcomes as good as total joint replacement. CONCLUSIONS Our results with the use of TOEFIT-PLUS replacement show that this implant is effective in the treatment of hallux rigidus advanced stages and has good clinical outcomes, i.e., maintenance of motion at the MTP joint of the big toe, pain alleviation and early weight bearing. Since hemiarthroplasty is associated with fewer complications whose potential treatment is easier, this approach seems to have a better prospect than total joint replacement.","[Bartak, V.] 1 LF UK, Ortoped Klin 1, Prague 15000 5, Czech Republic; [Bartak, V.] FN Motol, Prague 15000 5, Czech Republic","Bartak, V, 1 LF UK, Ortoped Klin 1, V Uvalu 84, Prague 15000 5, Czech Republic","vbartak@email.cz",null,null,null,25,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2010,77,3,null,null,null,222,227,null,null,6,"Orthopedics","621EQ","ISI:000279557700008"]
["nemá","J","Meinhardt, A; Burkhardt, B; Zimmermann, M; Borkhardt, A; Kontny, U; Klingebiel, T; Berthold, F; Janka-Schaub, G; Klein, C; Kabickova, E; Klapper, W; Attarbaschi, A; Schrappe, M; Reiter, A",null,null,null,"Meinhardt, Andrea; Burkhardt, Birgit; Zimmermann, Martin; Borkhardt, Arndt; Kontny, Udo; Klingebiel, Thomas; Berthold, Frank; Janka-Schaub, Gritta; Klein, Christoph; Kabickova, Edita; Klapper, Wolfram; Attarbaschi, Andishe; Schrappe, Martin; Reiter, Alfred",null,"Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia","JOURNAL OF CLINICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"ACUTE-LYMPHOBLASTIC-LEUKEMIA; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; CHILDRENS ONCOLOGY GROUP; CENTRAL-NERVOUS-SYSTEM; ELDERLY-PATIENTS; INDUCED APOPTOSIS; CLINICAL-TRIALS; R-CHOP; ADOLESCENTS","Purpose The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined. We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL. Patients and Methods Patients younger than age 19 years with CD20(+) B-NHL with at least one measurable site were eligible. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1; concomitant therapy consisted of rasburicase, intrathecally (IT) triple drug (methotrexate, cytarabine, and prednisolone) on days 1 and 3 for CNS-positive patients and steroids only for anaphylaxis. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had >= 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity. Results From April 2004 to August 2008, 136 patients were enrolled. National Cancer Institute Common Toxicity Criteria 3/4 toxicities attributable to rituximab were general condition, 15%; fatigue, 13%; anaphylaxis, 7%; infection, 3%; glutamic-oxaloacetic transaminase/glutamic-pyruvic transaminase, 8%; no capillary leakage; and no toxic death. Forty-nine patients were not evaluable for response because of withdrawal from the study (n = 16), IT therapy in CNS-negative patients (n = 8), corticosteroid treatment (n = 3), technical inadequacy of response evaluation (n = 21), or no evaluable lesion (n = 1). Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma. A response was more frequently observed in BM (12 of 18) compared with solid tumor lesions (36 of 108; P = .007). Conclusion Rituximab is active as a single-agent in pediatric B-NHL even though the RR was lower than requested in the phase II plan.","Univ Giessen, Non Hodgkins Lymphoma Berlin Frankfurt Munster St, Giessen, Germany; Hosp Schleswig Holstein, Kiel, Germany; Hannover Med Sch, Ctr Child & Adolescent Med, D-3000 Hannover, Germany; Univ Dusseldorf, Ctr Child & Adolescent Med, Dusseldorf, Germany; Univ Freiburg, Ctr Child & Adolescent Med, D-7800 Freiburg, Germany; Goethe Univ Frankfurt, Frankfurt, Germany; Univ Cologne, Cologne, Germany; Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; St Anna Childrens Hosp, A-1090 Vienna, Austria","Reiter, A, Univ Giessen, Dept Pediat Hematol & Oncol, Ctr Child & Adolescent Med, Feulgenstr 12, D-35392 Giessen, Germany","alfred.reiter@paediat.med.uni-giessen.de","Deutsche Kinderkrebsstiftung (Bonn, Germany) [A 2006/6 DKS 2006.08]; Deutsche Kinderkrebsstiftung (Czech Republic) [IGA NS/9997-4, MZO FNM 2005]","Supported by the Deutsche Kinderkrebsstiftung, Grants No. A 2006/6 DKS 2006.08 (Bonn, Germany) and IGA NS/9997-4 and MZO FNM 2005 (Czech Republic).",null,33,1,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2009.26.6791","J CLIN ONCOL","J. Clin. Oncol.","JUL 1",2010,28,19,null,null,null,3115,3121,null,null,7,"Oncology","617AX","ISI:000279254300005"]
["nemá","J","Reekie, J; Mocroft, A; Ledergerber, B; Beniowski, M; Clotet, B; van Lunzen, J; Chiesi, A; Pradier, C; Machala, L; Lundgren, JD",null,null,null,"Reekie, J.; Mocroft, A.; Ledergerber, B.; Beniowski, M.; Clotet, B.; van Lunzen, J.; Chiesi, A.; Pradier, C.; Machala, L.; Lundgren, J. D.","EuroSIDA Study Grp","History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change*","HIV MEDICINE",null,"English","Article",null,null,null,null,null,"virological failure; antiretroviral therapy; virological suppression; viral rebound","HIV-INFECTED PATIENTS; CLINICAL PROGRESSION; REBOUND RATES; CELL COUNT; ADHERENCE; SUCCESS; VIREMIA; NONADHERENCE; COPIES/ML; EUROSIDA","Objectives HIV-infected persons experience different patterns of viral suppression after initiating combination antiretroviral therapy (cART). The relationship between such differences and risk of virological failure after starting a new antiretroviral could help with patient monitoring strategies. Methods A total of 1827 patients on cART starting at least one new antiretroviral from 1 January 2000 while maintaining a suppressed viral load were included in the analysis. Poisson regression analysis identified factors predictive of virological failure after baseline in addition to traditional demographic variables. Baseline was defined as the date of starting new antiretrovirals. Results Four hundred and fifty-one patients (24.7%) experienced virological failure, with an incidence rate (IR) of 7.3 per 100 person-years of follow-up (PYFU) [95% confidence interval (CI) 6.7-8.0]. After adjustment, patients who had rebounded in the year prior to baseline had a 2.4-times higher rate of virological failure after baseline (95% CI 1.77-3.26; P <.0001), while there was no increased incidence in patients whose last viral rebound was > 3 years prior to baseline [Incidence rate ratio (IRR) 1.06; 95% CI 0.75-1.50; P=0.73] compared with patients who had never virally rebounded. Patients had an 86% (95% CI 1.36-2.55; P <.0001), 53% (95% CI 1.06-2.04; P=0.02) and 5% (95% CI 0.80-1.38; P=0.72) higher virological failure rate after baseline if they were virally suppressed < 50%, 50-70% and 70-90% of the time they were on cART prior to baseline, respectively, compared with those virally suppressed > 90% of the time. Discussion Intensive monitoring after a treatment switch is required in patients who have rebounded recently or have a low percentage of time suppressed while on cART. Consideration should be given to increasing the provision of adherence counselling.","[Reekie, J.] UCL, Sch Med, HIV Epidemiol Biostat Grp, Res Dept Infect & Populat Hlth,Div Populat Hlth, London NW3 2PF, England; [Ledergerber, B.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Beniowski, M.] Specialist Hosp, Dept AIDS Diagnost & Therapy, Chorzow, Poland; [Clotet, B.] Hosp Badalona Germans Trias & Pujol, Badalona, Spain; [van Lunzen, J.] Univ Med Ctr Hamburg Eppendorf, Infect Dis Unit, Hamburg, Germany; [Chiesi, A.] Ist Super Sanita, I-00161 Rome, Italy; [Pradier, C.] Hop Archet, Nice, France; [Machala, L.] Charles Univ Prague, Fac Med 3, Dept Infect Dis, Prague, Czech Republic; [Lundgren, J. D.] Univ Copenhagen, Panum Inst, Copenhagen HIV Programme, DK-2200 Copenhagen, Denmark; [Lundgren, J. D.] Rigshosp, Ctr Viral Dis, DK-2100 Copenhagen, Denmark; [Machala, L.] Charles Univ Prague, Fac Med 2, Dept Infect Dis 1, Prague, Czech Republic","Reekie, J, UCL, Sch Med, HIV Epidemiol Biostat Grp, Res Dept Infect & Populat Hlth,Div Populat Hlth, Royal Free Campus,Rowland Hill St, London NW3 2PF, England","j.reekie@pcps.ucl.ac.uk","European Commission [CT94-1637, CT97-2713, QLK2-2000-00773, LSHP-CT-2006-018632]; Bristol-Myers Squibb ; GlaxoSmithKline ; Roche ; Gilead ; Pfizer ; Merck and Co. ; Tibotec ; Boehringer-Ingelheim ; Swiss Federal Office for Education and Science ","Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773) and the 6th Framework (LSHP-CT-2006-018632) programmes. Current support also includes unrestricted grants from Bristol-Myers Squibb, GlaxoSmithKline, Roche, Gilead, Pfizer, Merck and Co., Tibotec and Boehringer-Ingelheim. The participation of centres from Switzerland was supported by a grant from the Swiss Federal Office for Education and Science.",null,36,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1464-2662",null,"10.1111/j.1468-1293.2009.00816.x","HIV MED","HIV Med.","AUG",2010,11,7,null,null,null,469,478,null,null,10,"Infectious Diseases","619QG","ISI:000279444100008"]
["nemá","J","Dickinson, AM; Pearce, KF; Norden, J; O'Brien, SG; Holler, E; Bickeboller, H; Balavarca, Y; Rocha, V; Kolb, HJ; Hromadnikova, I; Sedlacek, P; Niederwieser, D; Brand, R; Ruutu, T; Apperleyy, J; Szydlo, R; Goulmy, E; Siegert, W; de Witte, T; Gratwohl, A",null,null,null,"Dickinson, Anne M.; Pearce, Kim F.; Norden, Jean; O'Brien, Stephen G.; Holler, Ernst; Bickeboeller, Heike; Balavarca, Yesilda; Rocha, Vanderson; Kolb, Hans-Jochem; Hromadnikova, Ilona; Sedlacek, Petr; Niederwieser, Dietger; Brand, Ronald; Ruutu, Tapatti; Apperleyy, Jane; Szydlo, Richard; Goulmy, Els; Siegert, Wolfgang; de Witte, Theo; Gratwohl, Alois",null,"Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,"English","Article",null,null,null,null,null,"genetic risk factors; statistical modeling; hematopoietic stem cell transplantation","VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; INTERLEUKIN-10 PROMOTER POLYMORPHISM; CHRONIC MYELOGENOUS LEUKEMIA; GENE POLYMORPHISM; ALLOGENEIC TRANSPLANTATION; IL-10 POLYMORPHISMS; FOLLOW-UP; RECEPTOR; SURVIVAL","Background Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate. Design and Methods In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RAI), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score. Results Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score. Conclusions Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.","[Dickinson, Anne M.] Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Pearce, Kim F.] Newcastle Univ, Sch Math & Stat, ISRU, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Holler, Ernst] Univ Klinikum Hamatol Onkol, Regensburg, Germany; [Bickeboeller, Heike; Balavarca, Yesilda] Univ Gottingen, Dept Genet & Epidemiol, D-3400 Gottingen, Germany; [Rocha, Vanderson] Hop St Louis, Paris, France; [Kolb, Hans-Jochem] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; [Hromadnikova, Ilona] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Niederwieser, Dietger] Univ Klin Leipzig, Klin & Poliklin, Leipzig, Germany; [Brand, Ronald] Leiden Univ Hosp, Dept Med Stat, Leiden, Netherlands; [Ruutu, Tapatti] Univ Cent Hosp, Dept Med, Div Hematol, Helsinki, Finland; [Apperleyy, Jane; Szydlo, Richard] Hammersmith Hosp, Dept Haematol, London, England; [Goulmy, Els] Univ Med Ctr, Leiden, Netherlands; [Siegert, Wolfgang] Virchow Klinikum Charite, Berlin, Germany; [de Witte, Theo] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands; [Gratwohl, Alois] Univ Basel, Univ Hosp, Basel, Switzerland","Dickinson, AM, Newcastle Univ, Sch Med, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England","a.m.dickinson@ncl.ac.uk","European Leukemia Net [LSH-2002-2.2.0-3]; Swiss National Research Foundation [3200B0-118176]; Swiss Cancer League ; Regional Cancer League ; Horton Foundation. ; Amgen Europe GmbH ; F Hoffmann-La Roche ; Gilead Sciences ; Miltenyi Biotec GmbH ; Schering-Plough International Inc. ; Celegene International SARL ; Chugai Sanofi Aventis SNC ; Fresenius Biotech GmbH ; Gambro BCT ; Genzyme ; Pfizer ; Berlex AG (Schering AG Germany) ; Therakos ; Bristol Myers Squibb ; Novartis ; Cephalon ; Laboratoires Pierre Fabre ; GE Healthcare ; European Commission [QLRI-CT-200000010]; TRANSEUROPE [QLK3-CT-2002-01936]; STEMDIAGNOSTICS [LSHB-CT-0377030]","the work was supported in part by the European Leukemia Net LSH-2002-2.2.0-3, by a grant from the Swiss National Research Foundation, 3200B0-118176 the Swiss Cancer League, the Regional Cancer League and the Horton Foundation. The EBMT is supported by grants from the corporate members: Amgen Europe GmbH, F Hoffmann-La Roche, Gilead Sciences, Miltenyi Biotec GmbH, Schering-Plough International Inc., Celegene International SARL, Chugai Sanofi Aventis SNC, Fresenius Biotech GmbH, Gambro BCT, Genzyme, Pfizer, Berlex AG (Schering AG Germany), Therakos, Bristol Myers Squibb, Novartis, Cephalon, Laboratoires Pierre Fabre and GE Healthcare. The work was also supported by European Commission Framework V and VI grants EUROBANK (contract number QLRI-CT-200000010) TRANSEUROPE (contract number QLK3-CT-2002-01936) and STEMDIAGNOSTICS (contract number LSHB-CT-0377030.",null,47,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2009.016220","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JUN",2010,95,6,null,null,null,922,927,null,null,6,"Hematology","614IW","ISI:000279051100012"]
["nemá","J","Mejstrikova, E; Volejnikova, J; Fronkova, E; Zdrahalova, K; Kalina, T; Sterba, J; Jabali, Y; Mihal, V; Blazek, B; Cerna, Z; Prochazkova, D; Hak, J; Zemanova, Z; Jarosova, M; Oltova, A; Sedlacek, P; Schwarz, J; Zuna, J; Trka, J; Stary, J; Hrusak, O",null,null,null,"Mejstrikova, Ester; Volejnikova, Jana; Fronkova, Eva; Zdrahalova, Katerina; Kalina, Tomas; Sterba, Jaroslav; Jabali, Yahia; Mihal, Vladimir; Blazek, Bohumir; Cerna, Zdena; Prochazkova, Daniela; Hak, Jiri; Zemanova, Zuzana; Jarosova, Marie; Oltova, Alexandra; Sedlacek, Petr; Schwarz, Jiri; Zuna, Jan; Trka, Jan; Stary, Jan; Hrusak, Ondrej",null,"Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,"English","Article",null,null,null,null,null,"pediatric acute lymphoblastic leukemia; pediatric acute myeloid leukemia; mixed phenotype leukemia; biphenotypic leukemia; aberrant antigens; cytometry; acute hybrid leukemia","ACUTE LYMPHOBLASTIC LEUKEMIAS; BIPHENOTYPIC ACUTE-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; RECEPTOR GENE REARRANGEMENTS; ACTIVATING FLT3 MUTATIONS; ACUTE MYELOID-LEUKEMIA; MYELOPEROXIDASE ACTIVITY; FUSION GENE; CHILDHOOD; DIFFERENTIATION","Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers. Discussions surrounding it have focused on scoring details, and information is limited regarding its biological, clinical and prognostic significance. The recent World Health Organization classification is simpler and could replace the EGIL scoring system after transformation into unambiguous guidelines. Design and Methods Simple immunophenotypic criteria were used to classify all cases of childhood acute leukemia in order to provide therapy directed against acute lymphoblastic leukemia or acute myeloid leukemia. Prognosis, genotype and immunoglobulin/T-cell receptor gene rearrangement status were analyzed. Results The incidences of MPAL were 28/582 and 4/107 for children treated with acute lymphoblastic leukemia and acute myeloid leukemia regimens, respectively. In immunophenotypic principal component analysis, MPAL treated as T-cell acute lymphoblastic leukemia clustered between cases of non-mixed T-cell acute lymphoblastic leukemia and acute myeloid leukemia, while other MPAL cases were included in the respective non-mixed B-cell progenitor acute lymphoblastic leukemia or acute myeloid leukemia clusters. Analogously, immunoglobulin/T-cell receptor gene rearrangements followed the expected pattern in patients treated as having acute myeloid leukemia (non-rearranged, 4/4) or as having B-cell progenitor acute lymphoblastic leukemia (rearranged, 20/20), but were missing in 3/5 analyzed cases of MPAL treated as having T-cell acute lymphobastic leukemia. In patients who received acute lymphoblastic leukemia treatment, the 5-year event-free survival of the MPAL cases was worse than that of the non-mixed cases (53+/-10% and 76+/-2% at 5 years, respectively, P=0.0075), with a more pronounced difference among B lineage cases. The small numbers of MPAL cases treated as T-cell acute lymphoblastic leukemia or as acute myeloid leukemia hampered separate statistics. We compared prognosis of all subsets with the prognosis of previously published cohorts. Conclusions Simple immunophenotypic criteria are useful for therapy decisions in MPAL. In B lineage leukemia, MPAL confers poorer prognosis. However, our data do not justify a preferential use of current acute myeloid leukemia-based therapy in MPAL.","[Mejstrikova, Ester; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, CLIP, Dept Pediat Hematol Oncol, Prague 15006 5, Czech Republic; [Mejstrikova, Ester; Volejnikova, Jana; Fronkova, Eva; Zdrahalova, Katerina; Kalina, Tomas; Sedlacek, Petr; Zuna, Jan; Trka, Jan; Stary, Jan; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Mejstrikova, Ester; Volejnikova, Jana; Fronkova, Eva; Zdrahalova, Katerina; Kalina, Tomas; Sedlacek, Petr; Zuna, Jan; Trka, Jan; Stary, Jan; Hrusak, Ondrej] Univ Hosp Motol, Prague, Czech Republic; [Sterba, Jaroslav; Oltova, Alexandra] Univ Hosp, Dept Pediat Oncol, Brno, Czech Republic; [Sterba, Jaroslav] Univ Hosp, Dept Med Genet, Brno, Czech Republic; [Jabali, Yahia] Reg Hosp, Dept Pediat, Ceske Budejovice, Czech Republic; [Mihal, Vladimir] Palacky Univ, Fac Med, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Mihal, Vladimir; Jarosova, Marie] Univ Hosp, Olomouc, Czech Republic; [Blazek, Bohumir] Teaching Hosp Ostrava, Dept Pediat, Ostrava, Czech Republic; [Cerna, Zdena] Univ Hosp Plzen, Dept Pediat, Plzen, Czech Republic; [Prochazkova, Daniela] Masaryk Hosp Usti nad Labem, Dept Pediat, Usti Nad Labem, Czech Republic; [Hak, Jiri] Fac Med Hradec Kralove, Dept Pediat, Hradec Kralove, Czech Republic; [Zemanova, Zuzana] Gen Univ Hosp, Inst Clin Biochem & Lab Diagnost, Ctr Oncocytogenet, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague 15006 5, Czech Republic; [Jarosova, Marie] Palacky Univ, Fac Med, Dept Hematooncol, CR-77147 Olomouc, Czech Republic; [Schwarz, Jiri] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Hrusak, O, Charles Univ Prague, Fac Med 2, CLIP, Dept Pediat Hematol Oncol, V Uvalu 84, Prague 15006 5, Czech Republic","ester.mejstrikova@lfmotol.cuni.cz; ondrej.hrusak@lfmotol.cuni.cz","Charles University [7393/2007, 7539/2007]; Czech Ministry of Health [NPV 2806064]; FNM-MZO [2005]; Czech Ministry of Education [MSM0021620813]; [NS10004]; [MZdNR9531-3]; [GACR310/09/P058]; [P301/10/1877]","this work was supported by Charles University grants 7393/2007, 7539/2007, Czech Ministry of Health NPV 2806064, FNM-MZO 2005, NS10004 and MZdNR9531-3, GACR310/09/P058 and P301/10/1877 and by the Czech Ministry of Education with grant n. MSM0021620813.",null,37,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2009.014506","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JUN",2010,95,6,null,null,null,928,935,null,null,8,"Hematology","614IW","ISI:000279051100013"]
["nemá","J","Hromadka, R; Bartak, V; Popelka, S; Pokorny, D; Jahoda, D; Sosna, A",null,null,null,"Hromadka, Rastislav; Bartak, Vladislav; Popelka, Stanislav; Pokorny, David; Jahoda, David; Sosna, Antonin",null,"Ankle Block Implemented Through Two Skin Punctures","FOOT & ANKLE INTERNATIONAL",null,"English","Article",null,null,null,null,null,"Ankle Block; Foot Block; Anesthesia of the Foot","PERIPHERAL-NERVE BLOCK; FOREFOOT SURGERY; REGIONAL ANESTHESIA; FOOT","Background: Recently, peripheral nerve blocks have increasingly been used in orthopedic surgery. The foot block is an alternative for anesthesia in cases of forefoot and midfoot operations. We propose a modification of the block technique due to potential difficulties concerning the tibial nerve. Materials and Methods: The spatial position of the tibial nerve in the neurovascular bundle, proximal to entering the tarsal tunnel and sural nerve behind lateral malleolus was measured on 60 dissected preparations. Modification of the block technique was proposed. A tibial nerve block was administered by inserting a needle, at an area above the upper edge of the heel bone, tangential to the Achilles tendon. The needle was then withdrawn and redirected to the frontal plane and inserted through the tissue, anterior to the Achilles tendon and laterally behind the lateral malleolus to block the sural nerve. A block of the saphenous nerve superficial and deep peroneal nerves was implemented by needle insertion subcutaneously two centimeters proximal to the crest of the ankle joint. The technique was then evaluated in the clinical part of the study in 84 operative procedures. Results: The tibial nerve is located 21.1 mm +/- 2.1 mm from the medial aspect of the Achilles tendon and 11.6 mm +/- 1.3 mm deep in the neurovascular bundle. The distance from the posterior margin of the lateral malleolus to the sural nerve is 18.3 mm +/- 1.9 mm. We achieved a 93% success rate in implementation of the complete foot block in 84 operations. Conclusion: The technique, proposed in the anatomical portion of the study and evaluated in the clinical part, had a similar success rate when compared to techniques published in the literature. Though comparable to currently used techniques, this technique provides easier positioning of a patient and a complete block of the foot can be done with two skin injection sites.","[Hromadka, Rastislav; Bartak, Vladislav; Popelka, Stanislav; Pokorny, David; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic","Hromadka, R, Motol Univ Hosp, Orthopaed Clin 1, V Uvalu 84, Prague 15006 5, Czech Republic","rastho@gmail.com",null,null,null,17,0,"AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC","SEATTLE","2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA","1071-1007",null,"10.3113/FAI.2010.0619","FOOT ANKLE INT","Foot Ankle Int.","JUL",2010,31,7,null,null,null,619,623,null,null,5,"Orthopedics","620HR","ISI:000279490300010"]
["nemá","J","Hubacek, JA; Stanek, V; Gebauerova, M; Pilipcincova, A; Dlouha, D; Poledne, R; Aschermann, M; Skalicka, H; Matouskova, J; Kruger, A; Penicka, M; Hrabakova, H; Veselka, J; Hajek, P; Lanska, V; Adamkova, V; Pit'ha, J",null,null,null,"Hubacek, Jaroslav A.; Stanek, Vladimir; Gebauerova, Marie; Pilipcincova, Alexandra; Dlouha, Dana; Poledne, Rudolf; Aschermann, Michal; Skalicka, Hana; Matouskova, Jana; Kruger, Andreas; Penicka, Martin; Hrabakova, Hana; Veselka, Josef; Hajek, Petr; Lanska, Vera; Adamkova, Vera; Pit'ha, Jan",null,"A FTO variant and risk of acute coronary syndrome","CLINICA CHIMICA ACTA",null,"English","Article",null,null,null,null,null,"Acute coronary syndrome; FTO; Polymorphism; Body mass index","BODY-MASS INDEX; GENE VARIANT; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; COMMON VARIANT; FOOD-INTAKE; FAT MASS; OBESITY; ASSOCIATION; POPULATION","Background: The Fro gene plays an important role in the determination of body weight and BMI and it has been suspected of being associated with all-case mortality. Methods: We have analyzed the FTO rs17817449 variant in consecutive 1092 male patients with acute coronary syndrome (ACS) and in 1191 randomly selected Caucasian individuals (population controls). Results: The FTO variant was significantly associated with BMI both in controls (P<0.02) and ACS patients (P<0.01). In both groups, BMI was highest in GC homozygotes and lowest in IT homozygotes. There was a significant difference between the ACS patients and controls in the frequency of the FTO genotype GC (21.4% vs. 15.9%, P<0.005). FTO GG homozygotes had a significantly increased risk of ACS, compared with TT homozygotes which was independent of age and BMI (odds ratio 1.49, 95% confidence interval 1.16-1.93). The odds ratio of ACS patients for the GC genotype remained significant even after the exclusion of diabetics (100 controls and 339 ACS patients), with OR 1.32 (95% Cl 1.01-1.72). Conclusions: This study provides an evidence of an association between the FTO variant and risk of ACS in Caucasian males. (C) 2010 Elsevier B.V. All rights reserved.","[Hubacek, Jaroslav A.; Stanek, Vladimir; Gebauerova, Marie; Pilipcincova, Alexandra; Dlouha, Dana; Poledne, Rudolf; Lanska, Vera; Adamkova, Vera; Pit'ha, Jan] Inst Clin & Expt Med, Prague, Czech Republic; [Hubacek, Jaroslav A.; Dlouha, Dana; Poledne, Rudolf; Pit'ha, Jan] Cardiovasc Res Ctr, Prague, Czech Republic; [Hubacek, Jaroslav A.; Aschermann, Michal; Skalicka, Hana; Adamkova, Vera] Univ S Bohemia, Fac Publ Hlth & Social Studies, Ceske Budejovice, Czech Republic; [Matouskova, Jana] Gen Teaching Hosp, Dept Internal Med 2, Prague, Czech Republic; [Kruger, Andreas] Homolka Hosp, Dept Cardiol, Prague, Czech Republic; [Penicka, Martin; Hrabakova, Hana; Veselka, Josef] Univ Hosp Kralovske Vinohrady, Dept Cardiol, Cardioctr, Prague, Czech Republic; [Hajek, Petr] Teaching Hosp Motol, Dept Cardiol, Prague, Czech Republic","Hubacek, JA, IKEM DEM LMG, Videnska 1958-9, Prague 14021 4, Czech Republic","jahb@ikem.cz","IGA, MH, Czech Republic [NR-9093-4/2006]","This project was supported by grant no. NR-9093-4/2006 (IGA, MH, Czech Republic).",null,34,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0009-8981",null,"10.1016/j.cca.2010.03.037","CLIN CHIM ACTA","Clin. Chim. Acta","AUG 5",2010,411,"15-16",null,null,null,1069,1072,null,null,4,"Medical Laboratory Technology","617RP","ISI:000279299100011"]
["nemá","J","Vodicka, P; Polivkova, Z; Sytarova, S; Demova, H; Kucerova, M; Vodickova, L; Polakova, V; Naccarati, A; Smerhovsky, Z; Ambrus, M; Cerna, M; Hemminki, K",null,null,null,"Vodicka, Pavel; Polivkova, Zdenka; Sytarova, Sylvie; Demova, Hana; Kucerova, Marie; Vodickova, Ludmila; Polakova, Veronika; Naccarati, Alessio; Smerhovsky, Zdenek; Ambrus, Miloslav; Cerna, Marie; Hemminki, Kari",null,"Chromosomal damage in peripheral blood lymphocytes of newly diagnosed cancer patients and healthy controls","CARCINOGENESIS",null,"English","Article",null,null,null,null,null,null,"INTERMEDIATE END-POINTS; CYTOGENETIC BIOMARKERS; GENETIC POLYMORPHISMS; DNA-REPAIR; ABERRATIONS; RISK; FREQUENCY; MICRONUCLEI; INSTABILITY; ANEUPLOIDY","Background: The majority of human cancers arise from cells unable to maintain genomic stability. Recent prospective studies indicated that enhanced chromosomal aberrations (CAs) frequencies are predictive of gastrointestinal and lung cancers. However, studies on incident cancer patients are lacking; thus, we investigated chromosomal damage in newly diagnosed cancer patients and healthy individuals. Methods: We analyzed chromosomal damage in peripheral blood lymphocytes in a group of 300 incident cancer patients (with different malignancies) in comparison with 300 healthy controls. Results and Conclusions: The frequencies of aberrant cells (ACs) and CAs were significantly higher in patients (2.38 +/- 1.56 and 2.53 +/- 1.69, respectively) as compared with controls (1.81 +/- 1.31 and 1.94 +/- 1.47, respectively, P < 0.01). The percentual difference in chromatid-type aberrations (CTAs) between patients and controls was moderately significant (1.37 +/- 1.20 and 1.11 +/- 0.99, respectively, P < 0.05), whereas the difference in chromosome-type aberrations (CSAs) was stronger (1.16 +/- 1.24 versus 0.83 +/- 1.12, P < 0.01). Using binomial logistic regression, the estimated odds ratios and 95% confidence interval for ACs were 1.33 (1.18-1.49), P < 0.01; for CAs, 1.27 (1.14-1.41), P < 0.01; for CTA 1.24 (1.07-1.44), P < 0.01 and for CSA, 1.27 (1.10-1.47), P < 0.01. By stratifying patients for distinct neoplasia, markers of chromosomal damage were significantly enhanced in patients with breast, prostate and head/neck cancers, whereas no effect was recorded in patients affected by gastrointestinal cancers. The present study shows for the first time evidence of increased chromosomal damage in lymphocytes of incident cancer patients compared with healthy controls. The effects were observed in different cancer types but as the number of patients was relatively small, further studies are warranted.","[Vodicka, Pavel; Vodickova, Ludmila; Polakova, Veronika; Naccarati, Alessio] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14200 4, Czech Republic; [Vodicka, Pavel; Polivkova, Zdenka; Sytarova, Sylvie; Demova, Hana; Kucerova, Marie; Polakova, Veronika; Cerna, Marie] Charles Univ Prague, Fac Med 3, Dept Genet Biol & Genet, Prague, Czech Republic; [Vodickova, Ludmila; Smerhovsky, Zdenek] Natl Inst Publ Hlth, Toxicogen Unit, Prague 10042, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Dept Epidemiol, Prague 15000, Czech Republic; [Ambrus, Miloslav] Fac Hosp Kralovske Vinohrady, Dept Radiol & Oncol, Prague 10042, Czech Republic; [Hemminki, Kari] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany; [Hemminki, Kari] Lund Univ, Ctr Primary Hlth Care Res, S-20502 Malmo, Sweden","Vodicka, P, Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200 4, Czech Republic","pvodicka@biomed.cas.cz","Ministry of Health of the Czech Republic [NR 8563-5/2005, NR 9423-3/2007]","Ministry of Health of the Czech Republic, projects IGA (NR 8563-5/2005, NR 9423-3/2007).",null,36,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,"10.1093/carcin/bgq056","CARCINOGENESIS","Carcinogenesis","JUL",2010,31,7,null,null,null,1238,1241,null,null,4,"Oncology","620BD","ISI:000279473100009"]
["nemá","J","Opatrna, S; Matousovic, K; Klaboch, J; Schuck, O",null,null,null,"Opatrna, Sylvie; Matousovic, Karel; Klaboch, Jan; Schueck, Otto",null,"Importance of Serum [Na+] and [Cl-] Difference in Acid-Base Status Classification","ANESTHESIA AND ANALGESIA",null,"English","Letter",null,null,null,null,null,null,"STEWART; DISORDERS; DIAGNOSIS",null,"[Opatrna, Sylvie; Klaboch, Jan] Charles Univ Prague, Dept Med, Sch Med, Plzen, Czech Republic; [Opatrna, Sylvie; Klaboch, Jan] Teaching Hosp, Plzen, Czech Republic; [Matousovic, Karel; Schueck, Otto] Motol Univ Hosp, Prague, Czech Republic; [Matousovic, Karel; Schueck, Otto] Charles Univ Prague, Dept Med, Sch Med 2, Prague, Czech Republic","Opatrna, S, Charles Univ Prague, Dept Med, Sch Med, Plzen, Czech Republic","opatrna@fnplzen.cz",null,null,null,5,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0003-2999",null,"10.1213/ANE.0b013e3181dd8a33","ANESTH ANALG","Anesth. Analg.","JUL",2010,111,1,null,null,null,243,243,null,null,1,"Anesthesiology","617LF","ISI:000279281500047"]
["nemá","J","Svehlik, M; Zwick, EB; Steinwender, G; Saraph, V; Linhart, WE",null,null,null,"Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Saraph, Vinay; Linhart, Wolfgang E.",null,"Genu recurvatum in cerebral palsy - part A: influence of dynamic and fixed equinus deformity on the timing of knee recurvatum in children with cerebral palsy","JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B",null,"English","Article",null,null,null,null,null,"cerebral palsy; electromyography; equines; gait analysis; knee hyperextension; musculoskeletal modelling","MULTILEVEL SURGERY; GAIT ANALYSIS; CROUCH GAIT; HAMSTRINGS; ANKLE; LENGTHS; CONTRACTURE; MANAGEMENT; STANCE","The aim of the study was to confirm the hypothesis of the influence of the dynamic and fixed equinus deformity on the timing of knee recurvation (hyperextension). According to our hypothesis, dynamic equinus is linked to early and fixed equinus and to late knee hyperextension. A group 35 children with cerebral palsy (47 lower limbs) was divided into two subgroups according to the timing of maximum knee hyperextension. Clinical examination confirmed our hypothesis. Gait analysis and musculoskeletal modelling results were compared with 12 normally developing children. Both recurvatum groups had forefoot landing and neither achieved normal ankle dorsiflexion. Electromyographic examination revealed an abnormally high soleus activity in a single stance. Muscle length changes of medial gastrocnemius and soleus were in agreement with our hypothesis. Such a finding might simplify the decision as to which treatment to select for equinus deformity, present in patients with genu recurvatum. J Pediatr Orthop B 19:366-372 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Saraph, Vinay; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Orthopaed & Paediat Surg, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Dept Children & Adult Orthopaed, Sch Med 2, Prague, Czech Republic","Svehlik, M, Med Univ Graz, Dept Paediat Orthopaed & Paediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria","martin.spejlik@seznam.cz",null,null,null,28,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1060-152X",null,"10.1097/BPB.0b013e32833a5f72","J PEDIATR ORTHOPAED PART B","J. Pediatr. Orthop.-Part B","JUL",2010,19,4,null,null,null,366,372,null,null,7,"Orthopedics; Pediatrics","615QR","ISI:000279151000018"]
["nemá","J","Zwick, EB; Svehlik, M; Steinwender, G; Saraph, V; Linhart, WE",null,null,null,"Zwick, Ernst B.; Svehlik, Martin; Steinwender, Gerhard; Saraph, Vinay; Linhart, Wolfgang E.",null,"Genu recurvatum in cerebral palsy - part B: hamstrings are abnormally long in children with cerebral palsy showing knee recurvatum","JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B",null,"English","Article",null,null,null,null,null,"cerebral palsy; electromyography; gait analysis; hamstrings; knee hyperextension; musculoskeletal modelling","GAIT ANALYSIS; CROUCH GAIT; LENGTHS","Hyperextension of the knee in stance (knee recurvatum) is a common disorder in patients with spastic cerebral palsy (CP). A group 35 children with CP (47 lower limbs) was divided into two subgroups according to the timing of maximum knee extension during the stance phase of gait. Gait analysis and musculoskeletal modelling data were compared with a control group of 12 normally developing children. We observed no difference in kinematics between the CP groups who showed an equinus position of the foot at initial contact. Both groups showed increased external extensor moments across the knee. The muscle-tendon lengths of the hamstrings were abnormally long at initial contact, and in both recurvatum groups, contracted faster compared with the control group. Surface electromyography revealed prolonged activity of the hamstrings in stance and early activation in swing. Abnormally long hamstrings at initial contact together with equinus position of the foot are the main causes of genu recurvatum in children with CP. J Pediatr Orthop B 19:373-378 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Svehlik, Martin] Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, A-8036 Graz, Austria; [Zwick, Ernst B.; Svehlik, Martin; Steinwender, Gerhard; Saraph, Vinay; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Orthopaed, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Sch Med 2, Dept Children & Adult Orthopaed, Prague, Czech Republic","Svehlik, M, Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, Auenbruggerpl 34, A-8036 Graz, Austria","martin.spejlik@seznam.cz",null,null,null,22,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1060-152X",null,"10.1097/BPB.0b013e32833822d5","J PEDIATR ORTHOPAED PART B","J. Pediatr. Orthop.-Part B","JUL",2010,19,4,null,null,null,373,378,null,null,6,"Orthopedics; Pediatrics","615QR","ISI:000279151000019"]
["nemá","J","Castellani, C; Macek, M; Cassiman, JJ; Duff, A; Massie, J; ten Kate, LP; Barton, D; Cutting, G; Dallapiccola, B; Dequeker, E; Girodon, E; Grody, W; Highsmith, EW; Kaariainen, H; Kruip, S; Morris, M; Pignatti, PF; Pypops, U; Schwarz, M; Soller, M; Stuhrman, M; Cuppens, H",null,null,null,"Castellani, Carlo; Macek, Milan, Jr.; Cassiman, Jean-Jacques; Duff, Alistair; Massie, John; ten Kate, Leo P.; Barton, David; Cutting, Garry; Dallapiccola, Bruno; Dequeker, Elisabeth; Girodon, Emmanuelle; Grody, Wayne; Highsmith, Edward W.; Kaariainen, Helenal; Kruip, Stephan; Morris, Michael; Pignatti, Pier Franco; Pypops, Ulrike; Schwarz, Martin; Soller, Maria; Stuhrman, Manfred; Cuppens, Harry",null,"Benchmarks for Cystic Fibrosis carrier screening: A European consensus document","JOURNAL OF CYSTIC FIBROSIS",null,"English","Review",null,null,null,null,null,"Cystic Fibrosis; CFTR; Genetic analysis; Carrier screening; Carrier testing","LUNG-DISEASE; PRENATAL-DIAGNOSIS; GENETIC MODIFIERS; PREGNANT-WOMEN; MUTATIONS; IDENTIFICATION; POPULATIONS; ASSOCIATION; EXPERIENCE; ATTITUDES","This paper presents an overview of the conclusions from an international conference convened to address current issues related to the provision of Cystic Fibrosis carrier screening within Europe. Consensus was not aimed at stating whether such a programme should be implemented. Instead the focus was to provide a framework for countries and agencies who are considering or planning its establishment. The general principles and target population of Cystic Fibrosis carrier screening, advantages and disadvantages, health economics, monitoring and future evaluative and research directions were covered. A range of screening strategies have been assessed and compared: pre-conceptional and prenatal screening; individual and couple screening; sequential and simultaneous sampling or testing. Furthermore, technical issues were examined with respect to the choice of the panel of mutations, its detection rate, sensitivity, management of intermediate 'at-risk' couples, screening approach to different populations and ethnic minorities, and assurance of laboratory quality control. The consensus statement also aims to establish the benchmarks for communicating with health care providers, the general public and potential and actual participants before and after the genetic test. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Castellani, Carlo] Verona Cyst Fibrosis Ctr, Verona, Italy; [Macek, Milan, Jr.] Charles Univ Prague 2, Sch Med, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic; [Dequeker, Elisabeth] Katholieke Univ Leuven, Ctr Human Genet, Biomed Qual Assurance Res Unit, Louvain, Belgium; [Duff, Alistair] St James Univ Hosp, Leeds Reg Cyst Fibrosis Unit, Leeds, W Yorkshire, England; [Massie, John] Royal Childrens Hosp, Dept Resp Med, Melbourne, Vic, Australia; [ten Kate, Leo P.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [ten Kate, Leo P.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Barton, David] Our Ladys Hosp Sick Children, Natl Ctr Med Genet, Dublin, Ireland; [Cutting, Garry] Johns Hopkins Univ, Baltimore, MD USA; [Dallapiccola, Bruno] Osped Pediat Bambino Gesu, IRCCS, Rome, Italy; [Girodon, Emmanuelle] Hop Henri Mondor, Serv Biochim & Genet, F-94010 Creteil, France; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Path & Lab Med, Div Med Genet, Los Angeles, CA USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Med Genet, Los Angeles, CA 90024 USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Human Genet, Div Med Genet, Los Angeles, CA USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Path & Lab Med, Div Mol Pathol, Los Angeles, CA USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Mol Pathol, Los Angeles, CA 90024 USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Human Genet, Div Mol Pathol, Los Angeles, CA USA; [Highsmith, Edward W.] Mayo Clin, Mol Genet Lab, Rochester, MN USA; [Kaariainen, Helenal] Natl Inst Hlth & Welf, Helsinki, Finland; [Kruip, Stephan] Mukoviszidose eV German CF Selfhelp Assoc, Bonn, Germany; [Morris, Michael] Hop Univ Geneve, Serv Med Genet, Lab Diagnost Mol, Geneva, Switzerland; [Pignatti, Pier Franco] Univ Verona, Sect Biol & Genet, I-37100 Verona, Italy; [Schwarz, Martin] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; [Soller, Maria] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; [Stuhrman, Manfred] Hannover Med Sch, Inst Humangenet, Hannover, Germany","Castellani, C, Azienda Osped Univ Integrata Verona, Cyst Fibrosis Ctr, Piazzale Stefani 1, I-37126 Verona, Italy","carlo.castellani@ospedaleuniverona.it","Mukoviszidose ev ; Cystic Fibrosis Foundation ; EuroCareCF [LSHM-CT-2005-018932]; EuroGenTest NoE [LSHB-CT-2004-512148]; Bayer HealthCare ; Solvay Pharmaceuticals ; Luminex ; Abbott Molecular ; Innogenetics ","The organisers of the Consensus Conference would like to thank Wolf Rogowski for external health economic advice as well as the organisations which supported the meeting: Mukoviszidose ev, Cystic Fibrosis Foundation, EuroCareCF (LSHM-CT-2005-018932) and the EuroGenTest NoE (LSHB-CT-2004-512148). Supported by MZOFNM2005 to MM. This consensus conference was sponsored by some commercial companies: Bayer HealthCare, Solvay Pharmaceuticals, Luminex, Abbott Molecular, Innogenetics. These companies had no role in the design and conduct of the consensus conference, and in the preparation, review, or approval of the manuscript.",null,81,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,"10.1016/j.jcf.2010.02.005","J CYST FIBROS","J. Cyst. Fibros","MAY",2010,9,3,null,null,null,165,178,null,null,14,"Respiratory System","614BG","ISI:000279029400003"]
["nemá","J","Tlaskal, T; Chaloupecky, V; Hucin, B; Gebauer, R; Krupickova, S; Reich, O; Skovranek, J; Tax, P",null,null,null,"Tlaskal, Tomas; Chaloupecky, Vaclav; Hucin, Bohumil; Gebauer, Roman; Krupickova, Sylvia; Reich, Oleg; Skovranek, Jan; Tax, Petr",null,"Long-term results after correction of persistent truncus arteriosus in 83 patients","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,"English","Proceedings Paper","23rd  Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery","OCT 18-21, 2009","Vienna, AUSTRIA",null,null,"Congenital heart disease; Persistent truncus arteriosus; Surgery; Long-term results; Re-interventions","OUTFLOW TRACT RECONSTRUCTION; INTERRUPTED AORTIC-ARCH; NEONATAL REPAIR; EXPERIENCE; VALVE; MANAGEMENT; OUTCOMES; REOPERATION; SURVIVAL; CONDUIT","Objective: This study aims to analyse long-term results after correction of truncus arteriosus in all patients operated in one institution over 28 years. Methods: Between 1981 and 2009, 83 patients, median age 54 days, underwent repair of truncus arteriosus. Interrupted aortic arch was present in 14 (17%), severe truncal valve insufficiency in 10 (12%) and non-confluent pulmonary arteries in five (6%) patients. Repair with reconstruction of the right ventricular to pulmonary artery continuity was performed using a valved conduit in 80, and other methods in three patients. At the same time, correction of interrupted aortic arch was done in 14 and truncal valve repair in eight patients. Survivors were repeatedly examined echocardiographically for assessment of residual heart lesions. Results: The early mortality was 19 (23%). Out of 35 patients operated between 1981 and 1996, 17(46%) died, and out of 48 patients operated between 1997 and 2009, two (4%) died. Operation before 1997 ( p = 0.001) and aortic cross-clamping time >90 min ( p = 0.009) were found to be risk factors of death. Eight (10%) patients died late, a median of 68 days after surgery. Fifty-seven (69%) patients were followed for 10.9 +/- 6.7 years. Three (4%) patients were lost. Twenty-five (30%) patients are alive with their original conduit 7.5 +/- 5.2 years after correction. Twenty-eight patients required 41 re-operations for conduit dysfunction with first replacement at mean 5.8 +/- 4.1 (range 0.1-14.1 years) years after correction. Nine (11%) patients required 12 truncal valve replacements. Eleven (13%) patients required balloon dilatation or stent for conduit obstruction, pulmonary branch stenosis, aortic arch obstruction or stenosis of vena cava. Recent clinical examination was undertaken in 53 (64%) patients and 49 (59% or 77% of early survivors) are in good/very good condition. Conclusions: Truncus arteriosus remains a challenging heart disease. With growing experience, the early mortality decreased to 4%, but numerous re-interventions for conduit obstruction, pulmonary branch stenosis and truncal valve insufficiency are required. Surgery before 1997 and prolonged cross-clamping were risk factors of death. Pulmonary homografts had the best re-intervention-free survival. Statistically, however, the difference between conduits was not significant. Dysplastic valve and truncal valve insufficiency represent risk factors presenting the need for truncal valve replacement. (C) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.","[Tlaskal, Tomas] Univ Hosp Motol, Kardiocentrum, Prague 15006 5, Czech Republic; Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic","Tlaskal, T, Univ Hosp Motol, Kardiocentrum, V Uvalu 84, Prague 15006 5, Czech Republic","tomas.tlaskal@lfmotol.cuni.cz",null,null,null,25,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1010-7940",null,"10.1016/j.ejcts.2009.12.022","EUR J CARDIO-THORAC SURG","Eur. J. Cardio-Thorac. Surg.","JUN",2010,37,6,null,null,null,1278,1284,null,null,7,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","614UY","ISI:000279086500008"]
["nemá","J","Kabzinska, D; Strugalska-Cynowska, H; Kostera-Pruszczyk, A; Ryniewicz, B; Posmyk, R; Midro, A; Seeman, P; Barankova, L; Zimon, M; Baets, J; Timmerman, V; Guergueltcheva, V; Tournev, I; Sarafov, S; De Jonghe, P; Jordanova, A; Hausmanowa-Petrusewicz, I; Kochanski, A",null,null,null,"Kabzinska, Dagmara; Strugalska-Cynowska, Halina; Kostera-Pruszczyk, Anna; Ryniewicz, Barbara; Posmyk, Renata; Midro, Alina; Seeman, Pavel; Barankova, Lucia; Zimon, Magdalena; Baets, Jonathan; Timmerman, Vincent; Guergueltcheva, Velina; Tournev, Ivailo; Sarafov, Stayko; De Jonghe, Peter; Jordanova, Albena; Hausmanowa-Petrusewicz, Irena; Kochanski, Andrzej",null,"L239F founder mutation in GDAP1 is associated with a mild Charcot-Marie-Tooth type 4C4 (CMT4C4) phenotype","NEUROGENETICS",null,"English","Article",null,null,null,null,null,"Phenotype-genotype correlations in CMT4A disease; Founder effect; The L239F mutation in the GDAP1 gene","DIFFERENTIATION-ASSOCIATED PROTEIN-1; AUTOSOMAL RECESSIVE CMT; GLUTATHIONE TRANSFERASE; VOCAL CORD; DISEASE; GENE; FAMILY; NEUROPATHY; IDENTIFICATION; VARIABILITY","Over 40 mutations in the GDAP1 gene have been shown to segregate with Charcot-Marie-Tooth disease (CMT). Among these, only two mutations, i.e., S194X and Q163X have been reported in a sufficient number of CMT families to allow for the construction of reliable phenotype-genotype correlations. Both the S194X and Q163X mutations have been shown to segregate with an early-onset and severe neuropathy resulting in loss of ambulance at the beginning of the second decade of life. In this study, we identified the L239F mutation in the GDAP1 gene in one Bulgarian and five Polish families. We hypothesized that the L239F mutation may result from a founder effect in the European population since this mutation has previously been reported in Belgian, Czech, and Polish patients. In fact, we detected a common disease-associated haplotype within the 8q13-q21 region in the Polish, German, Italian, Czech, and Bulgarian CMT families. Like the previously detected \"regional\" S194X and Q163X mutations, respectively present in Maghreb countries and in patients of Spanish descent, the L239F mutation seems to be the most common GDAP1 pathogenic variant in the Central and Eastern European population. Given the likely presence of a common ancestor harboring the L239F mutation, we decided to compare the phenotypes of the CMT (L239F) patients collected in this study with those of previously reported cases. In contrast to CMT4A caused by the S194X and Q163X mutations, the CMT phenotype resulting from the L239F substitution represents a milder clinical entity with a long-preserved period of ambulance at least until the end of the second decade of life.","[Kabzinska, Dagmara; Strugalska-Cynowska, Halina; Hausmanowa-Petrusewicz, Irena; Kochanski, Andrzej] Polish Acad Sci, Mossakowski Med Res Ctr, Neuromuscular Unit, PL-02106 Warsaw, Poland; [Kostera-Pruszczyk, Anna; Ryniewicz, Barbara] Med Univ Warsaw, Dept Neurol, Warsaw, Poland; [Posmyk, Renata; Midro, Alina] Med Univ Bialystok, Dept Clin Genet, Bialystok, Poland; [Seeman, Pavel; Barankova, Lucia] Charles Univ Prague, Sch Med 2, Dept Child Neurol, Prague, Czech Republic; [Zimon, Magdalena; Baets, Jonathan; De Jonghe, Peter; Jordanova, Albena] Univ Antwerp VIB, Dept Mol Genet, Neurogenet Grp, B-2020 Antwerp, Belgium; [Zimon, Magdalena; Baets, Jonathan; De Jonghe, Peter; Jordanova, Albena] Univ Antwerp, Inst Born Bunge, Neurogenet Lab, B-2020 Antwerp, Belgium; [Baets, Jonathan; De Jonghe, Peter] Univ Hosp Antwerpen UZA, Div Neurol, Antwerp, Belgium; [Timmerman, Vincent] Univ Antwerp VIB, Dept Mol Genet, Peripheral Neuropathy Grp, B-2610 Antwerp, Belgium; [Guergueltcheva, Velina; Tournev, Ivailo; Sarafov, Stayko] Med Univ Sofia, Dept Neurol, Sofia, Bulgaria","Kochanski, A, Polish Acad Sci, Mossakowski Med Res Ctr, Neuromuscular Unit, Pawinskiego 5, PL-02106 Warsaw, Poland","andko@cmdik.pan.pl","Polish Ministry of Science and Higher Education [402276336]; Bulgarian Ministry of Education and Science [VUL-317]; Fund for Scientific Research (FWO-Flanders) ; Medical Foundation Queen Elisabeth (GSKE) ; Association Belge contre les Maladies Neuromusculaires (ABMM) ; Flemish Government ; Belgian Federal Science Policy Office (BELSPO) [P6/43]","The authors thank Ms. Jadwiga Kedzierska for her skillfull technical assistance. This study was supported by the Grant No. 402276336 from the Polish Ministry of Science and Higher Education to A. K. and by the Grant No. VUL-317 from the Bulgarian Ministry of Education and Science to V. G., I. T., and A.J. The work of the Belgian team was supported by the Fund for Scientific Research (FWO-Flanders), the Medical Foundation Queen Elisabeth (GSKE), the Association Belge contre les Maladies Neuromusculaires (ABMM), the Methusalem excellence grant of the Flemish Government, and the Interuniversity Attraction Poles P6/43 program of the Belgian Federal Science Policy Office (BELSPO). MZ and JB are supported by PhD fellowships of the FWO-Flanders.",null,20,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1364-6745",null,"10.1007/s10048-010-0237-6","NEUROGENETICS","Neurogenetics","JUL",2010,11,3,null,null,null,357,366,null,null,10,"Genetics & Heredity; Clinical Neurology","612YO","ISI:000278942200009"]
["nemá","J","Sykorova, V; Dvorakova, S; Ryska, A; Vcelak, J; Vaclavikova, E; Laco, J; Kodetova, D; Kodet, R; Cibula, A; Duskova, J; Hlobilkova, A; Astl, J; Vesely, D; Betka, J; Hoch, J; Smutny, S; Cap, J; Vlcek, P; Novak, Z; Bendlova, B",null,null,null,"Sykorova, V.; Dvorakova, S.; Ryska, A.; Vcelak, J.; Vaclavikova, E.; Laco, J.; Kodetova, D.; Kodet, R.; Cibula, A.; Duskova, J.; Hlobilkova, A.; Astl, J.; Vesely, D.; Betka, J.; Hoch, J.; Smutny, S.; Cap, J.; Vlcek, P.; Novak, Z.; Bendlova, B.",null,"BRAF(V600E) mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic","JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION",null,"English","Article",null,null,null,null,null,"BRAF mutation; genetics; genotype-phenotype correlation; papillary carcinoma; thyroid","CHERNOBYL NUCLEAR ACCIDENT; BRAF V600E MUTATION; HIGH PREVALENCE; RET/PTC REARRANGEMENTS; CLINICOPATHOLOGICAL FEATURES; SIGNALING PATHWAY; GENE MUTATION; HIGH-RISK; B-RAF; CANCER","Background: Activating point mutation of the BRAF gene, the most common genetic alteration reported in papillary thyroid carcinomas (PTC), has been associated with poor prognostic characteristics. Aim: Our objective was to determine the frequency of BRAF(v6000E) mutation in PTC tumor tissues from the period 1960-2007 and to correlate it with clinicopathological parameters. Subjects and methods: DNAs were extracted from 242 PTCs, 23 sporadic medullary carcinomas, one anaplastic carcinoma and 6 poorly differentiated carcinomas. The presence of BRAF(v600E) mutation was determined using single strand conformation polymorphism method and verified by direct sequencing. Results: BRAF(v600E) mutation was detected in 81 of 242 PTCs (33.5%), in one of 6 poorly differentiated carcinomas (16.7%) and in anaplastic carcinoma. BRAF(v000E) mutation was much less frequent in the follicular variant compared to classical variant and mixed follicular-classical variant of PTCs (p=0.001). BRAF(v000E) mutation was significantly associated with presence of nodal metastasis (p=0.029), more advanced TNM stage (p=0.014) and recurrence of disease (p=0.008). The mutation correlated with a higher age at diagnosis (p=0.049) and with a greater tumor size (p=0.041). Multivariate analysis confirmed these findings. The prevalence of BRAF(v000E) mutation before 1986 was significantly lower than after it (p=0.008). Conclusions: Our data suggest that BRAF(v000E) mutation is associated with high-risk clinicopathological characteristics of PTC and worse prognosis of patients. The frequency of the mutation significantly varied during the observed period but rather because of the different age distribution of patients in particular periods than as a consequence of Chernobyl accident. (J. Endocrinol. Invest. 33: 318-324, 2010) (C) 2010, Editrice Kurtis","[Sykorova, V.; Dvorakova, S.; Vcelak, J.; Vaclavikova, E.; Bendlova, B.] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 1, Czech Republic; [Ryska, A.; Laco, J.] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic; [Ryska, A.; Laco, J.; Cap, J.] Univ Hosp, Hradec Kralove, Czech Republic; [Kodetova, D.; Kodet, R.; Cibula, A.] 2nd Fac Med, Dept Pathol & Mol Med, Prague, Czech Republic; [Duskova, J.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague, Czech Republic; [Hlobilkova, A.] Palacky Univ, Fac Med, Inst Pathol & Lab Mol Pathol, CR-77147 Olomouc, Czech Republic; [Astl, J.; Vesely, D.; Betka, J.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Astl, J.; Vesely, D.; Betka, J.] Charles Univ Prague, Fac Hosp Motol, Prague, Czech Republic; [Hoch, J.; Smutny, S.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Cap, J.] Charles Univ Prague, Dept Internal Med 2, Fac Med, Hradec Kralove, Czech Republic; [Vlcek, P.] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Novak, Z.] Inst Endocrinol, Dept Clin Endocrinol, Prague 11694 1, Czech Republic","Sykorova, V, Inst Endocrinol, Dept Mol Endocrinol, Narodni 8, Prague 11694 1, Czech Republic","vlassyk@seznam.cz","IGA [MH CR NR/9165-3]; [MZO-00179906]; [MZO-00064203/6704]","We thank all the patients for their kind participation in the study. We thank log. Martin Hill, D.Sc., for performing multivariate analysis. This study was supported by grant IGA MH CR NR/9165-3 and by research projects MZO-00179906 and MZO-00064203/6704.",null,48,0,"EDITRICE KURTIS S R L","MILAN","VIA LUIGI ZOJA 30, 20153 MILAN, ITALY","0391-4097",null,"10.3275/6722","J ENDOCRINOL INVEST","J. Endocrinol. Invest.","MAY",2010,33,5,null,null,null,318,324,null,null,7,"Endocrinology & Metabolism","611YU","ISI:000278862200007"]
["nemá","J","Hromadnikova, I; Zejskova, L; Kotlabova, K; Jancuskova, T; Doucha, J; Dlouha, K; Krofta, L; Jirasek, JE; Vlk, R",null,null,null,"Hromadnikova, Ilona; Zejskova, Lenka; Kotlabova, Katerina; Jancuskova, Tereza; Doucha, Jindrich; Dlouha, Klara; Krofta, Ladislav; Jirasek, Jan E.; Vlk, Radovan",null,"Quantification of Extracellular DNA Using Hypermethylated RASSF1A, SRY, and GLO Sequences-Evaluation of Diagnostic Possibilities for Predicting Placental Insufficiency","DNA AND CELL BIOLOGY",null,"English","Article",null,null,null,null,null,null,"FREE FETAL DNA; NONINVASIVE PRENATAL-DIAGNOSIS; QUANTITATIVE PCR MEASUREMENT; MATERNAL PLASMA; GROWTH RESTRICTION; PREGNANT-WOMEN; PREECLAMPSIA; ABNORMALITIES; ELEVATION; MARKER","This study evaluated quantification of fetal extracellular DNA in maternal plasma for differentiation between cases at risk of onset of placental-insufficiency-related complications and normal pregnancies. Using real-time polymerase chain reaction, fetal (sex-determining region Y [SRY] and hypermethylated RASSF1A sequence) and total (beta-globin [GLO] gene) extracellular DNA was examined in 70 normal pregnancies, 18 at risk of placental-insufficiency-related pregnancy complications, 24 preeclampsia with or without (w or w/o) intrauterine growth retardation (IUGR) (median 34.0 week), and 11 IUGR (median 28.5 week). IUGR was diagnosed when estimated fetal weight was below the 10th percentile for evaluated gestational age. Although increased levels of extracellular DNA were detected in pregnancies with preeclampsia w or w/o IUGR relative to controls (RASSF1A, p<0.001; SRY, p = 0.009; GLO, p<0.001), quantities of fetal extracellular DNA in IUGR were not statistically significant (RASSF1A, p = 0.21; SRY, p = 0.2). RASSF1A, SRY, and GLO achieved 93.1%, 93.6%, and 92.1% accuracy for differentiation between normal pregnancy and preeclampsia w or w/o IUGR. Lower sensitivity was observed for pregnancies with onset of IUGR (RASSF1A, 60.0%; SRY, 80.0%; GLO, 72.7%), but did not influence final accuracy (RASSF1A, 91.6%; SRY, 92.5%; GLO, 89.5%). Among 18 patients at risk, 8 pregnancies involving 3 female and 5 male fetuses developed preeclampsia (n = 4), IUGR (n = 3), and chronic placentopathy causing hypoxia (n = 1). Elevation of extracellular DNA was demonstrated in 3/5 (SRY), 1/8 (hypermethylated RASSF1A), and 4/8 (GLO) patients at the earliest 26 weeks and at the latest 2 weeks before the onset of symptoms. These data indicate that fetal and total extracellular DNA concentrations can be significantly elevated in plasma of patients who later developed placental-insufficiency-related pregnancy complications. However, this is strongly individualized, and not a rule for all cases, and probably depends on the actual occurrence of excessive placental trophoblast apoptosis.","[Hromadnikova, Ilona; Zejskova, Lenka; Kotlabova, Katerina; Jancuskova, Tereza] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000, Czech Republic; [Doucha, Jindrich; Vlk, Radovan] Charles Univ Prague, Clin Obstet & Gynecol, Fac Med 2, Univ Hosp Motol, Prague 10000, Czech Republic; [Dlouha, Klara; Krofta, Ladislav; Jirasek, Jan E.] Inst Care Mother & Child, Prague, Czech Republic","Hromadnikova, I, Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000, Czech Republic","ilona.hromadnikova@lf3.cuni.cz","MSM [0021620806]","We thank the staff of the Clinic of Obstetrics and Gynecology and the Institute for the Care of Mother and Child for their participation in the collection of data. We would also like to thank Prof. Y.M. Dennis Lo from the Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, for his valuable suggestions concerning digestion of extracellular DNA by methylation-sensitive restriction enzyme. This work was supported by the grant project MSM 0021620806.",null,23,0,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1044-5498",null,"10.1089/dna.2009.0971","DNA CELL BIOL","DNA Cell Biol.","JUN",2010,29,6,null,null,null,295,301,null,null,7,"Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity","612BM","ISI:000278871500004"]
["nemá","J","Kozubenko, N; Turnovcova, K; Kapcalova, M; Butenko, O; Anderova, M; Rusnakova, V; Kubista, M; Hampl, A; Jendelova, P; Sykova, E",null,null,null,"Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Butenko, Olena; Anderova, Miroslava; Rusnakova, Vendula; Kubista, Mikael; Hampl, Ales; Jendelova, Pavla; Sykova, Eva",null,"Analysis of In Vitro and In Vivo Characteristics of Human Embryonic Stem Cell-Derived Neural Precursors","CELL TRANSPLANTATION",null,"English","Article",null,null,null,null,null,"Human embryonic stem cells (hESCs); Neural differentiation; Fluorescent-activated cell sorting; RT-PCR; Transplantation","FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; GAMMA-AMINOBUTYRIC-ACID; PROGENITOR CELLS; DOPAMINERGIC-NEURONS; SUBVENTRICULAR ZONE; RECEPTOR SUBUNITS; MARKER PROMININ-1; PATCH-CLAMP; HUMAN BRAIN","During the last decade, much progress has been made in developing protocols for the differentiation of human embryonic stem cells (hESCs) into a neural phenotype. The appropriate agent for cell therapy is neural precursors (NPs). Here, we demonstrate the derivation of highly enriched and expandable populations of proliferating NPs from the CCTL14 line of hESCs. These NPs could differentiate in vitro into functionally active neurons, as confirmed by immunohistochemical staining and electrophysiological analysis. Neural cells differentiated in vitro from hESCs exhibit broad cellular heterogeneity with respect to developmental stage and lineage specification. To analyze the population of the derived NPs, we used fluorescence-activated cell sorting (FACS) and characterized the expression of several pluripotent and neural markers, such as Nanog, SSEA-4, SSEA-1, TRA-1-60, CD24, CD133, CD56 (NCAM), beta-III-tubulin, NF70, nestin, CD271 (NGFR), CD29, CD73, and CD105 during long-term propagation. The analyzed cells were used for transplantation into the injured rodent brain; the tumorigenicity of the transplanted cells was apparently eliminated following long-term culture. These results complete the characterization of the CCTL14 line of hESCs and provide a framework for developing cell selection strategies for neural cell-based therapies.","[Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Butenko, Olena; Anderova, Miroslava; Hampl, Ales; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Anderova, Miroslava; Hampl, Ales; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Anderova, Miroslava; Hampl, Ales; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Rusnakova, Vendula; Kubista, Mikael] Acad Sci Czech Republic, Inst Biotechnol, Prague 14220 4, Czech Republic; [Kubista, Mikael] TATAA Bioctr, Lundberg Lab, Gothenburg, Sweden; [Hampl, Ales] Masaryk Univ, Fac Med, Brno, Czech Republic","Sykova, E, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic","sykova@biomed.cas.cz","Academy of Sciences of the Czech Republic [AV0Z50390703, AVO250520701]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538, LC554]; Academy of Science [IAA500520809]; Grant Agency of the Czech Republic [305/09/0717, 309/08/H079]; EC [FP6, LSHB-CT-2006-037328, LSHM-CT-2005-019063]","We thank Radek Sindelka for contributing to the RT-PCR expression analysis and James Dutt for critical reading of the manuscript. Support was provided by grants AV0Z50390703 and AVO250520701 from the Academy of Sciences of the Czech Republic, grants 1M0538 and LC554 from the Ministry of Education, Youth and Sports of the Czech Republic, grant IAA500520809 from the grant agency of the Academy of Science, 305/09/0717 and 309/08/H079 from the Grant Agency of the Czech Republic, the EC FP6 projects STEMS (LSHB-CT-2006-037328), and ENINET (LSHM-CT-2005-019063).",null,58,0,"COGNIZANT COMMUNICATION CORP","ELMSFORD","3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA","0963-6897",null,null,"CELL TRANSPLANT","Cell Transplant.",null,2010,19,4,null,null,null,471,486,null,null,16,"Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation","612YU","ISI:000278942800009"]
["nemá","J","Pourova, R; Janousek, P; Jurovcik, M; Dvorakova, M; Malikova, M; Raskova, D; Bendova, O; Leonardi, E; Murgia, A; Kabelka, Z; Astl, J; Seeman, P",null,null,null,"Pourova, Radka; Janousek, Petr; Jurovcik, Michal; Dvorakova, Marcela; Malikova, Marcela; Raskova, Dagmar; Bendova, Olga; Leonardi, Emanuela; Murgia, Alessandra; Kabelka, Zdenek; Astl, Jaromir; Seeman, Pavel",null,"Spectrum and Frequency of SLC26A4 Mutations Among Czech Patients with Early Hearing Loss with and without Enlarged Vestibular Aqueduct (EVA)","ANNALS OF HUMAN GENETICS",null,"English","Article",null,null,null,null,null,"Deafness; EVA; hearing loss; MLPA; Pendred; SLC26A4","GENOTYPE-PHENOTYPE CORRELATIONS; PENDRED-SYNDROME; PDS GENE; CONGENITAL DEAFNESS; TEMPORAL BONE; GJB2; IDENTIFICATION; IMPAIRMENT; FAMILIES; PREVALENCE","P>Mutations in SLC26A4 cause Pendred syndrome (PS) - hearing loss with goitre - or DFNB4 - non-syndromic hearing loss (NSHL) with inner ear abnormalities such as Enlarged Vestibular Aqueduct (EVA) or Mondini Dysplasia (MD). We tested 303 unrelated Czech patients with early hearing loss (298 with NSHL and 5 with PS), all GJB2-negative, for SLC26A4 mutations and evaluated their clinical and radiological phenotype. Among 115 available HRCT/MRI scans we detected three MD (2.6%), three Mondini-like affections (2.6%), 16 EVA (13 bilateral - 19.2% and 15.6% respectively) and 61 EVA/MD-negative scans (73.4%). We found mutation(s) in 26 patients (8.6%) and biallelic mutations in eight patients (2.7%) out of 303 tested. In 18 of 26 (69%) patients, no second mutation could be detected even using MLPA. The spectrum of SLC26A4 mutations in Czech patients is broad without any prevalent mutation. We detected 21 different mutations (four novel). The most frequent mutations were p.Val138Phe and p.Leu445Trp (18% and 8.9% of pathogenic alleles respectively). Among 13 patients with bilateral EVA, six patients (50%) carry biallelic mutations. In EVA -negative patients no biallelic mutations were found but 4.9% had monoallelic mutations. SLC26A4 mutations are present mostly in patients with EVA/MD and/or progressive HL and those with affected siblings.","[Pourova, Radka; Seeman, Pavel] Charles Univ Prague, Dept Paediat Neurol, DNA Lab, Fac Med 2, Prague 15006 5, Czech Republic; [Janousek, Petr; Jurovcik, Michal; Kabelka, Zdenek] Charles Univ Prague, Fac Med 2, Dept Otorhinolaryngol, Prague 15006 5, Czech Republic; [Dvorakova, Marcela] Charles Univ Prague, Fac Med 2, Dept Radiol Tech, Prague 15006 5, Czech Republic; [Malikova, Marcela] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Raskova, Dagmar] Clin St Kliment, Prague 17000 7, Czech Republic; [Raskova, Dagmar] Gennet, Prague, Czech Republic; [Bendova, Olga; Astl, Jaromir] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Bendova, Olga; Astl, Jaromir] Univ Hosp Motol, Prague, Czech Republic; [Leonardi, Emanuela; Murgia, Alessandra] Univ Padua, Rare Dis Ctr, Dept Paediat, Padua, Italy","Pourova, R, Charles Univ Prague, Dept Paediat Neurol, DNA Lab, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic","radka.pourova@post.cz","Institute of Human Genetics in Erlangen ; [IGA NS 9913/4]","Supported by IGA NS 9913/4. We thank Dr. K. Huehne, O. Zwenger, V. Matejas, S. Uebe and Prof. B. Rautenstrauss from the Institute of Human Genetics in Erlangen for their kind support and cooperation.",null,38,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0003-4800",null,"10.1111/j.1469-1809.2010.00581.x","ANN HUM GENET","Ann. Hum. Genet.","JUL",2010,74,null,"Part 4",null,null,299,307,null,null,9,"Genetics & Heredity","612PW","ISI:000278914200002"]
["nemá","J","Zhang, F; Seeman, P; Liu, PF; Weterman, MAJ; Gonzaga-Jauregui, C; Towne, CF; Batish, SD; De Vriendt, E; De Jonghe, P; Rautenstrauss, B; Krause, KH; Khajavi, M; Posadka, J; Vandenberghe, A; Palau, F; Van Maldergem, L; Baas, F; Timmerman, V; Lupski, JR",null,null,null,"Zhang, Feng; Seeman, Pavel; Liu, Pengfei; Weterman, Marian A. J.; Gonzaga-Jauregui, Claudia; Towne, Charles F.; Batish, Sat Dev; De Vriendt, Els; De Jonghe, Peter; Rautenstrauss, Bernd; Krause, Klaus-Henning; Khajavi, Mehrdad; Posadka, Jan; Vandenberghe, Antoon; Palau, Francesc; Van Maldergem, Lionel; Baas, Frank; Timmerman, Vincent; Lupski, James R.",null,"Mechanisms for Nonrecurrent Genomic Rearrangements Associated with CMT1A or HNPP: Rare CNVs as a Cause for Missing Heritability","AMERICAN JOURNAL OF HUMAN GENETICS",null,"English","Article",null,null,null,null,null,null,"TOOTH DISEASE TYPE-1A; SEGMENTAL DUPLICATIONS; COMPLEX REARRANGEMENTS; HEREDITARY NEUROPATHY; REPLICATION SLIPPAGE; PRESSURE PALSIES; ALU ELEMENTS; GENE; DNA; RECOMBINATION","Genomic rearrangements involving the peripheral myelin protein gene (PMP22) in human chromosome 17p12 are associated with neuropathy: duplications cause Charcot-Marie-Tooth disease type IA (CMT1A), whereas deletions lead to hereditary neuropathy with liability to pressure palsies (HNPP). Our previous studies showed that >99% of these rearrangements are recurrent and mediated by nonallelic homologous recombination (NAHR). Rare copy number variations (CNVs) generated by nonrecurrent rearrangements also exist in 17p12, but their underlying mechanisms are not well understood. We investigated 21 subjects with rare CNVs associated with CMT1A or HNPP by oligonucleotide-based comparative genomic hybridization microarrays and breakpoint sequence analyses, and we identified 17 unique CNVs, including two genomic deletions, ten genomic duplications, two complex rearrangements, and three small exonic deletions. Each of these CNVs includes either the entire PMP22 gene, or exon(s) only, or ultraconserved potential regulatory sequences upstream of PMP22, further supporting the contention that PMP22 is the critical gene mediating the neuropathy phenotypes associated with 17p12 rearrangements. Breakpoint sequence analysis reveals that, different from the predominant NAHR mechanism in recurrent rearrangement, various molecular mechanisms, including nonhomologous end joining, Alu-Alu-mediated recombination, and replication-based mechanisms (e.g., FoSTeS and/or MMBIR), can generate nonrecurrent 17p12 rearrangements associated with neuropathy. We document a multitude of ways in which gene function can be altered by CNVs. Given the characteristics, including small size, structural complexity, and location outside of coding regions, of selected rare CNVs, their identification remains a challenge for genome analysis. Rare CNVs may potentially represent an important portion of \"missing heritability\" for human diseases.","[Zhang, Feng; Liu, Pengfei; Gonzaga-Jauregui, Claudia; Khajavi, Mehrdad; Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Zhang, Feng] Fudan Univ, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Zhang, Feng] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 200433, Peoples R China; [Zhang, Feng] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Seeman, Pavel; Posadka, Jan] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague 15006 5, Czech Republic; [Seeman, Pavel; Posadka, Jan] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Weterman, Marian A. J.; Baas, Frank] Univ Amsterdam, Acad Med Ctr, Neurogenet Lab, NL-1105 AZ Amsterdam, Netherlands; [Towne, Charles F.; Batish, Sat Dev] Athena Diagnosit Inc, Worcester, MA 01605 USA; [De Vriendt, Els; De Jonghe, Peter; Timmerman, Vincent] Univ Antwerp VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; [De Vriendt, Els; De Jonghe, Peter; Timmerman, Vincent] Univ Antwerp, B-2610 Antwerp, Belgium; [Rautenstrauss, Bernd] Ctr Med Genet, D-80335 Munich, Germany; [Rautenstrauss, Bernd; Krause, Klaus-Henning] Univ Munich, Friedrich Baur Inst, D-80336 Munich, Germany; [Vandenberghe, Antoon] Biomnis Inc, F-69357 Lyon, France; [Palau, Francesc] CSIC, Inst Biomed, Valencia 46010, Spain; [Palau, Francesc] CIBERER, Valencia 46010, Spain; [Van Maldergem, Lionel] Univ Liege, Ctr Genet Humaine, B-4000 Liege, Belgium; [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA","Lupski, JR, Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA","jlupski@bcm.tmc.edu","National Institute of Neurological Disorders and Stroke (NINDS, NIH) [R01NS058529]; Texas Children's Hospital General Clinical Research Center (GCRC) [M01RR00188]; Intellectual and Developmental Disabilities Research Centers (IDDRC) [P30HD024064]; Shanghai Pujiang Program ; Ministry of Education of China [NCET-09-0322]; Ministry of Health of Czech Republic [IGA NS 10554-3]; University of Antwerp ; FWO-Flanders ; Belgian Federal Science Policy Office (BEL-SPO) [P6/43]; BMBF [01ES0815]","We thank all participating subjects and families for their kind cooperation in the study. We also thank Drs. E. Ehler, V. Farhanova, R. Mazanec, and J. Zvolska for sending patients to the CMT1A DNA diagnostics. This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS, NIH) grant R01NS058529 to J.R.L.; Texas Children's Hospital General Clinical Research Center (GCRC) grant M01RR00188; and Intellectual and Developmental Disabilities Research Centers (IDDRC) grant P30HD024064. F.Z. is supported by Shanghai Pujiang Program and the Ministry of Education of China grant NCET-09-0322. P.S. is supported by Ministry of Health of Czech Republic grant IGA NS 10554-3. P.D.J. and V.T. are supported by a Methusalem grant of the University of Antwerp, the Fund for Scientific Research (FWO-Flanders), and the Interuniversity Attraction Poles program (P6/43) of the Belgian Federal Science Policy Office (BEL-SPO). B.R. is supported by the BMBF grant 01ES0815. J.R.L. is a consultant for Athena Diagnostics, 23andMe, and Ion Torrent Systems Inc., and holds multiple US and European patents for DNA diagnostics. Furthermore, the Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular diagnostic testing (Medical Genetics Laboratories).",null,54,0,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0002-9297",null,"10.1016/j.ajhg.2010.05.001","AMER J HUM GENET","Am. J. Hum. Genet.","JUN 11",2010,86,6,null,null,null,892,903,null,null,12,"Genetics & Heredity","613AT","ISI:000278948900007"]
["nemá","J","Pokorny, D; Slouf, M; Vesely, F; Fulin, P; Jahoda, D; Sosna, A",null,null,null,"Pokorny, D.; Slouf, M.; Vesely, F.; Fulin, P.; Jahoda, D.; Sosna, A.",null,"Distribution of UHMWPE Wear Particles in Periprosthetic Tissues of Total Hip Replacements","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"total hip replacement; polyethylene wear; aseptic loosening","JOINT REPLACEMENTS; QUANTIFICATION; ARTHROPLASTY; DEBRIS; STEM","INTRODUCTION Information on the distribution of UHMWPE wear particles around joint replacements is essential for the understanding of aseptic loosening of implants. MATERIAL AND METHODS Samples of soft tissue from around total hip arthroplasty (THA), which had a typical appearance of polyethylene granuloma, were collected from the places corresponding to the radiological zones of Gruen and DeLee. The samples were taken from 45 patients (group N1). Since the samples varied in macroscopic appearance and/or the technique of processing, a sub-group of 15 more uniform samples (group N2) were collected by the first author in order to ensure the maximum reliability. The samples were examined for the extent of tissue damage and the amount of particles in each zone. The comprehensive orthopaedic evaluation of tissue damage was carried out as follows: the first author studied the joint replacement revision protocol and pre-operative radiograph in each patient. He evaluated the degree of damage in each zone and wrote down the results in the form of an ordered series according to increasing damage (relational statement). This ordered series was called orthopaedist's statement (OS). The amount of particles in each zone around THA was assessed by the IRc method developed in the laboratory of the second author. IRc method yielded numbers that were proportional to the volume of biologically active particles with size 0.1-10) mu m in given zones. The set of numbers from IRc method for each individual case of THA was ordered in a series (relational statement). This ordered series was called a measurement statement (MS) and could be directly compared with orthopaedist's statement (OS). The OS's and MS's for each patient were statistically evaluated, independently for each group (N1=45, N2=15), and two hypotheses were tested: a) distribution of particles in various zones around THA is uniform, b) there is an agreement between OS and MS. RESULTS The number of UHMWPE wear particles in different periprosthetic zones within each patient was significantly different in both groups (N1 and N2) at the significance level of P=0.001. The OS's and MS's were identical at the significance level P=0.05. Moreover, maximum amount of particles was found in zones ill and 7 in 40 patients out of 45. DISCUSSION Polyethylene wear debris is considered one of the major causes of THR failures. However, neither national nor international literature has provided a study that would show a statistically significant relationship between the numbers of wear particles in individual zones and the extent of tissue damage in these zones. This is most probably due to the fact that four independent methods had to be developed in order to compare OS's and MS's: 1) accurate technique of tissue sampling during THA revisions, 2) accurate method of isolating wear particles from the tissues collected, 3) efficient, reliable and reproducible quantification of UHMWPE particles and 4) correct method of statistical analysis for comparison of the orthopaedist's statements and the measurement statements for all patients involved. CONCLUSION The distribution of wear particles in the periprosthetic tissues of THA is not uniform, i.e. the amount of wear particles of each patient varies from zone to zone. The extent of tissue damage in each zone, as assessed by the orthopaedic surgeon (OS), was in a good agreement with the volume of 0.1-10 mu m particles obtained by IRc measurement (MS) of the zone. We have provided conclusive evidence that the highest number of particles is accumulated in zone Ill and zone 7. As the number of particles the zones varies and the greatest damage is repeatedly found in areas with the highest particle numbers, it can be concluded with certainly that wear particles are one of the main causes of aseptic joint implant failure.","[Pokorny, D.; Vesely, F.; Fulin, P.; Jahoda, D.; Sosna, A.] FN Motol, Ortoped Klin LF UK 1, Prague 5, Czech Republic; [Slouf, M.] Akad CR, Ustav Makromol Chem, Prague, Czech Republic; LF UK, Ostav Biofyziky & Informatiky 1, Prague, Czech Republic; Prirodovedecke Fak UK, Katedra Biochem, Prague, Czech Republic","Pokorny, D, FN Motol, Ortoped Klin LF UK 1, V Uvalu 84, Prague 5, Czech Republic","david.pokorny@LF1.cuni.cz",null,null,null,15,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2010,77,2,null,null,null,87,92,null,null,6,"Orthopedics","590GM","ISI:000277213200001"]
["nemá","J","Popelka, S; Vavrik, P; Landor, I; Hach, J; Pech, J; Sosna, A",null,null,null,"Popelka, S.; Vavrik, P.; Landor, I.; Hach, J.; Pech, J.; Sosna, A.",null,"Our Experience with AES Total Ankle Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"total ankle replacement; rheumatoid arthritis; arthritis of the ankle; polyethylene wear; complications","FOLLOW-UP; CONSECUTIVE ANKLES; GAIT ANALYSIS; ARTHROPLASTY; STAR; ARTHRODESIS; NAIL","PURPOSE OF THE STUDY The method of choice for the treatment of severe ankle arthritis is either arthrodesis or joint arthroplasty. Each has its advantages and disadvantages. Arthrodesis is the definitive therapy for severe ankle destruction and instability Joint arthroplasty has an advantage in maintaining ankle mobility. However, its range of indications and its reliability and durability are more limited. The aim of this study is to present our experience with the AES prosthesis and draw attention to some drawbacks of this surgical treatment. MATERIAL From September 2003 till June 2008, 51 AES ankle replacements were carried out in 51 patients (33 women and 18 men). Their average age at the time of surgery was 53.8 years. The youngest patient was 23 and the oldest was 88 years old. The indication for surgery was rheumatoid arthritis in 10, primary arthritis in six and post-traumatic ankle arthritis in 35 patients. METHODS The patients were evaluated in 2008. The follow-up ranged from 4 months to 5 years. The patients were examined for ankle joint mobility and pain. Radiographs were assessed for potential signs of component loosening. RESULTS The results presented here are short-term ones. The pre-operative AOFAS score of 33.7 increased to 82.3 points post-operatively. The range of motion was on average 20 degrees of plantar flexion and 5 to 10 degrees of dorsiflexion. Thirty-five patients (68.7 %) were free from pain, 11 (21.5 %) experienced slight pain while walking, and five (9.8 %) patients reported more intensive pain in the joint treated. Intra-operative complications included a fracture of the medial malleolus in two (3.9 %) patients subsequently treated with screw osteosynthesis. Post-operatively, seven (13.7 %) patients experienced slow healing of the operative wound. One patient had dislocation of the polyethylene liner at 3 months after surgery. Revision surgery was carried out in seven (13.7 %) patients. Two patients suffering from increasing pain around medial malleolus underwent revision and removal of ossifications. One patient developed necrosis of the talus at 1 year after surgery. She underwent extraction of the prosthesis and ankle arthrodesis with a retrograde locking nail inserted through the heel. A large bony effect arising due to extraction of the necrotic talus was repaired using bone graft. Three (5.8 %) patients developed post-operative instability of the ankle that required revision surgery, The radiographs of another three (5.8 %) patients showed bone cysts and signs of tibial component loosening. Of these, one patient underwent surgical revision with replacement of the polyethylene liner. Cavities were freed from granuloma induced by polyethylene wear debris, and filled with bone graft from the iliac crest. DISCUSSION Total ankle replacement is a complicated surgical procedure that may results in various technical difficulties and complications. These are inversely proportional to the surgeon's experience, as also shown by literature data. CONCLUSIONS The longevity of a total ankle replacement depends, much more than in other joint replacements, on an accurate implantation technique and correct indication.","[Popelka, S.; Vavrik, P.; Landor, I.; Hach, J.; Pech, J.; Sosna, A.] FN Motol, I Ortoped Klin 1, LF UK, Prague 5, Czech Republic","Popelka, S, FN Motol, I Ortoped Klin 1, LF UK, Uvalu 84, Prague 5, Czech Republic","mudr.popelka@volny.cz",null,null,null,37,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2010,77,1,null,null,null,24,31,null,null,8,"Orthopedics","567XS","ISI:000275482700004"]
["nemá","J","Cejka, C; Platenik, J; Sirc, J; Ardan, T; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, C.; Platenik, J.; Sirc, J.; Ardan, T.; Michalek, J.; Brunova, B.; Cejkova, J.",null,"Changes of Corneal Optical Properties after UVB Irradiation Investigated Spectrophotometrically","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Corneal hydration; Corneal light absorption; Absorption coefficients; UVB rays","RABBIT CORNEA; ALDEHYDE DEHYDROGENASE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; PHOTOREFRACTIVE KERATECTOMY; ULTRAVIOLET-LIGHT; PROTECTIVE ROLE; EPITHELIUM; EYE; RAYS","Ozone depletion leads to an increase in UV rays of solar radiation reaching the surface of the Earth which is harmful to biological systems. Of the eye, the cornea is directly open to increased amount of UV rays of which mainly UVB rays are capable to induce reactive oxygen species damaging the cells. Previous studies showed that the irradiation of the cornea with UVB rays leads to morphological as well as metabolic disturbances of the cornea. Also, corneal hydration and corneal light absorption are increased after UVB rays. These changes were observed after five days of repeated irradiation of the cornea with UVB rays. The aim of the present paper was to examine how early the changes of corneal hydration and light absorption occur after UVB irradiation. The rabbit corneas were irradiated with UVB rays for one, two, three or four days. Corneal light absorption was examined spectrophotometrically and corneal hydration measured by pachymeter (as corneal thickness). Results show that changes of corneal hydration and light absorption appear early after UVB irradiation and increase along with the number of irradiations. In conclusion, irradiation of the rabbit cornea with UVB rays leads to harmful changes of its optical properties.","[Cejka, C.; Ardan, T.; Cejkova, J.] Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Prague 14220 4, Czech Republic; [Platenik, J.] Charles Univ Prague, Fac Med 1, Inst Med Biochem, Prague, Czech Republic; [Sirc, J.; Michalek, J.] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Cejka, C.; Brunova, B.] Charles Univ Prague, Fac Med 2, Eye Clin Children & Adults, Prague, Czech Republic","Cejkova, J, Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Videnska 1083, Prague 14220 4, Czech Republic","cejkova@biomed.cas.cz","Grant Agency of Charles University of the Czech Republic [47/2006/C/2.LF]; Academy of Sciences of the Czech Republic [AV0Z50390512]","Supported by a grant from the Grant Agency of Charles University of the Czech Republic No. 47/2006/C/2.LF and by a grant from the Academy of Sciences of the Czech Republic AV0Z50390512.",null,37,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,4,null,null,null,591,597,null,null,7,"Physiology","653AQ","ISI:000282054700013"]
["nemá","J","Trc, T; Handl, M; Havlas, V",null,null,null,"Trc, Tomas; Handl, Milan; Havlas, Vojtech",null,"The anterior talo-fibular ligament reconstruction in surgical treatment of chronic lateral ankle instability","INTERNATIONAL ORTHOPAEDICS",null,"English","Article",null,null,null,null,null,null,"STRESS RADIOGRAPHY; TENDON GRAFT; ARTHROGRAPHY; TEARS; JOINT","Chronic lateral ankle instability causes significant problems in physical activity and accelerates development of osteoarthritic changes. The results of treatment for chronic ankle instability are often meets controversial. A surgical reconstruction of ATFL as described in this paper was performed during the period 1997-2005 on 47 patients (26 male, 21 female), with a mean age of 29.3 years. The average follow-up period was 46.2 months. All patients had clinical examination, X-ray and MRI. The mean values of the Good score improved from an average 3.32 prior to surgery to 1.19 one year after the operation. Paired t-tests showed improvements of great significance (p < 10(-28)). The Good score prior to surgery ranged from 2-4, whereas the scores one year after surgery were either 1 or 2, with a score of 1 being recorded in 38 cases (81%). In the postoperative follow-up, MRI showed a newly-formed ligament structure in all cases. The authors describe their own technique for a reconstruction of lateral ankle instability using remnants of the former ATFL. The scar tissue seems to be sufficient to form a new duplicated structure providing good stability. MRI proved to be a sensitive and specific method for identifying the extent of talo-fibular ligament injury.","[Trc, Tomas; Handl, Milan; Havlas, Vojtech] Charles Univ Prague, Fac Med 2, Dept Orthopaed Surg, Prague 15006 5, Czech Republic","Havlas, V, Charles Univ Prague, Fac Med 2, Dept Orthopaed Surg, V Uvalu 84, Prague 15006 5, Czech Republic","tomas.trc@fnmotol.cz; vojtech.havlas@seznam.cz",null,null,null,25,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,"10.1007/s00264-010-0995-7","INT ORTHOP","Int. Orthop.","OCT",2010,34,7,null,null,null,991,996,null,null,6,"Orthopedics","652CU","ISI:000281979500010"]
["nemá","J","Hort, J; O'Brien, JT; Gainotti, G; Pirttila, T; Popescu, BO; Rektorova, I; Sorbi, S; Scheltens, P",null,null,null,"Hort, J.; O'Brien, J. T.; Gainotti, G.; Pirttila, T.; Popescu, B. O.; Rektorova, I.; Sorbi, S.; Scheltens, P.","EFNS Scientist Panel Dementia","EFNS guidelines for the diagnosis and management of Alzheimer’s disease","EUROPEAN JOURNAL OF NEUROLOGY",null,"English","Article",null,null,null,null,null,"cerebral venous thrombosis; diagnosis; heparin treatment; outcome; thrombolysis","MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID BIOMARKERS; MODERATE ALZHEIMERS-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CREUTZFELDT-JAKOB-DISEASE; PLACEBO-CONTROLLED TRIAL; MENTAL-STATE-EXAMINATION; CUED-RECALL TEST; DOUBLE-BLIND; DIFFERENTIAL-DIAGNOSIS","Background: Cerebral venous and sinus thrombosis (CVST) is a rather rare disease which accounts for < 1% of all strokes. Diagnosis is still frequently overlooked or delayed as a result of the wide spectrum of clinical symptoms and the often subacute or lingering onset. Current therapeutic measures which are used in clinical practice include the use of anticoagulants such as dose-adjusted intravenous heparin or body weight-adjusted subcutaneous low-molecular-weight heparin (LMWH), the use of thrombolysis and symptomatic therapy including control of seizures and elevated intracranial pressure. Methods: We searched MEDLINE (National Library of Medicine), the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Library to review the strength of evidence to support these interventions and the preparation of recommendations on the therapy of CVST based on the best available evidence. Review articles and book chapters were also included. Recommendations were reached by consensus. Where there was a lack of evidence but consensus was clear we stated our opinion as good practice points. Results and conclusions: Patients with CVST without contraindications for anticoagulation (AC) should be treated either with body weight-adjusted subcutaneous LMWH or with dose-adjusted intravenous heparin (level B recommendation). Concomitant intracranial haemorrhage (ICH) related to CVST is not a contraindication for heparin therapy. The optimal duration of oral anticoagulant therapy after the acute phase is unclear. Oral AC may be given for 3 months if CVST was secondary to a transient risk factor, for 6-12 months in patients with idiopathic CVST and in those with \"mild\" thrombophilia, such as heterozygous factor V Leiden or prothrombin G20210A mutation and high plasma levels of factor VIII. Indefinite AC should be considered in patients with recurrent episodes of CVST and in those with one episode of CVST and 'severe' thrombophilia, such as antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation, antiphospholipid antibodies and combined abnormalities (good practice point). There is insufficient evidence to support the use of either systemic or local thrombolysis in patients with CVST. If patients deteriorate despite adequate AC and other causes of deterioration have been ruled out, thrombolysis may be a therapeutic option in selected cases, possibly in those without large ICH and threatening herniation (good practice point). There are no controlled data about the risks and benefits of certain therapeutic measures to reduce an elevated intracranial pressure (with brain displacement) in patients with severe CVST. However, in severe cases with impending herniation craniectomy can be used as a life-saving intervention (good practice point).","[Hort, J.] Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2, Prague 15018 5, Czech Republic; [O'Brien, J. T.] Newcastle Univ, Inst Hlth & Aging, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Hort, J.] Motol Hosp, Prague 15018 5, Czech Republic; [Gainotti, G.] Catholic Univ, Policlin Gemelli, Neuropsychol Serv, Rome, Italy; [Pirttila, T.] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Popescu, B. O.] Carol Davila Univ Med & Pharm, Univ Hosp, Dept Neurol, Bucharest, Romania; [Rektorova, I.] Masaryk Univ, Dept Neurol 1, Brno, Czech Republic; [Rektorova, I.] St Annes Hosp, Brno, Czech Republic; [Sorbi, S.] Univ Florence, Dept Neurol & Psychiat Sci, I-50121 Florence, Italy; [Scheltens, P.] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Scheltens, P.] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands","Hort, J, Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2, Uvalu 84, Prague 15018 5, Czech Republic","jakub.hort@seznam.cz",null,null,null,100,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-5101",null,"10.1111/j.1468-1331.2010.03040.x","EUR J NEUROLOGY","Eur. J. Neurol.","OCT",2010,17,10,null,null,null,1236,1248,null,null,13,"Clinical Neurology; Neurosciences","649UK","ISI:000281799200006"]
["nemá","J","Lemez, P; Attarbaschi, A; Bene, MC; Bertrand, Y; Castoldi, G; Forestier, E; Garand, R; Haas, OA; Kagialis-Girard, S; Ludwig, WD; Matutes, E; Mejstrikova, E; Pages, MP; Pickl, W; Porwit, A; Orfao, A; Schabath, R; Stary, J; Strobl, H; Talmant, P; van't Veer, MB; Zemanova, Z",null,null,null,"Lemez, Petr; Attarbaschi, Andishe; Bene, Marie C.; Bertrand, Yves; Castoldi, Gianluigi; Forestier, Erik; Garand, Richard; Haas, Oskar A.; Kagialis-Girard, Sandrine; Ludwig, Wolf-Dieter; Matutes, Estella; Mejstrikova, Ester; Pages, Marie-Pierre; Pickl, Winfried; Porwit, Anna; Orfao, Alberto; Schabath, Richard; Stary, Jan; Strobl, Herbert; Talmant, Pascaline; van't Veer, Mars B.; Zemanova, Zuzana","European Grp Immunological Charact","Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases","EUROPEAN JOURNAL OF HAEMATOLOGY",null,"English","Article",null,null,null,null,null,"Tetraploid acute lymphoblastic leukemia; polyploidy; childhood; classification; immunophenotyping; molecular genetics; prognosis","ACUTE MYELOID LEUKEMIAS; NORDIC COUNTRIES; EXPRESSION; CHILDREN; FUSION; CLASSIFICATION; REDUCTION; DIAGNOSIS; IMPACT; TRIALS","Objectives: Patients with near-tetraploid (karyotype: 81 - 103 chromosomes) acute lymphoblastic leukemia (NT-ALL) constitute about 1% of childhood ALL and data reported on them are limited and controversial. The aim of the study was to enlarge the knowledge on these rarely occurring ALL. Methods: The members of the European Group for Immunophenotyping of Leukemias (EGIL) searched retrospectively their databases for NT-ALL patients. Results: We collected data of 36 European children from seven European countries with NT-ALL diagnosed since 1992. All patients reached complete remission (CR) after induction chemotherapy. Their blasts were negative for peroxidase and BCR-ABL1. Ten children were diagnosed as T-cell ALL (T-ALL) EGIL categories (T-I n = 2, T-II n = 2, T-III n = 3, T-IV n = 3) and four displayed various structural chromosomal abnormalities. Eight of 10 T-ALL remained in 1st CR; one died in CR from sepsis and one is alive in 2nd CR. Median survival was 88 (7-213) months. B-cell precursor (BCP) ALL was diagnosed in 26 children. Thirteen were positive for ETV6-RUNX1 and are alive in 1st CR for 32-147 months. Ten children were ETV6-RUNX1 negative and remained in 1st CR for 16-163 months. One girl with hypodiploid and NT metaphases and ETV6-RUNX1-negative BCP-ALL and one of two boys with NT-BCP-ALL not examined for ETV6-RUNX1 died of infection after stem cell transplantation in 2nd/3rd CR. Secondary myelodysplastic syndrome developed in two patients with NT-BCP-ALL. Conclusions: Our data demonstrate immunophenotypic, cytogenetic, and molecular heterogeneity of NT-ALL and favorable prognosis of most NT-ALL across different immunophenotypic and/or genetic ALL subtypes.","[Lemez, Petr] Hosp Jihlava, Dept Hematol & Blood Transfus, Jihlava 58633, Czech Republic; [Attarbaschi, Andishe; Haas, Oskar A.] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Bene, Marie C.] CHU, GEIL Lab Immunol, Nancy, France; [Bene, Marie C.] Fac Med, Nancy, France; [Bertrand, Yves] Hop Debrousse, Dept Pediat Hematol, Lyon, France; [Castoldi, Gianluigi] Univ Ferrara, Inst Hematol, I-44100 Ferrara, Italy; [Forestier, Erik] Umea Univ, Dept Clin Sci, Pediat Unit, Umea, Sweden; [Garand, Richard; Talmant, Pascaline] Univ Hosp, Hematol Lab, Nantes, France; [Kagialis-Girard, Sandrine; Pages, Marie-Pierre] Hop Debrousse, Hematol Lab, Lyon, France; [Ludwig, Wolf-Dieter; Schabath, Richard] HELIOS Clin, Dept Hematol Oncol Tumor Biol, Berlin, Germany; [Matutes, Estella] Royal Marsden Hosp, Dept Haematol Oncol, London SW3 6JJ, England; [Mejstrikova, Ester; Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Mejstrikova, Ester; Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Pickl, Winfried; Strobl, Herbert] Univ Vienna, Inst Immunol, Vienna, Austria; [Porwit, Anna] Karolinska Univ Hosp & Inst, Dept Pathol, Stockholm, Sweden; [Orfao, Alberto] Univ Salamanca, Serv Citometria, E-37008 Salamanca, Spain; [van't Veer, Mars B.] Dr Daniel Den Hoed Canc Ctr, NL-3008 AE Rotterdam, Netherlands; [Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague, Czech Republic","Lemez, P, Hosp Jihlava, Dept Hematol & Blood Transfus, Vrchlickeho 59, Jihlava 58633, Czech Republic","plemez@post.cz","European LeukemiaNet [WP10]; Czech Ministry of Education [MSM0021620813, MZOVFN2005]; Swedish Childhood Cancer Foundation ","A part of data from 9 patients reported here (Case 4, 10, 13-16, 20, 23, 32) have been published previously (8). We thank Jaroslav Jelinek, MD, Ph.D., for his useful comments and support. This work was supported in part by the WP10 of the European LeukemiaNet and several authors were supported by grants from the Czech Ministry of Education MSM0021620813 (E.M., J.S., Z.Z.), MZOVFN2005 (Z.Z.) and the Swedish Childhood Cancer Foundation (E.F.).",null,39,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0902-4441",null,"10.1111/j.1600-0609.2010.01493.x","EUR J HAEMATOL","Eur. J. Haematol.","OCT",2010,85,4,null,null,null,300,308,null,null,9,"Hematology","652YU","ISI:000282049300003"]
["nemá","J","Pleskacova, J; Hersmus, R; Oosterhuis, JW; Setyawati, BA; Faradz, SM; Cools, M; Wolffenbuttel, KP; Lebl, J; Drop, SL; Looijenga, LH",null,null,null,"Pleskacova, J.; Hersmus, R.; Oosterhuis, J. W.; Setyawati, B. A.; Faradz, S. M.; Cools, M.; Wolffenbuttel, K. P.; Lebl, J.; Drop, S. L.; Looijenga, L. H.",null,"Tumor Risk in Disorders of Sex Development","SEXUAL DEVELOPMENT",null,"English","Article",null,null,null,null,null,"Disorders of sex development; Germ cell tumors; Pathogenesis; Risk","GERM-CELL TUMORS; CARCINOMA-IN-SITU; TESTICULAR DYSGENESIS SYNDROME; C-KIT; DEVELOPMENT DSD; ENVIRONMENTAL ASPECTS; EXPRESSION; GENE; DIFFERENTIATION; GONADS","Certain patients with disorders of sex development (DSD), who bear Y chromosome material in their karyotype, are at increased risk for the development of type II germ cell tumors (GCT), which arise from early fetal germ cells. DSD gonads frequently harbor immature germ cells which express early fetal germ cell markers. Some of them (e.g. OCT3/4 and NANOG) seem to be of pathogenetic relevance in GCT development providing cells with the ability of pluripotency, proliferation and apoptosis suppression. Also TSPY (testis-specific protein Y-encoded), the main candidate for the so-called gonadoblastoma locus on Y chromosome, is over-expressed in germ cells of DSD patients and possibly contributes to their survival and proliferation. Nowadays, the use of immunohistochemical methods is highly relevant in identifying DSD gonads at risk. The risk for GCT development varies. While the prevalence of GCT is 15% in patients with partial androgen insensitivity, it may reach more than 30% in patients with gonadal dysgenesis. Patients with complete androgen insensitivity and ovotesticular DSD develop malignancies in 0.8% and 2.6% of cases, respectively. However, these data may be biased for various reasons. To better estimate the risk in individual groups of DSD, further investigations on large patient series are needed. Copyright (c) 2010 S. Karger AG, Basel","[Hersmus, R.; Oosterhuis, J. W.; Looijenga, L. H.] Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Josephine Nefkens Inst, Dr Daniel Den Hoed Canc Ctr, NL-3000 CA Rotterdam, Netherlands; [Pleskacova, J.; Lebl, J.] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Setyawati, B. A.; Faradz, S. M.] Diponegro Univ, Dept Human Genet, Ctr Biomed Res, Fac Med, Semarang, Indonesia; [Cools, M.] Ghent Univ Hosp, Dept Pediat, Div Pediat Endocrinol, B-9000 Ghent, Belgium; [Wolffenbuttel, K. P.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Urol, Rotterdam, Netherlands; [Drop, S. L.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Endocrinol, Rotterdam, Netherlands","Looijenga, LH, Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Josephine Nefkens Inst, Dr Daniel Den Hoed Canc Ctr, Bldg Be,Room 430B,POB 2040, NL-3000 CA Rotterdam, Netherlands","l.looijenga@erasmusmc.nl","Novo Nordisk A/S ; Translational Research Grant Erasmus MC ; Flanders Research Foundation-FWO ","This work was supported in part by ESPE Research Fellowship, sponsored by Novo Nordisk A/S (J.P.) as well as the Translational Research Grant Erasmus MC 2006 (R. H.) and The Flanders Research Foundation-FWO (M.C.).",null,61,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1661-5425",null,"10.1159/000314536","SEX DEV","Sex. Dev.",null,2010,4,"2010-05-04",null,null,null,259,269,null,null,11,"Developmental Biology","648AZ","ISI:000281664100009"]
["nemá","J","Seeman, T; Seemanova, E; Nuernberg, G; Nuernberg, P; Janssen, S; Otto, EA",null,null,null,"Seeman, Tomas; Seemanova, Eva; Nuernberg, Gudrun; Nuernberg, Peter; Janssen, Sabine; Otto, Edgar A.",null,"Polycystic kidney and hepatic disease with mental retardation is nephronophthisis 11 caused by MKS3/TMEM67 mutations","PEDIATRIC NEPHROLOGY",null,"English","Letter",null,null,null,null,null,null,null,null,"[Seeman, Tomas] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Sch Med 2, Prague 15006, Czech Republic; [Seemanova, Eva] Charles Univ Prague, Dept Clin Genet, Inst Biol & Med Genet, Univ Hosp Motol,Med Sch 2, Prague 15006, Czech Republic; [Nuernberg, Gudrun; Nuernberg, Peter] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Janssen, Sabine; Otto, Edgar A.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA","Seeman, T, Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic","tomas.seeman@lfmotol.cuni.cz",null,null,null,4,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,"10.1007/s00467-010-1591-1","PEDIAT NEPHROL","Pediatr. Nephrol.","NOV",2010,25,11,null,null,null,2375,2376,null,null,2,"Pediatrics; Urology & Nephrology","648WN","ISI:000281725200025"]
["nemá","J","Filous, A; Hlozanek, M; Hladikova, M",null,null,null,"Filous, Ales; Hlozanek, Martin; Hladikova, Marie",null,"The Occurrence and Features of the Atypical Birefringence Pattern in Scanning Laser Polarimetry Using GDxVCC in Healthy Children and Its Impact on the Retinal Nerve Fiber Layer Thickness Values","JOURNAL OF GLAUCOMA",null,"English","Article",null,null,null,null,null,"glaucoma; children; scanning laser polarimetry; GDxVCC; atypical birefringence pattern","VARIABLE CORNEAL COMPENSATION; OPTICAL COHERENCE TOMOGRAPHY; GLAUCOMATOUS EYES; POLARIZATION COMPENSATION; DIAGNOSTIC-ACCURACY; OCULAR HYPERTENSION; SENSITIVITY; RETARDATION; DEFECTS; VCC","Purpose: To investigate the occurrence and features of the atypical birefringence pattern (ABP) images in scanning laser polarimetry with variable corneal compensation (GDxVCC) in healthy children and to assess their impact on the values of the retinal nerve fiber layer (RNFL) thickness. Methods: GDxVCC scans in 120 healthy white school-aged children with mean age +/- standard deviation (SD) 12.85 +/- 3.0 years were evaluated using typical scan score (TSS) calculation and by subjective grading of the scans. Statistical analysis including the impact of ABP on the RNFL thickness in GDxVCC Temporal-Superior-Nasal-Inferior-Temporal (TSNIT) parameters was done. Results: The ABP was found in 18 out of 120 patients (15%) at cutoff value of TSS < 80. Subjective evaluation of the scans raised the frequency of ABP to 20% of patients. The mean +/- SD values of TSNIT Average, Superior Average, and Inferior Average in 26 eyes with ABP versus 214 eyes with normal birefringence pattern were 66.99 +/- 7.29 mm versus 58.00 +/- 6.22 mm (P = 7.2E to -11), 78.43 +/- 9.27 mm versus 72.33 +/- 8.72 mm (P = 0.001) and 80.87 +/- 12.01 mm versus 70.00 +/- 10.20 mm (P = 0.000001), respectively. The same comparison in TSNIT SD showed minimal difference and was 25.42 +/- 5.84 mm versus 26.41 +/- 4.81 mm (P = 0.41). Conclusions: The occurrence of ABP in children is not rare and may significantly distort the measured values of the RNFL thickness in TSNIT parameters using GDxVCC.","[Filous, Ales; Hlozanek, Martin] Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Prague 15006, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Dept Med Informat, Fac Med 2, Prague 15006, Czech Republic","Filous, A, Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic","ales.filous@lfmotol.cuni.cz",null,null,null,31,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1057-0829",null,"10.1097/IJG.0b013e3181ca7318","J GLAUCOMA","J. Glaucoma","SEP",2010,19,7,null,null,null,450,455,null,null,6,"Ophthalmology","651EX","ISI:000281909100005"]
["nemá","J","van Middendorp, JJ; Pouw, MH; Hayes, KC; Williams, R; Chhabra, HS; Putz, C; Veth, RPH; Geurts, ACH; Aito, S; Kriz, J; McKinley, W; van Asbeck, FWA; Curt, A; Fehlings, MG; Van de Meent, H; Hosman, AJF",null,null,null,"van Middendorp, J. J.; Pouw, M. H.; Hayes, K. C.; Williams, R.; Chhabra, H. S.; Putz, C.; Veth, R. P. H.; Geurts, A. C. H.; Aito, S.; Kriz, J.; McKinley, W.; van Asbeck, F. W. A.; Curt, A.; Fehlings, M. G.; Van de Meent, H.; Hosman, A. J. F.","EM-SCI Study Grp Collaborators","Diagnostic criteria of traumatic central cord syndrome. Part 2: A Questionnaire Survey among Spine Specialists","SPINAL CORD",null,"English","Article",null,null,null,null,null,"central cord syndrome; spinal cord injury; diagnostic criteria; survey","MRI-PATHOLOGICAL CORRELATIONS; CLINICAL-TRIALS; ICCP PANEL; INJURY; GUIDELINES; RECOVERY; CONDUCT; MANAGEMENT; SCI","Study design: A questionnaire survey. Objectives: To evaluate the need for the introduction of quantitative diagnostic criteria for the traumatic central cord syndrome (TCCS). Setting: An online questionnaire survey with participants from all over the world. Methods: An invitation to participate in an eight-item online survey questionnaire was sent to surgeon members of AOSpine International. Results: Out of 3340 invited professionals, 157 surgeons (5%) from 41 countries completed the survey. Whereas most of the respondents (75%) described greater impairment of the upper extremities than of the lower extremities in their own TCCS definitions, symptoms such as sensory deficit (39%) and bladder dysfunctions (24%) were reported less frequently. Initially, any difference in motor strength between the upper and lower extremities was considered most frequently (23%) as a 'disproportionate' difference in power. However, after presenting literature review findings, the majority of surgeons (61%) considered a proposed difference of at least 10 points of power (based on the Medical Research Council scale) in favor of the lower extremities as an acceptable cutoff criterion for a diagnosis of TCCS. Most of the participants (40%) felt that applying a single criterion to the diagnosis of TCCS is insufficient for research purposes. Conclusion: Various definitions of TCCS were used by physicians involved in the spinal trauma care. The authors consider a difference of at least 10 motor score points between upper and lower extremity power a clear diagnostic criterion. For clinical research purposes, this diagnostic criterion can be considered as a face valid addendum to the commonly applied TCCS definition as introduced by Schneider et al. Spinal Cord (2010) 48, 657-663; doi:10.1038/sc.2010.72; published online 29 June 2010","[van Middendorp, J. J.; Pouw, M. H.; Veth, R. P. H.; Hosman, A. J. F.] Radboud Univ Nijmegen, Med Ctr, Spine Unit, Dept Orthopaed, NL-6500 HB Nijmegen, Netherlands; [Hayes, K. C.] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; [Williams, R.] Princess Alexandra Hosp, Dept Orthopaed Surg, Brisbane, Qld 4102, Australia; [Chhabra, H. S.] Indian Spinal Injuries Ctr, Spine Serv, New Delhi, India; [Putz, C.] Orthopaed Univ Hosp Heidelberg, Spine Surg & Spinal Cord Injury Ctr, Heidelberg, Germany; [Geurts, A. C. H.; Van de Meent, H.] Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [Aito, S.] Careggi Univ Hosp, Spinal Unit, Florence, Italy; [Kriz, J.] Univ Hosp Motol, Dept Rehabil & Sports Med, Prague, Czech Republic; [McKinley, W.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [van Asbeck, F. W. A.] Univ Med Ctr, Rehabil Ctr De Hoogstraat, Utrecht, Netherlands; [van Asbeck, F. W. A.] Univ Med Ctr, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; [Curt, A.] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland; [Fehlings, M. G.] Univ Toronto, Toronto Western Hosp, Spinal Program, Dept Surg, Toronto, ON M5T 2S8, Canada","van Middendorp, JJ, Radboud Univ Nijmegen, Med Ctr, Spine Unit, Dept Orthopaed, 357,POB 9101, NL-6500 HB Nijmegen, Netherlands","jvanmiddendorp@gmail.com","Acute Zorgregio Oost ; Internationale Stiftung fur Forschung in Paraplegie (IFP) ","We thank all participating members of the European Multicenter Study of Human Spinal Cord Injury (EM-SCI) and the 48th ISCoS annual scientific meeting participants for their cooperation in the preparation of this study. We also thank Dr John F Ditunno Jr for his thorough and insightful comments during earlier phases of this study. We are grateful to the AOSpine International employees, with special thanks to Michael Fawcett, Vera Capaul and Mary Anne Smith, for their enthusiasm and willingness to facilitate this survey study. We acknowledge the participating AOSpine members for their time, answers and valuable comments on the survey. This study was supported by 'Acute Zorgregio Oost' and the 'Internationale Stiftung fur Forschung in Paraplegie (IFP)'.",null,34,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1362-4393",null,"10.1038/sc.2010.72","SPINAL CORD","Spinal Cord","SEP",2010,48,9,null,null,null,657,663,null,null,7,"Clinical Neurology; Rehabilitation","646XB","ISI:000281577000003"]
["nemá","J","Gennery, AR; Slatter, MA; Grandin, L; Taupin, P; Cant, AJ; Veys, P; Amrolia, PJ; Gaspar, HB; Davies, EG; Friedrich, W; Hoenig, M; Notarangelo, LD; Mazzolari, E; Porta, F; Bredius, RGM; Lankester, AC; Wulffraat, NM; Seger, R; Gungor, T; Fasth, A; Sedlacek, P; Neven, B; Blanche, S; Fischer, A; Cavazzana-Calvo, M; Landais, P",null,null,null,"Gennery, Andrew R.; Slatter, Mary A.; Grandin, Laure; Taupin, Pierre; Cant, Andrew J.; Veys, Paul; Amrolia, Persis J.; Gaspar, H. Bobby; Davies, E. Graham; Friedrich, Wilhelm; Hoenig, Manfred; Notarangelo, Luigi D.; Mazzolari, Evelina; Porta, Fulvio; Bredius, Robbert G. M.; Lankester, Arjen C.; Wulffraat, Nico M.; Seger, Reinhard; Guengoer, Tayfun; Fasth, Anders; Sedlacek, Petr; Neven, Benedicte; Blanche, Stephane; Fischer, Alain; Cavazzana-Calvo, Marina; Landais, Paul","European Group For Blood; European Society For","Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,"English","Article",null,null,null,null,null,"Primary immunodeficiency; severe combined immunodeficiency; Wiskott-Aldrich syndrome; CD40 ligand deficiency; chronic granulomatous disease; hematopoietic stem cell transplantation","BONE-MARROW-TRANSPLANTATION; CHRONIC GRANULOMATOUS-DISEASE; WISKOTT-ALDRICH-SYNDROME; COMBINED IMMUNE-DEFICIENCY; HYPER-IGM SYNDROME; THYMIC OUTPUT; EXPERIENCE; RECONSTITUTION; BLOOD; DIAGNOSIS","Background: Hematopoietic stem cell transplantation remains the only treatment for most patients with severe combined immunodeficiencies (SCIDs) or other primary immunodeficiencies (non-SCID PIDs). Objective: To analyze the long-term outcome of patients with SCID and non-SCID PID from European centers treated between 1968 and 2005. Methods: The product-limit method estimated cumulative survival; the log-rank test compared survival between groups. A Cox proportional-hazard model evaluated the impact of independent predictors on patient survival. Results: In patients with SCID, survival with genoidentical donors (n = 25) from 2000 to 2005 was 90%. Survival using a mismatched relative (n = 96) has improved (66%), similar to that using an unrelated donor (n = 46; 69%; P = .005). Transplantation after year 1995, a younger age, B+ phenotype, genoidentical and phenoidentical donors, absence of respiratory impairment, or viral infection before transplantation were associated with better prognosis on multivariate analysis. For nonSCID PID, in contrast with patients with SCID, we confirm that, in the 2000 to 2005 period, using an unrelated donor (n = 124) gave a 3-year survival rate similar to a genoidentical donor (n = 73), 79% for both. Survival was 76% in phenoidentical transplants (n = 23) and worse in mismatched related donor transplants (n = 47; 46%; P = .016). Conclusion: This is the largest cohort study of such patients with the longest follow-up. Specific issues arise for different patient groups. Patients with B-SCID have worse survival than other patients with SCID, despite improvements in each group. For non-SCID PID, survival is worse than SCID, although more conditions are now treated. Individual disease categories now need to be analyzed so that disease-specific prognosis may be better understood and the best treatments planned. (J Allergy Clin Immunol 2010;126:602-10.)","[Gennery, Andrew R.] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Gennery, Andrew R.; Slatter, Mary A.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Gennery, Andrew R.; Slatter, Mary A.; Cant, Andrew J.] Newcastle Upon Tyne Hosp, Fdn Trust, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Cavazzana-Calvo, Marina] Paris Descartes Univ, Hop Necker Enfants Malad, Hopitaux Paris, Dept Biotherapy, Paris, France; [Veys, Paul; Amrolia, Persis J.; Gaspar, H. Bobby; Davies, E. Graham] Great Ormond St Childrens Hosp, Dept Bone Marrow Transplantat, London, England; [Friedrich, Wilhelm; Hoenig, Manfred] Univ Ulm, D-89069 Ulm, Germany; [Notarangelo, Luigi D.; Mazzolari, Evelina; Porta, Fulvio] Univ Brescia Spedali Civili, Brescia, Italy; [Bredius, Robbert G. M.; Lankester, Arjen C.] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RA Leiden, Netherlands; [Wulffraat, Nico M.] Univ Med Ctr, Immunol Sect, Dept Pediat, Utrecht, Netherlands; [Seger, Reinhard; Guengoer, Tayfun] Univ Childrens Hosp, Div Immunol Hematol Oncol, Zurich, Switzerland; [Fasth, Anders] Univ Gothenburg, Pediat Immunol & Infect Dis Unit, Dept Pediat, Gothenburg, Sweden; [Sedlacek, Petr] Univ Hosp Motol V Uvalu, Prague, Czech Republic","Gennery, AR, Newcastle Gen Hosp, Ward 23,Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England","a.r.gennery@ncl.ac.uk",null,null,null,40,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749",null,"10.1016/j.jaci.2010.06.015","J ALLERG CLIN IMMUNOL","J. Allergy Clin. Immunol.","SEP",2010,126,3,null,null,null,602,"U342",null,null,20,"Allergy; Immunology","646CF","ISI:000281512500029"]
["nemá","J","Matejas, V; Hinkes, B; Alkandari, F; Al-Gazali, L; Annexstad, E; Aytac, MB; Barrow, M; Blahova, K; Bockenhauer, D; Cheong, HI; Maruniak-Chudek, I; Cochat, P; Dotsch, J; Gajjar, P; Hennekam, RC; Janssen, F; Kagan, M; Kariminejad, A; Kemper, MJ; Koenig, J; Kogan, J; Kroes, HY; Kuwertz-Broking, E; Lewanda, AF; Medeira, A; Muscheites, J; Niaudet, P; Pierson, M; Saggar, A; Seaver, L; Suri, M; Tsygin, A; Wuhl, E; Zurowska, A; Uebe, S; Hildebrandt, F; Antignac, C; Zenker, M",null,null,null,"Matejas, Verena; Hinkes, Bernward; Alkandari, Faisal; Al-Gazali, Lihadh; Annexstad, Ellen; Aytac, Mehmet B.; Barrow, Margaret; Blahova, Kveta; Bockenhauer, Detlef; Cheong, Hae Il; Maruniak-Chudek, Iwona; Cochat, Pierre; Doetsch, Joerg; Gajjar, Priya; Hennekam, Raoul C.; Janssen, Francoise; Kagan, Mikhail; Kariminejad, Ariana; Kemper, Markus J.; Koenig, Jens; Kogan, Jillene; Kroes, Hester Y.; Kuwertz-Broeking, Eberhard; Lewanda, Amy F.; Medeira, Ana; Muscheites, Jutta; Niaudet, Patrick; Pierson, Michel; Saggar, Anand; Seaver, Laurie; Suri, Mohnish; Tsygin, Alexey; Wuehl, Elke; Zurowska, Aleksandra; Uebe, Steffen; Hildebrandt, Friedhelm; Antignac, Corinne; Zenker, Martin",null,"Mutations in the Human Laminin beta 2 (LAMB2) Gene and the Associated Phenotypic Spectrum","HUMAN MUTATION",null,"English","Article",null,null,null,null,null,"LAMB2; Pierson syndrome; nephrotic syndrome; autosomal recessive; podocyte; laminin; ocular malformation","CONGENITAL NEPHROSIS SYNDROME; DISTINCT EYE ABNORMALITIES; PIERSON-SYNDROME; MESANGIAL SCLEROSIS; MESSENGER-RNA; MICROCORIA; MICE; READTHROUGH","Mutations of LAMB2 typically cause autosomal recessive Pierson syndrome, a disorder characterized by congenital nephrotic syndrome, ocular and neurologic abnormalities, but may occasionally be associated with milder or oligosymptomatic disease variants. LAMB2 encodes the basement membrane protein laminin beta 2, which is incorporated in specific heterotrimeric laminin isoforms and has an expression pattern corresponding to the pattern of organ manifestations in Pierson syndrome. Herein we review all previously reported and several novel LAMB2 mutations in relation to the associated phenotype in patients from 39 unrelated families. The majority of disease-causing LAMB2 mutations are truncating, consistent with the hypothesis that loss of laminin beta 2 function is the molecular basis of Pierson syndrome. Although truncating mutations are distributed across the entire gene, missense mutations are clearly clustered in the N-terminal LN domain, which is important for inter-molecular interactions. There is an association of missense mutations and small in frame deletions with a higher mean age at onset of renal disease and with absence of neurologic abnormalities, thus suggesting that at least some of these may represent hypomorphic alleles. Nevertheless, genotype alone does not appear to explain the full range of clinical variability, and therefore hitherto unidentified modifiers are likely to exist. Hum Mutat 31:992-1002, 2010. (c) 2010 Wiley-Liss, Inc.","[Matejas, Verena; Uebe, Steffen; Zenker, Martin] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Human Genet, D-8520 Erlangen, Germany; [Hinkes, Bernward; Doetsch, Joerg] Univ Childrens Hosp, Erlangen, Germany; [Hinkes, Bernward; Hildebrandt, Friedhelm] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Hinkes, Bernward; Hildebrandt, Friedhelm] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Hinkes, Bernward; Hildebrandt, Friedhelm] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Al-Gazali, Lihadh] UAE Univ, Fac Med & Hlth Sci, Dept Pediat, Al Ain, U Arab Emirates; [Annexstad, Ellen] NICU Oslo Univ Hosp, Oslo, Norway; [Aytac, Mehmet B.] Istanbul Univ, Cerrahpapa Med Fac, Dept Pediat Nephrol, Istanbul, Turkey; [Barrow, Margaret] Leicester Royal Infirm, Leicester, Leics, England; [Blahova, Kveta] Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Cheong, Hae Il] Seoul Natl Univ, Childrens Hosp, Dept Pediat, Seoul, South Korea; [Maruniak-Chudek, Iwona] Med Univ Silesia, Dept Neonatal Intens Care, Katowice, Poland; [Cochat, Pierre] Univ Lyon 1, Hop Edouard Herriot, Dept Pediat, F-69365 Lyon, France; [Gajjar, Priya] Univ Cape Town, Dept Paediat Med, ZA-7700 Rondebosch, South Africa; [Hennekam, Raoul C.] UCL, Inst Child Hlth, Great Ormond St Hosp Children, Dept Clin Genet, London, England; [Hennekam, Raoul C.] UVA, Acad Med Ctr, Dept Pediat, Amsterdam, Netherlands; [Janssen, Francoise] Univ Libre Bruxelles, Hop Univ Enfants, Dept Pediat Nephrol, Brussels, Belgium; [Kagan, Mikhail] Orenburg Reg Childrens Hosp, Dept Gastroenterol & Nephrol, Orenburg, Russia; [Kariminejad, Ariana] Kariminejad Najmabadi Pathol & Genet Ctr, Tehran, Iran; [Kemper, Markus J.] Univ Hosp Hamburg Eppendorf, Hamburg, Germany; [Koenig, Jens; Kuwertz-Broeking, Eberhard] Univ Childrens Hosp, Munster, Germany; [Kogan, Jillene] Cincinnati Childrens Hosp, Dept Human Genet, Cincinnato, OH USA; [Kroes, Hester Y.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands; [Lewanda, Amy F.] Inova Fairfax Hosp Children, Falls Church, VA USA; [Medeira, Ana] Hosp Santa Maria, Lisbon, Portugal; [Muscheites, Jutta] Univ Rostock, Univ Childrens Hosp, D-2500 Rostock 1, Germany; [Niaudet, Patrick] Hop Necker Enfants Malad, Serv Nephrol Pediat, F-75730 Paris, France; [Pierson, Michel] Univ Childrens Hosp Nancy, Nancy, France; [Saggar, Anand] St Georges Univ London, London, England; [Seaver, Laurie] Kapiolani Med Specialists, Honolulu, HI USA; [Seaver, Laurie] Univ Hawaii, John A Burns Sch Med, Dept Pediat, Honolulu, HI 96822 USA; [Suri, Mohnish] Nottingham Univ Hosp NHS Trust, Clin Genet Serv, Nottingham, England; [Tsygin, Alexey] Sci Ctr Childrens Hlth, Moscow, Russia; [Wuehl, Elke] Univ Heidelberg, Ctr Pediat & Adolescent Med, D-6900 Heidelberg, Germany; [Zurowska, Aleksandra] Med Univ Gdansk, Dept Pediat & Adolescent Nephrol & Hypertens, Gdansk, Poland; [Antignac, Corinne] Univ Paris 05, INSERM, U574, Paris, France; [Antignac, Corinne] Hop Necker Enfants Malad, AP HP, Dept Genet, Paris, France; [Zenker, Martin] Otto Von Guericke Univ, Univ Hosp Magdeburg, Inst Human Genet, D-39120 Magdeburg, Germany","Zenker, M, Otto Von Guericke Univ, Univ Hosp Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany","martin.zenker@med.ovgu.de","German Research Foundation (DFG) [SFB 423, TP A19]","We are indebted to the families of our patients for participation in our study. We are grateful to the members of the GPN (Gesellschaft fur Padiatrische Nephrologie) and Dr. Mike Urban for providing us with DNA samples from patients with syndromic forms of NS, and to Jeffrey H. Miner for helpful discussion. Grant sponsor: the German Research Foundation (DFG); grant number: SFB 423, TP A19 (to M.Z.).",null,33,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,"10.1002/humu.21304","HUM MUTAT","Hum. Mutat.","SEP",2010,31,9,null,null,null,992,1002,null,null,11,"Genetics & Heredity","647PN","ISI:000281631000002"]
["nemá","J","Viero, C; Shibuya, I; Kitamura, N; Verkhratsky, A; Fujihara, H; Katoh, A; Ueta, Y; Zingg, HH; Chvatal, A; Sykova, E; Dayanithi, G",null,null,null,"Viero, Cedric; Shibuya, Izumi; Kitamura, Naoki; Verkhratsky, Alexei; Fujihara, Hiroaki; Katoh, Akiko; Ueta, Yoichi; Zingg, Hans H.; Chvatal, Alexandr; Sykova, Eva; Dayanithi, Govindan",null,"Oxytocin: Crossing the Bridge between Basic Science and Pharmacotherapy","CNS NEUROSCIENCE & THERAPEUTICS",null,"English","Review",null,null,null,null,null,"ACTH; Analgesics; Behavior; c-fos-mRFP1 fusion gene; CNS; Development; Drug design; eGFP; eCFP; Glial cells; Heart; HPA; Hypothalamus; Neurohypophysis; Neuropeptides; PNS; Receptors; Stress; Transgenic rat model; Vasopressin","GREEN FLUORESCENT PROTEIN; RAT SUPRAOPTIC NUCLEUS; STIMULATED ADRENOCORTICOTROPIN RELEASE; HYPOTHALAMIC-NEUROHYPOPHYSEAL SYSTEM; INTRACELLULAR TRANSDUCTION SIGNALS; CAVEOLIN-1 ENRICHED DOMAINS; RANDOMIZED CONTROLLED-TRIAL; VASOPRESSIN V-1A RECEPTORS; SPINAL-CORD SYNAPTOSOMES; ANTERIOR-PITUITARY-CELLS","P>Is oxytocin the hormone of happiness? Probably not. However, this small nine amino acid peptide is involved in a wide variety of physiological and pathological functions such as sexual activity, penile erection, ejaculation, pregnancy, uterus contraction, milk ejection, maternal behavior, osteoporosis, diabetes, cancer, social bonding, and stress, which makes oxytocin and its receptor potential candidates as targets for drug therapy. In this review, we address the issues of drug design and specificity and focus our discussion on recent findings on oxytocin and its heterotrimeric G protein-coupled receptor OTR. In this regard, we will highlight the following topics: (i) the role of oxytocin in behavior and affectivity, (ii) the relationship between oxytocin and stress with emphasis on the hypothalamo-pituitary-adrenal axis, (iii) the involvement of oxytocin in pain regulation and nociception, (iv) the specific action mechanisms of oxytocin on intracellular Ca2+ in the hypothalamo neurohypophysial system (HNS) cell bodies, (v) newly generated transgenic rats tagged by a visible fluorescent protein to study the physiology of vasopressin and oxytocin, and (vi) the action of the neurohypophysial hormone outside the central nervous system, including the myometrium, heart and peripheral nervous system. As a short nine amino acid peptide, closely related to its partner peptide vasopressin, oxytocin appears to be ideal for the design of agonists and antagonists of its receptor. In addition, not only the hormone itself and its binding to OTR, but also its synthesis, storage and release can be endogenously and exogenously regulated to counteract pathophysiological states. Understanding the fundamental physiopharmacology of the effects of oxytocin is an important and necessary approach for developing a potential pharmacotherapy.","[Dayanithi, Govindan] Acad Sci Czech Republic, Inst Expt Med, Lab Physiol Calcium Signaling,VVI, Dept Cellular Neurophysiol,CNRS,EU Ctr Excellence, Prague 14220 4, Czech Republic; [Viero, Cedric] Cardiff Univ, Sch Med, Dept Cardiol, Wales Heart Res Inst, Cardiff, S Glam, Wales; [Shibuya, Izumi; Kitamura, Naoki] Tottori Univ, Dept Vet Physiol, Tottori 680, Japan; [Verkhratsky, Alexei] Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; [Fujihara, Hiroaki; Katoh, Akiko; Ueta, Yoichi] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 807, Japan; [Zingg, Hans H.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Chvatal, Alexandr; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, EU Ctr Excellence, Prague 14220 4, Czech Republic","Dayanithi, G, Acad Sci Czech Republic, Inst Expt Med, Lab Physiol Calcium Signaling,VVI, Dept Cellular Neurophysiol,CNRS,EU Ctr Excellence, Videnska 1083, Prague 14220 4, Czech Republic","gdaya@univ-montp2.fr","Centre National de la Recherche Scientifique- France ; Japanese Society for Promotion of Science [FY2008, S-08216]; Grant Agency of the Czech Republic [GACR 309/08/1381, GACR 305/08/1384, GACR 309/09/1597]; Academy of Sciences of the Czech Republic [AVOZ 50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]","G. Dayanithi is supported by the \"Centre National de la Recherche Scientifique\"- France, the Japanese Society for Promotion of Science Fellowship Program (#FY2008; S-08216), and research facilities from the Institute of Experimental Medicine of the Academy of Sciences of the Czech Republic. This work was supported by the Grant Agency of the Czech Republic grants GACR 309/08/1381, GACR 305/08/1384, and GACR 309/09/1597; the Academy of Sciences of the Czech Republic grant AVOZ 50390512 and the Ministry of Education, Youth and Sports of the Czech Republic grants LC554 and 1M0538. We are very grateful to James Dutt, IEM ASCR, Prague, for critical reading and language editing of the manuscript.",null,161,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1755-5930",null,"10.1111/j.1755-5949.2010.00185.x","CNS NEUROSCI THER","CNS Neurosci.  Ther.",null,2010,16,5,null,null,null,"e138","e156",null,null,19,"Neurosciences; Pharmacology & Pharmacy","647TY","ISI:000281643500001"]
["nemá","J","Cerny, R; Kapla, J; Machala, L",null,null,null,"Cerny, R.; Kapla, J.; Machala, L.",null,"Focal Affections of CNS in Patients with HIV Infection","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Review",null,null,null,null,null,"HIV; focal CNS affections; brain toxoplasmosis; primary lymphoma","CENTRAL-NERVOUS-SYSTEM; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-DEFICIENCY-SYNDROME; RESONANCE-IMAGING FINDINGS; SCLEROSIS-LIKE ILLNESS; NEUROLOGICAL COMPLICATIONS; VIRUS-INFECTION; SYNDROME AIDS","Focal affections of the CNS are an important cause of morbidity and mortality in HIV-infected patients. HIV infection is rarely considered in patients with focal CNS symptomatology in the Czech Republic, a setting with low prevalence of HIV positivity. Nevertheless, delay in establishing a correct diagnosis has a negative influence on the patient's prognosis and puts health-care workers at risk of infection. The most important causes of focal CNS affections in HIV-positive patients are: brain toxoplasmosis, primary CNS lymphoma, and progressive multifocal leuko-encephalopathy. The aetiology of other focal CNS affections in HIV-positive persons is similar to the situation in the normal population, but the incidence of these CNS affections in HIV-positive patients tends to be higher. A possible connection with HIV infection should be always taken in account, in order to establish a correct diagnosis as soon as possible, when the therapy can be most effective.","[Cerny, R.] 2 LF UK FN & Motole, Neurol Klin Dospelych, Prague 15006 5, Czech Republic; [Kapla, J.] Klin Infektnich Nemoci LF UK FN, Hradec Kralove, Czech Republic; [Machala, L.] LF UK FN Na, I Infekcni Klin 2, LF UK Klin, Prague, Czech Republic","Cerny, R, 2 LF UK FN & Motole, Neurol Klin Dospelych, Uvalu 84, Prague 15006 5, Czech Republic","rudolf.cerny@lfmotol.cuni.cz",null,null,null,48,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,4,null,null,null,374,378,null,null,5,"Neurosciences; Surgery","648IK","ISI:000281685800002"]
["nemá","J","Kotaskova, J; Marusic, P",null,null,null,"Kotaskova, J.; Marusic, P.",null,"Functional Significance of a Temporal Lobe","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Review",null,null,null,null,null,"temporal pole; epilepsy; emotion recognition; social cognition; theory of mind","FACIAL EMOTION RECOGNITION; FAMOUS FACES; EPILEPSY; MEMORY; HIPPOCAMPUS; CORTEX; BRAIN; POLE; PROSOPAGNOSIA; PERFORMANCE","The temporal pole is the least explored part of the temporal lobe, and not only anatomically. Its functional significance is also poorly understood. Due to the large number of connections with the amygdala and orbitofrontal cortex involved, the temporal pole is assumed to be part of the limbic system. It is involved in recognition of facial and emotional features, social-emotional empathy (theory of mind), naming of objects and persons and other memory functions, matters that are not routinely tested in neuropsychological assessment. An important expansion of knowledge of temporal pole functions has been enabled by the use of functional neuro-imaging methods, especially positron emission tomography and functional magnetic resonance. An impairment of functions associated with the temporal pole has been observed in Alzheimer's disease, schizophrenia and psychosis. The aim of this review is to summarize basic knowledge of temporal pole function in temporal lobe epilepsy patients.","[Kotaskova, J.; Marusic, P.] LF UK FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic","Kotaskova, J, LF UK FN Motole, Neurol Klin 2, Uvalu 84, Prague 15006 5, Czech Republic","jana.amlerova@seznam.cz",null,null,null,38,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,4,null,null,null,387,391,null,null,5,"Neurosciences; Surgery","648IK","ISI:000281685800004"]
["nemá","J","Kolar, P; Stulik, J; Kyncl, M",null,null,null,"Kolar, P.; Stulik, J.; Kyncl, M.",null,"Dynamic Magnetic Resonance Imaging of a Lumbar Spine - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"vertebrogenic syndromes; postural function; dynamic magnetic resonance imaging","STABILIZATION; KINEMATICS; DYNESYS; MRI","Patients with vertebrogenic problems are usually examined by magnetic resonance imaging (MRI) in the stationary, relaxed supine position only. This position, however, does not allow sufficient evaluation of morphological findings since these may vary under different postural, spine-loading situations. This has been confirmed by MRI assessment with the patient standing or by dynamic MRI assessment with the patient bending forwards or backwards. At this time, there is no MRI device in the Czech Republic that permits assessment with the patient standing or bending, so we perform MRI assessment while inducing stabilizing muscle activity. For lumbar spine evaluation, MRI analysis at the same time as hip flexion against some small resistance or just gravity proves to be spine-loading and therefore dynamic, since the patient needs to activate not only hip flexors, but also spinal stabilizers. Such an MRI assessment allows for intradiscal movement, shape measurement, and a degree of stability, allowing regional anatomical parameter measurements and analysis of disc/nerve root relationships during dynamic postural loading. Disturbed function of soft tissue structures in response to various postural situations may result in discrepancies between subjective symptoms, neurological signs, and morphological findings arising out of the static supine position. Stability analysis by means of dynamic MRI studies may also assist in determining the optimum surgical procedure for any given patient.","2 LF UK FN & Motole, Klin Rehabil Telovychovneho Lekarstvi, Prague 15006 5, Czech Republic; [Stulik, J.] FN Motole, Oddeleni Spondylochirurg, Prague, Czech Republic; [Kyncl, M.] FN Motole, LF UK Praze, Klin Zobrazovacfch Metod 2, Prague, Czech Republic; [Kolar, P.] FN Motole, LF UK Praze, Klin Rehabil Telovychovneho Lekarstvi 2, Prague 15006 5, Czech Republic","Kolar, P, 2 LF UK FN & Motole, Klin Rehabil Telovychovneho Lekarstvi, Uvalu 84, Prague 15006 5, Czech Republic","pavel.kolar@fnmotol.cz",null,null,null,10,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,4,null,null,null,438,442,null,null,5,"Neurosciences; Surgery","648IK","ISI:000281685800014"]
["nemá","J","Kopkan, L; Hess, A; Huskova, Z; Cervenka, L; Navar, LG; Majid, DSA",null,null,null,"Kopkan, Libor; Hess, Arthur; Huskova, Zuzana; Cervenka, Ludek; Navar, L. Gabriel; Majid, Dewan S. A.",null,"High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity","AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY",null,"English","Article",null,null,null,null,null,"superoxide anion; nitric oxide; kidney function; hypertension","NITRIC-OXIDE SYNTHASE; THICK ASCENDING LIMB; ARTERIAL-PRESSURE RESPONSE; ACTIVATED PROTEIN-KINASE; BLOOD-PRESSURE; OXIDATIVE STRESS; HYPERTENSIVE-RATS; NACL ABSORPTION; NADPH OXIDASE; RENAL INJURY","Kopkan L, Hess A, Huskova Z, Cervenka L, Navar LG, Majid DS. High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. Am J Physiol Renal Physiol 299: F656-F663, 2010. First published July 7, 2010; doi:10.1152/ajprenal.00047.2010.-A deficiency in nitric oxide (NO) generation leads to salt-sensitive hypertension, but the role of increased superoxide (O-2(-)) in such salt sensitivity has not been delineated. We examined the hypothesis that an enhancement in O-2(-) activity induced by high-salt (HS) intake under deficient NO production contributes to the development of salt-sensitive hypertension. Endothelial NO synthase knockout (eNOS KO; total n = 64) and wild-type (WT; total n = 58) mice were given diets containing either normal (NS; 0.4%) or high-salt (HS; 4%) for 2 wk. During this period, mice were chronically treated with a O-2(-) scavenger, tempol (400 mg/l), or an inhibitor of NADPH oxidase, apocynin (1 g/l), in drinking water or left untreated (n = 6-8 per group). Blood pressure was measured by radiotelemetry and 24-h urine samples were collected in metabolic cages. Basal mean arterial pressure (MAP) in eNOS KO was higher (125 +/- 4 vs. 106 +/- 3 mmHg) compared with WT. Feeding HS diet did not alter MAP in WT but increased it in eNOS KO to 166 +/- 9 mmHg. Both tempol and apocynin treatment significantly attenuated the MAP response to HS in eNOS KO (134 +/- 3 and 139 +/- 4 mmHg, respectively). Basal urinary 8-isoprostane excretion rates (UIsoV), a marker for endogenous O-2(-) activity, were similar (2.8 +/- 0.2 and 2.4 +/- 0.3 ng/day) in both eNOS KO and WT mice. However, HS increased UIsoV more in eNOS KO than in WT (4.6 +/- 0.3 vs. 3.8 +/- 0.2 ng/day); these were significantly attenuated by both tempol and apocynin treatment. These data indicate that an enhancement in O-2(-) activity contributes substantially to the development of salt-sensitive hypertension under NO-deficient conditions.","[Kopkan, Libor; Hess, Arthur; Navar, L. Gabriel; Majid, Dewan S. A.] Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA; [Kopkan, Libor; Hess, Arthur; Navar, L. Gabriel; Majid, Dewan S. A.] Tulane Univ, Hlth Sci Ctr, Renal Ctr Excellence, New Orleans, LA 70112 USA; [Kopkan, Libor; Huskova, Zuzana; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Kopkan, Libor; Huskova, Zuzana; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Majid, DSA, Tulane Univ, Hlth Sci Ctr, Dept Physiol, 1430 Tulane Ave, New Orleans, LA 70112 USA","majid@tulane.edu","National Heart, Lung, and Blood Institute [HL-66432, HL-18426]; Louisiana Board of Regents and Tulane Enhancement ; Grant Agency of the Academy of Sciences of the Czech Republic [KJB-502030801]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9699-4]; Czech Science Foundation [305/08/P053]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Center for Cardiovascular Research [1M6798582302]; European Union [CZ.2.16/3.1.00/22126]; American Heart Association ","This study was supported by the National Heart, Lung, and Blood Institute Grants HL-66432 and HL-18426 and Louisiana Board of Regents and Tulane Enhancement fund. L. Kopkan is also supported by Grant KJB-502030801 from Grant Agency of the Academy of Sciences of the Czech Republic and Grant NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. Z. Huskova is supported by Grant No. 305/08/P053 awarded by Czech Science Foundation. L. Cervenka is currently supported by institutional finance support from the Institute for Clinical and Experimental Medicine (no. MZO 00023001) and Center for Cardiovascular Research (no. 1M6798582302). Some financial support from European Union (Operational Program Prague Competitiveness project-CEVKOON; no. CZ.2.16/3.1.00/22126) was also used in this study. A. Hess was a medical student supported by American Heart Association summer student research fellowship program.",null,51,0,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","1931-857X",null,"10.1152/ajprenal.00047.2010","AMER J PHYSIOL-RENAL PHYSIOL","Am. J. Physiol.-Renal Physiol.","SEP",2010,299,3,null,null,null,"F656","F663",null,null,8,"Physiology; Urology & Nephrology","646KC","ISI:000281537700019"]
["nemá","J","Nesnidal, P; Stulik, J; Sebesta, P",null,null,null,"Nesnidal, P.; Stulik, J.; Sebesta, P.",null,"Pulmonary Polymethylmetacrylate Embolism: A Rare Complication of Percutaneous Vertebroplasty","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"complications; polymethylmetacrylate; pulmonary embolism; vertebroplasty","ACRYLIC CEMENT; POLYMETHYLMETHACRYLATE; EMBOLIZATION; KYPHOPLASTY; FRACTURES; LEAKAGE","Percutaneous vertebroplasty is a minimally invasive surgical technique involving transpedicular injection of polymethylmetacrylate into the vertebral body. The aim of this procedure is to enhance the mechanical strength of a pathologically changed vertebra. Currently, the method is most often used for painful osteoporotic vertebral fractures, aggressive haemangiomas, necrotic lesions and spinal tumours, particularly the metastatic ones. Although this method is less invasive, relatively straight-forward and effective, there may be complications. The authors present the case of a 70-year-old woman who, on the second day after surgery, developed a rare symptomatic pulmonary polymethylmetacrylate embolism after percutaneous vertebroplasty performed for osteoporotic fractures of the lumbar spine.","[Nesnidal, P.; Stulik, J.; Sebesta, P.] Spondylochirurg Oddeleni FN Motol, Prague 15006 5, Czech Republic; [Stulik, J.; Sebesta, P.] 3 Chirurg Klinika 1 LF UK, Prague, Czech Republic; [Stulik, J.; Sebesta, P.] FN Motol, Prague, Czech Republic; [Stulik, J.] Ortoped Klin Deti & Dospelych 2 LF UK, Prague, Czech Republic","Nesnidal, P, Spondylochirurg Oddeleni FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic","pnesnidal@centrum.cz",null,null,null,17,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2010,77,4,null,null,null,337,340,null,null,4,"Orthopedics","646JE","ISI:000281535100012"]
["nemá","J","Maxova, H; Vasil'kova, M; Novotna, J; Vajnerova, O; Banasova, A; Vizek, M; Herget, J",null,null,null,"Maxova, Hana; Vasil'kova, Marianna; Novotna, Jana; Vajnerova, Olga; Banasova, Alena; Vizek, Martin; Herget, Jan",null,"Prevention of Mast Cell Degranulation by Disodium Cromoglycate Delayed the Regression of Hypoxic Pulmonary Hypertension in Rats","RESPIRATION",null,"English","Article",null,null,null,null,null,"Chronic hypoxia; Disodium cromoglycate; Hypoxic pulmonary hypertension; Mast cells; Rat; Recovery","BLOOD-PRESSURE; RECOVERY; COLLAGEN; INHIBITION; EXPRESSION; ARTERIES","Background: Pulmonary vascular remodeling induced by chronic hypoxia regresses after return to normoxia. This regression is associated with an increased amount of collagenase in pulmonary mast cells and increased collagenolytic and elastolytic activity in the lung tissue. Objective: The role of lung mast cells during recovery from chronic hypoxia was tested by the inhibition of their degranulation by disodium cromoglycate (DSCG). Methods: Male Wistar rats (n = 46) were exposed to isobaric hypoxia (3 weeks, F(i)O(2)0.1). Thirteen of them were tested immediately at the end of exposure, 17 were treated with DSCG during the first 4 days of recovery and tested on the 5th or 14th day of recovery, 16 untreated animals were measured at the same time intervals. These groups were compared with 12 animals kept in normoxia. The rats were anesthetized (Thiopental) and their pulmonary arterial blood pressure (PAP), cardiac output and heart weight were tested, as well as the collagen composition of the walls of the peripheral pulmonary arteries. Results: DSCG applied during the first 4 days of recovery from chronic hypoxia blocked the decrease in PAP during the early phase of recovery and had no influence on PAP at a later phase. DSCG administration prevents collagen splitting in peripheral pulmonary vessels at the early phase of recovery. PAP and right ventricle hypertrophy were normalized after 14 days of return to normoxia. Conclusions: Mast cell degranulation plays a role in the regression of pulmonary hypertension during the early phase of recovery from chronic hypoxia. Copyright (C) 2010 S. Karger AG, Basel","[Maxova, Hana; Vasil'kova, Marianna; Banasova, Alena; Vizek, Martin] Charles Univ Prague, Sch Med 2, Dept Pathol Physiol, CZ-15000 Prague 5, Czech Republic; [Vajnerova, Olga; Herget, Jan] Charles Univ Prague, Sch Med 2, Dept Physiol, CZ-15000 Prague, Czech Republic; [Novotna, Jana] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, CZ-15000 Prague 5, Czech Republic; [Maxova, Hana; Novotna, Jana; Vajnerova, Olga; Vizek, Martin; Herget, Jan] Cardiovasc Res Ctr, Prague, Czech Republic","Maxova, H, Charles Univ Prague, Sch Med 2, Dept Pathol Physiol, Plzenska 130-221, CZ-15000 Prague 5, Czech Republic","hana.maxova@lfmotol.cuni.cz","Grant Agency of Charles University [7228/2007]; Grant Agency of the Czech Republic [305/08/0108]; Cardiovascular Research Centre [MSMT 1M0510]","The study was supported by the Grant Agency of Charles University 7228/2007, the Grant Agency of the Czech Republic 305/08/0108, and by the Cardiovascular Research Centre MSMT 1M0510.",null,19,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0025-7931",null,"10.1159/000312403","RESPIRATION","Respiration",null,2010,80,4,null,null,null,335,339,null,null,5,"Respiratory System","642OB","ISI:000281224000010"]
["nemá","J","Kubinova, S; Sykova, E",null,null,null,"Kubinova, Sarka; Sykova, Eva",null,"Nanotechnologies in regenerative medicine","MINIMALLY INVASIVE THERAPY & ALLIED TECHNOLOGIES",null,"English","Review",null,null,null,null,null,"Nanotechnology; regenerative medicine; nanofibers; cell therapy; iron-oxide nanoparticles","PEPTIDE NANOFIBER SCAFFOLD; MAGNETIC-RESONANCE TRACKING; IRON-OXIDE NANOPARTICLES; MESENCHYMAL STEM-CELLS; SPINAL-CORD-INJURY; IN-VIVO; ELECTROSPUN NANOFIBERS; ANTIBACTERIAL PROPERTIES; MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELLS","Nanotechnology offers promising perspectives in biomedical research as well as in clinical practice. To cover some of the latest nanotechnology trends in regenerative medicine, this review will focus on the use of nanomaterials for tissue engineering and cell therapy. Nanofibrous materials that mimic the native extracellular matrix and promote the adhesion of various cells are being developed as tissue-engineered scaffolds for the skin, bone, vasculature, heart, cornea, nervous system, and other tissues. A range of novel materials has been developed to enhance the bioactive or therapeutic properties of these nanofibrous scaffolds via surface modifications, including the immobilization of functional cell-adhesive ligands and bioactive molecules such as drugs, enzymes and cytokines. As a new approach, nanofibers prepared by using industrial scale needleless technology have been recently introduced, and their use as scaffolds to treat spinal cord injury or as cell carriers for the regeneration of the injured cornea is the subject of much current study. Cell therapy is a modern approach of regenerative medicine for the treatment of various diseases or injuries. To follow the migration and fate of transplanted cells, superparamagnetic iron oxide nanoparticles have been developed for cell labeling and non-invasive MRI monitoring of cells in the living organism, with successful applications in, e. g, the central nervous system, heart, liver and kidney and also in pancreatic islet and stem cell transplantation.","[Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Sykova, E, Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic","sykova@biomed.cas.cz","GAAV [IAA 500 390 902]; EC [LSHM-CT-2005-019063]; GACR [203/09/1242, KAN201110651, P108/10/1560, KAN200520804]; [AVOZ 503 90 703]; [1M0538]; [LC 554]","We thank James Dutt for critical reading of the manuscript. This work was supported through the grants: AVOZ 503 90 703, 1M0538, LC 554, GAAV IAA 500 390 902, the EC FP6 project ENINET (LSHM-CT-2005-019063), GACR 203/09/1242, KAN201110651, P108/10/1560, KAN200520804.",null,95,0,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","1364-5706",null,"10.3109/13645706.2010.481398","MINIM INVASIVE THER ALLIED T","Minim. Invasive Ther. Allied Technol.","JUN-AUG",2010,19,"2010-04-03",null,null,null,144,156,null,null,13,"Surgery","643JV","ISI:000281293500004"]
["nemá","J","Cap, J; Ceeova, V; Skacha, M; Rezek, P; Vlcek, P; Blaha, M",null,null,null,"Cap, J.; Ceeova, V.; Skacha, M.; Rezek, P.; Vlcek, P.; Blaha, M.",null,"Plasma Filtration in the Treatment of Graves' Ophthalmopathy: A Randomized Study","JOURNAL OF CLINICAL APHERESIS",null,"English","Article",null,null,null,null,null,"thyroid-associated ophthalmopathy; treatment; plasma filtration; clinical activity score","PLASMAPHERESIS; EXCHANGE; IMMUNOADSORPTION; IMMUNOGLOBULINS; EXOPHTHALMOS; THERAPY; DISEASE; SERUM","The aim of this study was to perform a randomized study to evaluate the role of plasma filtration in the treatment of severe thyroid-associated ophthalmopathy (TAO). 20 patients were enrolled, and all patients were treated with methylprednisolone IV pulses. 10 randomly chosen patients were also subjected to plasma filtration (twice weekly in Weeks 1, 2, 4, 7, and 10). The procedure proved to be safe. All immunoglobulin classes as well as autoantibodies directed against thyroglobulin, thyroid peroxidase, and TSH receptor exhibited statistically significantly decreases. Some markers of cell-mediated immunity such as soluble antigen CD30 and monocyte chemotactic protein 1 decreased, but serum levels of other markers such as CD40 ligand and soluble protein Fas/Apo-1 did not change significantly. The decrease of immunoglobulins was long lasting, whereas cytokine levels returned to basal values before the next apheresis. Although the clinical activity score (CAS) dropped in all patients, it occurred more rapidly in patients treated with plasma filtration. The CAS difference between the two groups was statistically significant (p = 0.027). The amplitude of visual evoked potentials improved after 3 months in the plasma filtration group. At the end of the study, there was no difference between patients treated with aphereses and the control group. Eye muscle width and proptosis measured by CT scan did not differ between the two groups. We conclude that apheresis can decrease disease activity more rapidly than standard high-dose IV glucocorticoid therapy. Whether this superior treatment effect could potentially avoid surgical procedures remains to be determined. J. Clin. Apheresis 25:209-215, 2010. (C) 2010 Wiley-Liss. Inc.","[Cap, J.; Ceeova, V.; Blaha, M.] Charles Univ Prague, Fac Med, Dept Internal Med 2, Hradec Kralove, Czech Republic; [Cap, J.; Ceeova, V.; Blaha, M.] Charles Univ Prague, Teaching Hosp, Hradec Kralove, Czech Republic; [Skacha, M.; Rezek, P.; Vlcek, P.] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Skacha, M.; Rezek, P.; Vlcek, P.] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic","Cap, J, Univ Hosp, Dept Internal Med 2, Sokolska 581, Hradec Kralove 50005, Czech Republic","capj@lfhk.cuni.cz","Czech Ministry of Health Agency IGA [NR 9181-3]","Contract grant sponsor: The Czech Ministry of Health Agency IGA; Contract grant number: NR 9181-3",null,28,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0733-2459",null,"10.1002/jca.20244","J CLINICAL APHERESIS","J. Clin. Apheresis",null,2010,25,4,null,null,null,209,215,null,null,7,"Hematology","641ZH","ISI:000281171800005"]
["nemá","J","Pleskacova, J; Rucklova, K; Popelova, J; Cerny, S; Syrucek, M; Snajderova, M; Lebl, J",null,null,null,"Pleskacova, Jana; Rucklova, Kristina; Popelova, Jana; Cerny, Stepan; Syrucek, Martin; Snajderova, Marta; Lebl, Jan",null,"Aortic dissection and rupture in a 16-year-old girl with Turner syndrome following previous progression of aortic dilation","EUROPEAN JOURNAL OF PEDIATRICS",null,"English","Article",null,null,null,null,null,"Turner syndrome; Aortic dissection; Progression of aortic dilation","NORMAL-CHILDREN; ABNORMALITIES; DILATATION; DIMENSIONS; ADULTS; YOUNG","Aortic dissection occurs in Turner syndrome with substantially higher frequency in comparison to the general population, and its prevention is one of the main aims of cardiologic follow-up. Findings of cystic medial necrosis in the aortic wall and a high prevalence of aortic dilation suggest that a form of aortopathy exists in Turner syndrome. However, little is known about natural development of aortic dilation prior to dissection. We present a 16-year-old girl with Turner syndrome with a bicuspid aortic valve, aortic stenosis, and dilation of ascending aorta, who underwent annual echocardiographic examinations from early childhood. Significant progressions of proximal aortic dilation occurred twice at the age of 10 and 15 years. Thereafter, another rapid progression was observed during 8 months and within 3 weeks preceding dissection. Acute aortic dissection was diagnosed while the girl was waiting for elective surgery. She was successfully operated. Frequent estimations of aortic diameter in Turner patients with abnormal findings may help to anticipate this life-threatening event. Additionally, we learned that rapid progression of aortic dilation should lead to immediate surgery to prevent more risky urgent intervention following the dissection.","[Pleskacova, Jana; Rucklova, Kristina; Snajderova, Marta; Lebl, Jan] Univ Hosp Motol, Dept Pediat, Prague 15006 5, Czech Republic; [Pleskacova, Jana; Rucklova, Kristina; Snajderova, Marta; Lebl, Jan] Charles Univ Prague, Prague, Czech Republic; [Popelova, Jana; Cerny, Stepan] Hosp Na Homolce, Dept Cardiac Surg, Prague, Czech Republic; [Syrucek, Martin] Hosp Na Homolce, Dept Pathol, Prague, Czech Republic","Pleskacova, J, Univ Hosp Motol, Dept Pediat, V Uvalu 84, Prague 15006 5, Czech Republic","pleskac.jana@seznam.cz","Czech Ministry of Health [VZMZO 64203-6306]; MSM [0021620814]","This article was written with research project support from the Czech Ministry of Health MZOFNM2005 (VZMZO 64203-6306) and of MSM (0021620814).",null,15,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,"10.1007/s00431-010-1197-4","EUR J PEDIAT","Eur. J. Pediatr.","OCT",2010,169,10,null,null,null,1283,1286,null,null,4,"Pediatrics","642SV","ISI:000281238700019"]
["nemá","J","Charvat, J; Chlumsky, J; Szabo, M; Zakovicova, E; Zamrazil, V",null,null,null,"Charvat, Jiri; Chlumsky, Jaromir; Szabo, Marcela; Zakovicova, Eva; Zamrazil, Vaclav",null,"The association of masked hypertension in treated type 2 diabetic patients with carotid artery IMT","DIABETES RESEARCH AND CLINICAL PRACTICE",null,"English","Article",null,null,null,null,null,"Masked hypertension; Type 2 diabetes mellitus; Carotid intima-media thickness; Carotid distensibility","TARGET ORGAN DAMAGE; BLOOD-PRESSURE; HOME HYPERTENSION; OFFICE; MELLITUS; PEOPLE","Objectives: To evaluate the association of masked hypertension (MH) in treated type 2 diabetic patients without history of cardiovascular disease with carotid artery target organ damage. Methods: Sixty-four type 2 diabetic patients treated for hypertension with office BP below 140/90 mm Hg were examined by 24-h BP monitoring and carotid sonography. MH was diagnosed if daily mean ambulatory BP was >= 135/85 mm Hg. The association of MH with carotid artery parameters was evaluated. Results: The average age of patients was 62 +/- 5 years. Twenty-four patients had MH (37.5%). Carotid artery IMT was 0.74 +/- 0.08 mm in patients with MH and 0.69 +/- 0.06 mm without MH (p = 0.03). The distensibility of common carotid artery was 0.24 +/- 0.07 mmHg(-1) in patients with MH and 0.29 +/- 0.1 mm Hg-1 without MH (p = 0.14). After adjustment for age, gender, smoking, duration of diabetes, BMI and clinic blood pressure (BP) values the association of MH with carotid artery IMT was sustained. Conclusion: Masked hypertension in treated type 2 diabetic patients is associated with carotid artery IMT. (C) 2010 Elsevier Ireland Ltd. All rights reserved.","[Charvat, Jiri; Chlumsky, Jaromir; Szabo, Marcela; Zakovicova, Eva; Zamrazil, Vaclav] Charles Univ Prague, Fac Hosp 2, Dept Med, Prague 15006 5, Czech Republic","Charvat, J, Charles Univ Prague, Fac Hosp 2, Dept Med, V Uvalu 84, Prague 15006 5, Czech Republic","jiri.charvat@lfmotol.cuni.cz","IGA Ministry of Health of Czech republic [NR/ 9520-3]","Supported by a grant from IGA Ministry of Health of Czech republic, NR/ 9520-3.",null,22,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0168-8227",null,"10.1016/j.diabres.2010.04.014","DIABETES RES CLIN PRACT","Diabetes Res. Clin. Pract.","SEP",2010,89,3,null,null,null,239,242,null,null,4,"Endocrinology & Metabolism","643AB","ISI:000281263000007"]
["nemá","J","Zolotarevova, E; Entlicher, G; Pavlova, E; Slouf, M; Pokorny, D; Vesely, F; Gallo, J; Sosna, A",null,null,null,"Zolotarevova, E.; Entlicher, G.; Pavlova, E.; Slouf, M.; Pokorny, D.; Vesely, F.; Gallo, J.; Sosna, A.",null,"Distribution of polyethylene wear particles and bone fragments in periprosthetic tissue around total hip joint replacements","ACTA BIOMATERIALIA",null,"English","Article",null,null,null,null,null,"Joint replacement; Polyethylene; Wear particles distribution; Periprosthetic tissue; Defense mechanism","UHMWPE WEAR; IN-VIVO; RADIOGRAPHIC APPEARANCE; DEBRIS; ARTHROPLASTY; OSTEOLYSIS; SIZE; QUANTIFICATION; COLLAGENASES; MACROPHAGES","Ultra-high molecular molecular weight polyethylene (UHMWPE) wear particles play a significant role in failures of total joint replacements (TJRs). In this work, we investigated the distribution of these wear particles in periprosthetic tissues obtained from nine revisions of hip TJR. In the first step, all periprosthetic tissues were combined and mechanically separated into granuloma tissue (containing hard granules visible to the naked eye) and surrounding tissue (without visible granules). In the second step, the tissues were hydrolyzed by protease from Streptomyces griseus and granules were separated by filtration; this divided the sample into four groups: (i) lyzate and (ii) non-degraded large granules from the granuloma tissue plus (iii) lyzate and (iv) non-degraded small granules from the surrounding tissue. In the third step, the large as well as small granules were hydrolyzed by collagenase from Clostridium histolyticum. In the last step, the UHMWPE wear particles from all four groups were purified by HNO3 digestion and weighed. The purity of the isolated particles was verified by scanning electron microscopy, infrared spectroscopy and energy-dispersive X-ray analysis. Of the total amount of polyethylene particles in the whole granuloma tissue, 72% of particles in the size range 0.1-10 mu m and 68% of those larger than 10 pm were found in granules. Therefore, the formation of granules significantly lowers the effective amount of wear particles available for interaction with reactive cells and seems to be a natural defense mechanism. (C) 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","[Zolotarevova, E.; Entlicher, G.] Charles Univ Prague, Fac Sci, Prague 12840 2, Czech Republic; [Pavlova, E.; Slouf, M.] Inst Macromol Chem AS CR, Vvi, Prague 16206 6, Czech Republic; [Pokorny, D.; Vesely, F.; Sosna, A.] Charles Univ Prague, Orthoped Clin, Fac Med 1, Fac Hosp Motol, Prague 15606 5, Czech Republic; [Gallo, J.] Palacky Univ, Fac Med, Orthoped Clin, Olomouc 77520, Czech Republic","Zolotarevova, E, Charles Univ Prague, Fac Sci, Hlavova 8, Prague 12840 2, Czech Republic","ezolotarevova@gmail.com","Ministry of Education, Youth and Sports of the Czech Republic [MSMT 2B06096]","This work was supported by grant of the Ministry of Education, Youth and Sports of the Czech Republic (MSMT 2B06096).",null,28,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1742-7061",null,"10.1016/j.actbio.2010.04.010","ACTA BIOMATER","Acta Biomater.","SEP",2010,6,9,null,null,null,3595,3600,null,null,6,"Engineering, Biomedical; Materials Science, Biomaterials","643SG","ISI:000281318400026"]
["nemá","J","Zuna, J; Zaliova, M; Muzikova, K; Meyer, C; Lizcova, L; Zemanova, Z; Brezinova, J; Votava, F; Marschalek, R; Stary, J; Trka, J",null,null,null,"Zuna, Jan; Zaliova, Marketa; Muzikova, Katerina; Meyer, Claus; Lizcova, Libuse; Zemanova, Zuzana; Brezinova, Jana; Votava, Felix; Marschalek, Rolf; Stary, Jan; Trka, Jan",null,"Acute Leukemias with ETV6/ABL1 (TEL/ABL) Fusion: Poor Prognosis and Prenatal Origin","GENES CHROMOSOMES & CANCER",null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; CHRONIC MYELOID-LEUKEMIA; ETV6-ABL GENE REARRANGEMENT; TYROSINE KINASE; TEL-ABL; CYTOGENETIC CHARACTERIZATION; MYELOPROLIFERATIVE DISORDER; IMATINIB-MESYLATE; BCR-ABL","The ETV6/ABL1 (TEL/ABL) fusion gene is a rare aberration in malignant disorders. Only 19 cases of ETV6/ABL1-positive hematological malignancy have been published, diagnosed with chronic myeloid leukemia, other types of chronic myeloproliferative neoplasm, acute myeloid leukemia or acute lymphoblastic leukemia (ALL). This study reports three new cases (aged 8 months, 5 years, and 33 years) of ALL with the ETV6/ABL1 fusion found by screening 392 newly diagnosed ALL patients (335 children and 57 adults). A thorough review of the literature and an analysis of all published data, including the three new cases, suggest poor prognosis of ETV6/ABL1-positive acute leukemias. The course of the disease in the two pediatric patients is characterized by minimal residual disease monitoring, using quantification of both the ETV6/ABL1 transcript and immunoreceptor gene rearrangements. Eosinophilia could not be confirmed as a hallmark of the ETV6/ABL1-positive disease. Studies of neonatal blood spots demonstrated that, in the child diagnosed at five years, the ETV6/ABL1 fusion initiating the ALL originated prenatally. (C) 2010 Wiley-Liss, Inc.","[Zuna, Jan; Zaliova, Marketa; Muzikova, Katerina; Stary, Jan; Trka, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Zuna, Jan; Zaliova, Marketa; Muzikova, Katerina; Stary, Jan; Trka, Jan] Univ Hosp Motol, Prague, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Goethe Univ Frankfurt, Bioctr, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol,ZAFES, Frankfurt, Germany; [Lizcova, Libuse; Zemanova, Zuzana] Gen Univ Hosp, Inst Clin Biochem & Lab Diagnost, Ctr Oncocytogenet, Prague, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague 15006 5, Czech Republic; [Brezinova, Jana] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Votava, Felix] Charles Univ Prague, Fac Med 3, Dept Pediat, Prague 15006 5, Czech Republic","Zuna, J, Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic","jan.zuna@lfmotol.cuni.cz","[MSM0021620813]; [IGA-MZ NS10004]; [MZOFNM2005]; [MZOVFN2005]","Grant numbers: MSM0021620813, IGA-MZ NS10004, MZOFNM2005, MZOVFN2005.",null,41,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1045-2257",null,"10.1002/gcc.20796","GENE CHROMOSOME CANCER","Gene Chromosomes Cancer","OCT",2010,49,10,null,null,null,873,884,null,null,12,"Oncology; Genetics & Heredity","640ZC","ISI:000281091900002"]
["nemá","J","Amant, F; Brepoels, L; Halaska, MJ; Gziri, MM; Van Calsteren, K",null,null,null,"Amant, Frederic; Brepoels, Lieselot; Halaska, Michael J.; Gziri, Mina Mhallem; Van Calsteren, Kristel",null,"Gynaecologic cancer complicating pregnancy: An overview","BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY",null,"English","Article",null,null,null,null,null,"cancer; pregnancy; radiotherapy; surgery; chemotherapy; neonatal","OF-THE-LITERATURE; ENDODERMAL SINUS TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; METASTATIC BREAST-CANCER; TERM-FOLLOW-UP; VAGINAL RADICAL TRACHELECTOMY; EPITHELIAL OVARIAN-CARCINOMA; CHEMOTHERAPY IN-UTERO; CELL LUNG-CANCER; NEOADJUVANT CHEMOTHERAPY","Cancer complicating pregnancy endangers two lives. Any approach should look at both maternal and foetal safety. Maternal prognosis will not improve by terminating the pregnancy. Imaging for staging purposes is possible, and sonar and magnetic resonance imaging are the preferred examinations. Abdominopelvic computed tomography exposes the foetus to the highest doses radiation and should be avoided. Provided a thorough maternal monitoring to ensure a stable uteroplacental blood flow and foetal oxygenation, surgical techniques that are used in non-pregnant patients are also safe for pregnant patients. Radiotherapy of the upper part of the body is possible during pregnancy, but during the third trimester the close distance may put the foetus at risk. Chemotherapy during the second or third trimester can be administered without increasing the incidence of congenital malformations. A systematic analysis, especially on the long-term outcome of the offspring after cancer treatment during pregnancy is still lacking. Here, we present a summary of issues related to the diagnosis and treatment of gynaecological malignancies during pregnancy. Firstly, we describe general diagnostic and cancer-treatment-related problems. In the second part, organ pathology including breast, cervical, ovarian, endometrial and vulvar cancer is discussed. (C) 2009 Elsevier Ltd. All rights reserved.","[Amant, Frederic; Brepoels, Lieselot; Van Calsteren, Kristel] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Gziri, Mina Mhallem] Catholic Univ Louvain, Louvain, Belgium","Amant, F, Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Louvain, Belgium","Frederic.amant@uz.kuleuven.ac.be","F.W.O. [G. 0358.06, SCIE2006-17]; K.U.Leuven ","Frederic Amant is clinical researcher for F.W.O.: Kristel Van Calsteren is aspirant for F.W.O.; This work is supported by F.W.O. Project G. 0358.06, 'Stichting tegen kanker Project SCIE2006-17', Research Fund K.U.Leuven.",null,162,2,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1521-6934",null,"10.1016/j.bpobgyn.2009.08.001","BEST PRACT RES CLIN OBSTET GY","Best Pract. Res. Clin. Obstet. Gynaecol.","FEB",2010,24,1,null,null,null,61,79,null,null,19,"Obstetrics & Gynecology","638VR","ISI:000280926100007"]
["nemá","J","Charvat, J; Chlumsky, J; Zakovicova, E; Kvapil, M",null,null,null,"Charvat, J.; Chlumsky, J.; Zakovicova, E.; Kvapil, M.",null,"Common Carotid Artery Intima-media Thickness is not Increased but Distensibility is Reduced in Normotensive Patients with Type 2 Diabetes compared with Control Subjects","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,"English","Article",null,null,null,null,null,"TYPE 2 DIABETES MELLITUS; COMMON CAROTID ARTERY; INTIMA-MEDIA THICKNESS; ATHEROMA; DISTENSIBILITY","CARDIOVASCULAR MORTALITY; METABOLIC SYNDROME; BLOOD-PRESSURE; ATHEROSCLEROSIS; STIFFNESS; RISK; MANIFESTATIONS; CHOLESTEROL; DYSFUNCTION; MELLITUS","This study evaluated carotid artery parameters in normotensive patients with type 2 diabetes compared with nondiabetic control subjects. Using a high-resolution B-mode ultrasound scanner, common carotid artery intima-media thickness (IMT) and carotid tree atheroma thickness were measured in 82 patients with type 2 diabetes and 41 controls. The distensibility of the common carotid artery was calculated using the Reneman equation. Distensibility was significantly decreased and atheroma thickness was significantly increased in the diabetes group. There was no significant difference in IMT between the two groups. Stepwise linear regression analysis revealed an association between common carotid artery distensibility and post-ischaemic dilatation of the brachial artery (a measure of endothelial function), body mass index and diabetes duration in patients with type 2 diabetes. In conclusion, common carotid artery IMT in normotensive patients with type 2 diabetes is comparable to that of control subjects, whereas atheroma thickness is higher and arterial stiffness more pronounced in those with type 2 diabetes, indicating the existence of atherosclerotic changes in normotensive type 2 diabetes patients.","[Charvat, J.; Chlumsky, J.; Zakovicova, E.; Kvapil, M.] Charles Univ Prague, Fac Med 2, Dept Med, Prague 15006 5, Czech Republic","Charvat, J, Charles Univ Prague, Fac Med 2, Dept Med, V Uvalu 84, Prague 15006 5, Czech Republic","jiri.charvat@lfmotol.cuni.cz","Ministry of Health of the Czech Republic [NR/9520-3]","This work was supported by a grant from the Ministry of Health of the Czech Republic (NR/9520-3).",null,26,0,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","MAY-JUN",2010,38,3,null,null,null,860,869,null,null,10,"Medicine, Research & Experimental; Pharmacology & Pharmacy","635SY","ISI:000280677800013"]
["nemá","J","Rob, L; Pluta, M; Skapa, P; Robova, H",null,null,null,"Rob, Lukas; Pluta, Marek; Skapa, Petr; Robova, Helena",null,"Advances in fertility-sparing surgery for cervical cancer","EXPERT REVIEW OF ANTICANCER THERAPY",null,"English","Review",null,null,null,null,null,"cervical cancer; fertility-sparing surgery; radical trachelectomy; sentinel lymph node; simple trachelectomy","ABDOMINAL RADICAL TRACHELECTOMY; SENTINEL LYMPH-NODES; OF-THE-LITERATURE; VAGINAL TRACHELECTOMY; NEOADJUVANT CHEMOTHERAPY; PELVIC LYMPHADENECTOMY; PARAMETRIAL INVOLVEMENT; PRESERVING SURGERY; PATHOLOGICAL EVALUATION; CONSERVATIVE SURGERY","This article reviews the literature on fertility-sparing surgery in early cervical cancer. The article evaluates selection criteria, preoperative management and the most frequent surgical procedures used for preservation of fertility in cervical cancer. The article also analyzes oncological, fertility and pregnancy results. Oncological outcomes are not statistically different among single groups (vaginal radical trachelectomy, abdominal radical trachelectomy, simple trachelectomy or cone with or without neoadjuvant chemotherapy). Oncological results after fertility-sparing procedures in women with tumors smaller than 2 cm are comparable with women with the same risk factors after radical hysterectomy. Pregnancy following fertility-sparing surgery is associated with a variety of adverse pregnancy outcomes, especially second-trimester loss and preterm delivery. Less radical procedures (simple trachelectomy or cone with or without neoadjuvant chemotherapy) show statistically significant better pregnancy results. The pregnancy rate after abdominal radical trachelectomy was dramatically lower than in women treated with other types of fertility-sparing surgery. In the future, it will be necessary to optimize the technique and management of fertility-sparing surgery in order to attain good oncological results. Pregnancy outcomes should be given high priority. Fertility-sparing surgery is valuable for women who want to preserve their reproductive capability.","[Rob, Lukas; Pluta, Marek; Robova, Helena] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Div Gynecol Oncol, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol Anat & Mol Med, Prague, Czech Republic","Rob, L, Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Div Gynecol Oncol, Prague, Czech Republic","lukas.rob@lfmotol.cuni.cz","[NS 9914-4]","This work was supported by grant NS 9914-4. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.",null,83,0,"EXPERT REVIEWS","LONDON","UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND","1473-7140",null,"10.1586/ERA.10.61","EXPERT REV ANTICANCER THER","Expert Rev. Anticancer Ther","JUL",2010,10,7,null,null,null,1101,1114,null,null,14,"Oncology","633XJ","ISI:000280540200021"]
["nemá","J","Lurbe, E; Cifkova, R; Cruickshank, JK; Dillon, MJ; Ferreira, I; Invitti, C; Kuznetsova, T; Laurent, S; Mancia, G; Morales-Olivas, F; Rascher, W; Redon, J; Schaefer, F; Seeman, T; Stergiou, G; Wuhl, E; Zanchetti, A",null,null,null,"Lurbe, E.; Cifkova, R.; Cruickshank, J. K.; Dillon, M. J.; Ferreira, I.; Invitti, C.; Kuznetsova, T.; Laurent, S.; Mancia, G.; Morales-Olivas, F.; Rascher, W.; Redon, J.; Schaefer, F.; Seeman, T.; Stergiou, G.; Wuehl, E.; Zanchetti, A.",null,"Management of high blood pressure in children and adolescents: Recommendations of the European Society of Hypertension","ANALES DE PEDIATRIA",null,"Spanish","Article",null,null,null,null,null,null,null,null,"[Lurbe, E.] Univ Valencia, Dept Pediat, Consorcio Hosp Gen, Valencia, Spain; [Lurbe, E.; Redon, J.] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid, Spain; [Cifkova, R.] Inst Clin & Expt Med, Dept Cardiol Prevent, Prague, Czech Republic; [Cruickshank, J. K.] Univ Manchester, Grp Invest Cardiovasc, Manchester Royal Infirm, Div Ciencia Cardiovasc & Endocrina, Manchester, Lancs, England; [Dillon, M. J.] UCL Inst Salud Infantil, Unidad Nefrourol, London, England; [Ferreira, I.] Univ Maastricht, Dept Med Interna & Epidemiol Clin & Evaluac Tecno, Inst Invest Cardiovasc Maastricht CARIM, Inst Invest Cuidado & Salud Publ CAPHRI,Ctr Med, Maastricht, Netherlands; [Invitti, C.] IRCCS, Unidad Enfermedades Metabol & Diabet, Inst Auxol Italiano, Milan, Italy; [Kuznetsova, T.] Univ Leuven, Lab Hipertens, Leuven, Belgium; [Laurent, S.] Hosp Europeo Georges Pompidou, Dept Farmacol, Paris, France; [Mancia, G.] Univ Milano Bicocca, Osped San Gerardo, Milan, Italy; [Morales-Olivas, F.] Univ Valencia, Dept Farmacol, Valencia, Spain; [Rascher, W.] Univ Klinikum, Kinder & Jugendklin, Erlangen, Germany; [Redon, J.] Univ Valencia, Dept Med Interna, Hosp Clin, Valencia, Spain; [Schaefer, F.; Wuehl, E.] Univ Heidelberg, Div Nefrol Pediat, Ctr Med Pediat & Adolescencia, Heidelberg, Germany; [Seeman, T.] Charles Univ Prague, Dept Pediat, Hosp Univ Motol, Prague, Czech Republic","Lurbe, E, Univ Valencia, Dept Pediat, Consorcio Hosp Gen, Valencia, Spain",null,null,null,null,0,0,"EDICIONES DOYMA S A","BARCELONA","TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN","1695-4033",null,"10.1016/j.anpedi.2010.04.001","AN PEDIATR","An. Pediatr.","JUL",2010,73,1,null,null,null,51,51,null,null,1,"Pediatrics","630YZ","ISI:000280314200011"]
["nemá","J","Vanourkova, Z; Kramer, HJ; Huskova, Z; Cervenka, L; Vaneckova, I",null,null,null,"Vanourkova, Z.; Kramer, H. J.; Huskova, Z.; Cervenka, L.; Vaneckova, I.",null,"Despite Similar Reduction of Blood Pressure and Renal ANG II and ET-1 Levels Aliskiren but not Losartan Normalizes Albuminuria in Hypertensive Ren-2 Rats","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Ren-2 rats; Hypertension; Renin-angiotensin system; Endothelin system; RAS blockade; Aliskiren; Losartan; Albuminuria","ENDOTHELIN RECEPTOR BLOCKADE; RENIN-ANGIOTENSIN SYSTEM; CONVERTING ENZYME; MAST-CELLS; KIDNEY; EXPRESSION; ACTIVATION; DISEASE; FLUID","The relationship between angiotensin II (ANG II) and endothelin-1 (ET-1) is known to be complex; both peptides can initiate and potentiate the gene expression of each other. This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels. 3-month-old male Ren-2 transgenic rats (TGR) were treated either with losartan (5 mg kg(-1) day(-1)) or aliskiren (10 mg kg(-1) day(-1)) for 10 weeks. At the end of the experiment, rats were decapitated and cortical and papillary parts of kidneys were separated. Plasma and tissue ANG II levels were measured by RIA and tissue ET-1 concentrations by ELISA. In all four groups of animals ET-1 levels were lowest in renal cortex and more than 100-fold higher in the papilla. Cortical and papillary ET-1 concentrations in untreated TGR significantly exceeded those of control HanSD rats and were significantly depressed by both drugs. In both strains, papillary ANG II concentrations were moderately but significantly higher than cortical ANG II, TGR exhibited higher ANG II levels both in cortex and papilla as compared to control HanSD rats. Aliskiren and losartan at the doses used depressed similarly the levels of ANG II in cortex and papilla and reduced ET-1 significantly in the renal cortex and papilla below control levels in HanSD rats. Albuminuria, which was more than twice as high in TGR as in HanSD rats, was normalized with aliskiren and reduced by 28 % with losartan, although MAP was reduced to a similar degree by both drugs. Despite similar reductions of MAP and renal ET-1 and ANG II levels aliskiren appears to be more effective than losartan, at the doses used, in reducing albuminuria in heterozygous hypertensive Ren-2 rats.","[Vanourkova, Z.; Huskova, Z.; Cervenka, L.; Vaneckova, I.] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Vanourkova, Z.; Huskova, Z.; Cervenka, L.; Vaneckova, I.] Inst Clin & Expt Med, Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, H. J.] Univ Bonn, Nephrol Sect, Med Policlin, Dept Med, D-5300 Bonn, Germany; [Cervenka, L.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Vaneckova, I, Inst Physiol AS CR, Dept Expt Hypertens, Videnska 1083, CZ-14220 Prague 4, Czech Republic","ivanava@biomed.cas.cz","Institute for Clinical and Experimental Medicine [MZ 00023001]; Czech Science Foundation [305/07/0167, 305/07/J004, 305/08/P053, 305/08/J006]; German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) [433/14-2, 436 TSE 113/50, 436 TSE 113/56, 436 TSE 113/57/0-1]; German Academic Exchange Service (DAAD) ","I. V. is supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZ 00023001) and the Czech Science Foundation (grants Nr. 305/07/0167 and 305/07/J004). H.J.K. is supported by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft; grants No. 433/14-2 and 436 TSE 113/50, 113/56 and 113/57/0-1) and the German Academic Exchange Service (DAAD). Portions of this work were performed during the stay of Z.V. as a visiting scientist at the University of Bonn, which was supported by a grant from the Deutsche Forschungsgemeinschaft, Bonn (grants No. 433/14-2). Czech Science Foundation supported also Z.H. (grant Nr. 305/08/P053) and L. C. (grant Nr. 305/08/J006).",null,38,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,3,null,null,null,339,345,null,null,7,"Physiology","631QW","ISI:000280363700004"]
["nemá","J","Kabicek, P; Sulek, S; Seidl, Z; Vaneckova, M; Kabickova, E; Vobruba, V; Wenchich, L; Zeman, J",null,null,null,"Kabicek, Pavel; Sulek, Stepan; Seidl, Zdenek; Vaneckova, Manuela; Kabickova, Edita; Vobruba, Vaclav; Wenchich, Laszlo; Zeman, Jiri",null,"Posterior Reversible Encephalopathy Syndrome (PRES) in 5-year-old girl with nephrotic syndrome","NEUROENDOCRINOLOGY LETTERS",null,"English","Article",null,null,null,null,null,"Posterior Reversible Encephalopathy Syndrome (PRES); children; nephrotic syndrome; hypertension; brain angioedema; MRI","STATUS EPILEPTICUS","OBJECTIVE: Posterior Reversible Encephalopathy Syndrome (PRES) is a rare complication of nephrotic syndrome in children. This clinical condition is caused by localized brain angioedema mostly in parieto-occipital region and results in dramatic and acute features as sudden loss of consciousness, epileptic paroxysms, strong headache or visual disturbances. Uncontrolled hypertension often participates in PRES development. CASE: We present the case of a 5-year-old girl treated for relapse of nephrotic syndrome. RESULTS: At the time of edema regression and weight reduction, a sudden loss of consciousness and worsening of hypertension occurred. Brain MRI demonstrated extended multifocal changes strongly suspicious of encephalitis. After exclusion of herpetic encephalitis, the clinical picture was classified as PRES. Successful antihypertensive treatment led to general improvement of the girl's health within 48 hours and resolution of MRI brain hyperintensities occurred within the next three months. CONCLUSIONS: The aim of our case report is to us remind of possible development of PRES at the time of edema regression in nephrotic syndrome.","[Kabicek, Pavel; Sulek, Stepan; Vobruba, Vaclav; Wenchich, Laszlo; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Gen Univ Hosp, Prague 12808 2, Czech Republic; [Kabicek, Pavel; Sulek, Stepan; Seidl, Zdenek; Vaneckova, Manuela; Vobruba, Vaclav; Wenchich, Laszlo; Zeman, Jiri] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Seidl, Zdenek; Vaneckova, Manuela] Charles Univ Prague, Dept Radiol, Gen Univ Hosp, Prague 12808 2, Czech Republic; [Kabickova, Edita] Charles Univ Prague, Dept Pediat Hematooncol, Univ Hosp Motol, Prague 12808 2, Czech Republic; [Kabickova, Edita] Charles Univ Prague, Fac Med 2, Prague 12808 2, Czech Republic","Kabicek, P, Charles Univ Prague, Dept Pediat & Adolescent Med, Gen Univ Hosp, Ke Karlovu 2, Prague 12808 2, Czech Republic","p.kabicek@post.cz","[MSM 0021620849]; [MZ0VFN2005]; [MZ0FNM2005]","This work was carried out thanks to the support of the following grants: MSM 0021620849, MZ0VFN2005 and MZ0FNM2005.",null,11,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2010,31,3,null,null,null,297,300,null,null,4,"Endocrinology & Metabolism; Neurosciences","632XG","ISI:000280462300003"]
["nemá","J","Feberova, J; Dostalova, T; Hladikova, M; Kasal, P; Polasek, J; Seydlova, M; Janda, A; Schwarz, D",null,null,null,"Feberova, Jitka; Dostalova, Tatjana; Hladikova, Marie; Kasal, Pavel; Polasek, Jan; Seydlova, Michaela; Janda, Ales; Schwarz, Daniel",null,"Evaluation of 5-year Experience with E-learning Techniques at Charles University in Prague. Impact on Quality of Teaching and Students' Achievements","NEW EDUCATIONAL REVIEW",null,"English","Article",null,null,null,null,null,"e-learning; Moodle; Learning Management System; medical informatics; quality of teaching; distance learning; blended learning; long term trends","MEDICAL-EDUCATION","Since 2004 implementation of e-learning has been systematically and continuously encouraged and supported at Charles University (CU). Open source system Moodle was chosen as an optimal Learning Management System for creation and management of e-learning courses. Evaluation of the five-year experience with e-learning shows that the continuous support of a suitable environment for the management of e-learning courses leads to the development of spontaneous implementation of this approach into the teaching process. A positive impact of e-learning on teaching outcomes was demonstrated by a course focused on medical informatics.","[Feberova, Jitka; Polasek, Jan] Charles Univ Prague, Ctr Comp, Prague, Czech Republic; [Feberova, Jitka; Hladikova, Marie; Kasal, Pavel] Sch Med 2, Dept Med Informat, Prague, Czech Republic; [Dostalova, Tatjana; Seydlova, Michaela] Sch Med 2, Dept Paediat Stomatol, Prague, Czech Republic; [Janda, Ales] Sch Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Schwarz, Daniel] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic","Feberova, J, Charles Univ Prague, Ctr Comp, Prague, Czech Republic",null,null,null,null,22,0,"WYDAWNICTWO ADAM MARSZALEK","TORUN","UL LUBICKA 44, TORUN, 87-100, POLAND","1732-6729",null,null,"NEW EDUC REV","New Educ. Rev.",null,2010,21,2,null,null,null,110,120,null,null,11,"Education & Educational Research","632MV","ISI:000280429700009"]
["nemá","J","Lizcova, L; Zemanova, Z; Malinova, E; Jarosova, M; Mejstrikova, E; Smisek, P; Pospisilova, D; Stary, J; Michalova, K",null,null,null,"Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Jarosova, Marie; Mejstrikova, Ester; Smisek, Petr; Pospisilova, Dagmar; Stary, Jan; Michalova, Kyra",null,"A novel recurrent chromosomal aberration involving chromosome 7 in childhood myelodysplastic syndrome","CANCER GENETICS AND CYTOGENETICS",null,"English","Article",null,null,null,null,null,null,"IN-SITU HYBRIDIZATION; MYELOID DISORDERS; MONOSOMY-7; LEUKEMIA; CHILDREN; ADOLESCENTS; DELETION","Monosomy 7 and/or deletion of the long arm of chromosome 7 is a common cytogenetic aberration in children with myelodysplastic syndrome (MDS) and is associated with poor outcome. In this report, we present an unusual cytogenetic abnormality leading to loss of both the whole short and whole long arms of chromosome 7, which was found in the bone marrow cells of three pediatric patients with MDS. Using a combination of conventional and molecular cytogenetic methods, a tiny \"dot-like\" marker chromosome was found and described as der(7)del(7)(p11)del(7)(q11). Together with one previously published case, this chromosomal aberration represents a new rare recurrent karyotypic abnormality involving chromosome 7 in children with MDS. (C) 2010 Elsevier Inc. All rights reserved.","[Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague 12808, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Fac Med 1, Prague 12808, Czech Republic; [Jarosova, Marie] Univ Hosp, Dept Hematooncol, Olomouc 77900, Czech Republic; [Jarosova, Marie; Pospisilova, Dagmar] Palacky Univ, Olomouc 77900, Czech Republic; [Mejstrikova, Ester; Smisek, Petr; Stary, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Mejstrikova, Ester; Smisek, Petr; Stary, Jan] Univ Hosp Motol, Prague 15006, Czech Republic; [Pospisilova, Dagmar] Univ Hosp, Dept Paediat, Olomouc 77900, Czech Republic","Lizcova, L, Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, U Nemocnice 2, Prague 12808, Czech Republic","libuse.lizcova@vfn.cz","Czech Ministry of Education [MSM 21620813, MSM LC535]; Czech Ministry of Health [MZOVFN2005]","This work was supported by grants from Czech Ministry of Education MSM 21620813, MSM LC535, and Czech Ministry of Health MZOVFN2005.",null,12,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,"10.1016/j.cancergencyto.2010.05.004","CANCER GENET CYTOGENET","Cancer Genet. Cytogenet.","AUG",2010,201,1,null,null,null,52,56,null,null,5,"Oncology; Genetics & Heredity","632JR","ISI:000280420000010"]
["nemá","J","Spacek, M; Hubacek, P; Markova, J; Zajac, M; Vernerova, Z; Kozak, T",null,null,null,"Spacek, M.; Hubacek, P.; Markova, J.; Zajac, M.; Vernerova, Z.; Kozak, T.",null,"Can We Use EBV-DNA Monitoring to Predict Disease Relapse in EBV-Positive Hodgkin Lymphoma Patients?","ACTA HAEMATOLOGICA",null,"English","Article",null,null,null,null,null,null,"EPSTEIN-BARR-VIRUS; QUANTITATIVE-ANALYSIS; PLASMA; MARKER; LOAD; CELL; PCR",null,"[Spacek, M.; Markova, J.; Kozak, T.] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, CZ-10034 Prague, Czech Republic; [Vernerova, Z.] Univ Hosp Kralovske Vinohrady, Dept Pathol, CZ-10034 Prague, Czech Republic; Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Hubacek, P.] Motol Univ Hosp, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Hubacek, P.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zajac, M.] Motol Univ Hosp, Dept Med Microbiol, Prague, Czech Republic","Spacek, M, Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Srobarova 50, CZ-10034 Prague, Czech Republic","m.spacek@fnkv.cz","Ministry of Health of the Czech Republic [NR9166]","The authors wish to acknowledge the laboratory technician Jana Sumova for laboratory work, Katerina Klaskova for gathering of the data, and Jan Stuchly for statistical analysis. This work was supported by a grant from the Ministry of Health of the Czech Republic (NR9166).",null,14,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0001-5792",null,"10.1159/000313790","ACTA HAEMATOL","Acta Haematol.",null,2010,124,1,null,null,null,23,26,null,null,4,"Hematology","632XA","ISI:000280461600006"]
["nemá","J","Burger, T; Lucova, M; Moritz, RE; Oelschlager, HHA; Druga, R; Burda, H; Wiltschko, W; Wiltschko, R; Nemec, P",null,null,null,"Burger, Tomas; Lucova, Marcela; Moritz, Regina E.; Oelschlaeger, Helmut H. A.; Druga, Rastislav; Burda, Hynek; Wiltschko, Wolfgang; Wiltschko, Roswitha; Nemec, Pavel",null,"Changing and shielded magnetic fields suppress c-Fos expression in the navigation circuit: input from the magnetosensory system contributes to the internal representation of space in a subterranean rodent","JOURNAL OF THE ROYAL SOCIETY INTERFACE",null,"English","Article",null,null,null,null,null,"magnetic compass; hippocampus; entorhinal cortex; place cells; grid cells; head direction cells","HIPPOCAMPAL PLACE CELLS; BLIND MOLE-RAT; IMMEDIATE-EARLY GENES; HEAD-DIRECTION CELLS; FREELY-MOVING RAT; COMPASS ORIENTATION; VISUAL-SYSTEM; SPATIAL REPRESENTATION; TRANSCRIPTION FACTORS; SPALAX-EHRENBERGI","The neural substrate subserving magnetoreception and magnetic orientation in mammals is largely unknown. Previous experiments have demonstrated that the processing of magnetic sensory information takes place in the superior colliculus. Here, the effects of magnetic field conditions on neuronal activity in the rodent navigation circuit were assessed by quantifying c-Fos expression. Ansell's mole-rats (Fukomys anselli), a mammalian model to study the mechanisms of magnetic compass orientation, were subjected to natural, periodically changing, and shielded magnetic fields while exploring an unfamiliar circular arena. In the undisturbed local geomagnetic field, the exploration of the novel environment and/or nesting behaviour induced c-Fos expression throughout the head direction system and the entorhinal-hippocampal spatial representation system. This induction was significantly suppressed by exposure to periodically changing and/or shielded magnetic fields; discrete decreases in c-Fos were seen in the dorsal tegmental nucleus, the anterodorsal and the laterodorsal thalamic nuclei, the postsubiculum, the retrosplenial and entorhinal cortices, and the hippocampus. Moreover, in inactive animals, magnetic field intensity manipulation suppressed c-Fos expression in the CA1 and CA3 fields of the hippocampus and the dorsal subiculum, but induced expression in the polymorph layer of the dentate gyrus. These findings suggest that key constituents of the rodent navigation circuit contain populations of neurons responsive to magnetic stimuli. Thus, magnetic information may be integrated with multimodal sensory and motor information into a common spatial representation of allocentric space within this circuit.","[Burger, Tomas; Lucova, Marcela; Nemec, Pavel] Charles Univ Prague, Fac Sci, Dept Zool, CZ-12844 Prague 2, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Inst Anat, Fac Med 1, CZ-12844 Prague, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Inst Anat, Fac Med 2, CZ-12844 Prague 2, Czech Republic; [Moritz, Regina E.; Burda, Hynek] Univ Duisburg Essen, Dept Gen Zool, Essen, Germany; [Wiltschko, Wolfgang; Wiltschko, Roswitha] Goethe Univ Frankfurt, Dept Zool, Frankfurt, Germany; [Oelschlaeger, Helmut H. A.; Nemec, Pavel] Goethe Univ Frankfurt, Inst Anat Dr Senckenberg Anat 3, Frankfurt, Germany","Nemec, P, Charles Univ Prague, Fac Sci, Dept Zool, Vinicna 7, CZ-12844 Prague 2, Czech Republic","pgnemec@natur.cuni.cz","Czech Science Foundation [206/06/1469, 206/09/1364]; Ministry of Education, Youth and Sport of the Czech Republic [0021620828]","We cordially thank Clemens Poth for his assistance during the experimental stage of this study, Herve Cadiou, Martin Prevorovsky, Petr Telensky and four anonymous reviewers for commenting on the manuscript. Our work was supported by the Czech Science Foundation (206/06/1469 & 206/09/1364; to P.N.) and the Ministry of Education, Youth and Sport of the Czech Republic (0021620828; to P.N.).",null,108,0,"ROYAL SOC","LONDON","6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND","1742-5689",null,"10.1098/rsif.2009.0551","J R SOC INTERFACE","J. R. Soc. Interface","SEP 6",2010,7,50,null,null,null,1275,1292,null,null,18,"Multidisciplinary Sciences","631FT","ISI:000280332700003"]
["nemá","J","Halaska, MJ; Novackova, M; Mala, I; Pluta, M; Chmel, R; Stankusova, H; Robova, H; Rob, L",null,null,null,"Halaska, Michael J.; Novackova, Marta; Mala, Ivana; Pluta, Marek; Chmel, Roman; Stankusova, Hana; Robova, Helena; Rob, Lukas",null,"A Prospective Study of Postoperative Lymphedema After Surgery for Cervical Cancer","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,"English","Article",null,null,null,null,null,"Cervical cancer; Lymphedema; Prevalence; Multifrequency bioelectrical impedance analysis; MFBIA","BREAST-CANCER; BIOELECTRICAL-IMPEDANCE; RADICAL TRACHELECTOMY; RISK-FACTORS; RADIOTHERAPY; EDEMA; CARCINOMA; HISTORY; ARM","Objective: Lymphedema is a severe postoperative complication in oncological surgery. Multifrequency bioelectrical impedance analysis (MFBIA) is a new method for early lymphedema detection. The objective was to establish the methodology of MFBIA for lower-limb lymphedema and to detect a lymphedema in patients undergoing cervical cancer surgery. Methods: From a population of 60 patients undergoing cervical cancer surgery, 39 underwent radical hysterectomy Wertheim III (RAD group), and 21 underwent conservative surgery (laparoscopic lymphadenectomy plus simple trachelectomy/simple hysterectomy CONS group). A control group of 29 patients (CONTR group) was used to determine the SD of impedance at zero frequency (R-0). Patients were examined before surgery and at 3 and 6 months after surgery by MFBIA and by measuring the circumference of the lower limbs. Results: No differences were found between the CONS and RAD groups on age, height, weight, and histopathologic type of tumor. However, the number of dissected lymph nodes differed significantly between the groups (17.3 in the CONS group vs 25.8 in the RAD group, P = 0.0012). The SD of R-0 in the CONTR group was 36.0 and 39.0 for the right and the left leg, respectively. No difference in prevalence of lymphedema based on circumference method was found (35.9% in the RAD and 47.6% in the CONS groups, not statistically significant). Conclusions: No difference in the prevalence of lymphedema was found between the CONS and RAD groups. A methodology for MFBIA for the detection of lower-limb lymphedema was described.","[Halaska, Michael J.; Novackova, Marta; Pluta, Marek; Chmel, Roman; Robova, Helena; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic; [Stankusova, Hana] Fac Hosp Motol, Dept Radiotherapy & Oncol, Prague, Czech Republic; [Mala, Ivana] Univ Econ, Fac Stat, Prague, Czech Republic","Halaska, MJ, Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic","mhalaska@centrum.cz","Ministry of Health of the Czech Republic [IGA MZ NR 9455-3]","The work was supported by a grant from the Ministry of Health of the Czech Republic (IGA MZ NR 9455-3).",null,27,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,"10.1111/IGC.0b013e3181da29d0","INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","JUL",2010,20,5,null,null,null,900,904,null,null,5,"Oncology; Obstetrics & Gynecology","628TG","ISI:000280144000032"]
["nemá","J","Kanderova, V; Hrusak, O; Kalina, T",null,null,null,"Kanderova, Veronika; Hrusak, Ondrej; Kalina, Tomas",null,"Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells","EXPERIMENTAL HEMATOLOGY",null,"English","Article",null,null,null,null,null,null,"CARCINOEMBRYONIC ANTIGEN CEA; PANCREATIC ADENOCARCINOMA CELLS; ADHESION MOLECULES; KOR-SA3544 ANTIGEN; LIPID RAFTS; CD66C; FIBRONECTIN; INTEGRINS; SURVIVAL; AVIDITY","Objective. The aberrant expression of myeloid antigens on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon. So far, there have been no reports of a functional consequence of this aberrant expression. The granulocytic marker carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6, CD66c) is a GPI-anchored molecule that is reported to be the most frequently aberrantly expressed myeloid marker in ALL with a strong correlation with genotype. Materials and Methods. We mimicked CEACAM6 signaling in ALL cells by cross-linking with anti-CEACAM6 antibody. Next, we measured a response to CEACAM6 signaling by integrin subunits expression, integrin ligand binding, phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2), Akt, and p38 mitogen-activated protein kinase (MAPK) and apoptosis by flow cytometry. Results. Following CEACAM6 cross-linking in ALL cells, we detected Erk1/2, Akt, and p38 MAPK phosphorylation and integrin upregulation, as well as enhanced binding of integrin ligands (vascular cell adhesion molecule-1 [VCAM-1] and intercellular cell adhesion molecule-1 [ICAM-1]). However, CEACAM6 signaling resulted in an increase in apoptosis, unlike other GPI-anchored molecules, such as CD24. Conclusion. The present study is the first to demonstrate the functional consequences of CEACAM6 cross-linking in B-cell precursor ALL cells. (C) 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.","[Kalina, Tomas] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Kalina, T, Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic","tomas.kalina@lfmotol.cuni.cz","Charles University (Prague, Czech Republic) [GAUK 7539/2007]; Czech Ministry of Health (Prague, Czech Republic) [NS/10473-3]; Ministry of Sports, Youth and Education (Prague, Czech Republic) [VZ MSMT 0021620813]","This work was supported by grants from Charles University (Prague, Czech Republic) no. GAUK 7539/2007, Czech Ministry of Health (Prague, Czech Republic) no. NS/10473-3 and by a research project of the Ministry of Sports, Youth and Education (Prague, Czech Republic) no. VZ MSMT 0021620813.",null,31,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0301-472X",null,"10.1016/j.exphem.2010.03.018","EXP HEMATOL","Exp. Hematol.","AUG",2010,38,8,null,null,null,653,660,null,null,8,"Hematology; Medicine, Research & Experimental","631EW","ISI:000280330400005"]
["nemá","J","Balgobind, BV; Hollink, IHIM; Reinhardt, D; van Wering, ER; de Graaf, SSN; Baruchel, A; Stary, J; Beverloo, HB; de Greef, GE; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, Brian V.; Hollink, Iris H. I. M.; Reinhardt, Dirk; van Wering, Elisabeth R.; de Graaf, Siebold S. N.; Baruchel, Andre; Stary, Jan; Beverloo, H. Berna; de Greef, Georgine E.; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,"Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique","EUROPEAN JOURNAL OF CANCER",null,"English","Article",null,null,null,null,null,"MLL-PTD; MLPA; Paediatric AML","DEPENDENT PROBE AMPLIFICATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; NORMAL CYTOGENETICS; PROGNOSTIC IMPACT; ADULT PATIENTS; TRISOMY 11; FLT3 GENE; AML; ACTIVATION; MUTATIONS","Mixed-lineage leukaemia (MLL)-partial tandem duplications (PTDs) are found in 3-5% of adult acute myeloid leukaemia (AML), and are associated with poor prognosis. In adult AML, MLL-PTD is only detected in patients with trisomy 11 or internal tandem duplications of FLT3 (FLT3-ITD). To date, studies in paediatric AML are scarce, and reported large differences in the frequency of MLL-PTD, frequently utilising mRNA RT-PCR only to detect MLL-PTDs. We studied the frequency of MLL-PTD in a large cohort of paediatric AML (n = 276) and the results from two different methods, i.e. mRNA RT-PCR, and multiplex ligation-dependent probe amplification (MLPA), a method designed to detect copy number differences of specific DNA sequences. In some patients with an MLL-rearrangement, MLL-PTD transcripts were detected, but were not confirmed by DNA-MLPA, indicating that DNA-MLPA can more accurately detect MLL-PTD compared to mRNA RT-PCR. In paediatric AML, MLL-PTD was detected in 7/276 patients (2.5%). One case had a trisomy 11, while the others had normal cytogenetics. Furthermore 4 of the 7 patients revealed a FLT3-ITD, which was significantly higher compared with the other AML cases (p = 0.016). In conclusion, using DNA-MLPA as a novel screenings technique in combination with mRNA RT-PCR a low frequency of MLL-PTD in paediatric AML was found. Larger prospective studies are needed to further define the prognostic relevance of MLL-PTD in paediatric AML. (C) 2010 Elsevier Ltd. All rights reserved.","[van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Dept Paediat Oncol Haematol, Erasmus MC, NL-3000 CB Rotterdam, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [van Wering, Elisabeth R.; de Graaf, Siebold S. N.] DCOG, The Hague, Netherlands; [Baruchel, Andre] St Louis Hosp, Paris, France; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [de Graaf, Siebold S. N.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands","van den Heuvel-Eibrink, MM, Sophia Childrens Univ Hosp, Dept Paediat Oncol Haematol, Erasmus MC, Room Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands","m.vandenheuvel@erasmusmc.nl","NWO 'Netherlands Organisation for Scientific Research' ; Kinder-Oncologisch Centrum Rotterdam (KOCR) ","This project was funded by the NWO 'Netherlands Organisation for Scientific Research' (B.V.B.) and by the Kinder-Oncologisch Centrum Rotterdam (KOCR) (B.V.B. and I.H.I.M.H.).",null,43,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049",null,"10.1016/j.ejca.2010.02.019","EUR J CANCER","Eur. J. Cancer","JUL",2010,46,10,null,null,null,1892,1899,null,null,8,"Oncology","627JO","ISI:000280035500031"]
["nemá","J","Cakrt, O; Chovanec, M; Funda, T; Kalitova, P; Betka, J; Zverina, E; Kolar, P; Jerabek, J",null,null,null,"Cakrt, Ondrej; Chovanec, Martin; Funda, Tomas; Kalitova, Petra; Betka, Jan; Zverina, Eduard; Kolar, Pavel; Jerabek, Jaroslav",null,"Exercise with visual feedback improves postural stability after vestibular schwannoma surgery","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,"English","Article",null,null,null,null,null,"Vestibular schwannoma; Vestibular rehabilitation; Visual feedback; Center of pressure; Posturography; Quality of life","ACOUSTIC NEUROMA SURGERY; SENSORY INTERACTION; BALANCE","We analyzed the effect of 2-week individualized visual feedback-based balance training on the postural control of patients undergoing retrosigmoid microsurgical removal of vestibular schwannoma. We performed prospective evaluation of 17 patients allocated into two groups: feedback group (9 patients, mean age 37 years) and standard physiotherapy group (8 patients, mean age 44 years). Patients in both the groups were treated once per day by intensive rehabilitation from 5th to 14th postoperative day. Rehabilitation of patients in the feedback group was performed using the visual feedback and force platform. Results were evaluated on the beginning and at the end of rehabilitation program (e.g. 5th and 14th postoperative day). Outcome measures included posturography during quiet stance under four different conditions by the modified Clinical Test for Sensory Interaction of Balance. Body sway was evaluated from center of foot pressure. Compensation of Center of pressure (CoP) parameters in stance on firm surface was similar in the control and feedback groups. However, in stance on foam surface with eyes closed the patients from the feedback group were better compensated and CoP parameters differed significantly (p < 0.05). This prospective clinical study suggests that specific exercises with visual feedback improve vestibulospinal compensation in patients after vestibular schwannoma surgery and thus can improve their quality of life.","[Cakrt, Ondrej; Kolar, Pavel] Charles Univ Prague, Dept Rehabil & Exercise Med, Fac Hosp Motol, Fac Med 2, Prague 15006 5, Czech Republic; [Cakrt, Ondrej; Funda, Tomas; Jerabek, Jaroslav] Czech Tech Univ, Joint Ctr Biomed Engn, Fac Biomed Engn, CR-16635 Prague, Czech Republic; [Chovanec, Martin; Kalitova, Petra; Betka, Jan; Zverina, Eduard] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Hosp Motol, Fac Med 1, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Zverina, Eduard] Charles Univ Prague, Fac Med 3, Dept Neurosurg, Fac Hosp Kralovske Vinohrady, Prague 15006 5, Czech Republic; [Jerabek, Jaroslav] Charles Univ Prague, Dept Neurol, Fac Hosp Motol, Fac Med 2, Prague 15006 5, Czech Republic","Cakrt, O, Charles Univ Prague, Dept Rehabil & Exercise Med, Fac Hosp Motol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","ondrej.cakrt@lf2.cuni.cz","Internal Grant Agency of the Ministry of Health of Czech Republic [NS/9909-3]","This study was supported by the research project of Internal Grant Agency of the Ministry of Health of Czech Republic no. NS/9909-3. The authors thank Pavla Polechova for her contribution to this study.",null,15,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,"10.1007/s00405-010-1227-x","EUR ARCH OTO-RHINO-LARYNGOL","Eur. Arch. Oto-Rhino-Laryn.","SEP",2010,267,9,null,null,null,1355,1360,null,null,6,"Otorhinolaryngology","629TX","ISI:000280223700005"]
["nemá","J","Ladenstein, R; Valteau-Couanet, D; Brock, P; Yaniv, I; Castel, V; Laureys, G; Malis, J; Papadakis, V; Lacerda, A; Ruud, E; Kogner, P; Garami, M; Balwierz, W; Schroeder, H; Beck-Popovic, M; Schreier, G; Machin, D; Potschger, U; Pearson, A",null,null,null,"Ladenstein, Ruth; Valteau-Couanet, Dominique; Brock, Penelope; Yaniv, Isaac; Castel, Victoria; Laureys, Genevieve; Malis, Josef; Papadakis, Vassilios; Lacerda, Ana; Ruud, Ellen; Kogner, Per; Garami, Miklos; Balwierz, Walentyna; Schroeder, Henrik; Beck-Popovic, Maja; Schreier, Guenter; Machin, David; Potschger, Ulrike; Pearson, Andrew",null,"Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study","JOURNAL OF CLINICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; FEBRILE NEUTROPENIA; STAGE-4 NEUROBLASTOMA; ONCOLOGY-GROUP; METASTATIC NEUROBLASTOMA; DAILY FILGRASTIM; CHILDREN OLDER; GROWTH-FACTORS","Purpose To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High- Risk Neuroblastoma- 1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim). Patients and Methods From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 mu g/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled. Results The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P = .001), severe leucopenia (P = .001), neutropenia (P = .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest. Conclusion Following these results, PPG-GSF was advised for all patients on rapid COJEC induction.","[Ladenstein, Ruth] St Anna Childrens Hosp, A-1090 Vienna, Austria; St Anna Childrens Hosp, Childrens Canc Res Inst, Austrian Inst Technol, A-1090 Vienna, Austria; Inst Gustave Roussy, Villejuif, France; Great Ormond St Hosp Sick Children, London, England; Univ Leicester, Childrens Canc & Leukaemia Grp, Leicester, Leics, England; Royal Marsden Hosp, Sutton, Surrey, England; Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; Hosp Univ Infantil La Fe, Valencia, Spain; Ghent Univ Hosp, B-9000 Ghent, Belgium; Univ Hosp Motol, Prague, Czech Republic; Athens Gen Paediat Hosp, Athens, Greece; Portuguese Inst Oncol, Lisbon, Portugal; Univ Oslo, Rikshosp, N-0027 Oslo, Norway; Karolinska Hosp, Astrid Lindgren Childrens Hosp, S-10401 Stockholm, Sweden; Semmelweiss Univ, Budapest, Hungary; Jagiellonian Univ, Coll Med, Krakow, Poland; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Univ Lausanne Hosp, Lausanne, Switzerland","Ladenstein, R, St Anna Childrens Hosp, Kinderspitalgasse 6, A-1090 Vienna, Austria","ruth.ladenstein@ccri.at","EC [QLRI-CT2002-01768]; Cancer Research UK (United Kingdom) [C8346/A8177]; Amgen International and Amgen UK ","Supported by EC Grants No. QLRI-CT2002-01768 and C8346/A8177 from Cancer Research UK (United Kingdom), and from Amgen International and Amgen UK.",null,54,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2009.27.3524","J CLIN ONCOL","J. Clin. Oncol.","JUL 20",2010,28,21,null,null,null,3516,3524,null,null,9,"Oncology","626YE","ISI:000280003700018"]
["nemá","J","Babjuk, M",null,null,null,"Babjuk, Marko",null,"Second Resection for Non-Muscle-Invasive Bladder Carcinoma: Current Role and Future Perspectives","EUROPEAN UROLOGY",null,"English","Article",null,null,null,null,null,null,"TRANSURETHRAL RESECTION; RECURRENCE; DIAGNOSIS; CANCER; TUMORS; TUR",null,"[Babjuk, Marko] Charles Univ Prague, FN Motol, Fac Med 2, Dept Urol, Prague 15006 5, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Fac Med 1, Dept Urol, Prague 15006 5, Czech Republic","Babjuk, M, Charles Univ Prague, FN Motol, Fac Med 2, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic","marek.babjuk@lfmotol.cuni.cz","GE Healthcare ","Marko Babjuk has received honoraria from GE Healthcare for lectures at meetings on bladder cancer.",null,9,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,"10.1016/j.eururo.2010.04.019","EUR UROL","Eur. Urol.","AUG",2010,58,2,null,null,null,191,192,null,null,2,"Urology & Nephrology","623MR","ISI:000279745100002"]
["nemá","J","Tlaskal, T; Vojtovic, P; Reich, O; Hucin, B; Gebauer, R; Kucera, V",null,null,null,"Tlaskal, Tomas; Vojtovic, Pavel; Reich, Oleg; Hucin, Bohumil; Gebauer, Roman; Kucera, Vladimir",null,"Improved results after the primary repair of interrupted aortic arch: impact of a new management protocol with isolated cerebral perfusion","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,"English","Proceedings Paper","23rd  Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery","OCT 18-21, 2009","Vienna, AUSTRIA",null,null,"Congenital heart defects; Interrupted aortic arch; Primary repair in neonates; Isolated cerebral perfusion; Long-term results","VENTRICULAR SEPTAL-DEFECT; LOW-FLOW PERFUSION; OUTFLOW TRACT OBSTRUCTION; HEART-SURGEONS-SOCIETY; CIRCULATORY SUPPORT; TRUNCUS ARTERIOSUS; STAGE REPAIR; OUTCOMES; EXPERIENCE; INFANT","Objective: The aim of this retrospective study was to analyse results and risk factors of death after the repair of the interrupted aortic arch, and to compare results obtained with the use of deep hypothermic circulatory arrest versus isolated cerebral perfusion. Methods: The primary repair of the interrupted aortic arch and associated heart lesions was performed in 50 consecutive patients. The median age was 5 days and the mean weight was 3.1 +/- 0.6 kg. The interrupted aortic arch was of type A in 12 (24%) patients, type B in 37(74%) and type C in one (2%) patient. Ventricular septal defect was present in 48 (96%) patients, subaortic stenosis in 15 (30%), truncus arteriosus in 14 (28%), transposition of the great arteries in two (4%), aortopulmonary window in two (4%) and double-outlet right ventricle in one (2%). The surgery consisted of reconstruction of the aortic arch by direct anastomosis and repair of associated heart lesions. In 25 (50%) patients, aortic arch reconstruction was performed using hypothermic circulatory arrest (group I) and in 25 by isolated cerebral perfusion (group II). The duration of cardiopulmonary bypass, aortic cross-clamping and circulatory arrest or isolated cerebral perfusion was 191 +/- 46 min, 90 +/- 24 min and 40 +/- 14 min, respectively, in group I; and 194 +/- 39 min, 74 +/- 20 min and 31 +/- 6 min, respectively, in group II. Results: There were 10(20%) deaths in this series, eight (32%) in group land two (8%) in group II. Out of 12 patients operated before 1995, seven (58%) patients died; and out of 38 patients operated between 1995 and 2009, three (8%) patients died (p = 0.008). By Cox multifactorial analysis, the earlier date of operation represented the only risk factor of death (p = 0.037). Twelve (71%) survivors in group I and five (22%) survivors in group II required re-intervention, most often for subaortic stenosis, aortic arch obstruction or conduit obstruction. All patients remain in the New York Heart Association (NYHA) class I or II at median 12.6 years in group I, and 1.7 years in group II, respectively, after surgery. Conclusions: Interrupted aortic arch can be repaired in neonates with a mortality of 5-10%. The results depend on experience. Isolated cerebral perfusion was joined with decreased mortality but it did not influence the occurrence of neurological complications. (C) 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.","[Tlaskal, Tomas] Univ Hosp Motol, Kardioctr, Prague 15006 5, Czech Republic; Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic","Tlaskal, T, Univ Hosp Motol, Kardioctr, V Uvalu 84, Prague 15006 5, Czech Republic","tomas.tlaskal@lfmotol.cuni.cz",null,null,null,25,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1010-7940",null,"10.1016/j.ejcts.2010.01.052","EUR J CARDIO-THORAC SURG","Eur. J. Cardio-Thorac. Surg.","JUL",2010,38,1,null,null,null,52,58,null,null,7,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","623ML","ISI:000279744400011"]
["nemá","J","Musil, Z; Puchmajerova, A; Krepelova, A; Vicha, A; Panczak, A; Vesela, J; Widimsky, J; Turkova, H; Lisy, J; Kohoutova, M",null,null,null,"Musil, Zdenek; Puchmajerova, Alena; Krepelova, Anna; Vicha, Ales; Panczak, Ales; Vesela, Jitka; Widimsky, Jiri; Turkova, Hana; Lisy, Jiri; Kohoutova, Milada",null,"Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family?","CANCER GENETICS AND CYTOGENETICS",null,"English","Letter",null,null,null,null,null,null,"PHEOCHROMOCYTOMA; TUMORS",null,"[Musil, Zdenek; Krepelova, Anna; Panczak, Ales; Vesela, Jitka; Kohoutova, Milada] Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Prague 12800 2, Czech Republic; [Musil, Zdenek; Panczak, Ales; Vesela, Jitka; Widimsky, Jiri; Turkova, Hana; Kohoutova, Milada] Gen Teaching Hosp, Prague 12800 2, Czech Republic; [Puchmajerova, Alena; Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague 12800 2, Czech Republic; [Musil, Zdenek] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Prague 12800 2, Czech Republic; [Puchmajerova, Alena; Krepelova, Anna; Vicha, Ales] Motol Univ Hosp, Prague, Czech Republic; [Vicha, Ales] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 12800 2, Czech Republic; [Widimsky, Jiri; Turkova, Hana] Charles Univ Prague, Fac Med 1, Dept Med 3, Dept Endocrinol & Metab, Prague 12800 2, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Dept Radiol Tech, Prague 12800 2, Czech Republic","Musil, Z, Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Albertov 4, Prague 12800 2, Czech Republic","musil.z@seznam.cz",null,null,null,11,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,"10.1016/j.cancergencyto.2009.11.010","CANCER GENET CYTOGENET","Cancer Genet. Cytogenet.","MAR",2010,197,2,null,null,null,189,192,null,null,4,"Oncology; Genetics & Heredity","626OB","ISI:000279974200013"]
["nemá","J","Hradsky, O; Dusatkova, P; Lenicek, M; Bronsky, J; Nevoral, J; Vitek, L; Lukas, M; Zeniskova, I; Cinek, O",null,null,null,"Hradsky, Ondrej; Dusatkova, Petra; Lenicek, Martin; Bronsky, Jiri; Nevoral, Jiri; Vitek, Libor; Lukas, Milan; Zeniskova, Ivana; Cinek, Ondrej",null,"The CTLA4 variants may interact with the IL23R-and NOD2-conferred risk in development of Crohn's disease","BMC MEDICAL GENETICS",null,"English","Article",null,null,null,null,null,null,"GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; SUSCEPTIBILITY LOCI; GENETIC-VARIATION; CZECH POPULATION; POLYMORPHISMS; ATG16L1; PHENOTYPE; AUTOPHAGY; MULTIPLE","Background: The CTLA4 (cytotoxic T-lymphocyte antigen 4) gene is associated with several immunopathologic diseases and because of its important immuno-regulatory role it may be considered also a plausible candidate for a genetic association with inflammatory bowel diseases. Previously published studies found no association of CTLA4 with Crohn's disease itself, but some indicated an association with its subphenotypes. The aim of this study was to assess the association in the Czech population, using a set of markers shown to associate with other diseases. Methods: Six polymorphisms within the CTLA4 region were investigated in 333 patients with Crohn's disease and 482 unrelated healthy controls, all Caucasians of Czech origin. The genotypes of the SNPs were determined using the TaqMan SNP genotyping assays. Haplotypes were reconstructed using an expectation-maximization algorithm, and their association with the condition was assessed using log-linear modeling. Then, potential interactions were tested between the CTLA4 variants and other genetic factors known to confer the disease susceptibility. Results: No crude associations with Crohn's disease were found for the tested CTLA4 variants under the log-additive or dominant models. However, when stratified for the genetic risk conferred by the variants in the NOD2 (the p.Leu1007fsX1008, rs5743293) or the IL23R (p.R381Q, rs11209026), a significant negative association emerged for the minor alleles of CTLA4 CT60 (rs3087243), JO31 (rs11571302), JO27-1 (rs11571297) polymorphisms. This negative association with CTLA4 was apparent only in the strata defined by presence minor alleles at the NOD2 rs5743293 (here the CTLA4 CT60 A coffered an OR = 0.43, 95% CI 0.19 -0.95 for the presence of CT60 A), or IL23R rs11209026 (here the OR for presence of CT60 A was 0.23, 95% CI 0.07 -0.71). We observed this effect also for the haplotype consisting of minor alleles of the three tightly linked CTLA4 markers. Furthermore, this haplotype was associated with the younger age at diagnosis (OR 1.52, 95% CI 1.09 -2.11, p = 0.014). Conclusions: A protective effect of a CTLA4 haplotype was unmasked after stratification for the risk variants in the NOD2 and IL23R genes, and may point towards the biological relevance of the molecule in the pathogenesis of the disease.","[Hradsky, Ondrej; Dusatkova, Petra; Bronsky, Jiri; Nevoral, Jiri; Cinek, Ondrej] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Hradsky, Ondrej; Dusatkova, Petra; Bronsky, Jiri; Nevoral, Jiri; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Lenicek, Martin; Vitek, Libor; Lukas, Milan] Charles Univ Prague, Fac Med 1, Inst Clin Biochem & Lab Diagnost, Prague, Czech Republic; [Lukas, Milan] ISCARF IVF Lighthouse, IBD Clin & Res Ctr, Prague, Czech Republic; [Zeniskova, Ivana] Keske BudEjovice Hosp AS, Keske Budejovice, Czech Republic","Hradsky, O, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic","ondrej.hradsky@lfmotol.cuni.cz","Czech Ministry of Health [MZOFNM2005]; University Hospital Motol ; IGA [NR/9219-3/2007]","This study was supported by grants from the Czech Ministry of Health (MZOFNM2005), the University Hospital Motol and IGA - NR/9219-3/2007. Drs V. Valtrova, P. Szitanyi, R. Petro, M. Bortlik and V. Starzykova are gratefully acknowledged for providing us with samples and clinical data from their patients.",null,33,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,"10.1186/1471-2350-11-91","BMC MED GENET","BMC Med. Genet.","JUN 10",2010,11,null,null,null,null,null,null,91,null,9,"Genetics & Heredity","625UL","ISI:000279920800002"]
["nemá","J","Gjesing, AP; Larsen, LH; Torekov, SS; Hainerova, IA; Kapur, R; Johansen, A; Albrechtsen, A; Boj, S; Holst, B; Harper, A; Urhammer, SA; Borch-Johnsen, K; Pisinger, C; Echwald, SM; Eiberg, H; Astrup, A; Lebl, J; Ferrer, J; Schwartz, TW; Hansen, T; Pedersen, O",null,null,null,"Gjesing, Anette P.; Larsen, Lesli H.; Torekov, Signe S.; Hainerova, Irena Aldhoon; Kapur, Rahul; Johansen, Anders; Albrechtsen, Anders; Boj, Sylvia; Holst, Birgitte; Harper, Angela; Urhammer, Soren A.; Borch-Johnsen, Knut; Pisinger, Charlotta; Echwald, Soren M.; Eiberg, Hans; Astrup, Arne; Lebl, Jan; Ferrer, Jorge; Schwartz, Thue W.; Hansen, Torben; Pedersen, Oluf",null,"Family and Population-Based Studies of Variation within the Ghrelin Receptor Locus in Relation to Measures of Obesity","PLOS ONE",null,"English","Article",null,null,null,null,null,null,"HORMONE SECRETAGOGUE RECEPTOR; FOOD-INTAKE; GENE; ASSOCIATION; LINKAGE","Background: The growth hormone secretagogue receptor (GHSR) is mediating hunger sensation when stimulated by its natural ligand ghrelin. In the present study, we tested the hypothesis that common and rare variation in the GHSR locus are related to increased prevalence of obesity and overweight among Whites. Methodology/Principal Findings: In a population-based study sample of 15,854 unrelated, middle-aged Danes, seven variants were genotyped to capture common variation in an 11 kbp region including GHSR. These were investigated for their individual and haplotypic association with obesity. None of these analyses revealed consistent association with measures of obesity. A -151C/T promoter mutation in the GHSR was found in two unrelated obese patients. One family presented with complete co-segregation, but the other with incomplete co-segregation. The mutation resulted in an increased transcriptional activity (p < 0.02) and introduction of a specific binding for Sp-1-like nuclear extracts relative to the wild type. The -151C/T mutation was genotyped in the 15,854 Danes with a minor allele frequency of 0.01%. No association with obesity in carriers (mean BMI: 27 +/- 4 kg/m(2)) versus non-carriers (mean BMI: 28 +/- 5 kg/m(2)) (p > 0.05) could be shown. Conclusions/Significance: In a population-based study sample of 15,854 Danes no association between GHSR genotypes and measures of obesity and overweight was found. Also, analyses of GHSR haplotypes lack consistent associations with obesity related traits. A rare functional GHSR promoter mutation variant was identified, yet there was no consistent relationship with obesity in neither family- nor population-based studies.","[Gjesing, Anette P.; Torekov, Signe S.; Kapur, Rahul; Hansen, Torben; Pedersen, Oluf] Hagedorn Res Inst, Gentofte, Denmark; [Larsen, Lesli H.; Johansen, Anders; Albrechtsen, Anders; Borch-Johnsen, Knut; Echwald, Soren M.; Hansen, Torben; Pedersen, Oluf] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Larsen, Lesli H.; Astrup, Arne] Univ Copenhagen, Inst Human Nutr, Copenhagen, Denmark; [Hainerova, Irena Aldhoon] Charles Univ Prague, Dept Paediat, Prague, Czech Republic; [Hainerova, Irena Aldhoon] Charles Univ Prague, Ctr Res Diabet Metab & Nutr, Fac Med 3, Prague, Czech Republic; [Boj, Sylvia; Ferrer, Jorge] Inst Invest Biomed August Pi & Sunyer, Hosp Clin Barcelona, Endocrinol Unit, Barcelona, Spain; [Holst, Birgitte; Schwartz, Thue W.] Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; [Harper, Angela] Royal Vet & Agr Univ, Inst Human Nutr, Copenhagen, Denmark; [Urhammer, Soren A.] Hvidovre Univ Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark; [Pisinger, Charlotta] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Echwald, Soren M.] Exiqon, Vedbaek, Denmark; [Eiberg, Hans] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen, Denmark; [Pisinger, Charlotta; Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; [Borch-Johnsen, Knut; Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark; [Lebl, Jan] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic","Gjesing, AP, Hagedorn Res Inst, Gentofte, Denmark","apri@hagedorn.dk","University of Copenhagen ; Danish Diabetes Association ; European Union [LSHM-CT-2005-018734]; Danish Medical Research Council ; Danish Agency for Science Technology and Innovation [271-06-0539]; Czech Research Project of MSM [0021620814]; Novo Nordisk ","The study is part of the DanORC project (http://www.danorc.dk) and was additionally supported by the University of Copenhagen, the Danish Diabetes Association, the European Union (HEPADIP, grant no. LSHM-CT-2005-018734), the Danish Medical Research Council, the Danish Agency for Science Technology and Innovation (grant no. 271-06-0539), the Czech Research Project of MSM No. 0021620814 and a European Society of Paediatric Endocrinology (ESPE) research fellowship sponsored by Novo Nordisk. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,19,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,"10.1371/journal.pone.0010084","PLOS ONE","PLoS One","APR 9",2010,5,4,null,null,null,null,null,"e10084",null,8,"Biology; Multidisciplinary Sciences","580WU","ISI:000276482100010"]
["nemá","J","van Stralen, KJ; Tizard, EJ; Jager, KJ; Schaefer, F; Vondrak, K; Groothoff, JW; Podracka, L; Holmberg, C; Jankauskiene, A; Lewis, MA; van Damme-Lombaerts, R; Mota, C; Niaudet, P; Novljan, G; Peco-Antic, A; Sahpazova, E; Toots, U; Verrina, E",null,null,null,"van Stralen, Karlijn J.; Tizard, E. Jane; Jager, Kitty J.; Schaefer, Franz; Vondrak, Karel; Groothoff, Jaap W.; Podracka, Ludmila; Holmberg, Christer; Jankauskiene, Augustina; Lewis, M. A.; van Damme-Lombaerts, Rita; Mota, Conceicao; Niaudet, Patrick; Novljan, Gregor; Peco-Antic, Amira; Sahpazova, Emilija; Toots, Uelle; Verrina, Enrico",null,"Determinants of eGFR at start of renal replacement therapy in paediatric patients","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,"English","Article",null,null,null,null,null,"children; dialysis; GFR; Schwartz; start of RRT","GLOMERULAR-FILTRATION-RATE; PLASMA CREATININE CONCENTRATION; KIDNEY-TRANSPLANTATION; CHILDREN; DIALYSIS; FAILURE; ADOLESCENTS; INITIATION; TIME","Methods. Data were collected as part of the European Society of Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association registry from 14 European countries and referred to incident paediatric patients starting on renal replacement therapy (RRT) between 2002 and 2007 under the age of 18 years. Estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula. Data were adjusted for age, gender, treatment modality at start, primary cause of renal failure (PRD) and regions in Europe (eGFR(adj)). Results. Median eGFR in the 938 patients starting RRT was 10.4 mL/min/1.73 m(2) (5th and 95th percentile: 4.0-26.9). Twenty-six patients (2.8%), mainly infants with Finnish-type nephropathy, started with eGFR levels > 50 mL/min/1.73 m(2). Younger age, female gender, starting on dialysis and having a short time between the first visit to a paediatric nephrologist (PN) and start of RRT were associated with lower eGFR at start of RRT. Gender differences were only present during adolescent age and disappeared when using the same K value for both genders. The various PRDs showed large differences in the rate of decline in eGFR between the first visit to a PN and start of RRT; however, this did not result in differences in eGFR(adj) at start of RRT. Conclusions. The main determinants of eGFR at start of RRT were age, gender, treatment modality at start, and the time between the first visit to a PN and start of RRT. Research is needed to determine the consequences of these differences.","[van Stralen, Karlijn J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med, ESPN ERA EDTA Registry, NL-1105 AZ Amsterdam, Netherlands; [Tizard, E. Jane] Bristol Royal Hosp Children, Dept Paediat Nephrol, Bristol, Avon, England; [Schaefer, Franz] Univ Heidelberg, Childrens Hosp, D-6900 Heidelberg, Germany; [Vondrak, Karel] Univ Hosp Prague Motol, Dept Paediat, Prague, Czech Republic; [Podracka, Ludmila] Univ Hosp, Dept Pediat, Kosice, Slovakia; [Holmberg, Christer] Helsinki Univ Hosp, Dept Pediat Nephrol, Helsinki, Finland; [Jankauskiene, Augustina] Vilnius Univ, Children Hosp, Vilnius, Lithuania; [Lewis, M. A.] Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester M27 1HA, Lancs, England; [van Damme-Lombaerts, Rita] Univ Hosp Leuven, Dept Paediat Nephrol & Organ Transplantat, Louvain, Belgium; [Mota, Conceicao] Ctr Hosp Porto, Dept Pediat Nephrol, Oporto, Portugal; [Niaudet, Patrick] Hop Necker Enfants Malad, Paris, France; [Novljan, Gregor] Ljubljana Childrens Hosp, Univ Med Ctr, Dept Pediat Nephrol, Ljubljana, Slovenia; [Peco-Antic, Amira] Univ Childrens Hosp, Belgrade, Serbia; [Sahpazova, Emilija] Pediat Clin, Dept Nephrol, Skopje, Macedonia; [Toots, Uelle] SA Tallinna Lastehaigla, Tallinn, Estonia; [Verrina, Enrico] G Gaslini Inst Children, Nephrol Dialysis & Transplantat Unit, Genoa, Italy","van Stralen, KJ, Univ Amsterdam, Acad Med Ctr, Dept Med, ESPN ERA EDTA Registry, NL-1105 AZ Amsterdam, Netherlands","K.J.vanStralen@amc.uva.nl","European Society of Paediatric Nephrology (ESPN) ; European Renal Association (ERA-EDTA) ; NephroQUEST project ; European Union [2006114]","The ESPN/ERA-EDTA registry is funded by the European Society of Paediatric Nephrology (ESPN), the European Renal Association (ERA-EDTA) and the NephroQUEST project. The NephroQUEST project has received funding from the European Union in the framework of the Public Health Programme (projec number 2006114). Furthermore, Amgen has provided an unrestricted educational grant to assist the ESPN in the financial support of the Registry.",null,26,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,"10.1093/ndt/gfq215","NEPHROL DIALYSIS TRANSPLANT","Nephrol. Dial. Transplant.","OCT",2010,25,10,null,null,null,3325,3332,null,null,8,"Transplantation; Urology & Nephrology","654ML","ISI:000282172300031"]
["nemá","J","Kotlin, R; Reicheltova, Z; Suttnar, J; Salaj, P; Hrachovinova, I; Riedel, T; Maly, M; Oravec, M; Kvasnicka, J; Dyr, JE",null,null,null,"Kotlin, Roman; Reicheltova, Zuzana; Suttnar, Jiri; Salaj, Peter; Hrachovinova, Ingrid; Riedel, Tomas; Maly, Martin; Oravec, Milan; Kvasnicka, Jan; Dyr, Jan Evangelista",null,"Two novel fibrinogen variants in the C-terminus of the B beta-chain: fibrinogen Rokycany and fibrinogen Znojmo","JOURNAL OF THROMBOSIS AND THROMBOLYSIS",null,"English","Article",null,null,null,null,null,"Fibrinogen; Missense mutation; Hypofibrinogenemia; Thrombosis; Dysfibrinogenemia","GAMMA-CHAIN; CONGENITAL AFIBRINOGENEMIA; HYPOFIBRINOGENEMIA; DYSFIBRINOGENEMIA; MUTATIONS; SUBSTITUTION; SECRETION; ALPHA; BIOSYNTHESIS; FRAGMENT","Hereditary dysfibrinogenemia is a rare disorder wherein an inherited abnormality in fibrinogen structure may result in defective fibrin function and/or structure. Congenital hypofibrinogenemia is a rare autosomal bleeding disorder, either recessive or dominant, characterized by a low fibrinogen plasma level. A 28-year-old asymptomatic woman (fibrinogen Rokycany) and a 54-year-old man with thrombosis and pulmonary embolism (fibrinogen Znojmo) were investigated for a suspected fibrinogen mutation after abnormal coagulation tests results were obtained. DNA sequencing showed the heterozygous point mutation B beta Asn351Lys in fibrinogen Rokycany and the heterozygous point mutation B beta Arg237Ser in fibrinogen Znojmo, respectively. The kinetics of fibrinopeptide release was found to be normal in both cases. Fibrinolysis was impaired in the Znojmo variant. The average fibril diameters of Znojmo fibrin was slightly increased, but not differing significantly from normal; formed by less fibrils with abrupt fibril terminations. Rheological studies revealed a softer clot. Rokycany fibrin was formed by significantly narrower fibrils than normal fibrin; and the clot was denser than the control clot. Rheological studies revealed a stiffer clot. Impaired fibrinolysis and abnormal clot morphology may be the cause of thrombotic episodes in the patient with Znojmo mutation. New cases of hypofibrinogenemia and dysfibrinogenemia, found by routine coagulation testing, were genetically identified as a novel fibrinogen variants B beta Asn351Lys (fibrinogen Rokycany) and B beta Arg237Ser (fibrinogen Znojmo), respectively.","[Kotlin, Roman; Reicheltova, Zuzana; Suttnar, Jiri; Salaj, Peter; Hrachovinova, Ingrid; Riedel, Tomas; Dyr, Jan Evangelista] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Riedel, Tomas] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague, Czech Republic; [Maly, Martin; Oravec, Milan] Motol Univ Hosp, Dept Cardiol, Prague 15006 5, Czech Republic; [Kvasnicka, Jan] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Kvasnicka, Jan] Thrombot Ctr Gen Univ Hosp, Prague 12808 2, Czech Republic","Kotlin, R, Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic","kotlinr@uhkt.cz","The Internal Grant Agency of The Ministry of Health of the Czech Republic [NS 9636-3/2008]; The Ministry of Health of the Czech Republic [2373601, MZO VFN2005]; The Academy of Sciences of the Czech Republic [KAN200670701]","This work was supported by a grant of The Internal Grant Agency of The Ministry of Health of the Czech Republic, number NS 9636-3/2008; by a grant of The Ministry of Health of the Czech Republic, number 2373601; by a grant of The Academy of Sciences of the Czech Republic, number KAN200670701; and by a grant of The Ministry of Health of the Czech Republic, number MZO VFN2005.",null,33,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0929-5305",null,"10.1007/s11239-010-0505-1","J THROMB THROMBOLYSIS","J. Thromb. Thrombolysis","OCT",2010,30,3,null,null,null,311,318,null,null,8,"Hematology; Peripheral Vascular Disease","655BD","ISI:000282215300008"]
["nemá","J","Vrzalova, Z; Hruba, Z; Hrabincova, ES; Pouchla, S; Votava, F; Kolouskova, S; Fajkusova, L",null,null,null,"Vrzalova, Zuzana; Hruba, Zuzana; Hrabincova, Eva ST'Ahlova; Pouchla, Slavka; Votava, Felix; Kolouskova, Stanislava; Fajkusova, Lenka",null,"Identification of CYP21A2 mutant alleles in Czech patients with 21-hydroxylase deficiency","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",null,"English","Article",null,null,null,null,null,"congenital adrenal hyperplasia; steroid 21-hydroxylase; 21-hydroxylase deficiency; pseudogene; chimeric gene","CONGENITAL ADRENAL-HYPERPLASIA; STEROID 21-HYDROXYLASE; RCCX MODULE; CHIMERIC CYP21P/CYP21; MUTATIONAL SPECTRUM; GENE CONVERSIONS; MOLECULAR-BASIS; COMPLEMENT; COMPONENT; DISEASE","Congenital adrenal hyperplasia (CAH) is comprised of a group of autosomal recessive disorders caused by an enzymatic deficiency which impairs the biosynthesis of cortisol and, in most of the severe cases, also the biosynthesis of aldosterone. Approximately 90-95% of all the CAH cases are due to mutations in the steroid 21-hydroxylase gene (CYP21A2). In this study, the molecular genetic analysis of CYP21A2 was performed in 267 Czech probands suspected of 21-hydroxylase deficiency (21OHD). 21OHD was confirmed in 241 probands (2 mutations were detected). In 26 probands, a mutation was found only in 1 CYP21A2 allele. A set of 30 different mutant alleles was determined. We describe i) mutated CYP21A2 alleles carrying novel point mutations (p.Thr168Asn, p.Ser 169X and p.Pro386Arg), ii) mutated CYP21A2 alleles carrying the novel chimeric gene designated as CH-7, which was detected in 21.4% of the mutant alleles, iii) an unusual genotype with a combination of the CYP21A2 duplication, 2 point mutations and the CYP21A2 large-scale gene conversion on the second allele, and (iv) a detailed analysis of the chimeric CYP21A1P/CYP21A2 genes. In conclusion, our genotyping approach allowed for the accurate identification of the CYP21A2 gene mutations in 21OHD patients and their families and provided some useful information on diagnosis and genetic counselling.","[Vrzalova, Zuzana; Hruba, Zuzana; Hrabincova, Eva ST'Ahlova; Pouchla, Slavka; Fajkusova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, CZ-62500 Brno, Czech Republic; [Votava, Felix] Charles Univ Prague, Fac Med 3, Dept Pediat, CZ-10034 Prague, Czech Republic; [Votava, Felix] Univ Hosp Kralovske Vinohrady, CZ-10034 Prague, Czech Republic; [Kolouskova, Stanislava] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague, Czech Republic; [Kolouskova, Stanislava] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Fajkusova, Lenka] Masaryk Univ, Fac Sci, Inst Expt Biol, Dept Funct Genom & Prote, CZ-62500 Brno, Czech Republic","Fajkusova, L, Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Cernopolni 9, CZ-62500 Brno, Czech Republic","lenkafajkusova@volny.cz","Internal Grant Agency of the Czech Ministry of Health [NR9308-3, NS9981-3]; Czech Ministry of Education [LC06023, MSM0021622415, MSM0021620814]","This study was supported by the Internal Grant Agency of the Czech Ministry of Health (grant nos. NR9308-3 and NS9981-3) and by the Czech Ministry of Education (project nos. LC06023, MSM0021622415 and MSM0021620814).",null,31,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1107-3756",null,"10.3892/ijmm_00000504","INT J MOL MED","Int. J. Mol. Med.","OCT",2010,26,4,null,null,null,595,603,null,null,9,"Medicine, Research & Experimental","651HF","ISI:000281917800021"]
["nemá","J","Rakusan, D; Kujal, P; Kramer, HJ; Huskova, Z; Vanourkova, Z; Vernerova, Z; Mrazova, I; Thumova, M; Cervenka, L; Vaneckova, I",null,null,null,"Rakusan, Dan; Kujal, Petr; Kramer, Herbert J.; Huskova, Zuzana; Vanourkova, Zdenka; Vernerova, Zdenka; Mrazova, Iveta; Thumova, Monika; Cervenka, Ludek; Vaneckova, Ivana",null,"Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats","AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY",null,"English","Article",null,null,null,null,null,"losartan; hypertension; direct renin inhibition; glomerular size; morphometry; washout period; blood pressure","DIRECT RENIN INHIBITION; FILTRATION BARRIER INJURY; BLOOD-PRESSURE; RECEPTOR BLOCKADE; (PRO)RENIN RECEPTOR; HYPERTENSIVE-RATS; PODOCYTE INJURY; AT(1)R BLOCKADE; ANGIOTENSIN-II; ORGAN DAMAGE","Rakusan D, Kujal P, Kramer HJ, Huskova Z,Vanourkova Z,Vernerova Z, Mrazova I, Thumova M, Cervenka L, Vaneckova I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 299: F758-F766, 2010. First published July 28, 2010; doi:10.1152/ajprenal.00259.2010.-The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments. BP was monitored by telemetry from the age of 32 days on (young rats) and at 100 days (adult rats). Aliskiren (10 mg.kg(-1).day(-1) in osmotic minipumps) or losartan (5 mg.kg(-1).day(-1) in drinking water) treatment was applied for 28 days in young rats and for 70 days in adult rats. In young untreated TGR, severe hypertension rapidly evolved. Adult untreated TGR exhibited stable established hypertension. Both aliskiren and losartan fully prevented the development of hypertension and cardiac hypertrophy in young TGR and normalized BP and cardiac hypertrophy in adult TGR. After cessation of aliskiren treatment in both young and adult TGR BP and cardiac hypertrophy were persistently reduced, while after losartan withdrawal BP and cardiac hypertrophy rapidly increased. In adult aliskiren-treated rats proteinuria was significantly reduced compared with losartan (the effect persisting after withdrawal of treatment), and this decrease strongly correlated with normalization of glomerular size in these animals. In conclusion, aliskiren and losartan had similar antihypertensive effects during chronic treatment, but the antihypertensive and organoprotective effects of aliskiren were persistent even after the 12-day washout period. The durable effect on proteinuria can possibly be attributed to the normalization of glomerular morphology.","[Rakusan, Dan] Charles Univ Prague, Dept Med, Fac Med 1, Nephrol Sect, Prague, Czech Republic; [Rakusan, Dan; Kujal, Petr; Huskova, Zuzana; Vanourkova, Zdenka; Vernerova, Zdenka; Mrazova, Iveta; Thumova, Monika; Cervenka, Ludek; Vaneckova, Ivana] Charles Univ Prague, Inst Clin & Expt Med, Ctr Med Expt, Prague, Czech Republic; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Huskova, Zuzana; Vanourkova, Zdenka; Mrazova, Iveta; Thumova, Monika; Cervenka, Ludek; Vaneckova, Ivana] Charles Univ Prague, Cardiovasc Res Ctr, Prague, Czech Republic","Vaneckova, I, Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic","ivanava@biomed.cas.cz","Ministry of Health [NS/9703-4]; Institute for Clinical and Experimental Medicine [MZ 00023001]; Czech Science Foundation [305/07/J004, 308/08/J006]; Center for Cardiovascular Research [1M6798582302]; German Research Foundation [Deutsche Forschungsgemeinschaft (DFG) [433/14-2, 436 TSE 113/50, 113/56, 113/57/0-1]; German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)] ; DFG [433/14-2]","This study was in part supported by the Internal Grant Agency of the Ministry of Health (No. NS/9703-4). I. Vaneckova is also supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZ 00023001) and the Czech Science Foundation (Grant No. 305/07/J004). D. Rakusan is a Ph.D. student supported by the Center for Cardiovascular Research (1M6798582302). H. J. Kramer is supported by the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG); Grant Nos. 433/14-2 and 436 TSE 113/50, 113/56, and 113/57/0-1] and the German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)]. Portions of this work were performed during Z. Vanourkova's stay as a visiting scientist at the University of Bonn, which was supported by a grant from the DFG, Bonn (Grant No. 433/14-2). The Czech Science Foundation also supported L. Cervenka (Grant No. 308/08/J006).",null,38,0,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","1931-857X",null,"10.1152/ajprenal.00259.2010","AMER J PHYSIOL-RENAL PHYSIOL","Am. J. Physiol.-Renal Physiol.","OCT",2010,299,4,null,null,null,"F758","F766",null,null,9,"Physiology; Urology & Nephrology","658IP","ISI:000282484000009"]
["nemá","J","Sermet-Gaudelus, I; Girodon, E; Sands, D; Stremmler, N; Vavrova, V; Deneuville, E; Reix, P; Bui, S; Huet, F; Lebourgeois, M; Munck, A; Iron, A; Skalicka, V; Bienvenu, T; Roussel, D; Lenoir, G; Bellon, G; Sarles, J; Macek, M; Roussey, M; Fajac, I; Edelman, A",null,null,null,"Sermet-Gaudelus, Isabelle; Girodon, Emanuelle; Sands, Dorota; Stremmler, Nathalie; Vavrova, Vera; Deneuville, Eric; Reix, Philippe; Bui, Stephanie; Huet, Frederic; Lebourgeois, Muriel; Munck, Anne; Iron, Albert; Skalicka, Veronika; Bienvenu, Thierry; Roussel, Delphine; Lenoir, Gerard; Bellon, Gabriel; Sarles, Jacques; Macek, Milan; Roussey, Michel; Fajac, Isabelle; Edelman, Aleksander",null,"Clinical Phenotype and Genotype of Children with Borderline Sweat Test and Abnormal Nasal Epithelial Chloride Transport","AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE",null,"English","Article",null,null,null,null,null,"cystic fibrosis transmembrane conductance regulator (CFTR); cystic fibrosis; nasal potential difference; CFTR-related disorders","TRANSMEMBRANE REGULATOR GENE; NONCLASSIC CYSTIC-FIBROSIS; CFTR-RELATED DISEASES; POTENTIAL DIFFERENCE; MUTATIONS; REARRANGEMENTS; MECHANISMS; CONSENSUS; ADULTS","Rationale: The diagnosis of cystic fibrosis (CF) is based on a characteristic clinical picture in association with a sweat chloride (Cl-) concentration greater than 60 mmol/L or the identification of two CF-causing mutations. A challenging problem is the significant number of children for whom no definitive diagnosis is possible because they present with symptoms suggestive of CF, a sweat chloride level in the intermediate range between 30 and 60 mmol/L, and only one or no identified CF-causing mutation. Objectives: To investigate the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in the airways of children with intermediate sweat tests and inconclusive genetic findings in correlation with clinical phenotype and genotype. Methods: We developed a composite nasal potential difference (NPD) diagnostic score to discriminate patients with CF from non-CF patients. We tested NPD in 50 children (age, 6 mo to 18 yr) with equivocal diagnoses and correlated the NPD diagnostic score with clinical phenotypes and genotypes. Measurements and Main Results: Fifteen of the 50 children had NPD scores in the CF range. Eight of the 15 carried two CFTR mutations compared with only 5 of the 35 children with normal NPD scores (P = 0.01). They were significantly younger at evaluation and had recurrent lower respiratory tract infections, chronic productive coughs, and chronic Staphylococcus aureus colonization significantly more often than the 35 children with normal NPD results. Conclusions: Evaluation of CFTR function in the nasal epithelium of children with inconclusive CF diagnoses can be a useful diagnostic tool and help clinicians to individualize therapeutic strategy.","[Sermet-Gaudelus, Isabelle; Lebourgeois, Muriel; Lenoir, Gerard] Hop Necker Enfants Malad, AP HP, CRCM, F-75730 Paris, France; [Sermet-Gaudelus, Isabelle; Roussel, Delphine; Edelman, Aleksander] Univ Paris 05, Inst Natl Sante & Rech Med, U845, Paris, France; [Girodon, Emanuelle] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Biochim Genet, Paris, France; [Sands, Dorota] Inst Mother & Child Hlth, Cyst Fibrosis Ctr, Warsaw, Poland; [Stremmler, Nathalie; Sarles, Jacques] Hop Enfants La Timone, Ctr Reference & Competence Mucoviscidose, Marseille, France; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Charles Univ Prague, Cyst Fibrosis Ctr, Dept Pediat & Biol, Prague, Czech Republic; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Charles Univ Prague, Cyst Fibrosis Ctr, Dept Med Genet, Prague, Czech Republic; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Fac Med, Prague, Czech Republic; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Univ Hosp Motol, Prague, Czech Republic; [Deneuville, Eric; Roussey, Michel] Hop Sud, Ctr Reference & Competence Mucoviscidose, Rennes, France; [Reix, Philippe; Bellon, Gabriel] Hop Debrousse, Ctr Reference & Competence Mucoviscidose, Lyon, France; [Bui, Stephanie] Grp Pellegrin Hop Enfants, Ctr Reference & Competence Mucoviscidose, Bordeaux, France; [Huet, Frederic] Hop Enfants Bocage, Ctr Reference & Competence Mucoviscidose, Dijon, France; [Munck, Anne] Hop Robert Debre, Ctr Reference & Competence Mucoviscidose, F-75019 Paris, France; [Bienvenu, Thierry] Hop Cochin, Serv Biochim Genet, F-75674 Paris, France; [Fajac, Isabelle] Hop Cochin, Ctr Reference & Competence Mucoviscidose, F-75674 Paris, France","Sermet-Gaudelus, I, Hop Necker Enfants Malad, AP HP, CRCM, 156 Rue Vaugirard, F-75730 Paris, France","isabelle.sermet@nck.aphp.fr","Vaincre la Mucoviscidose ; ABCF2 Association ; Assistance Publique-Hopitaux de Paris [MZ0FNM2005]","Supported by Vaincre la Mucoviscidose, the ABCF2 Association, and Assistance Publique-Hopitaux de Paris, MZ0FNM2005.",null,33,0,"AMER THORACIC SOC","NEW YORK","1740 BROADWAY, NEW YORK, NY 10019-4374 USA","1073-449X",null,"10.1164/rccm.201003-0382OC","AMER J RESPIR CRIT CARE MED","Am. J. Respir. Crit. Care Med.","OCT 1",2010,182,7,null,null,null,929,936,null,null,8,"Critical Care Medicine; Respiratory System","660UZ","ISI:000282673200013"]
["nemá","J","Janda, A; Sedlacek, P; Honig, M; Friedrich, W; Champagne, M; Matsumoto, T; Fischer, A; Neven, B; Contet, A; Bensoussan, D; Bordigoni, P; Loeb, D; Savage, W; Jabado, N; Bonilla, FA; Slatter, MA; Davies, EG; Gennery, AR",null,null,null,"Janda, Ales; Sedlacek, Petr; Hoenig, Manfred; Friedrich, Wilhelm; Champagne, Martin; Matsumoto, Tadashi; Fischer, Alain; Neven, Benedicte; Contet, Audrey; Bensoussan, Danielle; Bordigoni, Pierre; Loeb, David; Savage, William; Jabado, Nada; Bonilla, Francisco A.; Slatter, Mary A.; Davies, E. Graham; Gennery, Andrew R.",null,"Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly","BLOOD",null,"English","Article",null,null,null,null,null,null,"BONE-MARROW-TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; THYMUS TRANSPLANTATION; CHARGE SYNDROME; CONSTITUTION; INFANTS","Seventeen patients transplanted with hematopoietic cells to correct severe T lymphocyte immunodeficiency resulting from complete DiGeorge anomaly were identified worldwide, and retrospective data were obtained using a questionnaire-based survey. Patients were treated at a median age of 5 months (range, 2-53 months) between 1995 and 2006. Bone marrow was used in 11 procedures in 9 cases: 6 from matched unrelated donors, 4 from human leukocyte antigen (HLA)-identical siblings, and one haploidentical parent with T-cell depletion. Unmobilized peripheral blood was used in 8 cases: 5 from HLA-identical siblings, one from a matched unrelated donor, one from an HLA-identical parent, and one unrelated matched cord blood. Conditioning was used in 5 patients and graftversus-host disease prophylaxis in 11 patients. Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. Median survival among deceased patients (10 patients) was 7 months after transplantation (range, 2-18 months). The overall survival rate was 41%, with a median follow-up of 5.8 years (range, 4-11.5 years). Among survivors, median CD3 and CD4 counts were 806 (range, 644-1224) and 348 (range, 225-782) cells/mm(3), respectively, CD4(+)/CD45RA(+) cells remained very low, whereas mitogen responses were normalized. (Blood. 2010;116(13):2229-2236)","[Janda, Ales; Sedlacek, Petr] Charles Univ Prague, Dept Pediat Hematol & Oncol, Univ Hosp Motol, Prague, Czech Republic; [Janda, Ales; Sedlacek, Petr] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Hoenig, Manfred; Friedrich, Wilhelm] Univ Ulm, Dept Pediat, D-7900 Ulm, Germany; [Champagne, Martin] CHU Ste Justine, Dept Pediat Hematol & Oncol, Montreal, PQ, Canada; [Matsumoto, Tadashi] Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 852, Japan; [Fischer, Alain; Neven, Benedicte] Necker Enfants Malades Hosp, AP HP, Pediat Immunohematol Unit, Paris, France; [Contet, Audrey; Bensoussan, Danielle; Bordigoni, Pierre] Vandouevre, Dept Pediat, Nancy, France; [Loeb, David; Savage, William] Johns Hopkins Univ Hosp, Baltimore, MD 21205 USA; [Jabado, Nada] McGill Univ, Dept Pediat, Montreal Childrens Hosp Res Inst, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Bonilla, Francisco A.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Slatter, Mary A.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Davies, E. Graham] Great Ormond St Hosp Sick Children, Dept Immunol, London, England","Janda, A, Charles Univ Prague, Dept Pediat Hematol & Oncol, Univ Hosp Motol, Prague, Czech Republic","ales.janda@lfmotol.cuni.cz","Czech Ministry of Education [VZ MSM CR 21620812]; Czech Ministry of Health [MZOFNM2005]","This work was supported in part by the Czech Ministry of Education (grant VZ MSM CR 21620812) and the Czech Ministry of Health (grant MZOFNM2005).",null,26,0,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2010-03-275966","BLOOD","Blood","SEP 30",2010,116,13,null,null,null,2229,2236,null,null,8,"Hematology","656VR","ISI:000282369700009"]
["nemá","J","Kotlin, R; Blazek, B; Suttnar, J; Maly, M; Kvasnicka, J; Dyr, JE",null,null,null,"Kotlin, Roman; Blazek, Bohumir; Suttnar, Jiri; Maly, Martin; Kvasnicka, Jan; Dyr, Jan E.",null,"Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens","BLOOD COAGULATION & FIBRINOLYSIS",null,"English","Article",null,null,null,null,null,"dysfibrinogenemia; fibrinogen; fibrinopeptide A; missense mutation","AMINO-ACID SUBSTITUTIONS; A-ALPHA; FIBRINOGEN VARIANT; POLYMERIZATION SITE; THROMBIN; CYS; FIBRINOPEPTIDE; ARG","A 2-year-old asymptomatic boy and his relatives were investigated for a suspected fibrinogen mutation after coagulation tests revealed a decreased functional fibrinogen level (family A). Eight-year-old and 1-year-old asymptomatic brothers were investigated for a suspected fibrinogen mutation after coagulation tests revealed a decreased functional fibrinogen level and prolonged thrombin time (family B). To identify whether genetic mutations were responsible for these dysfibrinogens, DNA extracted from the blood was analyzed. Fibrin polymerization and fibrinolysis were measured by a turbidimetric method at 450 nm. DNA analysis was performed by the Sanger method. Mass spectroscopy was performed on a Biflex IV mass spectrometer. DNA sequencing showed the heterozygous point mutation A alpha Arg16His in the fibrinogen of family A and the heterozygous point mutation A alpha Arg16Cys in the fibrinogen of family B. Kinetics of fibrinopeptide release, fibrinolysis, and fibrin polymerization were impaired in the carriers of the mutations in both families. Mass spectroscopy showed the presence of mutant fibrinogen chains in circulation. Scanning electron microscopy revealed thicker fibrin fibers, differing significantly from the normal control in both cases. Two cases of asymptomatic dysfibrinogenemias, found by routine coagulation testing, were genetically identified as new cases of fibrinogen variants Aa Arg16His and Aa Arg16Cys. Blood Coagul Fibrinolysis 21:640-648 (c) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Kotlin, Roman; Suttnar, Jiri; Dyr, Jan E.] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Blazek, Bohumir] Univ Hosp Ostrava, Dept Pediat, Ostrava, Czech Republic; [Maly, Martin] Motol Univ Hosp, Dept Cardiol, Prague, Czech Republic; [Kvasnicka, Jan] First Fac Med, Dept Med 1, Clin Dept Hematol & Nephrol, Prague, Czech Republic; [Kvasnicka, Jan] Gen Teaching Hosp, Prague, Czech Republic","Kotlin, R, Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic","kotlinr@uhkt.cz","Internal Grant Agency of the Ministry of Health of the Czech Republic [NS 9636-3/2008]; Academy of Sciences of the Czech Republic [KAN200670701]; Ministry of Health of the Czech Republic [2373601, MZO VFN2005]","The work was supported by a grant of The Internal Grant Agency of the Ministry of Health of the Czech Republic, number NS 9636-3/2008, by a grant of The Ministry of Health of the Czech Republic, number 2373601, by a grant of The Academy of Sciences of the Czech Republic, number KAN200670701, and by a grant of The Ministry of Health of the Czech Republic, number MZO VFN2005.",null,30,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0957-5235",null,"10.1097/MBC.0b013e32833e4284","BLOOD COAGULAT FIBRINOL","Blood Coagul. Fibrinolysis","OCT",2010,21,7,null,null,null,640,648,null,null,9,"Hematology","658IK","ISI:000282483500004"]
["nemá","J","Druga, R; Mares, P; Kubova, H",null,null,null,"Druga, Rastislau; Mares, Pavel; Kubova, Hana",null,"Time course of neuronal damage in the hippocampus following lithium-pilocarpine status epilepticus in 12-day-old rats","BRAIN RESEARCH",null,"English","Article",null,null,null,null,null,"Immature rats; Degenerating cells; Fluoro-Jade B; Interneurons; Pyramidal cells","TEMPORAL-LOBE EPILEPSY; NUCLEUS REUNIENS THALAMI; TRAUMATIC BRAIN-INJURY; FLUORO-JADE-B; KAINIC ACID; MEDIODORSAL NUCLEUS; RECURRENT SEIZURES; IMMATURE BRAIN; FIELD CA1; DEGENERATION","Status epilepticus (SE) leads to serious damage in hippocampus of the adult brain. Much less is known about immature brain where neuronal degeneration may have different localization and time course. Lithium-pilocarpine SE was induced in 12-day-old male Wistar rats. Six different intervals after SE (from 4 h to 1 week) were studied using Fluoro-Jade B staining. Three to four animals were used for every interval. Severity of damage in individual parts of hippocampal formation was semi-quantified. A consistent neuronal damage occurred in all hippocampal fields (CA 1, CA 3, dentate gyrus) at all survival intervals. Hippocampal fields CA 1 and CA 3 exhibited degeneration of interneurons located mainly in stratum oriens and pyramidale at shorter intervals (4-12 h). Massive degeneration of pyramidal cells started at 24 h in CA 1 and at 48 h in CA 3. Dentate gyrus exhibited degenerating neurons in granular layer with a peak at short intervals (4-8 h), and molecular layer was spared. The lower blade of dentate gyrus was more affected than the upper blade. Damage of hilar neurons was neglibile. Our results demonstrate that SE elicited in immature rats causes acute neurodegeneration in the hippocampus. Time course of this degeneration is different for individual parts of hippocampal formation and for individual cell types. (C) 2010 Elsevier B.V. All rights reserved.","[Druga, Rastislau; Mares, Pavel; Kubova, Hana] Acad Sci Czech Republic, Dept Dev Epileptol, Inst Physiol, CZ-14220 Prague 4, Czech Republic; [Druga, Rastislau] Charles Univ Prague, Fac Med 2, Dept Anat, Prague, Czech Republic","Druga, R, Acad Sci Czech Republic, Dept Dev Epileptol, Inst Physiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic","rastislav.dmga@lf1.cuni.cz","Grant Agency of the Czech Republic [304/04/0464, 304/07/1137]; Academy of Sciences of the Czech Republic [AV0Z 50110905]","This study was supported by grants of the Grant Agency of the Czech Republic Nr. 304/04/0464 and 304/07/1137 and Research Project No. AV0Z 50110905 of the Academy of Sciences of the Czech Republic.",null,35,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993",null,"10.1016/j.brainres.2010.07.072","BRAIN RES","Brain Res.","OCT 8",2010,1355,null,null,null,null,174,179,null,null,6,"Neurosciences","658QK","ISI:000282504300017"]
["nemá","J","Harrison, CJ; Haas, O; Harbott, J; Biondi, A; Stanulla, M; Trka, J; Izraeli, S",null,null,null,"Harrison, Christine J.; Haas, Oskar; Harbott, Jochen; Biondi, Andrea; Stanulla, Martin; Trka, Jan; Izraeli, Shai",null,"Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group","BRITISH JOURNAL OF HAEMATOLOGY",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukaemia; risk stratification; reverse transcriptase polymerase chain reaction; cytogenetics; fluorescence in situ hybridization","DEPENDENT PROBE AMPLIFICATION; MINIMAL RESIDUAL DISEASE; INTRACHROMOSOMAL AMPLIFICATION; CHROMOSOME-21 IAMP21; GENOMIC ALTERATIONS; MLL TRANSLOCATIONS; EXPRESSION DATA; BCP-ALL; CHILDREN; FUSION","Treatment of childhood acute lymphoblastic leukaemia (ALL) has improved considerably in recent years. A contributing factor has been the improved stratification for treatment according to a number of factors, including genetic determinants of outcome. Here we review the current diagnostic criteria of genetic abnormalities in precursor B-ALL (BCP-ALL), including the relevant technical approaches and the application of the most appropriate methods for the detection of each abnormality. The abnormalities with the most significant impact for treatment and management of BCP-ALL are t(9;22)(q34;q11)/BCR-ABL1, t(4;11)(q21;q23)/MLL-AFF1 and near-haploidy/low hypodiploidy for high risk stratification and, to a lesser extent, t(12;21)(p13;q22)/ETV6-RUNX1 and high hyperdiploidy for good risk management. Apart from the numerical abnormalities, these can be routinely tested for by reverse transcription polymerase chain reaction, providing a basic yet informative screen. However, cytogenetics, particularly fluorescence in situ hybridization may provide reliable alternative detection methods dependent upon the preferred technical approach within each protocol.","[Harrison, Christine J.] Newcastle Univ, Leukaemia Res Cytogenet Grp, No Inst Canc Res, Sir James Spence Inst,Royal Victoria Infirmary, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Haas, Oskar] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Harbott, Jochen] Univ Giessen, Dept Paediat Haematol & Oncol, Oncogenet Lab, Giessen, Germany; [Biondi, Andrea] Univ Milano Bicocca, Dept Paediat, Hosp S Gerardo, Monza, Italy; [Stanulla, Martin] Univ Med Ctr Schleswig Holstein, Dept Paediat, Lubeck, Germany; [Trka, Jan] Charles Univ Prague, Dept Paediat Haematol Oncol, Fac Med 2, Prague, Czech Republic; [Trka, Jan] Univ Hosp Motol, Prague, Czech Republic; [Izraeli, Shai] Tel Aviv Univ, Edmond & Lily Safra Childrens Hosp, Chaim Sheba Med Ctr, Leukaemia Res Ctr, IL-69978 Tel Aviv, Israel","Harrison, CJ, Newcastle Univ, Leukaemia Res Cytogenet Grp, No Inst Canc Res, Sir James Spence Inst,Royal Victoria Infirmary, Level 5, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England","christine.harrison@newcastle.ac.uk",null,null,null,52,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,"10.1111/j.1365-2141.2010.08314.x","BRIT J HAEMATOL","Br. J. Haematol.","OCT",2010,151,2,null,null,null,132,142,null,null,11,"Hematology","656XN","ISI:000282374500002"]
["nemá","J","Kotaska, K; Urinovska, R; Klapkova, E; Prusa, R; Rob, L; Binder, T",null,null,null,"Kotaska, K.; Urinovska, R.; Klapkova, E.; Prusa, R.; Rob, L.; Binder, T.",null,"Re-Evaluation of Cord Blood Arterial and Venous Reference Ranges for pH, pO(2), pCO(2), According to Spontaneous or Cesarean Delivery","JOURNAL OF CLINICAL LABORATORY ANALYSIS",null,"English","Article",null,null,null,null,null,"umbilical cord blood; blood gas; pH","UMBILICAL-CORD; GAS ANALYSIS; VALUES","Umbilical cord blood gas analysis (pO(2) and pCO(2)) is now recommended in all high-risk baby deliveries and in some centers it is performed routinely following all deliveries. The aim of this study was to re-evaluate cord blood arterial and venous reference ranges for pH, pO(2), pCO(2) in newborns, delivered by spontaneous vaginal delivery (SVD) and by cesarean section (CS) performed in Faculty Hospital Motol. Two groups of subjects were selected for the study. Group I consisted of 303 newborns with SVD. Group II consisted of 189 newborns delivered by cesarean section. Cord blood samples were analyzed for standard blood gas and pH, using the analytical device Rapid Lab 845 and Rapid Lab 865. We obtained reference values expressed as range (lower and upper reference value expressed as 2.5 and 97.5 percentiles) for cord blood in newborns with SVD: arterial cord blood: pH = 7.01-7.39; pCO(2) = 4.12-11.45 kPa; pO(2) = 1.49-5.06 kPa; venous cord blood: pH = 7.06-7.44; pCO(2) = 3.33-9.85 kPa; pO(2) = 1.80-6.29 kPa. We also obtained reference values for cord blood in newborns delivered by CS: arterial cord blood: pH = 7.05-7.39; pCO(2) = 5.01-10.60 kPa; pO(2) = 1.17-5.94 kPa; venous cord blood: pH = 7.10-7.42; pCO(2) = 3.88-9.36 kPa; pO(2) = 1.98-7.23 kPa. Re-evaluated reference ranges play essential role in monitoring conditions of newborns with spontaneous and caesarean delivery. J. Clin. Lab. Anal. 24:300-304, 2010. (C) 2010 Wiley-Liss, Inc.","[Kotaska, K.; Urinovska, R.; Klapkova, E.; Prusa, R.] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006 5, Czech Republic; [Kotaska, K.; Urinovska, R.; Klapkova, E.; Prusa, R.; Rob, L.; Binder, T.] Fac Hosp Motol, Prague, Czech Republic; [Rob, L.; Binder, T.] Charles Univ Prague, Dept Obstet & Adult & Paediat Gynaecol, Fac Med 2, Prague 15006 5, Czech Republic","Kotaska, K, Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Clin Biochem & Pathobiochem, Vuvalu 84, Prague 15006 5, Czech Republic","kotaska@email.cz",null,null,null,16,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0887-8013",null,"10.1002/jcla.20405","J CLIN LAB ANAL","J. Clin. Lab. Anal.",null,2010,24,5,null,null,null,300,304,null,null,5,"Medical Laboratory Technology","658JN","ISI:000282486400004"]
["nemá","J","Simko, F; Pechanova, O; Pelouch, V; Krajcirovicova, K; Celec, P; Palffy, R; Bednarova, K; Vrankova, S; Adamcova, M; Paulis, L",null,null,null,"Simko, Fedor; Pechanova, Olga; Pelouch, Vaclav; Krajcirovicova, Kristina; Celec, Peter; Palffy, Roland; Bednarova, Kristina; Vrankova, Stanislava; Adamcova, Michaela; Paulis, Ludovit",null,"Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril","JOURNAL OF HYPERTENSION",null,"English","Article",null,null,null,null,null,"captopril; cardiac hypertrophy; continuous light and L-NAME-induced hypertension; fibrosis; melatonin","SPONTANEOUSLY HYPERTENSIVE-RATS; BLOOD-PRESSURE; VASCULAR REACTIVITY; N-ACETYLCYSTEINE; HEART-DISEASE; HYPERTROPHY; PINEALECTOMY; SIMVASTATIN; REGRESSION; EXPOSURE","Objective Blood pressure enhancement induced by continuous light exposure represents an attractive but rarely investigated model of experimental hypertension. Design and methods The aim of this study was to show whether the combination of continuous light (24 h/day) exposure and chronic N-G-nitro-L-arginine-methyl ester (L-NAME) treatment induces remodelling of the left ventricle and whether captopril or melatonin can modify these potential alterations. Six groups of 3-month-old Wistar rats (nine per group) were treated for 6 weeks: control (untreated), L-NAME (40 mg/kg per day), exposed to continuous light, L-NAME treated and exposed to continuous light (L24), L24 rats treated with either captopril 100 mg/kg per day, or melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP), relative weights of the left ventricle, endothelial nitric oxide synthase (eNOS) and angiotensin-converting enzyme (ACE) expression in tissues, malondialdehyde and advanced oxidation protein product concentrations in the plasma and hydroxyproline levels in collagenous protein fractions were measured. Results The continuous light and L-NAME treatment led to hypertension, left ventricular hypertrophy (LVH) and fibrosis. An increase in SBP was completely prevented by captopril and partly by melatonin in the L24 group. Both drugs reduced oxidative damage and attenuated enhanced expression of ACE in the myocardium. Neither of the drugs prevented the attenuation of eNOS expression in the combined hypertensive model. Only captopril reduced LVH development in L24, whereas captopril and melatonin reduced left ventricular hydroxyproline concentrations in soluble and insoluble collagen, respectively. The total hydroxyproline concentration was reduced only by melatonin. Conclusion In hypertension induced by a combination of continuous light and L-NAME treatment, melatonin and captopril protect the heart against pathological left ventricular remodelling differently. J Hypertens 28 (suppl 1): S13-S18 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Simko, Fedor; Krajcirovicova, Kristina; Celec, Peter; Palffy, Roland; Bednarova, Kristina; Paulis, Ludovit] Comenius Univ, Sch Med, Dept Pathophysiol, Bratislava 81108, Slovakia; [Simko, Fedor] Comenius Univ, Sch Med, Clin Med 3, Bratislava 81108, Slovakia; [Pechanova, Olga; Vrankova, Stanislava; Paulis, Ludovit] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Pelouch, Vaclav] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, Hradec Kralove, Czech Republic; [Pelouch, Vaclav] Cardiovasc Res Ctr, Prague, Czech Republic; [Celec, Peter] Comenius Univ, Inst Mol Biomed, Bratislava 81108, Slovakia; [Adamcova, Michaela] Charles Univ Prague, Sch Med, Dept Physiol, Hradec Kralove, Czech Republic; [Paulis, Ludovit] Charite, Cardiovasc Res Ctr, D-13353 Berlin, Germany","Simko, F, Comenius Univ, Sch Med, Dept Pathophysiol, Sasinkova 4, Bratislava 81108, Slovakia","fedor.simko@fmed.uniba.sk","VEGA [1/0187/09, 2/0178/09]; [APVV-0538-07]; [MSM0021620820]","This study was supported by research grants of VEGA no 1/0187/09 and 2/0178/09, APVV-0538-07 and MSM0021620820.",null,43,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,"10.1097/01.hjh.0000388489.28213.08","J HYPERTENSION","J. Hypertens.","SEP",2010,28,null,null,"Suppl. 1",null,"S13","S18",null,null,6,"Peripheral Vascular Disease","660SZ","ISI:000282665800003"]
["nemá","J","Robova, H; Halaska, M; Pluta, M; Skapa, P; Strnad, P; Lisy, J; Rob, L",null,null,null,"Robova, Helena; Halaska, Michael; Pluta, Marek; Skapa, Petr; Strnad, Pavel; Lisy, Jiri; Rob, Lukas",null,"The Role of Neoadjuvant Chemotherapy and Surgery in Cervical Cancer","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,"English","Review",null,null,null,null,null,"Neoadjuvant chemotherapy; Cervical cancer","GYNECOLOGIC-ONCOLOGY-GROUP; RADICAL TRACHELECTOMY; CENTROPELVIC RECURRENCE; PREOPERATIVE SELECTION; SQUAMOUS CARCINOMA; HYSTERECTOMY; TRIAL; SIZE","The role of neoadjuvant chemotherapy (NAC) in \"bulky\" and locally advanced cervical cancer has been of interest for the last 25 years, and in many countries, NAC has become the standard of care. In the present paper, we review our 10 years' experience with high-dose-density NAC in cervical cancer management in 141 women (CervNAC I protocol). High-dose-density neoadjuvant chemotherapy and radical surgery has resulted in high clinical response rates and seems to be feasible in the management of stage IB bulky cervical cancer. Neoadjuvant chemotherapy reduces tumor volume and positivity of lymph nodes and thus minimizes the need for postoperative radiotherapy or chemoradiotherapy. Tumor size reduction and node negativity allows less radical surgical procedures such as modified radical hysterectomy or nerve-sparing radical hysterectomy. Early and especially late toxicity of our high-dose density chemotherapy is acceptable. Neoadjuvant chemotherapy followed by surgery represents a valid alternative to primary chemoradiotherapy in young and sexually active patients. Five-year survival in patients who underwent surgery in our study was 80.6%. Currently, 3 papers with 3 approaches have been published on NAC before fertility-sparing surgery. One of the limitations of fertility-preserving surgery is deep stromal invasion and tumors larger than 2 cm. The idea underlying NAC is to reduce the size of the cervical tumor to preserve fertility. In the present paper, we also review our experience with high-dose-density NAC in fertility-sparing surgery in 15 women (LAP3-NAC protocol).","[Robova, Helena; Halaska, Michael; Pluta, Marek; Strnad, Pavel; Rob, Lukas] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Prague 15000 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15000 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague 15000 5, Czech Republic","Rob, L, Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, V Uvalu 84, Prague 15000 5, Czech Republic","lukas.rob@lfmotol.cuni.cz","[MZ0FNM2005]","This work was supported by grant MZ0FNM2005.",null,18,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,"10.1111/IGC.0b013e3181f60d73","INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","OCT",2010,20,null,null,"Suppl. 2",null,"S42","S46",null,null,5,"Oncology; Obstetrics & Gynecology","673DZ","ISI:000283640600011"]
["nemá","J","Lysak, D; Kalina, T; Martinek, J; Pikalova, Z; Vokurkova, D; Jaresova, M; Marinov, I; Ondrejkova, A; Spacek, M; Stehlikova, O",null,null,null,"Lysak, D.; Kalina, T.; Martinek, J.; Pikalova, Z.; Vokurkova, D.; Jaresova, M.; Marinov, I.; Ondrejkova, A.; Spacek, M.; Stehlikova, O.",null,"Interlaboratory variability of CD34+stem cell enumeration. A pilot study to national external quality assessment within the Czech Republic","INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY",null,"English","Article",null,null,null,null,null,"CD34+cells; enumeration; variability; ISHAGE; survey; interlaboratory","CD34(+) HEMATOPOIETIC STEM; FLOW-CYTOMETRY; PROGENITOR CELLS; SINGLE; TRANSPLANTATION; MULTICENTER; RECIPIENTS; ASSAY","We present the results of a pilot study concerning the interlaboratory variability of CD34+ enumeration. Three surveys, each including a set of samples, were sent to participating Czech flow cytometry laboratories. The efficacy of this exercise was determined by the reduction in interlaboratory variation and the influence of method used on assay outcome. The variability in results of CD34+ enumeration declined with time. The mean coefficient of variation (CV) of measurement among laboratories dropped, from 58% in first survey to 32% in last survey. All tested variables (gating strategy, platform methodology, sample preparation) affected the variability of the assay. Sample preparation method was associated with a significant bias of absolute CD34+ cell counts. Initially, the outcome of the measurement was also affected by the participating laboratory (identified by a unique laboratory number; ULN). However, laboratories with poorer performance modified their protocols during the study, and the ULN ceased to influence the variability. This study was successful in reducing the interinstitutional variability of CD34+ enumeration. It was shown that the implementation of a standardized protocol does not guarantee accurate measurement. Our research design represents a useful tool, which allows verification of the proper use of a standardized method, the training of operators and feedback in response to the survey results.","[Lysak, D.] Charles Univ Hosp, Dept Hematol & Oncol, Plzen 30460, Czech Republic; [Kalina, T.] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Martinek, J.] P&R Lab, Novy Jicin, Czech Republic; [Pikalova, Z.] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic; [Vokurkova, D.] Univ Hosp Hradec Kralove, Inst Clin Immunol & Allergol, Hradec Kralove, Czech Republic; [Jaresova, M.] IKEM, Diagnost Immunol Lab, Prague, Czech Republic; [Marinov, I.] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Ondrejkova, A.] Reg Hosp T Bati, Dept Pulmonol, Zlin, Czech Republic; [Spacek, M.] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague, Czech Republic; [Stehlikova, O.] Univ Hosp Brno, Dept Internal Med Hematooncol, Brno, Czech Republic","Lysak, D, Charles Univ Hosp, Dept Hematol & Oncol, Alej Svobody 80, Plzen 30460, Czech Republic","lysak@fnplzen.cz","Ministry of Health of the Czech Republic [IGA NR/9268-3]","The study was supported by the grant of the Ministry of Health of the Czech Republic (IGA NR/9268-3).",null,23,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1751-5521",null,"10.1111/j.1751-553X.2010.01244.x","INT J LAB HEMATOL","Int. J. Lab. Hematol.","DEC",2010,32,6,"Part 1",null,null,"E229","E236",null,null,8,"Hematology","672OL","ISI:000283595500006"]
["nemá","J","Durila, M; Kalincik, T; Jurcenko, S; Pelichovska, M; Hadacova, I; Cvachovec, K",null,null,null,"Durila, Miroslav; Kalincik, Tomas; Jurcenko, Sergej; Pelichovska, Martina; Hadacova, Ivana; Cvachovec, Karel",null,"Arteriovenous differences of hematological and coagulation parameters in patients with sepsis","BLOOD COAGULATION & FIBRINOLYSIS",null,"English","Article",null,null,null,null,null,"antithrombin; arteriovenous difference; D-dimer; hemostasis; sepsis; thromboelastography","VENOUS-BLOOD; ORGAN FAILURE; ARTERIAL; SURGERY; DISEASE","In critically ill patients, either arterial or venous blood is usually available for sampling and measurement of basic coagulation parameters. The aim of this study was to examine whether in these patients the values of coagulation parameters differ significantly with respect to the source of the blood samples. In a group of 44 patients with severe sepsis, we compared the values of coagulation, thromboelastography and selected hematological parameters between the arterial and venous blood. In most of the investigated parameters (international normalized ratio, activated partial thromboplastin time, fibrinogen concentration, erythrocyte count, leukocyte and platelet count, hemoglobin level and thromboelastography parameters), we did not find significant differences (P>0.1). However, we found a significantly lower antithrombin activity and a significantly higher D-dimer concentration in venous blood compared to arterial blood (P<0.05). This could be associated with increased consumption of antithrombin and generation of D-dimer as a consequence of microthrombi formation in the capillaries. We therefore conclude that for the purpose of assessment of coagulation status in septic patients, arterial and venous blood cannot be treated as equivalent. Blood Coagul Fibrinolysis 21: 770-774 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Durila, Miroslav; Jurcenko, Sergej; Pelichovska, Martina; Cvachovec, Karel] Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Inst Postgrad Med Educ, Prague 15006 5, Czech Republic; [Kalincik, Tomas] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Kalincik, Tomas] Charles Univ Prague, Dept Neurol, Fac Med 1, Gen Univ Hosp, Prague 15006 5, Czech Republic; [Hadacova, Ivana] Charles Univ Prague, Dept Clin Hematol, Fac Med 2, Prague 15006 5, Czech Republic","Durila, M, Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Inst Postgrad Med Educ, V Uvalu 84, Prague 15006 5, Czech Republic","durila4@yahoo.com","Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education, Charles University in Prague, Czech Republic ","The financial support was provided by Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education, Charles University in Prague, Czech Republic.",null,13,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0957-5235",null,"10.1097/MBC.0b013e32834013d7","BLOOD COAGULAT FIBRINOL","Blood Coagul. Fibrinolysis","DEC",2010,21,8,null,null,null,770,774,null,null,5,"Hematology","674EZ","ISI:000283718400010"]
["nemá","J","Rampichova, M; Filova, E; Varga, F; Lytvynets, A; Prosecka, E; Kolacna, L; Motlik, J; Necas, A; Vajner, L; Uhlik, J; Amler, E",null,null,null,"Rampichova, Michala; Filova, Eva; Varga, Ferdinand; Lytvynets, Andriy; Prosecka, Eva; Kolacna, Lucie; Motlik, Jan; Necas, Alois; Vajner, Ludek; Uhlik, Jiri; Amler, Evzen",null,"Fibrin/Hyaluronic Acid Composite Hydrogels as Appropriate Scaffolds for In Vivo Artificial Cartilage Implantation","ASAIO JOURNAL",null,"English","Article",null,null,null,null,null,null,"ARTICULAR-CARTILAGE; CHONDROCYTES; REPAIR; REGENERATION; DEFECTS","Hydrogels prepared from a mixture of fibrin and high-molecular weight (MW) hyaluronic acid (HA) were found to be suitable scaffolds for chondrocyte seeding and pig knee cartilage regeneration. Collagen in the hydrogels is not necessary for the formation of biomechanically stable tissue. Regenerated cartilage showed very good biomechanical and histological properties only 6 months after implantation. Notably, the quality of the healing process was dependent on the initial chondrocyte concentration of the scaffolds. These experiments were performed according to good laboratory practice (GLP). ASAIO Journal 2010; 56:563-568.","[Rampichova, Michala; Varga, Ferdinand; Prosecka, Eva; Kolacna, Lucie; Amler, Evzen] Charles Univ Prague, Inst Biophys, Fac Med 2, Prague 15006 5, Czech Republic; [Rampichova, Michala; Filova, Eva; Lytvynets, Andriy; Prosecka, Eva; Kolacna, Lucie; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Motlik, Jan] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic; [Necas, Alois] Univ Vet & Pharmaceut Sci, Fac Vet Med, Dept Surg & Orthoped, Small Anim Clin, Brno, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15006 5, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Acad Sci Czech Republic, Inst Physiol, Dept Breeding & Zoohyg Lab Anim, Vvi, Prague, Czech Republic","Amler, E, Charles Univ Prague, Inst Biophys, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","evzen.amler@lfmotol.cuni.cz","Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth, and Sports of the Czech Republic [NPV II 2B06130]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151, P304/10/1307]; EU [214539]; Grant Agency of Charles University [119209]","Supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), the Ministry of Education, Youth, and Sports of the Czech Republic (research programs NPV II 2B06130), the Grant Agency of the Academy of Sciences (grant no. IAA500390702), the Czech Science Foundation (grant numbers GA202/09/1151 and P304/10/1307), the EU project BIOSCENT (ID number 214539), and the Grant Agency of Charles University (grant no. 119209). The authors are grateful to Sam Norris for proof reading of this manuscript.",null,19,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1058-2916",null,"10.1097/MAT.0b013e3181fcbe24","ASAIO J","Asaio J.","NOV-DEC",2010,56,6,null,null,null,563,568,null,null,6,"Engineering, Biomedical; Transplantation","674FH","ISI:000283719600014"]
["nemá","J","Makukh, H; Krenkova, P; Tyrkus, M; Bober, L; Hancarova, M; Hnateyko, O; Macek, M",null,null,null,"Makukh, Halyna; Krenkova, Petra; Tyrkus, Marta; Bober, Lyudmyla; Hancarova, Miroslava; Hnateyko, Oleh; Macek, Milan, Jr.",null,"A high frequency of the Cystic Fibrosis 2184insA mutation in Western Ukraine: Genotype-phenotype correlations, relevance for newborn screening and genetic testing","JOURNAL OF CYSTIC FIBROSIS",null,"English","Article",null,null,null,null,null,"Cystic fibrosis (OMIM 219700); CFTR gene; Genotype phenotype correlations; Western Ukraine; 2184insA; DNA diagnostics; Newborn screening; Sequencing","CFTR GENE","We present the first comprehensive report on the distribution and genotype-phenotype correlations of CF-causing mutations in Western Ukraine (former Galicia). The 2184insA mutation was identified in 17 unrelated CF patients, 2 of whom are homozygotes for this allele. This mutation is associated with the classical form of CF. The high frequency of 2184insA mutation (7.20% of all mutated CF chromosomes) suggests that it is likely of Galician origin, from where it has spread throughout Europe and beyond. The achieved 83.71% mutation detection rate fulfills the minimal pre-requisite for introduction of the \"two-tier\" (IRT/DNA) newborn screening program. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Krenkova, Petra; Hancarova, Miroslava; Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, CZ-15006 Prague 5, Czech Republic; [Krenkova, Petra; Hancarova, Miroslava; Macek, Milan, Jr.] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Makukh, Halyna; Tyrkus, Marta; Bober, Lyudmyla; Hnateyko, Oleh] Ukrainian Acad Med Sci, Inst Hereditary Pathol, Lvov, Ukraine","Macek, M, Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","milan.macek.jr@lfmotol.cuni.cz","Eurogentest Fellowship [FP6-512148]; Czech Ministry of Health [MZOFNM2005]","Supported by the Eurogentest Fellowship (FP6-512148) to HM and by MZOFNM2005 from the Czech Ministry of Health to MM. We also acknowledge proofreading of the manuscript by Dr. A. Melnyk (Chicago, USA), graphical design by Dr. M. Turnovec (Prague, Czech Republic) and help of Dr. S. Koceva (Skopje, Macedonia) and Dr. J. Feigelson (Paris, France) with sequencing of selected WU patients.",null,18,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,"10.1016/j.jcf.2010.06.001","J CYST FIBROS","J. Cyst. Fibros","SEP",2010,9,5,null,null,null,371,375,null,null,5,"Respiratory System","670HJ","ISI:000283411500012"]
["nemá","J","van Herpen, CML; Mauer, ME; Mesia, R; Degardin, M; Jelic, S; Coens, C; Betka, J; Bernier, J; Remenar, E; Stewart, JS; Preiss, JH; van den Weyngaert, D; Bottomley, A; Vermorken, JB",null,null,null,"van Herpen, C. M. L.; Mauer, M. E.; Mesia, R.; Degardin, M.; Jelic, S.; Coens, C.; Betka, J.; Bernier, J.; Remenar, E.; Stewart, J. S.; Preiss, J. H.; van den Weyngaert, D.; Bottomley, A.; Vermorken, J. B.","EORTC Head Neck Grp","Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)","BRITISH JOURNAL OF CANCER",null,"English","Article",null,null,null,null,null,"HRQOL; symptoms; head and neck cancer","SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; CLINICAL-TRIALS; RADIOTHERAPY; CHEMORADIATION; DYSPHAGIA; CETUXIMAB; QLQ-C30; SPEECH","BACKGROUND: The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients' health-related quality of life (HRQOL) and symptoms was investigated. METHODS: HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-H&N35). The primary HRQOL scale was global HRQOL per protocol. RESULTS: Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent. CONCLUSION: Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner. British Journal of Cancer (2010) 103, 1173-1181. doi:10.1038/sj.bjc.6605860 www.bjcancer.com Published online 14 September 2010 (C) 2010 Cancer Research UK","[van Herpen, C. M. L.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; [Mauer, M. E.; Coens, C.; Bottomley, A.] EORTC Headquarters, European Org Res & Treatment Canc, Brussels, Belgium; [Mesia, R.] Inst Catala Oncol, Barcelona, Spain; [Degardin, M.] Ctr Oscar Lambret, F-59020 Lille, France; [Jelic, S.] Inst Oncol & Radiol, Belgrade, Serbia; [Betka, J.] Univ Hosp Motol, Prague, Czech Republic; [Bernier, J.] Clin Genolier, Genolier, Switzerland; [Remenar, E.] Natl Inst Oncol, Budapest, Hungary; [Stewart, J. S.] Charing Cross Hosp, London, England; [Preiss, J. H.] Caritasklin St Theresia, Saarbrucken, Germany; [van den Weyngaert, D.] Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; [Vermorken, J. B.] Univ Ziekenhuis Antwerpen, Edegem, Belgium","van Herpen, CML, Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, 452,POB 9101, NL-6500 HB Nijmegen, Netherlands","C.vanherpen@onco.umcn.nl","Sanofi-Aventis ; National Cancer Institute (Bethesda, MD, USA) [5U10-CA11488-29, 5U10 CA11488-39]; EORTC Charitable Trust ","Sanofi-Aventis financially sponsored this trial. In addition, the QOL analysis was in part supported by Grant numbers 5U10-CA11488-29 through to 5U10 CA11488-39 from the National Cancer Institute (Bethesda, MD, USA), as well as by the EORTC Charitable Trust. We thank all EORTC investigators who participated in this study and the EORTC Headquarters staff who worked for this study. We thank all the patients for participating in this clinical trial to help us understand the best way to treat this cancer. The clinical trials.gov registry number was NCT00003888.",null,30,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0007-0920",null,"10.1038/sj.bjc.6605860","BRIT J CANCER","Br. J. Cancer","OCT 12",2010,103,8,null,null,null,1173,1181,null,null,9,"Oncology","671WL","ISI:000283542900006"]
["nemá","J","Hanova, M; Stetina, R; Vodickova, L; Vaclavikova, R; Hlavac, P; Smerhovsky, Z; Naccarati, A; Polakova, V; Soucek, P; Kuricova, M; Manini, P; Kumar, R; Hemminki, K; Vodicka, P",null,null,null,"Hanova, Monika; Stetina, Rudolf; Vodickova, Ludmila; Vaclavikova, Radka; Hlavac, Pavel; Smerhovsky, Zdenek; Naccarati, Alessio; Polakova, Veronika; Soucek, Pavel; Kuricova, Miroslava; Manini, Paola; Kumar, Rajiv; Hemminki, Kari; Vodicka, Pavel",null,"Modulation of DNA repair capacity and mRNA expression levels of XRCC1, hOGG1 and XPC genes in styrene-exposed workers","TOXICOLOGY AND APPLIED PHARMACOLOGY",null,"English","Article",null,null,null,null,null,"Styrene exposure; Genotoxicity; DNA repair; DNA repair rates; Gene expression","SINGLE-STRAND BREAKS; CYTOGENETIC BIOMARKERS; URINARY METABOLITES; LAMINATION WORKERS; DAMAGE; POLYMORPHISMS; LYMPHOCYTES; ADDUCTS; CELLS; SUSCEPTIBILITY","Decreased levels of single-strand breaks in DNA (SSBs), reflecting DNA damage, have previously been observed with increased styrene exposure in contrast to a dose-dependent increase in the base-excision repair capacity. To clarify further the above aspects, we have investigated the associations between SSBs, micronuclei, DNA repair capacity and mRNA expression in XRCC1, hOGG1 and XPC genes on 71 styrene-exposed and 51 control individuals. Styrene concentrations at workplace and in blood characterized occupational exposure. The workers were divided into low (below 50 mg/m(3)) and high (above 50 mg/m(3)) styrene exposure groups. DNA damage and DNA repair capacity were analyzed in peripheral blood lymphocytes by Cornet assay. The mRNA expression levels were determined by qPCR. A significant negative correlation was observed between SSBs and styrene concentration at workplace (R = -0.38, p = 0.001); SSBs were also significantly higher in men (p = 0.001). The capacity to repair irradiation-induced DNA damage was the highest in the low exposure group (1.34 +/- 1.00 SSB/10(9) Da), followed by high exposure group (0.72 +/- 0.81 SSB/10(9) Da) and controls (0.65 +/- 0.82 SSB/10(9) Da). The mRNA expression levels of XRCC1, hOGG1 and XPC negatively correlated with styrene concentrations in blood and at workplace (p < 0.001) and positively with SSBs (p < 0.001). Micronuclei were not affected by styrene exposure, but were higher in older persons and in women (p < 0.001). In this study, we did not confirm previous findings on an increased DNA repair response to styrene-induced genotoxicity. However, negative correlations of SSBs and mRNA expression levels of XRCC1, hOGG1 and XPC with styrene exposure warrant further highly-targeted study. (C) 2010 Elsevier Inc. All rights reserved.","[Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14220, Czech Republic; [Hanova, Monika] Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, Prague, Czech Republic; [Stetina, Rudolf] Purkynje Mil Med Acad, Hradec Kralove, Czech Republic; [Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Soucek, Pavel] Natl Inst Publ Hlth, Prague, Czech Republic; [Hlavac, Pavel] Reg Hyg Stn, Dept Occup Med, Hradec Kralove, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Kuricova, Miroslava] Slovak Med Univ, Res Base, Bratislava, Slovakia; [Manini, Paola] Univ Parma, Dept Clin Med Nephrol & Hlth Sci, I-43100 Parma, Italy; [Kumar, Rajiv; Hemminki, Kari] German Canc Res Ctr Deutsch Krebs Forsch Zentrum, Heidelberg, Germany","Vodicka, P, Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14220, Czech Republic","pvodicka@biomed.cas.cz","Grant Agency of the Czech Academy of Sciences [IAA500390806]; Internal Grant Agency of Czech Ministry of Health [NR 9423-3]","This study was supported by Grant Agency of the Czech Academy of Sciences IAA500390806 and by Internal Grant Agency of Czech Ministry of Health NR 9423-3. We thank to Jana Slyskova, Ivona Hlavata and Dr. Barbara Pardini Naccarati for their technical help and support.",null,35,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0041-008X",null,"10.1016/j.taap.2010.07.027","TOXICOL APPL PHARMACOL","Toxicol. Appl. Pharmacol.","NOV 1",2010,248,3,null,null,null,194,200,null,null,7,"Pharmacology & Pharmacy; Toxicology","667OO","ISI:000283203600004"]
["nemá","J","Mrazova, M; Celec, P",null,null,null,"Mrazova, Marcela; Celec, Peter",null,"A Systematic Review of Randomized Controlled Trials Using Music Therapy for Children","JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE",null,"English","Review",null,null,null,null,null,null,"INTERACTIVE MUSIC; PRETERM INFANTS; LIVE MUSIC; ADOLESCENTS; AUTISM; BRAIN; BEHAVIORS; ATTENTION; ANXIETY; STRESS","Background: Music therapy is a promising approach widening the potential applications of psychotherapy. Music influences both, psychologic and physiologic parameters, and children are especially responsive to this form of therapy. Many aspects of its action mechanisms remain to be elucidated, underscoring the need for evidence-based medicine (EBM) for clinical use of music therapy. Aims: This review seeks to highlight some of the issues of music therapy research and to initiate a discussion about the need for international multicenter cooperation to bring scientifically sound evidence of the benefits of music therapy in pediatric patients. Methods: Scientific bibliographic databases were searched for randomized controlled trials on use of music therapy for children. Identified articles were evaluated according to criteria for scientific quality. Results: Twenty-eight studies were identified. Most of the trials were biased by the number of participants, and some trials showed the need to improve design of control groups. Indeed, the novelty of this area of study has produced a large number of different studies (with variability in diagnoses, interventions, control groups, duration, and/or outcome parameters), and there is a need for a more homogeneous and systematic approach. Available studies highlight the need to address reproducibility issues. Conclusions: This analysis identifies the need for a subsequent series of clinical studies on the efficacy of music in the pediatric population, with more focus on eligibility criteria with respect to EBM and reproducibility.","[Celec, Peter] Comenius Univ, Inst Mol Biomed, Bratislava 81108, Slovakia; [Mrazova, Marcela] Charles Univ Prague, Dept Child Psychiat, Med Sch 2, Prague, Czech Republic; [Celec, Peter] Comenius Univ, Inst Pathophysiol, Bratislava 81108, Slovakia; [Celec, Peter] Comenius Univ, Dept Mol Biol, Bratislava 81108, Slovakia","Celec, P, Comenius Univ, Inst Mol Biomed, Sasinkova 4, Bratislava 81108, Slovakia","petercelec@gmail.com",null,null,null,54,0,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1075-5535",null,"10.1089/acm.2009.0430","J ALTERN COMPLEMENT MED","J. Altern. Complement Med.","OCT",2010,16,10,null,null,null,1089,1095,null,null,7,"Integrative & Complementary Medicine","665SH","ISI:000283055300012"]
["nemá","J","Rotthier, A; Auer-Grumbach, M; Janssens, K; Baets, J; Penno, A; Almeida-Souza, L; Van Hoof, K; Jacobs, A; De Vriendt, E; Schlotter-Weigel, B; Loscher, W; Vondracek, P; Seeman, P; De Jonghe, P; Van Dijck, P; Jordanova, A; Hornemann, T; Timmerman, V",null,null,null,"Rotthier, Annelies; Auer-Grumbach, Michaela; Janssens, Katrien; Baets, Jonathan; Penno, Anke; Almeida-Souza, Leonardo; Van Hoof, Kim; Jacobs, An; De Vriendt, Els; Schlotter-Weigel, Beate; Loscher, Wolfgang; Vondracek, Petr; Seeman, Pavel; De Jonghe, Peter; Van Dijck, Patrick; Jordanova, Albena; Hornemann, Thorsten; Timmerman, Vincent",null,"Mutations in the SPTLC2 Subunit of Serine Palmitoyltransferase Cause Hereditary Sensory and Autonomic Neuropathy Type I","AMERICAN JOURNAL OF HUMAN GENETICS",null,"English","Article",null,null,null,null,null,null,"SPHINGOLIPID METABOLISM; BIOSYNTHESIS; ACCUMULATION; HOMEOSTASIS; INHIBITION; PHENOTYPE; FUMONISIN; DISEASES; PROTEIN; GENES","Hereditary sensory and autonomic neuropathy type I (HSAN-I) is an axonal peripheral neuropathy associated with progressive distal sensory loss and severe ulcerations Mutations in the first subunit of the enzyme serine palmitoyltransferase (SPT) have been associated with HSAN-I The SPT enzyme catalyzes the first and rate-limiting step in the de novo sphingolipid synthesis pathway However, different studies suggest the implication of other genes in the pathology of HSAN-I Therefore, we screened the two other known subunits of SPT, SPTLC2 and SPTLC3, in a cohort of 78 HSAN patients No mutations were found in SPTLC3, but we identified three heterozygous missense mutations in the SPTLC2 subunit of with four families presenting with a typical HSAN-I phenotype We demonstrate that these mutations result in a partial to complete loss of SPT activity in vitro and in vivo Moreover, they cause the accumulation of the atypical and neurotoxic sphingoid metabolite I-deoxy-sphinganine Our findings extend the genetic heterogeneity in HSAN-I and enlarge the group of HSAN neuropathies associated with SPT defects. We further show that HSAN-I is consistently associated with an Increased formation of the neurotoxic 1-deoxysphinganine, suggesting a common pathomechanism for HSAN-I.","[Rotthier, Annelies; Janssens, Katrien; Almeida-Souza, Leonardo; Van Hoof, Kim; Jacobs, An; Timmerman, Vincent] Univ Antwerp, Peripheral Neuropathy Grp, VIB Dept Mol Genet, B-2610 Antwerp, Belgium; [Baets, Jonathan; De Vriendt, Els; De Jonghe, Peter; Jordanova, Albena] Univ Antwerp, Neurogenet Grp, VIB Dept Mol Genet, B-2610 Antwerp, Belgium; [Rotthier, Annelies; Janssens, Katrien; Baets, Jonathan; Almeida-Souza, Leonardo; Van Hoof, Kim; Jacobs, An; De Vriendt, Els; De Jonghe, Peter; Jordanova, Albena; Timmerman, Vincent] Univ Antwerp, Neurogenet Lab, Inst Born Bunge, B-2610 Antwerp, Belgium; [Auer-Grumbach, Michaela] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria; [Baets, Jonathan; De Jonghe, Peter] Univ Antwerp Hosp, Dept Neurol, B-2650 Antwerp, Belgium; [Penno, Anke; Hornemann, Thorsten] Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland; [Penno, Anke] Competence Ctr Syst Physiol & Metab Dis, CH-8093 Zurich, Switzerland; [Schlotter-Weigel, Beate] Univ Munich, Friedrich Baur Inst, Dept Neurol, D-80336 Munich, Germany; [Loscher, Wolfgang] Innsbruck Med Univ, Dept Neurol, A-6020 Innsbruck, Austria; [Vondracek, Petr] Univ Hosp & Masaryk Univ, Dept Paediat Neurol, CZ-61300 Brno, Czech Republic; [Seeman, Pavel] Charles Univ Prague, Sch Med Prague 2, Dept Child Neurol, CZ-15006 Prague, Czech Republic; [Van Dijck, Patrick] Katholieke Univ Leuven, VIB Dept Mol Microbiol, Mol Cell Biol Lab, B-3001 Louvain, Belgium; [Hornemann, Thorsten] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Hornemann, Thorsten] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, CH-8057 Zurich, Switzerland","Timmerman, V, Univ Antwerp, Peripheral Neuropathy Grp, VIB Dept Mol Genet, B-2610 Antwerp, Belgium",null,"University of Antwerp ; FWO-Flanders ; Medical Foundation Queen Elisabeth ; Association Beige centre les Maladies Neuromusculaires ; Belgian Federal Science Policy Office (BELSPO) ; Austrian Science Fond (FWF) [P19455-05]; Institute for Science and Technology (IWT) ; EMBO ; BELSPO ; IGA MH CR grant [10552-3]; German Society for Clinical Chemistry and Laboratory Medicine ; Gebert Ruf Foundation ; European Commission [LSHM-CT-2006-037631]","We are grateful to the patients and their families for their cooperation in our research project We thank the Genetic Service Facility (VIB) for DNA sequencing and Ilse Palmans and Deborah Seys for technical assistance with the yeast assays. This project was funded in part by a Methusalem grant of the University of Antwerp, the Fund for Scientific Research (FWO-Flanders), the Medical Foundation Queen Elisabeth (GSKE), the Association Beige centre les Maladies Neuromusculaires (ABMM), the Interuniversity Attraction Poles P6/43 program of the Belgian Federal Science Policy Office (BELSPO), and the Austrian Science Fond (FWF, P19455-05) A R and J B are supported by Ph D. fellowships of the Institute for Science and Technology (IWT) and FWO-Flanders, respectively A R received an EMBO Short Term Fellowship K J holds a postdoctoral fellowship from BELSPO PS is supported by an IGA MH CR grant (no 10552-3) Support for HT. was provided by the German Society for Clinical Chemistry and Laboratory Medicine (DGKL), the Gebert Ruf Foundation, and the European Commission (LSHM-CT-2006-037631)",null,35,0,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0002-9297",null,"10.1016/j.ajhg.2010.09.010","AMER J HUM GENET","Am. J. Hum. Genet.","OCT 8",2010,87,4,null,null,null,513,522,null,null,10,"Genetics & Heredity","665LU","ISI:000283037600007"]
["nemá","J","Janousek, J; Gebauer, RA; Weidenbach, M",null,null,null,"Janousek, J.; Gebauer, R. A.; Weidenbach, M.",null,"Pediatric dysrhythmia","MONATSSCHRIFT KINDERHEILKUNDE",null,"German","Article",null,null,null,null,null,"Cardiac dysrhythmia; Tachycardia, supraventricular; Arrhythmia, genetic; Heart failure; Death, sudden","LONG-QT SYNDROME; RADIOFREQUENCY CATHETER ABLATION; SUPRAVENTRICULAR TACHYCARDIA; CHILDREN; RECURRENCE","Diagnosis and therapy of cardiac dysrhythmia has become an important subspecialization in pediatric cardiology. The limited possibilities of antiarrhythmic drug therapy and antibradycardia pacing have been expanded by completely new and fascinating developments over the last 30 years. Curative treatment for the majority of tachyarrhythmias has been achieved by catheter ablation. Secondary as well as primary prevention of sudden arrhythmic death has become possible thanks to implantable defibrillators. Multiple hereditary life-threatening arrhythmia syndromes have been discovered and give a fascinating insight into the molecular genetic background of arrhythmogenesis. Cardiac resynchronization therapy has evolved into one of the few causal treatment strategies for heart failure and points toward intriguing remodeling processes at the cellular level. The following article provides practical as well as background knowledge of some of these developments.","[Janousek, J.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006, Czech Republic; [Janousek, J.] Univ Hosp Motol, Kardioctr, Prague 15006, Czech Republic; [Gebauer, R. A.; Weidenbach, M.] Univ Leipzig, Herzzentrum, Klin Kinderkardiol, Leipzig, Germany","Janousek, J, Univ Hosp Motol, Cardiovasc Res Ctr, V Uvalu 84, Prague 15006, Czech Republic","jan.janousek@lfmotol.cuni.cz",null,null,null,15,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0026-9298",null,"10.1007/s00112-010-2176-6","MONATSSCHR KINDERHEILK","Mon.schr. Kinderheilkd.","OCT",2010,158,10,null,null,null,938,945,null,null,8,"Pediatrics","662RT","ISI:000282829900008"]
["nemá","J","Formankova, R; Sedlacek, P; Keslova, P; Sramkova, L; Zizkova, H; Stary, J",null,null,null,"Formankova, Renata; Sedlacek, Petr; Keslova, Petra; Sramkova, Lucie; Zizkova, Hana; Stary, Jan",null,"Adoptive immunotherapy, chemotherapy, and second allogeneic transplant in the treatment of post-transplant relapse of acute leukemia in children: a single center experience","LEUKEMIA & LYMPHOMA",null,"English","Letter",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHIMERISM",null,"[Formankova, Renata; Sedlacek, Petr; Keslova, Petra; Sramkova, Lucie; Stary, Jan] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Zizkova, Hana] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Formankova, R, Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic","renata.formankova@lfmotol.cuni.cz",null,null,null,11,0,"TAYLOR & FRANCIS LTD","ABINGDON","4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND","1042-8194",null,"10.3109/10428194.2010.504873","LEUK LYMPHOMA","Leuk. Lymphoma","OCT",2010,51,10,null,null,null,1936,1940,null,null,5,"Oncology; Hematology","663NS","ISI:000282895200028"]
["nemá","J","Simunkova, K; Hampl, R; Hill, M; Kriz, L; Hrda, P; Janickova-Zdarska, D; Zamrazil, V; Vrbikova, J; Vondra, K",null,null,null,"Simunkova, Katerina; Hampl, Richard; Hill, Martin; Kriz, Lubomir; Hrda, Pavlina; Janickova-Zdarska, Denisa; Zamrazil, Vaclav; Vrbikova, Jana; Vondra, Karel",null,"Adrenocortical function in young adults with diabetes mellitus type 1","JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY",null,"English","Article",null,null,null,null,null,"Diabetes mellitus type 1; Low-dose Synacthen test; Young adults; Salivary cortisol; Adrenocortical function","PITUITARY-ADRENAL AXIS; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; STEROID 21-HYDROXYLASE AUTOANTIBODIES; CORTICOSTEROID-BINDING GLOBULIN; AUTOIMMUNE-DISEASES MARKERS; CLINICAL ADDISONS-DISEASE; HYPOTHALAMIC-PITUITARY; CORTISOL RESPONSE; FOLLOW-UP; ACTH TEST","In 75 young adults with diabetes mellitus type 1 (DM 1) we have performed a cross-sectional study to gain more information about their adrenocortical function. We have found in a surprisingly large portion of patients (25%) a subnormal response (<500 nmol/L, low responders) of the serum cortisol during low-dose Synacthen test, accompanied by significantly decreased stimulated values of aldosterone and salivary cortisol. Basal serum cortisol, aldosterone, and dehydroepiandrosterone sulphate (in women only) were significantly reduced in low responders as well, while ACTH, cortisol binding globulin, plasma renin activity, urinary free cortisol/24 h, and salivary cortisol did not differ. The results indicate that the disorder of adrenocortical function in low responders occurs in all adrenocortical zones. The patients with the highest risk in respect to revealed hypocorticalism were DM 1 with autoimmune thyroiditis, 13 out of 36 in contrast to 5 out of 39 suffered from isolated form of DM 1, with onset around 30 years, independently on sex. The biorhythm of salivary cortisol in low responders under real-life conditions did not significantly differ from normal responders, except of the decreased values in the morning. Antibodies against 21-hydroxylase and adrenal cortex were negative in the entire group of diabetics studied. In conclusion, this is the first study to demonstrate in as much as 25% of young adults with DM 1 patients without any signs of adrenal autoimmunity decreased both basal and stimulated serum cortisol and aldosterone levels, implying existence of subclinical primary hypocorticalism. (c) 2010 Elsevier Ltd. All rights reserved.","[Simunkova, Katerina; Hampl, Richard; Hill, Martin; Kriz, Lubomir; Hrda, Pavlina; Vrbikova, Jana; Vondra, Karel] Inst Endocrinol, Prague 11694, Czech Republic; [Janickova-Zdarska, Denisa; Zamrazil, Vaclav] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Internal Med, Prague 15006 5, Czech Republic","Simunkova, K, Inst Endocrinol, Narodni Trida 8, Prague 11694, Czech Republic","ksimunkova@endo.cz; kvondra@endo.cz","Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR) [NR/9154-3]","We thank the study participants and our excellent research nurses. We thank the members of our steroid research group. The study was supported by grant NR/9154-3 of the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR).",null,36,1,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-0760",null,"10.1016/j.jsbmb.2010.04.017","J STEROID BIOCHEM MOL BIOL","J. Steroid Biochem. Mol. Biol.","OCT",2010,122,"2010-03-01",null,null,"Sp. Iss. SI",35,41,null,null,7,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","663FN","ISI:000282868500006"]
["nemá","J","Martin, RCG; Howard, J; Tomalty, D; Robbins, K; Padr, R; Bosnjakovic, PM; Tatum, C",null,null,null,"Martin, R. C. G.; Howard, J.; Tomalty, D.; Robbins, K.; Padr, R.; Bosnjakovic, P. M.; Tatum, Cliff",null,"Toxicity of Irinotecan-Eluting Beads in the Treatment of Hepatic Malignancies: Results of a Multi-Institutional Registry","CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY",null,"English","Article",null,null,null,null,null,"Irinotecan; Image guided liver directed therapy; Precision chemoembolization; Toxicity","DNA TOPOISOMERASE-I; COLORECTAL-CANCER; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER METASTASES; CAMPTOTHECIN ANALOGS; ANTITUMOR-ACTIVITY; CPT-11; VITRO; TACE","Purpose To evaluate the predictors of toxicity of drug-eluting beads loaded with irinotecan (DEBIRI) in the treatment of hepatic malignancies. Materials and Methods A total of 330 patients were enrolled in a prospective, open-label, multicenter, multinational, single-arm study administering two types of drug-eluting beads (DEBIRI and drug-eluting beads loaded with doxorubicin). Complications were graded by Cancer Therapy Evaluation Program's Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. All events requiring additional physician treatment or requiring extended hospital stay or readmission within 30 days were included. Results A total of 109 patients received 187 DEBIRI treatments (range 1 to 5 per patient). The most common histology was metastatic colorectal cancer in 76% of patients, cholangiocarcinoma in 7% of patients, and other metastatic disease in 17% of patients. There were 35 patients (19%) with irinotecan treatments who sustained 158 treatment-related adverse events, with the median CTCAE event grade being CTCAE grade 2 (range 1 to 5). The most common adverse events were postembolic symptoms (42%). Multivariate analysis identified pretreatment and treatment-related risk factors as follows: lack of pretreatment with hepatic arterial lidocaine (p = 0.005), >= 3 treatments (p = 0.05), achievement of complete stasis (p = 0.04), treatment with >100 mg DEBIRI in 1 treatment (p = 0.03), and bilirubin >2.0 mu g/dl with >50% liver involvement (p = 0.05). These factors were predictive of adverse events and significantly greater hospital length of stay. Conclusions DEBIRI is safe when appropriate technique and treatment are used. Adverse events can be predicted based on pretreatment-and treatment-related factors, and their occurrence can become part of the informed consent process. Continued standardization of this treatment will lead to fewer adverse events and improved patient quality of life.","[Martin, R. C. G.] Univ Louisville, Dept Surg, Div Surg Oncol, Louisville, KY 40292 USA; [Howard, J.] N Mississippi Med Ctr, Tupelo, MS USA; [Tomalty, D.] Huntsville Dist Mem Hosp, Huntsville, AL USA; [Robbins, K.] Baptist Hlth, Little Rock, AR USA; [Padr, R.] FN Motole, Motole, Czech Republic; [Bosnjakovic, P. M.] Ctr Nis Serbia, Nish, Serbia; [Tatum, Cliff] Norton Hosp, Dept Radiol, Louisville, KY USA","Martin, RCG, Univ Louisville, Dept Surg, Div Surg Oncol, Louisville, KY 40292 USA","rcmart03@gwise.louisville.edu","Biocompatibles ","Supported by an Unrestricted Educational Grant from Biocompatibles. RCGM: Consultant Biocompatibles.",null,22,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0174-1551",null,"10.1007/s00270-010-9937-4","CARDIOVASC INTERVEN RADIOL","Cardiovasc. Interv. Radiol.","OCT",2010,33,5,null,null,null,960,966,null,null,7,"Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging","661EM","ISI:000282706700012"]
["nemá","J","Durilova, M; Stechova, K; Petruzelkova, L; Stavikova, V; Ulmannova, T; Nevoral, J",null,null,null,"Durilova, Marianna; Stechova, Katerina; Petruzelkova, Lenka; Stavikova, Vendula; Ulmannova, Tereza; Nevoral, Jiri",null,"Is there any relationship between cytokine spectrum of breast milk and occurence of eosinophilic colitis?","ACTA PAEDIATRICA",null,"English","Article",null,null,null,null,null,"Atopy; Breast milk; Cytokine; ELISA; Eosinophilic colitis","FED INFANTS; ALLERGIC COLITIS; T-CELLS; IL-18; GAMMA; INTERLEUKIN-10; PROCTOCOLITIS; MICROFLORA; PROBIOTICS; DISEASES","Aim: The aim of our study was to analyse cytokine composition of human milk and its relationship to the development of eosinophilic colitis (EC). Methods: Cytokines were measured by ELISA method in breast milk of 20 mothers of infants who developed EC and 20 controls. Results: We found significantly higher concentrations of interferon-gamma (IFN-gamma) (Th1 cytokine) in breast milk received by EC infants compared to controls (p = 0.0004). In contrary, IL-18 (Th1-inducing cytokine) was significantly higher in breast milk received by healthy infants comparing to EC infants (p = 0.001). Regulatory cytokine transforming growth factor beta1 (TGF-beta1) showed higher concentrations in breast milk received by healthy infants, although the difference from EC group was not significant (p = 0.072). Conclusion: The results of our study showed that infants with EC were receiving breast milk with a possibly risky cytokine pattern indicating cytokine imbalance, impaired immunoregulation and the early Th1 shift.","[Durilova, Marianna; Stechova, Katerina; Petruzelkova, Lenka; Stavikova, Vendula; Ulmannova, Tereza; Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic","Stechova, K, Charles Univ Prague, Dept Paediat, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic","info@labao.cz","Internal Grant Agency of Ministry of Health, Czech Rep. [NR 8310-5]","This project was supported by Internal Grant Agency of Ministry of Health, Czech Rep. No NR 8310-5. We express our thanks to Katerina Flajsmanova-Tesarova for the laboratory processing of breast milk samples.",null,25,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0803-5253",null,"10.1111/j.1651-2227.2010.01907.x","ACTA PAEDIAT","Acta Paediatr.","NOV",2010,99,11,null,null,null,1666,1670,null,null,5,"Pediatrics","660KP","ISI:000282641600013"]
["nemá","J","Van Calsteren, K; Verbesselt, R; Ottevanger, N; Halaska, M; Heyns, L; Van Bree, R; de Bruijn, E; Chai, D; Delforge, M; Noens, L; Renard, V; Witteveen, E; Rob, L; de Hoon, J; Amant, F",null,null,null,"Van Calsteren, Kristel; Verbesselt, Rene; Ottevanger, Nelleke; Halaska, Michael; Heyns, Liesbeth; Van Bree, Rieta; de Bruijn, Ernst; Chai, Daniel; Delforge, Michel; Noens, Lucien; Renard, Vincent; Witteveen, Els; Rob, Lukas; de Hoon, Jan; Amant, Frederic",null,"Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study","ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA",null,"English","Article",null,null,null,null,null,"Chemotherapy; pharmacokinetics; pregnancy; baboon","RENAL-FUNCTION; PACLITAXEL; TISSUES; FORMULA","Objective. To determine the impact of physiologic changes of pregnancy on pharmacokinetics of chemotherapeutic agents. Design. A preclinical and a clinical case-control trial. Setting. Institute of Primate Research Nairobi and collaborating hospitals in Belgium, the Netherlands and Czech Republic. Population. Pregnant and nonpregnant women and baboons receiving chemotherapy. Methods. Chemotherapy pharmacokinetics was compared between the pregnant and nonpregnant state. Standard-dosed chemotherapy regimens were administered in pregnant and nonpregnant baboons/women, followed by serial blood samplings. Drug plasma levels were determined using high performance liquid chromatography and atomic absorption spectrometry. Main outcome measures. Area under the curve (AUC), maximal plasma concentration, terminal elimination half-life, clearance and distribution volume of each drug in pregnant and nonpregnant state. Results. Intraindividual comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in three and two baboons, respectively. In the clinical trial, two patients were exposed to doxorubicin and one patient was exposed to paclitaxel/platinum during and after pregnancy. Furthermore, a pooled analysis was performed based on 16 cycles of pregnant and 11 cycles of nonpregnant women. Numbers of pregnant/nonpregnant patients were 5/2, 7/5, 4/4 and 2/2 for paclitaxel, doxorubicin, epirubicin and platinum, respectively. For all drugs tested in the preclinical and clinical study, a decreased AUC and maximal plasma concentration and an increased distribution volume and clearance were observed in pregnancy. Conclusions. Although numbers were too small for statistical significance, pregnancy-associated physiologic alterations appear to lead to a decrease in plasma exposure of chemotherapeutic drugs. The importance of long-term follow-up of women treated with chemotherapy during pregnancy is underscored.","[Amant, Frederic] Katholieke Univ Leuven, Leuven Canc Inst LKI, Dept Obstet & Gynecol, Div Gynecol Oncol,Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Verbesselt, Rene; de Hoon, Jan] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Ctr Clin Pharmacol, B-3000 Louvain, Belgium; [Ottevanger, Nelleke] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Halaska, Michael; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynecol, Div Gynecol Oncol, Fac Med 2, Prague, Czech Republic; [de Bruijn, Ernst] Katholieke Univ Leuven, Lab Med Oncol, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Chai, Daniel] Natl Museums Kenya, Inst Primate Res, Dept Reprod Biol, Nairobi, Kenya; [Delforge, Michel] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium; [Noens, Lucien] Ghent Univ Hosp, Dept Hematol, B-9000 Ghent, Belgium; [Renard, Vincent] AZ Sint Lucas, Deparment Radiotherapy Oncol & Hematol, Ghent, Belgium; [Witteveen, Els] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands","Amant, F, Katholieke Univ Leuven, Leuven Canc Inst LKI, Dept Obstet & Gynecol, Div Gynecol Oncol,Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium","Frederic.amant@uz.kuleuven.ac.be","Research Foundation-Flanders (F.W.O.) [G. 0358.06]; Research Fund-K.U.Leuven [OT/07/053]; Clinical Research Fund University Hospital Gasthuisberg and Nationaal kankerplan [FOD NKP 29 038]","We are very grateful to Gunther Guetens and Sonia Demarsin for their assistance in the analyses. This research is supported by Research Foundation-Flanders (F.W.O.) [Project G. 0358.06], 'Stichting tegen kanker [Project SCIE2006-17], Research Fund-K.U.Leuven [OT/07/053], Clinical Research Fund University Hospital Gasthuisberg and Nationaal kankerplan [FOD NKP 29 038]. FA is clinical researcher for Research Foundation-Flanders (F.W.O.); KVC is aspirant for Research Foundation-Flanders (F.W.O.).",null,15,0,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","0001-6349",null,"10.3109/00016349.2010.512070","ACTA OBSTET GYNECOL SCAND","Acta Obstet. Gynecol. Scand.","OCT",2010,89,10,null,null,null,1338,1345,null,null,8,"Obstetrics & Gynecology","664MD","ISI:000282963700016"]
["nemá","J","Melichercik, P; Jahoda, D; Bartak, V; Klapkova, E; Nyc, O; Pokorny, D",null,null,null,"Melichercik, P.; Jahoda, D.; Bartak, V.; Klapkova, E.; Nyc, O.; Pokorny, D.",null,"In Vitro Assessment of Vancomycin Released from Bone Grafts","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"osteomyelitis; vancomycin; bone grafts; local carriers of antibiotics; VRSA; MRSA","RESISTANT STAPHYLOCOCCUS-AUREUS; LATE HEMATOGENOUS INFECTION; CANCELLOUS BONE; PROSTHETIC JOINT; REVISION; HIP; ALLOGRAFTS; ANTIBIOTICS; OSTEOMYELITIS; COMPLICATIONS","PURPOSE OF THE STUDY Infections of the musculoskeletal system present a serious problem in orthopaedic and trauma medicine because, typically, they are often recurrent and associated with the development of resistance to antibiotics. The aim of this study was to ascertain whether the local concentration of vancomycin released from cancellous bone grafts exceeded the minimum inhibitory concentration (MIC) for vancomycin-resistant Staphylococcus aureus (VRSA >= 16 mg/L) during a 16-day in vitro experiment. MATERIAL AND METHODS Morselised grafts of spongy bone were selected as ideal local carriers of antibiotic. They were impregnated with vancomycin (Edicin (R)). Its concentration was assessed by Agilent 1200 high performance liquid chromatography coupled with a diode array detector (Agilent Technologies, USA). Morselised bone was impregnated with vancomycin at 0.1 g antibiotic per 10 g bone, and 20 samples each weighing 1 g were prepared. They were placed in test tubes with phosphate buffer at pH = 7.4 and maintained in a thermostat at 37 degrees C. During the 16-day period, buffer samples were taken at intervals and examined for vancomycin concentration by the above-described method. RESULTS During the whole experimental period, the level of released vancomycin was high above the MIC for VRSA. The maximum average concentration was obtained between day 2 and day 4 and it reached 507.68 mg/L. At this interval the vancomycin level was stable, because there was no significant difference (p > .0.005) between the values of the 2nd and the 4th day. Then a gradual decrease in antibiotic levels was detected, with an average concentration of 332.29 mg/L recorded at 16 days. DISCUSSION Recently, the occurrence of methicilin-resistant Staphylococcus aureus (MRSA) infections has been increasing as well as the risk of VRSA infections, and therefore our experiment was set up to assess the releasing properties of bone grafts impregnated with vancomycin The levels of released vancomycin were much higher than the MIC for VRSA for the whole period of measurement. This finding is different from the results of an in vitro study by Witso et al., in which the vancomycin level dropped below the MIC after 2 weeks. The decrease in vancomycin levels following its maximum values was greater than it had been expected although the samples were diluted only minimally. There are several explanations for this finding. However, from the clinical point of view it is important that, for a sufficiently long period, vancomycin is maintained at a level exceeding the MIC for VRSA. CONCLUSIONS In an in vitro experiment under conditions simulating a human internal environment, the elution of antibiotic from vancomycin-impregnated cancellous bone grafts was investigated. The local vancomycin concentrations much exceeded the MIC for VRSA for more than 2 weeks. The highest levels, i.e. the total vancomycin amount, were recorded at 2 to 4 days after carrier application. Based on the experimental results, vancomycin-loaded bone grafts can be recommended for local treatment of the musculoskeletal system infected with antibiotic-sensitive staphylococci, MRSA strains or possibly also for VRSA infections.","[Melichercik, P.; Jahoda, D.; Bartak, V.; Pokorny, D.] LF UK FN Motol, Ortoped Klin 1, Prague 15000 5, Czech Republic; [Klapkova, E.] LF UK FN Motol, Ustav Klin Biochem Patobiochem 2, Prague, Czech Republic; [Nyc, O.] LF UK FN Motol, Ustav Lekarske Mikrobiol, Prague, Czech Republic","Melichercik, P, LF UK FN Motol, Ortoped Klin 1, V Uvalu 84, Prague 15000 5, Czech Republic","pmeliche@seznam.cz",null,null,null,30,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2010,77,5,null,null,null,411,415,null,null,5,"Orthopedics","673PT","ISI:000283676100008"]
["nemá","J","Gohring, G; Michalova, K; Beverloo, HB; Betts, D; Harbott, J; Haas, OA; Kerndrup, G; Sainati, L; Bergstraesser, E; Hasle, H; Stary, J; Trebo, M; van den Heuvel-Eibrink, MM; Zecca, M; van Wering, ER; Fischer, A; Noellke, P; Strahm, B; Locatelli, F; Niemeyer, CM; Schlegelberger, B",null,null,null,"Goehring, Gudrun; Michalova, Kyra; Beverloo, H. Berna; Betts, David; Harbott, Jochen; Haas, Oskar A.; Kerndrup, Gitte; Sainati, Laura; Bergstraesser, Eva; Hasle, Henrik; Stary, Jan; Trebo, Monika; van den Heuvel-Eibrink, Marry M.; Zecca, Marco; van Wering, Elisabeth R.; Fischer, Alexandra; Noellke, Peter; Strahm, Brigitte; Locatelli, Franco; Niemeyer, Charlotte M.; Schlegelberger, Brigitte",null,"Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome","BLOOD",null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; CYTOGENETIC ABNORMALITIES; THERAPY; MDS","To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome. (Blood. 2010;116(19):3766-3769)","[Fischer, Alexandra; Noellke, Peter; Strahm, Brigitte; Niemeyer, Charlotte M.] Univ Hosp, Dept Adolescent & Pediat Med, D-79106 Freiburg, Germany; [Goehring, Gudrun; Schlegelberger, Brigitte] Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; [Michalova, Kyra] Charles Univ Prague, Ctr Oncocytogenet, Gen Fac Hosp, Prague, Czech Republic; [Beverloo, H. Berna] Erasmus Univ, Dept Clin Genet, Med Ctr, NL-3000 DR Rotterdam, Netherlands; [Beverloo, H. Berna; van den Heuvel-Eibrink, Marry M.; van Wering, Elisabeth R.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Betts, David; Bergstraesser, Eva] Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland; [Harbott, Jochen] Univ Giessen, Dept Pediat Hematol Oncol, Giessen, Germany; [Haas, Oskar A.; Trebo, Monika] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Kerndrup, Gitte] Univ Hosp, Inst Pathol, Odense, Denmark; [Sainati, Laura] Univ Padua, Clin Oncoematol Pediat, Padua, Italy; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [van den Heuvel-Eibrink, Marry M.] Erasmus Univ, Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands; [Zecca, Marco] Univ Pavia, Dept Pediat, Ist Ricovero & Cura Carattere Sci, Policlin San Matteo, I-27100 Pavia, Italy; [Locatelli, Franco] Bambino Gesu Pediat Hosp, Dept Pediat Hematol & Oncol, Rome, Italy","Niemeyer, CM, Univ Hosp, Dept Adolescent & Pediat Med, Mathildenstr 1, D-79106 Freiburg, Germany","charlotte.niemeyer@uniklinik-freiburg.de","COST Action (EuGESMA) [BM0801]; Czech Ministry of Education [MSM0021620813]","This work was supported by COST Action BM0801 (EuGESMA) and by the Czech Ministry of Education (MSM0021620813).",null,17,0,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2010-04-280313","BLOOD","Blood","NOV 11",2010,116,19,null,null,null,3766,3769,null,null,4,"Hematology","678VM","ISI:000284110400016"]
["nemá","J","Suchanek, O; Podrazil, M; Fischerova, B; Bocinska, H; Budinsky, V; Stejskal, D; Spisek, R; Bartunkova, J; Kolar, P",null,null,null,"Suchanek, Ondrej; Podrazil, Michal; Fischerova, Barbara; Bocinska, Helena; Budinsky, Vit; Stejskal, David; Spisek, Radek; Bartunkova, Jirina; Kolar, Pavel",null,"Intensive physical activity increases peripheral blood dendritic cells","CELLULAR IMMUNOLOGY",null,"English","Article",null,null,null,null,null,"Dendritic cells; Costimulatory molecules; Catecholamines; Physical exercise; Top sport","TOLL-LIKE RECEPTORS; IMMUNE-RESPONSE; EXERCISE; EXPRESSION; MATURATION; HUMANS; SYSTEM; IL-6","We analyzed the frequency and absolute numbers of circulating myeloid and plasmacytoid DCs in peripheral blood and evaluated their maturation status to test the hypothesis that significant physical stress to the body might induce measurable changes in DCs subsets, phenotype and function, which would complete existing knowledge about the response of the cellular immune system to an acute exercise in top sportsmen. We evaluated the heart rate and draw blood samples before and after the physical load in 18 profesional ice-hockey players. We observed an increase in leukocytes numbers with a predominant increase in the population of DCs and lymphocytes after exercise. Both myeloid and plasmacytoid DCs increased significantly. We found a correlation between the increase of peripheral blood DCs and serum epinephrine and norepinephrine levels. Increase in peripheral blood DCs also correlates with the extent of heart rate elevation during exercise. (C) 2010 Published by Elsevier Inc.","[Spisek, Radek] Charles Univ Prague, Inst Immunol, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Fischerova, Barbara; Bocinska, Helena; Kolar, Pavel] Charles Univ Prague, Dept Rehabil, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Stejskal, David] Prostejov Hosp, Dept Lab Med, Prostejov, Czech Republic","Spisek, R, Charles Univ Prague, Inst Immunol, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 15006 5, Czech Republic","radek.spisek@lfmotol.cuni.cz","Czech Ministry of Education [VZ MSM 0021620812]; Ministry of Health Czech Republic [IGA NS10489-3/2009]","This study was supported by Research Project VZ MSM 0021620812 from The Czech Ministry of Education and by Grant IGA NS10489-3/2009 from the Ministry of Health Czech Republic.",null,27,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0008-8749",null,"10.1016/j.cellimm.2010.08.010","CELL IMMUNOL","Cell. Immunol.",null,2010,266,1,null,null,null,40,45,null,null,6,"Cell Biology; Immunology","680RB","ISI:000284251000006"]
["nemá","J","Sramek, J; Jirsak, V; Barna, M; Nesnidal, P",null,null,null,"Sramek, J.; Jirsak, V.; Barna, M.; Nesnidal, P.",null,"Development of the PLIF and TLIF Techniques","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"posterior lumbar interbody fusion; transforaminal lumbar interbody fusion","LUMBAR INTERBODY FUSION; FOLLOW-UP","PLIF (posterior lumbar interbody fusion) and TLIF (transforaminal lumbar interbody fusion) are surgical techniques employed in cases of degenerative lumbar spinal disorders. They involve a surgical approach to the area of the lumbar intervertebral disc, its resection, and subsequent application of biocompatible material that will achieve fusion of two or more vertebrae. Briggs and Milligan published the PLIF method in 1944, involving application of cancellous bone grafts into the intervertebral space. Others, but mainly Cloward, further improved this technique. Bagby and Kuslich introduced a cylindrical stainless steel cage in the 1980's, while Brantigan used a rectangular cage made of a polyether-etherketone polymer (PEEK), reinforced with carbon fiber. Implants of variable shape and materials characterize spinal fusion technique improvements in the 1990's. Current trends work towards the development of a stand-alone cage without the need for posterior stabilization. Though the PLIF and TLIF techniques have been extensively used and verified, lumbar fusion may become unstable or even fail when biomechanical laws are neglected.","[Sramek, J.] Fak Biomed Inzenyrstvi CVUT, Kladno, Czech Republic; [Jirsak, V.] Fak Stavebni CVUT, Prague, Czech Republic; [Barna, M.; Nesnidal, P.] FN Motole, Spondylochirurg Oddeleni, Prague, Czech Republic","Sramek, J, Untere Bergstr 42, Bogen 94327, Czech Republic","jiri.sramek@spinesurgery.cz",null,null,null,37,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,5,null,null,null,492,496,null,null,5,"Neurosciences; Surgery","673EB","ISI:000283640800002"]
["nemá","J","Zitka, O; Kukacka, J; Krizkova, S; Huska, D; Adam, V; Masarik, M; Prusa, R; Kizek, R",null,null,null,"Zitka, O.; Kukacka, J.; Krizkova, S.; Huska, D.; Adam, V.; Masarik, M.; Prusa, R.; Kizek, R.",null,"Matrix Metalloproteinases","CURRENT MEDICINAL CHEMISTRY",null,"English","Review",null,null,null,null,null,"Matrix metalloproteinases; collagen; tissue inhibitors of matrix metalloproteinases; cysteine switch; zinc; metallothionein; tumour disease","HYPOMATURATION AMELOGENESIS IMPERFECTA; EPITHELIAL-CELL APOPTOSIS; GROWTH-PROMOTING ACTIVITY; PREVENTS CARDIAC RUPTURE; ACTIVATED PROTEIN-KINASE; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; GENE-EXPRESSION","Matrix metalloproteinases (MMPs), also known as matrixins, belong to a group of zinc-dependent proteins, which are thought to play a central role in the breakdown of extracellular matrix. Collagen, elastin, gelatin and casein are major components cleaved by MMPs. The breakdown of these components is essential for many physiological processes such as embryonic development, morphogenesis, reproduction, and tissue resorption and remodelling. MMPs also participate in pathological processes such as arthritis, cancer, cardiovascular and neurological diseases. This review summarizes current knowledge regarding these proteins, their participation in physiological and pathophysiological roles, their involvement in activation and inhibition, and their interactions with other metal-binding proteins including metallothioneins.","[Zitka, O.; Krizkova, S.; Huska, D.; Adam, V.; Kizek, R.] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Kukacka, J.; Prusa, R.] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Masarik, M.] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-66243 Brno, Czech Republic","Kizek, R, Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz","GA AV [IAA401990701]; GACR [301/09/P436]; IGAMZ [10200-3]","Financial support from GA AV IAA401990701, GACR 301/09/P436 and IGAMZ 10200-3 is highly acknowledged. The authors wish to express their thanks to Dr. Grace J. Chavis for language correction.",null,221,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","0929-8673",null,null,"CURR MEDICINAL CHEM","Curr. Med. Chem.","NOV",2010,17,31,null,null,null,3751,3768,null,null,18,"Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy","686RV","ISI:000284714300011"]
["nemá","J","Dusatkova, P; Vesela, K; Pruhova, S; Lebl, J; Cinek, O",null,null,null,"Dusatkova, P.; Vesela, K.; Pruhova, S.; Lebl, J.; Cinek, O.",null,"Lack of PAX4 mutations in 53 Czech MODYX families","DIABETIC MEDICINE",null,"English","Letter",null,null,null,null,null,null,"CLINICAL CHARACTERISTICS; YOUNG",null,"[Dusatkova, P.; Vesela, K.; Pruhova, S.; Lebl, J.; Cinek, O.] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic","Dusatkova, P, Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic",null,null,null,null,8,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0742-3071",null,"10.1111/j.1464-5491.2010.03126.x","DIABETIC MED","Diabetic Med.","DEC",2010,27,12,null,null,null,1459,1460,null,null,2,"Endocrinology & Metabolism","678JR","ISI:000284070400018"]
["nemá","J","Zejskova, L; Jancuskova, T; Kotlabova, K; Doucha, J; Hromadnikova, I",null,null,null,"Zejskova, L.; Jancuskova, T.; Kotlabova, K.; Doucha, J.; Hromadnikova, I.",null,"Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma - Next step toward reliable non-invasive prenatal diagnostics","EXPERIMENTAL AND MOLECULAR PATHOLOGY",null,"English","Article",null,null,null,null,null,"DNA quantification; Hypermethylated RASSF1A sequence; SRY; GLO; Real-time PCR","REAL-TIME PCR; QUANTITATIVE-ANALYSIS; GENDER DETERMINATION; SEX DETERMINATION; DNA-METHYLATION; SERUM; RHD; PREECLAMPSIA; WOMEN; PLACENTA","We determined the feasibility of universal fetal marker detection in maternal circulation. Using real-time PCR, we compared the levels of fetal (SRY and hypermethylated RASSF1A) and total (GLO gene and total RASSF1A) extracellular DNA and fractions of extracellular fetal DNA (SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A) in maternal circulation. Sensitivity and specificity reached 100% as the fetal-specific hypermethylated RASSF1A sequence was detected in all 151 examined plasma samples derived from 70 normal pregnancies with a singleton male (n = 51) or female (n = 19) fetus sampled throughout gestation and absent in nonpregnant individuals (n =29). A strong positive correlation was observed between fetal-derived hypermethylated RASSF1A and SRY (p = 0.66. P<0.001), total RASSF1A and GLO (rho=0.65,P<0.001), SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A ratio (rho=0.62, P<0.001) in maternal plasma. The results indicate that a universal fetal marker could be useful not only for the confirmation of the presence of fetal cell-free DNA in maternal plasma but could enable quantification of cell-free fetal DNA in pregnancy associated disorders, independently of the sex of the fetus. (C) 2010 Elsevier Inc. All rights reserved.","[Zejskova, L.; Jancuskova, T.; Kotlabova, K.; Hromadnikova, I.] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000 10, Czech Republic; [Doucha, J.] Charles Univ Prague, Clin Obstet & Gynecol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic","Zejskova, L, Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000 10, Czech Republic","lenka.zej@centrum.cz","Ministry of Education, Youth and Sports, Czech Republic [MSM 0021620806]","We thank Prof. J.E. Jirasek from the Institute for the Care of Mother and Child, for his participation in the collection and processing of placenta tissue samples. This work was supported by grant project MSM 0021620806 from The Ministry of Education, Youth and Sports, Czech Republic.",null,26,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0014-4800",null,"10.1016/j.yexmp.2010.09.002","EXP MOL PATHOL","Exp. Mol. Pathol.","DEC",2010,89,3,null,null,null,241,247,null,null,7,"Pathology","686FX","ISI:000284683300007"]
["nemá","J","Smetana, K; Zapotocky, M",null,null,null,"Smetana, K.; Zapotocky, M.",null,"The Effect of a Histone Deacetylase Inhibitor - Valproic Acid - on Nucleoli in Human Leukaemic Myeloblasts","FOLIA BIOLOGICA",null,"English","Article",null,null,null,null,null,null,"IN-VITRO; SIZE; INSIGHTS; DENSITY; TUMORS; BLOOD; CELLS; DRUG","The present study was undertaken to provide more information on nucleolar changes induced by a histone deacetylase inhibitor such as valproic acid in leukaemic myeloblasts at the single-cell level. For this study, RNA in nucleoli was visualized by a simple but sensitive cytochemical procedure in unfixed cytospins of short-term bone marrow cultures from patients suffering from acute myeloid leukaemia. Valproic acid in leukaemic myeloblasts markedly reduced the nucleolar size and also produced significant transformation of \"active\" to \"resting\" and \"inactive\" nucleoli that reflected the alteration of the nucleolar transcription in sensitive myeloblasts. On this occasion it should be added that valproic acid significantly increased the incidence of altered myeloblasts that changed to apoptotic cells or apoptotic bodies and cell ghosts. In contrast to the above-mentioned decreased nucleolar size, the nucleolar RNA concentration, expressed by computer-assisted RNA image densitometry in valproic acid-treated myeloblasts, was not significantly changed. The results of the present study clearly indicated that the nucleolar size and transformation of \"active\" to \"sleeping\" or \"inactive\" nucleoli are convenient markers of the sensitivity and alteration of leukaemic myeloblasts produced by a histone deacetylase inhibitor, valproic acid, at the single-cell level.","[Smetana, K.] Inst Hematol & Blood Transfus, Prague 12820 2, Czech Republic; [Zapotocky, M.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Smetana, K, Inst Hematol & Blood Transfus, U Nemocnice 1, Prague 12820 2, Czech Republic","karel.smetana@uhkt.cz","Ministry of Health of the Czech Republic [VZ 0002373601]; Ministry of Education, Youth and Sports of the Czech Republic [VZ 0021620813]","The present study was supported in part by the Research Development Project VZ 0002373601 of the Ministry of Health of the Czech Republic and Research Development Project VZ 0021620813 of the Ministry of Education, Youth and Sports of the Czech Republic.",null,28,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2010,56,5,null,null,null,201,205,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","680SO","ISI:000284254900002"]
["nemá","J","Poledne, R; Hubacek, JA; Stanek, V; Aschermann, M; Matouskova, J; Veselka, J; Widimsky, P; Cifkova, R; Lanska, V; Pitha, J",null,null,null,"Poledne, R.; Hubacek, J. A.; Stanek, V.; Aschermann, M.; Matouskova, J.; Veselka, J.; Widimsky, P.; Cifkova, R.; Lanska, V.; Pitha, J.",null,"Why We Are Not Able to Find the Coronary Heart Disease Gene - apoE As an Example","FOLIA BIOLOGICA",null,"English","Article",null,null,null,null,null,null,"PREMATURE MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-E POLYMORPHISM; CARDIOVASCULAR-DISEASE; E GENOTYPES; RISK; ASSOCIATION; MEN; INDIVIDUALS; POPULATION","The apoprotein E gene ranks among the most discussed candidate genes for cardiovascular disease. We studied whether the association between apoprotein E gene polymorphism and manifestation of acute coronary syndrome is modulated by the presence/absence of traditional cardiovascular risk factors. The population under study were 1066 patients (men under 65 years) admitted between 2006 2009 to five coronary care units in Prague (GENetic DEtermination of Myocardial Infarction in Prague) and the control population (1066 age-matched men selected from the Czech population sample). The frequency of disadvantage genotype E4(+) was significantly higher (P < 0.01) in acute coronary syndrome patients (22.38%) than in controls (16.76%). When the acute coronary syndrome group was step by step limited to non-smokers, non-diabetics and normotensive individuals, the odds ratio displayed a gradual increase from 1.35 (for the entire group) through 1.48 (non-smokers), 1.53 (non-smokers+non-diabetics) to 1.71 (non-smokers+non-diabetics+normotensives). The effect of the apoprotein E gene on the individual risk of acute coronary syndrome is non-homogenous within the patient groups. This association of apoprotein E gene with acute coronary syndrome is strongly modified by the presence/absence of traditional cardiovascular factors of atherosclerosis in a high-risk Czech population.","[Poledne, R.; Hubacek, J. A.; Stanek, V.; Cifkova, R.; Lanska, V.; Pitha, J.] IKEM, Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Poledne, R.; Hubacek, J. A.; Pitha, J.] IKEM, Cardiovasc Res Ctr, Prague 14021 4, Czech Republic; [Aschermann, M.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Aschermann, M.] Gen Univ Hosp, Dept Med 2, Dept Cardiovasc Med, Prague, Czech Republic; [Veselka, J.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Veselka, J.] Motol Univ Hosp, Dept Cardiol, Prague, Czech Republic; [Matouskova, J.] Na Homolce Hosp, Dept Cardiol, Prague, Czech Republic; [Widimsky, P.] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Widimsky, P.] Kralovske Vinohrady Univ Hosp, Cardioctr, Dept Cardiol, Prague, Czech Republic","Poledne, R, IKEM, Inst Clin & Expt Med, Videnska 1958-9, Prague 14021 4, Czech Republic","rudolf.poledne@ikem.cz","Internal Grant Agency of the Ministry of Health of the Czech Republic [9093-4/2006]","This work was supported by project No. 9093-4/2006; Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,21,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL PRAGUE","Folia Biol.-Prague",null,2010,56,5,null,null,null,218,222,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","680SO","ISI:000284254900005"]
["nemá","J","Huska, D; Adam, V; Krizkova, S; Hrabeta, J; Eckschlager, T; Stiborova, M; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Krizkova, Sona; Hrabeta, Jan; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene",null,"An electrochemical study of interaction of an anticancer alkaloid ellipticine with DNA","CHIMICA OGGI-CHEMISTRY TODAY",null,"English","Article",null,null,null,null,null,"ellipticine; DNA; square wave voltammetry; adsorptive transfer technique; neuroblastoma cell lines; intercalation","NEUROBLASTOMA-CELL LINES; DRUG ELLIPTICINE; ADDUCT FORMATION; CYTOCHROMES P450; STRIPPING VOLTAMMETRY; DOXORUBICIN; 13-HYDROXYELLIPTICINE; 9-HYDROXYELLIPTICINE; DEOXYGUANOSINE; BIOACTIVATION","Ellipticine (5,11-demethyl-6H-pyridol(4,3-b) carbazole) and its derivates belong to prototype compounds acting predominantly by DNA-damaging mechanisms and serving as cytotoxic agents. The aim of this work was to study the intercalation of the ellipticine into DNA. For this purpose we utilized adsorptive transfer stripping technique (AdTS) coupled with square wave voltammetry (SWV). Primarily, we investigated the influence of ellipticine on genomic DNA electrochemical signals. Decrease in redox signal of cytosine/adenine (at -1.4 V) was observed as a result of ellipticine intercalation into DNA. The decrease was proportional to increasing concentration of ellipticine. In additional experiments we investigated the changes in the reduction signal of cytosine/adenine (CA) in a genomic dsDNA, dsDNA treated with ellipticine in vitro and dsDNA isolated from UKF-NB-3 neuroblastoma cells treated with 1 mu M ellipticine. In the mentioned cases, the changes were determined.","[Huska, Dalibor; Adam, Vojtech; Krizkova, Sona; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic",null,"GAAV [KAN208130801]; GACR [102/08/1546, P301/10/0356]; Ministry of Education of the Czech Republic [MSM 0021620808, 1M0505]","Financial support from GAAV (KAN208130801), GACR (102/08/1546, P301/10/0356) and the Ministry of Education of the Czech Republic (MSM 0021620808 and 1M0505) is highly acknowledged.",null,30,0,"TEKNOSCIENZE PUBL","MILANO","VIALE BRIANZA 22, 20127 MILANO, ITALY","1973-8250",null,null,"CHIM OGGI","Chim. Oggi-Chem. Today","SEP-OCT",2010,28,5,null,"Suppl. S",null,15,17,null,null,3,"Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary","672KP","ISI:000283582200004"]
["nemá","J","Huska, D; Adam, V; Hubalek, J; Trnkova, L; Eckschlager, T; Stiborova, M; Provaznik, I; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Eckschlager, Tomas; Stiborova, Marie; Provaznik, Ivo; Kizek, Rene",null,"Off-line coupling of automated pipetting system with square wave voltammetry as a tool for study of drug-DNA interaction","CHIMICA OGGI-CHEMISTRY TODAY",null,"English","Article",null,null,null,null,null,"ellipticine; DNA; square wave voltammetry; adsorptive transfer technique; automation","CHINESE-HAMSTER FIBROBLASTS; CELL-CYCLE ARREST; ELLIPTICINE DERIVATIVES; ELECTROCHEMICAL-BEHAVIOR; SERIES; 9-HYDROXYELLIPTICINE; SENSITIVITY; RESISTANCE; INHIBITORS; MECHANISM","Manual handling with DNA and drugs can be a source of errors, which can be eliminated also by automation of whole process of sample preparation. The aim of this work was to study interaction between DNA and ellipticine by using of off-line coupled automated pipetting system with adsorptive transfer stripping technique (AdTS) square wave voltammetry (SWV). Interaction between dsDNA and ellipticine was evident from the decrease of CA signal. Six ng of ellipticine per ml resulted in a statistically significant decrease in CA signal (the decrease was higher than the standard deviation of determinations, Student t-test). The decrease in CA signal corresponded to increasing ellipticine concentrations.","[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-60200 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic; [Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CZ-61200 Brno, Czech Republic","Kizek, R, Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic",null,"GAAV [KAN208130801]; GACR [102/08/1546, P301/10/0356]; Ministry of Education of the Czech Republic [MSM 0021620808, MSM 0021630513, 1M0505, MSM 0021622412]","Financial support from GAAV (KAN208130801), GACR (102/08/1546, P301/10/0356) and the Ministry of Education of the Czech Republic (MSM 0021620808, MSM 0021630513, 1M0505 and MSM 0021622412) is highly acknowledged.",null,29,0,"TEKNOSCIENZE PUBL","MILANO","VIALE BRIANZA 22, 20127 MILANO, ITALY","1973-8250",null,null,"CHIM OGGI","Chim. Oggi-Chem. Today","SEP-OCT",2010,28,5,null,"Suppl. S",null,18,20,null,null,3,"Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary","672KP","ISI:000283582200005"]
["nemá","J","Vlkova, M; Fronkova, E; Kanderova, V; Janda, A; Ruzickova, S; Litzman, J; Sediva, A; Kalina, T",null,null,null,"Vlkova, Marcela; Fronkova, Eva; Kanderova, Veronika; Janda, Ales; Ruzickova, Sarka; Litzman, Jiri; Sediva, Anna; Kalina, Tomas",null,"Characterization of Lymphocyte Subsets in Patients with Common Variable Immunodeficiency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression","JOURNAL OF IMMUNOLOGY",null,"English","Article",null,null,null,null,null,null,"PERIPHERAL-BLOOD; ANTIGEN RECEPTOR; CVID PATIENTS; UP-REGULATION; COMPARTMENT; EXPANSION; DISEASE; DIFFERENTIATION; ABNORMALITIES; DEFICIENCY","Increased proportions of naive B cell subset and B cells defined as CD27(neg)CD21(neg)CD38(neg) are frequently found in patients with common variable immunodeficiency (CVID) syndrome. Current methods of polychromatic flow cytometry and PCR-based detection of kappa deletion excision circles allow for fine definitions and replication history mapping of infrequent B cell subsets. We have analyzed B cells from 48 patients with CVID and 49 healthy controls to examine phenotype, frequency, and proliferation history of naive B cell subsets. Consistent with previous studies, we have described two groups of patients with normal (CVID-21norm) or increased (CVID-21lo) proportions of CD27(neg)CD21(neg)CD38(neg) B cells. Upon further analyses, we found two discrete subpopulations of this subset based on the expression of CD24. The B cell subsets showed a markedly increased proliferation in CVID-21lo patients as compared with healthy controls, suggesting developmental arrest rather than increased bone marrow output. Furthermore, when we analyzed CD21(pos) naive B cells, we found two different subpopulations based on IgM and CD24 expression. They correspond to follicular (FO) I and FO II cells previously described in mice. FO I subset is significantly underrepresented in CVID-21lo patients. A comparison of the replication history of naive B cell subsets in CVID patients and healthy controls implies refined naive B cell developmental scheme, in which human transitional B cells develop into FO II and FO I. We propose that the CD27(neg)CD21(neg)CD38(neg) B cells increased in some of the CVID patients originate from the two FO subsets after loss of CD21 expression. The Journal of Immunology, 2010, 185: 6431-6438.","[Vlkova, Marcela; Litzman, Jiri] Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno 65691, Czech Republic; [Vlkova, Marcela; Litzman, Jiri] Masaryk Univ, Fac Med, Brno 65691, Czech Republic; [Fronkova, Eva; Kanderova, Veronika; Janda, Ales; Kalina, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Sediva, Anna] Charles Univ Prague, Dept Immunol, Sch Med 2, Prague, Czech Republic; [Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic; [Fronkova, Eva; Kanderova, Veronika; Kalina, Tomas] Childhood Leukemia Invest Prague, Prague, Czech Republic; [Ruzickova, Sarka] Acad Sci Czech Republic, Inst Biotechnol, Lab Diagnost Autoimmune Dis, VVI, Prague, Czech Republic","Vlkova, M, Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Pekarska 53, Brno 65691, Czech Republic","marcela.vlkova@fnusa.cz","Czech Ministry of Health [NT-11414, 10398-3, MZ0FNM2005]; Grant Agency of the Czech Republic [310/09/P058]; Ministry of Education, Sports, and Youth of the Czech Republic [AVOZ50520701]","This work was supported by Grants NT-11414, 10398-3, and MZ0FNM2005 from the Czech Ministry of Health, Grant Agency of the Czech Republic 310/09/P058, and Research Plan AVOZ50520701 from the Ministry of Education, Sports, and Youth of the Czech Republic.",null,34,0,"AMER ASSOC IMMUNOLOGISTS","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","0022-1767",null,"10.4049/jimmunol.0903876","J IMMUNOL","J. Immunol.","DEC 1",2010,185,11,null,null,null,6431,6438,null,null,8,"Immunology","681KJ","ISI:000284311500007"]
["nemá","J","Hainerova, IA; Lebl, J",null,null,null,"Hainerova, Irena Aldhoon; Lebl, Jan",null,"Mechanisms of Appetite Regulation","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,"English","Article",null,null,null,null,null,null,"NEUROMEDIN-U; OBESITY; MUTATIONS; GENE; DEFICIENCY",null,"[Hainerova, Irena Aldhoon; Lebl, Jan] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 10034 10, Czech Republic; [Hainerova, Irena Aldhoon] Charles Univ Prague, Ctr Res Diabet Metab & Nutr, Fac Med 3, Prague 10034 10, Czech Republic","Hainerova, IA, Charles Univ Prague, Dept Pediat, Fac Med 2, Srobarova 50, Prague 10034 10, Czech Republic","ihainer@hotmail.com","Czech Ministry of Education [MSM 0021620814]","The studies of monogenic obesity are supported by a research project from the Czech Ministry of Education No. MSM 0021620814.",null,10,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,"10.1097/MPG.0b013e3181f84208","J PEDIAT GASTROENTEROL NUTR","J. Pediatr. Gastroenterol. Nutr.","DEC",2010,51,null,null,"Suppl. 3",null,"S123","S124",null,null,2,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","687WX","ISI:000284810100005"]
["nemá","J","Hill, M; Zarubova, J; Marusic, P; Vrbikova, J; Velikova, M; Kancheva, R; Kancheva, L; Kubatova, J; Duskova, M; Zamrazilova, L; Kazihnitkova, H; Simunkova, K; Starka, L",null,null,null,"Hill, Martin; Zarubova, Jana; Marusic, Petr; Vrbikova, Jana; Velikova, Marta; Kancheva, Radmila; Kancheva, Lyudmila; Kubatova, Jana; Duskova, Michaela; Zamrazilova, Ludmila; Kazihnitkova, Hana; Simunkova, Katerina; Starka, Luboslav",null,"Effects of valproate and carbamazepine monotherapy on neuroactive steroids, their precursors and metabolites in adult men with epilepsy","JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY",null,"English","Article",null,null,null,null,null,"Epilepsy; Neuroactive steroids; Pregnanolone isomers; Androstanes; GC-MS; Carbamazepine; Valproate","CORTICOTROPIN-RELEASING HORMONE; ANTIEPILEPTIC DRUGS; DEHYDROEPIANDROSTERONE-SULFATE; SEXUAL FUNCTION; PSYCHONEUROENDOCRINE ASPECTS; AFTERDISCHARGE THRESHOLDS; ANTICONVULSANT METABOLITE; TEMPOROLIMBIC EPILEPSY; REPRODUCTIVE-STEROIDS; CATAMENIAL EPILEPSY","Only limited data is available concerning the role of unconjugated Delta(5) C19-steroids and almost no data exists regarding the neuroactive C21 and C19 3 alpha-hydroxy-5 alpha/beta-metabolites in men with epilepsy. To evaluate the alterations in serum neuroactive steroids and related substances in adult men with epilepsy on valproate and carbamazepine monotherapy, we have measured 26 unconjugated steroids, 18 steroid polar conjugates, gonadotropins and sex hormone binding globulin (SHBG) in 6 and 11 patients on valproate and carbamazepine monotherapy, respectively, and in 19 healthy adult men, using the GC-MS and immunoassays. Decreased testosterone, free androgen index, free testosterone, androstenediol,- 5 alpha-androstane-3 alpha,17 beta-diol (androstanediol), androsterone, epiandrosterone. DHEA. 7 beta-hydroxy-DHEA, and DHEAS levels were associated with epilepsy per se. Valproate (VPA) therapy increased 5 alpha-dlihydrotestosterone, androsterone, epiandrosterone, DHEA. DHEAS, and 7 beta-hydroxy-DHEA levels. Decrease in pregnenolone and 17-hydroxypregnenolone were associated with epilepsy with no effect of antiepileptic drugs (AEDs). Alternatively, the increase in progesterone levels was linked to epilepsy and VPA further Increased progesterone levels. Reduced steroid 20 alpha-hydroxy-metabolites and cortisol were connected with epilepsy without an effect of AEDs. Carbamazepine induced only slight decrease in isopregnanolone, 5 alpha,20 alpha-tetrahydroprogesterone, and androstanediol levels. (C) 2010 Elsevier Ltd. All rights reserved.","[Hill, Martin] Inst Endocrinol, Steroid Hormone Unit, CZ-11694 Prague 1, Czech Republic; [Hill, Martin] Fac Med 1, Dept Obstet & Gynecol, Prague, Czech Republic; [Hill, Martin] Gen Teaching Hosp, Prague, Czech Republic; [Zarubova, Jana] Thomayers Teaching Hosp, Dept Neurol, CZ-14059 Prague, Czech Republic; [Marusic, Petr] Charles Univ Prague, Fac Med 2, Motol Hosp, CZ-15006 Prague 5, Czech Republic; [Simunkova, Katerina] Charles Univ Prague, Dept Gen Teaching Hosp 3, Fac Med 1, CZ-11001 Prague 1, Czech Republic","Hill, M, Inst Endocrinol, Steroid Hormone Unit, Narodni Trida 8, CZ-11694 Prague 1, Czech Republic","mhill@endo.cz; jvrbikova@endo.cz; mvelikova@endo.cz; rkanceva@endo.cz; jkubatova@endo.cz; mduskova@endo.cz; lzamrazilova@endo.cz; hkazihnitkova@endo.cz; ksimunkova@endo.cz; lstarka@endo.cz","IGA [1A/8649-5]","Grant project IGA 1A/8649-5 supported this research.",null,67,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-0760",null,"10.1016/j.jsbmb.2010.06.003","J STEROID BIOCHEM MOL BIOL","J. Steroid Biochem. Mol. Biol.","OCT",2010,122,4,null,null,null,239,252,null,null,14,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","673TW","ISI:000283687100016"]
["nemá","J","Votavova, H; Forsterova, K; Campr, V; Sritesky, J; Velenska, Z; Pytlik, R; Kubackova, K; Prochazka, B; Kodet, R; Spicka, I; Krejcova, H; Trneny, M; Klener, P",null,null,null,"Votavova, H.; Forsterova, K.; Campr, V.; Sritesky, J.; Velenska, Z.; Pytlik, R.; Kubackova, K.; Prochazka, B.; Kodet, R.; Spicka, I.; Krejcova, H.; Trneny, M.; Klener, P.",null,"Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction","NEOPLASMA",null,"English","Article",null,null,null,null,null,"Gene expression; primary mediastinal B-cell lymphoma; diffuse large B-cell lymphoma; formalin fixed; paraffin embedded tissue; real-time quantitative polymerase chain reaction","REL","Primary mediastinal B-cell lymphoma (PMBL) seems to be reliably distinguished from diffuse large B-cell lymphoma (DLBCL) with microarray technology. We measured expression of Fcer2, Pdl2 and Blk genes using real-time quantitative polymerase chain reaction (RTqPCR) on formalin fixed, paraffin embedded material (FFPE) and suggested a formula to discriminate PMBL from DLBCL. For 39/82 included patients the diagnosis of PMBL was expected clinico-pathologically. Diagnosis of 10/39 and 2/43 of clinically considered PMBLs and DLBCLs, respectively, was not genetically confirmed. Compared to confirmed PMBLs, unconfirmed ones showed clinical features similar to DLBCLs, e.g. spleen infiltration (p=0,028) and decreased invasiveness in pericardium (p=0,045). They tended to have more common infradiaphragmatic involvement, less often tumor sclerosis or fluidothorax. There were no immunohistochemical differences between genetically confirmed and unconfirmed PMBLs. New approach of distinguishing PMBL and DLBCL is presented. It is based on expression of three genes in routinely available FFPE material using RTqPCR.","[Votavova, H.; Forsterova, K.; Pytlik, R.; Spicka, I.; Krejcova, H.; Trneny, M.; Klener, P.] Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Clin Haematol, Prague, Czech Republic; [Votavova, H.; Forsterova, K.; Sritesky, J.; Velenska, Z.; Pytlik, R.; Spicka, I.; Krejcova, H.; Trneny, M.; Klener, P.] Gen Teaching Hosp, Prague, Czech Republic; [Campr, V.; Kodet, R.] Charles Univ Prague, Fac Med 2, Teaching Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic; [Sritesky, J.; Velenska, Z.] Charles Univ Prague, Fac Med 1, Dept Pathol, Prague, Czech Republic; [Kubackova, K.] Teaching Hosp Motol, Dept Radiat & Oncol, Prague, Czech Republic; [Prochazka, B.] Natl Inst Publ Hlth, Dept Biostat & Informat, Prague, Czech Republic","Votavova, H, Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Clin Haematol, Prague, Czech Republic","tafka@seznam.cz","Ministry of Education, Youth and Sports, Czech Republic [MSMT 0021620808]; Ministry of Health, Czech Republic [NS9791-4/2008]","This work was supported by Ministry of Education, Youth and Sports, Czech Republic [Grant MSMT 0021620808] and by Ministry of Health, Czech Republic [Grant NS9791-4/2008].",null,18,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,"10.4149/neo_2010_05_449","NEOPLASMA","Neoplasma",null,2010,57,5,null,null,null,449,454,null,null,6,"Oncology","674PX","ISI:000283760800009"]
["nemá","J","Pivonkova, H; Benesova, J; Butenko, O; Chvatal, A; Anderov, M",null,null,null,"Pivonkova, Helena; Benesova, Jana; Butenko, Olena; Chvatal, Alexandr; Anderov, Miroslava",null,"Impact of global cerebral ischemia on K+ channel expression and membrane properties of glial cells in the rat hippocampus","NEUROCHEMISTRY INTERNATIONAL",null,"English","Article",null,null,null,null,null,"CNS injury; Patch-clamp; K+ channels; Proliferation; Kir4.1; Astrocytes; NG2 glia","SPINAL-CORD-INJURY; OLIGODENDROCYTE PROGENITOR CELLS; POTASSIUM CHANNELS; ELECTROPHYSIOLOGICAL PROPERTIES; PHYSIOLOGICAL-PROPERTIES; REACTIVE ASTROCYTES; NG2-POSITIVE CELLS; GENE-EXPRESSION; PROLIFERATION; BRAIN","Astrocytes and NG2 glia respond to CNS injury by the formation of a glial scar. Since the changes in K+ currents in astrocytes and NG2 glia that accompany glial scar formation might influence tissue outcome by altering K+ ion homeostasis, we aimed to characterize the changes in K+ currents in hippocampal astrocytes and NG2 glia during an extended time window of reperfusion after ischemic injury. Global cerebral ischemia was induced in adult rats by bilateral, 15-min common carotid artery occlusion combined with low-pressure oxygen ventilation. Using the patch-clamp technique, we investigated the membrane properties of hippocampal astrocytes and NG2 glia in situ 2 hours, 6 hours, 1 day, 3 days, 7 days or 5 weeks after ischemia. Astrocytes in the CA1 region of the hippocampus progressively depolarized starting 3 days after ischemia, which coincided with decreased Kir4.1 protein expression in the gliotic tissue. Other K+ channels described previously in astrocytes, such as Kir2.1, Kir5.1 and TREK1, did not show any changes in their protein content in the hippocampus after ischemia: however, their expression switched from neurons to reactive astrocytes, as visualized by immunohistochemistry. NG2 glia displayed increased input resistance, decreased membrane capacitance, increased delayed outwardly rectifying and A-type K+ currents and decreased inward K+ currents 3 days after ischemia, accompanied by their proliferation. Our results show that the membrane properties of astrocytes after ischemia undergo complex alterations, which might profoundly influence the maintenance of K+ homeostasis in the damaged tissue, while NG2 glia display membrane currents typical of proliferating cells. (C) 2010 Elsevier Ltd. All rights reserved.","[Pivonkova, Helena; Benesova, Jana; Butenko, Olena; Chvatal, Alexandr; Anderov, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Prague 14220 4, Czech Republic; [Butenko, Olena; Chvatal, Alexandr] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic","Anderov, M, Acad Sci Czech Republic, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, 1083 Videnska, Prague 14220 4, Czech Republic","anderova@biomed.cas.cz","Grant Agency of the Czech Republic [305/09/0717, P303/10/1338]; Academy of Sciences of the Czech Republic [AVOZ 50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]","We thank Hana Hronova and Helena Pavlikova for technical assistance and Petr Pivonka for developing software for patch-clamp data analysis. We also thank James Dutt for helpful comments and suggestions. This work was supported by the Grant Agency of the Czech Republic - grant 305/09/0717, P303/10/1338, the Academy of Sciences of the Czech Republic grant AVOZ 50390512 and the Ministry of Education, Youth and Sports of the Czech Republic grants LC554 and 1M0538.",null,58,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0197-0186",null,"10.1016/j.neuint.2010.08.016","NEUROCHEM INT","Neurochem. Int.","DEC",2010,57,7,null,null,null,783,794,null,null,12,"Biochemistry & Molecular Biology; Neurosciences","682XY","ISI:000284437500011"]
["nemá","J","Cerny, R; Rozsypal, H; Kozner, P; Machala, L",null,null,null,"Cerny, Rudolf; Rozsypal, Hanus; Kozner, Pavel; Machala, Ladislav",null,"Bilateral Holmes-Adie syndrome as an early manifestation of the HIV neuropathy","NEUROLOGICAL SCIENCES",null,"English","Article",null,null,null,null,null,"Holmes-Adie syndrome; Tonic pupil; Areflexia; HIV; Polyneuropathy","VIRUS-INFECTION; TONIC PUPILS; DISEASE; AREFLEXIA","A 38-year-old HIV-1 infected woman affected with bilateral tonic pupils. Ophthalmologic examination confirmed Holmes Adie syndrome (HAS), and peripheral distal polyneuropathy, orthostatic hypotension and leg hyperhidrosis were detected on further workup. The HAS can be either idiopathic or associated with neuropathy of various etiology (autoimmune, paraneoplastic and infectious). In our patient, the pupillotonia was the first and early symptom of hitherto unrecognized HIV neuropathy. HAS has been previously observed in association with syphilis, Lyme borreliosis, herpes simplex and parvovirus B19 infection. Our case is the first report of HAS in a case of HIV infection.","[Machala, Ladislav] Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Prague 18081, Czech Republic; [Machala, Ladislav] Charles Univ Prague, Dept Infect Dis, Fac Med 3, Prague 18081, Czech Republic; [Kozner, Pavel] Univ Hosp Bulovka, Dept Ophthalmol, Prague, Czech Republic; [Rozsypal, Hanus] Charles Univ Prague, Dept Infect & Trop Dis, Fac Med 1, Univ Hosp Bulovka, Prague 18081, Czech Republic; [Cerny, Rudolf] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 18081, Czech Republic","Machala, L, Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Budinova 2, Prague 18081, Czech Republic","ladimachala@centrum.cz",null,null,null,24,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1590-1874",null,"10.1007/s10072-010-0355-9","NEUROL SCI","Neurol. Sci.","OCT",2010,31,5,null,null,null,661,663,null,null,3,"Clinical Neurology; Neurosciences","668LR","ISI:000283271900021"]
["nemá","J","Prajerova, I; Honsa, P; Chvatal, A; Anderova, M",null,null,null,"Prajerova, I.; Honsa, P.; Chvatal, A.; Anderova, M.",null,"DISTINCT EFFECTS OF SONIC HEDGEHOG AND Wnt-7a ON DIFFERENTIATION OF NEONATAL NEURAL STEM/PROGENITOR CELLS IN VITRO","NEUROSCIENCE",null,"English","Article",null,null,null,null,null,"morphogen; potassium currents; sodium currents; membrane properties; patch-clamp; neurogenesis","POSTNATAL SUBVENTRICULAR ZONE; WNT/BETA-CATENIN PATHWAY; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; PROGENITOR CELLS; ADULT BRAIN; HIPPOCAMPAL NEUROGENESIS; PRECURSOR CELLS; NEURONAL DIFFERENTIATION; FUNCTIONAL-NEURONS","Sonic hedgehog (Shh) and Wnt-7a are morphogens involved in embryonic as well as ongoing adult neurogenesis. Their effects on the differentiation and membrane properties of neonatal neural stem/progenitor cells (NS/PCs) were studied in vitro using NS/PCs transduced with either Shh or Wnt-7a. Eight days after the onset of in vitro differentiation the cells were analyzed for the expression of neuronal and glial markers using immunocytochemical and Western blot analysis, and their membrane properties were characterized using the patch-clamp technique. Our results showed that both Shh and Wnt-7a increased the numbers of cells expressing neuronal markers; however, quantitative immunocytochemical analysis showed that only Wnt-7a enhanced the outgrowth and the development of processes in these cells. In addition, Wnt-7a markedly suppressed gliogenesis. The electrophysiological analysis revealed that Wnt-7a increased, while Shh decreased the incidence of cells displaying a neuron-like current pattern, represented by outwardly rectifying K+ currents and tetrodotoxin-sensitive Na+ currents. Additionally, Wnt-7a increased cell proliferation only at the early stages of differentiation, while Shh promoted proliferation within the entire course of differentiation. Thus we can conclude that Shh and Wnt-7a interfere differently with the process of neuronal differentiation and that they promote distinct stages of neuronal differentiation in neonatal NS/PCs. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.","[Prajerova, I.; Honsa, P.; Chvatal, A.; Anderova, M.] Acad Sci Czech Republic, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Prague 14220 4, Czech Republic; [Prajerova, I.; Honsa, P.; Chvatal, A.] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic; [Chvatal, A.; Anderova, M.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic","Anderova, M, Acad Sci Czech Republic, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220 4, Czech Republic","anderova@biomed.cas.cz","Grant Agency of the Czech Republic [305/09/0717, 309/08/H079]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]; Grant Agency of Charles University [GAUK62/2006/C/2.LF]","Acknowledgments The authors would like to thank to Prof. S. Krauss (Center for Molecular Biology and Neuroscience and Institute of Medical Microbiology, Rikshospitalet, Oslo, Norway) for the generous gift of transduced NSIPCs. Further, we would like to thank to Dr. D. Kunke (Center for Molecular Biology and Neuroscience and Institute of Medical Microbiology, Rikshospitalet, Oslo, Norway) and to Dr. O. Machon (Institute of Molecular Genetics, ASCR, v. vi., Prague, Czech Republic) for their initial assistance with the cell cultures. We also thank James Dutt for helpful comments and suggestions. This study was supported by the following grants: 305/09/0717 and 309/08/H079 from the Grant Agency of the Czech Republic, AVOZ50390512 from the Academy of Sciences of the Czech Republic, LC554 and 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic and GAUK62/2006/C/2.LF from the Grant Agency of Charles University.",null,77,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0306-4522",null,"10.1016/j.neuroscience.2010.09.023","NEUROSCIENCE","Neuroscience","DEC 15",2010,171,3,null,null,null,693,711,null,null,19,"Neurosciences","686XT","ISI:000284733700006"]
["nemá","J","Starkova, J; Zamostna, B; Mejstrikova, E; Krejci, R; Drabkin, HA; Trka, J",null,null,null,"Starkova, Julia; Zamostna, Blanka; Mejstrikova, Ester; Krejci, Roman; Drabkin, Harry A.; Trka, Jan",null,"HOX Gene Expression in Phenotypic and Genotypic Subgroups and Low HOXA Gene Expression as an Adverse Prognostic Factor in Pediatric ALL","PEDIATRIC BLOOD & CANCER",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; aberrant gene expression; hematopoiesis; homeodomain genes","ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; HOMEOBOX GENE; HOX11L2 EXPRESSION; POOR-PROGNOSIS; CANCER; MLL; OVEREXPRESSION","Background. HOX genes play an important role in both normal lymphopoiesis and leukemogenesis. However, HOX expression patterns in leukemia cells compared to normal lymphoid progenitors have not been systematically studied in acute lymphoblastic leukemia (ALL) subtypes. Procedure. The RNA expression levels of HOXA, HOXB, and CDX1/2 genes were analyzed by qRT-PCR in a cohort of 61 diagnostic pediatric ALL samples and FACS-sorted subpopulations of normal lymphoid progenitors. Results. The RNA expression of HOXA7-10, HOXA13, and HOXB2-4 genes was exclusively detected in leukemic cells and immature progenitors. The RNA expression of HOXB6 and CDX2 genes was exclusively detected in leukemic cells but not in B-lineage cells at any of the studied developmental stages. HOXA3-4, HOXA7, and HOXB3-4 genes were differentially expressed between BCP-ALL and T-ALL subgroups, and among genotypically defined MLL/AF4, TEL/AML1, BCR/ABL, hyperdiploid and normal karyotype subgroups. However, this differential expression did not define specific clusters in hierarchical cluster analysis. HOXA7 gene was low expressed at the RNA level in patients with hyperdiploid leukemia, whereas wHOXB7 and CDX2 genes were low expressed in TEL/AML1-positive and BCR/ABL-positive cases, respectively. In contrast to previous findings in acute myeloid leukemia, high HOXA RNA expression was associated with an excellent prognosis in Cox's regression model (P = 0.03). In MLL/AF4-positive ALL, lower HOXA RNA expression correlated with the methylation status of their promoters. Conclusions. HOX gene RNA expression cannot discriminate leukemia subgroups or relative maturity of leukemic cells. However, HOXA RNA expression correlates with prognosis, and particular HOX genes are expressed in specific genotypically characterized subgroups. Pediatr Blood Cancer. 2010;55:1072-1082. (C) 2010 Wiley-Liss, Inc.","[Starkova, Julia] Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, CLIP, Prague 15006, Czech Republic; [Zamostna, Blanka] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague, Czech Republic; [Drabkin, Harry A.] Med Univ S Carolina, Dept Hematol Oncol, Charleston, CA USA","Starkova, J, Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, CLIP, V Uvalu 84, Prague 15006, Czech Republic","julia.starkova@lfmotol.cuni.cz","MSMTVZ [MSM0021620813]; GACR [301/08/P532]; IGA [NR9526]","Grant sponsor: MSMTVZ; Grant number: MSM0021620813; Grant sponsor: GACR; Grant number: 301/08/P532; Grant sponsor: IGA; Grant number: NR9526.",null,45,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,"10.1002/pbc.22749","PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","DEC 1",2010,55,6,null,null,null,1072,1082,null,null,11,"Oncology; Hematology; Pediatrics","674OT","ISI:000283757600008"]
["nemá","J","Tomek, V; Vlk, R; Tlaskal, T; Skovranek, J",null,null,null,"Tomek, Viktor; Vlk, Radovan; Tlaskal, Tomas; Skovranek, Jan",null,"Successful Pericardio-Amniotic Shunting for Fetal Intrapericardial Teratoma","PEDIATRIC CARDIOLOGY",null,"English","Article",null,null,null,null,null,null,"IN-UTERO; MANAGEMENT; THERAPY; HYDROPS",null,"[Tomek, Viktor; Tlaskal, Tomas; Skovranek, Jan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Tomek, Viktor; Tlaskal, Tomas; Skovranek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Vlk, Radovan] Univ Hosp Motol, Dept Obstet & Gynecol, Prague, Czech Republic","Tomek, V, Univ Hosp Motol, Kardioctr, Prague, Czech Republic","viktor.tomek@fnmotol.cz","Czech Ministry of Health [MZOFNM2005]","This publication was supported by a grant of the Czech Ministry of Health (MZOFNM2005).",null,11,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,"10.1007/s00246-010-9774-x","PEDIAT CARDIOL","Pediatr. Cardiol.","NOV",2010,31,8,null,null,null,1236,1238,null,null,3,"Cardiac & Cardiovascular Systems; Pediatrics","679JJ","ISI:000284157400019"]
["nemá","J","Barinka, F; Druga, R",null,null,null,"Barinka, F.; Druga, R.",null,"Calretinin Expression in the Mammalian Neocortex: A Review","PHYSIOLOGICAL RESEARCH",null,"English","Review",null,null,null,null,null,"Calcium-binding proteins; Interneurons; Inhibition; Neuroprotection; Neurovascular coupling","CALCIUM-BINDING PROTEINS; LOCAL-CIRCUIT NEURONS; MONKEY PREFRONTAL CORTEX; HUMAN TEMPORAL CORTEX; TERM POTENTIATION INDUCTION; MICE LACKING CALRETININ; NITRIC-OXIDE SYNTHASE; PRIMARY VISUAL-CORTEX; RAT FRONTAL-CORTEX; IMMUNOREACTIVE NEURONS","In the mammalian neocortex, the calcium-binding protein calretinin is expressed in a subset of cortical interneurons. In the recent years, research on interneurons is one of the most rapidly growing fields in neuroscience. This review summarizes the actual knowledge of the functions of calretinin in neuronal homeostasis and particularly of the distribution, connectivity and physiological properties of calretinin expressing interneurons in the neocortex of rodents and primates, including humans. The possible neuroprotective role of calretinin and the presumed \"resistance\" of calretinin-expressing interneurons to various pathological processes are also discussed.","[Barinka, F.; Druga, R.] Charles Univ Prague, Dept Anat, Fac Med 2, Prague 12800, Czech Republic; [Druga, R.] Charles Univ Prague, Dept Anat, Fac Med 1, Prague 12800, Czech Republic; [Druga, R.] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic","Druga, R, Charles Univ Prague, Dept Anat, Fac Med 2, U Nemocnice 3, Prague 12800, Czech Republic","rastislav.druga@lf1.cuni.cz","Grant Agency of Charles University [35407]; Grant Agency of the Czech Republic [304/07/1137, 309/07/1136]","This work was supported by Grant Agency of Charles University, Grant No. 35407 and by Grant Agency of the Czech Republic, Grant No. 304/07/1137 and 309/07/1136.",null,108,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,665,677,null,null,13,"Physiology","683QC","ISI:000284489300005"]
["nemá","J","Zemanek, D; Tomasov, P; Prichystalova, P; Linhartova, K; Veselka, J",null,null,null,"Zemanek, D.; Tomasov, P.; Prichystalova, P.; Linhartova, K.; Veselka, J.",null,"Evaluation of the Right Ventricular Function in Hypertrophic Obstructive Cardiomyopathy: A Strain and Tissue Doppler Study","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Hypertrophic obstructive cardiomyopathy; Right ventricle; Strain; Strain rate; Tissue Doppler imaging; Tei index","TEI-INDEX; EUROPEAN-SOCIETY; ECHOCARDIOGRAPHY; QUANTIFICATION; HYPERTENSION; CARDIOLOGY; DISEASES","We investigated the utility of strain, strain rate, and tissue Doppler imaging (TDI) for the evaluation of the right ventricle (RV) impairment in patients with a hypertrophic obstructive cardiomyopathy (HOCM) who underwent a successful alcohol septal ablation (ASA) and were without RV hypertrophy. A group of 19 patients suffering from HOCM with 22 controls was compared. The parameters of TDI were evaluated in mitral and tricuspid annulus. Strain and strain rate derived from TDI were assessed in an apical free wall of RV, as well as in basal segments of the left ventricle. Between both groups, there were significant differences only in isovolumic pre-ejection time (79.2 +/- 17.3 ms vs. 58.5 +/- 8.1 ms, p<0.01), isovolumic relaxation time (104.7 +/- 26.2 ms vs. 77.3 +/- 24.5 ms, p<0.01), myocardial performance (Tei) index measured from TDI (0.61 +/- 0.14 vs. 0.49 +/- 0.09, p<0.01), and early peak diastolic velocity of TDI (10.6 +/- 1.67 cm/s vs. 12.6 +/- 2.21 cm/s; p<0.05). Our results suggest the impairment of both systolic and diastolic RV function in patients suffering from HOCM. TDI-related parameters appear to be more sensitive than strain and strain rate for evaluation.","[Zemanek, D.; Tomasov, P.; Linhartova, K.; Veselka, J.] Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc,Med Sch 1 & 2, Prague 15000, Czech Republic; [Prichystalova, P.] Brno Univ Technol, Fac Mech Engn, Inst Math, Brno, Czech Republic","Zemanek, D, Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc,Med Sch 1 & 2, V Uvalu 84, Prague 15000, Czech Republic","zejada@seznam.cz","Internal Grant Agency, Ministry of Health, Czech Republic [NR/9164-3]; Ministry of Health, Czech Republic [000064203]","This study was supported by grant NR/9164-3 from the Internal Grant Agency, Ministry of Health, Czech Republic and by grant Nr. 000064203 from Ministry of Health, Czech Republic.",null,16,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,697,702,null,null,6,"Physiology","683QC","ISI:000284489300008"]
["nemá","J","Maxova, H; Bacakova, L; Lisa, V; Novotna, J; Tomasova, H; Vizek, M; Herget, J",null,null,null,"Maxova, H.; Bacakova, L.; Lisa, V.; Novotna, J.; Tomasova, H.; Vizek, M.; Herget, J.",null,"Production of Proteolytic Enzymes in Mast Cells, Fibroblasts, Vascular Smooth Muscle and Endothelial Cells Cultivated Under Normoxic or Hypoxic Conditions","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Hypoxia; Metalloproteinases; Tryptase; Chymase; Immunofluorescence","MATRIX METALLOPROTEINASES; I COLLAGEN; EXPRESSION; LUNG; TRYPTASE; RAT; ACTIVATION; DEGRANULATION; ANEURYSMS; PROMOTES","Matrix metalloproteinases (MMPs) is a family of proteolytic enzymes involved in remodeling of extracellular matrix. Although proteolytic enzymes are produced by many cell types, mast cells seem to be more important than other types in remodeling of pulmonary arteries during hypoxia. Therefore, we tested in vitro production of MMPs and serine proteases in four cell types (mast cells, fibroblasts, vascular smooth muscle cells and endothelial cells) cultivated for 48 h under normoxic or hypoxic (3 % O-2) conditions. MMP-13 was visualized by immunohistochemistry, MMP-2 and MMP-9 were detected by zymography in cell lysates. Enzymatic activities (MMPs, tryptase and chymase) were estimated in the cultivation media. Hypoxia had a minimal effect on total MMP activity in the cultivation media of all types of cells, but immunofluorescence revealed higher intensity of MMP-13 in the cells exposed to hypoxia except of fibroblasts. Tryptase activity was three times higher and chymase activity twice higher in mast cells cultivated in hypoxia than in those cultured in normoxia. Among all cell types studied here, mast cells are the most abundant source of proteolytic enzymes under normoxic and hypoxic conditions. Moreover, in these cells hypoxia increases the production of both specific serine proteases tryptase and chymase, which can act as MMPs activators.","[Maxova, H.; Vizek, M.] Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Novotna, J.] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Bacakova, L.; Lisa, V.] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Maxova, H.; Bacakova, L.; Novotna, J.; Tomasova, H.; Vizek, M.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Maxova, H, Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","hana.maxova@lfmotol.cuni.cz","Grant Agency of the Czech Republic [305/08/0108]; Centre for Cardiovascular Research [1M0510]","This work was supported by the Grant Agency of the Czech Republic (No. 305/08/0108) and by the Centre for Cardiovascular Research (No. 1M0510). Mr. Robin Healey (Czech Technical University, Prague) is gratefully acknowledged for his language revision of the manuscript.",null,41,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,711,719,null,null,9,"Physiology","683QC","ISI:000284489300010"]
["nemá","J","Rampichova, M; Kostakova, E; Filova, E; Prosecka, E; Plencner, M; Ocheretna, L; Lytvynets, A; Lukas, D; Amler, E",null,null,null,"Rampichova, M.; Kostakova, E.; Filova, E.; Prosecka, E.; Plencner, M.; Ocheretna, L.; Lytvynets, A.; Lukas, D.; Amler, E.",null,"Non-Woven PGA/PVA Fibrous Mesh as an Appropriate Scaffold for Chondrocyte Proliferation","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"PGA; PVA; Non-woven textile; Chondrocyte; Tissue engineering","IN-VITRO; ARTICULAR-CARTILAGE; HYALURONIC-ACID; DEGRADATION; HYDROGELS; FIXATION; IMPLANTS; DELIVERY; MATRIX; BONE","Non-woven textile mesh from polyglycolic acid (PGA) was found as a proper material for chondrocyte adhesion but worse for their proliferation. Neither hyaluronic acid nor chitosan nor polyvinyl alcohol (PVA) increased chondrocyte adhesion. However, chondrocyte proliferation suffered from acidic byproducts of PGA degradation. However, the addition of PVA and/or chitosan into a wet-laid non-woven textile mesh from PGA improved chondrocyte proliferation seeded in vitro on the PGA-based composite scaffold namely due to a diminished acidification of their microenvironment. This PVA/PGA composite mesh used in combination with a proper hydrogel minimized the negative effect of PGA degradation without dropping positive parameters of the PGA wet-laid non-woven textile mesh. In fact, presence of PVA and/or chitosan in the PGA-based wet-laid non-woven textile mesh even advanced the PGA-based wet-laid non-woven textile mesh for chondrocyte seeding and artificial cartilage production due to a positive effect of PVA in such a scaffold on chondrocyte proliferation.","[Amler, E.] Charles Univ Prague, Fac Med 2, Dept Biophys, Inst Biophys, Prague 15006 5, Czech Republic; [Rampichova, M.; Filova, E.; Prosecka, E.; Plencner, M.; Lytvynets, A.; Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Kostakova, E.; Ocheretna, L.; Lukas, D.] Tech Univ Liberec, Fac Text Engn, Liberec, Czech Republic; [Amler, E.] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic","Amler, E, Charles Univ Prague, Fac Med 2, Dept Biophys, Inst Biophys, V Uvalu 84, Prague 15006 5, Czech Republic","evzen.amler@lfmotol.cuni.cz","Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [2B06130, 1M0510]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151, P304/10/1307]; EU [214539]; Grant Agency of the Charles University [119209]","Supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), Ministry of Education, Youth and Sports of the Czech Republic (research programs NPV II 2B06130 and 1M0510), Grant Agency of the Academy of Sciences grant No. IAA500390702, by Czech Science Foundation grants No. GA202/09/1151 and P304/10/1307, EU project BIOSCENT ID number 214539, and the Grant Agency of the Charles University grant No. 119209.",null,23,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,773,781,null,null,9,"Physiology","683QC","ISI:000284489300017"]
["nemá","J","Kunova, M; Matulka, K; Eiselleova, L; Trckova, P; Hampl, A; Dvorak, P",null,null,null,"Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Trckova, Petra; Hampl, Ales; Dvorak, Petr",null,"Development of humanized culture medium with plant-derived serum replacement for human pluripotent stem cells","REPRODUCTIVE BIOMEDICINE ONLINE",null,"English","Article",null,null,null,null,null,"animal protein-free culture; high-density culture; human embryonic stem cells; humanized culture medium; plant-derived serum supplement; VegetaCell","FIBROBLAST-GROWTH-FACTOR; PROLONGED UNDIFFERENTIATED GROWTH; HUMAN FEEDER CELLS; SELF-RENEWAL; HUMAN BLASTOCYSTS; ANIMAL-CELLS; LINES; PROTEIN; SUPPORT; MAINTENANCE","For human embryonic stem cells (ESC) to be used in cell replacement therapies, they must be grown under good manufacturing conditions in a chemically defined medium that lacks animal proteins. This study examined the ability of a newly designed medium containing the plant-derived serum replacement VegetaCell and other reagents of human origin to support undifferentiated growth and pluripotency of human ESC. This medium was tested in several culture systems, using human fibroblasts as a feeder layer or Matrigel in a feeder-free culture. Even under the most stringent feeder-free conditions without conditioned medium, human ESC exhibited an undifferentiated morphology, expressed markers of undifferentiated cells, demonstrated high alkaline phosphatase activity and multilineage differentiation and retained a normal karyotype. Compared with human ESC grown in standard culture conditions, human ESC maintained in humanized VegetaCell medium show longer cell cycles and decreased cell death. The availability of an animal protein-free medium supplemented with the low-cost VegetaCell reagent expands the repertoire of media for culturing human ESC as well as induced pluripotent stem cells for drug testing and cell replacement therapy. (C) 2010, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","[Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Trckova, Petra; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic; [Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Trckova, Petra; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Ctr Chem Genet, Brno, Czech Republic; [Hampl, Ales; Dvorak, Petr] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Embryol, Prague, Czech Republic; [Hampl, Ales; Dvorak, Petr] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Dvorak, P, Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic","pdvorak@med.muni.cz","Ministry of Education, Youth and Sport of the Czech Republic [MSM0021622430, LC06077]; Academy of Sciences of the Czech Republic [AV0Z50390512, AV0Z50390703]; EC [LSHG-CT-2006-018739]","This study was supported by funding from the Ministry of Education, Youth and Sport of the Czech Republic (MSM0021622430, LC06077), the Academy of Sciences of the Czech Republic (AV0Z50390512, AV0Z50390703) and EC FP6 (contract LSHG-CT-2006-018739).",null,48,0,"REPRODUCTIVE HEALTHCARE LTD","CAMBRIDGE","DUCK END FARM, DRY DRAYTON, CAMBRIDGE, CB3 8DB, ENGLAND","1472-6483",null,"10.1016/j.rbmo.2010.06.027","REPROD BIOMED ONLINE","Reprod. Biomed. Online","NOV",2010,21,5,null,null,null,676,686,null,null,11,"Obstetrics & Gynecology; Reproductive Biology","687SA","ISI:000284797000016"]
["nemá","J","Wawrzycki, B; Chodorowska, G; Pietrzak, A; Jazienicka, I; Skomra, D; Kowal, M; Dybiec, E; Hercogova, J",null,null,null,"Wawrzycki, Bartlomiej; Chodorowska, Grazyna; Pietrzak, Aldona; Jazienicka, Iwona; Skomra, Danuta; Kowal, Malgorzata; Dybiec, Ewa; Hercogova, Jana",null,"THERAPEUTIC HOTLINE: Primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide","DERMATOLOGIC THERAPY",null,"English","Article",null,null,null,null,null,"cyclophosphamide; myelodysplastic syndrome; primary cutaneous CD4+small; medium-sized pleomorphic T-cell lymphoma","WHO-EORTC; CLASSIFICATION","Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy. We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.","[Wawrzycki, Bartlomiej; Chodorowska, Grazyna; Pietrzak, Aldona; Jazienicka, Iwona] Med Univ Lublin, Chair Dermatol Venereol & Pediat Dermatol, PL-20080 Lublin, Poland; [Wawrzycki, Bartlomiej; Chodorowska, Grazyna; Pietrzak, Aldona; Jazienicka, Iwona] Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, PL-20080 Lublin, Poland; [Skomra, Danuta] Med Univ Lublin, Dept Clin Pathomorphol, Prague, Czech Republic; [Kowal, Malgorzata] Med Univ Lublin, Chair Hematooncol & Bone Marrow Transplantat, Prague, Czech Republic; [Kowal, Malgorzata] Med Univ Lublin, Dept Hematooncol & Bone Marrow Transplantat, Prague, Czech Republic; [Dybiec, Ewa] Med Univ Lublin, Dept Pediat Radiol, Prague, Czech Republic; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Wawrzycki, B, Med Univ Lublin, Chair Dermatol Venereol & Pediat Dermatol, Radziwillowska 13, PL-20080 Lublin, Poland","bartekwawrzycki@o2.pl",null,null,null,14,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,"10.1111/j.1529-8019.2010.01372.x","DERMATOL THER","Dermatol. Ther.","NOV-DEC",2010,23,6,null,null,null,676,681,null,null,6,"Dermatology","676WI","ISI:000283949000010"]
["nemá","J","Hlavata, I; Vrana, D; Smerhovsky, Z; Pardini, B; Naccarati, A; Vodicka, P; Novotny, J; Mohelnikova-Duchonova, B; Soucek, P",null,null,null,"Hlavata, Ivona; Vrana, David; Smerhovsky, Zdenek; Pardini, Barbara; Naccarati, Alessio; Vodicka, Pavel; Novotny, Jan; Mohelnikova-Duchonova, Beatrice; Soucek, Pavel",null,"Association between exposure-relevant polymorphisms in CYP1B1,EPHX1,NQ01,GSTM1,GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population","ONCOLOGY REPORTS",null,"English","Article",null,null,null,null,null,"colorectal cancer; cytochrome P450; glutathione S-transferase; polymorphism; risk","S-TRANSFERASE M1; BODY-MASS INDEX; COLON-CANCER; GENETIC POLYMORPHISMS; EPOXIDE HYDROLASE; CIGARETTE-SMOKING; METAANALYSIS; GSTM1; SUSCEPTIBILITY; EXPRESSION","Associations of functional single nucleotide polymorphisms in cytochrome P450 1B1, epoxide hydrolase 1, NAD(P)H:quinone oxidoreductase 1, glutathione S-transferase Pi-1 and deletions of glutathione S-transferases Mu-1 and theta-1 with colorectal cancer risk were investigated in a hospital-based case-control study on 495 matched pairs of Czech Caucasians. Polymorphisms were assessed by polymerase chain reaction restriction fragment length polymorphism-based methods, allele-specific multiplex and allelic discrimination by real-time polymerase chain reaction. Carriers of variant Ser allele in codon 453 of cytochrome P450 1B1 (rs1800440) were at a significantly lower risk of colorectal cancer compared to carriers of the wild-type allele (adjusted odds ratio, aOR=0.68. CI=0.51-0.89, p=0.006). The combination of polymorphisms in codons 453 and 432 (rs1056836) of cytochrome P450 I B I further increased the protective effect (aOR=0.53, CI=0.34-0.83, p=0.005). The glutathione S-transferase Mu-1 deletion was associated with a moderately elevated colorectal cancer risk (aOR=1.30, CI=1.01-1.68, p=0.044). Combination of glutathione S-transferase Mu-1 and theta-1 deletion was associated with a significantly higher colorectal cancer risk compared to the presence of both full-length genes (aOR=1.58, CI=1.01-2.47, p=0.044). Genetic polymorphisms in glutathione S-transferase Pi-1, NAD(P)H:quinone oxidoreductase 1, epoxide hydrolase 1 and deduced epoxid hydrolase 1 activity did not modify the risk of colorectal cancer. These results provide further evidence that interaction between metabolic gene variants contributes to colorectal carcinogenesis.","[Hlavata, Ivona; Vrana, David; Smerhovsky, Zdenek; Mohelnikova-Duchonova, Beatrice; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042, Czech Republic; [Hlavata, Ivona] Charles Univ Prague, Fac Med 3, Prague 10000, Czech Republic; [Novotny, Jan] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic; [Vrana, David; Mohelnikova-Duchonova, Beatrice] Gen Teaching Hosp, Fac Med 1, Prague 12108, Czech Republic; [Novotny, Jan] Gen Teaching Hosp, Dept Oncol, Prague 12108, Czech Republic; [Vrana, David] Hosp Atlas, Dept Med, Zlin 76001, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol, Prague 15006, Czech Republic; [Pardini, Barbara; Naccarati, Alessio; Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14220, Czech Republic","Soucek, P, Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042, Czech Republic","psoucek@szu.cz","Internal Grant Agency of the Czech Ministry of Health [IGA 10230-3]; Czech Science Foundation [GACR 310/07/1430]; Grant Agency of Charles University [GAUK 15109/2009]","The authors are grateful to Simona Susova, Ing, from the National Institute of Public Health, Prague Czech Republic, for taking part in genotyping analyses. The study was supported by grants of the Internal Grant Agency of the Czech Ministry of Health, no. IGA 10230-3, the Czech Science Foundation no. GACR 310/07/1430 and the Grant Agency of Charles University no. GAUK 15109/2009.",null,47,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,"10.3892/or_0000992","ONCOL REP","Oncol. Rep.","NOV",2010,24,5,null,null,null,1347,1353,null,null,7,"Oncology","666JX","ISI:000283112200031"]
["nemá","J","Kolar, P; Sulc, J; Kyncl, M; Sanda, J; Neuwirth, J; Bokarius, AV; Kriz, J; Kobesova, A",null,null,null,"Kolar, P.; Sulc, J.; Kyncl, M.; Sanda, J.; Neuwirth, J.; Bokarius, A. V.; Kriz, J.; Kobesova, A.",null,"Stabilizing function of the diaphragm: dynamic MRI and synchronized spirometric assessment","JOURNAL OF APPLIED PHYSIOLOGY",null,"English","Article",null,null,null,null,null,"diaphragm; stabilizing function; dynamic magnetic resonance imaging; lung function; thorax","OBSTRUCTIVE PULMONARY-DISEASE; INTRAABDOMINAL PRESSURE; RESPIRATORY ACTIVATION; POSTURAL ACTIVITY; HEALTHY-SUBJECTS; TRUNK MUSCLES; MOVEMENT; MOTION; CONTRACTION; FLUOROSCOPY","The aim was to describe diaphragmatic behavior during postural limb activities and examine the ventilatory and stabilizing functions of the diaphragm. Thirty healthy subjects were examined in the supine position using a dynamic MRI system assessed simultaneously with specialized spirometric readings. The diaphragmatic excursions (DEs) were measured at three diaphragmatic points in the sagittal plane; the diaphragm positions (DPs) as related to a reference horizontal baseline were determined. Measurements were taken during tidal breathing (TB) and isometric flexion of upper or lower extremities against external resistance together with TB. Mean DE in both upper and lower postural limb activities was greater compared with the TB condition (P < 0.05), with the effect greater for lower limb activities. Inspiratory DPs in the upper and lower extremity activities were lower compared with TB alone (P < 0.01). Expiratory DP was lower only for lower extremity activities (P < 0.01). DP was most affected at the apex of the crescent and crural (posterior) portion of the diaphragm. DEs correlated strongly with tidal volume (VT) in all conditions. Changes in DEs relative to the initial value were minimal for upper and lower extremities but were related to lower values of VT (P < 0.03). Significant involvement of the diaphragm in the limb postural activities was found. Resulting DEs and DPs differed from the TB conditions, especially in lower extremity activities. The differences between the percent changes of DEs vs. VT found for lower extremity activities were confirmed by both ventilatory and postural diaphragm recruitment in response to postural demands.","[Kolar, P.; Sulc, J.; Kriz, J.; Kobesova, A.] Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, Prague 15900 5, Czech Republic; [Kolar, P.; Sulc, J.; Kyncl, M.; Sanda, J.; Kriz, J.; Kobesova, A.] Univ Hosp Motol, Prague 15900 5, Czech Republic; [Kyncl, M.; Sanda, J.] Charles Univ Prague, Dept Med Imaging, Fac Med 2, Prague 15900 5, Czech Republic; [Neuwirth, J.] Charles Univ Prague, Radiol Clin, Fac Med, Prague 15900 5, Czech Republic; [Neuwirth, J.] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Bokarius, A. V.] Comprehens Care Consultants, Los Angeles, CA USA","Kobesova, A, Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, V Uvalu 84, Prague 15900 5, Czech Republic","alenamudr@me.com","Foundation \"Movement Without Help,\" Prague, Czech Republic ","This study was supported by the Foundation \"Movement Without Help,\" Prague, Czech Republic.",null,37,0,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","8750-7587",null,"10.1152/japplphysiol.01216.2009","J APPL PHYSIOL","J. Appl. Physiol.","OCT",2010,109,4,null,null,null,1064,1071,null,null,8,"Physiology; Sport Sciences","695BF","ISI:000285344900017"]
["nemá","J","Mohapl, M; Vanek, P; Bradac, O; Horinek, D; Saur, K; Mohaplova, M",null,null,null,"Mohapl, M.; Vanek, P.; Bradac, O.; Horinek, D.; Saur, K.; Mohaplova, M.",null,"Comparison of the Benefits of the Lumbar Infusion Test and Lumbar Drainage in the Treatment of Hydrocephalus","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"normal pressure hydrocephalus; lumbar infusion test; external lumbar drainage","NORMAL-PRESSURE HYDROCEPHALUS; CEREBROSPINAL-FLUID; PREDICTIVE VALUE; SHUNT SURGERY; CSF DRAINAGE","The authors present the results of a prospective study comparing the benefits of the lumbar infusion test and external lumbar drainage in the diagnosis of normal-pressure hydrocephalus. Over a period of 24 months, 60 patients (age 29-83, average 66.5) were examined. The main symptom was gait impairment (53 patients), while disturbances of memory were noted in 44 subjects and incontinence in 36 individuals. All three were present in 28 subjects. A lumbar infusion test was performed on all patients, with a resistance to outflow >12 mmHg/ml/min or more considered as the level of cerebrospinal fluid resorption impairment. A lumbar infusion test followed immediately after the lumbar infusion test procedure and the effect of cerebrospinal fluid derivation was evaluated after 120 hours. The lumbar infusion test was positive in 23 subjects and 19 individuals in this group showed significant improvement after external lumbar drainage, while no significant improvement was observed in 4 of them. In the group with negative lumbar infusion test, an improvement was noted in 12 of the 37 subjects. The lumbar infusion test is a simple and effective method of diagnostic evaluation in patients in whom a diagnosis of normal-pressure hydrocephalus is suspected. Due to lower sensitivity, the diagnostic algorithm should also include lumbar drainage test in the event of negative or borderline results.","[Mohapl, M.; Vanek, P.; Bradac, O.; Horinek, D.; Saur, K.] UVN Praha, LF UK 1, Neurochirurg Klin, Prague 16902, Czech Republic; [Mohapl, M.; Vanek, P.; Bradac, O.; Horinek, D.; Saur, K.] UVN Praha, IPVZ, Prague 16902, Czech Republic; [Mohaplova, M.] 2 LF UK, Detska Psychiat Klin, Prague, Czech Republic; [Mohaplova, M.] FN Motole, Prague, Czech Republic","Mohapl, M, UVN Praha, LF UK 1, Neurochirurg Klin, Vojenske Nemocnice 1 200, Prague 16902, Czech Republic","milan.mohapl@gmail.com",null,null,null,30,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,6,null,null,null,685,688,null,null,4,"Neurosciences; Surgery","696MY","ISI:000285446700008"]
["nemá","J","Schwabova, J; Zahalka, F; Komarek, V; Maly, T; Hrasky, P; Gryc, T; Zumrova, A",null,null,null,"Schwabova, J.; Zahalka, F.; Komarek, V.; Maly, T.; Hrasky, P.; Gryc, T.; Zumrova, A.",null,"A Scale for the Assessment and Rating of Ataxia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"scale for the assessment and rating of ataxia; International Cooperative Ataxia Rating Scale; autosomal dominant spinocerebelar ataxia; ataxia; Friedreich's ataxia; posturography","SPINOCEREBELLAR ATAXIA; FRIEDREICHS-ATAXIA; CEREBELLAR-ATAXIA; ANTERIOR LOBE; RELIABILITY; DISEASE; STABILOMETRY; VALIDITY; ATROPHY; STANCE","The goal of this study was to test the validity of the Scale for Assessment and Rating of Ataxia (SARA), published in 2006, using patients with autosomal dominant spino-cereberal ataxia (AD SCA) and Friedreich's ataxia (FRDA). The data obtained was compared with that acquired from the International Cooperative Ataxia Rating Scale (ICARS) and correlated with selected posturographic parameters (PP). A total of 30 patients - 17 AD SCA and 13 FRDA - were examined. Time-monitored ICARS and SARA scales were employed. Posturographic examination on a tensometric platform followed, as per standard protocol. The results were statistically processed with tests for non-parametric correlation (Kendall's tau-b). ICARS and SARA exhibited high correlation in both groups and with AD SCA (p <0.001); mid-level correlation was evident with FRDA (p <0.05); ICARS with PP and standing and walking - part of ICARS - correlated closely with PP in both groups (p <0.01); SARA correlated at mid-level with PP in both groups and with AD SCA (p <0.05). FRDA patients did not correlate. The validity of the SARA scale, including its lower time demands, was demonstrated to be in agreement with the literature. Correlations between the scales and selected PP were established, as well as the possibility of using posturography when reviewing the validity of these scales with ataxia patients. Surprisingly, the results of the SARA scale did not correlate with PP in FRDA (p >0.05) patients and the correlation between ICARS and SARA in FRDA patients was lower (tau b = 0.545; p <0.05). The reason for this may lie in the lower number of FRDA patients tested, but SARA may just be less sensitive to the more distinctive symptoms in the dorsal column.","[Schwabova, J.; Komarek, V.; Zumrova, A.] UK 2 LF, Klin Detske Neurol, Prague 15000 5, Czech Republic; [Schwabova, J.; Komarek, V.; Zumrova, A.] FN Motole, Prague 15000 5, Czech Republic; [Zahalka, F.; Maly, T.; Hrasky, P.; Gryc, T.] FTVS UK, Lab Sportovni Motoriky, Prague, Czech Republic","Schwabova, J, UK 2 LF, Klin Detske Neurol, Uvalu 84, Prague 15000 5, Czech Republic","jaroslava.schwabova@lfmotol.cuni.cz",null,null,null,25,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2010,73,6,null,null,null,689,693,null,null,5,"Neurosciences; Surgery","696MY","ISI:000285446700009"]
["nemá","J","Balgobind, BV; Zwaan, CM; Reinhardt, D; Arentsen-Peters, TJCM; Hollink, IHIM; de Haas, V; Kaspers, GJL; de Bont, ESJM; Baruchel, A; Stary, J; Meyer, C; Marschalek, R; Creutzig, U; den Boer, ML; Pieters, R; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, B. V.; Zwaan, C. M.; Reinhardt, D.; Arentsen-Peters, T. J. C. M.; Hollink, I. H. I. M.; de Haas, V.; Kaspers, G. J. L.; de Bont, E. S. J. M.; Baruchel, A.; Stary, J.; Meyer, C.; Marschalek, R.; Creutzig, U.; den Boer, M. L.; Pieters, R.; van den Heuvel-Eibrink, M. M.",null,"High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome","LEUKEMIA",null,"English","Article",null,null,null,null,null,"MLL; BRE; pediatric AML",null,"Translocations involving the mixed lineage leukemia (MLL) gene, localized at 11q23, frequently occur in pediatric acute myeloid leukemia (AML). We recently reported differences in prognosis between the different translocation partners, suggesting differences in biological background. To unravel the latter, we used microarrays to generate gene expression profiles of 245 pediatric AML cases, including 53 MLL-rearranged cases. Thereby, we identified a specific gene expression signature for t(9;11)(p22;q23), and identified BRE (brain and reproductive organ expressed) to be discriminative for t(9;11)(p22;q23) (P<0.001) when compared with other MLL subtypes. Patients with high BRE expression showed a significantly better 3-year relapse-free survival (pRFS) (80 +/- 13 vs 30 +/- 10%, P=0.02) within MLL-rearranged AML cases. Moreover, multivariate analysis identified high BRE expression as an independent favorable prognostic factor within pediatric AML for RFS (HR=0.2, P=0.04). No significant differences were identified for 3-year event-free survival or for 3-year overall survival. Forced expression of BRE did not result in altered cell proliferation, apoptosis or drug sensitivity, which could explain the favorable outcome. In conclusion, overexpression of the BRE gene is predominantly found in MLL-rearranged AML with t(9;11)(p22;q23). Although further investigation for the role of BRE in leukemogenesis and outcome is warranted, high BRE expression is an independent prognostic factor for pRFS in pediatric AML. Leukemia (2010) 24, 2048-2055;doi:10.1038/leu.2010.211; published online 23 September 2010","[van den Heuvel-Eibrink, M. M.] Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus MC, NL-3000 CB Rotterdam, Netherlands; [Reinhardt, D.] Hannover Med Sch, AML BFM Study Grp, D-3000 Hannover, Germany; [de Haas, V.] DCOG, The Hague, Netherlands; [Kaspers, G. J. L.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [de Bont, E. S. J. M.] Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands; [Baruchel, A.] Hop St Louis, Paris, France; [Stary, J.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Meyer, C.; Marschalek, R.] DCAL, Inst Pharmaceut Biol, ZAFES, Frankfurt, Germany; [Creutzig, U.] Univ Hosp Muenster, Munster, Germany","van den Heuvel-Eibrink, MM, Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus MC, Room Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands","m.vandenheuvel@erasmusmc.nl","NWO 'Netherlands Organization for Scientfic Research' ; KOCR 'Kinder-Oncologisch Centrum Rotterdam' ","We thank Dr Yiu-Loon Chui, Department of Chemical Pathology and Sir YK Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China, for providing the BRE antibody. Furthermore, we thank Dr E Hulleman for her input in the transfection experiments. This work was funded by the NWO 'Netherlands Organization for Scientfic Research' (BVB) and KOCR 'Kinder-Oncologisch Centrum Rotterdam' (BVB, IHIM).",null,43,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2010.211","LEUKEMIA","Leukemia","DEC",2010,24,12,null,null,null,2048,2055,null,null,8,"Oncology; Hematology","695OF","ISI:000285380900009"]
["nemá","J","Haberlova, J; Seeman, P",null,null,null,"Haberlova, Jana; Seeman, Pavel",null,"Utility of Charcot-Marie-Tooth Neuropathy Score in Children With Type 1A Disease","PEDIATRIC NEUROLOGY",null,"English","Article",null,null,null,null,null,null,"DUPLICATION","The aim of this study was to evaluate the utility of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) for evaluation of disease severity in young children with Charcot-Marie-Tooth type 1A. Current validated scoring scales for Charcot-Marie-Tooth are the CMTNS and the Neuropathy Impairment Score (NIS). Both work well for adult patients, and usually also for children over 10 years of age. There is no validation of scales for young children. Children with genetically proven Charcot-Marie-Tooth type 1A disease (n = 20, aged 3 to 10 years) were examined clinically, followed by electrophysiologic examination, and were scored under the CMTNS scale. The clinical symptoms were mild; the two most frequent symptoms were difficulty in heel walking and lower limb areflexia. The score was maximally abnormal in four of the nine categories. Categories for sensation, sensory symptoms, and motor symptoms of the arms were normal in all cases. The score was below 8 for all tested children. To conclude, the CMTNS in children aged 10 years and younger has limited sensitivity; out of nine categories, only four are useful. Thus, evaluation of disease severity and progression in young children with Charcot-Marie-Tooth disease remains limited, and there is need for other, effective scoring systems. (C) 2010 by Elsevier Inc. All rights reserved.","[Haberlova, Jana] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15006, Czech Republic; [Haberlova, Jana] Charles Univ Prague, Univ Hosp Motol, Prague 15006, Czech Republic","Haberlova, J, Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, V Uvalu 84, Prague 15006, Czech Republic","jana.haberlova@gmail.com","[IGA MZ NR 9517-3]","This work was supported under IGA MZ NR 9517-3.",null,14,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0887-8994",null,"10.1016/j.pediatrneurol.2010.06.004","PEDIAT NEUROL","Pediatr. Neurol.","DEC",2010,43,6,null,null,null,407,410,null,null,4,"Clinical Neurology; Pediatrics","691JY","ISI:000285077300005"]
["nemá","J","Pochop, P; Darsova, D; Kukacka, J; Tesfaye, H; Vajner, L; Uhlik, J; Kodetova, D; Malis, J; Dotrelova, D",null,null,null,"Pochop, Pavel; Darsova, Denisa; Kukacka, Jiri; Tesfaye, Hundie; Vajner, Ludek; Uhlik, Jiri; Kodetova, Daniela; Malis, Josef; Dotrelova, Dagmar",null,"Intravitreal carboplatin concentration and area under concentration versus time curve after intravitreal and periocular delivery","EUROPEAN JOURNAL OF OPHTHALMOLOGY",null,"English","Proceedings Paper","17th Congress of the SOE","JUN 13-16, 2009","Amsterdam, NETHERLANDS","SOE",null,"AUC; Carboplatin concentration; Local treatment; Intravitreal seeding; Periocular injection; Rabbit; Retinoblastoma; Transcorneal","TRANSGENIC MURINE RETINOBLASTOMA; SUBCONJUNCTIVAL CARBOPLATIN; INTRAOCULAR RETINOBLASTOMA; CHEMOTHERAPY; PHARMACOKINETICS; CRYOTHERAPY; THERAPY; EYE","PURPOSE. To determine platinum (Pt) concentrations and area under the concentration versus time curve (AUC) of the vitreous humor after periocular or transcorneal intravitreal administration of carboplatin in rabbits. METHODS. Eighteen albino rabbits were included in an in vivo experiment. Each animal received a single dose of either 30 mg of carboplatin by periocular injection (POI30 group: n=6) or 15 mg by periocular injection (POI15 group: n=6), or 0.05 mg by transcorneal intravitreal injection (TII group: n=6), respectively, into the right eye. Vitreous humor from the right eyes and plasma samples were collected post dose at 1, 2, 6, 24, 48, 168, and 336 hours or 448 hours, respectively. Flameless atomic absorption spectroscopy was employed to analyze total platinum concentrations in blood and vitreous humor AUC was calculated using the trapezoidal rule. RESULTS. Pt concentration was mostly <1 mg/L (0-3.15 mg/L) in the vitreous humor samples and >= 2 mg/L (2.33-7.3 mg/L) in the blood samples 1 hour after administration in POI groups. Markedly higher Pt concentrations were found 1 hour after intravitreal (Ill) administration (10.285-66.759 mg/L) and decreased below 1 mg/L no less than 168 hours after administration. The mean AUC for Pt in vitreous humor was significantly lower (p=0.0001) after both POI30 and POI15 administration compared to TII route (8.955 +/- 2.464 mg/L/min). CONCLUSIONS. These findings proved that intravitreal carboplatin delivery enables the achievement of relatively stable concentrations and AUC of platinum in the rabbit vitreous humor This moreover suggests that transcorneal intravitreal delivery of carboplatin aiming to treat retinoblastoma vitreous seeding is a promising mode of chemotherapy. (Eur J Ophthalmol 2010; 20: 745-51)","[Pochop, Pavel; Darsova, Denisa; Dotrelova, Dagmar] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Prague 15006 5, Czech Republic; [Kukacka, Jiri; Tesfaye, Hundie] Charles Univ Prague, Fac Med 2, Div Clin Pharm, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, Prague 15006 5, Czech Republic; [Kodetova, Daniela] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Malis, Josef] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic","Pochop, P, Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Uvalu 84, Prague 15006 5, Czech Republic","pavel.pochop@gmail.com",null,null,null,13,0,"WICHTIG EDITORE","MILAN","72/74 VIA FRIULI, 20135 MILAN, ITALY","1120-6721",null,null,"EUR J OPHTHALMOL","Eur. J. Ophthalmol.","JUL-AUG",2010,20,4,null,null,null,745,751,null,null,7,"Ophthalmology","629JF","ISI:000280191600016"]
["nemá","J","Bartakova, LV; Fila, L; Adamek, S; Pozniak, J; Maly, M; Burkert, J; Simonek, J; Lischke, R",null,null,null,"Bartakova, L. V.; Fila, L.; Adamek, S.; Pozniak, J.; Maly, M.; Burkert, J.; Simonek, J.; Lischke, R.",null,"Lung Transplantation in Cystic Fibrosis Patients in the Czech Republic: Initial Single-Center Experience","TRANSPLANTATION PROCEEDINGS",null,"English","Article",null,null,null,null,null,null,"BURKHOLDERIA-CEPACIA COMPLEX; INTERNATIONAL-SOCIETY; SURVIVAL; INFECTION; HEART","Background. Lung transplantation is a well established treatment for advanced lung diseases. Methods. We compared the clinical results of patients with cystic fibrosis (CF) entered into the waiting list with those of patients after lung transplantation. Results. Among 36 patients with CF on the waiting list, 23 underwent lung transplantation, 8 died, 3 are still on the waiting list, and 2 were excluded from the waiting list. The median waiting list time of 0.48 years (range, 0.03-2.37) was insignificantly longer for patients who died compared with transplanted patients (0.97 vs 0.44 years). Mortality of waiting-list patients was 25.8%. The median survival of transplant patients of 7.48 years (range 0.00-10.85 years) was significantly lower among patients who were colonized (BCC) versus those who were not Burkholderia cepacia complex (0.19 vs 7.48 years; P = .041). The 1-, 3-, and 5-year patient survivals after lung transplantation were 72.9, 54.4, and 54.4, respectively. Conclusion. The results of patients with cystic fibrosis on the waiting list versus after lung transplantation in our center were similar to those reported in the literature. We confirmed a less favorable prognosis of BCC-colonized patients.","[Lischke, R.] Univ Hosp Motol, Thorac & Lung Transplantat Div, Transplantat Ctr, Prague, Czech Republic; [Bartakova, L. V.; Fila, L.] Charles Univ Prague, Sch Med 2, Dept Pulmonol, Prague, Czech Republic; [Burkert, J.] Charles Univ Prague, Sch Med 2, Dept Cardiac Surg, Prague, Czech Republic; [Adamek, S.; Pozniak, J.; Simonek, J.; Lischke, R.] Charles Univ Prague, Sch Med 1, Dept Surg 3, Thorac & Lung Transplantat Div, Prague, Czech Republic; [Maly, M.] Natl Inst Publ Hlth, Dept Biostat & Informat, Prague, Czech Republic","Lischke, R, Univ Hosp Motol, Thorac & Lung Transplantat Div, Transplantat Ctr, V Uvalu 85, Prague, Czech Republic",null,"VZ grant [00000064203]","Supported by VZ grant no. 00000064203.",null,17,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0041-1345",null,"10.1016/j.transproceed.2010.09.007","TRANSPLANT PROC","Transplant. Proc.","NOV",2010,42,9,null,null,null,3711,3713,null,null,3,"Immunology; Surgery; Transplantation","689ZO","ISI:000284969800067"]
["nemá","J","Pruhova, S; Dusatkova, P; Sumnik, Z; Kolouskova, S; Pedersen, O; Hansen, T; Cinek, O; Lebl, J",null,null,null,"Pruhova, Stepanka; Dusatkova, Petra; Sumnik, Zdenek; Kolouskova, Stanislava; Pedersen, Oluf; Hansen, Torben; Cinek, Ondrej; Lebl, Jan",null,"Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations","PEDIATRIC DIABETES",null,"English","Article",null,null,null,null,null,"dHPLC; diabetes; founder effect; GCK-MODY; glucokinase","MODY; YOUNG; GENE; IDENTIFICATION; HNF-1-ALPHA; DIAGNOSIS; CHILDREN; POLYMORPHISMS; MELLITUS","Background: Glucokinase diabetes, also called GCK-MODY or maturity-onset diabetes of the young type 2 (MODY2), is caused by heterozygous mutations in the gene encoding glucokinase (GCK). Objective: The aim of study was to investigate the current prevalence of GCK mutations in a large cohort of Czech patients with typical clinical appearance of GCK-MODY. In addition, we reanalyzed the negative results obtained previously by screening using the denaturing high-performance liquid chromatography (dHPLC). Methods: We studied 140 unrelated Czech probands with clinical picture of GCK-MODY who were referred to our center from the whole of the Czech Republic between the years 1999-2009 by direct sequencing of GCK gene. Results: A mutation in GCK was identified in 103 of 140 probands (74%). We identified 46 different GCK mutations of which 13 were novel. Several mutations were detected in multiple families: p.Glu40Lys (20 families), p.Gly318Arg (12), p.Leu315His (7) and p.Val33Ala (six families). Direct sequencing detected a GCK mutations in 9 of 20 previously dHPLC-negative samples; the sensitivity of the dHPLC screening was calculated as 84%. Conclusions: The study shows a relatively high proportion of GCK mutations among individuals with GCK-like phenotype, confirming the effectiveness of carefully applied clinical criteria prior to genetic testing. In the Czech MODY registry, GCK-MODY represents the biggest subgroup of MODY (35%). We report several prevalent GCK mutations with a likely founder effect in the Czech population. Furthermore, our results provide ground for a possible recommendation to reinspect all negative results previously obtained by screening using dHPLC.","[Pruhova, Stepanka; Dusatkova, Petra; Sumnik, Zdenek; Kolouskova, Stanislava; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Pruhova, Stepanka] Charles Univ Prague, Dept Pediat, Univ Hosp Kralovske Vinohrady, CZ-15006 Prague, Czech Republic; [Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Pedersen, Oluf] Univ Aarhus, Aarhus, Denmark; [Pedersen, Oluf] Univ Copenhagen, Inst Biomed Sci, Copenhagen, Denmark; [Hansen, Torben] Univ So Denmark, Odense, Denmark","Lebl, J, Charles Univ Prague, Dept Pediat, Univ Hosp Motol, V Uvalu 84, CZ-15006 Prague, Czech Republic","jan.lebl@lfmotol.cuni.cz","Norway through the Norwegian Financial Mechanism [CZ0100]; Czech Ministry of Health [MZ000064203]","The study was supported by a grant 'Monogenic diabetes in childhood: from genetics to therapy' from Norway through the Norwegian Financial Mechanism (No CZ0100) and by an institutional grant from the Czech Ministry of Health (grant MZ000064203).",null,25,1,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,"10.1111/j.1399-5448.2010.00646.x","PEDIATR DIABETES","Pediatr. Diabetes","DEC",2010,11,8,null,null,null,529,535,null,null,7,"Endocrinology & Metabolism; Pediatrics","688NA","ISI:000284854900004"]
["nemá","J","Bojar, M; Zajac, M; Meluzinova, E; Houzvickova, E; Libertinova, J; Liskova, P; Mat'oska, V; Nyc, O; Minarikova, M",null,null,null,"Bojar, M.; Zajac, M.; Meluzinova, E.; Houzvickova, E.; Libertinova, J.; Liskova, P.; Mat'oska, V.; Nyc, O.; Minarikova, M.",null,"Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis","MULTIPLE SCLEROSIS",null,"English","Letter",null,null,null,null,null,null,"NEUTRALIZING ANTIBODIES; INTERFERON-BETA",null,"[Bojar, M.; Meluzinova, E.; Houzvickova, E.; Libertinova, J.; Liskova, P.; Minarikova, M.] Charles Univ Prague, Dept Neurol, Prague Med Sch 2, Univ Hosp Motol, Prague, Czech Republic; [Zajac, M.; Nyc, O.] Charles Univ Prague, Inst Clin Microbiol, Prague Med Sch 2, Univ Hosp Motol, Prague, Czech Republic; [Mat'oska, V.] Hosp Na Homolce, Lab Mol Diagnost, Prague, Czech Republic","Bojar, M, Charles Univ Prague, Dept Neurol, Prague Med Sch 2, Univ Hosp Motol, Prague, Czech Republic","martin.bojar@lfmotol.cuni.cz",null,null,null,6,0,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","1352-4585",null,"10.1177/1352458510382248","MULT SCLER","Mult. Scler.","DEC",2010,16,12,null,null,null,1529,1530,null,null,2,"Clinical Neurology","687EW","ISI:000284762800018"]
["nemá","J","Kutil, B; Ostadal, P; Vejvoda, J; Kukacka, J; Cepova, J; Alan, D; Kruger, A; Vondrakova, D",null,null,null,"Kutil, Barbara; Ostadal, Petr; Vejvoda, Jiri; Kukacka, Jiri; Cepova, Jana; Alan, David; Krueger, Andreas; Vondrakova, Dagmar",null,"Alterations in serum selenium levels and their relation to troponin I in acute myocardial infarction","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,"English","Article",null,null,null,null,null,"Selenium; Acute coronary syndrome; Myocardial infarction; Troponin I","ISCHEMIA-REPERFUSION INJURY; CARDIOVASCULAR-DISEASES; OXIDATIVE STRESS; TRACE-ELEMENTS; CARDIAC TISSUE; RISK; RAT","Selenium (Se) is an essential trace element with antioxidant function. The aim of the present study was to estimate the alterations of Se serum level during the acute phase of myocardial infarction and its relation to biomarkers of myocardial necrosis. Serum Se levels were measured at admission and after 24 h in 60 consecutive patients with acute coronary syndrome (both with and without ST elevation). Troponin I (TnI) was assessed at admission and then twice daily for 3 days; patients with normal levels were excluded. Fifty-five patients with acute MI (positive TnI) were included into the analysis. During the first day of hospitalization, patients received standard therapy, including acetylsalicylic acid, clopidogrel, and heparin or enoxaparin; all underwent urgent coronary angiography and percutaneous intervention, when appropriate. Mean Se levels at baseline and 24 h later were comparable (67.1 +/- 2.1 vs. 67.2 +/- 1.8 mu g/L, ns). Linear regression has shown significant correlation between baseline Se levels and peak TnI (y = 3.4x - 116, r(2) = 0.13, P = 0.008). Positive correlation was found also between the peak TnI and the difference from baseline to 24 h (y = 2.2x + 115, r(2) = 0.08, P = 0.04). Moreover, close negative correlation was observed between baseline Se levels and the difference from baseline to 24 h (y = -0.9x + 62.7, r(2) = 0.55, P < 0.001). Our results have shown marked individual changes in Se levels during the acute phase of MI as well as correlation between Se levels and peak TnI. These results suggest that alterations in serum Se may be related to the extent of myocardial infarction.","[Kutil, Barbara; Ostadal, Petr; Krueger, Andreas; Vondrakova, Dagmar] Na Homolce Hosp, Dept Cardiol, Ctr Cardiovasc, Prague 15030, Czech Republic; [Kutil, Barbara] Charite, D-13353 Berlin, Germany; [Vejvoda, Jiri; Alan, David] Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Prague, Czech Republic; [Kukacka, Jiri; Cepova, Jana] Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Prague, Czech Republic","Ostadal, P, Na Homolce Hosp, Dept Cardiol, Ctr Cardiovasc, Roentgenova 2, Prague 15030, Czech Republic","ostadal@yahoo.com","Czech Ministry of Health [00000064203]","This study was supported by the grant of the Czech Ministry of Health, Nr. 00000064203.",null,24,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,"10.1007/s11010-010-0555-x","MOL CELL BIOCHEM","Mol. Cell. Biochem.","DEC",2010,345,"2011-02-01",null,null,null,23,27,null,null,5,"Cell Biology","689DI","ISI:000284907100003"]
["nemá","J","Cejka, C; Ardan, T; Sirc, J; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, Cestmir; Ardan, Taras; Sirc, Jakub; Michalek, Jiri; Brunova, Blanka; Cejkova, Jitka",null,"The influence of various toxic effects on the cornea and changes in corneal light transmission","GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY",null,"English","Article",null,null,null,null,null,"Spectrophotometric method; Corneal hydration; Corneal light transmission","RABBIT CORNEA; ULTRAVIOLET-B; UVB RAYS; HUMAN EYES; TRANSPARENCY; EXPRESSION; ALKALI; LENS; ENDOTHELIUM; IRRADIATION","Purpose Normal corneal hydration is necessary for the maintenance of corneal transparency. Damage of the corneal epithelium or endothelium by various external influences disturbs the mechanism by which the cornea maintains normal hydration and transparency. The cornea swells, and the corneal thickness increases, resulting in increased scatter and the development of corneal opacity. The transmission of light across the cornea is changed. The purpose of this study is to investigate spectrophotometrically the corneal light transmission under the influence of the various factors affecting the cornea. Methods We developed a spectrophotometric method to measure the light transmission across the cornea under the influence of various factors affecting the cornea, such as treatment with 0.9% NaCl, saline, or phosphate buffered saline (PBS), solutions employed as placebo eye drops (negative controls) in experimental studies, agents toxic to the cornea, such as diluted acids or alkalis. The method distinguishes between changes in corneal light transmission caused by altered corneal thickness (the level of hydration) and changes resulting from other corneal disturbances which in turn affect corneal light transmission. Results The results obtained show that the corneal light transmission is decreased following the application of toxic substances on the corneal surface. This decrease is highly dependent on the severity of the corneal injury evoked by individual noxes, and the resulting changes in corneal hydration and transparency. Conclusions The influence of various influences applied to the cornea, manifested as changes in corneal light transmission, can be measured using our spectrophotometric method with a high degree of sensitivity.","[Cejka, Cestmir; Ardan, Taras; Cejkova, Jitka] Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Ctr Excellence, Prague 14220 4, Czech Republic; [Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Dept Hydrogels Med, Prague 5, Czech Republic; [Cejka, Cestmir; Brunova, Blanka] Charles Univ Prague, Eye Clin Children & Adults, Fac Med 2, Prague 5, Motol, Czech Republic","Cejkova, J, Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Ctr Excellence, Videnska 1083, Prague 14220 4, Czech Republic","cestmir.cejka@seznam.cz; ardan@biomed.cas.cz; sirc@imc.cas.cz; jiri@imc.cas.cz; brunova.blanka@post.cz; cejkova@biomed.cas.cz","Academy of Sciences of the Czech Republic [AVOZ50390512]","Supported by a grant from the Academy of Sciences of the Czech Republic AVOZ50390512",null,52,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0721-832X",null,"10.1007/s00417-010-1438-2","GRAEF ARCH CLIN EXP OPHTHAL","Graefes Arch. Clin. Exp. Ophthalmol.","DEC",2010,248,12,null,null,null,1749,1756,null,null,8,"Ophthalmology","687WW","ISI:000284810000009"]
["nemá","J","Soukup, J; Papezova, H; Kubena, AA; Mikolajova, V",null,null,null,"Soukup, J.; Papezova, H.; Kubena, A. A.; Mikolajova, V.",null,"Dissociation in non-clinical and clinical sample of Czech adolescents. Reliability and validity of the Czech version of the Adolescent Dissociative Experiences Scale","EUROPEAN PSYCHIATRY",null,"English","Article",null,null,null,null,null,"A-DES; Dissociation; ADHD; Adolescents; Intercultural","CHILDHOOD SEXUAL-ABUSE; GENERAL-POPULATION; SOMATOFORM DISSOCIATION; PSYCHOMETRIC CHARACTERISTICS; AFFECT DYSREGULATION; TRAUMA; SYMPTOMS; QUESTIONNAIRE; STUDENTS; CHILDREN","Objective. - The purpose of this study was to examine psychometric properties of the Czech language version of the Adolescent Dissociative Experiences Scale (A-DES) [2]. Method. - 653 non-clinical participants and 162 adolescent psychiatric inpatients completed Czech versions of the A-DES and the Somatoform Dissociation Questionnaire (SDQ-20), and provided further information (data regarding demographic variables, diagnoses, further psychopathology). Results. - The Czech A-DES has very good internal consistency, test-retest reliability and a good validity, though its predictive power is limited. The ADES scores significantly correlate with the measure of somatoform dissociation, a presence of clinician-observed dissociative symptoms, reported traumatic experiences, self injurious behavior, and polysymptomatic diagnostic picture. A-DES scores were significantly higher in ADHD group, but not in a group with a diagnosis of a dissociative disorder. Conclusion. - The authors stress that all adolescent psychiatric patients who show more complex behavioral disturbances, have histories of trauma, show self-injurious behaviors or have ADHD diagnosis should be screened for dissociation. (C) 2010 Elsevier Masson SAS. All rights reserved.","[Soukup, J.] Gen Teaching Hosp, Dependency Treatment Ctr, Prague, Czech Republic; [Papezova, H.] Charles Univ Prague, Med Sch 1, Psychiat Clin, Prague, Czech Republic; [Kubena, A. A.] Charles Univ Prague, Sch Pharm, Dept Social & Clin Pharm, Hradec Kralove, Czech Republic; [Kubena, A. A.] Charles Univ Prague, Sch Nat Sci, Dept Philosophy & Hist Sci, Prague, Czech Republic; [Mikolajova, V.] Charles Univ Prague, Med Sch 2, Child Psychiat Clin, Prague, Czech Republic","Soukup, J, Oddeleni Lecby Zavislosti VFN, Apolinarska 4, Prague 12000, Czech Republic","honzasoukup@yahoo.com",null,null,null,35,0,"ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER","PARIS","23 RUE LINOIS, 75724 PARIS, FRANCE","0924-9338",null,"10.1016/j.eurpsy.2010.03.011","EUR PSYCHIAT","Eur. Psychiat.","NOV",2010,25,7,null,null,null,390,395,null,null,6,"Psychiatry","689IH","ISI:000284920800005"]
["nemá","J","Krsek, P; Jahodova, A; Maton, B; Jayakar, P; Dean, P; Korman, B; Rey, G; Dunoyer, C; Vinters, HV; Resnick, T; Duchowny, M",null,null,null,"Krsek, Pavel; Jahodova, Alena; Maton, Bruno; Jayakar, Prasanna; Dean, Patricia; Korman, Brandon; Rey, Gustavo; Dunoyer, Catalina; Vinters, Harry V.; Resnick, Trevor; Duchowny, Michael",null,"Low-grade focal cortical dysplasia is associated with prenatal and perinatal brain injury","EPILEPSIA",null,"English","Article",null,null,null,null,null,"Cortical dysplasia; Epilepsy surgery; MRI; EEG; Neuropsychological assessment","NEURONAL MIGRATION DISORDERS; DEVELOPMENTAL NEUROPATHOLOGY; PEDIATRIC EPILEPSY; CEREBRAL-PALSY; MATTER LESIONS; WHITE-MATTER; MALFORMATIONS; CHILDREN; DAMAGE; CLASSIFICATION","P>Purpose: Prenatal and perinatal adverse events are reported to have a pathogenetic role in focal cortical dysplasia (FCD). However, no data are available regarding the prevalence and significance of this association. A cohort of children with significant prenatal and perinatal brain injury and histologically proven mild malformations of cortical development (mMCD) or FCD was analyzed. Methods: We retrospectively evaluated a surgical series of 200 patients with histologically confirmed mMCD/FCD. Combined historical and radiologic inclusion criteria were used to identify patients with prenatal and perinatal risk factors. Electroclinical, imaging, neuropsychological, surgical, histopathologic, and seizure outcome data were reviewed. Results: Prenatal and perinatal insults including severe prematurity, asphyxia, bleeding, hydrocephalus, and stroke occurred in 12.5% of children with mMCD/FCD (n = 25). Their epilepsy was characterized by early seizure onset, high seizure frequency, and absence of seizure control. Patients with significant prenatal and perinatal risk factors had more abnormal neurologic findings, lower intelligence quotient (IQ) scores, and slower background EEG activity than mMCD/FCD subjects without prenatal or perinatal brain injury. MRI evidence of cortical malformations was identified in 74% of patients. Most patients underwent large multilobar resections or hemispherectomies; 54% were seizure-free 2 years after surgery. Histologically \"milder\" forms of cortical malformations (mMCD and FCD type I) were observed most commonly in our series. Conclusions: Surgically remediable low-grade cortical malformations may occur in children with significant prenatally and perinatally acquired encephalopathies and play an important role in the pathogenesis of their epilepsy. Presurgical detection of dysplastic cortex has important practical consequences for surgical planning.","[Duchowny, Michael] Univ Miami, Miller Sch Med, Miami Childrens Hosp, Dept Neurol,Brain Inst, Miami, FL 33136 USA; [Krsek, Pavel; Jahodova, Alena] Charles Univ Prague, Motol Univ Hosp, Sch Med 2, Dept Pediat Neurol, Prague, Czech Republic; [Maton, Bruno; Jayakar, Prasanna; Dean, Patricia; Dunoyer, Catalina; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Inst Brain, Comprehens Epilepsy Program, Miami, FL USA; [Korman, Brandon; Rey, Gustavo] Miami Childrens Hosp, Inst Brain, Neuropsychol Sect, Miami, FL USA; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA","Duchowny, M, Univ Miami, Miller Sch Med, Miami Childrens Hosp, Dept Neurol,Brain Inst, 3200 SW 60th Court, Miami, FL 33136 USA","michael.duchowny@mch.com","Kontakt Program [ME09042]; Daljit S. & Elaine Sarkaria Chair in Diagnostic Medicine ; [MZOFNM2005]","Supported by grants MZOFNM2005 and Kontakt Program ME09042. HV Vinters supported by the Daljit S. & Elaine Sarkaria Chair in Diagnostic Medicine. Statistical analysis was conducted by Zbynek Hrncir, MSc.",null,46,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,"10.1111/j.1528-1167.2010.02730.x","EPILEPSIA","Epilepsia","DEC",2010,51,12,null,null,null,2440,2448,null,null,9,"Clinical Neurology","688KU","ISI:000284849000011"]
["nemá","J","Kujal, P; Chabova, VC; Vernerova, Z; Walkowska, A; Kompanowska-Jezierska, E; Sadowski, J; Vanourkova, Z; Huskova, Z; Opocensky, M; Skaroupkova, P; Schejbalova, S; Kramer, HJ; Rakusan, D; Maly, J; Netuka, I; Vaneckova, I; Kopkan, L; Cervenka, L",null,null,null,"Kujal, Petr; Chabova, Vera Certikova; Vernerova, Zdenka; Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Vanourkova, Zdenka; Huskova, Zuzana; Opocensky, Martin; Skaroupkova, Petra; Schejbalova, Stanislava; Kramer, Herbert J.; Rakusan, Dan; Maly, Jan; Netuka, Ivan; Vaneckova, Ivana; Kopkan, Libor; Cervenka, Ludek",null,"Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?","CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY",null,"English","Article",null,null,null,null,null,"alpha and beta adrenergic receptor antagonist; angiotensin-converting enzyme inhibitor; angiotensin-II receptor antagonist type 1; end-organ damage; glomerulosclerosis; hypertension; renin-angiotensin-aldosterone system; renoprotection","CONVERTING ENZYME-INHIBITORS; PROGRESSIVE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; END-ORGAN DAMAGE; INTRARENAL ANGIOTENSIN; GLOMERULAR INJURY; HYPERTENSIVE RATS; OXIDATIVE STRESS; SYSTEM BLOCKADE; MASS REDUCTION","P>1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a 'RAS-independent' antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD.","[Kujal, Petr; Chabova, Vera Certikova; Vanourkova, Zdenka; Huskova, Zuzana; Opocensky, Martin; Skaroupkova, Petra; Schejbalova, Stanislava; Rakusan, Dan; Maly, Jan; Kopkan, Libor; Cervenka, Ludek] Charles Univ Prague, Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Fac Med 3, Dept Pathol, CZ-14000 Prague, Czech Republic; [Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Charles Univ Prague, Fac Med 1, Dept Nephrol, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, CZ-14000 Prague 4, Czech Republic; [Kujal, Petr; Chabova, Vera Certikova; Vanourkova, Zdenka; Huskova, Zuzana; Rakusan, Dan; Netuka, Ivan; Vaneckova, Ivana; Kopkan, Libor; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Chabova, Vera Certikova] Polish Acad Sci, Mossakowski Med Res Ctr, Lab Renal & Body Fluid Physiol, Warsaw, Poland; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany","Cervenka, L, Charles Univ Prague, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Czech Science Foundation (GACR) [305/08/J006]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/10500-3, NS/10499-3, NS/9703-4, NS/9699-4]; German Research Foundation (DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; Grant Agency of Academy of Science of Czech Republic (GAAV) [KJB 502030801]; EU [CZ.2.16/3.1.00/22126]; GACR [305/07/0167, 305/07/J004]","This study was supported by grant No. 305/08/J006 awarded to LC by Czech Science Foundation (GACR). PK, JM, MO and IN. are supported by the Center for Cardiovascular Research (1M6798582302) and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). VCC is supported by grant No. NS/10500-3 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. ZV is supported by grant No. NS/10499-3 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. IV is supported by grants from GACR No. 305/07/0167 and No. 305/07/J004. HJK is supported by grants from the German Research Foundation (DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1). ZH is supported by grant No. 305/08/P053 awarded by GACR. LC is also supported by grants No. NS/9703-4 and NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. LK is supported by grant No. KJB 502030801 awarded by Grant Agency of Academy of Science of Czech Republic (GAAV). This study also received financial support from the EU by the Operational Program Prague - Competitiveness; project 'CEVKOON' (#CZ.2.16/3.1.00/22126).",null,55,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0305-1870",null,"10.1111/j.1440-1681.2010.05453.x","CLIN EXP PHARMACOL PHYSIOL","Clin. Exp. Pharmacol. Physiol.","DEC",2010,37,12,null,null,null,1159,1169,null,null,11,"Pharmacology & Pharmacy; Physiology","687HF","ISI:000284768900010"]
["nemá","J","Horak, Z; Pokorny, D; Fulin, P; Slouf, M; Jahoda, D; Sosna, A",null,null,null,"Horak, Z.; Pokorny, D.; Fulin, P.; Slouf, M.; Jahoda, D.; Sosna, A.",null,"Polyetheretherketone (PEEK). Part I: Prospects for Use in Orthopaedics and Traumatology","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Review",null,null,null,null,null,"PAEK; PEEK; polyetheretherketone; joint replacement; total hip arthroplasty","INTERBODY LUMBAR FUSION; TOTAL HIP-ARTHROPLASTY; CARBON-FIBER IMPLANT; PEEK; BIOCOMPATIBILITY; CRYSTALLIZATION; IRRADIATION; COMPOSITES; EXPERIENCE; MORPHOLOGY","On the basis of current studies, polyaryletherketone (PAEK) polymers appear to be materials with great prospects for medical application. The most important member of this family of semi-crystalline thermoplastics is polyetheretherketone (PEEK) with its composites. The excellent properties of this material find their use in the treatment of various disorders of the skeletal system. At present they are used with advantage to construct spinal implants, and replacements for other orthopaedic applications and for dental and trauma medicine are at advanced stages of clinical testing.","[Pokorny, D.; Jahoda, D.; Sosna, A.] I Ortoped Klin 1 LF UK, FN Motol, Prague 5, Czech Republic; [Horak, Z.] Ustav Makromol Chem AV CR, Skupina Vyvoje Recyklace Polymernich Mat, Prague, Czech Republic; [Fulin, P.] PGS, 1 Lekarska Fak UK, Prague, Czech Republic; [Slouf, M.] Ustav Makromol Chem AV CR, Skupina Morfol Polymeru, Prague, Czech Republic","Pokorny, D, I Ortoped Klin 1 LF UK, FN Motol, V Uvalu 84, Prague 5, Czech Republic","david.pokorny@LF1.cuni.cz",null,null,null,37,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2010,77,6,null,null,null,463,469,null,null,7,"Orthopedics","704US","ISI:000286081700004"]
["nemá","J","Rakusan, D; Burgelova, M; Vaneckova, I; Vanourkova, Z; Huskova, Z; Skaroupkova, P; Mrazova, I; Opocensky, M; Kramer, HJ; Netuka, I; Maly, J; Alenina, N; Bader, M; Santos, RAS; Cervenka, L",null,null,null,"Rakusan, Dan; Buergelova, Marcela; Vaneckova, Ivana; Vanourkova, Zdenka; Huskova, Zuzana; Skaroupkova, Petra; Mrazova, Iveta; Opocensky, Martin; Kramer, Herbert J.; Netuka, Ivan; Maly, Jan; Alenina, Natalia; Bader, Michael; Santos, Robson A. S.; Cervenka, Ludek",null,"Knockout of Angiotensin 1-7 Receptor Mas Worsens the Course of Two-Kidney, One-Clip Goldblatt Hypertension: Roles of Nitric Oxide Deficiency and Enhanced Vascular Responsiveness to Angiotensin II","KIDNEY & BLOOD PRESSURE RESEARCH",null,"English","Article",null,null,null,null,null,"Two-kidney, one-clip Goldblatt hypertension; Mas receptor knockout mice; Nitric oxide deficiency","REN-2 TRANSGENIC RATS; RENAL FUNCTIONAL-RESPONSES; END-ORGAN DAMAGE; BLOOD-PRESSURE; DEPENDENT HYPERTENSION; OXIDATIVE STRESS; INTRARENAL INFUSION; NORMOTENSIVE RATS; KIDNEY-DISEASE; MICE","Aims: The present study was performed to evaluate the effects of target disruption of the G-protein-coupled receptor Mas for angiotensin 1-7 [Ang(1-7)] in knockout mice on the course of two-kidney, one-clip (2K1C) Goldblatt hypertension. Methods: Knockout and wild-type mice underwent clipping of one renal artery. Blood pressure (BP) was monitored by radiotelemetry. The mice were either untreated or chronically treated with the superoxide (O-2(-)) scavenger tempol (400 mg/l) or the inhibitor of NADPH oxidase apocynin (1 g/l) administered in drinking water. Results: Knockout mice responded to clipping by accelerated increases in BP and the final BP was significantly higher than that in wildtype mice. Chronic treatment with tempol or apocynin elicited similar antihypertensive effects in 2K1C/knockout as in 2K1C/wild-type mice. Acute nitric oxide synthase inhibition caused greater BP increases in 2K1C/wild-type than in 2K1C/knockout mice. Conclusion: Our present findings support the notion that the angiotensin-converting enzyme 2-Ang(1-7)-Mas axis serves as an important endogenous physiological counterbalancing mechanism that partially attenuates the hypertensinogenic actions of the activated renin-angiotensin system. The impairment in this axis may contribute to the deterioration of the course of 2K1C Goldblatt hypertension. Copyright (C) 2010 S. Karger AG, Basel","[Rakusan, Dan; Vaneckova, Ivana; Vanourkova, Zdenka; Huskova, Zuzana; Skaroupkova, Petra; Mrazova, Iveta; Opocensky, Martin; Maly, Jan; Cervenka, Ludek] Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Rakusan, Dan] Charles Univ Prague, Dept Med 1, Thomayer Teaching Hosp, CZ-14000 Prague 4, Czech Republic; [Buergelova, Marcela] Charles Univ Prague, Dept Nephrol, Transplant Ctr, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Vaneckova, Ivana; Vanourkova, Zdenka; Huskova, Zuzana; Netuka, Ivan; Cervenka, Ludek] Charles Univ Prague, Cardiovasc Res Ctr, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, CZ-14000 Prague 4, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany; [Alenina, Natalia; Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany; [Santos, Robson A. S.] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil","Cervenka, L, Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic","luce@medicon.cz","Grant Agency of Academy of Science of Czech Republic (GAAV) [IAA 511-700-701]; EU [CZ.2.16/3.1.00/22126]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Czech Science Foundation (GACR) [305/08/J006, 305/07/0167, 305/07/J004, 305/08/P053]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/10499-3, NS/9703-4]; German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]","This study was supported by grant No. IAA 511-700-701 awarded to M.B. by the Grant Agency of Academy of Science of Czech Republic (GAAV). This study was also financially supported by the EU by the Operational Program Prague Competitiveness, project 'CEVKOON' (No. CZ.2.16/3.1.00/22126). Z.V. and I.N. are partly supported by the Center for Cardiovascular Research (1M6798582302). L.C. receives institutional financial support from the Institute for Clinical and Experimental Medicine (MZO 00023001) and by grant No. 305/08/J006 awarded by the Czech Science Foundation (GACR) and by grant NS/10499-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic. I.V. is supported by grants No. 305/07/0167 and No. 305/07/J004 awarded by GACR and by grant NS/9703-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. Z.H. is supported by grant No. 305/08/P053 awarded by GACR. H.J. Kramer is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1).",null,43,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,"10.1159/000320689","KIDNEY BLOOD PRESSURE RES","Kidney Blood Pressure Res.",null,2010,35,6,null,null,null,476,488,null,null,13,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","699ZQ","ISI:000285702300054"]
["nemá","J","Humlova, Z; Klamova, H; Janatkova, I; Malickova, K; Kralikova, P; Sterzl, I; Roth, Z; Hamsikova, E; Vonka, V",null,null,null,"Humlova, Zuzana; Klamova, Hana; Janatkova, Ivana; Malickova, Karin; Kralikova, Petra; Sterzl, Ivan; Roth, Zdenek; Hamsikova, Eva; Vonka, Vladimir",null,"Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment","CLINICAL & DEVELOPMENTAL IMMUNOLOGY",null,"English","Article",null,null,null,null,null,null,"CHRONIC MYELOGENOUS LEUKEMIA; DERMATOMYOSITIS-LIKE ERUPTION; DOSE-DEPENDENT MANNER; ABL-KINASE INHIBITOR; T-CELL PROLIFERATION; C-REACTIVE PROTEIN; INTERFERON-ALPHA; IMATINIB MESYLATE; BCR-ABL; IFN-ALPHA","In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.","[Humlova, Zuzana; Sterzl, Ivan] Charles Univ Prague, Fac Med 1, Dept Immunol & Microbiol, Prague 12111 2, Czech Republic; [Humlova, Zuzana; Sterzl, Ivan] Gen Teaching Hosp Prague, Prague 12111 2, Czech Republic; [Humlova, Zuzana; Janatkova, Ivana; Malickova, Karin] Charles Univ Prague, Fac Med 1, Dept Clin Biochem & Lab Med, Prague 12111 2, Czech Republic; [Klamova, Hana] Inst Hematol & Blood Transfus, Clin Dept, CR-12820 Prague 2, Czech Republic; [Kralikova, Petra] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Roth, Zdenek] Natl Inst Hlth, Dept Biostat, Prague 10000 10, Czech Republic; [Hamsikova, Eva; Vonka, Vladimir] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic","Humlova, Z, Charles Univ Prague, Fac Med 1, Dept Immunol & Microbiol, Karlovo Namesti 32, Prague 12111 2, Czech Republic","zuzana.humlova@seznam.cz","Internal Granting Agency of the Ministry of Health, Czech Republic (IGA MZCR) [NC/6957-3, NR/9075-3]; Institute of Hematology and Blood Transfusion [000 273 3601]","Supported by grants from the Internal Granting Agency of the Ministry of Health, Czech Republic (IGA MZCR NC/6957-3, and NR/9075-3) and by Research Project No. 000 273 3601, Institute of Hematology and Blood Transfusion. The authors express their indebtedness to H. Tlaskalova for critical reading of the manuscript.",null,46,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1740-2522",null,"10.1155/2010/137320","CLIN DEV IMMUNOL","Clin. Dev. Immunol.",null,2010,null,null,null,null,null,null,null,137320,null,17,"Immunology","706QA","ISI:000286231700001"]
["nemá","J","Krizkova, S; Masarik, M; Majzlik, P; Kukacka, J; Kruseova, J; Adam, V; Prusa, R; Eckschlager, T; Stiborova, M; Kizek, R",null,null,null,"Krizkova, Sona; Masarik, Michal; Majzlik, Petr; Kukacka, Jiri; Kruseova, Jarmila; Adam, Vojtech; Prusa, Richard; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene",null,"Serum metallothionein in newly diagnosed patients with childhood solid tumours","ACTA BIOCHIMICA POLONICA",null,"English","Proceedings Paper","16th European Bioenergetics Conference","JUL 17-22, 2010","Warsaw, POLAND","Nencki Inst Expt Biol, Polish Biochem Soc, Sect Bioenerget","Univ Warsaw, Old Lib","metallothionein; cancer; serum; Brdicka reaction; marker","BRDICKA REACTION; BREAST-CANCER; GENE-EXPRESSION; BLOOD-SERUM; ORAL-CAVITY; CELL LINES; ANTIBODIES; MARKER; LEVEL; ZINC","Tumour markers are substances produced by malignant cells or by the organism as a response to cancer development. Determination of their levels can, therefore, be used to monitor the risk, presence and prognosis of a cancer disease or to monitor the therapeutic response or early detection of residual disease. Time-consuming imaging methods, examination of cerebrospinal fluid or tumour tissue and assays for hormones and tumour markers have been used for cancer diagnosis. However, no specific marker for diagnosis of childhood solid tumours has been discovered yet. In this study, metallothionein (MT) was evaluated as a prospective marker for such diseases. Serum metallothionein levels of patients with childhood solid tumours were determined using differential pulse voltammetry - Brdicka reaction. A more than 5-fold increase in the amount of metallothionein was found in sera of patients suffering from cancer disease, compared with those in sera of healthy donors. The average metallothionein level in the sera of healthy volunteers was 0.5 +/- 0.2 mu mol.dm(-3) and was significantly different (P<0.05, determined using the Schefe test) from the average MT level found in serum samples of patients suffering from childhood solid tumours (3.4 +/- 0.8 mu mol.dm(-3)). Results found in this work indicate that the MT level in blood serum can be considered as a promising marker for diagnostics, prognosis and estimation of therapy efficiency of childhood tumours.","[Krizkova, Sona; Majzlik, Petr; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Brno, Czech Republic; [Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, Brno, Czech Republic; [Kukacka, Jiri] Czech Tech Univ, Fac Biomed Engn, Dept Biomed Technol, CR-16635 Prague, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic; [Kukacka, Jiri; Kruseova, Jarmila; Prusa, Richard; Eckschlager, Tomas] Charles Univ Prague, Fac Hosp Motol, Prague, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, Prague, Czech Republic","Kizek, R, Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,58,0,"ACTA BIOCHIMICA POLONICA","WARSAW","PASTEURA 3, 02-093 WARSAW, POLAND","0001-527X",null,null,"ACTA BIOCHIM POL","Acta Biochim. Pol.",null,2010,57,4,null,null,null,561,566,null,null,6,"Biochemistry & Molecular Biology","700GP","ISI:000285726300023"]
["nemá","J","Krizkova, S; Masarik, M; Eckschlager, T; Adam, V; Kizek, R",null,null,null,"Krizkova, Sona; Masarik, Michal; Eckschlager, Tomas; Adam, Vojtech; Kizek, Rene",null,"Effects of redox conditions and zinc(II) ions on metallothionein aggregation revealed by chip capillary electrophoresis","JOURNAL OF CHROMATOGRAPHY A",null,"English","Proceedings Paper","25th International Symposium on Microscale BioSeparations (MSB 2010)","MAR 21-25, 2010","Prague, CZECH REPUBLIC",null,null,"Metallothionein; Chip capillary electrophoresis; Zinc; Redox conditions; Aggregation","PLASMA-MASS SPECTROMETRY; CE-ICP-MS; ZONE-ELECTROPHORESIS; METAL-BINDING; HYPHENATED TECHNIQUES; ISOFORMS; LIVER; PROTEINS; CADMIUM; POLYMERIZATION","Metallothioneins (MTs) belong to cysteine-rich proteins with unique higher structure. One of the most known MT's functions is metals detoxification and maintaining their homeostasis in a cell. Structure of MT with naturally occurred zinc(II) ions can be affected by concentration of metal ions as well as redox milieu inside a cell, however the exact explanation and biochemical effects of the structural changes are still missing. In this study we used capillary electrophoresis on chip coupled with fluorescence detection to determine structural changes of MT with increasing concentration of zinc(II) ions and under various redox conditions. To investigate the structural-dependent effects, reduced and/or oxidized apo-MT (MT without natural occurred metal ion) was prepared. Zinc binding into reduced and/or oxidized apo-MT was compared. MT was incubated with 0, 5, 15, 25, 50 and 100 mu M ZnCl2 for 1 h in 37 degrees C. Formation of MT aggregates with increasing zinc concentration was observed by spectrophotometry, chip capillary electrophoresis, and SDS-PAGE. We found out that reduced MT forms aggregates more readily compared to oxidized MT. Using the chip capillary electrophoresis allowed us relative quantification of MT aggregation as a decrease in the area of the signal corresponding to the monomer form of MT (Mw 15 kDa, migration time 26.5 s) and its ratio to total signal (sum of all signals measured by the electrophoresis). The dependences had an exponential character with equation y = 2.4 x e(-001x), R-2 = 0.945 for 15 kDa peak area and y = 0.11 X e(-0.01x), R-2 = 0.938 for decrease of 15 kDa peak area ratio to the total signal. Zn-MT interaction was 30% faster during the first 15 min and 50% faster during the whole experiment for reduced MT. It can be concluded that formation of MT aggregates is dependent on redox state and Zn(II) concentration. (C) 2010 Elsevier B.V. All rights reserved.","[Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic","Kizek, R, Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz",null,null,null,58,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0021-9673",null,"10.1016/j.chroma.2010.07.022","J CHROMATOGR A","J. Chromatogr. A","DEC 17",2010,1217,51,null,null,null,7966,7971,null,null,6,"Biochemical Research Methods; Chemistry, Analytical","696GK","ISI:000285429700006"]
["nemá","J","Pokorny, D; Fulin, P; Slouf, M; Jahoda, D; Landor, I; Sosna, A",null,null,null,"Pokorny, D.; Fulin, P.; Slouf, M.; Jahoda, D.; Landor, I.; Sosna, A.",null,"Polyetheretherketone (PEEK). Part II: Application in Clinical Practice","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Review",null,null,null,null,null,"polyetheretherketone; PEEK; joint replacement; wear; shoulder arthroplasty; total hip arthroplasty; total knee arthroplasty","FIBER-REINFORCED PEEK; TOTAL HIP-ARTHROPLASTY; IN-VITRO; BIOLOGICAL RESPONSE; FEMORAL STEM; ORTHOPEDIC IMPLANTS; TENSILE PROPERTIES; KNEE REPLACEMENT; BEARING SURFACES; CAMBRIDGE CUP","Polyetheretherketone (PEEK) is one of the up-to-date organic polymer thermoplastics with applications in orthopaedics and trauma medicine. This study presents a detailed analysis of its tests and applications in clinical medicine, A wide range of PEEK modifications and composites are commercially available, e.g., PEEK-Classix, PEEK-Optima, Endolign and Motis. They differ in their physical properties, which makes them suitable for different applications. Other forms, so-called PEEK bioactive composites, contain beta-tricalcium phosphate and hydroxyapatite. Research in this field is also concerned with the surface finish of this polymer thermoplastic and involves macroporous titanium and hydroxyapatite layers, or treatment with laser for an exactly defined surface structure. The clinical applications of PEEK and its composites include, in addition to components for spinal surgery, osteosynthesis plates, screws, intramedullary nails or external fixators, which are implants still at the stage of prototypes. In this review, attention is paid to the use of PEEK thermoplastics for joint replacement. Mid-term studies involving hundreds of patients have shown that, for instance, the VerSys Epoch Fullcoat Hip System (Zimmer) has a markedly lower stress-shielding effect. Carbon fibre-reinforced (CFR-PEEK) composites are used to make articulating components for total hip replacement. Their convenient properties allow for production of much thinner liners and an enlargement of the femoral head diameter, thus reducing the wear of joint implants. CFR-PEEK composites are particularly effective for hip resurfacing in which the Mitch PCR (Stryker) acetabular component has been used with good results. The MOTIS polymer acetabular cup (Invibio Ltd.) is another example. Further PEEK applications include the construction of finger-joint prostheses (Mathys AG), suture anchors (Stryker) and various kinds of augmentations (Medin). Based on the information obtained, the authors suggest further use for CFR-PEEK composites, such as the construction of articulating liners for total shoulder joint replacement, particularly in reverse shoulder arthroplasty.","[Pokorny, D.; Jahoda, D.; Landor, I.; Sosna, A.] I Ortoped Klin 1LF UK, FN Motol, Prague 15000 5, Czech Republic; [Fulin, P.] I Lekafska Fak UK, PGS, Prague, Czech Republic; [Slouf, M.] Ustav Makromol Chem AV CR, Skupina Morfol Polymeru, Prague, Czech Republic","Pokorny, D, I Ortoped Klin 1LF UK, FN Motol, V Uvalu 84, Prague 15000 5, Czech Republic","david.pokorny@LF1.cuni.cz",null,null,null,61,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2010,77,6,null,null,null,470,478,null,null,9,"Orthopedics","704US","ISI:000286081700005"]
["nemá","J","Krizkova, S; Fabrik, I; Huska, D; Adam, V; Babula, P; Hrabeta, J; Eckschlager, T; Pochop, P; Darsova, D; Kukacka, J; Prusa, R; Trnkova, L; Kizek, R",null,null,null,"Krizkova, Sona; Fabrik, Ivo; Huska, Dalibor; Adam, Vojtech; Babula, Petr; Hrabeta, Jan; Eckschlager, Tomas; Pochop, Pavel; Darsova, Denisa; Kukacka, Jiri; Prusa, Richard; Trnkova, Libuse; Kizek, Rene",null,"An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,"English","Article",null,null,null,null,null,"tumor disease; metallothionein; platinum based anticancer drugs; anticancer therapy; resistance; retinoblastoma","DIFFERENTIAL-PULSE VOLTAMMETRY; TUMOR-CELL LINES; CANCER-MORTALITY; EUROPEAN-UNION; CISPLATIN RESISTANCE; STRESS; DNA; BIOSENSOR; MECHANISM; ANTIBODIES","The drugs based on platinum metals represent one of the oldest, but also one of the most effective groups of chemotherapeutic agents. Thanks to many clinical studies it is known that resistance of tumor cells to drugs is a frequent cause of chemotherapy failure. With regard to platinum based drugs, multidrug resistance can also be connected with increased expression of low-molecular weight protein metallothionein (MT). This study aimed at investigating the interactions of MT with cisplatin or carboplatin, using the adsorptive transfer technique coupled with differential pulse voltammetry Brdicka reaction (AdTS DPV Brdicka reaction), and a comparison of in vitro results with results obtained in vivo. The results obtained from the in vitro study show a strong affinity between platinum based drugs and MT. Further, we analyzed extracts of neuroblastoma cell lines treated with cisplatin or carboplatin. It is clear that neuroblastoma UKF-NB-4 cisplatin-resistant and cisplatin-sensitive cell lines unlikely respond to the presence of the platinum-based cytostatics cisplatin and carboplatin. Finally, we determined the level of MT in samples from rabbits treated with carboplatin and patients with retinoblastoma treated with the same drug.","[Krizkova, Sona; Fabrik, Ivo; Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Dept Nat Drugs, Fac Pharm, CZ-61242 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas; Pochop, Pavel; Darsova, Denisa; Kukacka, Jiri; Prusa, Richard] Teaching Hosp Motol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Pochop, Pavel; Darsova, Denisa] Charles Univ Prague, Dept Ophthalmol Children & Adults, CZ-15006 Prague 5, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R, Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic","kizek@sci.muni.cz","IGA MZ Czech Republic [NR/95323/2007]; [GA AV IAA401990701]; [IGA MZ 10200-3]; [INCHEMBIOL MSM0021622412]; [LPR 2011]","This work was supported by grants: GA AV IAA401990701, IGA MZ Czech Republic NR/95323/2007, IGA MZ 10200-3, INCHEMBIOL MSM0021622412 and LPR 2011.",null,64,0,"MDPI AG","BASEL","KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND","1422-0067",null,"10.3390/ijms11124826","INT J MOL SCI","Int. J. Mol. Sci.","DEC",2010,11,12,null,null,null,4826,4842,null,null,17,"Chemistry, Multidisciplinary","700BV","ISI:000285708000004"]
["nemá","J","Frederic, A; Sarah, D; Kristel, V; Sibylle, L; Michael, H; Lieselot, B; Jos, B; Fatima, C; Oreste, G; Lieven, L; Olivier, M; Patrick, N; Nelleke, O; Steven, P; Fedro, P; Roman, R; Hans-Jorg, S; Henk, S; Marie-Rose, C; David, C; Andreas, D",null,null,null,"Frederic, Amant; Sarah, Deckers; Kristel, Van Calsteren; Sibylle, Loibl; Michael, Halaska; Lieselot, Brepoels; Jos, Beijnen; Fatima, Cardoso; Oreste, Gentilini; Lieven, Lagae; Olivier, Mir; Patrick, Neven; Nelleke, Ottevanger; Steven, Pans; Fedro, Peccatori; Roman, Rouzier; Hans-Joerg, Senn; Henk, Struikmans; Marie-Rose, Christiaens; David, Cameron; Andreas, Du Bois",null,"Breast cancer in pregnancy: Recommendations of an international consensus meeting","EUROPEAN JOURNAL OF CANCER",null,"English","Review",null,null,null,null,null,"Cancer; Pregnancy; Breast; Guideline; Consensus; Chemotherapy; Radiotherapy; Surgery; Biological","CHEMOTHERAPY IN-UTERO; ANTENATAL CORTICOSTEROIDS; NONOBSTETRIC SURGERY; HUMAN PLACENTA; TRASTUZUMAB; RADIOTHERAPY; CARCINOMA; OUTCOMES; TAMOXIFEN; RADIATION","Purpose: To provide guidance for clinicians about the diagnosis, staging and treatment of breast cancer occurring during an otherwise uncomplicated pregnancy. Methods: An international expert Panel convened to address a series of questions identified by a literature review and personal experience. Issues relating to the diagnosis and management of breast cancer after delivery were outside the scope. Results: There is a paucity of large and/or randomized studies. Based on cohort studies, case series and case reports, the recommendations represent the best available evidence, albeit of a lower grade than is optimal. Recommendations: In most circumstances, serious consideration should be given to the option of treating breast cancer whilst continuing with the pregnancy. Each woman should ideally be referred to a centre with sufficient expertise, given a clear explanation of treatment options. Most diagnostic and staging examinations can be performed adequately and safely during pregnancy. Treatment should however be adapted to the clinical presentation and the trimester of the pregnancy: surgery can be performed during all trimesters of pregnancy; radiotherapy can be considered during the first and second trimester but should be postponed during the third trimester; and standard chemotherapies can be used during the second and third trimester. Since neonatal morbidity mainly appears to be related to prematurity, delivery should not be induced before 37 weeks, if at all possible. Conclusions: The treatment of breast cancer in pregnancy should be executed by experienced specialists in a multidisciplinary setting and should adhere as closely as possible to standard protocols. (C) 2010 Elsevier Ltd. All rights reserved.","[Frederic, Amant] Katholieke Univ Leuven, Div Gynecol Oncol, Dept Obstet & Gynecol, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Frederic, Amant; Patrick, Neven; Marie-Rose, Christiaens] Katholieke Univ Leuven, Multidisciplinary Breast Ctr, Leuven Canc Inst LKI, UZ Gasthuisberg, B-3000 Louvain, Belgium; [Sibylle, Loibl] Ambulantes Krebszentrum Frankfurt, German Breast Grp, Dept Med, Frankfurt, Germany; [Sibylle, Loibl] Ambulantes Krebszentrum Frankfurt, Dept Res, Frankfurt, Germany; [Michael, Halaska] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Lieselot, Brepoels] Univ Hosp Gasthuisberg, Nucl Med, Leuven, Belgium; [Jos, Beijnen] Slotervaart Hosp, Netherlands Canc Inst, Amsterdam, Netherlands; [Fatima, Cardoso] Bordet Inst, Brussels, Belgium; [Oreste, Gentilini] European Inst Oncol, Breast Surg Unit, Milan, Italy; [Olivier, Mir] Paris Descartes Univ, French CALG Grp Cancers Associes La Grosesse, Paris, France; [Nelleke, Ottevanger] Radboudziekenhuis, Nijmegen, Netherlands; [Fedro, Peccatori] European Inst Oncol, Dept Med, Div Hematol Oncol, Milan, Italy; [Roman, Rouzier] Hop Tenon, French CALG Grp Canc Associes La Grosesse, F-75970 Paris, France; [Hans-Joerg, Senn] Tumor & Breast Ctr ZeTuP, St Gallen, Schweiz, Switzerland; [Henk, Struikmans] Medisch Ctr Haaglanden, The Hague, Netherlands; [David, Cameron] Western Gen Hosp, Ctr Canc, Edinburgh, Midlothian, Scotland; [David, Cameron] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; [Andreas, Du Bois] Dr Horst Schmidt Klin, Cooperat Breast Ctr, Dept Gynecol & Gynecol Oncol, Wiesbaden, Germany","Frederic, A, Katholieke Univ Leuven, Div Gynecol Oncol, Dept Obstet & Gynecol, Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium","Frederic.amant@uz.kuleuven.ac.be",null,null,null,90,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049",null,"10.1016/j.ejca.2010.09.010","EUR J CANCER","Eur. J. Cancer","DEC",2010,46,18,null,null,null,3158,3168,null,null,11,"Oncology","701IY","ISI:000285812800013"]
["nemá","J","Svehlik, M; Zwick, EB; Steinwender, G; Kraus, T; Linhart, WE",null,null,null,"Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhard; Kraus, Tanja; Linhart, Wolfgang E.",null,"Dynamic Versus Fixed Equinus Deformity in Children With Cerebral Palsy: How Does the Triceps Surae Muscle Work?","ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION",null,"English","Article",null,null,null,null,null,"Biomechanics; Cerebral palsy; Equinus deformity; Gait; Muscle; Rehabilitation","GASTROCNEMIUS RECESSION; MULTILEVEL SURGERY; PLANTAR FLEXORS; GAIT ANALYSIS; CROUCH GAIT; ANKLE; CONTRACTURE; LENGTHS; WALKING; SOLEUS","Svehlik M, Zwick EB, Steinwender G, Kraus T, Linhart WE. Dynamic versus fixed equinus deformity in children with cerebral palsy: how does the triceps surae muscle work? Arch Phys Med Rehabil 2010;91:1897-1903. Objectives: To detect outcome measures that could help differentiate between dynamic and fixed equinus (FEQ) deformities in children with cerebral palsy, and secondary, to describe the function of the gastrocnemius and soleus (SOL) muscles when either dynamic triceps surae tightness or FEQ contracture is present. Design: A group-comparison study. Setting: Gait analysis laboratory. Participants: Children (N=23; 31 limbs) with cerebral palsy; 12 limbs showed a fixed contracture (FEQ group) and 19 limbs showed dynamic tightness of the triceps muscle (dynamic equinus group). Healthy children (N=12) without a neurologic or orthopedic disorder served as the control group. Interventions: Not applicable. Main Outcome Measures: Time-distance, kinematic and kinetic gait variables, muscle-tendon length, and velocity parameters. Results: Maximal ankle dorsiflexion angles were decreased in both equinus groups compared with the control group. Ankle range of motion, maximal power generation of the plantar flexors, and its timing during the gait cycle were different among groups. The ankle slope parameter showed substantial differences among groups. Muscle-tendon length parameters for the SOL and the medial (MGAC) and lateral gastrocnemius muscles were abnormal in both equinus groups compared with the control group. Maximal muscle lengths of the MGAC and SOL were longer in the dynamic equinus than FEQ group. Peak lengthening velocity of the triceps surae muscle was significantly slower for all triceps surae muscles in the FEQ group than in the dynamic equinus group and occurred in the early swing phase. Conclusions: The presented results indicate that peak lengthening velocity of the triceps surae muscle might be one of the discriminating factors between FEQ and dynamic equinus deformity in children with cerebral palsy. This could help clinical decision making for treatment of an equinus gait pattern.","[Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhard; Kraus, Tanja; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Orthopaed, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Fac Med 2, Dept Children & Adult Orthopaed & Traumatol, Prague, Czech Republic","Svehlik, M, Med Univ Graz, Dept Paediat Orthopaed, Auenbruggerpl 34, A-8036 Graz, Austria","martin.spejlik@seznam.cz",null,null,null,33,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0003-9993",null,"10.1016/j.apmr.2010.09.005","ARCH PHYS MED REHABIL","Arch. Phys. Med. Rehabil.","DEC",2010,91,12,null,null,null,1897,1903,null,null,7,"Rehabilitation; Sport Sciences","700KY","ISI:000285738900012"]
["nemá","J","Jelinek, M; Kocourek, T; Remsa, J; Miksovsky, J; Zemek, J; Smetana, K; Dvorankova, B; Luxbacher, T",null,null,null,"Jelinek, Miroslav; Kocourek, Tomas; Remsa, Jan; Miksovsky, Jan; Zemek, Josef; Smetana, Karel, Jr.; Dvorankova, Barbora; Luxbacher, Thomas",null,"Diamond/graphite content and biocompatibility of DLC films fabricated by PLD","APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING",null,"English","Article",null,null,null,null,null,null,"ION IMPLANTATION-DEPOSITION; CARBON-FILMS; NANOCRYSTALLINE DIAMOND; PROTEIN ADSORPTION; BACTERIAL ADHESION; AMORPHOUS-CARBON; THIN-FILMS; IN-VITRO; COATINGS; KERATINOCYTES","Biocompatibility and physicochemical properties of diamond-like carbon (DLC) thin layers prepared by pulsed laser deposition method were studied. The films of high and low diamond/graphite content were prepared by changing the laser energy density on the graphite target from 4 to 11 J cm(-2). The bonds and surface properties as roughness, atomic force microscopy topology, contact angle parameters, and zeta potential were measured. The cell adhesion/proliferation on DLC layers was tested using normal human fibroblasts and keratinocytes.","[Jelinek, Miroslav; Kocourek, Tomas; Remsa, Jan; Miksovsky, Jan; Zemek, Josef] Inst Phys ASCR, Prague 18221 8, Czech Republic; [Jelinek, Miroslav; Kocourek, Tomas; Miksovsky, Jan] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Luxbacher, Thomas] Anton Paar GmbH, Graz, Austria","Jelinek, M, Inst Phys ASCR, Slovance 2, Prague 18221 8, Czech Republic","jelinek@fzu.cz","Ministry of Education, Youth and Sports of the Czech Republic and to Institutional research [MSM 6840770012, 0021620806, AV010100521, AV010100522]","We thank to grants MSM 6840770012 and 0021620806 from Ministry of Education, Youth and Sports of the Czech Republic and to Institutional research plan No. AV010100521 and AV010100522.",null,29,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0947-8396",null,"10.1007/s00339-010-5912-9","APPL PHYS A-MAT SCI PROCESS","Appl. Phys. A-Mater. Sci. Process.","DEC",2010,101,4,null,null,"Sp. Iss. SI",579,583,null,null,5,"Materials Science, Multidisciplinary; Physics, Applied","692ZV","ISI:000285195300001"]
["nemá","J","Buggiani, G; Krysenka, A; Grazzini, M; Vasku, V; Hercogova, J; Lotti, T",null,null,null,"Buggiani, Gionata; Krysenka, Alena; Grazzini, Marta; Vasku, Vladimir; Hercogova, Jana; Lotti, Torello",null,"Paraneoplastic vasculitis and paraneoplastic vascular syndromes","DERMATOLOGIC THERAPY",null,"English","Article",null,null,null,null,null,"paraneoplastic; syndromes; vasculitis","MOLECULAR-WEIGHT HEPARIN; GIANT-CELL ARTERITIS; TROUSSEAUS-SYNDROME; TISSUE FACTOR; CUTANEOUS VASCULITIS; LEUKOCYTOCLASTIC VASCULITIS; MONOCLONAL-ANTIBODY; ADHESION MOLECULES; SYSTEMIC-DISEASE; SOLID TUMORS","Paraneoplastic syndromes are localized or diffuse pathologic manifestations that may occur in subjects affected by neoplastic diseases, even occult ones. Among the many clinical manifestations of paraneoplastic syndromes, cutaneous ones are quite common. It is estimated that skin manifestations may represent the very first diagnostic sign of a neoplastic disease in about 1% of patients. Many paraneoplastic syndromes with skin manifestations are caused by vascular alterations. In case of solid tumors, migrant thrombophlebitis and blood hypercoagulability can be seen, whereas in case of hematological neoplasms, vasculitis, and erythromelalgia can occur. Paraneoplastic vasculitis and paraneoplastic vascular syndromes are challenging issues in dermatology and general medicine. The present article will review the actual knowledge in the argument, together with providing hints for its diagnosis and management.","[Buggiani, Gionata; Krysenka, Alena; Grazzini, Marta; Lotti, Torello] Univ Florence, Sch Med, Univ Unit Dermatol, I-50129 Florence, Italy; [Vasku, Vladimir] St Anns Fac Hosp, Brno Med Fac, Dept Dermatovenereol, Brno, Czech Republic; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Buggiani, G, Univ Florence, Sch Med, Univ Unit Dermatol, Via Lorenzo Magnif 104, I-50129 Florence, Italy","gionata.buggiani@unifi.it",null,null,null,66,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,"10.1111/j.1529-8019.2010.01367.x","DERMATOL THER","Dermatol. Ther.","NOV-DEC",2010,23,6,null,null,null,597,605,null,null,9,"Dermatology","676WI","ISI:000283949000005"]
["nemá","J","Necas, A; Proks, P; Urbanova, L; Srnec, R; Stehlik, L; Crha, M; Rauser, P; Planka, L; Amler, E; Vojtova, L; Jancar, J",null,null,null,"Necas, Alois; Proks, Pavel; Urbanova, Lucie; Srnec, Robert; Stehlik, Ladislav; Crha, Michal; Rauser, Petr; Planka, Ladislav; Amler, Evzen; Vojtova, Lucy; Jancar, Josef",null,"Radiographic Assessment of Implant Failures of Titanium 3.5 LCP vs. 4.5 LCP Used for Flexible Bridging Osteosynthesis of Large Segmental Femoral Diaphyseal Defects in a Miniature Pig Model","ACTA VETERINARIA BRNO",null,"English","Article",null,null,null,null,null,"Fracture fixation; bone healing; comminuted fracture; nonunion; ostectomy; buttress plate","DYNAMIC COMPRESSION PLATE; MESENCHYMAL STEM-CELLS; LIMITED CONTACT; BONE-MARROW; INTRAMEDULLARY PIN; GAP MODEL; FIXATION; REGENERATION; STRAIN; REPAIR","The study describes types, absolute and relative numbers of implant failures in flexible bridging osteosynthesis using a six-hole 3.5 mm titanium Locking Compression Plate (n = 9) or a five-hole LCP 4.5 mm titanium (n = 40) selected for the fixation of segmental ostectomy of femoral diaphysis in the miniature pig used as an in vivo model in a study on the healing of a critically sized bone defect using transplantation of mesenchymal stem cells combined with biocompatible scaffolds within a broader research project. Occasional implant failure was evaluated based on radiographic examination of femurs of animals 2, 4, 8, 12 and 16 weeks after surgery. When bone defect was stabilized using 3.5 mm LCP, in 6 cases (66.7%) the screw was broken/lost in the proximal fragment of the femur 2 weeks after implantation (n = 4) and 4 weeks after implantation (n = 2). In 4 cases of these, the implant failure was accompanied also by loosening of the screw in position 3 in the proximal fragment of the femur. During ostectomy stabilization with 4.5 mm LCP, in 3 cases (7.5%) LCP was broken at the place of the empty central plate hole (without inserted screw) at the level of the segmental bone defect. Compared to the six-hole 3.5 mm LCP, the five-hole titanium 4.5 mm LCP is more suitable implant for flexible bridging osteosynthesis of a critically sized segmental defect of femoral diaphysis in the miniature pig. The results of this study will allow reducing implant failures in time-and cost-demanding transplantation experiments focused on bone healing.","[Necas, Alois; Urbanova, Lucie; Srnec, Robert; Crha, Michal; Rauser, Petr] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Brno 61242, Czech Republic; [Proks, Pavel; Stehlik, Ladislav] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Diagnost Imaging, Brno 61242, Czech Republic; [Planka, Ladislav] Fac Hosp Brno, Dept Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic; [Vojtova, Lucy; Jancar, Josef] Brno Univ Technol, Inst Mat Chem, Brno, Czech Republic","Necas, A, Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Palackeho 1-3, Brno 61242, Czech Republic","necas@eurosat.cz","Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130]","This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (Research Project NPV II 2B06130).",null,37,2,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213",null,"10.2754/avb201079040599","ACTA VET BRNO","Acta Vet. BRNO","DEC",2010,79,4,null,null,null,599,"U101",null,null,10,"Veterinary Sciences","722FV","ISI:000287418300012"]
["nemá","J","Necas, A; Proks, P; Urbanova, L; Srnec, R; Stehlik, L; Crha, M; Rauser, P; Planka, L; Janovec, J; Dvorak, M; Amler, E; Vojtova, L; Jancar, J",null,null,null,"Necas, Alois; Proks, Pavel; Urbanova, Lucie; Srnec, Robert; Stehlik, Ladislav; Crha, Michal; Rauser, Petr; Planka, Ladislav; Janovec, Jan; Dvorak, Milan; Amler, Evzen; Vojtova, Lucy; Jancar, Josef",null,"Healing of Large Segmental Bone Defect after Implantation of Autogenous Cancellous Bone Graft in Comparison to Hydroxyapatite and 0.5% Collagen Scaffold Combined with Mesenchymal Stem Cells","ACTA VETERINARIA BRNO",null,"English","Article",null,null,null,null,null,"Fracture fixation; bone healing; comminuted fracture; callus; ostectomy; buttress plate","PHYSEAL DEFECTS; TRANSPLANTATION; REGENERATION; RADIOGRAPHY; CARTILAGE; REPAIR; RATS","At present, attention is focused on research into possibilities of healing large bone defects by the method of mini-invasive osteosynthesis, using implantation of biomaterials and mesenchymal stem cells (MSCs). This study evaluates the healing of segmental femoral defects in miniature pigs based on the radiological determination of the callus: cortex ratio at 16 weeks after ostectomy. The size of the formed callus was significantly larger (p < 0.05) in animals after transplantation of an autogenous cancellous bone graft (group A, callus : cortex ratio of 1.77 +/- 0.33) compared to animals after transplantation of cylindrical scaffold from hydroxyapatite and 0.5% collagen (group S, callus : cortex ratio of 1.08 +/- 0.13), or in animals after transplantation of this scaffold seeded with MSCs (group S + MSCs, callus: cortex ratio of 1.15 +/- 0.18). No significant difference was found in the size of callus between animals of group S and animals of group S + MSCs. Unlike a scaffold in the shape of the original bone column, a freely placed autogenous cancellous bone graft may allow the newly formed tissue to spread more to the periphery of the ostectomy defect. Implanted cylindrical scaffolds (with and without MSCs) support callus formation directly in the center of original bone column in segmental femoral ostectomy, and can be successfully used in the treatment of large bone defects.","[Necas, Alois; Urbanova, Lucie; Srnec, Robert; Crha, Michal; Rauser, Petr; Janovec, Jan; Dvorak, Milan] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Brno 61242, Czech Republic; [Proks, Pavel; Stehlik, Ladislav] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Diagnost Imaging, Brno 61242, Czech Republic; [Planka, Ladislav] Fac Hosp Brno, Dept Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic; [Vojtova, Lucy; Jancar, Josef] Brno Univ Technol, Inst Mat Chem, Brno, Czech Republic","Necas, A, Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Palackeho 1-3, Brno 61242, Czech Republic","necas@eurosat.cz","Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130]","This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (Research Project NPV II 2B06130). Preliminary results of the study were presented at the conference \"School, Science, Practice II\" in 2009 in Kosice and published in the proceedings.",null,35,2,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213",null,"10.2754/avb201079040607","ACTA VET BRNO","Acta Vet. BRNO","DEC",2010,79,4,null,null,null,607,"U108",null,null,7,"Veterinary Sciences","722FV","ISI:000287418300013"]
["nemá","J","Tomasov, P; Linhartova, K; Antonova, P; Adlova, R; Alan, D; Veselka, J",null,null,null,"Tomasov, Pavol; Linhartova, Katerina; Antonova, Petra; Adlova, Radka; Alan, David; Veselka, Josef",null,"Combined percutaneous treatment of atrial septal defect and pulmonic or aortic stenosis in adult patients","ARCHIVES OF MEDICAL SCIENCE",null,"English","Article",null,null,null,null,null,"heart septal defects; septal occluder device; balloon valvuloplasty","BALLOON VALVULOPLASTY; VALVE STENOSIS; CLOSURE","Combined atrial septal defect and pulmonic or aortic stenosis are relatively uncommon conditions in adult patients, with few reported cases of percutaneous treatment. We present two patients with secundum type atrial septal defect and concomitant pulmonic or aortic stenosis and their treatment by transcatheter techniques.","[Tomasov, Pavol; Linhartova, Katerina; Antonova, Petra; Adlova, Radka; Alan, David; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Prague 15006, Czech Republic","Tomasov, P, Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Uvalu 84, Prague 15006, Czech Republic","p.tomasov@seznam.cz","Czech Ministry of Health [MZOFNM2005]","Supported by the Czech Ministry of Health MZOFNM2005.",null,7,0,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,"10.5114/aoms.2010.19312","ARCHIV MED SCI","Arch. Med. Sci.","DEC",2010,6,6,null,null,null,976,980,null,null,5,"Medicine, General & Internal","703MN","ISI:000285982100025"]
["nemá","J","Zemanek, D; Veselka, J; Adla, T; Setina, M; Ferda, J",null,null,null,"Zemanek, David; Veselka, Josef; Adla, Teodor; Setina, Marek; Ferda, Jiri",null,"Uncommon cause of obstruction in the left ventricular outflow tract by a metastasis of adenocarcinoma","ARCHIVES OF MEDICAL SCIENCE",null,"English","Article",null,null,null,null,null,"left ventricular obstruction; cardiac metastasis",null,"Cardiac metastases are rare diagnoses among cardiac disorders. This case demonstrates a unique presence of an obstruction in the left ventricular outflow tract caused by the metastasis of a renal carcinoma. Adequate diagnostic and therapeutic procedures were lifesaving in this potentially fatal diagnosis.","[Zemanek, David; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Sch Med 1, Prague 16000, Czech Republic; [Adla, Teodor] Charles Univ Prague, Dept Imaging Methods, Univ Hosp Motol, Sch Med 1, Prague 16000, Czech Republic; [Setina, Marek] Charles Univ Prague, Dept Cardiac Surg, Univ Hosp Motol, Sch Med 1, Prague 16000, Czech Republic; [Ferda, Jiri] Charles Univ Prague, Teaching Hosp, Radiodiagnost Clin, Prague 16000, Czech Republic","Zemanek, D, Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Sch Med 1, K Cervnemu Vrchu 844-2A, Prague 16000, Czech Republic","zejada@seznam.cz",null,null,null,3,0,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,"10.5114/aoms.2010.19313","ARCHIV MED SCI","Arch. Med. Sci.","DEC",2010,6,6,null,null,null,981,983,null,null,3,"Medicine, General & Internal","703MN","ISI:000285982100026"]
["nemá","J","Adamek, S; Matouskova, O; Pafko, P; Slanar, O; Perlik, F",null,null,null,"Adamek, S.; Matouskova, O.; Pafko, P.; Slanar, O.; Perlik, F.",null,"The role of diclofenac and piritramide in the management of acute postoperative pain in hernioplasty","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,"English","Article",null,null,null,null,null,"analgesia; diclofenac; piritramide; hernioplasty; postoperative pain; human",null,"Objectives: The aim of the study was to compare the effects of diclofenac and piritramide in acute postoperative pain after hernioplasty. Background: In the treatment of moderate acute postoperative pain, non-steroidal anti-inflammatory drugs and opioids play the major role. The data on safety and effect of analgesia based on opioid and non-opioid drugs are still a controversial topic. Methods: We compared the first-line treatment effects of diclofenac and piritramide in 105 patients after hernioplasty in a retrospective manner. The subsequent therapy combined piritramide with diclofenac. We evaluated the intensity of pain and its relief using a visual analogue scale (VAS). We also evaluated the necessity of application of other analgesics. Results: One hour after the application of the first analgesic dose, we observed complete pain relief in 39.5 % of patients treated with piritramide and in 19.4 % of patients treated with diclofenac (chi(2)=5.17; p = 0.02). After the use of piritramide, the pain relief (3.84 +/- 1.27 mm) was significantly higher than after diclofenac (3.34 +/- 0.77 mm). Another injection was needed in 76 % and 54 % of patients subjected to first-line treatment based on diclofenac and piritramide, respectively. Conclusion: We observed that the first-line analgesic treatment based on piritramide was more effective when compared to that based on diclofenac (Tab. 3, Ref. 3). Full Text in free PDF www.bmj.sk.","[Adamek, S.; Pafko, P.] First Fac Med, Dept Surg 3, Prague, Czech Republic; [Adamek, S.; Pafko, P.] Univ Hosp Motol, Prague, Czech Republic; [Matouskova, O.; Slanar, O.; Perlik, F.] First Fac Med, Inst Pharmacol, Prague, Czech Republic; [Matouskova, O.; Slanar, O.; Perlik, F.] Gen Univ Hosp, Prague, Czech Republic","Pafko, P, 1 LF UK, Dept Surg 3, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","pavel.pafko@lfmotol.cuni.cz","[VZ MSM 0021620849]; [VZ MSM 0021620820]","Supported in part by grants No. VZ MSM 0021620849 and VZ MSM 0021620820.",null,2,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2010,111,11,null,null,null,616,618,null,null,3,"Medicine, General & Internal","708IH","ISI:000286355000008"]
["nemá","J","Sterbakova, G; Vyskocil, V; Linhartova, K",null,null,null,"Sterbakova, Gabriela; Vyskocil, Vaclav; Linhartova, Katerina",null,"Bisphosphonates in Calcific Aortic Stenosis: Association with Slower Progression in Mild Disease - A Pilot Retrospective Study","CARDIOLOGY",null,"English","Article",null,null,null,null,null,"Aortic stenosis; Valve calcification; Bisphosphonates; Osteoporosis","ARTERY CALCIFICATION; VITAMIN-D; ECHOCARDIOGRAPHY; RECOMMENDATIONS; ROSUVASTATIN; IBANDRONATE; TRIAL","Objectives: An association between aortic valve calcification and osteoporosis has been observed. The aim of this study was to assess the association between bisphosphonate treatment for osteoporosis and the progression of calcific aortic stenosis (AS). Methods: A retrospective study of patients with AS (mean gradient >= 10 mm Hg), preserved renal function and two echocardiographies >8 months apart was performed. The patients were divided into those treated with bisphosphonates for osteoporosis and those not treated and then subdivided into mild (mean gradient <30 mm Hg) and moderate-to-severe AS groups. We compared the annualized gradient change between the groups and identified predictors of AS progression. Results: We analyzed the outcomes of 103 patients (51% females, age 68 +/- 10 years, follow-up 29 +/- 13 months), of whom 57 had mild and 46 moderate-to-severe AS. Bisphosphonates were taken by 28 patients, of whom 22 had mild and 6 moderate-to-severe AS. In the patients with mild AS, the annualized mean gradient change was lower in the bisphosphonate-treated than in the untreated patients (0.1 +/- 3.3 vs. 2.8 +/- 3.3 mm Hg/year; p = 0.002) and was negatively associated with bisphosphonate treatment (beta coefficient -2.36%, 95% confidence interval -4.47 to -0.26; p = 0.028) independent of age, gender and baseline gradient. Conclusion: Bisphosphonate treatment was independently associated with slower progression of mild AS in patients with preserved renal function. Copyright (C) 2010 S. Karger AG, Basel","[Linhartova, Katerina] Charles Univ Prague, Sch Med 2, Hosp Motol, Cardiovasc Ctr,Dept Cardiol, CZ-15006 Prague, Czech Republic; [Sterbakova, Gabriela] Charles Univ Prague, Sch Med Hosp, Dept Med 1, Plzen, Czech Republic; [Vyskocil, Vaclav] Charles Univ Prague, Sch Med Hosp, Dept Orthoped Surg, Plzen, Czech Republic","Linhartova, K, Charles Univ Prague, Sch Med 2, Hosp Motol, Cardiovasc Ctr,Dept Cardiol, V Uvalu 84, CZ-15006 Prague, Czech Republic","linhartkaterina@seznam.cz","Czech Ministry of Health [MZOFNM2005]","This study was supported by the cardiovascular research project of the Czech Ministry of Health, MZOFNM2005.",null,22,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0008-6312",null,"10.1159/000321418","CARDIOLOGY","Cardiology",null,2010,117,3,null,null,null,184,189,null,null,6,"Cardiac & Cardiovascular Systems","714JI","ISI:000286805500006"]
["nemá","J","Knotek, P",null,null,null,"Knotek, Petr",null,"Psychological processes in chronic pain, their structure and dynamics","CESKOSLOVENSKA PSYCHOLOGIE",null,"Czech","Article",null,null,null,null,null,"chronic pain; psychological and behavioral processes","CHRONIC MUSCULOSKELETAL PAIN; ATTENTION; MODEL; MECHANISMS; BEHAVIORS; ILLNESS; SPOUSE; FEAR","This article shows a complex viewpoint on present models of psychological processes in chronic pain that stems from researches based on neurophysiologic and psychological experiments or a multivariate analysis of clinical data. Modern conceptions of psychological changes are based on Melzack - Wall's Gate Controle Theory, Lazarus and Folkman's cognitive theory of stress, and the concept of learned pain behavior of Wilbert E. Fordyce. Two groups of models follow these above mentioned conceptions: A model of consecutive stages of psychological changes in people with chronic pain (Wade, Dougherty, Archer, Price, 1996; Knotek, Knotkova 2008), and models that focus on feedback processes during the development of psychological changes in people with chronic pain (survey in Asmundson, Vlaeyen, Crombez, 2004). A new model that includes essential aspects of both above mentioned models has been recently tested (Knotek, 2009). The article proposes an extended theoretical model that includes two triggering processes, pain and cognitive processing of pain. The main stages of psychological processes consist of fear and observation of pain, pain assessment and coping with pain, changes of affects and motivation, and adaptive or maladaptive behavior. The changes of affects and motivation have an influence on self-perception which via feedback influences cognitive processing of pain. The basic vision for the future research of chronic pain is the Neuromatrix Theory of Pain of Roland Melzack (2005) that sees pain as multidimensional experience caused by neurosignature (patterns of impulses of neural network that represent body - self neuromatrix in the brain).","[Knotek, Petr] FN Motol, Ctr Laceni & Vyzkum Stavu, Prague 15006 5, Czech Republic; [Knotek, Petr] FN Motol, Oddeleni Klin Psychol, Prague 15006 5, Czech Republic","Knotek, P, FN Motol, Ctr Laceni & Vyzkum Stavu, V Uvalu 84, Prague 15006 5, Czech Republic","petr.knotek@fnmotol.cz",null,null,null,68,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2010,54,6,null,null,null,546,563,null,null,18,"Psychology, Multidisciplinary","709NT","ISI:000286448100002"]
["nemá","J","Melter, O; Radojevic, B",null,null,null,"Melter, O.; Radojevic, B.",null,"Small colony variants of Staphylococcus aureus - review","FOLIA MICROBIOLOGICA",null,"English","Review",null,null,null,null,null,null,"CYSTIC-FIBROSIS PATIENTS; PSEUDOMONAS-AERUGINOSA; METHICILLIN-RESISTANT; INTRACELLULAR PERSISTENCE; ANTIBIOTIC-RESISTANCE; RECURRENT INFECTIONS; EXFOLIATIVE TOXINS; ENDOTHELIAL-CELLS; LUNG INFECTION; HEMB MUTANT","Bacterial variants of Staphylococcus aureus called small colony variants (SCVs) originate by mutations in metabolic genes, resulting in emergence of auxotrophic bacterial subpopulations. These variants are not particularly virulent but are able to persist viable inside host cells. SCVs show their characteristic auxotrophic growth deficiency and depressed alpha-cytotoxin activity. Environmental pressure such as antibiotics, select for isogenic SCV cells that are frequently found coexisting with their parent wild-type strains in a mixed bacterial culture. SCV strains often grow on blood agar as non-pigmented or pinpoint pigmented colonies and their key biochemical tests are often non-reactive. Their altered metabolism or auxotrophism can result in long generation time and thus SCV phenotype, more often than not SCV can be overgrown by their wild-type counterparts and other competitive respiratory flora. This could affect laboratory detection. Thus, molecular methods, such as 16S rRNA partial sequencing or amplification of species-specific DNA targets (e.g. coagulase, nuclease) directly from clinical material or isolated bacterial colonies, become the method of choice. Patients at risk of infection by S. aureus SCVs include cystic fibrosis patients (CF), patients with skin and foreign-body related infections and osteomyelitis, as they suffer from chronic staphylococcal infections and are subject to long-term antibiotic therapy. Molecular evidence of SCV development has not been found except for some random mutations of the thymidylate synthase gene (thyA) described in SCV S. aureus strains of CF patients. These variants are able to bypass the antibiotic effect of folic acid antagonists such as sulfonamides and trimethoprim. Resistance to gentamicin and aminoglycosides in the hemin or menadione auxotrophic SCVs was hypothesized as being due to decreased influx of the drugs into cells as a result of decreased ATP production and decreased electrochemical gradient on cell membranes.","[Melter, O.; Radojevic, B.] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague 15006 5, Motol, Czech Republic","Melter, O, Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Uvalu 84, Prague 15006 5, Motol, Czech Republic","oto.melter@lfmotol.cuni.cz","[MZ 0 FNM 2005]","We thank A. Malmgren for reviewing the manuscript. This work was supported by the research project MZ 0 FNM 2005.",null,72,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,"10.1007/s12223-010-0089-3","FOLIA MICROBIOL PRAGUE","Folia Microbiol.","NOV",2010,55,6,null,null,null,548,558,null,null,11,"Biotechnology & Applied Microbiology; Microbiology","709UG","ISI:000286466300002"]
["nemá","J","Svehlik, M; Slaby, K; Trc, T; Radvansky, J",null,null,null,"Svehlik, Martin; Slaby, Krystof; Trc, Tomas; Radvansky, Jiri",null,"Detecting Postoperative Change in Children With Cerebral Palsy: Net Nondimensional Versus Body Mass Oxygen Normalization","JOURNAL OF APPLIED BIOMECHANICS",null,"English","Article",null,null,null,null,null,"exercise performance; orthopaedic surgery; gait analysis; kinematics","ENERGY-EXPENDITURE; O-2 COST; WALKING; GAIT; SURGERY","The aim of the study is to investigate whether the net nondimensional oxygen utilization scheme is able to detect postoperative improvement in the energy cost of walking in children with cerebral palsy and to compare it with a body mass normalization scheme. We evaluated 10 children with spastic cerebral palsy before and 9 months after equinus deformity surgery. Participants walked at a given speed of 2 km/hr and 3 km/hr on a treadmill. Oxygen utilization was measured, and mass relative VO2 and net nondimensional VO2 were calculated. Coefficient of variation was used for the description of variability among subjects. Postoperatively, gait kinematics normalized and the mass relative VO2 and net nondimensional VO2 showed significant improvement. Net nondimensional VO2 is able to detect postoperative improvement with smaller variability among subjects than body mass related normalization in children with cerebral palsy.","[Svehlik, Martin; Trc, Tomas] Charles Univ Prague, Orthopaed Dept Children & Adults, Sch Med 2, Prague, Czech Republic; [Slaby, Krystof; Radvansky, Jiri] Charles Univ Prague, Dept Rehabil & Sports Med, Sch Med 2, Prague, Czech Republic","Svehlik, M, Charles Univ Prague, Orthopaed Dept Children & Adults, Sch Med 2, Prague, Czech Republic",null,null,null,null,19,0,"HUMAN KINETICS PUBL INC","CHAMPAIGN","1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA","1065-8483",null,null,"J APPL BIOMECH","J. Appl. Biomech.","NOV",2010,26,4,null,null,null,512,515,null,null,4,"Engineering, Biomedical; Sport Sciences","699VJ","ISI:000285690700016"]
["nemá","J","Filova, E; Burdikova, Z; Rampichova, M; Bianchini, P; Capek, M; Kostakova, E; Amler, E; Kubinova, L",null,null,null,"Filova, Eva; Burdikova, Zuzana; Rampichova, Michala; Bianchini, Paolo; Capek, Martin; Kostakova, Eva; Amler, Evzen; Kubinova, Lucie",null,"Analysis and three-dimensional visualization of collagen in artificial scaffolds using nonlinear microscopy techniques","JOURNAL OF BIOMEDICAL OPTICS",null,"English","Article",null,null,null,null,null,"second-harmonic generation imaging; multiphoton microscopy; tissue engineering; artificial scaffolds; collagen","2ND-HARMONIC GENERATION; ARTICULAR-CARTILAGE; BIOLOGICAL TISSUES; IN-VIVO; FLUORESCENCE; MATRIX; REPAIR; CELLS; TRANSPLANTATION; RECONSTRUCTION","Extracellularly distributed collagen and chondrocytes seeded in gelatine and poly-epsilon-caprolactone scaffolds are visualized by two-photon excitation microscopy (TPEM) and second-harmonic generation (SHG) imaging in both forward and backward nondescanned modes. Joint application of TPEM and SHG imaging in combination with stereological measurements of collagen enables us not only to take high-resolution 3-D images, but also to quantitatively analyze the collagen volume and a spatial arrangement of cell-collagen-scaffold systems, which was previously impossible. This novel approach represents a powerful tool for the analysis of collagen-containing scaffolds with applications in cartilage tissue engineering. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3509112]","[Kubinova, Lucie] Acad Sci Czech Republic, Inst Physiol, Dept Biomath, Vvi, CR-14220 Prague, Czech Republic; [Filova, Eva; Rampichova, Michala; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Rampichova, Michala; Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Czech Republic; [Bianchini, Paolo] Italian Inst Technol Nanophys, I-16163 Genoa, Italy; [Capek, Martin] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Kostakova, Eva] Tech Univ, Fac Text Engn, Liberec 46117, Czech Republic","Kubinova, L, Acad Sci Czech Republic, Inst Physiol, Dept Biomath, Vvi, Videnska 1083, CR-14220 Prague, Czech Republic","kubinova@biomed.cas.cz","Academy of Sciences of the Czech Republic [AV0Z50110509, AV0Z50390512, AV0Z50390703]; Ministry of Education, Youth and Sports of the Czech Republic [LC06063, MSM6840770012, NPV II 2B06130, 1M0510]; Czech Science Foundation [GA102/08/0691, GA202/09/1151, GAP304/10/1307]; EU [214539, 7E09088]; Grant Agency of the Academy of Sciences [IAA500390702]","The presented study was supported by the Academy of Sciences of the Czech Republic (research projects No. AV0Z50110509, AV0Z50390512, and AV0Z50390703), the Ministry of Education, Youth and Sports of the Czech Republic (research programs LC06063, MSM6840770012, NPV II 2B06130, and 1M0510), the Czech Science Foundation (Nos. GA102/08/0691, GA202/09/1151, and GAP304/10/1307), the EU project BIOSCENT (ID number 214539, and 7E09088), and the Grant Agency of the Academy of Sciences No. IAA500390702.",null,26,0,"SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS","BELLINGHAM","1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA","1083-3668",null,"10.1117/1.3509112","J BIOMED OPT","J. Biomed. Opt.","NOV-DEC",2010,15,6,null,null,null,null,null,66011,null,7,"Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging","719AI","ISI:000287171100044"]
["nemá","J","Mehta, G; Macek, M; Mehta, A + Workgroup 35 členů",null,null,null,"Mehta, Gita; Macek, Milan, Jr.; Mehta, Anil","European Registry Working Grp","Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries","JOURNAL OF CYSTIC FIBROSIS",null,"English","Article",null,null,null,null,null,"Database; Rare disease; Geography; Chronic disease; Genetics; p.Phe508del; CFTR","UK; POPULATION; AGE; SEGREGATION; MUTATIONS; MORTALITY; SURVIVAL; OUTCOMES; CF","Background: A 35 country European cystic fibrosis (CF) demographic registry was developed to compare outcomes (EuroCareCF EC-FP6). Methods: We applied methods that had successfully created country-specific registries inviting wide participation to obtain consent and collate demographic and CFTR genotype data. Results: Among 29,095 patients, a widely different country-specific prevalence of childhood CF exists that cannot be explained by differential population frequency of mutant-CFTR or case under-ascertainment with a significant paucity of the homozygous p.Phe508del genotype that presents in childhood in >90% of cases. Conclusions: Excess premature childhood CF mortality may still occur. The better resourced Western Europe now has a similar to 5% mortality for childhood CF, which is not apparent in many of the European countries reported here. In addition, a female survival disadvantage exists. The reasons require further investigation. We showcase the value of simple data collection in one rare disease, which might interest those managing rare diseases across the globe. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Mehta, Gita; Mehta, Anil] Univ Dundee, Div Med Sci, Dundee DD1 9SY, Scotland; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, CZ-15006 Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp, CZ-15006 Prague, Czech Republic","Mehta, A, Univ Dundee, Div Med Sci, Dundee DD1 9SY, Scotland","a.mehta@dundee.ac.uk","European Commission ; European Community [LSHM-CT-2005-018932]; MZOFNM ","Funding from the European Commission for the EuroCareCF project is gratefully acknowledged, as also is help from the project Scientific Coordinator, D.N. Sheppard (Bristol, UK), as this has allowed this wide-ranging project, encompassing so many countries in Europe, to be set up for the first time. EuroCareCF was supported by the European Community's Sixth Framework Programme for Research, priority 1 \"Life Sciences, Genomics and Biotechnology for Health\", contract number LSHM-CT-2005-018932. We also acknowledge the support of MZOFNM2005 to MM.",null,29,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,"10.1016/j.jcf.2010.08.002","J CYST FIBROS","J. Cyst. Fibros","DEC",2010,9,null,null,"Suppl. 2",null,"S5","S64",null,null,60,"Respiratory System","717QG","ISI:000287061900003"]
["nemá","J","Zakovicova, E; Charvat, J; Kukacka, J; Chlumsky, J; Svab, P; Kvapil, M",null,null,null,"Zakovicova, E.; Charvat, J.; Kukacka, J.; Chlumsky, J.; Svab, P.; Kvapil, M.",null,"Circulating Serum Matrix Metalloproteinase-3 and Metalloproteinase-9 Are Not Associated with Echocardiographic Parameters of Diastolic Function in Asymptomatic Type 2 Diabetic Patients","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,"English","Article",null,null,null,null,null,"TYPE 2 DIABETES MELLITUS; ALBUMINURIA; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; ECHOCARDIOGRAPHY","HEART-FAILURE; TISSUE DOPPLER; DYSFUNCTION; MATRIX-METALLOPROTEINASE-9; INHIBITOR; TURNOVER; GENE; MMP9","Serum concentrations of matrix metalloproteinase (MMP) 3 and MMP9 were evaluated in 82 asymptomatic type 2 diabetes mellitus patients without cardiovascular complications and in 41 non-diabetic control subjects. In the asymptomatic diabetic patients, the correlations of these concentrations with diabetes duration, selected biochemical parameters such as glycated haemoglobin (HbA(1c)), and echocardiographic parameters of diastolic function were also assessed. Pulsed and tissue Doppler echocardiography was performed in the two groups. Mean +/- SD age was 61 +/- 6 years for the asymptomatic diabetic patients and 61 +/- 5 years for controls. Mean +/- SD concentrations of MMP3 and MMP9 were significantly higher in the asymptomatic diabetic patients (67.5 +/- 10.4 and 77.8 +/- 28.8 mu g/l, respectively) than in controls (47.2 +/- 6.1 and 51.1 +/- 13.7 mu g/l, respectively). In the asymptomatic diabetic patients, MMP3 correlated only with albuminuria (r = 0.341) and MMP9 only with HbA(1c) (r = 0.262); neither MMP was correlated with echocardiographic parameters of diastolic function. Thus, in asymptomatic type 2 diabetic patients without cardiovascular complications, serum MMP3 and MMP9 were elevated, MMP9 was associated with HbA(1c) and MMP3 was associated with albuminuria, however, MMP3 and MMP9 were not associated with echocardiographic parameters of diastolic function.",null,"Charvat, J, Charles Univ Prague, Dept Med, Fac Hosp 2, V Uvalu 84, Prague 15006 5, Czech Republic","jiri.charvat@lfmotol.cuni.cz","Internal Grant Agency of the Ministry of Health of the Czech Republic [NR/9520-3]","This work was supported by grant NR/9520-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,23,0,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","NOV-DEC",2010,38,6,null,null,null,2093,2099,null,null,7,"Medicine, Research & Experimental; Pharmacology & Pharmacy","730SK","ISI:000288054400025"]
["nemá","J","Stary, J; Jabali, Y; Trka, J; Hrusak, O; Gajdos, P; Hrstkova, H; Sterba, J; Blazek, B; Hak, J; Prochazkova, D; Cerna, Z; Smisek, P; Sedlacek, P; Vavra, V; Mihal, V; Hrodek, O",null,null,null,"Stary, J.; Jabali, Y.; Trka, J.; Hrusak, O.; Gajdos, P.; Hrstkova, H.; Sterba, J.; Blazek, B.; Hak, J.; Prochazkova, D.; Cerna, Z.; Smisek, P.; Sedlacek, P.; Vavra, V.; Mihal, V.; Hrodek, O.","Czech Pediat Hematology Working","Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic","LEUKEMIA",null,"English","Article",null,null,null,null,null,null,"TRIAL; CHILDREN",null,"[Stary, J.; Trka, J.; Hrusak, O.; Gajdos, P.; Smisek, P.; Sedlacek, P.; Vavra, V.; Hrodek, O.] Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.; Trka, J.; Hrusak, O.; Gajdos, P.; Smisek, P.; Sedlacek, P.; Vavra, V.; Hrodek, O.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Jabali, Y.] Reg Hosp, Dept Pediat, Ceske Budejovice, Czech Republic; [Hrstkova, H.] Univ Hosp Brno, Dept Pediat, Brno, Czech Republic; [Hrstkova, H.; Sterba, J.] Masaryk Univ, Childrens Hosp, Brno, Czech Republic; [Sterba, J.] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic; [Blazek, B.] Teaching Hosp, Dept Pediat & Adolescent Med, Ostrava, Czech Republic; [Hak, J.] Teaching Hosp, Dept Pediat, Hradec Kralove, Czech Republic; [Prochazkova, D.] Masaryks Hosp, Dept Pediat, Usti Nad Labem, Czech Republic; [Cerna, Z.] Charles Univ Prague, Teaching Hosp, Dept Pediat, Plzen, Czech Republic; [Mihal, V.] Palacky Univ, Univ Hosp, Dept Pediat, Olomouc, Czech Republic","Stary, J, Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic","jan.stary@lfmotol.cuni.cz",null,null,null,4,4,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2009.255","LEUKEMIA","Leukemia","FEB",2010,24,2,null,null,null,425,428,null,null,4,"Oncology; Hematology","553WO","ISI:000274397700016"]
["nemá","J","Trc, T; Chladek, P; Havlas, V",null,null,null,"Trc, T.; Chladek, P.; Havlas, V.",null,"Drilling and plombage (core decompression) of a femora head avascular necrosis","OSTEOLOGIE",null,"English","Article",null,null,null,null,null,"Avascular necrosis; femoral head; forage; core decompression; press-fit grafting","HIP; OSTEONECROSIS; OSTEOTOMY","The treatment of femoral head necrosis of adults is still rather problematic. Conservative treatment has been reported relatively unsuccessful and surgical treatment does not show convincing results either. The most effective seems to be a surgical treatment in early stages of the disease, however, the diagnosis still remains relatively complicated. For the late stages (2B and above) the most effective treatment option is represented by core decompression and vascular grafting. However, drilling and plombage (especially when using press-fit technique) seems to be successful, although not excellent. The authors describe their own method of drilling and plombage of the necrotic zone of the femoral head in 41 patients with X-ray detected necrotic changes of the femoral head. The pain measured by VAS was seen to decrease after surgery in all patients significantly. The Jacobs score was also observed to have increased (from fair to good outcome). We have not observed any large femoral head collapse after surgery, moreover, in some cases an improvement of the round shape of the femoral head was seen. It is important to mention that in all cases femoral heads with existing necrotic changes (flattening or collapse) were treated. Although the clinical improvement after surgery was not significantly high, the method we describe is a safe and simple method of diminishing pain in attempt to prepare the femoral head for further treatment in a future, without significant restriction of the indication due to necrosis (osteochondroplasty, resurfacing, THR).","[Trc, T.; Chladek, P.; Havlas, V.] Charles Univ Prague, Dept Orthopaed Surg, Fac Med 2, Prague 15008 5, Czech Republic","Trc, T, Charles Univ Prague, Dept Orthopaed Surg, Fac Med 2, V Uvalu 84, Prague 15008 5, Czech Republic","tomas.trc@fnmotol.cz",null,null,null,22,0,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","1019-1291",null,null,"OSTEOLOGIE","Osteologie",null,2010,19,1,null,null,null,36,39,null,null,4,"Orthopedics","711EG","ISI:000286569300007"]
["nemá","J","Chladek, P; Trc, T",null,null,null,"Chladek, P.; Trc, T.",null,"Avascular necrosis of the femoral head in young adults - a double-stage solution with forage and remodeling osteochondroplasty","OSTEOLOGIE",null,"German","Article",null,null,null,null,null,"Avascular necrosis; femoral head; bone grafting; femoroacetabular impingement","FEMOROACETABULAR IMPINGEMENT; HIP; OSTEOARTHRITIS; OSTEONECROSIS","Avascular necrosis of the femoral head remains despite significant advances in medicine, an important pre-arthritis. Attitudes on the indication for a surgical procedure and its radicalism (joint-preserving procedure vs. arthroplasty) are different and changing. During the initial collapse of the head and an uncertain prognosis quod vitam, the indication for total hip replacement can be provided also in the end of the second decade relatively generous. But for patients who are in remission of a systemic disease, this can be considered critical even on the border of the third or fourth decade. Because of its simplicity, low morbidity and a good analgesic effect the removal of necrotic areas with a following autologous bone grafting is recommended in such cases. For further functional problems or pain after this surgery a femoroacetabular impingement syndrome must be excluded, which should be treated by open dislocation of the hip. However, the indication for any osteotomy should be made cautiously. They deteriorate the anatomy at the upper end of the femur and thus the conditions for the implantation of an endoprosthesis, which ultimately often cannot be prevented.","[Chladek, P.; Trc, T.] Karls Univ Prag, Orthopad Klin, Med Fak 2, Prague, Czech Republic","Chladek, P, Karls Univ Prag, Orthopad Klin, Med Fak 2, V Uvalu 84, Cz Prag 5, Czech Republic","tomas.trc@lfmotol.cuni.cz",null,null,null,13,0,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","1019-1291",null,null,"OSTEOLOGIE","Osteologie",null,2010,19,1,null,null,null,40,45,null,null,6,"Orthopedics","711EG","ISI:000286569300008"]
["nemá","J","Ostadalova, I; Charvatova, Z; Wilhelm, J",null,null,null,"Ostadalova, I.; Charvatova, Z.; Wilhelm, J.",null,"Lipofuscin-Like Pigments in the Rat Heart During Early Postnatal Development: Effect of Selenium Supplementation","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Early postnatal development; Heart; Lipofuscin-like pigment; Selenium; Radical oxygen species","LIPID-PEROXIDATION; CARDIAC MYOCYTES; AMBIENT OXYGEN; ACCUMULATION; CELL; AGE; AUTOPHAGY; MECHANISMS; PERIOD; MOUSE","The aim of the study was to characterize a) the lipofuscin-like pigment (LFP) accumulation (an indicator of ROS production) in the rat heart during early postnatal period and b) possible antioxidative role of selenium. Experimental animals received Na2SeO3 in drinking water during gravidity and up to day 15 post partum. Two fluorophores of LFP in the hearts of 1-, 4-, 7- and 15-day-old rats were evaluated by fluorescent analysis. The highest level of heart/body weight ratio in control rats was observed on day 4, in the Se-supplemented rats on day 7. Cardiac LFP content in controls increased from postnatal day 4, in the hearts of Se-supplemented rats the LFP content increased already from day 1. As compared with the Se-supplemented group the LFP content of control hearts was significantly higher on day 1 but significantly lower on day 4. LFP concentration in control hearts decreased from postnatal day 1 to 4; this decrease was followed by significant increase until day 7 and decrease to day 15. LFP concentration in the Se-supplemented hearts was the highest on postnatal day 7; it differed from controls on day 1 and 4. Significant changes of LFP suggest an important role of ROS during critical ontogenetic period.","[Ostadalova, I.] Acad Sci Czech Republic, Inst Physiol, Dept Dev Cardiol, CR-14220 Prague 4, Czech Republic; [Ostadalova, I.; Charvatova, Z.; Wilhelm, J.] Ctr Expt Cardiovasc Res, Prague, Czech Republic; [Wilhelm, J.] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, Prague, Czech Republic","Ostadalova, I, Acad Sci Czech Republic, Inst Physiol, Dept Dev Cardiol, Videnska 1083, CR-14220 Prague 4, Czech Republic","iostadal@biomed.cas.cz","MSMT [1M0510]; AVOZ [501 10509]","This study was supported by grant of MSMT 1M0510, and grant AVOZ 501 10509.",null,30,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,6,null,null,null,881,886,null,null,6,"Physiology","700CW","ISI:000285711400005"]
["nemá","J","Pitha, J; Hubacek, JA; Pithova, P",null,null,null,"Pitha, J.; Hubacek, J. A.; Pithova, P.",null,"The Connexin 37 (1019C > T) Gene Polymorphism Is Associated With Subclinical Atherosclerosis in Women With Type 1 and 2 Diabetes and in Women With Central Obesity","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Connexin 37 gene; Atherosclerosis; Ankle brachial index-women; Diabetes mellitus; Central obesity","CORONARY-ARTERY-DISEASE; RISK","The gene for connexin 37 (Cx37) is considered to be one of the candidate genes for cardiovascular disease. We evaluated the association between Cx37 (1019C>T) gene polymorphism (Pro319Ser) and ankle brachial blood pressure index (ABI) in women with type 1 (n=178) and type 2 (n=111) diabetes, and in women from general population (n=862). All women were genotyped for Cx37 polymorphism. In addition to traditional cardiovascular risk factors, ABI was analyzed. In women with type 1 diabetes, ABI significantly decreased from TT to CC carriers (p for trend=0.008). A similar trend was seen in women with type 2 diabetes (p=0.050) and in women with waist circumference above 75(th) percentile (94 cm; n=208) of the general population (p=0.049). The gene for Cx37 was associated with subclinical atherosclerosis in women with type 1 and 2 diabetes and in women with advanced central obesity. The presence of C allele indicated increased risk.","[Pitha, J.] Inst Clin & Expt Med, Lab Atherosclerosis Res, Prague 14021 4, Czech Republic; [Pithova, P.] Teaching Hosp Motol, Sch Med 2, Dept Med, Prague, Czech Republic","Pitha, J, Inst Clin & Expt Med, Lab Atherosclerosis Res, Videnska 1952-8, Prague 14021 4, Czech Republic","japi@medicon.cz","Internal Grant Agency of the Ministry of Health of the Czech Republic [NR/9026-4/2006]","Supported by grant NR/9026-4/2006 (Internal Grant Agency of the Ministry of Health of the Czech Republic).",null,13,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,6,null,null,null,1029,1032,null,null,4,"Physiology","700CW","ISI:000285711400021"]

{"sheet":"Original export ISI WoS 2011","index":2,"n_rows":80,"n_cols":51,"rows_kept":80,"cut":false,"hidden":false,"merged":[]}
[null,"INFO: Tento sešit obsahuje data z ISI WoS \"tak jak byla získána v okamžiku rešerše\" pro právě platný rok (tedy: 2011)."]
[]
[]
[]
["PT","AU","BA","ED","GP","AF","CA","TI","SO","SE","LA","DT","CT","CY","CL","SP","HO","DE","ID","AB","C1","RP","EM","FU","FX","CR","NR","TC","PU","PI","PA","SN","BN","DI","J9","JI","PD","PY","VL","IS","PN","SU","SI","BP","EP","AR","DI","PG","SC","GA","UT"]
["J","Wilhelm, J; Ivica, J; Kagan, D; Svoboda, P",null,null,null,"Wilhelm, Jiri; Ivica, Josko; Kagan, Dmytro; Svoboda, Petr",null,"Early postnatal development of rat brain is accompanied by generation of lipofuscin-like pigments","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,"English","Article",null,null,null,null,null,"Brain; Early development; Lipofuscin-like pigments; Fluorescence; Rat","LOW-DENSITY-LIPOPROTEIN; BODY GAMMA-IRRADIATION; LIPID-PEROXIDATION; OXIDATIVE STRESS; FREE-RADICALS; MITOCHONDRIA; CELLS; ERYTHROCYTES; ACCUMULATION; MECHANISMS","The increased generation of free radicals results in the formation of fluorescent end-products of lipid peroxidation, lipofuscin-like pigments (LFPs). The authors observed that LFPs are generated in rat brain after a normal birth during 5 postnatal days. The experimental design of the study comprised 10 groups of animals. The authors measured prenatal values 1 day and 7 days before birth, and then the animals were sampled on postnatal day 1, 2, 5, 10, 15, 25, 35, and 90. Maximum LFP concentration is achieved on the postnatal day 2. Starting from postnatal day 10, LFP concentration returns to prenatal values. A new rise in LFP concentration is observed at 3 months of age. This is associated with the beginning of the aging process. LFPs were characterized by fluorescence spectroscopy using tridimensional excitation spectra, synchronous spectra and their derivatives, and HPLC with fluorescence detection. It was possible to discern several tens of fluorescent compounds of unknown structure that are generated and metabolized during early development. The authors suggest that LFPs are formed after respiratory burst of microglia phagocytosing apoptotic cells.","[Wilhelm, Jiri; Ivica, Josko] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Kagan, Dmytro; Svoboda, Petr] CR Acad Sci, Inst Physiol, Prague 14220 4, Czech Republic","Wilhelm, J, Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","jiri.wilhelm@lfmotol.cuni.cz","Grant Agency of AS CR [IAA500110606]; Centre of Neurosciences (Ministry of Education of the Czech Republic) [LC 554]; Academy of Sciences of the Czech Republic [AV0Z50110509]","This study was supported by Grant Agency of AS CR (IAA500110606), The Centre of Neurosciences (project of Ministry of Education of the Czech Republic LC 554), and by the Academy of Sciences of the Czech Republic (AV0Z50110509).",null,27,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,"10.1007/s11010-010-0623-2","MOL CELL BIOCHEM","Mol. Cell. Biochem.","JAN",2011,347,"2011-02-01",null,null,null,157,162,null,null,6,"Cell Biology","696DG","ISI:000285421500017"]
["J","Mohelnikova-Duchonova, B; Marsakova, L; Vrana, D; Holcatova, I; Ryska, M; Smerhovsky, Z; Slamova, A; Schejbalova, M; Soucek, P",null,null,null,"Mohelnikova-Duchonova, Beatrice; Marsakova, Lenka; Vrana, David; Holcatova, Ivana; Ryska, Miroslav; Smerhovsky, Zdenek; Slamova, Alena; Schejbalova, Miriam; Soucek, Pavel",null,"Superoxide Dismutase and Nicotinamide Adenine Dinucleotide Phosphate Quinone Oxidoreductase Polymorphisms and Pancreatic Cancer Risk","PANCREAS",null,"English","Article",null,null,null,null,null,"pancreas; cancer; susceptibility; superoxide dismutase; quinone oxidoreductase","GENE POLYMORPHISMS; OXIDATIVE STRESS; OVARIAN-CANCER; FREE-RADICALS; BLADDER; MNSOD; LUNG; ADENOCARCINOMA; EXPRESSION; PROSTATE","Objectives: Pancreatic carcinoma etiology and molecular pathogenesis is weakly understood. According to the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, an association of functional polymorphisms in oxidative stress-modifying genes superoxide dismutase 2 (SOD2 [Ala16Val, rs4880]), SOD3 (Arg231Gly, rs1799895), nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase (NQO1 [Pro187Ser, rs1800566], and NQO2 (Phe47Leu, rs1143684) with pancreatic cancer risk was studied. Methods: Polymorphisms were studied by allelic discrimination. Results: In a hospital-based case-control study on 500 individuals (235 cases and 265 controls) of Czech white origin, SOD2, SOD3, NQO1, and NQO2 polymorphisms showed no significant association with pancreatic cancer risk. Major lifestyle factors such as smoking and alcohol, coffee, or tea consumption did not modify the effect of the studied polymorphisms. Conclusions: The first European study of the SOD2, SOD3, NQO1, and NQO2 roles in pancreatic cancer etiology did not find significant associations. Despite this observation, other populations with different lifestyle(s) may be at risk and should be further studied.","[Mohelnikova-Duchonova, Beatrice; Marsakova, Lenka; Vrana, David; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Holcatova, Ivana; Slamova, Alena; Schejbalova, Miriam] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic; [Marsakova, Lenka] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Vrana, David] Charles Univ Prague, Dept Oncol, Prague, Czech Republic; [Holcatova, Ivana; Slamova, Alena; Schejbalova, Miriam] Gen Teaching Hosp, Prague, Czech Republic; [Ryska, Miroslav] Charles Univ Prague, Dept Surg, Fac Med 2, Prague, Czech Republic; [Ryska, Miroslav] Cent Mil Hosp, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Inst Epidemiol, Fac Med 2, Prague, Czech Republic","Soucek, P, Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic","psoucek@szu.cz","Internal Grant Agency of the Ministry of Health, Prague, Czech Republic [9422-3]","This study was supported by grant No. 9422-3 from the Internal Grant Agency of the Ministry of Health, Prague, Czech Republic.",null,37,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0885-3177",null,"10.1097/MPA.0b013e3181f74ad7","PANCREAS","Pancreas","JAN",2011,40,1,null,null,null,72,78,null,null,7,"Gastroenterology & Hepatology","695MX","ISI:000285375900015"]
["J","Marek, J; Tomek, V; Skovranek, J; Povysilova, V; Samanek, M",null,null,null,"Marek, Jan; Tomek, Viktor; Skovranek, Jan; Povysilova, Viera; Samanek, Milan",null,"Prenatal ultrasound screening of congenital heart disease in an unselected national population: a 21-year experience","HEART",null,"English","Article",null,null,null,null,null,null,"OUTLET RIGHT VENTRICLE; FETAL DIAGNOSIS; CARDIAC-MALFORMATIONS; AORTIC-VALVE; SURVIVAL; FETUSES; PREVALENCE; CHILDREN; BORN; ECHOCARDIOGRAPHY","Objective To determine the prevalence and spectrum of congenital heart disease (CHD) and the impact of a national prenatal ultrasound screening programme on outcome in a well-characterised population. Design and setting A comprehensive registry was created of all paediatric and fetal patients with CHD over a 21-year period (1986-2006) in the Czech Republic. The centralised healthcare system enabled confirmation of prenatal and postnatal findings clinically and by post mortem. Patients and results In the entire cohort of 9475 fetuses referred for detailed cardiac evaluation, 1604 (16.9%) had CHD, of which 501 (31.2%) had additional extracardiac anomalies. In the pregnancies which continued, 59 (8.6%) of 685 fetuses died in utero, and 626 (91.4%) babies were born alive. Prenatal detection rate was highest in double outlet right ventricle (77.3%) and hypoplastic left heart (50.6%). Detection rate increased significantly (p<0.001) for 12/17 lesions comparing 1986-1999 and 2000-2006. In recent years, detection of hypoplastic left heart reached 95.8% while transposition of the great arteries was diagnosed antenatally in only 25.6%. Conclusion The nationwide prenatal ultrasound screening programme enabled detection of major cardiac abnormalities in 1/3 of patients born with any CHD and 80% of those with critical forms. Nevertheless, owing to the severity of lesions and associated extracardiac anomalies, the overall mortality of antenatally diagnosed CHD remains high. These findings are important for the understanding natural history of CHD for the establishing of screening programmes in Europe.","[Marek, Jan; Tomek, Viktor; Skovranek, Jan; Samanek, Milan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Marek, Jan; Tomek, Viktor; Skovranek, Jan; Samanek, Milan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Povysilova, Viera] Univ Hosp Motol, Inst Pathol & Mol Biol, Sch Med 2, Prague, Czech Republic","Marek, J, Great Ormond St Hosp Sick Children, London WC1N 3JH, England","marekj@gosh.nhs.uk","Ministry of Health of the Czech Republic [MZO-0064203/6203]","This work was supported by a grant from the Ministry of Health of the Czech Republic: MZO-0064203/6203.",null,39,0,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,"10.1136/hrt.2010.206623","HEART","Heart","JAN",2011,97,2,null,null,null,124,130,null,null,7,"Cardiac & Cardiovascular Systems","695OE","ISI:000285380800008"]
["J","Spacek, M; Hubacek, P; Markova, J; Zajac, M; Vernerova, Z; Kamaradova, K; Stuchly, J; Kozak, T",null,null,null,"Spacek, Martin; Hubacek, Petr; Markova, Jana; Zajac, Miroslav; Vernerova, Zdenka; Kamaradova, Katerina; Stuchly, Jan; Kozak, Tomas",null,"Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients","APMIS",null,"English","Article",null,null,null,null,null,"Hodgkin lymphoma; Epstein-Barr virus; PCR; LMP1; EBER","LYMPHOPROLIFERATIVE DISEASE; QUANTITATIVE-ANALYSIS; GENOMES; MARKER; LOAD; CELL; PCR","Epstein-Barr virus (EBV) is associated with approximately one-third of Hodgkin lymphoma (HL) cases. EBV-DNA is often present in the plasma and whole blood of EBV-associated HL patients. However, the significance of EBV-DNA monitoring is debated. In a cohort of 165 adult HL patients, EBV-DNA viral load was prospectively monitored both in the plasma and whole blood. Diagnostic tissue samples of all patients were histologically reviewed; in 72% nodular sclerosis was detected, 24% presented with mixed cellularity (MC), and 5% had other type of HL. Tissues from 150 patients were also analyzed for the presence of latent EBV infection using in situ hybridization for EBV-encoded RNA (EBER) and immunohistochemistry for latent membrane protein (LMP1). Using these methods, 29 (19%) patients were classified as EBV positive. Using real-time quantitative PCR, 22 (76%) of EBV-positive HL patients had detectable EBV-DNA in the plasma and 19 (66%) patients in whole blood prior to therapy. In the group of EBV-negative HL cases, three (2%) patients had detectable plasma EBV-DNA and 30 (25%) patients whole blood EBV-DNA before treatment. EBV-positive HL was significantly associated with EBV-DNA positivity both in the plasma and whole blood in pretreatment samples, increasing age and MC subtype. Serial analysis of plasma EBV-DNA showed that response to therapy was associated with decline in viral load. Moreover, significantly increased plasma EBV-DNA level recurred before disease relapse in one patient. Our results further suggest that the assessment of plasma EBV-DNA viral load might be of value for estimation of prognosis and follow-up of patients with EBV-positive HL.","[Spacek, Martin; Markova, Jana; Kozak, Tomas] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague 10034 10, Czech Republic; [Spacek, Martin; Markova, Jana; Vernerova, Zdenka; Kozak, Tomas] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Hubacek, Petr; Stuchly, Jan] Charles Univ Prague, Dept Paediat Hematol & Oncol, Motol Univ Hosp, Prague, Czech Republic; [Hubacek, Petr; Kamaradova, Katerina; Stuchly, Jan] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zajac, Miroslav] Motol Univ Hosp, Dept Med Microbiol, Prague, Czech Republic; [Vernerova, Zdenka] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Pathol, Prague, Czech Republic; [Kamaradova, Katerina] Charles Univ Prague, Dept Pathol & Mol Med, Motol Univ Hosp, Prague, Czech Republic; [Stuchly, Jan] CLIP Childhood Leukemia Invest Prague, Prague, Czech Republic; [Stuchly, Jan] Charles Univ Prague, Fac Math & Phys, Dept Numer Math, Prague, Czech Republic","Spacek, M, Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Srobarova 50, Prague 10034 10, Czech Republic","m.spacek@fnkv.cz","Ministry of Health of the Czech Republic [NR9166]","The authors acknowledge the laboratory technician Jana Sumova for laboratory work and Katerina Klaskova for gathering of the data. The authors have no conflicts of interest with respect to the topic of the study. This work was supported by a grant (NR9166) from the Ministry of Health of the Czech Republic.",null,23,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0903-4641",null,"10.1111/j.1600-0463.2010.02685.x","APMIS","APMIS","JAN",2011,119,1,null,null,null,10,16,null,null,7,"Immunology; Microbiology; Pathology","692LF","ISI:000285153600002"]
["J","Bruha, R; Marecek, Z; Pospisilova, L; Nevsimalova, S; Vitek, L; Martasek, P; Nevoral, J; Petrtyl, J; Urbanek, P; Jiraskova, A; Ferenci, P",null,null,null,"Bruha, Radan; Marecek, Zdenek; Pospisilova, Lenka; Nevsimalova, Sona; Vitek, Libor; Martasek, Pavel; Nevoral, Jiri; Petrtyl, Jaromir; Urbanek, Petr; Jiraskova, Alena; Ferenci, Peter",null,"Long-term follow-up of Wilson Disease: natural history, treatment, mutations analysis and phenotypic correlation","LIVER INTERNATIONAL",null,"English","Article",null,null,null,null,null,"D-penicillamine; long-term outcome; mutational analysis; Wilson disease; zinc salts","CLINICAL PRESENTATION; H1069Q MUTATION; DIAGNOSIS; COPPER; GENE; ZINC; ATP7B","Background and aims: Wilson disease (WD) is an inherited disorder of copper metabolism. When treated, the outcome can be excellent, although the long-term survival has yet to be well documented. The aim of this study was to describe the long-term outcome of a cohort of patients with WD and to assess those factors affecting the phenotypic manifestation of WD. Methods: The presence of mutations to the ATP7B gene, the clinical manifestations, treatments and the long-term outcomes were analysed retrospectively in 117 patients with WD (59 men and 58 women, aged at evaluation 38.5 +/- 11, range 16-63 years). Results: Fifty-five patients with a neurological presentation, 51 patients with a hepatic presentation and 11 asymptomatic patients were followed up for an average of 15.1 +/- 10 years (median 12 years, range 1-41 years). The H1069Q ATP7B gene mutation was the most frequent genetic variant (54.3%); the frequency of this mutation did not differ between patients with either the hepatic or the neurological presentation (P = 0.099). D-penicillamine or zinc salts (81 and 17% respectively) were used for treatment, and three patients underwent liver transplantation. The majority of symptomatic patients became asymptomatic, or improved, during the follow-up (82% patients with hepatic presentation, 69% with neurological presentation). The long-term survival of patients with WD did not differ from that of the general Czech population (P = 0.95). Conclusions: Long-term follow-up shows a satisfactory response in the great majority of adequately treated patients with WD and survival coincides with that of the general population.","[Bruha, Radan; Vitek, Libor; Petrtyl, Jaromir; Jiraskova, Alena] Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Gen Teaching Hosp, Prague 12808 2, Czech Republic; [Marecek, Zdenek; Urbanek, Petr] Charles Univ Prague, Dept Internal Med, Fac Med 1, Prague 12808 2, Czech Republic; [Marecek, Zdenek; Urbanek, Petr] Charles Univ Prague, Cent Mil Hosp, Prague 12808 2, Czech Republic; [Pospisilova, Lenka; Martasek, Pavel] Charles Univ Prague, Lab Mitochondrial Disorders, Dept Pediat, Fac Med 1, Prague 12808 2, Czech Republic; [Nevsimalova, Sona] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 12808 2, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 12808 2, Czech Republic; [Ferenci, Peter] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria","Bruha, R, Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Gen Teaching Hosp, U Nemocnice 2, Prague 12808 2, Czech Republic","bruha@cesnet.cz","Czech Ministry of Health [9406/3]","This study was supported by Grant IGA MZ CR No. 9406/3, provided by the Czech Ministry of Health.",null,31,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1478-3223",null,"10.1111/j.1478-3231.2010.02354.x","LIVER INT","Liver Int.","JAN",2011,31,1,null,null,null,83,91,null,null,9,"Gastroenterology & Hepatology","690NH","ISI:000285011000011"]
["J","Patil, S; Jirak, D; Saudek, F; Hajek, M; Scheffler, K",null,null,null,"Patil, S.; Jirak, D.; Saudek, F.; Hajek, M.; Scheffler, K.",null,"Positive contrast visualization of SPIO-labeled pancreatic islets using echo-dephased steady-state free precession","EUROPEAN RADIOLOGY",null,"English","Article",null,null,null,null,null,"Pancreatic islets; Positive contrast; Iron-oxide; Echo-dephasing; Susceptibility","IRON-OXIDE NANOPARTICLES; MAGNETIC-RESONANCE; CELLS; TRANSPLANTATION; PARTICLES; GRASP; MRI","Objective MRI has recently been introduced as a promising method of monitoring the transplanted pancreatic islets labelled with superparamagnetic iron oxide (SPIO). However, the traditional T-2*-weighted approach frequently yields ambiguous results because of the negative contrast of the SPIO particles on the background of other body components. This obstacle could be overcome with the use of a novel method known as echo-dephased steady state free precession (SSFP), generating positive contrast in the presence of paramagnetic material. Methods In phantoms, we achieved exact localisation and clear positive contrast visualisation of human SPIO labelled islets. Using the proposed method we demonstrated the ability to detect even a single pancreatic islet against a homogeneous background. Results In vivo experiments in rats confirmed reliable and accurate localisation of transplanted SPIO labelled islets. Conclusion The echo-dephased SSFP technique could successfully visualise SPIO-labelled human and rat pancreatic islets yielding a positive contrast.","[Jirak, D.; Hajek, M.] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, Prague 14021, Czech Republic; [Patil, S.] Siemens Corp, Ctr Appl Med Imaging, Corp Res, Baltimore, MD USA; [Saudek, F.] Inst Clin & Expt Med, Ctr Diabet, Prague 14021, Czech Republic; [Patil, S.; Scheffler, K.] Univ Basel Hosp, Dept Radiol, Div Radiol Phys, CH-4031 Basel, Switzerland; [Jirak, D.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Jirak, D, Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, Videnska 1958-9, Prague 14021, Czech Republic","daniel.jirak@ikem.cz","EU [201842]; Swiss National Science Foundation [325230-118377]","We thank J. Kriz, E. Dovolilova and Z. Berkova from the Laboratory of Pancreatic Islets, Diabetes Center at the Institute for Clinical and Experimental Medicine, Prague, for providing pancreatic islets. This work was supported by a grant from the ENCITE - Seventh EU Framework Program 201842, and a grant from the Swiss National Science Foundation No. 325230-118377. S. Patil and D. Jirak contributed equally to this article.",null,20,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0938-7994",null,"10.1007/s00330-010-1909-1","EUROPEAN RADIOL","Eur. Radiol.","JAN",2011,21,1,null,null,null,214,220,null,null,7,"Radiology, Nuclear Medicine & Medical Imaging","689AO","ISI:000284899700029"]
["J","Honetschlagerova, Z; Huskova, Z; Vanourkova, Z; Sporkova, A; Kramer, HJ; Hwang, SH; Tsai, HJ; Hammock, BD; Imig, JD; Cervenka, L; Kopkan, L",null,null,null,"Honetschlaegerova, Zuzana; Huskova, Zuzana; Vanourkova, Zdenka; Sporkova, Alexandra; Kramer, Herbert J.; Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.; Imig, John D.; Cervenka, Ludek; Kopkan, Libor",null,"Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension","JOURNAL OF PHYSIOLOGY-LONDON",null,"English","Article",null,null,null,null,null,null,"INTRARENAL ANGIOTENSIN-II; END-ORGAN DAMAGE; DEPENDENT MALIGNANT HYPERTENSION; AT(1) RECEPTOR BLOCKADE; ARACHIDONIC-ACID; NITRIC-OXIDE; EPOXYEICOSATRIENOIC ACIDS; BLOOD-PRESSURE; IN-VITRO; INFLAMMATION","Non-technical summary Arachidonic acid metabolites called epoxyeicosatrienoic acids (EETs) influence vascular tone and renal tubular sodium and water transport and thus have been implicated in the control of blood pressure. Inhibition of the enzyme soluble epoxide hydrolase (sEH), which reduces EET degradation to the corresponding diols, leads to substantial attenuation of malignant hypertension in a transgenic rat strain harbouring the mouse renin gene particularly via an improvement of renal function. The observed antihypertensive and renoprotective effects of this novel pharmacological approach provide a potentially new direction in antihypertensive therapy. Abstract In the present study, we examined the effects of soluble epoxide hydrolase (sEH) inhibition on the development of angiotensin II-dependent hypertension and on renal function in transgenic rats with inducible expression of the mouse renin gene (strain name Cyp1a1-Ren-2). Hypertension was induced in these rats by indole-3-carbinol (I3C; 0.3% in the diet) for 12 days. The sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) was given in two doses (13 or 26 mg l-1) in drinking water. Blood pressure (BP), body weight (BW) and renal excretory parameters were monitored in conscious animals during the experiment. Renal haemodynamics was assessed at the end of treatment in anaesthetized rats. I3C administration resulted in severe hypertension with a rise in systolic BP from 118 +/- 2 to 202 +/- 3 mmHg, a loss of BW from 266 +/- 5 to 228 +/- 4 g and a rise in proteinuria from 14 +/- 2 to 34 +/- 3 mg day-1. Both doses of c-AUCB significantly attenuated the development of hypertension (systolic BP of 181 +/- 4 and 176 +/- 4 mmHg, respectively), the loss in BW (256 +/- 4 and 259 +/- 3 g, respectively) and the degree of proteinuria (27 +/- 2 and 25 +/- 3 mg day-1, respectively) to a similar extent. Moreover, c-AUCB prevented the reduction in renal plasma flow (5.4 +/- 0.4 vs. 4.6 +/- 0.3 ml min-1 g-1) and significantly increased sodium excretion (0.84 +/- 0.16 vs. 0.38 +/- 0.08 mu mol min-1 g-1) during I3C administration. These data suggest that the oral administration of c-AUCB displays antihypertensive effects in Ren-2 transgenic rats with inducible malignant hypertension via an improvement of renal function.","[Honetschlaegerova, Zuzana; Huskova, Zuzana; Vanourkova, Zdenka; Sporkova, Alexandra; Cervenka, Ludek; Kopkan, Libor] Inst Clin & Expt Med, Dept Expt Med, CZ-14021 Prague 4, Czech Republic; [Honetschlaegerova, Zuzana; Huskova, Zuzana; Vanourkova, Zdenka; Sporkova, Alexandra; Kopkan, Libor] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.] Univ Calif Davis, UCD Canc Ctr, Davis, CA 95616 USA","Kopkan, L, Inst Clin & Expt Med, Dept Expt Med, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic","libor.kopkan@ikem.cz","Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA) [NS/9699-4]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Center for Cardiovascular Research [1M6798582302]; Grant Agency of the Academy of Science of the Czech Republic [KJB 502030801]; Czech Science Foundation (GACR) [305/08/P053, P303/10/P170, 305/08/J006]; Deutsche Forschungsgemeinschaft (DFG) [436 TSE 113/57/0-1]; Deutscher Akademischer Austauschdienst (DAAD) ; NIH [HL59699, DK38226]; Howard Hughes Foundation ; NIEHS [R01 ES02710, P42 ES004699]; IGA [NS/10499-3]; EU [CZ.2.16/3.1.00/22126]","This study was supported by grant NS/9699-4 awarded to L.K. by the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA) and also by institutional finance support from the Institute for Clinical and Experimental Medicine (no. MZO 00023001) and financial support from the Center for Cardiovascular Research (no. 1M6798582302). L.K. and Z.Ho. are also partly supported by grant KJB 502030801 from the Grant Agency of the Academy of Science of the Czech Republic. Z.Hu. is supported by grant No. 305/08/P053 and A.S. is supported by grant P303/10/P170 awarded by the Czech Science Foundation (GACR). H.J.K. is supported by the Deutsche Forschungsgemeinschaft (DFG) No. 436 TSE 113/57/0-1 and Deutscher Akademischer Austauschdienst (DAAD). J.D.I. is an Established Investigator of the American Heart Association and these studies were supported by NIH grants HL59699 and DK38226. H.-J.T. was supported in part by the Howard Hughes Foundation and a fellowship from the NIEHS Supported Basic Research Program. Partial support was provided by NIEHS Grant R01 ES02710 and NIEHS Superfund Basic Research Program P42 ES004699 awarded to B.D.H.. L.C. is currently supported by grant No. 305/08/J006 (GACR) and grant NS/10499-3 (IGA). This study was also supported by the EU by the Operational Program Prague - Competitiveness; project 'CEVKOON' (no. CZ.2.16/3.1.00/22126).",null,47,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0022-3751",null,"10.1113/jphysiol.2010.199505","J PHYSIOL-LONDON","J. Physiol.-London","JAN",2011,589,1,null,null,null,207,219,null,null,13,"Neurosciences; Physiology","700RB","ISI:000285760900020"]
["J","Martin, RCG; Joshi, J; Robbins, K; Tomalty, D; Bosnjakovik, P; Derner, M; Padr, R; Rocek, M; Scupchenko, A; Tatum, C",null,null,null,"Martin, Robert C. G.; Joshi, Jonathan; Robbins, Ken; Tomalty, Dana; Bosnjakovik, Petar; Derner, Milous; Padr, Radek; Rocek, Miloslav; Scupchenko, Alexander; Tatum, Cliff",null,"Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study","ANNALS OF SURGICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"PHASE-II TRIAL; ARTERIAL INFUSION; RANDOMIZED-TRIAL; FOLINIC-ACID; CANCER; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; MULTICENTER; RADIOEMBOLIZATION","Introduction. Response rates and overall outcome for patients who have failed first-line and in some cases second-line chemotherapy are as low as 12% and 7 months, respectively. The aim of this study is to evaluate the efficacy of hepatic arterial sulfonate hydrogel microsphere (drug-eluting beads), irinotecan preloaded therapy (DEBIRI) in metastatic colorectal cancer refractory to systemic chemotherapy. Methods. This was a multicenter multinational single-arm study of metastatic colorectal cancer patients who received DEBIRI after failing systemic chemotherapy from 10/2006 to 8/2008. Primary endpoints were safety, tolerance, tumor response rates, and overall survival. Results. Fifty-five patients who had received prior systemic chemotherapy and who underwent a total of 99 DEBIRI treatments were reviewed. The median number of DEBIRI treatments was 2 (range 1-5), median treatment dose was 100 mg (range 100-200 mg), with total hepatic treatment of 200 mg (range 200-650 mg), with 86% of treatments performed as lobar infusion and 30% of patients treated with concurrent simultaneous chemotherapy. Adverse events occurred in 28% of patients with median grade of 2 (range 1-3) with no deaths at 30 days post procedure. Response rates were 66% at 6 months and 75% at 12 months. Overall survival in these patients was 19 months, with progression-free survival of 11 months. Conclusions. Hepatic arterial drug-eluting bead, irinotecan (DEBIRI) was safe and effective in treatment of metastatic colorectal cancer (MCC) refractory to multiple lines of systemic chemotherapy. DEBIRI is an acceptable therapy for treatment of metastatic colorectal cancer to the liver.","[Martin, Robert C. G.; Joshi, Jonathan] Univ Louisville, Sch Med, Div Surg Oncol, Louisville, KY 40292 USA; [Robbins, Ken] Baptist Hlth, Little Rock, AR USA; [Tomalty, Dana] Huntsville Dist Mem Hosp, Huntsville, AL USA; [Bosnjakovik, Petar] Univ Clin Ctr, Inst Radiol, Nish, Serbia; [Derner, Milous] Inst Clin & Intervent Radiol, Usti Nad Labem, Czech Republic; [Rocek, Miloslav] Inst Clin & Intervent Radiol IKEM, Dept Diagnost & Intervent Radiol, Prague 4, Czech Republic; [Padr, Radek] Charles Univ Prague, Univ Hosp Motol, Dept Radiol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Scupchenko, Alexander] Reg Oncol Dispenser, Samara, Russia; [Tatum, Cliff] Norton Radiol, Louisville, KY USA","Martin, RCG, Univ Louisville, Sch Med, Div Surg Oncol, Louisville, KY 40292 USA","Robert.Martin@louisville.edu","Biocompatibles ","The research registry reported on herein received support from an unrestricted educational grant from Biocompatibles. R.C.G.M. has served as a consultant for Biocompatibles.",null,26,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1068-9265",null,"10.1245/s10434-010-1288-5","ANNALS SURG ONCOLOGY","Ann. Surg. Oncol.","JAN",2011,18,1,null,null,null,192,198,null,null,7,"Oncology; Surgery","710BU","ISI:000286486700032"]
["J","Cerny, V; Herold, I; Cvachovec, K; Sevcik, P; Adamus, M",null,null,null,"Cerny, Vladimir; Herold, Ivan; Cvachovec, Karel; Sevcik, Pavel; Adamus, Milan",null,"Guidelines for Managing Neuromuscular Block: Not Only Czech Beer Deserves a Taste","ANESTHESIA AND ANALGESIA",null,"English","Letter",null,null,null,null,null,null,"MANAGEMENT",null,"[Cerny, Vladimir] Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada; [Herold, Ivan] Hosp Mlada Boleslav, Dept Anesthesia & Intens Care, Mlada Boleslav, Czech Republic; [Cvachovec, Karel] Charles Univ Prague, Fac Hosp Motol, Dept Anesthesia & Intens Care, Prague, Czech Republic; [Sevcik, Pavel] Masaryk Univ, Fac Hosp Brno, Fac Med, Dept Anesthesia & Intens Care, Brno, Czech Republic; [Adamus, Milan] Palacky Univ, Fac Hosp Olomouc, Fac Med & Dent, Dept Anesthesia & Intens Care, CR-77147 Olomouc, Czech Republic","Cerny, V, Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada","milan.adamus@seznam.cz",null,null,null,8,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0003-2999",null,"10.1213/ANE.0b013e3181fff10b","ANESTH ANALG","Anesth. Analg.","FEB",2011,112,2,null,null,null,482,482,null,null,1,"Anesthesiology","711GV","ISI:000286576000034"]
["J","Booth, C; Gilmour, KC; Veys, P; Gennery, AR; Slatter, MA; Chapel, H; Heath, PT; Steward, CG; Smith, O; O'Meara, A; Kerrigan, H; Mahlaoui, N; Cavazzana-Calvo, M; Fischer, A; Moshous, D; Blanche, S; Pachlopnick-Schmid, J; Latour, S; de Saint-Basile, G; Albert, M; Notheis, G; Rieber, N; Strahm, B; Ritterbusch, H; Lankester, A; Hartwig, NG; Meyts, I; Plebani, A; Soresina, A; Finocchi, A; Pignata, C; Cirillo, E; Bonanomi, S; Peters, C; Kalwak, K; Pasic, S; Sedlacek, P; Jazbec, J; Kanegane, H; Nichols, KE; Hanson, IC; Kapoor, N; Haddad, E; Cowan, M; Choo, S; Smart, J; Arkwright, PD; Gaspar, HB",null,null,null,"Booth, Claire; Gilmour, Kimberly C.; Veys, Paul; Gennery, Andrew R.; Slatter, Mary A.; Chapel, Helen; Heath, Paul T.; Steward, Colin G.; Smith, Owen; O'Meara, Anna; Kerrigan, Hilary; Mahlaoui, Nizar; Cavazzana-Calvo, Marina; Fischer, Alain; Moshous, Despina; Blanche, Stephane; Pachlopnick-Schmid, Jana; Latour, Sylvain; de Saint-Basile, Genevieve; Albert, Michael; Notheis, Gundula; Rieber, Nikolaus; Strahm, Brigitte; Ritterbusch, Henrike; Lankester, Arjan; Hartwig, Nico G.; Meyts, Isabelle; Plebani, Alessandro; Soresina, Annarosa; Finocchi, Andrea; Pignata, Claudio; Cirillo, Emilia; Bonanomi, Sonia; Peters, Christina; Kalwak, Krzysztof; Pasic, Srdjan; Sedlacek, Petr; Jazbec, Janez; Kanegane, Hirokazu; Nichols, Kim E.; Hanson, I. Celine; Kapoor, Neena; Haddad, Elie; Cowan, Morton; Choo, Sharon; Smart, Joanne; Arkwright, Peter D.; Gaspar, Hubert B.",null,"X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease","BLOOD",null,"English","Article",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; BARR-VIRUS INFECTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CUTTING EDGE; T-CELLS; LYMPHOCYTIC VASCULITIS; ENCODING GENE; SAP; ACTIVATION; MONONUCLEOSIS","X-linked lymphoproliferative disease (XLP1) is a rare immunodeficiency characterized by severe immune dysregulation and caused by mutations in the SH2D1A/SAP gene. Clinical manifestations are varied and include hemophagocytic lymphohistiocytosis (HLH), lymphoma and dysgammaglobulinemia, often triggered by Epstein-Barr virus infection. Historical data published before improved treatment regimens shows very poor outcome. We describe a large cohort of 91 genetically defined XLP1 patients collected from centers worldwide and report characteristics and outcome data for 43 patients receiving hematopoietic stem cell transplant (HSCT) and 48 untransplanted patients. The advent of better treatment strategies for HLH and malignancy has greatly reduced mortality for these patients, but HLH still remains the most severe feature of XLP1. Survival after allogeneic HSCT is 81.4% with good immune reconstitution in the large majority of patients and little evidence of posttransplant lymphoproliferative disease. However, survival falls to 50% in patients with HLH as a feature of disease. Untransplanted patients have an overall survival of 62.5% with the majority on immunoglobulin replacement therapy, but the outcome for those untransplanted after HLH is extremely poor (18.8%). HSCT should be undertaken in all patients with HLH, because outcome without transplant is extremely poor. The outcome of HSCT for other manifestations of XLP1 is very good, and if HSCT is not undertaken immediately, patients must be monitored closely for evidence of disease progression. (Blood. 2011;117(1):53-62)","[Booth, Claire; Gilmour, Kimberly C.; Veys, Paul; Gaspar, Hubert B.] Inst Child Hlth, Ctr Immunodeficiency, Mol Immunol Unit, London WC1N 1EH, England; [Gennery, Andrew R.; Slatter, Mary A.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Chapel, Helen] Univ Oxford, Dept Clin Immunol, Nuffield Dept Med, Oxford, England; [Chapel, Helen] Oxford Radcliffe Hosp, Oxford, England; [Heath, Paul T.] St George Hosp, London, England; [Steward, Colin G.] Royal Hosp Children, Bone Marrow Transplant Unit, Bristol, Avon, England; [Smith, Owen; O'Meara, Anna; Kerrigan, Hilary] Our Ladys Childrens Hosp, Dept Haematol & Oncol, Dublin, Ireland; [Mahlaoui, Nizar; Cavazzana-Calvo, Marina; Fischer, Alain; Moshous, Despina; Blanche, Stephane; Pachlopnick-Schmid, Jana] Assistance Publ Hop Paris, Hop Necker Enfants Malad, Unite Immuno Hematol & Rhumatol Pediat, Paris, France; [Latour, Sylvain; de Saint-Basile, Genevieve] Hop Necker Enfants Malad, INSERM, U678, Paris, France; [Albert, Michael; Notheis, Gundula; Rieber, Nikolaus] Univ Munich, Dr Von Haunerschen Kinderspital, Dept Pediat Hematol Oncol & Infect Immun, D-80337 Munich, Germany; [Strahm, Brigitte] Univ Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Ritterbusch, Henrike] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Lankester, Arjan] Leiden Univ, Med Ctr, Dept Pediat, Div Immunol Haematol Oncol Bone Marrow Transplant, Leiden, Netherlands; [Hartwig, Nico G.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat Infect Dis & Immunol, Rotterdam, Netherlands; [Meyts, Isabelle] Univ Hosp Leuven, Dept Paediat, Louvain, Belgium; [Plebani, Alessandro; Soresina, Annarosa] Univ Brescia, Dept Pediat, Brescia, Italy; [Finocchi, Andrea] Univ Roma Tor Vergata, Childrens Hosp Bambino Gesu, Dept Pediat, Unit Immunoinfectivol, Rome, Italy; [Pignata, Claudio; Cirillo, Emilia] Univ Naples Federico 2, Dept Pediat, Naples, Italy; [Bonanomi, Sonia] Uni Milano Bicocca, Osped San Gerardo, Pediat Clin, Ctr Trapianto Midollo Osseo, Monza, Italy; [Peters, Christina] St Anna Childrens Hosp, Bone Marrow Transplantat Unit, A-1090 Vienna, Austria; [Kalwak, Krzysztof] Med Acad Wroclaw, Dept Paediat Haematol & Oncol, Wroclaw, Poland; [Pasic, Srdjan] Mother & Child Hlth Inst Dr Vukan Cupic, Dept Paediat Immunol, Belgrade, Serbia; [Pasic, Srdjan] Mother & Child Hlth Inst Dr Vukan Cupic, Dept Pathol, Belgrade, Serbia; [Pasic, Srdjan] Mother & Child Hlth Inst Dr Vukan Cupic, Dept Transfus Med, Belgrade, Serbia; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Jazbec, Janez] Univ Ljubljana, Med Ctr, Div Hematol & Oncol, Dept Pediat, Ljubljana 61000, Slovenia; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med, Dept Paediat, Toyama 930, Japan; [Nichols, Kim E.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Hanson, I. Celine] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Kapoor, Neena] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Res Immunol Bone Marrow Transplantat, Los Angeles, CA 90033 USA; [Haddad, Elie] Univ Montreal, Ctr Hosp Univ St Justine, Dept Pediat & Microbiol & Immunol, Montreal, PQ, Canada; [Cowan, Morton] Univ Calif San Francisco, Childrens Hosp, Pediat Blood & Marrow Transplant Div, San Francisco, CA 94143 USA; [Choo, Sharon; Smart, Joanne] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester, Lancs, England","Gaspar, HB, Inst Child Hlth, Ctr Immunodeficiency, Mol Immunol Unit, 30 Guilford St, London WC1N 1EH, England","h.gaspar@ich.ucl.ac.uk","Wellcome Trust [082159/2/07/2]","This work was supported by the Wellcome Trust (082159/2/07/2; C.B. is a Clinical Research Fellow).",null,41,1,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2010-06-284935","BLOOD","Blood","JAN 6",2011,117,1,null,null,null,53,62,null,null,10,"Hematology","703FO","ISI:000285963900014"]
["J","Zuna, J; Madzo, J; Krejci, O; Zemanova, Z; Kalinova, M; Muzikova, K; Zapotocky, M; Starkova, J; Hrusak, O; Horak, J; Trka, J",null,null,null,"Zuna, Jan; Madzo, Jozef; Krejci, Ondrej; Zemanova, Zuzana; Kalinova, Marketa; Muzikova, Katerina; Zapotocky, Michal; Starkova, Julia; Hrusak, Ondrej; Horak, Jiri; Trka, Jan",null,"ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia","BLOOD",null,"English","Letter",null,null,null,null,null,null,null,null,"[Zuna, Jan; Madzo, Jozef; Krejci, Ondrej; Kalinova, Marketa; Muzikova, Katerina; Zapotocky, Michal; Starkova, Julia; Hrusak, Ondrej; Trka, Jan] Charles Univ Prague, Childhood Leukaemia Invest Prague, Prague 15006 5, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Fac Med 1, Prague 15006 5, Czech Republic; [Horak, Jiri] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15006 5, Czech Republic; [Zuna, Jan; Madzo, Jozef; Krejci, Ondrej; Kalinova, Marketa; Muzikova, Katerina; Zapotocky, Michal; Starkova, Julia; Hrusak, Ondrej; Trka, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006 5, Czech Republic","Zuna, J, Charles Univ Prague, Childhood Leukaemia Invest Prague, V Uvalu 84, Prague 15006 5, Czech Republic","jan.zuna@lfmotol.cuni.cz",null,null,null,0,2,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2010-09-309070","BLOOD","Blood","JAN 6",2011,117,1,null,null,null,368,369,null,null,2,"Hematology","703FO","ISI:000285963900052"]
["J","Kuipers, JE; Coenen, EA; Balgobind, BV; Stary, J; Baruchel, A; de Haas, V; de Bont, ESJM; Reinhardt, D; Kaspers, GJL; Cloos, J; Danen-van Oorschot, AA; den Boer, ML; Marschalek, R; Meyer, C; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Kuipers, Jenny E.; Coenen, Eva A.; Balgobind, Brian V.; Stary, Jan; Baruchel, Andre; de Haas, Valerie; de Bont, Eveline S. J. M.; Reinhardt, Dirk; Kaspers, Gertjan J. L.; Cloos, Jacqueline; Danen-van Oorschot, Astrid A.; den Boer, Monique L.; Marschalek, Rolf; Meyer, Claus; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,"High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)","BLOOD",null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; DRUG SENSITIVITY; ONCOLOGY-GROUP; IN-VIVO; CELL; CHILDREN; RESISTANCE; CHILDHOOD; TSLC1; AML","Pediatric mixed-lineage leukemia (MLL)-rearranged acute monoblastic leukemia with t(9;11)(p22;q23) has a favorable outcome compared with other MLL-rearranged AML. The biologic background for this difference remains unknown. Therefore, we compared gene expression profiles (GEPs; Affymetrix HGU133 + 2.0) of 26 t(9; 11)(p22;q23) patients with 42 other MLL-rearranged AML. patients to identify differentially expressed genes. IGSF4, a cell-cell adhesion molecule, was found to be highly expressed in t(9; 11)(p22; q23) patients, which was confirmed by real-time quantitative polymerase chain reaction and Western blot. IGSF4 expression within t(9;11)(p22;q23) patients was 4.9 times greater in French-American-British morphology classification (FAB)-M5 versus other FAB-types (P = .001). Methylation status investigation showed that high IGSF4-expressing t(9;11)(p22;q23) patients with FAB-M5 have no promoter hypermethylation, whereas all other cases do. Cell-line incubation with demethylating agent decitabine resulted in promoter demethylation and increased expression of IGSF4. Down-regulation of IGSF4 by siRNA did not affect proliferation or drug sensitivity. In a cohort of 79 MLL-rearranged AML cases, we show significant better overall survival for cases with high IGSF4 expression (5-year overall survival 0.70 vs 0.37, P = .03) In conclusion, we identified IGSF4 overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit. (Blood.2011;117(3):928-935)","[van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] St Louis Hosp, Paris, France; [de Haas, Valerie] DCOG, The Hague, Netherlands; [de Bont, Eveline S. J. M.] Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [Kaspers, Gertjan J. L.; Cloos, Jacqueline] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Marschalek, Rolf; Meyer, Claus] Goethe Univ Frankfurt, ZAFES, DCAL, Inst Pharmaceut Biol, Frankfurt, Germany","van den Heuvel-Eibrink, MM, Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Room Sp2568,Dr Molewaterpl 60, NL-3000 CB Rotterdam, Netherlands","m.vandenheuvel@erasmusmc.nl","Pediatric Oncology Foundation Rotterdam (KOCR) ; NWO (Netherlands Organization for Scientific Research) ; Foundation KiKa, Amstelveen, The Netherlands ; Deutsche Krebshilfe [107819]","Pediatric Oncology Foundation Rotterdam (KOCR) has funded part of the work of E.A.C. and B.V.B. The work of B.V.B. was also funded by the NWO (Netherlands Organization for Scientific Research). The work of J.E.K. and A.A.D.-v.O. was supported by a grant from the Foundation KiKa, Amstelveen, The Netherlands. R.M. has been partially funded by grant 107819 from Deutsche Krebshilfe.",null,32,0,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2010-05-286138","BLOOD","Blood","JAN 20",2011,117,3,null,null,null,928,935,null,null,8,"Hematology","709GM","ISI:000286426300025"]
["J","Schmid, JP; Canioni, D; Moshous, D; Touzot, F; Mahlaoui, N; Hauck, F; Kanegane, H; Lopez-Granados, E; Mejstrikova, E; Pellier, I; Galicier, L; Galambrun, C; Barlogis, V; Bordigoni, P; Fourmaintraux, A; Hamidou, M; Dabadie, A; Le Deist, F; Haerynck, F; Ouachee-Chardin, M; Rohrlich, P; Stephan, JL; Lenoir, C; Rigaud, S; Lambert, N; Milili, M; Schiff, C; Chapel, H; Picard, C; de Saint Basile, G; Blanche, S; Fischer, A; Latour, S",null,null,null,"Schmid, Jana Pachlopnik; Canioni, Danielle; Moshous, Despina; Touzot, Fabien; Mahlaoui, Nizar; Hauck, Fabian; Kanegane, Hirokazu; Lopez-Granados, Eduardo; Mejstrikova, Ester; Pellier, Isabelle; Galicier, Lionel; Galambrun, Claire; Barlogis, Vincent; Bordigoni, Pierre; Fourmaintraux, Alain; Hamidou, Mohamed; Dabadie, Alain; Le Deist, Francoise; Haerynck, Filomeen; Ouachee-Chardin, Marie; Rohrlich, Pierre; Stephan, Jean-Louis; Lenoir, Christelle; Rigaud, Stephanie; Lambert, Nathalie; Milili, Michele; Schiff, Claudin; Chapel, Helen; Picard, Capucine; de Saint Basile, Genevieve; Blanche, Stephane; Fischer, Alain; Latour, Sylvain",null,"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)","BLOOD",null,"English","Article",null,null,null,null,null,null,"NATURAL-KILLER-CELLS; BARR-VIRUS INFECTION; SAP FAMILY ADAPTERS; HUMORAL IMMUNITY; T-CELLS; DISEASE; SLAM; GENE; XIAP; LYMPHOHISTIOCYTOSIS","X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions. (Blood. 2011; 117(5): 1522-1529)","[Schmid, Jana Pachlopnik; Moshous, Despina; Hauck, Fabian; Lenoir, Christelle; Rigaud, Stephanie; Lambert, Nathalie; de Saint Basile, Genevieve; Fischer, Alain; Latour, Sylvain] Hop Necker Enfants Malad, INSERM, U768, Lab Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; [Schmid, Jana Pachlopnik; Moshous, Despina; Hauck, Fabian; Rigaud, Stephanie; Picard, Capucine; de Saint Basile, Genevieve; Fischer, Alain; Latour, Sylvain] Univ Paris 05, Inst Federatif Rech Necker Enfants Malades IFR94, Paris, France; [Schmid, Jana Pachlopnik; Moshous, Despina; Touzot, Fabien; Mahlaoui, Nizar; de Saint Basile, Genevieve; Blanche, Stephane; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol Pediat, F-75015 Paris, France; [Canioni, Danielle] Hop Necker Enfants Malad, AP HP, Serv Anat & Cytol Pathol, F-75015 Paris, France; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med, Dept Pediat, Toyama 930, Japan; [Lopez-Granados, Eduardo; Chapel, Helen] Univ Oxford, Nuffield Dept Med, Dept Clin Immunol, Oxford, England; [Mejstrikova, Ester] Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Prague, Czech Republic; [Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Pellier, Isabelle] CHU Angers, Unite Hematol Immunol Oncol Pediat, Angers, France; [Pellier, Isabelle] Ctr Rech Cancerol Nantes Angers, INSERM, U892, Nantes, France; [Galicier, Lionel] Hop St Louis, Serv Immunohematol, AP HP, F-75475 Paris, France; [Galambrun, Claire; Barlogis, Vincent] Hop Enfants La Timone, Serv Hematol Pediat, Marseille, France; [Bordigoni, Pierre] CHU Nancy, Dept Hematooncol Pediat & Transplantat Medullaire, Vandoeuvre Les Nancy, France; [Fourmaintraux, Alain] Grp Hosp Sud Reunion, Serv Neonatol, St Pierre, Reunion; [Hamidou, Mohamed] CHU Nantes, F-44035 Nantes 01, France; [Dabadie, Alain] CHU Rennes, Serv Hepatogastroenterol, Rennes, France; [Le Deist, Francoise] Univ Montreal, Dept Microbiol & Immunol, CHU St Justine, Montreal, PQ H3C 3J7, Canada; [Le Deist, Francoise] Univ Montreal, Dept Pediat, CHU St Justine, Montreal, PQ H3C 3J7, Canada; [Haerynck, Filomeen] Ghent Univ Hosp, Dept Child Immunol, B-9000 Ghent, Belgium; [Ouachee-Chardin, Marie] CHU Hop Robert Debre, AP HP, Serv Hematol, Paris, France; [Rohrlich, Pierre] INSERM, UMR645, Besancon, France; [Rohrlich, Pierre] Univ Franche Comte, F-25030 Besancon, France; [Rohrlich, Pierre] CHU Besancon, Serv Pediat, F-25030 Besancon, France; [Stephan, Jean-Louis] CHU St Etienne, Hop Nord, Unite Hematol & Oncol Pediat, St Etienne, France; [Lambert, Nathalie; Picard, Capucine] Hop Necker Enfants Malad, Ctr Etud Deficits Immunitaires, F-75015 Paris, France; [Milili, Michele; Schiff, Claudin] Ctr E3 Ctr Immunol Marseille Luminy, Marseille, France; [Picard, Capucine] Hop Necker Enfants Malad, INSERM, U980, GHMI, F-75015 Paris, France","Latour, S, Hop Necker Enfants Malad, INSERM, U768, Lab Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France","sylvain.latour@inserm.fr","Inserm ; Agence Nationale de la Recherche [ANR-05-MIM-010, ANR-08-MIEN-012-01]; XLP Research Trust (United Kingdom) ; Czech Ministery of Health [NS 10 480-3]; Fondazione Ettore e Valeria Rossi ; Walter und Gertrud Siegenthaler Stiftung ","This work was supported by grants from Inserm, the Agence Nationale de la Recherche (ANR-05-MIM-010 and ANR-08-MIEN-012-01; S.L.), the XLP Research Trust (United Kingdom; S.L.), the Czech Ministery of Health (NS 10 480-3; E.M.), the Fondazione Ettore e Valeria Rossi (J.P.S.), and the Walter und Gertrud Siegenthaler Stiftung (J.P.S.). S.L. is a senior scientist of Center National de la Recherche Scientifique (CNRS, France).",null,36,0,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,"10.1182/blood-2010-07-298372","BLOOD","Blood","FEB 3",2011,117,5,null,null,null,1522,1529,null,null,8,"Hematology","715WV","ISI:000286925500018"]
["J","Dzirbikova, Z; Kiss, A; Okuliarova, M; Kopkan, L; Cervenka, L; Zeman, M",null,null,null,"Dzirbikova, Zuzana; Kiss, Alexander; Okuliarova, Monika; Kopkan, Libor; Cervenka, Ludek; Zeman, Michal",null,"Expressions of per1 Clock Gene and Genes of Signaling Peptides Vasopressin, Vasoactive Intestinal Peptide, and Oxytocin in the Suprachiasmatic and Paraventricular Nuclei of Hypertensive TGR[mREN2]27 Rats","CELLULAR AND MOLECULAR NEUROBIOLOGY",null,"English","Article",null,null,null,null,null,"Hypertension; Circadian rhythm; Suprachiasmatic nucleus; Paraventricular nucleus; Vasopressin; Oxytocin","MESSENGER-RNA EXPRESSION; BLOOD-PRESSURE CONTROL; CIRCADIAN-RHYTHMS; TGR(MREN-2)27 RATS; TRANSGENIC RATS; ANGIOTENSIN-II; HYPOTHALAMUS; HEART; BRAIN; RECEPTORS","Hypertensive rats with multiple extra copies of the renin gene (TGR) exert an inverted circadian blood pressure (BP) profile. We investigated whether circadian oscillations in the hypothalamic suprachiasmatic nucleus (SCN), a main circadian oscillator, and the paraventricular nucleus (PVN), involved in BP control, are influenced in TGR rats. The expression of the clock gene per1, a marker of circadian timing, was measured in the SCN and PVN. Moreover, the expression of genes encoding vasopressin (AVP), vasoactive intestinal peptide (VIP) in the SCN, and AVP and oxytocin (OXT) in the PVN were studied by in situ hybridization. Expression of the per1 gene showed a distinct circadian rhythm in both the SCN and PVN with no differences observed between the TGR and control Sprague-Dawley (SD) rats. The expression of avp in the SCN was rhythmic in both strains and moderately higher in TGR than in SD rats while no significant changes were found in the PVN. The expression of vip in the SCN and oxt in the PVN did not differ between both strains. Our results may indicate that changes occurring downstream to the SCN are responsible for the development of the inverted BP rhythm in TGR hypertensive rats.","[Dzirbikova, Zuzana; Okuliarova, Monika; Zeman, Michal] Comenius Univ, Fac Nat Sci, Dept Anim Physiol & Ethol, Bratislava 84215, Slovakia; [Kiss, Alexander] Slovak Acad Sci, Inst Expt Endocrinol, SK-83306 Bratislava, Slovakia; [Kopkan, Libor; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Kopkan, Libor; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Zeman, M, Comenius Univ, Fac Nat Sci, Dept Anim Physiol & Ethol, Mlynska Dolina B2, Bratislava 84215, Slovakia","mzeman@fns.uniba.sk","Institute for Clinical and Experimental Medicine [MZO 00023001]; [APVV 20-022-704]; [APVV-0214-07]; [CENDO]","This study was supported by the grants APVV No. 20-022-704, APVV-0214-07, CENDO. L.C. and L.K. are supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). We thank professor D. Jezova (Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia) for providing the avp probe.",null,34,0,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0272-4340",null,"10.1007/s10571-010-9612-y","CELL MOL NEUROBIOL","Cell. Mol. Neurobiol.","MAR",2011,31,2,null,null,null,225,232,null,null,8,"Cell Biology; Neurosciences","726VC","ISI:000287753500005"]
["J","Kremlacek, J; Valis, M; Masopust, J; Urban, A; Zumrova, A; Talab, R; Kuba, M; Kubova, Z; Langrova, J",null,null,null,"Kremlacek, Jan; Valis, Martin; Masopust, Jiri; Urban, Ales; Zumrova, Alena; Talab, Radomir; Kuba, Miroslav; Kubova, Zuzana; Langrova, Jana",null,"An Electrophysiological Study of Visual Processing in Spinocerebellar Ataxia Type 2 (SCA2)","CEREBELLUM",null,"English","Article",null,null,null,null,null,"Spinocerebellar ataxia type 2; Visual evoked potentials; Event-related potentials; Motion processing","MOTION-ONSET VEPS; EVOKED-POTENTIALS; PATTERN; PROGRESSION; DISEASE","Reports of visual functional impairment in spinocerebellar ataxia type 2 (SCA2) have been studied previously using pattern reversal visually evoked potentials (VEPs) with contradictory results. To provide additional evidence to this area, visual functions were studied using VEPs and event-related potentials (ERPs) in a group of ten patients with genetically verified SCA2. The electrophysiological examination included pattern reversal and motion-onset VEPs as well as visually driven oddball ERPs with an evaluation of a target and a pre-attentive response. In six patients, we found abnormal visual/cognitive processing that differed from normal values in latency, but not in the amplitude of the dominant VEP/ERP peaks. Among the VEPs/ERPs used, the motion-onset VEPs exhibited the highest sensitivity and showed a strong Spearman correlation to SCA2 duration (from r = 0.82 to r = 0.90, p < 0.001) and clinical state assessed by Brief Ataxia Rating Scale (from r = 0.71 (p = 0.022) to r = 0.80 (p < 0.001)). None of the VEP/ERP latencies showed a correlation to the triplet repeats of the SCA2 gene. In three patients, we did not find any visual/cognitive pathology, and one subject showed only a single subtle prolongation of the VEP peak. The observed visual/cognitive deficit was related to the subjects' clinical state and the illness duration, but no relationship to the genetic marker of SCA2 was found. From the VEP/ERP types used, the motion-onset VEPs seems to be the most promising candidate for clinical state monitoring rather than a tool for early diagnostic use.","[Kremlacek, Jan; Kuba, Miroslav; Kubova, Zuzana; Langrova, Jana] Charles Univ Prague, Fac Med, Dept Pathophysiol, Hradec Kralove 50038, Czech Republic; [Kremlacek, Jan; Valis, Martin; Talab, Radomir] Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Neurol, Fac Med, Hradec Kralove 50038, Czech Republic; [Masopust, Jiri; Urban, Ales] Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Psychiat, Fac Med, Hradec Kralove 50038, Czech Republic; [Zumrova, Alena] Charles Univ Prague, Fac Med 2, Neurogenet Ctr, Hradec Kralove 50038, Czech Republic; [Zumrova, Alena] Fac Hosp Motol, Prague, Czech Republic","Kremlacek, J, Charles Univ Prague, Fac Med, Dept Pathophysiol, Simkova 870, Hradec Kralove 50038, Czech Republic","jan.kremlacek@lfhk.cuni.cz","Grant Agency of the Czech Republic [309/09/0869]","This study is supported by Grant Agency of the Czech Republic 309/09/0869.",null,28,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1473-4222",null,"10.1007/s12311-010-0220-7","CEREBELLUM","Cerebellum","MAR",2011,10,1,null,null,null,32,42,null,null,11,"Neurosciences","721DB","ISI:000287330600005"]
["J","Ambros, IM; Brunner, B; Aigner, G; Bedwell, C; Beiske, K; Benard, J; Bown, N; Combaret, V; Couturier, J; Defferrari, R; Gross, N; Jeison, M; Lunec, J; Marques, B; Martinsson, T; Mazzocco, K; Noguera, R; Schleiermacher, G; Speleman, F; Stallings, R; Tonini, GP; Tweddle, DA; Valent, A; Vicha, A; Van Roy, N; Villamon, E; Ziegler, A; Preuner, S; Drobics, M; Ladenstein, R; Amann, G; Schuit, RJL; Potschger, U; Ambros, PF",null,null,null,"Ambros, Inge M.; Brunner, Bettina; Aigner, Gerhard; Bedwell, Clare; Beiske, Klaus; Benard, Jean; Bown, Nick; Combaret, Valerie; Couturier, Jerome; Defferrari, Raffaella; Gross, Nicole; Jeison, Marta; Lunec, John; Marques, Barbara; Martinsson, Tommy; Mazzocco, Katia; Noguera, Rosa; Schleiermacher, Gudrun; Speleman, Frank; Stallings, Ray; Tonini, Gian Paolo; Tweddle, Deborah A.; Valent, Alexander; Vicha, Ales; Van Roy, Nadine; Villamon, Eva; Ziegler, Andrea; Preuner, Sandra; Drobics, Mario; Ladenstein, Ruth; Amann, Gabriele; Schuit, Robert J. L.; Poetschger, Ulrike; Ambros, Peter F.",null,"A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma","CLINICAL CANCER RESEARCH",null,"English","Article",null,null,null,null,null,null,"DEPENDENT PROBE AMPLIFICATION; PEDIATRIC-ONCOLOGY-GROUP; MYCN AMPLIFICATION; GENETIC-MARKERS; CHROMOSOME 1P; TUMORS; STRATIFICATION; CLASSIFICATION; IDENTIFICATION; HETEROGENEITY","Purpose: Precise and comprehensive analysis of neuroblastoma genetics is essential for accurate risk evaluation and only pangenomic/multilocus approaches fulfill the present-day requirements. We present the establishment and validation of the PCR-based multiplex ligation-dependent probe amplification (MLPA) technique for neuroblastoma. Experimental Design: A neuroblastoma-specific MLPA kit was designed by the SIOP Europe Neuroblastoma Biology Committee in cooperation with MRC-Holland. The contained target sequences cover 19 chromosomal arms and reference loci. Validation was performed by single locus and pangenomic techniques (n = 174). Dilution experiments for determination of minimal tumor cell percentage were performed and testing of reproducibility was checked by interlaboratory testing (n = 15). Further 156 neuroblastomas were used for establishing the amplification cutoff level. Results: The MLPA technique was tested in 310 neuroblastomas and 8 neuroblastoma cell lines (including validation and amplification cutoff level testing). Intertechnique validation showed a high concordance rate (99.5%). Interlaboratory MLPA testing (kappa = 0.95, P < 0.01) revealed 7 discrepant of 1,490 results (0.5%). Validation by pangenomic techniques showed a single discordance of 190 consensus results (0.5%). The test results led to formulation of interpretation standards and to a kit revision. The minimal tumor cell percentage was fixed at 60%. Conclusions: The recently designed neuroblastoma-specific MLPA kit covers all chromosomal regions demanded by the International Neuroblastoma Risk Group for therapy stratification and includes all hitherto described genetic loci of prognostic interest for future studies and can be modified or extended at any time. Moreover, the technique is cost effective, reliable, and robust with a high interlaboratory and intertechnique concordance. Clin Cancer Res; 17(4); 792-804. (C) 2011 AACR.","[Ambros, Inge M.; Brunner, Bettina; Ziegler, Andrea; Preuner, Sandra; Poetschger, Ulrike; Ambros, Peter F.] CCRI, St Anna Kinderkrebsforsch, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Aigner, Gerhard; Drobics, Mario] Technol GmbH, AIT Austrian Inst, Informat Management & eHlth, Safety & Secur Dept, Vienna, Austria; [Ladenstein, Ruth] St Anna Childrens Hosp, Vienna, Austria; [Amann, Gabriele] Univ Vienna, Inst Klin Pathol, Vienna, Austria; [Lunec, John; Tweddle, Deborah A.] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Beiske, Klaus] Oslo Univ Hosp, Rikshosp, Dept Pathol, Oslo, Norway; [Benard, Jean; Valent, Alexander] Inst Gustave Roussy, Serv Pathol Mol, Dept Biol & Pathol Med, Villejuif, France; [Combaret, Valerie] Ctr Leon Berard, Lab Rech Translat, F-69373 Lyon, France; [Couturier, Jerome] Inst Curie Hosp, Serv Genet Oncol, Unite Cytogenet, Paris, France; [Schleiermacher, Gudrun] Inst Curie, Dept Pediat Oncol, Paris, France; [Defferrari, Raffaella; Mazzocco, Katia; Tonini, Gian Paolo] Natl Inst Canc Res, Genoa, Italy; [Gross, Nicole] Univ Hosp, Dept Pediat, Lausanne, Switzerland; [Jeison, Marta] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol Dept, Ca Cytogenet Lab, Petah Tiqwa, Israel; [Marques, Barbara] Inst Nacl Saude Dr Ricardo Jorge, Dept Genet, Lisbon, Portugal; [Martinsson, Tommy] Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Biomed, Dept Clin Genet, Gothenburg, Sweden; [Noguera, Rosa; Villamon, Eva] Univ Valencia, Med Sch Valencia, Dept Pathol, Valencia, Spain; [Speleman, Frank; Van Roy, Nadine] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Stallings, Ray] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Stallings, Ray] Our Ladys Childrens Hosp, Childrens Res Ctr, Crumlin, Ireland; [Vicha, Ales] 2nd Med Fac, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Vicha, Ales] Fac Hosp Motol, Prague, Czech Republic; [Schuit, Robert J. L.] MRC Holland, Amsterdam, Netherlands","Ambros, IM, CCRI, St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Zimmermannpl 10, A-1090 Vienna, Austria","ambros@ccri.at","Jubilaumsfondsprojekt [13422]; St. Anna Kinderkrebsforschung ; Italian Neuroblastoma Foundation, Neuroblastoma Society ; Cancer Research UK ; UK Department of Health ; Instituto de Salud Carlos III [RD06/0020/70102]; Fundacion de la Association Espanola Contra el Cancer (FAECC) [20090840]; Societe Francaise des Cancers de l'Entfant (SFCE) ; Federation Enfants Sante ; National Resource Centre for Childhood Solid Tumours (KSSB), Norway ","This work was funded in part by the Jubilaumsfondsprojekt (13422); the St. Anna Kinderkrebsforschung; the Italian Neuroblastoma Foundation, Neuroblastoma Society; Cancer Research UK and the UK Department of Health; Instituto de Salud Carlos III (RD06/0020/70102) and the Fundacion de la Association Espanola Contra el Cancer (FAECC; 20090840); the Societe Francaise des Cancers de l'Entfant (SFCE); the Federation Enfants & Sante; and the National Resource Centre for Childhood Solid Tumours (KSSB), Norway.",null,33,0,"AMER ASSOC CANCER RESEARCH","PHILADELPHIA","615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA","1078-0432",null,"10.1158/1078-0432.CCR-10-0830","CLIN CANCER RES","Clin. Cancer Res.","FEB 15",2011,17,4,null,null,null,792,804,null,null,13,"Oncology","728ZM","ISI:000287913200018"]
["J","Tapia, G; Cinek, O; Rasmussen, T; Witso, E; Grinde, B; Stene, LC; Ronningen, KS",null,null,null,"Tapia, German; Cinek, Ondrej; Rasmussen, Trond; Witso, Elisabet; Grinde, Bjorn; Stene, Lars Christian; Ronningen, Kjersti Skjold",null,"Human Enterovirus RNA in Monthly Fecal Samples and Islet Autoimmunity in Norwegian Children With High Genetic Risk for Type 1 Diabetes The MIDIA study","DIABETES CARE",null,"English","Article",null,null,null,null,null,null,"BETA-CELL AUTOIMMUNITY; INFECTIONS; PREVALENCE; INFANTS; COHORT","OBJECTIVE- To test whether the frequency of human enterovirus RNA in fecal samples collected monthly from early infancy was associated with development of multiple islet autoantibodies in children with the highest risk HLA genotype. RESEARCH DESIGN AND METHODS- Individuals carrying the HLA DRB1*0401-DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*02 genotype were identified at birth and followed with monthly stool samples from age 3 to 35 months. Blood samples taken at age 3, 6, 9, and 12 months and then annually were tested for autoantibodies to insulin, GAD 65 and IA-2. Among 911 children, 27 developed positivity for two or more islet autoantiboclies in two or more consecutive samples (case subjects). Two control subjects per case subject were matched by follow-up time, date of birth, and county of residence. Stool samples were analyzed for enterovirus with a semiquantitative real-time RT-PCR. RESULTS- The frequency of human enterovirus RNA in stool samples from case subjects before seroconversion (43 of 339, 12.7%) did not differ from the frequency in control subjects (94 of 692, 13.6%) (P = 0.97). Results remained essentially unchanged after adjustment for potential confounders, restriction to various time windows before seroconversion, or infections in the 1st year of life or after inclusion of samples collected after seroconversion. There was no difference in the average quantity of enterovirus RNA or in the frequency of repeatedly positive samples. The estimated relative risk for islet autoimmunity per enterovirus RNA positive sample during follow-up (nested case-control analysis) was 1.12 (95% CI 0.66-1.91). CONCLUSIONS- There was no support for the hypothesis that fecal shedding of enteroviral RNA is a major predictor of advanced islet autoimmunity.","[Tapia, German; Rasmussen, Trond; Witso, Elisabet; Grinde, Bjorn; Stene, Lars Christian; Ronningen, Kjersti Skjold] Norwegian Inst Publ Hlth, Oslo, Norway; [Tapia, German; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Tapia, G, Norwegian Inst Publ Hlth, Oslo, Norway","german.tapia@fhi.no","Norwegian Organization for Health and Rehabilitation [2005/2/0128]; Prague, the Czech Republic [A/CZ0046/1/0014]; Ministry of Education of the Czech Republic [MSM0021620814]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515N50]; Norwegian Diabetes Association ; NewGeneris [Food-CT-2005-016320]","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (2005/2/0128), the EEA/Norway funds (grant A/CZ0046/1/0014 through the Research Support Fund, Prague, the Czech Republic), the Ministry of Education of the Czech Republic (grant MSM0021620814), the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, and 166515N50), the Norwegian Diabetes Association, Children with Diabetes Foundation (Denver, CO), and NewGeneris (grant Food-CT-2005-016320).",null,14,0,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,"10.2337/dc10-1413","DIABETES CARE","Diabetes Care","JAN",2011,34,1,null,null,null,151,155,null,null,5,"Endocrinology & Metabolism","710FT","ISI:000286497000031"]
["J","Maruta, C; Guerreiro, M; de Mendonca, A; Hort, J; Scheltens, P",null,null,null,"Maruta, C.; Guerreiro, M.; de Mendonca, A.; Hort, J.; Scheltens, P.",null,"The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia","EUROPEAN JOURNAL OF NEUROLOGY",null,"English","Article",null,null,null,null,null,"dementia diagnosis; neuropsychological tests","PRIMARY DEGENERATIVE DEMENTIA; FRONTAL-LOBE DEMENTIA; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; DEPRESSION SCALE; SENILE-DEMENTIA; RATING-SCALE; TEST-BATTERY; DISORDERS","Background and purpose: The centres dedicated to dementia throughout Europe use different neuropsychological tests in clinical practice. The European Federation of Neurological Societies task force on neuropsychological tests produced this survey on neuropsychological tests currently being used in different European countries to gather knowledge on the practice of dementia centres and to promote the harmonization of such instruments and future multicentre collaborations. Methods: National representatives of 34 countries received a questionnaire and 25 (73.5%) sent it back. Results: A few instruments, Mini-Mental State Examination (MMSE), Trail Making Test (TMT), Verbal Fluency and Clock Drawing Test, were available in all countries. Wechsler Adult Intelligence Scales and MMSE were reported to be valid, respectively, in 20 (80%) and 19 (76%) countries, whereas Verbal Fluency and Stroop Test are valid in 18 (72%) of them. Of the 25 countries, 17 have validation norms for Clock Drawing Test and TMT (68%), and Neuropsychiatric Inventory, Alzheimer's Disease Assessment Scale - Cognitive Subscale, Rey Complex Figure Test, Digit Symbol and Beck Depression Inventory were standardized in 16 countries (64%). The remaining tests were validated, at most, in about half of them. Not all countries certificate neuropsychology. Conclusions: Despite the substantial differences in the tools used by the EFNS countries for most domains surveyed by the questionnaire, there is at least one neuropsychological instrument used by about 80% of the countries. There is clearly the need for a broader consensus in the use of neuropsychological tests for dementia diagnosis.","[Maruta, C.; Guerreiro, M.; de Mendonca, A.] Univ Lisbon, Inst Mol Med, Fac Med, P-1699 Lisbon, Portugal; [Hort, J.] Charles Univ Prague, Memory Clin, Dept Neurol, Fac Med 2, Prague, Czech Republic; [Hort, J.] Motol Hosp Prague, Prague, Czech Republic; [Scheltens, P.] Vrije Univ Amsterdam, Dept Neurol, Med Ctr, Amsterdam, Netherlands","de Mendonca, A, Inst Mol Med, Neurosci Lab, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal","mendonca@fm.ul.pt","Fundacao para a Ciencia e Tecnologia ; Fundacao Calouste Gulbenkian ","Carolina Maruta, Manuela Guerreiro and Alexandre de Mendonca receive funding from Fundacao para a Ciencia e Tecnologia and Fundacao Calouste Gulbenkian.",null,103,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-5101",null,"10.1111/j.1468-1331.2010.03134.x","EUR J NEUROLOGY","Eur. J. Neurol.","FEB",2011,18,2,null,null,null,279,"E23",null,null,10,"Clinical Neurology; Neurosciences","706NP","ISI:000286225400016"]
["J","Carlsen, KCL; Hedlin, G; Bush, A; Wennergren, G; de Benedictis, FM; De Jongste, JC; Baraldi, E; Pedroletti, C; Barbato, A; Malmstrom, K; Pohunek, P; Pedersen, S; Piacentini, GL; Middelveld, RJM; Carlsen, KH",null,null,null,"Carlsen, K. C. Lodrup; Hedlin, G.; Bush, A.; Wennergren, G.; de Benedictis, F. M.; De Jongste, J. C.; Baraldi, E.; Pedroletti, C.; Barbato, A.; Malmstrom, K.; Pohunek, P.; Pedersen, S.; Piacentini, G. L.; Middelveld, R. J. M.; Carlsen, K. H.","PSACI Grp","Assessment of problematic severe asthma in children","EUROPEAN RESPIRATORY JOURNAL",null,"English","Article",null,null,null,null,null,"Asthma; child; diagnostics; severe","QUALITY-OF-LIFE; EXHALED NITRIC-OXIDE; EXERCISE-INDUCED BRONCHOCONSTRICTION; RANDOMIZED CONTROLLED-TRIAL; TO-TREAT ASTHMA; LUNG-FUNCTION; DIFFICULT ASTHMA; AIRWAY HYPERRESPONSIVENESS; SPUTUM INDUCTION; CHILDHOOD ASTHMA","Assessment of problematic severe asthma in children should be performed in a stepwise manner to ensure an optimal approach. A four-step assessment scheme is proposed. First, a full diagnostic work-up is performed to exclude other diseases which mimic asthma. Secondly, a multi-disciplinary assessment is performed to identify issues that may need attention, including comorbidities. Thirdly, the pattern of inflammation is assessed, and finally steroid responsiveness is documented. Based upon these four steps an optimal individualised treatment plan is developed. In this article the many gaps in our current knowledge in all these steps are highlighted, and recommendations for current clinical practice and future research are made. The lack of good data and the heterogeneity of problematic severe asthma still limit our ability to optimise the management on an individual basis in this small, but challenging group of patients.","[Carlsen, K. C. Lodrup] Univ Oslo, Dept Paediat, Women & Childrens Div, Oslo Univ Hosp, NO-0407 Oslo, Norway; [Carlsen, K. C. Lodrup; Carlsen, K. H.] Univ Oslo, Fac Med, NO-0407 Oslo, Norway; [Hedlin, G.; Pedroletti, C.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Bush, A.] Royal Brompton Hosp, Dept Resp Paediat, London SW3 6LY, England; [Wennergren, G.] Univ Gothenburg, Dept Paediat, Queen Silvia Childrens Hosp, Gothenburg, Sweden; [de Benedictis, F. M.] Salesi Childrens Hosp, Dept Paediat, Ancona, Italy; [De Jongste, J. C.] Erasmus Univ, Med Center, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; [Baraldi, E.; Barbato, A.] Univ Padua, Sch Med, Dept Paediat, Padua, Italy; [Malmstrom, K.] Univ Helsinki, Cent Hosp, Dept Allergy, Helsinki, Finland; [Pohunek, P.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Pohunek, P.] Univ Hosp Motol, Prague, Czech Republic; [Pedersen, S.] Univ So Denmark, Dept Paediat, Kolding Hosp, Kolding, Denmark; [Piacentini, G. L.] Univ Verona, Dept Paediat, I-37100 Verona, Italy; [Middelveld, R. J. M.] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, S-10401 Stockholm, Sweden","Carlsen, KCL, Univ Oslo, Dept Paediat, Women & Childrens Div, Oslo Univ Hosp, NO-0407 Oslo, Norway","k.c.l.carlsen@medisin.uio.no","Global Allergy and Asthma European Network (GA2LEN; EU) [FOOD-CT-2004-506378]","This article was initiated and financially supported by the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN; EU contract number FOOD-CT-2004-506378).",null,80,0,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,"10.1183/09031936.00091410","EUR RESP J","Eur. Resp. J.","FEB",2011,37,2,null,null,null,432,440,null,null,9,"Respiratory System","713IF","ISI:000286730400030"]
["J","Skoumalova, A; Ivica, J; Santorova, P; Topinkova, E; Wilhelm, J",null,null,null,"Skoumalova, A.; Ivica, J.; Santorova, P.; Topinkova, E.; Wilhelm, J.",null,"The lipid peroxidation products as possible markers of Alzheimer's disease in blood","EXPERIMENTAL GERONTOLOGY",null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Diagnostic biomarkers; Oxidative stress; Lipofuscin-like pigments","MILD COGNITIVE IMPAIRMENT; FREE-RADICAL DAMAGE; OXIDATIVE STRESS; MALONDIALDEHYDE; ERYTHROCYTES; BIOMARKERS; BRAIN","Oxidative stress, which is present in Alzheimer's disease (AD), results in the formation of various end-products of free radical reactions with proteins and lipids. At present there are no reliable diagnostic biomarkers of AD in the blood. Therefore, specific products of lipid peroxidation in the blood of AD patients were investigated. Lipophilic extracts of erythrocytes in the group of patients with AD (n = 44) and age-matched controls (n = 16) were studied. The end-products of lipid peroxidation, so called lipofuscin-like pigments (LFP), were analysed by fluorescence spectroscopy. It was found that the level of these products is significantly increased in erythrocytes of AD patients compared to controls. LFP were further separated by means of HPLC into individual fractions to study their composition in AD and controls. The specific fraction of LFP in AD patients, which was isolated, might represent a disease-specific product in the blood. (c) 2010 Elsevier Inc. All rights reserved.","[Skoumalova, A.; Ivica, J.; Santorova, P.; Wilhelm, J.] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15006, Czech Republic; [Topinkova, E.] Charles Univ Prague, Dept Geriatr, Fac Med 1, Prague 15006, Czech Republic; [Topinkova, E.] Gen Fac Hosp, Prague, Czech Republic","Skoumalova, A, Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Plzenska 221-130, Prague 15006, Czech Republic","alice.skoumalova@lfmotol.cuni.cz","Czech Science Foundation [220 032]","This research was supported by The Czech Science Foundation, grant number 220 032.",null,22,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0531-5565",null,"10.1016/j.exger.2010.09.015","EXP GERONTOL","Exp. Gerontol.","JAN",2011,46,1,null,null,null,38,42,null,null,5,"Geriatrics & Gerontology","710UP","ISI:000286542800006"]
["J","Balgobind, BV; Van den Heuvel-Eibrink, MM; De Menezes, RX; Reinhardt, D; Hollink, IHIM; Arentsen-Peters, STJCM; van Wering, ER; Kaspers, GJL; Cloos, J; de Bont, ESJM; Cayuela, JM; Baruchel, A; Meyer, C; Marschalek, R; Trka, J; Stary, J; Beverloo, HB; Pieters, R; Zwaan, CM; den Boer, ML",null,null,null,"Balgobind, Brian V.; Van den Heuvel-Eibrink, Marry M.; De Menezes, Renee X.; Reinhardt, Dirk; Hollink, Iris H. I. M.; Arentsen-Peters, Susan T. J. C. M.; van Wering, Elisabeth R.; Kaspers, Gertjan J. L.; Cloos, Jacqueline; de Bont, Evelien S. J. M.; Cayuela, Jean-Michel; Baruchel, Andre; Meyer, Claus; Marschalek, Rolf; Trka, Jan; Stary, Jan; Beverloo, H. Berna; Pieters, Rob; Zwaan, C. Michel; den Boer, Monique L.",null,"Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,"English","Article",null,null,null,null,null,"pediatric acute myeloid leukemia; gene expression profile; cytogenetic subtype; classification; microarray","ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; NORMAL KARYOTYPE; PROGNOSTIC-SIGNIFICANCE; CEBPA MUTATIONS; GROUP-B; AML 10; FLT3","Background Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or specificity. Design and Methods We examined the potential of gene expression profiles to classify pediatric acute myeloid leukemia. Gene expression microarray data of 237 children with acute myeloid leukemia were collected and a double-loop cross validation approach was used to generate a subtype-predictive gene expression profile in the discovery cohort (n=157) which was then tested for its true predictive value in the independent validation cohort (n=80). The classifier consisted of 75 probe sets, representing the top 15 discriminating probe sets for MLL-rearranged, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive acute myeloid leukemia. Results These cytogenetic subtypes represent approximately 40% of cases of pediatric acute myeloid leukemia and were predicted with 92% and 99% accuracy in the discovery and independent validation cohort, respectively. However, for NPM1, CEBPA, MLL(-PTD), FLT3(-ITD), KIT, PTPN11 and N/K-RAS gene expression signatures had limited predictive value. This may be caused by a limited frequency of these mutations and by underlying cytogenetics. This latter is exemplified by the fact that different gene expression signatures were discovered for FLT3-ITD in patients with normal cytogenetics and in those with t(15;17)(q21;q22)-positive acute myeloid leukemia, which pointed to HOXB-upregulation being specific for FLT3-ITD+ cytogenetically normal acute myeloid leukemia. Conclusions In conclusion, gene expression profiling correctly predicted the most prevalent cytogenetic subtypes of pediatric acute myeloid leukemia with high accuracy. In clinical practice, this gene expression signature may replace multiple diagnostic tests for approximately 40% of pediatric acute myeloid leukemia cases whereas only for the remaining cases (predicted as 'acute myeloid leukemia-other') are additional tests indicated. Moreover, the discriminative genes reveal new insights into the biology of acute myeloid leukemia subtypes that warrants follow-up as potential targets for new therapies.","[den Boer, Monique L.] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, NL-3000 CB Rotterdam, Netherlands; [De Menezes, Renee X.] LUMC, Ctr Human & Clin Genet, Leiden, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [van Wering, Elisabeth R.] DCOG, The Hague, Netherlands; [Kaspers, Gertjan J. L.; Cloos, Jacqueline] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [de Bont, Evelien S. J. M.] Beatrix Childrens Hosp, Groningen, Netherlands; [Cayuela, Jean-Michel; Baruchel, Andre] St Louis Hosp, Paris, France; [Meyer, Claus; Marschalek, Rolf] DCAL, ZAFES, Inst Pharmaceut Biol, Frankfurt, Germany; [Trka, Jan; Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic","den Boer, ML, Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, Room Sp2456,POB 2060, NL-3000 CB Rotterdam, Netherlands","m.l.denboer@eras-musmc.nl","'Netherlands Organisation for Scientific Research' (NWO) ; Dutch Cancer Society [EMCR 2005-3662, EMCR 2003-2871]; Center of Medical Systems Biology (CMSB) ; Quality of Life Foundation, the Netherlands ; Czech Ministry of Education [COST-OC09051]","BVB was funded by the 'Netherlands Organisation for Scientific Research' (NWO). RXM was partially funded by the Dutch Cancer Society (grant EMCR 2005-3662) and the Center of Medical Systems Biology (CMSB) established by the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NGI/NWO). HBB was partly funded by the Dutch Cancer Society (grant EMCR 2003-2871). This research was sponsored by a grant from the Quality of Life Foundation, the Netherlands (R.P, MLDB). JT was funded by the Czech Ministry of Education (grant COST-OC09051).",null,56,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2010.029660","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","FEB",2011,96,2,null,null,null,221,230,null,null,10,"Hematology","726ZI","ISI:000287766500009"]
["J","Anderova, M; Vorisek, I; Pivonkova, H; Benesova, J; Vargova, L; Cicanic, M; Chvatal, A; Sykova, E",null,null,null,"Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Benesova, Jana; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva",null,"Cell death/proliferation and alterations in glial morphology contribute to changes in diffusivity in the rat hippocampus after hypoxia-ischemia","JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM",null,"English","Article",null,null,null,null,null,"astrocytes; extracellular volume; microglia; neurons; NG2-glia; tortuosity; water diffusion","EXTRACELLULAR-SPACE; IN-SITU; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; SPINAL-CORD; BRAIN; INJURY; ASTROCYTES; CORTEX; PROLIFERATION","To understand the structural alterations that underlie early and late changes in hippocampal diffusivity after hypoxia/ischemia (H/I), the changes in apparent diffusion coefficient of water (ADC(W)) were studied in 8-week-old rats after H/I using diffusion-weighted magnetic resonance imaging (DW-MRI). In the hippocampal CA1 region, ADC(W) analyses were performed during 6 months of reperfusion and compared with alterations in cell number/cell-type composition, glial morphology, and extracellular space (ECS) diffusion parameters obtained by the real-time iontophoretic method. In the early phases of reperfusion (1 to 3 days) neuronal cell death, glial proliferation, and developing gliosis were accompanied by an ADC(W) decrease and tortuosity increase. Interestingly, ECS volume fraction was decreased only first day after H/I. In the late phases of reperfusion (starting 1 month after H/I), when the CA1 region consisted mainly of microglia, astrocytes, and NG2-glia with markedly altered morphology, ADC(W), ECS volume fraction and tortuosity were increased. Three-dimensional confocal morphometry revealed enlarged astrocytes and shrunken NG2-glia, and in both the contribution of cell soma/processes to total cell volume was markedly increased/decreased. In summary, the ADC(W) increase in the CA1 region underlain by altered cellular composition and glial morphology suggests that considerable changes in extracellular signal transmission might occur in the late phases of reperfusion after H/I. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 894-907; doi:10.1038/jcbfm.2010.168; published online 29 September 2010","[Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab,Vvi, Prague 14220 4, Czech Republic; [Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Benesova, Jana; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva] Acad Sci Czech Republic, Dept Neurosci, Prague 14220 4, Czech Republic; [Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Vorisek, Ivan; Sykova, Eva] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, Prague, Czech Republic","Anderova, M, Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab,Vvi, Videnska 1083, Prague 14220 4, Czech Republic","anderova@biomed.cas.cz","Grant Agency of the Czech Republic [305/09/0717, 309/09/1597, P303/10/1338]; Ministry of Education, Youth and Sports of the Czech Republic [AVOZ 50390512, LC554]; Ministry of Health of the Czech Republic [MZ0IKEM2005]","This study was supported by Grants 305/09/0717, 309/09/1597, and P303/10/1338 from the Grant Agency of the Czech Republic, AVOZ 50390512, LC554 from the Ministry of Education, Youth and Sports of the Czech Republic and grant MZ0IKEM2005 from the Ministry of Health of the Czech Republic.",null,38,0,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0271-678X",null,"10.1038/jcbfm.2010.168","J CEREBR BLOOD FLOW METABOL","J. Cereb. Blood Flow Metab.","MAR",2011,31,3,null,null,null,894,907,null,null,14,"Endocrinology & Metabolism; Hematology; Neurosciences","727ZS","ISI:000287842700011"]
["J","MacManus, DG; Miller, DH; Kappos, L; Gold, R; Havrdova, E; Limmroth, V; Polman, CH; Schmierer, K; Yousry, TA; Eraksoy, M; Meluzinova, E; Dufek, M; Yang, M; O'Neill, GN; Dawson, K",null,null,null,"MacManus, D. G.; Miller, D. H.; Kappos, L.; Gold, R.; Havrdova, E.; Limmroth, V.; Polman, C. H.; Schmierer, K.; Yousry, T. A.; Eraksoy, M.; Meluzinova, E.; Dufek, M.; Yang, M.; O'Neill, G. N.; Dawson, K.",null,"BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis","JOURNAL OF NEUROLOGY",null,"English","Article",null,null,null,null,null,"Clinical trial; Multiple sclerosis; MRI; Dimethyl fumarate; BG-12; Hypointense lesions","RESONANCE-IMAGING FINDINGS; T1-WEIGHTED SPIN-ECHO; FUMARIC-ACID ESTERS; HYPOINTENSE LESIONS; NRF2; ACTIVATION; EXPRESSION; GENES; CELLS; INDUCTION","BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd+ lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd+ lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd+ lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd+ lesions in patients from the BG-12 group and 221 Gd+ lesions in patients from the placebo group. The percentage of Gd+ lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p < 0.0001). In addition to reducing frequency of new Gd+ lesions, BG-12 significantly reduced probability of their evolution to T1-hypointense lesions in patients with MS compared with placebo.","[MacManus, D. G.; Miller, D. H.; Schmierer, K.; Yousry, T. A.] UCL, Inst Neurol, NMR Res Unit, London WC1N 3BG, England; [Schmierer, K.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci & Trauma, Neuroimmunol Grp, London E1 1BB, England; [Kappos, L.] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Gold, R.] St Josef Hosp, Univ Clin Bochum, D-44791 Bochum, Germany; [Havrdova, E.] Charles Univ Prague, Fac Med 1, Prague 12108 2, Czech Republic; [Limmroth, V.] Univ Cologne, Cologne City Hosp, D-51109 Cologne, Germany; [Polman, C. H.] Vrije Univ Amsterdam Med Ctr, NL-1007 MB Amsterdam, Netherlands; [Eraksoy, M.] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Istanbul, Turkey; [Meluzinova, E.] Charles Univ Prague, Motol Univ Hosp, Sch Med 2, Dept Neurol, Prague, Czech Republic; [Dufek, M.] Masaryk Univ, CS-60177 Brno, Czech Republic; [Yang, M.; O'Neill, G. N.; Dawson, K.] Biogen Idec Inc, Cambridge, MA 02142 USA","Miller, DH, UCL, Inst Neurol, NMR Res Unit, London WC1N 3BG, England","d.miller@ion.ucl.ac.uk","Biogen Idec, Inc. ; Swiss MS Society ; Czech Ministry of Education [MSM 0021620849]; Biogen Idec ; UK Department of Health's National Institute for Health Research Biomedical Research Center (UCLH/UCL Comprehensive Biomedical Research Trust) ; MS Society of Great Britain and Northern Ireland ; GlaxoSmithKline ; Novartis ; Acorda Therapeutics ; Actelion Pharmaceuticals ; Allozyne ; BaroFold ; Bayer Health Care ; BayerSchering Pharma ; Bayhill ; Boehringer-Ingelheim ; Eisai ; Elan ; Genmab ; Merck-Serono ; Medici-Nova ; Sanofi-Aventis ; Santhera Pharmaceuticals ; Shire ; Roche ; Teva ; UCB ; Wyeth ; Swiss National Research Foundation ; European Union ; Gianni Rubatto ; Roche Research Foundations ; BayerSchering ; Genzyme ; Actelion ; Antisense Therapeutics ; Bayer ; MSD ; Pfizer ; Schering AG ; NIHR UCLH Comprehensive Biomedical Research Centre ; MRC ; Wellcome Trust ","The authors acknowledge the contributions of Hema Gowda and Matthew Hasson, Scientific Connexions, Newtown, PA, USA, for technical and editorial assistance in preparing this manuscript for submission. Their work was funded by Biogen Idec, Inc. The authors also acknowledge the role of Virginia Santana with respect to MRI data management. Ludwig Kappos is supported by the Swiss MS Society. Eva Havrdova is supported by the Czech Ministry of Education (Research Program MSM 0021620849). This study was supported by Biogen Idec. Funding was received from the UK Department of Health's National Institute for Health Research Biomedical Research Center's funding scheme (UCLH/UCL Comprehensive Biomedical Research Trust). The NMR Research Unit at the UCL Institute of Neurology is supported by the MS Society of Great Britain and Northern Ireland. Statistical analyses were conducted by M. Yang, MS, Biogen Idec, Cambridge, MA. Please see online resource 1 for a list of BG-12 Phase 2b Study Investigators. D. G. MacManus declares no conflicts of interest. D. H. Miller has received honoraria through payments to his employer, UCL Institute of Neurology, for advisory committees and/or consultancy in multiple sclerosis studies from BayerSchering, Biogen Idec, GlaxoSmithKline, and Novartis. He has received research grant support through his employer for performing central MRI analysis for multiple sclerosis trials from Biogen Idec, GlaxoSmithKline, and Novartis. L. Kappos has served as a principal investigator and member or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials in multiple sclerosis and other neurological diseases. Sponsoring companies for these trials include Acorda Therapeutics, Actelion Pharmaceuticals, Allozyne, BaroFold, Bayer Health Care, BayerSchering Pharma, Bayhill, Biogen Idec, Boehringer-Ingelheim, Eisai, Elan, Genmab, GlaxoSmithKline, Merck-Serono, Medici-Nova, Novartis, Sanofi-Aventis, Santhera Pharmaceuticals, Shire, Roche, Teva, UCB, Wyeth, and others. He has lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis; in many cases these lectures have been sponsored by nonrestricted educational grants from one or another of the above-listed companies. Honoraria and other payments for all these activities have been exclusively used for funding research of his department. Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by nonrestricted grants from one or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, and the Gianni Rubatto, Novartis, and Roche Research Foundations. R. Gold has served as a speaker or consultant for and received scientific grant support from BayerSchering, Biogen Idec, Merck-Serono, Novartis, and Teva. E. Havrdova has received honoraria for lecturing and consulting from Bayer Health Care, Biogen Idec, Genzyme, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. She has received funding for clinical trials and served on advisory boards for Actelion, Bayer Health Care, Biogen Idec, Genzyme, GlaxoSmithKline, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. V. Limmroth has received research support and honoraria for consultancy from Antisense Therapeutics, Bayer, Biogen Idec, GlaxoSmithKline, Merck-Serono, MSD, Pfizer, Sanofi-Aventis, and Teva. C. H. Polman has received consulting fees from Actelion, Antisense Therapeutics, BayerSchering, Biogen Idec, GlaxoSmithKline, Merck-Serono, Novartis, Roche, Teva, and UCB; lecture fees from Biogen Idec, Novartis, Schering AG, and Teva; and grant support from BayerSchering, Biogen Idec, GlaxoSmithKline, Merck-Serono, Novartis, Teva, and UCB. K. Schmierer received research support from Biogen Idec to perform the MRI analysis of the phase 2b trial of BG-12. He has received honoraria for speaking from Merck-Serono, Novartis, and Sanofi-Aventis. T. A. Yousry has served on a scientific advisory board for UCB; received honoraria and funding for travel for serving on scientific boards for Biogen Idec; and received research support from Biogen Idec, GlaxoSmithKline, Novartis, the NIHR UCLH Comprehensive Biomedical Research Centre, the MS Society of Great Britain and Northern Ireland, the MRC, and the Wellcome Trust. He serves on the editorial board for European Radiology. M. Eraksoy serves on the medical advisory board for Biogen Idec. E. Meluzinova declares no conflicts of interest. M. Dufek has served as a subinvestigato for a clinical trial for Biogen Idec (109MS301). M. Yang, K. Dawson, and G.N. O'Neill are employees of and have equity interest in Biogen Idec.",null,26,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0340-5354",null,"10.1007/s00415-010-5777-z","J NEUROL","J. Neurol.","MAR",2011,258,3,null,null,null,449,456,null,null,8,"Clinical Neurology","729BZ","ISI:000287924200014"]
["J","Vaneckova, I; Huskova, Z; Vanourkova, Z; Cervenka, L",null,null,null,"Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek",null,"Castration Has Antihypertensive and Organoprotective Effects in Male but Not in Female Heterozygous Ren-2 Rats","KIDNEY & BLOOD PRESSURE RESEARCH",null,"English","Article",null,null,null,null,null,"Ren-2 rats; Hypertension; Sexual dimorphism; Age; Sex hormones; Renin-angiotensin system","SPONTANEOUSLY HYPERTENSIVE-RATS; RENIN-ANGIOTENSIN SYSTEM; END-ORGAN DAMAGE; TRANSGENIC RATS; BLOOD-PRESSURE; RECEPTOR BLOCKADE; AT(2) RECEPTORS; RENAL-DISEASE; SEX-HORMONES; NITRIC-OXIDE","Gender differences in the regulation of blood pressure (BP) and the contributions of the renin-angiotensin system remain controversial. We assessed the effect of castration on BP and organ damage, as well as angiotensin II (ANG II), estradiol and testosterone levels in heterozygous Ren-2 transgenic (TGR) rats and transgene-negative Hannover Sprague-Dawley control rats. Male TGR had severe hypertension throughout the experiment, while the BP of female TGR declined after 5 months to normotensive levels. Ovariectomy had no effect on BP, cardiac hypertrophy or proteinuria in female Ren-2 TGR. On the contrary, BP and cardiac hypertrophy were significantly reduced in castrated male TGR as compared to sham-operated TGR. Moreover, proteinuria in these animals was normalized to the levels of control rats. ANG II levels did not differ between male and female TGR, and no effect of castration on plasma and tissue ANG II levels was found either in male or female TGR at the end of the experiment. In conclusion, the contribution of the renin-angiotensin system to the gender difference in BP homeostasis seems to be negligible in aging heterozygous Ren-2 transgenic rats. Copyright (C) 2010 S. Karger AG, Basel","[Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Ctr Med Expt, Prague, Czech Republic; [Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Inst Clin & Expt Med, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Vaneckova, I, Acad Sci Czech Republic, Inst Physiol, Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic","ivanava@biomed.cas.cz","Czech Science Foundation (GACR) [305/08/J006, 305/07/J004]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/10500-3, NS/10499-3]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; EU [CZ.2.16/3.1.00/22126]","We thank Mrs. Dagmar Markova and Radka Kuzelkova for their excellent technical assistance and Josef Zicha for his valuable comments during the preparation of the manuscript. This study was supported by grant No. 305/08/J006 awarded to L.C. and grant No. 305/07/J004 awarded to I.V. by the Czech Science Foundation (GACR) and by grants No. NS/10500-3 and No. NS/10499-3 by the Internal Grant Agency of the Ministry of Health of the Czech Republic. I.V. was also supported by the Center for Cardiovascular Research (1M6798582302) and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). This study was also supported by the financial support from the EU by the Operational Program Prague - Competitiveness; project 'CEVKOON' (No. CZ.2.16/3.1.00/22126).",null,36,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,"10.1159/000322618","KIDNEY BLOOD PRESSURE RES","Kidney Blood Pressure Res.",null,2011,34,1,null,null,null,46,52,null,null,7,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","710VQ","ISI:000286545500006"]
["J","Rob, L; Skapa, P; Robova, H",null,null,null,"Rob, Lukas; Skapa, Petr; Robova, Helena",null,"Fertility-sparing surgery in patients with cervical cancer","LANCET ONCOLOGY",null,"English","Review",null,null,null,null,null,null,"VAGINAL RADICAL TRACHELECTOMY; OF-THE-LITERATURE; NEOADJUVANT CHEMOTHERAPY; PELVIC LYMPHADENECTOMY; PRESERVING SURGERY; ABDOMINAL TRACHELECTOMY; PARAMETRIAL INVOLVEMENT; CONSERVATIVE SURGERY; INITIAL-EXPERIENCE; DARGENTS OPERATION","There are several types of fertility saving procedures that can be done in patients with cervical cancer, which differ in terms of surgical approach and extent of paracervical resection. This review assesses oncological and pregnancy results after different procedures. The oncological results of vaginal radical trachelectomies (VRT) and abdominal radical trachelectomies (ART) are similar for tumours less than 2 cm in size, and are now considered safe surgical procedures. Oncological outcomes of VRT and ART in tumours larger than 2 cm are also identical, but the results cannot be considered satisfactory. Preliminary findings of less radical procedures (ie, deep cone and simple trachelectomy) in patients with tumours less than 2 cm, and negative sentinel and other pelvic lymph nodes, are comparable with the results of VRT and ART Downstaging tumours larger than 2 cm by neoadjuvant chemotherapy is still an experimental procedure and will need multicentre cooperation to verify its oncological safety. Pregnancy results vary statistically with the different methods.","[Rob, Lukas; Skapa, Petr; Robova, Helena] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L, Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Uvalu 84, Prague 15000 5, Czech Republic","lukas.rob@Ifmotol.cuni.cz","[MZ0FNM2005]","This work was supported by grant MZ0FNM2005.",null,75,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,"10.1016/S1470-2045(10)70084-X","LANCET ONCOL","Lancet Oncol.","FEB",2011,12,2,null,null,null,192,200,null,null,9,"Oncology","720NB","ISI:000287286300026"]
["J","Zaliova, M; Madzo, J; Cario, G; Trka, J",null,null,null,"Zaliova, M.; Madzo, J.; Cario, G.; Trka, J.",null,"Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing","LEUKEMIA",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; TEL/AML1; fusion gene; RNAi; childhood leukemia","ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; FUSION GENE; PRELEUKEMIC ACTIVITY; TEL-AML1; DIFFERENTIATION; PROMOTER; T(12/21); PROTEIN; TRANSLOCATIONS","Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, we applied RNA interference to silence TEL/AML1 in leukemic cells. We designed and tested 11 different oligonucleotides targeting the TEL/AML1 fusion site. Using most efficient siRNAs, we achieved an average of 74-86% TEL/AML1 protein knockdown in REH and UOC-B6 leukemic cells, respectively. TEL/AML1 silencing neither decreased cell viability, nor induced apoptosis. On the contrary, it resulted in the modest but significant increase in the S phase fraction and in higher proliferation rate. Opposite effects on cell cycle distribution and proliferation were induced by AML1 silencing, thus, supporting our hypothesis that TEL/AML1 may block AML1-mediated promotion of G1/S progression through the cell cycle. In line with the lack of major effect on phenotype, we found no significant changes in clonogenic potential and global gene expression pattern upon TEL/AML1 depletion. Our data suggest that though TEL/AML1 is important for the (pre)leukemic clone development, it may be dispensable for leukemic cell survival and would not be a suitable target for gene-specific therapy. Leukemia (2011) 25, 313-320; doi:10.1038/leu.2010.277; published online 26 November 2010","[Zaliova, M.; Madzo, J.; Trka, J.] Charles Univ Prague, Dept Paediat Haematol & Oncol, CLIP, Sch Med 2,Fac Med 2, Prague 15006 5, Czech Republic; [Zaliova, M.; Madzo, J.; Trka, J.] Univ Hosp Motol, Prague, Czech Republic; [Cario, G.] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany","Zaliova, M, Charles Univ Prague, Dept Paediat Haematol & Oncol, CLIP, Sch Med 2,Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","marketa.zaliova@lfmotol.cuni.cz","[MSM0021620813]; [MZ0FNM2005]","This work was supported by grants MSM0021620813 and MZ0FNM2005.",null,37,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2010.277","LEUKEMIA","Leukemia","FEB",2011,25,2,null,null,null,313,320,null,null,8,"Oncology; Hematology","719GC","ISI:000287188600016"]
["J","Connolly, SJ; Eikelboom, J; Joyner, C; Diener, HC; Hart, R; Golitsyn, S; Flaker, G; Avezum, A; Hohnloser, SH; Diaz, R; Talajic, M; Zhu, J; Pais, P; Budaj, A; Parkhomenko, A; Jansky, P; Commerford, P; Tan, RS; Sim, KH; Lewis, BS; Van Mieghem, W; Lip, GYH; Kim, JH; Lanas-Zanetti, F; Gonzalez-Hermosillo, A; Dans, AL; Munawar, M; O'Donnell, M; Lawrence, J; Lewis, G; Afzal, R; Yusuf, S + Workgroup 993 členů",null,null,null,"Connolly, Stuart J.; Eikelboom, John; Joyner, Campbell; Diener, Hans-Christoph; Hart, Robert; Golitsyn, Sergey; Flaker, Greg; Avezum, Alvaro; Hohnloser, Stefan H.; Diaz, Rafael; Talajic, Mario; Zhu, Jun; Pais, Prem; Budaj, Andrzej; Parkhomenko, Alexander; Jansky, Petr; Commerford, Patrick; Tan, Ru San; Sim, Kui-Hian; Lewis, Basil S.; Van Mieghem, Walter; Lip, Gregory Y. H.; Kim, Jae Hyung; Lanas-Zanetti, Fernando; Gonzalez-Hermosillo, Antonio; Dans, Antonio L.; Munawar, Muhammad; O'Donnell, Martin; Lawrence, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim",null,"Apixaban in Patients with Atrial Fibrillation","NEW ENGLAND JOURNAL OF MEDICINE",null,"English","Article",null,null,null,null,null,null,"ANTITHROMBOTIC THERAPY; KNEE REPLACEMENT; PREVENT STROKE; WARFARIN; ASPIRIN; TRIAL; THROMBOPROPHYLAXIS; ANTICOAGULATION; METAANALYSIS; CLOPIDOGREL","BACKGROUND Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients. METHODS In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior. The mean follow up period was 1.1 years. The primary outcome was the occurrence of stroke or systemic embolism. RESULTS Before enrollment, 40% of the patients had used a vitamin K antagonist. The data and safety monitoring board recommended early termination of the study because of a clear benefit in favor of apixaban. There were 51 primary outcome events (1.6% per year) among patients assigned to apixaban and 113 (3.7% per year) among those assigned to aspirin (hazard ratio with apixaban, 0.45; 95% confidence interval [CI], 0.32 to 0.62; P<0.001). The rates of death were 3.5% per year in the apixaban group and 4.4% per year in the aspirin group (hazard ratio, 0.79; 95% CI, 0.62 to 1.02; P = 0.07). There were 44 cases of major bleeding (1.4% per year) in the apixaban group and 39 (1.2% per year) in the aspirin group (hazard ratio with apixaban, 1.13; 95% CI, 0.74 to 1.75; P = 0.57); there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin. The risk of a first hospitalization for cardiovascular causes was reduced with apixaban as compared with aspirin (12.6% per year vs. 15.9% per year, P<0.001). The treatment effects were consistent among important subgroups. CONCLUSIONS In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage.","[Connolly, Stuart J.; Eikelboom, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Connolly, Stuart J.; Eikelboom, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim] Hamilton Hlth Sci, Hamilton, ON, Canada; [Joyner, Campbell] Univ Toronto, Toronto, ON, Canada; [Diener, Hans-Christoph] Univ Duisburg Essen, Essen, Germany; [Hart, Robert] Univ Texas San Antonio, San Antonio, TX USA; [Golitsyn, Sergey] Russian Cardiol Res & Prod Ctr, Moscow, Russia; [Flaker, Greg] Univ Missouri, Columbia, MO 65211 USA; [Avezum, Alvaro] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany; [Diaz, Rafael] Estudios Clin Latinoamer, Rosario, Argentina; [Talajic, Mario] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada; [Zhu, Jun] Chinese Acad Med Sci, FuWai Hosp, Beijing 100037, Peoples R China; [Zhu, Jun] Peking Union Med Coll, Beijing 100021, Peoples R China; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Pais, Prem] Res Inst, Bangalore, Karnataka, India; [Budaj, Andrzej] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; [Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine; [Jansky, Petr] Univ Hosp Motol, Prague, Czech Republic; [Commerford, Patrick] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Sim, Kui-Hian] Clin Res Ctr, Sarawak, Malaysia; [Tan, Ru San] Natl Heart Ctr, Singapore, Singapore; [Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel; [Van Mieghem, Walter] Ziekenhuis Oost Limburg Campus, St Jan, Genk, Belgium; [Lip, Gregory Y. H.] City Hosp, Birmingham, W Midlands, England; [Kim, Jae Hyung] Catholic Univ Korea, St Pauls Hosp, Seoul, South Korea; [Lanas-Zanetti, Fernando] Univ La Frontera, Temuco, Chile; [Gonzalez-Hermosillo, Antonio] Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico; [Dans, Antonio L.] Univ Philippines, Coll Med, Manila, Philippines; [Munawar, Muhammad] Harapan Kita Hosp, Jakarta, Indonesia; [O'Donnell, Martin] HRB Clin Res Facil, Galway, Ireland; [Lawrence, John] Bristol Myers Squibb Co, Princeton, NJ USA","Connolly, SJ, McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada","stuart.connolly@phri.ca","Boehringer Ingelheim ; Sanofi-Aventis ; Portola ; Merck ; Eli Lilly ; AstraZeneca ; Novartis ; Bristol-Myers Squibb ; Abbott ; Bayer Vital ; CoAxia ; D-Pharm ; Fresenius ; GlaxoSmithKline ; Janssen-Cilag ; Knoll ; Merck Sharpe and Dohme ; Medtronic ; MindFrame ; Neurobiological Technologies ; Novo-Nordisk ; Paion ; Parke-Davis ; Pfizer ; Sankyo ; Schering-Plough ; Servier ; Solvay ; Thrombogenics ; Wyeth ; Yamaguchi ; Takeda ; Bayer ; Borschagovskiy ; Astellas ; Orion ; Daiichi ; Biotronic ; St. Jude Medical ","Dr. Connolly reports receiving payment for serving on the boards of Boehringer Ingelheim, Sanofi-Aventis, Portola, and Merck, consulting fees from Boehringer Ingelheim, Sanofi-Aventis, Portola, and Merck, grant support on behalf of his institution, McMaster University, from Boehringer Ingelheim, Sanofi-Aventis, Portola, and Bristol-Myers Squibb, and lecture fees from Boehringer Ingelheim, Sanofi-Aventis, and Portola; Dr. Eikelboom, receiving consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, AstraZeneca, and Novartis and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, and AstraZeneca; Dr. Joyner, receiving honoraria from Hamilton Health Sciences as the cochair of the RELY adjudication committee; Dr. Diener, receiving payment for serving on the boards of Abbott, AstraZeneca, Boehringer Ingelheim, CoAxia, D-Pharm, GlaxoSmithKline, Janssen-Cilag, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Sanofi-Aventis, Servier, and Solvay, consulting fees from Abbott, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, CoAxia, D-Pharm, Fresenius, GlaxoSmithKline, Janssen-Cilag, Knoll, Merck Sharpe and Dohme, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth, and Yamaguchi, grant support on behalf of his institution, University Duisburg-Essen, from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Janssen-Cilag, and Sanofi-Aventis, lecture fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Bayer Vital, Boehringer Ingelheim, CoAxia, D-Pharm, GlaxoSmithKline, Merck Sharpe and Dohme, MindFrame, Neurobiological Technologies, Novartis, Sanofi-Aventis, Servier, Solvay, and Thrombogenics, payment from Boehringer Ingelheim and Sanofi-Aventis for manuscript preparation, and payment from Boehringer Ingelheim for developing educational presentations; Dr. Flaker, receiving payment for serving as a consultant on Bristol-Myers Squibb's advisory board; Dr. Avezum, receiving payment from Boehringer Ingelheim for giving lectures in the Satellite Symposium; Dr. Hohnloser, receiving consulting fees from Boehringer Ingelheim, St. Jude Medical, Sanofi-Aventis, and Cardiome, and lecture fees from Boehringer Ingelheim, St. Jude Medical, Sanofi-Aventis, and Cardiome; Dr. Talajic, receiving consulting fees from Boehringer Ingelheim and Bristol-Myers Squibb, grant support on behalf of his institution, the Montreal Heart Institute, from Boehringer Ingelheim, and lecture fees from Boehringer Ingelheim and Bristol-Myers Squibb; Dr. Budaj, receiving consulting fees from Sanofi-Aventis, Eli Lilly, Novartis, and AstraZeneca, grant support both for himself and on behalf of his institution, Grochowski Hospital, from Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, Bristol-Myers Squibb, and AstraZeneca, lecture fees from Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca, and reimbursement for travel, accommodations, or meeting expenses from Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca; Dr. Parkhomenko, receiving consulting fees from AstraZeneca, Merck Sharpe and Dohme, Bayer, Takeda, GlaxoSmithKline, Borschagovskiy, Servier, Sanofi-Aventis, Astellas, and Boehringer Ingelheim, lecture fees from Servier, Orion, GlaxoSmithKline, and Pfizer, and payment from Servier and Pfizer for developing educational presentations; Dr. Commerford, having testified as an expert witness on the importance of anticoagulation in atrial fibrllation, receiving consulting fees from UpToDate and reimbursement for committee meeting expenses on behalf of his institution, the Cardiac Clinic, from Boehringer Ingelheim, Sanofi-Aventis, and Bristol-Myers Squibb; Dr. Tan, receiving payment for serving on a regional advisory board for Bayer; Dr. Lewis, receiving consulting fees from Bristol-Myers Squibb; Dr. Lip, receiving consulting fees from Astellas, Boehringer Ingelheim, Bayer, Daiichi, Merck, Portola, Biotronic, Sanofi-Aventis, and AstraZeneca, grant support on behalf of his institution, City Hospital, from Bayer, lecture fees from Boehringer Ingelheim, Bayer, Merck, and Sanofi-Aventis, and payment from Boehringer Ingelheim for developing educational presentations; Dr. Lawrence, being an employee of Bristol-Myers Squibb; and Dr. Yusuf, receiving consulting fees from Boehringer Ingelheim, Sanofi-Aventis, Novartis, AstraZeneca, Bristol-Myers Squibb, and Glaxo-SmithKline, and grant support from Boehringer Ingelheim, Sanofi-Aventis, Novartis, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported. Supported by Bristol-Myers Squibb and Pfizer.",null,25,0,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,"10.1056/NEJMoa1007432","N ENGL J MED","N. Engl. J. Med.","MAR 3",2011,364,9,null,null,null,806,817,null,null,12,"Medicine, General & Internal","729DJ","ISI:000287928400006"]
["J","Fric, P; Gabrovska, D; Nevoral, J",null,null,null,"Fric, Premysl; Gabrovska, Dana; Nevoral, Jiri",null,"Celiac disease, gluten-free diet, and oats","NUTRITION REVIEWS",null,"English","Review",null,null,null,null,null,"avenin; celiac disease; gluten-free diet; oats","T-CELL RESPONSES; DERMATITIS-HERPETIFORMIS; CEREAL PROTEINS; VILLOUS ATROPHY; TOXIC GLIADIN; UNITED-STATES; CHILDREN; ADULT; FOODS; AVENINS","Oats in a gluten-free diet increase the diet's nutritional value, but their use remains controversial. Contamination with prolamins of other cereals is frequent, and some clinical and experimental studies support the view that a subgroup of celiac patients may be intolerant to pure oats. Thus, this issue is more complex than previously suggested. In order to produce oats that are safe for all celiac patients, the following topics should be addressed: selection of oat cultivars with low avenin content, research on such recombinant varieties of oats, development of assay methods to detect avenins in oat products, guidelines for the agricultural processing of oats and the manufacture of oat products, as well as guidelines for following up with celiac patients who consume oats.","[Fric, Premysl] Charles Univ Prague, Dept Med, Fac Med 1, CZ-16902 Prague 6, Czech Republic; [Fric, Premysl] Charles Univ Prague, Cent Mil Hosp, CZ-16902 Prague 6, Czech Republic; [Gabrovska, Dana] Food Res Inst, Dept Nutrit Subst, Prague, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Pediat, Fac Med 2, CZ-16902 Prague, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Hosp Motol, CZ-16902 Prague, Czech Republic","Fric, P, Charles Univ Prague, Dept Med, Fac Med 1, CZ-16902 Prague 6, Czech Republic","premysl.fric@uvn.cz",null,null,null,75,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0029-6643",null,"10.1111/j.1753-4887.2010.00368.x","NUTR REV","Nutr. Rev.","FEB",2011,69,2,null,null,null,107,115,null,null,9,"Nutrition & Dietetics","715LI","ISI:000286885600005"]
["J","Zaliova, M; Meyer, C; Cario, G; Vaskova, M; Marschalek, R; Stary, J; Zuna, J; Trka, J",null,null,null,"Zaliova, Marketa; Meyer, Claus; Cario, Gunnar; Vaskova, Martina; Marschalek, Rolf; Stary, Jan; Zuna, Jan; Trka, Jan",null,"TEL/AML1-Positive Patients Lacking TEL Exon 5 Resemble Canonical TEL/AML1 Cases","PEDIATRIC BLOOD & CANCER",null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; childhood leukemia; TEL/AML1","ACUTE LYMPHOBLASTIC-LEUKEMIA; FUSION PROTEIN; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTIONAL REPRESSION; TEL-AML1 TRANSLOCATION; PRELEUKEMIC ACTIVITY; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; BONE-MARROW; STEM-CELLS","Background. The TEL/AML1 fusion gene which represents the most frequent genetic abnormality in childhood ALL, usually results from genomic breakpoints in TEL intron 5 and AML1 intron 1 or 2. At the protein level, the helix loop helix domain and exon 5-coded central region of TEL are typically fused to almost entire AML1 including DNA-binding domain. Procedure. We identified two ALL patients with genomic breakpoints within TEL intron 4 resulting in variant TEL/AML1 fusion lacking the TEL exon 5-coded central region. This region was supposed to play an important role in TEL/AML1 function, particularly in TEL/AML1-mediated transcriptional repression of AML1 targets. We aimed at investigating the impact of the loss of this region on disease behavior and TEL/AML1 function. We compared clinical and biological characteristics, treatment response, and outcome of the variant versus classical TEL/AML1 cases, analyzed genome wide gene expression profiles and performed reporter gene assay. Results. No distinct differences between variant and classical TEL/AML1 cases were observed including gene expression profiling and detailed immunophenotyping. By using reporter gene assay, we showed that the loss of the central region does not influence the TEL/AML1-mediated transcriptional repression. Conclusions. The deletion of the central region did not affect the TEL/AML1-specific phenotype; we did not find any relevant differences in clinical and biological features when variant versus classical TEL/AML1-positive cases were compared. Thus, our data does not support hypothesis that the central region of TEL is indispensable for TEL/AML1 driven leukemogenesis. Pediatr Blood Cancer. 2011;56:217-225. (C) 2010 Wiley-Liss, Inc.","[Zaliova, Marketa] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CLIP,Fac Med 2, Prague 15006 5, Czech Republic; [Zaliova, Marketa; Vaskova, Martina; Stary, Jan; Zuna, Jan; Trka, Jan] Univ Hosp Motol, Prague, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Goethe Univ Frankfurt, Inst Pharmaceut Biol, ZAFES,Bioctr, Diagnost Ctr Acute Leukemia, Frankfurt, Germany; [Cario, Gunnar] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany","Zaliova, M, Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CLIP,Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic","marketa.zaliova@lfmotol.cuni.cz","[MSM0021620813]; [MZOFNM2005]","This work was supported by grants MSM0021620813 and MZOFNM2005. Authors would like to acknowledge all participating centers within the Czech Pediatric Hematology Working Group (CPH) for clinical management and sample collection.",null,47,0,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,"10.1002/pbc.22686","PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","FEB",2011,56,2,null,null,null,217,225,null,null,9,"Oncology; Hematology; Pediatrics","703YI","ISI:000286017500009"]
["J","Tapia, G; Cinek, O; Rasmussen, T; Grinde, B; Stene, LC; Ronningen, KS",null,null,null,"Tapia, German; Cinek, Ondrej; Rasmussen, Trond; Grinde, Bjorn; Stene, Lars C.; Ronningen, Kjersti S.",null,"Longitudinal study of parechovirus infection in infancy and risk of repeated positivity for multiple islet autoantibodies: the MIDIA study","PEDIATRIC DIABETES",null,"English","Article",null,null,null,null,null,"diabetes mellitus; type 1; epidemiology; human parechovirus; nested case; control study; polymerase chain reaction","STOOL SAMPLES; NORWEGIAN INFANTS; IDENTIFICATION; CHILDREN; ENTEROVIRUS; ASSOCIATION","The objective of this study was to investigate a possible association between human parechovirus infections in early infancy, diagnosed in fecal samples, and the development of islet autoimmunity. In the 'Environmental Triggers of Type 1 Diabetes: The MIDIA study', newborns with the highest genetic risk for type 1 diabetes were identified and followed with regular fecal sampling and questionnaires. A nested case-control study, including 27 children who developed islet autoimmunity (repeatedly positive for two or three autoantibodies) and 53 children matched for age and community of residence was used. Monthly stool samples from these children were analyzed for human parechovirus using a semi-quantitative real-time polymerase chain reaction. There was no significant difference in the prevalence of human parechovirus in stool samples when cases and controls were compared: 13.0 and 11.1%, respectively. There was also not any difference as to the number of infection episodes. In analyses restricted to samples collected 3, 6 or 12 months prior to seroconversion for islet autoantibodies, there was a suggestive association in the shortest time window of 3 months (20.8 vs. 8.8%, odds ratio = 3.2, 95% CI 1.2 - 8.5, uncorrected p = 0.022). No symptoms were associated with human parechovirus infection. A subset of the positive samples (n = 31) were sequenced, suggesting that human parechovirus 1 was the dominant genotype. The present study does not support strong associations between human parechovirus infections and the signs of islet autoimmunity. The weak association of parechovirus present in the last 3 months before development of autoimmunity warrants further investigation.","[Tapia, German; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Dept Genes & Environm, N-0403 Oslo, Norway; [Tapia, German; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Rasmussen, Trond] Norwegian Inst Publ Hlth, Dept Informat Syst, N-0403 Oslo, Norway; [Grinde, Bjorn] Norwegian Inst Publ Hlth, Dept Virol, N-0403 Oslo, Norway; [Stene, Lars C.] Norwegian Inst Publ Hlth, Dept Chron Dis, N-0403 Oslo, Norway","Tapia, G, Norwegian Inst Publ Hlth, Dept Genes & Environm, Postboks 4404 Nydalen, N-0403 Oslo, Norway","german.tapia@fhi.com","The Norwegian Organization for Health and Rehabilitation [2005/2/0128]; EEA/Norway, Prague, The Czech Republic [A/CZ0046/1/0014]; The Ministry of Education of the Czech Republic [MSM0021620814]; The Czech ministry of Health [NT 11465-5]; The Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; The Norwegian Diabetes Association ; Children with Diabetes Foundation (Denver, CO, USA) ; NewGeneris [Food-CT-2005-016320]","This study and the MIDIA project were funded by The Norwegian Organization for Health and Rehabilitation (grant 2005/2/0128), the EEA/Norway (grant A/CZ0046/1/0014 through the Research Support Fund, Prague, The Czech Republic), The Ministry of Education of the Czech Republic (grant MSM0021620814), The Czech ministry of Health (grant NT 11465-5), The Research Council of Norway (grants 135893/330, 155300/320, 156477/730, 166515/V50), The Norwegian Diabetes Association, and Children with Diabetes Foundation (Denver, CO, USA), NewGeneris (grants Food-CT-2005-016320). We thank the public health care nurses for their effort in the recruitment to the MIDIA study and to the follow-up of high-risk children, the staff at the Biobank, Norwegian Institute of Public Health for DNA extraction and genotyping. In particular, we would like to express our gratitude to all the parents for their efforts in handling their child's type 1 diabetes risk, for providing delivered blood and fecal samples from their children and completing the questionnaires.",null,16,0,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,"10.1111/j.1399-5448.2010.00658.x","PEDIATR DIABETES","Pediatr. Diabetes","FEB",2011,12,1,null,null,null,58,62,null,null,5,"Endocrinology & Metabolism; Pediatrics","711UT","ISI:000286617600010"]
["J","Wadstrom, J; Biglarnia, A; Gjertsen, H; Sugitani, A; Fronek, J",null,null,null,"Wadstrom, Jonas; Biglarnia, Alireza; Gjertsen, Henrik; Sugitani, Atsushi; Fronek, Jiri",null,"Introducing Hand-Assisted Retroperitoneoscopic Live Donor Nephrectomy: Learning Curves and Development Based on 413 Consecutive Cases in Four Centers","TRANSPLANTATION",null,"English","Article",null,null,null,null,null,"Hand assistance; Hand-assisted retroperitoneoscopic nephrectomy; Live donor nephrectomy; Living donors; Morbidity; Safety; Learning curve; Multicenter; Review","LAPAROSCOPIC PARTIAL NEPHRECTOMY; RANDOMIZED CONTROLLED-TRIAL; RADICAL NEPHRECTOMY; SINGLE-CENTER; TRANSPERITONEAL; COMPLICATIONS; EXPERIENCE; SURGERY; KIDNEY; RHABDOMYOLYSIS","Background. Hand-assisted and retroperitoneoscopic techniques reduce the risk of bleeding and intraabdominal complications in living donor nephrectomy (LDN). This study reports on our four-center experience, development, and learning curves from the first 413 LDNs using a hand-assisted retroperitoneoscopic (HARS) technique. Methods. The first 413 consecutive donors operated on using HARS were included in the study. Donor demographics, perioperative and postoperative data, complications, and recipient outcomes have been compiled. The data were analyzed as a whole and separately for each center, looking at center differences and learning curves over time. Results. Significant differences were found in donor demographics between centers for the variables: age, body mass index, number of arteries, and side of operation. Mean operating time was 170.2 min, with significant differences between centers. Operating time was also significantly influenced by learning curves, sex/body mass index, and side of operation. Warm ischemia time differed significantly between centers and was influenced by center-wise learning and number of arteries. Overall conversion rate was 2.4% and differed significantly between centers. There was no mortality and no intraabdominal complications. Apart from the conversions and one pulmonary embolism, there were no major intraoperative or postoperative complications. Overall 3-month graft survival was 99%, with 96% immediate onset of function and 1% ureteral complications. Conclusions. The HARS technique reduces the risk of intraabdominal complications. It can be implemented with excellent donor and recipient outcomes despite different population demographics and center/surgeon-related tradition and experience. On the basis of our experience, we recommend the technique to increase the safety margin of LDN.","[Wadstrom, Jonas; Biglarnia, Alireza] Univ Uppsala Hosp, Dept Surg, SE-75185 Uppsala, Sweden; [Gjertsen, Henrik] Karolinska Univ Hosp, Dept Transplantat Surg, Stockholm, Sweden; [Sugitani, Atsushi] Fujita Hlth Univ, Dept Organ Transplantat & Regenerat Med, Aichi, Japan; [Fronek, Jiri] Univ London St Georges Hosp, Renal Transplant Unit, London, England; [Fronek, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Wadstrom, J, Univ Uppsala Hosp, Dept Surg, SE-75185 Uppsala, Sweden","jonas.wadstrom@akademiska.se","medical faculty of Uppsala University ","This work was supported by the medical faculty of Uppsala University.",null,80,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0041-1337",null,"10.1097/TP.0b013e3182052baf","TRANSPLANTATION","Transplantation","FEB 27",2011,91,4,null,null,null,462,469,null,null,8,"Immunology; Surgery; Transplantation","718MR","ISI:000287127600017"]
["J","Vlcek, M; Landor, I; Visna, P; Vavrik, P; Sindelarova, J; Sosna, A",null,null,null,"Vlcek, M.; Landor, I.; Visna, P.; Vavrik, P.; Sindelarova, J.; Sosna, A.",null,"Multidirectional Screw Fixation in the Treatment of Distal Radius Fractures Using Angle-Stable Plates","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"intra-articular fractures of the distal radius; volar approach; angle-stable locking plate; multidirectional angle-stabile screw","DORSALLY DISPLACED FRACTURES; LOCKING PLATING SYSTEM; VOLAR PLATE; SURGICAL-TREATMENT; INTERNAL-FIXATION; OPEN REDUCTION; PART; PALMAR; COMPLICATIONS; MANAGEMENT","PURPOSE OF THE STUDY Intra-articular fractures of the distal radius are treated predominantly by open reduction and internal fixation with various types of angle-stable plates. In this study we compare functional and radiographic outcomes in patients with intra-articular distal radius fractures treated with either angle-stable plates with rigid-direction screw insertion or multidirectional angle-stable plates. MATERIAL AND METHODS The LCP group included 37 patients with an average age of 50 years (range 20-81 years) who were treated using angle-stable plates with rigid-direction screw insertion (LOP, Synthes). The APTUS group comprising 41 patients with an average age of 48.9 years (range 22-77 years) was treated by angle-stable implants in which screws can pivot freely in all directions (Aptus, Medartis). There was no significant difference between the groups in relation to fracture severity, age or other relevant characteristics. In all cases we used the volar approach. The final evaluation of treatment outcome was made at 12 months after surgery. We measured the range of wrist motion and hand grip strength, and compared the values with those obtained in the contralateral wrist. The results evaluated on the scoring systems of Gartland and Werley and of Castaing, and the DASH score were compared between the groups. The findings on radiographs were compared with the anatomical standard in the distal radius region. RESULTS In the LOP group, the average values, as compared with the contralateral side, were as follows: volar flexion, 84.2 %; dorsal flexion, 82.4 %; radial deviation, 83.2 %; ulnar deviation, 89.1 %; pronation, 98.6 %; supination, 97.4 %. In the APTUS group, the values in comparison with the other wrist were: volar flexion, 84.1 %; dorsal flexion, 91.8 %; radial deviation, 95.1 %; ulnar deviation, 92.8 %; pronation, 99.0 %; supination, 98.1 %. The values statistically comparable with the contralateral side were those in pronation, supination and hand grip strength in both groups. In addition, in the APTUS group, the values corresponding to the healthy wrist function were achieved in both radial and ulnar deviation. There were no differences in the values based on the scoring systems between the LOP and APTUS groups. As for the radiographic parameters, only the reconstruction of radial length was optimal. The other parameters differed from the anatomical standard. However, all patients met the criteria of successful healing of a distal radius fracture. Secondary fragment displacement during healing was recorded in two patients of the LOP group and in one of the APTUS group. Transient irritation of the median nerve was observed in five LOP group patients and in only one APTUS group patient. One patient in each group had an extensor tendon rupture. Reflex sympathetic dystrophy syndrome was diagnosed in two LOP group patients and in three APTUS group patients. DISCUSSION The surgical treatment of complex fractures of the distal radius using the angle-stable implants has generally achieved very good functional and radiographic outcomes with a low rate of complications. In the APTUS group, in contrast to the LOP group, the extent of radial and ulnar deviation corresponded to that found in the healthy wrist. The reason was a low-profile design of the plate and the screws, and the system with multidirectional angle-stable screws. The fewer cases of median nerve irritation in the APTUS group can be explained by the use of a different operative approach reducing the risk of direct mechanical nerve injury. In contrast to other authors, flexor tendon ruptures were not recorded in our groups. CONCLUSIONS The treatment of distal radius fractures by the angle-stable locking plate system from the volar approach achieved comparable functional and radiographic outcomes with both rigid-direction screw insertion and multidirectional screw insertion.","[Vlcek, M.; Landor, I.; Vavrik, P.; Sosna, A.] FN Motole, LF UK 1, Ortoped Klin 1, Prague 15006 5, Czech Republic; [Visna, P.] Zent Klin Bad Berka, Klin Orthopadie & Unfallchirug, Bad Berka, Germany; [Sindelarova, J.] Fak Strojni CVUT, Lab Biomech Cloveka, Prague, Czech Republic","Landor, I, FN Motol, LF UK 1, Ortoped Klin 1, V Uvalu 84, Prague 15006 5, Czech Republic","landor@atlas.cz",null,null,null,37,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC",1283829,null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2011,78,1,null,null,null,27,33,null,null,7,"Orthopedics","731XJ","ISI:000288143500004"]
["J","Veigl, D; Vavrik, P; Pokorny, D; Slouf, M; Pavlova, E; Landor, I",null,null,null,"Veigl, D.; Vavrik, P.; Pokorny, D.; Slouf, M.; Pavlova, E.; Landor, I.",null,"Comparison of in Vivo Characteristics of Polyethylene Wear Particles Produced by a Metal and a Ceramic Femoral Component in Total Knee Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"total knee replacement; zirconia ceramic femoral component; comparative study; polyethylene wear; in vivo measurement","MOLECULAR-WEIGHT POLYETHYLENE; UHMWPE WEAR; TOTAL HIP; PERIPROSTHETIC OSTEOLYSIS; JOINT REPLACEMENT; SYNOVIAL-FLUID; ARTHROPLASTY; QUANTIFICATION; PROSTHESIS; TISSUES","PURPOSE OF THE STUDY The aim of the study was to evaluate in vivo and compare, in terms of the quality and number of ultra high-molecular polyethylene (UHMWPE) wear particles, total knee replacements of identical construction differing only in the material used for femoral component production, i.e., CoCrMo alloy or ZrO2 ceramics. MATERIAL AND METHODS Samples of pen-prosthetic granuloma tissue were collected in two patients with total knee replacement suffering from implant migration, who were matched in relevant characteristics. The primary knee replacement in Patient 1 with a CoCrMo femoral component was done 7.2 years and in Patient 2 with a ZrO2 implant 6.8 years before this assessment. The polyethylene wear-induced granuloma was analysed by the MORF method enabling us to assess the shape and size of wear debris and the IRc method for assessment of particle concentration. RESULTS In the granuloma tissue samples of Patient 1, on the average, particles were 0.30 mm in size and their relative volume was 0.19. In the Patient 2 tissue samples, the average size of particles was 0.33 mm and their relative volume was 0.26. There was no significant difference in either particle morphology or their concentration in the granuloma tissue between the two patients. DISCUSSION One of the options of how to reduce the production of polyethylene wear particles is to improve the tribological properties of contacting surfaces in total knee replacement by substituting a cobalt-chrome femoral component with a zirconia ceramic femoral component. The previous in vitro testing carried out with a mechanical simulator under conditions approaching a real weight-bearing in the human body did show a nearly three-fold decrease in the number of UHMWPE wear particles in zirconia components. The evaluation of granuloma tissue induced by the activity of a real prosthetic joint for nearly seven years, however, did not reveal any great difference in either quality or quantity of polyethylene debris between the two replacements. The difference of surface roughness between CoCrMo (Ra = 0.05) and ZrO2 (Ra = 0.02) components did not play any role in in vivo conditions. CONCLUSIONS In accordance with a previous clinical study, this evaluation of the quality and quantity of UHMWPE wear particles produced by a ceramic femoral component in vivo failed to demonstrate any advantage of zirconia ceramic components over the cobalt-chrome femoral components so far used.","[Veigl, D.; Vavrik, P.; Pokorny, D.; Landor, I.] I Ortoped Klin 1 LF UK, Prague 15000 5, Czech Republic; [Veigl, D.; Vavrik, P.; Pokorny, D.; Landor, I.] FN Motol, Prague, Czech Republic; [Slouf, M.; Pavlova, E.] Ustav Makromol Chem AV CR, Prague, Czech Republic","Vavrik, P, I Ortoped Klin 1 LF UK, V Uvalu 83, Prague 15000 5, Czech Republic","pvavrik@atlas.cz",null,null,null,49,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC",1283829,null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2011,78,1,null,null,null,49,55,null,null,7,"Orthopedics","731XJ","ISI:000288143500008"]
["J","Veselka, J; Zemanek, D; Hajek, P; Maly, M; Adlova, R; Martinkovicova, L; Tomasov, P; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tomasov, Pavol; Tesar, David",null,"Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention","AMERICAN JOURNAL OF CARDIOLOGY",null,"English","Article",null,null,null,null,null,null,"PERIPROCEDURAL MYOCARDIAL-INFARCTION; PREPROCEDURAL STATIN THERAPY; RANDOMIZED-TRIAL; MICROEMBOLIZATION; METAANALYSIS; IMPACT","Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p = 0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p < 0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1295-1299)","[Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tomasov, Pavol; Tesar, David] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague, Czech Republic","Veselka, J, Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague, Czech Republic","veselka.josef@seznam.cz","Ministry of Health of the Czech Republic [00064203]","This work was supported by Grant 00064203 from the Ministry of Health of the Czech Republic.",null,18,0,"EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","BRIDGEWATER","685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA",2647676,null,"10.1016/j.amjcard.2010.12.040","AMER J CARDIOL","Am. J. Cardiol.","MAY 1",2011,107,9,null,null,null,1295,1299,null,null,5,"Cardiac & Cardiovascular Systems","764CI","ISI:000290605600008"]
["J","Oschlies, I; Burkhardt, B; Chassagne-Clement, C; d'Amore, ES; Hansson, U; Hebeda, K; Mc Carthy, K; Kodet, R; Maldyk, J; Mullauer, L; Porwit, A; Schmatz, AI; Tinguely, M; Abramov, D; Wotherspoon, A; Zimmermann, M; Reiter, A; Klapper, W",null,null,null,"Oschlies, Ilske; Burkhardt, Birgit; Chassagne-Clement, Catherine; d'Amore, Emanuel S.; Hansson, Ulrika; Hebeda, Konnie; Mc Carthy, Keith; Kodet, Roman; Maldyk, Jadwiga; Muellauer, Leonhard; Porwit, Anna; Schmatz, Ana-Iris; Tinguely, Marianne; Abramov, Dimitry; Wotherspoon, Andrew; Zimmermann, Martin; Reiter, Alfred; Klapper, Wolfram",null,"Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial: Experiences and Preliminary Recommendations From the European Childhood Lymphoma Pathology Panel","AMERICAN JOURNAL OF SURGICAL PATHOLOGY",null,"English","Article",null,null,null,null,null,"MPAL; TdT; CD34; lymphoblastic; ALL; precursor; B-LBL; T-LBL","MERKEL CELL-CARCINOMA; TRANSCRIPTION FACTORS; ACUTE LEUKEMIAS; EXPRESSION; PAX5; SURVIVAL; PITFALL; LINEAGE; TDT","The majority of lymphoblastic (precursor cell) neoplasms presents as leukemias. Consequently, the guidelines for lineage determination and subtyping of precursor cell neoplasms were primarily established for flow cytometry methods. Large-scale studies of nonleukemic lymphoblastic lymphomas are lacking so far. We analyzed a large series of pediatric patients with lymphoblastic lymphoma treated within a prospective randomized trial (the Euro-LB 02 study). Among 193 lymphomas, in which a detailed immunohistochemical analysis was carried out, there were several unusual and diagnostically challenging morphologic and immunophenotypical variants. These included 11 lymphomas with mixed phenotypes expressing markers of at least 2 hematopoietic lineages, 7 terminal deoxynucleotide transferase-negative lymphoblastic lymphomas, and 3 undifferentiated hematopoietic neoplasms that could not be assigned to any lineage with certainty. Our data indicate that World Health Organzation guidelines for lineage determination and subtyping of precursor cell leukemia need to be adapted before they can be applied to immunohistochemical diagnosis of lymphoma. Using the experience from this cohort we suggest a resource-saving diagnostic staining panel for the immunohistochemical analysis of precursor cell neoplasms in formalin-fixed paraffin-embedded tissue.","[Oschlies, Ilske; Abramov, Dimitry; Klapper, Wolfram] Univ Kiel, Dept Pathol, Hematopathol Sect, D-2300 Kiel, Germany; [Oschlies, Ilske; Abramov, Dimitry; Klapper, Wolfram] Univ Kiel, Lymph Node Registry, D-2300 Kiel, Germany; [Burkhardt, Birgit; Zimmermann, Martin; Reiter, Alfred] Univ Giessen, NHL BFM Study Ctr, Dept Pediat Hematol & Oncol, Giessen, Germany; [Schmatz, Ana-Iris] Leibniz Univ Hannover, Dept Pediat Hematol, D-30167 Hannover, Germany; [Schmatz, Ana-Iris] Leibniz Univ Hannover, Dept Oncol, D-30167 Hannover, Germany; [Chassagne-Clement, Catherine] Ctr Leon Berard, Dept Biopathol, F-69373 Lyon, France; [d'Amore, Emanuel S.] Osped San Bortolo, Dept Pathol, Vicenza, Italy; [Hansson, Ulrika] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Porwit, Anna] Karolinska Univ Hosp & Inst, Dept Pathol, Stockholm, Sweden; [Hebeda, Konnie] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands; [Mc Carthy, Keith] Chettenham Gen Hosp, Dept Pathol, Cheltenham, Glos, England; [Wotherspoon, Andrew] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England; [Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague, Czech Republic; [Maldyk, Jadwiga] Childrens Hosp, Dept Pathol, Warsaw, Poland; [Tinguely, Marianne] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Muellauer, Leonhard] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Kodet, Roman] Charles Univ Prague, Fac Hosp, Prague, Czech Republic","Klapper, W, Univ Hosp Schleswig Holstein, Hematopathol Sect, Arnold Heller Str 3,Haus 14, D-24105 Kiel, Germany","wklapper@path.uni-kiel.de","Deutsche Krebshilfe Bonn [102595, 107813]; national study groups of participating centers ; TransAid foundation ; Kinderkrebsinitiative Buchholz, Holm-Seppensen, Germany ; Kinder-Krebs-Initiative Buchholz, Holm-Seppensen ; national study groups for pediatric Non-Hodgkin Lymphoma of the participating pathologists ; Deutsche Krebshilfe [107813]","Supported by the Deutsche Krebshilfe Bonn (projekt Nr. 102595 and 107813) and national study groups of participating centers. D. A. was supported by the TransAid foundation. W. K. and I.O. were supported by the Kinderkrebsinitiative Buchholz, Holm-Seppensen, Germany. Supported by the Kinder-Krebs-Initiative Buchholz, Holm-Seppensen and the national study groups for pediatric Non-Hodgkin Lymphoma of the participating pathologists. The NHL-BFM study center as the international coordination center of the trial was supported by the Deutsche Krebshilfe (grant No. 107813).",null,29,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0147-5185",null,"10.1097/PAS.0b013e318213e90e","AMER J SURG PATHOL","Am. J. Surg. Pathol.","JUN",2011,35,6,null,null,null,836,844,null,null,9,"Pathology; Surgery","763NW","ISI:000290567400007"]
["J","van der Linden, P; Gazdzik, TS; Jahoda, D; Heylen, RJ; Skowronski, JC; Pellar, D; Kofranek, I; Gorecki, AZ; Fagrell, B; Keipert, PE; Hardiman, YJ; Levy, H",null,null,null,"van der Linden, Philippe; Gazdzik, Tadeusz S.; Jahoda, David; Heylen, Rene J.; Skowronski, Jan C.; Pellar, David; Kofranek, Ivo; Gorecki, Andrzej Z.; Fagrell, Bengt; Keipert, Peter E.; Hardiman, Yun J.; Levy, Howard","6090 Study Investigators","A Double-Blind, Randomized, Multicenter Study of MP4OX for Treatment of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty Under Spinal Anesthesia","ANESTHESIA AND ANALGESIA",null,"English","Article",null,null,null,null,null,null,"ACUTE-RENAL-FAILURE; ACID-BASE STATUS; HEMOGLOBIN MP4; UNCONTROLLED HEMORRHAGE; ORTHOPEDIC-SURGERY; ANESTHETIZED SWINE; BLOOD SUBSTITUTES; ELDERLY-PATIENTS; OXYGEN; HEMOSPAN","BACKGROUND: MP4OX (oxygenated polyethylene glycol-modified hemoglobin) is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. In this study, we investigated the ability of MP4OX to treat hypotensive episodes. In addition, the tolerability profile of MP4OX in a large surgical population was established. METHODS: Patients from 21 study sites in 5 countries, scheduled to undergo primary hip arthroplasty under spinal anesthesia, were randomized in a double-blind manner to receive MP4OX or hydroxyethyl starch (HES) solution (Voluven (R); HES 130/0.4). Patients received the first 250-mL dose of investigational product when systolic blood pressure decreased to the predefined dosing trigger. A second 250-mL dose was given only if the systolic blood pressure decreased to the same trigger level after administration of the first dose. The primary efficacy outcome was total duration of all hypotensive episodes during surgery and the first 6 hours after skin closure. RESULTS: Of the 474 patients randomized, 405 reached the dosing trigger and received at least 1 dose. The mean total duration of all hypotensive episodes was significantly shorter (P < 0.0001) in the MP4OX group (52.4 +/- 71.50 minutes; range, 3-442 minutes) compared with the HES group (137.6 +/- 120.21 minutes; range, 5-435 minutes). The overall incidence of adverse events (AEs) in the intent-to-treat population was similar between the MP4OX and HES groups (75.2% vs 73.4%; P = 0.733). Transient increases in laboratory values were reported in more patients in the MP4OX group versus HES controls for aspartate aminotransferase (13.4% vs 7.4%; P = 0.052), alanine aminotransferase (6.9% vs 4.9%; P = 0.409), lipase (9.7% vs 3.6%; P = 0.015), and troponin (8.1% vs 2.0%; P = 0.006). There was no significant difference in the incidence of serious AEs reported (6.4% in MP4OX group vs 3.0% in HES controls; P = 0.106). Certain AEs did occur more frequently in the MP4OX group, including nausea (23.8% vs 14.3%; P = 0.016), bradycardia (14.9% vs 5.9%; P = 0.003), hypertension (8.4% vs 2.5%; P = 0.009), and oliguria (5.9% vs 1.5%; P = 0.019). The composite morbidity and ischemia end points did not reveal any differences between the 2 treatment groups. CONCLUSIONS: Administration of MP4OX achieved the end point of treating perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. The study was not powered to demonstrate clinical benefit based on the composite morbidity or ischemia outcomes. Although efficacy end points with sufficient power were met, MP4OX is not being proposed for use in routine surgery where the risk-benefit profile would not be favorable based on the safety profile demonstrated in this study. (Anesth Analg 2011; 112: 759-73)","[Keipert, Peter E.; Hardiman, Yun J.; Levy, Howard] Sangart Inc, San Diego, CA 92121 USA; [van der Linden, Philippe] CHU Brugmann, Dept Anesthesiol, Brussels, Belgium; [Gazdzik, Tadeusz S.] Wojewodzki Szpital Specjalistyczny 5, Katedra & Oddzial Klin Ortoped, Sosnowiec, Poland; [Jahoda, David] Ortoped Klin, Fakultni Nemocnice V Motole 1, Prague, Czech Republic; [Heylen, Rene J.] ZOL Genk, Dept Anesthesiol, Genk, Belgium; [Skowronski, Jan C.] Samodzielny Publ Szpital Klin AM, Klin Ortoped & Traumatol AMB, Bialystok, Poland; [Pellar, David] Fakultni Nemocnice Hradec Kralove, Ortoped Klin, Hradec Kralove, Czech Republic; [Kofranek, Ivo] Fakultni Nemocnice Bulovce, Ortoped Klin, Prague, Czech Republic; [Gorecki, Andrzej Z.] Szpital Klin Dzieciatka Jezus, Katedra & Klin Ortoped & Traumatol, Warsaw, Poland; [Fagrell, Bengt] Karolinska Inst, Stockholm, Sweden; [Fagrell, Bengt] Karolinska Univ Hosp, Stockholm, Sweden","Levy, H, Sangart Inc, 6175 Lusk Blvd, San Diego, CA 92121 USA","hlevy@sangart.com","Sangart, Inc., San Diego, CA ","Sponsored and supported by Sangart, Inc., San Diego, CA.",null,34,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA",401463,null,"10.1213/ANE.0b013e31820c7b5f","ANESTH ANALG","Anesth. Analg.","APR",2011,112,4,null,null,null,759,773,null,null,15,"Anesthesiology","739ET","ISI:000288697000005"]
["J","Cmejla, R; Ludikova, B; Pospisilova, D; Sukova, M; Blatny, J",null,null,null,"Cmejla, Radek; Ludikova, Barbora; Pospisilova, Dagmar; Sukova, Martina; Blatny, Jan",null,"Can mutations in the ribosomal protein S26 (RPS26) gene lead to Klippel-Feil syndrome in Diamond-Blackfan anemia patients? An update from the Czech Diamond-Blackfan Anemia registry","BLOOD CELLS MOLECULES AND DISEASES",null,"English","Letter",null,null,null,null,null,null,null,null,"[Ludikova, Barbora; Pospisilova, Dagmar] Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Cmejla, Radek] Inst Hematol & Blood Transfus, Dept Cell Physiol, CR-12820 Prague, Czech Republic; [Sukova, Martina] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Blatny, Jan] Univ Hosp Brno, Dept Pediat Hematol, Brno, Czech Republic","Pospisilova, D, Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic","pospisid@fnol.cz",null,null,null,8,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1079-9796",null,"10.1016/j.bcmd.2011.02.003","BLOOD CELLS MOLECULES DIS","Blood Cells Mol. Dis.","APR 15",2011,46,4,null,null,null,300,301,null,null,2,"Hematology","753DV","ISI:000289746800007"]
["J","Vasovcak, P; Senkerikova, M; Hatlova, J; Krepelova, A",null,null,null,"Vasovcak, Peter; Senkerikova, Maria; Hatlova, Jana; Krepelova, Anna",null,"Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: Case report","BMC MEDICAL GENETICS",null,"English","Article",null,null,null,null,null,null,"SYNDROME PLEASE STAND; GASTROINTESTINAL POLYPOSIS; GERMLINE MUTATIONS; PTEN/MMAC1 GENE; DISEASE; HAMARTOMA; PATHWAY; WILL","Background: Cowden syndrome (CS) is a cancer predisposition syndrome associated with increased risk of breast, thyroid, and endometrial cancers, and is characterized by development of benign mucocutaneous lesions. Case presentation: Here we report on a 58-year-old woman with multiple primary malignancies and subtle mucocutaneous lesions such as small polyps and wart-like papulas. Over a period of 23 years, she developed various malignant neoplasms including thyroid, ovarian, stomach, and colon carcinomas, and a benign meningioma. Direct sequencing analysis of the PTEN gene revealed a novel germline mutation (c.438delT, p.Leu146X). Conclusion: This case demonstrates that Cowden syndrome is a multi-system disease that can result in the development of multiple malignant and benign tumors.","[Vasovcak, Peter; Krepelova, Anna] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Vasovcak, Peter; Krepelova, Anna] Univ Hosp Motol, Prague, Czech Republic; [Senkerikova, Maria] Univ Hosp, Dept Med Genet, Hradec Kralove, Czech Republic; [Hatlova, Jana] Fac Med, Fingerlands Dept Pathol, Hradec Kralove, Czech Republic","Vasovcak, P, Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic","pevas78@hotmail.com","[VZ MZO 00064203]","Supported by: VZ MZO 00064203",null,28,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,"10.1186/1471-2350-12-38","BMC MED GENET","BMC Med. Genet.","MAR 15",2011,12,null,null,null,null,null,null,38,null,4,"Genetics & Heredity","741HR","ISI:000288855300001"]
["J","Stolz, A; Pafko, P; Harustiak, T; Smejkal, M; Simonek, J; Schutzner, J; Lischke, R",null,null,null,"Stolz, A.; Pafko, P.; Harustiak, T.; Smejkal, M.; Simonek, J.; Schutzner, J.; Lischke, R.",null,"Risk factor analysis for early mortality and morbidity following pneumonectomy for non-small cell lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,"English","Article",null,null,null,null,null,"pneumonectomy; mortality; lung cancer","BRONCHOPLEURAL FISTULA; INDUCTION CHEMOTHERAPY; COMPLICATIONS; RESECTION; THERAPY; CARCINOMA; INCREASE","Objectives: The purpose of this report is to analyze factors affecting morbidity and mortality following pneumonectomy for non-small cell lung cancer (NSCLC). Methods: We reviewed our institutional experience with all consecutive patients undergoing pneumonectomy for NSCLC from 1998 to 2010. Patients were analyzed with regard to hospital mortality and morbidity and long-term outcome. Results: There were 310 patients following pneumonectomy. Overall 30-day mortality rate was 5.5%. Chronic obstructive pulmonary disease, induction therapy, smoking habits and obesity had no statistical influence on short-term outcome. Coronary artery disease and respiratory failure were identified as risk factors for increased 30-day mortality (p<0.01). Right pneumonectomy and presence of respiratory failure with mechanical ventilation increases the incidence of bronchopleural fistula (p<0.01). Conclusions: Patients with right pneumonectomies are at increased risk. Coronary artery disease and respiratory failure adversely affect morbidity and mortality after this procedure (Tab. 3, Ref. 19). Full Text in free PDF www.bmj.sk.","[Stolz, A.; Pafko, P.; Harustiak, T.; Smejkal, M.; Simonek, J.; Schutzner, J.; Lischke, R.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, CZ-15000 Prague 5, Czech Republic","Stolz, A, Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, V Uvalu 84, CZ-15000 Prague 5, Czech Republic","stolz@seznam.cz",null,null,null,19,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA",2683956,null,null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,4,null,null,null,165,169,null,null,5,"Medicine, General & Internal","749WW","ISI:000289503300002"]
["J","Stolz, A; Pafko, P; Lischke, R; Harustiak, T; Simonek, J; Schutzner, J; Adamek, S",null,null,null,"Stolz, A.; Pafko, P.; Lischke, R.; Harustiak, T.; Simonek, J.; Schutzner, J.; Adamek, S.",null,"Time trend in the surgical therapy of lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,"English","Article",null,null,null,null,null,"lung cancer; mortality; time trends","CARCINOMA; RESECTION; SURVIVAL; LONG","Background: The purpose of our study was to clarify results of surgery for non-small cell lung cancer (NSCLC) and its time trends. Methods: We retrospectively reviewed our prospective database of patients who underwent surgery for NSCLC between 1998 and 2009 in our institution. Patients were divided into two equal 6-year periods according to the year of surgery (1998-2003 and 2004-2009). Results: One thousand, four hundred and twelve patients underwent operation for NSCLC. We performed 985 lobectomies with 30-days mortality of 1.8 % and 300 pneumonectomies with 30-days mortality of 5.7 %. Median of survival of all 1412 patients was 4.3 year and 5-year survival was 45 %. The percentage of female patients, lobectomies and adenocarcinomas increased over time, as well as the age of our patients. Outcome improved over time, with significant decrease in a 30-days mortality after pneumonectomy (8.2 % vs 2.3 %, p=0.029). The overall 3-year survival improved in patients with stage III (30 % vs 40 %, p=0.012). Conclusion: Outcomes of lung resection for NSCLC improved over time despite a worsening of some elements of preoperative status. The shift in histological distribution was associated with an increasing proportion of patients with stage I, a lower operative mortality and better 3- and 5-year survival. These trends are due to improvement of preoperative evaluation, preoperative and postoperative care (Tab. 1, Fig. 2, Ref. 9). Full Text in free PDF www.bmj.sk.","[Stolz, A.; Pafko, P.; Lischke, R.; Harustiak, T.; Simonek, J.; Schutzner, J.; Adamek, S.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, CZ-15000 Prague 5, Czech Republic","Adamek, S, Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, V Uvalu 84, CZ-15000 Prague 5, Czech Republic","sadamek@post.cz",null,null,null,9,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA",2683956,null,null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,4,null,null,null,174,176,null,null,3,"Medicine, General & Internal","749WW","ISI:000289503300004"]
["J","Hanova, M; Vodickova, L; Vaclavikova, R; Smerhovsky, Z; Stetina, R; Hlavac, P; Naccarati, A; Slyskova, J; Polakova, V; Soucek, P; Kumar, R; Hemminki, K; Vodicka, P",null,null,null,"Hanova, Monika; Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Stetina, Rudolf; Hlavac, Pavel; Naccarati, Alessi; Slyskova, Jana; Polakova, Veronika; Soucek, Pavel; Kumar, Rajiv; Hemminki, Kari; Vodicka, Pavel",null,"DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (Tp53, p21(CDKNIA), BCL2 and BAX) with respect to occupational exposure to styrene","CARCINOGENESIS",null,"English","Article",null,null,null,null,null,null,"SINGLE-STRAND BREAKS; POLYMORPHISMS; P53; WORKERS; ASSOCIATION; BIOMARKERS; P21; SUSCEPTIBILITY; P21(WAF1/CIP1); LYMPHOCYTES","We studied the relationship between DNA damage, DNA repair rates and messenger RNA (mRNA) expression levels of cell cycle genes TP53, p21(CDKNIA), BCL2 and BAX in a group of 71 styrene-exposed workers and 51 control individuals. The exposure was assessed by measuring the concentration of styrene at workplace and in blood. Parameters of DNA damage [measured as single-strand breaks (SSBs) and endonuclease III-sensitive sites], gamma-irradiation-specific DNA repair rates and mRNA levels of studied genes were analyzed in peripheral blood lymphocytes. The workers were divided into low (<50 mg/m(3)) and high (>50 mg/m(3)) styrene exposure groups. We found negative correlations between mRNA expression of TP53, BCL2, BAX and styrene exposure (P < 0.001 for all parameters). In contrast, p21(CDKNIA) mRNA expression significantly increased with increasing styrene exposure (P = 0.001). SSBs and endonuclease Insensitive sites increased with increasing mRNA levels of TP53 (P < 0.001 for both) and BCL2 (P = 0.038, P = 0.002, respectively), whereas the same parameters decreased with increasing mRNA levels of p21(CDKNIA) (P < 0.001, P = 0.007, respectively). gamma-Irradiation-specific DNA repair rates increased with p21(CDKNIA) mRNA levels up to the low exposure level (P = 0.044). Our study suggests a possible relationship between styrene exposure, DNA damage and transcript levels of key cell cycle genes.","[Hanova, Monika; Vodickova, Ludmila; Naccarati, Alessi; Slyskova, Jana; Polakova, Veronika; Vodicka, Pavel] Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Prague 4, Czech Republic; [Hanova, Monika; Slyskova, Jana] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, CR-12844 Prague 2, Czech Republic; [Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Stetina, Rudolf] Purkinje Mil Med Acad, Dept Toxicol, Hradec Kralove 50001, Czech Republic; [Hlavac, Pavel] Dept Occupat Med, Reg Hyg Stn, Hradec Kralove 50101, Czech Republic; [Kumar, Rajiv; Hemminki, Kari] DKFZ, German Canc Res Ctr, D-69120 Heidelberg, Germany","Vodicka, P, Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Videnska 1083, Prague 4, Czech Republic","pvodicka@biomed.cas.cz","Grant Agency of the Academy of Sciences of the CR [IAA500390806]; Grant Agency of the Czech Republic-The Czech Science Foundation (Grantova agentura Ceske republiky) [310/07/1430, A/CZ0046/2/0012]","The Grant Agency of the Academy of Sciences of the CR (IAA500390806), Grant Agency of the Czech Republic-The Czech Science Foundation (Grantova agentura Ceske republiky) (310/07/1430, A/CZ0046/2/0012).",null,36,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,"10.1093/carcin/bgq213","CARCINOGENESIS","Carcinogenesis","JAN",2011,32,1,null,null,null,74,79,null,null,6,"Oncology","707RF","ISI:000286303000012"]
["J","Jakubova, R; Mickova, A; Buzgo, M; Rampichova, M; Prosecka, E; Tvrdik, D; Amler, E",null,null,null,"Jakubova, R.; Mickova, A.; Buzgo, M.; Rampichova, M.; Prosecka, E.; Tvrdik, D.; Amler, E.",null,"Immobilization of thrombocytes on PCL nanofibres enhances chondrocyte proliferation in vitro","CELL PROLIFERATION",null,"English","Article",null,null,null,null,null,null,"PLATELET-RICH PLASMA; STEM-CELLS; CHONDROGENIC DIFFERENTIATION; TISSUE-REPAIR; FIBROCYTES; EXPANSION; MATRIX","Objectives: The aim of this study was to develop functionalized nanofibres as a simple delivery system for growth factors (GFs) and make nanofibre cell-seeded scaffold implants a one-step intervention. Materials and methods: We have functionalized polycaprolactone (PCL) nanofibres with thrombocytes adherent on them. Immobilized, these thrombocytes attached to nanofibre scaffolds were used as a nanoscale delivery system for native (autologous) proliferation and differentiation factors, in vitro. Pig chondrocytes were seeded on the thrombocyte-coated scaffolds and levels of proliferation and differentiation of these cells were compared with those seeded on non-coated scaffolds. Results: Immobilized thrombocytes on PCL nanofibres effectively enhanced chondrocyte proliferation due to time-dependent degradation of thrombocytes and release of their GFs. Conclusions: These simply functionalized scaffolds present new possibilities for nanofibre applications, as smart cell scaffolds equipped with a GF delivery tool.","[Jakubova, R.; Mickova, A.; Buzgo, M.; Prosecka, E.; Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Motol, Czech Republic; [Jakubova, R.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague 15006 5, Motol, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Gen Teaching Hosp, Prague 15006 5, Motol, Czech Republic; [Buzgo, M.] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague 15006 5, Motol, Czech Republic","Jakubova, R, Charles Univ Prague, Fac Med 2, Inst Biophys, Uvalu 84, Prague 15006 5, Motol, Czech Republic","jakubova@biomed.cas.cz","Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130, 1M0510, P304/10/1307]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151]; EU [7E09088]; Grant Agency of the Charles University [119009, 96610, 119209, 97110, 80009]","This study was supported by the Academy of Sciences of the Czech Republic (Institutional research plans AV0Z50390703 and AV0Z50390512), Ministry of Education, Youth and Sports of the Czech Republic (research programs NPV II 2B06130, 1M0510, P304/10/1307), and Grant Agency of the Academy of Sciences grant no. IAA500390702 and by Czech Science Foundation grant no. GA202/09/1151, EU project BIOSCENT ID number 7E09088, the Grant Agency of the Charles University grants No.119009, 96610, 119209, 97110, 80009.",null,32,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0960-7722",null,"10.1111/j.1365-2184.2011.00737.x","CELL PROLIFERATION","Cell Prolif.","APR",2011,44,2,null,null,null,183,191,null,null,9,"Cell Biology","735XW","ISI:000288455000009"]
["J","Darsova, D; Dotrelova, D",null,null,null,"Darsova, D.; Dotrelova, D.",null,"Bilateral Syphylitic Chorioretinitis in a 33-year-old Pervitin User","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"atypical form of posterior uveitis; neurochorioretinitis; neurosyphilis; syphilis","SYPHILIS","Neurochorioretinitis is an inflammatory process affecting the optic nerve, choroid and retina. Neurochoroiditis is the least frequent type of optic neuritis. It is most often associated with viral infections and cat-scratch fever, less common with syphilis and Lyme disease The authors describe the clinical course of neurochoroiditis in a 33-year-old, otherwise healthy woman who was referred to our clinic with acute decreased central visual acuity (6/60) in the right eye. She had complained of headache, low-grade fever, hoarseness and generalized Skin rash four months previously. However, her symptoms had resolved spontaneously. She reported pervitin (methyl amphetamine) abuse within the previous year. Ophthalmic examination disclosed bilateral neurochorioretinitis, perivasculitis and a dusty vitreous haze. Fluorescein angiography revealed vasculitis. Positive direct and indirect treponemal tests confirmed a diagnosis of syphylis. Early recognition of the clinical manifestation of syphilis and prompt commencement of treatment with crystalline penicillin improved functional and anatomical changes in both eyes within four weeks. This data should may helpful in the exact diagnosis of neurosyphilis. The case report illustrates syphilis diagnosed by an ophthalmologist in terms of the atypical form of posterior uveitis.","[Darsova, D.] FN Motole, Prague 15006 5, Czech Republic; [Darsova, D.] Ocni Klin & Dospelych 2 LF UK, Prague 15006 5, Czech Republic","Darsova, D, Ocni Klin & Dospelych 2 LF UK, V Uvalu 84, Prague 15006 5, Czech Republic","denisa.darsova@centrum.cz",null,null,null,9,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2011,74,2,null,null,null,197,200,null,null,4,"Neurosciences; Surgery","751GG","ISI:000289604900009"]
["J","Hrdlicka, M",null,null,null,"Hrdlicka, Michal",null,"Autobiographies of persons with autism: unknown views on inner experience of autistic handicap","CESKOSLOVENSKA PSYCHOLOGIE",null,"Czech","Article",null,null,null,null,null,"autism; Asperger syndrome; autobiographies",null,"The article analyses three autobiographies of autistic individuals translated into the Czech language Nobody nowhere (Donna Williams), Life behind glass (Wendy Lawson), and Life with Asperger syndrome: a story of psychotherapy (Christine Preissmann). It shows, how the authors describe their specific symptoms and interests, family and partner relationships and career. The analysis focuses on strategies that were selected by the authors for coping with the autistic handicap. It comes to a conclusion that autistic persons consider different symptoms to be the worst than those conventionally described in textbooks and monographs on autism. In these three autobiographies, sensory overload in stressful situations was estimated from the subjective point of view to be the most unpleasant symptom.","Lekarska Fak UK Praha 1, Detska Psychiat Klin, LF UK & FN Motol 2, Prague 15006 5, Motol, Czech Republic","Hrdlicka, M, Lekarska Fak UK Praha 1, Detska Psychiat Klin, LF UK & FN Motol 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic","Michal.Hrdlicka@lfmotol.cuni.cz",null,null,null,22,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2011,55,1,null,null,null,82,89,null,null,8,"Psychology, Multidisciplinary","743NE","ISI:000289024200008"]
["J","Soucek, O; Lebl, J; Snajderova, M; Kolouskova, S; Rocek, M; Hlavka, Z; Cinek, O; Rittweger, J; Sumnik, Z",null,null,null,"Soucek, Ondrej; Lebl, Jan; Snajderova, Marta; Kolouskova, Stanislava; Rocek, Miloslav; Hlavka, Zdenek; Cinek, Ondrej; Rittweger, Joern; Sumnik, Zdenek",null,"Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages","CLINICAL ENDOCRINOLOGY",null,"English","Article",null,null,null,null,null,null,"QUANTITATIVE COMPUTED-TOMOGRAPHY; GROWTH-HORMONE TREATMENT; PROXIMAL RADIUS; FRACTURES; THERAPY; ABSORPTIOMETRY; OSTEOPOROSIS; CHILDREN; SPINE; SIZE","P>Objective An increased rate of fractures has been reported in patients with Turner syndrome (TS). We aimed to assess bone geometry and volumetric bone mineral density (vBMD) at the radius in girls with TS and to evaluate the relationships between bone parameters and fracture history. Methods and design Sixty-seven girls with TS aged 6-19 years treated currently or in the past with growth hormone (GH) and/or oestrogens were examined using peripheral quantitative computed tomography. Results were compared to reference data. Results Cortical area and cortical thickness were low in all age groups (all P < 0 center dot 001). Height-adjusted total bone area at the diaphysis was increased in prepubertal and postpubertal girls (mean Z-score 1 center dot 0, P < 0 center dot 05 for both) and normal in the pubertal group (mean Z-score 0 center dot 1). Cortical vBMD was decreased (mean age-specific Z-scores -2 center dot 0, -1 center dot 6 and -1 center dot 0 for prepubertal, pubertal and postpubertal groups, respectively, P < 0 center dot 01 for all groups). Height- , age- and cortical thickness-adjusted cortical vBMD was positively correlated to the duration of GH therapy (P = 0 center dot 012) and to oestrogen administration (P = 0 center dot 047). Girls with a history of fractures had lower total vBMD at the metaphysis compared to nonfractured TS girls (mean Z-scores -1 center dot 7 vs -0 center dot 9, P = 0 center dot 04). Conclusions There is a cortical bone deficit in girls with TS characterized by low cortical area, thin cortex and probably decreased cortical vBMD. Early commencement of GH therapy, as well as oestrogen replacement, is associated with higher cortical vBMD. Further studies should investigate the potential causality of this relation.","[Soucek, Ondrej; Lebl, Jan; Snajderova, Marta; Kolouskova, Stanislava; Cinek, Ondrej; Sumnik, Zdenek] Univ Hosp Motol, Dept Pediat, Fac Med 2, Prague 15006, Czech Republic; [Rocek, Miloslav] Univ Hosp Motol, Dept Radiol Tech, Fac Med 2, Prague 15006, Czech Republic; [Hlavka, Zdenek] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague, Czech Republic; [Rittweger, Joern] German Aerosp Ctr DLR, Inst Aerosp Med, Cologne, Germany; [Rittweger, Joern] Manchester Metropolitan Univ, Inst Biomed Res Human Movement & Hlth, Manchester M15 6BH, Lancs, England","Soucek, O, Univ Hosp Motol, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","ondrej.soucek@lfmotol.cuni.cz","Charles University [GAUK 47609]; Czech Ministry of Health [VZ MZ 64203]; Czech Ministry of Education [MSMT 21620819]","This work was supported by Charles University (GAUK 47609), Czech Ministry of Health (VZ MZ 64203) and Czech Ministry of Education (MSMT 21620819).",null,36,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-0664",null,"10.1111/j.1365-2265.2010.03955.x","CLIN ENDOCRINOL","Clin. Endocrinol.","APR",2011,74,4,null,null,null,445,452,null,null,8,"Endocrinology & Metabolism","730YK","ISI:000288073300006"]
["J","Botev, R; Mallie, JP; Wetzels, JFM; Couchoud, C; Schuck, O",null,null,null,"Botev, Rossini; Mallie, Jean-Pierre; Wetzels, Jack F. M.; Couchoud, Cecile; Schueck, Otto",null,"The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas: Current Limitations and Quo Vadis","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,"English","Article",null,null,null,null,null,null,"CHRONIC KIDNEY-DISEASE; BODY-SURFACE AREA; CHRONIC RENAL-INSUFFICIENCY; COCKCROFT-GAULT EQUATIONS; S-CYSTATIN-C; SERUM CREATININE; TRANSPLANT RECIPIENTS; SUBCUTANEOUS INJECTION; PREDICTIVE PERFORMANCE; NONDIABETIC PATIENTS","The GFR has a paramount diagnostic and staging role in the Kidney Disease Outcome Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease (K/DOQI-CKD). The most widely used serum creatinine-based formulas in adults for estimated GFR (eGFR) are the Cockcroft-Gault (CG) and Modification of Diet in Renal Disease Study (MDRD). Recently, a new Chronic Kidney Disease Epidemiology Collaboration equation has been developed. Review of the literature revealed that CG and MDRD formulas correctly assigned overall only 64% and 62%, respectively, of the subjects to their actual K/DOQI-CKD classification's GFR groups as determined by measured GFR (mGFR). This suggests that approximately 10 million (38%) subjects may have been misclassified on the basis of estimated CKD prevalence of 26.3 million adults in the United States. The purpose of this review is to help the clinician understand the limitations of using eGFR in daily practice. We also elaborate upon issues such as the differences among markers of mGFR, the validity of adjusting GFR for body surface area in certain populations, the limited data on boundaries for normal mGFR according to age, gender, and race, the need for calibration of a wide spectrum of serum creatinine measurements, the lack of actual eGFR value above 60 ml/min per 1.73 m(2) and reference for normal mGFR in the clinical laboratories' reports, and the performance evaluation of the eGFR formulas. Several pitfalls have to be overcome before we can reliably determine health and disease in daily nephrology practice to preserve the first rule of practicing medicine: primum non nocere. Clin J Am Soc Nephrol 6: 937-950, 2011. doi: 10.2215/CJN.09241010","[Botev, Rossini] Hawaii Permanent Med Grp, Dept Nephrol, Honolulu, HI 96819 USA; [Mallie, Jean-Pierre] Nancy Univ, Nancy, France; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6525 ED Nijmegen, Netherlands; [Couchoud, Cecile] Agence Biomed, French ESRD Registry REIN, La Plaine St Denis, France; [Schueck, Otto] Univ Hosp Motol, Internal Clin, Prague, Czech Republic","Botev, R, Hawaii Permanent Med Grp, Dept Nephrol, 3288 Moanalua Rd, Honolulu, HI 96819 USA","Rossini.C.Botev@kp.org",null,null,null,107,0,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,"10.2215/CJN.09241010","CLIN J AM SOC NEPHROL","Clin. J. Am. Soc. Nephrol.","APR",2011,6,4,null,null,null,937,950,null,null,14,"Urology & Nephrology","746DU","ISI:000289223600034"]
["J","Malikova, H; Liscak, R; Vojtech, Z; Prochazka, T; Vymazal, J; Vladyka, V; Druga, R",null,null,null,"Malikova, Hana; Liscak, Roman; Vojtech, Zdenek; Prochazka, Tomas; Vymazal, Josef; Vladyka, Vilibald; Druga, Rastislav",null,"Stereotactic radiofrequency amygdalohippocampectomy: Does reduction of entorhinal and perirhinal cortices influence good clinical seizure outcome?","EPILEPSIA",null,"English","Article",null,null,null,null,null,"Temporal lobe epilepsy; Surgery; MRI; Volumetry","TEMPORAL-LOBE EPILEPSY; SELECTIVE AMYGDALOHIPPOCAMPECTOMY; INTRINSIC CONNECTIONS; RESECTION; SURGERY; EXTENT; LOBECTOMY; MEMORY; AMYGDALA; COMPLEX","Purpose: Stereotactic radiofrequency amygdalohippocampectomy (SAHE) has been modified recently in our center for the therapy of mesial temporal epilepsy (MTLE). It has promising clinical results comparable with microsurgical amygdalohippocampectomy despite smaller volume reduction of the hippocampus. We hypothesized that the extent of perirhinal and entorhinal cortex (PRC, EC) reduction could explain the clinical outcome. Therefore, we performed, retrospectively, volumetric analysis of PRC and EC and compared it with the seizure control. Methods: Twenty-six consecutive patients with MTLE treated by SAHE were included. PRC and EC volumes were measured from magnetic resonance imaging (MRI) records obtained before and 1 year after SAHE. The clinical outcome was assessed each year after SAHE using Engel's classification. Key Findings: Twenty-six patients were analyzed. The volume of PRC decreased by 46 +/- 17% (p < 10(-12)); EC volume decreased by 56 +/- 20% (p < 10(-10)). Two years after the procedure, 73% of patients were classified as Engel's I, 19% as Engel's II; in 2 (8%) the treatment failed (were reoperated). Eighteen patients finished 3 years follow-up; 72% of them were classified as Engel's I, 17% as Engel's II, and in 2 (11%) above-mentioned patients the treatment failed. Thirteen patients finished 4 years of follow-up, 11 of them as Engel's I. There was no significant correlation of the clinical outcome to PRC and EC volume reductions. Significance: The clinical effect of SAHE is not clearly explained by the volume reductions of PRC and EC (nor of the hippocampus and the amygdala). It promotes opinion that the extent of resection/destruction is not important for seizure outcomes.","[Malikova, Hana; Vymazal, Josef] Hosp Na Homolce, Dept Radiol, Prague 15000 5, Czech Republic; [Malikova, Hana; Druga, Rastislav] Charles Univ Prague, Fac Med 2, Inst Anat, Prague, Czech Republic; [Liscak, Roman; Vladyka, Vilibald] Hosp Na Homolce, Dept Stereotact & Radiat Neurosurg, Prague 15000 5, Czech Republic; [Vojtech, Zdenek; Prochazka, Tomas] Hosp Na Homolce, Dept Neurol, Prague 15000 5, Czech Republic; [Vymazal, Josef] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic","Malikova, H, Hosp Na Homolce, Dept Radiol, Roentgenova 2, Prague 15000 5, Czech Republic","hana.malikova@homolka.cz","Czech Ministry of Education [MSMT 0021620849]; Grant Agency of the Czech Republic [309/07/1337]","JV was supported by the Czech Ministry of Education (research program MSMT 0021620849). RD was supported by the Grant Agency of the Czech Republic grant No. 309/07/1337.",null,38,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,"10.1111/j.1528-1167.2011.03048.x","EPILEPSIA","Epilepsia","MAY",2011,52,5,null,null,null,932,940,null,null,9,"Clinical Neurology","762QK","ISI:000290494300013"]
["J","Jiruska, P; Marusic, P; Jefferys, JGR; Krsek, P; Cmejla, R; Sebronova, V; Komarek, V",null,null,null,"Jiruska, Premysl; Marusic, Petr; Jefferys, John G. R.; Krsek, Pavel; Cmejla, Roman; Sebronova, Vera; Komarek, Vladimir",null,"Sturge-Weber syndrome: a favourable surgical outcome in a case with contralateral seizure onset and myoclonic-astatic seizures","EPILEPTIC DISORDERS",null,"English","Article",null,null,null,null,null,"Sturge-Weber syndrome; myoclonic-astatic seizures; contralateral seizure onset; epilepsy surgery","SECONDARY BILATERAL SYNCHRONY","Sturge-Weber syndrome is a neurocutaneous disorder classically characterized by the presence of facial port-wine stain and ipsilateral leptomeningeal angiomatosis. It is often associated with refractory epilepsy which requires surgical treatment. We present a case of a patient who initially presented with partial seizures of temporo-occipital origin, ipsilateral to the pial angiomatosis. During the course of the disease, the patient developed medically refractory epilepsy with partial seizures originating predominantly from the contralateral temporo-occipital area as well as myoclonic and myoclonicastatic seizures. Resection of the occipital and temporal lobe affected by the pial angioma resulted in favourable outcome. Bilateral dysfunction observed in Sturge-Weber syndrome may result in an increased capability of focal discharges to generate synchronous epileptiform activity leading to an increased incidence of generalised seizures, most probably via a mechanism of secondary bilateral synchrony. [Published with video sequences]","[Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Jiruska, Premysl; Jefferys, John G. R.] Univ Birmingham, Neuronal Networks Grp, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Jiruska, Premysl; Krsek, Pavel; Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Dept Pediat Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Cmejla, Roman] Czech Tech Univ, Dept Circuit Theory, Fac Elect Engn, CR-16635 Prague, Czech Republic","Marusic, P, Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic","petr.marusic@fnmotol.cz","Epilepsy Research UK [A0937]; Motol Hospital [VZ MZOFNM2005-6504]","This work was supported by grants from Epilepsy Research UK (A0937) and Motol Hospital (VZ MZOFNM2005-6504).",null,13,0,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361",null,"10.1684/epd.2011.0407","EPILEPTIC DISORD","Epileptic Disord.","MAR",2011,13,1,null,null,"Sp. Iss. 1",76,81,null,null,6,"Clinical Neurology","742LW","ISI:000288946300011"]
["J","Hobzova, R; Pradny, M; Zhunusbekova, NM; Sirc, J; Guryca, V; Michalek, J",null,null,null,"Hobzova, Radka; Pradny, Martin; Zhunusbekova, Nazym M.; Sirc, Jakub; Guryca, Vilem; Michalek, Jiri",null,"Bioactive support for cell cultivation and potential grafting. Part 1: Surface modification of 2-hydroxyethyl methacrylate hydrogels for avidin immobilization","E-POLYMERS",null,"English","Article",null,null,null,null,null,null,"BIOTIN BINDING SYSTEM; TISSUE ENGINEERING APPLICATIONS; BIODEGRADABLE POLYMERS; CHONDROCYTE ADHESION; CULTURE; KERATINOCYTES; ATTACHMENT; CARRIERS; PROTEIN; GROWTH","Synthetic hydrogels are often used in biomedical applications as many of them are compatible with living tissue and moreover they can meet most criteria for artificial tissue properties. For applications in tissue engineering modification of polymer surface using some bioactive compounds (e. g. saccharides, proteins) for promoting the process of cell adhesion and proliferation is widely used. In this work, a series of modified hydrogels was prepared by three different methods: by copolymerization of 2-hydroxyethyl methacrylate with methacrylic acid, by hydrolysis and oxidation of poly(2-hydroxyethyl methacrylate) to obtain carboxyl-rich supports. The influence of the reaction conditions of the hydrogel surface treatment on the total carboxylic group content and the swelling degree was studied. The modified hydrogels were characterized by attenuated total reflectance FT-IR spectroscopy and refractive index measurements. Obtained carboxylic groups on the hydrogel surface have allowed the immobilization of avidin in two ways: 1) electrostatically through dissociated carboxylic groups and 2) covalently bonded through activated carboxylic groups by N-hydroxysuccinimide. The capacity of hydrogels for avidin immobilization was determined by Bradford spectrophotometric method. The results so far obtained from the preliminary biological tests showed that immobilized avidin on the hydrogel surface provides better adhesion and proliferation of keratinocytes compared to supports without avidin.","[Hobzova, Radka; Pradny, Martin; Zhunusbekova, Nazym M.; Sirc, Jakub; Guryca, Vilem; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Hobzova, Radka; Pradny, Martin; Sirc, Jakub; Michalek, Jiri] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic","Hobzova, R, Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic","hobzova@imc.cas.cz","Academy of Sciences of the Czech Republic [1QS400500558]","This work was supported by the Academy of Sciences of the Czech Republic (project 1QS400500558). The authors thank B. Dvorankova, Ph.D. for implementing the pilot biological experiments.",null,26,0,"EUROPEAN POLYMER FEDERATION","STRASBOURG","1, QUAI LEZAY-MARNESIA, F067000 STRASBOURG, FRANCE","1618-7229",null,null,"E-POLYMERS","e-Polymers","MAY 11",2011,null,null,null,null,null,null,null,43,null,17,"Polymer Science","762KF","ISI:000290474600001"]
["J","Spisek, R",null,null,null,"Spisek, Radek",null,"Immunology in the heart of the High Tatra mountains","EUROPEAN JOURNAL OF IMMUNOLOGY",null,"English","Editorial Material",null,null,null,null,null,null,null,null,"Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic","Spisek, R, Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic","radek.spisek@lfmotol.cuni.cz",null,null,null,9,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0014-2980",null,null,"EUR J IMMUNOL","Eur. J. Immunol.","MAR",2011,41,3,null,null,null,561,565,null,null,5,"Immunology","731HU","ISI:000288097700001"]
["J","Babjuk, M; Oosterlinck, W; Sylvester, R; Kaasinen, E; Bohle, A; Palou-Redorta, J; Roupret, M",null,null,null,"Babjuk, Marko; Oosterlinck, Willem; Sylvester, Richard; Kaasinen, Eero; Boehle, Andreas; Palou-Redorta, Juan; Roupret, Morgan",null,"EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update","EUROPEAN UROLOGY",null,"English","Article",null,null,null,null,null,"Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; EAU Guidelines; Follow-up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma","BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; RANDOMIZED CLINICAL-TRIALS; IMMEDIATE POSTOPERATIVE INSTILLATION; INTRAVESICAL MITOMYCIN-C; FOLLOW-UP CYSTOSCOPY; LONG-TERM EFFICACY; PHASE-III TRIAL; IN-SITU; TRANSURETHRAL RESECTION","Context and objective: To present the 2011 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC). Evidence acquisition: Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence (LE) and grade of recommendation (GR) were assigned. Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. In papillary tumours, the risks of both recurrence and progression may be estimated for individual patients using the scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups-separately for recurrence and progression-is pivotal to recommending adjuvant treatment. For patients with a low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is recommended. Patients with an intermediate or high risk of recurrence and an intermediate risk of progression should receive one immediate instillation of chemotherapy followed by a minimum of 1 yr of bacillus Calmette-Guerin (BCG) intravesical immunotherapy or further instillations of chemotherapy. Papillary tumours with a high risk of progression and CIS should receive intravesical BCG for 1 yr. Cystectomy may be offered to the highest risk patients, and it is at least recommended in BCG failure patients. The long version of the guidelines is available from the EAU Web site (www.uroweb.org). Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Babjuk, Marko] Charles Univ Prague, Dept Urol, Fac Med 2, Hosp Motol, Prague 15006 5, Czech Republic; [Oosterlinck, Willem] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Dept Biostat, Brussels, Belgium; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Urol, Hyvinkaa, Finland; [Boehle, Andreas] HELIOS Agnes Karll Hosp, Dept Urol, Bad Schwartau, Germany; [Palou-Redorta, Juan] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, E-08193 Barcelona, Spain; [Roupret, Morgan] Univ Paris 06, Fac Med, Dept Urol, Pitie Salpetriere Hosp,AP HP,GHU Est, Paris, France","Babjuk, M, Charles Univ Prague, Dept Urol, Fac Med 2, Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic","marek.babjuk@lfmotol.cuni.cz","GSK ; Astra Zeneca ; Pfizer Foundation ","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Marko Babjuk receives speaker honoraria from GE Healthcare and GSK. Willem Oosterlinck is a company consultant and receives fellowship and travel grants from GSK, receives speaker honoraria from Pfizer, participates in trials for Amgen, Astra Zeneca, and Astellas, and receives fellowships and travel and research grants from Astra Zeneca. Morgan Roupret has nothing to disclose. Juan Palou-Redorta is a consultant and receives speaker honoraria from Sanofi-Pasteur and General Electric. He also participates in trials for General Electric. Andreas Bohle receives speaker honoraria from Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen receives research grants from the Pfizer Foundation and for a research group at Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he received speaker honoraria from the Kyowa 2008 EAU Satellite Symposium.",null,72,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,"10.1016/j.eururo.2011.03.017","EUR UROL","Eur. Urol.","JUN",2011,59,6,null,null,null,997,1008,null,null,12,"Urology & Nephrology","756MM","ISI:000290015300023"]
["J","Roupret, M; Zigeuner, R; Palou, J; Boehle, A; Kaasinen, E; Sylvester, R; Babjuk, M; Oosterlinck, W",null,null,null,"Roupret, Morgan; Zigeuner, Richard; Palou, Juan; Boehle, Andreas; Kaasinen, Eero; Sylvester, Richard; Babjuk, Marko; Oosterlinck, Willem",null,"European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update","EUROPEAN UROLOGY",null,"English","Article",null,null,null,null,null,"Guidelines; Urothelial carcinoma; Prognosis; Urinary markers; Renal pelvis; Ureter; Laparoscopy; Ureteroscopy; Nephroureterectomy","LAPAROSCOPIC RADICAL NEPHROURETERECTOMY; SINGLE-CENTER EXPERIENCE; IN-SITU HYBRIDIZATION; LONG-TERM EXPERIENCE; RENAL PELVIS; PROGNOSTIC-FACTORS; CALMETTE-GUERIN; MULTIINSTITUTIONAL ANALYSIS; MICROSATELLITE INSTABILITY; URETEROSCOPIC MANAGEMENT","Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper urinary tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract, carcinoma, transitional cell, renal pelvis, ureter, bladder cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis: There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The TNM classification 2009 is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions: These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities; tumour location, grade and stage; and molecular marker status. (C) 2011 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Roupret, Morgan] Univ Paris 06, Fac Med Pierre & Marie Curie, Assistance Publ Hop Paris, Dept Urol,Pitie Salpetriere Hosp,GHU Est, Paris, France; [Zigeuner, Richard] Med Univ Graz, Dept Urol, Graz, Austria; [Palou, Juan] Fundacio Puigvert, Dept Urol, Barcelona, Spain; [Boehle, Andreas] HELIOS Agnes Karll Hosp, Dept Urol, D-23611 Bad Schwartau, Germany; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Urol, Hysinkaa, Finland; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Dept Biostat, B-1200 Brussels, Belgium; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Oosterlinck, Willem] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium","Roupret, M, Hop Pitie, Dept Urol, 47-83 Bvd Hop, F-75013 Paris, France","morgan.roupret@psl.aphp.fr","Pfizer Foundation ; Pfizer ; Astra Zeneca ; Sanofi-Aventis ","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Juan Palou is a consultant and honorarium speaker for Sanofi-Pasteur and a consultant, honorarium speaker, and trial participant for General Electric. Andreas Boehle is an honorarium speaker for Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen has received research grants from the Pfizer Foundation and for a research group from Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he was an honorarium speaker for the Kyowa 2008 EAU Satellite Symposium. Marko Babjuk is an honorarium speaker for GE Healthcare and Novartis. Willem Oosterlinck is an honorarium speaker for Organan, Sanofi-Aventis, Novartis, and Pfizer; he participates in trials conducted by Amgen, Astra Zeneca, Novartis, and Astellas; he has received fellowships and travel grants from Astra Zeneca and Sanofi-Aventis and research grants from Astra Zeneca.",null,117,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,"10.1016/j.eururo.2010.12.042","EUR UROL","Eur. Urol.","APR",2011,59,4,null,null,null,584,594,null,null,11,"Urology & Nephrology","730DT","ISI:000288013700027"]
["J","Hollink, IHIM; van den Heuvel-Eibrink, MM; Arentsen-Peters, STCJM; Zimmermann, M; Peeters, JK; Valk, PJM; Balgobind, BV; Sonneveld, E; Kaspers, GJL; de Bont, ESJM; Trka, J; Baruchel, A; Creutzig, U; Pieters, R; Reinhardt, D; Zwaan, CM",null,null,null,"Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Arentsen-Peters, Susan T. C. J. M.; Zimmermann, Martin; Peeters, Justine K.; Valk, Peter J. M.; Balgobind, Brian V.; Sonneveld, Edwin; Kaspers, Gertjan J. L.; de Bont, Eveline S. J. M.; Trka, Jan; Baruchel, Andre; Creutzig, Ursula; Pieters, Rob; Reinhardt, Dirk; Zwaan, C. Michel",null,"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,"English","Article",null,null,null,null,null,"Pediatric acute myeloid leukemia; CEBPA mutation; promoter hypermethylation; molecular marker; prognostic significance","BINDING-PROTEIN-ALPHA; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION PROFILES; CELLULAR-DRUG RESISTANCE; FACTOR-C/EBP-ALPHA; TRANSCRIPTION FACTOR; PROGNOSTIC-SIGNIFICANCE; INITIATING CELLS; AML; DIFFERENTIATION","Background Dysfunctioning of CCAAT/enhancer binding protein alpha (C/EBP alpha) in acute myeloid leukemia can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable outcome, but this may be restricted to the case of double mutations in CEBPA in adult acute myeloid leukemia. In pediatric acute myeloid leukemia, data on the impact of these mutations are limited to one series, and data on promoter hypermethylation are lacking. Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia. Design and Methods We screened a large pediatric cohort (n=252) for CEBPA single and double mutations by direct sequencing, and for promoter hypermethylation by methylation-specific polymerase chain reaction. Furthermore, we determined the gene-expression profiles (Affymetrix HGU133 plus 2.0 arrays) of this cohort (n=237). Results Thirty-four mutations were identified in 20 out of the 252 cases (7.9%), including 14 double-mutant and 6 single-mutant cases. CEBPA double mutations conferred a significantly better 5-year overall survival compared with single mutations (79% versus 25%, respectively; P=0.04), and compared with CEBPA wild-type acute myeloid leukemia excluding core-binding factor cases (47%; P=0.07). Multivariate analysis confirmed that the double mutations were an independent favorable prognostic factor for survival (hazard ratio 0.23, P=0.04). The combination of screening for promoter hypermethylation and gene expression profiling identified five patients with silenced CEBPA, of whom four cases relapsed. All cases characteristically expressed T-lymphoid markers. Moreover, unsupervised clustering of gene expression profiles showed a clustering of CEBPA double-mutant and silenced cases, pointing towards a common hallmark of abrogated C/EBP alpha-functioning in these acute myeloid leukemias. Conclusions We showed the independent favorable outcome of patients with CEBPA double-mutant acute myeloid leukemia in a large pediatric series. This molecular marker may, therefore, improve risk-group stratification in pediatric acute myeloid leukemia. For the first time, CEBPA-silenced cases are suggested to confer a poor outcome in pediatric acute myeloid leukemia, indicating that further investigation of this aberration is needed. Furthermore, clustering of gene expression profiles provided insight into the biological similarities and diversities of the different aberrations in CEBPA in pediatric acute myeloid leukemia.","[Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, AML BFM Study Grp, Hannover, Germany; [Peeters, Justine K.; Valk, Peter J. M.] Erasmus MC, Rotterdam, Netherlands; [Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Sonneveld, Edwin; Kaspers, Gertjan J. L.] DCOG, The Hague, Netherlands; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [de Bont, Eveline S. J. M.] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] Hop St Louis, Paris, France; [Creutzig, Ursula] Univ Hosp, AML BFM Study Grp, Munster, Germany","Zwaan, CM, Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","c.m.zwaan@eras-musmc.nl","KOCR foundation ; Netherlands Organisation for Scientific Research (NWO) ; Deutsche Krebshilfe ; Czech Ministry of Education [MSM0021620813]","this work was funded by the KOCR foundation (IHIMH and BVB) and the Netherlands Organisation for Scientific Research (NWO) (BVB). This work was further supported in part by the Deutsche Krebshilfe (DR), and the Czech Ministry of Education (MSM0021620813) (JT).",null,43,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2010.031336","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","MAR",2011,96,3,null,null,null,384,392,null,null,9,"Hematology","740BQ","ISI:000288767000008"]
["J","Klukowska, A; Komrska, V; Jansen, M; Laguna, P",null,null,null,"Klukowska, A.; Komrska, V.; Jansen, M.; Laguna, P.",null,"Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate (R): interim report from an ongoing prospective clinical study","HAEMOPHILIA",null,"English","Article",null,null,null,null,null,"factor VIII; haemophilia A; inhibitors; Octanate (R); previously untreated patients; surgery","SEVERE HEMOPHILIA-A; RISK-FACTORS; TOLERANCE INDUCTION; IMMUNE TOLERANCE; CANAL COHORT; FACTOR-IX; RECOMBINANT; CONCENTRATE; PRODUCTS; CHILDREN","For patients with haemophilia A (HA), lifelong replacement therapy with factor VIII (FVIII) concentrates is the treatment of choice. Octanate (R) is a plasma-derived, human, von Willebrand factor-stabilized FVIII product with demonstrated haemostatic efficacy in patients with HA. The aim of this ongoing study is to assess the immunogenicity of Octanate (R) in previously untreated patients (PUPs), monitoring for development of FVIII inhibitors. Interim data on 39 PUPs treated for bleeding, prophylactically and for surgical coverage are reported. Two of 39 subjects (5.1%) developed clinically relevant inhibitor titres over the course of the study. Another two displayed inhibitors that disappeared spontaneously without Octanate (R) dose change. All inhibitors developed under on-demand treatment and before exposure day (ED) 50. Remarkably, no inhibitor was observed in PUPs receiving prophylaxis with Octanate (R). Of 39 subjects, 30 had exceeded 50 EDs at the time of this analysis. All inhibitor subjects were found to have large FVIII gene defects, either intron 22-inversions or large deletions. Octanate (R) was well-tolerated and the adverse event profile was consistent with the population studied. The haemostatic efficacy of Octanate (R) in prophylaxis and treatment of bleeding were generally rated as 'excellent', and no complication was reported for surgery. Notable FVIII activity was present in blood at 15 min postadministration, and levels remained high at 1 h. Mean incremental in vivo recovery (IVR) was 2.0 (+/- 0.6) % IU-1kg-1. These interim results indicate Octanate (R) to be an efficacious, well-tolerated human FVIII product for management of HA in PUPs, associated with a minimal risk of inhibitors.","[Klukowska, A.; Laguna, P.] Med Univ Warsaw, Dept Pediat Hematol & Oncol, PL-00576 Warsaw, Poland; [Komrska, V.] Motol Univ Hosp, Prague, Czech Republic; [Jansen, M.] Octapharma, Vienna, Austria","Klukowska, A, Med Univ Warsaw, Dept Pediat Hematol & Oncol, Marszalkowska 24, PL-00576 Warsaw, Poland","aklukowska@poczta.onet.pl","Octapharma Ltd. ","MJ is an employee of Octapharma Ag, Vienna, Austria and AK has received speaker fees from Octapharma Ltd.",null,36,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-8216",null,"10.1111/j.1365-2516.2010.02428.x","HAEMOPHILIA","Haemophilia","MAY",2011,17,3,null,null,null,399,406,null,null,8,"Hematology","754YQ","ISI:000289894200003"]
["J","Ferlito, A; Robbins, KT; Shah, JP; Medina, JE; Silver, CE; Al-Tamimi, S; Fagan, JJ; Paleri, V; Takes, RP; Bradford, CR; Devaney, KO; Stoeckli, SJ; Weber, RS; Bradley, PJ; Suarez, C; Leemans, CR; Coskun, HH; Pitman, KT; Shaha, AR; de Bree, R; Hartl, DM; Haigentz, M; Rodrigo, JP; Hamoir, M; Khafif, A; Langendijk, JA; Owen, RP; Sanabria, A; Strojan, P; Poorten, VV; Werner, JA; Bien, S; Woolgar, JA; Zbaren, P; Betka, J; Folz, BJ; Genden, EM; Talmi, YP; Strome, M; Botas, JHG; Olofsson, J; Kowalski, LP; Holmes, JD; Hisa, Y; Rinaldo, A",null,null,null,"Ferlito, Alfio; Robbins, K. Thomas; Shah, Jatin P.; Medina, Jesus E.; Silver, Carl E.; Al-Tamimi, Shawkat; Fagan, Johannes J.; Paleri, Vinidh; Takes, Robert P.; Bradford, Carol R.; Devaney, Kenneth O.; Stoeckli, Sandro J.; Weber, Randal S.; Bradley, Patrick J.; Suarez, Carlos; Leemans, C. Rene; Coskun, H. Hakan; Pitman, Karen T.; Shaha, Ashok R.; de Bree, Remco; Hartl, Dana M.; Haigentz, Missak, Jr.; Rodrigo, Juan P.; Hamoir, Marc; Khafif, Avi; Langendijk, Johannes A.; Owen, Randall P.; Sanabria, Alvaro; Strojan, Primoz; Poorten, Vincent Vander; Werner, Jochen A.; Bien, Stanislaw; Woolgar, Julia A.; Zbaeren, Peter; Betka, Jan; Folz, Benedikt J.; Genden, Eric M.; Talmi, Yoav P.; Strome, Marshall; Gonzalez Botas, Jesus Herranz; Olofsson, Jan; Kowalski, Luiz P.; Holmes, Jon D.; Hisa, Yasuo; Rinaldo, Alessandra",null,"PROPOSAL FOR A RATIONAL CLASSIFICATION OF NECK DISSECTIONS","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK",null,"English","Editorial Material",null,null,null,null,null,null,"HEAD; CHEMORADIATION; TERMINOLOGY; SURGERY; ACADEMY; UPDATE",null,"[Ferlito, Alfio; Rinaldo, Alessandra] Univ Udine, ENT Clin, Dept Surg Sci, I-33100 Udine, Italy; [Robbins, K. Thomas] So Illinois Univ, Sch Med, Div Otolaryngol Head & Neck Surg, Springfield, IL USA; [Shah, Jatin P.; Shaha, Ashok R.] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA; [Medina, Jesus E.] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK USA; [Silver, Carl E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA; [Silver, Carl E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Otolaryngol Head & Neck Surg, Bronx, NY 10467 USA; [Al-Tamimi, Shawkat] Royal Med Serv, King Hussein Med Ctr, Dept Otolaryngol Head & Neck Surg, Amman, Jordan; [Fagan, Johannes J.] Univ Cape Town, Fac Hlth Sci, Div Otolaryngol, ZA-7925 Cape Town, South Africa; [Paleri, Vinidh] Newcastle Upon Tyne Fdn Hosp NHS Trust, Dept Otolaryngol Head & Neck Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Takes, Robert P.] Radboud Univ Nijmegen, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-6525 ED Nijmegen, Netherlands; [Bradford, Carol R.] Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; [Devaney, Kenneth O.] Allegiance Hlth, Dept Pathol, Jackson, MI USA; [Stoeckli, Sandro J.] Kantonsspital, Dept Otorhinolaryngol Head & Neck Surg, St Gallen, Switzerland; [Weber, Randal S.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Bradley, Patrick J.] Univ Nottingham Hosp, Dept Otorhinolaryngol Head & Neck Surg, Nottingham NG7 2UH, England; [Suarez, Carlos; Rodrigo, Juan P.] Hosp Univ Cent Asturias, Dept Otolaryngol, Oviedo, Spain; [Suarez, Carlos; Rodrigo, Juan P.] Inst Univ Oncol Principado Asturias, Oviedo, Spain; [Leemans, C. Rene; de Bree, Remco] Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands; [Coskun, H. Hakan] Uludag Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Bursa, Turkey; [Pitman, Karen T.] Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, Jackson, MS 39216 USA; [Hartl, Dana M.] Inst Gustave Roussy, Dept Otolaryngol Head & Neck Surg, Villejuif, France; [Hartl, Dana M.] Sorbonne Nouvelle, Lab Phonet & Phonol, Paris, France; [Haigentz, Missak, Jr.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Oncol, Bronx, NY 10467 USA; [Hamoir, Marc] St Luc Univ Hosp & Canc Ctr, Dept Head & Neck Surg, Head & Neck Oncol Program, Brussels, Belgium; [Khafif, Avi] Assuta Med Ctr, ARM Ctr Adv Otolaryngol Head & Neck Surg, Head & Neck Surg & Oncol Unit, Tel Aviv, Israel; [Langendijk, Johannes A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands; [Owen, Randall P.] Mt Sinai Sch Med, Dept Surg, Div Metab Endocrine & Minimally Invas Surg, New York, NY USA; [Sanabria, Alvaro] Univ La Sabana Fdn Abood Shaio, Dept Surg, Bogota, Colombia; [Strojan, Primoz] Inst Oncol, Dept Radiat Oncol, Ljubljana, Slovenia; [Poorten, Vincent Vander] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Werner, Jochen A.] Univ Marburg, Dept Otolaryngol Head & Neck Surg, Marburg, Germany; [Bien, Stanislaw] Holy Cross Canc Ctr, Dept Otolaryngol Head & Neck Surg, Kielce, Poland; [Woolgar, Julia A.] Univ Liverpool Dent Hosp, Liverpool, Merseyside, England; [Zbaeren, Peter] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Bern, Switzerland; [Betka, Jan] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Folz, Benedikt J.] Karl Hansen Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Bad Lippspringe, Germany; [Genden, Eric M.] Mt Sinai Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA; [Talmi, Yoav P.] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Head & Neck Serv, IL-69978 Tel Aviv, Israel; [Strome, Marshall] Cleveland Clin, Head & Neck Inst, Dept Otolaryngol & Communicat Disorders, Cleveland, OH 44106 USA; [Gonzalez Botas, Jesus Herranz] Univ Hosp A Coruna, Dept Otorhinolaryngol, La Coruna, Spain; [Olofsson, Jan] Haukeland Hosp, Dept Otolaryngol Head & Neck Surg, N-5021 Bergen, Norway; [Kowalski, Luiz P.] Ctr Tratamento & Pesquisa Hosp Canc AC Camargo, Dept Otorhinolaryngol Head & Neck Surg, Sao Paulo, Brazil; [Holmes, Jon D.] Univ Alabama, Dept Oral & Maxillofacial Surg, Birmingham, AL USA; [Hisa, Yasuo] Kyoto Prefectural Univ Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan","Ferlito, A, Univ Udine, ENT Clin, Dept Surg Sci, I-33100 Udine, Italy","a.ferlito@uniud.it",null,null,null,24,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1043-3074",null,"10.1002/hed.21614","HEAD NECK-J SCI SPEC HEAD NEC","Head Neck-J. Sci. Spec. Head Neck","MAR",2011,33,3,null,null,null,445,450,null,null,6,"Otorhinolaryngology; Surgery","721RP","ISI:000287372900024"]
["J","Lenicek, M; Duricova, D; Komarek, V; Gabrysova, B; Lukas, M; Smerhovsky, Z; Vitek, L",null,null,null,"Lenicek, Martin; Duricova, Dana; Komarek, Viktor; Gabrysova, Bronislava; Lukas, Milan; Smerhovsky, Zdenek; Vitek, Libor",null,"Bile Acid Malabsorption in Inflammatory Bowel Disease: Assessment by Serum Markers","INFLAMMATORY BOWEL DISEASES",null,"English","Article",null,null,null,null,null,"bile acid malabsorption; Crohn's disease; 7 alpha-hydroxycholest-4-en-3-one; ileal disease; inflammatory bowel disease","CHRONIC DIARRHEA; DIURNAL-VARIATION; CROHNS-DISEASE; HUMAN ILEAL; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; HYPEROXALURIA; TRANSPORTER; ABSORPTION; EXPRESSION; THERAPY","Background: Bile acid malabsorption (BAM) is a common feature of Crohn's disease (CD). We aimed to determine whether BAM develops only in patients with a resected distal ileum or if it also occurs in patients who have not undergone surgery for CD. Methods: The study included 347 patients with CD or ulcerative colitis (UC) and 119 healthy subjects (controls). BAM was assessed by measurement of serum levels of 7 alpha-hydroxycholest-4-en-3-one (C4) and fibroblast growth factor 19 (FGF19). We surveyed members of the European Crohn's and Colitis Organization and International Organization for the Study of Inflammatory Bowel Disease to collect current information about BAM diagnosis. Results: The severity of BAM was associated with resection of the distal ileum. Compared with controls, patients who received moderate or extensive ileal resection had significantly increased levels of serum C4 (12 versus 62 versus 243 mu g/L, respectively; P < 0.001). However, BAM was also present in a substantial number of the patients with CD who were not treated by surgery who had ileitis or colitis (14% and 11%, respectively). There was an indirect, proportional relationship between levels of C4 and FGF19 (P < 0.001). Conclusions: The most severe BAM occurs in CD patients after resection of the distal ileum, but BAM can occur in surgically untreated CD patients, regardless of disease localization. Laboratory tests for BAM should become a part of the algorithm for diagnosis of CD to identify patients who might respond to therapies such as bile acid sequestrants. FGF19 appears to be a reliable marker of BAM.","[Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, Prague 12808 2, Czech Republic; [Lenicek, Martin; Gabrysova, Bronislava; Lukas, Milan; Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Clin Biochem & Lab Diagnost, Prague 12808 2, Czech Republic; [Duricova, Dana; Komarek, Viktor; Lukas, Milan] ISCARE IVF, IBD Res Ctr, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol 2, Prague 12808 2, Czech Republic; [Smerhovsky, Zdenek] Natl Inst Publ Hlth, Prague, Czech Republic","Vitek, L, Charles Univ Prague, Fac Med 1, Dept Internal Med 4, U Nemocnice 2, Prague 12808 2, Czech Republic","vitek@cesnet.cz","Czech Ministry of Education [2B06155]; Czech Ministry of Health [NR-9219-3/2007]","Supported by government grants from both the Czech Ministry of Education (No. 2B06155) and the Czech Ministry of Health (No. NR-9219-3/2007). The granting agencies had no influence on the collection, analysis, interpretation of data, writing of the report, nor on the decision to submit the article for publication.",null,33,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1078-0998",null,"10.1002/ibd.21502","INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","JUN",2011,17,6,null,null,null,1322,1327,null,null,6,"Gastroenterology & Hepatology","761ZQ","ISI:000290442400030"]
["J","Rockova, S; Nevoral, J; Rada, V; Marsik, P; Sklenar, J; Hinkova, A; Vlkova, E; Marounek, M",null,null,null,"Rockova, Sarka; Nevoral, Jiri; Rada, Vojtech; Marsik, Petr; Sklenar, Jan; Hinkova, Andrea; Vlkova, Eva; Marounek, Milan",null,"Factors affecting the growth of bifidobacteria in human milk","INTERNATIONAL DAIRY JOURNAL",null,"English","Article",null,null,null,null,null,null,"OLIGOSACCHARIDES; INFANTS; PREBIOTICS; PROTEINS","Five strains of bifidobacteria of human origin and 2 strains of bifidobacteria of animal origin were tested for growth in 10 samples of human milk. Growth of Bifidobacterium bifidum in human milk was accompanied by a decrease in pH and production of acids. The number of viable cells of Bifidobacterium animalis was decreased from 6 log cfu mL(-1) to 3 log cfu mL(-1) after incubation in human milk. There were significant differences (P < 0.05) between bacterial counts of B. bifidum and B. animalis in milk samples tested. Resistance to lysozyme and the ability to utilise human milk oligosaccharides (HMOs) were identified as the most important factors affecting the growth of bifidobacteria in human milk. Four out of 5 strains of human origin were resistant to lysozyme and utilised HMOs. In contrast, B. animalis was susceptible to lysozyme and did not utilise HMOs. (C) 2011 Elsevier Ltd. All rights reserved.","[Rockova, Sarka; Rada, Vojtech; Vlkova, Eva] Czech Univ Life Sci, Dept Microbiol Nutr & Dietet, Fac Agrobiol Food & Nat Resources, Prague 16521 6, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic; [Marsik, Petr] Acad Sci CR, Joint Lab Inst Expt Bot, Vvi, Plant Biotechnol Lab, Prague 16502 6, Czech Republic; [Marsik, Petr] Res Inst Crop Prod, Vvi, Prague 16502 6, Czech Republic; [Sklenar, Jan] Acad Sci CR, Inst Microbiol, Dept Immunol, Prague 14220, Czech Republic; [Hinkova, Andrea] Prague Inst Chem Technol, Dept Carbohydrate Chem & Technol, CR-16628 Prague 6, Czech Republic; [Marounek, Milan] Acad Sci CR, Inst Anim Physiol & Genet, Vvi, Prague 14220, Czech Republic","Rada, V, Czech Univ Life Sci, Dept Microbiol Nutr & Dietet, Fac Agrobiol Food & Nat Resources, Kamycka 129, Prague 16521 6, Czech Republic","rada@af.czu.cz","Ministry of Education, Youth and Sports of Czech Republic [6046070901]; Czech Science Foundation [523/07/0572, 525/08/H060]","This study was supported by grant MSM No. 6046070901 of Ministry of Education, Youth and Sports of Czech Republic and by grants 523/07/0572, and 525/08/H060 of the Czech Science Foundation. We thank Dr. Ingrid Kocourkova from the Institute for the Care of Mother and Child (Prague, Czech Republic) for supplying us with human milk samples.",null,25,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0958-6946",null,"10.1016/j.idairyj.2011.02.005","INT DAIRY J","Int. Dairy J.","JUL",2011,21,7,null,null,null,504,508,null,null,5,"Food Science & Technology","758YR","ISI:000290205100008"]
["J","Rotnaglova, E; Tachezy, R; Salakova, M; Prochazka, B; Kosl'abova, E; Vesela, E; Ludvikova, V; Hamsikova, E; Klozar, J",null,null,null,"Rotnaglova, Eliska; Tachezy, Ruth; Salakova, Martina; Prochazka, Bohumir; Kosl'abova, Eva; Vesela, Eva; Ludvikova, Viera; Hamsikova, Eva; Klozar, Jan",null,"HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers","INTERNATIONAL JOURNAL OF CANCER",null,"English","Article",null,null,null,null,null,"HPV; tonsillar cancer; prognosis; antibodies","HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMA; NECK-CANCER; RISK-FACTORS; PHYSICAL STATUS; OROPHARYNGEAL CANCERS; FAVORABLE PROGNOSIS; POSITIVE HEAD; ORAL-CAVITY; SURVIVAL","The association of high-risk human papillomaviruses (HR HPVs) with tonsillar cancer (TC) has been documented. Because patients with HPV-associated tumors show better survival rates, modification of their treatment regimen is being considered. It is therefore crucial to find markers for the identification of patients whose tumors are linked to viral infection. A cohort of 109 patients with primary TC was screened for HPV DNA presence in the tumor tissues and HPV-specific antibodies in sera. Data regarding risk factors and clinical parameters were collected. Forty-five specimens were analyzed for the expression of viral E6 and E2-region mRNA, and the p16 and p53 protein expression status was assessed by immunohistochemistry. The overall prevalence of HPV DNA in TC tissues was 65.1%. Ninety-three percent of HR HPV DNA-positive samples expressed E6*I mRNA. E2-region mRNA expression was detected in 36% of positive samples, which implies that the virus is integrated in 64% of HPV DNA/RNA-positive tumors. p16 overexpression and the presence of antibodies specific to HPV16 E6/E7 oncoproteins correlated well with HPV DNA and RNA presence. The disease-specific survival rate of patients with HPV DNA-positive tumors was significantly higher than that of HPV DNA-negative patients. In addition to providing further evidence of the involvement of HPV infection in the etiopathogenesis of a proportion of TC cases, our study demonstrates that p16 immunostaining and anti-E6/E7 antibodies as surrogate markers of HPV involvement represent specific, sensitive and clinically accessible assays for the identification of TC patients who have a considerably better prognosis.","[Klozar, Jan] Charles Univ Prague, Motol Univ Hosp, Inst Postgrad Med Educ, Dept Otolaryngol & Head & Neck Surg,Fac Med 1, Prague 15006 5, Czech Republic; [Rotnaglova, Eliska; Tachezy, Ruth; Salakova, Martina; Kosl'abova, Eva; Ludvikova, Viera; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic; [Prochazka, Bohumir] Natl Inst Publ Hlth, Dept Sci Informat & Biostat, Prague, Czech Republic; [Vesela, Eva] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic","Klozar, J, Charles Univ Prague, Motol Univ Hosp, Inst Postgrad Med Educ, Dept Otolaryngol & Head & Neck Surg,Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic","jan.klozar@lfmotol.cuni.cz","Grant Agency of the Ministry of Health of the Czech Republic [NR 9466-3]; Grant Agency of the 1st Faculty of Medicine, Charles University in Prague [GAUK 8808]; Charles University in Prague [260 510]","Grant sponsor: Grant Agency of the Ministry of Health of the Czech Republic; Grant number: NR 9466-3; Grant sponsor: Grant Agency of the 1st Faculty of Medicine, Charles University in Prague; Grant number: GAUK 8808; Grant sponsor: Charles University in Prague (University Research Support Grant); Grant number: 260 510",null,50,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0020-7136",null,"10.1002/ijc.25889","INT J CANCER","Int. J. Cancer","JUL 1",2011,129,1,null,null,null,101,110,null,null,10,"Oncology","756BS","ISI:000289987300010"]
["J","Cardwell, CR; Stene, LC; Joner, G; Bulsara, MK; Cinek, O; Rosenbauer, J; Ludvigsson, J; Svensson, J; Goldacre, MJ; Waldhoer, T; Jarosz-Chobot, P; Gimeno, SGA; Chuang, LM; Roberts, CL; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Devoti, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Radon, K; Glatthaar, C; Patterson, CC",null,null,null,"Cardwell, Chris R.; Stene, Lars C.; Joner, Geir; Bulsara, Max K.; Cinek, Ondrej; Rosenbauer, Joachim; Ludvigsson, Johnny; Svensson, Jannet; Goldacre, Michael J.; Waldhoer, Thomas; Jarosz-Chobot, Przemyslawa; Gimeno, Suely G. A.; Chuang, Lee-Ming; Roberts, Christine L.; Parslow, Roger C.; Wadsworth, Emma J. K.; Chetwynd, Amanda; Brigis, Girts; Urbonaite, Brone; Sipetic, Sandra; Schober, Edith; Devoti, Gabriele; Ionescu-Tirgoviste, Constantin; de Beaufort, Carine E.; Stoyanov, Denka; Buschard, Karsten; Radon, Katja; Glatthaar, Christopher; Patterson, Chris C.",null,"Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies","INTERNATIONAL JOURNAL OF EPIDEMIOLOGY",null,"English","Article",null,null,null,null,null,"Diabetes mellitus; type 1; epidemiology; birth order; meta-analysis","MATERNAL AGE; EARLY-LIFE; MELLITUS; CHILDREN; DETERMINANTS; ONSET; IDDM; INFECTIONS; DELIVERY; UK","Background The incidence rates of childhood onset type 1 diabetes are almost universally increasing across the globe but the aetiology of the disease remains largely unknown. We investigated whether birth order is associated with the risk of childhood diabetes by performing a pooled analysis of previous studies. Methods Relevant studies published before January 2010 were identified from MEDLINE, Web of Science and EMBASE. Authors of studies provided individual patient data or conducted pre-specified analyses. Meta-analysis techniques were used to derive combined odds ratios (ORs), before and after adjustment for confounders, and investigate heterogeneity. Results Data were available for 6 cohort and 25 case-control studies, including 11 955 cases of type 1 diabetes. Overall, there was no evidence of an association prior to adjustment for confounders. After adjustment for maternal age at birth and other confounders, a reduction in the risk of diabetes in second- or later born children became apparent [fully adjusted OR = 0.90 95% confidence interval (CI) 0.83-0.98; P = 0.02] but this association varied markedly between studies (I-2 = 67%). An a priori subgroup analysis showed that the association was stronger and more consistent in children < 5 years of age (n = 25 studies, maternal age adjusted OR = 0.84 95% CI 0.75, 0.93; I-2 = 23%). Conclusion Although the association varied between studies, there was some evidence of a lower risk of childhood onset type 1 diabetes with increasing birth order, particularly in children aged < 5 years. This finding could reflect increased exposure to infections in early life in later born children.","[Cardwell, Chris R.] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; [Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, Lars C.] Oslo Univ Hosp, Oslo Diabet Res Ctr, Oslo, Norway; [Joner, Geir] Univ Oslo, Inst Hlth Management & Hlth Econ, Oslo, Norway; [Bulsara, Max K.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Bulsara, Max K.] Univ Notre Dame, Inst Hlth & Rehabil Res, Fremantle, Australia; [Cinek, Ondrej] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, Joachim] Univ Dusseldorf, Leibniz Inst, Inst Biometr & Epidemiol, German Diabet Ctr, Dusseldorf, Germany; [Ludvigsson, Johnny] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, Johnny] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Svensson, Jannet] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, Thomas] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Jarosz-Chobot, Przemyslawa] Med Univ Silesia, Dept Pediat Endocrinol & Diabet, Katowice, Poland; [Gimeno, Suely G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Roberts, Christine L.] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia; [Parslow, Roger C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, Emma J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, Amanda] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Brigis, Girts] Riga Stradins Univ, Dept Publ Hlth & Epidemiol, Riga, Latvia; [Urbonaite, Brone] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, Sandra] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, Edith] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Devoti, Gabriele] Univ Lecce, Dept Social Sci & Commun, I-73100 Lecce, Italy; [Ionescu-Tirgoviste, Constantin] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, Carine E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, Denka] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, Karsten] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark; [Radon, Katja] Hosp LMU Munich, Inst Occupat & Environm Med, Munich, Germany; [Radon, Katja] Hosp LMU Munich, Outpatient Clin Occupat & Environm Med, Munich, Germany; [Glatthaar, Christopher] Sir Charles Gairdner Hosp, Perth, WA, Australia","Cardwell, CR, Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland","c.cardwell@qub.ac.uk","Czech Republic Ministry of Education [MSM 0021620814]; Department of Health of Taiwan [DOH 90-TD1028]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Swedish Child Diabetes Foundation ; NHS National Coordinating Centre for Research Capacity Development UK ; Australian National Health and Medical Research Council (NHMRC) [457302]; Research Council of Norway ; German Research Foundation [HE 234/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes UK ; Northern Ireland Department of Health and Social Services ","This pooled analysis was not directly funded but the authors acknowledge support for the conduct of the original studies from the following: the Czech Republic Ministry of Education (grant MSM 0021620814), Department of Health of Taiwan (DOH 90-TD1028), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 94/0943-0), The Swedish Child Diabetes Foundation, the NHS National Coordinating Centre for Research Capacity Development UK, Australian National Health and Medical Research Council (NHMRC) (project grant #457302), the Research Council of Norway, the German Research Foundation (grant HE 234/1-1), the Ministry for Science and Technological Development of Serbia (No. 145084, 2006-2010), EUBIROD funded by the European Commission Health Information Strand (DG-SANCO 2005, Contract No 2007115), Diabetes UK and the Northern Ireland Department of Health and Social Services.",null,48,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0300-5771",null,"10.1093/ije/dyq207","INT J EPIDEMIOL","Int. J. Epidemiol.","APR",2011,40,2,null,null,null,363,374,null,null,12,"Public, Environmental & Occupational Health","745LB","ISI:000289165800015"]
["J","Foltan, R; Hoffmannova, J; Pavlikova, G; Hanzelka, T; Klima, K; Horka, E; Adamek, S; Sedy, J",null,null,null,"Foltan, Rene; Hoffmannova, Jirina; Pavlikova, Gabriela; Hanzelka, Tomas; Klima, Karel; Horka, Edita; Adamek, Svatopluk; Sedy, Jiri",null,"The influence of orthognathic surgery on ventilation during sleep","INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY",null,"English","Article",null,null,null,null,null,"orthognathic surgery; obstructive sleep apnea; ventilation; sleep","MANDIBULAR SETBACK SURGERY; APNEA SYNDROME; AIRWAY SIZE; MAXILLOMANDIBULAR ADVANCEMENT; EXPANSION","Orthognathic surgery has varying effects on respiratory parameters. The authors undertook a prospective study of patients requiring mandibular advancement, mandibular setback and maxillary Le Fort I advancement, and surgically assisted rapid maxillary expansion (SARME). Breathing parameters were monitored in a sleep laboratory the night before the operation and in a mean of 9.5 months after the operation. In patients treated with mandibular advancement, the respiratory disturbance index (RDI), oxygen desaturation index (ODI), and number of obstructive apnoeas (OAs) improved significantly. In patients treated with mandibular setback and maxillary Le Fort I advancement, the RDI, ODI, index of flow limitations (IFL), number of obstructive hypopnoeas (OHs), OA, and oxygen saturation deteriorated. In contrast, patients treated with SARME improved only mildly. These results indicate that bimaxillary surgery for Class III malocclusion increased upper airway resistance, probably because of a more dorsal positioning of the base of the tongue, representing an iatrogenic obstructive sleep apnoea (OSA). A young person would probably be able to balance such a decline in respiratory function using different adaptative mechanisms. Mandibular advancement significantly improved respiratory parameters during sleep. The possible effect of orthognathic surgery on the upper airways should be incorporated into the treatment plan.","[Horka, Edita; Sedy, Jiri] Charles Univ Prague, Inst Dent Res, Fac Med 1, Prague 12800 2, Czech Republic; [Horka, Edita; Sedy, Jiri] Gen Univ Hosp, Prague 12800 2, Czech Republic; [Foltan, Rene; Hoffmannova, Jirina; Pavlikova, Gabriela; Hanzelka, Tomas; Klima, Karel] Charles Univ Prague, Dept Oral & Maxillofacial Surg, Fac Med 1, Prague 12800 2, Czech Republic; [Adamek, Svatopluk] Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Adamek, Svatopluk] Teaching Hosp Motol, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic","Sedy, J, Charles Univ Prague, Inst Dent Res, Fac Med 1, Karlovo Namesti 32, Prague 12800 2, Czech Republic","jirisedy@hotmail.com",null,null,null,22,0,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0901-5027",null,"10.1016/j.ijom.2010.10.006","INT J ORAL MAXILLOFAC SURG","Int. J. Oral Maxillofac. Surg.","FEB",2011,40,2,null,null,null,146,149,null,null,4,"Dentistry, Oral Surgery & Medicine; Surgery","736DQ","ISI:000288471100004"]
["J","Trc, T; Bohmova, J",null,null,null,"Trc, Tomas; Bohmova, Jana",null,"Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)","INTERNATIONAL ORTHOPAEDICS",null,"English","Article",null,null,null,null,null,null,"ANTIRHEUMATIC DRUG TRIALS; CLINICAL-TRIALS; ARTHRITIS","This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged >= 40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days. Follow-up took place after two weeks and after one, two and three months. Primary [visual analogue scale (VAS), Western Ontario and McMaster Universities (WOMAC Index)] and secondary outcomes variables, assessed at weeks two, four, eight and 12, were KOA pain intensity measured by quadruple visual analogue scales in the target knee, the WOMAC total score index, patient's and investigator's global assessments of disease activity, joint assessment, use of rescue medication (ibuprofen 400 mg tablets) and assessment of Quality of Life index (SF-36 Questionnaire). Safety and tolerability were also evaluated. Clear improvement was observed in both joint pain and symptoms in patients with KOA treated with EHC (Colatech (R)) and significant differences were observed. Mean reductions from baseline for EHC 10 g daily and GS 1.5 g, respectively, were KOA pain intensity reduction in the target knee for Colatech (R) (p<0.05): WOMAC index decrease <= 15 points at the last visit (day 90) for Colatech (R) in 16 patients (34.04%) (p<0.05) and for glucosamine in six patients (13.04%); total score index for painful joints: Colatech (R) 1.6 (p<0.05) and glucosamine 1.8; total score index for swollen joints: Colatech (R) 0.5 (p<0.05) and glucosamine 0.7; patient's global assessment of efficacy as the sum of improvement good + ideal: 80.8% for Colatech (R) and 46.6% for glucosamine (p<0.05). EHC (Colatech (R)) showed superior improvement over GS in the SF-36 Questionnaire in the Physical Health Index (42.0 for Colatech and 40.0 for glucosamine). The incidence of adverse events was similar in both groups. Both EHC and GS were well tolerated.","[Trc, Tomas] Charles Univ Prague, Orthopaed Clin, Sch Med 2, Prague, Czech Republic; [Bohmova, Jana] Fac Hosp Brno, Dept Rheumatol, Brno, Czech Republic","Trc, T, Charles Univ Prague, Orthopaed Clin, Sch Med 2, Prague, Czech Republic","tomas.trc@lfmotol.cuni.cz",null,null,null,20,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,"10.1007/s00264-010-1010-z","INT ORTHOP","Int. Orthop.","MAR",2011,35,3,null,null,null,341,348,null,null,8,"Orthopedics","742RA","ISI:000288961000005"]
["J","Hrdlicka, M; Vodicka, J; Havlovicova, M; Urbanek, T; Blatny, M; Dudova, I",null,null,null,"Hrdlicka, Michal; Vodicka, Jan; Havlovicova, Marketa; Urbanek, Tomas; Blatny, Marek; Dudova, Iva",null,"Brief Report: Significant Differences in Perceived Odor Pleasantness Found in Children with ASD","JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS",null,"English","Article",null,null,null,null,null,"Autism; Asperger's syndrome; Sensory abnormalities; Olfactory; Pleasantness; Sniffin' Sticks","OLFACTORY SENSITIVITY; AUTISM; IDENTIFICATION; DISORDER; METAANALYSIS; INDIVIDUALS; STIMULI","The aim of our study was to explore possible differences in estimation of odor pleasantness in children with autism spectrum disorders (ASD) compared to controls. Thirty-five patients with Asperger's syndrome and high functioning autism (mean age 10.8 +/- A 3.6 years; 31 boys) were compared with 35 healthy control subjects (mean age 10.4 +/- A 2.4 years; 28 boys). Odor pleasantness was assessed on a 5-point scale using the Sniffin' Sticks test (Identification part of the test). Patients with ASD, compared to healthy controls, perceived the smell of cinnamon and pineapple as significantly less pleasant (p < 0.05); at the trend level, the same was true of cloves (p < 0.1). The possibility of olfactory dysfunctions as an autism biomarker is discussed.","[Hrdlicka, Michal; Dudova, Iva] Charles Univ Prague, Fac Med 2, Dept Child Psychiat, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 15006, Czech Republic; [Vodicka, Jan] Univ Pardubice, Fac Hlth Studies, Dept Otorhinolaryngol & Head & Neck Surg, Pardubice, Czech Republic; [Havlovicova, Marketa] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006, Czech Republic; [Urbanek, Tomas; Blatny, Marek] Acad Sci Czech Republic, Inst Psychol, Brno, Czech Republic","Hrdlicka, M, Charles Univ Prague, Fac Med 2, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic","michal.hrdlicka@lfmotol.cuni.cz",null,null,null,21,0,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0162-3257",null,"10.1007/s10803-010-1084-x","J AUTISM DEV DISORD","J. Autism Dev. Disord.","APR",2011,41,4,null,null,null,524,527,null,null,4,"Psychology, Developmental","733JQ","ISI:000288259400015"]
["J","Henry, DH; Costa, L; Goldwasser, F; Hirsh, V; Hungria, V; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Willenbacher, W; Woll, PJ; Wang, JM; Jiang, Q; Jun, S; Dansey, R; Yeh, H",null,null,null,"Henry, David H.; Costa, Luis; Goldwasser, Francois; Hirsh, Vera; Hungria, Vania; Prausova, Jana; Scagliotti, Giorgio Vittorio; Sleeboom, Harm; Spencer, Andrew; Vadhan-Raj, Saroj; von Moos, Roger; Willenbacher, Wolfgang; Woll, Penella J.; Wang, Jianming; Jiang, Qi; Jun, Susie; Dansey, Roger; Yeh, Howard",null,"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","JOURNAL OF CLINICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"KAPPA-B LIGAND; PLACEBO-CONTROLLED TRIAL; LONG-TERM EFFICACY; SKELETAL COMPLICATIONS; RECEPTOR ACTIVATOR; SOLID TUMORS; LUNG-CANCER; PHASE-III; PAMIDRONATE; BISPHOSPHONATES","Purpose This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. Patients and Methods Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). Results Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. Conclusion Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment. J Clin Oncol 29: 1125-1132. (C) 2011 by American Society of Clinical Oncology","[Henry, David H.] Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19106 USA; Hosp Santa Maria, Lisbon, Portugal; Inst Mol Med, Lisbon, Portugal; Teaching Hosp Cochin, Paris, France; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil; Univ Hosp Motol, Prague, Czech Republic; Univ Torino, Orbassano, Italy; HagaZiekenhuis Leyenburg, The Hague, Netherlands; Alfred Hosp, Melbourne, Vic, Australia; Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; Kantonsspital Graubunden, Chur, Switzerland; Med Univ Innsbruck, Innsbruck, Austria; Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England; Amgen Inc, Thousand Oaks, CA USA","Henry, DH, Penn Hosp, Joan Karnell Canc Ctr, 230 W Washington Sq, Philadelphia, PA 19106 USA","davidhenry@pennoncology.com","Amgen, Thousand Oaks, CA ; Amgen ; Centocor Ortho Biotech ; Watson Pharmaceuticals ; Novartis ","Supported by Amgen, Thousand Oaks, CA. Research Funding: David H. Henry, Amgen, Centocor Ortho Biotech, Watson Pharmaceuticals; Luis Costa, Amgen, Novartis; Harm Sleeboom, Amgen, Novartis; Saroj Vadhan-Raj, Amgen; Wolfgang Willenbacher, Amgen; Penella J. Woll, Amgen",null,39,1,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2010.31.3304","J CLIN ONCOL","J. Clin. Oncol.","MAR 20",2011,29,9,null,null,null,1125,1132,null,null,8,"Oncology","736YZ","ISI:000288532500024"]
["J","Bronsky, J; Mitrova, K; Karpisek, M; Mazoch, J; Durilova, M; Fisarkova, B; Stechova, K; Prusa, R; Nevoral, J",null,null,null,"Bronsky, Jiri; Mitrova, Katarina; Karpisek, Michal; Mazoch, Jiri; Durilova, Marianna; Fisarkova, Barbora; Stechova, Katerina; Prusa, Richard; Nevoral, Jiri",null,"Adiponectin, AFABP, and Leptin in Human Breast Milk During 12 Months of Lactation","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,"English","Article",null,null,null,null,null,"adipocyte fatty acid-binding protein; adiponectin; breast milk; leptin; nutritional programming","ACID-BINDING PROTEIN; RECEPTOR ISOFORM; FOOD-INTAKE; SERUM; ADIPOSITY; OBESITY; MOTHERS; LIFE; INFANTS","Objectives: Adiponectin, adipocyte fatty acid-binding protein (AFABP), and leptin have been shown to be present in human breast milk (BM). We determined intraindividual changes of BM levels of these proteins during 12 months of lactation. Subjects and Methods: Proteins were measured using a high-sensitivity enzyme-linked immunosorbent assay method in 72 healthy mothers after delivery (day 0, D0) and after 1, 3, 6, and 12 months of lactation. Results: Adiponectin levels in BM on D0 were 22.8 +/- 0.8 (mean +/- standard error of the mean), in 1 month (M1) 22.0 +/- 0.6, in 3 months (M3) 20.5 +/- 0.6, in 6 months (M6) 21.4 +/- 0.8, and in 12 months (M12) 25.7 +/- 1.4 ng/mL. AFABP levels were 12.3 +/- 2.0, 6.2 +/- 1.3, 1.3 +/- 0.2, 2.5 +/- 1.0, and 4.6 +/- 1.9 ng/mL, respectively. Leptin levels were 0.3 +/- 0.04, 0.2 +/- 0.03, 0.1 +/- 0.01, 0.1 +/- 0.02, and 0.2 +/- 0.04 ng/mL, respectively. We found significantly higher levels of adiponectin in M12 in comparison to M3 and M6 (P = 0.0026), higher levels of AFABP in D0 and M1 when compared with M3, M6, and M12 (P < 0.0001), and higher levels of leptin on D0 than in M1, M3, M6, and M12 (P < 0.0001). AFABP levels correlated negatively with infants' body weight in M1, but there was no correlation throughout the lactation period between body weight and other proteins. We found positive correlation between adiponectin, AFABP, and leptin throughout the lactation. Conclusions: All of the hormones were detectable in BM up to 12 months of lactation, with decreasing trend until M3 and subsequent increase till M12. We speculate that higher levels in M6 and M12 may be caused by longer intervals between breast-feeding due to the introduction of complementary food.","[Bronsky, Jiri; Mitrova, Katarina; Durilova, Marianna; Stechova, Katerina; Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Med Fac 2, Prague 15006 5, Czech Republic; [Prusa, Richard] Univ Hosp Motol, Med Fac 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Karpisek, Michal; Mazoch, Jiri] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Human Pharmacol & Toxicol, Brno, Czech Republic; [Fisarkova, Barbora] Charles Univ Prague, Dept Neonatol, Med Fac 2, Prague 15006 5, Czech Republic","Bronsky, J, Charles Univ Prague, Dept Paediat, Med Fac 2, V Uvalu 84, Prague 15006 5, Czech Republic","bronsky@email.cz","VZ MZO [64203/6903]","The present study was supported by research grant VZ MZO 64203/6903 (VZ FNM 2005).",null,19,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,"10.1097/MPG.0b013e3182062fcc","J PEDIAT GASTROENTEROL NUTR","J. Pediatr. Gastroenterol. Nutr.","APR",2011,52,4,null,null,null,474,477,null,null,4,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","737AZ","ISI:000288541100021"]
["J","Nyc, O; Pituch, H; Matejkova, J; Obuch-Woszczatynski, P; Kuijper, EJ",null,null,null,"Nyc, Otakar; Pituch, Hanna; Matejkova, Jana; Obuch-Woszczatynski, Piotr; Kuijper, Ed J.",null,"Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland","LANCET",null,"English","Letter",null,null,null,null,null,null,null,null,"[Nyc, Otakar; Matejkova, Jana] Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 5, Czech Republic; [Pituch, Hanna; Obuch-Woszczatynski, Piotr] Med Univ Warsaw, Dept Med Microbiol, Warsaw, Poland; [Kuijper, Ed J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands","Nyc, O, Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 5, Czech Republic","otakar.nyc@seznam.cz",null,null,null,3,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","APR 23",2011,377,9775,null,null,null,1407,1407,null,null,1,"Medicine, General & Internal","755UF","ISI:000289963000025"]
["J","Strahm, B; Nollke, P; Zecca, M; Korthof, ET; Bierings, M; Furlan, I; Sedlacek, P; Chybicka, A; Schmugge, M; Bordon, V; Peters, C; O'Marcaigh, A; de Heredia, CD; Bergstraesser, E; Moerloose, BD; van den Heuvel-Eibrink, MM; Stary, J; Trebo, M; Wojcik, D; Niemeyer, CM; Locatelli, F",null,null,null,"Strahm, B.; Noellke, P.; Zecca, M.; Korthof, E. T.; Bierings, M.; Furlan, I.; Sedlacek, P.; Chybicka, A.; Schmugge, M.; Bordon, V.; Peters, C.; O'Marcaigh, A.; de Heredia, C. D.; Bergstraesser, E.; Moerloose, B. D.; van den Heuvel-Eibrink, M. M.; Stary, J.; Trebo, M.; Wojcik, D.; Niemeyer, C. M.; Locatelli, F.","EWOG-MDS Study Grp","Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","LEUKEMIA",null,"English","Article",null,null,null,null,null,"myelodysplastic syndrome; stem cell transplantation; children","ACUTE MYELOID-LEUKEMIA; JUVENILE MYELOMONOCYTIC LEUKEMIA; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CHILDHOOD; GRAFT; CLASSIFICATION; EXPERIENCE; SURVIVAL; THERAPY","We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011","[Strahm, B.; Noellke, P.; Furlan, I.; Niemeyer, C. M.] Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany; [Zecca, M.] IRCCS Policlin, Dept Pediat, San Matteo, Italy; [Korthof, E. T.] Leiden Univ, Med Ctr, Div Stem Cell Transplantat, Dept Pediat, Leiden, Netherlands; [Bierings, M.] Univ Hosp Children, Dept Hematol, Utrecht, Netherlands; [Sedlacek, P.; Stary, J.] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Chybicka, A.; Wojcik, D.] Med Univ, Dept Pediat Bone Marrow Transplantat Oncol & Hema, Wroclaw, Poland; [Schmugge, M.; Bergstraesser, E.] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [Bordon, V.; Moerloose, B. D.] Ghent Univ Hosp, Dept Pediat Hematol & Oncol, B-9000 Ghent, Belgium; [Peters, C.; Trebo, M.] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [O'Marcaigh, A.] Our Ladys Hosp Sick Children, Dept Hematol & Oncol, Dublin, Ireland; [de Heredia, C. D.] Hosp Valle De Hebron, Dept Pediat Oncol & Hematol, Barcelona, Spain; [van den Heuvel-Eibrink, M. M.] Erasmus MC, Rotterdam, Netherlands; [van den Heuvel-Eibrink, M. M.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Locatelli, F.] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol & Oncol, Rome, Italy","Strahm, B, Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Mathildenstr 1, D-79106 Freiburg, Germany","brigitte.strahm@uniklinik-freiburg.de",null,null,null,29,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2010.297","LEUKEMIA","Leukemia","MAR",2011,25,3,null,null,null,455,462,null,null,8,"Oncology; Hematology","732CB","ISI:000288159500008"]
["J","Jech, R; Bares, M; Krepelova, A; Urgosik, D; Havrankova, P; Ruzicka, E",null,null,null,"Jech, Robert; Bares, Martin; Krepelova, Anna; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen",null,"DYT 6-A Novel THAP1 Mutation With Excellent Effect on Pallidal DBS","MOVEMENT DISORDERS",null,"English","Letter",null,null,null,null,null,null,"DEEP BRAIN-STIMULATION; DYSTONIA",null,"[Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Gen Univ Hosp, Prague, Czech Republic; [Bares, Martin] Masaryk Univ, Fac Med, St Annes Hosp, Dept Neurol 1, Brno, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic; [Urgosik, Dusan] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic","Jech, R, Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic","jech@cesnet.cz",null,null,null,7,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,"10.1002/mds.23599","MOVEMENT DISORD","Mov. Disord.","APR",2011,26,5,null,null,null,924,925,null,null,2,"Clinical Neurology","762AT","ISI:000290445400060"]
["J","Adamovicova, M; Jech, R; Urgosik, D; Spackova, N; Krepelova, A",null,null,null,"Adamovicova, Miriam; Jech, Robert; Urgosik, Dusan; Spackova, Natasa; Krepelova, Anna",null,"Pallidal Stimulation in Siblings with Pantothenate Kinase-Associated Neurodegeneration: Four-Year Follow-Up","MOVEMENT DISORDERS",null,"English","Letter",null,null,null,null,null,null,"DEEP BRAIN-STIMULATION; HALLERVORDEN-SPATZ-SYNDROME; IRON ACCUMULATION; DYSTONIA; MR",null,"[Adamovicova, Miriam] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic; [Adamovicova, Miriam; Jech, Robert; Spackova, Natasa] Gen Univ Hosp, Prague, Czech Republic; [Jech, Robert; Spackova, Natasa] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; [Urgosik, Dusan] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic","Adamovicova, M, Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic","adamovicova.m@seznam.cz",null,null,null,18,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,"10.1002/mds.23349","MOVEMENT DISORD","Mov. Disord.","JAN",2011,26,1,null,null,null,184,187,null,null,4,"Clinical Neurology","732IO","ISI:000288178400037"]
["J","Laczo, J; Andel, R; Vlcek, K; Matoska, V; Vyhnalek, M; Tolar, M; Bojar, M; Hort, J",null,null,null,"Laczo, Jan; Andel, Ross; Vlcek, Kamil; Matoska, Vaclav; Vyhnalek, Martin; Tolar, Martin; Bojar, Martin; Hort, Jakub",null,"Spatial Navigation and APOE in Amnestic Mild Cognitive Impairment","NEURODEGENERATIVE DISEASES",null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Mild cognitive impairment; Apolipoprotein E; Spatial navigation; Morris water maze; Memory","APOLIPOPROTEIN-E GENOTYPE; ALZHEIMERS-DISEASE; ELDERLY INDIVIDUALS; EPSILON-4 ALLELE; BRAIN-FUNCTION; E GENE; MEMORY; RISK; APOE-EPSILON-4; ATTENTION","Background: The effect of APOE epsilon 4 allele (epsilon 4) on spatial navigation in amnestic mild cognitive impairment (aMCI) is unknown. Objective: Our purpose was to examine the characteristics of spatial navigation impairment in epsilon 4-positive (epsilon 4+) and epsilon 4-negative (epsilon 4-) aMCI subgroups. Methods: Blood samples were collected to determine the APOE genotype. A total of 34 aMCI patients were stratified into aMCI-epsilon 4- (n = 23) and aMCI-epsilon 4+ (n = 11) groups. Control (n = 28) and mild Alzheimer's disease (AD; n = 16) groups were also used. We used a human analogue of the Morris water maze (enclosed arena 2.9 m in diameter) to examine body-centered (egocentric) and world-centered (allocentric) spatial navigation. Results: The aMCI-epsilon 4+ group performed poorer on spatial navigation than the aMCI-epsilon 4-group in both egocentric and allocentric tasks even though these 2 groups did not differ in global cognitive functioning or neuropsychological tests. The aMCI-epsilon 4+ and mild AD groups performed similarly on all Morris Water Maze tasks and were outperformed by the aMCI-epsilon 4- group, which also resembled the control group in performance on the egocentric tasks. The aMCI groups showed poor spatial navigation learning regardless of their epsilon 4 positivity. Conclusion: We found more profound deficits in spatial navigation in aMCI-epsilon 4+ relative to aMCI-epsilon 4- patients. The aMCI-epsilon 4+ group resembled the mild AD group in spatial navigation performance. Although the epsilon 4 genotype was indicative of spatial navigation performance, it was not indicative of the aMCI patients' ability to learn the tasks. Spatial navigation testing represents a promising area with respect to identifying individuals at higher risk for AD among the heterogeneous MCI population. Copyright (C) 2010 S. Karger AG, Basel","[Laczo, Jan; Vyhnalek, Martin; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Sch Med 2, Dept Neurol, Memory Disorders Unit, CZ-15006 Prague 5, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Memory Disorders Unit, Prague, Czech Republic; [Matoska, Vaclav] Homolka Hosp, Dept Clin Biochem Hematol & Immunol, Prague, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Hort, Jakub] Int Clin Res Ctr, Brno, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Tolar, Martin] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA","Hort, J, Charles Univ Prague, Sch Med 2, Dept Neurol, Memory Disorders Unit, Uvalu 84, CZ-15006 Prague 5, Czech Republic","Jakub.Hort@seznam.cz","Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; Ministry of Education, Youth and Sports of the Czech Republic [1M0517, LC554, AV0Z50110509]","The study was supported by the Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286, Ministry of Education, Youth and Sports of the Czech Republic Grants 1M0517 and LC554, and research project AV0Z50110509.",null,43,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854",null,"10.1159/000321581","NEURODEGENER DIS","Neurodegener. Dis.",null,2011,8,4,null,null,null,169,177,null,null,9,"Clinical Neurology; Neurosciences","763LT","ISI:000290559000002"]
["J","Gonsorcikova, L; Vaxillaire, M; Pruhova, S; Dechaume, A; Dusatkova, P; Cinek, O; Pedersen, O; Froguel, P; Hansen, T; Lebl, J",null,null,null,"Gonsorcikova, Lucie; Vaxillaire, Martine; Pruhova, Stepanka; Dechaume, Aurelie; Dusatkova, Petra; Cinek, Ondrej; Pedersen, Oluf; Froguel, Philippe; Hansen, Torben; Lebl, Jan",null,"Familial mild hyperglycemia associated with a novel ABCC8-V84I mutation within three generations","PEDIATRIC DIABETES",null,"English","Article",null,null,null,null,null,"ABCC8; diabetes; hyperglycemia; MODY; SUR1","NEONATAL DIABETES-MELLITUS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; CHANNEL SUBUNITS; GENE; DOMINANT","We present a unique case of a 19-year-old man with a positive family history of persistent mild hyperglycemia and a novel V84I mutation in ABCC8. The proband was initially detected to have fasting hyperglycemia (ranging 6.1-6.4 mmol/L) at the age of 12 years. Increased fasting blood glucose was also subsequently detected in five additional family members (in his twin brother, sister, mother, maternal aunt, and grandfather). The grandfather has been known to have mild diabetes since 30 years and has never been treated. After having excluded a causative mutation in five maturity-onset diabetes of the young genes (MODY1-4 and 6), we identified a novel ABCC8 V84I mutation, which segregated with autosomal dominant transmission of mild hyperglycemia within three generations. This mutation that is located in a conserved area of transmembrane domain TMD0 seems to be a rare cause of clinical phenotype resembling glucokinase-deficient diabetes.","[Gonsorcikova, Lucie; Pruhova, Stepanka; Dusatkova, Petra; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Vaxillaire, Martine; Dechaume, Aurelie; Froguel, Philippe] Univ Lille 2, Inst Pasteur, Lille Inst Biol, CNRS,UMR8090, Lille, France; [Pruhova, Stepanka] Charles Univ Prague, Fac Med 3, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, Gentofte, Denmark; [Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark","Lebl, J, Charles Univ Prague, Fac Med 2, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","jan.lebl@lfmotol.cuni.cz","Norway through the Norwegian Financial Mechanism [CZ0100]; Czech Ministry of Education [MSM 0021620814]; Czech Ministry of Health [MZ 000064203]","The study was supported by a grant from Norway through the Norwegian Financial Mechanism (No CZ0100), by an institutional grant from the Czech Ministry of Education (grant MSM 0021620814) and by an institutional grant from the Czech Ministry of Health (grant MZ 000064203). The authors would like to acknowledge the patient and his family. Klara Vesela is thanked for her technical assistance.",null,16,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,"10.1111/j.1399-5448.2010.00719.x","PEDIATR DIABETES","Pediatr. Diabetes","MAY",2011,12,3,"Part 2",null,null,266,269,null,null,4,"Endocrinology & Metabolism; Pediatrics","754XZ","ISI:000289892500009"]
["J","Kubrycht, J; Maxova, H; Nyc, O; Vajner, L; Novotna, J; Hezinova, A; Trnkova, A; Vrablova, K; Vytasek, R; Valouskova, V",null,null,null,"Kubrycht, J.; Maxova, H.; Nyc, O.; Vajner, L.; Novotna, J.; Hezinova, A.; Trnkova, A.; Vrablova, K.; Vytasek, R.; Valouskova, V.",null,"Isolation of Rat Lung Mast Cells for Purposes of One-Week Cultivation Using Novel Percoll Variant Percoll PLUS","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Hypoxia; Lung mast cells; Percoll; C-kit; Progenitor; Secretion","C-TYPE LECTIN; RBL-2H3 CELLS; MATRIX METALLOPROTEINASES; HISTAMINE-RELEASE; HYPOXIA; EXPRESSION; INTERLEUKIN-18; ACTIVATION; SEPARATION; VANCOMYCIN","Prolonged cultivation of separated rat lung mast cells (LMC) in vitro is necessary to better investigate a possible role of LMC in different stages of tissue remodeling induced by hypoxia. Rat lung mast cells (LMC) were separated using a protocol including an improved proteolytic extraction and two subsequent density gradient separations on Ficoll-Paque PLUS and a new generation of Percoll, i.e. Percoll PLUS. Instead of usual isotonic stock Percoll solution, an alternative \"asymptotically isotonic\" stock solution was more successful in our density separation of LMC on Percoll PLUS. Separated cells were cultivated for six days in media including stem cell factor, interleukins IL-3 and IL-6, and one of two alternative mixtures of antibiotics. These cultivations were performed without any contamination and with only rare changes in cell size and morphology. Model co-cultivation of two allogenic fractions of LMC often caused considerable rapid changes in cell morphology and size. In contrast to these observations no or rare morphological changes were found after cultivation under hypoxic conditions. In conclusions, we modified separation on Percoll PLUS to be widely used, altered LMC separation with respect to purposes of long-lasting cultivation and observed some model morphological changes of LMC.","[Kubrycht, J.; Maxova, H.; Vajner, L.; Novotna, J.; Hezinova, A.; Trnkova, A.; Vrablova, K.; Vytasek, R.; Valouskova, V.] Cardiovasc Res Ctr, Prague, Czech Republic; [Valouskova, V.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Maxova, H.; Hezinova, A.] Charles Univ Prague, Dept Pathol Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Vajner, L.; Vrablova, K.] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15000 5, Czech Republic; [Novotna, J.; Vytasek, R.] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15000 5, Czech Republic; [Nyc, O.] Charles Univ Prague, Dept Microbiol, Fac Med 2, Prague 15000 5, Czech Republic","Kubrycht, J, Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","jkub@post.cz","Grant Agency of the Czech Republic [305/08/0108]; Cardiovascular Research Centre [MSMT 1M0510]","The study was supported by the Grant Agency of the Czech Republic 305/08/0108 and by the Cardiovascular Research Centre MSMT 1M0510.",null,45,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,1,null,null,null,83,93,null,null,11,"Physiology","737IZ","ISI:000288563800009"]
["J","Pannasch, U; Vargova, L; Reingruber, J; Ezan, P; Holcman, D; Giaume, C; Sykova, E; Rouach, N",null,null,null,"Pannasch, Ulrike; Vargova, Lydia; Reingruber, Juergen; Ezan, Pascal; Holcman, David; Giaume, Christian; Sykova, Eva; Rouach, Nathalie",null,"Astroglial networks scale synaptic activity and plasticity","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA",null,"English","Article",null,null,null,null,null,"hippocampus; neuroglial interactions","LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL CELLS; GLUTAMATE UPTAKE; EXTRACELLULAR POTASSIUM; SILENT SYNAPSES; GLIAL-CELLS; TIME-COURSE; TRANSMISSION; EXCITABILITY; ASTROCYTES","Astrocytes dynamically interact with neurons to regulate synaptic transmission. Although the gap junction proteins connexin 30 (Cx30) and connexin 43 (Cx43) mediate the extensive network organization of astrocytes, their role in synaptic physiology is unknown. Here we show, by inactivating Cx30 and Cx43 genes, that astroglial networks tone down hippocampal synaptic transmission in CA1 pyramidal neurons. Gap junctional networking facilitates extracellular glutamate and potassium removal during synaptic activity through modulation of astroglial clearance rate and extracellular space volume. This regulation limits neuronal excitability, release probability, and insertion of postsynaptic AMPA receptors, silencing synapses. By controlling synaptic strength, connexins play an important role in synaptic plasticity. Altogether, these results establish connexins as critical proteins for extracellular homeostasis, important for the formation of functional synapses.","[Pannasch, Ulrike; Ezan, Pascal; Giaume, Christian; Rouach, Nathalie] CNRS, UMR 7241, Ctr Interdisciplinary Res Biol, F-75005 Paris, France; [Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006, Czech Republic; [Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006, Czech Republic; [Vargova, Lydia; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220, Czech Republic; [Reingruber, Juergen; Holcman, David] Ecole Normale Super, CNRS, UMR 8197, Inst Biol, F-75005 Paris, France; [Reingruber, Juergen; Holcman, David] Ecole Normale Super, INSERM, U1024, Dept Computat Biol & Math, F-75005 Paris, France; [Pannasch, Ulrike; Ezan, Pascal; Giaume, Christian; Rouach, Nathalie] Coll France, INSERM, U1050, F-75005 Paris, France","Rouach, N, CNRS, UMR 7241, Ctr Interdisciplinary Res Biol, F-75005 Paris, France","nathalie.rouach@college-de-france.fr","Human Frontier Science Program Organization ; Agence Nationale de la Recherche ; Institut National de la Sante et de la Recherche Medicale ; French Research Ministry ; Deutsche Forschungsgemeinschaft ; Franco Czech Barrande Program (Hubert Curien Program) ; Grant Agency of the Czech Republic [309/09/1597]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538]","We thank O. Chever, A. Tzingounis, D. Schmitz, and A. Koulakoff for helpful discussions and/or technical assistance, as well as K. Willecke for providing the Cx30<SUP>-/-</SUP>Cx43fl/fl:hGFAP-Cre mice. This work was supported by grants from the Human Frontier Science Program Organization (Career Development Award), Agence Nationale de la Recherche (Programme Jeunes Chercheurs), and Institut National de la Sante et de la Recherche Medicale (to N.R.); postdoctoral fellowships from the French Research Ministry and Deutsche Forschungsgemeinschaft (to U.P.); and a grant from the Franco Czech Barrande Program (Hubert Curien Program) (to N.R. and L.V.), Grant 309/09/1597 from the Grant Agency of the Czech Republic (to L.V. and E.S.), Grant AVOZ50390512 from the Academy of Sciences of the Czech Republic (to E.S.) and Grant 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic (to E.S.).",null,34,0,"NATL ACAD SCIENCES","WASHINGTON","2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA","0027-8424",null,"10.1073/pnas.1016650108","PROC NAT ACAD SCI USA","Proc. Natl. Acad. Sci. U. S. A.","MAY 17",2011,108,20,null,null,null,8467,8472,null,null,6,"Multidisciplinary Sciences","765OZ","ISI:000290719600076"]
["J","Pokorna, M; Necas, E; Skripsky, R; Kratochvil, J; Andrlik, M; Franek, O",null,null,null,"Pokorna, Milana; Necas, Emanuel; Skripsky, Roman; Kratochvil, Jaroslav; Andrlik, Michal; Franek, Ondrej",null,"How accurately can the aetiology of cardiac arrest be established in an out-of-hospital setting? Analysis by \"Concordance in Diagnosis Crosscheck Tables\"","RESUSCITATION",null,"English","Article",null,null,null,null,null,"Aetiology of cardiac arrest; Out-of-hospital care; Cardiopulmonary resuscitation; Thrombolytic therapy; Myocardial infarction; Pulmonary embolism","AUSTRALIAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; UTSTEIN STYLE; SUDDEN-DEATH; TASK-FORCE; SURVIVAL; DISEASE","Introduction: Several previous studies have focused on establishing the cause of cardiac arrest (CA) during cardiopulmonary resuscitation (CPR) provided in an out-of-hospital setting. Objectives: To analyze the ability of professional advanced life support providers to correctly establish the aetiology of cardiac arrest during out-of-hospital CPR. Study design: A retrospective cohort study analysing 211 cases of out-of-hospital cardiac arrest. Method: The aetiology assumed by out-of-hospital physicians was compared with the diagnosis that was later established by clinicians or pathologists. Results: Cases were sorted into five diagnostic groups and the overall diagnostic concordance was 74.4% (157 of 211 cases). The cardiac aetiology was presumed in 132 out of 211 patients and confirmed in 135 out of 211 patients. However, an analysis of individual cases of the cardiac causes of cardiac arrest revealed diagnostic matches in only 112 cases. Acute myocardial infarction (AMI) or pulmonary embolism (PE), both of which represent cases that can be potentially influenced by thrombolytic therapy, were presumed in 74 (53 + 21) and confirmed in 97 (77 + 20) cases, however with individual diagnostic matches in only 55 cases. Conclusion: This study demonstrates the importance of analysing concordance in presumed and definitive diagnosis of individual cases, since an overall comparison in a cohort of cases may be highly misleading. It introduces the method of the crosscheck table for visualization and comparison of presumed and final diagnoses. The two alternative approaches of inclusion rule for applying the thrombolytic therapy in out-of-hospital care were discussed with regard to the recent TROICA study. (C) 2010 Elsevier Ireland Ltd. All rights reserved.","[Pokorna, Milana; Skripsky, Roman; Kratochvil, Jaroslav; Franek, Ondrej] Emergency Med Serv Prague, Prague 10100 10, Czech Republic; [Pokorna, Milana; Kratochvil, Jaroslav] Univ Hosp Motol, Emergency Dept, Prague 15006, Czech Republic; [Pokorna, Milana; Skripsky, Roman] Charles Univ Prague, Fac Med 1, Dept Anesthesiol & Intens Care, Prague 14000, Czech Republic; [Necas, Emanuel; Andrlik, Michal] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague 12800, Czech Republic","Pokorna, M, Emergency Med Serv Prague, Korunni 98, Prague 10100 10, Czech Republic","MilanaP@seznam.cz","Ministry of Health of the Czech Republic [IGA NR/7970-3]; [MSM 0021620806]","The work was supported by the grants IGA NR/7970-3 provided by the Ministry of Health of the Czech Republic and MSM 0021620806. We would like to thank Petra Sukupova for her help in collecting data from the hospitals and all cooperative physicians of Prague's hospitals and departments of pathology.",null,40,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0300-9572",null,"10.1016/j.resuscitation.2010.11.026","RESUSCITATION","Resuscitation","APR",2011,82,4,null,null,null,391,397,null,null,7,"Critical Care Medicine; Emergency Medicine","750NS","ISI:000289555800006"]
["J","Sediva, A; Polouckova, A; Podrazil, M; Fronkova, E; Kalina, T",null,null,null,"Sediva, A.; Polouckova, A.; Podrazil, M.; Fronkova, E.; Kalina, T.",null,"Characterization of the B-cell compartment in a patient with Schnitzler syndrome","SCANDINAVIAN JOURNAL OF RHEUMATOLOGY",null,"English","Letter",null,null,null,null,null,null,"ANAKINRA",null,"[Sediva, A.; Polouckova, A.; Podrazil, M.] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague 15006, Czech Republic; [Fronkova, E.; Kalina, T.] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Sediva, A, Charles Univ Prague, Dept Immunol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","anna.sediv@fmotol.cuni.cz",null,null,null,10,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0300-9742",null,null,"SCAND J RHEUMATOL","Scand. J. Rheumatol.","MAR",2011,40,2,null,null,null,158,160,null,null,3,"Rheumatology","731RU","ISI:000288127800016"]
["J","Levova, K; Moserova, M; Kotrbova, V; Sulc, M; Henderson, CJ; Wolf, CR; Phillips, DH; Frei, E; Schmeiser, HH; Mares, J; Arlt, VM; Stiborova, M",null,null,null,"Levova, Katerina; Moserova, Michaela; Kotrbova, Vera; Sulc, Miroslav; Henderson, Colin J.; Wolf, C. Roland; Phillips, David H.; Frei, Eva; Schmeiser, Heinz H.; Mares, Jaroslav; Arlt, Volker M.; Stiborova, Marie",null,"Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model","TOXICOLOGICAL SCIENCES",null,"English","Article",null,null,null,null,null,"aristolochic acid; cytochrome P450; metabolism; DNA adducts; P-32-postlabeling","BALKAN ENDEMIC NEPHROPATHY; CHINESE HERBS NEPHROPATHY; DNA ADDUCT FORMATION; ANTICANCER DRUG ELLIPTICINE; PROSTAGLANDIN-H SYNTHASE; METABOLIC-ACTIVATION; UROTHELIAL CANCER; GENE-EXPRESSION; ENVIRONMENTAL-POLLUTANT; SUDAN-I","Aristolochic acid (AA) causes aristolochic acid nephropathy, Balkan endemic nephropathy, and their urothelial malignancies. To identify enzymes involved in the metabolism of aristolochic acid I (AAI), the major toxic component of AA we used HRN (hepatic cytochrome P450 [Cyp] reductase null) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes. AAI was demethylated by hepatic Cyps in vitro to 8-hydroxy-aristolochic acid I (AAIa), indicating that less AAI is distributed to extrahepatic organs in wild-type (WT) mice. Indeed, AAI-DNA-adduct levels were significantly higher in organs of HRN mice, having low hepatic AAI demethylation capacity, than in WT mice. Absence of AAI demethylation in HRN mouse liver was confirmed in vitro; hepatic microsomes from WT, but not from HRN mice, oxidized AAI to AAIa. To define the role of hepatic Cyps in AAI demethylation, modulation of AAIa formation by CYP inducers was investigated. We conclude that AAI demethylation is attributable mainly to Cyp1a1/2. The higher AAI-DNA adduct levels in HRN than WT mice were the result of the lack of hepatic AAI demethylation concomitant with a higher activity of cytosolic NAD(P)H:quinone oxidoreductase (Nqo1), which activates AAI. Mouse hepatic Cyp1a1/2 also activated AAI to DNA adducts under hypoxic conditions in vitro, but in renal microsomes, Por and Cyp3a are more important than Cyp1a for AAI-DNA adduct formation. We propose that AAI activation and detoxication in mice are dictated mainly by AAI binding affinity to Cyp1a1/2 or Nqo1, by their turnover, and by the balance between oxidation and reduction of AAI by Cyp1a.","[Levova, Katerina; Moserova, Michaela; Kotrbova, Vera; Sulc, Miroslav; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Henderson, Colin J.; Wolf, C. Roland] Biomed Res Inst, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; [Phillips, David H.; Arlt, Volker M.] Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumour Dis, Div Prevent Oncol, D-69120 Heidelberg, Germany; [Schmeiser, Heinz H.] German Canc Res Ctr, Res Grp Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; [Mares, Jaroslav] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Prague 15006 5, Czech Republic; [Mares, Jaroslav] Univ Hosp Motol, Prague 15006 5, Czech Republic","Stiborova, M, Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic","stiborov@natur.cuni.cz","Grant Agency of Czech Republic [303/09/0472, 305/09/H008]; Ministry of Education of Czech Republic [MSM0021620808, 1M0505]; Cancer Research UK ","The authors would like to thank to Grant Agency of Czech Republic (grants 303/09/0472, and 305/09/H008) and to the Ministry of Education of Czech Republic (grants MSM0021620808 and 1M0505). Work at the Biomedical Research Centre and Institute of Cancer Research is supported by Cancer Research UK.",null,77,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1096-6080",null,"10.1093/toxsci/kfr050","TOXICOL SCI","Toxicol. Sci.","MAY",2011,121,1,null,null,null,43,56,null,null,14,"Toxicology","753VG","ISI:000289807200005"]

{"sheet":"1-2011","index":3,"n_rows":331,"n_cols":60,"rows_kept":331,"cut":false,"hidden":false,"merged":[]}
["domácí autoři z/ze autoři celkem","domácí autoři","autoři celkem","autorský podíl","BIBLIODATA","URL","IF","TI","PT","AU","BA","ED","GP","AF","CA","TI","SO","SE","LA","DT","CT","CY","CL","SP","HO","DE","ID","AB","C1","RP","EM","FU","FX","CR","NR","TC","PU","PI","PA","SN","BN","DI","J9","JI","PD","PY","VL","IS","PN","SU","SI","BP","EP","AR","DI","PG","SC","GA","UT","UT"]
["4 z/ze 6",4,6,0.66666666666666663,"2011/78/1/27-33","http://www.achot.cz/detail.php?stat=425",1.6279999999999999,"Multidirectional Screw Fixation in the Treatment of Distal Radius Fractures Using Angle-Stable Plates","J","Vlcek, M; Landor, I; Visna, P; Vavrik, P; Sindelarova, J; Sosna, A",null,null,null,"Vlcek, M.; Landor, I.; Visna, P.; Vavrik, P.; Sindelarova, J.; Sosna, A.",null,"Multidirectional Screw Fixation in the Treatment of Distal Radius Fractures Using Angle-Stable Plates","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"intra-articular fractures of the distal radius; volar approach; angle-stable locking plate; multidirectional angle-stabile screw","DORSALLY DISPLACED FRACTURES; LOCKING PLATING SYSTEM; VOLAR PLATE; SURGICAL-TREATMENT; INTERNAL-FIXATION; OPEN REDUCTION; PART; PALMAR; COMPLICATIONS; MANAGEMENT","PURPOSE OF THE STUDY Intra-articular fractures of the distal radius are treated predominantly by open reduction and internal fixation with various types of angle-stable plates. In this study we compare functional and radiographic outcomes in patients with intra-articular distal radius fractures treated with either angle-stable plates with rigid-direction screw insertion or multidirectional angle-stable plates. MATERIAL AND METHODS The LCP group included 37 patients with an average age of 50 years (range 20-81 years) who were treated using angle-stable plates with rigid-direction screw insertion (LOP, Synthes). The APTUS group comprising 41 patients with an average age of 48.9 years (range 22-77 years) was treated by angle-stable implants in which screws can pivot freely in all directions (Aptus, Medartis). There was no significant difference between the groups in relation to fracture severity, age or other relevant characteristics. In all cases we used the volar approach. The final evaluation of treatment outcome was made at 12 months after surgery. We measured the range of wrist motion and hand grip strength, and compared the values with those obtained in the contralateral wrist. The results evaluated on the scoring systems of Gartland and Werley and of Castaing, and the DASH score were compared between the groups. The findings on radiographs were compared with the anatomical standard in the distal radius region. RESULTS In the LOP group, the average values, as compared with the contralateral side, were as follows: volar flexion, 84.2 %; dorsal flexion, 82.4 %; radial deviation, 83.2 %; ulnar deviation, 89.1 %; pronation, 98.6 %; supination, 97.4 %. In the APTUS group, the values in comparison with the other wrist were: volar flexion, 84.1 %; dorsal flexion, 91.8 %; radial deviation, 95.1 %; ulnar deviation, 92.8 %; pronation, 99.0 %; supination, 98.1 %. The values statistically comparable with the contralateral side were those in pronation, supination and hand grip strength in both groups. In addition, in the APTUS group, the values corresponding to the healthy wrist function were achieved in both radial and ulnar deviation. There were no differences in the values based on the scoring systems between the LOP and APTUS groups. As for the radiographic parameters, only the reconstruction of radial length was optimal. The other parameters differed from the anatomical standard. However, all patients met the criteria of successful healing of a distal radius fracture. Secondary fragment displacement during healing was recorded in two patients of the LOP group and in one of the APTUS group. Transient irritation of the median nerve was observed in five LOP group patients and in only one APTUS group patient. One patient in each group had an extensor tendon rupture. Reflex sympathetic dystrophy syndrome was diagnosed in two LOP group patients and in three APTUS group patients. DISCUSSION The surgical treatment of complex fractures of the distal radius using the angle-stable implants has generally achieved very good functional and radiographic outcomes with a low rate of complications. In the APTUS group, in contrast to the LOP group, the extent of radial and ulnar deviation corresponded to that found in the healthy wrist. The reason was a low-profile design of the plate and the screws, and the system with multidirectional angle-stable screws. The fewer cases of median nerve irritation in the APTUS group can be explained by the use of a different operative approach reducing the risk of direct mechanical nerve injury. In contrast to other authors, flexor tendon ruptures were not recorded in our groups. CONCLUSIONS The treatment of distal radius fractures by the angle-stable locking plate system from the volar approach achieved comparable functional and radiographic outcomes with both rigid-direction screw insertion and multidirectional screw insertion.","[Vlcek, M.; Landor, I.; Vavrik, P.; Sosna, A.] FN Motole, LF UK 1, Ortoped Klin 1, Prague 15006 5, Czech Republic; [Visna, P.] Zent Klin Bad Berka, Klin Orthopadie & Unfallchirug, Bad Berka, Germany; [Sindelarova, J.] Fak Strojni CVUT, Lab Biomech Cloveka, Prague, Czech Republic","Landor, I, FN Motol, LF UK 1, Ortoped Klin 1, V Uvalu 84, Prague 15006 5, Czech Republic","landor@atlas.cz",null,null,null,37,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","5415-01-01",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2011,78,1,null,null,null,27,33,null,null,7,"Orthopedics","731XJ","ISI:000288143500004",""]
["4 z/ze 6",4,6,0.66666666666666663,"2011/78/1/49-55","http://www.achot.cz/detail.php?stat=421",1.6279999999999999,"Comparison of in Vivo Characteristics of Polyethylene Wear Particles Produced by a Metal and a Ceramic Femoral Component in Total Knee Replacement","J","Veigl, D; Vavrik, P; Pokorny, D; Slouf, M; Pavlova, E; Landor, I",null,null,null,"Veigl, D.; Vavrik, P.; Pokorny, D.; Slouf, M.; Pavlova, E.; Landor, I.",null,"Comparison of in Vivo Characteristics of Polyethylene Wear Particles Produced by a Metal and a Ceramic Femoral Component in Total Knee Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,"Czech","Article",null,null,null,null,null,"total knee replacement; zirconia ceramic femoral component; comparative study; polyethylene wear; in vivo measurement","MOLECULAR-WEIGHT POLYETHYLENE; UHMWPE WEAR; TOTAL HIP; PERIPROSTHETIC OSTEOLYSIS; JOINT REPLACEMENT; SYNOVIAL-FLUID; ARTHROPLASTY; QUANTIFICATION; PROSTHESIS; TISSUES","PURPOSE OF THE STUDY The aim of the study was to evaluate in vivo and compare, in terms of the quality and number of ultra high-molecular polyethylene (UHMWPE) wear particles, total knee replacements of identical construction differing only in the material used for femoral component production, i.e., CoCrMo alloy or ZrO2 ceramics. MATERIAL AND METHODS Samples of pen-prosthetic granuloma tissue were collected in two patients with total knee replacement suffering from implant migration, who were matched in relevant characteristics. The primary knee replacement in Patient 1 with a CoCrMo femoral component was done 7.2 years and in Patient 2 with a ZrO2 implant 6.8 years before this assessment. The polyethylene wear-induced granuloma was analysed by the MORF method enabling us to assess the shape and size of wear debris and the IRc method for assessment of particle concentration. RESULTS In the granuloma tissue samples of Patient 1, on the average, particles were 0.30 mm in size and their relative volume was 0.19. In the Patient 2 tissue samples, the average size of particles was 0.33 mm and their relative volume was 0.26. There was no significant difference in either particle morphology or their concentration in the granuloma tissue between the two patients. DISCUSSION One of the options of how to reduce the production of polyethylene wear particles is to improve the tribological properties of contacting surfaces in total knee replacement by substituting a cobalt-chrome femoral component with a zirconia ceramic femoral component. The previous in vitro testing carried out with a mechanical simulator under conditions approaching a real weight-bearing in the human body did show a nearly three-fold decrease in the number of UHMWPE wear particles in zirconia components. The evaluation of granuloma tissue induced by the activity of a real prosthetic joint for nearly seven years, however, did not reveal any great difference in either quality or quantity of polyethylene debris between the two replacements. The difference of surface roughness between CoCrMo (Ra = 0.05) and ZrO2 (Ra = 0.02) components did not play any role in in vivo conditions. CONCLUSIONS In accordance with a previous clinical study, this evaluation of the quality and quantity of UHMWPE wear particles produced by a ceramic femoral component in vivo failed to demonstrate any advantage of zirconia ceramic components over the cobalt-chrome femoral components so far used.","[Veigl, D.; Vavrik, P.; Pokorny, D.; Landor, I.] I Ortoped Klin 1 LF UK, Prague 15000 5, Czech Republic; [Veigl, D.; Vavrik, P.; Pokorny, D.; Landor, I.] FN Motol, Prague, Czech Republic; [Slouf, M.; Pavlova, E.] Ustav Makromol Chem AV CR, Prague, Czech Republic","Vavrik, P, I Ortoped Klin 1 LF UK, V Uvalu 83, Prague 15000 5, Czech Republic","pvavrik@atlas.cz",null,null,null,49,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","5415-01-01",null,null,"ACTA CHIR ORTHOP TRAUMATOL CE","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2011,78,1,null,null,null,49,55,null,null,7,"Orthopedics","731XJ","ISI:000288143500008",""]
["8 z/ze 8",8,8,1,"2011/107/9/1295-1299","http://www.ncbi.nlm.nih.gov/pubmed/21349484",3.5750000000000002,"Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention","J","Veselka, J; Zemanek, D; Hajek, P; Maly, M; Adlova, R; Martinkovicova, L; Tomasov, P; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tomasov, Pavol; Tesar, David",null,"Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention","AMERICAN JOURNAL OF CARDIOLOGY",null,"English","Article",null,null,null,null,null,null,"PERIPROCEDURAL MYOCARDIAL-INFARCTION; PREPROCEDURAL STATIN THERAPY; RANDOMIZED-TRIAL; MICROEMBOLIZATION; METAANALYSIS; IMPACT","Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p = 0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p < 0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1295-1299)","[Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tomasov, Pavol; Tesar, David] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague, Czech Republic","Veselka, J, Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague, Czech Republic","veselka.josef@seznam.cz","Ministry of Health of the Czech Republic [00064203]","This work was supported by Grant 00064203 from the Ministry of Health of the Czech Republic.",null,18,0,"EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","BRIDGEWATER","685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA","9149-02-01",null,"10.1016/j.amjcard.2010.12.040","AMER J CARDIOL","Am. J. Cardiol.","MAY 1",2011,107,9,null,null,null,1295,1299,null,null,5,"Cardiac & Cardiovascular Systems","764CI","ISI:000290605600008",""]
["1 z/ze 18",1,18,5.5555555555555552E-2,"2011/35/6/836-844","http://www.ncbi.nlm.nih.gov/pubmed/21451365",4.0620000000000003,"Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial: Experiences and Preliminary Recommendations From the European Childhood Lymphoma Pathology Panel","J","Oschlies, I; Burkhardt, B; Chassagne-Clement, C; d'Amore, ES; Hansson, U; Hebeda, K; Mc Carthy, K; Kodet, R; Maldyk, J; Mullauer, L; Porwit, A; Schmatz, AI; Tinguely, M; Abramov, D; Wotherspoon, A; Zimmermann, M; Reiter, A; Klapper, W",null,null,null,"Oschlies, Ilske; Burkhardt, Birgit; Chassagne-Clement, Catherine; d'Amore, Emanuel S.; Hansson, Ulrika; Hebeda, Konnie; Mc Carthy, Keith; Kodet, Roman; Maldyk, Jadwiga; Muellauer, Leonhard; Porwit, Anna; Schmatz, Ana-Iris; Tinguely, Marianne; Abramov, Dimitry; Wotherspoon, Andrew; Zimmermann, Martin; Reiter, Alfred; Klapper, Wolfram",null,"Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial: Experiences and Preliminary Recommendations From the European Childhood Lymphoma Pathology Panel","AMERICAN JOURNAL OF SURGICAL PATHOLOGY",null,"English","Article",null,null,null,null,null,"MPAL; TdT; CD34; lymphoblastic; ALL; precursor; B-LBL; T-LBL","MERKEL CELL-CARCINOMA; TRANSCRIPTION FACTORS; ACUTE LEUKEMIAS; EXPRESSION; PAX5; SURVIVAL; PITFALL; LINEAGE; TDT","The majority of lymphoblastic (precursor cell) neoplasms presents as leukemias. Consequently, the guidelines for lineage determination and subtyping of precursor cell neoplasms were primarily established for flow cytometry methods. Large-scale studies of nonleukemic lymphoblastic lymphomas are lacking so far. We analyzed a large series of pediatric patients with lymphoblastic lymphoma treated within a prospective randomized trial (the Euro-LB 02 study). Among 193 lymphomas, in which a detailed immunohistochemical analysis was carried out, there were several unusual and diagnostically challenging morphologic and immunophenotypical variants. These included 11 lymphomas with mixed phenotypes expressing markers of at least 2 hematopoietic lineages, 7 terminal deoxynucleotide transferase-negative lymphoblastic lymphomas, and 3 undifferentiated hematopoietic neoplasms that could not be assigned to any lineage with certainty. Our data indicate that World Health Organzation guidelines for lineage determination and subtyping of precursor cell leukemia need to be adapted before they can be applied to immunohistochemical diagnosis of lymphoma. Using the experience from this cohort we suggest a resource-saving diagnostic staining panel for the immunohistochemical analysis of precursor cell neoplasms in formalin-fixed paraffin-embedded tissue.","[Oschlies, Ilske; Abramov, Dimitry; Klapper, Wolfram] Univ Kiel, Dept Pathol, Hematopathol Sect, D-2300 Kiel, Germany; [Oschlies, Ilske; Abramov, Dimitry; Klapper, Wolfram] Univ Kiel, Lymph Node Registry, D-2300 Kiel, Germany; [Burkhardt, Birgit; Zimmermann, Martin; Reiter, Alfred] Univ Giessen, NHL BFM Study Ctr, Dept Pediat Hematol & Oncol, Giessen, Germany; [Schmatz, Ana-Iris] Leibniz Univ Hannover, Dept Pediat Hematol, D-30167 Hannover, Germany; [Schmatz, Ana-Iris] Leibniz Univ Hannover, Dept Oncol, D-30167 Hannover, Germany; [Chassagne-Clement, Catherine] Ctr Leon Berard, Dept Biopathol, F-69373 Lyon, France; [d'Amore, Emanuel S.] Osped San Bortolo, Dept Pathol, Vicenza, Italy; [Hansson, Ulrika] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Porwit, Anna] Karolinska Univ Hosp & Inst, Dept Pathol, Stockholm, Sweden; [Hebeda, Konnie] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands; [Mc Carthy, Keith] Chettenham Gen Hosp, Dept Pathol, Cheltenham, Glos, England; [Wotherspoon, Andrew] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England; [Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague, Czech Republic; [Maldyk, Jadwiga] Childrens Hosp, Dept Pathol, Warsaw, Poland; [Tinguely, Marianne] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Muellauer, Leonhard] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Kodet, Roman] Charles Univ Prague, Fac Hosp, Prague, Czech Republic","Klapper, W, Univ Hosp Schleswig Holstein, Hematopathol Sect, Arnold Heller Str 3,Haus 14, D-24105 Kiel, Germany","wklapper@path.uni-kiel.de","Deutsche Krebshilfe Bonn [102595, 107813]; national study groups of participating centers ; TransAid foundation ; Kinderkrebsinitiative Buchholz, Holm-Seppensen, Germany ; Kinder-Krebs-Initiative Buchholz, Holm-Seppensen ; national study groups for pediatric Non-Hodgkin Lymphoma of the participating pathologists ; Deutsche Krebshilfe [107813]","Supported by the Deutsche Krebshilfe Bonn (projekt Nr. 102595 and 107813) and national study groups of participating centers. D. A. was supported by the TransAid foundation. W. K. and I.O. were supported by the Kinderkrebsinitiative Buchholz, Holm-Seppensen, Germany. Supported by the Kinder-Krebs-Initiative Buchholz, Holm-Seppensen and the national study groups for pediatric Non-Hodgkin Lymphoma of the participating pathologists. The NHL-BFM study center as the international coordination center of the trial was supported by the Deutsche Krebshilfe (grant No. 107813).",null,29,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0147-5185",null,"10.1097/PAS.0b013e318213e90e","AMER J SURG PATHOL","Am. J. Surg. Pathol.","JUN",2011,35,6,null,null,null,836,844,null,null,9,"Pathology; Surgery","763NW","ISI:000290567400007",""]
["1 z/ze 12",1,12,8.3333333333333329E-2,"2011/112/4/759-773","http://www.ncbi.nlm.nih.gov/pubmed/21317165",3.0830000000000002,"A Double-Blind, Randomized, Multicenter Study of MP4OX for Treatment of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty Under Spinal Anesthesia","J","van der Linden, P; Gazdzik, TS; Jahoda, D; Heylen, RJ; Skowronski, JC; Pellar, D; Kofranek, I; Gorecki, AZ; Fagrell, B; Keipert, PE; Hardiman, YJ; Levy, H",null,null,null,"van der Linden, Philippe; Gazdzik, Tadeusz S.; Jahoda, David; Heylen, Rene J.; Skowronski, Jan C.; Pellar, David; Kofranek, Ivo; Gorecki, Andrzej Z.; Fagrell, Bengt; Keipert, Peter E.; Hardiman, Yun J.; Levy, Howard","6090 Study Investigators","A Double-Blind, Randomized, Multicenter Study of MP4OX for Treatment of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty Under Spinal Anesthesia","ANESTHESIA AND ANALGESIA",null,"English","Article",null,null,null,null,null,null,"ACUTE-RENAL-FAILURE; ACID-BASE STATUS; HEMOGLOBIN MP4; UNCONTROLLED HEMORRHAGE; ORTHOPEDIC-SURGERY; ANESTHETIZED SWINE; BLOOD SUBSTITUTES; ELDERLY-PATIENTS; OXYGEN; HEMOSPAN","BACKGROUND: MP4OX (oxygenated polyethylene glycol-modified hemoglobin) is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. In this study, we investigated the ability of MP4OX to treat hypotensive episodes. In addition, the tolerability profile of MP4OX in a large surgical population was established. METHODS: Patients from 21 study sites in 5 countries, scheduled to undergo primary hip arthroplasty under spinal anesthesia, were randomized in a double-blind manner to receive MP4OX or hydroxyethyl starch (HES) solution (Voluven (R); HES 130/0.4). Patients received the first 250-mL dose of investigational product when systolic blood pressure decreased to the predefined dosing trigger. A second 250-mL dose was given only if the systolic blood pressure decreased to the same trigger level after administration of the first dose. The primary efficacy outcome was total duration of all hypotensive episodes during surgery and the first 6 hours after skin closure. RESULTS: Of the 474 patients randomized, 405 reached the dosing trigger and received at least 1 dose. The mean total duration of all hypotensive episodes was significantly shorter (P < 0.0001) in the MP4OX group (52.4 +/- 71.50 minutes; range, 3-442 minutes) compared with the HES group (137.6 +/- 120.21 minutes; range, 5-435 minutes). The overall incidence of adverse events (AEs) in the intent-to-treat population was similar between the MP4OX and HES groups (75.2% vs 73.4%; P = 0.733). Transient increases in laboratory values were reported in more patients in the MP4OX group versus HES controls for aspartate aminotransferase (13.4% vs 7.4%; P = 0.052), alanine aminotransferase (6.9% vs 4.9%; P = 0.409), lipase (9.7% vs 3.6%; P = 0.015), and troponin (8.1% vs 2.0%; P = 0.006). There was no significant difference in the incidence of serious AEs reported (6.4% in MP4OX group vs 3.0% in HES controls; P = 0.106). Certain AEs did occur more frequently in the MP4OX group, including nausea (23.8% vs 14.3%; P = 0.016), bradycardia (14.9% vs 5.9%; P = 0.003), hypertension (8.4% vs 2.5%; P = 0.009), and oliguria (5.9% vs 1.5%; P = 0.019). The composite morbidity and ischemia end points did not reveal any differences between the 2 treatment groups. CONCLUSIONS: Administration of MP4OX achieved the end point of treating perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. The study was not powered to demonstrate clinical benefit based on the composite morbidity or ischemia outcomes. Although efficacy end points with sufficient power were met, MP4OX is not being proposed for use in routine surgery where the risk-benefit profile would not be favorable based on the safety profile demonstrated in this study. (Anesth Analg 2011; 112: 759-73)","[Keipert, Peter E.; Hardiman, Yun J.; Levy, Howard] Sangart Inc, San Diego, CA 92121 USA; [van der Linden, Philippe] CHU Brugmann, Dept Anesthesiol, Brussels, Belgium; [Gazdzik, Tadeusz S.] Wojewodzki Szpital Specjalistyczny 5, Katedra & Oddzial Klin Ortoped, Sosnowiec, Poland; [Jahoda, David] Ortoped Klin, Fakultni Nemocnice V Motole 1, Prague, Czech Republic; [Heylen, Rene J.] ZOL Genk, Dept Anesthesiol, Genk, Belgium; [Skowronski, Jan C.] Samodzielny Publ Szpital Klin AM, Klin Ortoped & Traumatol AMB, Bialystok, Poland; [Pellar, David] Fakultni Nemocnice Hradec Kralove, Ortoped Klin, Hradec Kralove, Czech Republic; [Kofranek, Ivo] Fakultni Nemocnice Bulovce, Ortoped Klin, Prague, Czech Republic; [Gorecki, Andrzej Z.] Szpital Klin Dzieciatka Jezus, Katedra & Klin Ortoped & Traumatol, Warsaw, Poland; [Fagrell, Bengt] Karolinska Inst, Stockholm, Sweden; [Fagrell, Bengt] Karolinska Univ Hosp, Stockholm, Sweden","Levy, H, Sangart Inc, 6175 Lusk Blvd, San Diego, CA 92121 USA","hlevy@sangart.com","Sangart, Inc., San Diego, CA ","Sponsored and supported by Sangart, Inc., San Diego, CA.",null,34,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","2999-03-01",null,"10.1213/ANE.0b013e31820c7b5f","ANESTH ANALG","Anesth. Analg.","APR",2011,112,4,null,null,null,759,773,null,null,15,"Anesthesiology","739ET","ISI:000288697000005",""]
["1 z/ze 5",1,5,0.2,"2011/46/4/300-301","http://www.ncbi.nlm.nih.gov/pubmed/21414820",2.9009999999999998,"Can mutations in the ribosomal protein S26 (RPS26) gene lead to Klippel-Feil syndrome in Diamond-Blackfan anemia patients? An update from the Czech Diamond-Blackfan Anemia registry","J","Cmejla, R; Ludikova, B; Pospisilova, D; Sukova, M; Blatny, J",null,null,null,"Cmejla, Radek; Ludikova, Barbora; Pospisilova, Dagmar; Sukova, Martina; Blatny, Jan",null,"Can mutations in the ribosomal protein S26 (RPS26) gene lead to Klippel-Feil syndrome in Diamond-Blackfan anemia patients? An update from the Czech Diamond-Blackfan Anemia registry","BLOOD CELLS MOLECULES AND DISEASES",null,"English","Letter",null,null,null,null,null,null,null,null,"[Ludikova, Barbora; Pospisilova, Dagmar] Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Cmejla, Radek] Inst Hematol & Blood Transfus, Dept Cell Physiol, CR-12820 Prague, Czech Republic; [Sukova, Martina] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Blatny, Jan] Univ Hosp Brno, Dept Pediat Hematol, Brno, Czech Republic","Pospisilova, D, Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic","pospisid@fnol.cz",null,null,null,8,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1079-9796",null,"10.1016/j.bcmd.2011.02.003","BLOOD CELLS MOLECULES DIS","Blood Cells Mol. Dis.","APR 15",2011,46,4,null,null,null,300,301,null,null,2,"Hematology","753DV","ISI:000289746800007",""]
["2 z/ze 4",2,4,0.5,"2011/12//-","http://www.ncbi.nlm.nih.gov/pubmed/21406108",2.84,"Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: Case report","J","Vasovcak, P; Senkerikova, M; Hatlova, J; Krepelova, A",null,null,null,"Vasovcak, Peter; Senkerikova, Maria; Hatlova, Jana; Krepelova, Anna",null,"Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: Case report","BMC MEDICAL GENETICS",null,"English","Article",null,null,null,null,null,null,"SYNDROME PLEASE STAND; GASTROINTESTINAL POLYPOSIS; GERMLINE MUTATIONS; PTEN/MMAC1 GENE; DISEASE; HAMARTOMA; PATHWAY; WILL","Background: Cowden syndrome (CS) is a cancer predisposition syndrome associated with increased risk of breast, thyroid, and endometrial cancers, and is characterized by development of benign mucocutaneous lesions. Case presentation: Here we report on a 58-year-old woman with multiple primary malignancies and subtle mucocutaneous lesions such as small polyps and wart-like papulas. Over a period of 23 years, she developed various malignant neoplasms including thyroid, ovarian, stomach, and colon carcinomas, and a benign meningioma. Direct sequencing analysis of the PTEN gene revealed a novel germline mutation (c.438delT, p.Leu146X). Conclusion: This case demonstrates that Cowden syndrome is a multi-system disease that can result in the development of multiple malignant and benign tumors.","[Vasovcak, Peter; Krepelova, Anna] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Vasovcak, Peter; Krepelova, Anna] Univ Hosp Motol, Prague, Czech Republic; [Senkerikova, Maria] Univ Hosp, Dept Med Genet, Hradec Kralove, Czech Republic; [Hatlova, Jana] Fac Med, Fingerlands Dept Pathol, Hradec Kralove, Czech Republic","Vasovcak, P, Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic","pevas78@hotmail.com","[VZ MZO 00064203]","Supported by: VZ MZO 00064203",null,28,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,"10.1186/1471-2350-12-38","BMC MED GENET","BMC Med. Genet.","MAR 15",2011,12,null,null,null,null,null,null,38,null,4,"Genetics & Heredity","741HR","ISI:000288855300001",""]
["7 z/ze 7",7,7,1,"2011/112/4/165-169","http://www.ncbi.nlm.nih.gov/pubmed/21585120",0.317,"Risk factor analysis for early mortality and morbidity following pneumonectomy for non-small cell lung cancer","J","Stolz, A; Pafko, P; Harustiak, T; Smejkal, M; Simonek, J; Schutzner, J; Lischke, R",null,null,null,"Stolz, A.; Pafko, P.; Harustiak, T.; Smejkal, M.; Simonek, J.; Schutzner, J.; Lischke, R.",null,"Risk factor analysis for early mortality and morbidity following pneumonectomy for non-small cell lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,"English","Article",null,null,null,null,null,"pneumonectomy; mortality; lung cancer","BRONCHOPLEURAL FISTULA; INDUCTION CHEMOTHERAPY; COMPLICATIONS; RESECTION; THERAPY; CARCINOMA; INCREASE","Objectives: The purpose of this report is to analyze factors affecting morbidity and mortality following pneumonectomy for non-small cell lung cancer (NSCLC). Methods: We reviewed our institutional experience with all consecutive patients undergoing pneumonectomy for NSCLC from 1998 to 2010. Patients were analyzed with regard to hospital mortality and morbidity and long-term outcome. Results: There were 310 patients following pneumonectomy. Overall 30-day mortality rate was 5.5%. Chronic obstructive pulmonary disease, induction therapy, smoking habits and obesity had no statistical influence on short-term outcome. Coronary artery disease and respiratory failure were identified as risk factors for increased 30-day mortality (p<0.01). Right pneumonectomy and presence of respiratory failure with mechanical ventilation increases the incidence of bronchopleural fistula (p<0.01). Conclusions: Patients with right pneumonectomies are at increased risk. Coronary artery disease and respiratory failure adversely affect morbidity and mortality after this procedure (Tab. 3, Ref. 19). Full Text in free PDF www.bmj.sk.","[Stolz, A.; Pafko, P.; Harustiak, T.; Smejkal, M.; Simonek, J.; Schutzner, J.; Lischke, R.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, CZ-15000 Prague 5, Czech Republic","Stolz, A, Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, V Uvalu 84, CZ-15000 Prague 5, Czech Republic","stolz@seznam.cz",null,null,null,19,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","9248-06-01",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,4,null,null,null,165,169,null,null,5,"Medicine, General & Internal","749WW","ISI:000289503300002",""]
["7 z/ze 7",7,7,1,"2011/112/4/174-176","http://www.ncbi.nlm.nih.gov/pubmed/21585122",0.317,"Time trend in the surgical therapy of lung cancer","J","Stolz, A; Pafko, P; Lischke, R; Harustiak, T; Simonek, J; Schutzner, J; Adamek, S",null,null,null,"Stolz, A.; Pafko, P.; Lischke, R.; Harustiak, T.; Simonek, J.; Schutzner, J.; Adamek, S.",null,"Time trend in the surgical therapy of lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,"English","Article",null,null,null,null,null,"lung cancer; mortality; time trends","CARCINOMA; RESECTION; SURVIVAL; LONG","Background: The purpose of our study was to clarify results of surgery for non-small cell lung cancer (NSCLC) and its time trends. Methods: We retrospectively reviewed our prospective database of patients who underwent surgery for NSCLC between 1998 and 2009 in our institution. Patients were divided into two equal 6-year periods according to the year of surgery (1998-2003 and 2004-2009). Results: One thousand, four hundred and twelve patients underwent operation for NSCLC. We performed 985 lobectomies with 30-days mortality of 1.8 % and 300 pneumonectomies with 30-days mortality of 5.7 %. Median of survival of all 1412 patients was 4.3 year and 5-year survival was 45 %. The percentage of female patients, lobectomies and adenocarcinomas increased over time, as well as the age of our patients. Outcome improved over time, with significant decrease in a 30-days mortality after pneumonectomy (8.2 % vs 2.3 %, p=0.029). The overall 3-year survival improved in patients with stage III (30 % vs 40 %, p=0.012). Conclusion: Outcomes of lung resection for NSCLC improved over time despite a worsening of some elements of preoperative status. The shift in histological distribution was associated with an increasing proportion of patients with stage I, a lower operative mortality and better 3- and 5-year survival. These trends are due to improvement of preoperative evaluation, preoperative and postoperative care (Tab. 1, Fig. 2, Ref. 9). Full Text in free PDF www.bmj.sk.","[Stolz, A.; Pafko, P.; Lischke, R.; Harustiak, T.; Simonek, J.; Schutzner, J.; Adamek, S.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, CZ-15000 Prague 5, Czech Republic","Adamek, S, Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, V Uvalu 84, CZ-15000 Prague 5, Czech Republic","sadamek@post.cz",null,null,null,9,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","9248-06-01",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,4,null,null,null,174,176,null,null,3,"Medicine, General & Internal","749WW","ISI:000289503300004",""]
["1 z/ze 13",1,13,7.6923076923076927E-2,"2011/32/1/74-79","http://www.ncbi.nlm.nih.gov/pubmed/20966084",4.7949999999999999,"DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (Tp53, p21(CDKNIA), BCL2 and BAX) with respect to occupational exposure to styrene","J","Hanova, M; Vodickova, L; Vaclavikova, R; Smerhovsky, Z; Stetina, R; Hlavac, P; Naccarati, A; Slyskova, J; Polakova, V; Soucek, P; Kumar, R; Hemminki, K; Vodicka, P",null,null,null,"Hanova, Monika; Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Stetina, Rudolf; Hlavac, Pavel; Naccarati, Alessi; Slyskova, Jana; Polakova, Veronika; Soucek, Pavel; Kumar, Rajiv; Hemminki, Kari; Vodicka, Pavel",null,"DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (Tp53, p21(CDKNIA), BCL2 and BAX) with respect to occupational exposure to styrene","CARCINOGENESIS",null,"English","Article",null,null,null,null,null,null,"SINGLE-STRAND BREAKS; POLYMORPHISMS; P53; WORKERS; ASSOCIATION; BIOMARKERS; P21; SUSCEPTIBILITY; P21(WAF1/CIP1); LYMPHOCYTES","We studied the relationship between DNA damage, DNA repair rates and messenger RNA (mRNA) expression levels of cell cycle genes TP53, p21(CDKNIA), BCL2 and BAX in a group of 71 styrene-exposed workers and 51 control individuals. The exposure was assessed by measuring the concentration of styrene at workplace and in blood. Parameters of DNA damage [measured as single-strand breaks (SSBs) and endonuclease III-sensitive sites], gamma-irradiation-specific DNA repair rates and mRNA levels of studied genes were analyzed in peripheral blood lymphocytes. The workers were divided into low (<50 mg/m(3)) and high (>50 mg/m(3)) styrene exposure groups. We found negative correlations between mRNA expression of TP53, BCL2, BAX and styrene exposure (P < 0.001 for all parameters). In contrast, p21(CDKNIA) mRNA expression significantly increased with increasing styrene exposure (P = 0.001). SSBs and endonuclease Insensitive sites increased with increasing mRNA levels of TP53 (P < 0.001 for both) and BCL2 (P = 0.038, P = 0.002, respectively), whereas the same parameters decreased with increasing mRNA levels of p21(CDKNIA) (P < 0.001, P = 0.007, respectively). gamma-Irradiation-specific DNA repair rates increased with p21(CDKNIA) mRNA levels up to the low exposure level (P = 0.044). Our study suggests a possible relationship between styrene exposure, DNA damage and transcript levels of key cell cycle genes.","[Hanova, Monika; Vodickova, Ludmila; Naccarati, Alessi; Slyskova, Jana; Polakova, Veronika; Vodicka, Pavel] Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Prague 4, Czech Republic; [Hanova, Monika; Slyskova, Jana] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, CR-12844 Prague 2, Czech Republic; [Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Stetina, Rudolf] Purkinje Mil Med Acad, Dept Toxicol, Hradec Kralove 50001, Czech Republic; [Hlavac, Pavel] Dept Occupat Med, Reg Hyg Stn, Hradec Kralove 50101, Czech Republic; [Kumar, Rajiv; Hemminki, Kari] DKFZ, German Canc Res Ctr, D-69120 Heidelberg, Germany","Vodicka, P, Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Videnska 1083, Prague 4, Czech Republic","pvodicka@biomed.cas.cz","Grant Agency of the Academy of Sciences of the CR [IAA500390806]; Grant Agency of the Czech Republic-The Czech Science Foundation (Grantova agentura Ceske republiky) [310/07/1430, A/CZ0046/2/0012]","The Grant Agency of the Academy of Sciences of the CR (IAA500390806), Grant Agency of the Czech Republic-The Czech Science Foundation (Grantova agentura Ceske republiky) (310/07/1430, A/CZ0046/2/0012).",null,36,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,"10.1093/carcin/bgq213","CARCINOGENESIS","Carcinogenesis","JAN",2011,32,1,null,null,null,74,79,null,null,6,"Oncology","707RF","ISI:000286303000012",""]
["6 z/ze 7",6,7,0.8571428571428571,"2011/44/2/183-191","http://www.ncbi.nlm.nih.gov/pubmed/21401760",2.9169999999999998,"Immobilization of thrombocytes on PCL nanofibres enhances chondrocyte proliferation in vitro","J","Jakubova, R; Mickova, A; Buzgo, M; Rampichova, M; Prosecka, E; Tvrdik, D; Amler, E",null,null,null,"Jakubova, R.; Mickova, A.; Buzgo, M.; Rampichova, M.; Prosecka, E.; Tvrdik, D.; Amler, E.",null,"Immobilization of thrombocytes on PCL nanofibres enhances chondrocyte proliferation in vitro","CELL PROLIFERATION",null,"English","Article",null,null,null,null,null,null,"PLATELET-RICH PLASMA; STEM-CELLS; CHONDROGENIC DIFFERENTIATION; TISSUE-REPAIR; FIBROCYTES; EXPANSION; MATRIX","Objectives: The aim of this study was to develop functionalized nanofibres as a simple delivery system for growth factors (GFs) and make nanofibre cell-seeded scaffold implants a one-step intervention. Materials and methods: We have functionalized polycaprolactone (PCL) nanofibres with thrombocytes adherent on them. Immobilized, these thrombocytes attached to nanofibre scaffolds were used as a nanoscale delivery system for native (autologous) proliferation and differentiation factors, in vitro. Pig chondrocytes were seeded on the thrombocyte-coated scaffolds and levels of proliferation and differentiation of these cells were compared with those seeded on non-coated scaffolds. Results: Immobilized thrombocytes on PCL nanofibres effectively enhanced chondrocyte proliferation due to time-dependent degradation of thrombocytes and release of their GFs. Conclusions: These simply functionalized scaffolds present new possibilities for nanofibre applications, as smart cell scaffolds equipped with a GF delivery tool.","[Jakubova, R.; Mickova, A.; Buzgo, M.; Prosecka, E.; Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Motol, Czech Republic; [Jakubova, R.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague 15006 5, Motol, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Gen Teaching Hosp, Prague 15006 5, Motol, Czech Republic; [Buzgo, M.] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague 15006 5, Motol, Czech Republic","Jakubova, R, Charles Univ Prague, Fac Med 2, Inst Biophys, Uvalu 84, Prague 15006 5, Motol, Czech Republic","jakubova@biomed.cas.cz","Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130, 1M0510, P304/10/1307]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151]; EU [7E09088]; Grant Agency of the Charles University [119009, 96610, 119209, 97110, 80009]","This study was supported by the Academy of Sciences of the Czech Republic (Institutional research plans AV0Z50390703 and AV0Z50390512), Ministry of Education, Youth and Sports of the Czech Republic (research programs NPV II 2B06130, 1M0510, P304/10/1307), and Grant Agency of the Academy of Sciences grant no. IAA500390702 and by Czech Science Foundation grant no. GA202/09/1151, EU project BIOSCENT ID number 7E09088, the Grant Agency of the Charles University grants No.119009, 96610, 119209, 97110, 80009.",null,32,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0960-7722",null,"10.1111/j.1365-2184.2011.00737.x","CELL PROLIFERATION","Cell Prolif.","APR",2011,44,2,null,null,null,183,191,null,null,9,"Cell Biology","735XW","ISI:000288455000009",""]
["2 z/ze 2",2,2,1,"2011/74/2/197-200","není",0.246,"Bilateral Syphylitic Chorioretinitis in a 33-year-old Pervitin User","J","Darsova, D; Dotrelova, D",null,null,null,"Darsova, D.; Dotrelova, D.",null,"Bilateral Syphylitic Chorioretinitis in a 33-year-old Pervitin User","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,"Czech","Article",null,null,null,null,null,"atypical form of posterior uveitis; neurochorioretinitis; neurosyphilis; syphilis","SYPHILIS","Neurochorioretinitis is an inflammatory process affecting the optic nerve, choroid and retina. Neurochoroiditis is the least frequent type of optic neuritis. It is most often associated with viral infections and cat-scratch fever, less common with syphilis and Lyme disease The authors describe the clinical course of neurochoroiditis in a 33-year-old, otherwise healthy woman who was referred to our clinic with acute decreased central visual acuity (6/60) in the right eye. She had complained of headache, low-grade fever, hoarseness and generalized Skin rash four months previously. However, her symptoms had resolved spontaneously. She reported pervitin (methyl amphetamine) abuse within the previous year. Ophthalmic examination disclosed bilateral neurochorioretinitis, perivasculitis and a dusty vitreous haze. Fluorescein angiography revealed vasculitis. Positive direct and indirect treponemal tests confirmed a diagnosis of syphylis. Early recognition of the clinical manifestation of syphilis and prompt commencement of treatment with crystalline penicillin improved functional and anatomical changes in both eyes within four weeks. This data should may helpful in the exact diagnosis of neurosyphilis. The case report illustrates syphilis diagnosed by an ophthalmologist in terms of the atypical form of posterior uveitis.","[Darsova, D.] FN Motole, Prague 15006 5, Czech Republic; [Darsova, D.] Ocni Klin & Dospelych 2 LF UK, Prague 15006 5, Czech Republic","Darsova, D, Ocni Klin & Dospelych 2 LF UK, V Uvalu 84, Prague 15006 5, Czech Republic","denisa.darsova@centrum.cz",null,null,null,9,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESKA SLOV NEUROL NEUROCHIR","Cesk. Slov. Neurol. Neurochir.",null,2011,74,2,null,null,null,197,200,null,null,4,"Neurosciences; Surgery","751GG","ISI:000289604900009",""]
["1 z/ze 1",1,1,1,"2011/55/1/82-89","není",0.22600000000000001,"Autobiographies of persons with autism: unknown views on inner experience of autistic handicap","J","Hrdlicka, M",null,null,null,"Hrdlicka, Michal",null,"Autobiographies of persons with autism: unknown views on inner experience of autistic handicap","CESKOSLOVENSKA PSYCHOLOGIE",null,"Czech","Article",null,null,null,null,null,"autism; Asperger syndrome; autobiographies",null,"The article analyses three autobiographies of autistic individuals translated into the Czech language Nobody nowhere (Donna Williams), Life behind glass (Wendy Lawson), and Life with Asperger syndrome: a story of psychotherapy (Christine Preissmann). It shows, how the authors describe their specific symptoms and interests, family and partner relationships and career. The analysis focuses on strategies that were selected by the authors for coping with the autistic handicap. It comes to a conclusion that autistic persons consider different symptoms to be the worst than those conventionally described in textbooks and monographs on autism. In these three autobiographies, sensory overload in stressful situations was estimated from the subjective point of view to be the most unpleasant symptom.","Lekarska Fak UK Praha 1, Detska Psychiat Klin, LF UK & FN Motol 2, Prague 15006 5, Motol, Czech Republic","Hrdlicka, M, Lekarska Fak UK Praha 1, Detska Psychiat Klin, LF UK & FN Motol 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic","Michal.Hrdlicka@lfmotol.cuni.cz",null,null,null,22,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2011,55,1,null,null,null,82,89,null,null,8,"Psychology, Multidisciplinary","743NE","ISI:000289024200008",""]
["7 z/ze 9",7,9,0.77777777777777779,"2011/74/4/445-452","http://www.ncbi.nlm.nih.gov/pubmed/21138463",3.2010000000000001,"Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages","J","Soucek, O; Lebl, J; Snajderova, M; Kolouskova, S; Rocek, M; Hlavka, Z; Cinek, O; Rittweger, J; Sumnik, Z",null,null,null,"Soucek, Ondrej; Lebl, Jan; Snajderova, Marta; Kolouskova, Stanislava; Rocek, Miloslav; Hlavka, Zdenek; Cinek, Ondrej; Rittweger, Joern; Sumnik, Zdenek",null,"Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages","CLINICAL ENDOCRINOLOGY",null,"English","Article",null,null,null,null,null,null,"QUANTITATIVE COMPUTED-TOMOGRAPHY; GROWTH-HORMONE TREATMENT; PROXIMAL RADIUS; FRACTURES; THERAPY; ABSORPTIOMETRY; OSTEOPOROSIS; CHILDREN; SPINE; SIZE","P>Objective An increased rate of fractures has been reported in patients with Turner syndrome (TS). We aimed to assess bone geometry and volumetric bone mineral density (vBMD) at the radius in girls with TS and to evaluate the relationships between bone parameters and fracture history. Methods and design Sixty-seven girls with TS aged 6-19 years treated currently or in the past with growth hormone (GH) and/or oestrogens were examined using peripheral quantitative computed tomography. Results were compared to reference data. Results Cortical area and cortical thickness were low in all age groups (all P < 0 center dot 001). Height-adjusted total bone area at the diaphysis was increased in prepubertal and postpubertal girls (mean Z-score 1 center dot 0, P < 0 center dot 05 for both) and normal in the pubertal group (mean Z-score 0 center dot 1). Cortical vBMD was decreased (mean age-specific Z-scores -2 center dot 0, -1 center dot 6 and -1 center dot 0 for prepubertal, pubertal and postpubertal groups, respectively, P < 0 center dot 01 for all groups). Height- , age- and cortical thickness-adjusted cortical vBMD was positively correlated to the duration of GH therapy (P = 0 center dot 012) and to oestrogen administration (P = 0 center dot 047). Girls with a history of fractures had lower total vBMD at the metaphysis compared to nonfractured TS girls (mean Z-scores -1 center dot 7 vs -0 center dot 9, P = 0 center dot 04). Conclusions There is a cortical bone deficit in girls with TS characterized by low cortical area, thin cortex and probably decreased cortical vBMD. Early commencement of GH therapy, as well as oestrogen replacement, is associated with higher cortical vBMD. Further studies should investigate the potential causality of this relation.","[Soucek, Ondrej; Lebl, Jan; Snajderova, Marta; Kolouskova, Stanislava; Cinek, Ondrej; Sumnik, Zdenek] Univ Hosp Motol, Dept Pediat, Fac Med 2, Prague 15006, Czech Republic; [Rocek, Miloslav] Univ Hosp Motol, Dept Radiol Tech, Fac Med 2, Prague 15006, Czech Republic; [Hlavka, Zdenek] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague, Czech Republic; [Rittweger, Joern] German Aerosp Ctr DLR, Inst Aerosp Med, Cologne, Germany; [Rittweger, Joern] Manchester Metropolitan Univ, Inst Biomed Res Human Movement & Hlth, Manchester M15 6BH, Lancs, England","Soucek, O, Univ Hosp Motol, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","ondrej.soucek@lfmotol.cuni.cz","Charles University [GAUK 47609]; Czech Ministry of Health [VZ MZ 64203]; Czech Ministry of Education [MSMT 21620819]","This work was supported by Charles University (GAUK 47609), Czech Ministry of Health (VZ MZ 64203) and Czech Ministry of Education (MSMT 21620819).",null,36,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-0664",null,"10.1111/j.1365-2265.2010.03955.x","CLIN ENDOCRINOL","Clin. Endocrinol.","APR",2011,74,4,null,null,null,445,452,null,null,8,"Endocrinology & Metabolism","730YK","ISI:000288073300006",""]
["1 z/ze 5",1,5,0.2,"2011/6/4/937-950","http://www.ncbi.nlm.nih.gov/pubmed/21454722",4.8440000000000003,"The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas: Current Limitations and Quo Vadis","J","Botev, R; Mallie, JP; Wetzels, JFM; Couchoud, C; Schuck, O",null,null,null,"Botev, Rossini; Mallie, Jean-Pierre; Wetzels, Jack F. M.; Couchoud, Cecile; Schueck, Otto",null,"The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas: Current Limitations and Quo Vadis","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,"English","Article",null,null,null,null,null,null,"CHRONIC KIDNEY-DISEASE; BODY-SURFACE AREA; CHRONIC RENAL-INSUFFICIENCY; COCKCROFT-GAULT EQUATIONS; S-CYSTATIN-C; SERUM CREATININE; TRANSPLANT RECIPIENTS; SUBCUTANEOUS INJECTION; PREDICTIVE PERFORMANCE; NONDIABETIC PATIENTS","The GFR has a paramount diagnostic and staging role in the Kidney Disease Outcome Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease (K/DOQI-CKD). The most widely used serum creatinine-based formulas in adults for estimated GFR (eGFR) are the Cockcroft-Gault (CG) and Modification of Diet in Renal Disease Study (MDRD). Recently, a new Chronic Kidney Disease Epidemiology Collaboration equation has been developed. Review of the literature revealed that CG and MDRD formulas correctly assigned overall only 64% and 62%, respectively, of the subjects to their actual K/DOQI-CKD classification's GFR groups as determined by measured GFR (mGFR). This suggests that approximately 10 million (38%) subjects may have been misclassified on the basis of estimated CKD prevalence of 26.3 million adults in the United States. The purpose of this review is to help the clinician understand the limitations of using eGFR in daily practice. We also elaborate upon issues such as the differences among markers of mGFR, the validity of adjusting GFR for body surface area in certain populations, the limited data on boundaries for normal mGFR according to age, gender, and race, the need for calibration of a wide spectrum of serum creatinine measurements, the lack of actual eGFR value above 60 ml/min per 1.73 m(2) and reference for normal mGFR in the clinical laboratories' reports, and the performance evaluation of the eGFR formulas. Several pitfalls have to be overcome before we can reliably determine health and disease in daily nephrology practice to preserve the first rule of practicing medicine: primum non nocere. Clin J Am Soc Nephrol 6: 937-950, 2011. doi: 10.2215/CJN.09241010","[Botev, Rossini] Hawaii Permanent Med Grp, Dept Nephrol, Honolulu, HI 96819 USA; [Mallie, Jean-Pierre] Nancy Univ, Nancy, France; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6525 ED Nijmegen, Netherlands; [Couchoud, Cecile] Agence Biomed, French ESRD Registry REIN, La Plaine St Denis, France; [Schueck, Otto] Univ Hosp Motol, Internal Clin, Prague, Czech Republic","Botev, R, Hawaii Permanent Med Grp, Dept Nephrol, 3288 Moanalua Rd, Honolulu, HI 96819 USA","Rossini.C.Botev@kp.org",null,null,null,107,0,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,"10.2215/CJN.09241010","CLIN J AM SOC NEPHROL","Clin. J. Am. Soc. Nephrol.","APR",2011,6,4,null,null,null,937,950,null,null,14,"Urology & Nephrology","746DU","ISI:000289223600034",""]
["2 z/ze 7",2,7,0.2857142857142857,"2011/52/5/932-940","http://www.ncbi.nlm.nih.gov/pubmed/21453360",4.0519999999999996,"Stereotactic radiofrequency amygdalohippocampectomy: Does reduction of entorhinal and perirhinal cortices influence good clinical seizure outcome?","J","Malikova, H; Liscak, R; Vojtech, Z; Prochazka, T; Vymazal, J; Vladyka, V; Druga, R",null,null,null,"Malikova, Hana; Liscak, Roman; Vojtech, Zdenek; Prochazka, Tomas; Vymazal, Josef; Vladyka, Vilibald; Druga, Rastislav",null,"Stereotactic radiofrequency amygdalohippocampectomy: Does reduction of entorhinal and perirhinal cortices influence good clinical seizure outcome?","EPILEPSIA",null,"English","Article",null,null,null,null,null,"Temporal lobe epilepsy; Surgery; MRI; Volumetry","TEMPORAL-LOBE EPILEPSY; SELECTIVE AMYGDALOHIPPOCAMPECTOMY; INTRINSIC CONNECTIONS; RESECTION; SURGERY; EXTENT; LOBECTOMY; MEMORY; AMYGDALA; COMPLEX","Purpose: Stereotactic radiofrequency amygdalohippocampectomy (SAHE) has been modified recently in our center for the therapy of mesial temporal epilepsy (MTLE). It has promising clinical results comparable with microsurgical amygdalohippocampectomy despite smaller volume reduction of the hippocampus. We hypothesized that the extent of perirhinal and entorhinal cortex (PRC, EC) reduction could explain the clinical outcome. Therefore, we performed, retrospectively, volumetric analysis of PRC and EC and compared it with the seizure control. Methods: Twenty-six consecutive patients with MTLE treated by SAHE were included. PRC and EC volumes were measured from magnetic resonance imaging (MRI) records obtained before and 1 year after SAHE. The clinical outcome was assessed each year after SAHE using Engel's classification. Key Findings: Twenty-six patients were analyzed. The volume of PRC decreased by 46 +/- 17% (p < 10(-12)); EC volume decreased by 56 +/- 20% (p < 10(-10)). Two years after the procedure, 73% of patients were classified as Engel's I, 19% as Engel's II; in 2 (8%) the treatment failed (were reoperated). Eighteen patients finished 3 years follow-up; 72% of them were classified as Engel's I, 17% as Engel's II, and in 2 (11%) above-mentioned patients the treatment failed. Thirteen patients finished 4 years of follow-up, 11 of them as Engel's I. There was no significant correlation of the clinical outcome to PRC and EC volume reductions. Significance: The clinical effect of SAHE is not clearly explained by the volume reductions of PRC and EC (nor of the hippocampus and the amygdala). It promotes opinion that the extent of resection/destruction is not important for seizure outcomes.","[Malikova, Hana; Vymazal, Josef] Hosp Na Homolce, Dept Radiol, Prague 15000 5, Czech Republic; [Malikova, Hana; Druga, Rastislav] Charles Univ Prague, Fac Med 2, Inst Anat, Prague, Czech Republic; [Liscak, Roman; Vladyka, Vilibald] Hosp Na Homolce, Dept Stereotact & Radiat Neurosurg, Prague 15000 5, Czech Republic; [Vojtech, Zdenek; Prochazka, Tomas] Hosp Na Homolce, Dept Neurol, Prague 15000 5, Czech Republic; [Vymazal, Josef] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic","Malikova, H, Hosp Na Homolce, Dept Radiol, Roentgenova 2, Prague 15000 5, Czech Republic","hana.malikova@homolka.cz","Czech Ministry of Education [MSMT 0021620849]; Grant Agency of the Czech Republic [309/07/1337]","JV was supported by the Czech Ministry of Education (research program MSMT 0021620849). RD was supported by the Grant Agency of the Czech Republic grant No. 309/07/1337.",null,38,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,"10.1111/j.1528-1167.2011.03048.x","EPILEPSIA","Epilepsia","MAY",2011,52,5,null,null,null,932,940,null,null,9,"Clinical Neurology","762QK","ISI:000290494300013",""]
["5 z/ze 7",5,7,0.7142857142857143,"2011/13/1/76-81","http://www.ncbi.nlm.nih.gov/pubmed/21393095",1.198,"Sturge-Weber syndrome: a favourable surgical outcome in a case with contralateral seizure onset and myoclonic-astatic seizures","J","Jiruska, P; Marusic, P; Jefferys, JGR; Krsek, P; Cmejla, R; Sebronova, V; Komarek, V",null,null,null,"Jiruska, Premysl; Marusic, Petr; Jefferys, John G. R.; Krsek, Pavel; Cmejla, Roman; Sebronova, Vera; Komarek, Vladimir",null,"Sturge-Weber syndrome: a favourable surgical outcome in a case with contralateral seizure onset and myoclonic-astatic seizures","EPILEPTIC DISORDERS",null,"English","Article",null,null,null,null,null,"Sturge-Weber syndrome; myoclonic-astatic seizures; contralateral seizure onset; epilepsy surgery","SECONDARY BILATERAL SYNCHRONY","Sturge-Weber syndrome is a neurocutaneous disorder classically characterized by the presence of facial port-wine stain and ipsilateral leptomeningeal angiomatosis. It is often associated with refractory epilepsy which requires surgical treatment. We present a case of a patient who initially presented with partial seizures of temporo-occipital origin, ipsilateral to the pial angiomatosis. During the course of the disease, the patient developed medically refractory epilepsy with partial seizures originating predominantly from the contralateral temporo-occipital area as well as myoclonic and myoclonicastatic seizures. Resection of the occipital and temporal lobe affected by the pial angioma resulted in favourable outcome. Bilateral dysfunction observed in Sturge-Weber syndrome may result in an increased capability of focal discharges to generate synchronous epileptiform activity leading to an increased incidence of generalised seizures, most probably via a mechanism of secondary bilateral synchrony. [Published with video sequences]","[Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Jiruska, Premysl; Jefferys, John G. R.] Univ Birmingham, Neuronal Networks Grp, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Jiruska, Premysl; Krsek, Pavel; Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Dept Pediat Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Cmejla, Roman] Czech Tech Univ, Dept Circuit Theory, Fac Elect Engn, CR-16635 Prague, Czech Republic","Marusic, P, Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic","petr.marusic@fnmotol.cz","Epilepsy Research UK [A0937]; Motol Hospital [VZ MZOFNM2005-6504]","This work was supported by grants from Epilepsy Research UK (A0937) and Motol Hospital (VZ MZOFNM2005-6504).",null,13,0,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361",null,"10.1684/epd.2011.0407","EPILEPTIC DISORD","Epileptic Disord.","MAR",2011,13,1,null,null,"Sp. Iss. 1",76,81,null,null,6,"Clinical Neurology","742LW","ISI:000288946300011",""]
["4 z/ze 6",4,6,0.66666666666666663,"2011///-","http://www.e-polymers.org/journal/abstract.cfm?abstract_Id=3616",0.64400000000000002,"Bioactive support for cell cultivation and potential grafting. Part 1: Surface modification of 2-hydroxyethyl methacrylate hydrogels for avidin immobilization","J","Hobzova, R; Pradny, M; Zhunusbekova, NM; Sirc, J; Guryca, V; Michalek, J",null,null,null,"Hobzova, Radka; Pradny, Martin; Zhunusbekova, Nazym M.; Sirc, Jakub; Guryca, Vilem; Michalek, Jiri",null,"Bioactive support for cell cultivation and potential grafting. Part 1: Surface modification of 2-hydroxyethyl methacrylate hydrogels for avidin immobilization","E-POLYMERS",null,"English","Article",null,null,null,null,null,null,"BIOTIN BINDING SYSTEM; TISSUE ENGINEERING APPLICATIONS; BIODEGRADABLE POLYMERS; CHONDROCYTE ADHESION; CULTURE; KERATINOCYTES; ATTACHMENT; CARRIERS; PROTEIN; GROWTH","Synthetic hydrogels are often used in biomedical applications as many of them are compatible with living tissue and moreover they can meet most criteria for artificial tissue properties. For applications in tissue engineering modification of polymer surface using some bioactive compounds (e. g. saccharides, proteins) for promoting the process of cell adhesion and proliferation is widely used. In this work, a series of modified hydrogels was prepared by three different methods: by copolymerization of 2-hydroxyethyl methacrylate with methacrylic acid, by hydrolysis and oxidation of poly(2-hydroxyethyl methacrylate) to obtain carboxyl-rich supports. The influence of the reaction conditions of the hydrogel surface treatment on the total carboxylic group content and the swelling degree was studied. The modified hydrogels were characterized by attenuated total reflectance FT-IR spectroscopy and refractive index measurements. Obtained carboxylic groups on the hydrogel surface have allowed the immobilization of avidin in two ways: 1) electrostatically through dissociated carboxylic groups and 2) covalently bonded through activated carboxylic groups by N-hydroxysuccinimide. The capacity of hydrogels for avidin immobilization was determined by Bradford spectrophotometric method. The results so far obtained from the preliminary biological tests showed that immobilized avidin on the hydrogel surface provides better adhesion and proliferation of keratinocytes compared to supports without avidin.","[Hobzova, Radka; Pradny, Martin; Zhunusbekova, Nazym M.; Sirc, Jakub; Guryca, Vilem; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Hobzova, Radka; Pradny, Martin; Sirc, Jakub; Michalek, Jiri] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic","Hobzova, R, Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic","hobzova@imc.cas.cz","Academy of Sciences of the Czech Republic [1QS400500558]","This work was supported by the Academy of Sciences of the Czech Republic (project 1QS400500558). The authors thank B. Dvorankova, Ph.D. for implementing the pilot biological experiments.",null,26,0,"EUROPEAN POLYMER FEDERATION","STRASBOURG","1, QUAI LEZAY-MARNESIA, F067000 STRASBOURG, FRANCE","1618-7229",null,null,"E-POLYMERS","e-Polymers","MAY 11",2011,null,null,null,null,null,null,null,43,null,17,"Polymer Science","762KF","ISI:000290474600001",""]
["1 z/ze 1",1,1,1,"2011/41/3/561-565","http://www.ncbi.nlm.nih.gov/pubmed/21341257",5.1790000000000003,"Immunology in the heart of the High Tatra mountains","J","Spisek, R",null,null,null,"Spisek, Radek",null,"Immunology in the heart of the High Tatra mountains","EUROPEAN JOURNAL OF IMMUNOLOGY",null,"English","Editorial Material",null,null,null,null,null,null,null,null,"Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic","Spisek, R, Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic","radek.spisek@lfmotol.cuni.cz",null,null,null,9,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0014-2980",null,null,"EUR J IMMUNOL","Eur. J. Immunol.","MAR",2011,41,3,null,null,null,561,565,null,null,5,"Immunology","731HU","ISI:000288097700001",""]
["1 z/ze 7",1,7,0.14285714285714285,"2011/59/6/997-1008","http://www.ncbi.nlm.nih.gov/pubmed/21458150",7.6669999999999998,"EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update","J","Babjuk, M; Oosterlinck, W; Sylvester, R; Kaasinen, E; Bohle, A; Palou-Redorta, J; Roupret, M",null,null,null,"Babjuk, Marko; Oosterlinck, Willem; Sylvester, Richard; Kaasinen, Eero; Boehle, Andreas; Palou-Redorta, Juan; Roupret, Morgan",null,"EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update","EUROPEAN UROLOGY",null,"English","Article",null,null,null,null,null,"Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; EAU Guidelines; Follow-up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma","BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; RANDOMIZED CLINICAL-TRIALS; IMMEDIATE POSTOPERATIVE INSTILLATION; INTRAVESICAL MITOMYCIN-C; FOLLOW-UP CYSTOSCOPY; LONG-TERM EFFICACY; PHASE-III TRIAL; IN-SITU; TRANSURETHRAL RESECTION","Context and objective: To present the 2011 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC). Evidence acquisition: Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence (LE) and grade of recommendation (GR) were assigned. Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. In papillary tumours, the risks of both recurrence and progression may be estimated for individual patients using the scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups-separately for recurrence and progression-is pivotal to recommending adjuvant treatment. For patients with a low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is recommended. Patients with an intermediate or high risk of recurrence and an intermediate risk of progression should receive one immediate instillation of chemotherapy followed by a minimum of 1 yr of bacillus Calmette-Guerin (BCG) intravesical immunotherapy or further instillations of chemotherapy. Papillary tumours with a high risk of progression and CIS should receive intravesical BCG for 1 yr. Cystectomy may be offered to the highest risk patients, and it is at least recommended in BCG failure patients. The long version of the guidelines is available from the EAU Web site (www.uroweb.org). Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Babjuk, Marko] Charles Univ Prague, Dept Urol, Fac Med 2, Hosp Motol, Prague 15006 5, Czech Republic; [Oosterlinck, Willem] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Dept Biostat, Brussels, Belgium; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Urol, Hyvinkaa, Finland; [Boehle, Andreas] HELIOS Agnes Karll Hosp, Dept Urol, Bad Schwartau, Germany; [Palou-Redorta, Juan] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, E-08193 Barcelona, Spain; [Roupret, Morgan] Univ Paris 06, Fac Med, Dept Urol, Pitie Salpetriere Hosp,AP HP,GHU Est, Paris, France","Babjuk, M, Charles Univ Prague, Dept Urol, Fac Med 2, Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic","marek.babjuk@lfmotol.cuni.cz","GSK ; Astra Zeneca ; Pfizer Foundation ","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Marko Babjuk receives speaker honoraria from GE Healthcare and GSK. Willem Oosterlinck is a company consultant and receives fellowship and travel grants from GSK, receives speaker honoraria from Pfizer, participates in trials for Amgen, Astra Zeneca, and Astellas, and receives fellowships and travel and research grants from Astra Zeneca. Morgan Roupret has nothing to disclose. Juan Palou-Redorta is a consultant and receives speaker honoraria from Sanofi-Pasteur and General Electric. He also participates in trials for General Electric. Andreas Bohle receives speaker honoraria from Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen receives research grants from the Pfizer Foundation and for a research group at Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he received speaker honoraria from the Kyowa 2008 EAU Satellite Symposium.",null,72,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,"10.1016/j.eururo.2011.03.017","EUR UROL","Eur. Urol.","JUN",2011,59,6,null,null,null,997,1008,null,null,12,"Urology & Nephrology","756MM","ISI:000290015300023",""]
["1 z/ze 8",1,8,0.125,"2011/59/4/584-594","http://www.ncbi.nlm.nih.gov/pubmed/21269756",7.6669999999999998,"European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update","J","Roupret, M; Zigeuner, R; Palou, J; Boehle, A; Kaasinen, E; Sylvester, R; Babjuk, M; Oosterlinck, W",null,null,null,"Roupret, Morgan; Zigeuner, Richard; Palou, Juan; Boehle, Andreas; Kaasinen, Eero; Sylvester, Richard; Babjuk, Marko; Oosterlinck, Willem",null,"European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update","EUROPEAN UROLOGY",null,"English","Article",null,null,null,null,null,"Guidelines; Urothelial carcinoma; Prognosis; Urinary markers; Renal pelvis; Ureter; Laparoscopy; Ureteroscopy; Nephroureterectomy","LAPAROSCOPIC RADICAL NEPHROURETERECTOMY; SINGLE-CENTER EXPERIENCE; IN-SITU HYBRIDIZATION; LONG-TERM EXPERIENCE; RENAL PELVIS; PROGNOSTIC-FACTORS; CALMETTE-GUERIN; MULTIINSTITUTIONAL ANALYSIS; MICROSATELLITE INSTABILITY; URETEROSCOPIC MANAGEMENT","Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper urinary tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract, carcinoma, transitional cell, renal pelvis, ureter, bladder cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis: There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The TNM classification 2009 is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions: These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities; tumour location, grade and stage; and molecular marker status. (C) 2011 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Roupret, Morgan] Univ Paris 06, Fac Med Pierre & Marie Curie, Assistance Publ Hop Paris, Dept Urol,Pitie Salpetriere Hosp,GHU Est, Paris, France; [Zigeuner, Richard] Med Univ Graz, Dept Urol, Graz, Austria; [Palou, Juan] Fundacio Puigvert, Dept Urol, Barcelona, Spain; [Boehle, Andreas] HELIOS Agnes Karll Hosp, Dept Urol, D-23611 Bad Schwartau, Germany; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Urol, Hysinkaa, Finland; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Dept Biostat, B-1200 Brussels, Belgium; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Oosterlinck, Willem] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium","Roupret, M, Hop Pitie, Dept Urol, 47-83 Bvd Hop, F-75013 Paris, France","morgan.roupret@psl.aphp.fr","Pfizer Foundation ; Pfizer ; Astra Zeneca ; Sanofi-Aventis ","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Juan Palou is a consultant and honorarium speaker for Sanofi-Pasteur and a consultant, honorarium speaker, and trial participant for General Electric. Andreas Boehle is an honorarium speaker for Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen has received research grants from the Pfizer Foundation and for a research group from Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he was an honorarium speaker for the Kyowa 2008 EAU Satellite Symposium. Marko Babjuk is an honorarium speaker for GE Healthcare and Novartis. Willem Oosterlinck is an honorarium speaker for Organan, Sanofi-Aventis, Novartis, and Pfizer; he participates in trials conducted by Amgen, Astra Zeneca, Novartis, and Astellas; he has received fellowships and travel grants from Astra Zeneca and Sanofi-Aventis and research grants from Astra Zeneca.",null,117,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,"10.1016/j.eururo.2010.12.042","EUR UROL","Eur. Urol.","APR",2011,59,4,null,null,null,584,594,null,null,11,"Urology & Nephrology","730DT","ISI:000288013700027",""]
["1 z/ze 16",1,16,6.25E-2,"2011/96/3/384-392","http://www.ncbi.nlm.nih.gov/pubmed/21134981",6.4160000000000004,"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia","J","Hollink, IHIM; van den Heuvel-Eibrink, MM; Arentsen-Peters, STCJM; Zimmermann, M; Peeters, JK; Valk, PJM; Balgobind, BV; Sonneveld, E; Kaspers, GJL; de Bont, ESJM; Trka, J; Baruchel, A; Creutzig, U; Pieters, R; Reinhardt, D; Zwaan, CM",null,null,null,"Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Arentsen-Peters, Susan T. C. J. M.; Zimmermann, Martin; Peeters, Justine K.; Valk, Peter J. M.; Balgobind, Brian V.; Sonneveld, Edwin; Kaspers, Gertjan J. L.; de Bont, Eveline S. J. M.; Trka, Jan; Baruchel, Andre; Creutzig, Ursula; Pieters, Rob; Reinhardt, Dirk; Zwaan, C. Michel",null,"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,"English","Article",null,null,null,null,null,"Pediatric acute myeloid leukemia; CEBPA mutation; promoter hypermethylation; molecular marker; prognostic significance","BINDING-PROTEIN-ALPHA; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION PROFILES; CELLULAR-DRUG RESISTANCE; FACTOR-C/EBP-ALPHA; TRANSCRIPTION FACTOR; PROGNOSTIC-SIGNIFICANCE; INITIATING CELLS; AML; DIFFERENTIATION","Background Dysfunctioning of CCAAT/enhancer binding protein alpha (C/EBP alpha) in acute myeloid leukemia can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable outcome, but this may be restricted to the case of double mutations in CEBPA in adult acute myeloid leukemia. In pediatric acute myeloid leukemia, data on the impact of these mutations are limited to one series, and data on promoter hypermethylation are lacking. Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia. Design and Methods We screened a large pediatric cohort (n=252) for CEBPA single and double mutations by direct sequencing, and for promoter hypermethylation by methylation-specific polymerase chain reaction. Furthermore, we determined the gene-expression profiles (Affymetrix HGU133 plus 2.0 arrays) of this cohort (n=237). Results Thirty-four mutations were identified in 20 out of the 252 cases (7.9%), including 14 double-mutant and 6 single-mutant cases. CEBPA double mutations conferred a significantly better 5-year overall survival compared with single mutations (79% versus 25%, respectively; P=0.04), and compared with CEBPA wild-type acute myeloid leukemia excluding core-binding factor cases (47%; P=0.07). Multivariate analysis confirmed that the double mutations were an independent favorable prognostic factor for survival (hazard ratio 0.23, P=0.04). The combination of screening for promoter hypermethylation and gene expression profiling identified five patients with silenced CEBPA, of whom four cases relapsed. All cases characteristically expressed T-lymphoid markers. Moreover, unsupervised clustering of gene expression profiles showed a clustering of CEBPA double-mutant and silenced cases, pointing towards a common hallmark of abrogated C/EBP alpha-functioning in these acute myeloid leukemias. Conclusions We showed the independent favorable outcome of patients with CEBPA double-mutant acute myeloid leukemia in a large pediatric series. This molecular marker may, therefore, improve risk-group stratification in pediatric acute myeloid leukemia. For the first time, CEBPA-silenced cases are suggested to confer a poor outcome in pediatric acute myeloid leukemia, indicating that further investigation of this aberration is needed. Furthermore, clustering of gene expression profiles provided insight into the biological similarities and diversities of the different aberrations in CEBPA in pediatric acute myeloid leukemia.","[Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, AML BFM Study Grp, Hannover, Germany; [Peeters, Justine K.; Valk, Peter J. M.] Erasmus MC, Rotterdam, Netherlands; [Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Sonneveld, Edwin; Kaspers, Gertjan J. L.] DCOG, The Hague, Netherlands; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [de Bont, Eveline S. J. M.] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] Hop St Louis, Paris, France; [Creutzig, Ursula] Univ Hosp, AML BFM Study Grp, Munster, Germany","Zwaan, CM, Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands","c.m.zwaan@eras-musmc.nl","KOCR foundation ; Netherlands Organisation for Scientific Research (NWO) ; Deutsche Krebshilfe ; Czech Ministry of Education [MSM0021620813]","this work was funded by the KOCR foundation (IHIMH and BVB) and the Netherlands Organisation for Scientific Research (NWO) (BVB). This work was further supported in part by the Deutsche Krebshilfe (DR), and the Czech Ministry of Education (MSM0021620813) (JT).",null,43,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,"10.3324/haematol.2010.031336","HAEMATOL-HEMATOL J","Haematol-Hematol. J.","MAR",2011,96,3,null,null,null,384,392,null,null,9,"Hematology","740BQ","ISI:000288767000008",""]
["1 z/ze 4",1,4,0.25,"2011/17/3/399-406","http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2010.02428.x/abstract",2.5049999999999999,"Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate (R): interim report from an ongoing prospective clinical study","J","Klukowska, A; Komrska, V; Jansen, M; Laguna, P",null,null,null,"Klukowska, A.; Komrska, V.; Jansen, M.; Laguna, P.",null,"Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate (R): interim report from an ongoing prospective clinical study","HAEMOPHILIA",null,"English","Article",null,null,null,null,null,"factor VIII; haemophilia A; inhibitors; Octanate (R); previously untreated patients; surgery","SEVERE HEMOPHILIA-A; RISK-FACTORS; TOLERANCE INDUCTION; IMMUNE TOLERANCE; CANAL COHORT; FACTOR-IX; RECOMBINANT; CONCENTRATE; PRODUCTS; CHILDREN","For patients with haemophilia A (HA), lifelong replacement therapy with factor VIII (FVIII) concentrates is the treatment of choice. Octanate (R) is a plasma-derived, human, von Willebrand factor-stabilized FVIII product with demonstrated haemostatic efficacy in patients with HA. The aim of this ongoing study is to assess the immunogenicity of Octanate (R) in previously untreated patients (PUPs), monitoring for development of FVIII inhibitors. Interim data on 39 PUPs treated for bleeding, prophylactically and for surgical coverage are reported. Two of 39 subjects (5.1%) developed clinically relevant inhibitor titres over the course of the study. Another two displayed inhibitors that disappeared spontaneously without Octanate (R) dose change. All inhibitors developed under on-demand treatment and before exposure day (ED) 50. Remarkably, no inhibitor was observed in PUPs receiving prophylaxis with Octanate (R). Of 39 subjects, 30 had exceeded 50 EDs at the time of this analysis. All inhibitor subjects were found to have large FVIII gene defects, either intron 22-inversions or large deletions. Octanate (R) was well-tolerated and the adverse event profile was consistent with the population studied. The haemostatic efficacy of Octanate (R) in prophylaxis and treatment of bleeding were generally rated as 'excellent', and no complication was reported for surgery. Notable FVIII activity was present in blood at 15 min postadministration, and levels remained high at 1 h. Mean incremental in vivo recovery (IVR) was 2.0 (+/- 0.6) % IU-1kg-1. These interim results indicate Octanate (R) to be an efficacious, well-tolerated human FVIII product for management of HA in PUPs, associated with a minimal risk of inhibitors.","[Klukowska, A.; Laguna, P.] Med Univ Warsaw, Dept Pediat Hematol & Oncol, PL-00576 Warsaw, Poland; [Komrska, V.] Motol Univ Hosp, Prague, Czech Republic; [Jansen, M.] Octapharma, Vienna, Austria","Klukowska, A, Med Univ Warsaw, Dept Pediat Hematol & Oncol, Marszalkowska 24, PL-00576 Warsaw, Poland","aklukowska@poczta.onet.pl","Octapharma Ltd. ","MJ is an employee of Octapharma Ag, Vienna, Austria and AK has received speaker fees from Octapharma Ltd.",null,36,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-8216",null,"10.1111/j.1365-2516.2010.02428.x","HAEMOPHILIA","Haemophilia","MAY",2011,17,3,null,null,null,399,406,null,null,8,"Hematology","754YQ","ISI:000289894200003",""]
["1 z/ze 45",1,45,2.2222222222222223E-2,"2011/33/3/445-450","http://www.ncbi.nlm.nih.gov/pubmed/21086488",2.2829999999999999,"PROPOSAL FOR A RATIONAL CLASSIFICATION OF NECK DISSECTIONS","J","Ferlito, A; Robbins, KT; Shah, JP; Medina, JE; Silver, CE; Al-Tamimi, S; Fagan, JJ; Paleri, V; Takes, RP; Bradford, CR; Devaney, KO; Stoeckli, SJ; Weber, RS; Bradley, PJ; Suarez, C; Leemans, CR; Coskun, HH; Pitman, KT; Shaha, AR; de Bree, R; Hartl, DM; Haigentz, M; Rodrigo, JP; Hamoir, M; Khafif, A; Langendijk, JA; Owen, RP; Sanabria, A; Strojan, P; Poorten, VV; Werner, JA; Bien, S; Woolgar, JA; Zbaren, P; Betka, J; Folz, BJ; Genden, EM; Talmi, YP; Strome, M; Botas, JHG; Olofsson, J; Kowalski, LP; Holmes, JD; Hisa, Y; Rinaldo, A",null,null,null,"Ferlito, Alfio; Robbins, K. Thomas; Shah, Jatin P.; Medina, Jesus E.; Silver, Carl E.; Al-Tamimi, Shawkat; Fagan, Johannes J.; Paleri, Vinidh; Takes, Robert P.; Bradford, Carol R.; Devaney, Kenneth O.; Stoeckli, Sandro J.; Weber, Randal S.; Bradley, Patrick J.; Suarez, Carlos; Leemans, C. Rene; Coskun, H. Hakan; Pitman, Karen T.; Shaha, Ashok R.; de Bree, Remco; Hartl, Dana M.; Haigentz, Missak, Jr.; Rodrigo, Juan P.; Hamoir, Marc; Khafif, Avi; Langendijk, Johannes A.; Owen, Randall P.; Sanabria, Alvaro; Strojan, Primoz; Poorten, Vincent Vander; Werner, Jochen A.; Bien, Stanislaw; Woolgar, Julia A.; Zbaeren, Peter; Betka, Jan; Folz, Benedikt J.; Genden, Eric M.; Talmi, Yoav P.; Strome, Marshall; Gonzalez Botas, Jesus Herranz; Olofsson, Jan; Kowalski, Luiz P.; Holmes, Jon D.; Hisa, Yasuo; Rinaldo, Alessandra",null,"PROPOSAL FOR A RATIONAL CLASSIFICATION OF NECK DISSECTIONS","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK",null,"English","Editorial Material",null,null,null,null,null,null,"HEAD; CHEMORADIATION; TERMINOLOGY; SURGERY; ACADEMY; UPDATE",null,"[Ferlito, Alfio; Rinaldo, Alessandra] Univ Udine, ENT Clin, Dept Surg Sci, I-33100 Udine, Italy; [Robbins, K. Thomas] So Illinois Univ, Sch Med, Div Otolaryngol Head & Neck Surg, Springfield, IL USA; [Shah, Jatin P.; Shaha, Ashok R.] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA; [Medina, Jesus E.] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK USA; [Silver, Carl E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA; [Silver, Carl E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Otolaryngol Head & Neck Surg, Bronx, NY 10467 USA; [Al-Tamimi, Shawkat] Royal Med Serv, King Hussein Med Ctr, Dept Otolaryngol Head & Neck Surg, Amman, Jordan; [Fagan, Johannes J.] Univ Cape Town, Fac Hlth Sci, Div Otolaryngol, ZA-7925 Cape Town, South Africa; [Paleri, Vinidh] Newcastle Upon Tyne Fdn Hosp NHS Trust, Dept Otolaryngol Head & Neck Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Takes, Robert P.] Radboud Univ Nijmegen, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-6525 ED Nijmegen, Netherlands; [Bradford, Carol R.] Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; [Devaney, Kenneth O.] Allegiance Hlth, Dept Pathol, Jackson, MI USA; [Stoeckli, Sandro J.] Kantonsspital, Dept Otorhinolaryngol Head & Neck Surg, St Gallen, Switzerland; [Weber, Randal S.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Bradley, Patrick J.] Univ Nottingham Hosp, Dept Otorhinolaryngol Head & Neck Surg, Nottingham NG7 2UH, England; [Suarez, Carlos; Rodrigo, Juan P.] Hosp Univ Cent Asturias, Dept Otolaryngol, Oviedo, Spain; [Suarez, Carlos; Rodrigo, Juan P.] Inst Univ Oncol Principado Asturias, Oviedo, Spain; [Leemans, C. Rene; de Bree, Remco] Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands; [Coskun, H. Hakan] Uludag Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Bursa, Turkey; [Pitman, Karen T.] Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, Jackson, MS 39216 USA; [Hartl, Dana M.] Inst Gustave Roussy, Dept Otolaryngol Head & Neck Surg, Villejuif, France; [Hartl, Dana M.] Sorbonne Nouvelle, Lab Phonet & Phonol, Paris, France; [Haigentz, Missak, Jr.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Oncol, Bronx, NY 10467 USA; [Hamoir, Marc] St Luc Univ Hosp & Canc Ctr, Dept Head & Neck Surg, Head & Neck Oncol Program, Brussels, Belgium; [Khafif, Avi] Assuta Med Ctr, ARM Ctr Adv Otolaryngol Head & Neck Surg, Head & Neck Surg & Oncol Unit, Tel Aviv, Israel; [Langendijk, Johannes A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands; [Owen, Randall P.] Mt Sinai Sch Med, Dept Surg, Div Metab Endocrine & Minimally Invas Surg, New York, NY USA; [Sanabria, Alvaro] Univ La Sabana Fdn Abood Shaio, Dept Surg, Bogota, Colombia; [Strojan, Primoz] Inst Oncol, Dept Radiat Oncol, Ljubljana, Slovenia; [Poorten, Vincent Vander] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Werner, Jochen A.] Univ Marburg, Dept Otolaryngol Head & Neck Surg, Marburg, Germany; [Bien, Stanislaw] Holy Cross Canc Ctr, Dept Otolaryngol Head & Neck Surg, Kielce, Poland; [Woolgar, Julia A.] Univ Liverpool Dent Hosp, Liverpool, Merseyside, England; [Zbaeren, Peter] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Bern, Switzerland; [Betka, Jan] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Folz, Benedikt J.] Karl Hansen Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Bad Lippspringe, Germany; [Genden, Eric M.] Mt Sinai Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA; [Talmi, Yoav P.] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Head & Neck Serv, IL-69978 Tel Aviv, Israel; [Strome, Marshall] Cleveland Clin, Head & Neck Inst, Dept Otolaryngol & Communicat Disorders, Cleveland, OH 44106 USA; [Gonzalez Botas, Jesus Herranz] Univ Hosp A Coruna, Dept Otorhinolaryngol, La Coruna, Spain; [Olofsson, Jan] Haukeland Hosp, Dept Otolaryngol Head & Neck Surg, N-5021 Bergen, Norway; [Kowalski, Luiz P.] Ctr Tratamento & Pesquisa Hosp Canc AC Camargo, Dept Otorhinolaryngol Head & Neck Surg, Sao Paulo, Brazil; [Holmes, Jon D.] Univ Alabama, Dept Oral & Maxillofacial Surg, Birmingham, AL USA; [Hisa, Yasuo] Kyoto Prefectural Univ Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan","Ferlito, A, Univ Udine, ENT Clin, Dept Surg Sci, I-33100 Udine, Italy","a.ferlito@uniud.it",null,null,null,24,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1043-3074",null,"10.1002/hed.21614","HEAD NECK-J SCI SPEC HEAD NEC","Head Neck-J. Sci. Spec. Head Neck","MAR",2011,33,3,null,null,null,445,450,null,null,6,"Otorhinolaryngology; Surgery","721RP","ISI:000287372900024",""]
["1 z/ze 7",1,7,0.14285714285714285,"2011/17/6/1322-1327","http://www.ncbi.nlm.nih.gov/pubmed/21058331",4.6429999999999998,"Bile Acid Malabsorption in Inflammatory Bowel Disease: Assessment by Serum Markers","J","Lenicek, M; Duricova, D; Komarek, V; Gabrysova, B; Lukas, M; Smerhovsky, Z; Vitek, L",null,null,null,"Lenicek, Martin; Duricova, Dana; Komarek, Viktor; Gabrysova, Bronislava; Lukas, Milan; Smerhovsky, Zdenek; Vitek, Libor",null,"Bile Acid Malabsorption in Inflammatory Bowel Disease: Assessment by Serum Markers","INFLAMMATORY BOWEL DISEASES",null,"English","Article",null,null,null,null,null,"bile acid malabsorption; Crohn's disease; 7 alpha-hydroxycholest-4-en-3-one; ileal disease; inflammatory bowel disease","CHRONIC DIARRHEA; DIURNAL-VARIATION; CROHNS-DISEASE; HUMAN ILEAL; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; HYPEROXALURIA; TRANSPORTER; ABSORPTION; EXPRESSION; THERAPY","Background: Bile acid malabsorption (BAM) is a common feature of Crohn's disease (CD). We aimed to determine whether BAM develops only in patients with a resected distal ileum or if it also occurs in patients who have not undergone surgery for CD. Methods: The study included 347 patients with CD or ulcerative colitis (UC) and 119 healthy subjects (controls). BAM was assessed by measurement of serum levels of 7 alpha-hydroxycholest-4-en-3-one (C4) and fibroblast growth factor 19 (FGF19). We surveyed members of the European Crohn's and Colitis Organization and International Organization for the Study of Inflammatory Bowel Disease to collect current information about BAM diagnosis. Results: The severity of BAM was associated with resection of the distal ileum. Compared with controls, patients who received moderate or extensive ileal resection had significantly increased levels of serum C4 (12 versus 62 versus 243 mu g/L, respectively; P < 0.001). However, BAM was also present in a substantial number of the patients with CD who were not treated by surgery who had ileitis or colitis (14% and 11%, respectively). There was an indirect, proportional relationship between levels of C4 and FGF19 (P < 0.001). Conclusions: The most severe BAM occurs in CD patients after resection of the distal ileum, but BAM can occur in surgically untreated CD patients, regardless of disease localization. Laboratory tests for BAM should become a part of the algorithm for diagnosis of CD to identify patients who might respond to therapies such as bile acid sequestrants. FGF19 appears to be a reliable marker of BAM.","[Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, Prague 12808 2, Czech Republic; [Lenicek, Martin; Gabrysova, Bronislava; Lukas, Milan; Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Clin Biochem & Lab Diagnost, Prague 12808 2, Czech Republic; [Duricova, Dana; Komarek, Viktor; Lukas, Milan] ISCARE IVF, IBD Res Ctr, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol 2, Prague 12808 2, Czech Republic; [Smerhovsky, Zdenek] Natl Inst Publ Hlth, Prague, Czech Republic","Vitek, L, Charles Univ Prague, Fac Med 1, Dept Internal Med 4, U Nemocnice 2, Prague 12808 2, Czech Republic","vitek@cesnet.cz","Czech Ministry of Education [2B06155]; Czech Ministry of Health [NR-9219-3/2007]","Supported by government grants from both the Czech Ministry of Education (No. 2B06155) and the Czech Ministry of Health (No. NR-9219-3/2007). The granting agencies had no influence on the collection, analysis, interpretation of data, writing of the report, nor on the decision to submit the article for publication.",null,33,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1078-0998",null,"10.1002/ibd.21502","INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","JUN",2011,17,6,null,null,null,1322,1327,null,null,6,"Gastroenterology & Hepatology","761ZQ","ISI:000290442400030",""]
["1 z/ze 8",1,8,0.125,"2011/21/7/504-508","není",2.4089999999999998,"Factors affecting the growth of bifidobacteria in human milk","J","Rockova, S; Nevoral, J; Rada, V; Marsik, P; Sklenar, J; Hinkova, A; Vlkova, E; Marounek, M",null,null,null,"Rockova, Sarka; Nevoral, Jiri; Rada, Vojtech; Marsik, Petr; Sklenar, Jan; Hinkova, Andrea; Vlkova, Eva; Marounek, Milan",null,"Factors affecting the growth of bifidobacteria in human milk","INTERNATIONAL DAIRY JOURNAL",null,"English","Article",null,null,null,null,null,null,"OLIGOSACCHARIDES; INFANTS; PREBIOTICS; PROTEINS","Five strains of bifidobacteria of human origin and 2 strains of bifidobacteria of animal origin were tested for growth in 10 samples of human milk. Growth of Bifidobacterium bifidum in human milk was accompanied by a decrease in pH and production of acids. The number of viable cells of Bifidobacterium animalis was decreased from 6 log cfu mL(-1) to 3 log cfu mL(-1) after incubation in human milk. There were significant differences (P < 0.05) between bacterial counts of B. bifidum and B. animalis in milk samples tested. Resistance to lysozyme and the ability to utilise human milk oligosaccharides (HMOs) were identified as the most important factors affecting the growth of bifidobacteria in human milk. Four out of 5 strains of human origin were resistant to lysozyme and utilised HMOs. In contrast, B. animalis was susceptible to lysozyme and did not utilise HMOs. (C) 2011 Elsevier Ltd. All rights reserved.","[Rockova, Sarka; Rada, Vojtech; Vlkova, Eva] Czech Univ Life Sci, Dept Microbiol Nutr & Dietet, Fac Agrobiol Food & Nat Resources, Prague 16521 6, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic; [Marsik, Petr] Acad Sci CR, Joint Lab Inst Expt Bot, Vvi, Plant Biotechnol Lab, Prague 16502 6, Czech Republic; [Marsik, Petr] Res Inst Crop Prod, Vvi, Prague 16502 6, Czech Republic; [Sklenar, Jan] Acad Sci CR, Inst Microbiol, Dept Immunol, Prague 14220, Czech Republic; [Hinkova, Andrea] Prague Inst Chem Technol, Dept Carbohydrate Chem & Technol, CR-16628 Prague 6, Czech Republic; [Marounek, Milan] Acad Sci CR, Inst Anim Physiol & Genet, Vvi, Prague 14220, Czech Republic","Rada, V, Czech Univ Life Sci, Dept Microbiol Nutr & Dietet, Fac Agrobiol Food & Nat Resources, Kamycka 129, Prague 16521 6, Czech Republic","rada@af.czu.cz","Ministry of Education, Youth and Sports of Czech Republic [6046070901]; Czech Science Foundation [523/07/0572, 525/08/H060]","This study was supported by grant MSM No. 6046070901 of Ministry of Education, Youth and Sports of Czech Republic and by grants 523/07/0572, and 525/08/H060 of the Czech Science Foundation. We thank Dr. Ingrid Kocourkova from the Institute for the Care of Mother and Child (Prague, Czech Republic) for supplying us with human milk samples.",null,25,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0958-6946",null,"10.1016/j.idairyj.2011.02.005","INT DAIRY J","Int. Dairy J.","JUL",2011,21,7,null,null,null,504,508,null,null,5,"Food Science & Technology","758YR","ISI:000290205100008",""]
["2 z/ze 9",2,9,0.22222222222222221,"2011/129/1/101-110","http://www.ncbi.nlm.nih.gov/pubmed/21190188",4.7220000000000004,"HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers","J","Rotnaglova, E; Tachezy, R; Salakova, M; Prochazka, B; Kosl'abova, E; Vesela, E; Ludvikova, V; Hamsikova, E; Klozar, J",null,null,null,"Rotnaglova, Eliska; Tachezy, Ruth; Salakova, Martina; Prochazka, Bohumir; Kosl'abova, Eva; Vesela, Eva; Ludvikova, Viera; Hamsikova, Eva; Klozar, Jan",null,"HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers","INTERNATIONAL JOURNAL OF CANCER",null,"English","Article",null,null,null,null,null,"HPV; tonsillar cancer; prognosis; antibodies","HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMA; NECK-CANCER; RISK-FACTORS; PHYSICAL STATUS; OROPHARYNGEAL CANCERS; FAVORABLE PROGNOSIS; POSITIVE HEAD; ORAL-CAVITY; SURVIVAL","The association of high-risk human papillomaviruses (HR HPVs) with tonsillar cancer (TC) has been documented. Because patients with HPV-associated tumors show better survival rates, modification of their treatment regimen is being considered. It is therefore crucial to find markers for the identification of patients whose tumors are linked to viral infection. A cohort of 109 patients with primary TC was screened for HPV DNA presence in the tumor tissues and HPV-specific antibodies in sera. Data regarding risk factors and clinical parameters were collected. Forty-five specimens were analyzed for the expression of viral E6 and E2-region mRNA, and the p16 and p53 protein expression status was assessed by immunohistochemistry. The overall prevalence of HPV DNA in TC tissues was 65.1%. Ninety-three percent of HR HPV DNA-positive samples expressed E6*I mRNA. E2-region mRNA expression was detected in 36% of positive samples, which implies that the virus is integrated in 64% of HPV DNA/RNA-positive tumors. p16 overexpression and the presence of antibodies specific to HPV16 E6/E7 oncoproteins correlated well with HPV DNA and RNA presence. The disease-specific survival rate of patients with HPV DNA-positive tumors was significantly higher than that of HPV DNA-negative patients. In addition to providing further evidence of the involvement of HPV infection in the etiopathogenesis of a proportion of TC cases, our study demonstrates that p16 immunostaining and anti-E6/E7 antibodies as surrogate markers of HPV involvement represent specific, sensitive and clinically accessible assays for the identification of TC patients who have a considerably better prognosis.","[Klozar, Jan] Charles Univ Prague, Motol Univ Hosp, Inst Postgrad Med Educ, Dept Otolaryngol & Head & Neck Surg,Fac Med 1, Prague 15006 5, Czech Republic; [Rotnaglova, Eliska; Tachezy, Ruth; Salakova, Martina; Kosl'abova, Eva; Ludvikova, Viera; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic; [Prochazka, Bohumir] Natl Inst Publ Hlth, Dept Sci Informat & Biostat, Prague, Czech Republic; [Vesela, Eva] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic","Klozar, J, Charles Univ Prague, Motol Univ Hosp, Inst Postgrad Med Educ, Dept Otolaryngol & Head & Neck Surg,Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic","jan.klozar@lfmotol.cuni.cz","Grant Agency of the Ministry of Health of the Czech Republic [NR 9466-3]; Grant Agency of the 1st Faculty of Medicine, Charles University in Prague [GAUK 8808]; Charles University in Prague [260 510]","Grant sponsor: Grant Agency of the Ministry of Health of the Czech Republic; Grant number: NR 9466-3; Grant sponsor: Grant Agency of the 1st Faculty of Medicine, Charles University in Prague; Grant number: GAUK 8808; Grant sponsor: Charles University in Prague (University Research Support Grant); Grant number: 260 510",null,50,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0020-7136",null,"10.1002/ijc.25889","INT J CANCER","Int. J. Cancer","JUL 1",2011,129,1,null,null,null,101,110,null,null,10,"Oncology","756BS","ISI:000289987300010",""]
["1 z/ze 29",1,29,3.4482758620689655E-2,"2011/40/2/363-374","http://www.ncbi.nlm.nih.gov/pubmed/21149280",5.2619999999999996,"Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies","J","Cardwell, CR; Stene, LC; Joner, G; Bulsara, MK; Cinek, O; Rosenbauer, J; Ludvigsson, J; Svensson, J; Goldacre, MJ; Waldhoer, T; Jarosz-Chobot, P; Gimeno, SGA; Chuang, LM; Roberts, CL; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Devoti, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Radon, K; Glatthaar, C; Patterson, CC",null,null,null,"Cardwell, Chris R.; Stene, Lars C.; Joner, Geir; Bulsara, Max K.; Cinek, Ondrej; Rosenbauer, Joachim; Ludvigsson, Johnny; Svensson, Jannet; Goldacre, Michael J.; Waldhoer, Thomas; Jarosz-Chobot, Przemyslawa; Gimeno, Suely G. A.; Chuang, Lee-Ming; Roberts, Christine L.; Parslow, Roger C.; Wadsworth, Emma J. K.; Chetwynd, Amanda; Brigis, Girts; Urbonaite, Brone; Sipetic, Sandra; Schober, Edith; Devoti, Gabriele; Ionescu-Tirgoviste, Constantin; de Beaufort, Carine E.; Stoyanov, Denka; Buschard, Karsten; Radon, Katja; Glatthaar, Christopher; Patterson, Chris C.",null,"Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies","INTERNATIONAL JOURNAL OF EPIDEMIOLOGY",null,"English","Article",null,null,null,null,null,"Diabetes mellitus; type 1; epidemiology; birth order; meta-analysis","MATERNAL AGE; EARLY-LIFE; MELLITUS; CHILDREN; DETERMINANTS; ONSET; IDDM; INFECTIONS; DELIVERY; UK","Background The incidence rates of childhood onset type 1 diabetes are almost universally increasing across the globe but the aetiology of the disease remains largely unknown. We investigated whether birth order is associated with the risk of childhood diabetes by performing a pooled analysis of previous studies. Methods Relevant studies published before January 2010 were identified from MEDLINE, Web of Science and EMBASE. Authors of studies provided individual patient data or conducted pre-specified analyses. Meta-analysis techniques were used to derive combined odds ratios (ORs), before and after adjustment for confounders, and investigate heterogeneity. Results Data were available for 6 cohort and 25 case-control studies, including 11 955 cases of type 1 diabetes. Overall, there was no evidence of an association prior to adjustment for confounders. After adjustment for maternal age at birth and other confounders, a reduction in the risk of diabetes in second- or later born children became apparent [fully adjusted OR = 0.90 95% confidence interval (CI) 0.83-0.98; P = 0.02] but this association varied markedly between studies (I-2 = 67%). An a priori subgroup analysis showed that the association was stronger and more consistent in children < 5 years of age (n = 25 studies, maternal age adjusted OR = 0.84 95% CI 0.75, 0.93; I-2 = 23%). Conclusion Although the association varied between studies, there was some evidence of a lower risk of childhood onset type 1 diabetes with increasing birth order, particularly in children aged < 5 years. This finding could reflect increased exposure to infections in early life in later born children.","[Cardwell, Chris R.] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; [Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, Lars C.] Oslo Univ Hosp, Oslo Diabet Res Ctr, Oslo, Norway; [Joner, Geir] Univ Oslo, Inst Hlth Management & Hlth Econ, Oslo, Norway; [Bulsara, Max K.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Bulsara, Max K.] Univ Notre Dame, Inst Hlth & Rehabil Res, Fremantle, Australia; [Cinek, Ondrej] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, Joachim] Univ Dusseldorf, Leibniz Inst, Inst Biometr & Epidemiol, German Diabet Ctr, Dusseldorf, Germany; [Ludvigsson, Johnny] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, Johnny] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Svensson, Jannet] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, Thomas] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Jarosz-Chobot, Przemyslawa] Med Univ Silesia, Dept Pediat Endocrinol & Diabet, Katowice, Poland; [Gimeno, Suely G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Roberts, Christine L.] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia; [Parslow, Roger C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, Emma J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, Amanda] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Brigis, Girts] Riga Stradins Univ, Dept Publ Hlth & Epidemiol, Riga, Latvia; [Urbonaite, Brone] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, Sandra] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, Edith] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Devoti, Gabriele] Univ Lecce, Dept Social Sci & Commun, I-73100 Lecce, Italy; [Ionescu-Tirgoviste, Constantin] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, Carine E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, Denka] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, Karsten] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark; [Radon, Katja] Hosp LMU Munich, Inst Occupat & Environm Med, Munich, Germany; [Radon, Katja] Hosp LMU Munich, Outpatient Clin Occupat & Environm Med, Munich, Germany; [Glatthaar, Christopher] Sir Charles Gairdner Hosp, Perth, WA, Australia","Cardwell, CR, Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland","c.cardwell@qub.ac.uk","Czech Republic Ministry of Education [MSM 0021620814]; Department of Health of Taiwan [DOH 90-TD1028]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Swedish Child Diabetes Foundation ; NHS National Coordinating Centre for Research Capacity Development UK ; Australian National Health and Medical Research Council (NHMRC) [457302]; Research Council of Norway ; German Research Foundation [HE 234/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes UK ; Northern Ireland Department of Health and Social Services ","This pooled analysis was not directly funded but the authors acknowledge support for the conduct of the original studies from the following: the Czech Republic Ministry of Education (grant MSM 0021620814), Department of Health of Taiwan (DOH 90-TD1028), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 94/0943-0), The Swedish Child Diabetes Foundation, the NHS National Coordinating Centre for Research Capacity Development UK, Australian National Health and Medical Research Council (NHMRC) (project grant #457302), the Research Council of Norway, the German Research Foundation (grant HE 234/1-1), the Ministry for Science and Technological Development of Serbia (No. 145084, 2006-2010), EUBIROD funded by the European Commission Health Information Strand (DG-SANCO 2005, Contract No 2007115), Diabetes UK and the Northern Ireland Department of Health and Social Services.",null,48,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0300-5771",null,"10.1093/ije/dyq207","INT J EPIDEMIOL","Int. J. Epidemiol.","APR",2011,40,2,null,null,null,363,374,null,null,12,"Public, Environmental & Occupational Health","745LB","ISI:000289165800015",""]
["1 z/ze 8",1,8,0.125,"2011/40/2/146-149","http://www.ncbi.nlm.nih.gov/pubmed/21074368",1.444,"The influence of orthognathic surgery on ventilation during sleep","J","Foltan, R; Hoffmannova, J; Pavlikova, G; Hanzelka, T; Klima, K; Horka, E; Adamek, S; Sedy, J",null,null,null,"Foltan, Rene; Hoffmannova, Jirina; Pavlikova, Gabriela; Hanzelka, Tomas; Klima, Karel; Horka, Edita; Adamek, Svatopluk; Sedy, Jiri",null,"The influence of orthognathic surgery on ventilation during sleep","INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY",null,"English","Article",null,null,null,null,null,"orthognathic surgery; obstructive sleep apnea; ventilation; sleep","MANDIBULAR SETBACK SURGERY; APNEA SYNDROME; AIRWAY SIZE; MAXILLOMANDIBULAR ADVANCEMENT; EXPANSION","Orthognathic surgery has varying effects on respiratory parameters. The authors undertook a prospective study of patients requiring mandibular advancement, mandibular setback and maxillary Le Fort I advancement, and surgically assisted rapid maxillary expansion (SARME). Breathing parameters were monitored in a sleep laboratory the night before the operation and in a mean of 9.5 months after the operation. In patients treated with mandibular advancement, the respiratory disturbance index (RDI), oxygen desaturation index (ODI), and number of obstructive apnoeas (OAs) improved significantly. In patients treated with mandibular setback and maxillary Le Fort I advancement, the RDI, ODI, index of flow limitations (IFL), number of obstructive hypopnoeas (OHs), OA, and oxygen saturation deteriorated. In contrast, patients treated with SARME improved only mildly. These results indicate that bimaxillary surgery for Class III malocclusion increased upper airway resistance, probably because of a more dorsal positioning of the base of the tongue, representing an iatrogenic obstructive sleep apnoea (OSA). A young person would probably be able to balance such a decline in respiratory function using different adaptative mechanisms. Mandibular advancement significantly improved respiratory parameters during sleep. The possible effect of orthognathic surgery on the upper airways should be incorporated into the treatment plan.","[Horka, Edita; Sedy, Jiri] Charles Univ Prague, Inst Dent Res, Fac Med 1, Prague 12800 2, Czech Republic; [Horka, Edita; Sedy, Jiri] Gen Univ Hosp, Prague 12800 2, Czech Republic; [Foltan, Rene; Hoffmannova, Jirina; Pavlikova, Gabriela; Hanzelka, Tomas; Klima, Karel] Charles Univ Prague, Dept Oral & Maxillofacial Surg, Fac Med 1, Prague 12800 2, Czech Republic; [Adamek, Svatopluk] Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Adamek, Svatopluk] Teaching Hosp Motol, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic","Sedy, J, Charles Univ Prague, Inst Dent Res, Fac Med 1, Karlovo Namesti 32, Prague 12800 2, Czech Republic","jirisedy@hotmail.com",null,null,null,22,0,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0901-5027",null,"10.1016/j.ijom.2010.10.006","INT J ORAL MAXILLOFAC SURG","Int. J. Oral Maxillofac. Surg.","FEB",2011,40,2,null,null,null,146,149,null,null,4,"Dentistry, Oral Surgery & Medicine; Surgery","736DQ","ISI:000288471100004",""]
["1 z/ze 2",1,2,0.5,"2011/35/3/341-348","http://www.ncbi.nlm.nih.gov/pubmed/20401752",1.825,"Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)","J","Trc, T; Bohmova, J",null,null,null,"Trc, Tomas; Bohmova, Jana",null,"Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)","INTERNATIONAL ORTHOPAEDICS",null,"English","Article",null,null,null,null,null,null,"ANTIRHEUMATIC DRUG TRIALS; CLINICAL-TRIALS; ARTHRITIS","This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged >= 40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days. Follow-up took place after two weeks and after one, two and three months. Primary [visual analogue scale (VAS), Western Ontario and McMaster Universities (WOMAC Index)] and secondary outcomes variables, assessed at weeks two, four, eight and 12, were KOA pain intensity measured by quadruple visual analogue scales in the target knee, the WOMAC total score index, patient's and investigator's global assessments of disease activity, joint assessment, use of rescue medication (ibuprofen 400 mg tablets) and assessment of Quality of Life index (SF-36 Questionnaire). Safety and tolerability were also evaluated. Clear improvement was observed in both joint pain and symptoms in patients with KOA treated with EHC (Colatech (R)) and significant differences were observed. Mean reductions from baseline for EHC 10 g daily and GS 1.5 g, respectively, were KOA pain intensity reduction in the target knee for Colatech (R) (p<0.05): WOMAC index decrease <= 15 points at the last visit (day 90) for Colatech (R) in 16 patients (34.04%) (p<0.05) and for glucosamine in six patients (13.04%); total score index for painful joints: Colatech (R) 1.6 (p<0.05) and glucosamine 1.8; total score index for swollen joints: Colatech (R) 0.5 (p<0.05) and glucosamine 0.7; patient's global assessment of efficacy as the sum of improvement good + ideal: 80.8% for Colatech (R) and 46.6% for glucosamine (p<0.05). EHC (Colatech (R)) showed superior improvement over GS in the SF-36 Questionnaire in the Physical Health Index (42.0 for Colatech and 40.0 for glucosamine). The incidence of adverse events was similar in both groups. Both EHC and GS were well tolerated.","[Trc, Tomas] Charles Univ Prague, Orthopaed Clin, Sch Med 2, Prague, Czech Republic; [Bohmova, Jana] Fac Hosp Brno, Dept Rheumatol, Brno, Czech Republic","Trc, T, Charles Univ Prague, Orthopaed Clin, Sch Med 2, Prague, Czech Republic","tomas.trc@lfmotol.cuni.cz",null,null,null,20,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,"10.1007/s00264-010-1010-z","INT ORTHOP","Int. Orthop.","MAR",2011,35,3,null,null,null,341,348,null,null,8,"Orthopedics","742RA","ISI:000288961000005",""]
["3 z/ze 6",3,6,0.5,"2011/41/4/524-527","http://www.ncbi.nlm.nih.gov/pubmed/20697793",3.0630000000000002,"Brief Report: Significant Differences in Perceived Odor Pleasantness Found in Children with ASD","J","Hrdlicka, M; Vodicka, J; Havlovicova, M; Urbanek, T; Blatny, M; Dudova, I",null,null,null,"Hrdlicka, Michal; Vodicka, Jan; Havlovicova, Marketa; Urbanek, Tomas; Blatny, Marek; Dudova, Iva",null,"Brief Report: Significant Differences in Perceived Odor Pleasantness Found in Children with ASD","JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS",null,"English","Article",null,null,null,null,null,"Autism; Asperger's syndrome; Sensory abnormalities; Olfactory; Pleasantness; Sniffin' Sticks","OLFACTORY SENSITIVITY; AUTISM; IDENTIFICATION; DISORDER; METAANALYSIS; INDIVIDUALS; STIMULI","The aim of our study was to explore possible differences in estimation of odor pleasantness in children with autism spectrum disorders (ASD) compared to controls. Thirty-five patients with Asperger's syndrome and high functioning autism (mean age 10.8 +/- A 3.6 years; 31 boys) were compared with 35 healthy control subjects (mean age 10.4 +/- A 2.4 years; 28 boys). Odor pleasantness was assessed on a 5-point scale using the Sniffin' Sticks test (Identification part of the test). Patients with ASD, compared to healthy controls, perceived the smell of cinnamon and pineapple as significantly less pleasant (p < 0.05); at the trend level, the same was true of cloves (p < 0.1). The possibility of olfactory dysfunctions as an autism biomarker is discussed.","[Hrdlicka, Michal; Dudova, Iva] Charles Univ Prague, Fac Med 2, Dept Child Psychiat, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 15006, Czech Republic; [Vodicka, Jan] Univ Pardubice, Fac Hlth Studies, Dept Otorhinolaryngol & Head & Neck Surg, Pardubice, Czech Republic; [Havlovicova, Marketa] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006, Czech Republic; [Urbanek, Tomas; Blatny, Marek] Acad Sci Czech Republic, Inst Psychol, Brno, Czech Republic","Hrdlicka, M, Charles Univ Prague, Fac Med 2, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic","michal.hrdlicka@lfmotol.cuni.cz",null,null,null,21,0,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0162-3257",null,"10.1007/s10803-010-1084-x","J AUTISM DEV DISORD","J. Autism Dev. Disord.","APR",2011,41,4,null,null,null,524,527,null,null,4,"Psychology, Developmental","733JQ","ISI:000288259400015",""]
["1 z/ze 18",1,18,5.5555555555555552E-2,"2011/29/9/1125-1132","http://www.ncbi.nlm.nih.gov/pubmed/21343556",17.792999999999999,"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","J","Henry, DH; Costa, L; Goldwasser, F; Hirsh, V; Hungria, V; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Willenbacher, W; Woll, PJ; Wang, JM; Jiang, Q; Jun, S; Dansey, R; Yeh, H",null,null,null,"Henry, David H.; Costa, Luis; Goldwasser, Francois; Hirsh, Vera; Hungria, Vania; Prausova, Jana; Scagliotti, Giorgio Vittorio; Sleeboom, Harm; Spencer, Andrew; Vadhan-Raj, Saroj; von Moos, Roger; Willenbacher, Wolfgang; Woll, Penella J.; Wang, Jianming; Jiang, Qi; Jun, Susie; Dansey, Roger; Yeh, Howard",null,"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","JOURNAL OF CLINICAL ONCOLOGY",null,"English","Article",null,null,null,null,null,null,"KAPPA-B LIGAND; PLACEBO-CONTROLLED TRIAL; LONG-TERM EFFICACY; SKELETAL COMPLICATIONS; RECEPTOR ACTIVATOR; SOLID TUMORS; LUNG-CANCER; PHASE-III; PAMIDRONATE; BISPHOSPHONATES","Purpose This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. Patients and Methods Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). Results Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. Conclusion Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment. J Clin Oncol 29: 1125-1132. (C) 2011 by American Society of Clinical Oncology","[Henry, David H.] Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19106 USA; Hosp Santa Maria, Lisbon, Portugal; Inst Mol Med, Lisbon, Portugal; Teaching Hosp Cochin, Paris, France; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil; Univ Hosp Motol, Prague, Czech Republic; Univ Torino, Orbassano, Italy; HagaZiekenhuis Leyenburg, The Hague, Netherlands; Alfred Hosp, Melbourne, Vic, Australia; Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; Kantonsspital Graubunden, Chur, Switzerland; Med Univ Innsbruck, Innsbruck, Austria; Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England; Amgen Inc, Thousand Oaks, CA USA","Henry, DH, Penn Hosp, Joan Karnell Canc Ctr, 230 W Washington Sq, Philadelphia, PA 19106 USA","davidhenry@pennoncology.com","Amgen, Thousand Oaks, CA ; Amgen ; Centocor Ortho Biotech ; Watson Pharmaceuticals ; Novartis ","Supported by Amgen, Thousand Oaks, CA. Research Funding: David H. Henry, Amgen, Centocor Ortho Biotech, Watson Pharmaceuticals; Luis Costa, Amgen, Novartis; Harm Sleeboom, Amgen, Novartis; Saroj Vadhan-Raj, Amgen; Wolfgang Willenbacher, Amgen; Penella J. Woll, Amgen",null,39,1,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,"10.1200/JCO.2010.31.3304","J CLIN ONCOL","J. Clin. Oncol.","MAR 20",2011,29,9,null,null,null,1125,1132,null,null,8,"Oncology","736YZ","ISI:000288532500024",""]
["7 z/ze 9",7,9,0.77777777777777779,"2011/52/4/474-477","http://www.ncbi.nlm.nih.gov/pubmed/21407103",2.1829999999999998,"Adiponectin, AFABP, and Leptin in Human Breast Milk During 12 Months of Lactation","J","Bronsky, J; Mitrova, K; Karpisek, M; Mazoch, J; Durilova, M; Fisarkova, B; Stechova, K; Prusa, R; Nevoral, J",null,null,null,"Bronsky, Jiri; Mitrova, Katarina; Karpisek, Michal; Mazoch, Jiri; Durilova, Marianna; Fisarkova, Barbora; Stechova, Katerina; Prusa, Richard; Nevoral, Jiri",null,"Adiponectin, AFABP, and Leptin in Human Breast Milk During 12 Months of Lactation","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,"English","Article",null,null,null,null,null,"adipocyte fatty acid-binding protein; adiponectin; breast milk; leptin; nutritional programming","ACID-BINDING PROTEIN; RECEPTOR ISOFORM; FOOD-INTAKE; SERUM; ADIPOSITY; OBESITY; MOTHERS; LIFE; INFANTS","Objectives: Adiponectin, adipocyte fatty acid-binding protein (AFABP), and leptin have been shown to be present in human breast milk (BM). We determined intraindividual changes of BM levels of these proteins during 12 months of lactation. Subjects and Methods: Proteins were measured using a high-sensitivity enzyme-linked immunosorbent assay method in 72 healthy mothers after delivery (day 0, D0) and after 1, 3, 6, and 12 months of lactation. Results: Adiponectin levels in BM on D0 were 22.8 +/- 0.8 (mean +/- standard error of the mean), in 1 month (M1) 22.0 +/- 0.6, in 3 months (M3) 20.5 +/- 0.6, in 6 months (M6) 21.4 +/- 0.8, and in 12 months (M12) 25.7 +/- 1.4 ng/mL. AFABP levels were 12.3 +/- 2.0, 6.2 +/- 1.3, 1.3 +/- 0.2, 2.5 +/- 1.0, and 4.6 +/- 1.9 ng/mL, respectively. Leptin levels were 0.3 +/- 0.04, 0.2 +/- 0.03, 0.1 +/- 0.01, 0.1 +/- 0.02, and 0.2 +/- 0.04 ng/mL, respectively. We found significantly higher levels of adiponectin in M12 in comparison to M3 and M6 (P = 0.0026), higher levels of AFABP in D0 and M1 when compared with M3, M6, and M12 (P < 0.0001), and higher levels of leptin on D0 than in M1, M3, M6, and M12 (P < 0.0001). AFABP levels correlated negatively with infants' body weight in M1, but there was no correlation throughout the lactation period between body weight and other proteins. We found positive correlation between adiponectin, AFABP, and leptin throughout the lactation. Conclusions: All of the hormones were detectable in BM up to 12 months of lactation, with decreasing trend until M3 and subsequent increase till M12. We speculate that higher levels in M6 and M12 may be caused by longer intervals between breast-feeding due to the introduction of complementary food.","[Bronsky, Jiri; Mitrova, Katarina; Durilova, Marianna; Stechova, Katerina; Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Med Fac 2, Prague 15006 5, Czech Republic; [Prusa, Richard] Univ Hosp Motol, Med Fac 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Karpisek, Michal; Mazoch, Jiri] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Human Pharmacol & Toxicol, Brno, Czech Republic; [Fisarkova, Barbora] Charles Univ Prague, Dept Neonatol, Med Fac 2, Prague 15006 5, Czech Republic","Bronsky, J, Charles Univ Prague, Dept Paediat, Med Fac 2, V Uvalu 84, Prague 15006 5, Czech Republic","bronsky@email.cz","VZ MZO [64203/6903]","The present study was supported by research grant VZ MZO 64203/6903 (VZ FNM 2005).",null,19,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,"10.1097/MPG.0b013e3182062fcc","J PEDIAT GASTROENTEROL NUTR","J. Pediatr. Gastroenterol. Nutr.","APR",2011,52,4,null,null,null,474,477,null,null,4,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","737AZ","ISI:000288541100021",""]
["2 z/ze 5",2,5,0.4,"2011/377/9775/1407-1407","http://www.ncbi.nlm.nih.gov/pubmed/21515161",30.757999999999999,"Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland","J","Nyc, O; Pituch, H; Matejkova, J; Obuch-Woszczatynski, P; Kuijper, EJ",null,null,null,"Nyc, Otakar; Pituch, Hanna; Matejkova, Jana; Obuch-Woszczatynski, Piotr; Kuijper, Ed J.",null,"Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland","LANCET",null,"English","Letter",null,null,null,null,null,null,null,null,"[Nyc, Otakar; Matejkova, Jana] Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 5, Czech Republic; [Pituch, Hanna; Obuch-Woszczatynski, Piotr] Med Univ Warsaw, Dept Med Microbiol, Warsaw, Poland; [Kuijper, Ed J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands","Nyc, O, Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 5, Czech Republic","otakar.nyc@seznam.cz",null,null,null,3,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","APR 23",2011,377,9775,null,null,null,1407,1407,null,null,1,"Medicine, General & Internal","755UF","ISI:000289963000025",""]
["2 z/ze 21",2,21,9.5238095238095233E-2,"2011/25/3/455-462","http://www.ncbi.nlm.nih.gov/pubmed/21212791",8.2959999999999994,"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","J","Strahm, B; Nollke, P; Zecca, M; Korthof, ET; Bierings, M; Furlan, I; Sedlacek, P; Chybicka, A; Schmugge, M; Bordon, V; Peters, C; O'Marcaigh, A; de Heredia, CD; Bergstraesser, E; Moerloose, BD; van den Heuvel-Eibrink, MM; Stary, J; Trebo, M; Wojcik, D; Niemeyer, CM; Locatelli, F",null,null,null,"Strahm, B.; Noellke, P.; Zecca, M.; Korthof, E. T.; Bierings, M.; Furlan, I.; Sedlacek, P.; Chybicka, A.; Schmugge, M.; Bordon, V.; Peters, C.; O'Marcaigh, A.; de Heredia, C. D.; Bergstraesser, E.; Moerloose, B. D.; van den Heuvel-Eibrink, M. M.; Stary, J.; Trebo, M.; Wojcik, D.; Niemeyer, C. M.; Locatelli, F.","EWOG-MDS Study Grp","Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","LEUKEMIA",null,"English","Article",null,null,null,null,null,"myelodysplastic syndrome; stem cell transplantation; children","ACUTE MYELOID-LEUKEMIA; JUVENILE MYELOMONOCYTIC LEUKEMIA; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CHILDHOOD; GRAFT; CLASSIFICATION; EXPERIENCE; SURVIVAL; THERAPY","We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011","[Strahm, B.; Noellke, P.; Furlan, I.; Niemeyer, C. M.] Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany; [Zecca, M.] IRCCS Policlin, Dept Pediat, San Matteo, Italy; [Korthof, E. T.] Leiden Univ, Med Ctr, Div Stem Cell Transplantat, Dept Pediat, Leiden, Netherlands; [Bierings, M.] Univ Hosp Children, Dept Hematol, Utrecht, Netherlands; [Sedlacek, P.; Stary, J.] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Chybicka, A.; Wojcik, D.] Med Univ, Dept Pediat Bone Marrow Transplantat Oncol & Hema, Wroclaw, Poland; [Schmugge, M.; Bergstraesser, E.] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [Bordon, V.; Moerloose, B. D.] Ghent Univ Hosp, Dept Pediat Hematol & Oncol, B-9000 Ghent, Belgium; [Peters, C.; Trebo, M.] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [O'Marcaigh, A.] Our Ladys Hosp Sick Children, Dept Hematol & Oncol, Dublin, Ireland; [de Heredia, C. D.] Hosp Valle De Hebron, Dept Pediat Oncol & Hematol, Barcelona, Spain; [van den Heuvel-Eibrink, M. M.] Erasmus MC, Rotterdam, Netherlands; [van den Heuvel-Eibrink, M. M.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Locatelli, F.] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol & Oncol, Rome, Italy","Strahm, B, Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Mathildenstr 1, D-79106 Freiburg, Germany","brigitte.strahm@uniklinik-freiburg.de",null,null,null,29,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,"10.1038/leu.2010.297","LEUKEMIA","Leukemia","MAR",2011,25,3,null,null,null,455,462,null,null,8,"Oncology; Hematology","732CB","ISI:000288159500008",""]
["1 z/ze 6",1,6,0.16666666666666666,"2011/26/5/924-925","http://www.ncbi.nlm.nih.gov/pubmed/21425341",4.0140000000000002,"DYT 6-A Novel THAP1 Mutation With Excellent Effect on Pallidal DBS","J","Jech, R; Bares, M; Krepelova, A; Urgosik, D; Havrankova, P; Ruzicka, E",null,null,null,"Jech, Robert; Bares, Martin; Krepelova, Anna; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen",null,"DYT 6-A Novel THAP1 Mutation With Excellent Effect on Pallidal DBS","MOVEMENT DISORDERS",null,"English","Letter",null,null,null,null,null,null,"DEEP BRAIN-STIMULATION; DYSTONIA",null,"[Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Gen Univ Hosp, Prague, Czech Republic; [Bares, Martin] Masaryk Univ, Fac Med, St Annes Hosp, Dept Neurol 1, Brno, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic; [Urgosik, Dusan] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic","Jech, R, Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic","jech@cesnet.cz",null,null,null,7,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,"10.1002/mds.23599","MOVEMENT DISORD","Mov. Disord.","APR",2011,26,5,null,null,null,924,925,null,null,2,"Clinical Neurology","762AT","ISI:000290445400060",""]
["1 z/ze 5",1,5,0.2,"2011/26/1/184-187","http://www.ncbi.nlm.nih.gov/pubmed/20848620",4.0140000000000002,"Pallidal Stimulation in Siblings with Pantothenate Kinase-Associated Neurodegeneration: Four-Year Follow-Up","J","Adamovicova, M; Jech, R; Urgosik, D; Spackova, N; Krepelova, A",null,null,null,"Adamovicova, Miriam; Jech, Robert; Urgosik, Dusan; Spackova, Natasa; Krepelova, Anna",null,"Pallidal Stimulation in Siblings with Pantothenate Kinase-Associated Neurodegeneration: Four-Year Follow-Up","MOVEMENT DISORDERS",null,"English","Letter",null,null,null,null,null,null,"DEEP BRAIN-STIMULATION; HALLERVORDEN-SPATZ-SYNDROME; IRON ACCUMULATION; DYSTONIA; MR",null,"[Adamovicova, Miriam] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic; [Adamovicova, Miriam; Jech, Robert; Spackova, Natasa] Gen Univ Hosp, Prague, Czech Republic; [Jech, Robert; Spackova, Natasa] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; [Urgosik, Dusan] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic","Adamovicova, M, Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic","adamovicova.m@seznam.cz",null,null,null,18,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,"10.1002/mds.23349","MOVEMENT DISORD","Mov. Disord.","JAN",2011,26,1,null,null,null,184,187,null,null,4,"Clinical Neurology","732IO","ISI:000288178400037",""]
["4 z/ze 8",4,8,0.5,"2011/8/4/169-177","http://www.ncbi.nlm.nih.gov/pubmed/21124005",3.496,"Spatial Navigation and APOE in Amnestic Mild Cognitive Impairment","J","Laczo, J; Andel, R; Vlcek, K; Matoska, V; Vyhnalek, M; Tolar, M; Bojar, M; Hort, J",null,null,null,"Laczo, Jan; Andel, Ross; Vlcek, Kamil; Matoska, Vaclav; Vyhnalek, Martin; Tolar, Martin; Bojar, Martin; Hort, Jakub",null,"Spatial Navigation and APOE in Amnestic Mild Cognitive Impairment","NEURODEGENERATIVE DISEASES",null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Mild cognitive impairment; Apolipoprotein E; Spatial navigation; Morris water maze; Memory","APOLIPOPROTEIN-E GENOTYPE; ALZHEIMERS-DISEASE; ELDERLY INDIVIDUALS; EPSILON-4 ALLELE; BRAIN-FUNCTION; E GENE; MEMORY; RISK; APOE-EPSILON-4; ATTENTION","Background: The effect of APOE epsilon 4 allele (epsilon 4) on spatial navigation in amnestic mild cognitive impairment (aMCI) is unknown. Objective: Our purpose was to examine the characteristics of spatial navigation impairment in epsilon 4-positive (epsilon 4+) and epsilon 4-negative (epsilon 4-) aMCI subgroups. Methods: Blood samples were collected to determine the APOE genotype. A total of 34 aMCI patients were stratified into aMCI-epsilon 4- (n = 23) and aMCI-epsilon 4+ (n = 11) groups. Control (n = 28) and mild Alzheimer's disease (AD; n = 16) groups were also used. We used a human analogue of the Morris water maze (enclosed arena 2.9 m in diameter) to examine body-centered (egocentric) and world-centered (allocentric) spatial navigation. Results: The aMCI-epsilon 4+ group performed poorer on spatial navigation than the aMCI-epsilon 4-group in both egocentric and allocentric tasks even though these 2 groups did not differ in global cognitive functioning or neuropsychological tests. The aMCI-epsilon 4+ and mild AD groups performed similarly on all Morris Water Maze tasks and were outperformed by the aMCI-epsilon 4- group, which also resembled the control group in performance on the egocentric tasks. The aMCI groups showed poor spatial navigation learning regardless of their epsilon 4 positivity. Conclusion: We found more profound deficits in spatial navigation in aMCI-epsilon 4+ relative to aMCI-epsilon 4- patients. The aMCI-epsilon 4+ group resembled the mild AD group in spatial navigation performance. Although the epsilon 4 genotype was indicative of spatial navigation performance, it was not indicative of the aMCI patients' ability to learn the tasks. Spatial navigation testing represents a promising area with respect to identifying individuals at higher risk for AD among the heterogeneous MCI population. Copyright (C) 2010 S. Karger AG, Basel","[Laczo, Jan; Vyhnalek, Martin; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Sch Med 2, Dept Neurol, Memory Disorders Unit, CZ-15006 Prague 5, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Memory Disorders Unit, Prague, Czech Republic; [Matoska, Vaclav] Homolka Hosp, Dept Clin Biochem Hematol & Immunol, Prague, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Hort, Jakub] Int Clin Res Ctr, Brno, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Tolar, Martin] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA","Hort, J, Charles Univ Prague, Sch Med 2, Dept Neurol, Memory Disorders Unit, Uvalu 84, CZ-15006 Prague 5, Czech Republic","Jakub.Hort@seznam.cz","Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; Ministry of Education, Youth and Sports of the Czech Republic [1M0517, LC554, AV0Z50110509]","The study was supported by the Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286, Ministry of Education, Youth and Sports of the Czech Republic Grants 1M0517 and LC554, and research project AV0Z50110509.",null,43,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854",null,"10.1159/000321581","NEURODEGENER DIS","Neurodegener. Dis.",null,2011,8,4,null,null,null,169,177,null,null,9,"Clinical Neurology; Neurosciences","763LT","ISI:000290559000002",""]
["5 z/ze 10",5,10,0.5,"2011/12/3/266-269","http://www.ncbi.nlm.nih.gov/pubmed/21214702",2.6280000000000001,"Familial mild hyperglycemia associated with a novel ABCC8-V84I mutation within three generations","J","Gonsorcikova, L; Vaxillaire, M; Pruhova, S; Dechaume, A; Dusatkova, P; Cinek, O; Pedersen, O; Froguel, P; Hansen, T; Lebl, J",null,null,null,"Gonsorcikova, Lucie; Vaxillaire, Martine; Pruhova, Stepanka; Dechaume, Aurelie; Dusatkova, Petra; Cinek, Ondrej; Pedersen, Oluf; Froguel, Philippe; Hansen, Torben; Lebl, Jan",null,"Familial mild hyperglycemia associated with a novel ABCC8-V84I mutation within three generations","PEDIATRIC DIABETES",null,"English","Article",null,null,null,null,null,"ABCC8; diabetes; hyperglycemia; MODY; SUR1","NEONATAL DIABETES-MELLITUS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; CHANNEL SUBUNITS; GENE; DOMINANT","We present a unique case of a 19-year-old man with a positive family history of persistent mild hyperglycemia and a novel V84I mutation in ABCC8. The proband was initially detected to have fasting hyperglycemia (ranging 6.1-6.4 mmol/L) at the age of 12 years. Increased fasting blood glucose was also subsequently detected in five additional family members (in his twin brother, sister, mother, maternal aunt, and grandfather). The grandfather has been known to have mild diabetes since 30 years and has never been treated. After having excluded a causative mutation in five maturity-onset diabetes of the young genes (MODY1-4 and 6), we identified a novel ABCC8 V84I mutation, which segregated with autosomal dominant transmission of mild hyperglycemia within three generations. This mutation that is located in a conserved area of transmembrane domain TMD0 seems to be a rare cause of clinical phenotype resembling glucokinase-deficient diabetes.","[Gonsorcikova, Lucie; Pruhova, Stepanka; Dusatkova, Petra; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Vaxillaire, Martine; Dechaume, Aurelie; Froguel, Philippe] Univ Lille 2, Inst Pasteur, Lille Inst Biol, CNRS,UMR8090, Lille, France; [Pruhova, Stepanka] Charles Univ Prague, Fac Med 3, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, Gentofte, Denmark; [Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark","Lebl, J, Charles Univ Prague, Fac Med 2, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic","jan.lebl@lfmotol.cuni.cz","Norway through the Norwegian Financial Mechanism [CZ0100]; Czech Ministry of Education [MSM 0021620814]; Czech Ministry of Health [MZ 000064203]","The study was supported by a grant from Norway through the Norwegian Financial Mechanism (No CZ0100), by an institutional grant from the Czech Ministry of Education (grant MSM 0021620814) and by an institutional grant from the Czech Ministry of Health (grant MZ 000064203). The authors would like to acknowledge the patient and his family. Klara Vesela is thanked for her technical assistance.",null,16,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,"10.1111/j.1399-5448.2010.00719.x","PEDIATR DIABETES","Pediatr. Diabetes","MAY",2011,12,3,"Part 2",null,null,266,269,null,null,4,"Endocrinology & Metabolism; Pediatrics","754XZ","ISI:000289892500009",""]
["10 z/ze 10",10,10,1,"2011/60/1/83-93","http://www.ncbi.nlm.nih.gov/pubmed/20533857",1.43,"Isolation of Rat Lung Mast Cells for Purposes of One-Week Cultivation Using Novel Percoll Variant Percoll PLUS","J","Kubrycht, J; Maxova, H; Nyc, O; Vajner, L; Novotna, J; Hezinova, A; Trnkova, A; Vrablova, K; Vytasek, R; Valouskova, V",null,null,null,"Kubrycht, J.; Maxova, H.; Nyc, O.; Vajner, L.; Novotna, J.; Hezinova, A.; Trnkova, A.; Vrablova, K.; Vytasek, R.; Valouskova, V.",null,"Isolation of Rat Lung Mast Cells for Purposes of One-Week Cultivation Using Novel Percoll Variant Percoll PLUS","PHYSIOLOGICAL RESEARCH",null,"English","Article",null,null,null,null,null,"Hypoxia; Lung mast cells; Percoll; C-kit; Progenitor; Secretion","C-TYPE LECTIN; RBL-2H3 CELLS; MATRIX METALLOPROTEINASES; HISTAMINE-RELEASE; HYPOXIA; EXPRESSION; INTERLEUKIN-18; ACTIVATION; SEPARATION; VANCOMYCIN","Prolonged cultivation of separated rat lung mast cells (LMC) in vitro is necessary to better investigate a possible role of LMC in different stages of tissue remodeling induced by hypoxia. Rat lung mast cells (LMC) were separated using a protocol including an improved proteolytic extraction and two subsequent density gradient separations on Ficoll-Paque PLUS and a new generation of Percoll, i.e. Percoll PLUS. Instead of usual isotonic stock Percoll solution, an alternative \"asymptotically isotonic\" stock solution was more successful in our density separation of LMC on Percoll PLUS. Separated cells were cultivated for six days in media including stem cell factor, interleukins IL-3 and IL-6, and one of two alternative mixtures of antibiotics. These cultivations were performed without any contamination and with only rare changes in cell size and morphology. Model co-cultivation of two allogenic fractions of LMC often caused considerable rapid changes in cell morphology and size. In contrast to these observations no or rare morphological changes were found after cultivation under hypoxic conditions. In conclusions, we modified separation on Percoll PLUS to be widely used, altered LMC separation with respect to purposes of long-lasting cultivation and observed some model morphological changes of LMC.","[Kubrycht, J.; Maxova, H.; Vajner, L.; Novotna, J.; Hezinova, A.; Trnkova, A.; Vrablova, K.; Vytasek, R.; Valouskova, V.] Cardiovasc Res Ctr, Prague, Czech Republic; [Valouskova, V.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Maxova, H.; Hezinova, A.] Charles Univ Prague, Dept Pathol Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Vajner, L.; Vrablova, K.] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15000 5, Czech Republic; [Novotna, J.; Vytasek, R.] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15000 5, Czech Republic; [Nyc, O.] Charles Univ Prague, Dept Microbiol, Fac Med 2, Prague 15000 5, Czech Republic","Kubrycht, J, Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic","jkub@post.cz","Grant Agency of the Czech Republic [305/08/0108]; Cardiovascular Research Centre [MSMT 1M0510]","The study was supported by the Grant Agency of the Czech Republic 305/08/0108 and by the Cardiovascular Research Centre MSMT 1M0510.",null,45,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,1,null,null,null,83,93,null,null,11,"Physiology","737IZ","ISI:000288563800009",""]
["2 z/ze 8",2,8,0.25,"2011/108/20/8467-8472","http://www.ncbi.nlm.nih.gov/pubmed/21536893",9.4320000000000004,"Astroglial networks scale synaptic activity and plasticity","J","Pannasch, U; Vargova, L; Reingruber, J; Ezan, P; Holcman, D; Giaume, C; Sykova, E; Rouach, N",null,null,null,"Pannasch, Ulrike; Vargova, Lydia; Reingruber, Juergen; Ezan, Pascal; Holcman, David; Giaume, Christian; Sykova, Eva; Rouach, Nathalie",null,"Astroglial networks scale synaptic activity and plasticity","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA",null,"English","Article",null,null,null,null,null,"hippocampus; neuroglial interactions","LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL CELLS; GLUTAMATE UPTAKE; EXTRACELLULAR POTASSIUM; SILENT SYNAPSES; GLIAL-CELLS; TIME-COURSE; TRANSMISSION; EXCITABILITY; ASTROCYTES","Astrocytes dynamically interact with neurons to regulate synaptic transmission. Although the gap junction proteins connexin 30 (Cx30) and connexin 43 (Cx43) mediate the extensive network organization of astrocytes, their role in synaptic physiology is unknown. Here we show, by inactivating Cx30 and Cx43 genes, that astroglial networks tone down hippocampal synaptic transmission in CA1 pyramidal neurons. Gap junctional networking facilitates extracellular glutamate and potassium removal during synaptic activity through modulation of astroglial clearance rate and extracellular space volume. This regulation limits neuronal excitability, release probability, and insertion of postsynaptic AMPA receptors, silencing synapses. By controlling synaptic strength, connexins play an important role in synaptic plasticity. Altogether, these results establish connexins as critical proteins for extracellular homeostasis, important for the formation of functional synapses.","[Pannasch, Ulrike; Ezan, Pascal; Giaume, Christian; Rouach, Nathalie] CNRS, UMR 7241, Ctr Interdisciplinary Res Biol, F-75005 Paris, France; [Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006, Czech Republic; [Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006, Czech Republic; [Vargova, Lydia; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220, Czech Republic; [Reingruber, Juergen; Holcman, David] Ecole Normale Super, CNRS, UMR 8197, Inst Biol, F-75005 Paris, France; [Reingruber, Juergen; Holcman, David] Ecole Normale Super, INSERM, U1024, Dept Computat Biol & Math, F-75005 Paris, France; [Pannasch, Ulrike; Ezan, Pascal; Giaume, Christian; Rouach, Nathalie] Coll France, INSERM, U1050, F-75005 Paris, France","Rouach, N, CNRS, UMR 7241, Ctr Interdisciplinary Res Biol, F-75005 Paris, France","nathalie.rouach@college-de-france.fr","Human Frontier Science Program Organization ; Agence Nationale de la Recherche ; Institut National de la Sante et de la Recherche Medicale ; French Research Ministry ; Deutsche Forschungsgemeinschaft ; Franco Czech Barrande Program (Hubert Curien Program) ; Grant Agency of the Czech Republic [309/09/1597]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538]","We thank O. Chever, A. Tzingounis, D. Schmitz, and A. Koulakoff for helpful discussions and/or technical assistance, as well as K. Willecke for providing the Cx30<SUP>-/-</SUP>Cx43fl/fl:hGFAP-Cre mice. This work was supported by grants from the Human Frontier Science Program Organization (Career Development Award), Agence Nationale de la Recherche (Programme Jeunes Chercheurs), and Institut National de la Sante et de la Recherche Medicale (to N.R.); postdoctoral fellowships from the French Research Ministry and Deutsche Forschungsgemeinschaft (to U.P.); and a grant from the Franco Czech Barrande Program (Hubert Curien Program) (to N.R. and L.V.), Grant 309/09/1597 from the Grant Agency of the Czech Republic (to L.V. and E.S.), Grant AVOZ50390512 from the Academy of Sciences of the Czech Republic (to E.S.) and Grant 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic (to E.S.).",null,34,0,"NATL ACAD SCIENCES","WASHINGTON","2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA","0027-8424",null,"10.1073/pnas.1016650108","PROC NAT ACAD SCI USA","Proc. Natl. Acad. Sci. U. S. A.","MAY 17",2011,108,20,null,null,null,8467,8472,null,null,6,"Multidisciplinary Sciences","765OZ","ISI:000290719600076",""]
["2 z/ze 6",2,6,0.33333333333333331,"2011/82/4/391-397","http://www.ncbi.nlm.nih.gov/pubmed/21236546",2.7120000000000002,"How accurately can the aetiology of cardiac arrest be established in an out-of-hospital setting? Analysis by \"Concordance in Diagnosis Crosscheck Tables\"","J","Pokorna, M; Necas, E; Skripsky, R; Kratochvil, J; Andrlik, M; Franek, O",null,null,null,"Pokorna, Milana; Necas, Emanuel; Skripsky, Roman; Kratochvil, Jaroslav; Andrlik, Michal; Franek, Ondrej",null,"How accurately can the aetiology of cardiac arrest be established in an out-of-hospital setting? Analysis by \"Concordance in Diagnosis Crosscheck Tables\"","RESUSCITATION",null,"English","Article",null,null,null,null,null,"Aetiology of cardiac arrest; Out-of-hospital care; Cardiopulmonary resuscitation; Thrombolytic therapy; Myocardial infarction; Pulmonary embolism","AUSTRALIAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; UTSTEIN STYLE; SUDDEN-DEATH; TASK-FORCE; SURVIVAL; DISEASE","Introduction: Several previous studies have focused on establishing the cause of cardiac arrest (CA) during cardiopulmonary resuscitation (CPR) provided in an out-of-hospital setting. Objectives: To analyze the ability of professional advanced life support providers to correctly establish the aetiology of cardiac arrest during out-of-hospital CPR. Study design: A retrospective cohort study analysing 211 cases of out-of-hospital cardiac arrest. Method: The aetiology assumed by out-of-hospital physicians was compared with the diagnosis that was later established by clinicians or pathologists. Results: Cases were sorted into five diagnostic groups and the overall diagnostic concordance was 74.4% (157 of 211 cases). The cardiac aetiology was presumed in 132 out of 211 patients and confirmed in 135 out of 211 patients. However, an analysis of individual cases of the cardiac causes of cardiac arrest revealed diagnostic matches in only 112 cases. Acute myocardial infarction (AMI) or pulmonary embolism (PE), both of which represent cases that can be potentially influenced by thrombolytic therapy, were presumed in 74 (53 + 21) and confirmed in 97 (77 + 20) cases, however with individual diagnostic matches in only 55 cases. Conclusion: This study demonstrates the importance of analysing concordance in presumed and definitive diagnosis of individual cases, since an overall comparison in a cohort of cases may be highly misleading. It introduces the method of the crosscheck table for visualization and comparison of presumed and final diagnoses. The two alternative approaches of inclusion rule for applying the thrombolytic therapy in out-of-hospital care were discussed with regard to the recent TROICA study. (C) 2010 Elsevier Ireland Ltd. All rights reserved.","[Pokorna, Milana; Skripsky, Roman; Kratochvil, Jaroslav; Franek, Ondrej] Emergency Med Serv Prague, Prague 10100 10, Czech Republic; [Pokorna, Milana; Kratochvil, Jaroslav] Univ Hosp Motol, Emergency Dept, Prague 15006, Czech Republic; [Pokorna, Milana; Skripsky, Roman] Charles Univ Prague, Fac Med 1, Dept Anesthesiol & Intens Care, Prague 14000, Czech Republic; [Necas, Emanuel; Andrlik, Michal] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague 12800, Czech Republic","Pokorna, M, Emergency Med Serv Prague, Korunni 98, Prague 10100 10, Czech Republic","MilanaP@seznam.cz","Ministry of Health of the Czech Republic [IGA NR/7970-3]; [MSM 0021620806]","The work was supported by the grants IGA NR/7970-3 provided by the Ministry of Health of the Czech Republic and MSM 0021620806. We would like to thank Petra Sukupova for her help in collecting data from the hospitals and all cooperative physicians of Prague's hospitals and departments of pathology.",null,40,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0300-9572",null,"10.1016/j.resuscitation.2010.11.026","RESUSCITATION","Resuscitation","APR",2011,82,4,null,null,null,391,397,null,null,7,"Critical Care Medicine; Emergency Medicine","750NS","ISI:000289555800006",""]
["5 z/ze 5",5,5,1,"2011/40/2/158-160","http://www.ncbi.nlm.nih.gov/pubmed/20874520",2.5070000000000001,"Characterization of the B-cell compartment in a patient with Schnitzler syndrome","J","Sediva, A; Polouckova, A; Podrazil, M; Fronkova, E; Kalina, T",null,null,null,"Sediva, A.; Polouckova, A.; Podrazil, M.; Fronkova, E.; Kalina, T.",null,"Characterization of the B-cell compartment in a patient with Schnitzler syndrome","SCANDINAVIAN JOURNAL OF RHEUMATOLOGY",null,"English","Letter",null,null,null,null,null,null,"ANAKINRA",null,"[Sediva, A.; Polouckova, A.; Podrazil, M.] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague 15006, Czech Republic; [Fronkova, E.; Kalina, T.] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Sediva, A, Charles Univ Prague, Dept Immunol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic","anna.sediv@fmotol.cuni.cz",null,null,null,10,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0300-9742",null,null,"SCAND J RHEUMATOL","Scand. J. Rheumatol.","MAR",2011,40,2,null,null,null,158,160,null,null,3,"Rheumatology","731RU","ISI:000288127800016",""]
["1 z/ze 12",1,12,8.3333333333333329E-2,"2011/121/1/43-56","http://toxsci.oxfordjournals.org/content/121/1/43.abstract",4.8140000000000001,"Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model","J","Levova, K; Moserova, M; Kotrbova, V; Sulc, M; Henderson, CJ; Wolf, CR; Phillips, DH; Frei, E; Schmeiser, HH; Mares, J; Arlt, VM; Stiborova, M",null,null,null,"Levova, Katerina; Moserova, Michaela; Kotrbova, Vera; Sulc, Miroslav; Henderson, Colin J.; Wolf, C. Roland; Phillips, David H.; Frei, Eva; Schmeiser, Heinz H.; Mares, Jaroslav; Arlt, Volker M.; Stiborova, Marie",null,"Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model","TOXICOLOGICAL SCIENCES",null,"English","Article",null,null,null,null,null,"aristolochic acid; cytochrome P450; metabolism; DNA adducts; P-32-postlabeling","BALKAN ENDEMIC NEPHROPATHY; CHINESE HERBS NEPHROPATHY; DNA ADDUCT FORMATION; ANTICANCER DRUG ELLIPTICINE; PROSTAGLANDIN-H SYNTHASE; METABOLIC-ACTIVATION; UROTHELIAL CANCER; GENE-EXPRESSION; ENVIRONMENTAL-POLLUTANT; SUDAN-I","Aristolochic acid (AA) causes aristolochic acid nephropathy, Balkan endemic nephropathy, and their urothelial malignancies. To identify enzymes involved in the metabolism of aristolochic acid I (AAI), the major toxic component of AA we used HRN (hepatic cytochrome P450 [Cyp] reductase null) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes. AAI was demethylated by hepatic Cyps in vitro to 8-hydroxy-aristolochic acid I (AAIa), indicating that less AAI is distributed to extrahepatic organs in wild-type (WT) mice. Indeed, AAI-DNA-adduct levels were significantly higher in organs of HRN mice, having low hepatic AAI demethylation capacity, than in WT mice. Absence of AAI demethylation in HRN mouse liver was confirmed in vitro; hepatic microsomes from WT, but not from HRN mice, oxidized AAI to AAIa. To define the role of hepatic Cyps in AAI demethylation, modulation of AAIa formation by CYP inducers was investigated. We conclude that AAI demethylation is attributable mainly to Cyp1a1/2. The higher AAI-DNA adduct levels in HRN than WT mice were the result of the lack of hepatic AAI demethylation concomitant with a higher activity of cytosolic NAD(P)H:quinone oxidoreductase (Nqo1), which activates AAI. Mouse hepatic Cyp1a1/2 also activated AAI to DNA adducts under hypoxic conditions in vitro, but in renal microsomes, Por and Cyp3a are more important than Cyp1a for AAI-DNA adduct formation. We propose that AAI activation and detoxication in mice are dictated mainly by AAI binding affinity to Cyp1a1/2 or Nqo1, by their turnover, and by the balance between oxidation and reduction of AAI by Cyp1a.","[Levova, Katerina; Moserova, Michaela; Kotrbova, Vera; Sulc, Miroslav; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Henderson, Colin J.; Wolf, C. Roland] Biomed Res Inst, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; [Phillips, David H.; Arlt, Volker M.] Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumour Dis, Div Prevent Oncol, D-69120 Heidelberg, Germany; [Schmeiser, Heinz H.] German Canc Res Ctr, Res Grp Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; [Mares, Jaroslav] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Prague 15006 5, Czech Republic; [Mares, Jaroslav] Univ Hosp Motol, Prague 15006 5, Czech Republic","Stiborova, M, Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic","stiborov@natur.cuni.cz","Grant Agency of Czech Republic [303/09/0472, 305/09/H008]; Ministry of Education of Czech Republic [MSM0021620808, 1M0505]; Cancer Research UK ","The authors would like to thank to Grant Agency of Czech Republic (grants 303/09/0472, and 305/09/H008) and to the Ministry of Education of Czech Republic (grants MSM0021620808 and 1M0505). Work at the Biomedical Research Centre and Institute of Cancer Research is supported by Cancer Research UK.",null,77,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1096-6080",null,"10.1093/toxsci/kfr050","TOXICOL SCI","Toxicol. Sci.","MAY",2011,121,1,null,null,null,43,56,null,null,14,"Toxicology","753VG","ISI:000289807200005",""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
["  ",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]

{"sheet":"List3","index":4,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}